PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	FREEDMAN, BD; FLEISCHMANN, BK; PUNT, JA; GAULTON, G; HASHIMOTO, Y; KOTLIKOFF, MI				FREEDMAN, BD; FLEISCHMANN, BK; PUNT, JA; GAULTON, G; HASHIMOTO, Y; KOTLIKOFF, MI			IDENTIFICATION OF KV1.1 EXPRESSION BY MURINE CD4(-)CD8(-) THYMOCYTES - A ROLE FOR VOLTAGE-DEPENDENT K+ CHANNELS IN MURINE THYMOCYTE DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-BLOOD LYMPHOCYTES; CELL-VOLUME REGULATION; POTASSIUM CHANNELS; T-CELLS; CALCIUM INFLUX; CHARYBDOTOXIN; RECEPTOR; INTERLEUKIN-2; CA-2+; OSCILLATIONS	The patch-clamp recording technique and RNA-polymerase chain reaction were used to identify the voltage-dependent K+ channels expressed by murine fetal and adult CD4(-)CD8(-) thymocytes. Two distinct currents, encoded by the genes Kv1.1 and Kv1.3 were identified based upon their biophysical and pharmacologic characteristics and confirmed with RNA-polymerase chain reaction. Peptide blockers of Kv1.1 and Kv1.3 gene products were also applied to a murine fetal thymic organ culture system to investigate the developmental role of these K+ channels. Dendrotoxin (DTX) and charybdotoxin (CTX), antagonists of Kv1.1 and Kv1.3 channels, respectively, decreased thymocyte yields in organ culture without affecting thymocyte viability. DTX-treated thymi contained 56 +/- 8% (n = 8 experiments), and CTX-treated thymi contained 74 +/- 4% (n = 7 experiments) as many thymocytes as untreated lobes. DTX and CTX also altered the developmental progression of thymocytes in fetal organ culture. These data provide the first evidence of Kv1.1 expression in a lymphoid cell and indicate that thymocyte voltage-dependent K+ channels are critical to thymocyte preclonal expansion and/or maturation.	UNIV PENN,SCH VET MED,DEPT ANIM BIOL,PHILADELPHIA,PA 19104; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; SYNTEX INST IMMUNOL,NIIHARI,IBARAKI 30041,JAPAN	University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	FREEDMAN, BD (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104, USA.				NIAID NIH HHS [R01 AI060921] Funding Source: Medline; NIAMS NIH HHS [AR-39910] Funding Source: Medline; NICHD NIH HHS [HD-01056] Funding Source: Medline; PHS HHS [A132748] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039910] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEUTSCH C, 1994, P NATL ACAD SCI USA, V90, P10036; DEUTSCH CJ, 1979, J CELL PHYSIOL, V99, P79, DOI 10.1002/jcp.1040990110; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; FREEDMAN BD, 1992, J IMMUNOL, V149, P3784; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GELFAND EW, 1987, J IMMUNOL, V138, P527; GELFAND EW, 1984, J CELL PHYSIOL, V121, P533, DOI 10.1002/jcp.1041210312; GRAY LS, 1987, CELL, V50, P119, DOI 10.1016/0092-8674(87)90668-4; GRINSTEIN S, 1990, J GEN PHYSIOL, V95, P97, DOI 10.1085/jgp.95.1.97; GRINSTEIN S, 1989, AM J PHYSIOL, V257, pC197, DOI 10.1152/ajpcell.1989.257.2.C197; GRINSTEIN S, 1984, AM J PHYSIOL, V246, pC204, DOI 10.1152/ajpcell.1984.246.3.C204; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; GRISSMER S, 1995, MOL PHARMACOL, V45, P1227; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; HESS SD, 1993, J IMMUNOL, V150, P2620; JENKINSON EJ, 1981, J EXP MED, V153, P280, DOI 10.1084/jem.153.2.280; LEE SC, 1988, AM J PHYSIOL, V254, pC286, DOI 10.1152/ajpcell.1988.254.2.C286; LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094; LEWIS RS, 1988, SCIENCE, V239, P771, DOI 10.1126/science.2448877; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; MCKINNON D, 1986, J EXP MED, V164, P1846, DOI 10.1084/jem.164.6.1846; MILLS GB, 1985, J IMMUNOL, V134, P1640; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; OETTGEN HC, 1985, CELL, V40, P583, DOI 10.1016/0092-8674(85)90206-5; OLESON DR, 1993, J MEMBRANE BIOL, V132, P229; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; RINK TJ, 1980, BIOCHIM BIOPHYS ACTA, V595, P15, DOI 10.1016/0005-2736(80)90243-6; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TAKAHAMA Y, 1994, J EXP MED, V179, P1495, DOI 10.1084/jem.179.5.1495; TAKAHAMA Y, 1991, J IMMUNOL, V146, P1134; VANEWIJK W, 1994, IMMUNOL TODAY, V15, P214, DOI 10.1016/0167-5699(94)90246-1; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7	36	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22406	22411		10.1074/jbc.270.38.22406	http://dx.doi.org/10.1074/jbc.270.38.22406			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673227	hybrid			2022-12-25	WOS:A1995RW31400054
J	GRUPE, A; ALLEMAN, J; GOLDFINE, ID; SADICK, M; STEWART, TA				GRUPE, A; ALLEMAN, J; GOLDFINE, ID; SADICK, M; STEWART, TA			INHIBITION OF INSULIN-RECEPTOR PHOSPHORYLATION BY PC-1 IS NOT MEDIATED BY THE HYDROLYSIS OF ADENOSINE-TRIPHOSPHATE OR THE GENERATION OF ADENOSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DIFFERENTIATION ANTIGEN PC-1; CELL MEMBRANE GLYCOPROTEIN; RAT ADIPOCYTES; PHOSPHODIESTERASE; IDENTIFICATION; MONOPHOSPHATE; THREONINE; MUSCLE; ACID	Individuals with insulin resistance show increased levels of PC-1 expression in skeletal muscle and fibroblasts, and in transfected cell lines that overexpress PC-I there is a reduction in the insulin-stimulated insulin receptor tyrosine phosphorylation, As PC-1 is a type II transmembrane protein with extracellular phosphodiesterase and pyrophosphatase activity, increased expression of PC-1 at the cell surface will decrease extracellular adenosine triphosphate levels and increase extracellular adenosine levels, Consequently it is possible that PC-1-mediated insulin resistance could be caused either by a decrease in adenosine triphosphate or an indirect increase in adenosine levels, We have tested this hypothesis and find that the PC-1-mediated inhibition of insulin-stimulated insulin receptor autophosphorylation is not altered by agents that alter the level or action of adenosine. Further, a mutated PC-1 with a single amino acid change that abolishes the phosphodiesterase and pyrophosphatase activities is still able to inhibit insulin-stimulated insulin receptor phosphorylation, The results of these experiments indicate that the phosphodiesterase activity of PC-1 is not involved in the inhibition of insulin receptor autophosphorylation.	UNIV CALIF SAN FRANCISCO,MT ZION MED CTR,DIV DIABET & ENDOCRINE RES,SAN FRANCISCO,CA 94115	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	GRUPE, A (corresponding author), GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080, USA.							BELLI SI, 1994, BIOCHEM J, V304, P75, DOI 10.1042/bj3040075; BELLI SI, 1994, EUR J BIOCHEM, V226, P433, DOI 10.1111/j.1432-1033.1994.tb20068.x; BELLI SI, 1995, IN PRESS EUR J BIOCH; BUDOHOSKI L, 1984, FEBS LETT, V167, P1, DOI 10.1016/0014-5793(84)80820-0; CHALLISS RAJ, 1992, EUR J PHARM-MOLEC PH, V226, P121, DOI 10.1016/0922-4106(92)90172-R; CIARALDI TP, 1988, MOL CELL ENDOCRINOL, V60, P31, DOI 10.1016/0303-7207(88)90117-7; COLLIS MG, 1993, TRENDS PHARMACOL SCI, V14, P360; CULP JS, 1985, J BIOL CHEM, V260, P8320; FAIN JN, 1975, J BIOL CHEM, V250, P1027; HARAHAP AR, 1988, J IMMUNOL, V141, P2317; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAW WR, 1988, AM J PHYSIOL, V254, pH970, DOI 10.1152/ajpheart.1988.254.5.H970; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LINDEN J, 1994, TRENDS PHARMACOL SCI, V15, P298, DOI 10.1016/0165-6147(94)90011-6; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P1364, DOI 10.1021/bi00354a026; MUELLER CE, 1993, PHARM ACTA HELV, V68, P77; ODA Y, 1991, J BIOL CHEM, V266, P16791; OLAH ME, 1992, ANNU REV PHYSIOL, V54, P211, DOI 10.1146/annurev.physiol.54.1.211; QUON MJ, 1994, TRENDS ENDOCRIN MET, V5, P369, DOI 10.1016/1043-2760(94)90104-X; REBBE NF, 1991, P NATL ACAD SCI USA, V88, P5192, DOI 10.1073/pnas.88.12.5192; ROTH RA, 1992, J CELL BIOCHEM, V48, P12, DOI 10.1002/jcb.240480104; TAYLOR SI, 1991, ANNU REV MED, V42, P373, DOI 10.1146/annurev.me.42.020191.002105; TAYLOR WM, 1979, BIOCHEM J, V178, P381, DOI 10.1042/bj1780381; TERKELTAUB R, 1994, ARTHRITIS RHEUM, V37, P934, DOI 10.1002/art.1780370624; URIARTE M, 1993, BIOCHEM J, V293, P93, DOI 10.1042/bj2930093; VANDRIEL IR, 1987, J BIOL CHEM, V262, P4882; VERGAUWEN L, 1994, J CLIN INVEST, V93, P974, DOI 10.1172/JCI117104	28	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22085	22088		10.1074/jbc.270.38.22085	http://dx.doi.org/10.1074/jbc.270.38.22085			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673181	hybrid			2022-12-25	WOS:A1995RW31400003
J	HUANG, T; SCHIRCH, V				HUANG, T; SCHIRCH, V			MECHANISM FOR THE COUPLING OF ATP HYDROLYSIS TO THE CONVERSION OF 5-FORMYLTETRAHYDROFOLATE TO 5,10-METHENYLTETRAHYDROFOLATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHENYLTETRAHYDROFOLATE SYNTHETASE; PURIFICATION; POLYGLUTAMATES; INTERMEDIATE; PHOSPHATE; ENZYME; LIVER; ACID	5,10-Methenyltetrahydrofolate synthetase catalyzes the irreversible conversion of 5-formyl-tetrahydropteroylpolyglutamates (5-CHO-H(4)PteGlu(n)) to 5,10-methenyltetrahydropteroylpolyglutamates (5, 10-CH+-H(4)PteGlu(n)). The equilibrium of the nonenzymatic reaction, which equilibrates slowly in the absence of enzyme, greatly favors 5-CHO-H(4)PteGlu(n). The enzyme couples the reaction to the hydrolysis of ATP shifting the equilibrium to favor 5,10-CH+-H(4)PteGlu(n). Substrate-dependent non equilibrium isotope exchange of [H-3]ADP into ATP was observed, suggesting the formation of a phosphorylated intermediate of 5-CHO-H(4)PteGlu(n) during the enzyme catalyzed reaction, The competitive inhibitor 5-formyltetrahydrohomofolate also supported the ADP to ATP exchange, suggesting that this molecule could also form a phosphorylated intermediate, The initial rates of the ADP-ATP exchange with saturating ADP were about 70 s(-1) for both compounds, while the k(cat) values for product formation were 5 s(-1) for 5 CHO-H(4)PteGlu(n) and 0.005 s(-1) for 5-formyltetrahydrohomofolate. Starting with 5-[O-18]CHO-H(4)PteGlu(n), it was shown by P-31 NMR that the formyl oxygen of the substrate was transferred to the product phosphate during the reaction. This further supports the existence of a phosphorylated intermediate, The formyl group of 5-CHO-H(4)PteGlu(n) is known to be an equilibrium mixture of two rotamers. Stopped-Bow analysis of the enzymatic reaction showed that only one of the rotamers serves as a substrate for the enzyme.	VIRGINIA COMMONWEALTH UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, RICHMOND, VA 23298 USA	Virginia Commonwealth University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028143] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28143] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENKOVIC SJ, 1972, J AM CHEM SOC, V94, P7542, DOI 10.1021/ja00776a043; BERTRAND R, 1987, BIOCHIM BIOPHYS ACTA, V911, P154, DOI 10.1016/0167-4838(87)90004-5; BERTRAND R, 1989, J BIOL CHEM, V264, P8843; COHN M, 1978, P NATL ACAD SCI USA, V75, P200, DOI 10.1073/pnas.75.1.200; DOMANICO P, 1981, J MED CHEM, V24, P1086; FEENEY J, 1980, J CHEM SOC PERK T 2, P176, DOI 10.1039/p29800000176; FEENEY J, 1981, BIOCHEMISTRY-US, V20, P1837, DOI 10.1021/bi00510a019; GREENBERG DM, 1965, BIOCHEMISTRY-US, V4, P1872, DOI 10.1021/bi00885a026; GRIMSHAW CE, 1984, J BIOL CHEM, V259, P2728; HOPKINS S, 1984, J BIOL CHEM, V259, P5618; KAY LD, 1960, J BIOL CHEM, V235, P195; KOUNGA K, 1995, FEBS LETT, V364, P215, DOI 10.1016/0014-5793(95)00396-Q; KRUSCHWITZ HL, 1994, J BIOL CHEM, V269, P28757; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MACHOVER D, 1982, CANCER TREAT REP, V66, P1803; MARAS B, 1994, J BIOL CHEM, V269, P18429; MAY M, 1951, J AM CHEM SOC, V73, P3067, DOI 10.1021/ja01151a028; MEJILLANO MR, 1989, BIOCHEMISTRY-US, V28, P5136, DOI 10.1021/bi00438a034; PETERS JM, 1958, J AM CHEM SOC, V80, P2719, DOI 10.1021/ja01544a034; POE M, 1980, BIOCHEMISTRY-US, V19, P4576, DOI 10.1021/bi00561a006; SCHRIMSHER JL, 1986, BIOCHEMISTRY-US, V25, P4356, DOI 10.1021/bi00363a027; SCHWEITZER BI, 1990, FASEB J, V4, P2441, DOI 10.1096/fasebj.4.8.2185970; SEDDON AP, 1986, J BIOL CHEM, V261, P1538; STOVER P, 1993, TRENDS BIOCHEM SCI, V18, P102, DOI 10.1016/0968-0004(93)90162-G; STOVER P, 1992, ANAL BIOCHEM, V202, P82, DOI 10.1016/0003-2697(92)90210-X; STOVER P, 1991, J BIOL CHEM, V266, P1543; STOVER P, 1993, ADV EXP MED BIOL, V338, P723; TEMPLE C, 1984, CHEM BIOCH FOLATES, V1, P80	28	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22296	22300		10.1074/jbc.270.38.22296	http://dx.doi.org/10.1074/jbc.270.38.22296			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673211	hybrid			2022-12-25	WOS:A1995RW31400038
J	KITAGAWA, H; TANAKA, Y; TSUCHIDA, K; GOTO, F; OGAWA, T; LIDHOLT, K; LINDAHL, U; SUGAHARA, K				KITAGAWA, H; TANAKA, Y; TSUCHIDA, K; GOTO, F; OGAWA, T; LIDHOLT, K; LINDAHL, U; SUGAHARA, K			N-ACETYLGALACTOSAMINE (GALNAC) TRANSFER TO THE COMMON CARBOHYDRATE-PROTEIN LINKAGE REGION OF SULFATED GLYCOSAMINOGLYCANS - IDENTIFICATION OF UDP-GALNAC-CHONDRO-OLIGOSACCHARIDE ALPHA-N-ACETYLGALACTOSAMINYLTRANSFERASE IN FETAL BOVINE SERUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWARM MOUSE-TUMOR; CHONDROITIN-6-SULFATE PROTEOGLYCANS; SULFOTRANSFERASE ACTIVITIES; SHARK CARTILAGE; HEPARAN-SULFATE; ANIMAL SERA; PURIFICATION; BIOSYNTHESIS; 4-SULFATE	During the course of a study to elucidate the role of modification of the common polysaccharide-protein linkage structure, GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-Ser, in biosynthetic sorting mechanisms of the different sulfated glycosaminoglycan chains, a novel N-acetylgalactosamine (GalNAc) transferase was discovered in fetal bovine serum, The enzyme catalyzed the transfer of [H-3]GaINAc from UDP-[H-3]GaINAc to linkage tetrasaccharide and hexasaccharide serines synthesized chemically and to various regular oligosaccharides containing terminal D-glucuronic acid (GlcA), which were prepared from chondroitin and chondroitin sulfate using testicular hyaluronidase digestion, The labeled products obtained with the linkage tetra- and hexasaccharide serines and with the tetrasaccharide (GlcA beta 1-3GalNAc)(2) were resistant to digestion with chondroitinase AC-II and beta-N-acetylhexosaminidase but sensitive to alpha-N-acetylgalactosaminidase digestion, indicating that the enzyme is an alpha-N-acetylgalactosaminyltransferase. This finding is in contrast to that of Rohrmann ef al, (Rohrmann, K., Niemann, R,, and Buddecke, E, (1985) Ear, J, Biochem., 148, 463-469), who reported that a corresponding product was susceptible to digestion with beta-N-acetylhexosaminidase. The presence of a sulfate group at C4 of the penultimate GalNAc or Gal units markedly inhibited the transfer of GalNAc to the terminal GlcA, while a sulfate group at C6 of the GalNAc had Little effect on the transfer, Moreover, a slight but significant transfer of [(3)]GalNAc was observed to an oligosaccharide containing terminal 2-O-sulfated GlcA as acceptor, whereas no incorporation was detected into oligosaccharides containing terminal unsaturated or 3-O-sulfated GlcA units, These results suggest that this novel serum enzyme is a UDP-GalNAc:chondro-oligosaccharide alpha 1-3- or 1-4-N-acetylgalactosaminyltransferase. The possibility of involvement of this enzyme in glycosaminoglycan biosynthesis is discussed.	KOBE PHARMACEUT UNIV,DEPT BIOCHEM,HIGASHINADA KU,KOBE 658,JAPAN; INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN; UNIV TOKYO,GRAD SCH AGR & LIFE SCI,BUNKYO KU,TOKYO 113,JAPAN; UNIV UPPSALA,DEPT MED & PHYSIOL CHEM,CTR BIOMED,S-75123 UPPSALA,SWEDEN	Kobe Pharmaceutical University; RIKEN; University of Tokyo; Uppsala University			Ogawa, Tomoya/C-3655-2009; Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				CLAUSEN H, 1990, J BIOL CHEM, V265, P1139; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; ETCHISON JR, 1995, J BIOL CHEM, V270, P756, DOI 10.1074/jbc.270.2.756; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; GOTO F, 1992, TETRAHEDRON LETT, V33, P6841, DOI 10.1016/S0040-4039(00)61790-2; GOTO F, 1992, TETRAHEDRON LETT, V33, P5099, DOI 10.1016/S0040-4039(00)61200-5; GOTO F, 1993, PURE APPL CHEM, V65, P793, DOI 10.1351/pac199365040793; INOUE H, 1986, J BIOL CHEM, V261, P4460; KITAGAWA H, 1995, J BIOCHEM-TOKYO, V117, P1083, DOI 10.1093/oxfordjournals.jbchem.a124810; LIND T, 1993, J BIOL CHEM, V268, P20705; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; SUGAHARA K, 1992, EUR J BIOCHEM, V204, P401, DOI 10.1111/j.1432-1033.1992.tb16649.x; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGAHARA K, 1989, J BIOCHEM-TOKYO, V106, P910, DOI 10.1093/oxfordjournals.jbchem.a122951; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; SUGAHARA K, 1987, ARCH BIOCHEM BIOPHYS, V258, P391, DOI 10.1016/0003-9861(87)90360-2; SUGIURA M, 1982, J BIOL CHEM, V257, P9501; TANIGUCHI N, 1982, J BIOL CHEM, V257, P631	26	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22190	22195		10.1074/jbc.270.38.22190	http://dx.doi.org/10.1074/jbc.270.38.22190			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673197	hybrid			2022-12-25	WOS:A1995RW31400022
J	BARACCA, A; GABELLIERI, E; BAROGI, S; SOLAINI, G				BARACCA, A; GABELLIERI, E; BAROGI, S; SOLAINI, G			CONFORMATIONAL-CHANGES OF THE MITOCHONDRIAL F-1-ATPASE EPSILON-SUBUNIT INDUCED BY NUCLEOTIDE-BINDING AS OBSERVED BY PHOSPHORESCENCE SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEEF-HEART F1-ATPASE; LIVER ALCOHOL-DEHYDROGENASE; CHLOROPLAST COUPLING FACTOR; COLI F1 ATPASE; ESCHERICHIA-COLI; CATALYTIC SITES; ADENOSINE-TRIPHOSPHATASE; NONCATALYTIC SITES; TRYPTOPHAN PHOSPHORESCENCE; COOPERATIVE INTERACTIONS	Changes in conformation of the E-subunit of the bovine heart mitochondrial F-1-ATPase complex as a result of nucleotide binding have been demonstrated from the phosphorescence emission of tryptophan. The triplet state lifetime shows that whereas nucleoside triphosphate binding to the enzyme in the presence of Mg2+ increases the flexibility of the protein structure surrounding the chromophore, nucleoside diphosphate acts in an opposite manner, enhancing the rigidity of this region of the macromolecule. Such changes in dynamic structure of the epsilon-subunit are evident at high ligand concentration added to both the nucleotide depleted F-1 (Nd-F-1) and the F-1 preparation containing the three tightly bound nucleotides (F-1(2,1)). Since the effects observed are similar in both the F-1 forms, the binding to the low affinity sites must be responsible for the conformational changes induced in the epsilon-subunit. This is partially supported by the observation that the Trp lifetime is not significantly affected by adding an equimolar concentration of adenine nucleotide to Nd-F-1. The effects on protein structure of nucleotide binding to either catalytic or noncatalytic sites have been distinguished by studying the phosphorescence emission of the F-1 complex prepared with the three noncatalytic sites filled and the three catalytic sites vacant (F-1(3,0)). Phosphorescence lifetime measurements on this F-1 form demonstrate that the binding of Mg-NTP to catalytic sites induces a slight enhancement of the rigidity of the epsilon-subunit. This implies that the binding to the vacant noncatalytic site of F-1(2,1) must exert the opposite and larger effect of enhancing the flexibility of the protein structure observed in both Nd-F-1 and F-1(2,1). The observation that enhanced flexibility of the protein occurs upon addition of adenine nucleotides to F-1(2,1) in the absence of Mg2+ provides direct support for this suggestion. The connection between changes in structure and the possible functional role of the epsilon-subunit is discussed.	SCUOLA SUPER SANT ANNA, DIPARTIMENTO BIOCHIM G MORUZZI, I-56100 PISA, ITALY; UNIV BOLOGNA, IST BIOFIS, BOLOGNA, ITALY; CNR, I-56100 PISA, ITALY	Scuola Superiore Sant'Anna; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); University of Bologna; Consiglio Nazionale delle Ricerche (CNR)				SOLAINI, GIANCARLO/0000-0001-7825-0446; Gabellieri, Edi/0000-0003-0750-4095				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; ALOISE P, 1991, J BIOL CHEM, V266, P10368; BARACCA A, 1992, COMP BIOCHEM PHYS B, V101, P421, DOI 10.1016/0305-0491(92)90022-J; BARACCA A, 1989, BIOCHIM BIOPHYS ACTA, V976, P77, DOI 10.1016/S0005-2728(89)80191-4; BARACCA A, 1995, BIOCHEM BIOPH RES CO, V207, P369, DOI 10.1006/bbrc.1995.1197; BARACCA A, 1993, INT J BIOCHEM, V25, P701, DOI 10.1016/0020-711X(93)90356-J; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRAGG PD, 1987, BIOCHIM BIOPHYS ACTA, V894, P127, DOI 10.1016/0005-2728(87)90182-4; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; BURGARD S, 1994, J BIOL CHEM, V269, P17815; CHERNYAK BV, 1992, ARCH BIOCHEM BIOPHYS, V295, P247, DOI 10.1016/0003-9861(92)90514-W; CIONI P, 1989, EUR J BIOCHEM, V185, P573, DOI 10.1111/j.1432-1033.1989.tb15152.x; CIONI P, 1989, J MOL BIOL, V207, P237, DOI 10.1016/0022-2836(89)90453-1; CLELAND WW, 1979, ADV INORG BIOCHEM, V1, P163; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CROSS RL, 1982, J BIOL CHEM, V257, P2874; DIPIETRO A, 1980, BIOCHEMISTRY-US, V19, P5671, DOI 10.1021/bi00566a002; DIPIETRO A, 1988, BIOCHEM BIOPH RES CO, V152, P1319, DOI 10.1016/S0006-291X(88)80429-7; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; DUNN SD, 1982, J BIOL CHEM, V257, P7354; FRASCH WD, 1982, BIOCHEMISTRY-US, V21, P3636, DOI 10.1021/bi00258a017; GABELLIERI E, 1994, EUR J BIOCHEM, V221, P77, DOI 10.1111/j.1432-1033.1994.tb18716.x; GAY NJ, 1983, NATURE, V301, P262, DOI 10.1038/301262a0; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GROMETELHANAN Z, 1984, BIOCHEMISTRY-US, V23, P1022, DOI 10.1021/bi00300a034; GUELIN E, 1993, J BIOL CHEM, V268, P161; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V504, P364, DOI 10.1016/0005-2728(78)90060-9; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V463, P245, DOI 10.1016/0304-4173(78)90002-2; HARRIS DA, 1993, FEBS LETT, V316, P209, DOI 10.1016/0014-5793(93)81295-B; HATEFI Y, 1993, EUR J BIOCHEM, V218, P759, DOI 10.1111/j.1432-1033.1993.tb18431.x; ISSARTEL JP, 1983, BIOCHEMISTRY-US, V22, P3485, DOI 10.1021/bi00283a027; ISSARTEL JP, 1986, J BIOL CHEM, V261, P895; ISSARTEL JP, 1992, EXPERIENTIA, V48, P351, DOI 10.1007/BF01923429; JAULT JM, 1994, J BIOL CHEM, V269, P319; JOSHI S, 1990, J BIOL CHEM, V265, P14518; KAMP G, 1987, BIOCHIM BIOPHYS ACTA, V929, P121, DOI 10.1016/0167-4889(87)90166-2; KAWANO Y, 1988, J PHYSIOL-LONDON, V407, P243, DOI 10.1113/jphysiol.1988.sp017413; KIRONDE FAS, 1986, J BIOL CHEM, V261, P2544; KIRONDE FAS, 1987, J BIOL CHEM, V262, P3488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTTER R, 1993, J MOL BIOL, V229, P787, DOI 10.1006/jmbi.1993.1081; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MILGROM YM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P43, DOI 10.1016/0005-2728(90)90091-H; MILGROM YM, 1993, J BIOL CHEM, V268, P23179; NALIN CM, 1982, J BIOL CHEM, V257, P8055; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PEINNEQUIN A, 1992, BIOCHEMISTRY-US, V31, P2088, DOI 10.1021/bi00122a028; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENEFSKY HS, 1975, METHOD ENZYMOL, V55, P304; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; RICHTER ML, 1985, BIOCHEMISTRY-US, V24, P5755, DOI 10.1021/bi00342a011; ROSEN G, 1979, J BIOL CHEM, V254, P654; ROSING J, 1975, BIOCHIM BIOPHYS ACTA, V376, P13, DOI 10.1016/0005-2728(75)90201-7; RYRIE IJ, 1972, J BIOL CHEM, V247, P4553; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SENIOR AE, 1979, J BIOL CHEM, V254, P1319; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SOLAINI G, 1993, EUR J BIOCHEM, V214, P729, DOI 10.1111/j.1432-1033.1993.tb17974.x; STANLOTTER H, 1986, EUR J BIOCHEM, V154, P321, DOI 10.1111/j.1432-1033.1986.tb09400.x; STRAMBINI GB, 1983, BIOPHYS J, V43, P127, DOI 10.1016/S0006-3495(83)84331-8; STRAMBINI GB, 1987, BIOCHEMISTRY-US, V26, P6527, DOI 10.1021/bi00394a036; STRAMBINI GB, 1989, J MOL LIQ, V42, P155, DOI 10.1016/0167-7322(89)80031-5; STRAMBINI GB, 1986, BIOCHEMISTRY-US, V25, P2471, DOI 10.1021/bi00357a027; STRAMBINI GB, 1985, CHEM PHYS LETT, V115, P196, DOI 10.1016/0009-2614(85)80678-3; STRAMBINI GB, 1995, IN PRESS J AM CHEM S; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; XUE ZX, 1989, EUR J BIOCHEM, V179, P677, DOI 10.1111/j.1432-1033.1989.tb14600.x; [No title captured]	74	8	8	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21845	21851		10.1074/jbc.270.37.21845	http://dx.doi.org/10.1074/jbc.270.37.21845			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665607	hybrid			2022-12-25	WOS:A1995RU75700067
J	FENNEWALD, SM; RANDO, RF				FENNEWALD, SM; RANDO, RF			INHIBITION OF HIGH-AFFINITY BASIC FIBROBLAST GROWTH-FACTOR BINDING BY OLIGONUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; ANTISENSE OLIGODEOXYNUCLEOTIDES; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; CELL-PROLIFERATION; HEPARAN-SULFATE; TYPE-2 GROWTH; RNASE H; RECEPTOR; ANGIOPLASTY; PROTEINS	Oligonucleotides can be used to inhibit the binding of basic fibroblast growth factor to cells. Though standard phosphodiester oligonucleotides show a slight inhibition of binding, the oligonucleotides with phosphorothioate internucleoside linkages have inhibition levels equivalent to that of the polyanion heparin. Variations in sequence of the oligonucleotides does lead to differences in the inhibitory action of the oligonucleotides, This inhibition of basic fibroblast growth factor by phosphorothioate oligonucleotides may account for much of the published data on inhibition of various genes by proposed antisense oligonucleotides and needs to be taken into account when considering the mechanism of action of oligonucleotides in biological systems.			FENNEWALD, SM (corresponding author), TRIPLEX PHARMACEUT CORP,9391 GROGANS MILL RD,SUITE A1,THE WOODLANDS,TX 77380, USA.							AZAD RF, 1993, ANTIMICROB AGENTS CH, V37, P1945, DOI 10.1128/AAC.37.9.1945; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BERGAN R, 1994, NUCLEIC ACIDS RES, V22, P2150, DOI 10.1093/nar/22.11.2150; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; COWSERT LM, 1993, ANTIMICROB AGENTS CH, V37, P171, DOI 10.1128/AAC.37.2.171; DEGOLS G, 1991, NUCLEIC ACIDS RES, V19, P945, DOI 10.1093/nar/19.4.945; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; EDELMAN ER, 1994, CIRCULATION, V89, P770, DOI 10.1161/01.CIR.89.2.770; FENNEWALD SM, 1995, ANTIVIR RES, V26, P37, DOI 10.1016/0166-3542(94)00064-F; GAO WY, 1990, J BIOL CHEM, V265, P20172; GAO WY, 1992, MOL PHARMACOL, V41, P223; GAO WY, 1990, ANTIMICROB AGENTS CH, V34, P808, DOI 10.1128/AAC.34.5.808; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOODCHILD J, 1988, P NATL ACAD SCI USA, V85, P5507, DOI 10.1073/pnas.85.15.5507; HUANG RRC, 1990, MOL PHARMACOL, V37, P304; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LISZIEWICZ J, 1993, P NATL ACAD SCI USA, V90, P3860, DOI 10.1073/pnas.90.9.3860; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; MORE RS, 1993, EUR HEART J, V14, P1543, DOI 10.1093/eurheartj/14.11.1543; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NELSON PS, 1989, NUCLEIC ACIDS RES, V17, P7187, DOI 10.1093/nar/17.18.7187; OJWANG J, 1994, J ACQ IMMUN DEF SYND, V7, P560; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PEREZ JR, 1994, P NATL ACAD SCI USA, V91, P5957, DOI 10.1073/pnas.91.13.5957; Praseuth D, 1993, Antisense Res Dev, V3, P33; RAMANATHAN M, 1994, J BIOL CHEM, V269, P24564; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHMID KM, 1993, SEMIN THROMB HEMOST, V19, P155; SETH R, 1993, DEV BIOL, V158, P555, DOI 10.1006/dbio.1993.1213; SHI Y, 1994, CIRCULATION, V90, P944, DOI 10.1161/01.CIR.90.2.944; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VU H, 1991, TETRAHEDRON LETT, V32, P3005, DOI 10.1016/0040-4039(91)80672-S; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; Yaswen P, 1993, Antisense Res Dev, V3, P67	45	58	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21718	21721		10.1074/jbc.270.37.21718	http://dx.doi.org/10.1074/jbc.270.37.21718			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665590	hybrid			2022-12-25	WOS:A1995RU75700048
J	GHISLAIN, J; SUSSMAN, G; GOELZ, S; LING, LE; FISH, EN				GHISLAIN, J; SUSSMAN, G; GOELZ, S; LING, LE; FISH, EN			CONFIGURATION OF THE INTERFERON-ALPHA/BETA RECEPTOR COMPLEX DETERMINES THE CONTEXT OF THE BIOLOGICAL RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; INTERLEUKIN-2 RECEPTOR; EXTRACELLULAR DOMAIN; GAMMA RECEPTOR; HUMAN-CELLS; IFN-ALPHA; GENE; BINDING	Constituents of the Type 1 interferon (IFN) receptor (IFNABR) identified to date include the alpha and beta transmembrane subunits and the associated intracellular kinases, Jak 1 and Tyk 2, In this report, we demonstrate that a human cell type that expresses both subunits of IFNABR, together with Jak 1 and Tyk 2, exhibits a limited binding capacity for and is only partially sensitive to the effects of IFN-alpha/beta, despite adequate levels of the cytoplasmic transcription factors Stat1, Stat2, and Stat3. Specifically, a low affinity interaction between IFN-alpha/beta and cell surface receptors results in ISGF3 (Stat1:2) activation and an antiviral response, yet no IFN-inducible growth inhibition, Using a panel of murine cells that are variably configured with respect to the human IFNABR-alpha/beta subunits, we provide evidence that an additional component(s) encoded on human chromosome 21 is required to confer high affinity binding and IFN-inducible growth inhibition to cells that express the alpha and beta subunits of the IFNABR, The data indicate that transcriptional activation that leads to an antiviral response is mediated by IFN-alpha/beta activation of IFNABR-alpha and IFNABR-beta in the context of a low affinity interaction, yet a high affinity interaction is necessary for signal transducing events that mediate growth inhibition. We provide evidence that the extent of ISGF3 activation correlates directly with the magnitude of an antiviral but not a growth inhibitory response.	UNIV TORONTO,DEPT MICROBIOL,TORONTO,ON M5S 1A8,CANADA; BIOGEN INC,CAMBRIDGE,MA 02142	University of Toronto; Biogen								Aguet M, 1983, Interferon, V5, P1; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BAZAN JF, 1990, P NATL ACAD SCI USA, V18, P6934; BENOIT P, 1993, J IMMUNOL, V150, P707; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLAMONICI OR, 1995, J BIOL CHEM, V270, P8188, DOI 10.1074/jbc.270.14.8188; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1994, J BIOL CHEM, V269, P9598; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EID P, 1983, FEBS LETT, V156, P157, DOI 10.1016/0014-5793(83)80268-3; FALTYNEK CR, 1983, P NATL ACAD SCI-BIOL, V80, P3269, DOI 10.1073/pnas.80.11.3269; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; FISH EN, 1988, VIROLOGY, V165, P87, DOI 10.1016/0042-6822(88)90661-7; FISH EN, 1992, J INTERFERON RES, V12, P257, DOI 10.1089/jir.1992.12.257; FISH EN, 1989, J INTERFERON RES, V9, P97, DOI 10.1089/jir.1989.9.97; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GHISLAIN J, 1994, J IMMUNOL, V153, P3655; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GRAHAM FI, 1979, VIROLOGY, V62, P456; HANNIGAN GE, 1986, EUR J BIOCHEM, V15, P187; HANNIGAN GE, 1984, BIOCHEM BIOPH RES CO, V110, P537; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; JOSHI AR, 1982, J BIOL CHEM, V257, P3884; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KORN AP, 1994, J INTERFERON RES, V14, P1, DOI 10.1089/jir.1994.14.1; LIM JK, 1994, FEBS LETT, V350, P281, DOI 10.1016/0014-5793(94)00787-X; LING L, 1994, J INTERFERON RES, V15, P55; MILLER GT, 1993, J EXP MED, V178, P211, DOI 10.1084/jem.178.1.211; MOGENSEN KE, 1989, EXPERIENTIA, V45, P500, DOI 10.1007/BF01990498; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; RAZ R, 1994, J BIOL CHEM, V269, P24391; Raziuddin A, 1985, Prog Clin Biol Res, V202, P219; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; Stewart W E, 1981, INTERFERON SYSTEM; UZE G, 1991, EUR J IMMUNOL, V21, P447, DOI 10.1002/eji.1830210229; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANDENBROECKE C, 1988, J INTERFERON RES, V8, P803; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681	57	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21785	21792		10.1074/jbc.270.37.21785	http://dx.doi.org/10.1074/jbc.270.37.21785			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665599	hybrid			2022-12-25	WOS:A1995RU75700058
J	LEE, SH; KIM, JC; LEE, MS; HEO, WD; SEO, HY; YOON, HW; HONG, JC; LEE, SY; BAHK, JD; HWANG, I; CHO, MJ				LEE, SH; KIM, JC; LEE, MS; HEO, WD; SEO, HY; YOON, HW; HONG, JC; LEE, SY; BAHK, JD; HWANG, I; CHO, MJ			IDENTIFICATION OF A NOVEL DIVERGENT CALMODULIN ISOFORM FROM SOYBEAN WHICH HAS DIFFERENTIAL ABILITY TO ACTIVATE CALMODULIN-DEPENDENT ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING; NAD KINASE; MONOCLONAL-ANTIBODIES; PLANT CALMODULIN; MESSENGER-RNAS; PROTEIN; EXPRESSION; SEQUENCE; CDNA; GENES	Calmodulin plays pivotal roles in the transduction of various Ca2+-mediated signals and is one of the most highly conserved proteins in eukaryotic cells. In plants, multiple calmodulin isoforms with minor amino acid sequence differences were identified but their functional significances are unknown. To investigate the biological function of calmodulins in the regulation of calmodulin-dependent enzymes, we cloned cDNAs encoding calmodulins in soybean. Among the five cDNAs isolated from soybean, designated as SCam-1 to -5, SCaM-4 and -5 encoded very divergent calmodulin iso forms which have 32 amino acid substitutions from the highly conserved calmodulin, SCaM-1 encoded by SCaM-1 and SCaM-3. SCaM-4 protein produced in Escherichia coli showed typical characteristics of calmodulin such as Ca2+-dependent electrophoretic mobility shift and the ability to activate phosphodiesterase. However, the extent of mobility shift and antigenicity of SCaM-4 were different from those of SCaM-1. Moreover, SCaM-4 did not activate NAD kinase at all in contrast to SCaM-1. Also there were differences in the expression pattern of SCaM-1 and SCaM-4. Expression levels of SCaM-4 were approximately 5-fold lower than those of SCaM-1 in apical and elongating regions of hypocotyls. In addition, SCaM-4 transcripts were barely detectable in root whereas SCaM-1 transcripts were as abundant as in apical and elongating regions of hypocotyls. In conclusion, the different biochemical properties together with differential expression of SCaM-4 suggest that this novel calmodulin may have different functions in plant cells.	GYEONGSANG NATL UNIV,PLANT MOLEC BIOL & BIOTECHNOL RES CTR,CHINJU 660701,SOUTH KOREA; GYEONGSANG NATL UNIV,DEPT BIOCHEM,CHINJU 660701,SOUTH KOREA	Gyeongsang National University; Gyeongsang National University			Cho, Moo Je/F-1649-2010					BARNETT MJ, 1990, NUCLEIC ACIDS RES, V18, P3395, DOI 10.1093/nar/18.11.3395; BOTELLA JR, 1994, PLANT MOL BIOL, V24, P757, DOI 10.1007/BF00029857; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; CHAFOULEAS JG, 1983, METHOD ENZYMOL, V102, P104; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; CHOI YJ, 1993, MOL CELLS, V3, P255; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen P, 1988, CALMODULIN MOL ASPEC, V5; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER R, 1988, J BIOL CHEM, V263, P17055; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; Galea E, 1992, PCR Methods Appl, V2, P66; GAO ZH, 1993, J BIOL CHEM, V268, P20096; GAWIENOWSKI MC, 1993, PLANT MOL BIOL, V22, P215, DOI 10.1007/BF00014930; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HARMON AC, 1984, ANAL BIOCHEM, V141, P168, DOI 10.1016/0003-2697(84)90441-X; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HONG JC, 1989, PLANT CELL, V1, P937, DOI 10.1105/tpc.1.9.937; JABLONSKY PP, 1991, PLANT SCI, V76, P175, DOI 10.1016/0168-9452(91)90139-Y; JENA PK, 1989, P NATL ACAD SCI USA, V86, P3644, DOI 10.1073/pnas.86.10.3644; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1982, GRAFIT VERSION 3 0; LING V, 1992, PLANT PHYSIOL, V100, P970, DOI 10.1104/pp.100.2.970; LING V, 1989, PLANT PHYSIOL, V90, P714, DOI 10.1104/pp.90.2.714; LING V, 1991, PLANT PHYSIOL, V96, P1196, DOI 10.1104/pp.96.4.1196; MEANS AR, 1985, CALCIUM CELL PHYSL, P127; MUTO S, 1977, PLANT PHYSIOL, V59, P55, DOI 10.1104/pp.59.1.55; NOJIMA H, 1989, J MOL BIOL, V208, P269, DOI 10.1016/0022-2836(89)90388-4; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; OTA T, 1994, J MOL EVOL, V38, P642; PERERA IY, 1992, PLANT MOL BIOL, V19, P649, DOI 10.1007/BF00026791; ROBERTS DM, 1986, J BIOL CHEM, V261, P1491; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING LABORATO; SCHACHTELE C, 1988, CALCIUM BINDING PROT, V1, P83; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; WATTERSON DM, 1980, J BIOL CHEM, V255, P962	44	119	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21806	21812		10.1074/jbc.270.37.21806	http://dx.doi.org/10.1074/jbc.270.37.21806			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665602	hybrid			2022-12-25	WOS:A1995RU75700061
J	MARKSITZER, R; STIEF, A; MENOUD, PA; NAGAMINE, Y				MARKSITZER, R; STIEF, A; MENOUD, PA; NAGAMINE, Y			ROLE OF LFB3 IN CELL-SPECIFIC CAMP INDUCTION OF THE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MESSENGER-RNA DEGRADATION; EPIDERMAL GROWTH-FACTOR; NUCLEOTIDE-SEQUENCE; CATALYTIC SUBUNIT; DOWN-REGULATION; LLC-PK1 CELLS; EXPRESSION; REGION; FOS	In previous work we suggested that a kidney specific transcription factor LFB3 cooperates with cAMP-response element (CRE)-binding proteins within a cAMP regulatory unit comprised of three protein-binding domains and located 3.4 kilobase pairs upstream of the urokinase-type plasminogen activator (uPA) gene in LLC-PK1 cells (Menoud, P.-A., Matthies, R., Hofsteenge, J., and Nagamine, Y. (1993) Nucleic Acids Res, 21, 1845-1852). The two domains contain a CRE-like sequence, and the third domain is recognized by LFB3. The absolute requirement of LFB3 as well as the cooperation among the three domains for cAMP regulation were confirmed by transient transfection assays in F9 teratocarcinoma cells, in which the level of LFB3 was negligible. Suspecting a possible feedback regulation of LFB3 mRNA expression during cAMP-dependent uPA gene induction in LLC-PK1 cells, we measured LFB3 mRNA levels after cAMP treatment and found a strong reduction. This reduction was not due to a change in template activity of the LFB3 gene because run-on transcription showed no significant change in LFB3 gene transcription. RNA synthesis inhibitor-chase experiments indicated that the down-regulation was post-transcriptional. Interestingly, when the inhibitor was added at the same time as cAMP, the cAMP-induced decrease in LFB3 mRNA levels was abrogated, suggesting that ongoing RNA synthesis is required for the decrease. Similar effects on LFB3 mRNA metabolism were observed with all agents that induce uPA mRNA in LLC-PK1 cells, including 12-O-tetradecanoylphorbol-13-acetate, okadaic acid, colchicine, and cytochalasin. We discuss the significance of this regulation in uPA gene expression.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								AKASHI M, 1991, BLOOD, V78, P2005; ANDRUS L, 1988, J BIOL CHEM, V263, P6183; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BACH I, 1991, NUCLEIC ACIDS RES, V19, P3553, DOI 10.1093/nar/19.13.3553; BESSER D, 1995, IN PRESS CELL GROWTH; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DELANY AM, 1992, J CELL BIOCHEM, V50, P400, DOI 10.1002/jcb.240500409; DELMAS V, 1994, REV PHYSIOL BIOCH P, V124, P1, DOI 10.1007/BFb0031030; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HECKEL JL, 1990, CELL, V62, P447, DOI 10.1016/0092-8674(90)90010-C; HEMMINGS BA, 1986, FEBS LETT, V196, P126, DOI 10.1016/0014-5793(86)80226-5; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LEE JS, 1994, J BIOL CHEM, V269, P2887; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; MASSON N, 1992, MOL CELL BIOL, V12, P1096, DOI 10.1128/MCB.12.3.1096; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MENOUD PA, 1993, NUCLEIC ACIDS RES, V21, P1845, DOI 10.1093/nar/21.8.1845; NAGAMINE Y, 1991, EMBO J, V10, P117, DOI 10.1002/j.1460-2075.1991.tb07927.x; NAGAMINE Y, 1984, NUCLEIC ACIDS RES, V12, P9525, DOI 10.1093/nar/12.24.9525; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; ROACH AAD, 1994, ADV ENZYME REGUL, V34, P199; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SODERQUIST AM, 1986, J MEMBRANE BIOL, V90, P97, DOI 10.1007/BF01869927; STACEY KJ, 1994, FEBS LETT, V356, P311, DOI 10.1016/0014-5793(94)01294-6; TAMM I, 1978, ADV VIRUS RES, V22, P188; VONDERAHE D, 1990, NUCLEIC ACIDS RES, V18, P1991, DOI 10.1093/nar/18.8.1991; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; ZIEGLER A, 1990, J BIOL CHEM, V265, P21194; ZIEGLER A, 1991, J BIOL CHEM, V266, P21067	50	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21833	21838		10.1074/jbc.270.37.21833	http://dx.doi.org/10.1074/jbc.270.37.21833			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665606	hybrid			2022-12-25	WOS:A1995RU75700065
J	BJORKOY, G; OVERVATN, A; DIAZMECO, MT; MOSCAT, J; JOHANSEN, T				BJORKOY, G; OVERVATN, A; DIAZMECO, MT; MOSCAT, J; JOHANSEN, T			EVIDENCE FOR A BIFURCATION OF THE MITOGENIC SIGNALING PATHWAY ACTIVATED BY RAS AND PHOSPHATIDYLCHOLINE-HYDROLYZING PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; XENOPUS-LAEVIS OOCYTES; NF-KAPPA-B; RAF-1 KINASE; ONCOGENIC P21(RAS); ALPHA-THROMBIN; ZETA-ISOFORM; IN-VITRO; CELLS	NIH 3T3 cells stably transfected with the gene encoding phosphatidylcholine-hydrolyzing phospholipase C (PC-PLC) from Bacillus cereus display a chronic elevation of intracellular diacylglycerol levels and a transformed phenotype, We have used such PC-PLC-transformed cells to evaluate the roles of the cytoplasmic serine/threonine kinases Raf-1, zeta protein kinase C (zeta PKC) and protein kinase A (PKA) in oncogenesis and mitogenic signal transduction elicited by phosphatidylcholine hydrolysis, We demonstrate here that stable expression of dominant negative mutants of both zeta PKC and Raf-1 lead to reversion of PC-PLC-transformed cells, Interestingly, expression of kinase defective zeta PKC also reverted NIH 3T3 cells transformed by the v-Ha-ras oncogene, Activation of PKA in response to elevation of cAMP levels also lead to reversion of PC-PLC-induced transformation, implicating PKA as a negative regulator acting downstream of PC-PLC, On the other hand, inhibition or depletion of phorbol ester responsive PKCs attenuated but did not block the ability of PC-PLC-transformed cells to induce DNA synthesis in the absence of growth factors, These results clearly implicate both Raf-1 and zeta PKC as necessary downstream components for transduction of the mitogenic/oncogenic signal generated by PLC-mediated hydrolysis of phosphatidylcholine and suggest, together with other recent evidence, a bifurcation in the signaling pathway downstream of PC-PLC.	UNIV TROMSO,INST MED BIOL,DEPT BIOCHEM,N-9037 TROMSO,NORWAY; UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,E-28049 MADRID,SPAIN	UiT The Arctic University of Tromso; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Moscat, Jorge/A-7011-2009; Johansen, Terje/N-2971-2015	Johansen, Terje/0000-0003-1451-9578; Bjorkoy, Geir/0000-0003-0031-8361; Diaz-Meco, Maria/0000-0003-0147-0998				BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIAZMECO MT, 1995, J BIOL CHEM, V269, P31706; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; JOHANSEN T, 1994, MOL CELL BIOL, V14, P646, DOI 10.1128/MCB.14.1.646; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1994, J BIOL CHEM, V269, P17495; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; PRICE BD, 1989, J BIOL CHEM, V264, P16638; QUERESCHI SA, 1993, BIOCHEM BIOPH RES CO, V192, P969; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SANZ L, 1994, J BIOL CHEM, V269, P10044; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SOZERI O, 1992, ONCOGENE, V7, P2259; STEPHENS EV, 1993, ONCOGENE, V8, P19; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WRIGHT TM, 1992, BIOCHEM J, V285, P395, DOI 10.1042/bj2850395; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XU XX, 1993, MOL CELL BIOL, V13, P1522, DOI 10.1128/MCB.13.3.1522; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	61	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21299	21306						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673165				2022-12-25	WOS:A1995RU05400066
J	SEKLER, I; KOPITO, R; CASEY, JR				SEKLER, I; KOPITO, R; CASEY, JR			HIGH-LEVEL EXPRESSION, PARTIAL-PURIFICATION, AND FUNCTIONAL RECONSTITUTION OF THE HUMAN AE1 ANION-EXCHANGER IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; HIGH-EFFICIENCY TRANSFORMATION; HUMAN ERYTHROCYTE-MEMBRANE; INTACT YEAST-CELLS; PLASMA-MEMBRANE; TRANSPORT PROTEIN; DIRECTED MUTAGENESIS; BAND-3 PROTEIN; CLONING; DEGLYCOSYLATION	Human erythroid anion exchanger AE1 (Band 3) was expressed in the yeast Saccharomyces cerevisiae under the control of the constitutive promoter and transcriptional terminator of the yeast phosphoglycerate kinase gene, AE1 expression in stable yeast transformants was estimated to be approximately 0.7 mg AE1 per liter, Density gradient sedimentation analysis indicated that the AE1 protein was associated with a membrane fraction distinct from plasma membrane, most likely the endoplasmic reticulum. AE1 protein was solubilized from yeast membranes with lysophosphatidyl choline, and the protein, tagged with six histidines at its amino terminus, was purified to 35% homogeneity by metal chelation affinity chromatography, Size-exclusion chromatography in the presence of octaethylene glycol monododecyl ether indicated that the solubilized yeast-expressed AE1, like endogenous erythroid AE1, eluted at a stokes radius of 77 Angstrom, consistent with a dimeric oligomeric state, Binding of partially purified yeast expressed AE1 to 4-acetamido-4'-isothiocyanostilbene-2,2'-disulfonate resin was competitive with the transportable substrate chloride but not the nontransported anion citrate, suggesting that the structure of the anion binding site is preserved, The specific activity of sulfate transport by partially purified yeast AE1 was determined in proteoliposomes to be similar to that of authentic AE1 purified from erythrocyte membranes, These data show that this expression system has the capacity to produce functional mammalian plasma membrane anion exchangers at levels sufficient for biochemical and biophysical analysis.	STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA	Stanford University			Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; BARTEL D, 1989, EMBO J, V8, P3601, DOI 10.1002/j.1460-2075.1989.tb08533.x; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P207, DOI 10.1007/BF01870088; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CASEY JR, 1995, J BIOL CHEM, V270, P8521, DOI 10.1074/jbc.270.15.8521; CASEY JR, 1992, J BIOL CHEM, V267, P11940; CASEY JR, 1994, BIOCH CELL BIOL, V71; CASEY JR, 1989, METHOD ENZYMOL, V173, P494; EALKE KA, 1992, J BIOL CHEM, V89, P2834; EBLE R, 1992, BIOTECHNIQUES, V13, P18; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FALKE JJ, 1986, BIOCHEMISTRY-US, V25, P7888, DOI 10.1021/bi00372a015; FERREIRA GC, 1992, J BIOL CHEM, V267, P5460; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; HE XJ, 1993, AM J PHYSIOL, V264, pC1075, DOI 10.1152/ajpcell.1993.264.4.C1075; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOLZER KP, 1989, J BIOL CHEM, V264, P14389; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1991, J BIOL CHEM, V266, P11448; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MELLOR J, 1983, GENE, V24, P1, DOI 10.1016/0378-1119(83)90126-9; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; OKUBO K, 1994, J BIOL CHEM, V269, P1918; PIMPLIKAR SW, 1988, BIOCHIM BIOPHYS ACTA, V942, P253, DOI 10.1016/0005-2736(88)90027-2; PIMPLIKAR SW, 1986, J BIOL CHEM, V261, P9770; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; ROTH M, 1989, NATURE, V340, P659, DOI 10.1038/340659a0; RUETZ S, 1994, J BIOL CHEM, V269, P12277; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHNEIDER JC, 1991, METHOD ENZYMOL, V194, P373; SEKLER I, 1995, J BIOL CHEM, V270, P11251, DOI 10.1074/jbc.270.19.11251; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; THOMAS HA, 1989, AM J PHYSIOL, V26, pC537; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUITE MF, 1982, EMBO J, V1, P603, DOI 10.1002/j.1460-2075.1982.tb01215.x; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x	54	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21028	21034		10.1074/jbc.270.36.21028	http://dx.doi.org/10.1074/jbc.270.36.21028			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673129	hybrid			2022-12-25	WOS:A1995RU05400026
J	THOMAS, JL; FRIEDEN, C; NASH, WE; STRICKLER, RC				THOMAS, JL; FRIEDEN, C; NASH, WE; STRICKLER, RC			AN NADH-INDUCED CONFORMATIONAL CHANGE THAT MEDIATES THE SEQUENTIAL 3-BETA-HYDROXYSTEROID DEHYDROGENASE/ISOMERASE ACTIVITIES IS SUPPORTED BY AFFINITY LABELING AND THE TIME-DEPENDENT ACTIVATION OF ISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL 3-BETA-HYDROXY-5-ENE-STEROID DEHYDROGENASE; COLI DIHYDROFOLATE-REDUCTASE; STEROID 5->4-ENE-ISOMERASE; 3-BETA-HYDROXY-DELTA-5-STEROID DEHYDROGENASE; 5-ENE-4-ENE ISOMERASE; SUBSTRATE-BINDING; ACTIVE-SITE; PURIFICATION; PROTEIN; 5'-DIPHOSPHATE	3 beta-Hydroxysteroid dehydrogenase (3 beta-HSD) and steroid Delta-isomerase were copurified as a single protein from human placental microsomes, Because NADH is an essential activator of isomerase (K-act = 2.4 mu M, V-max = 0.6 mu mol/min/mg), the affinity alkylating nucleotide, 8-[(4-bromo-2,3- dioxobutyl)thio]adenosine 5'-diphosphate (8-BDB-TADP), was synthesized. 8-BDB-TADP activates isomerase (K-act = 338 mu M, V-max = 2.1 mu mol/min/mg) prior to inactivating the enzyme, The inactivation kinetics for isomerase fit the Kitz and Wilson model for time-dependent, irreversible inhibition by 8-BDB-TADP (K-I = 314 mu M, first order maximal rate constant k(obs) = 7.8 x 10(-3) s(-1)). NADH (50 mu M) significantly protects isomerase from inactivation by 8-BDB-TADP (100 mu M) The isomerase activity is inactivated more rapidly by 8-BDB-TADP as the concentration of the affinity alkylator increases from 67 mu M (t(1/2) = 8.4 min) to 500 mu M (t(1/2) = 2.4 min), In sharp contrast, the 3 beta-HSD activity is inactivated more slowly as the concentration of 8-BDB-TADP increases from 67 mu M (t(1/2) = 4.8 min) to 500 mu M (t(1/2) = 60.0 min), We hypothesized that the paradoxical kinetics of 3 beta-HSD inactivation is a consequence of the activation of isomerase by 8-BDB-TADP via a nucleotide induced shift in enzyme conformation, Biophysical support for an NADH-induced conformational change was obtained using stopped-flow fluorescence spectroscopy. The binding of NADH (10 mu M) quenches the intrinsic fluorescence of the enzyme protein in a time-dependent manner (rate constant k(app) = 8.1 X 10(-3) s(-1), t(1/2) = 85 s), A time lag is also observed for the activation of isomerase by NADH, This combination of affinity labeling and biophysical data using nucleotide derivatives supports our model for the sequential reaction mechanism; the cofactor product of the 3 beta-HSD reaction, NADH, activates isomerase by inducing a conformational change in the single, bifunctional enzyme protein,	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)	THOMAS, JL (corresponding author), WASHINGTON UNIV,SCH MED,DEPT OBSTET & GYNECOL,4911 BARNES HOSP PL,ST LOUIS,MO 63110, USA.				NICHD NIH HHS [HD-20055, R01 HD020055] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020055] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAILEY JM, 1987, J BIOL CHEM, V262, P12620; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLMAN RF, 1984, BIOCHEMISTRY-US, V23, P3281, DOI 10.1021/bi00309a025; DECAMP DL, 1988, BIOCHEMISTRY-US, V27, P7651, DOI 10.1021/bi00420a012; FRIEDEN C, 1990, P NATL ACAD SCI USA, V87, P4413, DOI 10.1073/pnas.87.12.4413; ISHIIOHBA H, 1986, J STEROID BIOCHEM, V25, P555; ISHIIOHBA H, 1986, J STEROID BIOCHEM, V24, P753; KITZ R, 1962, J BIOL CHEM, V237, P3245; LUUTHE V, 1991, BIOCHEMISTRY-US, V30, P8861; PENNER MH, 1985, J BIOL CHEM, V260, P5366; RUTHERFURD KJ, 1991, BIOCHEMISTRY-US, V30, P8108, DOI 10.1021/bi00247a003; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; STRICKLER RC, 1993, AM J OBSTET GYNECOL, V168, P1216, DOI 10.1016/0002-9378(93)90372-P; THOMAS JL, 1991, J STEROID BIOCHEM, V39, P471, DOI 10.1016/0960-0760(91)90240-6; THOMAS JL, 1988, J STEROID BIOCHEM, V31, P785, DOI 10.1016/0022-4731(88)90287-7; THOMAS JL, 1993, J BIOL CHEM, V268, P18507; THOMAS JL, 1989, J STEROID BIOCHEM, V33, P209, DOI 10.1016/0022-4731(89)90296-3; THOMAS JL, 1994, J SOC GYNECOL INVEST, V1, P155, DOI 10.1177/107155769400100211; THOMAS JL, 1990, J STEROID BIOCHEM, V36, P117, DOI 10.1016/0022-4731(90)90121-8; THOMAS JL, 1992, BIOCHEMISTRY-US, V31, P5522, DOI 10.1021/bi00139a014	20	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21003	21008		10.1074/jbc.270.36.21003	http://dx.doi.org/10.1074/jbc.270.36.21003			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673125	hybrid			2022-12-25	WOS:A1995RU05400022
J	KEYOMARSI, K; CONTE, D; TOYOFUKU, W; FOX, MP				KEYOMARSI, K; CONTE, D; TOYOFUKU, W; FOX, MP			DEREGULATION OF CYCLIN-E IN BREAST-CANCER	ONCOGENE			English	Article						BREAST CANCER; CELL CYCLE; CYCLIN E; ALTERNATIVE SPLICING	CELL-CYCLE; CANDIDATE ONCOGENE; ESOPHAGEAL CANCER; EXPRESSION; OVEREXPRESSION; PROTEIN; GENE; AMPLIFICATION; FIBROBLASTS; PHASE	Cyclin E, a regulatory subunit of cyclin dependent kinase-2, is thought to be rate limiting for the G1/S transition during the mammalian cell cycle. Previously, we showed severe alterations in cyclin E protein expression in human mammary epithelial cell lines and in surgical material obtained from patients with various malignancies. To understand the functional basis of these alterations we analyse here the regulation of cyclin E in breast cancer cells. We find that while cyclin E protein and its associated kinase activity in normal cells are cell cycle regulated, in tumor cells it remains in an active complex throughout the cell cycle. We also analysed cyclin E for possible deletions which could result in its constitutive function and found two novel truncated variants in its coding region. These variant forms of cyclin E were detected in several normal and tumor cell lines and tissue specimens. However, Western blot analysis indicated that only the multiple isoforms of cyclin E protein were expressed in tumor but not the normal tissue specimen, suggesting post transcriptional regulation of cyclin E. Lastly, in vitro analyses indicated that these truncated variant forms of cyclin E are biochemically active in their ability to phosphorylate histone H1. Collectively these observations suggest the presence of more than one form of cyclin E mRNA in all cells, normal and tumor. Once translated in tumor cells, the protein products of these truncated forms could give rise to a constitutively active form of cyclin E containing complexes.			KEYOMARSI, K (corresponding author), WADSWORTH CTR, DIV MOLEC MED, DIAGNOST ONCOL LAB, ALBANY, NY 12201 USA.		Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849				BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CRISSMAN HA, 1974, SCIENCE, V184, P1297, DOI 10.1126/science.184.4143.1297; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEACH FS, 1993, CANCER RES, V53, P1986; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOVEC H, 1994, ONCOGENE, V9, P323; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; SEWING A, 1994, J CELL SCI, V107, P581; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOULE HD, 1990, CANCER RES, V50, P6075; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	48	228	232	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					941	950						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675453				2022-12-25	WOS:A1995RU79800015
J	STRANICK, KS; PAYVANDI, F; ZAMBAS, DN; UMLAND, SP; EGAN, RW; BILLAH, MM				STRANICK, KS; PAYVANDI, F; ZAMBAS, DN; UMLAND, SP; EGAN, RW; BILLAH, MM			TRANSCRIPTION OF THE MURINE INTERLEUKIN-5 GENE IS REGULATED BY MULTIPLE PROMOTER ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; CIS-ACTING ELEMENT; T-CELLS; DIFFERENTIAL REGULATION; BINDING-PROTEINS; CDNA CLONE; GM-CSF; EXPRESSION; MOUSE; IL-4	Cis-acting regions in the 5'-flank of the mouse interleukin 5 (IL-5) gene involved in the specific and inducible regulation of IL-5 transcription in an untransformed mouse T cell clone, D10.G4.1, have been identified. Transient transfection assays with a series of deletion IL-5 promoter reporter constructs indicate that multiple regulatory elements in the 5'-flanking region of the IL-5 promoter play a role in regulating IL-5 transcription in Th2 cells. Negatively acting elements, NRE I and NRE II, map to the regions between positions -431 and -392 and positions -300 and -261. A positive regulatory element has been mapped to the region between positions -224 and -81. The activity of these elements is dependent on activation of the cells. A 40-bp sequence within this region, termed the IL-5 PRE, has been shown to bind at least two specific nuclear protein complexes from unstimulated and stimulated D10.G4.1 cells. An additional protein complex specific for this site has been identified in nuclear fractions from cells stimulated in the presence of the protein synthesis inhibitor, cycloheximide. Proteins that bind to these elements are likely to be important inducible and specific factors essential for control of IL-5 transcription in response to T cell receptor-mediated signaling events.			STRANICK, KS (corresponding author), SCHERING PLOUGH CORP, RES INST, DEPT ALLERGY, KENILWORTH, NJ 07033 USA.							ABRAMS JS, 1992, IMMUNOL REV, V127, P5, DOI 10.1111/j.1600-065X.1992.tb01406.x; BOHJANEN PR, 1990, P NATL ACAD SCI USA, V87, P5283, DOI 10.1073/pnas.87.14.5283; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUHN KW, 1993, P NATL ACAD SCI USA, V90, P9707, DOI 10.1073/pnas.90.20.9707; CAMPBELL HD, 1988, EUR J BIOCHEM, V174, P345, DOI 10.1111/j.1432-1033.1988.tb14104.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GAJEWSKI TF, 1989, IMMUNOL REV, V111, P79, DOI 10.1111/j.1600-065X.1989.tb00543.x; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.me.44.020193.000505; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; LEDERER JA, 1994, J IMMUNOL, V152, P77; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LEE HJ, 1993, J IMMUNOL, V151, P6135; LIWEBER M, 1993, J IMMUNOL, V151, P1371; Lund P K, 1994, Growth Regul, V4 Suppl 1, P1; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MCCAFFREY PG, 1994, NUCLEIC ACIDS RES, V22, P2134, DOI 10.1093/nar/22.11.2134; MIN LW, 1992, J IMMUNOL, V148, P1913; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUNOZ E, 1989, P NATL ACAD SCI USA, V86, P9461, DOI 10.1073/pnas.86.23.9461; NAORA H, 1994, J IMMUNOL, V153, P3466; NAORA H, 1994, BLOOD, V83, P3620; NAORA H, 1994, J IMMUNOL, V152, P5691; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; PARK JH, 1993, J BIOL CHEM, V268, P6299; Sambrook J, 1989, MOL CLONING LABORATO; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; STAYNOV DZ, 1992, IMMUNOLOGY, V75, P196; SZABO SJ, 1993, MOL CELL BIOL, V13, P4973; TAMURA T, 1993, J IMMUNOL, V151, P6051; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; TOKUMITSU H, 1993, BIOCHEM BIOPH RES CO, V196, P737, DOI 10.1006/bbrc.1993.2311; VANDERPOUWKRAAN T, 1992, EUR J IMMUNOL, V22, P1237, DOI 10.1002/eji.1830220519; VANSTRAATEN JFM, 1994, CYTOKINE, V6, P229, DOI 10.1016/1043-4666(94)90017-5; WOLFF CHJ, 1993, J IMMUNOL, V151, P1337; YOKOTA T, 1987, P NATL ACAD SCI USA, V84, P7388, DOI 10.1073/pnas.84.21.7388; YOKOTA T, 1984, P NATL ACAD SCI-BIOL, V81, P1070, DOI 10.1073/pnas.81.4.1070	51	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20575	20582		10.1074/jbc.270.35.20575	http://dx.doi.org/10.1074/jbc.270.35.20575			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657635	hybrid			2022-12-25	WOS:A1995RR58400054
J	VEKSLER, VI; KUZNETSOV, AV; ANFLOUS, K; MATEO, P; VANDEURSEN, J; WIERINGA, B; VENTURACLAPIER, R				VEKSLER, VI; KUZNETSOV, AV; ANFLOUS, K; MATEO, P; VANDEURSEN, J; WIERINGA, B; VENTURACLAPIER, R			MUSCLE CREATINE KINASE-DEFICIENT MICE .2. CARDIAC AND SKELETAL-MUSCLES EXHIBIT TISSUE-SPECIFIC ADAPTATION OF THE MITOCHONDRIAL-FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR DIFFUSION; SARCOPLASMIC-RETICULUM; ENERGY-METABOLISM; OUTER-MEMBRANE; RAT-HEART; PHOSPHOCREATINE; PHOSPHOKINASE; ADP; CARDIOMYOCYTES; RESPIRATION	Functional properties of in situ mitochondria and of mitochondrial creatine kinase were studied in saponin-skinned fibers taken from normal and M-creatine kinase-deficient mice. In control animals, apparent K-m values of mitochondrial respiration for ADP in cardiac (ventricular) and slow-twitch (soleus) muscles (137 +/- 16 mu M and 209 +/- 10 mu M, respectively) were manyfold higher than that in fast-twitch (gastrocnemius) muscle (7.5 +/- 0.5 mu M). Creatine substantially decreased the K-m values only in cardiac and slow-twitch muscles (73 +/- 11 mu M and 131 +/- 21 mu M, respectively), As compared to control, in situ mitochondria in transgenic ventricular and slow-twitch muscles showed two times lower K-m values for ADP, and the presence of creatine only slightly decreased the K-m values, In mutant fast-twitch muscle, a decrease rather than increase in mitochondrial sensitivity to ADP occurred, but creatine still had no effect. Furthermore, in these muscles, relatively low oxidative capacity was considerably elevated, It is suggested that in the mutant mice, impairment of energy transport function in ventricular and slow-twitch muscles is compensated by a facilitation of adenine nucleotide transportation between mitochondria and cellular ATPases; in fast-twitch muscle, mainly energy buffering function is depressed, and that is overcome by an increase in energy-producing potential.	UNIV NIJMEGEN,FAC MED SCI,DEPT HISTOL & CELL BIOL,6500 HB NIJMEGEN,NETHERLANDS; CARDIOL RES CTR,MOSCOW 121552,RUSSIA	Radboud University Nijmegen; National Medical Research Center of Cardiology	VEKSLER, VI (corresponding author), UNIV PARIS SUD,FAC PHARM,INSERM,CJF9211,CARDIOL CELLULAIRE & MOLEC LAB,F-92296 CHATENAY MALABRY,FRANCE.		Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020; Ventura-Clapier, Renee/0000-0002-7488-4123; Veksler, Vladimir/0000-0002-8869-9594				AWAJI Y, 1990, CARDIOVASC RES, V24, P547, DOI 10.1093/cvr/24.7.547; BASKIN RJ, 1970, J BIOL CHEM, V245, P1345; BYGRAVE FL, 1967, P NATL ACAD SCI USA, V57, P1409, DOI 10.1073/pnas.57.5.1409; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHEVLI R, 1979, BIOCHEM MED METAB B, V21, P162, DOI 10.1016/0006-2944(79)90068-1; CLARK JF, 1994, BIOCHEM J, V300, P211, DOI 10.1042/bj3000211; FIELD ML, 1994, CARDIOVASC RES, V28, P86, DOI 10.1093/cvr/28.1.86; FITCH CD, 1974, J BIOL CHEM, V249, P1060; FREYSSENET D, 1994, BBA-BIOENERGETICS, V1186, P232, DOI 10.1016/0005-2728(94)90182-1; GELLERICH FN, 1993, BIOCHIM BIOPHYS ACTA, V1142, P217, DOI 10.1016/0005-2728(93)90150-E; JACOBUS WE, 1985, BIOCHEM BIOPH RES CO, V133, P1035, DOI 10.1016/0006-291X(85)91240-9; JACOBUS WE, 1985, ANNU REV PHYSIOL, V47, P707; JOCKERSWRETOU E, 1977, HISTOCHEMISTRY, V54, P83, DOI 10.1007/BF00493332; KUSHMERICK MJ, 1992, AM J PHYSIOL, V263, pC598, DOI 10.1152/ajpcell.1992.263.3.C598; LEVITSKY DO, 1978, MEMBRANE BIOCHEM, V2, P81, DOI 10.3109/09687687809063859; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; PHILIPPI M, 1994, J EXP BIOL, V189, P1; POPOVICH BK, 1989, AM J PHYSIOL, V257, pE573, DOI 10.1152/ajpendo.1989.257.4.E573; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; SAKS VA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P134, DOI 10.1016/0005-2728(93)90166-D; SAKS VA, 1991, BIOCHIM BIOPHYS ACTA, V1074, P302, DOI 10.1016/0304-4165(91)90168-G; SAVABI F, 1991, J MOL CELL CARDIOL, V23, P1323, DOI 10.1016/0022-2828(91)90089-5; SEPPET EK, 1991, J APPL CARDIOL, V6, P301; SHAROV VG, 1977, BIOCHIM BIOPHYS ACTA, V468, P495, DOI 10.1016/0005-2736(77)90299-1; SHOUBRIDGE EA, 1985, BIOCHEM J, V232, P125, DOI 10.1042/bj2320125; TURNER DC, 1973, P NATL ACAD SCI USA, V70, P702, DOI 10.1073/pnas.70.3.702; VANDEURSEN J, 1992, NUCLEIC ACIDS RES, V20, P3815, DOI 10.1093/nar/20.15.3815; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VEKSLER V, 1994, J MOL CELL CARDIOL, V26, P335, DOI 10.1006/jmcc.1994.1042; VEKSLER VI, 1987, BIOCHIM BIOPHYS ACTA, V892, P191, DOI 10.1016/0005-2728(87)90174-5; VENTURACLAPIER R, 1995, J BIOL CHEM, V270, P19914, DOI 10.1074/jbc.270.34.19914; WALLIMANN T, 1994, CURR BIOL, V4, P42, DOI 10.1016/S0960-9822(00)00008-7; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WILLIMANN T, 1977, J CELL BIOL, V75, P297; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; YAMASHITA K, 1991, J MUSCLE RES CELL M, V12, P37, DOI 10.1007/BF01781172	36	158	162	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19921	19929		10.1074/jbc.270.34.19921	http://dx.doi.org/10.1074/jbc.270.34.19921			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650007	Green Published, hybrid			2022-12-25	WOS:A1995RQ99100039
J	KAMIYA, H; KASAI, H				KAMIYA, H; KASAI, H			FORMATION OF 2-HYDROXYDEOXYADENOSINE TRIPHOSPHATE, AN OXIDATIVELY DAMAGED NUCLEOTIDE, AND ITS INCORPORATION BY DNA-POLYMERASES - STEADY-STATE KINETICS OF THE INCORPORATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-PAIR; 8-HYDROXYGUANINE; SEQUENCES; INSERTION; PROTEIN; RAS	We found that hydroxylation occurs at the C-2 position of adenine by oxygen radical treatment (Fe2+-EDTA) of dA, dATP, and single- and double-stranded DNA. This oxidatively damaged base, 2-hydroxyadenine, was produced 3-6-fold and 40-fold less than 8-hydroxyguanine when monomers and polynucleotides, respectively, were treated. To determine whether the damaged nucleotide, 2-hydroxydeoxyadenosine triphosphate (2-OH-dATP), is incorporated into a growing DNA, and to reveal the kinds of nucleotides opposite which 2-OH-dATP is incorporated, calf thymus DNA polymerase alpha and the Klenow fragment of Escherichia coli DNA polymerase I were used in in vitro DNA synthesis in the presence of 2-OH-dATP. DNA polymerase alpha incorporated the nucleotide opposite T and C in the DNA template. On the other hand, in an experiment using the Klenow fragment, incorporation of 2-OH-dATP was observed only opposite T. Steady-state kinetic studies indicated that incorporation of 2-OH-dATP by DNA polymerase alpha opposite T was favored over that opposite C by a factor of only 4.5, These results indicate that 2-OH-dATP, an oxidatively damaged nucleotide, is a substrate for DNA polymerases and is incorporated incorrectly by the replicative DNA polymerase.	UNIV OCCUPAT & ENVIRONM HLTH,INST IND ECOL SCI,DEPT ENVIRONM ONCOL,YAKAHTANISHI KU,KITAKYUSHU,FUKUOKA 807,JAPAN	University of Occupational & Environmental Health - Japan			Kamiya, Hiroyuki/G-2383-2019	Kamiya, Hiroyuki/0000-0001-6866-5322				CHENG KC, 1992, J BIOL CHEM, V267, P166; DAVOLL J, 1951, J AM CHEM SOC, V73, P3174, DOI 10.1021/ja01151a052; DOSANJH MK, 1991, BIOCHEMISTRY-US, V30, P11595, DOI 10.1021/bi00113a015; FERSHT A, 1977, ENZYME STRUCTURE MEC, P91; KAMIYA H, 1995, CARCINOGENESIS, V16, P883, DOI 10.1093/carcin/16.4.883; KAMIYA H, 1992, CANCER RES, V52, P3483; KAMIYA H, 1995, NUCLEIC ACIDS RES, V23, P761, DOI 10.1093/nar/23.5.761; KAMIYA H, 1992, CHEM PHARM BULL, V40, P2792, DOI 10.1248/cpb.40.2792; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; NOFRE C, 1961, B SOC CHIM FR, V5, P530; PURMAL AA, 1994, NUCLEIC ACIDS RES, V22, P3930, DOI 10.1093/nar/22.19.3930; SEPIOL J, 1976, Z NATURFORSCH C, V31, P361; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SWITZER C, 1989, J AM CHEM SOC, V111, P8322, DOI 10.1021/ja00203a067; SWITZER CY, 1993, BIOCHEMISTRY-US, V32, P10489, DOI 10.1021/bi00090a027; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	20	146	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19446	19450		10.1074/jbc.270.33.19446	http://dx.doi.org/10.1074/jbc.270.33.19446			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642627				2022-12-25	WOS:A1995RP70300041
J	STOREY, A; MASSIMI, P; DAWSON, K; BANKS, L				STOREY, A; MASSIMI, P; DAWSON, K; BANKS, L			CONDITIONAL IMMORTALIZATION OF PRIMARY-CELLS BY HUMAN PAPILLOMAVIRUS TYPE-18 E6 AND EJ-RAS DEFINES AN E6 ACTIVITY IN G(0)/G(1) PHASE WHICH CAN BE SUBSTITUTED FOR MUTATIONS IN P53	ONCOGENE			English	Article						HPV; CELL CYCLE; CHECKPOINT; P53	RETINOBLASTOMA GENE-PRODUCT; CELLULAR TUMOR-ANTIGEN; DNA-BINDING FUNCTION; PRIMARY MOUSE CELLS; TRANSFORMING ACTIVITY; HUMAN KERATINOCYTES; CERVICAL-CARCINOMA; TRANSCRIPTION FACTOR; ADENOVIRUS E1A; E7 FUNCTIONS	The human papillomavirus (HPV) type 18 E6 gene cooperates with activated Ha-ras to immortalize primary mouse cells in culture. Using a plasmid where HPV18 E6 expression is regulated by the glucocorticoid inducible MMTV LTR, we have generated immortalized cell lines in which the continued expression of E6 was necessary for maintenance of the transformed phenotype. In the absence of exogenously added hormone these cells were found to arrest in G(0)/G(1). Furthermore, we demonstrate that the effects of E6 were essentially p53 independent and therefore define a novel function by which E6 is able to modulate cell proliferation. In addition, when the E6 dependent cells were maintained under conditions of prolonged growth arrest by the removal of E6, revertant cells were isolated which were no longer dependent on E6 expression for continued proliferation. These revertant cells were found to have acquired a mutation in the cellular gene p53, suggesting that certain p53 mutations are dominant over an E6 requirement in this assay.	ROYAL LONDON HOSP, DEPT EXPTL DERMATOL, IMPERIAL CANC RES FUND, SKIN TUMOUR LAB, LONDON E1 2BL, ENGLAND	Barts Health NHS Trust; Royal London Hospital; Cancer Research UK	STOREY, A (corresponding author), INT CTR GENET ENGN & BIOTECHNOL, AREA SCI PK, PADRICIANO 99, I-34012 TRIESTE, ITALY.			Storey, Alan/0000-0003-2001-9772				ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; ANSORGE W, 1982, EXP CELL RES, V140, P31, DOI 10.1016/0014-4827(82)90152-5; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANKS L, 1988, VIROLOGY, V165, P326, DOI 10.1016/0042-6822(88)90695-2; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1990, ONCOGENE, V5, P833; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KEEN N, 1994, ONCOGENE, V9, P1493; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATLASHEWSKI G, 1987, CANCER CELL, V5, P195; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MOSNER J, 1994, ONCOGENE, V9, P3321; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1991, ONCOGENE, V6, P589; PIM D, 1994, ONCOGENE, V9, P1869; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; STOREY A, 1994, KERATINOCYTE HDB, P439; TAYLOR IW, 1980, J HISTOCHEM CYTOCHEM, V28, P1021, DOI 10.1177/28.9.6157714; THOMAS M, 1995, ONCOGENE, V10, P261; TSUNOKAWA Y, 1986, P NATL ACAD SCI USA, V83, P2200, DOI 10.1073/pnas.83.7.2200; VANDENBRULE AJC, 1989, J MED VIROL, V29, P20, DOI 10.1002/jmv.1890290105; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986	76	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					653	661						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651728				2022-12-25	WOS:A1995RQ46900006
J	COLE, F; FASY, TM; RAO, SS; DEPERALTA, MA; KOHTZ, DS				COLE, F; FASY, TM; RAO, SS; DEPERALTA, MA; KOHTZ, DS			GROWTH-FACTORS THAT REPRESS MYOBLAST DIFFERENTIATION SUSTAIN PHOSPHORYLATION OF A SPECIFIC SITE ON HISTONE-H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC ENHANCER; DNA-BINDING; RNA GENES; TRANSCRIPTIONAL ACTIVATION; MYOGENIC DIFFERENTIATION; CHROMATIN; PROTEINS; INVITRO; SEQUENCE; STATES	A monoclonal antibody (12D11) is presented that binds an epitope on histone H1 only when it is phosphorylated. Skeletal myoblasts, which are cultured in high mitogen medium to induce proliferation and inhibit differentiation, contain histone HI reactive with monoclonal antibody 12D11, whereas differentiated myocytes and adult skeletal muscle do not. Phosphorylation of H1 at the 12D11 epitope, as assessed by antibody binding, is also induced and maintained in myoblasts cultured in low mitogen medium supplemented with transforming growth factor beta, which blocks differentiation but allows the cells to withdraw from the cell cycle (Olson, E., Sternberg, E., Hu, J., Spizz, G., and Wilcox, C. (1986) J. Cell Biol. 103, 1799-1805; Massague, J., Cheipetz, S., Endo, T., and Nadal-Ginard, B. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 8206-8210). These observations suggest that phosphorylation of histone H1 at the 12D11 epitope is associated with the negative regulation of myoblast differentiation by growth factors.	CUNY MT SINAI SCH MED,DEPT PATHOL,1 GUSTAVE LEVY PL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai				Cole, Francesca/0000-0001-6391-2363	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040659, R01HL043583] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43583, HL40659] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AJIRO K, 1990, J BIOL CHEM, V265, P6494; AJIRO K, 1981, BIOCHEMISTRY-US, V20, P1445, DOI 10.1021/bi00509a007; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; FASY TM, 1979, BIOCHIM BIOPHYS ACTA, V564, P322, DOI 10.1016/0005-2787(79)90229-6; Feghali Rebecca, 1992, Gene Expression, V2, P49; FELSENFELD G, 1992, NATURE, V355, P218; GOSPODAROWICZ D, 1976, J CELL BIOL, V70, P395, DOI 10.1083/jcb.70.2.395; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HASHIMOTO S, 1984, P NATL ACAD SCI-BIOL, V81, P6637, DOI 10.1073/pnas.81.21.6637; JERZMANOWSKI A, 1990, J BIOL CHEM, V265, P10726; KOHTZ DS, 1987, J CELL BIOL, V104, P897, DOI 10.1083/jcb.104.4.897; KONIGSBERG IR, 1963, SCIENCE, V140, P1273, DOI 10.1126/science.140.3573.1273; KONIGSBERG IR, 1978, DEV BIOL, V63, P11, DOI 10.1016/0012-1606(78)90109-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1969, P NATL ACAD SCI USA, V64, P1276, DOI 10.1073/pnas.64.4.1276; LANGAN TA, 1968, SCIENCE, V162, P579, DOI 10.1126/science.162.3853.579; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI L, 1992, GENE DEV, V6, P76; LIN RL, 1991, GENE DEV, V5, P1601, DOI 10.1101/gad.5.9.1601; LINKHART TA, 1980, J SUPRAMOL STRUCT, V14, P384; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MONESTIER M, 1989, MOL IMMUNOL, V26, P749, DOI 10.1016/0161-5890(89)90035-7; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROTH SY, 1988, J CELL BIOL, V107, P2473, DOI 10.1083/jcb.107.6.2473; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; SHIMAMURA A, 1989, MOL CELL BIOL, V9, P5573, DOI 10.1128/MCB.9.12.5573; SLATER CR, 1976, DEV BIOL, V50, P264, DOI 10.1016/0012-1606(76)90151-2; STAYNOV DZ, 1988, EMBO J, V7, P3685, DOI 10.1002/j.1460-2075.1988.tb03250.x; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WOLFFE AP, 1989, EMBO J, V8, P527, DOI 10.1002/j.1460-2075.1989.tb03407.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	51	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1580	1585						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678408				2022-12-25	WOS:A1993KH62000015
J	DEBOER, HC; DEGROOT, PG; BOUMA, BN; PREISSNER, KT				DEBOER, HC; DEGROOT, PG; BOUMA, BN; PREISSNER, KT			TERNARY VITRONECTIN-THROMBIN-ANTITHROMBIN-III COMPLEXES IN HUMAN PLASMA - DETECTION AND MODE OF ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PROTEIN VITRONECTIN; PLASMINOGEN-ACTIVATOR INHIBITOR-1; BINDING DOMAIN; COAGULATION; COMPLEMENT; IDENTIFICATION; PURIFICATION; HEPARIN; MATRIX; SERUM	Radiolabeled antithrombin III (ATIII) was incubated at 37-degrees-C with purified vitronectin (VN) or fibrinogen-deficient plasma before thrombin was added to initiate complex formation. Incorporation of radiolabeled ATIII was detected using polyacrylamide gel electrophoresis (PAGE) and autoradiography. The PAGE conditions appeared to be crucial for the detection of VN.TAT complexes. In the absence of SDS, ternary complexes formed instantaneously, whereas in the presence of SDS, only 50% of the TAT was associated with VN after a 60-min incubation. Formation of ternary complexes could be confirmed by gel filtration of the plasma to which thrombin was added. Furthermore, TAT in patient plasmas (disseminated intravascular coagulation and sepsis) was found to bind to heparin-Sepharose, indicating that this endogenously formed TAT was also associated with VN. The amino-terminal region of VN and the thrombin moiety of the TAT complex were found to be responsible for their interaction, which was stabilized by disulfide bridges. These results indicate that in normal plasma all TAT is complexed with VN. This association alters the conformational state of plasma VN, which appears to be responsible for the clearance of thrombin complexes from the circulation.	MAX PLANCK INST PHYSIOL & CLIN RES,KERCKHOFF KLIN,HAEMOSTASIS RES UNIT,W-6350 BAD NAUHEIM,GERMANY	Kerckhoff Clinic; Max Planck Society	DEBOER, HC (corresponding author), UNIV HOSP UTRECHT,DEPT HAEMATOL G03647,BOX 85500,3508 GA UTRECHT,NETHERLANDS.							BHAKDI S, 1988, CLIN EXP IMMUNOL, V74, P459; BJORK I, 1992, J BIOL CHEM, V267, P1976; CONLAN MG, 1988, BLOOD, V72, P185; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DESWART CAM, 1984, THROMB HAEMOSTASIS, V52, P66; ELGUE G, 1990, THROMB HAEMOSTASIS, V63, P435; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FISH WW, 1979, EUR J BIOCHEM, V101, P31, DOI 10.1111/j.1432-1033.1979.tb04212.x; ILL CR, 1985, J BIOL CHEM, V260, P5610; IZUMI M, 1988, CELL STRUCT FUNCT, V13, P217, DOI 10.1247/csf.13.217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIMURO J, 1989, J BIOL CHEM, V264, P936; PODACK E R, 1979, Thrombosis and Haemostasis, V42, P170; PODACK ER, 1977, J IMMUNOL, V119, P2024; PODACK ER, 1986, J BIOL CHEM, V261, P7387; PREISSNER KT, 1990, BIOCHEM BIOPH RES CO, V168, P966, DOI 10.1016/0006-291X(90)91123-A; PREISSNER KT, 1988, BLOOD, V71, P1581; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1987, BIOCHEM J, V243, P105, DOI 10.1042/bj2430105; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; TOMASINI BR, 1986, BLOOD, V68, P737; TOMASINI BR, 1988, BLOOD, V72, P903	27	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1279	1283						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678252				2022-12-25	WOS:A1993KG07700077
J	TAKAHA, T; YANASE, M; OKADA, S; SMITH, SM				TAKAHA, T; YANASE, M; OKADA, S; SMITH, SM			DISPROPORTIONATING ENZYME (4-ALPHA-GLUCANOTRANSFERASE - EC 2.4.1.25) OF POTATO - PURIFICATION, MOLECULAR-CLONING, AND POTENTIAL ROLE IN STARCH METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUBCELLULAR-LOCALIZATION; ARABIDOPSIS LEAF; TRANSIT PEPTIDE; EXPRESSION; PLANTS; PROTEIN; GENE; BIOSYNTHESIS; CHLOROPLAST	Disproportionating enzyme (D-enzyme, 4-alpha-glucanotransferase; EC 2.4.1.25) has been purified to homogeneity from potato tubers and its activity characterized. The enzyme catalyzes the transfer of maltooligosaccharides from one 1,4-alpha-D-glucan molecule to another, or to glucose. Maltooligosaccharides are effective donor molecules, but short chain amylose and amylopectin may also function as donors. Enzyme activity is not affected by inorganic phosphate, 3-phosphoglycerate, or hexose phosphates. A cDNA clone encoding the enzyme was isolated using oligonucleotide probes derived from partial peptide sequences of the purified enzyme. The identity of the cDNA clone was confirmed by expression in Escherichia coli resulting in D-enzyme activity. The amino acid sequence deduced from the cDNA shows significant homology with a 4-alpha-glucanotransferase from Streptococcus. The deduced sequence indicates the presence of an amino-terminal plastid transit peptide of 52 amino acid residues and a mature polypeptide of 524 residues. D-enzyme mRNA is present in leaves, stems, roots, and stolons but is most abundant in developing and mature tubers. The amount of mRNA in leaves increases in response to light and to sucrose added to the medium. These results are discussed in terms of the function of D-enzyme in potato starch metabolism.	UNIV EDINBURGH, INST CELL & MOLEC BIOL, KINGS BLDG, MAYFIELD RD, EDINBURGH EH9 3JH, MIDLOTHIAN, SCOTLAND; EZAKI GLICO CO LTD, BIOCHEM RES LABS, OSAKA 555, JAPAN	University of Edinburgh; Ezaki Glico Co., Ltd.			Smith, Steven/HDM-9496-2022; Smith, Steven M/G-7183-2015	Smith, Steven M/0000-0001-5661-9994				AKAZAWA T, 1985, ANNU REV PLANT PHYS, V36, P441; BARHAM D, 1972, ANALYST, V97, P142, DOI 10.1039/an9729700142; BECK E, 1989, ANNU REV PLANT PHYS, V40, P95, DOI 10.1146/annurev.pp.40.060189.000523; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAY I, 1992, PLANT J, V2, P193; DEBOER D, 1988, EMBO J, V7, P2631, DOI 10.1002/j.1460-2075.1988.tb03115.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JOHNSON R, 1990, PLANT MOL BIOL, V14, P527, DOI 10.1007/BF00027498; KAKEFUDA G, 1986, PLANTA, V168, P175, DOI 10.1007/BF00402961; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KIM SR, 1991, PLANT MOL BIOL, V17, P973, DOI 10.1007/BF00037137; KLOSGEN RB, 1991, MOL GEN GENET, V225, P297, DOI 10.1007/BF00269862; KLOSGEN RB, 1989, MOL GEN GENET, V217, P155, DOI 10.1007/BF00330955; KOSSMANN J, 1991, MOL GEN GENET, V230, P39, DOI 10.1007/BF00290648; Kruger JN, 1990, PLANT PHYSL BIOCH MO, P59; LACKS SA, 1982, CELL, V31, P327, DOI 10.1016/0092-8674(82)90126-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee E. Y. C., 1971, ENZYMES, V5, P191; LIN TP, 1988, PLANT PHYSIOL, V86, P251, DOI 10.1104/pp.86.1.251; LIN TP, 1988, PLANT PHYSIOL, V86, P260, DOI 10.1104/pp.86.1.260; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; Maniatis T., 1982, MOL CLONING; MORI H, 1991, J BIOL CHEM, V266, P18446; MULLERROBER BT, 1990, MOL GEN GENET, V224, P136, DOI 10.1007/BF00259460; OKITA TW, 1979, PLANT PHYSIOL, V64, P187, DOI 10.1104/pp.64.2.187; PEAT S, 1956, J CHEM SOC, P44, DOI 10.1039/jr9560000044; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; PUGSLEY AP, 1988, MOL MICROBIOL, V2, P473, DOI 10.1111/j.1365-2958.1988.tb00053.x; ROCHASOSA M, 1989, EMBO J, V8, P23, DOI 10.1002/j.1460-2075.1989.tb03344.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwartz M, 1987, ESCHERICHIA COLI SAL, P1482; STEUP M, 1976, BIOCHEM BIOPH RES CO, V72, P1554, DOI 10.1016/S0006-291X(76)80191-X; VISSER RGF, 1989, PLANT SCI, V64, P185, DOI 10.1016/0168-9452(89)90023-X; VISSER RGF, 1991, PLANT MOL BIOL, V17, P691, DOI 10.1007/BF00037054; YOSHIO N, 1986, J JPN SOC STARCH SCI, V33, P244; [No title captured]	40	100	108	2	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1391	1396						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678257				2022-12-25	WOS:A1993KG07700094
J	SCHNEIDER, D; GOLD, L; PLATT, T				SCHNEIDER, D; GOLD, L; PLATT, T			SELECTIVE ENRICHMENT OF RNA SPECIES FOR TIGHT-BINDING TO ESCHERICHIA-COLI RHO-FACTOR	FASEB JOURNAL			English	Article						RHO-FACTOR; RNA BINDING; RNA STRUCTURE; SELEX; TRANSCRIPTION TERMINATION	DEPENDENT TRANSCRIPTION TERMINATION; CONSENSUS SEQUENCE; BASE-PAIRS; PROTEIN; SITE; POLYMERASE	We have applied the SELEX procedure (systematic evolution of ligands by exponential enrichment) to obtain RNA molecules that bind tightly to the Escherichia coli transcription termination factor rho. The starting pool was a population of RNA molecules 77 nucleotides (nt) long, in which was embedded a cassette of 30 nt of randomized sequence. The apparent dissociation constant of this RNA pool for hexameric rho factor was about 1 muM. After eight rounds of selection by filter binding, with RNA in either 10-fold or 40 to 100-fold excess at each step, the dissociation constant of the selected RNA had dropped by more than 500-fold to about 1 nm. Analysis of 29 clonal isolates from the population revealed that five had K(D)S substantially weaker than 10 nM (presumably background carryover), 40% were C-rich (as might have been predicted from rho's known substrate binding), and 40% had a strikingly preserved potential hairpin, in most cases of 6 base pairs with a 3 nt CAA loop and preceded by a CCCCA consensus. The rho-dependent trp t' terminator region includes a related potential hairpin structure; however, it is energetically unfavorable. The implications of the sequence findings for elucidating both static and dynamic aspects of rho factor recognition and response to its RNA target site are discussed.	UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,601 ELMWOOD AVE,ROCHESTER,NY 14642; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	University of Rochester; University of Colorado System; University of Colorado Boulder					NIGMS NIH HHS [GM 35658, GM 28685, GM 19963] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035658, R01GM019963, R37GM019963, R01GM028685] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIFANO P, 1991, CELL, V64, P553; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAUS I, 1990, J MOL BIOL, V212, P53, DOI 10.1016/0022-2836(90)90304-5; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GALLOWAY JL, 1988, J BIOL CHEM, V263, P1761; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; HART CM, 1991, J BIOL CHEM, V266, P24140; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; SCHNEIDER D, 1992, IN PRESS J MOL BIOL; SHARP JA, 1986, J BIOL CHEM, V261, P2524; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; TSURUSHITA N, 1989, J MOL BIOL, V210, P23, DOI 10.1016/0022-2836(89)90288-X; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TUERK C, 1992, POLYM CHAIN REACTION; ZALATAN F, 1992, J BIOL CHEM, V267, P19082	21	55	67	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					201	207		10.1096/fasebj.7.1.7678562	http://dx.doi.org/10.1096/fasebj.7.1.7678562			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	7678562				2022-12-25	WOS:A1993KH88000031
J	BERSE, B; BLUSZTAJN, JK				BERSE, B; BLUSZTAJN, JK			COORDINATED UP-REGULATION OF CHOLINE-ACETYLTRANSFERASE AND VESICULAR ACETYLCHOLINE TRANSPORTER GENE-EXPRESSION BY THE RETINOIC ACID RECEPTOR-ALPHA, CAMP, AND LEUKEMIA INHIBITORY FACTOR CILIARY NEUROTROPHIC FACTOR SIGNALING PATHWAYS IN A MURINE SEPTAL CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NEURONAL DIFFERENTIATION FACTOR; CYCLIC-AMP; TRANSCRIPTION; PROTEIN; NUCLEUS; MEMORY	The proteins responsible for acetylcholine (ACh) synthesis (choline acetyltransferase, ChAT) and storage (vesicular ACh transporter, VAChT) are encoded by two closely linked genes in vertebrates, with the VAChT coding sequence contained within the first intron of the ChAT gene, This unusual genomic organization suggests that the transcription of these two genes is coordinately regulated, Using Northern analysis we studied the modulation of ChAT and VAChT expression in a murine septal cell line (SN56) by three groups of agents: retinoids, trophic factors belonging to the leukemia inhibitory factor/ciliary neurotrophic factor (LIF/CNTF) family, and cAMP, All-trans-retinoic acid increased both ChAT and VAChT mRNA levels in SN56 cells up to 3.5-fold, and elevated intracellular ACh levels by 2.5-fold, This effect was mimicked by a retinoic acid receptor alpha (RAR alpha) agonist (Ro 40-6055) and prevented by a specific antagonist (Ro 41-5253), indicating that it was mediated by RAR alpha, ChAT- and VAChT-specific transcripts were also induced (up to 3-fold) by treatment with CNTF or LIF (20 ng/ml, 48 h), as well as by dibutyryl cAMP (1 mM), All these agents increased the ACh level in the cells (up to 2.5-fold). Dibutyryl cAMP had a greater effect on the level of VAChT mRNA (4-fold induction) than on the level of ChAT mRNA (2-fold induction), suggesting a quantitatively differential transcriptional regulation of the two genes by the cAMP pathway. The effects of the three groups of agents studied on ChAT and VAChT mRNA levels were additive, pointing to several independent mechanisms by which the cholinergic properties of septal neurons can be modulated.	BOSTON UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT PSYCHIAT, BOSTON, MA 02118 USA	Boston University; Boston University				Berse, Brygida/0000-0002-0735-2792; /0000-0001-8438-3122	NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHS [AG09525] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BANNER LR, 1994, P NATL ACAD SCI USA, V91, P7109, DOI 10.1073/pnas.91.15.7109; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BEJANIN S, 1992, J NEUROCHEM, V58, P1580, DOI 10.1111/j.1471-4159.1992.tb11383.x; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; BERRARD S, 1995, J NEUROCHEM, V65, P939; BLUSZTAJN JK, 1992, J NEUROSCI, V12, P793; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CASPER D, 1989, BRAIN RES, V478, P74, DOI 10.1016/0006-8993(89)91478-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFER P, 1995, ONCOGENE, V10, P985; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D; FUKADA K, 1985, P NATL ACAD SCI USA, V82, P8795, DOI 10.1073/pnas.82.24.8795; HAMMOND DN, 1986, SCIENCE, V234, P1237, DOI 10.1126/science.3775382; HEFTI F, 1985, NEUROSCIENCE, V14, P55, DOI 10.1016/0306-4522(85)90163-0; HERSH LB, 1992, NEUROCHEM RES, V17, P1063, DOI 10.1007/BF00967282; INOUE H, 1995, J NEUROCHEM, V64, P985; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOHNSON JA, 1994, J BIOL CHEM, V269, P18856; LEE HJ, 1990, DEV BRAIN RES, V52, P219, DOI 10.1016/0165-3806(90)90238-T; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LI YP, 1993, NEUROCHEM RES, V18, P271, DOI 10.1007/BF00969082; LONNERBERG P, 1995, P NATL ACAD SCI USA, V92, P4046, DOI 10.1073/pnas.92.9.4046; MATSUOKA I, 1989, BRAIN RES, V502, P53, DOI 10.1016/0006-8993(89)90460-5; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MISAWA H, 1993, J NEUROCHEM, V60, P1383, DOI 10.1111/j.1471-4159.1993.tb03299.x; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; PARK EA, 1993, J BIOL CHEM, V268, P613; PEDERSEN WA, 1995, J NEUROCHEM, V65, P50; POTTER PE, 1983, J NEUROCHEM, V41, P188, DOI 10.1111/j.1471-4159.1983.tb13668.x; RAO MS, 1993, NEURON, V11, P1175, DOI 10.1016/0896-6273(93)90229-K; ROGHANI A, 1994, P NATL ACAD SCI USA, V91, P10620, DOI 10.1073/pnas.91.22.10620; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; Sambrook J, 1989, MOL CLONING LABORATO; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SYMES AJ, 1995, J BIOL CHEM, V270, P8068, DOI 10.1074/jbc.270.14.8068; USDIN TB, 1995, TRENDS NEUROSCI, V18, P218, DOI 10.1016/0166-2236(95)93906-E; WU DH, 1994, J NEUROCHEM, V62, P1653; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	45	153	155	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22101	22104		10.1074/jbc.270.38.22101	http://dx.doi.org/10.1074/jbc.270.38.22101			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673184	hybrid			2022-12-25	WOS:A1995RW31400007
J	ELHAYEK, R; ANTONIU, B; WANG, JP; HAMILTON, SL; IKEMOTO, N				ELHAYEK, R; ANTONIU, B; WANG, JP; HAMILTON, SL; IKEMOTO, N			IDENTIFICATION OF CALCIUM RELEASE-TRIGGERING AND BLOCKING REGIONS OF THE II-III-LOOP OF THE SKELETAL-MUSCLE DIHYDROPYRIDINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SARCOPLASMIC-RETICULUM; CHARGE MOVEMENT; CHANNEL	In an attempt to identify and characterize functional domains of the rabbit skeletal muscle dihydropyridine receptor alpha(1), subunit II-III loop, we synthetized several peptides corresponding to different regions of the loop: peptides A, B, C, C1, C2, D (cf. Pig, 1). Peptide A (Thr(671)- Leu(690)) activated [H-3]ryanodine binding to, and induced Ca2+ release from, rabbit skeletal muscle triads, but none of the other peptides had such effects. Peptide A-induced Ca2+ release and activation of ryanodine binding were partially suppressed by an equimolar concentration of peptide C (Glu(724)-Pro(760)) but were not affected by the other peptides. These results suggest that the short stretch in the II-III loop, Thr(671)-Leu(690), is responsible for triggering SR Ca2+ release, while the other region, Glu(724)-Pro(760), functions as a blocker of the release trigger. A hypothesis is proposed to account for how these subdomains interact with the sarcoplasmic reticulum Ca2+ release channel protein during excitation-contraction coupling.	BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; BAYLOR COLL MED, DEPT MOLEC PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Boston Biomedical Research Institute; Baylor College of Medicine; Harvard University; Harvard Medical School				Hamilton, Susan/0000-0003-0241-9369	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016922] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 37044] Funding Source: Medline; NIAMS NIH HHS [AR 16922] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHANDLER WK, 1976, J PHYSIOL-LONDON, V254, P285, DOI 10.1113/jphysiol.1976.sp011233; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; ELHAYEK R, 1993, BIOPHYS J, V65, P779, DOI 10.1016/S0006-3495(93)81101-9; FILL M, 1988, TRENDS NEUROSCI, V11, P453, DOI 10.1016/0166-2236(88)90198-1; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; GARCIA J, 1994, J GEN PHYSIOL, V103, P125, DOI 10.1085/jgp.103.1.125; IKEMOTO N, 1984, J BIOL CHEM, V259, P3151; IKEMOTO N, 1988, METHOD ENZYMOL, V157, P469; Lu Xiangyang, 1995, Biophysical Journal, V68, pA372; LU XY, 1994, J BIOL CHEM, V269, P6511; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Nakai J., 1995, Biophysical Journal, V68, pA14; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROHRKASTEN A, 1988, J BIOL CHEM, V263, P15325; Smith Donald B., 1993, Methods in Molecular and Cellular Biology, V4, P220; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0	22	121	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22116	22118		10.1074/jbc.270.38.22116	http://dx.doi.org/10.1074/jbc.270.38.22116			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673188	hybrid			2022-12-25	WOS:A1995RW31400011
J	LI, XY; LI, J; HARRINGTON, J; LIEBER, MR; BURGERS, PMJ				LI, XY; LI, J; HARRINGTON, J; LIEBER, MR; BURGERS, PMJ			LAGGING-STRAND DNA-SYNTHESIS AT THE EUKARYOTIC REPLICATION FORK INVOLVES BINDING AND STIMULATION OF FEN-1 BY PROLIFERATING CELL NUCLEAR ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN PROTEIN INTERACTIONS; SACCHAROMYCES-CEREVISIAE; FACTOR-C; POLYMERASE-III; PURIFICATION; SYSTEM	The 5' --> 3'-exonuclease domain of Escherichia coli DNA polymerase I is required for the completion of lagging strand DNA synthesis, and yet this domain is not present in any of the eukaryotic DNA polymerases, Recently, the gene encoding the functional and evolutionary equivalent of this 5' --> 3'-exonuclease domain has been identified, It is called FEN-1 in mouse and human cells and RTH1 in Saccharomyces cerevisiae, This 42-kDa enzyme is required for Okazaki fragment processing. Here we report that FEN-1 physically interacts with proliferating cell nuclear antigen (PCNA), the processivity factor for DNA polymerases delta and epsilon. Through protein-protein interactions, PCNA focuses FEN-1 on branched DNA substrates (flap structures) and on nicked DNA substrates, thereby stimulating its activity 10-50-fold but only if PCNA can functionally assemble as a toroidal trimer around the DNA, This interaction is important in the physical orchestration of lagging strand synthesis and may have implications for how PCNA stimulates other members of the FEN-1 nuclease family in a broad range of DNA metabolic transactions.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOPHYS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Burgers, Peter M/AAW-6621-2021	Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345	NATIONAL CANCER INSTITUTE [R01CA051105, R37CA051105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NCI NIH HHS [CA51105] Funding Source: Medline; NIGMS NIH HHS [GM32431, GM43236, R01 GM032431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BAUER GA, 1988, BIOCHIM BIOPHYS ACTA, V951, P274, DOI 10.1016/0167-4781(88)90097-8; BAUER GA, 1988, J BIOL CHEM, V263, P917; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PODUST LM, 1994, NUCLEIC ACIDS RES, V22, P2970, DOI 10.1093/nar/22.15.2970; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; WAGA S, 1994, J BIOL CHEM, V269, P10923; YODER BL, 1991, J BIOL CHEM, V266, P22689	28	251	261	8	75	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22109	22112		10.1074/jbc.270.38.22109	http://dx.doi.org/10.1074/jbc.270.38.22109			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673186	hybrid			2022-12-25	WOS:A1995RW31400009
J	PRIGENT, SA; PILLAY, TS; RAVICHANDRAN, KS; GULLICK, WJ				PRIGENT, SA; PILLAY, TS; RAVICHANDRAN, KS; GULLICK, WJ			BINDING OF SHC TO THE NPXY MOTIF IS MEDIATED BY ITS N-TERMINAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE PHOSPHORYLATION; PROTEIN; RECEPTOR; KINASE; SITES	She is an SH2-containing adapter protein that binds to and is phosphorylated by a large number of growth factor receptors, Phosphorylated She is able to interact with the GrbB-Sos complex which is responsible for mediating nucleotide exchange on Ras. We have shown previously that binding of She to the epidermal growth factor (EGF)-like receptor, c-ErbB-3, is through an NPXY motif (Prigent, S, A., and Gullick, W, J, (1994) EMBO J. 13, 2831-2841) shared by middle T antigen, TrkA, and EGF receptor, It has recently been reported that a region distinct from the SH2 domain is able to bind to tyrosine-phosphorylated proteins. In this paper we have used fusion proteins of various She domains to show that it is the N-terminal domain of She that is primarily responsible for binding EGF receptor and c-ErbB-3. Furthermore, by competition studies with synthetic phosphopeptides we have shown that this N-terminal domain binds to the previously identified NPXY motif.	UNIV CALIF SAN DIEGO,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,MOLEC ONCOL LAB,ONCOL UNIT,LONDON W12 0HS,ENGLAND	University of California System; University of California San Diego; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Cancer Research UK; Imperial College London	PRIGENT, SA (corresponding author), UNIV CALIF SAN DIEGO,CTR CANC,LA JOLLA,CA 92093, USA.		Ravichandran, Kattur Soundarapandian/AAG-7319-2019	Ravichandran, Kattur Soundarapandian/0000-0003-2397-461X; pillay, tahir/0000-0002-9982-9710				BALDARI CT, 1995, ONCOGENE, V10, P1141; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DAMEN JE, 1993, BLOOD, V82, P2296; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PILLAY TS, 1992, FEBS LETT, V308, P38, DOI 10.1016/0014-5793(92)81045-N; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRIGENT SA, 1992, ONCOGENE, V7, P1273; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SAXTON TM, 1994, J IMMUNOL, V153, P623; SEGATTO O, 1993, ONCOGENE, V8, P2105; SMIT L, 1994, J BIOL CHEM, V269, P20209; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHU XY, 1994, J BIOL CHEM, V269, P5518	40	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22097	22100		10.1074/jbc.270.38.22097	http://dx.doi.org/10.1074/jbc.270.38.22097			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673183	hybrid			2022-12-25	WOS:A1995RW31400006
J	TIPPNER, D; WAGNER, R				TIPPNER, D; WAGNER, R			FLUORESCENCE ANALYSIS OF THE ESCHERICHIA-COLI TRANSCRIPTION REGULATOR-H-NS REVEALS 2 DISTINGUISHABLE COMPLEXES DEPENDENT ON BINDING TO SPECIFIC OR NONSPECIFIC DNA SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; RIBOSOMAL-RNA; CURVED DNA; PROTEIN H1; ELECTROPHORESIS; INVITRO; PHASE	Here we report a structural investigation of the transcription factor H-NS and its DNA interaction. H-NS has a general effect on transcription by compacting DNA; but for a number of specific genes, it is known to act directly as repressor or activator. The homodimeric protein binds to the major groove of DNA in a sequence-nonspecific manner, recognizing a curved conformation of the target DNA. H-NS consists of 136 amino acids with a single tryptophanyl residue at position 108. To overcome the apparent lack of any other structural details, we took advantage of the intrinsic fluorescence of Trp-108. Static and dynamic quenching constants obtained with the neutral quencher molecule acrylamide are consistent with a hydrophilic environment and high degree of solvent exposure for Trp-108. In addition, quenching studies in the presence of the anionic quencher iodide indicate a positively charged microenvironment for the same amino acid residue. Specific and nonspecific H-NS DNA complexes were studied by gel retardation and fluorescence analysis. While specific H-NS DNA complex formation is accompanied by a clear enhancement of the tryptophanyl fluorescence intensity, interaction in the presence of the nonspecific competitor DNA poly(dI-dC) decreases the fluorescence quantum yield.	UNIV DUSSELDORF,INST BIOL PHYS,D-40225 DUSSELDORF,GERMANY	Heinrich Heine University Dusseldorf								BARCELO F, 1991, BIOCHEMISTRY-US, V30, P4863, DOI 10.1021/bi00234a005; BERTIN P, 1990, BIOCHIMIE, V72, P889, DOI 10.1016/0300-9084(90)90008-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MP, 1994, J BIOL CHEM, V269, P12600; DERSCH P, 1993, MOL MICROBIOL, V8, P875, DOI 10.1111/j.1365-2958.1993.tb01634.x; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; FRIEDRICH K, 1988, FEBS LETT, V229, P197, DOI 10.1016/0014-5793(88)80826-3; HIGGINS CF, 1990, MOL MICROBIOL, V4, P2007, DOI 10.1111/j.1365-2958.1990.tb00559.x; HULTON CSJ, 1990, CELL, V63, P631, DOI 10.1016/0092-8674(90)90458-Q; ITO K, 1994, J BACTERIOL, V176, P7383, DOI 10.1128/JB.176.23.7383-7386.1994; LUCHT JM, 1994, J BIOL CHEM, V269, P6578; Maniatis T., 1982, MOL CLONING; MAY G, 1990, MOL GEN GENET, V224, P81, DOI 10.1007/BF00259454; MELLIES J, 1994, J BACTERIOL, V176, P3638, DOI 10.1128/JB.176.12.3638-3645.1994; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; PON CL, 1988, MOL GEN GENET, V212, P199, DOI 10.1007/BF00334684; PORTER ME, 1994, J BACTERIOL, V176, P4187, DOI 10.1128/JB.176.13.4187-4191.1994; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; SHINDO H, 1995, FEBS LETT, V360, P125, DOI 10.1016/0014-5793(95)00079-O; SOMERO GN, 1986, AM J PHYSIOL, V251, P197; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; SPASSKY A, 1977, EUR J BIOCHEM, V81, P79, DOI 10.1111/j.1432-1033.1977.tb11929.x; TIPPNER D, 1994, MOL MICROBIOL, V11, P589, DOI 10.1111/j.1365-2958.1994.tb00339.x; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; WAGNER R, 1994, ARCH MICROBIOL, V161, P100, DOI 10.1007/s002030050028; YAMADA H, 1990, J BIOCHEM-TOKYO, V108, P420, DOI 10.1093/oxfordjournals.jbchem.a123216; YAMADA H, 1991, MOL GEN GENET, V230, P332, DOI 10.1007/BF00290685; ZACHARIAS M, 1992, BIOCHEMISTRY-US, V31, P2621, DOI 10.1021/bi00124a024; ZACHARIAS M, 1991, BIOCHIMIE, V73, P699, DOI 10.1016/0300-9084(91)90050-B; ZUBER F, 1994, MOL MICROBIOL, V12, P231, DOI 10.1111/j.1365-2958.1994.tb01012.x	32	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22243	22247		10.1074/jbc.270.38.22243	http://dx.doi.org/10.1074/jbc.270.38.22243			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673203	hybrid			2022-12-25	WOS:A1995RW31400029
J	PAN, ZQ; REARDON, JT; LI, L; FLORESROZAS, H; LEGERSKI, R; SANCAR, A; HURWITZ, J				PAN, ZQ; REARDON, JT; LI, L; FLORESROZAS, H; LEGERSKI, R; SANCAR, A; HURWITZ, J			INHIBITION OF NUCLEOTIDE EXCISION-REPAIR BY THE CYCLIN-DEPENDENT KINASE INHIBITOR P21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; DNA POLYMERASE-DELTA; SACCHAROMYCES-CEREVISIAE; INVITRO REPLICATION; P53 PROTEIN; EPSILON; ORIGIN; COMPLEMENTATION; ACTIVATOR-1; INITIATION	p21, a p53-induced gene product that blocks cell cycle progression at the G(1) phase, interacts with both cyclin-dependent kinases and proliferating cell nuclear antigen (PCNA). PCNA functions as a processivity factor for DNA polymerases delta and epsilon and is required for both DNA replication and nucleotide excision repair. Previous studies have shown that p21 inhibits simian virus 40 (SV40) DNA replication in HeLa cell extracts by interacting with PCNA. In this report we show that p21 blocks nucleotide excision repair of DNA that has been damaged by either ultraviolet radiation or alkylating agents, and that this inhibition can be reversed following addition of PCNA. We have determined that p21 is more effective in blocking DNA resynthesis than in inhibiting the excision step. We further show that a peptide derived from the carboxyl terminus of p21, which specifically interacts with PCNA, inhibits polymerase delta-catalyzed elongation of DNA chains almost stoichiometrically relative to the concentration of PCNA. When added at higher levels, this peptide also blocks both SV40 DNA replication and nucleotide excision repair in HeLa cell extracts. These results indicate that p21 interferes with the function of PCNA in both in vitro DNA replication and nucleotide excision repair.	UNIV N CAROLINA, SCH MED, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Texas System; UTMD Anderson Cancer Center	PAN, ZQ (corresponding author), MEM SLOAN KETTERING CANC CTR, GRAD PROGRAM MOLEC BIOL, 1275 YORK AVE, BOX 97, NEW YORK, NY 10021 USA.				NCI NIH HHS [CA52461] Funding Source: Medline; NIGMS NIH HHS [GM38559, GM32833] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; BIGGERSTAFF M, 1992, J BIOL CHEM, V267, P6879; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHEN J, 1995, NATURE, V374, P336; CUNNINGHAM RP, 1985, P NATL ACAD SCI USA, V82, P474, DOI 10.1073/pnas.82.2.474; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FRIEDBERG EC, 1995, DNA REPAIR; FRITSCHE M, 1993, ONCOGENE, V8, P307; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KASTAN MB, 1991, CANCER RES, V51, P6304; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LANDEGENT JE, 1984, EXP CELL RES, V153, P61, DOI 10.1016/0014-4827(84)90448-8; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; LEE SH, 1989, P NATL ACAD SCI USA, V85, P9469; LEGERSKI RJ, 1977, J BIOL CHEM, V252, P8740; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSUNAGA T, 1995, IN PRESS J BIOL CHEM; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; NISHIDA C, 1988, J BIOL CHEM, V263, P501; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1994, CURR BIOL, V12, P1062; SIBGHATULLAH, 1990, BIOCHEMISTRY-US, V29, P5711, DOI 10.1021/bi00476a011; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SVOBODA DL, 1993, J BIOL CHEM, V268, P10694; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZENG XR, 1994, J BIOL CHEM, V269, P13748	57	162	168	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					22008	22016		10.1074/jbc.270.37.22008	http://dx.doi.org/10.1074/jbc.270.37.22008			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665622	Green Published, hybrid			2022-12-25	WOS:A1995RU75700087
J	FOHR, UG; HEIZMANN, CW; ENGELKAMP, D; SCHAFER, BW; COX, JS				FOHR, UG; HEIZMANN, CW; ENGELKAMP, D; SCHAFER, BW; COX, JS			PURIFICATION AND CATION-BINDING PROPERTIES OF THE RECOMBINANT HUMAN S100 CALCIUM-BINDING PROTEIN A3, AN EF-HAND MOTIF PROTEIN WITH HIGH-AFFINITY FOR ZINC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-100 PROTEIN; IDENTIFICATION; CALMODULIN; CALCYCLIN; CA-2+; GENE	The calcium-binding protein S100A3 is an unusual member of the S100 family, characterized by its very high content of Cys. In order to study the biochemical, cation-binding, and conformational properties, we produced and purified the recombinant human protein in Escherichia coli. The recombinant protein forms noncovalent homodimers, tetramers, and polymers in vitro with a subunit molecular weight of 11,712. The Zn2+- binding parameters of S100A3 were studied by equilibrium gel filtration and yielded a stoichiometry of four Zn2+ per monomer with a [Zn2+](0.5) of 11 mu M and a Hill coefficient of 1.4 at physiological ionic strength. The affinity for Ca2+ is too low to be determined by direct methods (K-Ca > 10 mM). Ca2+- and Zn2+-binding can be followed by optical methods: the Trp-45 fluorescence is high in the metal-free form and addition of Zn2+ and Ca2+, but not of Mg2+, leads to a 4-fold quenching. Ca2+ and Zn2+ promote also quite similar conformational changes in the Tyr and Trp environment as monitored by difference spectrophotometry. Fluorescence titrations with Zn2+ confirmed that there is one set of high affinity binding sites with a [Zn2+](0.5) of 8 mu M and a Hill coefficient of 1.3. Binding of Zn2+ to a second set of low affinity sites induces protein precipitation. Fluorescence titrations with Ca2+ confirmed the very low affinity of S100A3 for this ion with a [Ca2+](0.5) of 30 mM and slight negative cooperativity. Mg2+ has no effect on this binding curve. Of the 10 Cys residues in S100A3, 5 only are free thiols, and accessible to 5,5'-dithiobis(2-nitrobenzoic acid); they display a high reactivity in the metal-free and Ca2+ form, but a 20-fold lowered reactivity in the Zn2+ form of S100A3. Ca2+-binding promotes the formation of a solvent-accessible hydrophobic surface as monitored by the 60-fold fluorescence increase of 2-p- toluidinylnaphthalene-6-sulfonate, whereas Zn2+ has no noticeable influence. Our data indicate that Ca2+ and Zn2+ do not bind to the same sites and that under physiological conditions S100A3 is a Zn2+-binding rather than a Ca2+-binding protein; nevertheless, very specific conformational changes are introduced by either Ca2+ or Zn2+. Since no Zn2+ binding motif of known structure was identified in the primary sequence of S100A3, the results are suggestive for a novel Zn2+-binding motif.	UNIV ZURICH, DEPT PEDIAT, DIV CLIN CHEM, CH-8032 ZURICH, SWITZERLAND; UNIV GENEVA, DEPT BIOCHEM, CH-1211 GENEVA 4, SWITZERLAND	University of Zurich; University of Geneva				Schafer, Beat/0000-0001-5988-2915				BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BIANCHI R, 1993, J BIOL CHEM, V268, P12669; CARLSTROM G, 1993, J MOL BIOL, V231, P415, DOI 10.1006/jmbi.1993.1291; COX JA, 1994, J BIOL CHEM, V269, P32807; DAVIES BR, 1993, ONCOGENE, V8, P999; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; DURUSSEL I, 1993, BIOCHEMISTRY-US, V32, P6089, DOI 10.1021/bi00074a021; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; FILIPEK A, 1990, FEBS LETT, V264, P263, DOI 10.1016/0014-5793(90)80263-I; FRANCIS SH, 1994, J BIOL CHEM, V269, P22477; Heizmann C. W., 1995, CALCIUM REGULATION C; HILT DC, 1991, NOVEL CALCIUM BINDIN, P65; HOMMEL U, 1944, NAT STRUCT BIOL, V1, P384; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; ILICH P, 1988, BIOPHYS CHEM, V29, P341, DOI 10.1016/0301-4622(88)85056-7; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; LEUNG IKM, 1987, FEBS LETT, V214, P35, DOI 10.1016/0014-5793(87)80008-X; MANI RS, 1990, BIOCHEMISTRY-US, V29, P1398, DOI 10.1021/bi00458a009; MCCLURE WO, 1966, BIOCHEMISTRY-US, V5, P1908, DOI 10.1021/bi00870a018; PEDROCCHI M, 1994, BIOCHEMISTRY-US, V33, P6732, DOI 10.1021/bi00187a045; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; PEREZALVARADO G, 1944, NAT STRUCT BIOL, V1, P389; PERLMAN RK, 1994, J BIOL CHEM, V269, P33140; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwabe JWR, 1994, STRUCT BIOL, V1, P345; SZEBENYI DME, 1986, J BIOL CHEM, V261, P8761; TANAKA T, 1980, J BIOL CHEM, V255, P1078; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TOKUMITSU H, 1991, ARCH BIOCHEM BIOPHYS, V288, P202, DOI 10.1016/0003-9861(91)90184-K; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WETERMAN MAJ, 1992, CANCER RES, V52, P1291; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984; ZIMMER DB, 1993, CELL CALCIUM, V14, P323, DOI 10.1016/0143-4160(93)90053-9	37	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21056	21061		10.1074/jbc.270.36.21056	http://dx.doi.org/10.1074/jbc.270.36.21056			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673133	hybrid			2022-12-25	WOS:A1995RU05400031
J	TAWFIC, S; OLSON, MOJ; AHMED, K				TAWFIC, S; OLSON, MOJ; AHMED, K			ROLE OF PROTEIN-PHOSPHORYLATION IN POSTTRANSLATIONAL REGULATION OF PROTEIN B23 DURING PROGRAMMED CELL-DEATH IN THE PROSTATE-GLAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MATRIX PROTEIN; RAT VENTRAL PROSTATE; NUMATRIN B23; PROLIFERATION; INDUCTION; APOPTOSIS; GENE; IDENTIFICATION; KINASE; PHOSPHOPROTEIN-B23	Protein B23 is a nucleolar and nuclear matrix-associated phosphoprotein that is involved in ribosome synthesis, Its expression and phosphorylation in rat ventral prostate, an androgen target organ, are profoundly influenced by androgens, Induction of programmed cell death (apoptosis) in the prostatic epithelium by androgen deprivation in the animal induces an early decline in protein B23 in the absence of a corresponding loss of protein B23 mRNA. We have now demonstrated that prostatic nuclei retain the ability to transcribe the B23 mRNA and that a significant amount of this mRNA persists even after 7 days of androgen deprivation when >80% of the prostatic epithelial cells have undergone apoptosis. The B23 mRNA from these nuclei is also translatable in vitro. However, the majority of the B23 mRNA is associated with free and short stretch polysomes, which may account for the castration-induced decline in synthesis of protein B23 in vivo. In addition, the mechanism of down-regulation of protein B23 in apoptotic prostatic cells appears to relate to two coordinate signals, which include loss of phosphorylation of the protein as well as the expression of a protease active toward dephosphorylated protein B23, under these conditions.	UNIV MINNESOTA, DEPT VET AFFAIRS MED CTR, CELLULAR & MOLEC BIOCHEM RES LAB 151, MINNEAPOLIS, MN 55417 USA; UNIV MINNESOTA, DEPT VET AFFAIRS MED CTR, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55417 USA; UNIV MISSISSIPPI, MED CTR, DEPT BIOCHEM, JACKSON, MS 39216 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Mississippi; University of Mississippi Medical Center					NATIONAL CANCER INSTITUTE [R01CA015062, R37CA015062, U01CA015062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028349] Funding Source: NIH RePORTER; NCI NIH HHS [CA-15062] Funding Source: Medline; NIGMS NIH HHS [GM-28349] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED K, 1993, CELL MOL BIOL RES, V39, P451; BERGES R, 1993, CLIN CHEM, V39, P356; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BIGGIOGERA M, 1989, J HISTOCHEM CYTOCHEM, V37, P1371, DOI 10.1177/37.9.2768807; BRIEHL MM, 1991, MOL ENDOCRINOL, V5, P1381, DOI 10.1210/mend-5-10-1381; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHAN PK, 1985, EXP CELL RES, V161, P101, DOI 10.1016/0014-4827(85)90494-X; CHAN PK, 1990, BIOCHEM J, V270, P549, DOI 10.1042/bj2700549; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; ENGLISH HF, 1989, PROSTATE, V15, P233, DOI 10.1002/pros.2990150304; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEARNHEAD HO, 1995, FEBS LETT, V357, P242, DOI 10.1016/0014-5793(94)01367-A; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1991, EXP CELL RES, V194, P289, DOI 10.1016/0014-4827(91)90367-4; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FEUERSTEIN N, 1990, BIOCHIM BIOPHYS ACTA, V1087, P127, DOI 10.1016/0167-4781(90)90196-9; GELLERSEN B, 1992, ENDOCRINOLOGY, V131, P1017, DOI 10.1210/en.131.3.1017; GRAY NK, 1994, MOL BIOL REP, V19, P195, DOI 10.1007/BF00986961; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HERNANDEZVERDUN D, 1994, BIOESSAYS, V16, P179, DOI 10.1002/bies.950160308; INGBER DE, 1993, J CELL SCI, V104, P613; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KNOFLER M, 1993, J BIOL CHEM, V268, P11409; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; MAINWARING WI, 1973, BIOCHEM J, V134, P795, DOI 10.1042/bj1340795; MAINWARING WIP, 1983, J STEROID BIOCHEM, V19, P101, DOI 10.1016/S0022-4731(83)80012-0; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NAKAYASU H, 1991, P NATL ACAD SCI USA, V88, P10312, DOI 10.1073/pnas.88.22.10312; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OLSON MOJ, 1975, J MOL BIOL, V97, P611, DOI 10.1016/S0022-2836(75)80062-3; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; REIFELMILLER AE, 1994, J BIOL CHEM, V269, P23861; SMYTH MJ, 1994, CLIN EXP PHARMACOL P, V21, P67, DOI 10.1111/j.1440-1681.1994.tb02438.x; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; TAKEMURA M, 1994, BIOCHEM BIOPH RES CO, V199, P46, DOI 10.1006/bbrc.1994.1191; TAWFIC S, 1994, J BIOL CHEM, V269, P7489; TAWFIC S, 1994, J BIOL CHEM, V269, P24615; TAWFIC S, 1993, CELL MOL BIOL RES, V39, P43; TOKES ZA, 1989, J BIOL CHEM, V264, P15059; WANG DR, 1994, J BIOL CHEM, V269, P30994; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8; YUNG BYM, 1992, LIFE SCI, V51, P915, DOI 10.1016/0024-3205(92)90399-A	50	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21009	21015		10.1074/jbc.270.36.21009	http://dx.doi.org/10.1074/jbc.270.36.21009			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673126	hybrid			2022-12-25	WOS:A1995RU05400023
J	BARWELL, JA; BOCHKAREV, A; PFUETZNER, RA; TONG, H; YANG, DSC; FRAPPIER, L; EDWARDS, AM				BARWELL, JA; BOCHKAREV, A; PFUETZNER, RA; TONG, H; YANG, DSC; FRAPPIER, L; EDWARDS, AM			OVEREXPRESSION, PURIFICATION, AND CRYSTALLIZATION OF THE DNA-BINDING AND DIMERIZATION DOMAINS OF THE EPSTEIN-BARR-VIRUS NUCLEAR ANTIGEN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION; EBNA-1; CELLS; ENHANCER; PROMOTER; PROTEIN; ORIGIN	The Epstein-Barr virus nuclear antigen (EBNA) 1 binds to and activates DNA replication from the latent origin of Epstein-Barr virus. Six different fragments of EBNA1 that retain DNA binding activity were expressed in bacteria, purified, and crystallized. Two fragments, EBNA(470-619) and EBNA(470-607), formed well ordered crystals that diffracted beyond 2.5-Angstrom resolution. Two different EBNA(470-619) crystals were grown from sodium formate, pH 6-6.5. One crystal belonged to the trigonal space group 3 with unit cell dimensions a = b = 86.5 Angstrom and c = 31.8 Angstrom and with two molecules in the asymmetric unit. The other crystal, which appeared only twice and was likely related to the P3 crystal form, belonged to the trigonal space group P312 with cell dimensions a = b = 86.7 Angstrom and c = 31.8 Angstrom. Crystals of EBNA(470-607) were grown by lowering the salt concentration to 0-100 mM NaCl at pH 6.0. These crystals belonged to the orthorhombic space group P2(1)2(1)2(1) and had cell dimensions a = 59 Angstrom, b = 66.9 Angstrom, and c = 69.8 Angstrom with two molecules in the asymmetric unit.	MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8S 4B2,CANADA	McMaster University				Edwards, Aled/0000-0002-4782-6016				ADAMS A, 1987, J VIROL, V61, P1743, DOI 10.1128/JVI.61.5.1743-1746.1987; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; CHEN MR, 1993, J VIROL, V67, P4875, DOI 10.1128/JVI.67.8.4875-4885.1993; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; HEMMING SA, 1995, J MOL BIOL, V246, P308, DOI 10.1006/jmbi.1994.0086; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; Kornberg A., 1992, DNA REPLICATION; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; MIDDLETON T, 1992, J VIROL, V66, P489, DOI 10.1128/JVI.66.1.489-495.1992; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; SAMPLE J, 1992, J VIROL, V66, P4654, DOI 10.1128/JVI.66.8.4654-4661.1992; STILLMAN B, 1994, J BIOL CHEM, V269, P7047; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGDEN B, 1989, J VIROL, V63, P2644, DOI 10.1128/JVI.63.6.2644-2649.1989; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991	18	29	33	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20556	20559		10.1074/jbc.270.35.20556	http://dx.doi.org/10.1074/jbc.270.35.20556			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657632	hybrid			2022-12-25	WOS:A1995RR58400051
J	HUANG, XF; ARVAN, P				HUANG, XF; ARVAN, P			INTRACELLULAR-TRANSPORT OF PROINSULIN IN PANCREATIC BETA-CELLS - STRUCTURAL MATURATION PROBED BY DISULFIDE ACCESSIBILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; ENDOPLASMIC-RETICULUM; BREFELDIN-A; SECRETORY PATHWAY; PROTEIN-TRANSPORT; TREATED CELLS; INSULIN; OCCURS; GOLGI; ZINC	In pancreatic islets, formation of beta-secretory granule cores involves early proinsulin homohexamerization and subsequent insulin condensation. We examined proinsulin conformational maturation by monitoring accessibility of protein disulfide bonds. Proinsulin disulfides are intact immediately upon synthesis, but are greater than or equal to 90% sensitive to in vivo reduction with 2 mM dithiothreitol; wash out of dithiothreitol leads to reoxidation, proinsulin transport, and conversion to insulin. With t(1/2) similar to 10 min, newly synthesized proinsulin becomes resistant to disulfide reduction, correlating with endoplasmic reticulum (ER) export. However, inhibition of ER export with brefeldin A blocks acquisition of resistance to reduction, and once proinsulin arrives in the Golgi, it resists reduction despite brefeldin treatment, Moreover, in vivo, resistance of proinsulin disulfides is overcome after increasing [dithiothreitol] > 10-fold, or in vitro, in islets lysed in a zinc-free, but not a zinc-containing, medium. Employing 30 mM dithiothreitol in vivo, a further decrease in disulfide accessibility is observed following proinsulin conversion to insulin. Incubation of islets with chloroquine or zinc enhances and diminishes accessibility of insulin disulfides, respectively. We hypothesize that two major conformational changes culminating in granule core formation, proinsulin hexamerization and insulin condensation, are sensitive to zinc and occur upon ER exit and arrival in immature secre tory granules, respectively.	BETH ISRAEL HOSP,DIV ENDOCRINOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02215; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35209	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048280] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48280] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BENTLEY GA, 1992, J MOL BIOL, V228, P1163, DOI 10.1016/0022-2836(92)90323-C; BEWLEY TA, 1969, INT J PROT RES, V1, P117; Blundell T L, 1971, Recent Prog Horm Res, V27, P1; BLUNDELL TL, 1972, DIABETES, V21, P492, DOI 10.2337/diab.21.2.S492; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CARROLL RJ, 1988, P NATL ACAD SCI USA, V85, P8943, DOI 10.1073/pnas.85.23.8943; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHEN SY, 1991, J VIROL, V65, P1427, DOI 10.1128/JVI.65.3.1427-1439.1991; COLLEY KJ, 1987, J BIOL CHEM, V262, P10296; COLLINS PL, 1992, J GEN VIROL, V73, P849, DOI 10.1099/0022-1317-73-4-849; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; EMDIN SO, 1980, DIABETOLOGIA, V19, P174, DOI 10.1007/BF00275265; FARQUHAR MG, 1978, ENDOCRINOLOGY, V102, P296, DOI 10.1210/endo-102-1-296; FRANK BH, 1968, BIOCHEM BIOPH RES CO, V32, P155, DOI 10.1016/0006-291X(68)90362-8; FRANK BH, 1970, BIOCHEM BIOPH RES CO, V38, P284, DOI 10.1016/0006-291X(70)90710-2; FREEDMAN SD, 1993, EUR J CELL BIOL, V61, P229; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GOLD G, 1984, EXPERIENTIA, V40, P1105, DOI 10.1007/BF01971458; GOLDMAN J, 1974, BIOCHEMISTRY-US, V13, P4566, DOI 10.1021/bi00719a015; GRANT PT, 1972, BIOCHEM J, V126, P433, DOI 10.1042/bj1260433; GRUPPUSO PA, 1984, NEW ENGL J MED, V311, P629, DOI 10.1056/NEJM198409063111003; HOSHINA H, 1982, P NATL ACAD SCI-BIOL, V79, P7649, DOI 10.1073/pnas.79.24.7649; HOWELL SL, 1969, J CELL BIOL, V42, P695, DOI 10.1083/jcb.42.3.695; HUANG XF, 1994, J BIOL CHEM, V269, P20838; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JASCUR T, 1991, BIOCHEMISTRY-US, V30, P1908, DOI 10.1021/bi00221a025; JEFFREY PD, 1966, BIOCHEMISTRY-US, V5, P489, DOI 10.1021/bi00866a014; KAJI EH, 1993, J BIOL CHEM, V268, P22188; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KIM PS, 1993, J BIOL CHEM, V268, P4873; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MEANS GE, 1971, CHEM MODIFICATION PR, P37; MICHAEL J, 1987, J BIOL CHEM, V262, P16531; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; PALADE GE, 1975, SCIENCE, V230, P25; PETERS BP, 1984, J BIOL CHEM, V259, P5123; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; QUINN D, 1991, J CELL BIOL, V113, P987, DOI 10.1083/jcb.113.5.987; RUSS G, 1991, CELL REGUL, V2, P549, DOI 10.1091/mbc.2.7.549; SALPETER MM, 1981, J CELL BIOL, V91, P240, DOI 10.1083/jcb.91.1.240; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; STEINER DF, 1986, CLIN INVEST MED, V9, P328; STEINER DF, 1973, NATURE, V243, P528, DOI 10.1038/243528a0; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; VALETTI C, 1994, MOL BIOL CELL, V5, P1311, DOI 10.1091/mbc.5.12.1311; WAGNER DD, 1984, J CELL BIOL, V99, P2123, DOI 10.1083/jcb.99.6.2123; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8389, DOI 10.1021/bi00488a028	58	94	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20417	20423		10.1074/jbc.270.35.20417	http://dx.doi.org/10.1074/jbc.270.35.20417			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657617	hybrid			2022-12-25	WOS:A1995RR58400030
J	MASSON, L; LUN, YJ; MAZZA, A; BROUSSEAU, R; ADANG, MJ				MASSON, L; LUN, YJ; MAZZA, A; BROUSSEAU, R; ADANG, MJ			THE CRYIA(C) RECEPTOR PURIFIED FROM MANDUCA-SEXTA DISPLAYS MULTIPLE SPECIFICITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; THURINGIENSIS DELTA-ENDOTOXINS; SURFACE-PLASMON RESONANCE; BUTTERFLY PIERIS-BRASSICAE; PLANAR LIPID BILAYERS; BACILLUS-THURINGIENSIS; SELECTIVE CHANNELS; BINDING-SITES; BOMBYX-MORI; PROTEINS	The kinetic binding characteristics of four Bacillus thuringiensis CryI insecticidal crystal proteins to a Cry-binding protein, purified from Manduca sexta brush-border vesicles, were analyzed by an optical biosensor. This 120-kilodalton binding protein, previously determined to be aminopeptidase N, was converted to a 115-kilodalton water-soluble form by removing the attached glycosylphosphatidylinositol anchor with phospholipase C. The solubilized form recognized the three major subclasses of CryIA toxins but not CryIC even though all four CryI proteins are toxic to larvae of M. sexta. CryIA(a) and CryIA(b) toxins bound to a single site on the solubilized aminopeptidase N molecule whereas CryIA(c) bound to two distinct sites. Apparent kinetic rate constants were determined for each binding reaction. All three CryIA toxins exhibited moderately fast on rates (similar to 10(-5) M(-1) s(-1)) and a slow reversible off rate (similar to 10(-3) s(-1)). Although the second CryIA(c)-binding site retained a moderately fast association rate, it was characterized by a rate of dissociation from the aminopeptidase an order of magnitude faster than observed for the other CryIA-binding sites. CryIA(c) binding to both sites was strongly inhibited in the presence of N-acetylgalactosamine (IC50 = 5 mM) but not N-acetylglucosamine, mannose, or glucose. CryIA(a) and CryIA(b) binding were unaffected in the presence of the same sugars. Our results serve to illustrate both the complexity and the diverse nature of toxin interactions with Cry-binding proteins.	UNIV GEORGIA, DEPT ENTOMOL, ATHENS, GA 30602 USA	University System of Georgia; University of Georgia	MASSON, L (corresponding author), NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, 6100 ROYALMOUNT AVE, MONTREAL, PQ H4P 2R2, CANADA.							ADANG MJ, 1985, GENE, V36, P289, DOI 10.1016/0378-1119(85)90184-2; BORISOVA S, 1994, J MOL BIOL, V243, P530, DOI 10.1006/jmbi.1994.1678; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAVO A, 1992, J INVERTEBR PATHOL, V60, P247, DOI 10.1016/0022-2011(92)90005-O; ESTADA U, 1994, APPL ENVIRON MICROB, V60, P3840, DOI 10.1128/AEM.60.10.3840-3846.1994; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FENG Q, 1994, BIOCHEMISTRY-US, V33, P8521, DOI 10.1021/bi00194a017; FERRE J, 1991, P NATL ACAD SCI USA, V88, P5119, DOI 10.1073/pnas.88.12.5119; GARCZYNSKI SF, 1995, INSECT BIOCHEM MOLEC, V25, P409, DOI 10.1016/0965-1748(94)00072-7; GARCZYNSKI SF, 1991, APPL ENVIRON MICROB, V57, P2816, DOI 10.1128/AEM.57.10.2816-2820.1991; GROCHULSKI P, 1994, 6TH INT C INV PATH M; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOFMANN C, 1988, EUR J BIOCHEM, V173, P85, DOI 10.1111/j.1432-1033.1988.tb13970.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; INDRASITH LS, 1992, COMP BIOCHEM PHYS B, V102, P605, DOI 10.1016/0305-0491(92)90054-U; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; KNOWLES BH, 1991, P ROY SOC B-BIOL SCI, V245, P31, DOI 10.1098/rspb.1991.0084; KNOWLES BH, 1994, ADV INSECT PHYSIOL, V24, P275, DOI 10.1016/S0065-2806(08)60085-5; KNOWLES BH, 1987, BIOCHIM BIOPHYS ACTA, V924, P509, DOI 10.1016/0304-4165(87)90167-X; KNOWLES BH, 1986, J CELL SCI, V83, P89; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; MACINTOSH SC, 1991, P NATL ACAD SCI USA, V88, P8930, DOI 10.1073/pnas.88.20.8930; MARTINEZRAMIREZ AC, 1994, BIOCHEM BIOPH RES CO, V201, P782, DOI 10.1006/bbrc.1994.1769; MASSON L, 1990, BIOCHEM J, V269, P507, DOI 10.1042/bj2690507; MASSON L, 1995, J BIOL CHEM, V270, P11887, DOI 10.1074/jbc.270.20.11887; MASSON L, 1994, MOL MICROBIOL, V14, P851, DOI 10.1111/j.1365-2958.1994.tb01321.x; MASSON L, 1994, ANAL BIOCHEM, V218, P405, DOI 10.1006/abio.1994.1199; O'Shannessy D J, 1994, Curr Opin Biotechnol, V5, P65, DOI 10.1016/S0958-1669(05)80072-2; ODDOU P, 1993, EUR J BIOCHEM, V212, P145, DOI 10.1111/j.1432-1033.1993.tb17644.x; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PFANNENSTIEL MA, 1987, J BACTERIOL, V169, P796, DOI 10.1128/jb.169.2.796-801.1987; SANGADALA S, 1994, J BIOL CHEM, V269, P10088; SCHWARTZ JL, 1993, J MEMBRANE BIOL, V132, P53, DOI 10.1007/BF00233051; SCHWARTZ JL, 1991, BIOCHIM BIOPHYS ACTA, V1065, P250, DOI 10.1016/0005-2736(91)90237-3; SLATIN SL, 1990, BIOCHEM BIOPH RES CO, V169, P765, DOI 10.1016/0006-291X(90)90397-6; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; TABASHNIK BE, 1994, P NATL ACAD SCI USA, V91, P4120, DOI 10.1073/pnas.91.10.4120; VADLAMUDI RK, 1993, J BIOL CHEM, V268, P12334; VADLAMUDI RK, 1995, J BIOL CHEM, V270, P5490, DOI 10.1074/jbc.270.10.5490; VANFRANKENHUYZEN K, 1993, J INVERTEBR PATHOL, V62, P295, DOI 10.1006/jipa.1993.1116; VANRIE J, 1990, SCIENCE, V247, P72, DOI 10.1126/science.2294593; VANRIE J, 1989, EUR J BIOCHEM, V186, P239, DOI 10.1111/j.1432-1033.1989.tb15201.x; VANRIE J, 1990, APPL ENVIRON MICROB, V56, P1378, DOI 10.1128/AEM.56.5.1378-1385.1990; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; WOLFERSBERGER MG, 1990, EXPERIENTIA, V46, P475, DOI 10.1007/BF01954236	48	135	152	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20309	20315		10.1074/jbc.270.35.20309	http://dx.doi.org/10.1074/jbc.270.35.20309			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657602	hybrid			2022-12-25	WOS:A1995RR58400015
J	BISAHA, JG; SIMON, TC; GORDON, JI; BRESLOW, JL				BISAHA, JG; SIMON, TC; GORDON, JI; BRESLOW, JL			CHARACTERIZATION OF AN ENHANCER ELEMENT IN THE HUMAN APOLIPOPROTEIN C-III GENE THAT REGULATES HUMAN APOLIPOPROTEIN-A-I GENE-EXPRESSION IN THE INTESTINAL EPITHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL INTESTINE; HORMONE RECEPTOR SUPERFAMILY; CIS-ACTING ELEMENTS; E MESSENGER-RNA; STEM-CELL ZONE; TRANSGENIC MICE; GUT EPITHELIUM; PLASMA-LEVELS; MUCOUS CELLS; PANETH CELLS	Studies using transgenic mice indicate that expression of the human apolipoprotein (ape) A-I gene in the liver and small intestine is controlled by spatially distinct cis-acting DNA elements; hepatic expression is controlled by a domain defined by nucleotides -256 to -1, while small intestinal expression requires elements positioned 9 kilobases 3' to the gene, between nucleotides -1300 and -200 of the convergently transcribed apoC-III gene, In this report we have mapped this enhancer to a 260-base pair (bp) region of the apoC-III promoter spanning nucleotides -780 to -520, The elements contained within this 260-bp apoC-III domain are sufficient to direct a pattern of expression in villus-associated enterocytes distributed along the duodenal-to-ileal axis that resembles that of mouse and human apoA-I. However, the elements produce inappropriate activation of apoA-I expression in proliferating and nonproliferating crypt epithelial cells, and in subpopulations of cholecystokinin- and serotonin-producing enteroendocrine cells, Cis-acting suppressors of these inappropriate patterns of expression are located outside of nucleotides -1300 to -200 of the human apoC-III gene, DNase I protection and gel mobility gel shift assays identified two 21-bp sequences, nucleotides -745 to -725 and -700 to -680 of human apoC-III, which bind nuclear proteins present in a human enterocyte-like cell line (Caco-2), These sequences are conserved in the orthologous mouse apoC-III gene, The 260-bp apoC-III element is the first intestinal enhancer that has been identified in an in vivo system and should provide insights about how cell lineage-specific, differentiation-dependent, and cephalocaudal patterns of gene expression are established and maintained in the perpetually renewing gut epithelium, In addition, novel intestinal transcription factors may bind to the enhancer and regulate its activity.	ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Rockefeller University; Washington University (WUSTL)			Breslow, Jan L/B-7544-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008695, R01HL033714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08695, HL33714] Funding Source: Medline; NIDDK NIH HHS [DK30292] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGOTTI E, 1994, J BIOL CHEM, V269, P17371; AZROLAN N, 1990, J LIPID RES, V31, P1141; BJERKNES M, 1981, AM J ANAT, V160, P51, DOI 10.1002/aja.1001600105; BJERKNES M, 1981, AM J ANAT, V160, P77, DOI 10.1002/aja.1001600107; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHN SM, 1984, J BIOL CHEM, V259, P2456; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; ELSHOURBAGY NA, 1986, J BIOL CHEM, V261, P1998; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; GE RW, 1994, J BIOL CHEM, V269, P13185; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GREEN PHR, 1982, GASTROENTEROLOGY, V83, P1223; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAUER SJ, 1991, CIRCULATION S2, V84, P17; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; OPRINS A, 1994, J HISTOCHEM CYTOCHEM, V42, P497, DOI 10.1177/42.4.8126376; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; ROTH KA, 1990, P NATL ACAD SCI USA, V87, P6408, DOI 10.1073/pnas.87.16.6408; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; Sambrook J, 1989, MOL CLONING LABORATO; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SCHAEFER EJ, 1982, ARTERIOSCLEROSIS, V2, P16, DOI 10.1161/01.ATV.2.1.16; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SIMON TC, 1993, J BIOL CHEM, V268, P18345; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SMITH JD, 1988, J BIOL CHEM, V263, P8300; TRAHAIR JF, 1989, J CELL BIOL, V109, P3231, DOI 10.1083/jcb.109.6.3231; WALSH A, 1993, J LIPID RES, V34, P617; WALSH A, 1989, J BIOL CHEM, V264, P6488; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	51	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19979	19988		10.1074/jbc.270.34.19979	http://dx.doi.org/10.1074/jbc.270.34.19979			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650015	hybrid			2022-12-25	WOS:A1995RQ99100048
J	NATHAN, BP; CHANG, KC; BELLOSTA, S; BRISCH, E; GE, NF; MAHLEY, RW; PITAS, RE				NATHAN, BP; CHANG, KC; BELLOSTA, S; BRISCH, E; GE, NF; MAHLEY, RW; PITAS, RE			THE INHIBITORY EFFECT OF APOLIPOPROTEIN E4 ON NEURITE OUTGROWTH IS ASSOCIATED WITH MICROTUBULE DEPOLYMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORADIC ALZHEIMERS-DISEASE; RECEPTOR-RELATED PROTEIN; CENTRAL NERVOUS-SYSTEM; CHOLESTEROL TRANSPORT; E APOPROTEIN; CELLS; LIPOPROTEINS; BINDING; ALLELE; BRAIN	Evidence is presented for the differential effects of two isoforms of apolipoprotein (ape) E, apoE3 and apoE4, on neurite outgrowth and on the cytoskeleton of neuronal cells (Neuro aa) in culture. in the presence of a lipid source, apoE3 enhances and apoE4 inhibits neurite outgrowth. Immunocytochemical studies demonstrate that there is a higher concentration of apoE3 than apoE4 in both the cell bodies and neurites. Cells treated with apoE4 showed fewer microtubules and a greatly reduced ratio of polymerized to monomeric tubulin than did cells treated with apoE3. The effect of apoE4 on depolymerization of microtubules was shown by biochemical, immunocytochemical, and ultrastructural studies. The depolymerization of microtubules and the inhibition of neurite outgrowth associated with apoE4 suggest a mechanism whereby apoE4, which has been linked to the pathogenesis of Alzheimer's disease, may prevent normal neuronal remodeling from occurring later in life, when this neurodegenerative disorder develops.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV KANSAS,DEPT PHYSIOL & CELL BIOL,DIV BIOL SCI,LAWRENCE,KS 66045	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Kansas			Bellosta, Stefano/B-4473-2010	Bellosta, Stefano/0000-0001-5344-7824	NHLBI NIH HHS [HL41633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVILA J, 1994, CELL BIOL INT, V18, P309, DOI 10.1006/cbir.1994.1079; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BRAY PF, 1986, P NATL ACAD SCI USA, V83, P1480, DOI 10.1073/pnas.83.5.1480; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BROWNING PJ, 1994, J EXP MED, V180, P1949, DOI 10.1084/jem.180.5.1949; BU GJ, 1994, J BIOL CHEM, V269, P18521; CACERES A, 1992, NEURON, V9, P607, DOI 10.1016/0896-6273(92)90025-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAS HK, 1985, J BIOL CHEM, V260, P6240; HAN SH, 1994, J NEUROPATH EXP NEUR, V53, P535, DOI 10.1097/00005072-199409000-00013; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HUANG DY, 1994, NEUROSCI LETT, V182, P55, DOI 10.1016/0304-3940(94)90204-6; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; IQBAL K, 1986, LANCET, V2, P421; KEITH CH, 1990, CELL MOTIL CYTOSKEL, V17, P95, DOI 10.1002/cm.970170205; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1990, CURRENT OPINION LIPI, V1, P87; MANDELKOW EM, 1983, TRENDS BIOCHEM SCI, V18, P480; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; PERRY G, 1987, ALTERATIONS NEURONAL; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; RALL SC, 1986, METHOD ENZYMOL, V128, P273; REBECK GW, 1993, NEURON, V11, P575; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SHEA TB, 1992, J NEUROSCI RES, V32, P363, DOI 10.1002/jnr.490320308; SHEA TB, 1990, CELL BIOL INT REP, V14, P1093, DOI 10.1016/0309-1651(90)90017-S; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; TIWARI SC, 1993, ANAL BIOCHEM, V215, P96, DOI 10.1006/abio.1993.1560; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; YAN SCB, 1985, NEUROCHEM RES, V10, P1, DOI 10.1007/BF00964768; YU WQ, 1994, J NEUROSCI, V14, P5872	48	243	252	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19791	19799		10.1074/jbc.270.34.19791	http://dx.doi.org/10.1074/jbc.270.34.19791			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649988	hybrid, Green Submitted			2022-12-25	WOS:A1995RQ99100020
J	TINI, M; FRASER, RA; GIGUERE, V				TINI, M; FRASER, RA; GIGUERE, V			FUNCTIONAL INTERACTIONS BETWEEN RETINOIC ACID RECEPTOR-RELATED ORPHAN NUCLEAR RECEPTOR (ROR-ALPHA) AND THE RETINOIC ACID RECEPTORS IN THE REGULATION OF THE GAMMA-F-CRYSTALLIN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE LENS DEVELOPMENT; THYROID-HORMONE; RESPONSIVE ELEMENT; BINDING-SITE; NGFI-B; IDENTIFICATION; GENE; TRANSCRIPTION; EXPRESSION; INDUCTION	We have previously demonstrated that an everted repeat of the hexamer PuGGTCA located within the gamma F-crystallin promoter mediates activation of the murine gamma F-crystallin gene by retinoic acid and thyroid hormone receptors. Here, we show that the recently identified retinoic acid receptor-related orphan nuclear receptor (ROR alpha) is expressed in the murine lens and activates the gamma F-crystallin promoter. In contrast 60 the retinoic acid and thyroid hormone receptors, activation of the gamma F-crystallin promoter by ROR alpha requires binding to the single 3' half-site and spacer sequences of gamma F-crystallin hormone response element (gamma F-HRE). We further demonstrate that ROR alpha-dependent activation is repressed by the competitive binding of retinoic acid receptor/retinoid X receptor heterodimers to the gamma F-HRE in the absence of all-trans-retinoic acid. These studies suggest that the interplay of retinoid receptors and ROR alpha on the gamma F-HRE may constitute an important mechanism regulating gamma F-crystallin gene expression in the murine lens.	ROYAL VICTORIA HOSP,MOLEC ONCOL GRP,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3A 1A1,CANADA	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University			, MT/AAU-2370-2020	Giguere, Vincent/0000-0001-9567-3694				BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; BREITMAN ML, 1984, P NATL ACAD SCI-BIOL, V81, P7762, DOI 10.1073/pnas.81.24.7762; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARTER ME, 1993, J BIOL CHEM, V268, P13805; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; COULOMBRE JL, 1963, SCIENCE, V142, P1489, DOI 10.1126/science.142.3598.1489; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; GIGUERE V, 1990, MOL CELL BIOL, V10, P2335, DOI 10.1128/MCB.10.5.2335; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORING DR, 1993, DEV DYNAM, V196, P143, DOI 10.1002/aja.1001960208; GORING DR, 1992, EXP EYE RES, V54, P785, DOI 10.1016/0014-4835(92)90034-P; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; LIU QR, 1991, MOL CELL BIOL, V11, P1531, DOI 10.1128/MCB.11.3.1531; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOK S, 1989, NUCLEIC ACIDS RES, V17, P3563, DOI 10.1093/nar/17.9.3563; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCAVOY JW, 1980, DIFFERENTIATION, V17, P137, DOI 10.1111/j.1432-0436.1980.tb01091.x; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; MURERORLANDO M, 1987, DEV BIOL, V119, P260, DOI 10.1016/0012-1606(87)90227-2; RETNAKARAN R, 1994, MOL ENDOCRINOL, V8, P1234, DOI 10.1210/me.8.9.1234; REYER RW, 1977, EXP EYE RES, V24, P501, DOI 10.1016/0014-4835(77)90271-8; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; SYLVESTER I, 1994, NUCLEIC ACIDS RES, V22, P901, DOI 10.1093/nar/22.6.901; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; TINI M, 1994, MOL ENDOCRINOL, V8, P1494, DOI 10.1210/me.8.11.1494; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; YAMAMOTO Y, 1976, DEV GROWTH DIFFER, V18, P273	40	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20156	20161		10.1074/jbc.270.34.20156	http://dx.doi.org/10.1074/jbc.270.34.20156			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650034	hybrid			2022-12-25	WOS:A1995RQ99100071
J	VERGERES, G; MANENTI, S; WEBER, T; STURZINGER, C				VERGERES, G; MANENTI, S; WEBER, T; STURZINGER, C			THE MYRISTOYL MOIETY OF MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE (MARCKS) AND MARCKS-RELATED PROTEIN IS EMBEDDED IN THE MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-DISTRIBUTION; DEPENDENT BINDING; BOVINE BRAIN; PHOSPHORYLATION; RECEPTOR; AFFINITY; FAMILY; CELLS; TRANSFORMATION; MYRISTYLATION	Members of the myristoylated alanine-rich protein kinase C substrate (MARCKS) family are involved in several cellular processes such as secretion, motility, mitosis, and transformation, In addition to their ability to bind calmodulin and to cross-link actin filaments, reversible binding to the plasma membrane is most certainly an important component of the so far unknown functions of these proteins, We have therefore investigated the binding of murine MARCKS-related protein (MRP) to lipid vesicles, The partition coefficient, K-p, describing the affinity of myristoylated MRP for acidic lipid vesicles (20% phosphatidylserine, 80% phosphatidylcholine) is 5-8 x 10(3) M(-1), which is only 2-4 times larger than the partition coefficient for the unmyristoylated protein, Interestingly, the affinity of MRP for acidic lipid membranes is 20-30-fold smaller than reported for murine MARCKS (Rim, J., Shishido, T,, Jiang, X, Aderem, A, A, and McLaughlin, S, (1994) J. Biol, Chem. 269, 28214-28219), Since only a marginal binding could be observed with neutral phosphatidylcholine vesicles, we propose that electrostatic interactions are the major determinant of the binding of MRP to pure lipid membranes. Although the myristoyl moiety does not contribute drastically to the binding of MRP to vesicles, photolabeling experiments with a photoreactive phospholipid probe show that the fatty acid is embedded in the bilayer, The same membrane topology was found for bovine brain MARCKS, Since the relatively low affinity of MRP for vesicles is insufficient to account for a stable anchoring of the protein to cellular membranes, insertion of the myristoyl moiety into the bilayer might favor the interaction of MRP with additional factors required for the binding of the protein to intracellular membranes.	ETH ZURICH,DEPT BIOCHEM,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich	VERGERES, G (corresponding author), UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.		manenti, stephane/P-1518-2014; Weber, Thomas/A-2363-2008; Weber, Thomas/GLS-9125-2022	manenti, stephane/0000-0002-4793-3196; Weber, Thomas/0000-0002-0494-0484; Weber, Thomas/0000-0002-0494-0484				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLENIS J, 1992, CUR OPIN CELL BIOL, V119, P984; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; BUSCONI L, 1994, J BIOL CHEM, V269, P25016; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; DASILVA AM, 1990, J CELL BIOL, V111, P401, DOI 10.1083/jcb.111.2.401; DAVIDPFEUTY T, 1993, J CELL SCI, V105, P613; DENKAMP JAF, 1981, MEMBRANE STRUCTURE, P83; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; FRANCO M, 1993, J BIOL CHEM, V268, P24531; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P9695, DOI 10.1073/pnas.89.20.9695; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; HALLAK H, 1994, J BIOL CHEM, V269, P4571; HARRIS MPG, 1994, J MOL BIOL, V241, P136; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUANG M, 1994, J VIROL, V68, P5648, DOI 10.1128/JVI.68.9.5648-5655.1994; JAMES G, 1989, J BIOL CHEM, V264, P20928; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOBACH DF, 1993, GENOMICS, V17, P194, DOI 10.1006/geno.1993.1301; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MANENTI S, 1994, J BIOL CHEM, V269, P8309; MANENTI S, 1993, J BIOL CHEM, V268, P6878; MANENTI S, 1992, J BIOL CHEM, V267, P22310; MOENCH SJ, 1994, BIOCHEMISTRY-US, V17, P5791; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROSE SD, 1994, J NEUROCHEM, V63, P2314; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SIGAL CT, 1993, MOL CELL BIOL, V13, P3084, DOI 10.1128/MCB.13.5.3084; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2; VERGERES G, 1995, SIGNAL MECHANISMS H, V92, P125; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WEBER T, 1994, J BIOL CHEM, V269, P18353; WEBER T, 1995, J AM CHEM SOC, V117, P3084, DOI 10.1021/ja00116a013; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; YU G, 1992, VIROLOGY, V187, P46, DOI 10.1016/0042-6822(92)90293-X	55	75	81	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19879	19887		10.1074/jbc.270.34.19879	http://dx.doi.org/10.1074/jbc.270.34.19879			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650001	hybrid			2022-12-25	WOS:A1995RQ99100033
J	BACHURSKI, CJ; PRYHUBER, GS; GLASSER, SW; KELLY, SE; WHITSETT, JA				BACHURSKI, CJ; PRYHUBER, GS; GLASSER, SW; KELLY, SE; WHITSETT, JA			TUMOR-NECROSIS-FACTOR-ALPHA INHIBITS SURFACTANT PROTEIN-C GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS SYNDROME; TRANSGENIC MICE; PHORBOL ESTER; MOLECULAR-CLONING; FACTOR RECEPTORS; EXPRESSION; ADHESION; ELEMENTS; MOUSE; CYTOKINES	Pulmonary surfactant protein C (SP-C) is a 3.7-kDa, hydrophobic peptide secreted by alveolar type II epithelial cells. SP-C enhances surface tension lowering activity of surfactant phospholipids that is critical to the maintenance of alveolar volume at end expiration. The proinflammatory cytokine, tumor necrosis factor alpha (TNF-alpha), decreased SP-C mRNA within 24 h of intratracheal administration to mice. In vitro, TNF-alpha decreased SP-C mRNA in a time- and dose-dependent manner, reducing the steady state levels of SP-C mRNA by 3-5-fold. In contrast, TNF-alpha induced intercellular adhesion molecule-1 expression in both mouse lung and murine lung epithelial cell lines. Nuclear run-on analysis demonstrated that transcription of both the endogenous SP-C gene and a human SP-C promoter-driven transgene was inhibited by TNF-alpha. TNF-alpha decreased mouse SP-C chloramphenicol acetyltransferase mRNA in stably transfected murine lung epithelial cells, Deletion analysis of the SP-C promoter region demonstrated that TNF-alpha inhibited gene expression in constructs containing 320 base pairs 5' from the start of transcription of the mouse SP-C gene. Inhibition of surfactant protein C gene transcription by TNF-alpha may contribute to the abnormalities of surfactant homeostasis associated with pulmonary injury and infection.	CHILDRENS HOSP,MED CTR,DIV PULM BIOL,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center				Bachurski, Cindy/0000-0002-3118-0636	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007752] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07752, HL40043] Funding Source: Medline; NICHD NIH HHS [HD07200] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; BACHURSKI CJ, 1994, MOL CELL BIOL, V14, P4076, DOI 10.1128/MCB.14.6.4076; BEERS MF, 1992, AM J PHYSIOL, V263, pL151, DOI 10.1152/ajplung.1992.263.2.L151; BLOEMEN PGM, 1993, AM J RESP CELL MOL, V9, P586, DOI 10.1165/ajrcmb/9.6.586; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGITZ K, 1991, J BIOL CHEM, V206, P14024; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GREGORY TJ, 1991, J CLIN INVEST, V88, P1976, DOI 10.1172/JCI115523; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; HORLEY KJ, 1989, EMBO J, V8, P2889, DOI 10.1002/j.1460-2075.1989.tb08437.x; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LI YP, 1993, MOL CELL BIOL, V13, P3714, DOI 10.1128/MCB.13.6.3714; LOOK DC, 1994, J BIOL CHEM, V269, P8952; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MULLIGAN MS, 1993, AM J PATHOL, V142, P1739; PRYHUBER GS, 1994, AM J PHYSIOL, V267, pL16, DOI 10.1152/ajplung.1994.267.1.L16; PRYHUBER GS, 1990, J BIOL CHEM, V265, P20822; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STRIETER RM, 1993, CRIT CARE MED, V21, pS447, DOI 10.1097/00003246-199310001-00006; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; ULICH TR, 1991, AM J PATHOL, V138, P1485; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VILCEK J, 1991, J BIOL CHEM, V266, P7313; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; WHITSETT JA, 1992, AM J PHYSIOL, V262, pL688, DOI 10.1152/ajplung.1992.262.6.L688; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; WISPE JR, 1990, J CLIN INVEST, V86, P1954, DOI 10.1172/JCI114929	39	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19402	19407		10.1074/jbc.270.33.19402	http://dx.doi.org/10.1074/jbc.270.33.19402			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642621	hybrid			2022-12-25	WOS:A1995RP70300035
J	LOPEZ, I; BURNS, DJ; LAMBETH, JD				LOPEZ, I; BURNS, DJ; LAMBETH, JD			REGULATION OF PHOSPHOLIPASE-D BY PROTEIN-KINASE-C IN HUMAN NEUTROPHILS - CONVENTIONAL ISOFORMS OF PROTEIN-KINASE-C PHOSPHORYLATE A PHOSPHOLIPASE D-RELATED COMPONENT IN THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; PHOSPHATIDYLCHOLINE HYDROLYSIS; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; PHORBOL ESTERS; D ACTIVATION; HL-60 CELLS; CALCIUM; OVEREXPRESSION; MECHANISM	In a variety of intact cells, phorbol esters are known to activate phospholipase D. In a cell-free system consisting of plasma membrane and cytosol from human neutrophils, phorbol esters activated phospholipase D in an adenosine nucleotide triphosphate-dependent manner. ATP gamma S (adenosine 5'-O-(thiotriphosphate)) was 2-3-fold more effective than ATP, while ADP and AppNHp (adenyl-5'-yl imidodiphosphate) were ineffective, and activation was blocked by the kinase inhibitor staurosporine, In cytosol depleted of protein kinase C by chromatography on threonine Sepharose, phorbol ester-dependent activation was lost, but was restored upon addition of purified rat brain protein kinase C, The target for phosphorylation was shown to be the plasma membrane: plasma membrane was phosphorylated using ATP gamma S/phorbol 12,13-dibutyrate and protein kinase C and was reisolated to remove activators, Upon adding nucleotide depleted cytosol, activator-independent phospho lipase D activity was seen, Using this prephosphorylation protocol, PKC-dependent activation of plasma membranes was found to require micromolar calcium, implicating a conventional protein kinase C, Using recombinant isoforms of protein kinase C, only the conventional isoforms showed significant activation, with the following rank order of potency: beta(1) > alpha > gamma; the beta(2), delta, epsilon, eta, and zeta isoforms showed little or no activity. Thus, conventional isoform(s) of protein kinase C activate neutrophil phospholipase D by phosphorylating a target protein located in the plasma membrane.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; SPHINX PHARMACEUT,DURHAM,NC 27707	Emory University					NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER; NCI NIH HHS [CA46508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BELL RM, 1991, J BIOL CHEM, V266, P4661; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CABOT MC, 1989, FEBS LETT, V245, P85, DOI 10.1016/0014-5793(89)80197-8; CAO YZ, 1990, BIOCHEM BIOPH RES CO, V171, P955, DOI 10.1016/0006-291X(90)90777-K; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COOK SJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P265, DOI 10.1016/0167-4889(91)90166-U; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; ELDAR H, 1993, J BIOL CHEM, V268, P12560; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GO M, 1987, METHOD ENZYMOL, V141, P424; HARLOW E, 1988, ANTIBODIES LAB MANUA, P493; KISS Z, 1994, BIOCHEM J, V300, P751, DOI 10.1042/bj3000751; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; LAMBETH D, 1995, J BIOL CHEM, V270, P2431; LAMBETH JD, 1994, PROTEIN KINASE C, P121; LIN PY, 1992, EUR J BIOCHEM, V207, P163, DOI 10.1111/j.1432-1033.1992.tb17033.x; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MANGOURA D, 1993, P NATL ACAD SCI USA, V90, P2915, DOI 10.1073/pnas.90.7.2915; MCKINNON M, 1994, BBA-MOL CELL RES, V1222, P109, DOI 10.1016/0167-4889(94)90031-0; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MULLMANN TJ, 1990, BIOCHEM BIOPH RES CO, V170, P1197, DOI 10.1016/0006-291X(90)90520-W; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBEL D, 1991, SCAND J CLIN LAB INV, V51, P299, DOI 10.3109/00365519109091618; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PEMBER SO, 1983, ARCH BIOCHEM BIOPHYS, V221, P391, DOI 10.1016/0003-9861(83)90158-3; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; PFEILSCHIFTER J, 1993, FEBS LETT, V331, P267, DOI 10.1016/0014-5793(93)80350-4; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536; TETTENBORN CS, 1988, BIOCHEM BIOPH RES CO, V155, P249, DOI 10.1016/S0006-291X(88)81076-3; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; UINGS IJ, 1992, BIOCHEM J, V281, P597, DOI 10.1042/bj2810597; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANDERMEULEN J, 1990, BIOCHEM J, V271, P693, DOI 10.1042/bj2710693; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; YAMADA K, 1991, BIOCHEM BIOPH RES CO, V175, P159, DOI 10.1016/S0006-291X(05)81214-8; YANG SF, 1967, J BIOL CHEM, V242, P477	55	123	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19465	19472		10.1074/jbc.270.33.19465	http://dx.doi.org/10.1074/jbc.270.33.19465			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642630	hybrid			2022-12-25	WOS:A1995RP70300044
J	LINDBERG, RA; FISCHER, WH; HUNTER, T				LINDBERG, RA; FISCHER, WH; HUNTER, T			CHARACTERIZATION OF A HUMAN PROTEIN THREONINE KINASE ISOLATED BY SCREENING AN EXPRESSION LIBRARY WITH ANTIBODIES TO PHOSPHOTYROSINE	ONCOGENE			English	Article							TYROSINE KINASE; CONSERVED FEATURES; GENE-PRODUCT; CDNA CLONES; IDENTIFICATION; SERINE; PHOSPHORYLATION; FAMILY; AUTOPHOSPHORYLATION; ACID	We have studied the activity and substrate specificity of the catalytic domain of a protein kinase that was isolated in a screen of a human lambdagt11 fibroblast cDNA library with anti-phosphotyrosine antibodies. The sequence of this protein kinase would predict that it is a protein serine/threonine kinase, which at first seemed incongruent with the cloning method. However, recent reports indicate that some protein kinases can phosphorylate both tyrosine and serine/threonine residues. To determine whether this protein kinase, which we call PYT (for phosphotyrosine picked threonine kinase), was a dual-specificity protein kinase we investigated its substrate specificity when expressed in bacteria. The catalytic domain was active as a protein kinase when expressed from any of several promoters and when expressed as a TrpE fusion protein. All experiments that resulted in an active protein kinase, as judged by incorporation of P-32 by metabolic labeling, also resulted in the generation of proteins that were recognized by anti-phosphotyrosine antibodies. Phosphoamino acid analyses of the metabolically labeled proteins that were recognized by the antibodies consistently yielded large amounts of phosphothreonine and only trace amounts of phosphotyrosine. We mapped the phosphorylation sites in the phosphorylated PYT protein and found only phosphothreonine; 90% of the radioactivity mapped to a threonine in the region autophosphorylated by many protein kinases. These data demonstrate that PYT is primarily a protein threonine kinase, but that it can phosphorylate tyrosine to a small extent, making it a potential dual-specificity protein kinase.	SALK INST, PEPTIDE LAB, SAN DIEGO, CA 92186 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	Salk Institute; University of California System; University of California San Diego	LINDBERG, RA (corresponding author), SALK INST, MOLEC BIOL & VIROL LAB, POB 85800, SAN DIEGO, CA 92186 USA.				NATIONAL CANCER INSTITUTE [P30CA014195, R35CA039780] Funding Source: NIH RePORTER; NCI NIH HHS [CA-14195, CA-39780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; DOUVILLE EMJ, 1992, MOL CELL BIOL, V12, P2681, DOI 10.1128/MCB.12.6.2681; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FISCHER WH, 1991, METHODS NEUROSCI, V6, P69; FOSTER R, 1989, J BACTERIOL, V171, P272, DOI 10.1128/jb.171.1.272-279.1989; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; ICELY PL, 1991, J BIOL CHEM, V266, P16073; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KOZMA LM, 1991, METHOD ENZYMOL, V201, P28; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1991, METHOD ENZYMOL, V200, P557; LINDBERG RA, 1988, ONCOGENE, V3, P629; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YANSURA DG, 1990, METHOD ENZYMOL, V185, P161	29	35	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					351	359						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	7678926				2022-12-25	WOS:A1993KN00600014
J	VONZASTROW, M; LINK, R; DAUNT, D; BARSH, G; KOBILKA, B				VONZASTROW, M; LINK, R; DAUNT, D; BARSH, G; KOBILKA, B			SUBTYPE-SPECIFIC DIFFERENCES IN THE INTRACELLULAR SORTING OF G-PROTEIN-COUPLED RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VESICLES	We have examined the subcellular distribution of three subtypes of adrenergic receptor by immunocytochemical localization of wild-type and epitope-tagged proteins expressed in Cos-7 and K293 cells. Two subtypes (beta2 and Malpha2-10H) are localized in the plasma membrane at steady state in untreated cells, while another subtype (Malpha2-4H) is found both in the plasma membrane and in a population of intracellular vesicles. Within 15 min following the addition of adrenergic agonists, beta2 and Malpha2-10H receptors are differentially sorted; beta2 receptors are selectively internalized to intracellular vesicles, which are distinct from those containing Malpha2-4H receptors, while Malpha2-10H receptors remain in the plasma membrane. Subtype-specific sorting suggests a new class of functional properties that may differentiate the signaling and regulation of homologous G protein-coupled receptors.	STANFORD UNIV,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; STANFORD UNIV,DIV CARDIOVASC MED,STANFORD,CA 94305; STANFORD UNIV,DEPT PEDIAT,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; Stanford University				Kobilka, Brian/0000-0001-5958-3990	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32 GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; HARAGUCHI K, 1990, P NATL ACAD SCI USA, V87, P1208, DOI 10.1073/pnas.87.3.1208; INSEL PA, 1988, ALPHA 2 ADRENERGIC R, P281; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LINK R, 1992, MOL PHARMACOL, V42, P16; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; PERKINS JP, 1991, BETA ADRENERGIC RECE, P73; RANSNAS LA, 1989, P NATL ACAD SCI USA, V86, P7900, DOI 10.1073/pnas.86.20.7900; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RUFFOLO RR, 1991, PHARMACOL REV, V43, P475; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; SURYANARAYANA S, 1992, METHODS, V3, P193; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530	15	97	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					763	766						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678260				2022-12-25	WOS:A1993KG07700003
J	GERRITS, PM; OLSON, AL; PESSIN, JE				GERRITS, PM; OLSON, AL; PESSIN, JE			REGULATION OF THE GLUT4/MUSCLE-FAT GLUCOSE TRANSPORTER MESSENGER-RNA IN ADIPOSE-TISSUE OF INSULIN-DEFICIENT DIABETIC RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; DIFFERENTIAL REGULATION; PLASMA-MEMBRANE; EXPRESSION; CELLS; GLUT4; GENE; IDENTIFICATION; TRANSLOCATION; SUPPRESSION	Previous studies have documented that streptozotocin-induced insulin deficiency results in a marked decrease in adipose tissue GLUT4 glucose transporter mRNA levels (Sivitz, W. I., DeSautel, S. L., Kayano, T., Bell, G. I., and Pessin, J. E. (1989) Nature 340, 72-74). In this study, nuclear run-on analysis performed on diabetic and insulin-treated diabetic rats demonstrated that the decrease in GLUT4 mRNA occurs via a diabetes-induced decrease in GLUT4 transcription rate. The decrease in GLUT4 mRNA levels could be prevented by treatment of the diabetic animals with the adenosine receptor agonist phenylisopropyladenosine (PIA). Under these conditions, PIA completely blocked the elevation of intracellular cAMP levels associated with insulin deficiency. Surprisingly, isolation of primary rat adipocytes from control animals resulted in a rapid decrease (approximately 20-fold) in GLUT4 mRNA levels by 24 h with a concomitant increase (approximately 70-fold) in GLUT1 mRNA levels. This rapid loss of GLUT4 expression did not correlate with changes in adipocyte cAMP levels and was not prevented by treatment of the cells with either insulin and/or PIA. These data demonstrate that the decrease in GLUT4 transcription induced by insulin deficiency in vivo predominantly results from an increase in intracellular cAMP levels. In contrast, although GLUT4 transcription also decreases in adipocytes when removed from their normal physiological environment, this occurs independent of changes in cAMP levels.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042452, P30DK025295, K04DK001822] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42452, DK25295, DK01822] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HOFFMAN BB, 1986, J PHARMACOL EXP THER, V239, P715; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KAESTNER KH, 1991, P NATL ACAD SCI USA, V88, P1933, DOI 10.1073/pnas.88.5.1933; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; KAHN BB, 1991, J CLIN INVEST, V87, P561, DOI 10.1172/JCI115031; KAHN BB, 1991, J CLIN INVEST, V87, P2197, DOI 10.1172/JCI115254; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; MARSHALL S, 1984, J BIOL CHEM, V259, P6376; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; RHOADS DB, 1988, P NATL ACAD SCI USA, V85, P9042, DOI 10.1073/pnas.85.23.9042; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; RODBELL M, 1964, J BIOL CHEM, V239, P375; SELAWRY H, 1973, BIOCHEM BIOPH RES CO, V51, P198, DOI 10.1016/0006-291X(73)90528-7; SIVITZ WI, 1990, MOL ENDOCRINOL, V4, P583, DOI 10.1210/mend-4-4-583; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	28	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					640	644						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678005				2022-12-25	WOS:A1993KE60300096
J	COCQUERELLE, C; MASCREZ, B; HETUIN, D; BAILLEUL, B				COCQUERELLE, C; MASCREZ, B; HETUIN, D; BAILLEUL, B			MISSPLICING YIELDS CIRCULAR RNA MOLECULES	FASEB JOURNAL			English	Article						CIRCULAR RNA; C-ETS-1; MISSPLICING; PROTOONCOGENE	GENE; EXPRESSION; INTRON	We previously identified novel human ets-1 transcripts in which the normal order of exons is inverted, and demonstrated that although the order of exons is different than in the genomic DNA, splicing of these exons out of order occurs in pairs using genuine splice sites (1). Here we determine the structure of these novel transcripts, showing that they correspond to circular RNA molecules containing only exons in genomic order. These transcripts are stable molecules, localized in the cytoplasmic component of the cells. To our knowledge, this is the first case of circular transcripts being processed from nuclear pre-mRNA in eukaryotes. This new type of transcript might represent a novel aspect of gene expression and hold some interesting clues about the splicing mechanism.	INST RECH CANC, INSERM, U124, PL VERDUN, F-59045 LILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille								AEBI M, 1987, TRENDS GENET, V3, P102, DOI 10.1016/0168-9525(87)90193-4; BERGER SL, 1989, METHOD ENZYMOL, V180, P3; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; BISHOP JM, 1990, BIOSCIENCE REP, V10, P473, DOI 10.1007/BF01116609; BOVENBERG RAL, 1986, NUCLEIC ACIDS RES, V14, P8785, DOI 10.1093/nar/14.22.8785; COCQUERELLE C, 1992, EMBO J, V11, P1095, DOI 10.1002/j.1460-2075.1992.tb05148.x; DORVAL BC, 1991, J MOL BIOL, V221, P837, DOI 10.1016/0022-2836(91)80179-X; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GATTONI R, 1986, J MOL BIOL, V187, P379, DOI 10.1016/0022-2836(86)90440-7; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HALUSKA FG, 1987, TRENDS GENET, V3, P11, DOI 10.1016/0168-9525(87)90155-7; JORCYK CL, 1991, ONCOGENE, V6, P523; KERCKAERT JP, 1990, LEUKEMIA, V4, P16; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; REDDY ESP, 1988, ONCOGENE RES, V3, P239	20	780	866	5	76	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					155	160		10.1096/fasebj.7.1.7678559	http://dx.doi.org/10.1096/fasebj.7.1.7678559			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	7678559				2022-12-25	WOS:A1993KH88000023
J	PIERONI, JP; HARRY, A; CHEN, JQ; JACOBOWITZ, O; MAGNUSSON, RP; IYENGAR, R				PIERONI, JP; HARRY, A; CHEN, JQ; JACOBOWITZ, O; MAGNUSSON, RP; IYENGAR, R			DISTINCT CHARACTERISTICS OF THE BASAL ACTIVITIES OF ADENYLYL CYCLASE-2 AND CYCLASE-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHORBOL ESTER TREATMENT; BETA-GAMMA-SUBUNITS; HETEROLOGOUS DESENSITIZATION; INHIBITION; IDENTIFICATION; STIMULATION; DIVERSITY; CLONING; ENZYME	Regulation of basal activities of adenylyl cyclase (AC) 2 and 6, expressed in Sf9 cells by infection with recombinant baculovirus, was studied. An antipeptide antibody that recognizes AC2 and AC6 with equal sensitivity was used to establish that equivalent levels were expressed. Basal activities of AC2 and AC6 were compared at varying concentrations of Mg2+ or Mn2+ ions; AC2 had 15- and 10-fold greater activity than AC6, respectively. At 20 mM Mg2+, the K-m values for ATP were 88 and 39 mu M for AC2 and AC6, respectively, whereas their V-max values were 281 and 11 pmol/mg protein . min. With 100 mu M forskolin and either Mg2+ or Mn2+, the difference in activities between AC2 and AC6 was reduced to approximately 2-fold. Forskolin stimulated AC6 greater than 40-fold at 0.5-2 mM Mg2+, whereas AC2 was stimulated 4-6-fold. At 20 mM Mg2+, AC2 was stimulated 2-fold by forskolin, whereas AC6 was stimulated 18-fold. With Mg2+ alone, activities of AC2 and AC6 were not saturable up to 20 mM and yielded curvilinear Hofstee transformations. With forskolin, activities of both AC2 and AC6 were saturable by 10 mM Mg2+ and yielded linear Hofstee transformations. These data indicate that there are substantial differences in the basal enzymatic activities of adenylyl cyclase isoforms, due to differential regulation by Mg2+ ions rather than intrinsic catalytic capabilities. Thus the presence and relative abundance of adenylyl cyclase subtypes could greatly affect the resting cellular cAMP levels with consequent effects on important biological functions, such as differentiation and proliferation.			PIERONI, JP (corresponding author), CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029, USA.		jacobowitz, ofer/U-2592-2017	jacobowitz, ofer/0000-0003-2290-0520	NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761, T32DK007645] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44998] Funding Source: Medline; NIDDK NIH HHS [DK-38761, DK-07645] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BLAIR SS, 1995, NATURE, V373, P656, DOI 10.1038/373656a0; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; COLLIER HOJ, 1980, NATURE, V283, P625, DOI 10.1038/283625a0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; INGLESE J, 1993, J BIOL CHEM, V268, P23735; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; Pieroni J P, 1993, Curr Opin Neurobiol, V3, P345, DOI 10.1016/0959-4388(93)90127-K; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; RALL TW, 1982, HDB EXPT PHARM, V58, P3; RICH KA, 1984, J BIOL CHEM, V259, P7893; ROSS EM, 1978, J BIOL CHEM, V253, P6401; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SOMKUTI SG, 1982, J BIOL CHEM, V257, P6387; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	32	77	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21368	21373		10.1074/jbc.270.36.21368	http://dx.doi.org/10.1074/jbc.270.36.21368			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673172	hybrid			2022-12-25	WOS:A1995RU05400076
J	ROSENWALD, IB; KASPAR, R; ROUSSEAU, D; GEHRKE, L; LEBOULCH, P; CHEN, JJ; SCHMIDT, EV; SONENBERG, N; LONDON, IM				ROSENWALD, IB; KASPAR, R; ROUSSEAU, D; GEHRKE, L; LEBOULCH, P; CHEN, JJ; SCHMIDT, EV; SONENBERG, N; LONDON, IM			EUKARYOTIC TRANSLATION INITIATION-FACTOR 4E REGULATES EXPRESSION OF CYCLIN D1 AT TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; RNA 5' CAP; MESSENGER-RNA; CELL-CYCLE; GENE-EXPRESSION; MALIGNANT TRANSFORMATION; RODENT FIBROBLASTS; LYMPHOCYTES-T; GROWTH; PHOSPHORYLATION	Regulation of the cell cycle is orchestrated by cyclins and cyclin-dependent kinases. We have demonstrated previously that overexpression of eukaryotic translation initiation factor 4E (eIF-4E) in NIH 3T3 cells growing in 10% fetal calf serum leads to highly elevated levels of cyclin D1 protein without significant increase in cyclin D1 mRNA levels, suggesting that a post-transcriptional mechanism is involved. (Rosenwald, I. B., Lazaris-Karatzas, A., Sonenberg, N., and Schmidt, E. V. (1993) Mol. Cell. Biol. 13, 7358-7363). In the present reseach, we did not find any significant effect of eIF-4E on polysomal distribution of cyclin D1 mRNA. However, the total amount of cyclin D1 mRNA associated with polysomes was significantly increased by eIF-4E overexpression. Further, we determined that the levels of both cyclin D1 protein and mRNA are increased in serum-deprived cells overexpressing eIF-4E. Nuclear run-on experiments demonstrated that the rate of the cyclin D1 transcription is not down-regulated in serum-deprived cells overexpressing eIF-4E. Thus, elevated levels of eIF-4E may lead to increased transcription of the cyclin D1 gene, and this effect becomes visible when serum deprivation down-regulates the rate of cyclin D1 mRNA synthesis in control cells. However, artificial overexpression of cyclin D1 mRNA in serum-deprived cells in the absence of eIF-4E overexpression did not cause the elevation of cyclin D1 protein, and this overexpressed cyclin D1 mRNA accumulated in the nucleus, suggesting that one post-transcriptional role of eIF-4E is to transport cyclin D1 mRNA from the nucleus to cytoplasmic polysomes.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CTR CANC,BOSTON,MA 02129	Harvard University; Brigham & Women's Hospital; Harvard Medical School; McGill University; Harvard University; Harvard Medical School; Massachusetts General Hospital	ROSENWALD, IB (corresponding author), HARVARD MIT DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139, USA.				NCI NIH HHS [R01-CA63117-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK016272, DK-16272] Funding Source: Medline; NIGMS NIH HHS [R01 GM042504, GM-42504] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016272, R56DK016272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042504] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARVE SS, 1994, J IMMUNOL, V152, P1171; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EPIFANOVA OI, 1977, INT REV CYTOL      S, V5, P303; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; HERBER B, 1994, ONCOGENE, V9, P1295; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JEDLICKA P, 1991, J BIOL CHEM, V266, P15663; JIANG W, 1993, ONCOGENE, V8, P3447; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KASPAR RL, 1992, J BIOL CHEM, V267, P508; KHOCHBIN S, 1988, J MOL BIOL, V200, P55, DOI 10.1016/0022-2836(88)90333-6; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P6912; LOVEC H, 1994, ONCOGENE, V9, P323; MAO XH, 1992, J BIOL CHEM, V267, P20444; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; RONNING OW, 1981, J CELL PHYSIOL, V109, P411, DOI 10.1002/jcp.1041090306; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMITH M R, 1990, New Biologist, V2, P648; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WHITHER DA, 1991, MOL CELL BIOL, V11, P4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910	40	228	231	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21176	21180		10.1074/jbc.270.36.21176	http://dx.doi.org/10.1074/jbc.270.36.21176			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673150	hybrid			2022-12-25	WOS:A1995RU05400049
J	STDENIS, JF; BERTELOOT, A; VIDAL, H; ANNABI, B; VANDEWERVE, G				STDENIS, JF; BERTELOOT, A; VIDAL, H; ANNABI, B; VANDEWERVE, G			GLUCOSE-TRANSPORT AND GLUCOSE-6-PHOSPHATE HYDROLYSIS IN INTACT RAT-LIVER MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE-DISEASE TYPE-1A; GLUCOSE-6-PHOSPHATE TRANSPORT; MULTIFUNCTIONAL GLUCOSE-6-PHOSPHATASE; PROTEIN; SYSTEM; IDENTIFICATION; PYROPHOSPHATE; PHOSPHATE; KINETICS; VESICLES	Glucose transport was investigated in rat liver microsomes in relation to glucose 6-phosphatase (Glu-6-Pase) activity using a fast sampling, rapid filtration apparatus. 1) The rapid phase in tracer uptake and the burst phase in glucose 6-phosphate (Glu-6-P) hydrolysis appear synchronous, while the slow phase of glucose accumulation occurs during the steady-state phase of glucose production. 2) [C-14]Glucose efflux from preloaded microsomes can be observed upon addition of either cold Glu-6-P or Glu-6-Pase inhibitors, but not cold glucose. 3) Similar steady-state levels of intramicrosomal glucose are observed under symmetrical conditions of Glu-6-P or vanadate concentrations during influx and efflux experiments, and those levels are directly proportional to Glu-6-Pase activity. 4) The rates of both glucose influx and efflux are characterized by t(1/2) values that are independent of Glu-6-P concentrations. 5) Glucose efflux in the presence of saturating concentrations of vanadate was not blocked by 1 mM phloretin, and the initial rates of efflux appear directly proportional to intravesicular glucose concentrations. 6) It is concluded that glucose influx into microsomes is tightly linked to Glu-6-Pase activity, while glucose efflux may occur independent of hydrolysis, so that microsomal glucose transport appears unidirectional even though it can be accounted for by diffusion only over the accessible range of sugar concentrations.	UNIV MONTREAL,DEPT NUTR,ENDOCRINOL METAB LAB,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,DEPT BIOCHEM,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,GRP RECH TRANSPORT MEMBRANAIRE,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,DEPT PHYSIOL,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal			Vidal, Hubert/M-6674-2017	Vidal, Hubert/0000-0002-9467-0317				ARION WJ, 1980, J BIOL CHEM, V255, P396; BERTELOOT A, 1991, J BIOL CHEM, V266, P5497; BERTELOOT A, 1990, METHOD ENZYMOL, V192, P409; BERTELOOT A, 1995, J BIOL CHEM, V270, P21098, DOI 10.1074/jbc.270.36.21098; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUBLITZ C, 1988, BIOCHIM BIOPHYS ACTA, V965, P90, DOI 10.1016/0304-4165(88)90155-9; BURCHELL A, 1990, FASEB J, V4, P2978, DOI 10.1096/fasebj.4.12.2168325; BURCHELL A, 1994, BIOCHEM SOC T, V22, P658, DOI 10.1042/bst0220658; CHENU C, 1993, J MEMBRANE BIOL, V132, P95; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; NORDLIE RC, 1982, METHOD ENZYMOL, V87, P319; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; ROMANELLI A, 1994, BIOCHEM BIOPH RES CO, V200, P1491, DOI 10.1006/bbrc.1994.1619; SCHULZE HU, 1986, J BIOL CHEM, V261, P6571; SCHULZE HU, 1980, EUR J BIOCHEM, V106, P505, DOI 10.1111/j.1432-1033.1980.tb04597.x; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; SINGH J, 1981, BIOCHIM BIOPHYS ACTA, V678, P477, DOI 10.1016/0304-4165(81)90129-X; STDENIS JF, 1994, J CLIN ENDOCR METAB, V79, P955, DOI 10.1210/jc.79.4.955; STEIN WD, 1981, MEMBRANE TRANSPORT, P123; VIDAL H, 1992, FEBS LETT, V302, P197, DOI 10.1016/0014-5793(92)80439-N; WADDELL ID, 1988, FEBS LETT, V229, P179, DOI 10.1016/0014-5793(88)80822-6; WADDELL ID, 1991, BIOCHEM J, V275, P363, DOI 10.1042/bj2750363; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173; ZERR C, 1968, BIOCHEM BIOPH RES CO, V32, P129, DOI 10.1016/0006-291X(68)90357-4	25	32	32	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21092	21097		10.1074/jbc.270.36.21092	http://dx.doi.org/10.1074/jbc.270.36.21092			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673139	hybrid			2022-12-25	WOS:A1995RU05400037
J	THOMAS, DC; VEAUTE, X; FUCHS, RPP; KUNKEL, TA				THOMAS, DC; VEAUTE, X; FUCHS, RPP; KUNKEL, TA			FREQUENCY AND FIDELITY OF TRANSLESION SYNTHESIS OF SITE-SPECIFIC N-2-ACETYLAMINOFLUORENE ADDUCTS DURING DNA-REPLICATION IN A HUMAN CELL EXTRACT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED DNA; UV-IRRADIATED DNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; REPETITIVE SEQUENCES; ANGSTROM RESOLUTION; MUTAGENESIS; POLYMERASE; MUTATIONS; INVITRO	We have previously analyzed the effects of site-specific N-2-acetylaminofluorene (AAF) adducts on the efficiency and frameshift fidelity of SV40-based DNA replication in a human cell extract (Thomas, D. C., Veaute, X,, Kunkel, T. A., and Fuchs, R. P. P. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 7752-7756). Here we use two sets of substrates to examine the probability of replication termination and error-free and error-prone bypass of AAF adducts. The substrates contained site-specific adducts at one of three guanines in a NarI sequence (5'-GGCGCC-3') placed within the lacZ alpha reporter gene and located on the template for either leading or lagging strand replication. The presence of the adduct at any position strongly reduces the efficiency of a single round of replication in a HeLa cell extract, Product analysis reveals preferential replication of the undamaged strand and termination of replication of the damaged strand occurring one nucleotide before incorporation opposite either a leading or lagging strand adduct, Products resistant to restriction endonuclease cleavage at the adducted site were generated in amounts consistent with 16-48% lesion bypass during replication, Most of this bypass was error-free, However, two-nucleotide deletion errors were detected in the replication products of DNA containing an AAF adduct in either the leading or lagging strand, but only when present at the third guanine position. Collectively, the data suggest that the replication apparatus in a HeLa cell extract generates a template-primer slippage error at an AAF adduct once for every 30-100 bypass events.	NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709; ECOLE SUPER BIOTECHNOL STRASBOURG,CNRS,UPR CANCEROGENESE & MUTAGENESE & STRUCT,F-67400 ILLKIRCH GRAFFENS,FRANCE	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Centre National de la Recherche Scientifique (CNRS)			Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788				BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BELGUISEVALLADI.P, 1994, J MOL BIOL, V236, P151; BOYER JC, 1993, CANCER RES, V53, P3270; BURHANS WC, 1991, EMBO J, V10, P4351, DOI 10.1002/j.1460-2075.1991.tb05013.x; BURNOUF D, 1989, P NATL ACAD SCI USA, V86, P4147, DOI 10.1073/pnas.86.11.4147; CARTY MP, 1993, MOL CELL BIOL, V13, P533, DOI 10.1128/MCB.13.1.533; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; GARCIA A, 1993, P NATL ACAD SCI USA, V90, P5989, DOI 10.1073/pnas.90.13.5989; HAUSER J, 1988, MOL CELL BIOL, V8, P3267, DOI 10.1128/MCB.8.8.3267; IZUTA S, 1995, J BIOL CHEM, V270, P2595, DOI 10.1074/jbc.270.6.2595; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; KOFFELSCHWARTZ N, 1987, J MOL BIOL, V193, P651, DOI 10.1016/0022-2836(87)90348-2; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KORNBERG A, 1992, DNA PEPLICATION; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; LAMBERT IB, 1992, P NATL ACAD SCI USA, V89, P1310, DOI 10.1073/pnas.89.4.1310; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; MILHE C, 1994, NUCLEIC ACIDS RES, V22, P4646, DOI 10.1093/nar/22.22.4646; MINNICK DT, 1994, NUCLEIC ACIDS RES, V22, P5658, DOI 10.1093/nar/22.25.5658; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; RABKIN SD, 1984, J MOL BIOL, V178, P569, DOI 10.1016/0022-2836(84)90239-0; ROBERTS JD, 1993, BIOCHEMISTRY-US, V32, P4083, DOI 10.1021/bi00066a033; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; ROBERTS JD, 1995, IN PRESS DNA REPLICA; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; SCHAAPER RM, 1990, CARCINOGENESIS, V11, P1087, DOI 10.1093/carcin/11.7.1087; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; THOMAS DC, 1994, P NATL ACAD SCI USA, V91, P7752, DOI 10.1073/pnas.91.16.7752; THOMAS DC, 1993, P NATL ACAD SCI USA, V90, P7744, DOI 10.1073/pnas.90.16.7744; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; THOMAS DC, 1993, BIOCHEMISTRY-US, V32, P11476, DOI 10.1021/bi00094a002; VEAUTE X, 1993, SCIENCE, V261, P598, DOI 10.1126/science.8342022	36	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21226	21233		10.1074/jbc.270.36.21226	http://dx.doi.org/10.1074/jbc.270.36.21226			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673156	hybrid			2022-12-25	WOS:A1995RU05400056
J	ELKIND, NB; GOLDFINGER, N; ROTTER, V				ELKIND, NB; GOLDFINGER, N; ROTTER, V			SPOT-1, A NOVEL NLS-BINDING PROTEIN THAT INTERACTS WITH P53 THROUGH A DOMAIN ENCODED BY P(CA)(N) REPEATS	ONCOGENE			English	Article						NLS; P(CA)(N) REPEATS; P53; EXPRESSION LIBRARY	NUCLEAR-LOCALIZATION SIGNALS; WILD-TYPE P53; NF-KAPPA-B; CELL-CYCLE; LOCATION SIGNAL; CYTOPLASMIC RETENTION; KARYOPHILIC PROTEINS; COLORECTAL-CANCER; ESCHERICHIA-COLI; HUMAN-DISEASE	Nuclear Localization Signals (NLS) have been found to mediate the import of proteins into the nucleus. Proteins interacting directly with NLS control the subcellular localization of nucleophillic proteins. The p53 protein is spatially regulated throughout the cell cycle and this regulation has been shown to be dependent on the presence of its NLS sequences. We identified three novel cDNA clones that were isolated from an expression library because they encode polypeptides that bind a synthetic peptide containing the major NLS of p53 (NLS I). These clones were found to share a common domain encoded by p(CA)(n) repeats; a simple sequence length polymorphism (SSLP). This is the first report where p(CA)(n) repeats mere found to encode protein. One cDNA clone encodes a fun length, 16 kDa protein, designated spot-1, that is represented in cells predominantly as oligomers. spot-1 interacts with the NLS I of p53 through its p(CA)(n) repeat. Cell fractionation and immunofluorescence analysis demonstrated that spot-1 is a nuclear protein which, in fibroblasts, co-localizes with p53.	WEIZMANN INST SCI, DEPT CELL BIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BENDITT JO, 1989, P NATL ACAD SCI USA, V86, P9327, DOI 10.1073/pnas.86.23.9327; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; DANG CV, 1989, J BIOL CHEM, V264, P18019; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOLDFARB DS, 1988, CELL BIOL INT REP, V12, P809, DOI 10.1016/0309-1651(88)90090-2; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HARPER JW, 1993, CELL, V75, P805; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HURT EC, 1993, FEBS LETT, V325, P76, DOI 10.1016/0014-5793(93)81417-X; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; LACASSE EC, 1993, ENDOCRINOLOGY, V132, P1017, DOI 10.1210/en.132.3.1017; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; LI RH, 1992, EXP CELL RES, V202, P355, DOI 10.1016/0014-4827(92)90085-M; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEIER UT, 1992, CELL, V70, P127; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PANDEY S, 1991, BIOCHIM BIOPHYS ACTA, V1063, P81, DOI 10.1016/0005-2736(91)90356-D; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; RIGGINS GJ, 1992, NAT GENET, V2, P186, DOI 10.1038/ng1192-186; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; SHAN XY, 1994, J CELL BIOL, V126, P853, DOI 10.1083/jcb.126.4.853; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOCHAJ U, 1991, J CELL BIOL, V113, P1243, DOI 10.1083/jcb.113.6.1243; STOCHAJ U, 1992, J CELL BIOL, V117, P473, DOI 10.1083/jcb.117.3.473; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; Xue Zhixiong, 1994, Trends in Cell Biology, V4, P414, DOI 10.1016/0962-8924(94)90095-7; YONEDA Y, 1988, SCIENCE, V242, P275, DOI 10.1126/science.3051382; ZERRAHN J, 1992, ONCOGENE, V7, P1371	86	13	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					841	851						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675445				2022-12-25	WOS:A1995RU79800004
J	STONE, S; DAYANANTH, P; JIANG, P; WEAVERFELDHAUS, JM; TAVTIGIAN, SV; CANNONALBRIGHT, L; KAMB, A				STONE, S; DAYANANTH, P; JIANG, P; WEAVERFELDHAUS, JM; TAVTIGIAN, SV; CANNONALBRIGHT, L; KAMB, A			GENOMIC STRUCTURE, EXPRESSION AND MUTATIONAL ANALYSIS OF THE P15 (MTS2) GENE	ONCOGENE			English	Note						TUMORGENESIS; CDK INHIBITOR; CELL CYCLE	INHIBITION; KINASES; P21	The P15 gene (MTS2) encodes a cyclin-dependent kinase (CDK) inhibitor with considerable sequence identity and biochemical similarity to the CDK inhibitor p16. It is closely linked to the Pld gene (MTS1) and is homozygously deleted in many tumor cell lines. These features suggest that p15 may be a tumor suppressor. We have determined the genomic structure of P15 and examined its pattern of mRNA expression. In addition, we have shown that ectopic expression of p15 inhibits growth of tumor-derived cell lines. We have also searched for P15 mutations in tumor cell lines and in 9p21-linked melanoma kindreds. Other than the previously described homozygous deletions, no mutations of P15 were found. Collectively, these observations suggest a role for p15 in growth regulation, but a limited role for p15 in tumor progression.	MYRIAD GENET INC, SALT LAKE CITY, UT 84018 USA; UNIV UTAH, MED CTR, DEPT INTERNAL MED, SALT LAKE CITY, UT 84132 USA	Myriad Genetics, Inc; Utah System of Higher Education; University of Utah				albright, lisa/0000-0003-2602-3668				CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELSTAD MR, 1988, J IMMUNOL, V140, P1618; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1995, GENE DEV, V8, P6078; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HORI T, 1987, BLOOD, V70, P1069; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V265, P416, DOI 10.1126/science.265.5170.416; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAMB A, 1994, CSH S QUANT BIOL, V59, P38; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LI Y, 1994, ONCOGENE, V9, P2261; LI Y, 1994, CANCER RES, V54, P6078; LIU Q, 1995, ONCOGENE, V10, P1061; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sambrook J, 1989, MOL CLONING LABORATO; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STONE S, 1995, IN PRESS CANCER RES; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	34	112	124	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					987	991						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675459				2022-12-25	WOS:A1995RU79800021
J	CASEY, EB; ZHAO, HR; ABRAHAM, EC				CASEY, EB; ZHAO, HR; ABRAHAM, EC			ROLE OF GLYCINE-1 AND LYSINE-2 IN THE GLYCATION OF BOVINE GAMMA-B-CRYSTALLIN - SITE-DIRECTED MUTAGENESIS OF LYSINE TO THREONINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ANALYSIS; LENS CRYSTALLINS; EYE LENS; DIABETIC CATARACT; ALPHA-CRYSTALLINS; CROSS-LINKING; END-PRODUCTS; PROTEINS; GLYCOSYLATION; AGGREGATION	To determine the role of Gly-1 and Lys-8 of bovine gamma B crystallin in glycation and cross-linking, Lys-2 was changed to Thr by site-directed mutagenesis. A polymerase chain reaction was used to perform site directed mutagenesis on the third codon (AAG --> ACG) of bovine gamma B-crystallin cDNA. The wild type and mutant cDNAs were cloned into pMON5743 and expressed in JM101 Escherichia coli cells, and the identity of gamma B-crystallin was confirmed by Western blotting after purification by cation exchange high performance liquid chromatography. Glycation of gamma B-crystallin by [C-14]glucose was reduced significantly due to the mutation of Lys-2, supporting the view that Lys-2 is a major glycation site. Peptide mapping showed the presence of two major labeled peptides containing N-terminal sequences, and in the mutant these peptides had longer retention times and reduced radioactivity. Amino acid analysis, after glycation with [C-14]glucose, revealed N-terminal glycine as the most predominant glycation site. Lys-8 was glycated slower than Gly-1 but faster than Lys-163. Glycation with DL-glyceraldehyde showed an important role for both Gly-1 and Lys-2 in the glycation-mediated gamma B-crystallin cross-linking.	MED COLL GEORGIA,DEPT BIOCHEM & MOLEC BIOL,AUGUSTA,GA 30912	University System of Georgia; Augusta University					NATIONAL EYE INSTITUTE [R01EY007394] Funding Source: NIH RePORTER; NEI NIH HHS [EY 07394] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABRAHAM EC, 1991, EXP EYE RES, V52, P107, DOI 10.1016/0014-4835(91)90135-2; ABRAHAM EC, 1994, BIOCHEM BIOPH RES CO, V201, P1451, DOI 10.1006/bbrc.1994.1866; ABRAHAM EC, 1985, GLYCOSYLATED HEMOGLO, P33; ABRAHAM EC, 1989, MAILLARD REACTION AG, P123; ACHARYA AS, 1988, BIOCHEMISTRY-US, V27, P4522, DOI 10.1021/bi00412a045; ARAKI N, 1992, J BIOL CHEM, V267, P10211; BESWICK HT, 1987, BIOCHEM J, V246, P761, DOI 10.1042/bj2460761; BLOEMENDAL H, 1989, EXP EYE RES, V48, P465, DOI 10.1016/0014-4835(89)90029-8; Bloemendal H, 1981, MOL CELLULAR BIOL EY, P1; BLUNDELL T, 1981, NATURE, V289, P771, DOI 10.1038/289771a0; CHANG JY, 1983, METHOD ENZYMOL, V91, P455; HARDING JJ, 1987, P INT SOC EYE RES, V5, P95; Harding JJ, 1984, EYE B, V1b, P207; HAY RE, 1994, EXP EYE RES, V58, P573, DOI 10.1006/exer.1994.1052; HAY RE, 1987, BIOCHEM BIOPH RES CO, V146, P332, DOI 10.1016/0006-291X(87)90729-7; KODAMA T, 1988, INVEST OPHTH VIS SCI, V29, P145; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTHRA M, 1993, J BIOL CHEM, V268, P18119; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; MONNIER VM, 1989, MAILLARD REACTION AG, P1; NAKAYAMA H, 1993, DIABETES, V42, P345, DOI 10.2337/diabetes.42.2.345; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; ORTWERTH BJ, 1992, BIOCHIM BIOPHYS ACTA, V1117, P207, DOI 10.1016/0304-4165(92)90081-5; PENNINGTON J, 1994, BBA-MOL BASIS DIS, V1226, P163, DOI 10.1016/0925-4439(94)90024-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELL DR, 1989, J BIOL CHEM, V264, P21597; SHAPIRO R, 1980, J BIOL CHEM, V255, P3120; SIEZEN RJ, 1985, BIOCHEM BIOPH RES CO, V127, P153, DOI 10.1016/S0006-291X(85)80138-8; STEVENS VJ, 1978, P NATL ACAD SCI USA, V75, P2918, DOI 10.1073/pnas.75.6.2918; SUMMERS L, 1984, PEPTIDE PROTEIN REV, V3, P147; SWAMY MS, 1991, EXP EYE RES, V52, P439, DOI 10.1016/0014-4835(91)90040-L; SWAMY MS, 1987, INVEST OPHTH VIS SCI, V28, P1693; SWAMY MS, 1993, EXP EYE RES, V56, P177, DOI 10.1006/exer.1993.1025; SWAMY MS, 1989, CURR EYE RES, V8, P989, DOI 10.3109/02713688908997391; SWAMY MS, 1992, CURR EYE RES, V9, P833; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0	36	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20781	20786		10.1074/jbc.270.35.20781	http://dx.doi.org/10.1074/jbc.270.35.20781			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657661	hybrid			2022-12-25	WOS:A1995RR58400082
J	MARTIN, A; SHULMAN, MJ; TSUI, FWL				MARTIN, A; SHULMAN, MJ; TSUI, FWL			EPITOPE STUDIES INDICATE THAT HISTIDYL-TRANSFER-RNA SYNTHETASE IS A STIMULATING ANTIGEN IN IDIOPATHIC MYOSITIS	FASEB JOURNAL			English	Article						AUTOANTIBODIES; POLYMYOSITIS; ANTI-JO-1; HISTIDYL-TRANSFER-RNA SYNTHETASE; AUTOANTIBODIES	TRANSFER RNA-SYNTHETASE; MESSENGER-RNA; AUTOANTIBODY; DERMATOMYOSITIS; POLYMYOSITIS; AUTOIMMUNITY; EXPRESSION; POLYMERASE; INHIBITION; GENES	The most frequently found myositis-specific antibody, the anti-Jo-1 antibody (anti-HRS), binds to histidyl-tRNA synthetase (HRS). Although this antibody reacts with HRS, it is unclear whether HRS is the stimulating antigen or is merely a protein that cross-reacts with a yet undefined antigen. Because antibody directed against an unrelated antigen would not be expected to cross-react with HRS at multiple sites, we mapped the epitopes on HRS to resolve this issue. We found by Western blot analyses that immunoglobulins G (IgG) from 18 of 19 anti-HRS positive patient sera react with amino acids 2-44 and 286-509 of HRS. Patient IgG specific for these two epitopes were found not to inhibit HRS enzyme activity. Instead, the inhibitory property of anti-HRS was found to be associated with antibodies that do not react to HRS in immunoblots, indicating the presence of other epitopes. In addition, antibodies that react in immunoblots were found to represent only a small fraction of total anti-HRS antibody. Our finding that patient IgG recognized at least three distinct epitopes on HRS strongly suggests that the immunological response at some point in the disease is directed against HRS and not against a cross-reactive antigen.	UNIV TORONTO,DEPT IMMUNOL,TORONTO,ON M5S 1A8,CANADA	University of Toronto	MARTIN, A (corresponding author), TORONTO HOSP,WESTERN DIV,RES INST,CTR ARTHRIT,RES UNIT,MC 14-117,399 BATHHURST ST,TORONTO,ON M5T 2S8,CANADA.			Martin, Alberto/0000-0002-0795-0418				BENNE R, 1988, TRENDS GENET, V4, P181, DOI 10.1016/0168-9525(88)90072-8; BLANQUET S, 1983, MOL CELL BIOCHEM, V52, P3; BUNN CC, 1986, J EXP MED, V163, P1281, DOI 10.1084/jem.163.5.1281; DANG CV, 1988, FASEB J, V2, P2376, DOI 10.1096/fasebj.2.8.2452112; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; JAMES JA, 1995, J EXP MED, V181, P453, DOI 10.1084/jem.181.2.453; LINDLEY IG, 1977, J GEN VIROL, V34, P17; MANS RMW, 1991, EUR J BIOCHEM, V201, P303, DOI 10.1111/j.1432-1033.1991.tb16288.x; MATHEWS MB, 1984, J EXP MED, V160, P420, DOI 10.1084/jem.160.2.420; MATHEWS MB, 1983, NATURE, V304, P177, DOI 10.1038/304177a0; MILLER F W, 1990, Arthritis and Rheumatism, V33, pS23; MILLER FW, 1990, J CLIN INVEST, V85, P468, DOI 10.1172/JCI114461; MILLER FW, 1990, P NATL ACAD SCI USA, V87, P9933, DOI 10.1073/pnas.87.24.9933; MOINE H, 1990, J MOL BIOL, V216, P299, DOI 10.1016/S0022-2836(05)80321-3; PLOTZ PH, 1989, ANN INTERN MED, V111, P143, DOI 10.7326/0003-4819-111-2-143; RABEN N, 1992, NUCLEIC ACIDS RES, V20, P1075, DOI 10.1093/nar/20.5.1075; RABEN N, 1994, J BIOL CHEM, V269, P24277; RAMSDEN DA, 1989, J IMMUNOL, V143, P2267; REIMER G, 1987, J CLIN INVEST, V79, P65, DOI 10.1172/JCI112809; SALOMON R, 1974, NATURE, V249, P32, DOI 10.1038/249032a0; Sambrook J., 1989, MOL CLONING LAB MANU; SAMUELS DS, 1986, FEBS LETT, V209, P231; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TARGOFF IN, 1993, J INVEST DERMATOL, V100, pS116, DOI 10.1111/1523-1747.ep12356607; TARGOFF IN, 1990, J IMMUNOL, V144, P1737; TOPFER F, 1995, P NATL ACAD SCI USA, V92, P875, DOI 10.1073/pnas.92.3.875; TSUI F W, 1991, International Reviews of Immunology, V7, P225, DOI 10.3109/08830189109061776; TSUI FWL, 1987, NUCLEIC ACIDS RES, V15, P3349, DOI 10.1093/nar/15.8.3349; UIBO R, 1990, CLIN EXP IMMUNOL, V80, P19	29	32	44	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1995	9	12					1226	1233		10.1096/fasebj.9.12.7672516	http://dx.doi.org/10.1096/fasebj.9.12.7672516			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU816	7672516				2022-12-25	WOS:A1995RU81600013
J	POND, L; KUHN, LA; TEYTON, L; SCHUTZE, MP; TAINER, JA; JACKSON, MR; PETERSON, PA				POND, L; KUHN, LA; TEYTON, L; SCHUTZE, MP; TAINER, JA; JACKSON, MR; PETERSON, PA			A ROLE FOR ACIDIC RESIDUES IN DI-LEUCINE MOTIF-BASED TARGETING TO THE ENDOCYTIC PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; MANNOSE 6-PHOSPHATE RECEPTOR; INVARIANT CHAIN CONTAINS; CYTOPLASMIC DOMAIN; INTRACELLULAR-TRANSPORT; CARBOXYL-TERMINUS; CELL BIOLOGY; MOLECULES; INTERNALIZATION; COMPARTMENTS	Recent reports have suggested that major histocompatibility complex class II molecules load peptide through a specialized compartment of the endocytic pathway and are targeted to this pathway by association with invariant chain (Iip31). Therefore we used a site-directed mutagenesis approach to determine whether Iip31 possesses novel protein targeting signals. Our results indicate that two di-leucine-like pairs mediate Iip31 targeting and that an acidic amino acid residue four or five residues N-terminal to each Iip31 di-leucine-like pair is required for endocytic targeting. Results from additional testing with hybrid Iip31 molecules indicate that the acidic residues N-terminal to di-leucine pairs are critical for accumulation of these molecules in large endocytic vesicles and in some cases provide a structure favorable for internalization. The acidic residues N-terminal to di-leucine pairs are important in some sequence contexts in providing a structure favorable for internalization, whereas in other contexts an acidic residue is critical for targeting to, and formation of, large endocytic vesicles. Although our results do not support the idea that Iip31 possesses unique protein targeting motifs, they do suggest that di-leucine motifs may be recognized as part of a larger secondary structure. In addition, our data imply that the targeting motif requirements for internalization may differ from the requirements for further transport in the endocytic pathway.	RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; Michigan State University; Scripps Research Institute			Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429				AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BAKKE O, 1993, J CELL BIOCHEM, V17, P25; BREMNES B, 1994, J CELL SCI, V107, P2021; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DINTZIS SM, 1994, J BIOL CHEM, V269, P12159; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; OGATA S, 1994, J BIOL CHEM, V269, P5210; OLKKONEN VM, 1993, J CELL SCI, V106, P1249; PELCHENMATTHEWS A, 1991, J EXP MED, V173, P575, DOI 10.1084/jem.173.3.575; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PIETERS J, 1993, J CELL SCI, V106, P831; QUI Y, 1994, J CELL BIOL, V125, P595, DOI DOI 10.1083/JCB.125.3.595; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0	43	195	199	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19989	19997		10.1074/jbc.270.34.19989	http://dx.doi.org/10.1074/jbc.270.34.19989			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650016	hybrid			2022-12-25	WOS:A1995RQ99100049
J	WHEELAN, P; MURPHY, RC				WHEELAN, P; MURPHY, RC			METABOLISM OF 6-TRANS-ISOMERS OF LEUKOTRIENE B-4 IN CULTURED HEPATOMA-CELLS AND IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES - IDENTIFICATION OF A DELTA(6)-REDUCTASE METABOLIC PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-OXIDATION; PORCINE LEUKOCYTES; OMEGA-OXIDATION; RAT HEPATOCYTES; DIHYDRO; PRODUCTS; DEHYDROGENASE; MACROPHAGES; ETHANOL; POTENT	The intermediate metabolic events which degrade hydroxy polyunsaturated fatty acids is largely unknown. Such molecules are common products of lipid peroxidation and lipoxygenase catalyzed oxidation of arachidonic acid, Metabolism of two 5,12-dihydroxyeicosatetraenoic acids, 6-trans-LTB(4) (leukotriene B-4), and 6-trans-12-epi-LTB(4) was studied in HepG2 cells (a human-derived hepatoma cell line). Extensive metabolism was observed with a major metabolite identified as 4-hydroxy-6-dodecenoic acid for both epimers. Incubation of 6-trans-LTB(4) epimers at shorter times revealed the formation of intermediate metabolites, including 6-hydroxy-4,8-tetradecadienoic acid and 8-hydroxy-4,6,10-hexadecatrienoic acid suggesting beta-oxidation as the major pathway leading to the formation of the common terminal metabolite. Two additional metabolites were structurally elucidated as 5-oxo-6,7-dihydro-LTB(4) and 6,7-dihydro-LTB(4) which have not been previously described. Formation of 5-oxo-6,7-dihydro-LTB(4) and 6,7-dihydro-LTB(4) were also observed during metabolism of 6-trans-12-epi-LTB(4) in human polymorphonuclear leukocytes. Of particular interest is the metabolism of these compounds by beta-oxidation from the carboxyl terminus, a process which is not observed with leukotriene B-4 or leukotriene C-4. Identification of these metabolites suggested the operation of the 5-hydroxyeicosanoid dehydrogenase pathway followed by a Delta(6)-reductase metabolic pathway which has not been previously described, This pathway of beta-oxidation may limit the activity of various 5,12-diHETEs including nonenzymatic hydrolysis products of LTA(4) and also the recently described B-4-isoleukotrienes.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT K929,DENVER,CO 80206	National Jewish Health					NHLBI NIH HHS [HL25785] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025785, R37HL025785] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARRIER DJ, 1988, PROSTAG LEUKOTR ESS, V34, P27, DOI 10.1016/0952-3278(88)90021-X; DICZFALUSY U, 1994, PROG LIPID RES, V33, P403, DOI 10.1016/0163-7827(94)90025-6; ELLIS CK, 1979, J BIOL CHEM, V254, P4152; FAULER J, 1989, PROSTAG LEUKOTR ESS, V37, P193, DOI 10.1016/0952-3278(89)90085-9; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; HARRISON KA, 1995, J BIOL CHEM, V270, P17273, DOI 10.1074/jbc.270.29.17273; JEDLITSCHKY G, 1991, J BIOL CHEM, V266, P24763; KAEVER V, 1990, LIFE SCI, V46, P1495; LUO MJ, 1994, J BIOL CHEM, V269, P2384; LYNCH JM, 1986, J IMMUNOL, V137, P2653; MATHUR SN, 1990, J BIOL CHEM, V265, P21048; PALMBLAD J, 1981, BLOOD, V58, P658; PORTER NA, 1984, METHOD ENZYMOL, V105, P273; POWELL WS, 1984, J BIOL CHEM, V259, P3082; POWELL WS, 1992, J BIOL CHEM, V267, P19233; POWELL WS, 1988, J BIOL CHEM, V263, P2170; POWELL WS, 1990, BIOCHIM BIOPHYS ACTA, V1044, P147, DOI 10.1016/0005-2760(90)90230-U; POWELL WS, 1989, J BIOL CHEM, V264, P5364; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SAMUELSSON B, 1975, ANNU REV BIOCHEM, V44, P669, DOI 10.1146/annurev.bi.44.070175.003321; SCHONFELD W, 1988, IMMUNOLOGY, V65, P529; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; SHAK S, 1984, J BIOL CHEM, V259, P181; SHIRLEY MA, 1990, J BIOL CHEM, V265, P16288; SHIRLEY MA, 1992, J AM SOC MASS SPECTR, V3, P762, DOI 10.1016/1044-0305(92)87090-L; SHIRLEY MA, 1992, BIOCHEM BIOPH RES CO, V185, P604, DOI 10.1016/0006-291X(92)91667-F; SILVERSTEIN RM, 1981, SPECTROMETRIC IDENTI, P320; SOBERMAN RJ, 1988, J BIOL CHEM, V263, P7996; SUMIMOTO H, 1990, J BIOL CHEM, V265, P4348; WHEELAN P, 1993, J BIOL CHEM, V268, P25439; WHEELAN P, 1995, J AM SOC MASS SPECTR, V6, P40, DOI 10.1016/1044-0305(94)00090-M; WHEELAN P, 1995, IN PRESS ARCH BIOCH; YOKOMIZO T, 1993, J BIOL CHEM, V268, P18128; YOKUMOTO H, 1982, J BIOL CHEM, V257, P13576	35	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19845	19852		10.1074/jbc.270.34.19845	http://dx.doi.org/10.1074/jbc.270.34.19845			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649996	hybrid			2022-12-25	WOS:A1995RQ99100028
J	WOLUCKA, BA; DEHOFFMANN, E				WOLUCKA, BA; DEHOFFMANN, E			THE PRESENCE OF BETA-D-RIBOSYL-1-MONOPHOSPHODECAPRENOL IN MYCOBACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZORHIZOBIUM-CAULINODANS; STRUCTURAL FEATURES; ESCHERICHIA-COLI; POLYSACCHARIDE; BIOSYNTHESIS; LIPOPOLYSACCHARIDES; TUBERCULOSIS; ARABINOGALACTAN; CONFIGURATION; COMPLEX	Biosynthesis of the cell envelope in mycobacteria is largely unknown; however, several antituberculosis drugs apparently interfere with this process, Recently, we described a lipid intermediate for the biosynthesis of the cell wall arabinogalactan/arabinomannan of Mycobacterium smegmatis: beta-D-arabinofuranosyl-1-monophosphodecaprenol (Wolucka, B. A., McNeil, M. R., de Hoffmann, E., Chojnacki, T., and Brennan, P. J. (1994) J. Biol. Chem. 269, 23328-23335). In the present work, by means of gas chromatography-mass spectrometry, fast atom bombardment tandem mass spectrometry, and proton NMR, the major pentose-containing component of the polyprenyl-P-sugar family from M. smegmatis was characterized as beta-D-ribosyl-1-monophosphodecaprenol (decaprenyl-P-ribose). Additionally, the structure of a minor arabinose-containing compound, beta-D-arabinosyl-1-monophosphooctahydroheptaprenol, could be deduced. In vivo labeling experiments with [C-14]glucose demonstrated unequivocally that decaprenyl-P-ribose is actively synthesized in Mycobacterium tuberculosis H37Ra and Mycobacterium avium serovar 4. It is proposed that decaprenyl-P-ribose could be a precursor for the biosynthesis of either some unknown ribose-containing cell envelope polymers of mycobacteria or the arabinan part of the cell wall arabinogalactan/arabinomannan due to the presence of a 2'-epimerase activity at some late stages of the arabinogalactan/arabinomannan biosynthesis.			WOLUCKA, BA (corresponding author), UNIV CATHOLIQUE LOUVAIN, DEPT CHEM, 1 PL LOUIS PASTEUR, B-1348 LOUVAIN, BELGIUM.							AMANO KI, 1993, INFECT IMMUN, V61, P4350, DOI 10.1128/IAI.61.10.4350-4355.1993; BERST M, 1969, EUR J BIOCHEM, V11, P353, DOI 10.1111/j.1432-1033.1969.tb00779.x; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P-298; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; CHU CK, 1984, NUCLEOS NUCLEOT, V3, P1, DOI 10.1080/07328318408079416; CRISEL RM, 1975, J BIOL CHEM, V250, P4926; DABBS ER, 1995, ANTIMICROB AGENTS CH, V39, P1007, DOI 10.1128/AAC.39.4.1007; DAFFE M, 1990, J BIOL CHEM, V265, P6734; FARMER PB, 1973, J BIOL CHEM, V248, P1844; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; GOETHALS K, 1992, MOL PLANT MICROBE IN, V5, P405, DOI 10.1094/MPMI-5-405; HACKLAND PL, 1991, CARBOHYD RES, V219, P193; HOOK M, 1974, J BIOL CHEM, V249, P3908; JANN B, 1990, CURR TOP MICROBIOL, V150, P19; KOCHAROVA NA, 1989, J BIOL CHEM, V264, P15569; LEMASSU A, 1994, BIOCHEM J, V297, P351, DOI 10.1042/bj2970351; LINDBERG B, 1990, ADV CARBOHYD CHEM BI, V48, P279, DOI 10.1016/S0065-2318(08)60033-5; LVOV VL, 1991, BIOORG KHIM+, V17, P111; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; MCNEIL MR, 1991, RES MICROBIOL, V142, P451, DOI 10.1016/0923-2508(91)90120-Y; MERELLO S, 1994, J BIOL CHEM, V269, P20294; MERELLO S, 1995, MOL BIOCHEM PARASIT, V69, P73, DOI 10.1016/0166-6851(94)00195-S; MERGAERT P, 1993, P NATL ACAD SCI USA, V90, P1551, DOI 10.1073/pnas.90.4.1551; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; PINDAR DF, 1975, BIOCHEM J, V152, P617, DOI 10.1042/bj1520617; SAWADA S, 1985, J INFECT DIS, V152, P1290, DOI 10.1093/infdis/152.6.1290; SHASHKOV AS, 1993, CARBOHYD RES, V241, P177, DOI 10.1016/0008-6215(93)80104-M; SHIBAEV VN, 1986, ADV CARBOHYD CHEM BI, V44, P277; SUTHERLAND IW, 1973, J GEN MICROBIOL, V74, P259, DOI 10.1099/00221287-74-2-259; TAKAYAMA K, 1973, BIOCHIM BIOPHYS ACTA, V316, P212, DOI 10.1016/0005-2760(73)90011-8; TAKAYAMA K, 1970, J BIOL CHEM, V245, P6251; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; WAEGHE TJ, 1983, CARBOHYD RES, V123, P281, DOI 10.1016/0008-6215(83)88484-5; WATANABE M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P53, DOI 10.1016/0005-2760(92)90075-7; WIELAND F, 1988, BIOCHIMIE, V70, P1493, DOI 10.1016/0300-9084(88)90286-6; WILKINSON SG, 1983, CARBOHYD RES, V112, P241, DOI 10.1016/0008-6215(83)88289-5; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; WOLUCKA BA, 1995, J AM SOC MASS SPECTR, V6, P516, DOI 10.1016/1044-0305(95)00030-H; Wolucka Beata A., 1994, Acta Biochimica Polonica, V41, P345; YORK WS, 1986, METHOD ENZYMOL, V118, P3	41	28	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20151	20155		10.1074/jbc.270.34.20151	http://dx.doi.org/10.1074/jbc.270.34.20151			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650033	hybrid			2022-12-25	WOS:A1995RQ99100070
J	NAVARATNAM, DS; ESCOBAR, L; COVARRUBIAS, M; OBERHOLTZER, JC				NAVARATNAM, DS; ESCOBAR, L; COVARRUBIAS, M; OBERHOLTZER, JC			PERMEATION PROPERTIES AND DIFFERENTIAL EXPRESSION ACROSS THE AUDITORY RECEPTOR EPITHELIUM OF AN INWARD RECTIFIER K+ CHANNEL CLONED FROM THE CHICK INNER-EAR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNEL; CALCIUM-BINDING PROTEIN; SACCULAR HAIR-CELLS; XENOPUS-OOCYTES; FUNCTIONAL EXPRESSION; SUBUNIT STOICHIOMETRY; ELECTRICAL RESONANCE; BASILAR PAPILLA; COCHLEA; CURRENTS	The auditory receptor epithelium is an excellent model system for studying the differential expression of ion channel genes, An inward rectifier potassium cur rent is among those which have been measured in only subsets of chick cochlear hair cells. We have cloned and characterized an inward rectifier potassium channel (cIRK1) from the chick cochlear sensory epithelium, cIRK1 functional properties are similar to those of the native channel, and the transcript encoding cIRK1 is limited to the low frequency half of the epithelium. This localization is in agreement with the distribution of the native hair cell current, suggesting that the differential current expression is transcriptionally regulated. The primary structure of cIRK1 is highly homologous to the mouse inward rectifier IRK1. However, we found that cIRK1 exhibited reduced single-channel conductance (17 picosiemens) and lower sensitivity to Ba2+ block (K-1/2 = 12 mu M). We identified Gln-125 near the putative pore region as being responsible for these differences. Site-directed mutagenesis was used to change Gln-125 to Glu (the residue in IRK1), resulting in a channel with a single channel conductance of 28 picosiemens and a Ba2+ block of K-1/2 = 2 mu M. We propose that Gln-125 may form part of the external vestibule of the pore.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,DIV NEUROPATHOL,PHILADELPHIA,PA 19104; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT ANAT PATHOL & CELL BIOL,PHILADELPHIA,PA 19107	University of Pennsylvania; Jefferson University				Covarrubias, Manuel/0000-0002-0881-4143	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032337, R01NS032337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K08DC000069] Funding Source: NIH RePORTER; NIDCD NIH HHS [K08-DC-00069] Funding Source: Medline; NINDS NIH HHS [NS32337-02] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADELMAN WJ, 1978, J PHYSIOL-LONDON, V276, P13, DOI 10.1113/jphysiol.1978.sp012217; ARMSTRONG CM, 1988, BIOPHYS J, V30, P473; ART JJ, 1993, J PHYSIOL-LONDON, V470, P109, DOI 10.1113/jphysiol.1993.sp019850; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; CRAWFORD AC, 1981, J PHYSIOL-LONDON, V312, P377, DOI 10.1113/jphysiol.1981.sp013634; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; EATOCK RA, 1993, J NEUROSCI, V13, P1767; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER FP, 1992, HEARING RES, V61, P167, DOI 10.1016/0378-5955(92)90048-R; FUCHS PA, 1990, J PHYSIOL-LONDON, V429, P529, DOI 10.1113/jphysiol.1990.sp018271; FUCHS PA, 1988, J NEUROSCI, V8, P2460; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; HAGIWARA S, 1976, J GEN PHYSIOL, V67, P621, DOI 10.1085/jgp.67.6.621; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; HUDSPETH AJ, 1988, J PHYSIOL-LONDON, V400, P275, DOI 10.1113/jphysiol.1988.sp017120; HUNZIKER W, 1986, P NATL ACAD SCI USA, V83, P7578, DOI 10.1073/pnas.83.20.7578; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; ISHII K, 1994, FEBS LETT, V338, P107, DOI 10.1016/0014-5793(94)80126-6; JOSOPHSON IR, 1988, MOL CELL BIOCHEM, V80, P21; KOROTZER AR, 1992, GLIA, V6, P81, DOI 10.1002/glia.440060202; KOYAMA H, 1994, FEBS LETT, V341, P303, DOI 10.1016/0014-5793(94)80478-8; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LINDAU M, 1986, J GEN PHYSIOL, V88, P349, DOI 10.1085/jgp.88.3.349; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MINGHETTI PP, 1988, MOL ENDOCRINOL, V2, P355, DOI 10.1210/mend-2-4-355; MURROW BW, 1994, J PHYSIOL-LONDON, V480, P247, DOI 10.1113/jphysiol.1994.sp020357; OBERHOLTZER JC, 1994, DNA CELL BIOL, V13, P857, DOI 10.1089/dna.1994.13.857; OBERHOLTZER JC, 1988, P NATL ACAD SCI USA, V85, P3387, DOI 10.1073/pnas.85.10.3387; OBERHOLTZER JC, 1992, HEARING RES, V60, P103, DOI 10.1016/0378-5955(92)90063-S; PICKLES JO, 1992, TRENDS NEUROSCI, V15, P254, DOI 10.1016/0166-2236(92)90066-H; ROBERTS WM, 1993, NATURE, V363, P74, DOI 10.1038/363074a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINGAI R, 1986, BRAIN RES, V369, P65, DOI 10.1016/0006-8993(86)90513-5; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; TAGLIALATELA M, 1994, J BIOL CHEM, V269, P13867; TANAKA K, 1978, AM J ANAT, V153, P251, DOI 10.1002/aja.1001530206; TILNEY LG, 1986, DEV BIOL, V116, P100, DOI 10.1016/0012-1606(86)90047-3; VERY AA, 1994, PFLUG ARCH EUR J PHY, V428, P422, DOI 10.1007/BF00724528; von Bekesy G, 1960, EXPT HEARING; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0	55	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19238	19245		10.1074/jbc.270.33.19238	http://dx.doi.org/10.1074/jbc.270.33.19238			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642595	hybrid			2022-12-25	WOS:A1995RP70300009
J	MARTIN, JL; WILSON, JE; FURFINE, ES; HOPKINS, SE; FURMAN, PA				MARTIN, JL; WILSON, JE; FURFINE, ES; HOPKINS, SE; FURMAN, PA			BIOCHEMICAL-ANALYSIS OF HUMAN IMMUNODEFICIENCY VIRUS-1 REVERSE-TRANSCRIPTASE CONTAINING A MUTATION AT POSITION LYSINE-263	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING DOMAIN; RNASE-H ACTIVITY; DNA-POLYMERASE; PYRIDOXAL 5'-PHOSPHATE; MUTAGENESIS; SITE; RETROVIRUS; IDENTIFICATION; INHIBITION	Site-directed mutagenesis has been used to assess the importance of lysine 263 in substrate binding of human immunodeficiency virus-1 (HIV-1) reverse transcriptase. Previous studies have indicated that lysine 263 functions in the binding of 2'-deoxynucleoside 5'-triphosphate (dNTP) substrates (Basu, A., Tirumalai, R. S., and Modak, M. J. (1989) J. Biol. Chem. 264, 8746-8752). We studied this interaction directly by using site-specific mutagenesis to change lysine 263 to a serine. Highly purified mutant enzyme K263S bound natural dNTP substrates and primed polynucleic acid substrates with equal affinity when compared to the wild type reverse transcriptase. No difference was observed in the binding of 3'-azido-2',3'-dideoxythymidine 5'-triphosphate to the mutant reverse transcriptase on the basis of K(m) and K(i) determinations. The serine substitution had no effect on RNase H activity. These results indicate that lysine 263 is not essential in the binding of substrates to HIV-1 reverse transcriptase.	BURROUGHS WELLCOME CO,DIV EXPTL THERAPY,RES TRIANGLE PK,NC 27709	Burroughs Wellcome Fund	MARTIN, JL (corresponding author), BURROUGHS WELLCOME CO,DIV VIROL,3030 CORNWALLIS RD,RES TRIANGLE PK,NC 27709, USA.							BASU A, 1988, J BIOL CHEM, V263, P1648; BASU A, 1990, J BIOL CHEM, V265, P17162; BASU A, 1989, J BIOL CHEM, V264, P8746; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; FURFINE ES, 1991, J BIOL CHEM, V266, P406; FURMAN PA, 1991, P NATL ACAD SCI USA, V88, P6013, DOI 10.1073/pnas.88.14.6013; FURMAN PA, 1979, J VIROL, V32, P72, DOI 10.1128/JVI.32.1.72-77.1979; HAZRA AK, 1984, BIOCHEMISTRY-US, V23, P2073, DOI 10.1021/bi00304a030; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; KEDAR PS, 1990, BIOCHEMISTRY-US, V29, P3603, DOI 10.1021/bi00467a003; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15667; Maniatis T., 1982, MOL CLONING; MEYERS G, 1989, HUMAN RETROVIRUSES A; OLSEN DB, 1990, P NATL ACAD SCI USA, V87, P1451, DOI 10.1073/pnas.87.4.1451; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; REARDON JE, 1990, J BIOL CHEM, V265, P20302; RESTLE T, 1990, J BIOL CHEM, V265, P8986; REY MA, 1984, BIOCHEM BIOPH RES CO, V121, P126, DOI 10.1016/0006-291X(84)90696-X; Segel I.H., 1975, ENZYME KINETICS BEHA, P161; STARNES MC, 1989, J BIOL CHEM, V264, P7073; TISDALE M, 1988, J VIROL, V62, P3662, DOI 10.1128/JVI.62.10.3662-3667.1988; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504	28	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2565	2570						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679098				2022-12-25	WOS:A1993KK81500047
J	SAGGIORO, D; SORIO, C; CALDERAZZO, F; CALLEGARO, L; PANOZZO, M; BERTON, G; CHIECOBIANCHI, L				SAGGIORO, D; SORIO, C; CALDERAZZO, F; CALLEGARO, L; PANOZZO, M; BERTON, G; CHIECOBIANCHI, L			MECHANISM OF ACTION OF THE MONOSIALOGANGLIOSIDE G(M1) AS A MODULATOR OF CD4 EXPRESSION - EVIDENCE THAT G(M1)-CD4 INTERACTION TRIGGERS DISSOCIATION OF P56LCK FROM CD4, AND CD4 INTERNALIZATION AND DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN LYMPHOCYTES-T; CYTOPLASMIC DOMAIN; HIV INFECTION; SELECTIVE MODULATION; GANGLIOSIDES; INHIBITION; MOLECULES; CELLS; PHOSPHORYLATION	Analyzing the mechanisms underlying the capability of the monosialoganglioside G(M1) to induce CD4 modulation we observed that G(M1) has a dual effect on the CD4 molecule. G(M1) treatment of the lymphoma cell line MOLT-3 and CD4-transfected HeLa cells for times shorter than 30 min prevented binding of monoclonal antibodies (mAbs) recognizing epitopes located within the first NH2-terminal domains of CD4, but not of the OKT4 mAb, which binds to the region of CD4 proximal to the transmembrane domain. However, no binding of the OKT4 mAb was observed after a few hours of treatment with G(M1) in both MOLT-3 cells and HeLa cells transfected with an intact CD4 molecule, but not in HeLa cells transfected with a CD4 molecule lacking the bulk of the cytoplasmic domain, suggesting that modulation of CD4 by G(M1) depends on the integrity of the cytoplasmic domain. G(M1) treatment blocked binding of several mAbs which recognize epitopes located within the first two NH2-terminal domains of CD4 and did not induce CD4 down-modulation if MOLT-3 cells were preincubated with the OKT4A or the OKT4 mAbs. Immunoprecipitation studies with [S-35]methionine-labeled MOLT-3 cells showed that G(M1)-induced CD4 down-modulation was accompanied by CD4 degradation, and this was preceded by dissociation of p56lck from CD4. G(M1)-induced CD4 down-modulation, dissociation of p56lck from CD4, and CD4 degradation were unaffected by staurosporine, which, on the contrary, blocked these events in response to phorbol 12-myristate 13-acetate. These observations demonstrate that the first action of G(M1) is to mask epitopes located within the first two NH2-terminal domains; then, G(M1) triggers protein kinase C-independent signals which cause p56lck dissociation from CD4 and the delivery of the molecule to an intracellular compartment where it is eventually degraded.	UNIV VERONA, INST GEN PATHOL, I-37100 VERONA, ITALY; FIDIA RES LABS, PADUA, ITALY	University of Verona	SAGGIORO, D (corresponding author), UNIV PADUA, INTERUNIV CTR CANC RES, IST SCI TUMORI GENOVA, INST ONCOL, BIOTECHNOL SECT, I-35128 PADUA, ITALY.		Sorio, Claudio/F-2764-2018; Saggioro, Daniela/W-1443-2018	Sorio, Claudio/0000-0003-2739-4014; Saggioro, Daniela/0000-0002-7136-2821				ACRES RB, 1986, J BIOL CHEM, V261, P6210; BEDINGER P, 1988, NATURE, V334, P162, DOI 10.1038/334162a0; BLUE ML, 1987, J IMMUNOL, V139, P3949; BLUE ML, 1989, J IMMUNOL, V142, P374; CARREL S, 1988, EUR J IMMUNOL, V18, P333, DOI 10.1002/eji.1830180303; CHIECOBIANCHI L, 1989, AIDS, V3, P501, DOI 10.1097/00002030-198908000-00003; CROSS AS, 1991, J CLIN INVEST, V88, P2067, DOI 10.1172/JCI115536; DALGLEISH AG, 1986, IMMUNOL TODAY, V7, P142, DOI 10.1016/0167-5699(86)90080-0; DEROSSI A, 1991, VIROLOGY, V184, P187; GRASSI F, 1990, EUR J IMMUNOL, V20, P145, DOI 10.1002/eji.1830200121; HANDA A, 1991, BIOCHEM BIOPH RES CO, V175, P1, DOI 10.1016/S0006-291X(05)81191-X; HOXIE JA, 1988, J IMMUNOL, V140, P786; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; JASIN M, 1991, J VIROL, V65, P440, DOI 10.1128/JVI.65.1.440-444.1991; KAWAGUCHI T, 1989, BIOCHEM BIOPH RES CO, V158, P1050, DOI 10.1016/0006-291X(89)92828-3; KIEBEREMMONS T, 1989, BIOCHIM BIOPHYS ACTA, V989, P281; LAMARRE D, 1989, EMBO J, V8, P3271, DOI 10.1002/j.1460-2075.1989.tb08487.x; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X; MERKENSCHLAGER M, 1990, J IMMUNOL, V145, P2389; MIZUKAMI T, 1988, P NATL ACAD SCI USA, V85, P9273, DOI 10.1073/pnas.85.23.9273; MORRISON WJ, 1991, IMMUNOPHARMACOLOGY, V22, P77, DOI 10.1016/0162-3109(91)90032-T; NAKAKUMA H, 1989, JPN J CANCER RES, V80, P702, DOI 10.1111/j.1349-7006.1989.tb01700.x; OFFNER H, 1987, J IMMUNOL, V139, P3295; PARNES JR, 1989, ADV IMMUNOL, V44, P265; PELCHENMATTHEWS A, 1991, J EXP MED, V173, P575, DOI 10.1084/jem.173.3.575; POLI G, 1991, J CELL SCI, V100, P833; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SLECKMAN BP, 1988, J IMMUNOL, V141, P49; TRAVERS P, 1992, Current Biology, V2, P38, DOI 10.1016/0960-9822(92)90430-I; WEYAND CM, 1987, J IMMUNOL, V138, P1351	34	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1368	1375						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678256				2022-12-25	WOS:A1993KG07700091
J	MIURA, M; SURMACZ, E; BURGAUD, JL; BASERGA, R				MIURA, M; SURMACZ, E; BURGAUD, JL; BASERGA, R			DIFFERENT EFFECTS ON MITOGENESIS AND TRANSFORMATION OF A MUTATION AT TYROSINE-1251 OF THE INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; RAT GLIOBLASTOMA; IGF-1 RECEPTOR; CELLS; OVEREXPRESSION; PROTEIN; TRANSCRIPTION; FIBROBLASTS; EXPRESSION; CANCER	The wild type insulin-like growth factor I (IGF-I) receptor has both mitogenic and transforming activities. We have examined the effect of point mutations at tyrosine residues 1250 and 1251 on these two properties of the receptor, For this purpose, we stably transfected plasmids expressing mutant and wild type receptors into R(-) cells, which are 3T3-like cells, derived from mouse embryos with a targeted disruption of the IGF-I receptor genes, and therefore devoid of endogenous IGF-I receptors. A tyrosine to phenylalanine mutation of either the 1250 or 1251 residue, or both, has no effect on the ability of the receptor to transmit a mitogenic signal. However, the tyrosine 1251 mutant receptor and the double mutant have lost the ability to transform R(-) cells (colony formation in soft agar), even when the receptors are expressed at very high levels, while the Y1250F mutant is fully transforming. These experiments show that the 1251 tyrosine residue is required for the transforming activity of the IGF-I receptor.	THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,PHILADELPHIA,PA 19107	Jefferson University					NCI NIH HHS [CA 53484] Funding Source: Medline; NIGMS NIH HHS [GM 133694] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DEANGELIS T, 1995, J CELL PHYSIOL, V164, P214, DOI 10.1002/jcp.1041640126; DELALUNA S, 1988, GENE, V62, P121; FALCO JP, 1988, ONCOGENE, V2, P573; GIORGINO F, 1991, MOL ENDOCRINOL, V5, P452, DOI 10.1210/mend-5-3-452; HARRINGTON EA, 1994, EMBO J, V14, P3286; KALEBIC T, 1994, CANCER RES, V54, P5531; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LI SW, 1994, J BIOL CHEM, V269, P32558; LIU DL, 1993, J VIROL, V67, P6835, DOI 10.1128/JVI.67.11.6835-6840.1993; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; LONG L, 1995, CANCER RES, V55, P1006; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1994, CANCER RES, V54, P2472; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIETRZKOWSKI Z, 1992, MOL CELL BIOL, V12, P3883, DOI 10.1128/MCB.12.9.3883; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; RANDAZZO PA, 1990, EXP CELL RES, V190, P25, DOI 10.1016/0014-4827(90)90139-2; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; ROSE DW, 1994, P NATL ACAD SCI USA, V81, P797; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; TARTARE S, 1994, J BIOL CHEM, V269, P11449; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VALENTINIS B, 1994, ONCOGENE, V9, P825; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; ZONG CS, 1994, P NATL ACAD SCI USA, V61, P10982	52	109	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22639	22644		10.1074/jbc.270.38.22639	http://dx.doi.org/10.1074/jbc.270.38.22639			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673254	hybrid			2022-12-25	WOS:A1995RW31400088
J	TORIGOE, H; NAKAYAMA, T; IMAZATO, M; SHIMADA, I; ARATA, Y; SARAI, A				TORIGOE, H; NAKAYAMA, T; IMAZATO, M; SHIMADA, I; ARATA, Y; SARAI, A			THE AFFINITY MATURATION OF ANTI-4-HYDROXY-3-NITROPHENYLACETYL MOUSE MONOCLONAL-ANTIBODY - A CALORIMETRIC STUDY OF THE ANTIGEN-ANTIBODY INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES SUBTILISIN INHIBITOR; IMMUNE-RESPONSE; SOMATIC MUTATION; VARIABLE REGION; LIGAND-BINDING; HEAT-CAPACITY; C57BL/6 MICE; SURFACE-AREA; THERMODYNAMICS; NP	To understand the mechanism of affinity maturation, we examined the antigen-antibody interactions between 4-hydroxy-3-nitrophenylacetyl (NP) caproic acid and the Fab fragments of three anti-NP antibodies, N1G9, 3B44, and 3B62, by isothermal titration calorimetry. The analyses have revealed that all of these interactions are mainly driven by negative changes in enthalpy. The enthalpy changes decreased linearly with temperature in the range of 25-45 degrees C, producing negative changes in heat capacity. On the basis of the dependence of binding constants on the sodium chloride concentration, we have shown that, during the affinity maturation of the anti-NP antibody, the electrostatic effect does not significantly contribute to the increase in the binding affinity. We have found that, as the logarithm of the binding constants increases during the affinity maturation of the anti-NP antibody, the magnitudes of the corresponding enthalpy, heat capacity, and unitary entropy changes increase almost Linearly. On the basis of this correlation, we have concluded that, during the affinity maturation of the anti-NP antibody, a better surface complementarity is attained in the specific complex in order to obtain a higher binding affinity.	UNIV TOKYO,FAC PHARMACEUT SCI,TOKYO 113,JAPAN	University of Tokyo	TORIGOE, H (corresponding author), INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,GENE BANK,TSUKUBA,IBARAKI 305,JAPAN.							ALLEN D, 1988, EMBO J, V7, P1995, DOI 10.1002/j.1460-2075.1988.tb03038.x; ALLEN D, 1987, IMMUNOL REV, V96, P5, DOI 10.1111/j.1600-065X.1987.tb00506.x; AZUMA T, 1987, MOL IMMUNOL, V24, P287; BAINS G, 1992, BIOCHEMISTRY-US, V31, P12624, DOI 10.1021/bi00165a012; BARISAS BG, 1971, BIOCHEMISTRY-US, V10, P2816; BAUGH RJ, 1972, J BIOL CHEM, V247, P7498; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BOTHWELL ALM, 1982, NATURE, V298, P380, DOI 10.1038/298380a0; BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; BRUMMELL DA, 1993, BIOCHEMISTRY-US, V32, P1180, DOI 10.1021/bi00055a024; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; CONNELLY PR, 1994, P NATL ACAD SCI USA, V91, P1964, DOI 10.1073/pnas.91.5.1964; CONNELLY PR, 1993, BIOCHEMISTRY-US, V32, P5583, DOI 10.1021/bi00072a013; CREWS S, 1981, CELL, V25, P59, DOI 10.1016/0092-8674(81)90231-2; CUMANO A, 1985, EUR J IMMUNOL, V15, P512, DOI 10.1002/eji.1830150517; CUMANO A, 1986, EMBO J, V5, P2459, DOI 10.1002/j.1460-2075.1986.tb04522.x; FUKADA H, 1985, BIOCHEMISTRY-US, V24, P5109, DOI 10.1021/bi00340a023; GURNEY RW, 1953, IONIC PROCESSES SOLU, P89; HALSEY JF, 1975, BIOCHEMISTRY-US, V14, P800, DOI 10.1021/bi00675a024; HALSEY JF, 1975, BIOCHEMISTRY-US, V14, P5221, DOI 10.1021/bi00694a032; HERRON JN, 1986, BIOCHEMISTRY-US, V25, P4602, DOI 10.1021/bi00364a022; HIBBITS KA, 1994, BIOCHEMISTRY-US, V33, P3584, DOI 10.1021/bi00178a015; ITO W, 1993, J BIOL CHEM, V268, P16639; JACK RS, 1977, EUR J IMMUNOL, V8, P559; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JOHNSTON MF, 1974, BIOCHEMISTRY-US, V13, P390, DOI 10.1021/bi00699a026; KATO K, 1991, BIOCHEMISTRY-US, V30, P270, DOI 10.1021/bi00215a037; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KELLEY RF, 1992, BIOCHEMISTRY-US, V31, P5434, DOI 10.1021/bi00139a003; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; Langerman N, 1979, Methods Enzymol, V61, P261; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; MAKELA O, 1977, IMMUNOL REV, V34, P119, DOI 10.1111/j.1600-065X.1977.tb00370.x; MILOS M, 1988, J BIOL CHEM, V263, P9218; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; NAKAYAMA T, 1993, BIOCHEMISTRY-US, V32, P13961, DOI 10.1021/bi00213a028; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; SCHWARZ FP, 1991, J BIOL CHEM, V266, P24344; SCHWARZ FP, 1995, EUR J BIOCHEM, V228, P388; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; SIGURSKJOLD BW, 1992, J BIOL CHEM, V267, P8371; Siskind G W, 1969, Adv Immunol, V10, P1, DOI 10.1016/S0065-2776(08)60414-9; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; TAKAHASHI K, 1985, BIOCHEMISTRY-US, V24, P297, DOI 10.1021/bi00323a009; TANFORD C, 1980, HYDROPHOBIC EFFECT; TELLO D, 1993, BIOCHEM SOC T, V21, P943, DOI 10.1042/bst0210943; TSUMOTO K, 1994, J BIOL CHEM, V269, P28777; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WYSOCKI L, 1986, P NATL ACAD SCI USA, V83, P1847, DOI 10.1073/pnas.83.6.1847; YSERN X, 1994, J MOL BIOL, V238, P496	55	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22218	22222		10.1074/jbc.270.38.22218	http://dx.doi.org/10.1074/jbc.270.38.22218			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673199	hybrid			2022-12-25	WOS:A1995RW31400025
J	BALI, D; SVETLANOV, A; LEE, HW; FUSCODEMANE, D; LEISER, M; LI, BJ; BARZILAI, N; SURANA, M; HOU, H; FLEISCHER, N; DEPINHO, R; ROSSETTI, L; EFRAT, S				BALI, D; SVETLANOV, A; LEE, HW; FUSCODEMANE, D; LEISER, M; LI, BJ; BARZILAI, N; SURANA, M; HOU, H; FLEISCHER, N; DEPINHO, R; ROSSETTI, L; EFRAT, S			ANIMAL-MODEL FOR MATURITY-ONSET DIABETES OF THE YOUNG GENERATED BY DISRUPTION OF THE MOUSE GLUCOKINASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PANCREATIC BETA-CELL; MUTATIONS; ISLETS; RATS; HYPERGLYCEMIA; MELLITUS	Glucokinase catalyzes a rate-limiting step in glucose metabolism in hepatocytes and pancreatic beta cells and is considered the ''glucose sensor'' for regulation of insulin secretion, Patients with maturity-onset diabetes of the young (MODY) have heterozygous point mutations in the glucokinase gene that result in reduced enzymatic activity and decreased insulin secretion, However, it remains unclear whether abnormal liver glucose metabolism contributes to the MODY disease, Here we show that disruption of the glucokinase gene results in a phenotype similar to MODY in heterozygous mice, Reduced islet glucokinase activity causes mildly elevated fasting blood glucose levels. Hyperglycemic clamp studies reveal decreased glucose tolerance and abnormal liver glucose metabolism, These findings demonstrate a key role for glucokinase in glucose homeostasis and implicate both islets and liver in the MODY disease.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine								BYRNE MM, 1994, J CLIN INVEST, V93, P1120, DOI 10.1172/JCI117064; EFRAT S, 1994, P NATL ACAD SCI USA, V91, P2051, DOI 10.1073/pnas.91.6.2051; FROUGEL P, 1992, NATURE, V356, P162; GIACCARI A, 1992, J CLIN INVEST, V89, P36, DOI 10.1172/JCI115583; GIDHJAIN M, 1993, P NATL ACAD SCI USA, V90, P1932, DOI 10.1073/pnas.90.5.1932; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; LIANG Y, 1990, J BIOL CHEM, V265, P16863; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; ROSSETTI L, 1987, J CLIN INVEST, V80, P1037, DOI 10.1172/JCI113157; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; STURIS J, 1994, DIABETES, V43, P718, DOI 10.2337/diabetes.43.5.718; TAKEDA J, 1993, J BIOL CHEM, V268, P15200; VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0	17	122	125	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21464	21467		10.1074/jbc.270.37.21464	http://dx.doi.org/10.1074/jbc.270.37.21464			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665557	hybrid			2022-12-25	WOS:A1995RU75700010
J	FLYNN, A; PROUD, CG				FLYNN, A; PROUD, CG			SERINE-209, NOT SERINE-53, IS THE MAJOR SITE OF PHOSPHORYLATION IN INITIATION-FACTOR EIF-4E IN SERUM-TREATED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC PROTEIN-SYNTHESIS; CAP-BINDING-PROTEIN; TRANSLATIONAL CONTROL; MESSENGER-RNAS; FACTOR-II; OVEREXPRESSION; SEQUENCE; COMPLEX; SUBUNIT; GROWTH	Ser-53 has previously been considered the major phosphorylation site in eukaryotic initiation factor (eIF)-4E, and this appeared to be supported by studies using a S53A mutant. Recently, however, several lines of evidence have indicated that Ser-53 might not be the true phosphorylation site. This prompted us to re-examine the phosphorylation site in eIF-4E using factor purified from P-32-labeled, serum-treated Chinese hamster ovary cells. Isoelectric focusing and phosphoamino acid analysis indicated the existence of a single phosphorylated serine. Edman degradation of the major radiolabeled tryptic product from P-32-labeled eIF-4E showed that the phosphorylated site was positioned three residues from the N terminus of this peptide. There are three serines in the sequence of eIF-4E that are three residues away from a tryptic cleavage site (i.e. lysine or arginine). P-32-Labeled eIF-4E was digested with trypsin, Lys-C, or trypsin followed by Glu-C and subjected to two-dimensional mapping; the data obtained eliminated two of these potential sites, leaving Ser-209. Comigration of the synthetic peptide SGS(P)(TTK)-T-209 with the radiolabeled tryptic product on (i) reverse-phase chromatography and (ii) two-dimensional mapping at different pH values confirmed that Ser-209 is the major phosphorylation site in eIF-4E in serum-stimulated Chinese hamster ovary cells.			FLYNN, A (corresponding author), UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,UNIV WALK,BRISTOL BS8 1TD,AVON,ENGLAND.			Proud, Christopher/0000-0003-0704-6442	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BU X, 1993, J BIOL CHEM, V268, P4975; BU X, 1991, FEBS LETT, V283, P219, DOI 10.1016/0014-5793(91)80592-Q; CHOI SY, 1992, J BIOL CHEM, V267, P286; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DICKENS M, 1992, BIOCHEM J, V287, P201, DOI 10.1042/bj2870201; DUNCAN R, 1987, J BIOL CHEM, V262, P380; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KAUFMAN RJ, 1993, J BIOL CHEM, V268, P11902; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; MCCUBBIN WD, 1988, J BIOL CHEM, V263, P17663; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1993, EUR J BIOCHEM, V218, P39, DOI 10.1111/j.1432-1033.1993.tb18349.x; OLDFIELD S, 1994, EUR J BIOCHEM, V221, P399, DOI 10.1111/j.1432-1033.1994.tb18752.x; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; REDPATH NT, 1992, ANAL BIOCHEM, V202, P340, DOI 10.1016/0003-2697(92)90115-N; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; RYCHLIK W, 1992, NUCLEIC ACIDS RES, V20, P6415, DOI 10.1093/nar/20.23.6415; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6	27	136	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21684	21688		10.1074/jbc.270.37.21684	http://dx.doi.org/10.1074/jbc.270.37.21684			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665584	hybrid			2022-12-25	WOS:A1995RU75700042
J	DAVISSALINAS, J; VANNOSTRAND, WE				DAVISSALINAS, J; VANNOSTRAND, WE			AMYLOID BETA-PROTEIN AGGREGATION NULLIFIES ITS PATHOLOGICAL PROPERTIES IN CULTURED CEREBROVASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEREDITARY CEREBRAL-HEMORRHAGE; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; NEXIN-II; PEPTIDE; DOMAIN; CDNA; DEGENERATION; DERIVATIVES; CLEAVAGE	Alzheimer's disease and related disorders are characterized by deposition of aggregated amyloid beta-protein (A beta) and accompanying pathologic changes in the neuropil and in the walls of cerebral blood vessels. A beta induces neurotoxicity in vitro, and this effect is markedly enhanced when the peptide is preaggregated. Recently, we reported that freshly solubilized A beta(1-42) can induce cellular degeneration and a striking increase in the levels of cellular amyloid beta-protein precursor and soluble A beta peptide in cultured cerebrovascular smooth muscle cells (Davis-Salinas, J., Saporito-Irwin, S. M., Cotman, C. W., and Van Nostrand, W. E, (1995) J, Neurochem. 65, 931-934). In the present study, we show that preaggregation of A beta(1-42) abolishes the ability of the peptide to induce these cellular pathologic responses in these cells in vitro. These findings suggest that distinct mechanisms for A beta-induced cytotoxicity exist for cultured neurons and cerebrovascular smooth muscle cells, supporting that different processes may be involved in the parenchymal and cerebrovascular pathology of Alzheimer's disease and related disorders.	UNIV CALIF IRVINE,COLL MED,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL003229, R01HL049566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG000538] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03229, HL49566] Funding Source: Medline; NIA NIH HHS [AG00538] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURDICK D, 1992, J BIOL CHEM, V267, P546; CORIA F, 1989, J NEUROPATH EXP NEUR, V48, P368, DOI 10.1097/00005072-198905000-00207; DAVISSALINAS J, 1995, J NEUROCHEM, V65, P931; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; JOACHIM CL, 1988, BRAIN RES, V474, P100, DOI 10.1016/0006-8993(88)90673-7; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAWAI M, 1993, BRAIN RES, V623, P142, DOI 10.1016/0006-8993(93)90021-E; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRELLI F, 1988, J NEUROCHEM, V54, P648; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROZEMULLER AJM, 1993, AM J PATHOL, V142, P1449; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANDUINEN SG, 1987, P NATL ACAD SCI USA, V84, P5991; VANNOSTRAND WE, 1994, AMYLOID, V1, P1, DOI 10.3109/13506129409148618; VANNOSTRAND WE, 1989, NATURE, V341, P546; WANG R, 1991, J BIOL CHEM, V266, P16960; WISNIEWSKI HM, 1994, AMYLOID, V1, P8, DOI 10.3109/13506129409148619; WISNIEWSKI HM, 1994, ACTA NEUROPATHOL, V87, P233; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	39	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20887	20890		10.1074/jbc.270.36.20887	http://dx.doi.org/10.1074/jbc.270.36.20887			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673109	hybrid			2022-12-25	WOS:A1995RU05400005
J	FERNANDEZCANON, JM; PENALVA, MA				FERNANDEZCANON, JM; PENALVA, MA			MOLECULAR CHARACTERIZATION OF A GENE ENCODING A HOMOGENTISATE DIOXYGENASE FROM ASPERGILLUS-NIDULANS AND IDENTIFICATION OF ITS HUMAN AND PLANT HOMOLOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								We report here the first characterization of a gene encoding a homogentisate dioxygenase, the Aspergillus nidulans hmgA gene. The HmgA protein catalyzes an essential step in phenylalanine catabolism, and disruption of the gene results in accumulation of homogentisate in broths containing phenylalanine. hmgA putatively encodes a 448-residue polypeptide (M(r) = 50,168) containing 21 histidine and 23 tyrosine residues. This polypeptide has been expressed in Escherichia coli as a fusion to glutathione S-transferase, and the affinity-purified protein has homogentisate dioxygenase activity. A. nidulans, an ascomycete amenable to classical and reverse genetic analysis, is a good metabolic model to study inborn errors in human Phe catabolism. One such disease, alkaptonuria, was the first human inborn error recognized (Garrod, A. E. (1902) Lancet 2, 1616-1620) and results from loss of homogentisate dioxygenase. Here we take advantage of the high degree of conservation between the amino acid sequences of the fungal. and higher eukaryote enzymes of this pathway to identify expressed sequence tags encoding human and plant homologues of HmgA. This is a significant advance in characterizing the genetic defect(s) of alkaptonuria and illustrates the usefulness of our fungal model.	CSIC,CTR INVEST BIOL,DEPT MOLEC MICROBIOL,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Fernandez-canon, Jose/ADI-4196-2022; Fernández-Cañón, José Manuel/AAO-6088-2020; Fernández-Cañón, José Manuel/AAO-5607-2020; Penalva, Miguel A/G-2295-2015	Fernández-Cañón, José Manuel/0000-0002-8092-2181; Penalva, Miguel A/0000-0002-3102-2806				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; EDWARDS SW, 1955, METHOD ENZYMOL, V2, P292; ESPESO EA, 1992, MOL MICROBIOL, V6, P1457, DOI 10.1111/j.1365-2958.1992.tb00866.x; FERNANDEZCANON JM, 1995, IN PRESS P NATL ACAD; Garrod AE, 1902, LANCET, V2, P1616; JANOCHA S, 1994, GENOMICS, V19, P5, DOI 10.1006/geno.1994.1003; LADU BN, 1958, J BIOL CHEM, V230, P251; MCKUSICK VA, 1994, GENOMICS, V19, P3; OHLENDORF DH, 1988, NATURE, V336, P403, DOI 10.1038/336403a0; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; POLLAK MR, 1993, NAT GENET, V5, P201, DOI 10.1038/ng1093-201; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT TD, 1987, METHOD ENZYMOL, V152, P423; SCHMIDT SR, 1995, EUR J BIOCHEM, V228, P425, DOI 10.1111/j.1432-1033.1995.00425.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; ZIMMERMANN CR, 1980, CELL, V21, P709, DOI 10.1016/0092-8674(80)90434-1	18	99	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21199	21205		10.1074/jbc.270.36.21199	http://dx.doi.org/10.1074/jbc.270.36.21199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673153	hybrid, Green Published			2022-12-25	WOS:A1995RU05400053
J	LEGAULT, DJ; KELLY, RJ; NATSUKA, Y; LOWE, JB				LEGAULT, DJ; KELLY, RJ; NATSUKA, Y; LOWE, JB			HUMAN ALPHA(1,3/1,4)-FUCOSYL-TRANSFERASES DISCRIMINATE BETWEEN DIFFERENT OLIGOSACCHARIDE ACCEPTOR SUBSTRATES THROUGH A DISCRETE PEPTIDE FRAGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; ELAM-1-DEPENDENT CELL-ADHESION; SIALYL-LEWIS-X; DETERMINES EXPRESSION; CARBOHYDRATE LIGANDS; EMBRYONIC ANTIGEN; MOLECULAR-CLONING; LUNG INJURY; ELAM-1; RECOGNITION	Five different human alpha(1,3)-fucosyltransferase (alpha(1,3)-Fuc-T) genes have been cloned, Their corresponding enzymes catalyze the formation of various alpha(1,3)- and alpha(1,4)-fucosylated cell surface oligosaccharides, including several that mediate leukocyte-endothelial cell adhesion during inflammation, Inhibitors of such enzymes are predicted to operate as anti-inflammatory agents; in principle, the isolation or design of such agents may be facilitated by identifying peptide segment(s) within these enzymes that interact with their oligosaccharide acceptor substrates, Little is known, however, about the structural features of alpha(1,3)-Fuc-Ts that dictate acceptor substrate specificity. To begin to address this problem, we have created and functionally characterized a series of 21 recombinant alpha(1,3)-Fuc-T chimeras derived from three human alpha(1,3)-Fuc-Ts (Fuc-TIII, Fuc-TV, and Fuc-TVI) that maintain shared and distinct polypeptide domains and that exhibit common as well as idiosyncratic acceptor substrate specificities, The in vivo acceptor substrate specificities of these alpha(1,3)-Fuc-T chimeras, and of their wild type progenitors, were determined by characterizing the cell surface glycosylation phenotype determined by these enzymes, after expressing them in a mammalian cell line informative for the synthesis of four distinct alpha(1,3)- and alpha(1,4)-fucosylated cell surface oligosaccharides (Lewis x, sialyl Lewis x, Lewis a, and sialyl Lewis a), Our results indicate that as few as 11 nonidentical amino acids, found within a ''hypervariable'' peptide segment positioned at the NH2 terminus of the enzymes' sequence-constant COOH-terminal domains, determines whether or not these alpha(1,3)-Fuc-T can utilize type I acceptor substrates to form Lewis a and sialyl Lewis a moieties.	UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT MED,DIV NEPHROL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047455] Funding Source: NIH RePORTER; NIDDK NIH HHS [K11 DK02189] Funding Source: Medline; NIGMS NIH HHS [GM47455] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; AUSUBEL J, 1987, MOL BIOL LABORATORY, V2; AUSUBEL J, 1987, MOL BIOL LABORATORY, V1; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BERG EL, 1991, J BIOL CHEM, V266, P14869; BLASZCZYK M, 1984, ARCH BIOCHEM BIOPHYS, V233, P161, DOI 10.1016/0003-9861(84)90612-X; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BUERKE M, 1994, J CLIN INVEST, V93, P1140, DOI 10.1172/JCI117066; CHIA D, 1985, CANCER RES, V45, P435; ERNST LK, 1989, J BIOL CHEM, V265, P3436; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FEIZI T, 1991, TRENDS BIOCHEM SCI, V16, P84, DOI 10.1016/0968-0004(91)90038-W; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; LOWER JB, 1994, FRONTIERS MOL BIOL; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; Maniatis T, 1989, DECONTAMINATION DILU; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; MULLIGAN MS, 1993, J EXP MED, V178, P623, DOI 10.1084/jem.178.2.623; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; NATSUKA S, 1994, CURR OPIN STRUC BIOL, V4, P683, DOI 10.1016/S0959-440X(94)90166-X; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SAIKI RK, 1985, SCIENCE, V230, P1370; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SMITH PL, 1994, J BIOL CHEM, V269, P15162; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; VONANDRIAN UH, 1993, J CLIN INVEST, V91, P2893, DOI 10.1172/JCI116535; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YOUNG WW, 1981, J BIOL CHEM, V256, P967; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	47	78	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20987	20996		10.1074/jbc.270.36.20987	http://dx.doi.org/10.1074/jbc.270.36.20987			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673123	hybrid			2022-12-25	WOS:A1995RU05400020
J	RUSS, G; ESQUIVEL, F; YEWDELL, JW; CRESSWELL, P; SPIES, T; BENNICK, JR				RUSS, G; ESQUIVEL, F; YEWDELL, JW; CRESSWELL, P; SPIES, T; BENNICK, JR			ASSEMBLY, INTRACELLULAR-LOCALIZATION, AND NUCLEOTIDE-BINDING PROPERTIES OF THE HUMAN PEPTIDE TRANSPORTERS TAP1 AND TAP2 EXPRESSED BY RECOMBINANT VACCINIA VIRUSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; ENDOPLASMIC-RETICULUM; ANTIGEN PRESENTATION; MEMBRANE-PROTEINS; ABC TRANSPORTER; LYMPHOCYTES-T; MHC; REGION; TRANSLOCATION	The transporter associated with antigen processing (TAP) transports short peptides from the cytosol to the endoplasmic reticulum, where peptides assemble with class I molecules of the major histocompatibility complex, TAP is comprised of two subunits, termed TAP1 and TAP2, We produced recombinant vaccinia viruses that direct synthesis of the TAP subunits, either individually or together, Virus-encoded TAP is rapidly and efficiently assembled (t(1/2) of 5 min or less) by cells and does not spontaneously assemble in detergent extracts, By confocal immunofluorescence microscopy, TAP1 when expressed alone or with TAP2 is largely, if not exclusively, localized to the endoplasmic reticulum, Metabolic labeling with [2-H-3]mannose demonstrates that TAP1 (but not TAP2) possesses Asn-Linked oligosaccharides, but the lack of binding of [S-35]methionine-labeled TAP to concanavalin A-agarose suggests that the glycosylated form represents a minor population of TAP1, The two subunits of the assembled complex present in detergent extracts photolabeled equally with 8-azido-[alpha-P-32]ATP. Photolabeling of the two subunits was inhibited in parallel by various di- and trinucleotides, suggesting that their nucleotide binding sites function in a highly similar manner, Incubation of detergent extracts at 37 degrees C results in the rapid loss of TAP1 immunoreactivity, indicating either an unusual sensitivity to proteases or an irreversible conformation alteration.	YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; DANA FARBER CANC INST,BOSTON,MA 02115	Howard Hughes Medical Institute; Yale University; Harvard University; Dana-Farber Cancer Institute	RUSS, G (corresponding author), NIAID,VIRAL DIS LAB,BLDG 4,ROOM 205,BETHESDA,MD 20892, USA.		yewdell, jyewdell@nih.gov jonathan/A-1702-2012	Esquivel, Fernando/0000-0002-2962-0428				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOYLE DB, 1986, J GEN VIROL, V67, P1591, DOI 10.1099/0022-1317-67-8-1591; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; CORNWELL MM, 1987, FASEB J, P51; COUPAR BEH, 1988, GENE, V68, P1, DOI 10.1016/0378-1119(88)90593-8; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; EISENLOHR LC, 1992, CELL, V71, P963, DOI 10.1016/0092-8674(92)90392-P; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; GERHARD W, 1981, NATURE, V290, P713, DOI 10.1038/290713a0; HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; KAGEYAMA S, 1995, J IMMUNOL, V154, P567; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPHAM CK, 1993, J EXP MED, V177, P1633, DOI 10.1084/jem.177.6.1633; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; MOMBURG F, 1994, J EXP MED, V179, P1613, DOI 10.1084/jem.179.5.1613; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MORBACH S, 1993, J BIOL CHEM, V268, P18617; MULLER KM, 1994, J BIOL CHEM, V269, P14032; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; NEISIG A, 1995, J IMMUNOL, V154, P1273; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROELSE J, 1994, J EXP MED, V180, P1591, DOI 10.1084/jem.180.5.1591; RUSS G, 1991, CELL REGUL, V2, P549, DOI 10.1091/mbc.2.7.549; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1994, J EXP MED, V179, P533, DOI 10.1084/jem.179.2.533; SCHUMACHER TNM, 1994, P NATL ACAD SCI USA, V91, P13004, DOI 10.1073/pnas.91.26.13004; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SMITH GL, 1987, VIROLOGY, V160, P336, DOI 10.1016/0042-6822(87)90004-3; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TRAVIS SM, 1993, J BIOL CHEM, V268, P15336; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; WANG K, 1994, FEBS LETT, V350, P337, DOI 10.1016/0014-5793(94)00806-X; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; YEWDELL J, 1994, J IMMUNOL, V152, P1163; YEWDELL JW, 1988, CELL, V52, P843, DOI 10.1016/0092-8674(88)90426-6; YEWDELL JW, 1985, P NATL ACAD SCI USA, V82, P1785, DOI 10.1073/pnas.82.6.1785; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	56	72	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21312	21318		10.1074/jbc.270.36.21312	http://dx.doi.org/10.1074/jbc.270.36.21312			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673167	hybrid			2022-12-25	WOS:A1995RU05400068
J	BLAGOSKLONNY, MV; TORETSKY, J; NECKERS, L				BLAGOSKLONNY, MV; TORETSKY, J; NECKERS, L			GELDANAMYCIN SELECTIVELY DESTABILIZES AND CONFORMATIONALLY ALTERS MUTATED P53	ONCOGENE			English	Article						BENZOQUINONE ANSAMYCINS; GELDANAMYCIN; MUTATED P53; PROTEIN STABILITY	TUMOR-SUPPRESSOR PROTEIN; CANCER CELL-LINES; MUTANT P53; ACTIVATING MUTATIONS; BINDING-SITE; DNA-DAMAGE; COS CELLS; WILD-TYPE; GENE; TRANSFORMATION	Mutated p53 proteins interfere in the function of wild type p53 and may also serve as a dominant oncogene, The vast majority of p53 mutations result in a protein of altered conformation and prolonged half-life. We sought to examine whether geldanamycin, a drug capable of destabilizing several oncogene and proto-oncogene products, could alter the stability and DNA binding characteristics of several mutated p53 proteins, Brief exposure to GA destabilized the p53 protein of several breast, prostate and leukemic cell lines harboring mutated p53 alleles, resulting in a significant reduction in p53 steady state level and half-life. In contrast to its effects on mutated p53, GA altered neither steady state level nor inducibility of the wild type protein. In addition to its effects on protein stability, GA also altered the conformation of mutated p53, so that it was no longer detectable with a mutant conformation-specific antibody. Finally, mutated p53 protein isolated from GA-treated cells regained partial ability to bind a wild type-specific p53 DNA consensus sequence, These data indicate the feasability of pharmacologic intervention for altering the mutated p53 phenotype.	NCI,CLIN PHARMACOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AVILA MA, 1994, CANCER RES, V54, P2424; BARTEK J, 1990, ONCOGENE, V5, P893; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSIAO M, 1994, AM J PATHOL, V145, P702; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LU X, 1991, CELL, V70, P153; MILLER P, 1994, BIOCHEM BIOPH RES CO, V201, P1313, DOI 10.1006/bbrc.1994.1847; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MILNER J, 1990, ONCOGENE, V5, P1683; MURAKAMI Y, 1994, BIOCHEM J, V301, P63, DOI 10.1042/bj3010063; NEGRINI M, 1994, CANCER RES, V54, P1818; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PRICE BD, 1993, ONCOGENE, V8, P3055; RYAN JJ, 1994, LEUKEMIA RES, V18, P617, DOI 10.1016/0145-2126(94)90043-4; SHUE G, 1994, J BIOL CHEM, V269, P2702; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; UEHARA Y, 1989, CANCER RES, V49, P780; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHANG W, 1992, ONCOGENE, V7, P1645	52	181	184	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					933	939						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675452				2022-12-25	WOS:A1995RU79800014
J	CZAJA, C; LITWILLER, R; TOMLINSON, AJ; NAYLOR, S; TAVARES, P; LEGALL, J; MOURA, JJG; MOURA, I; RUSNAK, F				CZAJA, C; LITWILLER, R; TOMLINSON, AJ; NAYLOR, S; TAVARES, P; LEGALL, J; MOURA, JJG; MOURA, I; RUSNAK, F			EXPRESSION OF DESULFOVIBRIO-GIGAS DESULFOREDOXIN IN ESCHERICHIA-COLI - PURIFICATION AND CHARACTERIZATION OF MIXED-METAL ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-PASTEURIANUM RUBREDOXIN; PLASMA EMISSION-SPECTROSCOPY; AMINO-ACID-SEQUENCE; HEME IRON PROTEIN; HILDENBOROUGH; MOSSBAUER; RESONANCE; GENES; RBO	The dsr gene from Desulfovibrio gigas encoding the nonheme iron protein desulforedoxin was cloned using the polymerase chain reaction, expressed in Escherichia coli, and purified to homogeneity. The physical and spectroscopic properties of the recombinant protein resemble those observed for the native protein isolated from D. gigas. These include an alpha(2) tertiary structure, the presence of bound iron, and absorbance maxima at 370 and 506 nm in the UV/visible spectrum due to ligand-to-iron charge transfer bands. Low temperature electron paramagnetic resonance studies confirm the presence of a high spin ferric ion with g values of 7.7, 5.7, 4.1, and 1.8. Interestingly, E. coli produced two forms of desulforedoxin containing iron. One form was identified as a dimer with the metal-binding sites of both subunits occupied by iron while the second form contained equivalent amounts of iron and zinc and represents a dimer with one subunit occupied by iron and the second with zinc.	MAYO CLIN & MAYO FDN,HEMATOL RES SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,BIOMED MASS SPECTROMETRY FACIL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,DEPT QUIM,P-2825 MONTE DE CAPARICA,PORTUGAL; UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,CTR QUIM FINA & BIOTECNOL,P-2825 MONTE DE CAPARICA,PORTUGAL; UNIV GEORGIA,DEPT BIOCHEM & MOLEC BIOL,ATHENS,GA 30602	Mayo Clinic; Mayo Clinic; Mayo Clinic; Universidade Nova de Lisboa; Universidade Nova de Lisboa; University System of Georgia; University of Georgia			Moura, Isabel/D-6339-2013; Moura, José J G/D-6426-2013; Tavares, Pedro/B-3654-2008	Moura, Isabel/0000-0003-0971-4977; Moura, José J G/0000-0002-4726-2388; Tavares, Pedro/0000-0002-7398-2661	NIGMS NIH HHS [GM46865] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046865] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER M, 1995, IN PRESS J MOL BIOL, V251; BACHMAYE.H, 1967, P NATL ACAD SCI USA, V57, P122, DOI 10.1073/pnas.57.1.122; BRADDOCK WD, 1994, 42ND P ASMS C MASS S, P409; BRUMLIK MJ, 1990, J BACTERIOL, V172, P7289, DOI 10.1128/jb.172.12.7289-7292.1990; BRUMLIK MJ, 1989, J BACTERIOL, V171, P4996, DOI 10.1128/jb.171.9.4996-5004.1989; BRUSCHI M, 1979, BIOCHEM BIOPH RES CO, V90, P596, DOI 10.1016/0006-291X(79)91277-4; CHORY J, 1990, CURRENT PROTOCOLS MO; DEBRUNNER PG, 1977, IRON SULFUR PROTEINS, V3, P381; EIDSNESS MK, 1992, PROTEIN ENG, V5, P367, DOI 10.1093/protein/5.4.367; FASSEL VA, 1978, SCIENCE, V202, P183, DOI 10.1126/science.202.4364.183; LEE JC, 1974, ARCH BIOCHEM BIOPHYS, V165, P268, DOI 10.1016/0003-9861(74)90164-7; LOVENBERG W, 1969, BIOCHEMISTRY-US, V8, P141, DOI 10.1021/bi00829a020; LOVENBERG W, 1965, P NATL ACAD SCI USA, V54, P193, DOI 10.1073/pnas.54.1.193; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MOURA I, 1977, BIOCHEM BIOPH RES CO, V75, P1037, DOI 10.1016/0006-291X(77)91486-3; MOURA I, 1978, BIOCHIM BIOPHYS ACTA, V533, P156, DOI 10.1016/0005-2795(78)90559-7; MOURA I, 1991, J INORG BIOCHEM, V44, P127, DOI 10.1016/0162-0134(91)84025-5; MOURA I, 1980, J BIOL CHEM, V255, P2493; MOURA I, 1990, J BIOL CHEM, V265, P21596; NIXON DE, 1986, CLIN CHEM, V32, P1660; PEISACH J, 1971, J BIOL CHEM, V246, P5877; PHILLIPS WD, 1970, NATURE, V227, P574, DOI 10.1038/227574a0; RUSNAK F, 1995, INORG CHEM, V34, P3833, DOI 10.1021/ic00118a037; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIEKER LC, 1994, METHOD ENZYMOL, V243, P203; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1990, CURRENT PROTOCOLS MO; TAVARES P, 1994, J BIOL CHEM, V269, P10504; VERHAGEN MFJM, 1993, FEBS LETT, V336, P13, DOI 10.1016/0014-5793(93)81599-U; WILSON K, 1994, CURRENT PROTOCOLS MO; YACHANDRA VK, 1983, J AM CHEM SOC, V105, P6455, DOI 10.1021/ja00359a015	31	30	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20273	20277		10.1074/jbc.270.35.20273	http://dx.doi.org/10.1074/jbc.270.35.20273			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657596	Green Submitted, hybrid			2022-12-25	WOS:A1995RR58400009
J	NAGATA, Y; NAGAHISA, H; AIDA, Y; OKUTOMI, K; NAGASAWA, T; TODOKORO, K				NAGATA, Y; NAGAHISA, H; AIDA, Y; OKUTOMI, K; NAGASAWA, T; TODOKORO, K			THROMBOPOIETIN INDUCES MEGAKARYOCYTE DIFFERENTIATION IN HEMATOPOIETIC PROGENITOR FDC-P2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION FACTORS; GENE-EXPRESSION; RECEPTOR GENE; GROWTH	Thrombopoietin (Tpo) is a cytokine that specifically regulates megakaryocyte maturation and platelet production. Little is known about the molecular and cellular mechanism of the Tpo-induced megakaryocyte maturation process including polyploidization and platelet release. To study Tpo-induced megakaryocyte differentiation, a mouse cell line FD-TPO, which responds and grows with Tpo, was established from a interleukin-3-dependent hematopoietic progenitor cell line FDC-P2, The FD-TPO cells, expressing endogenous Tpo receptor, grew with Tpo in a dose-dependent manner. Further, Tpo stimulation dramatically induced expression of megakaryocyte/erythroid-specific transcription factors GATA-1 and NF-EP in FD-TPO cells. Flow cytometry analysis demonstrated that expression of platelet-specific cell surface antigens including CD61 (GPIIIa) dramatically increased in Tpo-stimulated FD-TPO cells and that expression of myeloid-specific antigens, Gr-l and Mac-1, decreased. Therefore, we concluded that the binding of Tpo to FD-TPO cells induces not only cell growth but also differentiation into mature megakaryocyte-like cells, and thus this cell line was found to be useful for the study of Tpo receptor-mediated growth and differentiation signals.	RIKEN,INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST CLIN MED,DIV HEMATOL,TSUKUBA,IBARAKI 305,JAPAN	RIKEN; University of Tsukuba								ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; CHIBA T, 1993, P NATL ACAD SCI USA, V90, P11593, DOI 10.1073/pnas.90.24.11593; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; METHIA N, 1993, BLOOD, V82, P1395; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; ORKIN SH, 1992, BLOOD, V80, P575; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; VISVADER JE, 1992, EMBO J, V12, P4557; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0	16	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19673	19675		10.1074/jbc.270.34.19673	http://dx.doi.org/10.1074/jbc.270.34.19673			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649975	hybrid			2022-12-25	WOS:A1995RQ99100002
J	SCHODERBEK, WE; ROBERSON, MS; MAURER, RA				SCHODERBEK, WE; ROBERSON, MS; MAURER, RA			2 DIFFERENT DNA ELEMENTS MEDIATE GONADOTROPIN-RELEASING-HORMONE EFFECTS ON EXPRESSION OF THE GLYCOPROTEIN HORMONE ALPHA-SUBUNIT GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; HYPOTHALAMIC-PITUITARY DISCONNECTION; BETA-LUTEINIZING HORMONE; PROTEIN KINASE-C; OVARIECTOMIZED EWES; PROLACTIN GENE; GROWTH-HORMONE; RAT; TRANSCRIPTION; STIMULATION	Transient transfection studies using gonadotrope-derived, alphaT3-1 cells were used to determine the DNA sequences of the mouse glycoprotein hormone alpha-subunit gene that mediate the transcriptional response to gonadotropin releasing hormone (GnRH). The roles of phorbol esters and cyclic AMP in mediating the GnRH response were also investigated. The initial studies demonstrated that a construct containing approximately 500 base pairs of alpha-subunit flanking sequence was sufficient to mediate responses to a GnRH agonist (GnRHa), phorbol myristate acetate (PMA) and a cAMP analog. Responses to combinations of cAMP and GnRHa or cAMP and PMA were approximately additive, whereas the response to the combination of GnRHa and PMA was similar to that seen with either of the agents alone. Cotransfection studies with an expression vector for the heat-stable inhibitor of the cAMP-dependent protein kinase demonstrated that GnRHa and PMA responses are not dependent on the cAMP-dependent kinase. Deletion analysis indicated that sequences between -507 and -205 were involved in mediating responses to GnRHa and PMA. To determine if this region alone could support responses to these agents, the -507 to -205 region was linked to a minimal promoter and tested in transient transfections. The results demonstrated that this region supports responses to GnRHa, PMA, and cAMP. Clustered point mutations of this region were used to further characterize sequences involved in the GnRH response. Mutations in two regions, one at positions -406 to -399 and one at positions -337 to -330, resulted in decreased responses to GnRH and PMA. There is no obvious sequence similarity between the two regions that are required for the GnRH response. An enhancer test demonstrated that multimers of the -416 to -385 region were able to function as a GnRH-responsive element when linked to a minimal promoter, although a single copy of this region was not sufficient to permit a response to GnRH. In contrast, multimers of the -344 to -300 region did not permit a response to GnRH, but enhanced basal transcription. These findings are consistent with the identification of a two-component GnRH response unit, which probably involves the functional cooperation of two different transcription factors. The observation that GnRH responsiveness appears to co-localize with PMA responsiveness suggests that GnRH effects on the alpha-subunit transcription are likely mediated by the protein kinase C pathway.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa					NICHD NIH HHS [HD07555] Funding Source: Medline; NIDDK NIH HHS [DK36407, DK25295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD007555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036407, P30DK025295] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS WV, 1988, J BIOL CHEM, V263, P13755; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIN JM, 1989, MOL ENDOCRINOL, V3, P1643, DOI 10.1210/mend-3-10-1643; CLARKE IJ, 1982, ENDOCRINOLOGY, V111, P1737, DOI 10.1210/endo-111-5-1737; DALKIN AC, 1989, ENDOCRINOLOGY, V125, P917, DOI 10.1210/endo-125-2-917; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DAY RN, 1989, J BIOL CHEM, V264, P431; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DING Y, 1991, MOL ENDOCRINOL, V5, P1239, DOI 10.1210/mend-5-9-1239; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; GORDON DF, 1988, DNA-J MOLEC CELL BIO, V7, P679, DOI 10.1089/dna.1988.7.679; HAMERNIK DL, 1986, ENDOCRINOLOGY, V119, P2704, DOI 10.1210/endo-119-6-2704; HAMERNIK DL, 1988, ENDOCRINOLOGY, V122, P959, DOI 10.1210/endo-122-3-959; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KATO Y, 1991, J MOL ENDOCRINOL, V7, P27, DOI 10.1677/jme.0.0070027; KIM KE, 1990, MOL CELL ENDOCRINOL, V74, P101, DOI 10.1016/0303-7207(90)90112-L; LALLOZ MRA, 1988, ENDOCRINOLOGY, V122, P1681, DOI 10.1210/endo-122-4-1681; LEAL JA, 1988, J CLIN ENDOCR METAB, V67, P1325, DOI 10.1210/jcem-67-6-1325; LEUNG K, 1987, MOL ENDOCRINOL, V1, P724, DOI 10.1210/mend-1-10-724; LEVINE JE, 1982, ENDOCRINOLOGY, V111, P1439, DOI 10.1210/endo-111-5-1439; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MCARDLE CA, 1987, J BIOL CHEM, V262, P5028; PAPAVASILIOU SS, 1986, P NATL ACAD SCI USA, V83, P4026, DOI 10.1073/pnas.83.11.4026; PEERS B, 1991, J BIOL CHEM, V266, P18127; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SALTON SRJ, 1988, MOL ENDOCRINOL, V2, P1033, DOI 10.1210/mend-2-11-1033; SCHODERBEK WE, 1992, MOL ENDOCRINOL, V6, P893, DOI 10.1210/me.6.6.893; SHUPNIK MA, 1990, MOL ENDOCRINOL, V4, P1444, DOI 10.1210/mend-4-10-1444; STANLEY HF, 1988, MOL ENDOCRINOL, V2, P1302, DOI 10.1210/mend-2-12-1302; WIERMAN ME, 1989, ENDOCRINOLOGY, V124, P272, DOI 10.1210/endo-124-1-272; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; YEO T, 1981, J ENDOCRINOL, V91, P33, DOI 10.1677/joe.0.0910033	36	90	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3903	3910						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680035				2022-12-25	WOS:A1993KN53300020
J	BRUEL, C; DIRAGO, JP; SLONIMSKI, PP; LEMESLEMEUNIER, D				BRUEL, C; DIRAGO, JP; SLONIMSKI, PP; LEMESLEMEUNIER, D			ROLE OF THE EVOLUTIONARILY CONSERVED CYTOCHROME-B TRYPTOPHAN-142 IN THE UBIQUINOL OXIDATION CATALYZED BY THE BC(1)-COMPLEX IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTER; DIURON-RESISTANT MUTATIONS; RHODOBACTER-SPHAEROIDES; C REDUCTASE; BC1 COMPLEX; ELECTRON-TRANSFER; MOLECULAR-BASIS; SEQUENCE-ANALYSIS; DEFICIENT MUTANT; WILD-TYPE	Trp-142 is a highly conserved residue of the cytochrome b subunit in the bc(1) complexes. To study the importance of this residue in the quinol oxidation catalyzed by the bc(1) complex, we characterized four yeast mutants with arginine, lysine, threonine, and serine at position 142. The mutant W142R was isolated previously as a respiration-deficient mutant unable to grow on nonfermentable carbon sources (Lemesle-Meunier, D., Brivet-Chevillotte, P., di Rage, J.-P, Slonimski, P. P., Bruel, C., Tron, T., and Forget, N. (1993) J. Biol. Chem. 268, 15626-15632). The mutants W142K, W142T, and W142S were obtained here as respiration-sufficient revertants from mutant W142R. Mutant W142R exhibited a decreased complex II turnover both in the presence and absence of antimycin A; this suggests that the structural effect of W142R in the bc(1) complex probably interferes with the correct assembly of the succinate-ubiquinone reductase complex. The mutations resulted in a parallel decrease in turnover number and apparent K-m, with the result that there was no significant change in the second-order rate constant for ubiquinol oxidation. Mutants W142K and W142T exhibited some resistance toward myxothiazol, whereas mutant W142R showed increased sensitivity. The cytochrome cc(1) reduction kinetics were found to be severely affected in mutants W142R, W142K, and W142T. The respiratory activities and the amounts of reduced cytochrome b measured during steady state suggest that the W142S mutation also modified the quinol-cytochrome c(1) electron transfer pathway. The cytochrome b reduction kinetics through center P were affected when Trp-142 was replaced with arginine or lysine, but not when it was replaced with threonine or serine. Of the four amino acids tested at position 142, only arginine resulted in a decrease in cytochrome b reduction through center N. These findings are discussed in terms of the structure and function of the quinol oxidation site and seem to indicate that Trp-142 is not critical to the kinetic interaction of ubiquinol with the reductase, but plays an important role in the electron transfer reactions that intervene between ubiquinol oxidation and cytochrome c(1) reduction.	LAB BIOENERGET & INGN PROT,CNRS,F-13402 MARSEILLE 20,FRANCE; UNIV PARIS 06,CTR GENET MOLEC,CNRS,PROPRE LAB,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay								ATTAASAFOADJEI E, 1991, P NATL ACAD SCI USA, V88, P492, DOI 10.1073/pnas.88.2.492; BENNOUN P, 1992, MOL GEN GENET, V234, P147, DOI 10.1007/BF00272356; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; BRASSEUR G, 1994, FEBS LETT, V354, P23, DOI 10.1016/0014-5793(94)01077-3; BRASSEUR R, 1988, J BIOL CHEM, V263, P12571; BRIVETCHEVILLOT.P, 1989, FEBS LETT, V255, P5, DOI 10.1016/0014-5793(89)81050-6; BRUEL C, 1993, BIOCHEM SOC T, V22, pS61; CHEVILLOTTEBRIV.P, 1983, EUR J BIOCHEM, V129, P653; CHEVILLOTTEBRIV.P, 1980, EUR J BIOCHEM, V111, P161; CHEVILLOTTEBRIV.P, 1987, BIOCHIMIE, V69, P25; COLSON AM, 1993, J BIOENERG BIOMEMBR, V25, P211, DOI 10.1007/BF00762583; COPPEE JY, 1994, J BIOL CHEM, V269, P4221; CROFTS A, 1992, BIOCHIM BIOPHYS ACTA, V1101, P162, DOI 10.1016/S0005-2728(05)80009-X; CROFTS A, 1987, CYTOCHROME SYSTEMS M, P617; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; CROFTS AR, 1985, ENZYMES BIOL MEMBR, P347; DALDAL F, 1989, EMBO J, V8, P3951, DOI 10.1002/j.1460-2075.1989.tb08578.x; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DEGLIESPOSTI M, 1991, ARCH BIOCHEM BIOPHYS, V289, P303; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; DIRAGO JP, 1990, FEBS LETT, V263, P93, DOI 10.1016/0014-5793(90)80713-S; DIRAGO JP, 1989, J BIOL CHEM, V264, P14543; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; DIRAGO JP, 1993, FEBS LETT, V328, P153, DOI 10.1016/0014-5793(93)80984-3; DIRAGO JP, 1990, J BIOL CHEM, V265, P15750; DIRAGO JP, 1986, FEBS LETT, V208, P208, DOI 10.1016/0014-5793(86)81019-5; DIRAGO JP, 1990, J BIOL CHEM, V265, P3332; FAYE G, 1973, BIOCHIMIE, V55, P779, DOI 10.1016/S0300-9084(73)80030-6; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; GIESSLER A, 1994, EUR J BIOCHEM, V222, P147, DOI 10.1111/j.1432-1033.1994.tb18852.x; HATEFI Y, 1980, J BIOL CHEM, V255, P5530; HAUSKA G, 1983, BIOCHIM BIOPHYS ACTA, V726, P97, DOI 10.1016/0304-4173(83)90002-2; HOWELL N, 1988, J MOL BIOL, V203, P607, DOI 10.1016/0022-2836(88)90195-7; HOWELL N, 1990, BIOCHEMISTRY-US, V29, P8970, DOI 10.1021/bi00490a013; HOWELL N, 1987, J BIOL CHEM, V262, P2411; KOMIYA H, 1988, P NATL ACAD SCI USA, V85, P9012, DOI 10.1073/pnas.85.23.9012; KOTYLAK Z, 1976, GENETIC FUNCTION MIT, P143; KOVAC L, 1967, SCIENCE, V158, P1564, DOI 10.1126/science.158.3808.1564; KOVACOVA V, 1968, BIOCHIM BIOPHYS ACTA, V162, P157, DOI 10.1016/0005-2728(68)90097-2; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; LEMESLEMEUNIER D, 1993, J BIOL CHEM, V268, P15626; LINK TA, 1993, J BIOENERG BIOMEMBR, V25, P221, DOI 10.1007/BF00762584; MEUNIER B, 1989, EUR J BIOCHEM, V184, P651, DOI 10.1111/j.1432-1033.1989.tb15062.x; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; SPECK SH, 1984, J BIOL CHEM, V259, P1064; TIAN GL, 1991, J MOL BIOL, V218, P744; TRON T, 1990, CURR GENET, V18, P413, DOI 10.1007/BF00309910; TRON T, 1991, EUR J BIOCHEM, V199, P753, DOI 10.1111/j.1432-1033.1991.tb16180.x; TRON T, 1991, FEBS LETT, V278, P26, DOI 10.1016/0014-5793(91)80075-E; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; WEBER S, 1988, FEBS LETT, V237, P31, DOI 10.1016/0014-5793(88)80165-0; YUN CH, 1991, BIOCHEMISTRY-US, V30, P6747, DOI 10.1021/bi00241a017; YUN CH, 1991, J BIOL CHEM, V266, P10967; YUN CH, 1992, J BIOL CHEM, V267, P5901	59	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22321	22328		10.1074/jbc.270.38.22321	http://dx.doi.org/10.1074/jbc.270.38.22321			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673215	hybrid			2022-12-25	WOS:A1995RW31400042
J	CHAN, SDH; ANTONIUCCI, DM; FOK, KS; ALAJOKI, ML; HARKINS, RN; THOMPSON, SA; WADA, HG				CHAN, SDH; ANTONIUCCI, DM; FOK, KS; ALAJOKI, ML; HARKINS, RN; THOMPSON, SA; WADA, HG			HEREGULIN ACTIVATION OF EXTRACELLULAR ACIDIFICATION IN MAMMARY-CARCINOMA CELLS IS ASSOCIATED WITH EXPRESSION OF HER2 AND HER3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; LIGAND; PROTEIN; ONCOGENE; PRODUCT; GENE; HER4/P180(ERBB4); DIFFERENTIATION	HER2, the erbB-2/neu proto-oncogene product, is a 185-kDa transmembrane glycoprotein related to the epidermal growth factor receptor. Overexpression of HERB was reported in several human adenocarcinomas, including mammary and ovarian carcinomas. A family of glycoproteins, the heregulin/neu differentiation factors, was characterized and implicated as the Ligands for HERS. Recently, it has been shown that HERB alone is not sufficient to reconstitute high affinity heregulin receptors and that HER3 or HER4 may be the required components of the heregulin receptors on mammary carcinoma cells (Sliwkowski, M. X., Schaefer, G., Akita, R. W., Lofgren, J. A, Fitzpatrick, V. D., Nuijens, A., Fendly, B. M., Cerione, R. A., Vandlen, R. L., and Carraway, K. L., III (1994) J. Biol. Chem. 269, 14661-14665; Plowman, G. D., Green, J. M., Culouscou, J. -M., Carlton, G. W., Rothwell, V. M., and Buckley, W. (1993) Nature 366, 473-475). Using the Cytosensor(R) to measure the extracellular acidification rate, we have examined the effects of recombinant human heregulin-alpha on three mammary carcinoma cell lines expressing HER2 (MDA-MB-453, SK-BR-3, and MCF-7), an ovarian carcinoma cell line expressing HERB (SH-OV-3), and CHO-K1 and 293-EBNA cells stably transfected with HERB. By reverse transcription polymerase chain reaction and Western blotting, we found that the breast cells also express HER3 and that the ovarian line co-expresses the HER4 message. A dramatic increase in the acidification rate was observed for the mammary carcinoma cells co-expressing high levels of HERS and HER3. In contrast, the ovarian cells expressing high levels of HERB and low levels of HER4 or CHO-K1 and 293-EBNA cells expressing HERB alone were not responsive to heregulin. When these same transfected cells were exposed to monoclonal anti-HER2 antibody followed by anti-IgG to cause aggregation of the HERB molecules, an increase in the acidification rate was observed, indicating coupling of transfected HERB to the signal transduction pathway. Transfection of HER2 into MCF-7 cells, on the other hand, gave 4-fold enhanced acidification responses. These data, together with the previously reported high affinity heregulin binding and activation of tyrosine phosphorylation in HERB and HER3 co-transfected cells support the role of HERB and HER3 as components of the heregulin receptor in breast cells.	MOLEC DEVICES CORP,SUNNYVALE,CA 94089; BERLEX BIOSCI,RICHMOND,CA 94804									AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CHEN SDH, 1994, FASEB J, V8, P668; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MCCONNELL HM, 1993, SCIENCE, V257, P1906; NAG B, 1992, J IMMUNOL, V148, P2040; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	32	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22608	22613		10.1074/jbc.270.38.22608	http://dx.doi.org/10.1074/jbc.270.38.22608			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673253	hybrid			2022-12-25	WOS:A1995RW31400084
J	CHOI, MY; MILLER, A; CHO, NY; ROTHMANDENES, LB				CHOI, MY; MILLER, A; CHO, NY; ROTHMANDENES, LB			IDENTIFICATION, CLONING, AND CHARACTERIZATION OF THE BACTERIOPHAGE-N4 GENE ENCODING THE SINGLE-STRANDED DNA BINDING-PROTEIN - A PROTEIN REQUIRED FOR PHAGE REPLICATION, RECOMBINATION, AND LATE TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; PURIFICATION	The coliphage N4-coded single-stranded DNA-binding protein (N4SSB) is essential for phage replication and for expression of the phage late genes, which are transcribed by the Escherichia coli sigma(70) RNA polymerase. As a first step in investigating the role of N4SSB in replication and transcriptional activation, we have identified and sequenced the N4SSB gene. The gene encodes a 265-amino acid protein with no apparent sequence homology to other single-stranded DNA-binding proteins. Ne present data indicating that N4SSB is also essential for phage recombination. Mutational analysis of the carboxyl terminus of the protein indicates that this region is required for protein-protein interactions with the N4 replication, N4 recombination, and E. coli transcriptional machineries, while the rest of the protein contains the determinants for single-stranded DNA binding.	UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,COMM DEV BIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago					NIAID NIH HHS [AI 12575] Funding Source: Medline; NIGMS NIH HHS [GM 35170] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035170] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; BOLLE A, 1969, J MOL BIOL, V31, P325; BROSIUS J, 1987, METHOD ENZYMOL, V153, P54; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P130; CHO NY, 1995, J MOL BIOL, V246, P461, DOI 10.1006/jmbi.1994.0098; GLASSBERG J, 1979, J BACTERIOL, V140, P14, DOI 10.1128/JB.140.1.14-19.1979; GLUCKSMANN MA, 1992, CELL, V70, P491, DOI 10.1016/0092-8674(92)90173-A; GUINTA D, 1986, VIROLOGY, V150, P33, DOI 10.1016/0042-6822(86)90263-1; KIM YT, 1992, J BIOL CHEM, V267, P15022; LINDBERG G, 1989, J BIOL CHEM, V264, P12700; LINDBERG GK, 1988, J BIOL CHEM, V263, P11319; LINDBERG GK, 1988, DNA REPLICATION MUTA, P130; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MALONE C, 1988, VIROLOGY, V162, P328, DOI 10.1016/0042-6822(88)90472-2; MARKIEWICZ P, 1992, GENE DEV, V6, P2010, DOI 10.1101/gad.6.10.2010; PRASAD BVV, 1987, J MOL BIOL, V193, P579; RIST JK, 1986, J BIOL CHEM, V261, P506; ROTHMANDENES LB, 1995, SEMIN VIROL, V6, P15, DOI 10.1016/S1044-5773(05)80005-8; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; VANDERLAAN K, 1977, VIROLOGY, V76, P596, DOI 10.1016/0042-6822(77)90241-0; WILLIAMS KR, 1990, BIOL NONSPECIFIC DNA, P197; ZIVIN R, 1980, VIROLOGY, V104, P205, DOI 10.1016/0042-6822(80)90378-5	24	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22541	22547		10.1074/jbc.270.38.22541	http://dx.doi.org/10.1074/jbc.270.38.22541			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673246	hybrid			2022-12-25	WOS:A1995RW31400075
J	DOBROWSKY, RT; JENKINS, GM; HANNUN, YA				DOBROWSKY, RT; JENKINS, GM; HANNUN, YA			NEUROTROPHINS INDUCE SPHINGOMYELIN HYDROLYSIS - MODULATION BY COEXPRESSION OF P75(NTR) WITH TRK RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; AFFINITY NGF RECEPTOR; TUMOR-NECROSIS-FACTOR; BINDING; PROTOONCOGENE; CELLS; DIFFERENTIATION; INTERNALIZATION; IDENTIFICATION	We examined neurotrophin-induced sphingomyelin hydrolysis in cells expressing solely the law affinity neurotrophin receptor, p75(NTR), and in PC12 cells that coexpress p75(NTR) and Trk receptors, Nerve growth factor (NGF), brain-derived neurotrophic factor, neurotrophin-3 (NT-3), and NT-5 stimulated sphingomyelin hydrolysis with similar kinetics in p75(NTR)-NIH-3T3 cells, Although brain-derived neurotrophic factor (10 ng/ml) was slightly more potent than NGF at inducing sphingomyelin hydrolysis, NT-3 and NT-5 induced significant hydrolysis (30-35%) at 0.1 to 1 ng/ml in p75(NTR)-NIH-3T3 cells, NT-3 did not induce sphingomyelin hydrolysis in Trk C-NIH-3T3 cells nor in cells expressing a mutated p75(NTR) containing a 57-amino acid cytoplasmic deletion, thus demonstrating the role of p75(NTR) in this signal transduction pathway, In p75(NTR)-NIH-3T3 cells, neurotrophin-induced sphingomyelin hydrolysis 1) localized to an internal pool of sphingomyelin, 2) was not a consequence of receptor internalization, and 3) showed no specificity with respect to the molecular species of sphingomyelin hydrolyzed, In contrast to cells expressing solely p75(NTR), NGF (100 ng/ml) did not induce sphingomyelin hydrolysis in PC12 cells, Interestingly, NT-3 (10 ng/ml) induced the same extent of sphingomyelin hydrolysis in PC12 cells as was apparent in p75(NTR)-NIH-3T3 cells. However, in the presence of NGF, NT-3 was unable to induce sphingomyelin hydrolysis, raising the possibility that Trk was modulating p75(NTR)-dependent sphingomyelin hydrolysis, Inhibition of Trk tyrosine kinase activity with 200 nM K252a enabled both NGF and NT-3 in the presence of NGF to induce sphingomyelin hydrolysis, These data support that p75(NTR) serves as a common signaling receptor for neurotrophins through induction of sphingomyelin hydrolysis and that crosstalk pathways exist between Trk and p75(NTR)-dependent signaling pathways.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University					NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BARDE YA, 1983, EMBO J, V1, P549; BARKER PA, 1994, J BIOL CHEM, V269, P30645; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BERG MM, 1992, J BIOL CHEM, V267, P13; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DAVIES AM, 1993, J NEUROSCI, V13, P4961; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; FEINSTEIN DL, 1990, FEBS LETT, V272, P7, DOI 10.1016/0014-5793(90)80437-N; FOLCH J, 1957, J BIOL CHEM, V226, P497; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HANNUM YA, 1994, BIOCH BIOPYYS ACTA, V1221, P54; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1990, EMBO J, V9, P1477, DOI 10.1002/j.1460-2075.1990.tb08265.x; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JUNGALWALA FB, 1979, J LIPID RES, V20, P579; KAHLE P, 1992, J BIOL CHEM, V267, P13917; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; LOEB DM, 1994, J BIOL CHEM, V269, P8901; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SZEBERENYI J, 1994, BBA-MOL CELL RES, V1222, P187, DOI 10.1016/0167-4889(94)90168-6; TAMURA HO, 1994, TOXICON, V32, P629, DOI 10.1016/0041-0101(94)90211-9; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VERDI JM, 1994, NEURON, V13, P733	63	216	220	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22135	22142		10.1074/jbc.270.38.22135	http://dx.doi.org/10.1074/jbc.270.38.22135			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673191	hybrid			2022-12-25	WOS:A1995RW31400015
J	KEATING, DH; CAREY, MR; CRONAN, JE				KEATING, DH; CAREY, MR; CRONAN, JE			THE UNMODIFIED (APO) FORM OF ESCHERICHIA-COLI ACYL CARRIER PROTEIN IS A POTENT INHIBITOR OF CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; BACTERIOPHAGE-T7 DNA-POLYMERASE; PURIFICATION; DEFICIENT; PROMOTER; GENETICS; SPINACH; MUTANT	Acyl carrier protein (ACP) is the carrier of fatty acids during their synthesis and utilization. ACPs (or ACP-like protein domains) have been found throughout biology and share significant amino acid sequence similarities. All ACPs undergo a post-translational modification in which 4'-phosphopantetheine is transferred from CoA to a specific serine of apo-ACP, This modification is essential for activity because fatty acids are bound in thioester linkage to the sulfhydryl of the prosthetic group. Overproduction of Escherichia coli ACP from multicopy plasmids strongly inhibits growth off. coli. We report that upon overexpression of ACP in E. coli post-translational modification is inefficient and the apo protein accumulates and blocks cell growth by inhibition of lipid metabolism. Moreover, a mutant form of ACP that is unable to undergo post-translational modification is a potent inhibitor of growth. Finally, we observed that an increase in the efficiency of modification of overexpressed ACP results in decreased toxicity. The accumulated apo-ACP acts as a potent in vitro inhibitor of the sn-glycerol 3-phosphate acyltransferase resulting in an inability to transfer the completed fatty acid to sn-glycerol 3-phosphate. The degree of inhibition depended upon the species of donor acyl chain, Utilization of cis-vaccenoyl-ACP by the sn-glycerol-3-phosphate acyltransferase was inhibited to a much greater extent by apo-ACP than was utilization of palmitoyl-ACP. l-Acyl glycerol-3-phosphate acyltransferase was also inhibited in vitro by apo-ACP, although not at physiologically relevant concentrations, These in vitro data are supported by in vivo labeling data, which showed a large decrease in cis-vaccenate incorporation into phospholipid during overproduction of ACP, but no decrease in the rate of synthesis of long chain acyl-ACPs. These data indicate that acylation of sn-glycerol S-phosphate is the major site of inhibition by apo-ACP.	UNIV ILLINOIS, DEPT MICROBIOL, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15650] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CHO HS, 1995, J BIOL CHEM, V270, P4216, DOI 10.1074/jbc.270.9.4216; COLEMAN J, 1990, J BIOL CHEM, V265, P17215; CRONAN JE, 1978, ANNU REV BIOCHEM, V47, P163, DOI 10.1146/annurev.bi.47.070178.001115; CRONAN JE, 1988, GENE, V70, P161, DOI 10.1016/0378-1119(88)90114-X; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1, P474; Davis R., 1980, ADV BACTERIAL GENETI; DAVIS TN, 1982, VIROLOGY, V120, P287, DOI 10.1016/0042-6822(82)90031-9; ELOVSON J, 1975, ARCH BIOCHEM BIOPHYS, V168, P490, DOI 10.1016/0003-9861(75)90279-9; GELMANN EP, 1972, J BACTERIOL, V112, P381, DOI 10.1128/JB.112.1.381-387.1972; GOELZ SE, 1981, BIOCHEMISTRY-US, V21, P189; GRANA D, 1988, GENETICS, V120, P319; GUERRA DJ, 1988, J BIOL CHEM, V263, P4386; HEATON MP, 1994, J BACTERIOL, V176, P681, DOI 10.1128/jb.176.3.681-690.1994; HOLAK TA, 1988, EUR J BIOCHEM, V175, P9, DOI 10.1111/j.1432-1033.1988.tb14159.x; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1983, J BIOL CHEM, V258, P5186; JIANG P, 1994, J BACTERIOL, V176, P2814, DOI 10.1128/JB.176.10.2814-2821.1994; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lipmann F, 1980, Adv Microb Physiol, V21, P227; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MORRIS LJ, 1967, J CHROMATOGR, V31, P69, DOI 10.1016/S0021-9673(01)86026-X; NACHIAPPAN V, 1994, ANAL BIOCHEM, V222, P283, DOI 10.1006/abio.1994.1487; POLACCO ML, 1981, J BIOL CHEM, V256, P5750; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; RAWLINGS M, 1993, THESIS U ILLINOIS UR; ROCK CO, 1979, J BIOL CHEM, V254, P7123; ROCK CO, 1980, ANAL BIOCHEM, V102, P362, DOI 10.1016/0003-2697(80)90168-2; ROCK CO, 1981, J BIOL CHEM, V256, P736; Sambrook J, 1989, MOL CLONING LABORATO; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THERISOD H, 1987, P NATL ACAD SCI USA, V84, P8235, DOI 10.1073/pnas.84.23.8235; Vagelos P. R., 1973, ENZYMES, V8, P155; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988; VANDENBOOM T, 1989, ANNU REV MICROBIOL, V43, P317, DOI 10.1146/annurev.micro.43.1.317	41	83	88	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22229	22235		10.1074/jbc.270.38.22229	http://dx.doi.org/10.1074/jbc.270.38.22229			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673201	hybrid			2022-12-25	WOS:A1995RW31400027
J	MAROM, M; HAKLAI, R; BENBARUCH, G; MARCIANO, D; EGOZI, Y; KLOOG, Y				MAROM, M; HAKLAI, R; BENBARUCH, G; MARCIANO, D; EGOZI, Y; KLOOG, Y			SELECTIVE-INHIBITION OF RAS-DEPENDENT CELL-GROWTH BY FARNESYLTHIOSALICYLIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLTRANSFERASE; POSTTRANSLATIONAL MODIFICATION; FARNESYL CYSTEINE; GAMMA-SUBUNIT; SIGNAL TRANSDUCTION; GTP-BINDING; METHYLATION; BRAIN; IDENTIFICATION; PRENYLATION	S-trans,trans-FarnesylthiosalicyIic acid (FTS) is a novel farnesylated rigid carboxylic acid derivative, In cell-free systems, it acts as a potent competitive inhibitor (K-i = 2.6 mu M) of the enzyme prenylated protein methyltransferase (PPMTase), which methylates the carboxyl-terminal S-prenylcysteine in a large number of prenylated proteins including has, In such systems, FTS inhibits Ras methylation but not Ras farnesylation. Inhibition of the PPMTase by FTS in homogenates or membranes of a variety of tissues and cell lines is inferred from a block in the methylation of exogenously added substrates such as N-acetyl-S-trans,trans-farnesyl-L-cysteine and of endogenous substrates including small GTP-binding proteins, FTS can also inhibit methylation of these proteins in intact cells (e.g. in Rat-1 fibroblasts, Ras transformed Rat-1, and B16 melanoma cells), Unlike in cell-free systems, however, relatively high concentrations of FTS (50-100 mu M) are required for partial blocking (10-40%) of protein methylation in the intact cells, Thus, FTS is a weak inhibitor of methylation in intact cells, Because methylation is the last step in the processing of Ras and related proteins, FTS is not likely to affect steps that precede it, e.g. protein prenylation. This may explain why the growth and gross morphology of a variety of cultured cell types (including Chinese hamster ovary, NIH3T3, Rat1, B16 melanoma, and PC12) is not affected by up to 25 mu M FTS and is consistent with the observed lack of FTS-induced cytotoxicity. Nevertheless, FTS reduces the levels of Ras in cell membranes and can inhibit Ras-dependent cell growth in vitro, independently of methylation, It inhibits the growth of human Ha-ras-transformed cells (EJ cells) and reverses their transformed morphology in a dose-dependent manner (0.1-10 mu M). The drug does not interfere with the growth of cells transformed by v-Raf or T-antigen but inhibits the growth of ErbB2-transformed cells and blocks the mitogenic effects of epidermal and basic fibroblast growth factors, thus implying its selectivity toward Ras growth signaling, possibly via modulation of Ras-Raf communication, Taken together, the results raise the possibility that FTS may specifically interfere with the interaction of Ras with a farnesylcysteine recognition domain in the cell membrane, This drug, and perhaps other farnesylated rigid carboxylic acid analogs, may be used for in vitro characterization of the PPMTase and for the identification of a putative Ras farnesylcysteine recognition domain in cell membranes.	GEORGE S WISE FAC LIFE SCI, DEPT BIOCHEM, TEL HASHOMER, ISRAEL; CHAIM SHEBA MED CTR, DEPT OBSTET & GYNECOL, IL-52621 TEL HASHOMER, ISRAEL; TEL AVIV UNIV, SACKLER SCH MED, IL-69978 TEL AVIV, ISRAEL; ISRAEL INST BIOL RES, IL-70450 NESS ZIONA, ISRAEL	Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine								ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ASHBY MN, 1993, YEAST, V9, P907, DOI 10.1002/yea.320090810; AUDUS KL, 1987, ANN NY ACAD SCI, V507, P9, DOI 10.1111/j.1749-6632.1987.tb45787.x; BACKLUND PS, 1990, J BIOL CHEM, V265, P15572; BENBARUCH G, 1993, BIOCHEM BIOPH RES CO, V195, P282, DOI 10.1006/bbrc.1993.2042; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; ENOMOTO T, 1990, CANCER RES, V50, P6139; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HAKLAI R, 1990, BIOCHEM PHARMACOL, V40, P1365, DOI 10.1016/0006-2952(90)90405-A; HAKLAI R, 1993, NEUROPEPTIDES, V24, P11, DOI 10.1016/0143-4179(93)90036-A; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P27705; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAVI S, 1981, P NATL ACAD SCI-BIOL, V78, P6144, DOI 10.1073/pnas.78.10.6144; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MA YT, 1994, BIOCHEMISTRY-US, V33, P5414, DOI 10.1021/bi00184a009; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MARCIANO D, 1995, J MED CHEM, V38, P1267, DOI 10.1021/jm00008a004; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAN EW, 1991, J BIOL CHEM, V266, P10719; VOLKER C, 1991, J BIOL CHEM, V266, P21515; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; YAMANE HK, 1989, J BIOL CHEM, V264, P20100; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	47	174	188	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22263	22270		10.1074/jbc.270.38.22263	http://dx.doi.org/10.1074/jbc.270.38.22263			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673206	hybrid			2022-12-25	WOS:A1995RW31400033
J	GUO, B; PHILLIPS, JD; YU, Y; LEIBOLD, EA				GUO, B; PHILLIPS, JD; YU, Y; LEIBOLD, EA			IRON REGULATES THE INTRACELLULAR DEGRADATION OF IRON REGULATORY PROTEIN-2 BY THE PROTEASOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; RESPONSIVE ELEMENT; MESSENGER-RNA; ORNITHINE DECARBOXYLASE; ACONITASE; FERRITIN; CLUSTER; PURIFICATION; TRANSLATION; EXPRESSION	Iron regulatory proteins (IRP1 and IRP2) are RNA-binding proteins that bind to specific structures, termed iron responsive elements (IREs), that are located in the 5'- or 3'-untranslated regions of mRNAs that encode proteins involved in iron homeostasis. IRP1 and IRP2 RNA binding activities are regulated by iron; IRP1 and IRP2 bind IREs with high affinity in iron-depleted cells and with low affinity in iron-repleted cells. The decrease in IRP1 RNA binding activity occurs by a switch between apoprotein and 4Fe-4S forms, without changes in IRP1 levels, whereas the decrease in IRP2 RNA binding activity reflects a reduction in IRP2 levels. To determine the mechanism by which iron decreases IRP2 levels, we studied IRP2 regulation by iron in rat hepatoma and human HeLa cells. The iron-dependent decrease in IRP2 levels was not due to a decrease in the amount of IRP2 mRNA or to a decrease in the rate of IRP2 synthesis. Pulse chase experiments demonstrated that iron resulted in a 3-fold increase in the degradation rate of IRP2. IRP2 degradation depends on protein synthesis, but not transcription, suggesting a requirement for a labile protein. IRP2 degradation is not prevented by lysosomal inhibitors or calpain II inhibitors, but is prevented by inhibitors that block proteasome function. These data suggest the involvement of the proteasome in iron-mediated IRP2 proteolysis.	UNIV UTAH,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT MED,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045201] Funding Source: NIH RePORTER; NCI NIH HHS [CA4201] Funding Source: Medline; NIGMS NIH HHS [GM45201] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; BEINERT H, 1993, FASEB J, V7, P1442, DOI 10.1096/fasebj.7.15.8262329; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; CAIRO G, 1994, J BIOL CHEM, V269, P6405; CAIRO G, 1994, J BIOL CHEM, V270, P700; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; GUO B, 1994, J BIOL CHEM, V269, P24252; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; HENDERSON BR, 1994, J BIOL CHEM, V268, P27327; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; MCCONLOGUE L, 1986, MOL CELL BIOL, V6, P2865, DOI 10.1128/MCB.6.8.2865; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROUAULT TA, 1992, BIOMETALS, V5, P131, DOI 10.1007/BF01061319; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SWENSON GR, 1994, NUCLEIC ACIDS RES, V22, P2627, DOI 10.1093/nar/22.13.2627; TANG CK, 1992, J BIOL CHEM, V267, P24466; THEIL EC, 1993, BIOFACTORS, V4, P87; WALDEN WE, 1989, J BIOL CHEM, V26, P13765; YU Y, 1992, J BIOL CHEM, V267, P19005	42	256	259	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21645	21651		10.1074/jbc.270.37.21645	http://dx.doi.org/10.1074/jbc.270.37.21645			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665579	hybrid			2022-12-25	WOS:A1995RU75700036
J	KOIZUMI, T; ODANI, N; OKUYAMA, T; ICHIKAWA, A; NEGISHI, M				KOIZUMI, T; ODANI, N; OKUYAMA, T; ICHIKAWA, A; NEGISHI, M			IDENTIFICATION OF A CIS-REGULATORY ELEMENT FOR DELTA(12)-PROSTAGLANDIN J(2)-INDUCED EXPRESSION OF THE RAT HEME OXYGENASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC ENDOTHELIAL-CELLS; HEAT-SHOCK; ANTIPROLIFERATIVE ACTIVITY; INTRACELLULAR GLUTATHIONE; TRANSCRIPTIONAL CONTROL; STRESS PROTEIN; MESSENGER-RNA; INDUCTION; PROSTAGLANDINS; 9-DEOXY-DELTA-9,DELTA-12(E)-PROSTAGLANDIN-D2	We recently reported that Delta(12)-prostaglandin (PG) J(2) caused various cells to synthesize heme oxygenase, HO-1 (Koizumi, T., Negishi, M., and Ichikawa, A. (1992) Prostaglandins 43, 121-131). Here we examined the molecular mechanism underlying the Delta 12-PGJ(2)-induced HO-1 synthesis. Delta(12)-PGJ(2) markedly stimulated the promoter activity of the 5'-flanking region of the rat HO-1 gene from -810 to +101 in rat basophilic leukemia cells. From functional analysis of various deletion mutant genes we found that the Delta 12-PGJ(2)-responsive element was localized in a region from -690 to -660, containing an E-box motif, which was essential for the Delta(12)-PGJ(2)-stimulated promoter activity. When the region containing the Delta(12)- PGJ(2)-responsive element was combined with a heterologous promoter, SV40 promoter, in the sense and antisense direction, the element showed an enhancer activity in response to Delta(12)-PGJ(2). Gel mobility shift assays demonstrated that Delta(12)-PGJ(2) specifically stimulated the binding of two nuclear proteins to the E-box motif of this region. These results indicate that Delta(12)-PGJ(2) induces the expression of the rat HO-1 gene through nuclear protein binding to a specific element having an E-box motif.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,SAKYO KU,KYOTO 606,JAPAN	Kyoto University								ALAM J, 1994, J BIOL CHEM, V269, P1001; AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; ATSMON J, 1990, CANCER RES, V50, P1879; ATSMON J, 1990, BIOCHEMISTRY-US, V29, P3760, DOI 10.1021/bi00467a023; BROCK TG, 1994, J BIOL CHEM, V269, P22069; CAGEN LM, 1976, J BIOL CHEM, V251, P6550; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; ISHIZAWA S, 1983, J BIOL CHEM, V258, P4220; ITO S, 1989, PROSTAG LEUKOTR ESS, V37, P219, DOI 10.1016/0952-3278(89)90033-1; KIKUCHI G, 1983, MOL CELL BIOCHEM, V53-4, P163; KOIZUMI T, 1992, PROSTAGLANDINS, V43, P121, DOI 10.1016/0090-6980(92)90081-4; KOIZUMI T, 1993, BIOCHEM PHARMACOL, V45, P2457, DOI 10.1016/0006-2952(93)90227-N; KOIZUMI T, 1991, BIOCHEM PHARMACOL, V42, P777, DOI 10.1016/0006-2952(91)90036-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LAVROVSKY Y, 1993, BIOCHEM BIOPH RES CO, V196, P336, DOI 10.1006/bbrc.1993.2253; LOPATA MA, 1983, NUCLEIC ACIDS RES, V11, P1475; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MULLER RM, 1987, J BIOL CHEM, V262, P6795; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NEGISHI M, 1993, PROG LIPID RES, V32, P417, DOI 10.1016/0163-7827(93)90017-Q; NOYORI R, 1993, SCIENCE, V259, P44, DOI 10.1126/science.8418493; OHNO K, 1988, J BIOL CHEM, V263, P19764; OHNO K, 1990, BIOCHEM BIOPH RES CO, V168, P551, DOI 10.1016/0006-291X(90)92356-5; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PARKER J, 1992, BIOCHEM PHARMACOL, V43, P1053, DOI 10.1016/0006-2952(92)90612-M; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; SATO M, 1989, J BIOL CHEM, V264, P10251; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; TAKETANI S, 1990, J BIOCHEM-TOKYO, V108, P28, DOI 10.1093/oxfordjournals.jbchem.a123156; TASAKI Y, 1991, PROSTAGLANDINS, V41, P303, DOI 10.1016/0090-6980(91)90001-V; TENHUNEN R, 1969, J BIOL CHEM, V24, P6388; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352	38	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21779	21784		10.1074/jbc.270.37.21779	http://dx.doi.org/10.1074/jbc.270.37.21779			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665598	hybrid			2022-12-25	WOS:A1995RU75700057
J	SHI, YW; LIU, HZ; VANDERBURG, G; SAMUEL, SJ; ISMAILBEIGI, F; JUNG, CY				SHI, YW; LIU, HZ; VANDERBURG, G; SAMUEL, SJ; ISMAILBEIGI, F; JUNG, CY			MODULATION OF GLUT1 INTRINSIC ACTIVITY IN CLONE-9 CELLS BY INHIBITION OF OXIDATIVE-PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE GLUCOSE TRANSPORTER; CYTOCHALASIN-B; PLASMA-MEMBRANE; BINDING; TRANSLOCATION; MECHANISM; PROTEINS; SITE	Brief (1-2 h) exposure of Clone 9 cells to inhibitors of oxidative phosphorylation such as azide is known to markedly increase glucose uptake. Clone 9 cells express GLUT1 but not GLUT2, -3, and -4, and the azide effect was not accompanied by any increase in cellular or plasma membrane GLUT1 level. To identify the molecular event underlying this apparent increase in GLUT1 intrinsic activity, we studied the acute effects of azide on the substrate binding activity of GLUT1 in Clone 9 cells by measuring glucose-sensitive cytochalasin B binding. The glucose-displaceable, cytochalasin B binding activity was barely detectable in membranes isolated from Clone 9 cells under control conditions but was readily detectable after a 60-min incubation of cells in the presence of 5 mM azide showing a 3-fold increase in binding capacity with no change in binding affinity. Furthermore, the cytochalasin B binding activity of purified human erythrocyte GLUT1 reconstituted in liposomes was significantly reduced in the presence of cytosol derived from azide-treated Clone 9 cells but not in the presence of cytosol from control cells; this effect was heat-labile and abolished by the presence of the peptide corresponding to the GLUT1 COOH-terminal sequence. These results suggest that a cytosolic protein in Clone 9 cells binds to GLUT1 at its COOH-terminal domain and inhibits its substrate binding and that azide-induced metabolic alteration releases GLUT1 from this inhibitory interaction. Studying the binding of cytosolic proteins derived from S-35-labeled Clone 9 cells to glutathione S-transferase fusion protein containing glucose transporter COOH-terminal sequences, we identified 28- and 70-kDa proteins that bind specifically to the cytoplasmic domain of GLUT1 and GLUT4 in vitro. We also found a P-32-labeled, 85-kDa protein that binds to GLUT4 but not to GLUT1 and only in cytosol derived from azide-treated cells, The roles, if any, of these glucose transporter-binding proteins in the azide-sensitive modulation of GLUT1 substrate binding activity in Clone 9 cells are yet to be determined.	VET ADM MED CTR, BIOPHYS LAB, BUFFALO, NY 14215 USA; SUNY BUFFALO, DEPT BIOPHYS SCI, BUFFALO, NY 14215 USA; CASE WESTERN RESERVE UNIV, DIV CLIN & MOLEC ENDOCRINOL, CLEVELAND, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Case Western Reserve University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD005506, R01HD005506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013376, R01DK045945] Funding Source: NIH RePORTER; NICHD NIH HHS [HD05506] Funding Source: Medline; NIDDK NIH HHS [DK13376, DK45945] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Battey, 1986, BASIC METHODS MOL BI; BELL GI, 1993, J BIOL CHEM, V268, P19161; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DIAMOND DL, 1993, J BIOL CHEM, V268, P6437; ELBRINK J, 1975, SCIENCE, V188, P1177, DOI 10.1126/science.1096301; INNIS MA, 1993, PCR PROTOCOL GUIDE M, P3; ISMAILBEIGI F, 1993, J MEMBRANE BIOL, V135, P1; JUNG CY, 1977, J BIOL CHEM, V252, P5456; KLEINZELLER A, 1965, MECANISMES REGULATIO, P371; LACHAAL M, 1990, J BIOL CHEM, V265, P15449; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LIU HZ, 1995, J BIOL CHEM, V270, P7869, DOI 10.1074/jbc.270.14.7869; LOWRY OH, 1964, J BIOL CHEM, V239, P18; MERCADO CL, 1989, AM J PHYSIOL, V257, pC19, DOI 10.1152/ajpcell.1989.257.1.C19; MORGAN HE, 1961, J BIOL CHEM, V236, P253; MORGAN HE, 1973, CURRENT TOPICS MEMBR, V4, P255; PASSONEAU J, 1962, BIOCHEM BIOPH RES CO, V7, P10, DOI 10.1016/0006-291X(62)90134-1; PINKOFSKY HB, 1978, J BIOL CHEM, V253, P4930; RANDLE PJ, 1958, BIOCHEM J, V70, P501, DOI 10.1042/bj0700501; REUSCH JEB, 1993, J BIOL CHEM, V268, P3348; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHETTY M, 1992, AM J PHYSIOL, V262, pC527, DOI 10.1152/ajpcell.1992.262.2.C527; SHETTY M, 1993, J BIOL CHEM, V268, P17225; SHETTY M, 1993, AM J PHYSIOL, V265, pC1224, DOI 10.1152/ajpcell.1993.265.5.C1224; SOGIN DC, 1980, BIOCHEMISTRY-US, V19, P5417, DOI 10.1021/bi00564a041; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; WOOD RE, 1969, J BIOL CHEM, V244, P1451	29	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21772	21778		10.1074/jbc.270.37.21772	http://dx.doi.org/10.1074/jbc.270.37.21772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665597	hybrid			2022-12-25	WOS:A1995RU75700056
J	LUND, BO; LUND, J				LUND, BO; LUND, J			NOVEL INVOLVEMENT OF A MITOCHONDRIAL STEROID HYDROXYLASE (P450C11) IN XENOBIOTIC METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADRENOCORTICAL TOXICITY; MICE; 3-METHYLSULFONYL-DDE; PROTEIN; CORTEX; CELLS; DDT	Adrenocortical mitochondrial cytochrome P450 isozymes of the Cyp11 family normally synthesize steroids with a very strict substrate specificity. However, for the first time, P450c11 was additionally shown to metabolize and bioactivate the adrenotoxic environmental pollutant 3-methylsulfonyl-2,2-bis(4-chlorophenyl)-1,1-dichloroethene (MeSO(2)-DDE). This conclusion is based on a striking correlation between inductions of MeSO(2)DDE and deoxycorticosterone metabolism by forskolin in the adrenocortical cell lines Y1 and Kin-8, inhibition of P450c11-dependent activities in. Y1 cells by MeSO(2)-DDE, and metabolism of MeSO(2)-DDE by non-steroidogenic COS cells after transfection with a cDNA encoding P450c11. The interaction between xenobiotics and glucocorticoid synthesis should focus more attention to xenobiotic-induced hormonal disturbances.	KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT MED NUTR,NOVUM,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet	LUND, BO (corresponding author), SWEDISH UNIV AGR SCI,UPPSALA BIOMED CTR,DEPT PHARMACOL TOXICOL,BOX 573,S-75123 UPPSALA,SWEDEN.							BAKER MT, 1984, BIOCHEM PHARMACOL, V33, P255, DOI 10.1016/0006-2952(84)90483-0; DOMALIK LJ, 1991, MOL ENDOCRINOL, V5, P1853, DOI 10.1210/mend-5-12-1853; HARAGUCHI K, 1989, CHEMOSPHERE, V19, P487, DOI 10.1016/0045-6535(89)90356-1; HORNSBY PJ, 1989, FREE RADICAL BIO MED, V6, P103, DOI 10.1016/0891-5849(89)90163-9; JENSEN S, 1976, Ambio, V5, P257; JONSSON CJ, 1994, ENVIRON TOXICOL CHEM, V13, P1303, DOI [10.1897/1552-8618(1994)13[1303:TAIBOT]2.0.CO;2, 10.1002/etc.5620130812]; JONSSON CJ, 1994, PHARMACOL TOXICOL, V74, P58; JONSSON CJ, 1992, REPROD TOXICOL, V6, P233, DOI 10.1016/0890-6238(92)90178-V; JONSSON CJ, 1991, FUND APPL TOXICOL, V16, P365, DOI 10.1016/0272-0590(91)90121-J; JONSSON CJ, 1994, TOXICOL LETT, V71, P169, DOI 10.1016/0378-4274(94)90177-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND BO, 1988, CHEM-BIOL INTERACT, V65, P25, DOI 10.1016/0009-2797(88)90028-2; LUND BO, 1994, ENVIRON TOXICOL CHEM, V13, P911, DOI 10.1897/1552-8618(1994)13[911:IVABAA]2.0.CO;2; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; SZABO S, 1989, TOXICOL PATHOL, V17, P317, DOI 10.1177/019262338901700208; TALALAY P, 1953, J BIOL CHEM, V205, P823; WONG M, 1989, J BIOL CHEM, V264, P12867; ZUBER MX, 1988, P NATL ACAD SCI USA, V85, P699, DOI 10.1073/pnas.85.3.699	18	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20895	20897		10.1074/jbc.270.36.20895	http://dx.doi.org/10.1074/jbc.270.36.20895			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673111	hybrid			2022-12-25	WOS:A1995RU05400007
J	MELCHIOR, GW; GREENLEE, KA; CASTLE, CK; PROUGH, MJ; MILNE, RW; MAROTTI, KR; KEZDY, FJ				MELCHIOR, GW; GREENLEE, KA; CASTLE, CK; PROUGH, MJ; MILNE, RW; MAROTTI, KR; KEZDY, FJ			EVIDENCE THAT CYNOMOLGUS MONKEY CHOLESTERYL ESTER TRANSFER PROTEIN HAS 2 NEUTRAL LIPID-BINDING SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN-DEFICIENT PLASMA; HIGH-DENSITY LIPOPROTEINS; MONOCLONAL-ANTIBODY; MESSENGER-RNA; INHIBITION; EXCHANGE; SEQUENCE; RABBIT	Two inhibitors of cynomolgus monkey cholesteryl ester transfer protein were evaluated. One, a monoclonal antibody made against purified cynomolgus monkey cholesteryl ester transfer protein, was capable of severely inhibiting triglyceride transfer, but had a variable effect on cholesteryl ester transfer. At low antibody to antigen ratios, there was what appeared to be a stoichiometric inhibition of cholesteryl ester transfer, but at high antibody to antigen ratios the inhibition of cholesteryl ester transfer was completely relieved, even though triglyceride transfer remained blocked. Fab fragments of the antibody had no effect whatsoever on cholesteryl ester transfer, but were capable of completely blocking triglyceride transfer. The other inhibitor, 6-chloromecuric cholesterol, severely inhibited cholesteryl ester transfer with minimal inhibition of triglyceride transfer. When both inhibitors were added to the assay, both cholesteryl ester and triglyceride transfer were inhibited; an indication that the inhibitors did not compete for the same binding site on cholesteryl ester transfer protein. When the antibody was given subcutaneously to cynomolgus monkeys at a dose which inhibited triglyceride transfer in the plasma by more than 90%, there was no detectable effect on the high density lipoprotein (HDL) cholesterol level, but the HDL triglyceride levels decreased from 13 +/- 2 to 1 +/- 0 mol/mol of HDL (mean +/- S.D.); an indication that the antibody uncoupled cholesteryl ester and triglyceride transfer in vivo. The 6-chloromecuric cholesterol could not be evaluated in vivo because it is a potent lecithin:cholesterol acyltransferase inhibitor. The fact that cholesteryl ester transfer can be inhibited without effect on triglyceride transfer and, conversely, that triglyceride transfer can be inhibited without effect on cholesteryl ester transfer indicates that these two lipids are not transferred by a single, non-discriminatory process.	UNIV OTTAWA,OTTAWA CIVIC HOSP,INST HEART,OTTAWA,ON K1Y 4E9,CANADA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa Heart Institute	MELCHIOR, GW (corresponding author), UPJOHN CO,ENDOCRINE PHARMACOL & METAB,7250-209-4,KALAMAZOO,MI 49001, USA.							AUYOUNG J, 1992, P NATL ACAD SCI USA, V89, P4094, DOI 10.1073/pnas.89.9.4094; BARTER PJ, 1980, J LIPID RES, V21, P238; BISGAIER CL, 1994, LIPIDS, V29, P811, DOI 10.1007/BF02536247; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; CHAJEK T, 1978, P NATL ACAD SCI USA, V75, P3445, DOI 10.1073/pnas.75.7.3445; EPPS DE, 1995, IN PRESS CHEM PHYS L; EVANS GF, 1994, J LIPID RES, V35, P1634; FUKASAWA M, 1992, J BIOCHEM-TOKYO, V111, P696, DOI 10.1093/oxfordjournals.jbchem.a123821; GAYNOR BJ, 1994, ATHEROSCLEROSIS, V110, P101, DOI 10.1016/0021-9150(94)90073-6; GLANTZ SA, 1992, PRIMER BIOSTATISTICS, P67; HA YC, 1982, COMP BIOCHEM PHYS B, V71, P265, DOI 10.1016/0305-0491(82)90252-8; HAMILTON JA, 1991, P NATL ACAD SCI USA, V88, P251; HESLER CB, 1988, J BIOL CHEM, V263, P5020; IHM J, 1982, J LIPID RES, V23, P361; JIANG XC, 1991, J BIOL CHEM, V266, P4631; KO KWS, 1994, J BIOL CHEM, V269, P28206; KOIZUMI J, 1985, ATHEROSCLEROSIS, V58, P175, DOI 10.1016/0021-9150(85)90064-4; MARGULIES DH, 1992, CURRENT PROTOCOLS IM; MELCHIOR GW, 1994, J BIOL CHEM, V269, P8044; MIN X, 1992, NATURE, V358, P209; MORTON RE, 1982, J LIPID RES, V23, P1058; MORTON RE, 1983, J BIOL CHEM, V258, P1751; PAPE ME, 1991, ARTERIOSCLER THROMB, V11, P1759, DOI 10.1161/01.ATV.11.6.1759; PATTNAIK NM, 1978, BIOCHIM BIOPHYS ACTA, V530, P428, DOI 10.1016/0005-2760(78)90163-7; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; RYE KA, 1992, STRUCTURE FUNCTION A, P401; SARCICH JL, 1994, J PROTEIN SCI, V14, P81; SCHUMAKER VN, 1973, ACCOUNTS CHEM RES, V6, P398, DOI 10.1021/ar50072a002; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; STEIN Y, 1990, BIOCHIM BIOPHYS ACTA, V1042, P138, DOI 10.1016/0005-2760(90)90068-9; SWENSON TL, 1989, J BIOL CHEM, V264, P14318; WANG S, 1992, J BIOL CHEM, V267, P17487; WANG SK, 1995, J BIOL CHEM, V270, P612, DOI 10.1074/jbc.270.2.612; WANG SK, 1993, J BIOL CHEM, V268, P1955; WHITLOCK ME, 1989, J CLIN INVEST, V84, P129, DOI 10.1172/JCI114132; YAMASHITA S, 1991, METABOLISM, V40, P756, DOI 10.1016/0026-0495(91)90097-G; ZILVERSMIT DB, 1975, BIOCHIM BIOPHYS ACTA, V409, P393, DOI 10.1016/0005-2760(75)90036-3	37	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21068	21074		10.1074/jbc.270.36.21068	http://dx.doi.org/10.1074/jbc.270.36.21068			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673135	hybrid			2022-12-25	WOS:A1995RU05400033
J	ONORATO, JJ; GILLIS, ME; LIU, Y; BENOVIC, JL; RUOHO, AE				ONORATO, JJ; GILLIS, ME; LIU, Y; BENOVIC, JL; RUOHO, AE			THE BETA-ADRENERGIC-RECEPTOR KINASE (GRK2) IS REGULATED BY PHOSPHOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSIN KINASE; G-PROTEINS; BETA-2-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; PHOSPHORYLATION; DESENSITIZATION; AGONIST; TRANSLOCATION; ACTIVATION; MECHANISM	The beta-adrenergic receptor kinase (beta ARK) is a member of growing family of G protein coupled receptor kinases (GRKs). beta ARK and other members of the GRK family play a role in the mechanism of agonist-specific desensitization by virtue of their ability to phosphorylate G protein-coupled receptors in an agonist-dependent manner. beta ARK activation is known to occur following the interaction of the kinase with the agonist-occupied form of the receptor substrate and heterotrimeric G protein beta gamma subunits. Recently, lipid regulation of GRK2, GRK3, and GRK5 have also been described. Using a mixed micelle assay, GRK2 (beta ARK1) was found to require phospholipid in order to phosphorylate the beta(2)-adrenergic receptor. As determined with a nonreceptor peptide substrate of beta ARK, catalytic activity of the kinase increased in the presence of phospholipid without a change in the K-m for the peptide. Data obtained with the heterobifunctional cross-linking agent N-3-[I-125] iodo-4-azidophenylpropionamido-S-(2-thiopyridyl)-cysteine ([I-125]ACTP) suggests that the activation by phospholipid was associated with a conformational change in the kinase. [I-125]ACTP incorporation increased 2-fold in the presence of crude phosphatidylcholine, and this increase in [I-125]ACTP labeling is completely blocked by the addition of MgATP. Furthermore, proteolytic mapping was consistent with the modification of a distinct site when GRK2 was labeled in the presence of phospholipid. While an acidic phospholipid specificity was demonstrated using the mixed micelle phosphorylation assay, a notable exception was observed with PIP2. In the presence of PIP2, kinase activity as well as [(125)]ACTP labeling was inhibited. These data demonstrate the direct regulation of GRK2 activity by phospholipids and supports the hypothesis that this effect is the result of a conformational change within the kinase.	THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,DEPT PHARMACOL,PHILADELPHIA,PA 19107; UNIV WISCONSIN,DEPT PHARMACOL,MADISON,WI 53706	Jefferson University; University of Wisconsin System; University of Wisconsin Madison	ONORATO, JJ (corresponding author), UNIV WISCONSIN,DEPT MED,4285 MSC,1300 UNIV AVE,MADISON,WI 53706, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047120, R01GM033138, R01GM044944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47120, GM33138, GM44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1990, SOC GEN PHY, V45, P87; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CERIONE RA, 1983, NATURE, V306, P562, DOI 10.1038/306562a0; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; DHANASEKARAN N, 1988, J BIOL CHEM, V263, P17942; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; GOMEZ J, 1992, MOL BIOL RECEPTORS T, P1; HAGA K, 1994, J BIOL CHEM, V269, P12594; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; ISHII K, 1994, J BIOL CHEM, V269, P1125; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; KONG GH, 1994, J BIOL CHEM, V269, P13084; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MAYOR F, 1987, J BIOL CHEM, V262, P6468; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	40	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21346	21353		10.1074/jbc.270.36.21346	http://dx.doi.org/10.1074/jbc.270.36.21346			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673171	hybrid			2022-12-25	WOS:A1995RU05400073
J	SAKURAI, T; HELL, JW; WOPPMANN, A; MILJANICH, GP; CATTERALL, WA				SAKURAI, T; HELL, JW; WOPPMANN, A; MILJANICH, GP; CATTERALL, WA			IMMUNOCHEMICAL IDENTIFICATION AND DIFFERENTIAL PHOSPHORYLATION OF ALTERNATIVELY SPLICED FORMS OF THE ALPHA(1A) SUBUNIT OF BRAIN CALCIUM CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CENTRAL-NERVOUS-SYSTEM; NEURONAL CLASS-C; OMEGA-AGA-IVA; 2 SIZE FORMS; SKELETAL-MUSCLE; FUNCTIONAL EXPRESSION; CA2+ CHANNELS; BETA-SUBUNIT; ALPHA-1 SUBUNIT	Biochemical properties of the alpha(1) subunits of class A brain calcium channels (alpha(1A)) were examined in adult rat brain membrane fractions using a site-directed antipeptide antibody (anti-CNA3) specific for alpha(1A). Anti-CNA3 specifically immunoprecipitated high affinity receptor sites for omega-conotoxin MVIIC (K-d similar to 100 pM), but not receptor sites for the dihydropyridine isradipine or for omega-conotoxin GVIA. In immunoblotting and immunoprecipitation experiments, anti-CNA3 recognized at least two distinct immunoreactive alpha(1A) polypeptides, a major form with an apparent molecular mass of 190 kDa and a minor, full-length form with an apparent molecular mass of 220 kDa. The 220- and 190-kDa alpha(1A) polypeptides were also specifically recognized by both anti-BI-Nt and anti-HI-1-Ct antibodies, which are directed against the NH2- and COOH-terminal ends of alpha(1A) predicted from cDNA sequence, respectively. These data indicate that the predicted NH2 and COOH termini are present in both size forms and therefore that these isoforms of alpha(1A) are created by alternative RNA splicing rather than post-translational proteolytic processing of the NH2 or COOH termini. The 220-kDa form was phosphorylated preferentially by cAMP-dependent protein kinase, whereas protein kinase C and cGMP-dependent protein kinase preferentially phosphorylated the 190-kDa form. Our results identify at least two distinct alpha(1A) subunits with different molecular mass, demonstrate that they may result from alternative mRNA splicing, and suggest that they may be differentially regulated by protein phosphorylation.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; NEUREX CORP,MENLO PK,CA 94025	University of Washington; University of Washington Seattle			Hell, Johannes W./P-5085-2019		NINDS NIH HHS [NS22625] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022625] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BOWERSOX SS, 1995, IN PRESS J PHARM EXP; BROWN AM, 1994, J PHYSIOL-LONDON, V475, P197, DOI 10.1113/jphysiol.1994.sp020061; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; CATTERALL WA, 1994, CURR OPIN CELL BIOL, V6, P607, DOI 10.1016/0955-0674(94)90083-3; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CATTERALL WA, 1994, CELLULAR MOL MECHANI, P275; COPPOLA T, 1994, FEBS LETT, V338, P1, DOI 10.1016/0014-5793(94)80105-3; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; FOURNIER F, 1993, FEBS LETT, V317, P118, DOI 10.1016/0014-5793(93)81504-S; FOURNIER F, 1993, PFLUG ARCH EUR J PHY, V423, P173, DOI 10.1007/BF00374391; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; GAUR S, 1994, NEUROPHARMACOLOGY, V33, P1211, DOI 10.1016/S0028-3908(05)80012-7; HELL JW, 1994, J BIOL CHEM, V269, P7390; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; HELL JW, 1993, J BIOL CHEM, V268, P19451; HILLMAN D, 1991, P NATL ACAD SCI USA, V88, P7076, DOI 10.1073/pnas.88.16.7076; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KRISTIPATI R, 1994, MOL CELL NEUROSCI, V5, P219, DOI 10.1006/mcne.1994.1026; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LUEBKE JI, 1993, NEURON, V11, P895, DOI 10.1016/0896-6273(93)90119-C; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER RJ, 1990, FASEB J, V4, P3291, DOI 10.1096/fasebj.4.15.1979294; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MOGUL DJ, 1993, NEURON, V10, P327, DOI 10.1016/0896-6273(93)90322-I; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; OUSLEY AH, 1994, P NATL ACAD SCI USA, V91, P12263, DOI 10.1073/pnas.91.25.12263; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; RANDALL A, 1995, J NEUROSCI, V15, P2995; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; REGAN LJ, 1991, J NEUROSCI, V11, P2259; REGEHR WG, 1994, NEURON, V12, P605, DOI 10.1016/0896-6273(94)90216-X; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; SOONG TW, 1994, 24TH SOC NEUR, V20; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; STEA A, 1994, SOC NEUR ABSTR, V20; SUGIURA Y, 1995, J NEUROCYTOL, V24, P15, DOI 10.1007/BF01370157; Swartz K. J., 1993, Society for Neuroscience Abstracts, V19, P1478; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; TURNER TJ, 1992, SCIENCE, V258, P310, DOI 10.1126/science.1357749; UCHITEL OD, 1992, P NATL ACAD SCI USA, V89, P3330, DOI 10.1073/pnas.89.8.3330; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI XY, 1991, J BIOL CHEM, V266, P21943; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WESTENBROEK RE, 1995, IN PRESS J NEUROSCI; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; WOPPMANN A, 1994, MOL CELL NEUROSCI, V5, P350, DOI 10.1006/mcne.1994.1042; WU LG, 1994, NEURON, V12, P1139, DOI 10.1016/0896-6273(94)90321-2; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	83	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21234	21242		10.1074/jbc.270.36.21234	http://dx.doi.org/10.1074/jbc.270.36.21234			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673157	hybrid			2022-12-25	WOS:A1995RU05400057
J	SOHN, RH; CHEN, J; KOBLAN, KS; BRAY, PF; GOLDSCHMIDTCLERMONT, PJ				SOHN, RH; CHEN, J; KOBLAN, KS; BRAY, PF; GOLDSCHMIDTCLERMONT, PJ			LOCALIZATION OF A BINDING-SITE FOR PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE ON HUMAN PROFILIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND ADENOSINE 5'-TRIPHOSPHATE; ACANTHAMOEBA PROFILIN; PHOSPHOLIPASE-C; PHOSPHOINOSITIDE-BINDING; ACTIN POLYMERIZATION; HUMAN PLATELET; PROFILACTIN; EXCHANGE; SEQUENCE; CELLS	Profilin is a small 12-15-kDa actin-binding protein, which in eukaryotic organisms is ubiquitous and necessary for normal cell growth and function. Although profilin's interactions with its three known ligands (actin monomers, phosphatidylinositol 4,5-bisphosphate (PIP2), and poly-L-proline (PLP)) have been well characterized in vitro, its precise role in cells remains largely unknown. By binding to clusters of PIP2, profilin is able to inhibit the hydrolysis of PIP2 by phospholipase C gamma 1 (PLC gamma 1). This ability is the result of profilin's affinity for PIP2, but the specific residues of profilin's amino acid sequence involved in the binding of PIP2 are not known. Using site-directed mutagenesis, we sought to localize regions of profilin important for this interaction by generating the following mutants of human profilin (named according to the wild-type amino acid altered, its position, and the amino acid substituted in its place): Y6F, D8A, L10R, K25Q, K53I, R74L, R88L, R88L/K90E, H119D, G121D, and K125Q. With the exception of L10R, all of the mutants were successfully expressed in Escherichia coli and purified by affinity chromatography on PLP-Sepharose. Only Y6F and K25Q demonstrated moderately less stringent binding to PLP, indicating that most of the mutations did not induce marked alterations of profilin's structure. When tested for their relative abilities to inhibit the hydrolysis of PIP2 by PLC gamma 1, most of the mutants were indistinguishable from wild-type profilin. Exceptions included D8A, which demonstrated increased inhibition of PLC gamma 1, and R88L, which demonstrated decreased inhibition of PLC gamma 1. To assess the importance of the region surrounding residue 88 of human profilin, three synthetic decapeptides selected to correspond to non-overlapping stretches of the human profilin sequence were tested for their abilities to inhibit PLC gamma 1. We found that only the decapeptide that matched the peptide stretch centered around residue 88 was able to inhibit PLC gamma 1 activity substantially and was able to do so at nearly wild-type profilin levels. Taken together with the finding that mutating residue 88 resulted in decreased inhibition of PLC gamma 1 activity, these data provide strong evidence that this region of human profilin represents an important binding site for PIP2.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DIV HEMATOL, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT ANAT & CELL BIOL, BALTIMORE, MD 21287 USA; MERCK RES LABS, DEPT CANC RES, W POINT, PA 19486 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Merck & Company								ARCHER SJ, 1994, FEBS LETT, V337, P145, DOI 10.1016/0014-5793(94)80262-9; BALASUBRAMANIAN MK, 1994, J CELL BIOL, V125, P1289, DOI 10.1083/jcb.125.6.1289; BALDASSARE JJ, 1989, BIOCHEMISTRY-US, V28, P6010, DOI 10.1021/bi00440a043; BJORKEGREN C, 1993, FEBS LETT, V333, P123, DOI 10.1016/0014-5793(93)80388-B; CAO LG, 1992, J CELL BIOL, V117, P1023, DOI 10.1083/jcb.117.5.1023; CARLSSON L, 1976, J MOL BIOL, V105, P353, DOI 10.1016/0022-2836(76)90098-X; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FEDOROV AA, 1994, P NATL ACAD SCI USA, V91, P8636, DOI 10.1073/pnas.91.18.8636; FINKEL T, 1994, P NATL ACAD SCI USA, V91, P1510, DOI 10.1073/pnas.91.4.1510; GIULIANO KA, 1994, J CELL BIOL, V124, P971, DOI 10.1083/jcb.124.6.971; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; KAISER DA, 1989, CELL MOTIL CYTOSKEL, V14, P251, DOI 10.1002/cm.970140211; KOBLAN KS, 1995, BIOCHEM J, V305, P745, DOI 10.1042/bj3050745; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P5910; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MAGDOLEN V, 1993, FEBS LETT, V316, P41, DOI 10.1016/0014-5793(93)81733-G; MALM B, 1983, J MUSCLE RES CELL M, V4, P569, DOI 10.1007/BF00712116; METZLER WJ, 1994, J BIOL CHEM, V269, P4620; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; POLLARD TD, 1991, CELL MOTIL CYTOSKEL, V20, P169, DOI 10.1002/cm.970200209; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; RAGHUNATHAN V, 1992, FEBS LETT, V297, P46, DOI 10.1016/0014-5793(92)80324-A; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; TOBACMAN LS, 1982, J BIOL CHEM, V257, P4166; TSENG PCH, 1984, J CELL BIOL, V98, P214, DOI 10.1083/jcb.98.1.214; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; VERHEYEN EM, 1994, DEVELOPMENT, V120, P717; VINSON VK, 1993, J CELL BIOL, V122, P1277, DOI 10.1083/jcb.122.6.1277; WAECHTER F, 1975, EUR J BIOCHEM, V57, P453, DOI 10.1111/j.1432-1033.1975.tb02320.x; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YU FX, 1992, J BIOL CHEM, V267, P14616	48	99	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21114	21120		10.1074/jbc.270.36.21114	http://dx.doi.org/10.1074/jbc.270.36.21114			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673143	hybrid			2022-12-25	WOS:A1995RU05400041
J	BIA, B; COWELL, JK				BIA, B; COWELL, JK			INDEPENDENT CONSTITUTIONAL GERMLINE MUTATIONS OCCURRING IN THE RB1 GENE IN COUSINS WITH BILATERAL RETINOBLASTOMA	ONCOGENE			English	Note						RB1 GENE; MUTATIONS	ONCOGENIC POINT MUTATIONS; HEREDITARY RETINOBLASTOMA; LOW-PENETRANCE; MECHANISMS; PEDIGREES	The inheritance of a genetic susceptibility to the development of retinoblastoma generally follows an autosomal mode of inheritance with high penetrance. Rare families, however, show evidence of incomplete penetrance where individuals can transmit the mutant gene without being affected themselves. In these families formal proof of this dogma requires the identification of the predisposing mutation. In this study we have identified the mutations in cousins with bilateral (hereditary) disease. Using SSCP and DNA sequencing, different constitutional mutations were detected in the affected cousins in this pedigree. One cousin carries a C-->T mutation in exon 8 generating a stop codon directly which was also present in his affected mother whereas the other cousin carries an 8 base pair deletion in exon 20. Neither half of the family carried the same mutation as the other. The mother of the patient with the 8 bp deletion carried neither of the mutations. Thus, we have demonstrated that the retinoblastomas in this family have developed as a result of independent, sporadic genetic events which occurred coincidentally in the same extended family rather than being due to a common mutation which manifests as incompletely penetrant, These observations have important implications for genetic counselling in this type of family.	INST CHILD HLTH,IMPERIAL CANC RES FUND,ONCOL GRP,HEMATOL ONCOL UNIT,LONDON WC1,ENGLAND					Cowell, John/0000-0002-2079-5950				BLANQUET V, 1993, HUM MOL GENET, V2, P975, DOI 10.1093/hmg/2.7.975; CONNOLLY MJ, 1983, HUM GENET, V65, P122, DOI 10.1007/BF00286647; Cowell John K., 1994, European Journal of Human Genetics, V2, P281; DRAPER GJ, 1992, BRIT J CANCER, V66, P211, DOI 10.1038/bjc.1992.244; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; GALLIE BL, 1982, BRIT J CANCER, V45, P513, DOI 10.1038/bjc.1982.87; HOGG A, 1992, ONCOGENE, V7, P1445; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; KATO MV, 1994, HUM MUTAT, V3, P44, DOI 10.1002/humu.1380030108; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRATZKE RA, 1994, ONCOGENE, V9, P1321; MATSUNAGA E, 1978, AM J HUM GENET, V30, P406; MUNIER FL, 1993, ARCH OPHTHALMOL-CHIC, V111, P1507, DOI 10.1001/archopht.1993.01090110073028; NAUMOVA A, 1994, AM J HUM GENET, V54, P264; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; ONADIM Z, 1991, BRIT J OPHTHALMOL, V75, P147, DOI 10.1136/bjo.75.3.147; ONADIM Z, 1993, BRIT J CANCER, V68, P958, DOI 10.1038/bjc.1993.461; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; VOGEL F, 1979, HUM GENET, V52, P1; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	20	6	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					977	979						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675457				2022-12-25	WOS:A1995RU79800019
J	MUKHOPADHYAY, T; ROTH, JA; MAXWELL, SA				MUKHOPADHYAY, T; ROTH, JA; MAXWELL, SA			ALTERED EXPRESSION OF THE P50 SUBUNIT OF THE NF-KAPPA-B TRANSCRIPTION FACTOR COMPLEX IN NON-SMALL-CELL LUNG-CARCINOMA	ONCOGENE			English	Note						NF-KAPPA-B; P50 SUBUNIT; NSCLC; ALTERATION	ADHESION MOLECULE-1; PROTEIN SUBUNITS; GENE-EXPRESSION; INDUCTION	Recent studies have implicated a role for the p50 subunit of the NF-kappa B transcription factor complex in tumorigenesis, Therefore, we investigated the expression of the p50 subunit of the NF-kappa B transcription factor complex in paired normal and non-small cell lung carcinoma (NSCLC) tissues. Here we show that nine of 11 (81.8%) fresh NSCLC tissues expressed from two- to 20-fold higher levels of the p50 subunit than normal lung tissue. Thirteen NSCLC cell lines also exhibited high levels of p50. Alterations in the normal NF-kappa B/rel pathway of regulation may play a role in the genesis of NSCLC.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT THORAC & CARDIOVASC SURG,THORAC MOLEC ONCOL SECT,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R37CA045187, R01CA045187, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA45187, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GHERSA P, 1992, J BIOL CHEM, V267, P19226; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GRUMONT RJ, 1994, P NATL ACAD SCI USA, V91, P4367, DOI 10.1073/pnas.91.10.4367; GRUMONT RJ, 1994, MOL CELL BIOL, V14, P8460, DOI 10.1128/MCB.14.12.8460; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; SATO H, 1993, ONCOGENE, V8, P395; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SEN R, 1986, CELL, V46, P921; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; THAKUR S, 1994, ONCOGENE, V9, P2335; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645	26	120	125	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					999	1003						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675461				2022-12-25	WOS:A1995RU79800023
J	CUNNINGHAM, SA; WAXHAM, MN; ARRATE, PM; BROCK, TA				CUNNINGHAM, SA; WAXHAM, MN; ARRATE, PM; BROCK, TA			INTERACTION OF THE FLT-1 TYROSINE KINASE RECEPTOR WITH THE P85 SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE - MAPPING OF A NOVEL SITE INVOLVED IN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POINT MUTATION; SH2 DOMAIN; FAMILY; MITOGENESIS; ACTIVATION; SEQUENCE; SYSTEM	We have examined the interactions of the p85 regulatory subunit of phosphatidylinositol 3-kinase with the endothelium-specific Flt-1 receptor tyrosine kinase using the yeast two-hybrid system. We find that both the amino- and carboxyl-terminal SH2 domains of p85 bind to Flt-1. We have performed site-directed mutagenesis on the carboxyl-terminal tail of the Flt-1 receptor in order to identify the site(s) that is responsible for the p85 interactions. A single tyrosine to phenylalanine change at position 1213 inhibits the binding of both p85 SH2 domains. Phosphopeptide mapping of the wild type and mutant protein expressed in insect cells verifies that this amino acid is a target for autophosphorylation. The amino acids following this tyrosine are VNA and thus define a novel binding site for p85.	UNIV TEXAS, HLTH SCI CTR, DEPT PHYSIOL & CELL BIOL, HOUSTON, TX 77225 USA; UNIV TEXAS, HLTH SCI CTR, DEPT ANAT & NEUROBIOL, HOUSTON, TX 77225 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	CUNNINGHAM, SA (corresponding author), TEXAS BIOTECHNOL CORP, DEPT PHARMACOL, SUITE 1920, 7000 FANNIN, HOUSTON, TX 77030 USA.			Waxham, M. Neal/0000-0003-4801-1190				CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAM K, 1994, J BIOL CHEM, V269, P20648; LAROSE L, 1995, J BIOL CHEM, V270, P3858, DOI 10.1074/jbc.270.8.3858; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Miller JH., 1972, EXPT MOL GENETICS; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; SUNG CK, 1994, J BIOL CHEM, V269, P12503; TERMAN BI, 1991, ONCOGENE, V6, P1677; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	90	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20254	20257		10.1074/jbc.270.35.20254	http://dx.doi.org/10.1074/jbc.270.35.20254			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657594	hybrid			2022-12-25	WOS:A1995RR58400006
J	GUITON, M; GUNNMOORE, FJ; GLASS, DJ; GEIS, DR; YANCOPOULOS, GD; TAVARE, JM				GUITON, M; GUNNMOORE, FJ; GLASS, DJ; GEIS, DR; YANCOPOULOS, GD; TAVARE, JM			NATURALLY-OCCURRING TYROSINE KINASE INSERTS BLOCK HIGH-AFFINITY BINDING OF PHOSPHOLIPASE C-GAMMA AND SHC TO TRKC AND NEUROTROPHIN-3 SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; INSULIN-RECEPTOR; PROTEIN-KINASE; RAT TRKC; CELLS; PHOSPHORYLATION; ACTIVATION; ENCODES; AUTOPHOSPHORYLATION; IDENTIFICATION	Neurotrophin-3 binds to the receptor tyrosine kinase, TrkC. Several naturally occurring splice variants of TrkC exist including those with 14- and 39 amino acid inserts within the tyrosine kinase homology region. When expressed in fibroblasts, full-length TrkC, but not the kinase insert variants, mediated neurotrophin-3-stimulated cell proliferation. We investigated the molecular basis of this signaling defect. The kinase inserts blocked the ability of TrkC to mediate neurotrophin-3 stimulated c-myc and c-fos transcription and activation of the AP-1 transcriptional complex. In cells expressing full-length TrkC, neurotrophin-3 promoted a sustained activation of mitogen-activated protein kinase; TrkC containing kinase inserts only mediated transient activation of mitogen-activated protein kinase. The kinase inserts specifically blocked neurotrophin-3-stimulated autophosphorylation of the phospholipase C gamma binding site on TrkC (tyrosine 789) resulting in a severe reduction in phospholipase C gamma association with TrkC and its tyrosine phosphorylation. Neurotrophin-3-stimulated phosphorylation of the She binding site (tyrosine 485) on TrkC, and tyrosine phosphorylation of She itself, was unaffected by the kinase inserts; however, the kinase inserts blocked high affinity She association with TrkC. It is proposed that the lack of high affinity binding of Shc and/or phospholipase C gamma to the TrkC kinase insert variants may be responsible for the inability of these variants to bring about a full biological response in fibroblasts.	UNIV BRISTOL, SCH MED SCI, DEPT BIOCHEM, BRISTOL BS8 1TD, AVON, ENGLAND; REGENERON PHARMACEUT INC, TARRYTOWN, NY 10591 USA	University of Bristol; Regeneron			Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Glass, David/0000-0001-6187-4164	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DICKENS M, 1992, BIOCHEM J, V287, P201, DOI 10.1042/bj2870201; DICKENS M, 1992, BIOCHEM BIOPH RES CO, V186, P244, DOI 10.1016/S0006-291X(05)80799-5; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GUITON M, 1994, J BIOL CHEM, V269, P30370; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LOEB DM, 1994, J BIOL CHEM, V269, P8901; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SOZERI O, 1992, ONCOGENE, V7, P2259; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; WHITE MF, 1988, J BIOL CHEM, V263, P2969; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6	40	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20384	20390		10.1074/jbc.270.35.20384	http://dx.doi.org/10.1074/jbc.270.35.20384			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657612	hybrid			2022-12-25	WOS:A1995RR58400025
J	LAGARKOVA, MA; IAROVAIA, OV; RAZIN, SV				LAGARKOVA, MA; IAROVAIA, OV; RAZIN, SV			LARGE-SCALE FRAGMENTATION OF MAMMALIAN DNA IN THE COURSE OF APOPTOSIS PROCEEDS VIA EXCISION OF CHROMOSOMAL DNA LOOPS AND THEIR OLIGOMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR-NECROSIS-FACTOR; INTERNUCLEOSOMAL FRAGMENTATION; CELL-DEATH; ENDONUCLEASE; MECHANISMS; CLEAVAGE	It has been shown recently that apoptotic degradation of genomic DNA in mammalian cells starts by excision of large DNA fragments ranging in size from 50 kilobases to more then 300 kilobases. Although it was suggested that the above fragments could represent chromosomal DNA loops, the supposition was not supported by direct experimental evidence. In present work, we have studied the specificity of nucleolar and euchromatic gene long-range fragmentation in mouse and human cells triggered to undergo apoptosis either by tumor necrosis factor or by serum deprivation. Separation of the excised large DNA fragments by pulsed field gel electrophoresis followed by Southern analysis has demonstrated that in all cases studied the above fragmentation proceeds in a specific way. Furthermore, the patterns of DNA long-range fragmentation in the cells undergoing apoptosis were indistinguishable from the patterns of DNA cleavage into chromosomal loops by the high salt-insoluble topoisomerase II of the nuclear matrix. These results suggest the conclusion that apoptotic degradation of chromosomal DNA starts by excision of DNA loops and their oligomers.	INT CTR GENET ENGN & BIOTECHNOL,I-34012 TRIESTE,ITALY; RUSSIAN ACAD SCI,INST GENE BIOL,MOSCOW 117334,RUSSIA	International Center for Genetic Engineering & Biotechnology (ICGEB); Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences			Razin, Sergey V/M-6701-2015; Iarovaia, Olga/AAV-2321-2021; Lagarkova, Maria/A-3296-2014	Razin, Sergey V/0000-0003-1976-8661; Lagarkova, Maria/0000-0001-9594-1134				ARENDS MJ, 1990, AM J PATHOL, V136, P593; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BROWN DG, 1993, J BIOL CHEM, V268, P3037; CAIN K, 1994, FEBS LETT, V349, P385, DOI 10.1016/0014-5793(94)80001-4; COHEN GM, 1994, J IMMUNOL, V153, P507; COHEN JJ, 1984, J IMMUNOL, V132, P38; FILIPSKI J, 1990, EMBO J, V9, P1319, DOI 10.1002/j.1460-2075.1990.tb08241.x; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; GROMOVA II, 1995, P NATL ACAD SCI USA, V92, P102, DOI 10.1073/pnas.92.1.102; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LASTER SM, 1988, J IMMUNOL, V141, P2629; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; RAZIN SV, 1993, COLD SPRING HARB SYM, V58, P25, DOI 10.1101/SQB.1993.058.01.006; REID TR, 1989, J BIOL CHEM, V264, P4583; RUGGIERO V, 1987, J IMMUNOL, V138, P2711; SUN XM, 1994, J BIOL CHEM, V269, P14857; ZHIVOTOVSKY B, 1994, BIOCHEM BIOPH RES CO, V202, P120, DOI 10.1006/bbrc.1994.1901	18	126	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20239	20241		10.1074/jbc.270.35.20239	http://dx.doi.org/10.1074/jbc.270.35.20239			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657590	hybrid			2022-12-25	WOS:A1995RR58400002
J	LANKESTER, AC; VANSCHIJNDEL, GMW; VANLIER, RAW				LANKESTER, AC; VANSCHIJNDEL, GMW; VANLIER, RAW			HEMATOPOIETIC-CELL PHOSPHATASE IS RECRUITED TO CD22 FOLLOWING B-CELL ANTIGEN RECEPTOR LIGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; VIABLE MOTHEATEN; HUMAN CD5+; PHOSPHORYLATION; ASSOCIATION; ACTIVATION; MICE; STIMULATION; DOMAINS; SUBSETS	Hematopoietic cell phosphatase is a nonreceptor protein tyrosine phosphatase that is preferentially expressed in hematopoietic cell lineages. Motheaten mice, which are devoid of (functional) hematopoietic cell phosphatase, have severe disturbances in the regulation of B cell activation and differentiation. Because signals transduced via the B cell antigen receptor are known to guide these processes, we decided to analyze molecular interactions between the hematopoietic cell phosphatase and the B cell antigen receptor. Ligation of the B cell antigen receptor induces moderate tyrosine phosphorylation of hema topoietic cell phosphatase and the formation of a multimolecular complex containing additional 68-70- and 135-kDa phosphoproteins. In resting B cells most of the hematopoietic cell phosphatase proteins reside in the cytosolic compartment, whereas after B cell antigen receptor cross-linking, a small fraction translocates toward the membrane where it specifically binds to the 135-kDa phosphoprotein. This 135-kDa glycoprotein was identified as CD22, a transmembrane associate of the B cell antigen receptor complex. Together these findings provide the first direct evidence that this cytoplasmic tyrosine phosphatase is involved in antigen receptor-mediated B cell activation, suggesting that in vivo B cell antigen receptor constituents or associated molecules may serve as substrate for its catalytic activity.	UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS	University of Amsterdam	LANKESTER, AC (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,PLESMANLAAN 125,1066 CX AMSTERDAM,NETHERLANDS.			van Lier, Rene/0000-0002-3201-7144				ANTIN JH, 1986, J IMMUNOL, V136, P505; BHAT NM, 1992, INT IMMUNOL, V4, P243, DOI 10.1093/intimm/4.2.243; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; BROWN VK, 1994, J BIOL CHEM, V269, P17238; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DEFRANCE T, 1992, EUR J IMMUNOL, V22, P2831, DOI 10.1002/eji.1830221112; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GREINER DL, 1986, J EXP MED, V164, P1129, DOI 10.1084/jem.164.4.1129; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P812, DOI 10.1002/eji.1830240406; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; LAW CL, 1994, J BIOL CHEM, V269, P12310; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SCHULTZ LD, 1976, J IMMUNOL, V116, P936; Schultz Leonard D., 1993, Cell, V73, P1445; SCHWARTZALBIEZ R, 1989, LEUKOCYTE TYPING, V4, P65; SIDMAN CL, 1978, J IMMUNOL, V121, P2392; SIDMAN CL, 1986, SCIENCE, V232, P1423, DOI 10.1126/science.3487115; SIDMAN CL, 1978, J IMMUNOL, V121, P2399; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VANNOESEL CJM, 1993, IMMUNOL TODAY, V14, P8, DOI 10.1016/0167-5699(93)90316-D; VANNOESEL CJM, 1992, J EXP MED, V175, P1511, DOI 10.1084/jem.175.6.1511; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZUPO S, 1991, EUR J IMMUNOL, V21, P351, DOI 10.1002/eji.1830210216	42	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20305	20308		10.1074/jbc.270.35.20305	http://dx.doi.org/10.1074/jbc.270.35.20305			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657601	hybrid			2022-12-25	WOS:A1995RR58400014
J	ARAGAY, AM; COLLINS, LR; POST, GR; WATSON, AJ; FERAMISCO, JR; BROWN, JH; SIMON, MI				ARAGAY, AM; COLLINS, LR; POST, GR; WATSON, AJ; FERAMISCO, JR; BROWN, JH; SIMON, MI			G(12) REQUIREMENT FOR THROMBIN-STIMULATED GENE-EXPRESSION AND DNA-SYNTHESIS IN 1321N1 ASTROCYTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ACTIVATION; PROTEOLYTIC MECHANISM; CALCIUM MOBILIZATION; PERTUSSIS TOXIN; FIBROBLASTS; G-ALPHA-12; EVENTS; RAS; PROTEINS; CLONING	Thrombin stimulation of 1321N1 astrocytoma cells leads to Ras-dependent AP-1-mediated transcriptional activation and to DNA replication. In contrast to what has been observed in most cell systems, in 1321N1 cells these responses are pertussis toxin-insensitive. The pertussis toxin-insensitive G-protein G(12) has been implicated in cell growth and transformation in different cell systems. We have examined the potential role of this protein in AP-1-mediated transcriptional activation and DNA synthesis in 1321N1 cells. Transient expression of an activated (GTPase-deficient) mutant of G alpha(12) increased AP-1-dependent gene expression. This response was inhibited by co-expression of a dominant negative Ala-15 Ras protein. To determine whether the pertussis toxin-insensitive G(12) protein is involved in the thrombin-stimulated DNA synthesis, an inhibitory antibody against the C-terminal sequence of G alpha(12) subunit was microinjected into 1321N1 cells. Microinjection of the anti-G alpha(12) resulted in a concentration-dependent inhibition of thrombin-stimulated DNA synthesis. In contrast, microinjection of nonimmune IgG or an antibody directed against the C terminus of G alpha(0) did not reduce the mitogenic response to thrombin. Furthermore, microinjection of the anti-G alpha(12) antibody had no effect on fibroblast growth factor-stimulated DNA synthesis. These results demonstrate a specific role for G alpha(12) in the mitogenic response to thrombin in human astroglial cells.	CALTECH,DIV BIOL,PASADENA,CA 91125; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	California Institute of Technology; University of California System; University of California San Diego			Aragay, Anna M/K-3813-2014	Aragay, Anna M/0000-0002-8240-4126	NCI NIH HHS [CA50528] Funding Source: Medline; NIGMS NIH HHS [GM34236, GM36927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034236, R01GM036927, R56GM036927, R01GM034236] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBAS J, 1993, J BIOL CHEM, V268, P22235; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BAFFY G, 1994, J BIOL CHEM, V269, P8483; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FAURE M, 1994, J BIOL CHEM, V269, P7851; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JONES LG, 1989, MOL PHARMACOL, V36, P142; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; NIETO M, 1994, MOL PHARMACOL, V46, P406; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANOBBERGHENSCH.E, 1985, EMBO J, V4, P2927; VOYNOYASENETSKA.T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKA.TA, 1994, ONCOGENE, V9, P2559; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WINITZ S, 1993, J BIOL CHEM, V268, P19196; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	30	91	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20073	20077		10.1074/jbc.270.34.20073	http://dx.doi.org/10.1074/jbc.270.34.20073			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650024	Green Accepted, hybrid			2022-12-25	WOS:A1995RQ99100060
J	HOURCADE, DE; WAGNER, LM; OGLESBY, TJ				HOURCADE, DE; WAGNER, LM; OGLESBY, TJ			ANALYSIS OF THE SHORT CONSENSUS REPEATS OF HUMAN-COMPLEMENT FACTOR-B BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROL PROTEIN MODULE; RECEPTOR TYPE-1; LIGAND-BINDING; FACTOR-H; C2; SUPERFAMILY; ACTIVATION; MECHANISMS; REJECTION; CLEAVAGE	Human factor B is required for the initiation and propagation of the complement alternative pathway, It also participates in the amplification of the complement classical pathway, Alone, factor B is a zymogen with Little known biochemical activity, but in the context of the alternative pathway convertases, the factor B serine protease is activated in a process that first involves the association with C3b and subsequently the cleavage of factor B into two fragments, Ba and Bb, Ba, the NH2-terminal fragment, is composed mainly of three tandem short consensus repeats, globular domains found in other complement proteins, It dissociates from the convertase during assembly, leaving the active C3 convertase, C3bBb, Previous reports suggest that the Ba region may be instrumental in convertase assembly, This hypothesis was tested using site-directed mutagenesis of recombinant factor B and monoclonal antibody epitope mapping to evaluate the relative importance of specific short consensus repeat amino acid residues, Three sites of interest were identified, Site 1 is a stretch of 19 contiguous amino acids in short consensus repeat 1 that form the epitope of a monoclonal antibody that effectively blocks factor B function. Site 2, composed of 6 contiguous amino acids in short consensus repeat 2, and site 3, consisting of 7 contiguous amino acids in short consensus repeat 3, were defined by mutations that reduce factor B hemolytic activity to 3% or less, Further analyses indicated that sites 2 and 3 contribute to factor B-C3b interactions.			HOURCADE, DE (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,DIV RHEUMATOL,660 S EUCLID,BOX 8045,ST LOUIS,MO 63110, USA.							BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BENTLEY DR, 1986, BIOCHEM J, V239, P339, DOI 10.1042/bj2390339; BORSOS T, 1967, J IMMUNOL, V99, P263; BRAUER RB, 1993, J IMMUNOL, V151, P7240; COLOMBATTI A, 1991, BLOOD, V77, P2305; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; ISHIKAWA N, 1990, J BIOL CHEM, V265, P19040; KATO Y, 1994, J IMMUNOL, V153, P4546; KRISTENSEN T, 1987, FASEB J, V46, P2463; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; KRYCH M, 1994, J BIOL CHEM, V269, P13273; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOLE JE, 1984, J BIOL CHEM, V259, P3407; Morgan B.P., 1990, COMPLEMENT; MULLEREBERHARD HJ, 1992, INFLAMMATION BASIC P, P33; NONAKA M, 1994, J IMMUNOL, V152, P2263; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; OGLESBY TJ, 1988, J IMMUNOL, V141, P926; PEELMAN LJ, 1991, IMMUNOGENETICS, V34, P192, DOI 10.1007/BF00205823; PERKINS SJ, 1993, BIOCHEM J, V295, P109, DOI 10.1042/bj2950109; PERKINS SJ, 1988, BIOCHEMISTRY-US, V27, P4004, DOI 10.1021/bi00411a017; PRUITT SK, 1991, TRANSPLANTATION, V52, P868, DOI 10.1097/00007890-199111000-00022; PRYZDIAL ELG, 1987, J BIOL CHEM, V262, P1519; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH CA, 1984, J EXP MED, V159, P324, DOI 10.1084/jem.159.1.324; UEDA A, 1987, J IMMUNOL, V138, P1143; VOLANAKIS JE, 1989, CURR TOP MICROBIOL I, V153, P1; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; Whaley K, 1985, METHODS COMPLEMENT C, P77	38	61	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19716	19722		10.1074/jbc.270.34.19716	http://dx.doi.org/10.1074/jbc.270.34.19716			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649982	hybrid			2022-12-25	WOS:A1995RQ99100010
J	KANAYA, E; KANAYA, S				KANAYA, E; KANAYA, S			RECONSTITUTION OF ESCHERICHIA-COLI RNASE HI FROM THE N-FRAGMENT WITH HIGH HELICITY AND THE C-FRAGMENT WITH A DISORDERED STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID-RESIDUES; RIBONUCLEASE-H; STAPHYLOCOCCAL NUCLEASE; PROTEIN; PEPTIDE; INTERMEDIATE; INITIATION; SUBSTITUTIONS; CONFORMATION	The Escherichia coli RNase HI variant with the Lys(86) --> Ala mutation is purified in two forms, as nicked and intact proteins. The nicked K86A protein, in which the N-fragment (Met(1)-Lys(87)) and the C-fragment (Arg(88)- Val(155)) remain associated, is enzymatically active. These N- and C-fragments were isolated and examined for reassociation. These peptides did not associate to form the nicked K86A protein at pH 3.0 in the absence of salt, but were associated, with a yield of 30-80%, when the pH was raised to 5.5 or when salt was added. Measurements of the CD spectra show that the alpha-helices are partially formed in the N-fragment at pH 3.0 in the absence of salt and are almost fully formed either at pH 5.5 or at pH 3.0 in the presence of 0.15 M NaCl. In contrast, the C-fragment remains almost fully disordered under these conditions. The N-fragment with this high (native-like) helicity shows the characteristics of a molten globule with respect to the content of the secondary and tertiary structures, the ability to bind a fluorescent probe (1-anilinonaphthalene-8-sulfonic acid), and the behavior on the thermal transition. These results suggest that the N-fragment contains an initial folding site, probably the alpha I-helix, and the completion of the folding in this site provides a surface that facilitates the folding of the C-fragment. This folding process may represent that of the intact RNase HI molecule.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN									ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BEALS JM, 1991, BIOCHEMISTRY-US, V30, P7680, DOI 10.1021/bi00245a004; BIERZYNSKI A, 1982, P NATL ACAD SCI-BIOL, V79, P2470, DOI 10.1073/pnas.79.8.2470; CHAFFOTTE A, 1991, BIOCHEMISTRY-US, V30, P8067, DOI 10.1021/bi00246a027; DABORA JM, 1994, PROTEIN SCI, V3, P1401, DOI 10.1002/pro.5560030906; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; FINK AL, 1994, BIOCHEMISTRY-US, V33, P12504, DOI 10.1021/bi00207a018; FONTANA A, 1990, PEPTIDES CHEM STRUCT, P557; GAY GD, 1994, BIOCHEMISTRY-US, V33, P7957, DOI 10.1021/bi00191a024; GAY GD, 1994, P NATL ACAD SCI USA, V91, P10943, DOI 10.1073/pnas.91.23.10943; GAY GD, 1994, BIOCHEMISTRY-US, V33, P7964, DOI 10.1021/bi00191a025; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; GRIKO YV, 1994, J MOL BIOL, V243, P93, DOI 10.1006/jmbi.1994.1632; HARADA D, 1994, P NATL ACAD SCI USA, V81, P10325; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1993, J BIOTECHNOL, V28, P117, DOI 10.1016/0168-1656(93)90129-B; KANAYA S, 1989, J BIOL CHEM, V264, P11546; KANAYA S, 1983, J BIOL CHEM, V258, P1276; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KIMURA S, 1992, J BIOL CHEM, V267, P21535; KIPPEN AD, 1994, BIOCHEMISTRY-US, V33, P3778, DOI 10.1021/bi00178a039; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; Miller J. H., 1972, EXPT MOL GENETICS, P433; MIRANKER A, 1993, SCIENCE, V262, P896, DOI 10.1126/science.8235611; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; NERI D, 1992, SCIENCE, V257, P1559, DOI 10.1126/science.1523410; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; OSTERHOUT JJ, 1989, BIOCHEMISTRY-US, V28, P7059, DOI 10.1021/bi00443a042; PENG ZY, 1994, BIOCHEMISTRY-US, V33, P2136, DOI 10.1021/bi00174a021; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; SANCHO J, 1992, J MOL BIOL, V224, P741, DOI 10.1016/0022-2836(92)90558-2; SANCHO J, 1992, J MOL BIOL, V224, P749, DOI 10.1016/0022-2836(92)90559-3; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; SHORTLE D, 1989, BIOCHEMISTRY-US, V28, P936, DOI 10.1021/bi00429a003; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; TANIUCHI H, 1971, J BIOL CHEM, V246, P2291; TASAYCO ML, 1992, SCIENCE, V255, P594, DOI 10.1126/science.1736361; Vesterberg O., 1971, METHODS ENZYMOLOGY, V22, P389; WALTHO JP, 1993, BIOCHEMISTRY-US, V32, P6337, DOI 10.1021/bi00076a006; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; [No title captured]	54	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19853	19860		10.1074/jbc.270.34.19853	http://dx.doi.org/10.1074/jbc.270.34.19853			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649997	hybrid			2022-12-25	WOS:A1995RQ99100029
J	KING, SC; FLEMING, SR; BRECHTEL, CE				KING, SC; FLEMING, SR; BRECHTEL, CE			LIGAND RECOGNITION PROPERTIES OF THE ESCHERICHIA-COLI 4-AMINOBUTYRATE TRANSPORTER ENCODED BY GABP - SPECIFICITY OF GAB PERMEASE FOR HETEROCYCLIC INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRATE; MELIBIOSE CARRIER; SUGAR; CLUSTER; GENE	4-aminobutyrate metabolism in Escherichia coli begins with transport across the cytoplasmic membrane via the GabP, which is encoded by gabP, Although GrabP is specific and exhibits poor affinity for many cellular constituents such as the alpha-amino acids, the range of compounds recognized with high affinity has yet to be investigated, In order to address this gap in knowledge, we developed a gabP-negative host strain, which permits evaluation of test compounds for inhibitory effects on cloned GabP (expression inducible by isopropyl-1-thio-beta-D-galactopyranoside). Using this inducible expression system, three structurally distinct categories of high affinity transport inhibitor were identified. The structural dissimilarity of these inhibitors significantly alters our view of ligand recognition by GabP, Any complete model must now account for the observation that inhibition of 4-aminobutyrate transport can be mediated either (i) by open chain analogs of 4-aminobutyrate, (ii) by cyclic amino acid analogs, or (iii) by planar heterocyclic compounds lacking a carboxyl group. Such results do not support a previously sustainable view of GabP that features a restrictive ligand recognition domain, unable to accommodate structures that differ very much from the native substrate, 4-aminobutyrate.			KING, SC (corresponding author), UNIV TEXAS,MED BRANCH,DEPT PHYSIOL & BIOPHYS,BASIC SCI BLDG,RTE F-41,GALVESTON,TX 77555, USA.				NINDS NIH HHS [5 RO1 NS31029-03] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031029] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN SA, 1989, ANNU REV PHYSIOL, V51, P459, DOI 10.1146/annurev.physiol.51.1.459; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; CHRISTENSEN HN, 1975, BIOL TRANSPORT, P346; HELLER KB, 1981, FEBS LETT, V129, P253, DOI 10.1016/0014-5793(81)80177-9; KAHANE S, 1978, J BACTERIOL, V135, P295, DOI 10.1128/JB.135.2.295-299.1978; KING SC, 1990, J BIOL CHEM, V265, P9638; METZER E, 1979, J BACTERIOL, V137, P1111, DOI 10.1128/JB.137.3.1111-1118.1979; METZER E, 1990, J BACTERIOL, V172, P3250, DOI 10.1128/jb.172.6.3250-3256.1990; NIEGEMANN E, 1993, ARCH MICROBIOL, V160, P454, DOI 10.1007/BF00245306; OLSEN SG, 1989, J BIOL CHEM, V264, P15982; SHINE J, 1974, P NATL ACAD SCI USA, V72, P1342; WILSON DM, 1981, BIOCHIM BIOPHYS ACTA, V649, P377, DOI 10.1016/0005-2736(81)90427-2; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; WRIGHT JK, 1986, ANNU REV BIOCHEM, V55, P225	14	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19893	19897		10.1074/jbc.270.34.19893	http://dx.doi.org/10.1074/jbc.270.34.19893			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650003	hybrid			2022-12-25	WOS:A1995RQ99100035
J	MCNALLY, AJ; MOTTER, K; JORDAN, F				MCNALLY, AJ; MOTTER, K; JORDAN, F			A LIBRARY OF MONOCLONAL-ANTIBODIES TO ESCHERICHIA-COLI K-12 PYRUVATE-DEHYDROGENASE COMPLEX - A BIOCHEMICAL-ANALYSIS AND THEIR ABILITY TO INHIBIT THE ENZYME COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIENZYME COMPLEX; ACTIVE-SITE; LIPOAMIDE DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; BIFUNCTIONAL ARSENOXIDE; INACTIVATION; PROTEINS; BROMOPYRUVATE; PYROPHOSPHATE; COMPONENT	A library of monoclonal antibodies to K-12 Escherichia colt pyruvate dehydrogenase complex (PDHc) and its pyruvate decarboxylating (EC 1,2,4,1; El) subunit is reported, 21 monoclonal antibodies were generated, and 20 were investigated, of which 9 were elicited to PDHc and 11 to pure El subunit; 19 were of the IgG1 isotype and one of the IgG3 isotype. According to an enzyme immunoassay, all 20 of the monoclonal antibodies bound the PDHc, and 17 bound the El subunit, According to Western blot analysis, 14 of the 19 monoclonal antibodies bound to the El subunit, The monoclonal antibodies inhibited PDHc from 0 to > 98%. The six monoclonal antibodies that displayed greater than 30% inhibition off. colt PDHc were unable to inhibit porcine heart PDHc nor did they bind porcine heart PDHc according to dot blot analysis, Radiolabeling gave binding constants ranging from 5 to 10 x 10(8) M(-1) on these six monoclonal antibodies, with greater than 80% of maximal inhibition achieved in less than 1 min, One of the six, 18A9, gave > 98% inhibition, required two antibodies/E1 subunit for maximum inhibition, and was shown to be a non-competitive inhibitor, Monoclonal antibody 15A9 was shown to counteract GTP-induced inhibition, while 1F2 influenced the conformation of El, allowing two antibodies, which did not previously bind El, to bind to it, A new mechanism-based kinetic assay is presented that is specific for the El component of S-keto acid dehydrogenases. This assay confirmed that the three most strongly inhibitory monoclonal antibodies specifically inhibited the El function while antibody 1F2 led to enhanced activity, suggesting an induced conformational change in PDHc or in E1.	RUTGERS STATE UNIV,DEPT CHEM,NEWARK,NJ 07102; RUTGERS STATE UNIV,DEPT BIOL,NEWARK,NJ 07102; ROCHE DIAGNOST SYST INC,SOMERVILLE,NJ 08876	Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Newark; Rutgers State University New Brunswick					NIGMS NIH HHS [GM-50380] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON SR, 1984, BIOCHEMISTRY-US, V23, P1269, DOI 10.1021/bi00301a039; ADAMSON SR, 1981, BIOCHEMISTRY-US, V20, P3418, DOI 10.1021/bi00515a018; ANGELIDES KJ, 1979, P NATL ACAD SCI USA, V76, P3279, DOI 10.1073/pnas.76.7.3279; ANNAN N, 1989, J AM CHEM SOC, V111, P8895, DOI 10.1021/ja00206a019; BISSWANGER H, 1971, EUR J BIOCHEM, V24, P376, DOI 10.1111/j.1432-1033.1971.tb19696.x; BISSWANGER H, 1980, BIOCHEM BIOPH RES CO, V95, P513, DOI 10.1016/0006-291X(80)90814-1; BJOERKLAND A, 1991, SCAND J IMMUNOL, V33, P749; BREMER J, 1969, EUR J BIOCHEM, V8, P535, DOI 10.1111/j.1432-1033.1969.tb00559.x; CRUMPTON MJ, 1986, CIBA F SYMP, V119, P93; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FLOURNOY DS, 1989, BIOCHEMISTRY-US, V28, P9594, DOI 10.1021/bi00451a007; GUNSALUS IC, 1954, MECHANISM ENZYME ACT, P545; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; HUPE DJ, 1987, ANAL BIOCHEM, V161, P20, DOI 10.1016/0003-2697(87)90645-2; JACKSON RH, 1983, J BIOL CHEM, V258, P1857; KLUGER R, 1977, J AM CHEM SOC, V99, P4504, DOI 10.1021/ja00455a052; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOIKE M, 1960, J BIOL CHEM, V235, P1924; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE PN, 1983, BIOCHEMISTRY-US, V22, P150, DOI 10.1021/bi00270a022; LOWE PN, 1984, BIOCHEMISTRY-US, V23, P91, DOI 10.1021/bi00296a015; MALDONADO ME, 1972, J BIOL CHEM, V247, P2711; Massy V, 1963, ENZYMES, V7, P275; MCNALLY A, 1992, BIOCHIM BIOPHYS ACTA, V1160, P179, DOI 10.1016/0167-4838(92)90005-X; MCNALLY AJ, 1995, J BIOL CHEM, V270, P19744, DOI 10.1074/jbc.270.34.19744; MCNALLY AJ, 1992, THESIS RUTGERS U GRA; MORRISON M, 1970, BIOCHEMISTRY-US, V9, P2995, DOI 10.1021/bi00817a010; MULLER R, 1980, J IMMUNOL METHODS, V34, P345, DOI 10.1016/0022-1759(80)90107-6; OLIVER RM, 1982, ELECTRON MICROS, V1, P1; PALMER JL, 1964, BIOCHEMISTRY-US, V3, P863, DOI 10.1021/bi00894a024; RADFORD SE, 1989, FEBS LETT, V250, P336, DOI 10.1016/0014-5793(89)80750-1; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; Reed LJ., 1969, METHOD ENZYMOL, P55; SCHONBRUNNHANEB.E, 1990, BIOCHEMISTRY-US, V29, P4880; SCHWARTZ ER, 1968, BIOCHEM BIOPH RES CO, V31, P495, DOI 10.1016/0006-291X(68)90504-4; SCHWARTZ ER, 1970, BIOCHEMISTRY-US, V9, P1434, DOI 10.1021/bi00808a019; SHEU KFR, 1984, J NEUROCHEM, V43, P1352, DOI 10.1111/j.1471-4159.1984.tb05394.x; SHEU KFR, 1985, ANN NEUROL, V17, P444; SPECKHARD DC, 1975, BIOCHEM BIOPH RES CO, V62, P614, DOI 10.1016/0006-291X(75)90443-X; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P155, DOI 10.1111/j.1432-1033.1983.tb07441.x; STEPHENS PE, 1983, EUR J BIOCHEM, V135, P519, DOI 10.1111/j.1432-1033.1983.tb07683.x; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P481, DOI 10.1111/j.1432-1033.1983.tb07490.x; STEVENSON KJ, 1978, BIOCHEMISTRY-US, V17, P2189, DOI 10.1021/bi00604a026; SURH CD, 1990, J IMMUNOL, V144, P2647; TSISELIUS A, 1956, ARCH BIOCHEM BIOPHYS, V65, P132; VANREGENMORTEL MHV, 1988, IMMUNOL LETT, V17, P95, DOI 10.1016/0165-2478(88)90076-4; VANREGENMORTEL MHV, 1986, CIBA F SYMP, V119, P76; YANG H, 1985, J BIOL CHEM, V260, P6049	49	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19736	19743		10.1074/jbc.270.34.19736	http://dx.doi.org/10.1074/jbc.270.34.19736			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649983	hybrid			2022-12-25	WOS:A1995RQ99100013
J	MCNALLY, AJ; MATTSSON, L; JORDAN, F				MCNALLY, AJ; MATTSSON, L; JORDAN, F			A LIBRARY OF MONOCLONAL-ANTIBODIES TO ESCHERICHIA-COLI K-12 PYRUVATE-DEHYDROGENASE COMPLEX - COMPETITIVE EPITOPE MAPPING STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; PROTEINS; BINDING	Presented here are competitive epitope mapping studies on a monoclonal antibody library to K-12 Escherichia coli pyruvate dehydrogenase complex (PDHc) and its pyruvate decarboxylating (EC1.2.4.1) subunit (El). Several of the monoclonal antibodies had been found to inhibit PDHc from 0 to 98%, Of the 10 monoclonal antibodies that showed the greatest inhibition of PDHc, 4 were elicited by PDHc and 6 by El, Surface plasmon resonance was used for competitive epitope mapping and revealed that these 10 monoclonal antibodies had at least 6 separate binding regions on the PDHc. The three monoclonal antibodies that demonstrated the strongest inhibition appeared to bind the same region on the PDHc. Mapping studies with the El antigen using an additional five monoclonal antibodies demonstrated that the two strongest inhibitor mono clonal antibodies (18A9 and 21C3) shared the same binding region on El, whereas the third strongest inhibitor (15A9) displayed an epitope region that overlapped the previous two on the El subunit. Antibody 15A9 had been shown to counteract GTP regulation of PDHc. Simultaneous multiple site binding experiments confirmed that the defined epitope regions were indeed independent. Limited competitive epitope binding experiments using radiolabeled El confirmed the surface plasmon resonance results.	RUTGERS STATE UNIV,DEPT CHEM,NEWARK,NJ 07102; RUTGERS STATE UNIV,DEPT BIOL,NEWARK,NJ 07102; ROCHE DIAGNOST SYST INC,SOMERVILLE,NJ 08876; PHARM BIOSENSOR,PISCATAWAY,NJ 08854	Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Newark; Rutgers State University New Brunswick					NIGMS NIH HHS [GM-50380] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANDRUP J, 1989, POLYM HDB, P469; BRICKER BJ, 1987, VIROLOGY, V161, P533, DOI 10.1016/0042-6822(87)90148-6; CULLEN DC, 1988, BIOSENSORS, V3, P211; DANIELS PB, 1988, SENSOR ACTUATOR, V15, P11, DOI 10.1016/0250-6874(88)85013-3; DUNN SD, 1985, J BIOL CHEM, V260, P418; Fagerstam L G, 1990, J Mol Recognit, V3, P208, DOI 10.1002/jmr.300030507; GRANZOW R, 1992, BIO-TECHNOL, V10, P390, DOI 10.1038/nbt0492-390; HIRSCHFELD T, 1967, APPL OPTICS, V6, P715, DOI 10.1364/AO.6.000715; HOPFIELD JJ, 1958, PHYS REV, V112, P1555, DOI 10.1103/PhysRev.112.1555; JASTREBOFF MM, 1985, BIOCHEMISTRY-US, V24, P587, DOI 10.1021/bi00324a007; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KOIKE M, 1960, J BIOL CHEM, V235, P1924; KRETSCHMANN E, 1968, Z NATURFORSCH, V230, P2135; LIEDBERG B, 1983, SENSOR ACTUATOR, V4, P299, DOI 10.1016/0250-6874(83)85036-7; LOFAS S, 1990, J CHEM SOC CHEM COMM, V21, P1526; LORENZO F, 1988, EUR J BIOCHEM, V176, P53, DOI 10.1111/j.1432-1033.1988.tb14250.x; MORRISON M, 1970, BIOCHEMISTRY-US, V9, P2995, DOI 10.1021/bi00817a010; OTTO A, 1968, Z PHYS, V216, P398, DOI 10.1007/BF01391532; PFEIFFER NE, 1987, J BIOL CHEM, V262, P11565; Raether H, 1977, PHYS THIN FILMS, V9, P145; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; SYTKOWSKI AJ, 1987, J BIOL CHEM, V262, P1161; VANREGENMORTEL MHV, 1988, IMMUNOL LETT, V17, P95, DOI 10.1016/0165-2478(88)90076-4; WELFORD K, 1991, OPT QUANT ELECTRON, V23, P1, DOI 10.1007/BF00619516; WILSON JE, 1987, CHEM MODIFICATION EN, P171	25	6	7	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19744	19751		10.1074/jbc.270.34.19744	http://dx.doi.org/10.1074/jbc.270.34.19744			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649984	hybrid			2022-12-25	WOS:A1995RQ99100014
J	MURASAWA, S; MATSUBARA, H; KIJIMA, K; MARUYAMA, K; MORI, Y; INADA, M				MURASAWA, S; MATSUBARA, H; KIJIMA, K; MARUYAMA, K; MORI, Y; INADA, M			STRUCTURE OF THE RAT V1A VASOPRESSIN RECEPTOR GENE AND CHARACTERIZATION OF ITS PROMOTER REGION AND COMPLETE CDNA SEQUENCE OF THE 3'-END	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ANTIDIURETIC-HORMONE; MOLECULAR-CLONING; MESSENGER-RNA; CHROMOSOMAL ASSIGNMENT; POTASSIUM CHANNEL; SUBSTANCE-P; EXPRESSION; ORGANIZATION; TRANSCRIPTION; LOCALIZATION	The gene encoding the rat Via arginine vasopressin (AVP) receptor was isolated, and its structural organization and 5'-flanking region were characterized, In addition, the complete cDNA sequence of the major transcript of the rat V1a receptor gene was determined, Southern blots demonstrated a single copy of the V1a receptor gene in the rat genome, spanning a region of 3.8 kilobases (kb) and consisting of two exons and one intron (1.8 kb). The location of the intron was unique among G protein coupled receptor genes in that the first exon encodes six of the seven transmembrane regions, the seventh region being encoded by the second exon, Primer extension, RNase protection, and rapid amplification of the 5'-end of the cDNA identified three transcriptional initiation sites (-405, -243, and -237), the major transcription initiation sites being mapped to positions -243 and -237 base pairs (bp) upstream of the ATG initiation codon (+1 bp), This portion of the 5'-flanking region has neither a TATA nor a CCAAT box, is GC-rich but has no GC box motif, and has features of promoters seen in housekeeping genes, Chimeras containing 2.2 kb of the 5'-flanking region and deletion analyses using the chloramphenicol acetyltransferase gene indicated that a ''minimal'' region, exhibiting promoter activity and tissue specificity, is located between nucleotides -296 and -221, when transfected into vascular smooth muscle cells, Gel mobility shift assay and Southwestern blotting suggested that similar to 30- and similar to 28-kDa nuclear proteins specifically bind to this region, Rapid amplification of the 3'-end of the cDNA showed that the major transcript terminates 442 bp downstream of the stop codon, in agreement with the mRNA size (2.1 kb), This study demonstrated a distinctive feature in the structural organization of the AVP-oxytocin receptor family genes, and characterization of the 5'-flanking region reported here will lead to a better understanding of the mechanism of transcriptional regulation of the rat Via AVP receptor gene.	KANSAI MED UNIV,DEPT INTERNAL MED 2,MORIGUCHI,OSAKA 570,JAPAN	Kansai Medical University								ARAI H, 1993, J BIOL CHEM, V268, P3463; AUSUBEL FM, 1983, CURRENT PROTOCOL MOL; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GERARD NP, 1990, J BIOL CHEM, V265, P20455; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; HOSODA K, 1992, J BIOL CHEM, V267, P18797; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P793, DOI 10.1210/me.6.5.793; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JARD S, 1986, MOL PHARMACOL, V30, P171; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MATSUBARA H, 1994, J CLIN INVEST, V93, P1592, DOI 10.1172/JCI117139; MATSUBARA H, 1991, J BIOL CHEM, V266, P13324; MATSUBARA H, 1993, J CLIN INVEST, V92, P1659, DOI 10.1172/JCI116751; Michell R H, 1979, Biochem Soc Trans, V7, P861; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MORI Y, 1993, J BIOL CHEM, V268, P26482; MURASAWA S, 1993, J BIOL CHEM, V268, P26996; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675; ROSEN F, 1995, P NATL ACAD SCI USA, V92, P200; SACHS A, 1993, J BIOL CHEM, V268, P22955; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SEIBOLD A, 1992, AM J HUM GENET, V51, P1078; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; TAKAHASHI K, 1992, EUR J BIOCHEM, V204, P1025, DOI 10.1111/j.1432-1033.1992.tb16724.x; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; THIBONNIER M, 1988, KIDNEY INT S25, V34, P852; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611	43	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20042	20050		10.1074/jbc.270.34.20042	http://dx.doi.org/10.1074/jbc.270.34.20042			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650021	hybrid			2022-12-25	WOS:A1995RQ99100056
J	PAPOV, VV; DIAMOND, TV; BIEMANN, K; WAITE, JH				PAPOV, VV; DIAMOND, TV; BIEMANN, K; WAITE, JH			HYDROXYARGININE-CONTAINING POLYPHENOLIC PROTEINS IN THE ADHESIVE PLAQUES OF THE MARINE MUSSEL MYTILUS-EDULIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-ANALYSIS; TANDEM MASS-SPECTROMETRY; PRECURSOR PROTEINS; HYDROXYPROLINE; HYDROLYSIS; ATTACHMENT; PEPTIDES; BYSSUS	An unusual polymorphic protein family of nine or more variants has been isolated from the byssal adhesive plaques and foot of the marine mussel Mytilus edulis. In accordance with established terminology, the family is referred to as IM. edulis foot protein 3 or simply Mefp-3. Variants of Mefp-S have molecular masses of about 6 kDa, isoelectric points greater than 10.5, and an amino acid composition dominated by six amino acids: glycine, asparagine, 3,4-dihydroxyphenylalanine (Dopa), tryptophan, arginine, and an unknown basic amino acid. The latter has been isolated and identified as 4-hydroxyarginine using fast atom bombardment mass spectrometry and appropriate standards. The primary structure of variant Mefp-3F has been determined by peptide mapping using automated Edman sequencing in combination with fast atom bombardment and matrix-assisted laser desorption ionization mass spectrometry: ADYYGPNYGPPRRYGGGNYNRYNRYGRRYGGYKGWNNGWNRGRRGKYW where Y represents Dopa, and R represents hydroxyarginine. Notably, the 4 occurrences of RY are marked by a resistance to trypsin digestion. Although the conversion of tyrosines to Dopa is essentially complete, hydroxylation of arginines varies between 40 and 80%. In contrast to other mussel adhesive proteins such as Mefp-1 and -2 which have large numbers of highly conserved, tandemly repeated peptide motifs, Mefp-3 has only short sporadic repeats. The specific function of Mefp-3 in byssal adhesion is unknown.	UNIV DELAWARE,COLL MARINE STUDIES,MARINE BIOL BIOCHEM PROGRAM,NEWARK,DE 19716; UNIV DELAWARE,DEPT CHEM,NEWARK,DE 19716; MIT,DEPT CHEM,CAMBRIDGE,MA 02139	University of Delaware; University of Delaware; Massachusetts Institute of Technology (MIT)					NCRR NIH HHS [RR00317] Funding Source: Medline; NIDCR NIH HHS [DE10042] Funding Source: Medline; NIGMS NIH HHS [GM05472] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM005472, R37GM005472] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER M, 1981, J CHEM SOC CHEM COMM, P325, DOI 10.1039/c39810000325; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BELL EA, 1964, BIOCHEM J, V91, P356, DOI 10.1042/bj0910356; BELL EA, 1963, NATURE, V197, P901, DOI 10.1038/197901a0; BENEDICT CV, 1986, J MORPHOL, V189, P261, DOI 10.1002/jmor.1051890305; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; BORDERS CL, 1994, PROTEIN SCI, V3, P541; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; DIAMOND TV, 1993, THESIS U DELAWARE NE; FILPULA DR, 1990, BIOTECHNOL PROGR, V6, P171, DOI 10.1021/bp00003a001; FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022; FUJITA Y, 1959, B CHEM SOC JPN, V32, P439, DOI 10.1246/bcsj.32.439; HANSEN DC, 1994, J COLLOID INTERF SCI, V168, P206, DOI 10.1006/jcis.1994.1410; HOLLECKER M, 1990, PROTEIN STRUCTURE PR, P145; INOUE K, 1995, J BIOL CHEM, V270, P6698, DOI 10.1074/jbc.270.12.6698; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; LAURSEN RA, 1992, RESULTS PROBLEMS CEL, P55; LITWACK G, 1960, EXPT BIOCH LABORATOR; MAKISUMI S, 1961, J BIOCHEM-TOKYO, V49, P284, DOI 10.1093/oxfordjournals.jbchem.a127296; MEEK KM, 1979, BIOCHIM BIOPHYS ACTA, V587, P112, DOI 10.1016/0304-4165(79)90225-3; MURAMOTO K, 1990, ANAL BIOCHEM, V189, P223, DOI 10.1016/0003-2697(90)90112-M; NOTTER MFD, 1988, EXP CELL RES, V177, P237, DOI 10.1016/0014-4827(88)90458-2; OLIVIERI MP, 1992, BIOMATERIALS, V13, P1000, DOI 10.1016/0142-9612(92)90150-M; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PAZ MA, 1991, J BIOL CHEM, V266, P689; QIN XX, 1995, J EXP BIOL, V198, P633; RZEPECKI LM, 1992, BIOL BULL, V183, P123, DOI 10.2307/1542413; SATO K, 1987, ANAL CHEM, V59, P1652, DOI 10.1021/ac00140a016; SIMPSON RJ, 1976, J BIOL CHEM, V251, P1936; SULSER H, 1975, Lebensmittel-Wissenschaft and Technologie, V8, P161; TAMARIN A, 1976, J MORPHOL, V149, P199, DOI 10.1002/jmor.1051490205; TAYLOR SW, 1994, J AM CHEM SOC, V116, P10803, DOI 10.1021/ja00102a063; TOUS GI, 1989, ANAL BIOCHEM, V179, P50, DOI 10.1016/0003-2697(89)90198-X; TSUGITA A, 1987, J BIOCHEM-TOKYO, V102, P1593, DOI 10.1093/oxfordjournals.jbchem.a122209; WAITE JH, 1991, ANAL BIOCHEM, V192, P429, DOI 10.1016/0003-2697(91)90560-G; WAITE JH, 1990, COMP BIOCHEM PHYS B, V97, P19, DOI 10.1016/0305-0491(90)90172-P; WAITE JH, 1981, SCIENCE, V212, P1038, DOI 10.1126/science.212.4498.1038; WAITE JH, 1985, BIOCHEMISTRY-US, V24, P5010, DOI 10.1021/bi00340a008; WAITE JH, 1992, MOL BIOCHEM PARASIT, V54, P143, DOI 10.1016/0166-6851(92)90107-U; WAITE JH, 1983, J BIOL CHEM, V258, P2911; WAITE JH, 1992, BIOCHEMISTRY-US, V31, P5733, DOI 10.1021/bi00140a007; WAITE JH, 1992, RESULTS PROBLEMS CEL, P27	42	270	293	5	66	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20183	20192		10.1074/jbc.270.34.20183	http://dx.doi.org/10.1074/jbc.270.34.20183			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650037	hybrid			2022-12-25	WOS:A1995RQ99100075
J	SCHMIDT, M; FASSELT, B; RUMENAPP, U; BIENEK, C; WIELAND, T; VANKOPPEN, CJ; JAKOBS, KH				SCHMIDT, M; FASSELT, B; RUMENAPP, U; BIENEK, C; WIELAND, T; VANKOPPEN, CJ; JAKOBS, KH			RAPID AND PERSISTENT DESENSITIZATION OF M3 MUSCARINIC ACETYLCHOLINE RECEPTOR-STIMULATED PHOSPHOLIPASE-D - CONCOMITANT SENSITIZATION OF PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL REGULATION; LYSOPHOSPHATIDIC ACID; PHOSPHATIDIC-ACID; GROWTH-FACTOR; PROTEIN; CELLS; FIBROBLASTS; ISOENZYMES; INHIBITION; ACTIVATION	Activation of muscarinic acetylcholine receptors (mAChR) in human embryonic kidney (HEK) cells stably expressing the human m3 subtype leads to stimulation of both phospholipase C (PLC) and D (PLD), mAChR-stimulated PLD was turned off after 2 min of receptor activation with either the full (carbachol) or partial agonist (pilocarpine) and remained completely suppressed for at least 4 h, Partial recovery was observed 24 h after agonist removal, This rapid arrest of PLD response was not due to a loss of cell surface receptors and was also not caused by negative feedback due to concomitant activation of protein kinase C, tyrosine phosphorylation, increase in cytosolic calcium, or activation of Gi proteins, Furthermore, PLD stimulation by directly activated protein kinase C and GTP-binding proteins was unaltered in carbachol-pretreated cells. Finally, neither prevention of PLD stimulation during carbachol pretreatment by genistein nor inhibition of protein synthesis by cycloheximide, added before or after carbachol challenge, resulted in recovery of mAChR-stimulated PLD, The short term carbachol pretreatment nearly completely abolished agonist-induced binding of guanosine 5'-O-(3-thiotriphosphate) to membranes or permeabilized adherent cells. Full recovery of this response was achieved after 4 h, Similar to transfected m3 mAChR, PLD stimulation by endogenously expressed purinergic receptors was also fully blunted after 2 min of agonist (ATP) treatment, Preexposure of HEK cells to either receptor agonist partially, but not completely, reduced PLD stimulation by the other agonist, In contrast to desensitization of PLD stimulation, 2 min of carbachol treatment led to a sensitization, by up to g-fold, of mAChR-stimulated inositol phosphate formation, This supersensitivity was also observed with pilocarpine, which acted as a full agonist on PLC. On the basis of these results, we conclude that the m3 mAChR stimulates PLD and PLC in HEK cells with distinct efficiencies and with very distinct durations of each response, The rapid and long lasting desensitization of the PLD response is apparently not due to a loss of cell surface receptors or PLD activation by GTP-binding proteins, but it may involve, at least initially, an uncoupling of receptors from GTP-binding proteins and most likely a loss of an as yet undefined essential transducing component.	UNIV ESSEN GESAMTHSCH,INST PHARMAKOL,D-45122 ESSEN,GERMANY	University of Duisburg Essen			Schmidt, Martina/C-5339-2018; Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Schmidt, Martina/0000-0003-3075-0630; Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261				BENAV P, 1993, EUR J BIOCHEM, V215, P455, DOI 10.1111/j.1432-1033.1993.tb18054.x; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BOARDER MR, 1994, TRENDS PHARMACOL SCI, V15, P57, DOI 10.1016/0165-6147(94)90111-2; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISCOE CP, 1994, BIOCHEM J, V298, P61, DOI 10.1042/bj2980061; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1992, BIOCHEM J, V288, P1; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; HA KS, 1993, J BIOL CHEM, V268, P10534; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JIANG H, 1994, MOL CELL BIOL, V14, P3676, DOI 10.1128/MCB.14.6.3676; LAZARENO S, 1993, LIFE SCI, V52, P449, DOI 10.1016/0024-3205(93)90301-I; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MCKENZIE FR, 1992, J BIOL CHEM, V267, P22759; MOEHREN G, 1994, J BIOL CHEM, V269, P838; NIETO M, 1994, MOL PHARMACOL, V46, P406; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; THOMPSON NT, 1991, TRENDS PHARMACOL SCI, V12, P404, DOI 10.1016/0165-6147(91)90617-2; THOMPSON NT, 1993, ADV PHARMACOL, V21, P199; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VANKOPPEN CJ, 1994, EUR J BIOCHEM, V222, P525; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WIELAND T, 1995, N-S ARCH PHARMACOL, V351, P329, DOI 10.1007/BF00169072	35	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19949	19956		10.1074/jbc.270.34.19949	http://dx.doi.org/10.1074/jbc.270.34.19949			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650010	hybrid			2022-12-25	WOS:A1995RQ99100043
J	BOOTH, JW; GUIDOTTI, G				BOOTH, JW; GUIDOTTI, G			AN ALLEGED YEAST POLYPHOSPHATE KINASE IS ACTUALLY DIADENOSINE-5',5'''-P-1,P-4-TETRAPHOSPHATE ALPHA,BETA-PHOSPHORYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PURIFICATION; PHOSPHATE; PHOSPHOTRANSFERASE; VACUOLES; CLEAVAGE; PROTEINS; GENE; PH	Polyphosphates are a major constituent of the yeast Saccharomyces cerevisiae. A purification of the enzyme polyphosphate kinase (E.C. 2.7.4.1) from this organism has been reported (Felter, S., and Stahl, A. J. C. (1973) Biochimie (Paris) 55, 245-251). The assay for activity used in this purification was the production of P-32-labeled nucleotide, presumed to be ATP, in the presence of [P-32]polyphosphate and ADP. We have found that this assay does not reflect the activity of a polyphosphate kinase but rather the combination of an exopolyphosphatase, releasing free [P-32]phosphate from the added [P-32]polyphosphate, and the ADP-[P-32]phosphate exchange activity of the enzyme diadenosine 5',5'''-P-1,P-4-tetraphosphate alpha,beta-phosphorylase (Ap(4)A phosphorylase). We also present direct evidence for the formation of an enzyme-AMP intermediate in the action of Ap(4)A phosphorylase.	HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Harvard University					NHLBI NIH HHS [HL08893] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHN KH, 1990, J BIOL CHEM, V265, P11734; AKIYAMA M, 1992, J BIOL CHEM, V267, P22556; ANDREEVA NA, 1993, YEAST, V9, P127, DOI 10.1002/yea.320090204; BEAUVOIT B, 1991, BIOCHEMISTRY-US, V30, P11212, DOI 10.1021/bi00111a004; BOURNE RM, 1991, BIOCHIM BIOPHYS ACTA, V1067, P81, DOI 10.1016/0005-2736(91)90028-7; DUNN T, 1994, J BIOL CHEM, V269, P7273; DURR M, 1979, ARCH MICROBIOL, V121, P169, DOI 10.1007/BF00689982; FELTER S, 1973, BIOCHIMIE, V55, P245, DOI 10.1016/S0300-9084(73)80122-1; FELTER S, 1970, B SOC CHIM BIOL, V52, P75; FRESCO LD, 1994, P NATL ACAD SCI USA, V91, P6624, DOI 10.1073/pnas.91.14.6624; GREENFIELD NJ, 1987, BIOCHIM BIOPHYS ACTA, V926, P205, DOI 10.1016/0304-4165(87)90205-4; GURANOWSKI A, 1985, J BIOL CHEM, V260, P3542; GURANOWSKI A, 1986, J BIOL CHEM, V261, P5943; HAROLD FM, 1966, BACTERIOL REV, V30, P772, DOI 10.1128/MMBR.30.4.772-794.1966; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KNLAEV IS, 1983, ADV MICROB PHYSL, V24, P83; KORNBERG A, 1956, BIOCHIM BIOPHYS ACTA, V20, P215, DOI 10.1016/0006-3002(56)90280-3; KORNBERG SR, 1957, BIOCHIM BIOPHYS ACTA, V26, P294, DOI 10.1016/0006-3002(57)90008-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINSON SL, 1975, J GEN MICROBIOL, V88, P65, DOI 10.1099/00221287-88-1-65; LIHC, 1973, BIOCHEM BIOPH RES CO, V53, P875, DOI 10.1016/0006-291X(73)90174-5; LORENZ B, 1994, J BIOL CHEM, V269, P22198; LUSBY EW, 1980, MOL GEN GENET, V178, P69, DOI 10.1007/BF00267214; NICOLAY K, 1983, ARCH MICROBIOL, V134, P270, DOI 10.1007/BF00407801; PLATEAU P, 1989, J BACTERIOL, V171, P6437, DOI 10.1128/jb.171.12.6437-6445.1989; PLATEAU P, 1990, J BACTERIOL, V172, P6892, DOI 10.1128/jb.172.12.6892-6899.1990; ROBINSON NA, 1986, J BIOL CHEM, V261, P4481; SCHUDDEMAT J, 1989, BIOCHIM BIOPHYS ACTA, V1010, P191, DOI 10.1016/0167-4889(89)90160-2; SHABALIN YA, 1989, BIOCHEMISTRY-MOSCOW+, V54, P50; SHABALIN YA, 1977, BIOCHEMISTRY-MOSCOW+, V42, P1291; TINSLEY CR, 1993, INFECT IMMUN, V61, P3703, DOI 10.1128/IAI.61.9.3703-3710.1993; URECH K, 1978, ARCH MICROBIOL, V116, P275, DOI 10.1007/BF00417851; WEIMBERG R, 1975, J BACTERIOL, V121, P1122, DOI 10.1128/JB.121.3.1122-1130.1975; WOOD HG, 1988, ANNU REV BIOCHEM, V57, P235, DOI 10.1146/annurev.bi.57.070188.001315; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WURST H, 1994, J BIOL CHEM, V269, P10996	36	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19377	19382		10.1074/jbc.270.33.19377	http://dx.doi.org/10.1074/jbc.270.33.19377			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642617	hybrid			2022-12-25	WOS:A1995RP70300031
J	FRANCOIS, JM; SHENG, ZL; SZCZESNA, D; POTTER, JD				FRANCOIS, JM; SHENG, ZL; SZCZESNA, D; POTTER, JD			THE FUNCTIONAL-ROLE OF THE DOMAINS OF TROPONIN-C INVESTIGATED WITH THROMBIN FRAGMENTS OF TROPONIN-C RECONSTITUTED INTO SKINNED MUSCLE-FIBERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; SR-2+ ACTIVATION PROPERTIES; CALCIUM-BINDING SITES; AMINO-ACID SEQUENCE; BIOLOGICAL-ACTIVITY; CENTRAL HELIX; AFFINITY; CONTRACTION; PROTEIN; CALMODULIN	Proteolysis of rabbit fast skeletal troponin-C (RSTnC) with thrombin produces four separate fragments containing the following Ca2+-binding site(s): TH1 (residues 1-120) sites I-III; TH2 (121-159) site IV; TH3 (1-100) sites I and II; and TH4 (101-120) site III. We studied the ability of these fragments 60 restore the steady state isometric force in TnC-depleted skinned skeletal muscle fibers, Interestingly, we found that all investigated fragments of RSTnC possessed some of the properties of native RSTnC, but none of them could fully regulate contraction in the fibers like intact RSTnC, TH1 was the most effective in the force restoration (65%) whereas the smaller fragments developed about 50% (TH3 and TH4) or 20% (TH2) of the initial force of unextracted fibers. Additionally, much higher concentrations of TH2, TH3, and TH4 compared to RSTnC or TH1 were necessary for force development suggesting a decreased affinity of these fragments to their binding site(s) in the fibers, Like intact RSTnC, TH1 was able to interact with the fibers in a Ca2+-independent (Mg2+-dependent) manner, indicating that at a minimum, Ca2+-binding site III is required for this type of binding, The initial binding of the other fragments to the TnC-depleted fibers occurred only in the presence of Ca2+, TH2 and TH4 appeared to bind to two different binding sites in the fibers, The binding to one of the sites caused partial force restoration, This binding of TH2 and TH4 was abolished when Ca2+ was removed, TH2 and TH4 binding to the second site required Ca2+ initially but was maintained in the presence of Mg2+. This interaction of TH2 and TH4 partially blocked the rebinding of RSTnC to the fibers, The latter results suggest that site III or IV in these small fragments, when removed from the constraints of the parent protein, may assume conformations that allow them to function, to a certain extent, like both the regulatory sites (I and II) and the Ca2+-Mg2+ sites (III and IV) of TnC.	UNIV MIAMI,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,MIAMI,FL 33101	University of Miami					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040727, R01AR037701] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR37701, AR40727] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMPHLETT GW, 1976, FEBS LETT, V72, P163, DOI 10.1016/0014-5793(76)80836-8; BABU A, 1988, J BIOL CHEM, V30, P15485; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BARSKAYA NV, 1982, BIOCHEM J, V207, P185, DOI 10.1042/bj2070185; COLLINS JH, 1991, BIOCHEMISTRY-US, V30, P702, DOI 10.1021/bi00217a017; COLLINS JH, 1976, NATURE, V259, P699, DOI 10.1038/259699a0; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; COLLINS JH, 1973, FEBS LETT, V36, P268, DOI 10.1016/0014-5793(73)80388-6; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; DEDMAN JR, 1977, J BIOL CHEM, V252, P2437; DOBROWOLSKI Z, 1991, J BIOL CHEM, V266, P5703; DOPHEIDE TA, 1967, J BIOL CHEM, V242, P1833; FARAH CS, 1994, J BIOL CHEM, V269, P5230; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRABAREK Z, 1986, J BIOL CHEM, V261, P608; GUTH K, 1987, J BIOL CHEM, V262, P13627; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HITCHCOCK SE, 1975, CALCIUM TRANSPORT CO, P447; HOAR PE, 1988, J MUSCLE RES CELL M, V9, P165, DOI 10.1007/BF01773738; INGRAHAM RH, 1984, J BIOL CHEM, V259, P9544; KERRICK WGL, 1985, J BIOL CHEM, V260, P5687; KERRICK WGL, 1975, J APPL PHYSIOL, V39, P1052, DOI 10.1152/jappl.1975.39.6.1052; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEAVIS PC, 1978, BIOCHIM BIOPHYS ACTA, V535, P281, DOI 10.1016/0005-2795(78)90094-6; MALIK NA, 1987, BIOCHIM BIOPHYS ACTA, V911, P221, DOI 10.1016/0167-4838(87)90011-2; MCCUBBIN WD, 1985, CAN J BIOCHEM CELL B, V63, P812, DOI 10.1139/o85-103; MILLER T, 1992, BIOPHYS J, V61, P280; NEGELE JC, 1992, J BIOL CHEM, V267, P825; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; POTTER JD, 1983, METHOD ENZYMOL, V102, P135; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; SHAW GS, 1990, SCIENCE, V249, P280, DOI 10.1126/science.2374927; SHENG Z, 1991, J BIOL CHEM, V266, P5711; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; WALL CM, 1981, BIOCHEM J, V195, P307, DOI 10.1042/bj1950307; WANG CLA, 1986, EUR J BIOCHEM, V154, P225, DOI 10.1111/j.1432-1033.1986.tb09383.x; WANG CLA, 1983, J BIOL CHEM, V258, P9175; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT HG, 1984, MET IONS BIOL SYST, V17, P381; ZOT HG, 1982, J BIOL CHEM, V257, P7678	49	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19287	19293		10.1074/jbc.270.33.19287	http://dx.doi.org/10.1074/jbc.270.33.19287			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642603	hybrid			2022-12-25	WOS:A1995RP70300017
J	HAYWARD, CPM; FURMANIAKKAZMIERCZAK, E; CIEUTAT, AM; MOORE, JC; BAINTON, DF; NESHEIM, ME; KELTON, JG; COTE, G				HAYWARD, CPM; FURMANIAKKAZMIERCZAK, E; CIEUTAT, AM; MOORE, JC; BAINTON, DF; NESHEIM, ME; KELTON, JG; COTE, G			FACTOR-V IS COMPLEXED WITH MULTIMERIN IN RESTING PLATELET LYSATES AND COLOCALIZES WITH MULTIMERIN IN PLATELET ALPHA-GRANULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-V; WEIBEL-PALADE BODIES; FACTOR-X ACTIVATION; BOVINE FACTOR-V; PROTHROMBINASE COMPLEX; FACTOR-VIII; PROCOAGULANT ACTIVITY; VONWILLEBRAND-FACTOR; MOLECULAR-WEIGHT; COMPLETE CDNA	Factor V stored in platelets is an important source of factor Va for the prothrombinase complex. Investigations of potential platelet factor Va-binding proteins, using factor Va light chain affinity chromatography, identified a disulfide-linked multimeric protein with a reduced mobility of 155 kDa in the column eluate, Immunodepletion and immunoblotting indicated that this protein was multimerin. Multimerin specifically bound factors V and Va and the isolated factor Va light chain, but not the heavy chain of factor Va. Factor V stored in platelets, but not plasma factor V, was found to be complexed with multimerin, Multimerin immunodepletion of resting platelet lysates was associated with the removal of factor V and the loss of factor V coagulant activity. Immunoelectron microscopic studies colocalized factor V with multimerin in the alpha-granules of resting platelets. With thrombin-induced platelet activation, we observed dissociation of factor Va-multimerin complexes, multimerin-independent membrane binding of factor Va, and prothrombinase activity that was not inhibitable by multimerin antibodies. This study indicates that platelet factor V is stored as a complex with multimerin and suggests a possible role for multimerin as a carrier protein for factor V stored in platelets.	MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8N 3Z5,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143	McMaster University; Queens University - Canada; University of California System; University of California San Francisco				Hayward, Catherine/0000-0002-2843-0817	NHLBI NIH HHS [HL-31610] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031610, R37HL031610] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAINTON DF, 1987, J EXP MED, V166, P1641, DOI 10.1084/jem.166.6.1641; BARUCH D, 1986, EUR J BIOCHEM, V154, P213, DOI 10.1111/j.1432-1033.1986.tb09381.x; BLOOM JW, 1979, THROMB RES, V15, P595, DOI 10.1016/0049-3848(79)90169-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHESNEY CM, 1981, P NATL ACAD SCI-BIOL, V78, P5180, DOI 10.1073/pnas.78.8.5180; CHIU HC, 1985, J CLIN INVEST, V75, P339, DOI 10.1172/JCI111706; CRAMER EM, 1985, BLOOD, V66, P710; ESMON CT, 1979, J BIOL CHEM, V254, P964; GERWITZ AM, 1986, BLOOD, V67, P1639; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HARRISON P, 1993, BLOOD REV, V7, P52, DOI 10.1016/0268-960X(93)90024-X; HAYWARD CPM, 1991, J BIOL CHEM, V266, P7114; HAYWARD CPM, 1995, PLATELETS, V6, P1, DOI 10.3109/09537109509013255; HAYWARD CPM, 1993, J CLIN INVEST, V91, P2630, DOI 10.1172/JCI116502; HAYWARD CPM, 1991, BLOOD, V77, P2556; HORSEWOOD P, 1991, BLOOD, V77, P1019; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1988, BLOOD, V71, P539; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KANE WH, 1980, J BIOL CHEM, V255, P1170; KANE WH, 1982, J BIOL CHEM, V257, P3963; KANE WH, 1987, BIOCHEMISTRY-US, V26, P6508, DOI 10.1021/bi00394a033; KELTON JG, 1990, BLOOD, V75, P2172; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lundblad R L, 1976, Methods Enzymol, V45, P156; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1981, BIOCHEMISTRY-US, V20, P28, DOI 10.1021/bi00504a005; MANN KG, 1990, BLOOD, V76, P1; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MILETECH JP, 1981, METHOD ENZYMOL, V80, P13137; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MILETICH JP, 1979, BLOOD, V54, P1015, DOI 10.1182/blood.V54.5.1015.1015; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NESHEIM ME, 1993, THROMB HAEMOSTASIS, V70, P80; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1986, J CLIN INVEST, V77, P405, DOI 10.1172/JCI112318; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PUSEY ML, 1984, BIOCHEMISTRY-US, V23, P6202, DOI 10.1021/bi00320a048; ROSING J, 1985, BLOOD, V65, P319; ROSING J, 1980, J BIOL CHEM, V255, P274; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SLOT JW, 1984, IMMUNOLABELLING ELEC, P129; SMITH JW, 1993, J IMMUNOL METHODS, V158, P77, DOI 10.1016/0022-1759(93)90260-E; TRACY PB, 1981, J BIOL CHEM, V256, P743; TRACY PB, 1984, J CLIN INVEST, V74, P1221, DOI 10.1172/JCI111531; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; TRACY PB, 1982, BLOOD, V60, P59; TRACY PB, 1985, J BIOL CHEM, V260, P2119; TRACY PB, 1992, METHOD ENZYMOL, V215, P329; TRACY PB, 1979, J BIOL CHEM, V254, P354; VANRIJN J, 1983, EUR J BIOCHEM, V133, P1; VISKUP RW, 1987, BLOOD, V69, P1188; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; WENCELDRAKE JD, 1986, BLOOD, V68, P244; WILBOURN B, 1993, BRIT J HAEMATOL, V83, P608, DOI 10.1111/j.1365-2141.1993.tb04698.x; ZWAAL RFA, 1992, BIOCHIM BIOPHYS ACTA, V1180, P1, DOI 10.1016/0925-4439(92)90019-J	61	49	49	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19217	19224		10.1074/jbc.270.33.19217	http://dx.doi.org/10.1074/jbc.270.33.19217			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642592	hybrid			2022-12-25	WOS:A1995RP70300006
J	LABARRIERE, N; SELVAIS, PL; LEMAIGRE, FP; MICHEL, A; MAITER, DM; ROUSSEAU, GG				LABARRIERE, N; SELVAIS, PL; LEMAIGRE, FP; MICHEL, A; MAITER, DM; ROUSSEAU, GG			A NOVEL TRANSCRIPTIONAL ACTIVATOR ORIGINATING FROM AN UPSTREAM PROMOTER IN THE HUMAN GROWTH-HORMONE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA-BINDING DOMAIN; ALTERNATIVE PROMOTER; SEQUENCE; DIMERIZATION; EXPRESSION; PITUITARY; PROTEINS; INVITRO	Transcription of the human growth hormone gene can start in vitro and in vivo 197 base pairs upstream from the cap site of growth hormone mRNA (Courtois, S. J., Lafontaine, D., and Rousseau, G. G. (1992) J. Biol. Chen. 267, 19736-19743). We have now characterized the mRNA that originates from this optional promoter and have found that it occurs in human hypophysis and placenta but not in 10 other tissues, This mRNA contains an open reading frame for a protein of 107 residues that shares sequence similarity with three domains of hepatic nuclear factor-1 alpha. With antibodies directed against a peptide corresponding to the C terminus of this protein, immunoreactive material was detected in a subset of cells of the adenohypophysis. When fused to the DNA-binding domain of the yeast transcription factor GALE, the protein stimulated transcription from a GAL4-sensitive reporter gene in transiently transfected pituitary and placental cells.	UNIV LOUVAIN,SCH MED,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOLEC PATHOL,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; UNIV LOUVAIN,SCH MED,DIABET & NUTR UNIT,B-1200 BRUSSELS,BELGIUM; UNIV MONS,BIOL CHEM LAB,B-7000 MONS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Mons			Labarriere, Nathalie/H-8876-2015	Labarriere, Nathalie/0000-0002-1407-6546; Lemaigre, Frederic/0000-0002-3609-434X				ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; BASSELDUBY R, 1994, MOL CELL BIOL, V14, P4596, DOI 10.1128/MCB.14.7.4596; BAUMHUETER S, 1990, GENE DEV, V49, P372; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; COURTOIS SJ, 1992, J BIOL CHEM, V267, P19736; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; Grant G, 1992, SYNTHETIC PEPTIDES; HSU DW, 1991, AM J PATHOL, V138, P897; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEMAIGRE FP, 1989, EUR J BIOCHEM, V181, P555, DOI 10.1111/j.1432-1033.1989.tb14760.x; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; NORDHEIM A, 1994, NATURE, V370, P177, DOI 10.1038/370177a0; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SELVAIS PL, 1993, NEUROENDOCRINOLOGY, V58, P539, DOI 10.1159/000126588; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342	25	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19205	19208		10.1074/jbc.270.33.19205	http://dx.doi.org/10.1074/jbc.270.33.19205			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642589	hybrid			2022-12-25	WOS:A1995RP70300003
J	KASTRINAKIS, WV; RAMCHURREN, N; RIEGER, KM; HESS, DT; LODA, M; STEELE, G; SUMMERHAYES, IC				KASTRINAKIS, WV; RAMCHURREN, N; RIEGER, KM; HESS, DT; LODA, M; STEELE, G; SUMMERHAYES, IC			INCREASED INCIDENCE OF P53 MUTATIONS IS ASSOCIATED WITH HEPATIC METASTASIS IN COLORECTAL NEOPLASTIC PROGRESSION	ONCOGENE			English	Article						P53; COLON; HEPATIC METASTASIS	GENE-MUTATIONS; PROGNOSTIC-SIGNIFICANCE; ALLELIC LOSS; CARCINOMA; CANCER; TUMORS; OVEREXPRESSION; TUMORIGENESIS; EXPRESSION; DELETIONS	Within a panel of 15 colon carcinoma cell lines we have characterized the p53 gene status using immunocytochemistry (ICC), SSCP and direct sequence analysis. Extension of this analysis to the use of ICC on 104 colonic lesions, representative of different stages of colonic neoplastic progression, showed an absence of detectable p53 nuclear staining in preneoplastic polyp lesions (20 cases) with staining of 52% (25/48) of primary colon carcinomas and 81% (29/36) of hepatic metastases, suggestive of an increased incidence of p53 mutations in late stage lesions of colonic cancer. To address this issue more directly, we analysed 18 primary colon carcinomas and hepatic metastases excised coincidentally from the same patients. In ICC, p53 nuclear staining was recorded in matching lesions from eight individuals where direct sequencing revealed identical mutations in each case. In four individuals no ICC staining was detected in either lesion and molecular analysis revealed wild type sequence in exons 4-9. In six individuals p53 nuclear staining was observed in the hepatic metastases of patients but not the primary lesion. Molecular analysis revealed point mutation events in hepatic metastases from these patients which were not detected in the primary tumor. The point mutations identified in colon carcinomas were predominantly transition events (83%) located in previously characterized codon hotspot regions. These results demonstrate an increased incidence of p53 mutations associated with secondary lesions of colorectal tumors suggestive of a role for p53 in the establishment of colorectal hepatic metastases.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT SURG,CANC BIOL LAB,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [P01CA044704, R23CA042944, T32CA009580, R01CA042944] Funding Source: NIH RePORTER; NCI NIH HHS [CA44704, CA42944, T32 CA 09580] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BELL SM, 1993, GASTROENTEROLOGY, V104, P57, DOI 10.1016/0016-5085(93)90835-Z; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DIX B, 1994, BRIT J CANCER, V70, P585, DOI 10.1038/bjc.1994.355; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IINO H, 1994, CANCER, V73, P1324, DOI 10.1002/1097-0142(19940301)73:5<1324::AID-CNCR2820730503>3.0.CO;2-W; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; PIGNATELLI M, 1992, INT J CANCER, V50, P638; PURDIE CA, 1991, AM J PATHOL, V138, P807; REMVIKOS Y, 1992, BRIT J CANCER, V66, P758, DOI 10.1038/bjc.1992.352; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCOTT N, 1991, BRIT J CANCER, V63, P317, DOI 10.1038/bjc.1991.74; SHIRASAWA S, 1991, CANCER RES, V51, P2874; STARZYNSKA T, 1992, BRIT J CANCER, V66, P558, DOI 10.1038/bjc.1992.314; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402	24	81	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					647	652						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651727				2022-12-25	WOS:A1995RQ46900005
J	BRATTON, DL				BRATTON, DL			RELEASE OF PLATELET ACTIVATION FACTOR FROM ACTIVATED NEUTROPHILS - TRANSGLUTAMINASE-DEPENDENT ENHANCEMENT OF TRANSBILAYER MOVEMENT ACROSS THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CA2+-ENRICHED HUMAN-ERYTHROCYTES; PROTEIN-CATALYZED TRANSFER; PHOSPHOLIPID ASYMMETRY; CROSS-LINKING; PROCOAGULANT ACTIVITY; RABBIT PLATELETS; LIPID ASYMMETRY; FACTOR PAF	Extracellular release of platelet activating factor (PAF) following synthesis in inflammatory cells is variable and modulated by a number of as yet undefined cellular mechanisms. Using human neutrophils loaded with the tritiated, nonmetabolizable PAF analog, 1-O-alkyl-2-N-methylcarbamyl-sn-glycero-3-phosphocholine (C-PAF), extracellular release was studied by techniques involving an albumin extraction method. Further modeling of plasma membrane events in the neutrophil was accomplished using movement across the membrane of erythrocyte ghosts. The data demonstrate that C-PAF release is dependent on cellular activation and is accompanied by alterations in the physical properties of the plasma membrane as measured by enhancement of merocyanine 540 (MC540) staining, as well as by bulk, nonspecific transbilayer movement of endogenous phospholipids as detected by the procoagulant activity of externalized phosphatidylserine (a phospholipid class usually sequestered in the plasma membrane inner leaflet). The finding that competitive inhibitors of transglutaminase significantly inhibited C-PAF release, enhancement of MC540 staining, and externalization of phosphatidylserine, strongly suggest a role for this enzyme in the enhancement of phospholipid transbilayer movement. Furthermore, the data suggest that recycling of C-PAF in the plasma membrane is likewise transglutaminase dependent and limits the net extracellular release of C-PAF which, like liberation of endogenously produced PAF, is dependent on extracellular ''acceptors'' and shown to be albumin concentration- and cell density-dependent.			BRATTON, DL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,1400 JACKSON ST,DENVER,CO 80206, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLAS SK, 1985, BIOCHIM BIOPHYS ACTA, V812, P234, DOI 10.1016/0005-2736(85)90543-7; BANKS JB, 1988, BIOCHIM BIOPHYS ACTA, V961, P48, DOI 10.1016/0005-2760(88)90129-4; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BETZ SJ, 1980, J IMMUNOL, V125, P2749; BETZ SJ, 1980, J IMMUNOL, V125, P2756; BEVERS EM, 1989, BIOCHEMISTRY-US, V28, P2382, DOI 10.1021/bi00432a007; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BITBOL M, 1988, P NATL ACAD SCI USA, V85, P6783, DOI 10.1073/pnas.85.18.6783; BRATTON DL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P24, DOI 10.1016/0005-2736(91)90330-B; BRATTON DL, 1988, BIOCHIM BIOPHYS ACTA, V941, P76, DOI 10.1016/0005-2736(88)90216-7; BRATTON DL, 1992, J IMMUNOL, V148, P514; BRATTON DL, 1992, IN PRESS HDB IMMUNOP; BUNGAY PJ, 1984, BIOCHEM J, V219, P819, DOI 10.1042/bj2190819; CHAM BE, 1976, J LIPID RES, V17, P176; CHIU D, 1981, BLOOD, V58, P398; CLAY KL, 1990, BIOCHIM BIOPHYS ACTA, V1046, P309, DOI 10.1016/0005-2760(90)90246-T; CLUZEL M, 1989, J IMMUNOL, V143, P3659; CLUZEL M, 1991, BIOCHEM J, V278, P453, DOI 10.1042/bj2780453; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; COMFURIUS P, 1985, BIOCHIM BIOPHYS ACTA, V815, P143, DOI 10.1016/0005-2736(85)90485-7; DALEKE DL, 1985, BIOCHEMISTRY-US, V24, P5406, DOI 10.1021/bi00341a019; DEVAUX PF, 1988, FEBS LETT, V234, P8, DOI 10.1016/0014-5793(88)81291-2; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; ELSTAD MR, 1988, J IMMUNOL, V140, P1618; FESUS L, 1984, MOL IMMUNOL, V21, P1161, DOI 10.1016/0161-5890(84)90005-1; FRANCK PFH, 1985, J CLIN INVEST, V75, P183, DOI 10.1172/JCI111672; GERRITSEN WJ, 1980, BIOCHIM BIOPHYS ACTA, V600, P607, DOI 10.1016/0005-2736(80)90464-2; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GUNZLER V, 1982, FEBS LETT, V150, P390, DOI 10.1016/0014-5793(82)80774-6; HAEST CWM, 1976, BIOCHIM BIOPHYS ACTA, V436, P353, DOI 10.1016/0005-2736(76)90199-1; HASLETT C, 1985, AM J PATHOL, V119, P101; HENRIKSSON P, 1985, J CLIN INVEST, V76, P528, DOI 10.1172/JCI112002; HENSELEIT U, 1990, BIOCHIM BIOPHYS ACTA, V1029, P127, DOI 10.1016/0005-2736(90)90445-T; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P2023, DOI 10.1021/bi00460a010; HOMAN R, 1988, BIOCHIM BIOPHYS ACTA, V938, P155, DOI 10.1016/0005-2736(88)90155-1; HOMMA H, 1987, J BIOL CHEM, V262, P10582; KARNOVSKY M, 1961, J BIOL CHEM, V236, P1895; KRAMP W, 1984, CHEM PHYS LIPIDS, V35, P49, DOI 10.1016/0009-3084(84)90032-X; LEYRAVAUD S, 1989, BIOCHIM BIOPHYS ACTA, V1005, P192, DOI 10.1016/0005-2760(89)90187-2; LINDHOUT T, 1982, BIOCHEMISTRY-US, V21, P5494, DOI 10.1021/bi00265a018; LORAND L, 1987, BIOCHEMISTRY-US, V26, P308, DOI 10.1021/bi00375a043; LORAND L, 1983, J BIOL CHEM, V258, P5300; LUDWIG CJ, 1986, ADV INFLAMMAT RES, V11, P111; LUDWIG JC, 1985, ARCH BIOCHEM BIOPHYS, V241, P337, DOI 10.1016/0003-9861(85)90555-7; LUMB RH, 1983, BIOCHIM BIOPHYS ACTA, V750, P217, DOI 10.1016/0005-2760(83)90021-8; LYNCH JM, 1986, J IMMUNOL, V137, P2653; Matsumoto M, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P705; MCEVOY L, 1988, J LEUKOCYTE BIOL, V44, P337, DOI 10.1002/jlb.44.5.337; MIDDELKOOP E, 1989, BIOCHIM BIOPHYS ACTA, V981, P151, DOI 10.1016/0005-2736(89)90093-X; MIDDELKOOP E, 1988, BIOCHIM BIOPHYS ACTA, V937, P281, DOI 10.1016/0005-2736(88)90250-7; MOHANDAS N, 1982, J BIOL CHEM, V257, P6537; MURTAUGH MP, 1984, J EXP MED, V159, P114, DOI 10.1084/jem.159.1.114; OFLAHERTY JT, 1986, J CLIN INVEST, V78, P381, DOI 10.1172/JCI112588; OFLAHERTY JT, 1987, BIOCHEM BIOPH RES CO, V147, P18, DOI 10.1016/S0006-291X(87)80081-5; OWEN RA, 1988, BIOCHIM BIOPHYS ACTA, V968, P220, DOI 10.1016/0167-4889(88)90011-0; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; PIACENTINI M, 1986, BIOCHEM J, V234, P435, DOI 10.1042/bj2340435; PUSZKIN EG, 1985, J BIOL CHEM, V260, P6012; RICHES DWH, 1990, J IMMUNOL, V145, P3062; SCHLEGEL RA, 1987, J CELL PHYSIOL, V132, P381, DOI 10.1002/jcp.1041320229; SCHNEIDER E, 1986, BIOCHIM BIOPHYS ACTA, V855, P325, DOI 10.1016/0005-2736(86)90078-7; SCHROFF G, 1981, EUR J IMMUNOL, V11, P637, DOI 10.1002/eji.1830110809; STEWART AG, 1991, IMMUNOLOGY, V72, P206; SUNE A, 1987, BIOCHEMISTRY-US, V26, P2972, DOI 10.1021/bi00385a003; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; TOKUMURA A, 1990, BIOCHIM BIOPHYS ACTA, V1044, P91, DOI 10.1016/0005-2760(90)90223-K; TOKUMURA A, 1987, THROMB RES, V47, P51; VALLARI DS, 1990, ARCH BIOCHEM BIOPHYS, V276, P538, DOI 10.1016/0003-9861(90)90756-O; VALONE FH, 1988, J IMMUNOL, V141, P3945; VERHALLEN PFJ, 1988, BIOCHIM BIOPHYS ACTA, V942, P150, DOI 10.1016/0005-2736(88)90284-2; VERHALLEN PFJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P206, DOI 10.1016/0005-2736(87)90170-2; WILLIAMSON P, 1983, BIOCHIM BIOPHYS ACTA, V732, P387, DOI 10.1016/0005-2736(83)90055-X; WILLIAMSON P, 1985, J CELL PHYSIOL, V123, P209, DOI 10.1002/jcp.1041230209; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210; ZACHOWSKI A, 1987, BIOCHIM BIOPHYS ACTA, V897, P197, DOI 10.1016/0005-2736(87)90328-2	75	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3364	3373						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679111				2022-12-25	WOS:A1993KM16100055
J	SHIMAMOTO, T; HSU, MY; INOUYE, S; INOUYE, M				SHIMAMOTO, T; HSU, MY; INOUYE, S; INOUYE, M			REVERSE TRANSCRIPTASES FROM BACTERIAL RETRONS REQUIRE SPECIFIC SECONDARY STRUCTURES AT THE 5'-END OF THE TEMPLATE FOR THE CDNA PRIMING REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; BRANCHED RNA; MYXOCOCCUS-XANTHUS; PHYLOGENETIC DISTRIBUTION; STIGMATELLA-AURANTIACA; 5' END; MSDNA; BIOSYNTHESIS; MUTAGENESIS	Multicopy single-stranded DNA (msDNA) is a peculiar molecule consisting of a single-stranded DNA that is branched out from an internal G residue of an RNA molecule (msdRNA) via a 2',5'-phosphodiester linkage. The genetic unit required for msDNA synthesis is designated ''retron'' and consists of msr (a gene for msdRNA), msd (a gene for msDNA), and a gene for reverse transcriptase (RT) in a single operon. To date, four different msDNAs have been isolated from Escherichia coli. They do not share any primary sequences in either RNA or DNA. To elucidate the specificity of bacterial RT for msDNA synthesis, the msr-msd region from retron-Ec67 was introduced into E. coli cells producing RT-Ec73, or the msr-msd region from retron-Ec73 into E. coli cells producing RT-Ec67. In both cases, msDNA was not synthesized. However, when the msdRNA coding regions (msr) for retron-Ec67 and -Ec73 were mutually exchanged and the chimeric genes were introduced into E. coli cells producing either RT-Ec67 or RT-Ec73, it was thus found that msDNA was produced only when msr and RT were from the same retron. Requirement of the msr region for msDNA synthesis by RT was further investigated by mutations in the msr region for retron-Ec67. These analyses revealed that there is a strict requirement for specific primary sequences as well as the secondary structure in msdRNA. This finding is discussed in relationship to the mechanism of the priming reaction of cDNA synthesis by eukaryotic retroviral RTs using tRNAs.			SHIMAMOTO, T (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.		Inouye, Sharon/R-7216-2019; Shimamoto, Tadashi/A-7109-2018	Shimamoto, Tadashi/0000-0002-5538-0595	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044012] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44012] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DHUNDALE A, 1988, J BIOL CHEM, V263, P9055; DHUNDALE A, 1987, CELL, V51, P1105, DOI 10.1016/0092-8674(87)90596-4; DHUNDALE AR, 1985, J BACTERIOL, V164, P914, DOI 10.1128/JB.164.2.914-917.1985; FURUICHI T, 1987, CELL, V48, P55, DOI 10.1016/0092-8674(87)90355-2; FURUICHI T, 1987, CELL, V48, P47, DOI 10.1016/0092-8674(87)90354-0; HERZER PJ, 1992, MOL MICROBIOL, V6, P345, DOI 10.1111/j.1365-2958.1992.tb01477.x; HERZER PJ, 1990, J BACTERIOL, V172, P6175, DOI 10.1128/jb.172.11.6175-6181.1990; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HSU MY, 1989, J BIOL CHEM, V264, P6214; HSU MY, 1992, J BIOL CHEM, V267, P13823; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P163; INOUYE M, 1992, J BACTERIOL, V174, P2419, DOI 10.1128/jb.174.8.2419-2424.1992; INOUYE M, 1992, REVERSE TRANSCRIPTAS; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; LAMPSON BC, 1990, J BIOL CHEM, V265, P8490; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; Maxam A M, 1980, Methods Enzymol, V65, P499; Miller J.H., 1972, EXPT MOL GENETICS; OHSHIMA A, 1992, P NATL ACAD SCI USA, V89, P1016, DOI 10.1073/pnas.89.3.1016; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUN J, 1991, J BACTERIOL, V173, P4171, DOI 10.1128/jb.173.13.4171-4181.1991; VARMUS H, 1985, RNA TUMOR VIRUSES, V2, P369; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; YEE T, 1984, CELL, V38, P203, DOI 10.1016/0092-8674(84)90541-5	31	39	39	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2684	2692						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679101				2022-12-25	WOS:A1993KK81500064
J	GEORGES, E; TSURUO, T; LING, V				GEORGES, E; TSURUO, T; LING, V			TOPOLOGY OF P-GLYCOPROTEIN AS DETERMINED BY EPITOPE MAPPING OF MRK-16 MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; BACTERIAL TRANSPORT PROTEINS; PEPTIDE-SYNTHESIS; 3-DIMENSIONAL STRUCTURE; CHINESE-HAMSTER; CDNA SEQUENCE; CELL-LINES; EXPRESSION; MEMBRANE; HOMOLOGY	There is growing evidence for the direct role of P-glycoprotein mediating multidrug resistance in tumor cells. P-glycoprotein is thought to function as an energy-dependent drug efflux pump. The monoclonal antibody MRK-16 binds to an external domain of P-glycoprotein and partially inhibits drug efflux in multidrug-resistant cells. As an approach toward elucidating the mechanism by which MRK-16 affects drug transport, we undertook the definition of the precise binding site of this antibody. In this study we have mapped the epitope of MRK-16 monoclonal antibody to a resolution of a single amino acid using a series of overlapping synthetic peptides. We demonstrate that MRK-16 recognizes only the class I isoform (MDR1) of human P-glycoprotein and that its epitope encompasses at least two (first and fourth) of the six predicted extracellular peptide loops. These results suggest that the epitope of MRK-16 is discontinuous and that the sequences involved which are separated by about 625 amino acids in the linear sequence must be spatially situated in close proximity in the native protein. Based on these results, we present a model for transmembrane alpha-helical packing of P-glycoprotein in the lipid bilayer. This may have implications for understanding the function of P-glycoprotein in drug transport.	PRINCESS MARGARET HOSP,ONTARIO CANC INST,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TOKYO,INST APPL MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Tokyo					NCI NIH HHS [CA37130] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037130] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BECK WT, 1981, P AM ASSOC CANC RES, V22, P204; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; BRADLEY G, 1990, J CELL PHYSIOL, V145, P398, DOI 10.1002/jcp.1041450303; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HAMADA H, 1987, ANAL BIOCHEM, V160, P483, DOI 10.1016/0003-2697(87)90080-7; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HAMADA H, 1988, J BIOL CHEM, V263, P1454; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; MITCHELL AR, 1978, J ORG CHEM, V43, P2845, DOI 10.1021/jo00408a022; MUKHOPADHYAY T, 1988, J NATL CANCER I, V80, P269, DOI 10.1093/jnci/80.4.269; NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; SANCHEZ JA, 1986, J GEN PHYSIOL, V87, P985, DOI 10.1085/jgp.87.6.985; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; Stewart JM, 1984, SOLID PHASE PEPTIDE; SUGAWARA I, 1988, CANCER RES, V48, P1926; SUGAWARA I, 1989, JPN J CANCER RES, V80, P1199, DOI 10.1111/j.1349-7006.1989.tb01655.x; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; 1969, BIOCHEM J, V113, P1	37	132	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1792	1798						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678410				2022-12-25	WOS:A1993KH62000046
J	MUGA, A; GONZALEZMANAS, JM; LAKEY, JH; PATTUS, F; SUREWICZ, WK				MUGA, A; GONZALEZMANAS, JM; LAKEY, JH; PATTUS, F; SUREWICZ, WK			PH-DEPENDENT STABILITY AND MEMBRANE INTERACTION OF THE PORE-FORMING DOMAIN OF COLICIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; MITOCHONDRIAL PRECURSOR PROTEIN; C-TERMINAL DOMAIN; PHOSPHOLIPID-VESICLES; PSEUDOMONAS EXOTOXIN; INSERTION; TOXIN; TRANSLOCATION; BINDING; DENATURATION	Thermal stability of the pore-forming domain of colicin A was studied by high sensitivity differential scanning calorimetry and circular dichroism spectroscopy. In the pH range between 8 and 5, the thermal denaturation of the protein in solution occurs at 66-69-degrees-C and is characterized by the calorimetric enthalpy of approximately 90 kcal/M. At pH below 5, there is a rapid pH-dependent destabilization of the pore-forming domain resulting in the lowering of the midpoint denaturation temperature and a decrease in the calorimetric enthalpy of denaturation. Circular dichroism spectra in the near and far ultraviolet show that the thermotropic transition is associated with collapse of the native tertiary structure of the pore-forming domain, although a large proportion of the helical secondary structure remains preserved. The present data indicate some similarity also between acid-induced and temperature-induced denaturation of the pore-forming domain of colicin A. Association of the pore-forming domain with phospholipid vesicles of dioleoylphosphatidylglycerol results in total disappearance of the calorimetric transition, even at pH values as high as 7. Since lipid binding also induces collapse of the near ultraviolet circular dichroism spectrum, these data indicate that interaction with the membrane facilitates a conformational change within the pore-forming domain to a looser (denaturated-like) state. These findings are discussed in relation to the recent model (van der Goot, F. G., Gonzalez-Manas, J. M., Lakey, J. H., Pattus, F. (1991) Nature 354, 408-410) which postulates that a flexible ''molten globule'' state is an intermediate on the pathway to membrane insertion of colicin A.	NATL RES COUNCIL CANADA,INST BIOL SCI,OTTAWA K1A 0R6,ONTARIO,CANADA; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	National Research Council Canada; European Molecular Biology Laboratory (EMBL)			Muga, Arturo/N-1174-2014	Muga, Arturo/0000-0003-0345-6882; Lakey, Jeremy/0000-0003-4646-9085				CAVARD D, 1979, EUR J BIOCHEM, V96, P519, DOI 10.1111/j.1432-1033.1979.tb13065.x; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; ENDO T, 1989, FEBS LETT, V249, P173, DOI 10.1016/0014-5793(89)80618-0; ENDO T, 1989, J BIOL CHEM, V264, P2951; FARAHBAKHSH ZT, 1989, BIOCHEMISTRY-US, V28, P580, DOI 10.1021/bi00428a025; GONZALEZMANAS JM, 1992, BIOCHEMISTRY-US, V31, P7294, DOI 10.1021/bi00147a013; JIANG JX, 1990, J BIOL CHEM, V265, P8636; KONISKY J, 1982, ANNU REV MICROBIOL, V36, P125, DOI 10.1146/annurev.mi.36.100182.001013; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; LAZDUNSKI CJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P445, DOI 10.1016/0304-4157(88)90003-2; LOHNER K, 1991, BIOCHEMISTRY-US, V30, P6620, DOI 10.1021/bi00240a035; MARTINEZ MC, 1983, EMBO J, V2, P1501, DOI 10.1002/j.1460-2075.1983.tb01614.x; MASSOTTE D, 1989, BIOCHEMISTRY-US, V28, P7713, DOI 10.1021/bi00445a029; MENESTRINA G, 1989, BIOPHYS J, V55, P393, DOI 10.1016/S0006-3495(89)82833-4; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P5829, DOI 10.1021/bi00476a026; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; PAIN R, 1991, NATURE, V354, P353, DOI 10.1038/354353a0; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; PATTUS F, 1990, EXPERIENTIA, V46, P180; PATTUS F, 1983, BIOCHEMISTRY-US, V22, P5698, DOI 10.1021/bi00294a003; RAMSAY G, 1989, BIOCHEMISTRY-US, V28, P529, DOI 10.1021/bi00428a018; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; TUCKER AD, 1986, J MOL BIOL, V190, P133, DOI 10.1016/0022-2836(86)90084-7; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; ZHAO JM, 1988, J BIOL CHEM, V263, P15369	28	68	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1553	1557						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678407				2022-12-25	WOS:A1993KH62000011
J	ZHU, GC; DECKER, SJ; MAYER, BJ; SALTIEL, AR				ZHU, GC; DECKER, SJ; MAYER, BJ; SALTIEL, AR			DIRECT ANALYSIS OF THE BINDING OF THE ABL SRC HOMOLOGY-2 DOMAIN TO THE ACTIVATED EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC SIGNALING PROTEINS; TYROSINE KINASES; PHOSPHOLIPASE-C; PHILADELPHIA-CHROMOSOME; STRUCTURAL SIMILARITY; ONCOGENIC ACTIVATION; SEQUENCE SIMILARITY; NUCLEOTIDE-SEQUENCE; REGULATORY DOMAIN; SH2 DOMAINS	Src homology regions 2 (SH2) and 3 (SH3) are noncatalytic domains that are conserved among several proteins implicated in the regulation of cell proliferation. Using bacterially expressed fusion proteins containing the SH2 domain of the abl tyrosine kinase, we have quantitated the binding of these domains to the activated epidermal growth factor (EGF) receptor (EGFR). A S-35-labeled abl SH2 fusion protein binds to the human EGFR immunoprecipitated from EGF-treated NIH3T3 cells that overexpress the receptor. This binding is totally dependent on the pretreatment of cells with EGF. The interaction is rapid, reaching 50% of maximum within 1 min, and attaining apparent equilibrium by 10 min. Dissociation of the complex is biphasic with a rapidly dissociating component (t1/2 of less than 1 min), as well as a slowly dissociable component. The S-35-labeled abl SH2 fusion protein specifically binds to the EGFR in a saturable manner and is differentially inhibited by unlabeled fusion proteins containing SH2 domains from phospholipase C, the p85 subunit of phosphatidylinositol-3 kinase, and the GTPase activation protein of ras. To identify residues critical for abl SH2-EGFR binding, six point mutants were constructed in the highly conserved FLVRES motif. Three mutants (V170L, E172Q, and E174Q) display binding affinities similar to that of wild type. However, three other mutants (R171K, S173C, and S175C) have greatly reduced affinity. Interestingly, the binding affinity to the EGFR determined by the in vitro assay directly correlates with the transforming ability of the corresponding v-abl constructs in vivo (Mayer, B. J., Jackson, P. K., Etten, R. A. V., and Baltimore, D. (1992) Mol. Cell. Biol. 12, 609-618). These data indicate that the Arg-171, Ser-173, and Ser-175 are critical for both transformation and abl SH2 domain binding to phosphotyrosine-containing proteins.	UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; WARNER LAMBER CO, PARKE DAVIS PHARMACEUT RES DIV, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; UNIV MICHIGAN, SCH MED, DEPT MICROBIOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; Pfizer; Rockefeller University; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NCI NIH HHS [CA08875, CA37754] Funding Source: Medline; NIDDK NIH HHS [DK33804] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008875, R01CA037754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033804, R23DK033804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GUAN K, 1991, J BIOL CHEM, V266, P12964; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JOHNSON KA, 1990, J VIROL, V64, P3337, DOI 10.1128/JVI.64.7.3337-3349.1990; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATUDA M, 1990, SCIENCE, V248, P1537; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHU GC, 1991, BIOCHEM BIOPH RES CO, V177, P771, DOI 10.1016/0006-291X(91)91855-7; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559	45	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1775	1779						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678409				2022-12-25	WOS:A1993KH62000043
J	HUFF, CA; YUSPA, SH; ROSENTHAL, D				HUFF, CA; YUSPA, SH; ROSENTHAL, D			IDENTIFICATION OF CONTROL ELEMENTS 3' TO THE HUMAN KERATIN-1 GENE THAT REGULATE CELL TYPE AND DIFFERENTIATION-SPECIFIC EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE EPIDERMAL-CELLS; BETA-GLOBIN GENE; TISSUE-SPECIFIC EXPRESSION; HUMAN TYPE-I; TERMINAL DIFFERENTIATION; TRANSCRIPTIONAL ENHANCER; CYTOKERATIN GENES; SILENCER ELEMENTS; TRANSGENIC MICE; C-FOS	To define DNA regulatory elements that mediate the response of the keratin 1 (K1) gene to Ca2+-induced differentiation, regions spanning the 5'- and 3'-flanking sequences, coding regions, and introns from the human K1 gene were cloned into vectors containing the chloramphenicol acetyltransferase (CAT) reporter gene and transfected into cultured mouse keratinocytes. A 4.3-kilobase (kb) region located 3' to the K1 gene stimulated CAT activity in response to increasing Ca2+ concentrations from 0.05 mM (basal cells) to 1.2 mm (differentiated cells). The 4.3-kb fragment was also active in human epidermal cells but inactive in NIH 3T3 cells and primary mouse fibroblasts. Deletion analysis localized the activity to the terminal 1682 base pairs (bp) of the flanking sequence which retained Ca2+ sensitivity in epidermal cells but was not active in mesenchymal cells. Removal of a 207-base pair element created an enhancer which was active in both epidermal and mesenchumal cells but was still Ca2+-inducible. Further deletions identified two elements which functioned synergistically to give maximal Ca2+-sensitive activity. Stably transfected epidermal cell lines expressed CAT under the direction of these elements when grafted onto nude mice to reconstitute an intact epidermis. Previously reported keratin regulatory motifs were not contained in the 1682-bp fragment, but an AP-1 site was identified in one of the synergistic subunits.	NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Rosenthal, Dean/0000-0002-7624-0209				ATWEH GF, 1988, MOL CELL BIOL, V8, P5047, DOI 10.1128/MCB.8.11.5047; AYER S, 1990, MOL CELL BIOL, V10, P3512, DOI 10.1128/MCB.10.7.3512; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BERG PE, 1989, NUCLEIC ACIDS RES, V17, P8833, DOI 10.1093/nar/17.21.8833; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BODINE DM, 1987, EMBO J, V6, P2997, DOI 10.1002/j.1460-2075.1987.tb02605.x; BOWDEN PE, 1984, EUR J BIOCHEM, V142, P29, DOI 10.1111/j.1432-1033.1984.tb08246.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNIO R, 1991, NUCLEIC ACIDS RES, V19, P2303, DOI 10.1093/nar/19.9.2303; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CHIN MT, 1989, J VIROL, V63, P2967, DOI 10.1128/JVI.63.7.2967-2976.1989; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CHOI Y, 1990, CELL REGUL, V1, P791, DOI 10.1091/mbc.1.11.791; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; DAY RN, 1990, MOL ENDOCRINOL, V4, P736, DOI 10.1210/mend-4-5-736; EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1979, CELL, V17, P573, DOI 10.1016/0092-8674(79)90265-4; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HARPER JR, 1988, J INVEST DERMATOL, V91, P150, DOI 10.1111/1523-1747.ep12464396; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1983, J CELL PHYSIOL, V116, P265, DOI 10.1002/jcp.1041160303; HIROCHIKA H, 1988, GENE DEV, V2, P54, DOI 10.1101/gad.2.1.54; HUG H, 1988, MOL CELL BIOL, V8, P3065, DOI 10.1128/MCB.8.8.3065; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; JACKSON AE, 1988, MOL ENDOCRINOL, V2, P1139, DOI 10.1210/mend-2-11-1139; JIANG CK, 1991, J INVEST DERMATOL, V96, P162, DOI 10.1111/1523-1747.ep12460939; JIANG CK, 1990, NUCLEIC ACIDS RES, V18, P247, DOI 10.1093/nar/18.2.247; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; JONAS EA, 1989, DEVELOPMENT, V106, P399; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KOLLIAS G, 1987, NUCLEIC ACIDS RES, V15, P5739, DOI 10.1093/nar/15.14.5739; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; Maniatis T., 1982, MOL CLONING; MARCHUK D, 1985, P NATL ACAD SCI USA, V82, P1609, DOI 10.1073/pnas.82.6.1609; MCNAB AR, 1990, P NATL ACAD SCI USA, V87, P6848, DOI 10.1073/pnas.87.17.6848; MERCOLA M, 1983, SCIENCE, V221, P663, DOI 10.1126/science.6306772; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PATARCA R, 1989, GENE, V85, P461, DOI 10.1016/0378-1119(89)90440-X; POIRIER MC, 1979, CANCER RES, V39, P1377; POPESCU NC, 1989, HUM GENET, V82, P109, DOI 10.1007/BF00284039; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; ROMANO V, 1988, CYTOGENET CELL GENET, V48, P148, DOI 10.1159/000132612; ROOP DR, 1988, CANCER RES, V48, P3245; ROOP DR, 1989, PHARM RETINOIDS SKIN, P1; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SNAPE AM, 1990, DEVELOPMENT, V109, P157; STEINERT PM, 1988, J BIOL CHEM, V263, P13333; TAKEMOTO Y, 1991, NUCLEIC ACIDS RES, V19, P2761, DOI 10.1093/nar/19.10.2761; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; YAMAGUCHI M, 1989, J CELL PHYSIOL, V141, P431, DOI 10.1002/jcp.1041410225; YAMAGUCHI M, 1989, J BIOL CHEM, V264, P16887; YUSPA SH, 1981, J INVEST DERMATOL, V76, P144, DOI 10.1111/1523-1747.ep12525490; YUSPA SH, 1980, TRANSPLANT P, V12, P114; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	73	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					377	384						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7677999				2022-12-25	WOS:A1993KE60300058
J	JOHNSON, TM; ROSENBERG, MP; MEISLER, MH				JOHNSON, TM; ROSENBERG, MP; MEISLER, MH			AN INSULIN-RESPONSIVE ELEMENT IN THE PANCREATIC ENHANCER OF THE AMYLASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; TRANSGENIC MICE; MESSENGER-RNA; NUCLEAR-PROTEIN; DIABETIC MICE; RAT PANCREAS; ACINAR-CELLS; DNA; BINDING; TRANSCRIPTION	We have identified a distinct insulin-responsive element (IRE) located within the pancreatic enhancer of the mouse amylase gene Amy-2.2. A 30-base pair (bp) fragment was previously shown to be sufficient to transfer insulin response to a heterologous promoter. The 30-bp fragment overlaps the tissue-specific pancreatic enhancer that binds the putative transcriptional activator PTF1. To determine whether enhancer and IRE activities could be separated, we introduced three 10-base pair substitutions into the 30-bp region. The mutated regulatory regions were cloned upstream of a heterologous promoter and transferred to transgenic mice. Mutants 1 and 2 retained PTF1 binding activity and insulin response. Mutant 3 retained PTF1 binding, but was defective in insulin response. The results indicate that the IRE is functionally distinct from the PTF1-binding site, although the two overlap physically. In contrast to the wild-type gene, mutant 3 is characterized by constitutive expression in diabetic animals, suggesting that a binding site for a repressor has been destroyed. A nuclear protein with affinity for the IRE was detected in normal and diabetic pancreas. This protein does not bind mutant 3, suggesting that it may be involved in negative regulation of amylase in diabetic pancreas.	UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; GLAXO RES INC,RES TRIANGLE PK,NC 27709	University of Michigan System; University of Michigan; GlaxoSmithKline					NIDDK NIH HHS [DK 36089] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036089] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENABDEL.A, 1965, BIOCHEM BIOPH RES CO, V18, P71, DOI 10.1016/0006-291X(65)90884-3; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLOOR JH, 1981, J BIOL CHEM, V256, P373; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; DRANGINIS A, 1984, J BIOL CHEM, V259, P2216; GIORGI D, 1984, EMBO J, V3, P1521, DOI 10.1002/j.1460-2075.1984.tb02005.x; GUMUCIO DL, 1985, J BIOL CHEM, V260, P3483; HJORTH JP, 1979, BIOCHEM GENET, V17, P665, DOI 10.1007/BF00502125; HOWARD G, 1989, NUCLEIC ACIDS RES, V17, P8185, DOI 10.1093/nar/17.20.8185; JOHNSON TM, 1990, DIABETES, V39, P757, DOI 10.2337/diabetes.39.6.757; KELLER SA, 1990, GENE DEV, V4, P1316, DOI 10.1101/gad.4.8.1316; KORC M, 1981, SCIENCE, V213, P351, DOI 10.1126/science.6166044; KRUSE F, 1988, MOL CELL BIOL, V8, P893, DOI 10.1128/MCB.8.2.893; MEISLER MH, 1989, ANNU REV PHYSIOL, V51, P701, DOI 10.1146/annurev.physiol.51.1.701; MEISTER A, 1989, J BIOL CHEM, V264, P20744; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; ORNITZ DM, 1985, NATURE, V313, P600, DOI 10.1038/313600a0; OSBORN L, 1988, J BIOL CHEM, V263, P16519; OSBORN L, 1987, MOL CELL BIOL, V7, P326, DOI 10.1128/MCB.7.1.326; PALLA JC, 1968, BIOCHIM BIOPHYS ACTA, V158, P25, DOI 10.1016/0304-4165(68)90068-8; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIBLER U, 1980, J MOL BIOL, V142, P93, DOI 10.1016/0022-2836(80)90208-9; SCHMID RM, 1992, AM J PHYSIOL, V262, pG971, DOI 10.1152/ajpgi.1992.262.6.G971; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SOLING HD, 1972, EUR J CLIN INVEST, V2, P199, DOI 10.1111/j.1365-2362.1972.tb00645.x; SOMMER L, 1991, CELL, V67, P987, DOI 10.1016/0092-8674(91)90371-5; SWIFT GH, 1989, GENE DEV, V3, P687, DOI 10.1101/gad.3.5.687; SWIFT GH, 1984, CELL, V38, P639, DOI 10.1016/0092-8674(84)90258-7; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679	36	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					464	468						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678001				2022-12-25	WOS:A1993KE60300071
J	PRESTON, GM; JUNG, JS; GUGGINO, WB; AGRE, P				PRESTON, GM; JUNG, JS; GUGGINO, WB; AGRE, P			THE MERCURY-SENSITIVE RESIDUE AT CYSTEINE-189 IN THE CHIP28 WATER CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTEGRAL MEMBRANE-PROTEIN; XENOPUS-OOCYTES; TRANSPORT; PURIFICATION; FAMILY	Water channels provide the plasma membranes of red cells and renal proximal tubules with high permeability to water, thereby permitting water to move in the direction of an osmotic gradient. Molecular identification of CHIP28 protein as the membrane water channel was first accomplished by measurement of osmotic swelling of Xenopus oocytes injected with CHIP28 RNA (Preston, G. M., Carroll, T. P., Guggino, W. B., and Agre, P. (1992) Science 256, 385-387). Since water channels are pharmacologically inhibited by submillimolar concentrations of Hg2+, site-directed mutagenesis was undertaken to demonstrate which of the 4 cysteines (87, 102, 152, or 189) is the Hg2+-sensitive residue in the CHIP28 molecule. Each cysteine was individually replaced by serine, and oocytes expressing each of the four mutants exhibited osmotic water permeability (P(f)) equivalent to wild-type CHIP28. After incubation in HgCl2, all were significantly inhibited, except C189S which was not inhibited even at 3 mM HgCl2. CHIP28 exists as a multisubunit complex in the native membrane; however, although oocytes injected with mixed CHIP28 and C189S RNAs exhibited P(f) corresponding to the sum of their individual activities, exposure to Hg2+ only reduced the P(f) to the level of the C189S mutant. Of the six substitutions at residue 189, only the serine and alanine mutants exhibited increased P(f) and had glycosylation patterns resembling wild-type CHIP28 on immunoblots. These studies demonstrated: (i) CHIP28 water channel activity is retained despite substitution of individual cysteines with serine; (ii) cysteine 189 is the Hg2+-sensitive residue; (iii) the subunits of the CHIP28 complex are individually active water pores; (iv) residue 189 is critical to proper processing of the CHIP28 protein.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, HUNTERIAN 103, 725 N WOLFE ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL ANAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NHLBI NIH HHS [HL48268, HL33991] Funding Source: Medline; NIDDK NIH HHS [DK32753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL048268, R01HL033991, R01HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032753, R01DK032753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, IN PRESS A BENZON S, V34; DAVIS JQ, 1984, J BIOL CHEM, V259, P1874; DENKER BM, 1988, J BIOL CHEM, V263, P15634; Finkelstein A., 1987, WATER MOVEMENT LIPID; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU L, 1990, BIOPHYS J, V57, P1117, DOI 10.1016/S0006-3495(90)82632-1; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SMITH BL, 1991, J BIOL CHEM, V266, P6407; SOLOMON AK, 1983, ANN NY ACAD SCI, V414, P97, DOI 10.1111/j.1749-6632.1983.tb31678.x; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG R, 1990, J BIOL CHEM, V265, P15375	23	431	453	4	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					17	20						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7677994				2022-12-25	WOS:A1993KE60300005
J	HAMALAINEN, ER; KEMPPAINEN, R; KUIVANIEMI, H; TROMP, G; VAHERI, A; PIHLAJANIEMI, T; KIVIRIKKO, KI				HAMALAINEN, ER; KEMPPAINEN, R; KUIVANIEMI, H; TROMP, G; VAHERI, A; PIHLAJANIEMI, T; KIVIRIKKO, KI			QUANTITATIVE POLYMERASE CHAIN-REACTION OF LYSYL OXIDASE MESSENGER-RNA IN MALIGNANTLY TRANSFORMED HUMAN CELL-LINES DEMONSTRATES THAT THEIR LOW LYSYL OXIDASE ACTIVITY IS DUE TO LOW QUANTITIES OF ITS MESSENGER-RNA AND LOW-LEVELS OF TRANSCRIPTION OF THE RESPECTIVE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MESSENGER-RNA; MOUSE CHROMOSOME-18; III PROCOLLAGEN; CDNA; MAPS; ASSIGNMENT; EXPRESSION; CLONING; CODON	Lysyl oxidase (EC 1.4.3.13), an extracellular copper amino oxidase, initiates the cross-linking of collagens and elastin by catalyzing oxidative deamination of the epsilon-amino group in certain lysine and hydroxylysine residues. We developed here a polymerase chain reaction (PCR) method for the quantification of lysyl oxidase mRNA in which a synthetic RNA is used as an internal standard for coamplification with the targeted mRNA. The amount of lysyl oxidase mRNA when studied by Northern blot analysis and the number of lysyl oxidase mRNA molecules when determined by the quantitative PCR method were found to be markedly low in various malignantly transformed cell lines relative to control cell fines, quantitative PCR indicating values of about 2-10% of those in the controls. No difference was found in the number of beta-actin mRNA molecules between the transformed cells and the controls. Nuclear runoff experiments indicated that most if not all of the decrease in the number of lysyl oxidase mRNA molecules can be explained by diminished transcription of the respective gene.	UNIV OULU,DEPT MED BIOCHEM,SF-90220 OULU,FINLAND; UNIV OULU,BIOCTR,COLLAGEN RES UNIT,SF-90220 OULU,FINLAND; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; HELSINKI UNIV,DEPT VIROL,SF-00018 HELSINKI,FINLAND	University of Oulu; University of Oulu; Jefferson University; University of Helsinki			Vaheri, Antti/AAV-1523-2020; Kemppainen, Robert/X-9105-2019; Kuivaniemi, Helena/Q-8178-2019; Tromp, Gerard/B-2677-2017	Kuivaniemi, Helena/0000-0001-5753-8766; Tromp, Gerard/0000-0002-7761-0806; Pihlajaniemi, Taina/0000-0002-1664-9045				ALAKOKKO L, 1989, BIOCHEM J, V260, P509, DOI 10.1042/bj2600509; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; CHANG YS, 1993, CYTOGENET CELL GENET, V63, P47, DOI 10.1159/000133500; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CZSISAR K, 1993, GENOMICS, V16, P401; DANKS DM, 1992, CONNECTIVE TISSUE IT, P487; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAMALAINEN ER, 1993, GENOMICS, V17, P544, DOI 10.1006/geno.1993.1369; HAMALAINEN ER, 1991, GENOMICS, V11, P508, DOI 10.1016/0888-7543(91)90057-L; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KAGAN HM, 1982, METHOD ENZYMOL, V82, P637; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1993, J BIOL CHEM, V268, P18435; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KIVIRIKKO KI, 1987, CONNECTIVE TISSUE DI, P263; KUIVANIEMI H, 1986, FEBS LETT, V195, P261, DOI 10.1016/0014-5793(86)80172-7; LOSSIE AC, 1993, MAMM GENOME, V4, P177, DOI 10.1007/BF00352234; MARIANI TJ, 1992, MATRIX, V12, P242, DOI 10.1016/S0934-8832(11)80067-3; MOCK BA, 1992, GENOMICS, V14, P822, DOI 10.1016/S0888-7543(05)80201-0; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Sambrook J, 1989, MOL CLONING LABORATO; TRACKMAN PC, 1991, BIOCHEMISTRY-US, V30, P8282, DOI 10.1021/bi00247a025; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TROMP G, 1989, J BIOL CHEM, V264, P19313; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WU Y, 1992, J BIOL CHEM, V267, P24199	28	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21590	21593		10.1074/jbc.270.37.21590	http://dx.doi.org/10.1074/jbc.270.37.21590			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665572	hybrid			2022-12-25	WOS:A1995RU75700027
J	ZHOU, A; PAQUET, L; MAINS, RE				ZHOU, A; PAQUET, L; MAINS, RE			STRUCTURAL ELEMENTS THAT DIRECT SPECIFIC PROCESSING OF DIFFERENT MAMMALIAN SUBTILISIN-LIKE PROHORMONE CONVERTASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATT-20 CELLS; PRO-REGION; SACCHAROMYCES-CEREVISIAE; SITE; KEX2; PC1; PROOPIOMELANOCORTIN; IDENTIFICATION; ENDOPROTEASE; MUTAGENESIS	PC1 and PC2 are two important subtilisin-like prohormone convertases (PC) that undergo differential endoproteolytic processing steps and sequentially mediate proopiomelanocortin (POMC) processing, To investigate the structural elements directing the processing of different PCs, we constructed a series of mutant and chimeric PC proteins and expressed them in cell lines with different patterns of expression of endogenous PCs: AtT-20, hEK293, and hLoVo cells. The COOH-terminally truncated PC1 underwent efficient proregion cleavage and rapid secretion in all three cell lines, while proregion cleavage and secretion were completely blocked in an active-site mutant of PC1. The truncated PC1 produced dramatic changes in POMC processing in AtT-20 cells. PC2 with the potential oxyanion hole Asp residue changed to Asn was processed and altered several aspects of POMC processing in a manner similar to that of wild-type PC2. PC1 protein with its proregion substituted with that of furin was cleaved after its proregion, producing active PC1 enzyme. A similar furin/PC2 fusion protein underwent proregion cleavage at low efficiency, By contrast, when the proregions of PC1 and PC2 were substituted with one another, both fusion proteins failed to cleave the foreign prosequences, were unable to undergo oligosaccharide maturation, and remained in the ER. Although inactive PC mutants could theoretically function as dominant negatives, none interfered with the processing of endogenous active PCs or with POMC processing. We conclude that the COOH-terminal of PC1 plays an important role in the routing or storage of PC1, the proregions of these PC proteins are replaceable in a molecule-specific manner, removal of proregion is essential for routing and for endoproteolytic activity, and the role of the potential oxyanion hole in PC2 is still unclear.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University				Zhou, An/0000-0002-9358-8012	NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00266] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BLOOMQUIST BT, 1993, CELL PHYSIOL BIOCHEM, V3, P197, DOI 10.1159/000154684; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; BRENNER C, 1993, CURR BIOL, V3, P498, DOI 10.1016/0960-9822(93)90040-U; BRYAN P, 1986, P NATL ACAD SCI USA, V83, P3743, DOI 10.1073/pnas.83.11.3743; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; EGNELL P, 1992, MOL MICROBIOL, V6, P1115, DOI 10.1111/j.1365-2958.1992.tb01549.x; GERMAIN D, 1992, FEBS LETT, V299, P283, DOI 10.1016/0014-5793(92)80132-Z; GERMAIN D, 1992, EUR J BIOCHEM, V204, P121, DOI 10.1111/j.1432-1033.1992.tb16613.x; GOODMAN LJ, 1994, BIOCHEM BIOPH RES CO, V201, P795, DOI 10.1006/bbrc.1994.1771; HORIMOTO T, 1994, J VIROL, V68, P6074, DOI 10.1128/JVI.68.9.6074-6078.1994; HORNBY PJ, 1993, NEUROENDOCRINOLOGY, V58, P555, DOI 10.1159/000126590; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LI YY, 1994, J BIOL CHEM, V269, P4169; LINDBERG I, 1991, MOL ENDOCRINOL, V5, P1361, DOI 10.1210/mend-5-10-1361; MAINS RE, 1990, TRENDS ENDOCRIN MET, V1, P388, DOI 10.1016/1043-2760(90)90097-M; MAINS RE, 1995, MOL ENDOCRINOL, V9, P3, DOI 10.1210/me.9.1.3; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILGRAM SL, 1994, J CELL SCI, V107, P737; MITCHELL WM, 1971, NATURE-NEW BIOL, V231, P99, DOI 10.1038/newbio231099a0; NOEL G, 1991, MOL ENDOCRINOL, V5, P404, DOI 10.1210/mend-5-3-404; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; RHODES CJ, 1993, J BIOL CHEM, V268, P4267; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; STEINER D F, 1991, Current Biology, V1, P375, DOI 10.1016/0960-9822(91)90198-6; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; VINDROLA O, 1993, NEUROPEPTIDES, V25, P151, DOI 10.1016/0143-4179(93)90096-S; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHOU Y, 1994, J BIOL CHEM, V269, P18408; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	52	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21509	21516		10.1074/jbc.270.37.21509	http://dx.doi.org/10.1074/jbc.270.37.21509			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665562	hybrid			2022-12-25	WOS:A1995RU75700017
J	BLAHOS, J; WHALIN, ME; KRUEGER, KE				BLAHOS, J; WHALIN, ME; KRUEGER, KE			IDENTIFICATION AND PURIFICATION OF A 10-KILODALTON PROTEIN ASSOCIATED WITH MITOCHONDRIAL BENZODIAZEPINE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIAZEPAM-BINDING INHIBITOR; STEROID-BIOSYNTHESIS; MOLECULAR-CLONING; DBI RECEPTOR; STEROIDOGENESIS; SITES; CHOLESTEROL; LIGANDS; CELLS; LOCALIZATION	The isoquinoline carboxamide photoaffinity probe PK14105, a ligand with selectivity for mitochondrial benzodiazepine receptors, has been established to photolabel an 18-kDa protein. When this radioactive probe is used to photolabel rat mitochondrial preparations, a protein of 10 kDa, in addition to the 18-kDa protein, is identified following electrophoretic separation and extended autoradiography. These proteins are referred to herein as pk10 and pk18, respectively. Both proteins exhibited the same specificity to a series of ligands used in competition photolabeling studies and are mutually present at apparently similar ratios across multiple tissues. Subcellular fractionation of rat adrenals indicated that pk10 and pk18 comigrated with the mitochondrial marker enzyme cytochrome c oxidase. In numerous paradigms examining specificity, photolabeling of pk18 invariably coincided with photolabeling of pk10. In detergent-solubilized extracts of rat adrenal mitochondria, pk18 and pk10 coimmunoprecipitated when using antisera raised against pk18. Furthermore, purification of the photolabeled proteins using nondenaturing conditions demonstrated that pk18 and pk10 copurify substantiating their intimate association. A set of three antisera, specific to different regions of pk18, did not recognize pk10 on Western blots. Likewise, partial amino acid sequence of peptide fragments indicate that pk10 is not derived from proteolytic cleavage of pk18. These data suggest that pk10 represents another component of mitochondrial benzodiazepine receptors whose identity is not apparent with any known protein.	GEORGETOWN UNIV,SCH MED,DEPT CELL BIOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,SCH MED,FIDIA GEORGETOWN INST NEUROSCI,WASHINGTON,DC 20007	Georgetown University; Georgetown University			Blahos, Jaroslav/G-4397-2014; Blahos, Jaroslav/G-8325-2017	Blahos, Jaroslav/0000-0003-3355-1469; Blahos, Jaroslav/0000-0001-9803-0061	NIMH NIH HHS [MH44284] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH044284] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; ANTKIEWICZMICHA.L, 1988, J BIOL CHEM, V263, P17317; ANTKIEWICZMICHA.L, 1988, MOL PHARMACOL, V34, P272; BARNEA ER, 1989, MOL CELL ENDOCRINOL, V64, P155, DOI 10.1016/0303-7207(89)90141-X; BESMAN MJ, 1989, P NATL ACAD SCI USA, V86, P4897, DOI 10.1073/pnas.86.13.4897; BOUJRAD N, 1993, P NATL ACAD SCI USA, V90, P5728, DOI 10.1073/pnas.90.12.5728; Bourguignon J.J., 1993, PERIPHERAL BENZODIAZ, P59; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAVALLARO S, 1992, P NATL ACAD SCI USA, V89, P10598, DOI 10.1073/pnas.89.22.10598; COX DA, 1991, J PHARMACOL EXP THER, V258, P702; DEBROEUCQ MC, 1986, EUR J PHARMACOL, V128, P269; DOBLE A, 1987, MOL PHARMACOL, V31, P42; GARNIER M, 1994, J BIOL CHEM, V269, P22105; GARNIER M, 1994, MOL PHARMACOL, V45, P201; HIRSCH JD, 1989, MOL PHARMACOL, V35, P157; HIRSCH JD, 1989, MOL PHARMACOL, V35, P164; KRUEGER KE, 1990, J BIOL CHEM, V265, P15015; KRUEGER KE, 1992, ANNU REV PHARMACOL, V32, P211, DOI 10.1146/annurev.pa.32.040192.001235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER SZ, 1988, PHARMACOL BIOCHEM BE, V29, P763, DOI 10.1016/0091-3057(88)90202-X; LEFUR G, 1983, LIFE SCI, V33, P449, DOI 10.1016/0024-3205(83)90794-4; LEFUR G, 1983, LIFE SCI, V32, P1839, DOI 10.1016/0024-3205(83)90062-0; MCCABE RT, 1989, FEBS LETT, V244, P263, DOI 10.1016/0014-5793(89)80541-1; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUKHIN AG, 1989, P NATL ACAD SCI USA, V86, P9813, DOI 10.1073/pnas.86.24.9813; MUKHIN AG, 1990, BIOCHEM PHARMACOL, V40, P983, DOI 10.1016/0006-2952(90)90483-2; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; PAROLA AL, 1989, J PHARMACOL EXP THER, V250, P1149; PAROLA AL, 1991, J BIOL CHEM, V266, P14082; RIOND J, 1991, EUR J PHARM-MOLEC PH, V208, P307, DOI 10.1016/0922-4106(91)90076-T; RIOND J, 1991, EUR J BIOCHEM, V195, P305, DOI 10.1111/j.1432-1033.1991.tb15707.x; RIOND J, 1989, FEBS LETT, V245, P238, DOI 10.1016/0014-5793(89)80229-7; ROMEO E, 1992, J PHARMACOL EXP THER, V262, P971; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; VERMA A, 1989, ANNU REV PHARMACOL, V29, P307; YANAGIBASHI K, 1989, J BIOCHEM, V106, P1026, DOI 10.1093/oxfordjournals.jbchem.a122958	38	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20285	20291		10.1074/jbc.270.35.20285	http://dx.doi.org/10.1074/jbc.270.35.20285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657598	hybrid			2022-12-25	WOS:A1995RR58400011
J	KOHOUT, TA; ROGERS, TB				KOHOUT, TA; ROGERS, TB			ANGIOTENSIN-II ACTIVATES THE NA+/HCO3- SYMPORT THROUGH A PHOSPHOINOSITIDE-INDEPENDENT MECHANISM IN CARDIAC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC-FREE CALCIUM; RAT-HEART MYOCYTES; INTRACELLULAR PH; PURKINJE-FIBER; ARACHIDONIC-ACID; K+ CHANNELS; EXCHANGE; MUSCLE; STIMULATION; BETA	Angiotensin II (AngII) is a hormone that alters contractility as well as myocyte growth in heart. Since many hormones that regulate cardiac contractility have also been found to modulate intracellular pH (pH(i)) the goal of this study was to determine if AngII altered pH(i) in cultured neonatal rat ventricular myocytes. Changes in pH(i) were monitored in single cells using the fluorescent pH indicator carboxy-seminaphthorhodafluor-1. Application of 100 nM AngII resulted in a rapid, receptor-mediated alkalinization of 0.08 +/- 0.02 pH unit. The Na+/H+ exchanger was not involved since the response was HCO3--dependent and amiloride-insensitive. Ammonia rebound experiments showed AngII increased the initial rate of recovery from an imposed acid load by 3.15-fold and showed that the hormone led to the selective activation of the Na+/HCO3- symport. In contrast, phorbol ester activation of protein kinase C led to the selective activation of Na+/H+ antiport in these cells. Pharmacological studies showed that the alkalinization was independent of the AngII receptor subtype 1 (AT(1)) phosphoinositide signaling path. In contrast, AngII activation of the symport was blocked by nanomolar AT(2) receptor antagonist PD 123319. Superfusion of the myocytes with exogenous arachidonic acid (5 mu M) mimicked the AngII-mediated alkalinization, further suggesting that the AT(2) signaling pathway underlies the response. In summary, while most of the known actions of AngII in heart are mediated through AT(1) receptors, activation of the Na+/HCO3- symport occurs through a distinct alternative path that is likely related to fatty acid production.	UNIV MARYLAND,SCH MED,BIOMED RES FACIL,DEPT BIOL CHEM,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028138, P01HL027867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008181] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-28138, HL-27867] Funding Source: Medline; NIGMS NIH HHS [GM-08181] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN IS, 1988, CIRC RES, V62, P524, DOI 10.1161/01.RES.62.3.524; BAKER KM, 1989, J PHARMACOL EXP THER, V251, P578; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BERK BC, 1990, J BIOL CHEM, V265, P19632; BLANK PS, 1992, AM J PHYSIOL, V263, pH276, DOI 10.1152/ajpheart.1992.263.1.H276; BOUNTRA C, 1989, J PHYSIOL-LONDON, V418, P163, DOI 10.1113/jphysiol.1989.sp017833; CANNELL MB, 1986, PFLUG ARCH EUR J PHY, V406, P536, DOI 10.1007/BF00583378; DAMRON DS, 1993, J BIOL CHEM, V268, P27335; DAMRON DS, 1993, CIRC RES, V72, P376, DOI 10.1161/01.RES.72.2.376; DART C, 1992, J PHYSIOL-LONDON, V451, P365, DOI 10.1113/jphysiol.1992.sp019169; DESILETS M, 1994, CIRC RES, V75, P862, DOI 10.1161/01.RES.75.5.862; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; ENGELMANN G L, 1990, Technique (Philadelphia), V2, P279; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; FLIEGEL L, 1993, BIOCHEM J, V296, P273, DOI 10.1042/bj2960273; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; GAMBASSI G, 1992, CIRC RES, V71, P870, DOI 10.1161/01.RES.71.4.870; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; IKENOUCHI H, 1994, J PHYSIOL-LONDON, V480, P203, DOI 10.1113/jphysiol.1994.sp020353; KEM DC, 1991, AM J PHYSIOL, V261, pC77, DOI 10.1152/ajpcell.1991.261.1.C77; KIM DH, 1990, CIRC RES, V67, P1040, DOI 10.1161/01.RES.67.4.1040; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; LAGADICGOSSMANN D, 1992, J PHYSIOL-LONDON, V458, P361, DOI 10.1113/jphysiol.1992.sp019422; LAGADICGOSSMANN D, 1993, J PHYSIOL-LONDON, V464, P49, DOI 10.1113/jphysiol.1993.sp019624; LEAF A, 1994, P NATL ACAD SCI USA, V91, P9886; LIU S, 1990, J GEN PHYSIOL, V96, P1247, DOI 10.1085/jgp.96.6.1247; LOKUTA A, 1994, J CARDIOVASC ELECTR, V5, P50, DOI 10.1111/j.1540-8167.1994.tb01114.x; LOKUTA AJ, 1994, J BIOL CHEM, V269, P4832; LOPEZ JJ, 1994, AM J PHYSIOL, V267, pH844, DOI 10.1152/ajpheart.1994.267.2.H844; ORCHARD CH, 1990, AM J PHYSIOL, V258, pC967, DOI 10.1152/ajpcell.1990.258.6.C967; PUCEAT M, 1995, J BIOL CHEM, V270, P1315, DOI 10.1074/jbc.270.3.1315; ROGERS TB, 1994, TRENDS CARDIOVAS MED, V4, P110, DOI 10.1016/1050-1738(94)90062-0; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; STOUFFER GA, 1992, CIRC RES, V70, P820, DOI 10.1161/01.RES.70.4.820; TERZIC A, 1992, J PHYSIOL-LONDON, V447, P275, DOI 10.1113/jphysiol.1992.sp019002; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TOBIAS LD, 1978, LIPIDS, V14, P181; VAUGHANJONES RD, 1979, J PHYSIOL-LONDON, V295, P83, DOI 10.1113/jphysiol.1979.sp012956; VAUGHANJONES RD, 1986, J PHYSIOL-LONDON, V379, P377, DOI 10.1113/jphysiol.1986.sp016259; VAUGHANJONES RD, 1990, J PHYSIOL-LONDON, V425, P429, DOI 10.1113/jphysiol.1990.sp018112; WALLERT MA, 1989, AM J PHYSIOL, V257, pC207, DOI 10.1152/ajpcell.1989.257.2.C207; WALLERT MA, 1992, AM J PHYSIOL, V263, pC1096, DOI 10.1152/ajpcell.1992.263.5.C1096	43	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20432	20438		10.1074/jbc.270.35.20432	http://dx.doi.org/10.1074/jbc.270.35.20432			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657618	hybrid			2022-12-25	WOS:A1995RR58400032
J	TERADA, K; MANCHIKALAPUDI, P; NOIVA, R; JAUREGUI, HO; STOCKERT, RJ; SCHILSKY, ML				TERADA, K; MANCHIKALAPUDI, P; NOIVA, R; JAUREGUI, HO; STOCKERT, RJ; SCHILSKY, ML			SECRETION, SURFACE LOCALIZATION, TURNOVER, AND STEADY-STATE EXPRESSION OF PROTEIN DISULFIDE-ISOMERASE IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PROLYL 4-HYDROXYLASE; BETA-SUBUNIT; IDENTIFICATION; ANTIBODIES; SIGNAL; CELLS	Protein disulfide isomerase in isolated rat hepatocytes was present at a concentration of 7 mu g/mg cell protein, representing a similar to 2-fold enrichment compared to isolated hepatic non-parenchymal cells. Though localized mainly in microsomal fractions of hepatocyte, direct immunofluorescence and cell surface radioiodination followed by immunoprecipitation revealed the presence of M(r) 57,000 disulfide isomerase at the cell surface. Electrostatic interaction of the protein with the cell surface was suggested by susceptibility to carbonate washing. Metabolic radiolabeling and immunoprecipitation studies also indicated that some of the newly synthesized M(r) 57,000 disulfide isomerase was secreted. Treatment of cells with colchicine markedly reduced the recovery of disulfide isomerase from the media, indicating microtubular directed secretion of the protein. Partial staphlococcal V8 proteolytic digestion of the secreted protein revealed a peptide pattern similar to that of the cellular protein. Immunoprecipitation with antibody specific to the -KDEL peptide retention sequence confirmed the presence of this sequence in the secreted protein. Studies of the turnover of disulfide isomerase revealed a half-life of approximately 96 h. Treatment of cells with tunicamycin or heat shock resulted in an increased recovery of newly synthesized disulfide isomerase from cell lysates but diminished recovery from the media. The secretion and cell surface distribution of disulfide isomerase in hepatocytes may be important for the pathogenesis of immune mediated liver injury.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; NATL CTR STUDY WILSONS DIS INC,NEW YORK,NY 10019; UNIV S DAKOTA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,VERMILLION,SD 57069; BROWN UNIV,RHODE ISL HOSP,DEPT PATHOL,PROVIDENCE,RI 02903	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of South Dakota; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital					NCI NIH HHS [CA61259] Funding Source: Medline; NIDDK NIH HHS [DK32972, DK41296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032972, P30DK041296] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAGI S, 1988, J HISTOCHEM CYTOCHEM, V36, P1533, DOI 10.1177/36.12.3192937; BERG RA, 1980, BIOCHEM J, V189, P491, DOI 10.1042/bj1890491; DELORENZ.F, 1966, J BIOL CHEM, V241, P1562; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; FREEDMAN RB, 1994, TRENDS BIOL SCI, V19, P332; HONSCHA W, 1993, BIOCHIM BIOPHYS ACTA, V1153, P175, DOI 10.1016/0005-2736(93)90403-M; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; LAMBERT N, 1985, BIOCHEM J, V228, P635, DOI 10.1042/bj2280635; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; Leffert H L, 1979, Methods Enzymol, V58, P536; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MARTIN JL, 1993, HEPATOLOGY, V18, P858, DOI 10.1002/hep.1840180417; MILLS ENC, 1983, BIOCHEM J, V213, P245, DOI 10.1042/bj2130245; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Naik S, 1992, Cell Transplant, V1, P61; NOIVA R, 1991, J BIOL CHEM, V266, P19645; NOIVA R, 1994, PROTEIN EXPRES PURIF, V5, P1, DOI 10.1006/prep.1994.1001; OTSU M, 1994, J BIOL CHEM, V269, P6874; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PUIG A, 1994, J BIOL CHEM, V269, P7764; SATO M, 1990, J BIOL CHEM, V265, P2533; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; YOKOI T, 1993, BIOCHIM BIOPHYS ACTA, V1158, P339, DOI 10.1016/0304-4165(93)90033-5; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984	24	131	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20410	20416		10.1074/jbc.270.35.20410	http://dx.doi.org/10.1074/jbc.270.35.20410			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657616	hybrid			2022-12-25	WOS:A1995RR58400029
J	ZHUANG, SB; WANG, EZ; WANG, CLA				ZHUANG, SB; WANG, EZ; WANG, CLA			IDENTIFICATION OF THE FUNCTIONALLY RELEVANT CALMODULIN-BINDING SITE IN SMOOTH-MUSCLE CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN GIZZARD CALDESMON; ATPASE ACTIVITY; ACTOMYOSIN ATPASE; MOLECULAR-WEIGHT; THIN-FILAMENTS; CROSS-LINKING; H-CALDESMON; ACTIN; MYOSIN; TROPOMYOSIN	The C-terminal region of smooth muscle caldesmon (CaD) interacts with calmodulin (CaM) and reverses CaD's inhibitory effect on the actomyosin ATPase activity. me have previously shown that the major CaM-binding site (site A) in this region is within the segment from Met-658 to Ser-666 (Zhan, Q., Wong, S. S., and Wang, C.-L. A. (1991) J. Biol. Chem. 266, 21810-21814). Recently, another segment (site B), Asn-675 to Lys-695, was reported to bind CaM (Mezgueldi, M., Derancourt, J., Calas, B., Kassab, R., and Fattoum, A (1994) J. Biol. Chem. 269, 12824-12832). To assess the functional relevance of these two putative CaM-binding sites, we have examined three synthetic peptides regarding their effects on CaM's ability to reverse CaD-induced inhibition of actomyosin ATPase activity: GS17C (Gly-651 to Ser-667), VG29C (Val-685 to Gly-713), each containing one CaM-binding site, and MG56C (Met-658 to Gly-713), which contains both sites. We found that although VG29C did bind CaM, its affinity was weakened by GS17C, and it failed to compete with CaD for CaM under the conditions where GS17C effectively displaced CaD from CaM. MG56C had an effect similar to that of GS17C. These experiments demonstrated that site A for CaM binding is involved in regulating the inhibitory property of CaD.	BOSTON BIOMED RES INST,MUSCLE RES GRP,BOSTON,MA 02114	Boston Biomedical Research Institute					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR41637] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAM LP, 1993, FEBS LETT, V322, P56, DOI 10.1016/0014-5793(93)81110-L; ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHALOVICH JM, 1992, J BIOL CHEM, V267, P16644; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; Fiske CH, 1925, J BIOL CHEM, V66, P375; FUJII T, 1987, J BIOL CHEM, V262, P2757; FURST DO, 1986, EMBO J, V5, P251, DOI 10.1002/j.1460-2075.1986.tb04206.x; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GRACEFFA P, 1991, J BIOL CHEM, V266, P20305; GRACEFFA P, 1987, FEBS LETT, V218, P139, DOI 10.1016/0014-5793(87)81034-7; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V164, P503, DOI 10.1016/0006-291X(89)91748-8; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; HUMPHREY MB, 1992, GENE, V112, P197, DOI 10.1016/0378-1119(92)90376-Z; IKEBE M, 1978, J BIOCHEM, V83, P1643, DOI 10.1093/oxfordjournals.jbchem.a132077; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; LEVINE BA, 1990, EUR J BIOCHEM, V193, P687, DOI 10.1111/j.1432-1033.1990.tb19388.x; MABUCHI K, 1991, J MUSCLE RES CELL M, V12, P145, DOI 10.1007/BF01774033; MABUCHI K, 1993, J MUSCLE RES CELL M, V14, P54, DOI 10.1007/BF00132180; MABUCHI Y, 1995, BIOPHYS J, V68, P359; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; MARSTON SB, 1985, BIOCHEM J, V231, P517, DOI 10.1042/bj2310517; MARSTON SB, 1991, BIOCHEM J, V279, P1; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; MEZGUELDI M, 1994, J BIOL CHEM, V269, P12824; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; NGAI PK, 1984, J BIOL CHEM, V259, P3656; NGAI PK, 1987, BIOCHEM J, V244, P417, DOI 10.1042/bj2440417; RISEMAN VM, 1989, J BIOL CHEM, V264, P2869; ROSENFELD SS, 1985, J BIOL CHEM, V260, P242; SMITH CWJ, 1985, FEBS LETT, V184, P115, DOI 10.1016/0014-5793(85)80665-7; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; VELAZ L, 1990, J BIOL CHEM, V265, P2929; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WANG CLA, 1991, J BIOL CHEM, V266, P13958; WANG CLA, 1988, BIOCHEM BIOPH RES CO, V156, P1033, DOI 10.1016/S0006-291X(88)80948-3; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; ZHAN Q, 1991, J BIOL CHEM, V266, P21810	46	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19964	19968		10.1074/jbc.270.34.19964	http://dx.doi.org/10.1074/jbc.270.34.19964			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650012	hybrid			2022-12-25	WOS:A1995RQ99100045
J	CAI, K; SCHIRCH, D; SCHIRCH, V				CAI, K; SCHIRCH, D; SCHIRCH, V			THE AFFINITY OF PYRIDOXAL 5'-PHOSPHATE FOR FOLDING INTERMEDIATES OF ESCHERICHIA-COLI SERINE HYDROXYMETHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE; GUANIDINE-HYDROCHLORIDE; TRYPTOPHAN SYNTHASE; COENZYME BINDING; BETA-2 SUBUNIT; PIG-HEART; DENATURATION; DISSOCIATION; PROTEINS; STEP	Escherichia coli serine hydroxymethyltransferase is a 94-kDa homodimer, Each subunit contains a covalently attached pyridoxal-P, which is required for catalytic activity, At which step pyridoxal-P binds in the folding pathway of E. coli serine hydroxymethyltransferase is addressed in this study, E. coli serine hydroxymethyltransferase is rapidly unfolded to an apparent random coil in 8 M urea, Removal of the urea initiates a complete refolding to the native holoenzyme in less than 10 min at 30 degrees C. Several intermediates on the folding pathway have been identified, The most important information was obtained during folding studies at 4 degrees C. At this temperature, the far-UV circular dichroism spectrum and the fluorescence spectrum of the 3 tryptophan residues become characteristic of the native apoenzyme in less than 10 min, Size exclusion chromatography shows that under these conditions the refolding enzyme is a mixture of monomeric and dimeric species. Continued incubation at 4 degrees C for 60 min results in the formation of only a dimeric species, Neither the monomer nor dimer formed at 4 degrees C bind pyridoxal phosphate. Raising the temperature to 30 degrees C results in the formation of a dimeric enzyme which rapidly binds pyridoxal phosphate forming active enzyme, These studies support the interpretation that pyridoxal phosphate binds only at the end of the folding pathway to a dimeric apoenzyme and plays no significant role in the folding mechanism.	VIRGINIA COMMONWEALTH UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,RICHMOND,VA 23298	Virginia Commonwealth University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028143] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28143] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ARTIGUES A, 1994, J BIOL CHEM, V269, P21990; BANIK U, 1995, J BIOL CHEM, V270, P7944, DOI 10.1074/jbc.270.14.7944; BLOND S, 1985, J MOL BIOL, V182, P597, DOI 10.1016/0022-2836(85)90245-1; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; Dempsey W., 1987, ESCHERICHIA COLI SAL, V1, P539; DEMPSEY WB, 1962, J BIOL CHEM, V237, P1113; DOMINICI P, 1993, BIOCHEM J, V295, P493, DOI 10.1042/bj2950493; FINK AL, 1988, FEBS LETT, V229, P123, DOI 10.1016/0014-5793(88)80810-X; GERSCHITZ J, 1978, EUR J BIOCHEM, V87, P591, DOI 10.1111/j.1432-1033.1978.tb12411.x; HEROLD M, 1992, FEBS LETT, V308, P26, DOI 10.1016/0014-5793(92)81042-K; HEROLD M, 1990, BIOCHEMISTRY-US, V29, P1907, DOI 10.1021/bi00459a035; HEROLD M, 1991, BIOCHEMISTRY-US, V30, P3612, DOI 10.1021/bi00229a004; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LEISTLER B, 1992, EUR J BIOCHEM, V205, P603, DOI 10.1111/j.1432-1033.1992.tb16818.x; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MCCORMICK DB, 1980, VITAMIN B6 METABOLIS, P1; PINEDA T, 1994, BBA-PROTEIN STRUCT M, V1207, P173, DOI 10.1016/0167-4838(94)00067-0; RAIBAUD O, 1976, J BIOL CHEM, V251, P2820; REYES AM, 1993, J BIOL CHEM, V268, P22281; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SEIFERT T, 1985, BIOCHEMISTRY-US, V24, P339, DOI 10.1021/bi00323a016; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P798, DOI 10.1021/bi00781a012; WEST SM, 1989, BIOCHEM J, V261, P189, DOI 10.1042/bj2610189; WEST SM, 1990, BIOCHEM J, V265, P45, DOI 10.1042/bj2650045; ZETINA CR, 1980, J MOL BIOL, V137, P401, DOI 10.1016/0022-2836(80)90165-5	27	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19294	19299		10.1074/jbc.270.33.19294	http://dx.doi.org/10.1074/jbc.270.33.19294			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642604	hybrid			2022-12-25	WOS:A1995RP70300018
J	STEFANSSON, S; CHAPPELL, DA; ARGRAVES, KM; STRICKLAND, DK; ARGRAVES, WS				STEFANSSON, S; CHAPPELL, DA; ARGRAVES, KM; STRICKLAND, DK; ARGRAVES, WS			GLYCOPROTEIN-330 LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN-2 MEDIATES ENDOCYTOSIS OF LOW-DENSITY LIPOPROTEINS VIA INTERACTION WITH APOLIPOPROTEIN B100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEYMANN NEPHRITIS ANTIGEN; ALPHA-2-MACROGLOBULIN RECEPTOR; MONOCLONAL-ANTIBODIES; LDL-RECEPTOR; IN-VITRO; BINDING; RABBIT; GP330; CELLS; RAT	The ability of glycoprotein 330/low density lipoprotein receptor-related protein-2 (LRP-2) to function as a lipoprotein receptor was investigated using cultured mouse F9 teratocarcinoma cells. Treatment with retinoic acid and dibutyryl cyclic AMP, which induces F9 cells to differentiate into endoderm-like cells, produced a 50-fold increase in the expression of LRP-2. Levels of the other members of the low density lipoprotein (LDL) receptor (LDLR) family, including LDLR, the very low density lipoprotein receptor, and LRP-1, were reduced, When LDL catabolism was examined in these cells, it was found that the treated cells endocytosed and degraded at 10-fold higher levels than untreated cells. The increased LDL uptake coincided with increased LRP-2 activity of the treated cells, as measured by uptake of both I-125-labeled monoclonal LRP-2 antibody and the LRP-2 ligand prourokinase. The ability of LDL to bind to LRP-2 was demonstrated by solid-phase binding assays. This binding was inhibitable by LRP-2 antibodies, receptor-associated protein (the antagonist of ligand binding for all members of the LDLR family), or antibodies to apoB100, the major apolipoprotein component of LDL. In cell assays, LRP-2 antibodies blocked the elevated I-125-LDL internalization and degradation observed in the retinoic acid/dibutyryl cyclic AMP treated F9 cells. A low level of LDL endocytosis existed that was likely mediated by LDLR since it could not be inhibited by LRP-2 antibodies, but was inhibited by excess LDL, receptor-associated protein, or apoB100 antibody. The results indicate that LRP-2 can function to mediate cellular endocytosis of LDL, leading to its degradation. LRP-2 represents the second member of the LDLR family identified as functioning in the catabolism of LDL.	AMER RED CROSS,JEROME H HOLLAND LAB,DEPT BIOCHEM,ROCKVILLE,MD 20855; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242	American Red Cross; University of Iowa					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49264] Funding Source: Medline; NIDDK NIH HHS [DK45598] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; ASSMANN KJM, 1986, VIRCHOWS ARCH A, V408, P541, DOI 10.1007/BF00705307; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BUCCARON MH, 1987, ANN INST PASTEUR IMM, V138, P707, DOI 10.1016/S0769-2625(87)80026-0; CARLSSON J, 1991, CLIN CHIM ACTA, V196, P167, DOI 10.1016/0009-8981(91)90070-S; CHAPPELL DA, 1993, J BIOL CHEM, V268, P25487; CHAPPELL DA, 1988, J CLIN INVEST, V82, P628, DOI 10.1172/JCI113642; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; Damjanov I, 1994, In Vivo, V8, P967; DIETSCHY JM, 1983, J LIPID RES, V24, P469; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GAFVELS ME, 1993, SOMAT CELL MOLEC GEN, V19, P557, DOI 10.1007/BF01233382; GIANTURCO SH, 1987, PLASMA LIPOPROTEINS, P183; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; Goldstein JL, 1983, METABOLIC BASIS INHE, P672; GUETHHALLONET C, 1994, DEVELOPMENT, V120, P3289; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1990, J BIOL CHEM, V265, P21355; HOMANICS GE, 1993, P NATL ACAD SCI USA, V90, P2389, DOI 10.1073/pnas.90.6.2389; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; KORENBERG JR, 1994, GENOMICS, V22, P88, DOI 10.1006/geno.1994.1348; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MILNE RW, 1982, FEBS LETT, V146, P97, DOI 10.1016/0014-5793(82)80712-6; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SHERMAN MI, 1978, DEV BIOL, V63, P27, DOI 10.1016/0012-1606(78)90110-0; STEFANSSON S, 1995, J CELL SCI, V108, P2361; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YAMAMOTO T, 1993, TRENDS CARDIOVAS MED, V3, P144, DOI 10.1016/1050-1738(93)90015-X; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	52	96	98	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19417	19421		10.1074/jbc.270.33.19417	http://dx.doi.org/10.1074/jbc.270.33.19417			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642623	hybrid			2022-12-25	WOS:A1995RP70300037
J	SUN, B; LATHAM, KA; DODSON, ML; LLOYD, RS				SUN, B; LATHAM, KA; DODSON, ML; LLOYD, RS			STUDIES ON THE CATALYTIC MECHANISM OF 5 DNA GLYCOSYLASES - PROBING FOR ENZYME-DNA IMINO INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; COLI ENDONUCLEASE-III; ESCHERICHIA-COLI; PYRIMIDINE DIMER; PHYSICAL ASSOCIATION; T4-ENDONUCLEASE-V; NICKING; REPAIR; 8-OXOGUANINE; RESIDUES	DNA glycosylases catalyze scission of the N-glycosylic bond linking a damaged base to the DNA sugar phosphate backbone, Some of these enzymes carry out a concomitant abasic (apyrimidinic/apurinic (AP)) lyase reaction at a rate approximately equal to that of the glycosylase step. As a generalization of the mechanism described for T4 endonuclease V, a repair glycosylase/AP lyase that is specific for ultraviolet light-induced cis-syn pyrimidine dimers, a hypothesis concerning the mechanism of these repair glycosylases has been proposed, This hypothesis describes the initial action of all DNA glycosylases as a nucleophilic attack at the sugar C-1' of the damaged base nucleoside, resulting in scission of the N-glycosylic bond. It is proposed that the enzymes that are only glycosylases differ in the chemical nature of the attacking nucleophile from the glycosylase/AP lyases. Those DNA glycosylases, which carry out the AP lyase reaction at a rate approximately equal to the glycosylase step, are proposed to use an amino group as the nucleophile, resulting in an imino enzyme DNA intermediate. The simple glycosylases, lacking the concomitant AP lyase activity, are proposed to use some nucleophile from the medium, e.g. an activated water molecule, This paper reports experimental tests of this hypothesis using five representative enzymes, and these data are consistent with this hypothesis.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston				Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [ES04091, ES06676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, R01ES004091] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BEHMOARAS T, 1981, NATURE, V292, P858, DOI 10.1038/292858a0; BJELLAND S, 1987, NUCLEIC ACIDS RES, V15, P2787, DOI 10.1093/nar/15.7.2787; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; CASTAING B, 1993, NUCLEIC ACIDS RES, V21, P2899, DOI 10.1093/nar/21.12.2899; CUNNINGHAM RP, 1994, DNA DAMAGE EFFECTS D, V726, P215; DEMPLE B, 1980, NATURE, V287, P203, DOI 10.1038/287203a0; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOI T, 1992, P NATL ACAD SCI USA, V89, P9420, DOI 10.1073/pnas.89.20.9420; DOSANJH MK, 1994, BIOCHEMISTRY-US, V33, P1624, DOI 10.1021/bi00173a002; GROLLMAN AP, 1994, DNA DAMAGE EFFECTS D, V726, P208; HORI N, 1992, NUCLEIC ACIDS RES, V20, P4761, DOI 10.1093/nar/20.18.4761; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; KOU CF, 1992, SCIENCE, V258, P434; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; LATHAM KA, 1995, J BIOL CHEM, V270, P3765, DOI 10.1074/jbc.270.8.3765; LATHAM KA, 1994, DNA DAMAGE EFFECTS D, V726, P181; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; LLOYD RS, 1995, DNA REPAIR MECH IMPA, P25; LLOYD RS, 1993, NUCLEASES, V2, P263; MANUEL RC, 1995, J BIOL CHEM, V270, P2652, DOI 10.1074/jbc.270.6.2652; MCMILLAN S, 1981, P NATL ACAD SCI USA, V78, P2742; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; PIERRE J, 1981, J BIOL CHEM, V256, P217; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; WARNER HR, 1981, J VIROL, V77, P4602	38	144	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19501	19508		10.1074/jbc.270.33.19501	http://dx.doi.org/10.1074/jbc.270.33.19501			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642635	hybrid			2022-12-25	WOS:A1995RP70300049
J	SANCHEZPRIETO, R; LLEONART, M; CAJAL, SRY				SANCHEZPRIETO, R; LLEONART, M; CAJAL, SRY			LACK OF CORRELATION BETWEEN P53 PROTEIN LEVEL AND SENSITIVITY TO DNA-DAMAGING AGENTS IN KERATINOCYTES CARRYING ADENOVIRUS E1A MUTANTS	ONCOGENE			English	Article						ONCOGENES; ADENOVIRUS E1A; E1A MUTANTS; DRUG RESISTANCE; APOPTOSIS; P53	WILD-TYPE P53; CELL-DEATH; TUMOR-SUPPRESSOR; APOPTOSIS; TRANSFORMATION; INDUCTION; GENE; EXPRESSION; CHECKPOINT; ONCOGENE	p53 tumor suppressor protein is required for efficient execution of apoptosis after DNA-damage in many cell systems. Since the oncogene E1a confers susceptibility to DNA-damaging agents and stabilizes p53 protein, we investigate whether the sensitivity to anticancer drugs of E1a-expressing cells was mediated by binding to a specific set of cellular proteins (p60, p105, p107 and p300) and related to the induction of apoptosis and the level of p53 protein. We studied the effect of cisplatin (CDDP), doxorubicin (DOX) and ionizing radiation (RX) on murine keratinocytes (PAM 212) transfected by the wild type E1a oncogene or several E1a mutants which bind to different subsets of cellular proteins. Keratinocytes transfected with the mutant d1787N (which binds to p60, p105, p107 and p300) showed a lethality in response to CDDP (10 mu g ml(-1)) fourfold higher than controls and threefold higher in response to DOX and radiation (5 grays). The sensitivity of keratinocytes carrying the mutant NTd1598 (binding to p105, p107 and p60) to DNA-damaging agents was similar to that of control keratinocytes, while mutant d1992/947 (binding only to p300) were resistant to CDDP and RX but sensitive to DOX. Apoptosis (after 24 h) studied by DNA fragmentation and flow cytometry was only observed in cells carrying the wild type E1a or the mutant d1787N. After treatment with DNA-damaging agents, p53 protein expression increased in all the cell lines and no rE1ation to sensitivity to anticancer agents or induction of apoptosis was observed. From these results, we conclude that cell sensitivity to cisplatin and ionizing radiation induced by the E1a oncogene requires binding to p105, p107 and p300 cellular proteins, while sensitivity to Doxorubicin requires binding only to p300. Interestingly, p53 protein levels were related to the binding to the p300 protein. The high levels of p53 after CDDP and DOX in the mutant d1922/947, which are only sensitive to DOX, suggest that E1a oncogene products may induce sensitivity to DNA-damaging agents by p53-related and unrelated pathways.	CLIN PUERTA DE HIERRO,DEPT PATHOL,E-28035 MADRID,SPAIN	Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda			Prieto, Ricardo/AAZ-7221-2021; Ramon y Cajal, Santiago/H-4955-2016; Sanchez-Prieto, Ricardo/AAY-4271-2021	Ramon y Cajal, Santiago/0000-0002-3867-1390; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lleonart Pajarin, Matilde/0000-0002-6196-7405				ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BARBEAU D, 1994, ONCOGENE, V9, P359; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CAJAL SRY, 1994, AM J PATHOL, V145, P846; CHU G, 1994, J BIOL CHEM, V269, P787; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; ELDEIRY WS, 1994, CANCER RES, V54, P1169; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS CA, 1993, CANCER RES, V53, P1735; FERNANDEZSARABI.MJ, 1993, NATURE, V366, P274; FLORINCHRISTENS.M, 1993, EXP CELL RES, V207, P57; FREEDMAN CA, 1980, PHARMACOLOGY, V20, P133; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOWE SW, 1994, J EXP MED, V266, P807; MARCHETTI E, 1994, INT J ONCOL, V5, P611; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P1295; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; RAFF MC, 1993, SCIENCE, V262, P694; SANCHEZPRIETO R, 1995, INT J CANCER, V60, P235; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	46	49	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					675	682						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651731				2022-12-25	WOS:A1995RQ46900009
J	BIRCH, OM; FUHRMANN, M; SHAW, NM				BIRCH, OM; FUHRMANN, M; SHAW, NM			BIOTIN SYNTHASE FROM ESCHERICHIA-COLI, AN INVESTIGATION OF THE LOW-MOLECULAR-WEIGHT AND PROTEIN-COMPONENTS REQUIRED FOR ACTIVITY IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC RIBONUCLEOTIDE REDUCTASE; PYRUVATE FORMATE-LYASE; BACILLUS-SPHAERICUS; MASS-SPECTROMETRY; BIOSYNTHESIS; DETHIOBIOTIN; SULFUR; ACID; BIOCONVERSION; ACTIVATION	We have developed a radiochemical method for the measurement of biotin synthase activity in vitro. A cell-free extract from an Escherichia coli strain containing a cloned bioB (biotin synthase) gene was incubated with [C-14]dethiobiotin, which was converted to [C-14]biotin, The assay was used to identify the low molecular weight compounds and two of the proteins that, in addition to the bioB gene product, are required for biotin synthase activity in vitro. The low molecular weight compounds are cysteine; S-adenosylmethionine thiamine pyrophosphate; Fe2+; a pyridine nucleotide (the most effective being NADPH); and one of the amino acids asparagine, aspartate, glutamine, or serine. The proteins are flavodoxin and ferredoxin (flavodoxin)-NADP(+) reductase (EC 1.18.1.2). A third thiamine pyrophosphate-dependent protein is also required for activity. When the cell-free extract was incubated with nonlabeled dethiobiotin and either [S-35]cysteine or [S-35]cystine, S-35 was incorporated into biotin, and we present further evidence that cysteine, and not S-adenosylmethionine or methionine, is the sulfur donor for the biotin synthase reaction.	LONZA AG,DEPT BIOTECHNOL,CH-3930 VISP,SWITZERLAND	Lonza Group								BALDET P, 1993, EUR J BIOCHEM, V217, P479, DOI 10.1111/j.1432-1033.1993.tb18267.x; BARKER DF, 1980, J BACTERIOL, V143, P789, DOI 10.1128/JB.143.2.789-800.1980; BAXTER RL, 1992, J CHEM SOC PERK T 1, P255, DOI 10.1039/p19920000255; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BIRCH OM, 1994, Patent No. 08023; BOWMAN WC, 1993, J BACTERIOL, V175, P7702, DOI 10.1128/JB.175.23.7702-7704.1993; Brown S W, 1991, Biotechnol Genet Eng Rev, V9, P295; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHEN VJ, 1989, J BIOL CHEM, V264, P21677; DEMOLL E, 1985, BIOCHEM BIOPH RES CO, V132, P217, DOI 10.1016/0006-291X(85)91010-1; DEMOLL E, 1983, BIOCHEM BIOPH RES CO, V110, P243, DOI 10.1016/0006-291X(83)91286-X; DEMOLL E, 1984, BIOCHEMISTRY-US, V23, P558, DOI 10.1021/bi00298a025; EISENBERG M, 1987, CELLULAR MOL BIOL, V1, P544; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; FERREIRA RB, 1987, PLANT PHYSIOL, V83, P869, DOI 10.1104/pp.83.4.869; FLORENTIN D, 1994, CR ACAD SCI III-VIE, V317, P485; FRIEDRICH W, 1987, HDB VITAMINE, P220; FUJISAWA A, 1993, FEMS MICROBIOL LETT, V110, P1; GAUDRY M, 1992, CHROMATORG SCI, V60, P441; Goldberg M. W., 1949, [No title captured], Patent No. [2489238, US 2489238]; GOLDBERG MW, 1949, Patent No. 2489232; GOLDBERG MW, 1949, Patent No. 2489235; HUGHES GJ, 1990, BIOCHEM J, V271, P641, DOI 10.1042/bj2710641; IFUKU O, 1994, EUR J BIOCHEM, V224, P173, DOI 10.1111/j.1432-1033.1994.tb20009.x; IFUKU O, 1992, BIOSCI BIOTECH BIOCH, V56, P1780, DOI 10.1271/bbb.56.1780; IFUKU O, 1994, EUR J BIOCHEM, V220, P585, DOI 10.1111/j.1432-1033.1994.tb18659.x; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; LEVYSCHIL S, 1993, APPL MICROBIOL BIOT, V38, P755, DOI 10.1007/BF00167141; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; MARQUET A, 1993, J AM CHEM SOC, V115, P2193; MARTI FB, 1983, THESIS EIDGENOSSISCH; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Mayhew S. G., 1992, CHEM BIOCH FLAVOENZY, V3, P389; MCGARRITY J, 1989, Patent No. 4876350; OHSAWA I, 1992, J FERMENT BIOENG, V73, P121, DOI 10.1016/0922-338X(92)90475-A; OSBORNE C, 1991, J BACTERIOL, V173, P1729, DOI 10.1128/jb.173.5.1729-1737.1991; REED KE, 1993, J BACTERIOL, V175, P1325, DOI 10.1128/JB.175.5.1325-1336.1993; REICHARD P, 1993, J BIOL CHEM, V268, P8383; ROLFE B, 1968, J BACTERIOL, V96, P515, DOI 10.1128/JB.96.2.515-524.1968; SAKURAI N, 1994, J FERMENT BIOENG, V77, P610, DOI 10.1016/0922-338X(94)90141-4; SANYAL I, 1994, J AM CHEM SOC, V116, P2637, DOI 10.1021/ja00085a061; SANYAL I, 1994, BIOCHEMISTRY-US, V33, P3625, DOI 10.1021/bi00178a020; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; ZHANG SG, 1994, ARCH BIOCHEM BIOPHYS, V309, P29, DOI 10.1006/abbi.1994.1079	48	91	97	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19158	19165		10.1074/jbc.270.32.19158	http://dx.doi.org/10.1074/jbc.270.32.19158			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642583				2022-12-25	WOS:A1995RN95400071
J	ISLAM, TC; BUGGE, TH; BOHM, S				ISLAM, TC; BUGGE, TH; BOHM, S			THE LONG TERMINAL REPEAT OF VL30 RETROTRANSPOSONS CONTAINS SEQUENCES THAT DETERMINE RETINOIC ACID-INDUCED TRANSCRIPTION IN CULTURED KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL CARCINOMA; RESPONSIVE ELEMENT; GENE-EXPRESSION; THYROID-HORMONE; RECEPTOR-GAMMA; DIFFERENTIATION; IDENTIFICATION; PROMOTERS; SKIN	The characterization of retinoic acid (RA)-regulated gene transcription in keratinocytes has important implications as to the function of retinoids in epidermal homeostasis and to the central role retinoids play in the pharmaco-therapy of a variety of skin disorders. We show that cultured mouse keratinocytes (Balb/MK) responded to RA with induced expression of VL30 retrotransposons. The induction was rapid, was present at nanomolar concentrations of RA, was independent of new protein synthesis, and occurred both in proliferating and differentiated keratinocytes. The long terminal repeat of a VL30 retrotransposon, expressed in mouse epidermis in vivo, was found to contain two RA-responsive elements (RREs) that independently conferred RA responsiveness on a heterologous promoter in both cultured Balb/MK cells and normal human keratinocytes. Functional characterization and in vitro binding analysis showed that the sequence requirement for binding of retinoid X receptor alpha (RXRalpha) and retinoic acid receptor (RAR, either alpha beta, or gamma) heterodimers, correlated with the sequence requirement for RA-induced transcription in keratinocytes. The VL30 RREs differed functionally from the RA response element present in the RAR-beta2 promoter, in that the VL30 RREs were non-responsive in fibroblasts cultured from human skin. The non-responsiveness correlated with a reduced complex formation between a VL30 RRE and endogenously expressed nuclear factors present in skin fibroblasts. The data suggest that a direct repeat of two half-sites, spaced by two base pairs, with the consensus sequence T(A/G)AACTTTT(T/C)ACC(T/C), bound RAR-RXR heterodimers and mediated, at constitutive receptor levels, a primary RA response on gene transcription specifically in keratinocytes.	KAROLINSKA INST, NOVUM, CTR BIOTECHNOL, BLICKAGANGEN 6, S-14157 HUDDINGE, SWEDEN; EUROPEAN MOLEC BIOL LAB, W-6900 HEIDELBERG, GERMANY	Karolinska Institutet; European Molecular Biology Laboratory (EMBL)								ASTROM A, 1990, BIOCHEM BIOPH RES CO, V173, P339, DOI 10.1016/S0006-291X(05)81062-9; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGHARD A, 1990, J BIOL CHEM, V265, P21086; BOHM S, 1990, CANCER RES, V50, P1626; BOHM S, 1991, J BIOL CHEM, V266, P24834; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHYTIL F, 1984, PHARMACOL REV, V36, P93; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; ELDER JT, 1992, J INVEST DERMATOL, V98, P673, DOI 10.1111/1523-1747.ep12499896; ELDER JT, 1991, J INVEST DERMATOL, V96, P425, DOI 10.1111/1523-1747.ep12469889; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1991, DNA CELL BIOL, V10, P623, DOI 10.1089/dna.1991.10.623; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KANNAN P, 1991, J VIROL, V65, P6343, DOI 10.1128/JVI.65.11.6343-6348.1991; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KESHET E, 1991, ADV CANCER RES, V56, P215; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MUNOZCANOVES P, 1990, J BIOL CHEM, V265, P20065; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; REISS M, 1988, IN VITRO CELL DEV B, V24, P537, DOI 10.1007/BF02629088; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; Sambrook J, 1989, MOL CLONING LABORATO; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STELLMACH V, 1991, P NATL ACAD SCI USA, V88, P4582, DOI 10.1073/pnas.88.11.4582; STRUHL K, 1990, CURRENT PROTOCOLS S, V11; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VOLLBERG TM, 1992, MOL ENDOCRINOL, V6, P667, DOI 10.1210/mend.6.5.1318502; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	49	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3251	3259						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679109				2022-12-25	WOS:A1993KM16100038
J	SACHAIS, BS; SNIDER, RM; LOWE, JA; KRAUSE, JE				SACHAIS, BS; SNIDER, RM; LOWE, JA; KRAUSE, JE			MOLECULAR-BASIS FOR THE SPECIES SELECTIVITY OF THE SUBSTANCE-P ANTAGONIST-CP-96,345	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; ADRENERGIC-RECEPTOR; CDNA; BINDING; GONADOTROPIN; ORGANIZATION; TACHYKININS; ANTAGONISTS; AFFINITY; PROTEINS	The non-peptide substance P (SP) antagonist 96,345 has a 90-fold selectivity for the human neurokinin-1 (NK-1) or SP receptor over the rat NK-1 receptor, while the agonist SP shows no such selectivity. The cloned NK-1 receptors from these two species have primary protein structures that differ in only 22 of 407 residues. Wild type, chimeric, and point-mutated NK-1 receptors have been created and functionally expressed to understand the structural basis of this species selectivity. Residue 290 in the seventh putative membrane-spanning region is responsible for 20-fold of the affinity difference seen for CP-96,345 between the rat and human NK-1 receptors. Residues in the second extracellular loop and in membrane-spanning region six contribute the additional 3-5-fold of the species difference. The direct or indirect action of these residues with this nonpeptidic antagonist is discussed. This study serves to emphasize the need for species-appropriate in vitro models for the screening of antagonists in the search for therapeutics, and provides useful information to model nonpeptidic antagonist interactions with peptide hormone receptors.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,660 S EUCLID,BOX 8108,ST LOUIS,MO 63110; PFIZER INC,DIV CENT RES,DEPT EXPLORATORY MED CHEM,GROTON,CT 06340; PFIZER INC,DEPT NEUROSCI,GROTON,CT 06340	Washington University (WUSTL); Pfizer; Pfizer			Sachais, Bruce/D-1236-2009		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021937, R55NS021937] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07805] Funding Source: Medline; NINDS NIH HHS [NS21937] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GERARD NP, 1991, BIOCHEMISTRY-US, V30, P10640, DOI 10.1021/bi00108a006; GITTER BD, 1991, EUR J PHARMACOL, V197, P237, DOI 10.1016/0014-2999(91)90532-U; GUAN XM, 1992, MOL PHARMACOL, V41, P695; HELKE CJ, 1990, FASEB J, V4, P1606, DOI 10.1096/fasebj.4.6.1969374; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HERSHEY AD, 1991, THESIS WASHINGTON U; HOPKINS B, 1991, BIOCHEM BIOPH RES CO, V180, P1110, DOI 10.1016/S0006-291X(05)81181-7; LEE CM, 1983, MOL PHARMACOL, V23, P563; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P51; LOWE JA, 1992, J MED CHEM, V35, P2591, DOI 10.1021/jm00092a009; MACDONALD MR, 1989, J BIOL CHEM, V264, P15578; MACDONALD SG, 1989, J NEUROCHEM, V53, P264, DOI 10.1111/j.1471-4159.1989.tb07323.x; MAGGIO JE, 1988, ANNU REV NEUROSCI, V11, P13, DOI 10.1146/annurev.neuro.11.1.13; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; PARKER I, 1986, PROC R SOC SER B-BIO, V229, P151, DOI 10.1098/rspb.1986.0079; PAYAN DG, 1989, ANNU REV MED, V40, P341; PERNOW B, 1983, PHARMACOL REV, V35, P85; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; TAKEDA Y, 1992, J NEUROCHEM, V59, P740, DOI 10.1111/j.1471-4159.1992.tb09430.x; TAKEDA Y, 1991, BIOCHEM BIOPH RES CO, V179, P1232, DOI 10.1016/0006-291X(91)91704-G; TOTA MR, 1990, J BIOL CHEM, V265, P16891; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	27	134	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2319	2323						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679096				2022-12-25	WOS:A1993KK81500013
J	NALEFSKI, EA; SHAW, KTY; RAO, A				NALEFSKI, EA; SHAW, KTY; RAO, A			AN ION-PAIR IN CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX HETERODIMERS CRITICAL FOR SURFACE EXPRESSION AND PEPTIDE PRESENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; ANTIGEN-BINDING SITE; MOUSE MHC ANTIGENS; A-BETA-CHAIN; INVARIANT-CHAIN; MONOCLONAL-ANTIBODIES; VIRAL PEPTIDES; INTRACELLULAR-TRANSPORT; 3-DIMENSIONAL STRUCTURE; ALPHA-CHAIN	In this report we demonstrate that the ion pair Arg-80 alpha and Asp-57 beta, located in the peptide-binding site of nearly all class II major histocompatibility complex (MHC) proteins, is important for surface expression and function of the murine class II heterodimer I-A(d). Charge reversal at either of these two residues by site-directed mutagenesis generated mutant class Il molecules that failed to appear at the cell surface. This defect in surface expression was partially reversed when the invariant chain was present or when the mutants were paired with the corresponding charge-reversed variant of the opposite chain. Surprisingly, surface expression was restored when cells expressing the single-site mutants were cultured at reduced temperature, In addition, the substitution of Asp-57 beta with residues found in alleles of class II molecules associated with diabetes resulted in heterodimers that were inefficiently expressed at the cell surface and presented foreign peptide poorly. Together, these results demonstrate that the formation of a salt-bridge between Arg-80 alpha and Asp-57 beta is required for efficient surface expression of class II MHC molecules, therefore representing an important step in the assembly and transport of functional class II heterodimers to the cell surface.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NIAID NIH HHS [AI22900] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022900] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1987, P NATL ACAD SCI USA, V84, P2435, DOI 10.1073/pnas.84.8.2435; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BRAUNSTEIN NS, 1987, P NATL ACAD SCI USA, V84, P2921, DOI 10.1073/pnas.84.9.2921; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUERSTEDDE JM, 1988, J EXP MED, V167, P473, DOI 10.1084/jem.167.2.473; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; ENGEL I, 1992, SCIENCE, V256, P1318, DOI 10.1126/science.1598575; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GLUTZMAN Y, 1981, CELL, V23, P175; GRIFFITH IJ, 1988, J EXP MED, V167, P541, DOI 10.1084/jem.167.2.541; GUILLET JG, 1986, NATURE, V324, P260, DOI 10.1038/324260a0; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; HWANG JK, 1988, NATURE, V334, P270, DOI 10.1038/334270a0; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KASIBHATLA S, 1993, J IMMUNOL, V151, P3140; KOCH N, 1982, EUR J IMMUNOL, V12, P909, DOI 10.1002/eji.1830121103; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LECHLER RI, 1990, J IMMUNOL, V144, P329; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; NALEFSKI EA, 1990, J BIOL CHEM, V265, P8842; NALEFSKI EA, 1992, J EXP MED, V175, P1553, DOI 10.1084/jem.175.6.1553; NALEFSKI EA, 1993, J IMMUNOL, V150, P3806; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4412, DOI 10.1073/pnas.91.10.4412; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1980, J IMMUNOL, V124, P533; OZATO K, 1980, J IMMUNOL, V125, P2473; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; REICH EP, 1994, J IMMUNOL, V152, P2279; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1994, NATURE, V370, P647, DOI 10.1038/370647a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; Sambrook J, 1989, MOL CLONING LABORATO; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; SYMINGTON FW, 1981, IMMUNOGENETICS, V14, P53, DOI 10.1007/BF00344299; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VANBLEEK GM, 1990, NATURE, V348, P213; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0	69	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22351	22360		10.1074/jbc.270.38.22351	http://dx.doi.org/10.1074/jbc.270.38.22351			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673219	hybrid			2022-12-25	WOS:A1995RW31400046
J	ORIAN, A; WHITESIDE, S; ISRAEL, A; STANCOVSKI, I; SCHWARTZ, AL; CIECHANOVER, A				ORIAN, A; WHITESIDE, S; ISRAEL, A; STANCOVSKI, I; SCHWARTZ, AL; CIECHANOVER, A			UBIQUITIN-MEDIATED PROCESSING OF NF-KAPPA-B TRANSCRIPTIONAL ACTIVATOR PRECURSOR P105 - RECONSTITUTION OF A CELL-FREE SYSTEM AND IDENTIFICATION OF THE UBIQUITIN-CARRIER PROTEIN, E2, AND A NOVEL UBIQUITIN-PROTEIN LIGASE, E3, INVOLVED IN CONJUGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53; DEGRADATION; BINDING; SUBUNIT; RESOLUTION; CLONING; E6-AP; E6	In most cases, the transcriptional factor NF-kappa B is a heterodimer consisting of two subunits, p50 and p65, which are encoded by two distinct genes of the Rel family. p50 is translated as a precursor of 105 kDa. The C-terminal domain of the precursor is rapidly degraded, forming the mature p50 subunit consisted of the N-terminal region of the molecule. The mechanism of generation of p50 is not known. It has been suggested that the ubiquitin-proteasome system is involved in the process; however, the specific enzymes involved and the mechanism of limited proteolysis, in which half of the molecule is spared, have been obscure. Palombella and colleagues (Palombella, V. J., Rando, O. J., Goldberg, A. L., and Maniatis, T. (1994) Cell 78, 773-785) have shown that ubiquitin is required for the processing in a cell-free system of a truncated, artificially constructed, 60-kDa precursor. They have also shown that proteasome inhibitors block the processing both in vitro and in vivo. In this study, we demonstrate reconstitution of a cell-free processing system and demonstrate directly that: (a) the ubiquitin-proteasome system is involved in processing of the intact p105 precursor, (b) conjugation of ubiquitin to the precursor is an essential intermediate step in the processing, (c) the recently discovered novel species of the ubiquitin-carrier protein, E2-F1, that is involved in the coqjugation and degradation of p53, is also required for the limited processing of the p105 precursor, and (d) a novel, similar to 320-kDa species of ubiquitin protein ligase, is involved in the process. This novel enzyme is distinct from EG-AP, the p53 conjugating ligase, and from E3 alpha, the ''N-end rule'' ligase.	TECHNION ISRAEL INST TECHNOL,DEPT BIOCHEM,IL-31096 HAIFA,ISRAEL; TECHNION ISRAEL INST TECHNOL,FAC MED,RAPPAPORT INST RES MED SCI,IL-31096 HAIFA,ISRAEL; INST PASTEUR,UNITE BIOL MOLEC EXPRESS GEN,F-75724 PARIS 15,FRANCE; UNIV WASHINGTON,SCH MED,ST LOUIS,MO 63110; CHILDRENS HOSP,DIV HEMATOL ONCOL,ST LOUIS,MO 63110	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Washington University (WUSTL); St. Louis Children's Hospital			Ciechanover, Aaron J/C-9166-2017					ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CIECHANOVER A, 1994, P NATL ACAD SCI USA, V269, P9582; COX JH, 1995, J IMMUNOL, V154, P511; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GANOTH D, 1988, J BIOL CHEM, V263, P12412; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MICHALEK MT, 1993, NATURE, V3, P552; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; REISS Y, 1988, J BIOL CHEM, V263, P2693; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SLAVICEK JM, 1988, EMBO J, V7, P3171, DOI 10.1002/j.1460-2075.1988.tb03184.x; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	47	133	135	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21707	21714		10.1074/jbc.270.37.21707	http://dx.doi.org/10.1074/jbc.270.37.21707			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665588	hybrid			2022-12-25	WOS:A1995RU75700046
J	WICE, BM; GORDON, JI				WICE, BM; GORDON, JI			A TETRASPAN MEMBRANE GLYCOPROTEIN PRODUCED IN THE HUMAN INTESTINAL EPITHELIUM AND LIVER THAT CAN REGULATE CELL DENSITY-DEPENDENT PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL-INTESTINE; DEGENERATION SLOW RDS; COLON CANCER-CELLS; MONOCLONAL-ANTIBODIES; ENTEROCYTIC DIFFERENTIATION; CD9 ANTIGEN; ANTIPROLIFERATIVE ANTIBODY; TRANSMEMBRANE PROTEINS; RETINITIS-PIGMENTOSA; SYNCYTIUM FORMATION	The human cell line HT-29 provides a model system for studying regulation of proliferation and differentiation in intestinal epithelial cell lineages: (i) HT-29 cells cultured in glucose resemble undifferentiated multipotent transit cells located in the lower half of intestinal crypts; (ii) proliferating HT-29 cells cultured in inosine resemble committed cells located in the upper half of the crypt; (iii) nonproliferating, confluent HT-29-inosine cells have features of differentiated enterocytes and goblet cells that overlie small intestinal villi. A cDNA library prepared from HT-29-inosine cells was screened with a series of subtracted cDNA probes to identify proteins that regulate proliferation/differentiation along the crypt-villus axis. A cDNA was recovered that encodes a 202-amino acid protein with four predicted membrane spanning domains and two potential sites for N-linked glycosylation. Levels of this new member of the superfamily of tetraspan membrane proteins (TMPs) increase dramatically as nondividing epithelial cells exit the proliferative compartment of the crypt-villus unit and migrate onto the villus. The protein is also produced in nondividing hepatocytes that have the greatest proliferative potential within liver acini. Three sets of observations indicate that in the appropriate cellular context, intestinal and liver (il)-TMP can mediate density-associated inhibition of proliferation. (i) Accumulation of il-TMP glycoforms precedes terminal differentiation of HT-29-inosine cells and occurs as they undergo density-dependent cessation of growth, il-TMP levels are lower and glycosylation less extensive in HT-29-glucose cells, which do not undergo growth arrest at confluence. (ii) HeLa cells normally do not produce il-TMP. Forced expression of il-TMP inhibits proliferation as cells approach confluence. The extent of il-TMP glycosylation in the transfected cells is similar to that observed in HT-29-inosine cells and greater than in HT-29-glucose cells, (iii) SW480 cells are derived from a human colon adenocarcinoma and do not express il-TMP. Like nontransfected HeLa cells, they do not stop dividing at confluence, whether grown in medium containing glucose or inosine. Expression of il-TMP has no effect on the growth properties of SW480 cells. The extent of il-TMP glycosylation in SW480 glucose cells is similar to that noted in HT-29-glucose cells, lending further support to the notion that il-TMP's activity is related to its state of N-glycosylation.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)					NIDDK NIH HHS [DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIKEN KD, 1994, DEV DYNAM, V201, P63, DOI 10.1002/aja.1002010107; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMIOT M, 1990, J IMMUNOL, V145, P4322; ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BEAULIEU JF, 1989, J BIOL CHEM, V264, P20000; BELL GM, 1992, J EXP MED, V175, P527, DOI 10.1084/jem.175.2.527; BOLLAG DM, 1991, PROTEIN METHODS, P203; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; CARROLL RC, 1990, BIOCHEM J, V266, P527, DOI 10.1042/bj2660527; CHANTRET I, 1988, CANCER RES, V48, P1936; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; DULUC I, 1994, J CELL BIOL, V126, P211, DOI 10.1083/jcb.126.1.211; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; FOLZ RJ, 1987, BIOCHEM BIOPH RES CO, V146, P870, DOI 10.1016/0006-291X(87)90611-5; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GIL ML, 1992, J IMMUNOL, V148, P2826; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; HATO T, 1990, BLOOD, V75, P1087; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HELLSTROM I, 1986, CANCER RES, V465, P3917; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HIXSON DC, 1984, EXP CELL RES, V152, P402, DOI 10.1016/0014-4827(84)90641-4; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; IMAI T, 1992, J IMMUNOL, V149, P2879; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; KALLIN B, 1992, MOL CELL BIOL, V11, P5338; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; Kellett M, 1992, Epithelial Cell Biol, V1, P147; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDBETTER JA, 1987, LEUKOCYTE TYPING, V3, P339; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P3503, DOI 10.1073/pnas.89.8.3503; MASELLISSMITH A, 1990, J IMMUNOL, V144, P1607; MATSUMOTO Y, 1992, HEPATOLOGY, V15, P1048, DOI 10.1002/hep.1840150613; NOJIMA Y, 1993, CELL IMMUNOL, V152, P249, DOI 10.1006/cimm.1993.1285; OGIERDENIS E, 1988, J BIOL CHEM, V263, P6031; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; OZAKI Y, 1991, EUR J BIOCHEM, V199, P347, DOI 10.1111/j.1432-1033.1991.tb16130.x; PATERSON DJ, 1987, J EXP MED, V165, P1, DOI 10.1084/jem.165.1.1; PAULUS U, 1993, J CELL SCI, V106, P473; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINTO M, 1982, BIOL CELL, V44, P193; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; Sambrook J, 1989, MOL CLONING LABORATO, P545; SCHICK MR, 1993, J IMMUNOL, V151, P1918; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SIGAL SH, 1992, AM J PHYSIOL, V263, pG139, DOI 10.1152/ajpgi.1992.263.2.G139; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; TRAVIS GH, 1992, NEURON, V9, P113, DOI 10.1016/0896-6273(92)90226-4; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; TRUGNAN G, 1987, J CELL BIOL, V104, P1199, DOI 10.1083/jcb.104.5.1199; ULSHAFER RJ, 1986, INVEST OPHTH VIS SCI, V27, P1587; WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213; WICE BM, 1985, J BIOL CHEM, V260, P139; WICE BM, 1992, J CELL BIOL, V116, P405, DOI 10.1083/jcb.116.2.405; WICE BM, 1981, J BIOL CHEM, V256, P7812; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P595, DOI 10.1111/j.1365-2184.1982.tb01066.x; YU J, 1994, J CELL BIOL, V125, P171, DOI 10.1083/jcb.125.1.171	78	53	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21907	21918		10.1074/jbc.270.37.21907	http://dx.doi.org/10.1074/jbc.270.37.21907			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665614	hybrid			2022-12-25	WOS:A1995RU75700075
J	BEHRENDS, S; HARTENECK, C; SCHULTZ, G; KOESLING, D				BEHRENDS, S; HARTENECK, C; SCHULTZ, G; KOESLING, D			A VARIANT OF THE ALPHA(2) SUBUNIT OF SOLUBLE GUANYLYL CYCLASE CONTAINS AN INSERT HOMOLOGOUS TO A REGION WITHIN ADENYLYL CYCLASES AND FUNCTIONS AS A DOMINANT-NEGATIVE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; MOLECULAR-CLONING; ACTIVITY REQUIRES; ENZYME SUBUNITS; RAT-KIDNEY; KINASE-C; EXPRESSION; RECEPTOR; LUNG; ACTIVATION	A variant of the alpha(2) subunit of soluble guanylyl cyclase (alpha(2i)) containing 31 additional amino acids was identified in a number of cell lines and tissues. The in-frame sequence of the insert was within the proposed catalytic domain of guanylyl cyclases and was homologous to a region within the putative catalytic domain of adenylyl cyclases. Messenger RNA for the new variant was detected in some but not all cell lines and tissues expressing the alpha(2) subunit, The novel form, as well as the alpha(2) subunit lacking the insert, were coexpressed with the beta(1) subunit in Sf9 and COS-7 cells; alpha(2)/beta(1), coexpression yielded a NO-sensitive recombinant protein, whereas the coexpressed alpha(2i)/beta(1) subunits exhibited no guanylyl or adenylyl cyclase activities. Because both subunits (alpha(2i)/ beta(1)) copurified, the novel variant retains its ability to heterodimerize. In coexpression experiments, the alpha(2i) subunit competed with the alpha(2) subunit for dimerization with the beta(1) subunit, thereby reducing alpha(2)/beta(1)-catalyzed guanylyl cyclase activity. These data show that the novel variant functions as a dominant negative protein and that post-transcriptional mRNA processing represents a potential mechanism for regulation of NO-sensitive guanylyl cyclase acitivity.	FREE UNIV BERLIN, INST PHARMAKOL, D-14195 BERLIN, GERMANY	Free University of Berlin			Behrends, Sönke/A-2551-2010	Behrends, Sönke/0000-0002-9068-0729				BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; DAYHOFF MOO, 1987, ATLAS PROTEIN SEQ S3, V5, P1; DUDA T, 1990, MOL CELL BIOCHEM, V93, P179; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; GARBERS DL, 1992, CELL, V71, P1; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GROEBE DR, 1990, NUCLEIC ACIDS RES, V18, P4033, DOI 10.1093/nar/18.13.4033; HARTENECK C, 1991, FEBS LETT, V292, P217, DOI 10.1016/0014-5793(91)80871-Y; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; KOESLING D, 1991, FASEB J, V5, P2785, DOI 10.1096/fasebj.5.13.1680765; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; KOESLING D, 1988, FEBS LETT, V239, P29, DOI 10.1016/0014-5793(88)80539-8; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MEI L, 1994, J BIOL CHEM, V269, P12254; MITTAL CK, 1977, J BIOL CHEM, V252, P3136; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKANE M, 1988, BIOCHEM BIOPH RES CO, V157, P1139, DOI 10.1016/S0006-291X(88)80992-6; NAKANE M, 1990, J BIOL CHEM, V265, P16841; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; POTTER LR, 1992, J BIOL CHEM, V267, P14531; POTTER LR, 1994, J BIOL CHEM, V269, P14636; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ G, 1984, METHOD ENZYMAT AN, V4, P369; SCHULTZ G, 1984, METHOD ENZYMAT AN, V4, P379; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; UJIIE K, 1994, J PHARMACOL EXP THER, V270, P761; UJIIE K, 1993, J CLIN INVEST, V91, P730, DOI 10.1172/JCI116255; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193; ZWILLER J, 1985, J BIOL CHEM, V260, P1350	39	61	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21109	21113		10.1074/jbc.270.36.21109	http://dx.doi.org/10.1074/jbc.270.36.21109			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673142	hybrid			2022-12-25	WOS:A1995RU05400040
J	HALLE, JP; STELZER, G; GOPPELT, A; MEISTERERNST, M				HALLE, JP; STELZER, G; GOPPELT, A; MEISTERERNST, M			ACTIVATION OF TRANSCRIPTION BY RECOMBINANT UPSTREAM STIMULATORY FACTOR-1 IS MEDIATED BY A NOVEL POSITIVE COFACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; HELIX-LOOP-HELIX; MAJOR LATE PROMOTER; TATA-BINDING PROTEIN; DNA TOPOISOMERASE-I; FACTOR USF; GENE-TRANSCRIPTION; MULTIPLE FORMS; COMPLEXES; IDENTIFICATION	The transcription factor USF1 belongs to the family of basic helix-loop helix proteins that are involved in the regulation of various important cellular processes. Here we characterized the factors involved in the activation of transcription by upstream stimulatory factor 1 (USF1) in a reconstituted class II gene transcription system. Activation of transcription by both wild type USF1 and a GAL-USF (amino acids 1-94 of the yeast activator protein GAL4 fused to amino acids 17-196 of USF) fusion protein required the presence of at least one positive cofactor. A novel positive cofactor (PC5) that functions specifically through the activation domain of USF1 was partially purified and biochemicaly distinguished from previously described positive cofactors. The mechanism by which PC5 mediates activation of transcription through USF1 was investigated in order-of-addition experiments. PC5 had to be present during binding of transcription factor (TF) IID to the TATA box to observe transcriptional activation, However, this event alone did not result in transcriptional activation, which also required the presence of the activator and of PC5 after binding of TFIID. Hence, PC5 may enter transcription during binding of TFIID to function in concert with the activator during subsequent steps in transcription.	UNIV MUNICH,GENZENTRUM,MOLEK BIOL LAB,D-81375 MUNICH,GERMANY	University of Munich				Halle, Joern-Peter/0000-0002-1178-5275				BUNGERT J, 1992, J MOL BIOL, V223, P885, DOI 10.1016/0022-2836(92)90250-N; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; KRETZSCHMAR M, 1994, MOL CELL BIOL, V6, P3927; LIEBERMAN P, 1994, MOL CELL BIOL, V14, P8365, DOI 10.1128/MCB.14.12.8365; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PERITZ LN, 1988, J BIOL CHEM, V263, P5005; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SIROTO M, 1994, NUCLEIC ACIDS RES, V22, P427; STELZER G, 1994, MOL CELL BIOL, V7, P4712; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	48	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21307	21311		10.1074/jbc.270.36.21307	http://dx.doi.org/10.1074/jbc.270.36.21307			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673166	hybrid			2022-12-25	WOS:A1995RU05400067
J	NICOLAES, GAF; TANS, G; THOMASSEN, MCLGD; HEMKER, HC; PABINGER, I; VARADI, K; SCHWARZ, HP; ROSING, J				NICOLAES, GAF; TANS, G; THOMASSEN, MCLGD; HEMKER, HC; PABINGER, I; VARADI, K; SCHWARZ, HP; ROSING, J			PEPTIDE-BOND CLEAVAGES AND LOSS OF FUNCTIONAL-ACTIVITY DURING INACTIVATION OF FACTOR VA AND FACTOR VA(R506Q) BY ACTIVATED PROTEIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-CATALYZED ACTIVATION; POOR ANTICOAGULANT RESPONSE; COAGULATION FACTOR-V; BOVINE FACTOR-X; PROTHROMBIN ACTIVATION; BLOOD-COAGULATION; S DEFICIENCY; PHOSPHOLIPIDS; PLASMA; THROMBOPHILIA	Factor V was purified from the plasma of an activated protein C (APC)-resistant patient who is homozygous for the mutation Arg(506) --> Gln (factor V-R506Q). Factor V-R506Q was converted by thrombin into factor Va which was further purified yielding a factor Va preparation that had the same cofactor activity in prothrombin activation as normal factor Va. Inactivation of low concentrations of normal factor Va (<5 nM) by 0.15 nM APC in the presence of phospholipid vesicles proceeded via a biphasic reaction that consisted of a rapid phase (k = 4.3 x 10(7) M(-1)s(-1)), yielding a reaction intermediate with reduced cofactor activity that was fully inactivated during the subsequent slow phase (k = 2.3 x 10(6) M(-1)s(-1)). Inactivation of factor Va(R506Q) proceeded via a monophasic reaction (k = 1.7 x 10(6) M(-1)s(-1)). Immunoblot analysis showed that APC-catalyzed inactivation of factor Va occurred via peptide bond cleavages in the heavy chain. The rapid phase of inactivation of normal factor Va was associated with cleavage at Arg(506) and full inactivation of factor Va required subsequent cleavage at Arg(306). The slow monophasic inactivation of factor Va(R506Q) correlated with cleavage at Arg(306). Cleavage at Arg(506) in normal factor Va resulted in accumulation of a reaction intermediate that exhibited 40% cofactor activity in prothrombin activation mixtures that contained a high factor Xa concentration (5 nM). Compared with native factor Va, the reaction intermediate retained virtually no cofactor activity at low factor Xa concentrations (0.3 nM). This demonstrates that factor Va that is cleaved at Arg(506) is impaired in its ability to interact with factor Xa. Michaelis-Menten kinetic analysis showed that cleavage at Arg(506) in membrane-bound factor Va was characterized by a low K-m for factor Va (20 nM) and k(cat) = 0.96 s(-1). For cleavage at Arg(306) in factor Va(R506Q) the kinetic parameters were K-m = 196 nM and k(cat) = 0.37 s(-1). This means that differences between APC-catalyzed inactivation of factors Va and Va(R506Q) become much less pronounced at high factor Va concentrations. When factor Va(R506Q) was inactivated by APC in the absence of phospholipids, cleavage at Arg(679) of the heavy chain also contributed to factor Va inactivation. Comparison of rate constants for APC-catalyzed cleavage at Arg(306), Arg(506) and Arg(679) in the absence and presence of phospholipids indicated that phospholipids accelerated these cleavages to a different extent. This indicates that the binding of factor Va to phospholipids changes the accessibility of the cleavage sites and/or the sequence of peptide bond cleavage by APC.	UNIV LIMBURG,CARDIOVASC RES INST MAASTRICHT,DEPT BIOCHEM,6200 MD MAASTRICHT,NETHERLANDS; UNIV HOSP VIENNA,DEPT HEMATOL & BLOOD COAGULAT,VIENNA,AUSTRIA; IMMUNO AG WIEN,VIENNA,AUSTRIA	Hasselt University; Maastricht University; University Hospital Vienna			Nicolaes, Gerry A.F./A-8421-2016	Nicolaes, Gerry A.F./0000-0002-2482-0412; Thomassen, Stella/0000-0002-9686-6364; Hemker, Coen/0000-0003-1669-2358				BAKKER HM, 1992, EUR J BIOCHEM, V208, P171, DOI 10.1111/j.1432-1033.1992.tb17171.x; BAKKER HM, 1994, J BIOL CHEM, V269, P20662; BEAUCHAMP NJ, 1994, BRIT J HAEMATOL, V88, P219, DOI 10.1111/j.1365-2141.1994.tb05005.x; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; FERSHT A, 1985, ENZYME STRUCTURE MEC, P128; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; GRUBER A, 1989, BLOOD, V73, P639; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN KG, 1990, BLOOD, V76, P1; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PLETCHER CH, 1982, J BIOL CHEM, V257, P5342; ROSING J, 1993, J BIOL CHEM, V268, P21130; ROSING J, 1980, J BIOL CHEM, V255, P274; SALA N, 1984, BLOOD, V63, P671; SCHIFFMAN S, 1969, BIOCHEMISTRY-US, V8, P1397, DOI 10.1021/bi00832a014; SCHWARZ HP, 1984, BLOOD, V64, P1297; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RL, 1973, J BIOL CHEM, V248, P2418; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; SUZUKI K, 1993, J BIOL CHEM, V258, P1914; TANS G, 1991, BLOOD, V77, P2641; TANS G, 1991, J BIOL CHEM, V266, P21864; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8	41	232	238	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21158	21166		10.1074/jbc.270.36.21158	http://dx.doi.org/10.1074/jbc.270.36.21158			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673148	hybrid			2022-12-25	WOS:A1995RU05400047
J	MCINTOSH, GG; ANDERSON, JJ; MILTON, I; STEWARD, M; PARR, AH; THOMAS, MD; HENRY, JA; ANGUS, B; LENNARD, TWJ; HORNE, CHW				MCINTOSH, GG; ANDERSON, JJ; MILTON, I; STEWARD, M; PARR, AH; THOMAS, MD; HENRY, JA; ANGUS, B; LENNARD, TWJ; HORNE, CHW			DETERMINATION OF THE PROGNOSTIC VALUE OF CYCLIN D1 OVEREXPRESSION IN BREAST-CANCER	ONCOGENE			English	Article						CYCLIN D1; MONOCLONAL ANTIBODY; IMMUNOHISTOCHEMISTRY; BREAST CANCER; PROGNOSIS	CELL-CYCLE; GENE AMPLIFICATION; DNA-REPLICATION; EXPRESSION; ONCOGENE; RETINOBLASTOMA; PROGRESSION; CARCINOMAS; SURVIVAL; C-ERBB-2	Cyclin D1 plays a critical role in the timing of the initiation of DNA synthesis in the normal cell cycle of mammalian cells, Deregulated expression of this protein has been seen in a variety of tumours either as a result of gene amplification or chromosomal translocation, in breast cancer and B cell malignancies respectively. In order to determine the role this putative oncoprotein plays in breast cancer, we have applied a new monoclonal antibody, recently produced in our laboratory, in an imnunohistochemical study of 93 primary breast carcinomas. We show that approximately 28% of the cases displayed enhanced expression of the cyclin D1 protein. Furthermore, either cyclin D1, cyclin D3, or both, were expressed in 69% of cases, suggesting that overexpression of any one member of this family may relieve cancer cells of their mitogenic stimulatory requirement. In addition, we show that those patients whose breast cancers co-express cyclin D1 with either epidermal growth factor receptor (EGFR) or the retinoblastoma protein (pRB) have a significantly poorer prognosis in comparison to those expressing cyclin D1 alone. Our observations indicate that, in a subset of breast cancers, aberrant cyclin D1 expression is a contributory factor to tumorigenesis and in association with EGFR or pRB expression, identify those tumours which may require more aggressive therapy.	NOVOCASTRA LABS, NEWCASTLE UPON TYNE NE2 4AA, TYNE & WEAR, ENGLAND; UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT SURG, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND	Newcastle University - UK	MCINTOSH, GG (corresponding author), UNIV NEWCASTLE UPON TYNE, ROYAL VICTORIA INFIRM, DEPT PATHOL, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND.		Angus, Brian/L-9246-2019	Angus, Brian/0000-0003-3598-7784				ADNANE J, 1989, ONCOGENE, V4, P1389; AJCHENBAUM F, 1992, J CELL BIOL, V268, P4113; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P71; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CARTER MJ, 1993, NUCLEIC ACIDS RES, V21, P1044, DOI 10.1093/nar/21.4.1044; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FURLANETTO RW, 1994, MOL ENDOCRINOL, V8, P510, DOI 10.1210/me.8.4.510; HARPER JW, 1993, CELL, V75, P805; HASTRICH D, 1992, J PATHOL S, V167, pA143; HENRY JA, 1993, INT J CANCER, V53, P774, DOI 10.1002/ijc.2910530512; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; KCOH KS, 1994, BIOCHEM BIOPH RES CO, V204, P91; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; LAMMIE GA, 1991, ONCOGENE, V6, P439; LI Y, 1994, ONCOGENE, V9, P2261; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1994, ONCOGENE, V9, P2159; Maniatis T, 1989, MOL CLONING; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCINTOSH EM, 1993, MUTAT RES, V289, P61, DOI 10.1016/0027-5107(93)90131-X; MORGAN JM, 1994, J PATHOL, V174, P301, DOI 10.1002/path.1711740410; MORISAKI T, 1994, CANCER RES, V54, P1113; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NANXIN L, 1994, ONCOGENE, V9, P3457; PALMERO I, 1993, ONCOGENE, V8, P1049; PEPPER DS, 1994, BIOCHIM BIOPHYS ACTA, V1198, P215; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SAWAN A, 1992, J PATHOL, V168, P23, DOI 10.1002/path.1711680105; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SURMACZ E, 1992, CANCER RES, V52, P4522; TAM SW, 1994, ONCOGENE, V9, P2663; THEILLET C, 1989, ONCOGENE, V4, P915; TINIAKOS DG, 1994, J PATHOL, V172, P19, DOI 10.1002/path.1711720106; WRIGHT C, 1989, CANCER RES, V49, P2087; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479; ZHANG SY, 1994, AM J CLIN PATHOL, V102, P695, DOI 10.1093/ajcp/102.5.695	52	212	215	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					885	891						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675447				2022-12-25	WOS:A1995RU79800009
J	SUEN, KL; BUSTELO, XR; BARBACID, M				SUEN, KL; BUSTELO, XR; BARBACID, M			LACK OF EVIDENCE FOR THE ACTIVATION OF THE RAS RAF MITOGENIC PATHWAY BY 14-3-3-PROTEINS IN MAMMALIAN-CELLS	ONCOGENE			English	Article						RAS PROTEINS; RAF KINASE; MEK; MAP KINASE; SIGNAL TRANSDUCTION	TYROSINE 3-MONOOXYGENASE; KINASE-C; TRANSFORMATION; IDENTIFICATION; FAMILY; DNA	We have isolated cDNA clones encoding the rodent 14-3-3 zeta and epsilon isoforms by screening bacteriophage expression libraries vith a probe derived from the carboxy-terminus of the Vav oncoprotein. These isoforms, however, did not recognize the full length Vav protein under physiological conditions. In agreement with previous studies (see D Morrison, Science 266, 56-57, 1994), these 14-3-3 proteins bound very efficiently to Raf. The interaction between 14-3-3 zeta and Raf involves the central region of 14-3-3 zeta which includes a motif related to annexins. 14-3-3 zeta binds to Raf independently of Ras and forms stable ternary complexes with these two molecules. In contrast to published reports, we have observed that the catalytic activity of Raf was not activated in Raf/14-3-3 zeta immunocomplexes. Likewise, purified preparations of 14-3-3 zeta had no effect on the kinase activity of Raf immunoprecipitates. In addition, Ras activated Raf regardless of whether it was bound or not to 14-3-3 zeta. Finally, overexpression of 14-3-3 zeta cDNA clones in NIH3T3 cells did not result in detectable morphologic transformation even when co-transfected with plasmids encoding Raf and/or Ras proteins. These observations argue against a critical regulatory role of the 14-3-3 proteins in the Raf mitogenic pathway.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC ONCOL,PRINCETON,NJ 08543	Bristol-Myers Squibb			Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072				AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHEN FS, 1994, FEBS LETT, V347, P128, DOI 10.1016/0014-5793(94)00520-6; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUADRADO A, 1993, ONCOGENE, V8, P2443; DU XP, 1994, J BIOL CHEM, V269, P18287; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ICHIMURA T, 1987, FEBS LETT, V219, P79, DOI 10.1016/0014-5793(87)81194-8; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LOEB LA, 1986, J BIOL CHEM, V262, P10467; LU GH, 1992, P NATL ACAD SCI USA, V89, P11490, DOI 10.1073/pnas.89.23.11490; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; RAPP UR, 1991, ONCOGENE, V6, P495; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROBINSON K, 1994, BIOCHEM J, V239, P853; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAKAHASHI N, 1991, J MOL BIOL, V217, P125; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; YAMAUCHI T, 1981, BIOCHEM BIOPH RES CO, V100, P807, DOI 10.1016/S0006-291X(81)80246-X	39	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					825	831						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675443				2022-12-25	WOS:A1995RU79800002
J	EASTMAN, J; WILSON, EJ; CERVENANSKY, C; ROSENBERRY, TL				EASTMAN, J; WILSON, EJ; CERVENANSKY, C; ROSENBERRY, TL			FASCICULIN-2 BINDS TO THE PERIPHERAL SITE ON ACETYLCHOLINESTERASE AND INHIBITS SUBSTRATE HYDROLYSIS BY SLOWING A STEP INVOLVING PROTON-TRANSFER DURING ENZYME ACYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED HYDROLYSIS; TORPEDO-CALIFORNICA; SPECIFICITY; LIGANDS; ESTERS; VENOM	The acetylcholinesterase active site consists of a gorge 20 Angstrom deep that is lined with aromatic residues, A serine residue near the base of the gorge defines an acylation site where an acyl enzyme intermediate is formed during the hydrolysis of ester substrates, Residues near the entrance to the gorge comprise a peripheral site where inhibitors like propidium and fasciculin 2, a snake neurotoxin, bind and interfere with catalysis, We report here the association and dissociation rate constants for fasciculin 2 interaction with the human enzyme in the presence of ligands that bind to either the peripheral site or the acylation site, These kinetic data confirmed that propidium is strictly competitive with fasciculin 2 for binding to the peripheral site, In contrast, edrophonium, N-methylacridinium, and butyrylthiocholine bound to the acylation site and formed ternary complexes with the fasciculin a-bound enzyme in which their affinities were reduced by about an order of magnitude from their affinities in the free enzyme. Steady state analysis of the inhibition of substrate hydrolysis by fasciculin 2 revealed that the ternary complexes had residual activity, For acetylthiocholine and phenyl acetate, saturating amounts of the toxin reduced the first-order rate constant k(cat) to 0.5-2% and the second-order rate constant k(cat)/K-app to 0.2-2% of their values with the uninhibited enzyme, To address whether fasciculin 2 inhibition primarily involved steric blockade of the active site or conformational interaction with the acylation site, deuterium oxide isotope effects on these kinetic parameters were measured, The isotope effect on k(cat)/K-app increased for both substrates when fasciculin 2 was bound to the enzyme, indicating that fasciculin 2 acts predominantly by altering the conformation of the active site in the ternary complex so that steps involving proton transfer during enzyme acylation are slowed,	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44120; INST INVEST BIOL,MONTEVIDEO 11600,URUGUAY	Case Western Reserve University; Instituto de Investigaciones Biologicas Clemente Estable Uruguay			Eastman, Joseph T./O-6150-2019	Eastman, Joseph T./0000-0003-3868-261X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016577] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-16577] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARAK D, 1994, J BIOL CHEM, V269, P6296; BARNETT P, 1977, J BIOL CHEM, V252, P7200; BERMAN HA, 1990, BIOCHEMISTRY-US, V29, P10640, DOI 10.1021/bi00499a010; BERNHARD SA, 1968, STRUCTURE FUNCTION E, P83; CERVENANSKY C, 1994, BBA-GEN SUBJECTS, V1199, P1, DOI 10.1016/0304-4165(94)90088-4; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GNAGEY AL, 1987, J BIOL CHEM, V262, P13290; HAAS R, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P131; HODGE AS, 1992, MOL PHARMACOL, V41, P937; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; KRUPKA RM, 1961, J AM CHEM SOC, V83, P1454, DOI 10.1021/ja01467a043; LEDU MH, 1992, J BIOL CHEM, V267, P22122; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; NACHMANSOHN D, 1951, ADV ENZYMOL REL S BI, V12, P259; NOLTE HJ, 1980, BIOCHEMISTRY-US, V19, P3705, DOI 10.1021/bi00557a011; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1994, J BIOL CHEM, V269, P11233; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; RAO M, 1993, J AM CHEM SOC, V115, P11676, DOI 10.1021/ja00078a003; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; ROSENBERRY TL, 1979, BIOPHYS J, V26, P263, DOI 10.1016/S0006-3495(79)85249-2; ROSENBERRY TL, 1984, J BIOL CHEM, V259, P5643; ROSENBERRY TL, 1977, BIOCHEMISTRY-US, V16, P3870, DOI 10.1021/bi00636a024; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; ROSENBERRY TL, 1975, P NATL ACAD SCI USA, V72, P3834, DOI 10.1073/pnas.72.10.3834; SCHALK I, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P117; SELWOOD T, 1993, J AM CHEM SOC, V115, P10477, DOI 10.1021/ja00076a002; SUSSMAN JL, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P95; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x	34	99	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19694	19701		10.1074/jbc.270.34.19694	http://dx.doi.org/10.1074/jbc.270.34.19694			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649979	hybrid			2022-12-25	WOS:A1995RQ99100007
J	MOYLE, WR; CAMPBELL, RK; RAO, SNV; AYAD, NG; BERNARD, MP; HAN, Y; WANG, YH				MOYLE, WR; CAMPBELL, RK; RAO, SNV; AYAD, NG; BERNARD, MP; HAN, Y; WANG, YH			MODEL OF HUMAN CHORIONIC-GONADOTROPIN AND LUTROPIN RECEPTOR INTERACTION THAT EXPLAINS SIGNAL-TRANSDUCTION OF THE GLYCOPROTEIN HORMONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; LEUCINE-RICH REPEATS; ALPHA-SUBUNIT; HUMAN CHORIOGONADOTROPIN; MONOCLONAL-ANTIBODIES; HIGH-AFFINITY; LINKED OLIGOSACCHARIDES; EXTRACELLULAR DOMAIN; LUTEINIZING-HORMONE; ANTIGENIC STRUCTURE	The goal of these studies was to devise a model that explains how human chorionic gonadotropin (hCG) interacts with lutropin (LH) receptors to elicit a hormone signal. Here we show that alpha-subunit residues near the N terminus, the exposed surface of the cysteine knot, and portions of the first and third loops most distant from the beta-subunit interface were recognized by antibodies that bound to hCG-receptor complexes. These observations were combined with similar data obtained for the beta-subunit (Cosowsky, L., Rao, S. N. V,, Macdonald, G. J., Papkoff, H., Campbell, R K,, and Moyle, W. R. (1995) J. Biol. Chem. 270, 20011-20019), information on residues of hCG that can be changed without disrupting hormone function, the crystal structure of deglycosylated hCG, and the crystal structure of a leucine-repeat protein to devise a model of hCG-receptor interaction. This model suggests that the extracellular domain of the LH receptor is ''U-'' or ''J''-shaped and makes several contacts with the transmembrane domain. High affinity hormone binding results from interactions between residues in the curved portion of the extracellular domain of the receptor and the groove in the hormone formed by the apposition of the second cr subunit loop and the first and third P-subunit loops. Most of the remainder of the hormone is found in the large space between the arms of the extracellular domain and makes few, if any, additional specific contacts with the receptor needed for high affinity binding. Signal transduction is caused by steric or other influences of the hormone on the distance between the arms of the extracellular domain, an effect augmented by the oligosaccharides. Because the extracellular domain is coupled at multiple sites to the transmembrane domain, the change in conformation of the extracellular domain is relayed to the transmembrane domain and subsequently to the cytoplasmic surface of the plasma membrane. While the model does not require the hormone to contact the transmembrane domain to initiate signal transduction, small portions of both subunits may be near the transmembrane domain and assist in initiating the hormonal signal. This is the first model that is consistent with all known information on the activity of the gonadotropins including the amounts of the hormone that are exposed in the hormone-receptor complex, the apparent lack of specific contacts between much of the hormone and the receptor, and the roles of the oligosaccharides in signal transduction. This model differs from existing models of hormone action in that the extracellular domain has a much larger role in hormone action than serving as a high affinity hormone trap.			MOYLE, WR (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT OBSTET & GYNECOL, 675 HOES LANE, PISCATAWAY, NJ 08854 USA.		Campbell, Robert/G-4112-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD014907, P01HD015454, R01HD024650, R37HD014907] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24650, HD15454, HD14907] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMSTRONG EG, 1986, BIOCHEM ACTION HORM, V13, P91; ARMSTRONG EG, 1984, J CLIN ENDOCR METAB, V59, P867, DOI 10.1210/jcem-59-5-867; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BIDART JM, 1989, ENDOCRINOLOGY, V124, P923, DOI 10.1210/endo-124-2-923; BIRKEN S, 1986, J BIOL CHEM, V261, P719; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CAMPBELL RK, 1992, MOL CELL ENDOCRINOL, V83, P195, DOI 10.1016/0303-7207(92)90159-4; CHARLESWORTH MC, 1991, ENDOCRINOLOGY, V128, P2907, DOI 10.1210/endo-128-6-2907; CHARLESWORTH MC, 1990, ENDOCRINOLOGY, V127, P2977, DOI 10.1210/endo-127-6-2977; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; CHEN WY, 1991, J BIOL CHEM, V266, P9355; COSOWSKY L, 1995, J BIOL CHEM, V270, P20011, DOI 10.1074/jbc.270.34.20011; CRUZ RI, 1987, J CLIN ENDOCR METAB, V64, P433, DOI 10.1210/jcem-64-3-433; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; EHRLICH PH, 1985, AM J REPROD IM MIC, V8, P48; EHRLICH PH, 1983, METHOD ENZYMOL, V50, P638; HOJO H, 1985, ENDOCRINOLOGY, V117, P2428, DOI 10.1210/endo-117-6-2428; HUANG JN, 1993, J BIOL CHEM, V268, P9311; JI I, 1991, J BIOL CHEM, V266, P13076; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LIU C, 1993, J BIOL CHEM, V268, P21613; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MILIUS RP, 1983, P NATL ACAD SCI-BIOL, V80, P7375, DOI 10.1073/pnas.80.24.7375; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1987, J BIOL CHEM, V262, P16920; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MOYLE WR, 1991, J BIOL CHEM, V266, P10807; MOYLE WR, 1988, J RECEPTOR RES, V8, P419, DOI 10.3109/10799898809049002; MOYLE WR, 1975, J BIOL CHEM, V250, P9163; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PANTEL J, 1993, BIOCHEM BIOPH RES CO, V195, P588, DOI 10.1006/bbrc.1993.2086; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; PRASAD L, 1993, J BIOL CHEM, V268, P10705; RAO SNV, 1994, TECHNIQUES PROTEIN C, V5, P413; REBOIS RV, 1984, J BIOL CHEM, V259, P8087; REBOIS RV, 1987, J BIOL CHEM, V262, P3891; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; VANDIJK S, 1993, ENDOCRINOLOGY, V132, P534, DOI 10.1210/en.132.2.534; WEARE JA, 1979, J BIOL CHEM, V254, P6972; WEINER RS, 1992, MOL CELL ENDOCRINOL, V85, P41, DOI 10.1016/0303-7207(92)90123-N; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; XIE YB, 1990, J BIOL CHEM, V265, P21411; YOO JK, 1993, J BIOL CHEM, V268, P13034	51	120	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20020	20031		10.1074/jbc.270.34.20020	http://dx.doi.org/10.1074/jbc.270.34.20020			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650020	hybrid			2022-12-25	WOS:A1995RQ99100053
J	VENTURACLAPIER, R; KUZNETSOV, AV; DALBIS, A; VANDEURSEN, J; WIERINGA, B; VEKSLER, VI				VENTURACLAPIER, R; KUZNETSOV, AV; DALBIS, A; VANDEURSEN, J; WIERINGA, B; VEKSLER, VI			MUSCLE CREATINE KINASE-DEFICIENT MICE .1. ALTERATIONS IN MYOFIBRILLAR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GUANIDINOPROPIONIC ACID; SKELETAL-MUSCLE; ADENOSINE-TRIPHOSPHATASE; CA-2+ SENSITIVITY; MYOSIN; FIBERS; ANALOG; TROPONIN; RATS; COMPARTMENTATION	The regulation of contractile activity in mice bearing a null mutation of the M-isoform of creatine kinase gene, has been investigated in tissue extracts and Triton X-100-treated preparations of ventricular, soleus, and gastrocnemius muscles of control and transgenic mice. Skinned fiber experiments did not evidence any statistical difference in the maximal force or the calcium sensitivity of either muscle type. Rigor tension development at a low MgATP concentration was greatly influenced by phosphocreatine in control but not in transgenic mice as should be expected. In calcium-activated ventricular preparations, although the force developed by each cross-bridge was the same in control and transgenic animals, the rate constant of tension changes appeared to be markedly slowed in transgenic animals. As the ventricular isomyosin pattern was not altered, we suggested that, in transgenic animals, cross-bridge cycling was hindered by a local decrease in the MgATP to MgADP ratio, due to lack of a local MgATP regenerating system. Myokinase activity was not significantly changed while activities of pyruvate kinase or glyceraldehyde-3-phosphate dehydrogenase were found to be increased in transgenic animals. These results show that no fundamental remodelling occurs in myofibrils of transgenic animals but that important adaptations modify the bioenergetic pathways including glycolytic metabolism.	UNIV PARIS 11, CNRS, URA 1131, F-91405 ORSAY, FRANCE; UNIV NIJMEGEN, FAC MED SCI, DEPT HISTOL & CELL BIOL, 6500 HB NIJMEGEN, NETHERLANDS; CARDIOL RES CTR, MOSCOW 121552, RUSSIA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Radboud University Nijmegen; National Medical Research Center of Cardiology	VENTURACLAPIER, R (corresponding author), UNIV PARIS SUD, FAC PHARM, INSERM, CJF9211, CARDIOL CELLULAIRE & MOLEC LAB, F-92296 CHATENAY MALABRY, FRANCE.		Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020; Ventura-Clapier, Renee/0000-0002-7488-4123; Veksler, Vladimir/0000-0002-8869-9594				ARRIODUPONT M, 1992, EUR J BIOCHEM, V207, P951, DOI 10.1111/j.1432-1033.1992.tb17129.x; BESSMAN SP, 1980, BIOCHEM BIOPH RES CO, V96, P1414, DOI 10.1016/0006-291X(80)90108-4; BRANDT PW, 1982, J GEN PHYSIOL, V79, P997, DOI 10.1085/jgp.79.6.997; COOKE R, 1985, BIOPHYS J, V48, P789, DOI 10.1016/S0006-3495(85)83837-6; D'ALBIS A, 1973, Febs Letters, V29, P292, DOI 10.1016/0014-5793(73)80042-0; DALBIS A, 1979, EUR J BIOCHEM, V99, P261, DOI 10.1111/j.1432-1033.1979.tb13253.x; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FOSSEL ET, 1987, AM J PHYSIOL, V252, pE124, DOI 10.1152/ajpendo.1987.252.1.E124; GARVEY JL, 1988, BIOCHEM J, V249, P709, DOI 10.1042/bj2490709; HOAR PE, 1987, PFLUG ARCH EUR J PHY, V410, P30, DOI 10.1007/BF00581892; HOH JFY, 1975, BIOCHEMISTRY-US, V14, P742, DOI 10.1021/bi00675a015; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; IYENGAR MR, 1984, J MUSCLE RES CELL M, V5, P527, DOI 10.1007/BF00713259; KAPELKO VI, 1988, J MOL CELL CARDIOL, V20, P465, DOI 10.1016/S0022-2828(88)80074-9; KUPRIYANOV VV, 1991, AM J PHYSIOL, V261, P45, DOI 10.1152/ajplung.1991.261.4.L45; LOMPRE AM, 1981, DEV BIOL, V84, P286, DOI 10.1016/0012-1606(81)90396-1; MAUGHAN DW, 1989, BIOPHYS J, V56, P717, DOI 10.1016/S0006-3495(89)82719-5; MAYOUX E, 1994, AM J PHYSIOL, V266, pH2051, DOI 10.1152/ajpheart.1994.266.5.H2051; MEKHFI H, 1990, AM J PHYSIOL, V258, pH1151, DOI 10.1152/ajpheart.1990.258.4.H1151; MEKHFI H, 1988, PFLUG ARCH EUR J PHY, V411, P378, DOI 10.1007/BF00587716; MOERLAND TS, 1989, AM J PHYSIOL, V257, pC810, DOI 10.1152/ajpcell.1989.257.4.C810; NASSAR R, 1991, CIRC RES, V69, P1470, DOI 10.1161/01.RES.69.6.1470; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; OTSU N, 1989, J HISTOCHEM CYTOCHEM, V37, P1465, DOI 10.1177/37.10.2778305; PAN BS, 1992, J BIOL CHEM, V267, P23052; RAY KP, 1976, FEBS LETT, V70, P11, DOI 10.1016/0014-5793(76)80716-8; SAKS VA, 1976, FEBS LETT, V62, P293, DOI 10.1016/0014-5793(76)80078-6; SAKS VA, 1984, BIOCHIM BIOPHYS ACTA, V803, P254, DOI 10.1016/0167-4889(84)90115-0; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; SHOUBRIDGE EA, 1985, BIOCHEM J, V232, P125, DOI 10.1042/bj2320125; SHOUBRIDGE EA, 1984, BIOCHIM BIOPHYS ACTA, V805, P79, DOI 10.1016/0167-4889(84)90039-9; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SOLARO RJ, 1988, CIRC RES, V63, P779, DOI 10.1161/01.RES.63.4.779; TALMADGE RJ, 1993, J APPL PHYSIOL, V75, P2337, DOI 10.1152/jappl.1993.75.5.2337; VANDEURSEN J, 1994, BBA-BIOENERGETICS, V1185, P327, DOI 10.1016/0005-2728(94)90248-8; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VEKSLER VI, 1995, J BIOL CHEM, V270, P19921, DOI 10.1074/jbc.270.34.19921; VENTURACLAPIER R, 1994, CIRC RES, V74, P920, DOI 10.1161/01.RES.74.5.920; VENTURACLAPIER R, 1994, MOL CELL BIOCHEM, V133, P125, DOI 10.1007/BF01267952; VENTURACLAPIER R, 1987, AM J PHYSIOL, V253, pC444, DOI 10.1152/ajpcell.1987.253.3.C444; VENTURACLAPIER R, 1987, J GEN PHYSIOL, V89, P815, DOI 10.1085/jgp.89.5.815; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; WEGMANN G, 1992, J MUSCLE RES CELL M, V13, P420, DOI 10.1007/BF01738037; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; YAMASHITA K, 1991, J MUSCLE RES CELL M, V12, P37, DOI 10.1007/BF01781172; ZWEIER JL, 1991, J BIOL CHEM, V266, P20296	48	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19914	19920		10.1074/jbc.270.34.19914	http://dx.doi.org/10.1074/jbc.270.34.19914			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650006	hybrid, Green Published			2022-12-25	WOS:A1995RQ99100038
J	LEHEL, C; OLAH, Z; JAKAB, G; SZALLASI, Z; PETROVICS, G; HARTA, G; BLUMBERG, PM; ANDERSON, WB				LEHEL, C; OLAH, Z; JAKAB, G; SZALLASI, Z; PETROVICS, G; HARTA, G; BLUMBERG, PM; ANDERSON, WB			PROTEIN-KINASE-C-EPSILON SUBCELLULAR-LOCALIZATION DOMAINS AND PROTEOLYTIC DEGRADATION SITES - A MODEL FOR PROTEIN-KINASE-C CONFORMATIONAL-CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; SIGNAL TRANSDUCTION; REGULATORY DOMAIN; PKC-EPSILON; CELLS; ASSOCIATION; ACTIVATION; ISOFORM; FIBROBLASTS; MORPHOLOGY	Protein kinase C (PKC) epsilon has been found to have unique properties among the PKC isozymes in terms of its membrane association, oncogenic potential, and substrate specificity, Recently we have demonstrated that PKC epsilon localizes to the Golgi network via its zinc finger domain and that both the holoenzyme and its zinc finger region modulate Golgi function. To further characterize the relationship between the domain organization and the subcellular localization of PKC epsilon, a series of NIH 3T3 cell lines were created, each overexpressing a different truncated version of PKC epsilon. The overexpressed proteins each were designed to contain an epsilon-epitope tag peptide at the COOH terminus to allow ready detection with an antibody specific for the tag. The subcellular localization of the recombinant proteins was analyzed by in vivo phorbol ester binding, immunocytochemistry, and cell fractionation followed by immunoblotting. Results revealed several regions of PKC epsilon that contain putative subcellular localization signals. The presence either of the hinge region or of a 33-amino-acid region including the pseudosubstrate sequence in the recombinant proteins resulted in association with the plasma membrane and cytoskeletal components. The catalytic domain was found predominantly in the cytosolic fraction. The accessibility and thus the dominance of these localization signals is likely to be affected by the overall conformation of the recombinant proteins. Regions with putative proteolytic degradation sites also were identified. The susceptibility of the overexpressed proteins to proteolytic degradation was dependent on the protein conformation. Based on these observations, a model depicting the interaction and hierarchy of the suspected localization signals and proteolytic degradation sites is presented.	NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; NINCDS,EXPTL NEUROPATHOL LAB,BETHESDA,MD; NINCDS,CLIN NEUROSCI BRANCH,BETHESDA,MD; NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Petrovics, Gyorgy/0000-0003-3732-284X; Szallasi, Zoltan/0000-0001-5395-7509				AKITA Y, 1994, J BIOL CHEM, V269, P4653; BAXTER G, 1992, J BIOL CHEM, V267, P1910; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10950, DOI 10.1021/bi00160a002; CACACE AM, 1993, ONCOGENE, V8, P2095; CHIDA K, 1994, MOL CELL BIOL, V14, P3782, DOI 10.1128/MCB.14.6.3782; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEKKER LV, 1993, J BIOL CHEM, V268, P19498; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LEHEL C, 1994, J BIOL CHEM, V269, P4761; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOSIOR M, 1991, BIOPHYS J, V60, P149, DOI 10.1016/S0006-3495(91)82038-0; MOSKALEWSKI S, 1992, J SUBMICR CYTOL PATH, V24, P359; NEWTON AC, 1994, J CELL BIOCHEM     S, V18, P68; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; SPUDICH A, 1992, CELL MOTIL CYTOSKEL, V22, P250, DOI 10.1002/cm.970220405; SZALLASI Z, 1995, MOL PHARMACOL, V47, P285; THOMAS TP, 1988, CANCER RES, V48, P1910; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159	38	69	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19651	19658		10.1074/jbc.270.33.19651	http://dx.doi.org/10.1074/jbc.270.33.19651			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642654	hybrid			2022-12-25	WOS:A1995RP70300070
J	LIU, J; SCHONEBERG, T; VANRHEE, M; WESS, J				LIU, J; SCHONEBERG, T; VANRHEE, M; WESS, J			MUTATIONAL ANALYSIS OF THE RELATIVE ORIENTATION OF TRANSMEMBRANE HELIX-I AND HELIX-VII IN G-PROTEIN-COUPLED RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTAGONIST BINDING; IDENTIFICATION; ACETYLCHOLINE; GENES; SELECTIVITY; EXPRESSION; RHODOPSIN; AGONIST; DOMAINS; DNA	Currently, detailed structural information about the arrangement of the seven transmembrane helices (TM I-VII) present in all G protein-coupled receptors is still lacking. We demonstrated previously that hybrid m2/m5 muscarinic acetylcholine receptors which contain m5 sequence in TRI I and m2 sequence in TM VII were unable to bind significant amounts of muscarinic radioligands (Pittel, Z., and Wess, J. (1994) Mol. Pharmacol. 45, 61-64). By using immunocytochemical and enzyme-linked immunosorbent assay techniques, we show in the present study that these pharmacologically inactive mutant receptors are present (at high levels) on the surface of transfected COS-7 cells. Strikingly, all misfolded m2/m5 hybrid receptors could be pharmacologically rescued by introduction of a single point mutation into either TM I (m5Thr(37) --> m2Ala(30)) or TM VII (m2Thr(423) --> m5His(478)). All experimental data are consistent with the notion that the two altered threonine residues face each other at the TM I/TM VII interface in the pharmacologically inactive m2/m5 hybrid receptors, thus interfering with proper helix-helix packing. Our data provide the first experimental evidence as to how TM I and TM VII are oriented relative to each other and also strongly suggest that the TM helices in G protein-coupled receptors are arranged in a counterclockwise fashion (as viewed from the extracellular membrane surface).	NIDDK, BIOORGAN CHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BLUML K, 1994, J BIOL CHEM, V269, P18870; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; HIBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7, DOI 10.1016/0165-6147(93)90106-T; Higuchi R., 1989, PCR TECHNOLOGY, P61; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; MATSUI H, 1995, MOL PHARMACOL, V47, P88; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NORDVALL G, 1993, J MED CHEM, V36, P967, DOI 10.1021/jm00060a003; PITTEL Z, 1994, MOL PHARMACOL, V45, P61; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; WATSON S, 1994, G PROTEIN LINKED REC, P1; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1990, MOL PHARMACOL, V38, P517; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WESS J, 1992, MOL PHARMACOL, V41, P369; ZHOU W, 1994, MOL PHARMACOL, V45, P165; ZOFFMANN S, 1993, FEBS LETT, V336, P506, DOI 10.1016/0014-5793(93)80865-R	39	65	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19532	19539		10.1074/jbc.270.33.19532	http://dx.doi.org/10.1074/jbc.270.33.19532			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642637	hybrid			2022-12-25	WOS:A1995RP70300053
J	NEWMYER, SL; DEMONTELLANO, PRO				NEWMYER, SL; DEMONTELLANO, PRO			HORSERADISH-PEROXIDASE HIS-42-]ALA, HIS-42-]VAL, AND PHE-41-]ALA MUTANTS - HISTIDINE CATALYSIS AND CONTROL OF SUBSTRATE ACCESS TO THE HEME IRON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; PROSTHETIC HEME; ABSOLUTE STEREOCHEMISTRY; LIGNIN PEROXIDASE; HYDROGEN-PEROXIDE; LINKED IONIZATION; CRYSTAL-STRUCTURE; RADICAL SITE; SODIUM-AZIDE; COMPOUND-I	Polyhistidine-tagged horseradish peroxidase (hHRP) and its F41A, H42A, and H42V mutants have been expressed in an insect cell system. Kinetic studies show that the rates of Compound I formation and peroxidative catalysis are greatly decreased by the His-42 mutation, Furthermore, Compound II is not detected during turnover of the His-42 mutants, Compounds I and II are the two- and one-electron oxidized intermediates, respectively, of hHRP. In peroxygenative catalysis, the F41A and H42A mutants catalyze thioanisole sulfoxidation 100 and 10 times faster, respectively, than hHRP. Styrene epoxidation is catalyzed by both the Phe-41 and His-42 mutants but not by wild type hHRP. The higher peroxygenase activity of the mutants reflects increased accessibility of the ferryl species. This is indicated by the finding that, contrary to the reaction with wild-type hHRP, reaction of phenyldiazene with the F41A mutant yields a new and unidentified product, and the same reaction with the His-42 mutants yields phenyl iron complexes, Phe-41 and His-42 thus shield the iron-centered catalytic species, and His-42 plays a key catalytic role in the formation of Compound I. The peroxygenase activities of the Phe-41 and His-42 mutants approach those of cytochrome P450.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco				Newmyer, Sherri/0000-0003-1039-5416	NIGMS NIH HHS [GM32488] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATOR MA, 1987, J BIOL CHEM, V262, P14954; ATOR MA, 1987, J BIOL CHEM, V262, P1542; BAGGER S, 1971, ACTA CHEM SCAND, V25, P976, DOI 10.3891/acta.chem.scand.25-0976; BAYNTON KJ, 1994, BBA-PROTEIN STRUCT M, V1206, P272, DOI 10.1016/0167-4838(94)90218-6; DEMONTELLANO PRO, 1983, J BIOL CHEM, V258, P558; DEMONTELLANO PRO, 1987, ACCOUNTS CHEM RES, V20, P289; DEMONTELLANO PRO, 1995, BIOCHEM SOC T, V23, P223, DOI 10.1042/bst0230223; DEMONTELLANO PRO, 1995, IN PRESS BIOCH PARIS; DEMONTELLANO PRO, 1991, ANN REV PHARM TOXICO, V32, P89; DEPILLIS GD, 1989, BIOCHEMISTRY-US, V28, P7947, DOI 10.1021/bi00445a059; DEPILLIS GD, 1990, ARCH BIOCHEM BIOPHYS, V280, P217, DOI 10.1016/0003-9861(90)90539-B; DOLPHIN D, 1974, P NATL ACAD SCI USA, V68, P614; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; EVERETT AJ, 1953, T FARADAY SOC, V49, P410, DOI 10.1039/tf9534900410; FARHANGRAZI ZS, 1994, BIOCHEMISTRY-US, V33, P5647, DOI 10.1021/bi00184a038; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FISHEL LA, 1987, BIOCHEMISTRY-US, V26, P351, DOI 10.1021/bi00376a004; FRUETEL J, 1994, J AM CHEM SOC, V116, P11643, DOI 10.1021/ja00105a003; FRUETEL JA, 1992, J AM CHEM SOC, V114, P6987, DOI 10.1021/ja00044a006; GOODIN DB, 1991, BIOCHEMISTRY-US, V30, P4953, DOI 10.1021/bi00234a017; HARRIS RZ, 1993, J BIOL CHEM, V268, P1637; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; HENRISSAT B, 1990, PROTEINS, V8, P251, DOI 10.1002/prot.340080307; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; KUNZE KL, 1983, J AM CHEM SOC, V105, P1380, DOI 10.1021/ja00343a057; MARKLUND S, 1973, ARCH BIOCHEM BIOPHYS, V154, P614, DOI 10.1016/0003-9861(73)90016-7; MILLER VP, 1992, J BIOL CHEM, V267, P8936; NAKAJIMA R, 1980, J BIOL CHEM, V255, P2067; OZAKI S, 1995, IN PRESS J AM CHEM S; OZAKI SI, 1994, J AM CHEM SOC, V116, P4487, DOI 10.1021/ja00089a052; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1993, J BIOL CHEM, V268, P4429; RAAG R, 1990, BIOCHEMISTRY-US, V29, P8119, DOI 10.1021/bi00487a019; RAMETTES RW, 1965, J AM CHEM SOC, V82, P5001; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; SANDERS SA, 1995, IN PRESS BIOCH SOC T, V23; SITTER AJ, 1985, J BIOL CHEM, V260, P7515; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SMITH AT, 1992, EUR J BIOCHEM, V207, P507, DOI 10.1111/j.1432-1033.1992.tb17077.x; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; SWANSON BA, 1991, J AM CHEM SOC, V113, P8146, DOI 10.1021/ja00021a046; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; WELINDER KG, 1985, EUR J BIOCHEM, V151, P497, DOI 10.1111/j.1432-1033.1985.tb09129.x; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]	46	129	130	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19430	19438		10.1074/jbc.270.33.19430	http://dx.doi.org/10.1074/jbc.270.33.19430			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642625	hybrid			2022-12-25	WOS:A1995RP70300039
J	SEELY, BL; REICHART, DR; STAUBS, PA; JHUN, BH; HSU, D; MAEGAWA, H; MILARSKI, KL; SALTIEL, AR; OLEFSKY, JM				SEELY, BL; REICHART, DR; STAUBS, PA; JHUN, BH; HSU, D; MAEGAWA, H; MILARSKI, KL; SALTIEL, AR; OLEFSKY, JM			LOCALIZATION OF THE INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR-BINDING SITES FOR THE SH2 DOMAIN PROTEINS P85, SYP, AND GTPASE-ACTIVATING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; STIMULATES TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; INTACT-CELLS; PHOSPHOLIPASE-C; IRS-1; SUBSTRATE; KINASE; ASSOCIATION	Potential signaling substrates for the insulin like growth factor I (IGF-I) receptor are SH2 domain proteins including the p85 subunit of phosphatidylinositol 3-kinase, the tyrosine phosphatase Syp, GTPase activating protein (GAP), and phospholipase C-gamma (PLC-gamma), In this study, we demonstrate an association between the IGF-I receptor and p85, Syp, and GAP, but not with PLC-gamma in lysates of cells overexpressing the human IGF I receptor, We further investigated these interactions using glutathione S-transferase (GST) fusion proteins containing the amino terminal SH2 domains of p85 or GAP, or both SH2 domains of Syp or PLC-gamma to precipitate the IGF-I receptor from purified receptor preparations and from whole cell lysates, p85-, Syp-, and GAP-GSTs precipitated the IGF-I receptor, whereas the PLC-gamma-GST did not, Using phosphopeptides corresponding to IGF-I receptor phosphorylation sites, we determined that the p85- and Syp-GST association with the IGF-I receptor could be inhibited by a carboxyl-terminal peptide containing pY1316 and that the GAP-GST association could be inhibited by a NPXY domain peptide, The GAP-GST binding site was confirmed by showing that a mutant IGF-I receptor with a deletion of the NPXY domain including tyrosine 950 was poorly precipitated by the GAP-GST, We conclude that p85 and Syp may bind directly to the IGF I receptor at tyrosine 1316, and that GAP may bind to the IGF-I receptor at tyrosine 950, An association between the IGF I receptor and PLC-gamma was not evident, p85, Syp, and GAP are potential modulators of IGF-I receptor signal transduction.	UNIV CALIF SAN DIEGO, DEPT MED, DIV ENDOCRINOL & METAB, LA JOLLA, CA 92093 USA; VET ADM MED CTR, MED RES SERV, SAN DIEGO, CA 92161 USA; WHITTIER DIABET PROGRAM, LA JOLLA, CA 92037 USA; SHIGA UNIV MED SCI, SHIGA 52021, JAPAN; WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Shiga University of Medical Science; Pfizer			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828; Maegawa, Hiroshi/0000-0002-4611-8149	NIDDK NIH HHS [DK 02162-02, DK 33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, K08DK002162, R37DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; FARIA TN, 1994, J BIOL CHEM, V269, P13922; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HSU D, 1994, ENDOCRINOLOGY, V134, P744, DOI 10.1210/en.134.2.744; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P208, DOI 10.1006/bbrc.1993.1805; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; OHMICHI M, 1992, J BIOL CHEM, V267, P21601; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1985, J BIOL CHEM, V260, P9470; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559	53	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19151	19157		10.1074/jbc.270.32.19151	http://dx.doi.org/10.1074/jbc.270.32.19151			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642582				2022-12-25	WOS:A1995RN95400070
J	MCCAFFREY, PG; PERRINO, BA; SODERLING, TR; RAO, A				MCCAFFREY, PG; PERRINO, BA; SODERLING, TR; RAO, A			NF-ATP, A LYMPHOCYTE-T DNA-BINDING PROTEIN THAT IS A TARGET FOR CALCINEURIN AND IMMUNOSUPPRESSIVE DRUGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; CYCLOSPORINE-A; KAPPA-B; ACTIVATION; IDENTIFICATION; REQUIREMENTS; SPECIFICITY; RECEPTOR; CELLS	The nuclear factor of activated T cells (NF-AT) is essential for transcription of the interleukin-2 gene upon T cell activation. Here we use a technique involving elution and renaturation of proteins from SDS-acrylamide gels to identify a DNA-binding component of NF-AT (NF-AT(p)) that is present in hypotonic extracts of T cells prior to activation and appears in nuclear extracts when T cells are activated. NF-AT(p) is present in resting T cells predominantly in a form migrating with an apparent molecular weight of 110,000-140,000, while NF-AT(p) from nuclear extracts of activated T cells migrates with a lower apparent molecular weight (90,000-125,000). This difference is likely to reflect dephosphorylation of NF-AT(p) since treatment of NF-AT(p) with calf intestinal phosphatase or the calcium- and calmodulin-dependent phosphatase calcineurin in vitro results in a similar decrease in its apparent molecular weight. We show that NF-AT(p) is dephosphorylated in cell lysates by a calcium-dependent process that is blocked by inclusion of EGTA or a specific peptide inhibitor of calcineurin in the cell lysis buffer. Moreover, dephosphorylation of NF-AT(p) in cell extracts is inhibited by prior treatment of T cells with the immunosuppressive drugs cyclosporin A or FK506, which inhibit the phosphatase activity of calcineurin when complexed with their specific binding proteins, cyclophilin and FK506-binding protein. This work identifies NF-AT(p) as a DNA-binding phosphoprotein and a target for the drug/immunophilin/calcineurin complexes thought to mediate the inhibition of interleukin-2 gene induction by cyclosporin A and FK506.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA	Harvard University; Harvard Medical School; Oregon Health & Science University	MCCAFFREY, PG (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR VIROL, BOSTON, MA 02115 USA.				NCI NIH HHS [CA42471] Funding Source: Medline; NIGMS NIH HHS [GM41292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA042471, R01CA042471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAMIESON C, 1991, J IMMUNOL, V147, P416; KING MM, 1987, J BIOL CHEM, V262, P10658; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788	21	283	293	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3747	3752						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679116				2022-12-25	WOS:A1993KM16100109
J	BARTOLOME, S; BERMUDEZ, A; DABAN, JR				BARTOLOME, S; BERMUDEZ, A; DABAN, JR			ELECTROPHORESIS OF CHROMATIN ON NONDENATURING AGAROSE GELS CONTAINING MG2+ - SELF-ASSEMBLY OF SMALL CHROMATIN FRAGMENTS AND FOLDING OF THE 30-NM FIBER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-ORDER STRUCTURE; X-RAY-SCATTERING; NUCLEOSOME CORE PARTICLE; LINKER LENGTH; COOPERATIVE BINDING; GLOBULAR DOMAIN; UNIT LENGTH; HISTONE H5; DNA; FIBERS	We show that nondenaturing agarose gels can be used for the study of the structure and dynamic properties of native (uncross-Linked) chromatin. In gels containing 1.7 mM Mg2+, chicken erythrocyte chromatin fragments having from about 6 to 50 nucleosomes produce well defined bands. These bands have an electrophoretic mobility that decreases only slightly with molecular weight. This surprising behavior is not observed in low ionic strength gels. Fragments with less than 6 nucleosomes and low content of histones H1-H5 give rise to broad bands in gels with Mg2+. In contrast, fragments containing only 3-4 nucleosomes but with the normal H1-H5 content are able to form associated structures with a mobility similar to that observed for high molecular weight chromatin. Electron microscopy results indicate that the associated fragments and the fragments of higher molecular weight show similar electrophoretic properties because they become very compact in the presence of Mg2+ and form cylindrical structures with a diameter of similar to 33 nn. Our results suggest that the interactions involved in the self-assembly of small fragments are the same that direct the folding of larger fragments; in both cases, the resulting compact chromatin structure is formed hom a basic element containing 5-7 nucleosomes.	UNIV AUTONOMA BARCELONA, FAC CIENCIES, DEPT BIOQUIM & BIOL MOLEC, E-08193 BARCELONA, SPAIN	Autonomous University of Barcelona			Daban, Joan-Ramon/G-8518-2017	Daban, Joan-Ramon/0000-0001-9946-6764				ARAGAY AM, 1991, BIOCHEMISTRY-US, V30, P5022, DOI 10.1021/bi00234a026; ARAGAY AM, 1988, J MOL BIOL, V204, P141, DOI 10.1016/0022-2836(88)90605-5; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ATHEY BD, 1990, J CELL BIOL, V111, P795, DOI 10.1083/jcb.111.3.795; BARTOLOME S, 1994, J CELL SCI, V107, P2983; BAVYKIN S, 1993, P NATL ACAD SCI USA, V90, P3918, DOI 10.1073/pnas.90.9.3918; BORDAS J, 1986, EUR BIOPHYS J BIOPHY, V13, P175, DOI 10.1007/BF00542561; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; BRADBURY EM, 1986, SUPRAMOLECULAR STRUC, P35; BUCKLE RS, 1992, J MOL BIOL, V223, P651, DOI 10.1016/0022-2836(92)90981-O; BUTLER PJG, 1984, EMBO J, V3, P2599, DOI 10.1002/j.1460-2075.1984.tb02180.x; DABAN JR, 1991, ANAL BIOCHEM, V199, P169, DOI 10.1016/0003-2697(91)90085-8; DIMITROV SI, 1990, J BIOMOL STRUCT DYN, V8, P23, DOI 10.1080/07391102.1990.10507787; GALLEGO F, 1995, BIOCHEMISTRY-US, V34, P6711, DOI 10.1021/bi00020a016; GERCHMAN SE, 1987, P NATL ACAD SCI USA, V84, P7802, DOI 10.1073/pnas.84.22.7802; GRAU LP, 1982, CHROMOSOMA, V87, P437; GRAZIANO V, 1994, NATURE, V368, P351, DOI 10.1038/368351a0; GRAZIANO V, 1988, J MOL BIOL, V203, P997, DOI 10.1016/0022-2836(88)90124-6; GREULICH KO, 1987, J MOL BIOL, V193, P709, DOI 10.1016/0022-2836(87)90353-6; HOROWITZ RA, 1994, J CELL BIOL, V125, P1, DOI 10.1083/jcb.125.1.1; JIN YJ, 1986, J BIOL CHEM, V261, P5805; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; KRAJEWSKI WA, 1993, BIOCHEM BIOPH RES CO, V193, P113, DOI 10.1006/bbrc.1993.1597; LANGMORE JP, 1983, J CELL BIOL, V96, P1120, DOI 10.1083/jcb.96.4.1120; LEUBA SH, 1994, P NATL ACAD SCI USA, V91, P11621, DOI 10.1073/pnas.91.24.11621; LEVINE A, 1993, J BIOL CHEM, V268, P21754; LIBERTINI LJ, 1988, BIOPOLYMERS, V27, P1459, DOI 10.1002/bip.360270911; MCGHEE JD, 1983, CELL, V33, P831, DOI 10.1016/0092-8674(83)90025-9; MITRA S, 1984, NATURE, V308, P247, DOI 10.1038/308247a0; MUYLDERMANS S, 1985, EUR J BIOCHEM, V150, P441, DOI 10.1111/j.1432-1033.1985.tb09040.x; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RENZ M, 1977, P NATL ACAD SCI USA, V74, P1879, DOI 10.1073/pnas.74.5.1879; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; RUIZCARRILLO A, 1980, BIOCHEMISTRY-US, V19, P2544, DOI 10.1021/bi00553a002; SACCONE GTP, 1983, FEBS LETT, V157, P111, DOI 10.1016/0014-5793(83)81126-0; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; STAYNOV DZ, 1983, INT J BIOL MACROMOL, V5, P3, DOI 10.1016/0141-8130(83)90071-5; STRUCK MM, 1992, J MOL BIOL, V224, P253, DOI 10.1016/0022-2836(92)90588-B; SUBIRANA JA, 1985, CHROMOSOMA, V91, P377, DOI 10.1007/BF00291012; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1985, EUR J BIOCHEM, V147, P143, DOI 10.1111/j.1432-1033.1985.tb08730.x; THOMAS JO, 1992, NUCLEIC ACIDS RES, V20, P187, DOI 10.1093/nar/20.2.187; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; WATANABE F, 1986, NUCLEIC ACIDS RES, V14, P3573, DOI 10.1093/nar/14.8.3573; WIDOM J, 1985, CELL, V43, P207, DOI 10.1016/0092-8674(85)90025-X; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; WILLIAMS SP, 1991, BIOPHYS J, V59, P606, DOI 10.1016/S0006-3495(91)82276-7; WILLIAMS SP, 1986, BIOPHYS J, V49, P233, DOI 10.1016/S0006-3495(86)83637-2; WOODCOCK CL, 1993, P NATL ACAD SCI USA, V90, P9021, DOI 10.1073/pnas.90.19.9021; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42; WORCEL A, 1981, P NATL ACAD SCI-BIOL, V78, P1461, DOI 10.1073/pnas.78.3.1461; ZENTGRAF H, 1984, J CELL BIOL, V99, P272, DOI 10.1083/jcb.99.1.272; ZLATANOVA J, 1994, P NATL ACAD SCI USA, V91, P5277, DOI 10.1073/pnas.91.12.5277	56	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22514	22521		10.1074/jbc.270.38.22514	http://dx.doi.org/10.1074/jbc.270.38.22514			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673242	hybrid			2022-12-25	WOS:A1995RW31400071
J	KNAUS, HG; EBERHART, A; KOCH, ROA; MUNUJOS, P; SCHMALHOFER, WA; WARMKE, JW; KACZOROWSKI, GJ; GARCIA, ML				KNAUS, HG; EBERHART, A; KOCH, ROA; MUNUJOS, P; SCHMALHOFER, WA; WARMKE, JW; KACZOROWSKI, GJ; GARCIA, ML			CHARACTERIZATION OF TISSUE-EXPRESSED ALPHA-SUBUNITS OF THE HIGH-CONDUCTANCE CA2+-ACTIVATED K+ CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; CHARYBDOTOXIN; PURIFICATION; INHIBITOR; POTENT	Purified high conductance calcium-activated potassium (maxi-K) channels from tracheal smooth muscle have been shown to consist of a 60-70-kDa alpha subunit, encoded by the slo gene, and a 31-kDa beta subunit. Although the size of the beta subunit is that expected for the product of the gene encoding this protein, the size of the alpha subunit is smaller than that predicted from the slo coding region, To determine the basis for this discrepancy, sequence-directed antibodies have been raised against slo. These antibodies specifically precipitate the in vitro translation product of mslo, which yields an alpha subunit of the expected molecular mass (135 kDa), Immunostaining experiments employing smooth muscle sarcolemma, skeletal muscle T-tubules, as well as membranes derived from GH(3) cells reveal the presence of an Lu subunit with an apparent molecular mass of 125 kDa, The difference in size of the alpha subunit as expressed in these membranes and the purified preparations is due to a highly reproducible proteolytic decay that occurs mostly at an advanced stage of the maxi-g channel purification, In the purified maxi-K channel preparations investigated, the full-length alpha subunit, an intermediate size product of 90 kDa, and the 65-kDa polypeptide, as well as other smaller fragments can be detected using appropriate antibodies, Proteolysis occurs exclusively at two distinct positions within the long C-terminal tail of slo, In addition, evidence for the tissue expression of distinct splice variants in membrane-bound as well as purified maxi-It channels is presented.	MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT MEMBRANE BIOCHEM & BIOPHYS, RAHWAY, NJ 07065 USA; MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT MOLEC BIOL & GENET, RAHWAY, NJ 07065 USA	Merck & Company; Merck & Company	KNAUS, HG (corresponding author), UNIV INNSBRUCK, INST BIOCHEM PHARMACOL, PETER MAYR STR 1, A-6020 INNSBRUCK, AUSTRIA.							ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; DWORETZKY SI, 1994, MOL BRAIN RES, V27, P189, DOI 10.1016/0169-328X(94)90203-8; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GIMENEZGALLEGO G, 1988, P NATL ACAD SCI USA, V85, P3329, DOI 10.1073/pnas.85.10.3329; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; KNAUS HG, 1994, J BIOL CHEM, V269, P23336; KNAUS HG, 1994, BIOCHEMISTRY-US, V33, P5819, DOI 10.1021/bi00185a021; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; KNAUS HG, 1995, BIOPHYS J, V68, P267; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MOSS GWJ, 1995, BIOPHYS J, V68, P29; PALLANCK L, 1994, HUM MOL GENET, V3, P1239, DOI 10.1093/hmg/3.8.1239; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5	20	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22434	22439		10.1074/jbc.270.38.22434	http://dx.doi.org/10.1074/jbc.270.38.22434			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673230	hybrid			2022-12-25	WOS:A1995RW31400059
J	APONE, S; HAUSCHKA, SD				APONE, S; HAUSCHKA, SD			MUSCLE GENE E-BOX CONTROL ELEMENTS - EVIDENCE FOR QUANTITATIVELY DIFFERENT TRANSCRIPTIONAL ACTIVITIES AND THE BINDING OF DISTINCT REGULATORY FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; CREATINE-KINASE GENE; MYOGENIC DETERMINATION FACTORS; DNA-BINDING; ENHANCER; PROTEIN; MYOD; ACTIVATION; SKELETAL; SITE	The muscle creatine kinase gene enhancer contains two regulatory elements (MCK-R and MCK-L) with the consensus E-box sequence (CAnnTG). A myocyte specific protein complex, MEF1, binds the MCK-R site. MEF1 contains several basic H-L-H myogenic determination factors (MDFs), each dimerized with ubiquitous members of the bH-L-H family (e.g. E12/E47). We now demonstrate that the ubiquitous bH-L-H factor E2-2 is a major component of the endogenous MCK-R site specific complex. Previous studies described the MCK-L site as a similar but low affinity MDF/bH-L-H heterodimer binding site. However, we find that the MCK-L site exhibits prefer ential binding of an unknown ubiquitous factor which contains neither E12/E47 nor E2-2, and that it exhibits differential transcriptional activity with muscle and non-muscle cells. The differential behavior of the MCK-L and MCK-R sites may be a general trait of E-box elements since one among several E-boxes in the MLC 1/3 enhancer also binds preferentially to the MCK-L factor. From our studies we now propose separate consensus sequences for MCK-R and MCK-L E-box types: AACAc/gc/gTGCa/t and GGa/cCANGTGGc/gNa/g. Our results suggest that while many muscle gene E-boxes are capa ble of binding the previously characterized spectrum of MDF/bH-L-H heterodimers in vitro, MCK-L type E-boxes probably bind qualitatively different factors in vivo.			APONE, S (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM,SJ-70,SEATTLE,WA 98195, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM018860] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039070] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39070, HL03174] Funding Source: Medline; NIADDK NIH HHS [AM18860] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1991, NUCLEIC ACIDS RES, V19, P5645, DOI 10.1093/nar/19.20.5645; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHAKRABORTY T, 1992, J BIOL CHEM, V267, P17498; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DIGMAN JD, 1983, NUCLEIC ACIDS RES, V11, P1475; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAUSCHKA SD, 1994, MYOLOGY, P3; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P678, DOI 10.1093/nar/18.3.678; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; JOHNSTON LA, 1992, MOL CELL BIOL, V12, P5123, DOI 10.1128/MCB.12.11.5123; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LIN H, 1992, J BIOL CHEM, V267, P4773; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TRASK RV, 1992, NUCLEIC ACIDS RES, V20, P2313, DOI 10.1093/nar/20.9.2313; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YI TM, 1991, NUCLEIC ACIDS RES, V19, P3027, DOI 10.1093/nar/19.11.3027; YUTZEY KE, 1992, NUCLEIC ACIDS RES, V20, P5105, DOI 10.1093/nar/20.19.5105; ZAHRADKA P, 1989, EXP CELL RES, V185, P8, DOI 10.1016/0014-4827(89)90032-3; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	43	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21420	21427		10.1074/jbc.270.36.21420	http://dx.doi.org/10.1074/jbc.270.36.21420			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673178	hybrid			2022-12-25	WOS:A1995RU05400083
J	POLLARD, S; THOMPSON, CL; STEPHENSON, FA				POLLARD, S; THOMPSON, CL; STEPHENSON, FA			QUANTITATIVE CHARACTERIZATION OF ALPHA-6 AND ALPHA-1-ALPHA-6 SUBUNIT-CONTAINING NATIVE GAMMA-AMINOBUTYRIC ACID(A) RECEPTORS OF ADULT-RAT CEREBELLUM DEMONSTRATES 2 ALPHA-SUBUNITS PER RECEPTOR OLIGOMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A RECEPTORS; BENZODIAZEPINE RECEPTOR; BINDING; BRAIN; SUBPOPULATIONS; POPULATIONS; ANTIBODIES	gamma-Aminobutyric acid(A) (GABA(A)) receptors were purified from adult rat cerebella by anti-alpha 6(1-16 Cys) antibody affinity chromatography, Immunoblots of the alpha 6 subunit-containing receptors showed the copurification of the alpha 1, beta 2/3, gamma 2, delta but not alpha 2 and alpha 3 GABA(A) receptor polypeptides. Further fractionation of this receptor subpopulation by anti-GABA(A) receptor subunit alpha 6(1-16 Cys) and anti-alpha 1(413-429) antibody affinity columns in series substantiated the coassociation of the alpha 1 and alpha 6 polypeptides, The percentage of coexistence of the two subunits was determined by quantitative immunoblotting, which found that 41 +/- 12% of alpha 6 subunit immunoreactivity is associated with the alpha 1 subunit, The ratios of the alpha 1:alpha 6 subunits in the double purified receptor preparations was found to be 1:1, thus determining directly for the first time subunit ratios within native GABA(A) receptors. The benzodiazepine pharmacology of the alpha 1 alpha 6 subunit-containing receptors was shown to be predominantly benzodiazepine insensitive by quantitative immunoprecipitation assays. These results are the first direct quantitative studies of subunit ratios within a population of native GABA(A) receptors.	UNIV LONDON,SCH PHARM,DEPT PHARMACEUT CHEM,LONDON WC1N 1AX,ENGLAND	University of London; University College London; University of London School of Pharmacy								BACKUS KH, 1993, NEUROREPORT, V5, P285, DOI 10.1097/00001756-199312000-00026; BENKE D, 1991, J BIOL CHEM, V266, P4478; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; DUGGAN MJ, 1992, J NEUROCHEM, V58, P72, DOI 10.1111/j.1471-4159.1992.tb09278.x; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; KERN W, 1994, J NEUROCHEM, V62, P764; KHAN ZU, 1994, J NEUROCHEM, V63, P371; KORPI ER, 1993, MOL PHARMACOL, V44, P87; LUDDENS H, 1991, TRENDS PHARMACOL SCI, V12, P49, DOI 10.1016/0165-6147(91)90495-E; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MATHEWS GC, 1994, NEURON, V13, P149, DOI 10.1016/0896-6273(94)90465-0; MCKERNAN RM, 1991, NEURON, V7, P667, DOI 10.1016/0896-6273(91)90379-E; MERTENS S, 1993, J BIOL CHEM, V268, P5965; NAYEEM N, 1994, J NEUROCHEM, V62, P815; NUSSER Z, 1995, BRAN RES ASS ABSTR, V12, P114; POLLARD S, 1993, J BIOL CHEM, V268, P3753; POLLARD S, 1991, FEBS LETT, V295, P81, DOI 10.1016/0014-5793(91)81390-T; QUIRK K, 1994, J BIOL CHEM, V269, P16020; SIEGHART W, 1987, J NEUROCHEM, V48, P46, DOI 10.1111/j.1471-4159.1987.tb13125.x; STEPHENSON FA, 1995, BIOCHEM J, V310, P1; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; STEPHENSON FA, 1991, MOL NEUROBIOL, P183; THOMPSON CL, 1992, NEUROSCI LETT, V144, P53, DOI 10.1016/0304-3940(92)90714-I; UUSIOUKARI M, 1992, J NEUROCHEM, V59, P568, DOI 10.1111/j.1471-4159.1992.tb09407.x; WIELAND HA, 1992, J BIOL CHEM, V267, P1426	26	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21285	21290		10.1074/jbc.270.36.21285	http://dx.doi.org/10.1074/jbc.270.36.21285			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673164	hybrid			2022-12-25	WOS:A1995RU05400064
J	HIRSCH, HH; NAIR, APK; BACKENSTOSS, V; MORONI, C				HIRSCH, HH; NAIR, APK; BACKENSTOSS, V; MORONI, C			INTERLEUKIN-3 MESSENGER-RNA STABILIZATION BY A TRANS-ACTING MECHANISM IN AUTOCRINE TUMORS LACKING INTERLEUKIN-3 GENE REARRANGEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; ACUTE LYMPHOCYTIC-LEUKEMIA; A-PARTICLE TRANSPOSITION; C-MYC RETROVIRUS; HEMATOPOIETIC-CELLS; MAST-CELLS; MALIGNANT TRANSFORMATION; NUCLEOTIDE-SEQUENCE; EUKARYOTIC CELLS; RICH SEQUENCES	Tumors obtained from v-Ha-ras-transformed PB-3c cells are characterized by autocrine interleukin-3 (IL3) expression, which occurs either without (class I tumors) or with enhanced transcription (class II tumors). To address possible post-transcriptional mechanisms of IL3 expression, IL3 mRNA stability was examined in both tumor classes. Increased stability of IL3 mRNA was detected in class I tumor lines (t(1/2) > 3 h), whereas rapid decay of IL3 transcripts (t(1/2) < 0.5 h) was found in class II tumor lines. In both tumor classes, the c-myc and interleukin-6 transcripts were short-lived. Transcripts of a constitutively expressed IL3 reporter gene were stable in class I tumor cells but unstable in class II tumor cells, suggesting that IL3 mRNA stabilization involved a trans-acting mechanism. Rapid decay of IL3 reporter transcripts was observed in untransformed PB-3c as well as in v-Ha-ras expressing precursor cells linking transcript stabilization to the tumor stage. Reporter transcript stabilization in class I tumor cells correlated with increased IL3 production. Deletion of the AU-rich element from the IL3 reporter gene further augmented IL3 mRNA levels as well as IL3 production, suggesting that the stabilizing mechanism in class I tumor cells is not equivalent to AU-rich element deletion.			HIRSCH, HH (corresponding author), UNIV BASEL,INST MED MICROBIOL,PETERSPL 10,CH-4003 BASEL,SWITZERLAND.			Hirsch, Hans H./0000-0003-0883-0423				ABRAMS JS, 1988, J IMMUNOL, V140, P131; ALGATE PA, 1993, ONCOGENE, V8, P1221; BALL PE, 1983, DIFFERENTIATION, V24, P74, DOI 10.1111/j.1432-0436.1983.tb01305.x; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BLANKENSTEIN T, 1990, J EXP MED, V171, P965, DOI 10.1084/jem.171.3.965; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; CAMPBELL HD, 1985, EUR J BIOCHEM, V150, P297, DOI 10.1111/j.1432-1033.1985.tb09020.x; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARTER BZ, 1991, LAB INVEST, V65, P610; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GRAFI G, 1993, MOL CELL BIOL, V13, P3487, DOI 10.1128/MCB.13.6.3487; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; GRIMALDI JC, 1989, BLOOD, V73, P2081; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HENICS T, 1994, J BIOL CHEM, V269, P5377; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; HIRSCH HH, 1993, J EXP MED, V178, P403, DOI 10.1084/jem.178.2.403; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; LESLIE KB, 1991, MOL CELL BIOL, V11, P5562, DOI 10.1128/MCB.11.11.5562; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MEEKER TC, 1990, BLOOD, V76, P285; NAIR APK, 1992, ONCOGENE, V7, P1963; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NAIR APK, 1994, NATURE, V369, P239, DOI 10.1038/369239a0; ROSS HJ, 1991, BLOOD, V77, P1787; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOHYAMA K, 1990, EMBO J, V9, P1823, DOI 10.1002/j.1460-2075.1990.tb08307.x; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	45	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20629	20635		10.1074/jbc.270.35.20629	http://dx.doi.org/10.1074/jbc.270.35.20629			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657642	hybrid			2022-12-25	WOS:A1995RR58400061
J	AZARANI, A; GOLTZMAN, D; ORLOWSKI, J				AZARANI, A; GOLTZMAN, D; ORLOWSKI, J			PARATHYROID-HORMONE AND PARATHYROID HORMONE-RELATED PEPTIDE INHIBIT THE APICAL NA+/H+ EXCHANGER NHE-3 ISOFORM IN RENAL-CELLS (OK) VIA A DUAL SIGNALING CASCADE INVOLVING PROTEIN-KINASE-A AND PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; EPIDERMAL GROWTH-FACTOR; OPOSSUM KIDNEY-CELLS; MOLECULAR-CLONING; PHEOCHROMOCYTOMA CELLS; FUNCTIONAL-PROPERTIES; OSTEOSARCOMA CELLS; PHORBOL ESTERS; BRUSH-BORDER; GENE FAMILY	Parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) interact with a common G protein-coupled receptor and stimulate production of diverse second messengers (i.e, cAMP, diacylglycerol, and inositol 1,4,5-trisphosphate) that varies depending on the target cell, In renal proximal tubule OK cells, PTH inhibits the activity of the apical membrane Na+H+ exchanger, although it is unclear whether the signal is transmitted through protein kinase A (PKA) and/or protein kinase C (PKC). To delineate the signaling circuitry, a series of synthetic PTH and PTHRP fragments were used that stimulate the adenylate cyclase-cAMP-PKA and/or phospholipase C-diacylglycerol-PHC pathways, Human PTH-(1-34) and PTHRP-(1-34) stimulated adenylate cyclase and PHC activity, whereas the PTH analogues, PTH-(3-34), PTH-(28-42), and PTH-(28-48), selectively enhanced only PI(C activity, However, each peptide fragment inhibited Na+/H+ exchanger activity by 40-50%, suggesting that PHC and possibly PRA were capable of transducing the PTH/PTHRP signal to the transporter, This was corroborated when forskolin and phorbol 12-myristate 13-acetate (PMA), direct agonists of adenylate cyclase and PKC, respectively, both inhibited the Na+/H+ exchanger. The specific PW antagonist, H-89, abolished the forskolin-mediated suppression of Na+/H+ exchanger activity, but did not prevent the inhibitory effects of PTH-(1-34) or PMA In comparison, the potent PKC inhibitor, chelerythrine chloride, prevented the inhibition of Na+/H+ exchanger activity mediated by PTH-(28-48) and PMA. but did not avert the negative regulation caused by PTH-(1-34) or forskolin, However, inhibition of both PKA and PRC prevented PTH-(1-34)-mediated suppression of Na+/H+ exchanger activity, indicating that PTH-(1-34) acted through both signaling pathways, In addition, Northern blot analysis revealed the presence of only the NHE-3 isoform of the Na+/H+ exchanger in OR cells, In summary, these results demonstrated that NHE-3 is expressed in OR cells and that activation of the PTH receptor can stimulate both the PKA and PKC pathways, each of which can independently lead to inhibition of NHE-3 activity.	MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA; ROYAL VICTORIA HOSP,CALCIUM RES LAB,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University; McGill University; Royal Victoria Hospital				Orlowski, John/0000-0001-7371-175X				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ALPERN RJ, 1990, PHYSIOL REV, V70, P79, DOI 10.1152/physrev.1990.70.1.79; BERNIER SM, 1991, ENDOCRINOLOGY, V128, P2752, DOI 10.1210/endo-128-6-2752; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; BOOKSTEIN C, 1994, J BIOL CHEM, V269, P29704; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; GOLTZMANN D, 1975, J BIOL CHEM, V250, P3199; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V416, P615, DOI 10.1007/BF00370605; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JOUISHOMME H, 1992, ENDOCRINOLOGY, V130, P53, DOI 10.1210/en.130.1.53; JOUISHOMME H, 1994, J BONE MINER RES, V9, P943; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KOYAMA H, 1978, IN VITRO CELL DEV B, V14, P239; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; MALMSTROM K, 1988, BIOCHEM J, V251, P207, DOI 10.1042/bj2510207; MILLER RT, 1987, J BIOL CHEM, V262, P9115; MRKIC B, 1992, J MEMBRANE BIOL, V130, P205; MRKIC B, 1993, PFLUG ARCH EUR J PHY, V424, P377, DOI 10.1007/BF00374897; MUFF R, 1992, ANNU REV PHYSIOL, V54, P67, DOI 10.1146/annurev.physiol.54.1.67; ORLOFF JJ, 1989, ENDOCR REV, V10, P476, DOI 10.1210/edrv-10-4-476; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; RABBANI SA, 1990, BIOCHEMISTRY-US, V29, P10080, DOI 10.1021/bi00495a010; RABBANI SA, 1988, ENDOCRINOLOGY, V123, P2709; RESHKIN SJ, 1991, J MEMBRANE BIOL, V124, P227, DOI 10.1007/BF01994356; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SOLEIMANI M, 1994, J BIOL CHEM, V269, P27973; SOLEIMANI M, 1994, J BIOL CHEM, V269, P1563; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE M, 1993, J MEMBRANE BIOL, V135, P93; VOYNOYASENETSKA.T, 1994, J BIOL CHEM, V269, P4721; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WANG Z, 1993, J BIOL CHEM, V268, P11925; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604; YU FH, 1993, J BIOL CHEM, V268, P25536	50	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20004	20010		10.1074/jbc.270.34.20004	http://dx.doi.org/10.1074/jbc.270.34.20004			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650018	hybrid			2022-12-25	WOS:A1995RQ99100051
J	GREGORI, L; FUCHS, C; FIGUEIREDOPEREIRA, ME; VANNOSTRAND, WE; GOLDGABER, D				GREGORI, L; FUCHS, C; FIGUEIREDOPEREIRA, ME; VANNOSTRAND, WE; GOLDGABER, D			AMYLOID BETA-PROTEIN INHIBITS UBIQUITIN-DEPENDENT PROTEIN-DEGRADATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; POLYACRYLAMIDE-GEL ELECTROPHORESIS; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; MULTIUBIQUITIN CHAIN; PRECURSOR PROTEIN; LYSOSOMAL SYSTEM; DOWNS-SYNDROME; TAU; COMPLEX	Intraneuronal accumulation of ubiquitin conjugates in inclusion bodies and neurofibrillary tangles is a pathological feature of neurodegenerative disorders such as Alzheimer's disease and Down's syndrome and of normal aging of the brain, Amyloid beta-protein (A beta) and its precursor are found in neurofibrillary tangle-containing neurons. A beta is the major component of extracellular plaques, We showed that A beta acts as an inhibitor of the ubiquitin-dependent protein degradation in vitro. We examined the effect of A beta on the steps of this proteolytic pathway that contribute to the level of ubiquitin conjugates in the cell, Neither conjugate formation nor conjugate deubiquitination was affected by the presence of A beta. However, A beta significantly reduced the rate of conjugate degradation. Our results indicate that A beta interacts with the proteolytic step of the ubiquitin degradative pathway, Since this step is performed by the 26 S proteasome, the effect of A beta on the catalytic core of this proteolytic complex, the 20 S proteasome, was determined, We found that A beta selectively inhibits the chymotrypsin-like activity of the 20 S proteasome. Under pathological conditions in the affected neuron, A beta could interfere with ubiquitin-dependent degradation by inhibiting the 26 S proteasome activity, This finding may explain the origin of the accumulation of ubiquitin conjugates.	SUNY STONY BROOK,SCH MED,DEPT PSYCHIAT & BEHAV SCI,NEW YORK,NY 11794; CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029; UNIV CALIF IRVINE,COLL MED,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of California System; University of California Irvine	GREGORI, L (corresponding author), SUNY STONY BROOK,SCH MED,CTR HLTH SCI,DEPT PSYCHIAT & BEHAV SCI,T-10,STONY BROOK,NY 11794, USA.							BHASIN R, 1991, P NATL ACAD SCI USA, V88, P10307, DOI 10.1073/pnas.88.22.10307; BHASIN R, 1994, AMYLOID, V1, P221, DOI 10.3109/13506129409146113; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; COLE GM, 1987, NEUROSCI LETT, V79, P207, DOI 10.1016/0304-3940(87)90698-7; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DICE JF, 1982, J BIOL CHEM, V257, P4624; DICKSON DW, 1988, AM J PATHOL, V132, P86; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; EYTAN E, 1993, J BIOL CHEM, V268, P4668; FIGUEIREDOPEREIRA, 1994, J NEUROCHEM, V63, P1578; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GREGORI L, 1990, J BIOL CHEM, V265, P8354; GREGORI L, 1994, BIOCHEM BIOPH RES CO, V203, P1731, DOI 10.1006/bbrc.1994.2386; GROPPER R, 1991, J BIOL CHEM, V266, P3602; GRUNDKEIQBAL I, 1989, P NATL ACAD SCI USA, V86, P2853, DOI 10.1073/pnas.86.8.2853; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1982, J BIOL CHEM, V258, P8206; HOUGH R, 1987, J BIOL CHEM, V262, P8303; JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIDD M, 1963, NATURE, V197, P192, DOI 10.1038/197192b0; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; LASZLO L, 1990, FEBS LETT, V261, P365, DOI 10.1016/0014-5793(90)80593-8; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; LOWE J, 1990, NEUROPATHOL APPL NEU, V1, P281; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTIACE LA, 1991, J NEUROPATH EXP NEUR, V50, P547, DOI 10.1097/00005072-199109000-00003; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASH.M, 1993, NEURON, V10, P1151; MURPHY GM, 1994, AM J PATHOL, V144, P1082; NIXON RA, 1992, ANN NY ACAD SCI, V674, P65; NUKINA N, 1987, P NATL ACAD SCI USA, V84, P3415, DOI 10.1073/pnas.84.10.3415; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; PERRY G, 1987, P NATL ACAD SCI USA, V84, P3033, DOI 10.1073/pnas.84.9.3033; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REFOLO LM, 1991, J NEUROSCI, V11, P3888; RIPELLINO JA, 1994, J NEUROSCI RES, V39, P211, DOI 10.1002/jnr.490390211; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHAW G, 1988, P NATL ACAD SCI USA, V85, P2854, DOI 10.1073/pnas.85.8.2854; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SPILLANTINI MG, 1990, P NATL ACAD SCI USA, V87, P3947, DOI 10.1073/pnas.87.10.3947; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YAMAGUCHI H, 1990, BRAIN RES, V537, P318, DOI 10.1016/0006-8993(90)90377-N	63	175	179	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19702	19708		10.1074/jbc.270.34.19702	http://dx.doi.org/10.1074/jbc.270.34.19702			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649980	hybrid			2022-12-25	WOS:A1995RQ99100008
J	RAO, MJ; IYER, KS; ACHARYA, AS				RAO, MJ; IYER, KS; ACHARYA, AS			POLYMERIZATION OF HEMOGLOBIN-S - QUINARY INTERACTIONS OF GLU-43(BETA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYHEMOGLOBIN-S; CRYSTAL-STRUCTURE; CARBOXYL GROUPS; FIBERS; REACTIVITY; SOLUBILITY	Hemoglobin S (HbS) Hoshida and three substituted forms of HbS Hoshida (the substituents being on the amide nitrogen of Gln-43(beta)) have been prepared by the amidation of Glu-43(beta) of HbS with ammonia, methylamine, glycine ethyl ester, and galactosamine. The O-2 affinity of HbS is increased slightly on amidation of Glu-43(beta). All the four amidated derivatives exhibited nearly the same oxygen affinity. On the other hand, the influence of amidation on the solubility exhibits some sensitivity to the chemical nature of the substituent on the Gln-43(beta). The solubility of HbS Hoshida (a case with no substitution on Gln-43(beta)), and the methyl-substituted derivatives are about 33 and 36% higher than that of HbS. The solubility of the HbS modified with the glycine ethyl ester or galactosamine is increased to 41 and 47%, respectively. The first derivative UV spectra of HbS Hoshida and its methyl derivative reflect very little perturbations in their alpha(1) beta(2) interface as compared with that of HbS, whereas the amidated derivatives with larger substituents on Gln-43(beta) reflected noticeable differences. Thus, the increase in the solubility and the oxygen affinity of HbS on the amidation of Glu-43(beta) is primarily a consequence of the loss of the negative charge at 43(beta), a residue proximal to the alpha 1 beta(2) interface. The copolymerization studies of amidated HbS with HbA and HbS with amidated HbA demonstrate that cis Glu-43(beta) is the ''active'' residue. This assignment is discrepant with the earlier implication of a trans configuration for this residue in the polymer (Edelstein, S. J. (1981) J. Mol. Biol. 150, 557-575). However, it is consistent with the solution studies of Nagel ct al. (Nagel, R. L., Bookchin, R. M., Johnson, J., Labie, D., Wajcman, H., Isaac-Sodeye, W. A., Honig, G. R., Schiliro, G., Crookstan, J. H., and Matsutomo, K. (1979) Proc. Not. Acad. Sci. U. S. A. 76, 670-672) and McCurdy ct al. (McCurdy, P. R., Lorkin, P. A., Casey, R., Lehmann, H., Uddin, D. E., and Dickson, L. G. (1974) Am. J. Med. 57, 665-760).	ALBERT EINSTEIN COLL MED,DEPT MED,DIV HEMATOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NHLBI NIH HHS [HL38655] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038655] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHARYA AS, 1985, BIOCHEMISTRY-US, V24, P4885, DOI 10.1021/bi00339a024; ACHARYA AS, 1991, MOL CONFORMATION BIO, P269; ADACHI K, 1979, J BIOL CHEM, V254, P7765; ADACHI K, 1993, FEBS LETT, V315, P47, DOI 10.1016/0014-5793(93)81130-R; BENESCH RE, 1978, ANAL BIOCHEM, V89, P162, DOI 10.1016/0003-2697(78)90737-6; BIHOREAU MT, 1992, PROTEIN SCI, V1, P145; BOOKCHIN RM, 1977, NATURE, V269, P526, DOI 10.1038/269526a0; BOOKCHIN RM, 1975, NATURE, V256, P667, DOI 10.1038/256667a0; BOOKCHIN RM, 1970, BIOCHIM BIOPHYS ACTA, V221, P373, DOI 10.1016/0005-2795(70)90279-5; BOOKCHIN RM, 1967, J BIOL CHEM, V242, P248; BOWMAN BH, 1964, BLOOD, V23, P193, DOI 10.1182/blood.V23.2.193.193; CABURIMARTIN J, 1986, BIOCHIM BIOPHYS ACTA, V874, P82, DOI 10.1016/0167-4838(86)90105-6; CRETEGNY I, 1993, J MOL BIOL, V230, P733, DOI 10.1006/jmbi.1993.1195; EDELSTEIN SJ, 1981, J MOL BIOL, V150, P557, DOI 10.1016/0022-2836(81)90381-8; IUCHI I, 1978, HEMOGLOBIN, V2, P235, DOI 10.3109/03630267809007069; MCCURDY PR, 1974, AM J MED, V57, P665, DOI 10.1016/0002-9343(74)90021-7; MONPLAISIR N, 1986, P NATL ACAD SCI USA, V83, P9363, DOI 10.1073/pnas.83.24.9363; Nagel R L, 1981, Methods Enzymol, V76, P760; NAGEL RL, 1979, P NATL ACAD SCI USA, V76, P670, DOI 10.1073/pnas.76.2.670; NAGEL RL, 1980, NATURE, V283, P832, DOI 10.1038/283832a0; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; RAO MJ, 1992, BIOCHEMISTRY-US, V31, P7231, DOI 10.1021/bi00147a004; RAO MJ, 1994, METHOD ENZYMOL, V231, P246; RAO MJ, 1991, J PROTEIN CHEM, V10, P129, DOI 10.1007/BF01024663; SEETHARAM R, 1983, J BIOL CHEM, V258, P4810; WATOWICH SJ, 1989, J MOL BIOL, V209, P821, DOI 10.1016/0022-2836(89)90610-4; WATOWICH SJ, 1993, J STRUCT BIOL, V111, P161, DOI 10.1006/jsbi.1993.1047; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2	28	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19250	19255		10.1074/jbc.270.33.19250	http://dx.doi.org/10.1074/jbc.270.33.19250			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642597	hybrid			2022-12-25	WOS:A1995RP70300011
J	SCHOONJANS, K; WATANABE, M; SUZUKI, H; MAHFOUDI, A; KREY, G; WAHLI, W; GRIMALDI, P; STAELS, B; YAMAMOTO, T; AUWERX, J				SCHOONJANS, K; WATANABE, M; SUZUKI, H; MAHFOUDI, A; KREY, G; WAHLI, W; GRIMALDI, P; STAELS, B; YAMAMOTO, T; AUWERX, J			INDUCTION OF THE ACYL-COENZYME-A SYNTHETASE GENE BY FIBRATES AND FATTY-ACIDS IS MEDIATED BY A PEROXISOME PROLIFERATOR RESPONSE ELEMENT IN THE C-PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; BETA-OXIDATION PATHWAY; ENOYL-COA HYDRATASE; ACTIVATED RECEPTOR; TRANSCRIPTIONAL REGULATION; MAMMALIAN-CELLS; RAT-LIVER; 3-HYDROXYACYL-COA DEHYDROGENASE; LIPOPROTEIN-LIPASE; CLOFIBRIC ACID	The long-chain acyl coenzyme A synthetase (ACS) gene gives rise to three transcripts containing different first exons preceded by specific regulatory regions A, B, and C. Exon-specific oligonucleotide hybridization indicated that only A-ACS mRNA is expressed in rat liver. Fibrate administration induced liver C-ACS strongly and A-ACS mRNA to a lesser extent. B-ACS mRNA remained undetectable. In primary rat hepatocytes and Fa-32 hepatoma cells C-ACS mRNA increased after treatment with fenofibric acid, alpha-bromopalmitate, tetradecylthioacetic acid, or alpha-linolenic acid. Nuclear run-on experiments indicated that fenofibric acid and alpha-bromopalmitate act at the transcriptional level. Transient transfections showed a 3.4-, 2.3-, and 2.2-fold induction of C-ACS promoter activity after fenofibric acid, alpha-bromopalmitate, and tetradecylthioacetic acid, respectively. Unilateral deletion and site-directed mutagenesis identified a peroxisome proliferator activator receptor (PPAR)-responsive element (PPRE) mediating the responsiveness to fibrates and fatty acids. This ACS PPRE contains three imperfect half sites spaced by 1 and 3 oligonucleotides and binds PPAR retinoid X receptor heterodimers in gel retardation assays. In conclusion, the regulation of C-ACS mRNA expression by fibrates and fatty acids is mediated by PPAR retinoid X receptor heterodimers interacting through a PPRE in the C-ACS promoter. PPAR therefore occupies a key position in the transcriptional control of a pivotal enzyme controlling the channeling of fatty acids into various metabolic pathways.	INST PASTEUR,BIOL REGULAT EUCARYOTES LAB,F-59019 LILLE,FRANCE; TOHOKU UNIV,GENE RES CTR,SENDAI,MIYAGI 981,JAPAN; UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND; CTR BIOCHIM,BIOL DEV TISSU ADIPEUX LAB,CNRS,UNITE MIXTE RECH 134,F-06108 NICE,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Tohoku University; University of Lausanne; Centre National de la Recherche Scientifique (CNRS)			Wahli, Walter/I-3194-2019; Staels, Bart/N-9497-2016; Auwerx, Johan/ABE-9307-2021; Wahli, Walter/B-1398-2009	Staels, Bart/0000-0002-3784-1503; Wahli, Walter/0000-0002-5966-9089; Schoonjans, Kristina/0000-0003-1247-4265; Auwerx, Johan/0000-0002-5065-5393				ALVARES K, 1994, CANCER RES, V54, P2303; APERLO C, 1995, IN PRESS GEN AMST; AUWERX JH, 1989, BIOCHEMISTRY-US, V28, P4563, DOI 10.1021/bi00437a009; AUWERX JH, 1988, BIOCHEMISTRY-US, V27, P2651, DOI 10.1021/bi00408a003; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; CHATTERJEE B, 1987, EUR J BIOCHEM, V166, P273, DOI 10.1111/j.1432-1033.1987.tb13511.x; CHATTERJEE B, 1983, BIOCHEM J, V214, P879, DOI 10.1042/bj2140879; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Groot P H, 1976, Adv Lipid Res, V14, P75; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HIJIKATA M, 1987, J BIOL CHEM, V262, P8151; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KHAN WA, 1992, J BIOL CHEM, V267, P3605; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; MCQUAID S, 1987, CANCER LETT, V37, P115, DOI 10.1016/0304-3835(87)90152-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NEVINS JR, 1987, METHOD ENZYMOL, V152, P234; OSUMI T, 1984, J BIOL CHEM, V259, P2031; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; REDDY JK, 1982, ANN NY ACAD SCI, V386, P81, DOI 10.1111/j.1749-6632.1982.tb21409.x; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SANGER TD, 1981, P NATL ACAD SCI USA, V78, P243; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SCHOONJANS K, 1993, EUR J BIOCHEM, V216, P615, DOI 10.1111/j.1432-1033.1993.tb18181.x; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; SUZUKI H, 1995, J BIOL CHEM, V270, P9676, DOI 10.1074/jbc.270.16.9676; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; SVOBODA DJ, 1966, J CELL BIOL, V30, P442, DOI 10.1083/jcb.30.2.442; TOKUNAGA K, 1987, CANCER RES, V47, P5616; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSONIS PA, 1988, NUCLEIC ACIDS RES, V16, P7745, DOI 10.1093/nar/16.15.7745; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VUDAC N, 1994, J BIOL CHEM, V269, P31012; WU PF, 1993, BIOCHIM BIOPHYS ACTA, V1170, P118, DOI 10.1016/0005-2760(93)90060-M; YAMAMOTO T, 1990, PROG OBESITY RES, P219; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	62	332	344	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19269	19276		10.1074/jbc.270.33.19269	http://dx.doi.org/10.1074/jbc.270.33.19269			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642600	hybrid			2022-12-25	WOS:A1995RP70300014
J	TOTH, I; BRIDGES, KR				TOTH, I; BRIDGES, KR			ASCORBIC-ACID ENHANCES FERRITIN MESSENGER-RNA TRANSLATION BY AN IRP/ACONITASE SWITCH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-RESPONSIVE ELEMENT; FE-S CLUSTER; RNA-BINDING; MESSENGER-RNA; ESCHERICHIA-COLI; PROTEIN; METABOLISM; ACONITASE; ANTIOXIDANT	Replenishment of ascorbate in cultured cells, which are almost uniformly vitamin-deficient, increases ferritin mRNA translation in response to iron by 20-fold (Toth, I., Rogers, J. T., McPhee, J. A., Elliott, S, M., Abramson, S. L., and Bridges, K. R. (1995) J. Biol, Chem. 270, 2846-2852). We now demonstrate that ascorbate increases cytosolic aconitase activity. The iron-responsive element-binding protein (IRP-1) exists in three states: bound to mRNA without aconitase activity, free in the cytosol without aconitase activity, and free in the cytosol with aconitase activity. Ascorbate converts free IRP-1 to the enzymatically active form. Enhanced ferritin synthesis with subsequent iron stimulation is due to the altered equilibrium of the free IRP-1. The cellular biology of iron is closely intertwined with that of ascorbate.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045794] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45794] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; BRIDGES KR, 1986, J BIOL CHEM, V261, P14273; BRIDGES KR, 1987, J BIOL CHEM, V262, P14773; BURNS JJ, 1957, NATURE, V180, P552, DOI 10.1038/180553a0; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; ENGLARD S, 1986, ANNU REV NUTR, V6, P365, DOI 10.1146/annurev.nu.06.070186.002053; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1993, ARCH BIOCHEM BIOPHYS, V301, P98, DOI 10.1006/abbi.1993.1120; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENTZE MW, 1988, GENE, V72, P201, DOI 10.1016/0378-1119(88)90145-X; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; HOFFMAN KE, 1991, AM J CLIN NUTR, V54, pS1188, DOI 10.1093/ajcn/54.6.1188s; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEVINE M, 1986, NEW ENGL J MED, V314, P892, DOI 10.1056/NEJM198604033141407; LIPSCHITZ DA, 1971, BRIT J HAEMATOL, V20, P155, DOI 10.1111/j.1365-2141.1971.tb07024.x; MEISTER A, 1994, J BIOL CHEM, V269, P9397; Moser U., 1991, HDB VITAMINS, P195; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NISHIKIMI M, 1991, AM J CLIN NUTR, V54, pS1203, DOI 10.1093/ajcn/54.6.1203s; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SEVANIAN A, 1991, AM J CLIN NUTR, V54, pS1129, DOI 10.1093/ajcn/54.6.1129s; SMITH L, 1955, Methods Biochem Anal, V2, P427, DOI 10.1002/9780470110188.ch13; Szent-Gyorgyi A, 1928, BIOCHEM J, V22, P1387, DOI 10.1042/bj0221387; TANG CK, 1992, J BIOL CHEM, V267, P24466; TOTH I, 1995, J BIOL CHEM, V270, P2846, DOI 10.1074/jbc.270.6.2846; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x	36	52	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19540	19544		10.1074/jbc.270.33.19540	http://dx.doi.org/10.1074/jbc.270.33.19540			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642638	hybrid			2022-12-25	WOS:A1995RP70300054
J	WAGGONER, DW; MARTIN, A; DEWALD, J; GOMEZMUNOZ, A; BRINDLEY, DN				WAGGONER, DW; MARTIN, A; DEWALD, J; GOMEZMUNOZ, A; BRINDLEY, DN			PURIFICATION AND CHARACTERIZATION OF A NOVEL PLASMA-MEMBRANE PHOSPHATIDATE PHOSPHOHYDROLASE FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-D; LYSOPHOSPHATIDIC ACID; SIGNAL-TRANSDUCTION; PHOSPHATIDYLCHOLINE HYDROLYSIS; SACCHAROMYCES-CEREVISIAE; HUMAN NEUTROPHILS; 2ND MESSENGER; NADPH OXIDASE	An N-ethylmaleimide-insensitive phosphatidate phosphohydrolase, which also hydrolyzes lysophosphatidate, was isolated from the plasma membranes of rat liver. The specific activity of an anionic form of the enzyme (53 kDa, pI < 4) was increased 2700-fold, A cationic form of the enzyme (51 kDa, pI = 9) was purified to homogeneity, but the fold purification was low because the activity of the highly purified enzyme was unstable. Immunoprecipitating antibodies raised against the homogeneous protein confirmed the identity of the cationic protein as the phosphohydrolase and were used to identify the anionic enzyme, Both forms are integral membrane glycoproteins that were converted to 28-kDa proteins upon treatment with N-glycanase F. Treatment of the anionic form with neuraminidase allowed it to be purified in the same manner as the cationic enzyme and yielded an immunoreactive protein with a molecular mass identical to the cationic protein, Thus, the two ionic forms most likely represent different sialated states of the protein. An immunoreactive 51-53-kDa protein was detected in rat liver, heart, kidney, skeletal muscle, testis, and brain. Little immunoreactive 51-53-kDa protein was detected in rat thymus, spleen, adipose, or lung tissue. This work provides the tools for determining the regulation and function of the phosphatidate phosphohydrolase in signal transduction and cell activation.	UNIV ALBERTA, SIGNAL TRANSDUCT LAB, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, LIPID & LIPOPROT RES GRP, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2S2, CANADA	University of Alberta; University of Alberta; University of Alberta				GOMEZ MUNOZ, ANTONIO/0000-0002-2539-016X				AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AKASAKI K, 1990, CHEM PHARM BULL, V38, P2766, DOI 10.1248/cpb.38.2766; AKASAKI K, 1991, J BIOCHEM-TOKYO, V110, P922, DOI 10.1093/oxfordjournals.jbchem.a123690; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BHAT BG, 1994, J BIOL CHEM, V269, P13172; BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BRINDLEY DN, 1987, CRC SERIES ENZYME BI, V1, P1; CABOT MC, 1988, FEBS LETT, V233, P153, DOI 10.1016/0014-5793(88)81374-7; CALLAGHAN JM, 1992, BIOCHEM J, V283, P63, DOI 10.1042/bj2830063; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; COLEMAN R, 1967, BIOCHIM BIOPHYS ACTA, V135, P573, DOI 10.1016/0005-2736(67)90089-2; DAY CP, 1992, BIOCHIM BIOPHYS ACTA, V1127, P87, DOI 10.1016/0005-2760(92)90205-A; DAY CP, 1993, CLIN SCI, V85, P281, DOI 10.1042/cs0850281; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FLEMING LN, 1995, BIOCHIM BIOPHYS ACTA, V1254, P161; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GODING JW, 1986, MONOCLONAL ANTIBODIE, P281; GOMEZMUNOZ A, 1992, FEBS LETT, V301, P103, DOI 10.1016/0014-5793(92)80219-7; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HAMES BD, 1990, GEL ELECTROPHORESIS, P136; Harlow E. L, 1988, ANTIBODIES LABORATOR, P100; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; IRVING HR, 1987, J BIOL CHEM, V262, P3440; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JAMAL Z, 1992, INT J OBESITY, V16, P789; JAMDAR SC, 1994, BIOCHEM J, V301, P793, DOI 10.1042/bj3010793; JONES GA, 1993, J BIOL CHEM, V268, P20845; KANOH H, 1992, J BIOL CHEM, V267, P25309; KAWAMURA S, 1991, JPN J CANCER RES, V82, P758, DOI 10.1111/j.1349-7006.1991.tb02699.x; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARD D, 1994, EUR J BIOCHEM, V220, P919, DOI 10.1111/j.1432-1033.1994.tb18695.x; LIN YP, 1989, J BIOL CHEM, V264, P8641; MARTIN A, 1991, METHOD ENZYMOL, V197, P553; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MITSUYAMA T, 1993, FEBS LETT, V328, P67, DOI 10.1016/0014-5793(93)80967-Y; MOEHREN G, 1994, J BIOL CHEM, V269, P838; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PERRY DK, 1993, J BIOL CHEM, V268, P25302; PETTITT TR, 1993, BIOCHEM J, V289, P487, DOI 10.1042/bj2890487; PUTNEY JW, 1980, NATURE, V284, P345, DOI 10.1038/284345a0; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; STRALFORS P, 1988, NATURE, V335, P554, DOI 10.1038/335554a0; SWARTS HGP, 1992, BIOCHIM BIOPHYS ACTA, V1107, P143, DOI 10.1016/0005-2736(92)90340-R; TAYLOR GS, 1993, BIOCHIM BIOPHYS ACTA, V1175, P219, DOI 10.1016/0167-4889(93)90026-L; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; VERMEULEN PS, 1994, THESIS U UTRECHT HOL; WIESER RJ, 1990, J CELL BIOL, V111, P2681, DOI 10.1083/jcb.111.6.2681; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; WRIGHT TM, 1992, BIOCHEM J, V285, P395, DOI 10.1042/bj2850395; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG H, 1990, J BIOL CHEM, V265, P21309	76	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19422	19429		10.1074/jbc.270.33.19422	http://dx.doi.org/10.1074/jbc.270.33.19422			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642624	hybrid			2022-12-25	WOS:A1995RP70300038
J	LUO, XN; REDDY, JC; YEYATI, PL; IDRIS, AH; HOSONO, S; HABER, DA; LICHT, JD; ATWEH, GF				LUO, XN; REDDY, JC; YEYATI, PL; IDRIS, AH; HOSONO, S; HABER, DA; LICHT, JD; ATWEH, GF			THE TUMOR-SUPPRESSOR GENE WT1 INHIBITS RAS-MEDIATED TRANSFORMATION	ONCOGENE			English	Article						WT1; TUMOR SUPPRESSORS; RAS-TRANSFORMATION	WILMS-TUMOR; HUMAN CHROMOSOME-11; PROMOTER ACTIVITY; NUDE MICE; CELL-LINE; GROWTH; PRODUCT; EXPRESSION; ONCOGENE; KIDNEY	Wilms' tumor belongs to a small group of pediatric neoplasms that have served as paradigms of human cancers in which recessive mutations play a primary role in tumorigenesis. WT1 is a candidate tumor suppressor gene that is mutationally inactivated in a proportion of both familial and sporadic Wilms' tumors. Recent studies demonstrated that WT1 can partially suppress growth of a Wilms' tumor cell line in vitro and in vivo. We investigated the ability of WT1 to inhibit the expression of the transformed phenotype in non-Wilms' tumor cells. The expression of WT1 cDNA in ras-transformed NIH3T3 cells yielded large, flat cells that exhibited complete contact-inhibition. These morphologic changes were associated with decreased proliferation, suppression of clonogenicity in soft agar and inhibition of tumor growth in nude mice. Moreover, expression of WT1 in non-transformed NIH3T3 cells resulted in similar morphologic changes and profound resistance to transformation by an activated uas oncogene. These studies suggest that tumor inhibition by WT1 in these cells may be achieved by interference with the ras-mediated signalling pathway.	CUNY MT SINAI SCH MED, DEPT MED, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, BROOKDALE CTR MOLEC BIOL, NEW YORK, NY 10029 USA; MASSACHUSETTS GEN HOSP, CTR CANC, GENET MOLEC LAB, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02129 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Licht, Jonathan/L-4239-2019	Licht, Jonathan/0000-0002-3942-1369	NATIONAL CANCER INSTITUTE [R01CA059998, R01CA037887, R23CA037887] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042919] Funding Source: NIH RePORTER; NCI NIH HHS [CA59998, CA37887] Funding Source: Medline; NHLBI NIH HHS [HL42919] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATWEH GF, 1985, NUCLEIC ACIDS RES, V13, P777, DOI 10.1093/nar/13.3.777; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAREL JC, 1989, J IMMUNOL, V143, P923; CARMICHAEL J, 1987, CANCER RES, V47, P943; CHANG KS, 1993, BLOOD, V82, pA191; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Favaloro J, 1980, Methods Enzymol, V65, P718; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GARVIN AJ, 1993, AM J PATHOL, V142, P375; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HUANG RP, 1994, ONCOGENE, V9, P1367; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KIVINEN L, 1993, ONCOGENE, V8, P2703; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	44	56	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					743	750						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651738				2022-12-25	WOS:A1995RQ46900016
J	MONTE, D; COUTTE, L; BAERT, JL; ANGELI, I; STEHELIN, D; DELAUNOIT, Y				MONTE, D; COUTTE, L; BAERT, JL; ANGELI, I; STEHELIN, D; DELAUNOIT, Y			MOLECULAR CHARACTERIZATION OF THE ETS-RELATED HUMAN TRANSCRIPTION FACTOR ER81	ONCOGENE			English	Note						ER81; TRANSCRIPTION FACTOR; ETS GENE; ALTERNATIVE SPLICING	GENE FAMILY; BINDING-PROTEIN; ONCOGENE FAMILY; C-ETS-1 PROTEIN; MESSENGER-RNAS; MEMBER; PEA3; ACTIVATION; EVOLUTION; DOMAIN	The PEA3 group is a homogeneous group of the ets transcription factor family and is composed df three known members, PEA3, ERM and ER81, which, on the amino acid (AA) level, are more than 95% identical within the DNA-binding domain (the Ets domain), more than 85% within a 32 AA domain (the acidic domain) localized in the amino-terminus and almost 50% identical overall. By screening a human kidney cDNA library with a specific probe obtained from mouse ER81 we isolated two clones of 1.6 and 1.5 kb in length encoding a 458 AA open reading frame. When compared to mouse ER81, the present human ER81 lacks the last 13 AA of the acidic domain and the 5 AA contiguous to the carboxy-terminal part of the acidic domain. Of the 458 AA of the human ER81 protein, 97% are identical to mouse ER81. Gel shift analysis indicates that the full-length human ER81 protein is able to bind specifically to an oligonucleotide containing the binding sites recognized by most of the Ets proteins. By transient expression in RK13 mammalian cells, human ER81 protein transactivated a reporter plasmid containing Ets binding sites, indicating that this molecule is a bonafide transcriptional activator, while by expression in Cos-1 transfected cells, we detected the presence of human ER81 protein in the nucleus using immunocytochemistry. In human tissues, ER81 mRNA is very highly expressed in brain, highly expressed in testis, lung and heart, moderately in spleen, small intestine, pancreas and colon, weakly in liver, prostate and thymus, very weakly in skeletal muscle, kidney and ovary and not in placenta and peripheral blood leukocytes. Analysis of human solid or haematopoietic tumour cell lines showed that most of them did not express ER81 detectably. Database searches revealed that ETV1 mRNA is highly similar to human ER81 described here, although it contains the full-length acidic domain present in mouse ER81. By screening a genomic DNA library, we characterized the intron-exon junction within the acidic domain of human ER81 and we showed that this junction corresponds to the site where the remaining AA of the acidic domain of ETV1 or mouse ER81 are inserted.	INST PASTEUR,CNRS,URA 1160,UNITE ONCOL MOLEC,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille				coutte, laurent/0000-0002-0031-4742; monte, didier/0000-0002-0613-6203				ALBAGLI O, 1994, ONCOGENE, V9, P3259; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CREPIEUX P, 1995, IN PRESS CRITICAL RE; Crepieux Pascale, 1993, Gene Expression, V3, P215; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JEON IS, 1995, ONCOGENE, V10, P1229; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LIANG H, 1994, STRUCT BIOL, V1, P871; MCLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251; MONTE D, 1994, ONCOGENE, V9, P1397; MONTE D, 1995, IN PRESS ANN ENDOCRI; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; POGNONEC P, 1989, ONCOGENE, V4, P691; ROMANOSPICA V, 1994, INT J ONCOL, V4, P521; SOUDANT N, 1994, NUCLEIC ACIDS RES, V22, P3871, DOI 10.1093/nar/22.19.3871; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YOGANATHAN T, 1992, EUR J BIOCHEM, V207, P195, DOI 10.1111/j.1432-1033.1992.tb17037.x; ZHAO HF, 1991, J BIOL CHEM, V266, P583	29	88	89	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					771	779						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651741				2022-12-25	WOS:A1995RQ46900020
J	CHEN, SG; TEPLOW, DB; PARCHI, P; TELLER, JK; GAMBETTI, P; AUTILIOGAMBETTI, L				CHEN, SG; TEPLOW, DB; PARCHI, P; TELLER, JK; GAMBETTI, P; AUTILIOGAMBETTI, L			TRUNCATED FORMS OF THE HUMAN PRION PROTEIN IN NORMAL BRAIN AND IN PRION DISEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOINOSITOL PHOSPHOLIPID ANCHOR; SCRAPIE-ASSOCIATED FORM; MOLECULAR-CLONING; CULTURED-CELLS; AGENT PROTEIN; HAMSTER BRAIN; PRP 27-30; MOUSE; CONVERSION; ACID	The cellular form of the prion protein (PrPc) is a glycoprotein anchored to the cell membrane by a glycosylphosphatidylinositol moiety. An aberrant form of PrPc that is partially resistant to proteases, PrPres, is a hallmark of prion diseases, which in humans include Creutzfeldt Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome, and fatal familial insomnia. We have characterized the major forms of PrP in normal and pathological human brains. A COOH-terminal fragment of PrPc, designated C1, is abundant in normal and CJD brains as well as in human neuroblastoma cells. Sequence analysis revealed that C1 contains alternative NH2 termini starting at His-111 or Met-112. Like PrPc, C1 is glycosylated, anchored to the cell membrane, and is heat stable. Consistent with the lack of the NH2-terminal region of PrPc, C1 is more acidic than PrPc and does not bind heparin. An additional fragment longer than C1, designated C2, is present in substantial amounts in CJD brains. Like PrPres, C2 is resistant to proteases and is detergent-insoluble. Our data indicate that C1 is a major product of normal PrPc metabolism, generated by a cleavage that disrupts the neurotoxic and amyloidogenic region of PrP comprising residues 106-126. This region remains intact in C2, suggesting a role for C2 in prion diseases.	CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106; HARVARD UNIV,SCH MED,DEPT NEUROL NEUROSCI,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BIOPOLYMER LAB,BOSTON,MA 02115	Case Western Reserve University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital			Parchi, Piero/L-9833-2015; Chen, Shu G./O-4750-2014; Chen, Shu G./AAK-7301-2021; Chen, Shu/Z-2943-2019	Parchi, Piero/0000-0002-9444-9524; Chen, Shu G./0000-0001-7180-3001; Chen, Shu G./0000-0001-7180-3001; 	NATIONAL INSTITUTE ON AGING [R35AG008992, R37AG008155] Funding Source: NIH RePORTER; NIA NIH HHS [AG08155, AG08992] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BORCHELT DR, 1993, GLYCOBIOLOGY, V3, P319, DOI 10.1093/glycob/3.4.319; BULER H, 1992, NATURE, V356, P577; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CAUGHEY B, 1993, J VIROL, V67, P634; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; DEEG MA, 1992, J BIOL CHEM, V267, P18573; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; GABRIEL JM, 1992, P NATL ACAD SCI USA, V89, P9097, DOI 10.1073/pnas.89.19.9097; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HOPE J, 1988, EUR J BIOCHEM, V172, P271, DOI 10.1111/j.1432-1033.1988.tb13883.x; HOPE J, 1994, BIOCHEM SOC T, V22, P159, DOI 10.1042/bst0220159; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARINI F, 1991, MOL BRAIN RES, V10, P343, DOI 10.1016/0169-328X(91)90093-D; LIAO YCJ, 1986, SCIENCE, V233, P364, DOI 10.1126/science.3014653; MANSON J, 1992, DEVELOPMENT, V115, P117; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MAURY CPJ, 1995, LAB INVEST, V72, P4; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; MOBLEY WC, 1988, P NATL ACAD SCI USA, V85, P9811, DOI 10.1073/pnas.85.24.9811; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; NORDSTEDT C, 1994, J BIOL CHEM, V269, P30773; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; PUCKETT C, 1991, AM J HUM GENET, V49, P320; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHINAGAWA M, 1986, J GEN VIROL, V67, P1745, DOI 10.1099/0022-1317-67-8-1745; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; WION D, 1988, INT J DEV NEUROSC, V64, P387	60	438	447	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19173	19180		10.1074/jbc.270.32.19173	http://dx.doi.org/10.1074/jbc.270.32.19173			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642585	hybrid			2022-12-25	WOS:A1995RN95400073
J	FINGAR, DC; HAUSDORFF, SF; BLENIS, J; BIRNBAUM, MJ				FINGAR, DC; HAUSDORFF, SF; BLENIS, J; BIRNBAUM, MJ			DISSOCIATION OF PP70 RIBOSOMAL-PROTEIN S6 KINASE FROM INSULIN-STIMULATED GLUCOSE-TRANSPORT IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OKADAIC ACID; MOLECULAR MECHANISM; SKELETAL-MUSCLE; PHORBOL ESTER; PHOSPHORYLATION; CELLS; IDENTIFICATION; ACTIVATION; METABOLISM; EXPRESSION	The metabolic and mitogenic actions of insulin have been proposed to be mediated by cellular serine/threonine kinases such as the ribosomal protein S6 kinases pp70-S6 (pp70-S6 kinase) and pp90rsk and the erk-encoded mitogen-activated protein kinases (pp42mapk and pp44mapk). Rapamycin completely blocked activation of pp70-S6 kinase by insulin in 3T3-L1 adipocytes, but did not inhibit insulin-stimulated glucose transport, translocation of GLUT4 to the cell surface, or activation of pp90rsk or pp44mapk by insulin. Concordant with the inhibition of kinase activity, rapamycin prevented the insulin-induced decrease in mobility of pp70-S6 kinase visualized by SDS-polyacrylamide gel electrophoresis, reflecting a reduction in the hormone-stimulated phosphorylation of the enzyme. The structurally related macrolide, FK506, had no effect on pp70-S6 kinase or hexose uptake. These data demonstrate that rapamycin blocks insulin activation of pp70-S6 kinase in 3T3-L1 adipocytes and that pp70-S6 kinase is not required in the signaling pathway leading to insulin-stimulated glucose transport.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,25 SHATTUCK ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM CELL & DEV BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School				Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [F32 DK08714, R01 DK39519] Funding Source: Medline; NIGMS NIH HHS [GM07226] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008714, R01DK039519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007226] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; TABARINI D, 1985, P NATL ACAD SCI USA, V82, P4369, DOI 10.1073/pnas.82.13.4369; TANTI JF, 1991, J BIOL CHEM, V266, P2099	30	104	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					3005	3008						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679106				2022-12-25	WOS:A1993KK81500109
J	PURI, PL; AVANTAGGIATI, ML; BURGIO, VL; CHIRILLO, P; COLLEPARDO, D; NATOLI, G; BALSANO, C; LEVRERO, M				PURI, PL; AVANTAGGIATI, ML; BURGIO, VL; CHIRILLO, P; COLLEPARDO, D; NATOLI, G; BALSANO, C; LEVRERO, M			REACTIVE OXYGEN INTERMEDIATES MEDIATE ANGIOTENSIN-II-INDUCED C-JUN-CENTER-DOT-C-FOS HETERODIMER DNA-BINDING ACTIVITY AND PROLIFERATIVE HYPERTROPHIC RESPONSES IN MYOGENIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CARDIAC-HYPERTROPHY; MOLECULAR CHARACTERIZATION; PROTEIN-SYNTHESIS; ARACHIDONIC-ACID; TYROSINE KINASE; ACTIVATION; PHOSPHORYLATION; MYOCYTES; INCREASE	Angiotensin II (Ang-II) receptor engagement activates many immediate early response genes in both vascular smooth muscle cells and cardiomyocytes whether a hyperplastic or hypertrophic response is taking place, Although the signaling pathways stimulated by Ang-II in different cell lines have been widely characterized, the correlation between the generation of different second messengers and specific physiological responses remains relatively unexplored, In this study, we report how in both C2C12 quiescent myoblasts and differentiated myotubes Ang II significantly stimulates AP1-driven transcription and c-Jun . c-Fos heterodimer DNA binding activity. Using a set of different protein kinase inhibitors, we could demonstrate that Ang-II-induced increase in API binding is not mediated by the cAMP-dependent pathway and that both protein kinase C and tyrosine kinases are involved. The observation that in quiescent myoblasts Ang-II increase of AP1 binding and induction of DNA synthesis and, in differentiated myotubes, Ang-II stimulation of protein synthesis are abolished by the cysteine-derivative and glutathione precursor N-acetyl-L-cysteine strongly suggests a role for reactive oxygen intermediates in the intracellular transduction of Ang-II signals for immediate early gene induction, cell proliferation, and hypertrophic responses.	UNIV ROMA LA SAPIENZA,FDN ANDREA CESALPINO,I-00161 ROME,ITALY; UNIV LAQUILA,DIPARTIMENTO MED INTERNA,I-67100 LAQUILA,ITALY; UNIV CAGLIARI,IST MED INTERNA,I-09124 CAGLIARI,ITALY	Sapienza University Rome; University of L'Aquila; University of Cagliari	PURI, PL (corresponding author), UNIV ROMA LA SAPIENZA,POLICLIN UMBERTO 1,IST CLIN MED 1,VIALE POLICLIN 155,I-00161 ROME,ITALY.		Natoli, gioacchino/J-2100-2018; Balsano, Clara/AAK-9870-2020; Natoli, gioacchino/ABB-8679-2020; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Natoli, Gioacchino/0000-0003-0711-2411; Puri, Pier Lorenzo/0000-0003-4964-0095; Levrero, Massimo/0000-0002-4978-0875				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1272, P129; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BAKER KM, 1989, J PHARMACOL EXP THER, V251, P578; BAKER KM, 1990, AM J PHYSIOL, V259, pH324, DOI 10.1152/ajpheart.1990.259.2.H324; BAKER KM, 1990, AM J PHYSIOL, V259, pH610, DOI 10.1152/ajpheart.1990.259.2.H610; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUTCHER RD, 1993, BIOCHEM BIOPH RES CO, V196, P1280, DOI 10.1006/bbrc.1993.2391; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GUY GR, 1993, J BIOL CHEM, V268, P2141; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HASSID A, 1986, J PHARMACOL EXP THER, V239, P334; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; KHAIRALLAH PA, 1983, PERSPECTIVE CARDIOVA, V8, P337; KOH GY, 1993, J CLIN INVEST, V92, P1548, DOI 10.1172/JCI116734; KOJIMA I, 1985, ENDOCRINOLOGY, V117, P1057, DOI 10.1210/endo-117-3-1057; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LASSEGUE B, 1991, BIOCHEM J, V276, P19, DOI 10.1042/bj2760019; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LINDPAINTNER K, 1991, CIRC RES, V68, P905, DOI 10.1161/01.RES.68.4.905; LINZ W, 1989, CLIN EXP HYPERTENS A, V11, P1325, DOI 10.3109/10641968909038172; LOKUTA AJ, 1994, J BIOL CHEM, V269, P4832; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; NATOLI G, 1994, MOL CELL BIOL, V14, P898; PAQUET JL, 1990, J HYPERTENS, V8, P565, DOI 10.1097/00004872-199006000-00010; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAO GN, 1993, ONCOGENE, V8, P2759; RIVERA V M, 1990, New Biologist, V2, P751; ROZENGURT E, 1990, EUR J CLIN INVEST, V21, P123; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIBANUMA M, 1988, J CELL PHYSIOL, V136, P379, DOI 10.1002/jcp.1041360224; STOUFFER GA, 1992, CIRC RES, V70, P820, DOI 10.1161/01.RES.70.4.820; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; Yaffe D, 1977, NATURE, V270, P725, DOI DOI 10.1038/270725A0	49	108	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22129	22134		10.1074/jbc.270.38.22129	http://dx.doi.org/10.1074/jbc.270.38.22129			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673190	hybrid			2022-12-25	WOS:A1995RW31400014
J	WREGGETT, KA; WELLS, JW				WREGGETT, KA; WELLS, JW			COOPERATIVITY MANIFEST IN THE BINDING-PROPERTIES OF PURIFIED CARDIAC MUSCARINIC RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; TERNARY COMPLEX MODEL; PROTEIN-LINKED RECEPTORS; ADENYLATE-CYCLASE SYSTEM; PIG CEREBRAL-CORTEX; ACETYLCHOLINE-RECEPTOR; ANTAGONIST BINDING; RAT-BRAIN; D2-DOPAMINE RECEPTOR; H-3 HISTAMINE	Muscarinic receptors were solubilized from porcine atria in digitonin-cholate and were purified by chromatography on DEAE-Sepharose and 3-(2'-aminobenzhydryloxy)tropane-Sepharose. The product identified on Western blots migrated with an apparent molecular mass of 60-75 kDa, with additional bands indicative of homotrimers (190 kDa) and homotetramers (240 kDa). Receptor eluted from the affinity column was accompanied by a mixture of guanyl nucleotide-binding proteins (G-proteins) identified on Western blots as G(i1/2), G(o), G(q/11), and G(s) (preparation M2G); the G-proteins were largely removed by further processing on hydroxyapatite (preparation M2). Solubilized purified receptors bound muscarinic ligands in an apparently cooperative manner. In studies at equilibrium, the antagonists [H-3]AF-DX 384, N-[H-3]methylscopolamine (NMS), and [H-3]quinuclidinylbenzilate (QNB) revealed Hill coefficients between about 0.8 and 1.2. Also, the apparent capacity for [H-3]QNB exceeded that for [H-3]AF-DX 384 and [H-3]NMS by about 1.5-fold in M2 and by S-fold in M2G. Binding to M2G at high concentrations of [H-3]QNB was fully inhibited by unlabeled NMS, which therefore affected sites not labeled at similar concentrations of [H-3]NMS. Oxotremorine-M displayed a biphasic inhibitory effect on the binding of [H-3]AF-DX 384 in M2 and M2G, suggesting that multiple states of affinity are intrinsic to the receptor; 5'-guanylylimidodiphosphate was without appreciable effect in M2 but resulted in a bell-shaped binding profile for the agonist in M2G. All of the data can be described in terms of cooperative interactions within a receptor that is at least tetravalent and presumably an oligomer. In the context of the model, copurifying G-proteins and guanyl nucleotides serve to regulate the degree of cooperativity between successive equivalents of muscarinic ligands.	UNIV TORONTO,FAC PHARM,TORONTO,ON M5S 2S2,CANADA	University of Toronto								AVISSAR S, 1983, P NATL ACAD SCI-BIOL, V80, P156, DOI 10.1073/pnas.80.1.156; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOYER JL, 1986, BIOCHEM BIOPH RES CO, V134, P172, DOI 10.1016/0006-291X(86)90543-7; CASTOLDI AF, 1991, RES COMMUN CHEM PATH, V74, P371; CHIDIAC P, 1992, BIOCHEMISTRY-US, V31, P10908, DOI 10.1021/bi00159a035; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; COULTER S, 1992, P NATL ACAD SCI USA, V89, P5842, DOI 10.1073/pnas.89.13.5842; DADI HK, 1984, EUR J BIOCHEM, V144, P617, DOI 10.1111/j.1432-1033.1984.tb08510.x; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; EHLERT FJ, 1990, MOL PHARMACOL, V38, P148; EHLERT FJ, 1985, MOL PHARMACOL, V28, P410; ENTZEROTH M, 1991, J RECEPTOR RES, V11, P141, DOI 10.3109/10799899109066395; FLORIO VA, 1985, J BIOL CHEM, V264, P3909; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GRAESER D, 1993, MOL PHARMACOL, V43, P434; HAGA K, 1986, J BIOL CHEM, V261, P133; HAGA K, 1983, J BIOL CHEM, V258, P3575; HERBERG JT, 1984, J BIOL CHEM, V259, P9285; HIRSCHBERG BT, 1994, J BIOL CHEM, V269, P26127; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; IKEGAYA T, 1990, J MOL CELL CARDIOL, V22, P343, DOI 10.1016/0022-2828(90)91467-L; JAHANGEER S, 1993, P NATL ACAD SCI USA, V90, P8782, DOI 10.1073/pnas.90.19.8782; KAUFMANN SH, 1987, ANAL BIOCHEM, V161, P89, DOI 10.1016/0003-2697(87)90656-7; KENT RS, 1980, MOL PHARMACOL, V17, P14; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JH, 1985, J PHARMACOL EXP THER, V233, P707; LEE TWT, 1986, BIOCHEMISTRY-US, V25, P7009, DOI 10.1021/bi00370a038; LEUNG E, 1990, MOL PHARMACOL, V38, P72; LIMBIRD LE, 1975, BIOCHEM BIOPH RES CO, V64, P1160, DOI 10.1016/0006-291X(75)90815-3; LIMBIRD LE, 1980, P NATL ACAD SCI-BIOL, V77, P775, DOI 10.1073/pnas.77.2.775; LUETJE CW, 1987, BIOCHEMISTRY-US, V26, P6892, DOI 10.1021/bi00396a003; MAEDA A, 1988, FEBS LETT, V239, P339, DOI 10.1016/0014-5793(88)80947-5; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Marquardt D. W., 1963, J SOC IND APPL MATH, V2, P431; MATESIC DF, 1991, FEBS LETT, V284, P184, DOI 10.1016/0014-5793(91)80680-2; MATESIC DF, 1991, MOL PHARMACOL, V40, P347; MATESIC DF, 1988, J BIOL CHEM, V264, P21638; MATTERA R, 1985, J BIOL CHEM, V260, P7410; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEUBIG RR, 1988, BIOCHEMISTRY-US, V27, P2374, DOI 10.1021/bi00407a019; NG GYK, 1994, J NEUROCHEM, V63, P1589; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; ONARAN HO, 1993, MOL PHARMACOL, V43, P245; PARKER EM, 1991, J BIOL CHEM, V266, P519; PETERSON GL, 1984, PREP BIOCHEM, V14, P33, DOI 10.1080/10826068408070612; PETERSON GL, 1984, P NATL ACAD SCI-BIOL, V81, P4993, DOI 10.1073/pnas.81.15.4993; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; POTTER LT, 1991, MOL PHARMACOL, V39, P211; POYNER DR, 1989, MOL PHARMACOL, V36, P420; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SEEMAN P, 1992, EUR J PHARM-MOLEC PH, V227, P139, DOI 10.1016/0922-4106(92)90121-B; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SINKINS WG, 1993, MOL PHARMACOL, V43, P583; SINKINS WG, 1993, MOL PHARMACOL, V43, P569; SPIEGEL AM, 1990, ADP RIBOSYLATION TOX, P207; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENTER JC, 1983, TRENDS PHARMACOL SCI, V4, P256; Wells J. W., 1992, RECEPTOR LIGAND INTE, P289; WELLS JW, 1990, EUR J PHARMACOL, V183, P1731, DOI 10.1016/0014-2999(90)92036-I; WONG HMS, 1986, BIOCHEMISTRY-US, V25, P6995, DOI 10.1021/bi00370a037; WREGGETT KA, 1984, MOL PHARMACOL, V26, P214; WREGGETT KA, 1987, BIOCHEM BIOPH RES CO, V147, P1070, DOI 10.1016/S0006-291X(87)80179-1; Wyman J, 1990, BINDING LINKAGE FUNC	70	156	160	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22488	22499		10.1074/jbc.270.38.22488	http://dx.doi.org/10.1074/jbc.270.38.22488			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673239	hybrid			2022-12-25	WOS:A1995RW31400068
J	MLINAR, B; BIAGI, BA; ENYEART, JJ				MLINAR, B; BIAGI, BA; ENYEART, JJ			LOSARTAN-SENSITIVE AII RECEPTORS LINKED TO DEPOLARIZATION-DEPENDENT CORTISOL SECRETION THROUGH A NOVEL SIGNALING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL GLOMERULOSA CELLS; GATED TRANSIENT CURRENTS; ANGIOTENSIN-II; FASCICULATA CELLS; ARACHIDONIC-ACID; CALCIUM CHANNELS; K+ CURRENT; RAT; STIMULATION; INHIBITION	In bovine adrenal zona fasciculata (AZF) cells, angiotensin II (AII) may stimulate depolarization-dependent Ca2+ entry and cortisol secretion through inhibition of a novel potassium channel (I-AC), which appears to set the resting potential of these cells, Aspects of the signaling pathway, which couples AII receptors to membrane depolarization and secretion, were characterized in patch clamp and membrane potential recordings and in secretion studies. AII mediated inhibition of I-AC, membrane depolarization, and cortisol secretion were all blocked by the AII type I (AT(1)) receptor antagonist losartan, These responses were unaffected by the AT(2) antagonist PD123319, Inhibition of I-AC by AII was prevented by intracellular application of guanosine 5'-O-2-(thio)diphosphate but was not affected by pre-incubation of cells with pertussis toxin, Although mediated through an AT(1) receptor, several lines of evidence indicated that AII inhibition of I-AC occurred through an unusual phospholipase C (PLC)-independent pathway. Acetylcholine, which activates PLC in AZF cells, did not inhibit I-AC. Neither the PLC antagonist neomycin nor PLC-generated second messengers prevented I-AC expression or mimicked the inhibition of this current by AII, I-AC expression and inhibition by AII were insensitive to variations in intracellular or extracellular Ca2+ concentration. AII-mediated inhibition of I-AC was markedly reduced by the non-hydrolyzable ATP analog adenosine 5'-(beta,gamma-imino)triphosphate and by the non-selective protein kinase inhibitor staurosporine. The protein phosphatase antagonist okadaic acid reversibly inhibited I-AC in whole cell recordings, These findings indicate that AII-stimulated effects on I-AC current, membrane voltage, and cortisol secretion are linked through a common AT(1) receptor, Inhibition of I-AC in AZF cells appears to occur through a novel signaling pathway, which may include a losartan-sensitive AT(1) receptor coupled through a pertussis-insensitive G protein to a staurosporine-sensitive protein kinase, Apparently, the mechanism linking AT(1) receptors to I-AC inhibition and Ca2+ influx in adrenocortical cells is separate from that involving inositol trisphosphate-stimulated Ca2+ release from intracellular stores, AII-stimulated cortisol secretion may occur through distinct parallel signaling pathways.	OHIO STATE UNIV, COLL MED, DEPT PHARMACOL, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, COLL MED, DEPT PHYSIOL, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, COLL MED, NEUROSCI PROGRAM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Mlinar, Boris/A-7034-2008	Mlinar, Boris/0000-0001-9082-0827	NIDDK NIH HHS [DK-40131] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040131] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBROZ C, 1992, ENDOCRINOLOGY, V131, P408, DOI 10.1210/en.131.1.408; BREGESTOVSKI P, 1986, NATURE, V319, P776, DOI 10.1038/319776a0; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CHIU AT, 1989, BIOCHEM BIOPH RES CO, V165, P196, DOI 10.1016/0006-291X(89)91054-1; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; CRAWFORD KW, 1992, MOL PHARMACOL, V41, P154; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; ELTON TS, 1992, BIOCHEM BIOPH RES CO, V184, P1067, DOI 10.1016/0006-291X(92)90700-U; ENYEART JJ, 1993, MOL ENDOCRINOL, V7, P1031, DOI 10.1210/me.7.8.1031; GOSPODAROWICZ D, 1977, ENDOCRINOLOGY, V100, P1080; HADJIAN AJ, 1984, BIOCHIM BIOPHYS ACTA, V804, P427, DOI 10.1016/0167-4889(84)90070-3; HADJIAN AJ, 1982, BIOCHIM BIOPHYS ACTA, V714, P157; HAHN AWA, 1993, BIOCHEM BIOPH RES CO, V192, P1260, DOI 10.1006/bbrc.1993.1552; HAJNOCZKY G, 1992, BIOCHEM PHARMACOL, V43, P1009, DOI 10.1016/0006-2952(92)90606-J; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KIRKWOOD A, 1991, NEURON, V6, P1009, DOI 10.1016/0896-6273(91)90240-Z; KOJIMA I, 1984, J BIOL CHEM, V259, P4448; KOJIMA I, 1985, J BIOL CHEM, V260, P9171; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; LOMBARDO D, 1985, J BIOL CHEM, V260, P7234; MARRION NV, 1991, NEURON, V6, P533, DOI 10.1016/0896-6273(91)90056-6; MCCARTHY RT, 1989, J GEN PHYSIOL, V94, P669, DOI 10.1085/jgp.94.4.669; MLINAR B, 1993, J BIOL CHEM, V268, P8640; MLINAR B, 1993, J GEN PHYSIOL, V102, P239, DOI 10.1085/jgp.102.2.239; MLINAR B, 1993, J GEN PHYSIOL, V102, P217, DOI 10.1085/jgp.102.2.217; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; ROBBINS J, 1993, J PHYSIOL-LONDON, V469, P153, DOI 10.1113/jphysiol.1993.sp019809; SANDBERG K, 1992, J BIOL CHEM, V267, P9455; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHWEITZER P, 1993, J NEUROSCI, V13, P2033; SMITH RD, 1992, ANNU REV PHARMACOL, V32, P135; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; VERGARA J, 1985, P NATL ACAD SCI USA, V82, P6352, DOI 10.1073/pnas.82.18.6352; WHEELER LA, 1987, J BIOL CHEM, V262, P6531; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0	40	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20942	20951		10.1074/jbc.270.36.20942	http://dx.doi.org/10.1074/jbc.270.36.20942			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673118	hybrid			2022-12-25	WOS:A1995RU05400015
J	YELISEEV, AA; KAPLAN, S				YELISEEV, AA; KAPLAN, S			A SENSORY TRANSDUCER HOMOLOGOUS TO THE MAMMALIAN PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR REGULATES PHOTOSYNTHETIC MEMBRANE COMPLEX-FORMATION IN RHODOBACTER-SPHAEROIDES-2.4.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS GENE-CLUSTER; RHODOPSEUDOMONAS-SPHAEROIDES; ESCHERICHIA-COLI; PROTEIN; CAPSULATUS; SEQUENCE; CONSTRUCTION; LOCALIZATION; EXPRESSION; CLONING	The Rhodobacter sphaeroides 2.4.1 tryptophan rich Sensory protein gene, tspO (formerly crtK, ORF160) encodes a 17-kDa protein which has an unusually high content of aromatic amino acids in general and of L-tryptophan in particular. The TspO protein was localized to the outer membrane of aerobically grown R. sphaeroides 2.4.1 by use of a polyclonal antibody against the purified protein. This protein is present in severalfold higher levels in photosynthetic as opposed to aerobic grown cells. Although tspO lies within the crt gene cluster, null mutations have an intact carotenoid biosynthetic pathway. In the TSPO1 mutant there was an increased production of carotenoids and bacteriochlorophyll relative to the wild type, particularly when cells were grown aerobically or semiaerobically. When present in trans the tspO gene restored ''normal'' pigment production to TSPO1. The effect of the tspO gene on pigment production was shown to take place at the level of gene expression. Because the tspO gene product of R. sphaeroides 2.4.1 shows significant sequence homology and similarity to the peripheral-type benzodoazepine receptor from mammalian sources, TspO-specific anti bodies when probed against liver and kidney mitochondrial protein showed strong cross-reactivity. The role of TspO in R. sphaeroides 2.4.1 and its relation to photosynthesis gene expression are discussed.	UNIV TEXAS,HLTH SCI CTR,SCH MED,DEPT MICROBIOL & MOLEC GENET,HOUSTON,TX 77030	University of Texas System; University of Texas Health Science Center Houston			Yeliseev, Alexei A/B-3143-2009		NIGMS NIH HHS [GM15590] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTKIEWICZMICHA.L, 1988, J BIOL CHEM, V263, P17317; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAKER ME, 1991, CELL, V65, P721, DOI 10.1016/0092-8674(91)90379-D; BOLLIVAR DW, 1992, BIOCHEM J, V282, P471, DOI 10.1042/bj2820471; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; DAVIS J, 1988, J BACTERIOL, V170, P320, DOI 10.1128/jb.170.1.320-329.1988; DEAL CD, 1983, J BIOL CHEM, V258, P6524; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONOHUE TJ, 1986, J BACTERIOL, V168, P962, DOI 10.1128/jb.168.2.962-972.1986; DRYDEN SC, 1993, J BACTERIOL, V175, P6392, DOI 10.1128/jb.175.20.6392-6402.1993; ERASO JM, 1994, J BACTERIOL, V176, P32, DOI 10.1128/JB.176.1.32-43.1994; EVANS MB, 1988, BIOCHIM BIOPHYS ACTA, V935, P292, DOI 10.1016/0005-2728(88)90224-1; GIULIANO G, 1988, MOL GEN GENET, V213, P78, DOI 10.1007/BF00333401; GOMELSKY M, 1995, J BACTERIOL, V177, P1634, DOI 10.1128/jb.177.6.1634-1637.1995; HARLOW E, 1988, ANTIBODIES LABORATOR; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KILEY PJ, 1988, MICROBIOL REV, V52, P50, DOI 10.1128/MMBR.52.1.50-69.1988; LACKS S, 1977, J MOL BIOL, V114, P153, DOI 10.1016/0022-2836(77)90289-3; LANG HP, 1995, J BACTERIOL, V177, P2064, DOI 10.1128/jb.177.8.2064-2073.1995; LEE JK, 1992, J BACTERIOL, V174, P1158, DOI 10.1128/jb.174.4.1158-1171.1992; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MARTIN JP, 1987, J BACTERIOL, V169, P2516, DOI 10.1128/jb.169.6.2516-2522.1987; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCENERY MW, 1992, P NATL ACAD SCI USA, P3170; MEINHARDT SW, 1985, ARCH BIOCHEM BIOPHYS, V236, P130, DOI 10.1016/0003-9861(85)90612-5; MOORE MD, 1989, J BACTERIOL, V171, P4385, DOI 10.1128/JB.171.8.4385-4394.1989; PASTORINO JG, 1994, J BIOL CHEM, V269, P31041; PENFOLD RJ, 1994, J BACTERIOL, V176, P2869, DOI 10.1128/JB.176.10.2869-2876.1994; Sambrook J, 1989, MOL CLONING LABORATO; Simon R., 1983, BIOTECHNOLOGY, V1, P37; TAI SP, 1985, J BACTERIOL, V164, P181, DOI 10.1128/JB.164.1.181-186.1985; VARGA AR, 1989, J BACTERIOL, V171, P5830, DOI 10.1128/jb.171.11.5830-5839.1989; WEISS RL, 1976, J BACTERIOL, V128, P668, DOI 10.1128/JB.128.2.668-670.1976; ZEILSTRARYALLS JH, 1995, J BACTERIOL, V177, P2760, DOI 10.1128/jb.177.10.2760-2768.1995	35	101	105	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21167	21175		10.1074/jbc.270.36.21167	http://dx.doi.org/10.1074/jbc.270.36.21167			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673149	hybrid			2022-12-25	WOS:A1995RU05400048
J	ZENG, FY; KAPHALIA, BS; ANSARI, GAS; WEIGEL, PH				ZENG, FY; KAPHALIA, BS; ANSARI, GAS; WEIGEL, PH			FATTY ACYLATION OF THE RAT ASIALOGLYCOPROTEIN RECEPTOR - THE 3 SUBUNITS FROM ACTIVE RECEPTORS CONTAIN COVALENTLY BOUND PALMITATE AND STEARATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN RECEPTOR; MEDIATED ENDOCYTOSIS; GALACTOSYL RECEPTORS; ISOLATED HEPATOCYTES; PALMITOYLATION; LIVER; CELLS; INACTIVATION; PROTEINS; DEGRADATION	Rat hepatic asialoglycoprotein receptors (ASGP-Rs) are hetero-oligomers composed of three homologous glycoprotein subunits, designated rat hepatic lectins (RHL) 1, 2, and 3. ASGP-Rs mediate the endocytosis and degradation of circulating glycoconjugates containing terminal N-acetylgalactosamine or galactose, including desialylated plasma glycoproteins. We have shown in permeable rat hepatocytes that the ligand binding activity of one subpopulation of receptors (designated State 2 ASGP-Rs) can be decreased or increased, respectively, by ATP and palmitoyl-CoA (Weigel, P. H., and Oka, J. A. (1993) J. Biol. Chem. 268, 27186-27190). We proposed that a reversible and cyclic acylation/deacylation process may regulate ASGP-R activity during endocytosis, receptor-ligand dissociation, and receptor recycling. In the accompanying paper (Zeng, F-Y., and Weigel, P. H. (1995) J. Biol. Chem. 270, 21388-21395), we show that the ligand binding activity of affinity-purified State 2 ASGP-Rs is decreased by treatment with hydroxylamine under mild conditions consistent with these ASGP-Rs being fatty acylated in vivo. In this study, we used a chemical method to determine the presence of covalently-bound fatty acids in individual ASGP-R subunits. The affinity-purified ASGP-R preparations were separated by SDS-polyacrylamide gel electrophoresis under nonreducing conditions, and the gel slices containing individual RHL subunits were treated with alkali to release covalently bound fatty acids, which were subsequently analyzed by gas chromatography and confirmed by gas chromatography-mass spectrometry. Both stearic and palmitic acids were detected in all three receptor subunits. Pretreatment of ASGP-Rs with hydroxylamine before SDS-polyacrylamide gel electrophoresis reduced the content of both fatty acids by 66-80%, indicating that most of these fatty acids are attached to cysteine residues via thioester linkages. Furthermore, when freshly isolated hepatocytes were cultured in the presence of [H-3]palmitate, all three RHL subunits in affinity-purified ASGP-Rs were metabolically labeled. We conclude that RHL1, RHL2, and RHL3 are modified by fatty acylation in intact cells.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73190; UNIV TEXAS,MED BRANCH,DEPT PATHOL,GALVESTON,TX 77555	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Texas System; University of Texas Medical Branch Galveston					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049695] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 04815] Funding Source: Medline; NIGMS NIH HHS [GM 49695] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE BL, 1987, J BIOL CHEM, V262, P17384; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; DRICKAMER K, 1987, KIDNEY INT, V32, P167; GRASSIE MA, 1993, BIOCH SOC T S, V21, P499; HAYNES PA, 1995, J BIOL CHEM, V269, P33146; HERZIG MCS, 1990, BIOCHEMISTRY-US, V29, P6437, DOI 10.1021/bi00479a015; HOLLAND EC, 1984, P NATL ACAD SCI-BIOL, V81, P7338, DOI 10.1073/pnas.81.23.7338; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; KAPHALIA BS, 1995, IN PRESS FUNDAM APPL; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KINDBERG GM, 1990, J BIOL CHEM, V265, P8999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MCABEE DD, 1987, J BIOL CHEM, V262, P1942; MEDH JD, 1991, J BIOL CHEM, V266, P8771; MURPHY RC, 1993, HDB LIPID RES, P290; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OMARY MB, 1981, J BIOL CHEM, V256, P4715; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P687; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TAKAHASHI T, 1985, BIOCHEM BIOPH RES CO, V126, P1054, DOI 10.1016/0006-291X(85)90292-X; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WEIGEL PH, 1994, MOL BIOL CELL, V5, P227, DOI 10.1091/mbc.5.2.227; WEIGEL PH, 1983, J BIOL CHEM, V258, P5089; WEIGEL PH, 1993, J BIOL CHEM, V268, P27186; WEIGEL PH, 1992, GLYCOCONJUGATES COMP, P421; ZENG FY, 1995, J BIOL CHEM, V270, P21388, DOI 10.1074/jbc.270.36.21388	37	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21382	21387		10.1074/jbc.270.36.21382	http://dx.doi.org/10.1074/jbc.270.36.21382			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673174	hybrid			2022-12-25	WOS:A1995RU05400078
J	ZENG, FY; WEIGEL, PH				ZENG, FY; WEIGEL, PH			HYDROXYLAMINE TREATMENT DIFFERENTIALLY INACTIVATES PURIFIED RAT HEPATIC ASIALOGLYCOPROTEIN RECEPTORS AND DISTINGUISHES 2 RECEPTOR POPULATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSYL RECEPTORS; COVALENT MODIFICATION; MEDIATED ENDOCYTOSIS; TRANSFERRIN RECEPTOR; ISOLATED HEPATOCYTES; EUKARYOTIC PROTEINS; ATP DEPLETION; PALMITIC ACID; LIVER; SUBPOPULATION	We previously showed that two subpopulations of asialoglycoprotein receptors (ASGP-Rs), designated State 1 and State 2 ASGP-Rs, are present in intact cells and that State 2 ASGP-Rs can be inactivated in permeable rat hepatocytes in a temperature- and ATP-dependent manner. These inactivated ASGP-Rs can be quantitatively reactivated by the addition of palmitoyl-CoA (Weigel, P. H., and Oka, J. A. (1993) J. Biol. Chem. 268, 27186-27190). Here we show that similar to 50% of purified rat ASGP-Rs are inactivated by treatment with hydroxylamine under mild conditions. The activity of affinity purified ASGP-Rs was assessed by measuring the specific binding of I-125-asialo-orosomucoid (ASOR) in a dot-blot assay after immobilization onto nitrocellulose. Treatment of ASGP-Rs in solution with 0.0125-1.0 M NH2OH, pH 7.4, at 4 degrees C for 4 h resulted in a progressive loss of ASOR binding activity, ASGP-R inactivation with NH2OH occurred more readily at basic pH or at room temperature, Similar treatment with Tris had no effect on ASGP-R activity. The kinetics of ASGP-R activity loss and the dose-response for this inactivation were both biphasic, indicating the presence of two equal populations of ASGP-Rs with different sensitivities to NH2OH. The more sensitive population of ASGP-Rs (similar to 50%) was inactivated by treatment with 0.2 M NH2OH (4 degrees C, 4 h) or with 1.0 M NH2OH (4 degrees C, 1 h) without detectable peptide cleavage as assessed by SDS-polyacrylamide gel electrophoresis, State 1 ASGP-Rs, purified from chloroquine- or monensin-treated hepatocytes, showed significantly less sensitivity to NH2OH treatment (both in kinetics and dose dependence). Furthermore, under mild conditions NH2OH caused dissociation and inactivation of similar to 50% of the total ASGP-Rs (State 1 and State 2) that were prebound to ASOR-Sepharose, whereas the same treatment caused dissociation of only <20% of State 1 ASGP-Rs from such preformed complexes, As shown in the accompanying paper (Zeng, F. Y., Kaphalia, B. S., Ansari, G. A. S., and Weigel, P. H. (1995) J. Biol. Chem. 270, 21382-21387) all three RHL subunits of active ASGP-Rs, in fact, contain covalently attached palmitate and stearate. In cultured cells, [H-3]palmitic acid is metabolically incorporated into all three subunits. These radio-labeled fatty acids are completely released from purified ASGP-Rs by mild NH2OH treatment. We conclude that the NH2OH-sensitive subpopulation of ASGP-Rs corresponds to the previously described State 2 ASGP-Rs and that these receptors require fatty acylation for their ligand binding activity.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73190	University of Oklahoma System; University of Oklahoma Health Sciences Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049695] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 49695] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM M, 1988, ARCH BIOCHEM BIOPHYS, V264, P553, DOI 10.1016/0003-9861(88)90321-9; ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; ANDERSEN TT, 1982, J BIOL CHEM, V257, P8036; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bornstein P, 1977, Methods Enzymol, V47, P132; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE BL, 1987, J BIOL CHEM, V262, P17384; DRICKAMER K, 1987, KIDNEY INT, V32, pS167; FIETE D, 1983, J BIOL CHEM, V25, P817; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HERZIG MCS, 1990, BIOCHEMISTRY-US, V29, P6437, DOI 10.1021/bi00479a015; KINDBERG GM, 1990, J BIOL CHEM, V265, P8999; KOCH N, 1986, J BIOL CHEM, V261, P3434; KWONG MY, 1994, PROTEIN SCI, V3, P147; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MCABEE DD, 1991, J CELL BIOCHEM, V45, P59, DOI 10.1002/jcb.240450113; MCABEE DD, 1988, BIOCHEMISTRY-US, V27, P2061, DOI 10.1021/bi00406a037; MCABEE DD, 1987, J BIOL CHEM, V262, P1942; MCABEE DD, 1990, J BIOL CHEM, V265, P629; MCPHAUL M, 1986, P NATL ACAD SCI USA, V83, P8863, DOI 10.1073/pnas.83.23.8863; MEDH JD, 1991, J BIOL CHEM, V266, P8771; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; OKA JA, 1983, BIOCHIM BIOPHYS ACTA, V763, P368, DOI 10.1016/0167-4889(83)90098-8; OKA JA, 1991, ARCH BIOCHEM BIOPHYS, V289, P362, DOI 10.1016/0003-9861(91)90424-H; OLSON EN, 1988, PROG LIPID RES, V27, P177, DOI 10.1016/0163-7827(88)90012-4; OMARY MB, 1981, J BIOL CHEM, V256, P4715; RAY DA, 1985, ANAL BIOCHEM, V145, P37, DOI 10.1016/0003-2697(85)90323-9; SAWYER JT, 1988, J BIOL CHEM, V263, P10534; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHMIDT MFG, 1985, J GEN VIROL, V66, P2635, DOI 10.1099/0022-1317-66-12-2635; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; SPIESS M, 1985, J BIOL CHEM, V260, P1979; STEER CJ, 1981, J BIOL CHEM, V256, P5851; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TILDON JT, 1972, J BIOL CHEM, V247, P1265; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TRAXLER KW, 1994, BIOCHEMISTRY-US, V33, P1718, DOI 10.1021/bi00173a014; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Weigel P H, 1993, Subcell Biochem, V19, P125; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WEIGEL PH, 1994, MOL BIOL CELL, V5, P227, DOI 10.1091/mbc.5.2.227; WEIGEL PH, 1983, J BIOL CHEM, V258, P5089; WEIGEL PH, 1993, J BIOL CHEM, V268, P27186; WEIGEL PH, 1992, GLYCOCONJUGATES COMP, P421; ZENG FY, 1995, J BIOL CHEM, V270, P21382, DOI 10.1074/jbc.270.36.21382; ZENG FY, 1994, FASEB J, V8, pA1406	53	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21388	21395		10.1074/jbc.270.36.21388	http://dx.doi.org/10.1074/jbc.270.36.21388			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673175	hybrid			2022-12-25	WOS:A1995RU05400079
J	KUROKAWA, M; OGAWA, S; TANAKA, T; MITANI, K; YAZAKI, Y; WITTE, ON; HIRAI, H				KUROKAWA, M; OGAWA, S; TANAKA, T; MITANI, K; YAZAKI, Y; WITTE, ON; HIRAI, H			THE AML1 EVI-1 FUSION PROTEIN IN THE T(3-21) TRANSLOCATION EXHIBITS TRANSFORMING ACTIVITY ON RAT1 FIBROBLASTS WITH DEPENDENCE ON THE EVI-1 SEQUENCE	ONCOGENE			English	Article						AMLI/EVI-1; TRANSFORMATION; FIBROBLAST; API ACTIVATION; C-JUN	CHRONIC MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; DROSOPHILA SEGMENTATION GENE; ZINC FINGER PROTEIN; C-JUN; TRANSCRIPTION FACTOR; MESSENGER-RNA; PHILADELPHIA-CHROMOSOME; PRE-B; T(15-17) TRANSLOCATION	The t(3;21) (q26;q22) chromosomal translocation associated with blastic crisis of chronic myelogenous leukemia (CML) results in the formation of a chimeric protein fusing the amino-terminal DNA-binding domain encoded by the AML1 gene to the carboxyl-terminal-encoding portion of the Evi-1 gene. In order to evaluate transforming activity of this protein, AML1/Evi-1 was introduced into Rat1 fibroblasts, Cells expressing the fusion product formed macroscopic colonies in soft agar, indicating that AML1/Evi-1 is a transforming gene. It was also demonstrated that introduction of AML1/Evi-1 into the Rat1 clones harboring BCR/ABL also conferred enhanced capacity for anchorage independent growth, Analyses of deletion mutants of AML1/Evi-1 revealed that removal of the second zinc finger domain within the Evi-1 sequence totally abrogated the ability of AML1/Evi-1 to transform Rat1 cells. We showed that the transforming effect is correlated with the AP-1 activation induced by AML1/Evi-1. Furthermore, me demonstrated that c-jan is transcriptionally activated in Rat1 cells transformed by AML1/Evi-1, suggesting that c-jun expression is under control of AML1/Evi-1. These results indicate that the oncogenic effect of the t(3;21) translocation is caused by the generation of a chimeric transcriptional factor and that AML1/Evi-1 could perform a pivotal role in leukemic progression of CML.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	University of Tokyo; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles			Tanaka, Tomoyuki U/A-4775-2008					ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHEN Z, 1991, CANCER GENET CYTOGEN, V57, P153, DOI 10.1016/0165-4608(91)90146-L; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COYLE T, 1988, AM J HEMATOL, V27, P56, DOI 10.1002/ajh.2830270113; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; ERICKSON P, 1992, BLOOD, V80, P1825; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIALKOW PJ, 1981, BLOOD, V58, P158, DOI 10.1182/blood.V58.1.158.158; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; IZUMI M, 1991, EXP CELL RES, V197, P229, DOI 10.1016/0014-4827(91)90427-V; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KANTARJIAN HM, 1993, BLOOD, V82, P691; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MANDANAS RA, 1992, LEUKEMIA, V6, P796; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MORISHITA K, 1990, ONCOGENE, V5, P1419; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NICHOLS J, 1992, BLOOD, V80, P2953; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, BLOOD, V81, P883; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUBIN CM, 1990, BLOOD, V76, P2594; RUBIN CM, 1987, BLOOD, V70, P1338; Sambrook J, 1989, MOL CLONING LABORATO; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SCHNEIDER NR, 1991, ANN GENET-PARIS, V34, P256; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SONOBE MH, 1991, ONCOGENE, V6, P1531; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	76	51	52	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					833	840						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675444				2022-12-25	WOS:A1995RU79800003
J	HARDIKAR, W; ANANTHANARAYANAN, M; SUCHY, FJ				HARDIKAR, W; ANANTHANARAYANAN, M; SUCHY, FJ			DIFFERENTIAL ONTOGENIC REGULATION OF BASOLATERAL AND CANALICULAR BILE-ACID TRANSPORT PROTEINS IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; POSTNATAL CHANGES; TAUROCHOLATE TRANSPORT; ECTO-ATPASE; EXPRESSION; SYSTEM; GLYCOPROTEINS; CLONING; BINDING; CELLS	The hepatic transport systems mediating bile acid uptake and excretion undergo independent, stage-specific expression during development in the rat. In this study, the mechanisms underlying ontogenic regulation of both the Na+-dependent basolateral bile acid transporter and canalicular bile acid transporter/ecto-ATPase were examined. Steady state mRNA levels for the basolateral transporter were less than 20% of adult values prior to birth, increased to 35% on the first postnatal day, and reached adult levels by 1 week of age. This was paralleled by transcription rates, which were low prior to birth, reached 47% by day 1, and were maximal by 1 week of age. Steady state mRNA levels for ecto-ATPase were 12% of adult values prior to birth and showed a a fold increase by the first day of life. Thereafter, there was a gradual increase in mRNA for this transporter, with adult levels being reached at 4 weeks of age. Transcription rates paralleled this increment, although adult levels were reached earlier. Surprisingly, for both transporters, the full complement of protein was present well before adult levels of mRNA were reached. The basolateral protein was expressed at 82% of adult levels on the first day of life but was of lower apparent molecular mass (39 kDa), a difference that persisted until 4 weeks of age. N-Glycanase digestion suggested that this difference could be fully accounted for by N-linked glycosylation. The ecto-ATPase protein was present at 33% of adult levels prior to birth, 77% by 1 day, and 84% of adult levels by 1 week of age. Unlike the basolateral transporter, the apparent molecular weight of this protein did not change during development, In summary, the ontogeny of bile acid transporters on the plasma membrane of the hepatocyte is complex and appears to be regulated at transcriptional, translational, and post-translational levels.	YALE UNIV, SCH MED, DEPT PEDIAT, GASTROENTEROL HEPATOL SECT, NEW HAVEN, CT 06520 USA	Yale University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020632, R01HD020632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20632] Funding Source: Medline; NIDDK NIH HHS [DK34989] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; ANANTHANARAYANAN M, 1994, AM J PHYSIOL-GASTR L, V267, pG637, DOI 10.1152/ajpgi.1994.267.4.G637; BLITZER BL, 1984, J BIOL CHEM, V259, P9295; BOYER JL, 1971, AM J PHYSIOL, V221, P1156, DOI 10.1152/ajplegacy.1971.221.4.1156; BOYER JL, 1993, P NATL ACAD SCI USA, V90, P435, DOI 10.1073/pnas.90.2.435; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIAMOND DJ, 1985, J MOL BIOL, V181, P41, DOI 10.1016/0022-2836(85)90323-7; HAGENBUCH B, 1990, J BIOL CHEM, V265, P5357; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; KATO S, 1988, BIOCHEM J, V253, P59, DOI 10.1042/bj2530059; LIN SH, 1989, J BIOL CHEM, V264, P14408; LIN SH, 1989, J BIOL CHEM, V264, P14403; MEIER PJ, 1987, BIOCHEM J, V242, P465, DOI 10.1042/bj2420465; MULLER M, 1991, J BIOL CHEM, V266, P18920; NOVAK DA, 1991, AM J PHYSIOL, V260, pG743, DOI 10.1152/ajpgi.1991.260.5.G743; NUNEZ E, 1994, J BIOL CHEM, V269, P16920; ODATAMAI S, 1991, BIOCHEM J, V280, P179, DOI 10.1042/bj2800179; ODATAMAI S, 1989, BIOCHEM J, V261, P371, DOI 10.1042/bj2610371; PANDAK WM, 1992, J LIPID RES, V33, P659; RUETZ S, 1987, J BIOL CHEM, V262, P11324; SAMBROOK KJ, 1989, MOL CLONING LABORATO; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SHAFRITZ DA, 1988, SEMIN LIVER DIS, V8, P285, DOI 10.1055/s-2008-1040550; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; SUCHY FJ, 1986, AM J PHYSIOL, V251, pG655, DOI 10.1152/ajpgi.1986.251.5.G665; SUCHY FJ, 1987, SEMIN LIVER DIS, V7, P77, DOI 10.1055/s-2008-1040567; SUCHY FJ, 1981, GASTROENTEROLOGY, V80, P1037; SUCHY FJ, 1985, AM J PHYSIOL, V248, pG648, DOI 10.1152/ajpgi.1985.248.6.G648; YAMAZAKI M, 1992, J HEPATOL, V14, P54, DOI 10.1016/0168-8278(92)90131-8	34	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20841	20846		10.1074/jbc.270.35.20841	http://dx.doi.org/10.1074/jbc.270.35.20841			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657669	hybrid			2022-12-25	WOS:A1995RR58400090
J	FRASER, IDC; MARSTON, SB				FRASER, IDC; MARSTON, SB			IN-VITRO MOTILITY ANALYSIS OF SMOOTH-MUSCLE CALDESMON CONTROL OF ACTIN-TROPOMYOSIN FILAMENT MOVEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT-CHAIN; THIN-FILAMENTS; BINDING FRAGMENT; ATPASE ACTIVITY; PHOSPHORYLATION; CALMODULIN; INHIBITION; SUBFRAGMENT-1; DISSOCIATION; ACTOMYOSIN	We have used the in vitro motility assay to investigate the effect of caldesmon on the movement of actin-tropomyosin filaments over thiophosphorylated smooth muscle myosin and skeletal muscle heavy meromyosin. Using either motor, incorporation of up to 8 nM caldesmon inhibited filament movement by decreasing the proportion of filaments motile from >85% to <30%. There was a minimal effect on filament attachment and a modest decrease in motile filament velocity in this concentration range. The reduction in the proportion of filaments motile could be completely reversed by incorporation of an excess of calmodulin at pCa 4.5. The expressed C-terminal fragment, 606C, which retains caldesmon's inhibitory capacity but does not bind to myosin, decreased the proportion of filaments motile but had no effect on velocity. We conclude that the velocity reduction by whole caldesmon is due to actin-myosin cross-linking. A significant decrease in filament attachment was observed when caldesmon was added to an excess over actin (>10 nM). In the absence of tropomyosin, addition of an excess of caldesmon caused a similar decrease in the filament density, but there was no effect on the proportion of filaments that were motile. Our results demonstrate that caldesmon can switch actin-tropomyosin from motile to non-motile states without controlling velocity of movement or weak binding affinity and show the inhibitory action of caldesmon in the motility assay to be functionally indistinguishable from that reported for troponin.	NATL HEART & LUNG INST, DEPT CARDIAC MED, LONDON SW3 6LY, ENGLAND	Imperial College London			Fraser, Iain DC/L-4735-2017	Fraser, Iain DC/0000-0003-2272-3907; Marston, Steven/0000-0001-6054-6070				BARANY M, 1993, ARCH BIOCHEM BIOPHYS, V305, P202, DOI 10.1006/abbi.1993.1412; BOGATCHEVA NV, 1993, BIOCHEM J, V290, P437, DOI 10.1042/bj2900437; CHALOVICH JM, 1990, ANN NY ACAD SCI, V599, P85, DOI 10.1111/j.1749-6632.1990.tb42367.x; CHALOVICH JM, 1991, J MUSCLE RES CELL M, V12, P503, DOI 10.1007/BF01738438; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; FRASER IDC, 1995, J BIOL CHEM, V270, P7836, DOI 10.1074/jbc.270.14.7836; GERTHOFFER WT, 1987, J PHARMACOL EXP THER, V240, P8; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HAEBERLE JR, 1992, J BIOL CHEM, V267, P23001; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HORIUCHI KY, 1995, J MUSCLE RES CELL M, V16, P11, DOI 10.1007/BF00125306; KHALIL RA, 1995, BIOPHYS J, V68, P75; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P1371, DOI 10.1016/S0006-291X(89)80155-X; MARSTON S, 1990, BIOCHEM J, V272, P305, DOI 10.1042/bj2720305; MARSTON S, 1992, J MUSCLE RES CELL M, V13, P206, DOI 10.1007/BF01874158; MARSTON SB, 1994, J BIOL CHEM, V269, P32104; MARSTON SB, 1992, J BIOL CHEM, V267, P16796; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1993, J BIOL CHEM, V268, P12317; MOODY CJ, 1985, FEBS LETT, V191, P107, DOI 10.1016/0014-5793(85)81003-6; MURPHY RA, 1994, FASEB J, V8, P311, DOI 10.1096/fasebj.8.3.8143937; NGAI PK, 1984, J BIOL CHEM, V259, P3656; OKAGAKI T, 1991, J BIOCHEM, V109, P858, DOI 10.1093/oxfordjournals.jbchem.a123471; PFITZER G, 1993, P NATL ACAD SCI USA, V90, P5904, DOI 10.1073/pnas.90.13.5904; RAYMENT I, 1994, TRENDS BIOCHEM SCI, V19, P129, DOI 10.1016/0968-0004(94)90206-2; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; WILLIAMS DL, 1984, BIOCHEMISTRY-US, V23, P4150, DOI 10.1021/bi00313a022; YAMAKITA Y, 1992, J BIOL CHEM, V267, P12022	40	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19688	19693		10.1074/jbc.270.34.19688	http://dx.doi.org/10.1074/jbc.270.34.19688			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649978	hybrid			2022-12-25	WOS:A1995RQ99100006
J	CHEN, ZQ; CHAKRABORTY, S; BANERJEE, R				CHEN, ZQ; CHAKRABORTY, S; BANERJEE, R			DEMONSTRATION THAT MAMMALIAN METHIONINE SYNTHASES ARE PREDOMINANTLY COBALAMIN-LOADED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL-TUBE DEFECTS; SYNTHETASE; MECHANISM; OXIDATION; FOLATE	Methionine synthase is an important cellular housekeeping enzyme and is dependent on the cofactor cobalamin, a derivative of vitamin B-12, for activity, It functions in two major metabolic pathways including the tetrahydrofolate-dependent one-carbon cycle and the salvage pathway for methionine, Its dysfunction has several physiological ramifications and leads to the development of megaloblastic anemia. In addition, it is suspected to be involved in the pathogenesis of neural tube defects. An issue that is central in weighing therapeutic options for methionine synthase-related disorders is the extent to which the enzyme exists as apoenzyme in vivo and, thus, can be potentially responsive to vitamin B-12 therapy. Despite the importance of this issue, the extent of holo- versus apoenzyme in mammalian tissue is controversial and unresolved. To address this question, we have developed a convenient anaerobic assay that employs titanium citrate to deliver low potential electron equivalents. The reductive activation of this enzyme is essential under in vitro assay conditions. We find that both the human placental and porcine liver methionine synthases exist predominantly in the holoenzyme form (90-100%) in the crude homogenate. In addition, the activity of the pure enzyme measured in the titanium citrate assay is also independent of exogenous cofactor, revealing that the cobalamin is tightly bound to the active site.	UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68583	University of Nebraska System; University of Nebraska Lincoln					NIDDK NIH HHS [DK45776] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045776, R01DK045776] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN RH, 1993, FASEB J, V7, P1344, DOI 10.1096/fasebj.7.14.7901104; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN ZQ, 1994, J BIOL CHEM, V269, P27193; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P513, DOI 10.1021/bi00376a025; CLARKE R, 1991, NEW ENGL J MED, V324, P114; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; FRASCA V, 1988, BIOCHEMISTRY-US, V27, P8458, DOI 10.1021/bi00422a025; FUJII K, 1977, ARCH BIOCHEM BIOPHYS, V178, P662, DOI 10.1016/0003-9861(77)90238-7; Fujii K, 1979, BIOCH ASPECTS NUTRIT, P173; GIANNOTTI C, 1982, ELECTRONIC SPECTRA B, P394; GREEN R, 1995, FOLATE HLTH DIS, P75; JACOBSEN DW, 1993, J INORG BIOCHEM, V50, P47, DOI 10.1016/0162-0134(93)80013-Y; KERWAR SS, 1971, ARCH BIOCHEM BIOPHYS, V142, P231, DOI 10.1016/0003-9861(71)90279-7; KIRKE PN, 1993, Q J MED, V86, P703; KOLHOUSE JF, 1991, J BIOL CHEM, V266, P23010; LOUGHLIN RE, 1964, J BIOL CHEM, V239, P2888; MATTHEWS RG, 1986, METHIONINE BIOSYNTHE, P697; MAYHEW SG, 1978, EUR J BIOCHEM, V85, P535, DOI 10.1111/j.1432-1033.1978.tb12269.x; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; PEEL JL, 1963, BIOCHEM J, V88, P296, DOI 10.1042/bj0880296; TAYLOR RT, 1967, J BIOL CHEM, V242, P1509; TAYLOR RT, 1967, J BIOL CHEM, V242, P1502; TAYLOR RT, 1974, ARCH BIOCHEM BIOPHYS, V165, P787, DOI 10.1016/0003-9861(74)90308-7; UTLEY CS, 1985, J BIOL CHEM, V260, P3656; WHITMAN WB, 1985, J BACTERIOL, V164, P164; ZEHNDER AJB, 1976, SCIENCE, V194, P1165, DOI 10.1126/science.793008	27	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19246	19249		10.1074/jbc.270.33.19246	http://dx.doi.org/10.1074/jbc.270.33.19246			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642596	hybrid			2022-12-25	WOS:A1995RP70300010
J	TRAN, H; TANAKA, A; LITVINOVICH, SV; MEDVED, LV; HAUDENSCHILD, CC; ARGRAVES, WS				TRAN, H; TANAKA, A; LITVINOVICH, SV; MEDVED, LV; HAUDENSCHILD, CC; ARGRAVES, WS			THE INTERACTION OF FIBULIN-1 WITH FIBRINOGEN - A POTENTIAL ROLE IN HEMOSTASIS AND THROMBOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; DOMAIN-STRUCTURE; CALCIUM-BINDING; PROTEIN; GLYCOPROTEIN; FIBRONECTIN; PLASMA; POLYMERIZATION; SEQUENCE; LIGANDS	The fibulins are an emerging family of extracellular matrix and blood proteins presently having two members designated fibulin-1 and -2. Fibulin-1 is the predominant fibulin in blood, present at a concentration of 30-40 mu g/ml (similar to 1000-fold higher than fibulin-2). During the course of isolating fibulin-1 from plasma by immunoaffinity chromatography, a 340-kDa polypeptide was consistently found to co-purify. This protein was identified as fibrinogen (Fg) based on its electrophoretic behavior and reactivity with Fg monoclonal antibodies. Radioiodinated fibulin-1 was shown to bind to Fg transferred onto nitrocellulose filters after SDS-polyacrylamide gel electrophoresis. In enzyme-linked immunosorbent assay, fibulin-1 bound to Fg (and fibrin) adsorbed onto microtiter well plastic, and conversely, Fg bound to fibulin-1-coated wells. The binding of Fg to fibulin-1 was also observed in surface plasmon resonance assays, and a dissociation constant (K-d) of 2.9 +/- 1.6 mu M was derived. In addition, fluorescence anisotropy experiments demonstrated that the interaction was also able to occur in fluid phase, which suggests that complexes of fibulin-1 and Fg could exist in the blood. To localize the portion of Fg that is responsible for interacting with fibulin-1, proteolytic fragments of Fg were evaluated for their ability to promote fibulin-1 binding. Fragments containing the carboxyl-terminal region of the B beta chain (residues 216-468) were able to bind to fibulin-1. In addition, it was found that fibulin-1 was able to incorporate into fibrin clots formed in vitro and was immunologically detected within newly formed fibrin-containing thrombi associated with human atherectomy specimens. The interaction between fibulin-1 and Fg highlights potential new roles for fibulin-1 in hemostasis as well as thrombosis.	AMER RED CROSS,JEROME H HOLLAND LAB,DEPT BIOCHEM,ROCKVILLE,MD 20855; AMER RED CROSS,JEROME H HOLLAND LAB,DEPT EXPTL PATHOL,ROCKVILLE,MD 20855	American Red Cross; American Red Cross				Medved, Leonid/0000-0002-3665-9849	NIGMS NIH HHS [GM42912] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042912] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER RJ, 1984, BIOCHEM J, V217, P67, DOI 10.1042/bj2170067; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; BALBONA K, 1992, J BIOL CHEM, V267, P20120; BALE MD, 1985, J BIOL CHEM, V260, P7502; BALE MD, 1986, J BIOL CHEM, V261, P862; BROWN JC, 1994, J CELL SCI, V107, P329; BUSBY TF, 1988, BIOCHEMISTRY-US, V27, P6127, DOI 10.1021/bi00416a045; CHAIKEN I, 1992, ANAL BIOCHEM, V201, P197, DOI 10.1016/0003-2697(92)90329-6; DOOLITTLE RF, 1980, PROTIDES BIOL FLUIDS, V28, P311; Fisher Robert J., 1994, Current Opinion in Biotechnology, V5, P389, DOI 10.1016/0958-1669(94)90047-7; Godyna S., 1994, Molecular Biology of the Cell, V5, p55A; GODYNA S, 1994, MATRIX BIOL, V14, P467; GORKUN OV, 1994, BIOCHEMISTRY-US, V33, P6986, DOI 10.1021/bi00188a031; GREEN AA, 1955, METHOD ENZYMOL, V1, P67, DOI 10.1016/0076-6879(55)01014-8; Ham TH, 1938, MEDICINE, V17, P413, DOI 10.1097/00005792-193812000-00002; HANTGAN RR, 1979, J BIOL CHEM, V254, P1272; INGHAM KC, 1988, J BIOL CHEM, V263, P4624; INGHAM KC, 1981, BIOCHIM BIOPHYS ACTA, V670, P181, DOI 10.1016/0005-2795(81)90007-6; KLUGE M, 1990, EUR J BIOCHEM, V193, P651, DOI 10.1111/j.1432-1033.1990.tb19383.x; LENDRUM AC, 1962, J CLIN PATHOL, V15, P401, DOI 10.1136/jcp.15.5.401; LITVINOVICH SV, 1995, EUR J BIOCHEM, V229, P605, DOI 10.1111/j.1432-1033.1995.tb20504.x; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; MEDVED LV, 1993, FEBS LETT, V320, P239, DOI 10.1016/0014-5793(93)80594-K; MEDVED LV, 1988, FEBS LETT, V232, P56, DOI 10.1016/0014-5793(88)80385-5; MEDVED LV, 1986, FEBS LETT, V202, P298, DOI 10.1016/0014-5793(86)80705-0; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; MOESSON MW, 1983, ANN NY ACAD SCI, V408, P97; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; SPENCE SG, 1992, DEV BIOL, V151, P473, DOI 10.1016/0012-1606(92)90186-K; WILSON CL, 1992, J CELL BIOL, V119, P923, DOI 10.1083/jcb.119.4.923; ZHANG HY, 1995, DEV BIOL, V167, P18, DOI 10.1006/dbio.1995.1003; ZHANG HY, 1993, DIFFERENTIATION, V52, P211, DOI 10.1111/j.1432-0436.1993.tb00633.x; ZHANG RZ, 1994, GENOMICS, V22, P425, DOI 10.1006/geno.1994.1404	36	77	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19458	19464		10.1074/jbc.270.33.19458	http://dx.doi.org/10.1074/jbc.270.33.19458			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642629	hybrid			2022-12-25	WOS:A1995RP70300043
J	VALERA, A; PUJOL, A; GREGORI, X; RIU, E; VISA, J; BOSCHI, F				VALERA, A; PUJOL, A; GREGORI, X; RIU, E; VISA, J; BOSCHI, F			EVIDENCE FROM TRANSGENIC MICE THAT MYC REGULATES HEPATIC GLYCOLYSIS	FASEB JOURNAL			English	Article						C-MYC; P-ENOLPYRUVATE CARBOXYKINASE GENE PROMOTER; GLYCOLYSIS; TRANSGENIC MICE; LIVER	GROWTH-HORMONE GENE; GLUCOSE-TRANSPORTER PROTEIN; LOOP-HELIX PROTEIN; C-MYC; MAMMALIAN GLUCOKINASE; GLYCOGEN-SYNTHASE; RAT HEPATOCYTES; MESSENGER-RNA; TRANSCRIPTION; EXPRESSION	The product of the c-myc proto-oncogene (c-Myc) is involved in the control of cell proliferation, differentiation, and apoptosis. It acts as a transcription factor that recognizes the CACGTG motif. This sequence has also been found in the glucose-responsive elements of genes involved in the control of liver glycolysis and lipogenesis. To determine whether c-Myc can regulate hepatic carbohydrate metabolism in vivo, transgenic mice that overexpress c-myc under control of the P-enolpyruvate carboxykinase (PEPCK) gene promoter have been generated. These mice showed a threefold increase in c-Myc protein in liver nuclei. Hepatocytes from transgenic mice were normal and did not acquire the fetal phenotype. However, transgenic mice showed higher levels (threefold) of L-type pyruvate kinase mRNA and enzyme activity than control mice. The increase in pyruvate kinase activity led to a three- to fivefold increase in liver lactate content and a fivefold induction of lactate production by hepatocytes in primary culture. The expression of the 6-phosphofructo-2-kinase gene was also increased in the liver of these transgenic mice. The induction of hepatic glycolysis was related with an increase in the expression (about fourfold) and activity (about threefold) of liver glucokinase, whereas no change was noted in hexokinase-I. This change in glucokinase activity led to an increase in both glucose 6-phosphate and glycogen contents in the liver of transgenic mice. The expression of the liver-specific glucose transporter GLUT2 was also increased in transgenic mice, whereas no change was noted in the mRNA concentration of GLUT1. Furthermore, the changes of liver glucose metabolism led to a marked reduction of blood glucose (25%) and insulin (40%) concentrations in starvation, whereas the fall in bath was only 10% in fed mice. Thus, liver glucose metabolism could determine the blood glucose and insulin set points in the transgenic mice. All these results indicated that the increase in c-Myc protein was able to induce liver glucose utilization and accumulation, and suggested that c-Myc transcription factor is involved in the control in vivo of liver carbohydrate metabolism.	UNIV AUTONOMA BARCELONA, SCH VET MED, DEPT BIOCHEM & MOLEC BIOL, E-08193 BARCELONA, SPAIN	Autonomous University of Barcelona				BOSCH, FATIMA/0000-0002-7705-5515; Pujol, Anna/0000-0002-3484-598X; Riu, Efren/0000-0002-2574-3578; Gregori, Xavier/0000-0002-5889-5252				ASANO T, 1992, DIABETES, V41, P22, DOI 10.2337/diabetes.41.1.22; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BANCROFT JD, 1982, THEORY PRACTICE HIST, P122; BANSKOTA NK, 1989, DIABETES, V38, P123, DOI 10.2337/diabetes.38.1.123; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BELL GI, 1993, J BIOL CHEM, V268, P19161; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CUIF MH, 1993, J BIOL CHEM, V268, P13769; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; DAVIDSON AL, 1987, ARCH BIOCHEM BIOPHYS, V253, P156, DOI 10.1016/0003-9861(87)90648-5; DECAUX JF, 1991, J BIOL CHEM, V266, P3432; FELIU JE, 1977, EUR J BIOCHEM, V81, P609, DOI 10.1111/j.1432-1033.1977.tb11988.x; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GROBHOLZ R, 1993, CANCER RES, V53, P4204; HOGAN B, 1986, MANIPULATING MOUSE E; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; Keppler D., 1984, METHOD ENZYMAT AN, V6, P11; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; LECAM A, 1976, EXP CELL RES, V98, P382, DOI 10.1016/0014-4827(76)90448-1; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU ZR, 1993, J BIOL CHEM, V268, P12787; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MESSINA JL, 1991, J BIOL CHEM, V266, P17995; MICHAL G, 1981, METHOD ENZYMAT AN, V6, P185; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OKA Y, 1990, DIABETES, V39, P441, DOI 10.2337/diabetes.39.4.441; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; PRINTZ RL, 1993, ANNU REV NUTR, V13, P463, DOI 10.1146/annurev.nu.13.070193.002335; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; RONGNOPARUT P, 1991, J BIOL CHEM, V265, P19263; SANDGREN EP, 1989, ONCOGENE, V4, P715; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; VALERA A, 1994, EUR J BIOCHEM, V222, P533, DOI 10.1111/j.1432-1033.1994.tb18895.x; VALERA A, 1993, FASEB J, V7, P791, DOI 10.1096/fasebj.7.9.8330686; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	59	73	77	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1995	9	11					1067	1078		10.1096/fasebj.9.11.7649406	http://dx.doi.org/10.1096/fasebj.9.11.7649406			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RP996	7649406				2022-12-25	WOS:A1995RP99600011
J	BERGER, HA; TRAVIS, SM; WELSH, MJ				BERGER, HA; TRAVIS, SM; WELSH, MJ			REGULATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CL- CHANNEL BY SPECIFIC PROTEIN-KINASES AND PROTEIN PHOSPHATASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL CHLORIDE CHANNELS; CANINE TRACHEAL EPITHELIUM; COLONIC CELL-LINE; AIRWAY EPITHELIA; ELECTROLYTE TRANSPORT; NUCLEOTIDE-SEQUENCE; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; XENOPUS OOCYTES; PHORBOL ESTER	Cystic fibrosis transmembrane conductance regulator (CFTR) is a regulated Cl- channel; in secretory epithelia, it is located in the apical membrane where it regulates transepithelial Cl- secretion. Previous studies have shown that cAMP-dependent protein kinase (PKA) can phosphorylate and activate CFTR Cl- channels. We asked whether other kinases would phosphorylate CFTR in vitro and activate CFTR Cl- channels in excised, inside-out patches of membrane from NIH 3T3 fibroblasts stably expressing recombinant CFTR. We found that both Ca2+-independent and Ca2+-dependent isoforms of protein kinase C (PKC) activated the CFTR Cl- channel. Consistent with this finding, PKC also phosphorylated CFTR in vitro. In contrast, the multifunctional Ca2+/calmodulin-dependent protein kinase failed to either activate or to phosphorylate CFTR Cl- channels, suggesting that this enzyme has no direct effect on CFTR. We found that cGMP-dependent protein kinase (cGK) (purified from bovine lung) phosphorylated CFTR in vitro. However, cGMP failed to increase the apical membrane Cl- permeability in human airway epithelia, and addition of cGMP, ATP, and cGK failed to activate CFTR Cl- channels. These results suggest that if cGK phosphorylates CFTR in vivo, it does so at sites not involved in CFTR Cl- channel activation. Because cAMP-dependent activation of CFTR Cl- channels and Cl- secretion in intact cells is reversible, we asked whether specific phosphatases can dephosphorylate and inactivate CFTR Cl- channels. Addition of protein phosphatase 2A (PP2A) decreased PKA-activated current by 67% within 10 min. The phosphatase inhibitor calyculin-A blocked the effect of PP2A. In contrast, neither protein phosphatases 1, 2B, nor two preparations of alkaline phosphatase inactivated PKA-phosphorylated CFTR Cl- channels. The effects of protein phosphatases on CFTR function were paralleled by their ability to dephosphorylate CFTR in vitro. Our data indicate that CFTR Cl- channels can be phosphorylated and activated by PKA as well as by Ca2+-dependent and Ca2+-independent isoforms of PKC and can be dephosphorylated and thus inactivated by PP2A.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, 500 EMRB, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa				Welsh, Michael/0000-0002-1646-6206; Berger, Herbert/0000-0003-4383-2643	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042385] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42385] Funding Source: Medline; PHS HHS [H1 07638] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON MP, 1990, AM J PHYSIOL, V258, pL294, DOI 10.1152/ajplung.1990.258.6.L294; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DEJONGE HR, 1989, BIOCHEM SOC T, V17, P816, DOI 10.1042/bst0170816; DEJONGE HR, 1976, NATURE, V262, P590, DOI 10.1038/262590a0; DEJONGE HR, 1981, ADV CYCLIC NUCLEOTID; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DEVOR DC, 1990, AM J PHYSIOL, V258, pC318, DOI 10.1152/ajpcell.1990.258.2.C318; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; FINN AL, 1992, AM J PHYSIOL, V263, pC172, DOI 10.1152/ajpcell.1992.263.1.C172; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GUARINO A, 1987, AM J PHYSIOL, V253, pG775, DOI 10.1152/ajpgi.1987.253.6.G775; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRIS H, 1990, CLIN CHIM ACTA, V186, P133, DOI 10.1016/0009-8981(90)90031-M; HEMMINGS BA, 1988, NUCLEIC ACIDS RES, V16, P11366, DOI 10.1093/nar/16.23.11366; HESCHELER J, 1987, EUR J BIOCHEM, V165, P261, DOI 10.1111/j.1432-1033.1987.tb11436.x; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOUSLEY PR, 1990, BIOCHEMISTRY-US, V29, P3578, DOI 10.1021/bi00466a022; HUOTT PA, 1988, J CLIN INVEST, V82, P514, DOI 10.1172/JCI113626; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KHEWGOODALL Y, 1988, FEBS LETT, V238, P265, DOI 10.1016/0014-5793(88)80493-9; LA BQ, 1991, AM J PHYSIOL, V260, pC1217; LIN MQ, 1992, AM J PHYSIOL, V262, pC1304, DOI 10.1152/ajpcell.1992.262.5.C1304; MCCANN JD, 1990, AM J PHYSIOL, V258, pL343, DOI 10.1152/ajplung.1990.258.6.L343; MCCANN JD, 1989, AM J PHYSIOL, V257, pL116, DOI 10.1152/ajplung.1989.257.2.L116; MCROBERTS JA, 1985, J BIOL CHEM, V260, P4163; MORRIS AP, 1990, CELL REGUL, V1, P951, DOI 10.1091/mbc.1.12.951; NAYUDU RV, 1989, FEBS LETT, V255, P163, DOI 10.1016/0014-5793(89)81082-8; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OSTEDGAARD LS, 1992, J BIOL CHEM, V267, P26142; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; REINHART PH, 1991, J NEUROSCI, V11, P1627; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SMITH JJ, 1990, AM J PHYSIOL, V258, pL369, DOI 10.1152/ajplung.1990.258.6.L369; SMITH PL, 1982, J MEMBRANE BIOL, V70, P217, DOI 10.1007/BF01870564; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; UBERALL F, 1991, CANCER RES, V51, P5821; VAANDRAGER AB, 1991, AM J PHYSIOL, V261, pG958, DOI 10.1152/ajpgi.1991.261.6.G958; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WELSH MJ, 1987, AM J PHYSIOL, V253, pC828, DOI 10.1152/ajpcell.1987.253.6.C828; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; WIDDICOMBE JH, 1986, AM J PHYSIOL, V251, pR818, DOI 10.1152/ajpregu.1986.251.4.R818; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC226, DOI 10.1152/ajpcell.1989.256.2.C226; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713	68	232	237	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2037	2047						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678414				2022-12-25	WOS:A1993KH62000082
J	KITZMAN, HH; MCMAHON, RJ; WILLIAMS, MG; FROST, SC				KITZMAN, HH; MCMAHON, RJ; WILLIAMS, MG; FROST, SC			EFFECT OF GLUCOSE DEPRIVATION ON GLUT-1 EXPRESSION IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-INDUCED TRANSLOCATION; CHICKEN-EMBRYO FIBROBLASTS; SENSITIVE HEXOSE UPTAKE; BRAIN GLIAL-CELLS; TRANSPORT ACTIVITY; PLASMA-MEMBRANE; MESSENGER-RNA; DIFFERENTIAL REGULATION; PROTEIN-SYNTHESIS; DEPENDENT REGULATION	Elevated glucose transport rates during glucose deprivation are phenomena that have been observed in several different types of cells in culture. We show here that glucose transport rates in 3T3-L1 adipocytes increased by 10-fold within 18 h in response to glucose deprivation, confirming earlier work by Van Putten and Krans (Van Putten, J. P. M., and Krans, H. M. J. (1985) J. Biol. Chem. 260, 7996-8001). Mannose and 3-O-methylglucose (a nonmetabolizable glucose analog), but not fructose or galactose, blocked the increase in transport activity. Although the increase in transport was dependent on new protein synthesis, only a small and transient increase in GLUT 1 mRNA (less than 2-fold) was observed. In addition, the level of the normal isoform of GLUT 1 (46 kDa) did not increase. A lower molecular mass isoform (37 kDa) was observed but not until 15 h after glucose removal, the appearance of which was clearly not correlated with the increase in activity. Further, the extracellular glucose concentration required to elicit accumulation of this form (p37) was 2 orders of magnitude less than that required for transport stimulation (5 muM versus 500 muM glucose; p37 accumulation and transport activation, respectively). Interestingly, p37 was seen in the presence of galactose, but not fructose, despite elevated transport activity with either sugar. The p37 isoform was slightly larger than N-glycosidase F-treated GLUT 1 (36 kDa), implying that this form is still glycosylated, albeit incompletely. It is not known if p37 is functional, but the time- and sugar-dependent appearance of the lower isoform suggests that p37 is not responsible for starvation-induced transport but potentially represents an underglycosylated precursor of the normal, 46-kDa isoform of GLUT 1.	UNIV FLORIDA,DEPT BIOCHEM & MOLEC BIOL,BOX 100245 JHMHC,GAINESVILLE,FL 32610	State University System of Florida; University of Florida					NIDDK NIH HHS [DK45035, DK39135] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK039135, R01DK045035] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1991, J BIOL CHEM, V266, P24632; ASANO T, 1989, J BIOL CHEM, V264, P3416; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BLOK J, 1988, J CELL BIOL, V106, P69, DOI 10.1083/jcb.106.1.69; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DULBECCO R, 1959, VIROLOGY, V8, P396, DOI 10.1016/0042-6822(59)90043-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEUGEAS JP, 1990, BIOCHIM BIOPHYS ACTA, V1030, P60, DOI 10.1016/0005-2736(90)90238-J; FROST SC, 1985, J BIOL CHEM, V260, P2646; FUNG KP, 1986, BIOCHEM BIOPH RES CO, V134, P1231, DOI 10.1016/0006-291X(86)90382-7; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GIBBS EM, 1988, BIOCHEMISTRY-US, V27, P6681, DOI 10.1021/bi00418a006; GODWIN AK, 1991, MOL CARCINOGEN, V4, P275, DOI 10.1002/mc.2940040406; GOULD GW, 1989, ARCH BIOCHEM BIOPHYS, V268, P264, DOI 10.1016/0003-9861(89)90588-2; HARRISON SA, 1991, P NATL ACAD SCI USA, V88, P7839, DOI 10.1073/pnas.88.17.7839; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HARRISON SA, 1991, J BIOL CHEM, V266, P19438; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HASPEL HC, 1986, J BIOL CHEM, V261, P6778; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KITAGAWA T, 1991, J BIOL CHEM, V266, P18066; KLETZIEN RF, 1975, J BIOL CHEM, V250, P593; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SG, 1978, P NATL ACAD SCI USA, V75, P5427, DOI 10.1073/pnas.75.11.5427; LEE SG, 1977, P NATL ACAD SCI USA, V74, P163, DOI 10.1073/pnas.74.1.163; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARSHALL S, 1991, FASEB J, V5, P3031, DOI 10.1096/fasebj.5.15.1743436; ORTIZ PA, 1992, BIOCHEMISTRY-US, V31, P5386, DOI 10.1021/bi00138a021; PESSIN JE, 1982, P NATL ACAD SCI-BIOL, V79, P2286, DOI 10.1073/pnas.79.7.2286; PETTENGELL K, 1989, BIOCHEM BIOPH RES CO, V161, P633, DOI 10.1016/0006-291X(89)92646-6; REED BC, 1990, ARCH BIOCHEM BIOPHYS, V279, P261, DOI 10.1016/0003-9861(90)90490-P; RIZZOLO LJ, 1976, BIOCHEMISTRY-US, V15, P3433, DOI 10.1021/bi00661a006; SHIU RPC, 1977, P NATL ACAD SCI USA, V74, P3840, DOI 10.1073/pnas.74.9.3840; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAI PKK, 1990, J BIOL CHEM, V265, P21828; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; VANPUTTEN JPM, 1985, J BIOL CHEM, V260, P7996; WALKER PS, 1989, J BIOL CHEM, V264, P6587; WALKER PS, 1988, J BIOL CHEM, V263, P15594; WONG WT, 1991, BIOCHEM J, V275, P313, DOI 10.1042/bj2750313; YAMADA K, 1983, J BIOL CHEM, V258, P9786; ZORZANO A, 1989, J BIOL CHEM, V264, P12358; ZUBAY G, 1988, BIOCHEMISTRY-US, P648	52	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1320	1325						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678253				2022-12-25	WOS:A1993KG07700083
J	SANTOCANALE, C; FOIANI, M; LUCCHINI, G; PLEVANI, P				SANTOCANALE, C; FOIANI, M; LUCCHINI, G; PLEVANI, P			THE ISOLATED 48,000-DALTON SUBUNIT OF YEAST DNA PRIMASE IS SUFFICIENT FOR RNA PRIMER SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE PROTEIN COMPLEX; SINGLE ESSENTIAL GENE; SACCHAROMYCES-CEREVISIAE; BACTERIOPHAGE-T4 GENE-41; REPLICATION FORK; ALPHA; PURIFICATION; POLYPEPTIDE; HELICASE; CLONING	The monoclonal antibody (mAb) 21A6, which specifically inhibits yeast DNA primase activity, has been used to verify whether only one of the two polypeptides of heterodimeric DNA primase (48 and 58 kDa) was responsible for DNA primase function in vitro. Immunoaffinity chromatography of a crude extract from cells of Saccharomyces cerevisiae on a mAb 21A6 protein A-Sepharose 6B column allowed the purification of the p48 primase polypeptide in an isolated form. This polypeptide was not derived through the dissociation of the four-subunit DNA polymerase alpha-primase complex, which can be purified from the same extract by affinity chromatography with a mAb recognizing the DNA polymerase alpha polypeptide. Therefore, free p48 was already present in the yeast extract and, possibly, within the cell. Isolated p48, devoid of any detectable p58 subunit, was sufficient for RNA primer synthesis, although free primase appeared to extend RNA primer-monomers to primer-multimers less efficiently. Primase activity associated with free p48 was highly unstable, indicating that although p48 bears the catalytic site, its association with the other polypeptides of the polymerase-primase complex plays an important role in stabilizing enzyme activity.	DIPARTIMENTO GENET & BIOL MICRORGANISMI,VIA CELORIA 26,I-20133 MILAN,ITALY; UNIV SASSARI,IST GENET,I-07100 SASSARI,ITALY	University of Sassari			Foiani, Marco/M-8234-2014	Foiani, Marco/0000-0003-4795-834X; Santocanale, Corrado/0000-0003-1337-5656; PLEVANI, PAOLO/0000-0003-1869-2626				BINTON DM, 1987, J BIOL CHEM, V262, P10873; BISWAS EE, 1987, BIOCHEMISTRY-US, V26, P5377, DOI 10.1021/bi00391a024; BROOKE RG, 1991, J BIOL CHEM, V266, P10093; BROOKE RG, 1991, J BIOL CHEM, V266, P3005; BROOKS M, 1989, J BIOL CHEM, V264, P3602; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; FOIANI M, 1989, MOL CELL BIOL, V9, P3081, DOI 10.1128/MCB.9.7.3081; FOIANI M, 1989, J BIOL CHEM, V264, P2189; FRANCESCONI S, 1991, P NATL ACAD SCI USA, V88, P3877, DOI 10.1073/pnas.88.9.3877; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P453; Kornberg A., 1991, DNA REPLICATION; KUCHTA RD, 1990, J BIOL CHEM, V265, P16158; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LUCCHINI G, 1987, EMBO J, V6, P737, DOI 10.1002/j.1460-2075.1987.tb04815.x; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; PAUSCH MH, 1988, CANCER CELL, V6, P359; PLEVANI P, 1987, NUCLEIC ACIDS RES, V15, P7975; PLEVANI P, 1984, J BIOL CHEM, V259, P7532; PLEVANI P, 1985, J BIOL CHEM, V260, P7102; PRUSSAK CE, 1989, J BIOL CHEM, V264, P4957; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; SINGH H, 1986, J BIOL CHEM, V261, P8564; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513	28	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1343	1348						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678254				2022-12-25	WOS:A1993KG07700087
J	CLEMENTI, E; SCIORATI, C; RICCIO, M; MILOSO, M; MELDOLESI, J; NISTICO, G				CLEMENTI, E; SCIORATI, C; RICCIO, M; MILOSO, M; MELDOLESI, J; NISTICO, G			NITRIC-OXIDE ACTION ON GROWTH FACTOR-ELICITED SIGNALS - PHOSPHOINOSITIDE HYDROLYSIS AND [CA2+](I) RESPONSES ARE NEGATIVELY MODULATED VIA A CGMP-DEPENDENT PROTEIN-KINASE-I PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; CELLULAR PROLIFERATION; INVERSE CORRELATION; DNA-SYNTHESIS; CELLS; ACTIVATION; HYPERPOLARIZATION; STIMULATION; INHIBITION; PLATELETS	The role of nitric oxide (NO) in the phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis and intracellular Ca2+ release responses induced by epidermal, platelet derived, and fibroblast growth factors was investigated in three cell Lines, a clone of NIH-3T3 fibroblasts overexpressing epidermal growth factor receptors and the tumoral epithelial cells A431 and KB. In all three cell types, pretreatment with NO donors decreased growth factor-induced PIP2 and Ca2+ responses, whereas pretreatment with NO synthase inhibitors increased them. The Ca2+-dependent PIP, hydroysis induced by micromolar concentrations-of the Ca2+ ionophore, ionomycin, was also modulated negatively and positively by NO donors and synthase inhibitors, respectively. In contrast, the Ca2+ content of the intracellular stores was unaffected by the various pretreatments employed. NO donors and synthase inhibitors induced an increase and decrease, respectively, of the intracellular cGMP formation in all three cell lines investigated, All of the effects of the NO donors were mimicked by 8-bromo-cGMP administration and abolished by pretreatment with the specific blocker of the cGMP-dependent protein kinase I, KT5823, which by itself mimicked the effects of the synthase inhibitors. Together with previous observations on G protein-coupled receptors, the present results demonstrate that PIP, hydrolysis and Ca2+ release occur under the feedback control of NO, independently of the phospholipase C (beta, gamma, or delta type) involved and of the mechanism of activation. Such a control, which appears to be effected by the cGMP-dependent protein kinase I acting at the level of the phospholipases C themselves, might ultimately contribute to the inhibitory role of NO on growth previously observed with various cell types.	IST SCI SAN RAFFAELE, DIBIT, MOLEC ONCOL UNIT, I-20132 MILAN, ITALY; UNIV MILAN, MILAN, ITALY; UNIV ROMA TOR VERGATA, MONDINO NEUROBIOL CTR, DEPT BIOL, ROME, ITALY; UNIV REGGIO CALABRIA, FAC PHARM, DEPT PHARMACOL, I-88021 CATANZARO, ITALY; CNR, CTR CYTOPHARMACOL, DEPT PHARMACOL, I-20133 MILAN, ITALY; CNR, B CECCARELLI CTR, I-20133 MILAN, ITALY	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; University of Rome Tor Vergata; Universita Mediterranea di Reggio Calabria; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR)	CLEMENTI, E (corresponding author), IST SCI SAN RAFFAELE, DIBIT, RECEPTOR BIOCHEM UNIT, VIA OLGETTINA 58, I-20132 MILAN, ITALY.		Miloso, Mariarosaria/AAC-7373-2021; sciorati, clara/K-4823-2016	sciorati, clara/0000-0003-2030-9366				BANNO Y, 1994, J BIOL CHEM, V269, P15846; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; CLEMENTI E, 1995, MOL PHARMACOL, V47, P517; CLEMENTI E, 1995, EUR J PHARM-MOLEC PH, V289, P113, DOI 10.1016/0922-4106(95)90176-0; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FISCHER GA, 1994, J BIOL CHEM, V269, P19216; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; JHON DY, 1993, J BIOL CHEM, V268, P6654; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LEE KH, 1994, J BIOL CHEM, V269, P14371; LINCOLN TM, 1994, HYPERTENSION, V23, P1141, DOI 10.1161/01.HYP.23.6.1141; MIYAZAKI M, 1992, EXP CELL RES, V200, P404, DOI 10.1016/0014-4827(92)90188-E; MUNOZFERNANDEZ MA, 1994, J NEUROCHEM, V62, P1330; NGUYEN BL, 1991, AM J PHYSIOL, V261, pH1043, DOI 10.1152/ajpheart.1991.261.4.H1043; PANDIELLA A, 1989, J BIOL CHEM, V264, P12914; PANDIELLA A, 1989, BIOCHEM BIOPH RES CO, V163, P1325, DOI 10.1016/0006-291X(89)91123-6; PERANOVICH TMS, 1995, BIOCHEM J, V305, P613, DOI 10.1042/bj3050613; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PUNJABI CJ, 1992, J IMMUNOL, V149, P2179; RASMUSSEN CD, 1989, TRENDS NEUROSCI, V12, P433, DOI 10.1016/0166-2236(89)90092-1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAHL MI, 1992, J BIOL CHEM, V267, P10447; XU X, 1994, J BIOL CHEM, V269, P12645	36	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22277	22282		10.1074/jbc.270.38.22277	http://dx.doi.org/10.1074/jbc.270.38.22277			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673208	hybrid			2022-12-25	WOS:A1995RW31400035
J	PEHRSON, JR				PEHRSON, JR			PROBING THE CONFORMATION OF NUCLEOSOME LINKER DNA IN-SITU WITH PYRIMIDINE DIMER FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-ORDER STRUCTURE; CHROMATIN FIBERS; LENGTH; MODEL; LIGHT; SUPERSTRUCTURE; PHOTOPRODUCTS; TRANSCRIPTION; ORGANIZATION; EXONUCLEASE	The distribution of pyrimidine dimers formed in nucleosomal DNA by irradiation of intact nuclei isolated from rat liver has been examined. Whereas pyrimidine dimer formation in the core region of the nucleosome occurred with peaks at approximately 10-nucleotide intervals as previously reported, the distribution of pyrimidine dimers through the linker region was nearly uniform. This distinction between core and linker DNA was found to be independent of linker length over a range of 38-60 nucleotides. Because there is now ample evidence that DNA curvature is the source of the peaks of pyrimidine dimer formation in the core region, the uniform distribution of pyrimidine dimers observed in the linker region indicates that linker DNA is relatively straight. This suggests that higher order chromatin structure in situ is based on a zigzag chain of nucleosomes.			PEHRSON, JR (corresponding author), UNIV PENN, SCH VET MED, DEPT ANIM BIOL, PHILADELPHIA, PA 19104 USA.				NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024019] Funding Source: NIH RePORTER; NCI NIH HHS [CA 06927] Funding Source: Medline; NIGMS NIH HHS [GM-24019, GM-49351] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER MM, 1984, NATURE, V309, P682, DOI 10.1038/309682a0; BORDAS J, 1986, EUR BIOPHYS J BIOPHY, V13, P175, DOI 10.1007/BF00542561; BROWN DW, 1993, BIOCHEMISTRY-US, V32, P10527, DOI 10.1021/bi00091a001; BURGOYNE LA, 1985, CYTOBIOS, V43, P141; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; BUTLER PJG, 1984, EMBO J, V3, P2599, DOI 10.1002/j.1460-2075.1984.tb02180.x; CARTWRIGHT IL, 1989, METHOD ENZYMOL, V170, P359; CECH T, 1977, CELL, V11, P631, DOI 10.1016/0092-8674(77)90080-0; COHEN LH, 1975, SCIENCE, V190, P994, DOI 10.1126/science.1237932; COLE RD, 1984, ANAL BIOCHEM, V136, P24, DOI 10.1016/0003-2697(84)90303-8; DOETSCH PW, 1985, NUCLEIC ACIDS RES, V13, P3285, DOI 10.1093/nar/13.9.3285; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; GALE JM, 1987, P NATL ACAD SCI USA, V84, P6644, DOI 10.1073/pnas.84.19.6644; GALE JM, 1990, PHOTOCHEM PHOTOBIOL, V51, P411, DOI 10.1111/j.1751-1097.1990.tb01732.x; GRAZIANO V, 1994, NATURE, V368, P351, DOI 10.1038/368351a0; HOROWITZ RA, 1994, J CELL BIOL, V125, P1, DOI 10.1083/jcb.125.1.1; JAHN CL, 1979, BIOCHEMISTRY-US, V18, P1442, DOI 10.1021/bi00575a009; MARION C, 1981, EUR J BIOCHEM, V120, P169, DOI 10.1111/j.1432-1033.1981.tb05685.x; MCGHEE JD, 1983, CELL, V33, P831, DOI 10.1016/0092-8674(83)90025-9; MEISTRICH ML, 1972, J MOL BIOL, V66, P83, DOI 10.1016/S0022-2836(72)80007-X; METZGER G, 1977, BIOCHEM BIOPH RES CO, V75, P703, DOI 10.1016/0006-291X(77)91529-7; OSIPOVA TN, 1980, EUR J BIOCHEM, V113, P183; PEARLMAN DA, 1985, SCIENCE, V227, P1304, DOI 10.1126/science.3975615; PEHRSON JR, 1989, P NATL ACAD SCI USA, V86, P9149, DOI 10.1073/pnas.86.23.9149; PEHRSON JR, 1992, NUCLEIC ACIDS RES, V20, P1321, DOI 10.1093/nar/20.6.1321; RATTNER JB, 1979, J CELL BIOL, V81, P453, DOI 10.1083/jcb.81.2.453; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROSE SM, 1984, J BIOL CHEM, V259, P8534; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; SEN D, 1986, BIOCHEMISTRY-US, V25, P3441, DOI 10.1021/bi00359a052; SMITH MF, 1990, J CELL BIOL, V110, P245, DOI 10.1083/jcb.110.2.245; SNAPKA RM, 1981, BIOCHEMISTRY-US, V20, P68, DOI 10.1021/bi00504a012; STAYNOV DZ, 1983, INT J BIOL MACROMOL, V5, P3, DOI 10.1016/0141-8130(83)90071-5; STRAUSS F, 1982, NUCLEIC ACIDS RES, V10, P2275, DOI 10.1093/nar/10.7.2275; SUBIRANA JA, 1985, CHROMOSOMA, V91, P377, DOI 10.1007/BF00291012; SUQUET C, 1993, J BIOL CHEM, V268, P23755; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1977, CELL, V10, P633, DOI 10.1016/0092-8674(77)90096-4; VANHOLDE KE, 1988, CHROMATIN, P291; WILLIAMS SP, 1986, BIOPHYS J, V49, P233, DOI 10.1016/S0006-3495(86)83637-2; WOODCOCK CL, 1993, P NATL ACAD SCI USA, V90, P9021, DOI 10.1073/pnas.90.19.9021; WOODCOCK CL, 1994, J CELL BIOL, V125, P11, DOI 10.1083/jcb.125.1.11; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42; WORCEL A, 1981, P NATL ACAD SCI-BIOL, V78, P1461, DOI 10.1073/pnas.78.3.1461; YAO J, 1991, BIOCHEMISTRY-US, V30, P8408, DOI 10.1021/bi00098a019; YAO J, 1990, P NATL ACAD SCI USA, V87, P7603, DOI 10.1073/pnas.87.19.7603; ZLATANOVA J, 1994, P NATL ACAD SCI USA, V91, P5277, DOI 10.1073/pnas.91.12.5277	47	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22440	22444						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673231				2022-12-25	WOS:A1995RW31400060
J	TEIXEIRA, SMR; KIRCHHOFF, LV; DONELSON, JE				TEIXEIRA, SMR; KIRCHHOFF, LV; DONELSON, JE			POSTTRANSCRIPTIONAL ELEMENTS REGULATING EXPRESSION OF MESSENGER-RNAS FROM THE AMASTIN TUZIN GENE-CLUSTER OF TRYPANOSOMA-CRUZI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; PROTEIN PARP GENES; MESSENGER-RNA; SURFACE GLYCOPROTEIN; BRUCEI; LEISHMANIA; PROMOTER; SEQUENCES; CELLS; SITE	The genome of Trypanosoma cruzi contains tandemly arrayed copies of the gene encoding amastin, an abundant protein on the surface of the amastigote stage of the parasite. The transcription rate of the amastin genes is the same in the different developmental stages, but the steady state level of the 1.4-kilobase amastin mRNA is 50-85 times higher in amastigotes than in epimastigotes or trypomastigotes (1). Here we show that the amastin genes alternate with genes encoding another protein, called tuzin, whose 1.7-kilobase mRNA is much less abundant in amastigotes. The 3'-untranslated region (UTR) of tuzin mRNA is only a few nucleotides in length or even nonexistent, in contrast with the 630-nucleotide 3'-UTR of amastin mRNA. No promoter elements were found upstream or within the amastin/tuzin gene cluster. However, in amastigotes, the protein synthesis inhibitor cycloheximide caused a 3-fold decrease in amastin mRNA and a 7-fold increase in tuzin mRNA. Furthermore, when the amastin 3'-UTR plus its downstream intergenic region were fused behind the luciferase coding region in a chimeric plasmid for transient transfections, luciferase activity increased 7-fold in amastigotes and decreased 5-fold in epimastigotes. Thus, developmental expression of these alternating genes is regulated by different mechanisms.	UNIV IOWA, DEPT BIOCHEM, IOWA CITY, IA 52242 USA; UNIV IOWA, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA; DEPT VET AFFAIRS MED CTR, IOWA CITY, IA 52242 USA; HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; Howard Hughes Medical Institute			Donelson, John E/F-5795-2010; TEIXEIRA, SANTUZA MR/I-8137-2013		NHLBI NIH HHS [HL 07121-20] Funding Source: Medline; NIAID NIH HHS [AI24711] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024711] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ALY R, 1994, NUCLEIC ACIDS RES, V22, P2922, DOI 10.1093/nar/22.15.2922; ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X; BROWN SD, 1992, MOL CELL BIOL, V12, P2644, DOI 10.1128/MCB.12.6.2644; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHUNG HM, 1992, PARASITOL TODAY, V8, P414, DOI 10.1016/0169-4758(92)90194-7; CHUNG SH, 1990, NUCLEIC ACIDS RES, V18, P4561, DOI 10.1093/nar/18.15.4561; CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; Cleveland DW, 1989, CURR OPIN CELL BIOL, V1, P1148, DOI 10.1016/S0955-0674(89)80065-1; DEARRUDA MV, 1990, MOL BIOCHEM PARASIT, V40, P35, DOI 10.1016/0166-6851(90)90077-Y; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIETRICH P, 1993, GENE, V125, P103, DOI 10.1016/0378-1119(93)90753-P; DONELSON JE, 1995, J BIOL CHEM, V270, P7783, DOI 10.1074/jbc.270.14.7783; DORN PL, 1991, MOL BIOCHEM PARASIT, V44, P133, DOI 10.1016/0166-6851(91)90229-Y; ERONDU NE, 1991, MOL BIOCHEM PARASIT, V49, P303, DOI 10.1016/0166-6851(91)90074-G; Fourney R.M., 1988, FOCUS, V10, P5; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GONZALEZ A, 1985, NUCLEIC ACIDS RES, V13, P5789, DOI 10.1093/nar/13.16.5789; GOTTLIEB E, 1992, P NATL ACAD SCI USA, V89, P7164, DOI 10.1073/pnas.89.15.7164; HEHL A, 1994, P NATL ACAD SCI USA, V91, P370, DOI 10.1073/pnas.91.1.370; HOFT DF, 1989, INFECT IMMUN, V57, P1959, DOI 10.1128/IAI.57.7.1959-1967.1989; HOFT DF, 1995, J PARASITOL, V81, P549, DOI 10.2307/3283851; HUANG J, 1991, EMBO J, V10, P3877, DOI 10.1002/j.1460-2075.1991.tb04957.x; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KAPOTAS N, 1993, NUCLEIC ACIDS RES, V21, P4067, DOI 10.1093/nar/21.17.4067; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; KIRCHHOFF LV, 1984, J IMMUNOL, V133, P2731; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LU HY, 1991, MOL BIOCHEM PARASIT, V44, P109, DOI 10.1016/0166-6851(91)90226-V; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; OTSU K, 1993, MOL BIOCHEM PARASIT, V57, P317, DOI 10.1016/0166-6851(93)90207-E; PEREIRA IS, 1982, ACTA TROP, V39, P275; PIZZI T, 1957, THESIS U CHILE SANTI; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; RUDENKO G, 1990, MOL CELL BIOL, V10, P3492, DOI 10.1128/MCB.10.7.3492; TEIXEIRA SMR, 1994, J BIOL CHEM, V269, P20509; TYLERCROSS RE, 1995, MOL BIOCHEM PARASIT, V72, P23, DOI 10.1016/0166-6851(95)00061-5; ULLU E, 1993, MOL CELL BIOL, V13, P720, DOI 10.1128/MCB.13.1.720; VAZQUEZ D, 1979, RIBOSOMES STRUCTURE, P847; WALDER JA, 1986, SCIENCE, V233, P569, DOI 10.1126/science.3523758; WILLIAMS RD, 1976, IN VITRO CELL DEV B, V12, P623; WILSON ME, 1989, J IMMUNOL, V143, P678; WILSON ME, 1993, J BIOL CHEM, V268, P15731; WONG S, 1993, MOL CELL BIOL, V13, P207, DOI 10.1128/MCB.13.1.207; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x	54	78	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22586	22594		10.1074/jbc.270.38.22586	http://dx.doi.org/10.1074/jbc.270.38.22586			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673251	hybrid			2022-12-25	WOS:A1995RW31400081
J	SAMOKHIN, GP; LORAND, L				SAMOKHIN, GP; LORAND, L			CONTACT WITH THE N-TERMINI IN THE CENTRAL E-DOMAIN ENHANCES THE REACTIVITIES OF THE DISTAL D-DOMAINS OF FIBRIN TO FACTOR-XIII(A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; THROMBIN-CATALYZED ACTIVATION; ALPHA-CHAIN; GAMMA-CHAIN; POLYMERIZATION SITES; PLASMIC DEGRADATION; STABILIZING FACTOR; BINDING-SITES; LOCALIZATION; PROMOTION	The reaction of Factor XIII(a) with fibrin is the last enzyme-catalyzed step on the coagulation cascade, leading to the formation of a normal blood clot. The finding that fibrin is preferred by the cross-linking enzyme about 10-fold over the circulating fibrinogen suggests the operation of a unique substrate-level control for the orderly functioning of the physiological process in the forward direction. An important task is to elucidate the molecular mechanism for the transmission of the signal generated by the thrombin catalyzed cleavage in the central E domain of fibrin to the distant Factor XIII(a)-reactive glutamine residues. By focusing on the substrate sites present in gamma chain remnants of D type domains of fibrinogen and by employing the approach of fragment complementation with the regulatory E domain, which represents the thrombin-modified portion of fibrin, we have now succeeded in reconstructing in solution the phenomenon of kinetic enhancement for the reaction with Factor XIII(a). Two D type preparations (truncated fibrinogen, similar to 250 kDa and D', similar to 105 kDa) were obtained by digestion of human fibrinogen with endo Lys-C. Neither product could be cross-linked by Factor XIII(a), but as shown by the incorporation of dansylcadaverine, both were acceptor substrates for the enzyme. The plasmin-derived D (similar to 105-kDa) product, however, could be cross-linked into DD dimers. In all cases, the admixture of E fragments exerted a remarkable boosting effect on the reactions with Factor XIII(a). Even with native fibrinogen as substrate, cross-linking of gamma chains was enhanced in the presence of E. Nondenaturing electrophoresis was used to demonstrate the complex forming potential of E fragments with fibrinogen, truncated fibrinogen, D', or D, The GPRP tetrapeptide mimic of the GPRV N-terminal sequence of the alpha chains in the E fragments, abolished both complex formation and the kinetic boosting effect of E on the reactions of substrates with Factor XIII(a). Thus, the N-terminal alpha chain sequences seem to act as organizing templates for spatially orienting the D domains, probably during the protofibrillar assembly of the fibrin units, for favorable reaction with Factor XIII(a).	NORTHWESTERN UNIV,SCH MED,DEPT MOLEC & CELL BIOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,FEINBERG CARDIOVASC RES INST,CHICAGO,IL 60611	Northwestern University; Northwestern University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016346, R01HL016346] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02212, HL16346] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEIL RE, 1973, BIOL REPROD, V8, P613, DOI 10.1093/biolreprod/8.5.613; BRUNERLORAND J, 1966, NATURE, V210, P1273; Chen R, 1971, Biochemistry, V10, P4487; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3244, DOI 10.1021/bi00282a032; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; CIERNIEWSKI CS, 1986, J BIOL CHEM, V261, P9116; COTTRELL BA, 1979, BIOCHEMISTRY-US, V18, P5405, DOI 10.1021/bi00591a023; CREDO RB, 1978, P NATL ACAD SCI USA, V75, P4234, DOI 10.1073/pnas.75.9.4234; CREDO RB, 1981, BIOCHEMISTRY-US, V20, P3770, DOI 10.1021/bi00516a016; Curtis C G, 1976, Methods Enzymol, V45, P177; DERANLEA.DA, 1966, BIOCHEMISTRY-US, V5, P1413, DOI 10.1021/bi00868a040; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; EHRLICH PH, 1983, BIOCHEMISTRY-US, V22, P4184, DOI 10.1021/bi00287a004; ELLIOTT BW, 1986, J BIOL CHEM, V261, P1259; FRETTO LJ, 1978, J BIOL CHEM, V253, P2184; FURLAN M, 1972, BIOCHIM BIOPHYS ACTA, V263, P631, DOI 10.1016/0005-2795(72)90044-X; Hart R G, 1970, Biol Reprod, V3, P347; HART RG, 1968, J REPROD FERTIL, V17, P223; HENRIKSSON P, 1974, PEDIATR RES, V8, P789, DOI 10.1203/00006450-197409000-00002; JANUS TJ, 1983, BIOCHEMISTRY-US, V22, P6269, DOI 10.1021/bi00295a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; LEWIS SD, 1985, BIOCHEMISTRY-US, V24, P6772, DOI 10.1021/bi00345a007; LORAND L, 1981, METHOD ENZYMOL, V80, P333; LORAND L, 1969, J CLIN INVEST, V48, P1054, DOI 10.1172/JCI106061; LORAND L, 1964, ARCH BIOCHEM BIOPHYS, V105, P58, DOI 10.1016/0003-9861(64)90235-8; LORAND L, 1962, NATURE, V195, P911, DOI 10.1038/195911b0; LORAND L, 1969, P NATL ACAD SCI USA, V63, P1247, DOI 10.1073/pnas.63.4.1247; LORAND L, 1968, BIOCHEMISTRY-US, V7, P1214, DOI 10.1021/bi00843a043; LORAND L, 1966, BIOCHEMISTRY-US, V5, P1747, DOI 10.1021/bi00869a043; Lorand L, 1980, Prog Hemost Thromb, V5, P245; LORAND L, 1972, ANN NY ACAD SCI, V202, P165; Lorand L., 1970, METHOD ENZYMOL, V19, P770; Lorand L., 1994, ANTICOAGULANTS PHYSL, P169; MARDER VJ, 1969, J BIOL CHEM, V244, P2111; MATSUEDA GR, 1988, FIBRINOGEN, V3, P133; MILLS DA, 1972, BIOCHIM BIOPHYS ACTA, V263, P619, DOI 10.1016/0005-2795(72)90043-8; MOCKROS LF, 1974, BIOPHYS CHEM, V2, P164, DOI 10.1016/0301-4622(74)80037-2; NASKI MC, 1991, BIOCHEMISTRY-US, V30, P934, DOI 10.1021/bi00218a008; NUSSENZWEIG V, 1961, ANN I PASTEUR PARIS, V100, P377; OLEXA SA, 1979, BIOCHEMISTRY-US, V18, P991, DOI 10.1021/bi00573a009; OLEXA SA, 1979, J BIOL CHEM, V254, P4925; OLEXA SA, 1981, BIOCHEMISTRY-US, V20, P6139, DOI 10.1021/bi00524a035; PIZZO SV, 1972, J BIOL CHEM, V247, P636; POZDNYAKOVA T M, 1987, Biokhimiya, V52, P592; POZDNYAKOVA TM, 1985, UKR BIOKHIM ZH+, V57, P3; POZDNYAKOVA TM, 1986, UKR BIOKHIM ZH+, V58, P10; POZDNYAKOVA TM, 1983, UKR BIOKHIM ZH+, V55, P614; PROCYK R, 1991, BLOOD, V77, P1469; RADEK JT, 1993, BIOCHEMISTRY-US, V32, P3527, DOI 10.1021/bi00065a002; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; ROBERTS W W, 1973, Biorheology, V10, P29; ROZENFEL'D M A, 1988, Molekulyarnaya Biologiya (Moscow), V22, P923; RYBACHUK VN, 1986, UKR BIOKHIM ZH+, V58, P3; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; SHEN L, 1983, J CLIN INVEST, V71, P1336, DOI 10.1172/JCI110885; SHIMIZU A, 1992, P NATL ACAD SCI USA, V89, P2888, DOI 10.1073/pnas.89.7.2888; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UGAROVA TP, 1992, J BIOL CHEM, V267, P13687; VARADI A, 1986, BIOCHEMISTRY-US, V25, P519, DOI 10.1021/bi00351a001; VARADI A, 1983, BIOCHEMISTRY-US, V22, P2440, DOI 10.1021/bi00279a021; VARADI A, 1984, BIOCHEMISTRY-US, V23, P2108, DOI 10.1021/bi00304a036; WILLIAMSASHMAN HG, 1977, BIOCHEM BIOPH RES CO, V79, P1192, DOI 10.1016/0006-291X(77)91132-9; YAMAZUMI K, 1992, P NATL ACAD SCI USA, V89, P2893, DOI 10.1073/pnas.89.7.2893	65	25	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21827	21832		10.1074/jbc.270.37.21827	http://dx.doi.org/10.1074/jbc.270.37.21827			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665605	hybrid			2022-12-25	WOS:A1995RU75700064
J	TRAIANEDES, K; FINDLAY, DM; MARTIN, TJ; GILLESPIE, MT				TRAIANEDES, K; FINDLAY, DM; MARTIN, TJ; GILLESPIE, MT			MODULATION OF THE SIGNAL RECOGNITION PARTICLE 54-KDA SUBUNIT (SRP54) IN RAT PREOSTEOBLASTS BY THE EXTRACELLULAR-MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALKALINE-PHOSPHATASE; DIFFERENTIAL DISPLAY; GENE-EXPRESSION; RETINOIC ACID; 54K SUBUNIT; CELL; PROTEIN; RNA; OSTEOPONTIN; SUBSTRATUM	Rat preosteoblastic cells, UMI201, develop a more mature phenotype when subcultured onto a type I collagen gel when compared with their growth on plastic. Basal osteopontin mRNA expression is up-regulated, whereas retinoic acid-induced alkaline phosphatase expression is reduced in cells on collagen when compared with cells plated onto plastic, We have used differential display polymerase chain reaction (PCR) of mRNA to identify other mRNA species that are regulated by collagen and/or retinoic acid in UMR201 cells. A number of differentially expressed PCR products were isolated, whose sequences did not correspond to known sequences in the data bank, However, one species which was up-regulated by growth on collagen showed 95 and 94% homology to the murine and canine 54-kDa subunit of the signal recognition particle (SRP54), respectively. In time course experiments, using reverse transcription PCR, it was found that SRP54 mRNA was up-regulated in UMR201 cells as early as 1 h after subculture onto collagen, when compared with cells subcultured onto plastic, and levels remained elevated after 48 h, The increased expression of SRP54 paralleled the increased expression of a known secreted protein, osteopontin, SRP54 recognizes signal sequences of proteins destined for secretion and retards them for further elongation in the endoplasmic reticulum, The increased expression may correlate with the synthesis of specific extracellular matrix molecules in differentiating osteoblasts.	ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA; UNIV MELBOURNE,ST VINCENTS HOSP,DEPT MED,FITZROY,VIC 3065,AUSTRALIA	St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne; University of Melbourne				Gillespie, Matthew/0000-0001-6543-8909				AMAYA Y, 1990, J BIOCHEM-TOKYO, V107, P457, DOI 10.1093/oxfordjournals.jbchem.a123067; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4772; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; CARON JM, 1990, MOL CELL BIOL, V10, P1239, DOI 10.1128/MCB.10.3.1239; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; HADLEY MA, 1985, J CELL BIOL, V101, P1511, DOI 10.1083/jcb.101.4.1511; HADLEY MA, 1988, IN VITRO CELL DEV, V29, P943; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; Jones Peter Lloyd, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P137; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, CURRENT PROTOCOLS MO; MASI L, 1992, CALCIFIED TISSUE INT, V51, P202, DOI 10.1007/BF00334548; NG DTW, 1994, CURR OPIN CELL BIOL, V6, P510, DOI 10.1016/0955-0674(94)90069-8; NG KW, 1988, J BONE MINER RES, V3, P53; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; POCKWINSE SM, 1992, J CELL BIOCHEM, V49, P310, DOI 10.1002/jcb.240490315; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SAGER R, 1993, FASEB J, V7, P964, DOI 10.1096/fasebj.7.10.8344495; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELSSON T, 1992, NUCLEIC ACIDS RES, V20, P5763, DOI 10.1093/nar/20.21.5763; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STREULI CH, 1990, J CELL BIOL, V110, P1405; TRAIANEDES K, 1993, J CELL PHYSIOL, V157, P243, DOI 10.1002/jcp.1041570206; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WEINREB M, 1990, J BONE MINER RES, V5, P831; ZHANG LX, 1993, MOL CARCINOGEN, V8, P123, DOI 10.1002/mc.2940080209	32	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20891	20894		10.1074/jbc.270.36.20891	http://dx.doi.org/10.1074/jbc.270.36.20891			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673110	hybrid			2022-12-25	WOS:A1995RU05400006
J	OWENSGRILLO, JK; HOFFMANN, K; HUTCHISON, KA; YEM, AW; DEIBEL, MR; HANDSCHUMACHER, RE; PRATT, WB				OWENSGRILLO, JK; HOFFMANN, K; HUTCHISON, KA; YEM, AW; DEIBEL, MR; HANDSCHUMACHER, RE; PRATT, WB			THE CYCLOSPORINE A-BINDING IMMUNOPHILIN CYP-40 AND THE FK506-BINDING IMMUNOPHILIN HSP56 BIND TO A COMMON SITE ON HSP90 AND EXIST IN INDEPENDENT CYTOSOLIC HETEROCOMPLEXES WITH THE UNTRANSFORMED GLUCOCORTICOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; UTERINE PROGESTIN RECEPTOR; 59-KILODALTON PROTEIN; POLYCLONAL ANTIBODY; ESTROGEN-RECEPTOR; COMPLEXES; COMPONENT; IDENTIFICATION; ASSOCIATION; P59	We have recently shown that hsp56, the FKBOG-binding immunophilin component of both the heat shock protein (hsp90 . hsp70 . hsp56) heterocomplex and the untransformed glucocorticoid receptor heterocomplex, is bound directly to hsp90 (Czar, M. J., Owens-Grillo, J. K., Dittmar, K. D., Hutchison, K. A., Zacharek, A. M., Leach, K. L., Deibel, M. R., and Pratt, W. B. (1994) J. Biol. Chem. 269, 11155-11161). In this work, we show that both untransformed glucocorticoid receptor and hsp90 heterocomplexes contain CyP-40, a 40-kDa immunophilin of the cyclosporin A-binding class. CyP-40 is present in both native glucocorticoid receptor heterocomplexes and receptor heterocomplexes reconstituted with rabbit reticulocyte lysate, and the presence of CyP-40 in the receptor heterocomplex is stabilized by molybdate. Immunoadsorption of hsp90 from cell lysate yields coimmunoadsorption of both hsp56 and CyP-40, showing that both immunophilins are in native heterocomplex with hsp90. However, immunoadsorption of hsp56 does not yield coimmunoadsorption of CyP-40; thus, the two immunophilins do not exist in the same heterocomplex with hsp90. Both purified CyP-40 and hsp56 bind directly to purified hsp90, and excess CyP-40 blocks the binding of hsp56, consistent with the presence of a common immunophilin binding site on hsp90. Our data also suggest that there are at least two types of untransformed glucocorticoid receptor-hsp90 heterocomplexes, one that contains hsp56 and another that contains CyP-40. The role played by the immunophilins in steroid receptor action is unknown, but it is clear that the peptidylprolyl isomerase activity of immunophilins is not required for glucocorticoid receptor-hsp90 heterocomplex assembly and proper folding of the hormone binding domain by the hsp90-associated protein folding system of reticulocyte lysate.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; UPJOHN CO,DEPT BIOCHEM,KALAMAZOO,MI 49001; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	University of Michigan System; University of Michigan; Pfizer; Yale University					NCI NIH HHS [T32 CA09676, CA28010] Funding Source: Medline; NIGMS NIH HHS [GM49858] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028010, T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALNEMRI ES, 1993, P NATL ACAD SCI USA, V90, P6839, DOI 10.1073/pnas.90.14.6839; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BOGUSKI MS, 1990, NATURE, V346, P114, DOI 10.1038/346114a0; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; CZAR MJ, 1994, MOL ENDOCRINOL, V8, P1731, DOI 10.1210/me.8.12.1731; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HIRST MA, 1990, MOL ENDOCRINOL, V4, P162, DOI 10.1210/mend-4-1-162; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; JOHNSON JL, 1994, J CELL BIOCHEM, V18, P344; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; NAKAO K, 1985, CAN J BIOCHEM CELL B, V63, P33, DOI 10.1139/o85-005; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1993, J STEROID BIOCHEM, V46, P269, DOI 10.1016/0960-0760(93)90216-J; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RATAJCZAK T, 1990, J STEROID BIOCHEM, V35, P543, DOI 10.1016/0022-4731(90)90197-Z; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANDHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, J BIOL CHEM, V268, P24270; SMITH DF, 1993, J BIOL CHEM, V268, P18365; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; TAI PKK, 1985, CAN J BIOCHEM CELL B, V63, P41, DOI 10.1139/o85-006; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; YEM AW, 1992, J BIOL CHEM, V267, P2868	44	161	167	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20479	20484		10.1074/jbc.270.35.20479	http://dx.doi.org/10.1074/jbc.270.35.20479			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657624	hybrid			2022-12-25	WOS:A1995RR58400039
J	IMLAY, JA				IMLAY, JA			A METABOLIC ENZYME THAT RAPIDLY PRODUCES SUPEROXIDE, FUMARATE REDUCTASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XANTHINE-OXIDASE; UBIQUINONE OXIDOREDUCTASE; NADH DEHYDROGENASE; ELECTRON-TRANSPORT; DISMUTASE MUTANTS; RESPIRATORY-CHAIN; HYDROGEN-PEROXIDE; BOUND FLAVIN; ANION; QUINONES	Aerobic organisms synthesize superoxide dismutases in order to escape injury from endogenous superoxide, An earlier study of Escherichia coli indicated that intracellular superoxide is formed primarily by autoxidation of components of the respiratory chain, In order to identify those components, inverted respiratory vesicles were incubated with five respiratory substrates, In most cases, essentially all of the superoxide was formed through autoxidation of fumarate reductase, despite the paucity of this anaerobic terminal oxidase in the aerobic cells from which the vesicles were prepared, In contrast, most dehydrogenases, the respiratory quinones, and the cytochrome oxidases did not produce any detectable superoxide, The propensity of fumarate reductase to generate superoxide could conceivably deluge cells with superoxide when anaerobic cells, which contain abundant fumarate reductase, enter an aerobic habitat, In fact, deletion or overexpression of the frd structural genes improved and retarded, respectively, the outgrowth of superoxide dismutase-attenuated cells when they were abruptly aerated, suggesting that fumarate reductase is a major source of superoxide in vivo, Steric inhibitors that bind adjacent to the flavin completely blocked superoxide production, indicating that the flavin, rather than an iron-sulfur cluster, is the direct electron donor to oxygen, Since the turnover numbers for superoxide formation by other flavoenzymes are orders of magnitude lower than that of fumarate reductase (1600 min(-1)), additional steric or electronic factors must accelerate its autoxidation.			IMLAY, JA (corresponding author), UNIV ILLINOIS, DEPT MICROBIOL, 131 BURRILL HALL, 407 S GOODWIN AVE, URBANA, IL 61801 USA.				NIGMS NIH HHS [GM49640] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049640] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1989, ARCH BIOCHEM BIOPHYS, V268, P26, DOI 10.1016/0003-9861(89)90561-4; AU DCT, 1984, J BACTERIOL, V157, P122, DOI 10.1128/JB.157.1.122-125.1984; BEYER RE, 1990, FREE RADICAL BIO MED, V8, P545, DOI 10.1016/0891-5849(90)90154-B; BLAUT M, 1989, J BIOL CHEM, V264, P13599; BOVERIS A, 1982, SUPEROXIDE DISMUTASE, V2, P15; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CECCHINI G, 1986, J BIOL CHEM, V261, P1808; CHANG EC, 1991, J BIOL CHEM, V266, P4417; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; EDMONDSON DE, 1973, J BIOL CHEM, V248, P8144; FLINT DH, 1992, BIOCHEMISTRY-US, V31, P10331, DOI 10.1021/bi00157a022; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GAUDU P, 1994, J BIOL CHEM, V269, P8182; GREEN MJ, 1984, METHOD ENZYMOL, V105, P3; GUEST JR, 1981, J GEN MICROBIOL, V122, P171; HILLE R, 1981, J BIOL CHEM, V256, P9090; IMLAY J, 1992, ARCH BIOCHEM BIOPHYS, V296, P337, DOI 10.1016/0003-9861(92)90581-G; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; IUCHI S, 1985, J BACTERIOL, V161, P1023, DOI 10.1128/JB.161.3.1023-1028.1985; KARGALIOGLU Y, 1994, J BACTERIOL, V176, P7653, DOI 10.1128/JB.176.24.7653-7658.1994; KITA K, 1989, J BIOL CHEM, V264, P2672; KOMAI H, 1969, J BIOL CHEM, V244, P1692; KUO CF, 1987, J BIOL CHEM, V262, P4724; LAND EJ, 1971, BIOCHIM BIOPHYS ACTA, V234, P34, DOI 10.1016/0005-2728(71)90126-5; LIN ECC, 1987, ESCHERICHIA COLI SAL, V1, P201; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; LYNCH RE, 1978, J BIOL CHEM, V253, P4697; MASSEY V, 1969, BIOCHEM BIOPH RES CO, V36, P891, DOI 10.1016/0006-291X(69)90287-3; MASSEY V, 1994, J BIOL CHEM, V36, P22458; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MEINHARDT SW, 1989, BIOCHEMISTRY-US, V28, P2153, DOI 10.1021/bi00431a029; MIKI T, 1992, J BIOL CHEM, V267, P18695; Miller J.H., 1972, EXPT MOL GENETICS; MISRA HP, 1972, J BIOL CHEM, V247, P3170; POOLE RK, 1975, BIOCHEM J, V152, P537, DOI 10.1042/bj1520537; POOLE RK, 1987, ESCHERICHIA COLI SAL, V1, P170; PORRAS AG, 1981, J BIOL CHEM, V256, P9096; Singer T P, 1974, Methods Biochem Anal, V22, P123, DOI 10.1002/9780470110423.ch3; SIX S, 1994, J BACTERIOL, V176, P6470, DOI 10.1128/JB.176.21.6470-6478.1994; TURRENS JF, 1987, MOL BIOCHEM PARASIT, V25, P55, DOI 10.1016/0166-6851(87)90018-1; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P75, DOI 10.1016/0005-2728(77)90070-6	49	113	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19767	19777						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649986				2022-12-25	WOS:A1995RQ99100017
J	GEREZ, L; ARAD, G; EFRAT, S; KETZINEL, M; KAEMPFER, R				GEREZ, L; ARAD, G; EFRAT, S; KETZINEL, M; KAEMPFER, R			POSTTRANSCRIPTIONAL REGULATION OF HUMAN INTERLEUKIN-2 GENE-EXPRESSION AT PROCESSING OF PRECURSOR TRANSCRIPTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; NUCLEOTIDE-SEQUENCE; LYMPHOCYTES-T; GROWTH-FACTOR; C-FOS; INDUCTION; SUPERINDUCTION; INTERFERON; STABILITY	Interleukin-2 (IL-2) regulates the clonal expansion of activated T cells and is produced in limited amounts during an immune response. Mitogenic induction of human IL-2 gene expression elicits a transient wave of unstable mRNA. We show here that transcription continues unabated during and well beyond the time when the wave is subsiding, yet few, if any, new mRNA molecules are generated once the wave has reached its maximum, Instead, IL-2 precursor transcripts accumulate, becoming the majority of expressed IL-2 RNA molecules. The flow of precursor transcripts into mature mRNA becomes inhibited in the course of induction. When translation is blocked (e.g. by cycloheximide), expression of IL-2 mRNA can be superinduced by 2 orders of magnitude. This superinduction is completely dependent upon transcription, yet is not accompanied by any significant increase in the rate of primary transcription or in mRNA stability. Instead, the processing of nuclear IL-2 precursor transcripts is greatly facilitated, resulting in pronounced superinduction of cytoplasmic mRNA Once its transcription has been induced, therefore, expression of the IL-2 gene is down-regulated extensively at the level of precursor RNA processing.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOLEC VIROL,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem				Kaempfer, Raymond/0000-0002-5865-4619				AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; ARAD G, 1995, CELL IMMUNOL, V160, P240, DOI 10.1016/0008-8749(95)80034-G; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EFRAT S, 1984, P NATL ACAD SCI-BIOL, V81, P2601, DOI 10.1073/pnas.81.9.2601; EFRAT S, 1982, NATURE, V297, P236, DOI 10.1038/297236a0; EFRAT S, 1984, BIOCHEM BIOPH RES CO, V123, P842, DOI 10.1016/0006-291X(84)90307-3; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; GULLBERG M, 1982, J IMMUNOL, V128, P746; HOLBROOK NJ, 1984, P NATL ACAD SCI-BIOL, V81, P1634, DOI 10.1073/pnas.81.6.1634; JARROUS N, 1994, J BIOL CHEM, V269, P23141; KETZINEL M, 1991, SCAND J IMMUNOL, V33, P593, DOI 10.1111/j.1365-3083.1991.tb02531.x; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; LEBENDIKER MA, 1987, EMBO J, V6, P585, DOI 10.1002/j.1460-2075.1987.tb04794.x; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LOWE WL, 1987, P NATL ACAD SCI USA, V84, P8946, DOI 10.1073/pnas.84.24.8946; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHWARTZ JL, 1983, MUTAT RES, V107, P413, DOI 10.1016/0027-5107(83)90180-X; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHAW J, 1987, MOL IMMUNOL, V24, P409, DOI 10.1016/0161-5890(87)90014-9; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; VAESSEN RTMJ, 1987, SCIENCE, V235, P1486, DOI 10.1126/science.3823900; WEIL D, 1990, MOL CELL BIOL, V10, P5865, DOI 10.1128/MCB.10.11.5865; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232	31	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19569	19575		10.1074/jbc.270.33.19569	http://dx.doi.org/10.1074/jbc.270.33.19569			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642643	hybrid			2022-12-25	WOS:A1995RP70300059
J	WU, DH; AHMED, SN; LIAN, W; HERSH, LB				WU, DH; AHMED, SN; LIAN, W; HERSH, LB			ACTIVATION OF RAT CHOLINE-ACETYLTRANSFERASE BY LIMITED PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; INHIBITION; EXPRESSION; ENZYME	In the past, purification of choline acetyltransferase (ChAT, EC 2.3.1.6), the enzyme responsible for the biosynthesis of the neurotransmitter acetylcholine, has yielded fragmented species of the enzyme. The nature and possible function of these forms of ChAT are not well understood, Using a bacterial expression system, recombinant rat ChAT in its active form has been purified to homogeneity. The purified enzyme was found to be activated to >25-fold when assayed at low ionic strength and >5-fold when assayed at high ionic strength by limited proteolysis with either trypsin or chymotrypsin, but not with proteinase K. The activated ChAT shows an increased K-m for both substrates, diminished sensitivity to salt activation and a pH optimum that is shifted approximately 1 pH unit, On a denaturing SDS-polyacrylamide gel, the activated ChAT is composed of three to four polypeptides; however, it migrates as an intact 68-kDa protein species on gel filtration, In order to delineate the site of cleavage by proteolysis, the newly generated fragments have been subjected to N-terminal sequencing, By comparing cleavage sites between trypsin and chymotrypsin, the putative activation sites were identified.			WU, DH (corresponding author), UNIV KENTUCKY,COLL MED,DEPT BIOCHEM,800 ROSE ST,LEXINGTON,KY 40536, USA.				NIA NIH HHS [AG05893] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R55AG005893, R01AG005893] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENECKE S, 1993, J NEUROCHEM, V61, P804, DOI 10.1111/j.1471-4159.1993.tb03590.x; BLOOM H, 1987, ELECTROPHORESIS, V8, P93; BRICE A, 1989, J NEUROSCI RES, V23, P266, DOI 10.1002/jnr.490230304; BRUCE G, 1989, NEUROCHEM RES, V14, P613, DOI 10.1007/BF00964869; BRUCE G, 1985, J NEUROCHEM, V45, P611, DOI 10.1111/j.1471-4159.1985.tb04030.x; CARBINI LA, 1993, J NEUROCHEM, V61, P247, DOI 10.1111/j.1471-4159.1993.tb03561.x; CHAO LP, 1975, J NEUROCHEM, V25, P261, DOI 10.1111/j.1471-4159.1975.tb06963.x; Cleland W W, 1979, Methods Enzymol, V63, P103; COZZARI C, 1983, BRAIN RES, V276, P109, DOI 10.1016/0006-8993(83)90552-8; CURRIER SF, 1974, P NATL ACAD SCI USA, V71, P3355, DOI 10.1073/pnas.71.9.3355; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; GLOVER VAS, 1971, J NEUROCHEM, V18, P571, DOI 10.1111/j.1471-4159.1971.tb11987.x; HAHN M, 1992, P NATL ACAD SCI USA, V89, P4387, DOI 10.1073/pnas.89.10.4387; HERSH LB, 1978, J NEUROCHEM, V30, P1077, DOI 10.1111/j.1471-4159.1978.tb12401.x; HERSH LB, 1982, J BIOL CHEM, V257, P2820; HERSH LB, 1984, J BIOL CHEM, V259, P1253; HERSH LB, 1978, J BIOL CHEM, V254, P11988; IBANEZ CF, 1991, P NATL ACAD SCI USA, V88, P3676, DOI 10.1073/pnas.88.9.3676; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAUTNER HG, 1977, CRC CR REV BIOCH MOL, V4, P341, DOI 10.3109/10409237709105460; MAUTNER HG, 1986, NEUROTRANSMITTER ENZ, V5, P273; MCGEER PL, 1984, LIFE SCI, V34, P2319, DOI 10.1016/0024-3205(84)90419-3; Nachmansohn D, 1943, J NEUROPHYSIOL, V6, P397, DOI 10.1152/jn.1943.6.5.397; ROSSIER J, 1977, INT REV NEUROL, V28, P283; RYAN RL, 1979, BIOCHEMISTRY-US, V18, P5357, DOI 10.1021/bi00591a016; SALVATERRA PM, 1985, J NEUROSCI, V5, P903; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASTRY BVR, 1981, J PHARMACOL EXP THER, V216, P378; SCHUBERTH J, 1966, BIOCHIM BIOPHYS ACTA, V122, P470, DOI 10.1016/0926-6593(66)90039-7; TUCEK S, 1988, HDB EXPT PHARM, V86, P129; WHITE HL, 1970, BIOCHIM BIOPHYS ACTA, V206, P343, DOI 10.1016/0005-2744(70)90151-8; WU DH, 1994, J NEUROCHEM, V62, P1653	32	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19395	19401		10.1074/jbc.270.33.19395	http://dx.doi.org/10.1074/jbc.270.33.19395			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642620	hybrid			2022-12-25	WOS:A1995RP70300034
J	ENGELKE, U; SMARDA, J; LIPSICK, JS				ENGELKE, U; SMARDA, J; LIPSICK, JS			BYPASS OF TPA-INDUCED DIFFERENTIATION AND CELL-CYCLE ARREST BY THE C-MYB DNA-BINDING DOMAIN	ONCOGENE			English	Article						MYB; CELL CYCLE; TPA	TRANSFORMATION; TRUNCATION; GENE; ACTIVATION; EXPRESSION; ONCOGENE; PROTEIN	Monoblasts transformed by v-Myb can be induced to differentiate into macrophages by treatment with phorbol ester (TPA). This differentiation occurs during both the G(1) and the G(2) phases of the cell cycle and is accompanied by cell cycle arrest. The introduction of a protein consisting of the three repeats (3R) of the c-Myb DNA-binding domain permits the by-pass of this phorbol ester-induced differentiation and cell cycle arrest. In particular, monoblasts which express the 3R protein progress through both the G(1)/S and G(2)/M transitions in the presence of phorbol ester. However, the 3R protein contains no detectable transcriptional activation domain. These results demonstrate that the c-Myb DNA-binding domain can regulate the cell cycle without functioning as a direct transcriptional activator.	STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305; MASARYK UNIV,FAC SCI,DEPT MOLEC BIOL & GENET,CS-61137 BRNO,CZECH REPUBLIC	Stanford University; Masaryk University Brno					FOGARTY INTERNATIONAL CENTER [R03TW000291] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043592] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW00291] Funding Source: Medline; NCI NIH HHS [R01 CA43592] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; GARCIA A, 1991, ONCOGENE, V6, P265; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; PESSANO S, 1979, MICROBIOLOGICA, V2, P379; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; SMARDA J, 1993, GENE, V137, P145; SMARDA J, 1994, ONCOGENE, V9, P237; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; SYMONDS G, 1984, MOL CELL BIOL, V4, P2587, DOI 10.1128/MCB.4.12.2587	21	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					735	741						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651737				2022-12-25	WOS:A1995RQ46900015
J	BURG, DL; HARRISON, ML; GEAHLEN, RL				BURG, DL; HARRISON, ML; GEAHLEN, RL			CELL CYCLE-SPECIFIC ACTIVATION OF THE PTK72 PROTEIN-TYROSINE KINASE IN LYMPHOCYTES-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ANTIGEN RECEPTOR; PHOSPHORYLATION; STIMULATION; ANTIIMMUNOGLOBULIN; PROLIFERATION; ASSOCIATION; PROTEOLYSIS	The engagement of cell-surface antigen receptors on B lymphocytes by anti-IgM antibodies leads to the rapid tyrosine phosphorylation and activation of the protein-tyrosine kinase, PTK72. High concentrations of anti-IgM, which promote cell cycle entry and progression through G1, result in a biphasic change in the state of tyrosine phosphorylation of PTK72. An initial, rapid increase is seen within 5 min, which slowly declines to the level found in resting cells over a period of 9 h. A second increase is then observed 18-30 h following the initial stimulation. Low concentrations of anti-IgM, which promote cell cycle entry but not progression through G1, result only in the initial, rapid phosphorylation. The polyclonal mitogens lipopolysaccharide and dextran sulfate, which stimulate both cell cycle entry and progression to late G1, result only in the second, late phase of tyrosine phosphorylation. This second phase of elevated tyrosine phosphorylation is cell cycle-dependent, as demonstrated by its appearance in cells blocked at G1/S and absence in cells blocked at G2/M. The increase in the tyrosine phosphorylation of PTK72 is accompanied by an increase in its activity with no change in its concentration. These data suggest a possible second role for PTK72 in the commitment of activated B cells to proliferation.	PURDUE UNIV,DEPT MED CHEM & PHARMACOGNOSY,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Geahlen, Robert/0000-0001-8400-2924	NATIONAL CANCER INSTITUTE [R01CA037372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007532] Funding Source: NIH RePORTER; NCI NIH HHS [CA37372] Funding Source: Medline; NIDDK NIH HHS [DK07532] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEFRANCO AL, 1985, J IMMUNOL, V135, P87; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; LANE PJL, 1990, J IMMUNOL, V144, P3684; MELCHERS F, 1985, P NATL ACAD SCI USA, V82, P7681, DOI 10.1073/pnas.82.22.7681; SEVERSON CD, 1987, IMMUNOL LETT, V15, P291, DOI 10.1016/0165-2478(87)90130-1; WETZEL GD, 1984, J IMMUNOL, V133, P2327; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	16	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2304	2306						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679095				2022-12-25	WOS:A1993KK81500010
J	BRENNAN, KJ; HARDEMAN, EC				BRENNAN, KJ; HARDEMAN, EC			QUANTITATIVE-ANALYSIS OF THE HUMAN ALPHA-SKELETAL ACTIN GENE IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY REGULATED EXPRESSION; MUSCLE-SPECIFIC EXPRESSION; CARDIAC ACTIN; STRIATED-MUSCLE; DNA-SEQUENCES; MESSENGER-RNA; MOUSE; TRANSCRIPTION; DIFFERENTIATION; PROMOTER	Three aspects of the regulation of the human alpha-skeletal actin gene are examined in this study by quantitative analysis of transgenic tissues: level of expression, tissue specificity, and developmental regulation. Previous in vitro and in vivo studies analyzing the 5' end of the gene have indicated that regulation of tissue-specific expression is promoter based. Transgenic mice were produced carrying either a 9.5-kilobase pair (kb) human alpha-skeletal actin gene fragment or a deletion construct with 2.2-kb of 5' sequences of human alpha-skeletal skeletal actin linked to the chloramphenicol acetyl-transferase reporter gene. We found that the 9.5-kb transgene was capable of expression in adult skeletal muscle at a level equivalent to that of the endogenous gene in a non-transgenic mouse. The deletion construct was also capable of high-level expression. Both transgenes were expressed in a striated muscle-specific manner and were correctly regulated during development. We conclude that these three parameters of regulation of the human alpha-skeletal actin gene are mediated by sequences within the region -2000 to +239 of the promoter.	CHILDRENS MED RES INST,MUSCLE DEV UNIT,LOCKED BAG 23,WENTWORTHVILLE,NSW 2145,AUSTRALIA	Children's Medical Research Institute - Australia			Hardeman, Edna C/F-8872-2012	Hardeman, Edna/0000-0003-1649-7712				AESADI G, 1991, NATURE, V352, P815; ALONSO S, 1990, J MOL BIOL, V211, P727, DOI 10.1016/0022-2836(90)90073-U; BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; BEALL CJ, 1989, GENE DEV, V3, P131, DOI 10.1101/gad.3.2.131; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; BOHELER KR, 1991, J CLIN INVEST, V88, P323, DOI 10.1172/JCI115295; BUCKINGHAM ME, 1983, EUKARYOTIC GENES THE, P365; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW KL, 1991, P NATL ACAD SCI USA, V88, P1301, DOI 10.1073/pnas.88.4.1301; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLLIE ESR, 1992, CELL GROWTH DIFFER, V3, P31; COX RD, 1992, DEV BIOL, V149, P228, DOI 10.1016/0012-1606(92)90279-P; COX RD, 1990, DIFFERENTIATION, V43, P183, DOI 10.1111/j.1432-0436.1990.tb00445.x; DONOGHUE MJ, 1991, P NATL ACAD SCI USA, V88, P5847, DOI 10.1073/pnas.88.13.5847; GARNER I, 1989, DEV BIOL, V134, P236, DOI 10.1016/0012-1606(89)90093-6; GRICHNIK JM, 1986, NUCLEIC ACIDS RES, V14, P1683, DOI 10.1093/nar/14.4.1683; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; GUNNING P, 1983, MOL CELL BIOL, V3, P1985, DOI 10.1128/MCB.3.11.1985; HALLAUER PL, 1988, MOL CELL BIOL, V8, P5072, DOI 10.1128/MCB.8.12.5072; HAYWARD LJ, 1986, J CELL BIOL, V102, P1485, DOI 10.1083/jcb.102.4.1485; HOGAN B, 1986, MANIPULATING MOUSE E; HU MCT, 1986, MOL CELL BIOL, V6, P15, DOI 10.1128/MCB.6.1.15; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; MCHUGH KM, 1991, DEV BIOL, V148, P442, DOI 10.1016/0012-1606(91)90263-3; MELLOUL D, 1984, EMBO J, V3, P983, DOI 10.1002/j.1460-2075.1984.tb01917.x; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; MINTY AJ, 1982, CELL, V30, P185, DOI 10.1016/0092-8674(82)90024-1; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; MUSCAT GEO, 1991, MOL ENDOCRINOL, V5, P802, DOI 10.1210/mend-5-6-802; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; PALMITER RD, 1974, BIOCHEMISTRY-US, V13, P3606, DOI 10.1021/bi00714a032; PETROPOULOS CJ, 1989, MOL CELL BIOL, V9, P3785, DOI 10.1128/MCB.9.9.3785; Sambrook J, 1989, MOL CLONING LABORATO; SEILERTUYNS A, 1984, P NATL ACAD SCI-BIOL, V81, P2980, DOI 10.1073/pnas.81.10.2980; SHANI M, 1986, MOL CELL BIOL, V6, P2624, DOI 10.1128/MCB.6.7.2624; SHANI M, 1988, MOL CELL BIOL, V8, P1006, DOI 10.1128/MCB.8.2.1006; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; SUTHERLAND CJ, 1991, DEV BIOL, V146, P167, DOI 10.1016/0012-1606(91)90457-E; TAYLOR A, 1988, GENOMICS, V3, P323, DOI 10.1016/0888-7543(88)90123-1; VANDEKERCKHOVE J, 1979, DIFFERENTIATION, V14, P123, DOI 10.1111/j.1432-0436.1979.tb01021.x; WALSH K, 1988, MOL CELL BIOL, V8, P1800, DOI 10.1128/MCB.8.4.1800; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0	44	147	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					719	725						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678010				2022-12-25	WOS:A1993KE60300108
J	JULLIENFLORES, V; DORSEUIL, O; ROMERO, F; LETOURNEUR, F; SARAGOSTI, S; BERGER, R; TAVITIAN, A; GACON, G; CAMONIS, JH				JULLIENFLORES, V; DORSEUIL, O; ROMERO, F; LETOURNEUR, F; SARAGOSTI, S; BERGER, R; TAVITIAN, A; GACON, G; CAMONIS, JH			BRIDGING RAL GTPASE TO RHO-PATHWAYS - RLIP76, A RAL EFFECTOR WITH CDC42/RAC GTPASE-ACTIVATING PROTEIN ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCES; GENE	RalA and RalB are GTPases of unknown function and are activated by proteins, RalGDS, that interact with the active form of another GTPase, Pas. To elucidate Pal function, we have searched for proteins interacting with an activated-form of RalA using the two-hybrid method and a Jurkat cell library. We have identified a partial cDNA encoding a protein, RLIP1, which binds to activated RalA and this binding requires an intact effector domain of RalA. Biochemical data with purified RalA confirm the genetic results, This protein also bears a region of homology with GTPase-activating protein (GAP) domains that are involved in the regulation of GTPases of the Rho family and, indeed, RLIP1 displays a GAP activity acting upon Rad and CDC42, but not RhoA. This GAP region is not required for RLIP1 binding to Pal. The whole cDNA was cloned, and it encodes a 76-kDa polypeptide, RLIP76, which also binds RalA. The Rho pathway is involved in membrane and cytoskeleton modifications after mitogenic stimulation and acts in parallel to and synergistically with the Pas pathway, We propose that these pathways are linked through a cascade composed of Pas --> RalGDS --> Pal --> RLIP76 --> CDC42/Rac1/Rho, allowing modulation of the Rho pathway by the Pas pathway.	FAC MED LARIBOISIERE,INSERM,U248,F-75010 PARIS,FRANCE; INST COCHIN GENET MOLEC,INSERM,U257,F-75014 PARIS,FRANCE; INST COCHIN GENET MOLEC,INSERM,U363,F-75014 PARIS,FRANCE; INST GENET MOLEC,CNRS,SD 401301,F-75010 PARIS,FRANCE; INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Romero, Francisco/K-2101-2014	Romero, Francisco/0000-0002-9588-6881				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERIF D, 1990, P NATL ACAD SCI USA, V87, P6639, DOI 10.1073/pnas.87.17.6639; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FRECH M, 1990, J BIOL CHEM, V265, P6353; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GASPAR ML, 1991, P NATL ACAD SCI USA, V88, P8606, DOI 10.1073/pnas.88.19.8606; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; Kaiser C., 1994, METHODS YEAST GENETI; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J, 1989, MOL CLONING LABORATO; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; XU XM, 1994, J BIOL CHEM, V269, P23569	34	277	286	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22473	22477		10.1074/jbc.270.38.22473	http://dx.doi.org/10.1074/jbc.270.38.22473			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673236	hybrid			2022-12-25	WOS:A1995RW31400065
J	DAVIS, RE; HARDWICK, C; TAVERNIER, P; HODGSON, S; SINGH, H				DAVIS, RE; HARDWICK, C; TAVERNIER, P; HODGSON, S; SINGH, H			RNA TRANSSPLICING IN FLATWORMS - ANALYSIS OF TRANS-SPLICED MESSENGER-RNAS AND GENES IN THE HUMAN PARASITE, SCHISTOSOMA-MANSONI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; C-ELEGANS; CAENORHABDITIS-ELEGANS; TRYPANOSOMA-BRUCEI; TRIMETHYLGUANOSINE CAP; LEADER SEQUENCE; TRANSCRIPTS; INFORMATION; EXPRESSION; MATURE	Characteristics of trans-splicing in Schistosoma mansoni were examined to explore the significance and determinants of spliced leader (SL) addition in flatworms. Only a small subset of mRNAs acquire the SL. Analysis of 30 trans-spliced mRNAs and four genes revealed no discernable patterns or common characteristics in the genes, mRNAs, or their encoded proteins that might explain the functional significance of SL addition. While the mRNA encoding the glycolytic enzyme enolase is trans-spliced, mRNAs encoding four other glycolytic enzymes are not, indicating trans-splicing is not prevalent throughout this metabolic pathway. Although the 3' end of flatworm SLs contribute an AUG to mRNAs, the SL AUG does not typically serve to provide a methionine for translation initiation of reading frames in recipient mRNAs. SL RNA expression exhibits no apparent sex, tissue, or cell specificity. Trans-spliced genes undergo both cis- and trans-splicing, and the sequence contexts for these respective acceptor sites are very similar. These results suggest trans-splicing in flatworms is most Likely associated either with some property conferred on recipient mRNAs by SL addition or related to some characteristic of the primary transcripts or transcription of trans-spliced genes.	UNIV CALIF SAN FRANCISCO, DEPT BIOL, SAN FRANCISCO, CA 94132 USA; BETHEL COLL, DEPT CHEM, ST PAUL, MN 55112 USA	University of California System; University of California San Francisco					NIAID NIH HHS [AI 32709] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI032709] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGAHIAN N, 1990, CELL, V61, P1157; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BLUMENTHAL T, 1995, TRENDS GENET, V11, P132, DOI 10.1016/S0168-9525(00)89026-5; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BOOTHROYD JC, 1982, GENE, V20, P281, DOI 10.1016/0378-1119(82)90046-4; BUEDING E, 1950, J GEN PHYSIOL, V33, P475, DOI 10.1085/jgp.33.5.475; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; CONRAD R, 1993, NUCLEIC ACIDS RES, V21, P913, DOI 10.1093/nar/21.4.913; CONRAD R, 1993, EMBO J, V12, P1249, DOI 10.1002/j.1460-2075.1993.tb05766.x; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; CRAIG SP, 1989, NUCLEIC ACIDS RES, V17, P1635, DOI 10.1093/nar/17.4.1635; DAVIS RE, 1988, MOL CELL BIOL, V8, P4745, DOI 10.1128/MCB.8.11.4745; DAVIS RE, 1994, J BIOL CHEM, V269, P20026; Davis Richard E., 1995, MBL (Marine Biology Laboratory) Lectures in Biology, V12, P299; DOSREIS MG, 1993, MOL BIOCHEM PARASIT, V59, P235, DOI 10.1016/0166-6851(93)90221-I; EMMERT DB, 1994, NUCLEIC ACIDS RES, V22, P3445, DOI 10.1093/nar/22.17.3445; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HUANG J, 1991, MOL CELL BIOL, V11, P3180, DOI 10.1128/MCB.11.6.3180; Huang X Y, 1992, Genet Eng (N Y), V14, P211; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAIRD PW, 1987, EMBO J, V6, P1055, DOI 10.1002/j.1460-2075.1987.tb04858.x; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARONEY PA, 1990, P NATL ACAD SCI USA, V87, P709, DOI 10.1073/pnas.87.2.709; NILSEN TW, 1992, INFECT AGENT DIS, V1, P212; NILSEN TW, 1994, SCIENCE, V264, P1868, DOI 10.1126/science.7912006; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAFF RA, 1994, ANNU REV ECOL SYST, V25, P351, DOI 10.1146/annurev.es.25.110194.002031; RAJKOVIC A, 1989, P NATL ACAD SCI USA, V86, P8217, DOI 10.1073/pnas.86.21.8217; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; ROTHER RP, 1992, BIOTECHNIQUES, V13, P524; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; STURROCK SS, 1993, BIOCOMPUTING RES UNI; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; TIELENS AGM, 1994, PARASITOL TODAY, V10, P346, DOI 10.1016/0169-4758(94)90245-3; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; Tschudi Christian, 1995, MBL (Marine Biology Laboratory) Lectures in Biology, V12, P255; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P3591, DOI 10.1093/nar/10.12.3591; VANDOREN K, 1990, MOL CELL BIOL, V10, P1769, DOI 10.1128/MCB.10.4.1769; VANDOREN K, 1988, NATURE, V335, P556; WALDER JA, 1986, SCIENCE, V233, P569, DOI 10.1126/science.3523758; WILLMER P, 1980, INVERTEBRATE RELATIO; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	57	56	65	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21813	21819		10.1074/jbc.270.37.21813	http://dx.doi.org/10.1074/jbc.270.37.21813			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665603	hybrid			2022-12-25	WOS:A1995RU75700062
J	ROSS, LH; FREEDMAN, JH; RUBIN, CS				ROSS, LH; FREEDMAN, JH; RUBIN, CS			STRUCTURE AND EXPRESSION OF NOVEL SPLICED LEADER RNA GENES IN CAENORHABDITIS-ELEGANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; CASEIN KINASE-II; C-ELEGANS; MESSENGER-RNA; DEVELOPMENTAL REGULATION; TRIMETHYLGUANOSINE CAP; TRANSSPLICING INVITRO; SPLICEOSOMAL SNRNAS; SEQUENCE; CLONING	Approximately 25% of Caenorhabditis elegans genes are organized as operons. Polycistronic transcripts are converted to monocistronic mRNAs by 3' cleavage/polyadenylation and 5' trans-splicing with untranslated, 5'-terminal exons called spliced leaders, (SLs). The 5' termini of mRNAs encoded by downstream genes in operons are accepters for greater than or equal to 7 recently discovered ''novel'' SLs and a classical SL (SL2). Diversity in SL exons is now partly explained by the discovery and characterization of five novel genes that encode C. elegans SL RNAs. These novel SL RNAs contain a 22- or 23-nucleotide SL followed by conserved splice donor and downstream sequences that are essential for catalysis of trans-splicing reactions. The SL3 alpha, SL4, and SL5 RNA genes are tightly clustered on chromosome III; their 114-nucleotide transcripts deliver three distinct SLs to mRNAs. The SL3 beta and SL3 gamma RNA genes are on chromosome I, but are not tightly linked. SL RNAs 3 alpha, 3 beta, and 3 gamma provide identical 5' leader exons, although their 3' sequences diverge. Transcription of SL 3-5 RNA genes appears to be driven by flanking DNA elements that are homologous with segments of promoters for the C. elegans SL2 RNA and small nuclear RNA genes. RNase protection assays demonstrated that novel SL RNAs are transcribed in vivo and accumulate in the poly(A(-)) RNA pool. SL3 exons are transferred to mRNAs as frequently as SL2 exons. In contrast, SL4 is appended to mRNAs 10% as frequently as SL3. The abundance of SL4 RNA increased 6-fold during postembryonic development, and the SL4 RNA gene promoter is active principally in hypodermal cells.			ROSS, LH (corresponding author), ALBERT EINSTEIN COLL MED,ATRAN LABS,DEPT MOLEC PHARMACOL,BRONX,NY 10461, USA.				NIDDK NIH HHS [DK44597] Funding Source: Medline; NIGMS NIH HHS [GM7288] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK044597] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BEKTESH SL, 1988, NUCLEIC ACIDS RES, V16, P5692, DOI 10.1093/nar/16.12.5692; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CONRAD R, 1993, EMBO J, V12, P1249, DOI 10.1002/j.1460-2075.1993.tb05766.x; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; CUMMINS C, 1988, MOL CELL BIOL, V8, P5339, DOI 10.1128/MCB.8.12.5339; EMMONS SW, 1984, CELL, V36, P599, DOI 10.1016/0092-8674(84)90339-8; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HANNON GJ, 1992, SCIENCE, V258, P1775, DOI 10.1126/science.1465612; HANNON GJ, 1990, EMBO J, V9, P1915, DOI 10.1002/j.1460-2075.1990.tb08318.x; HANNON GJ, 1991, J BIOL CHEM, V266, P22792; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HU E, 1991, J BIOL CHEM, V266, P19796; HU ED, 1990, J BIOL CHEM, V265, P5072; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KUWABARA PE, 1992, MOL BIOL CELL, V3, P461, DOI 10.1091/mbc.3.4.461; LAND M, 1994, J BIOL CHEM, V269, P9234; LAND M, 1994, J BIOL CHEM, V269, P14820; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; MARONEY PA, 1991, EMBO J, V10, P3869, DOI 10.1002/j.1460-2075.1991.tb04956.x; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Moore M., 1993, RNA WORLD, P303; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; NILSEN TW, 1989, MOL CELL BIOL, V9, P3543, DOI 10.1128/MCB.9.8.3543; Patel Nipam H., 1992, P377; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PA, 1987, CELL, V50, P147, DOI 10.1016/0092-8674(87)90207-8; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; SUL HS, 1984, J BIOL CHEM, V259, P1201; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thein SI., 1986, HUMAN GENETIC DIS PR, P33; THOMAS J, 1990, NUCLEIC ACIDS RES, V18, P2633, DOI 10.1093/nar/18.9.2633; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; ULLU E, 1990, NUCLEIC ACIDS RES, V18, P3319, DOI 10.1093/nar/18.11.3319; VANDOREN K, 1990, MOL CELL BIOL, V10, P1769, DOI 10.1128/MCB.10.4.1769; VANDOREN K, 1988, NATURE, V335, P556; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0	53	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					22066	22075		10.1074/jbc.270.37.22066	http://dx.doi.org/10.1074/jbc.270.37.22066			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665629	hybrid			2022-12-25	WOS:A1995RU75700095
J	FOURNIER, E; DUBREUIL, P; BIRNBAUM, D; BORG, JP				FOURNIER, E; DUBREUIL, P; BIRNBAUM, D; BORG, JP			MUTATION AT TYROSINE RESIDUE-1337 ABROGATES LIGAND-DEPENDENT TRANSFORMING CAPACITY OF THE FLT4 RECEPTOR	ONCOGENE			English	Article						ENDOTHELIUM; FLT4; PHOSPHORYLATION; RECEPTOR; SH2 DOMAIN; SHC	ENDOTHELIAL GROWTH-FACTOR; SH3 DOMAINS; SIGNAL TRANSDUCTION; KINASE; EXPRESSION; CELLS; VEGF; MOLECULES; BINDING	In humans, the FLT4 gene encodes two isoforms of a tyrosine kinase receptor, which differ in their carboxy terminal regions. As compared to the short form, the long form has an additional stretch of 65 amino acids containing three tyrosine residues (Y1333, Y1337 and Y1363). Once expressed in fibroblast cells, only the long form is able to elicit both anchorage-independent growth in a soft agar assay and tumors in nude mice, and thus appears endowed,vith a potential ligand-dependent transforming capacity. Replacement of tyrosine 1337 by phenylalanine abrogates the transforming capacity of the long form. This residue was identified as a potential autophosphorylation site, and a docking site for a substrate important in the signal transduction specific of the long FLT4 isoform. We demonstrate that the GRB2 and SHC cytoplasmic substrates are involved in FLT4 signal transduction. SHC interaction could be crucial to FLT4-mediated transforming activity associated with the long isoform. Finally, trancripts for the two forms are detected in tissues positive for FLT4 gene expression.	INSERM, U119, ONCOL MOLEC LAB, F-13009 MARSEILLE, FRANCE; INSERM, U119, HEMATOL FONCTIONNELLE & MOLEC LAB, F-13009 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			dubreuil, patrice/F-5346-2011; Borg, Jean-Paul/AAX-8096-2020; Dubreuil, Patrice/V-4816-2019	dubreuil, patrice/0000-0003-1155-1150; Borg, Jean-Paul/0000-0001-8418-3382; Dubreuil, Patrice/0000-0003-1155-1150				APRELIKOVA O, 1992, CANCER RES, V52, P746; BARLEON B, 1994, J CELL BIOCHEM, V54, P56, DOI 10.1002/jcb.240540107; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORG JP, 1995, ONCOGENE, V10, P973; BORG JP, 1995, IN PRESS MOL ANAL MA; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BROWN LF, 1993, AM J PATHOL, V143, P1255; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CASTERAN N, 1994, CELL MOL BIOL, V40, P443; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; EICHMANN A, 1993, MECH DEVELOP, V42, P33, DOI 10.1016/0925-4773(93)90096-G; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FINNERTY H, 1993, ONCOGENE, V8, P2293; GALLAND F, 1993, ONCOGENE, V8, P1233; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; HATVA E, 1995, AM J PATHOL, V146, P368; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; PARK JE, 1994, J BIOL CHEM, V269, P25646; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TESSLER S, 1994, J BIOL CHEM, V269, P12456; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILKS AF, 1994, BIOESSAYS, V16, P313, DOI 10.1002/bies.950160505; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	52	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					921	931						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675451				2022-12-25	WOS:A1995RU79800013
J	ELLIS, JA; LUZIO, JP				ELLIS, JA; LUZIO, JP			IDENTIFICATION AND CHARACTERIZATION OF A NOVEL PROTEIN (P137) WHICH TRANSCYTOSES BIDIRECTIONALLY IN CACO-2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; CANINE KIDNEY-CELLS; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; PLASMA-MEMBRANE; EPITHELIAL-CELLS; MDCK CELLS; DIFFERENTIAL SOLUBILIZATION; PHASE-SEPARATION; GROWTH-FACTOR; TRANSPORT	Antisera raised against detergent-extracted membrane fractions from the human intestinal epithelial cell line Caco-2 were used to screen a human colon cDNA library in a bacteriophage expression vector. This led to the identification, molecular cloning, and sequencing of a novel plasma membrane protein (p137) which was present in approximately equal amounts on the basolateral and apical surfaces of the cell. The pattern of extraction of p137 from membranes by Triton X-114 and its release from membranes after incubation with phosphatidylinositol-specific phospholipase C were consistent with it being a glycosylphosphatidylinositol-anchored membrane protein. Using antibodies raised against bacterial fusion proteins, it was shown that p137 was present on the cell surface as a reducible homodimer of 137 kDa subunits. There was constitutive release of p137 into the culture medium as a non-reducible 280-kDa entity. Pulse-chase experiments showed that newly synthesized p137 appeared at the basolateral side of a Caco-2 cell layer before appearing at the apical domain. Domain-specific surface biotinylation of Caco-2 cells at 4 degrees C, followed by chasing at 37 degrees C, demonstrated that p137 is capable of transcytosing in both directions across Caco-2 cells. The unusual plasma membrane domain distribution of this glycosylphosphatidylinositol-linked protein and its transcytosis characteristics demonstrate the existence of a previously uncharacterized apical to basolateral transcytotic pathway in Caco-2 cells.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Eckhardt, Erik/G-1567-2010					ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; APODACA G, 1993, J BIOL CHEM, V268, P23712; BANTING G, 1989, FEBS LETT, V254, P171; BARTLES JR, 1988, TRENDS BIOCHEM SCI, V13, P181, DOI 10.1016/0968-0004(88)90147-8; BELL GI, 1993, HUM MOL GENET, V2, P1793; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRAKE B, 1990, BIOCHEM J, V267, P631, DOI 10.1042/bj2670631; BRANDLI AW, 1991, J BIOL CHEM, V266, P8560; BRANDLI AW, 1990, J CELL BIOL, V111, P2909, DOI 10.1083/jcb.111.6.2909; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAN N, 1994, J BIOL CHEM, V269, P18849; ELLIS JA, 1992, BIOCHEM J, V283, P553, DOI 10.1042/bj2830553; FOOD MR, 1994, J BIOL CHEM, V269, P3034; Fritz B. A., 1994, Molecular Biology of the Cell, V5, p71A; GILBRAT JF, 1987, J MOL BIOL, V198, P425; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HASTEWELL J, 1991, ADV DRUG DELIVER REV, V7, P119, DOI 10.1016/0169-409X(91)90050-M; HOOPER NM, 1991, BIOCHEM J, V280, P745, DOI 10.1042/bj2800745; HOOPER NM, 1991, BIOCHEM J, V273, P301, DOI 10.1042/bj2730301; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; Hopkins C.R., 1986, SITE SPECIFIC DRUG D, P27; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; HOWELL S, 1994, J BIOL CHEM, V269, P16993; HUGHSON EJ, 1990, J CELL BIOL, V110, P337, DOI 10.1083/jcb.110.2.337; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; JACKMAN MR, 1994, J CELL SCI, V107, P2547; JESSUP JM, 1988, CANCER RES, V48, P1689; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V304, P80; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LEBIVIC A, 1993, J BIOL CHEM, V268, P6909; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; LUZIO JP, 1995, GENE PROBES PRACTICA, V2, P77; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; METZ CN, 1994, EMBO J, V13, P1741, DOI 10.1002/j.1460-2075.1994.tb06438.x; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; NEAME SJ, 1993, J CELL BIOL, V121, P1299, DOI 10.1083/jcb.121.6.1299; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PEREZ JH, 1988, BIOCHEM J, V251, P763, DOI 10.1042/bj2510763; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; SCHELL MJ, 1992, J CELL BIOL, V119, P1173, DOI 10.1083/jcb.119.5.1173; SIMINOSKI K, 1986, J CELL BIOL, V103, P1979, DOI 10.1083/jcb.103.5.1979; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P551, DOI 10.1093/nar/12.1Part2.551; STADEN R, 1986, NUCLEIC ACIDS RES, V14, P217, DOI 10.1093/nar/14.1.217; SZTUL E, 1993, J BIOL CHEM, V268, P1876; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031	62	31	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20717	20723		10.1074/jbc.270.35.20717	http://dx.doi.org/10.1074/jbc.270.35.20717			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657653	hybrid			2022-12-25	WOS:A1995RR58400073
J	ESCHENBRENNER, M; COVES, J; FONTECAVE, M				ESCHENBRENNER, M; COVES, J; FONTECAVE, M			THE FLAVIN REDUCTASE-ACTIVITY OF THE FLAVOPROTEIN COMPONENT OF SULFITE REDUCTASE FROM ESCHERICHIA-COLI - A NEW MODEL FOR THE PROTEIN-STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE; RIBONUCLEOTIDE REDUCTASE; PROSTHETIC GROUPS; HEMOFLAVOPROTEIN; ENTEROBACTERIA; OXIDOREDUCTASE; SEQUENCE; PARAMETERS; GENERATION; IRON	Sulfite reductase (SiR) from Escherichia coli has a alpha(8) beta(4) subunit structure, where alpha(8) is a flavoprotein (SiR-FP) containing both FAD and FMN as prosthetic groups. It also exhibits a NADPH:flavin oxidoreductase activity with exogenous riboflavin, FMN, and FAD serving as substrates. The flavin reductase activity may function during activation of ribonucleotide reductase or during ferrisiderophore reduction. A plasmid containing cysJ gene, coding for the alpha subunit, overexpresses flavin reductase activity by 100-fold, showing that a is the site of free flavin reduction. The overproducer allows a fast and simple preparation of large amounts of the flavoprotein. Kinetic studies of its flavin reductase activity demonstrates a ping-pong bisubstrate-biproduct reaction mechanism. NADP(+) inhibition studies show that both substrates, NADPH and free flavins, bind to the same site. While the FAD cofactor mediates the electron transfer between NADPH and free flavins, the FMN cofactor is not essential since a FMN-depleted SiR-FP retains a large proportion of activity. In contradiction with previous reports, SiR-FP is found to contain 1.6-1.7 flavin per alpha subunit. This result, together with the sequence homology between SiR-FP and NADPH-cytochrome P-450 reductase, suggests a new model for the structure of the protein with one FMN and one FAD prosthetic group per a subunit.	UNIV GRENOBLE 1,ETUD DYNAM & STRUCT SELECT LAB,CNRS,URA 332,F-38041 GRENOBLE 9,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)								BEINERT H, 1960, ENZYMES, V2, P339; BRADFORD MM, 1970, ANAL BIOCHEM, V72, P248; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; COVES J, 1993, J BIOL CHEM, V268, P18604; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; COVES J, 1993, BIOCHEM BIOPH RES CO, V192, P1403, DOI 10.1006/bbrc.1993.1572; DIRUSSO CC, 1990, J BACTERIOL, V172, P6459, DOI 10.1128/jb.172.11.6459-6468.1990; FAEDER EJ, 1974, J BIOL CHEM, V249, P1599; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; FONTECAVE M, 1993, BIOMETALS, V7, P3; FRANKLUND CV, 1993, J BACTERIOL, V175, P3002, DOI 10.1128/JB.175.10.3002-3012.1993; JABLONSKI E, 1977, BIOCHEMISTRY-US, V16, P2932, DOI 10.1021/bi00632a020; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; SIEGEL LM, 1974, J BIOL CHEM, V249, P1587; SIEGEL LM, 1973, J BIOL CHEM, V248, P251; SIEGEL LM, 1974, J BIOL CHEM, V249, P1572; SIEGEL LM, 1971, FLAVINS FLAVOPROTEIN, P523; TANNER J, 1994, J MOL BIOL, V241, P283, DOI 10.1006/jmbi.1994.1501; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WHITBY LG, 1953, BIOCHEM J, V54, P437, DOI 10.1042/bj0540437; ZENNO S, 1994, J BACTERIOL, V176, P3544, DOI 10.1128/JB.176.12.3544-3551.1994	24	41	45	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20550	20555		10.1074/jbc.270.35.20550	http://dx.doi.org/10.1074/jbc.270.35.20550			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657631	hybrid			2022-12-25	WOS:A1995RR58400050
J	QUELLE, FW; THIERFELDER, W; WITTHUHN, BA; TANG, B; COHEN, S; IHLE, JN				QUELLE, FW; THIERFELDER, W; WITTHUHN, BA; TANG, B; COHEN, S; IHLE, JN			PHOSPHORYLATION AND ACTIVATION OF THE DNA-BINDING ACTIVITY OF PURIFIED STAT1 BY THE JANUS PROTEIN-TYROSINE KINASES AND THE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; MOUSE-LIVER	The activation of Janus protein-tyrosine kinases (Jaks) and the subsequent phosphorylation and activation of latent signal transducers and activators of transcription (Stats) are common elements in signal transduction through the cytokine receptor superfamily. To assess the role and specificity of Jaks in Stat activation, we have utilized baculovirus expression systems to produce Stat1 and the Jaks. Co-expression of Stat1 with Tyk2, Jak1, or Jak2 resulted in the specific tyrosine phosphorylation of Stat1 at Tyr(701), the residue phosphorylated in mammalian cells stimulated with interferon gamma. Alternatively, Stat1, purified to apparent homogeneity from insect cell extracts, was phosphorylated at Tyr(701) Jak immune complex kinase reactions. Phosphorylation of purified Stat1 was necessary and sufficient for the acquisition of DNA binding activity. The specificity in both systems was indicated by the inability of a Jak2 catalytically inactive mutant (Jak2-Glu(882)) or the Tec protein-tyrosine kinase to phosphorylate Stat1. However, immune complex purified epidermal growth factor receptor was capable of phosphorylating purified Stat1 at Tyr(701) and activating its DNA binding activity in in vitro reactions.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; UNIV TENNESSEE, SCH MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; Vanderbilt University; University of Tennessee System; University of Tennessee Health Science Center			witthuhn, bruce/GSE-3193-2022	Quelle, Frederick/0000-0002-1184-6170	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NIDDK NIH HHS [R01 DK/HL42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COHEN S, 1982, P NATL ACAD SCI-BIOL, V79, P6237, DOI 10.1073/pnas.79.20.6237; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; MANO H, 1990, ONCOGENE, V5, P1781; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	28	142	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20775	20780		10.1074/jbc.270.35.20775	http://dx.doi.org/10.1074/jbc.270.35.20775			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657660	hybrid			2022-12-25	WOS:A1995RR58400081
J	GUALBERTO, A; BALDWIN, AS				GUALBERTO, A; BALDWIN, AS			P53 AND SP1 INTERACT AND COOPERATE IN THE TUMOR NECROSIS FACTOR-INDUCED TRANSCRIPTIONAL ACTIVATION OF THE HIV-1 LONG TERMINAL REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NF-KAPPA-B; MONOCLONAL-ANTIBODIES; CELL-PROLIFERATION; EXPRESSION; PROMOTER; PROTEIN; GENE; LYMPHOCYTES; MODULATION; ELEMENT	Tumor necrosis factor alpha (TNF) is a potent activator of transcription directed by the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR). We have recently reported that the p53 tumor suppressor gene product binds to a site within the Spl binding region of the HIV-1 LTR and contributes to the TNF induction of this promoter. In this study Re show that the transcription factor Spl cooperates with p53 in the transcriptional activation directed by the HIV-1 LTR. The presence of Spl increased p53 binding to its recognition sequence in the HIV-1 LTR, and experiments in Drosophila cells show that Spl is necessary for full transactivation by mutant p53. Importantly, TNF induced the association between p53 and Spl in Jurkat T cells. These data demonstrate a synergistic role for these proteins in the mechanism of TNF induction of HIV-1 LTR-mediated transcription and suggest that Spl may play an important role in modulating certain functions of p53.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Gualberto, Antonio/0000-0002-6590-839X	NCI NIH HHS [CA52515] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035098, R37AI035098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AZIZKHAN J, 1994, CRIT REV EUCARYOTIC, V3, P229; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BISWAS P, 1992, J EXP MED, V176, P739, DOI 10.1084/jem.176.3.739; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEFFIE A, 1993, MOL CELL BIOL, V3, P3415; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; GARCIA JA, 1994, PROG NUCLEIC ACID RE, V49, P157; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUALBERTO A, 1995, MOL CELL BIOL, V15, P3450; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V60, P5100; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	34	98	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19680	19683		10.1074/jbc.270.34.19680	http://dx.doi.org/10.1074/jbc.270.34.19680			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649977	Green Published, hybrid			2022-12-25	WOS:A1995RQ99100004
J	TAKENAKA, IM; LEUNG, SM; MCANDREW, SJ; BROWN, JP; HIGHTOWER, LE				TAKENAKA, IM; LEUNG, SM; MCANDREW, SJ; BROWN, JP; HIGHTOWER, LE			HSC70-BINDING PEPTIDES SELECTED FROM A PHAGE DISPLAY PEPTIDE LIBRARY THAT RESEMBLE ORGANELLAR TARGETING SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; KARYOPHILIC PROTEINS; BINDING-SPECIFICITY; UNFOLDED PROTEINS; HSP70; LIGANDS; INVITRO; ATPASE; HSC70; FORM	A 15-mer phage display random peptide library was screened with purified bovine Hsc70, and nucleotide sequence analysis of the selected clones showed a large enrichment for peptides containing basic sequences with at least KR, RR, or RR, Binding affinity for Hsc70 of representative peptides increased dramatically for heptamers compared with hexamers, The peptide RIVRKKK, had the highest affinity for Hsc70, and substitution analyses showed that hydrophobic residues followed by basic residues play important roles in maintaining this affinity, In contrast, NIVRKKK was a weaker stimulator of the Hsc70 ATPase activity compared with pigeon cytochrome c peptide and FYQLALT, a peptide optimized for binding to Hsc70, FYQLALT effectively blocked the binding of NIVRKKK to Hsc70, possibly by causing a conformational change that masked Hsc70's binding site for the basic peptide, Two hypotheses are offered to explain the two different peptide motifs, First, it is proposed that Hsc70 recognizes two different amino acid sequence motifs in its dual roles of chaperoning proteins to organelles (NIVRKKK-like sequences) and facilitating protein folding (FYQLALT-like sequences), Second, the NIVRKKK motif may be used to bind certain folded proteins with which Hsc70 interacts, such as itself, p53, and Dnaj2.	UNIV CONNECTICUT,DEPT MOLEC & CELL BIOL,STORRS,CT 06269; PATHOGENESIS INC,SEATTLE,WA 98119	University of Connecticut	TAKENAKA, IM (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,POB 4000,PRINCETON,NJ 08543, USA.							BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GRAGEROV A, 1994, J MOL BIOL, V241, P133, DOI 10.1006/jmbi.1994.1482; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; KEIBLER M, 1993, CELL, V74, P483; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; NADLER SG, 1992, SCIENCE, V258, P484, DOI 10.1126/science.1411548; OH S, 1993, BIOCHIM BIOPHYS ACTA, V1174, P114, DOI 10.1016/0167-4781(93)90104-L; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; ROBERTS D, 1993, GENE, V128, P67, DOI 10.1016/0378-1119(93)90154-U; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCOTT JK, 1992, TRENDS BIOCHEM SCI, V17, P241, DOI 10.1016/0968-0004(92)90401-T; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WANG TF, 1993, J BIOL CHEM, V268, P26049	32	102	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19839	19844		10.1074/jbc.270.34.19839	http://dx.doi.org/10.1074/jbc.270.34.19839			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649995	hybrid			2022-12-25	WOS:A1995RQ99100027
J	TECTOR, M; SALTER, RD				TECTOR, M; SALTER, RD			CALNEXIN INFLUENCES FOLDING OF HUMAN CLASS-I HISTOCOMPATIBILITY PROTEINS BUT NOT THEIR ASSEMBLY WITH BETA(2)-MICROGLOBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; ANTIGEN; MOLECULES; BETA-2-MICROGLOBULIN; PEPTIDE	Class I major histocompatibility complex heavy chains bind to calnexin before associating with beta(2)-microglobulin (beta(2)m) and peptides. Calnexin has been shown to retain in the endoplasmic reticulum those class I heavy chains which have not assembled properly and, thus, to serve as a quality control mechanism. In addition, calnexin may direct the folding of class I subunits or their subsequent assembly. We asked whether calnegin plays a role in the initial folding of HLA-B*0702 heavy chains by assessing disulfide bond formation in vivo. Our results show that class I heavy chains form intrachain disulfide bonds very soon after translation, and that calnexin is bound to both reduced and oxidized forms during this process. When a cell-permeable reducing agent, dithiothreitol, was added to cells, disulfide bond formation in newly synthesized heavy chains was substantially blocked, as was their association with calnexin. The reducing agent appeared to affect calnexin directly, since binding was similarly abolished to a subset of proteins which do not contain internal disulfide bonds. Addition of the glucosidase inhibitor castanospermine to cells, shown previously to disrupt calnexin binding to ligands, slowed formation of disulfide bonds but did not decrease the amount of assembled heavy chain-beta(2)m complexes that formed. Our data suggest that calnexin can promote disulfide bond formation in class I heavy chains but does not directly facilitate subsequent binding to beta(2)m.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Salter, Russell/0000-0003-4553-2986				ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ARUNACHALAM B, 1994, INT IMMUNOL, V6, P439, DOI 10.1093/intimm/6.3.439; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; LAMB CA, 1992, J IMMUNOL, V148, P3478; LE AQ, 1994, J BIOL CHEM, V269, P7514; LOO TW, 1994, J BIOL CHEM, V269, P28683; MIYAZAKI JI, 1986, P NATL ACAD SCI USA, V83, P757, DOI 10.1073/pnas.83.3.757; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MOORE SEH, 1993, J BIOL CHEM, V268, P3809; NEEFJES JJ, 1986, IMMUNOGENETICS, V23, P164, DOI 10.1007/BF00373817; NOBNER E, 1994, J EXP MED, V181, P3257; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; PARHAM P, 1979, J IMMUNOL, V123, P343; PIND S, 1995, J BIOL CHEM, V269, P2784; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; RIBAUDO RK, 1992, J IMMUNOL, V149, P2935; SAWYER JT, 1994, J BIOL CHEM, V269, P22440; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; TRAPANI JA, 1989, IMMUNOGENETICS, V29, P25, DOI 10.1007/BF02341610; WADA I, 1994, J BIOL CHEM, V269, P7464; WANG H, 1994, J BIOL CHEM, V269, P22276; WARBURTON RJ, 1994, HUM IMMUNOL, V34, P261; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WQU WJ, 1993, NATURE, V364, P771; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	38	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19638	19642		10.1074/jbc.270.33.19638	http://dx.doi.org/10.1074/jbc.270.33.19638			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642652	hybrid			2022-12-25	WOS:A1995RP70300068
J	MAYOL, X; GARRIGA, J; GRANA, X				MAYOL, X; GARRIGA, J; GRANA, X			CELL CYCLE-DEPENDENT PHOSPHORYLATION OF THE RETINOBLASTOMA-RELATED PROTEIN P130	ONCOGENE			English	Article						P130; RETINOBLASTOMA PROTEIN; CELL CYCLE; PHOSPHORYLATION; T98G CELLS; CYCLINS; CDKS	GENE-PRODUCT; INHIBITION; P107; E2F; TRANSACTIVATION; BINDING; CLONING; MEMBER; FAMILY	The retinoblastoma-related protein p130 is a putative negative regulator of cell proliferation in mammalian cells. In this study, p130 is exist in multiple phosphorylated forms in human cells. In glioblastoma T98G cells synchronized by serum deprivation, specific phosphorylated forms of p130 are found at different times after serum re-stimulation. Two phosphorylated forms of p130 only found in serum-arrested T98G cells and in early G(1) phase associate with the adenovirus oncoprotein E1A in vitro. One of these two forms corresponds to the in vivo E1A-associated p130 in 293 cells, which express endogenous E1A protein. Moreover, p130 undergoes an abrupt shift to a unique phosphorylated form in mid G(1) which is the only p130 form found during the remaining phases of the cell cycle. This phosphorylated form possesses an associated histone H1 kinase activity that is most active in late S phase and G(2)/M. The cell cycle-dependent expression pattern of cyclins in T98G cells is compatible with cyclin D1/CDK complexes driving the shift to this phosphorylated p130 form in mid G(1). These results suggest that the putative growth inhibitory function of p130 is regulated by phosphorylation of this protein. They also suggest that differential phosphorylation of p130 during the cell cycle plays distinct roles in the regulation of p130 function.			MAYOL, X (corresponding author), TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,3307 N BROAD ST,PHILADELPHIA,PA 19140, USA.		Mayol, Xavier/C-1391-2012	Mayol, Xavier/0000-0001-7288-195X; Grana, Xavier/0000-0001-7134-0473				ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GRANA X, 1995, ONCOGENE, V11, P211; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1988, ANTIBODIES LABORATOR; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HERMANN CH, 1991, J VIROL, V65, P5848; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; KITAGAWA M, 1995, ONCOGENE, V10, P229; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MAYOL X, 1993, ONCOGENE, V8, P2561; NEVINS JR, 1994, CURR OPIN GENE DEV, V4, P1130; PEEPER DS, 1995, ONCOGENE, V10, P39; POLLACK IF, 1990, J NEUROSURG, V73, P106, DOI 10.3171/jns.1990.73.1.0106; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	40	135	136	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					801	808						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651744				2022-12-25	WOS:A1995RQ46900024
J	KAECH, S; SCHNIERLE, B; WYSS, A; BALLMERHOFER, K				KAECH, S; SCHNIERLE, B; WYSS, A; BALLMERHOFER, K			MYRISTYLATION AND AMINO-TERMINAL PHOSPHORYLATION ARE REQUIRED FOR ACTIVATION OF PP60(C-SRC) DURING MITOSIS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; CYANOGEN-BROMIDE CLEAVAGE; MIDDLE-T-ANTIGEN; SRC FAMILY; MONOCLONAL-ANTIBODIES; LYMPHOCYTES-T; PP60C-SRC; P60C-SRC; RECEPTOR; MUTATION	pp60c-src, a cellular tyrosine kinase homologous to the retroviral v-src oncogene, becomes transiently activated during mitosis. Activation is accompanied by phosphorylation of three sites in the amino-terminal regulatory domain of the protein, threonine 34, threonine 46 and serine 72. These sites can be phosphorylated in vitro by a cell cycle-regulated kinase, p34cdc2, yet this does not result in increased kinase activity of pp60c-src. pp60c-src is negatively regulated by phosphorylation at tyrosine 527, and it has been shown that this site is transiently dephosphorylated in mitotic cells. The importance of tyrosine 527 in the regulation of pp60c-src is also emphasized by the fact that oncogenic mutants of pp60src lacking tyrosine 527 are constitutively active during the entire cell cycle. Here we report that a non-myristylated mutant of pp60c-src is not activated and only partially phosphorylated at the amino terminus in mitotic cells. Additional mutants lacking one (TTAc-src), two (AASc-src) and three (AAAc-src) cdc2 phosphorylation sites had slightly higher kinase activity than wild-type pp60c-src in interphase cells and were not activated during mitosis. However, all four mutant proteins were still transiently dephosphorylated at tyrosine 527 during mitosis, suggesting that myristylation and amino-terminal phosphorylation may be necessary but are clearly not sufficient for mitosis-specific activation.	FRIEDRICH MIESCHER INST, BOX 2543, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research			Schnierle, Barbara/AAG-8108-2019	Kaech Petrie, Stefanie/0000-0002-6246-6434; Ballmer-Hofer, Kurt/0000-0002-3800-9129				BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1990, PEPTIDES PROTEIN PHO, P86; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; EISEMAN E, 1992, NATURE, V355, P78; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUO K, 1990, ONCOGENE, V5, P921; LUO KX, 1991, METHOD ENZYMOL, V201, P149; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MUSTELIN T, 1990, ONCOGENE, V5, P809; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OKADA M, 1988, BIOCHEM BIOPH RES CO, V154, P796, DOI 10.1016/0006-291X(88)90210-0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PARTANEN J, 1991, ONCOGENE, V6, P2013; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shaw A, 1991, CURR OPIN CELL BIOL, V3, P862, DOI 10.1016/0955-0674(91)90061-3; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WYSS A, 1990, J VIROL, V64, P5163, DOI 10.1128/JVI.64.10.5163-5166.1990; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453	45	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					575	581						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	7679790				2022-12-25	WOS:A1993KN00800007
J	WANG, SK; WANG, XB; DENG, LP; RASSART, E; MILNE, RW; TALL, AR				WANG, SK; WANG, XB; DENG, LP; RASSART, E; MILNE, RW; TALL, AR			POINT MUTAGENESIS OF CARBOXYL-TERMINAL AMINO-ACIDS OF CHOLESTERYL ESTER TRANSFER PROTEIN - OPPOSITE FACES OF AN AMPHIPATHIC HELIX IMPORTANT FOR CHOLESTERYL ESTER TRANSFER OR FOR BINDING NEUTRALIZING ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; HUMAN-PLASMA	The cholesteryl ester transfer protein (CETP) mediates the transfer of neutral lipids between the plasma lipoproteins. A carboxyl-terminal sequence of CETP was recently shown to form the epitope of a neutralizing monoclonal antibody (TP2) and to be necessary for neutral lipid transfer activity. To determine the role of specific amino acids in the epitope and/or in lipid transfer activity, we made single amino acid substitution mutants between Pro446 and Ser476 by in vitro mutagenesis and expressed the mutants in mammalian cells. The binding of TP2 to CETP was abolished by mutations primarily of polar or charged amino acids that occurred periodically within the sequence between His466 and Leu475 and at amino acid Asp460; however, these mutants had well preserved cholesteryl ester (CE) transfer activity. By contrast, mutants of bulky hydrophobic amino acids in this region (particularly Leu475, Phe471, Leu468, Phe461, and Phe454) showed markedly decreased CE transfer specific activity, but essentially normal binding of TP2. The paradoxical effects on antibody binding and activity could be explained if amino acids determining monoclonal antibody binding and activity are disposed on opposite faces of an amphipathic helix between amino acids 465 and 476. This model was tested by substituting alanine residues for pairs of nonpolar amino acids which would be contiguous on a helix, resulting in low activity mutants equivalent to those produced by deletion of this region. We conclude that the hydrophobic face of a carboxyl-terminal helix of CETP is directly involved in the mechanism of CE transfer, and that TP2 inhibits activity by local sterical hindrance. The general hydrophobic character of this region, imparted by the bulky hydrophobic amino acids Leu and Phe, is important for normal CE transfer.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,DIV MOLEC MED,630 W 168TH ST,NEW YORK,NY 10032; CLIN RES INST MONTREAL,MONTREAL H2W 1R7,QUEBEC,CANADA; UNIV QUEBEC,DEPT SCI BIOL,MONTREAL H3C 3P8,QUEBEC,CANADA	Columbia University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Quebec; University of Quebec Montreal			Tall, Alan/AAT-8528-2021		NCI NIH HHS [MRCPG-27] Funding Source: Medline; NHLBI NIH HHS [HL22682] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022682, R01HL022682] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BRASSEUR R, 1991, J BIOL CHEM, V266, P16120; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GLOMSET JA, 1968, J LIPID RES, V9, P155; HESLER CB, 1988, J BIOL CHEM, V263, P5020; HESLER CB, 1987, J BIOL CHEM, V262, P2275; HODGES RS, 1988, J BIOL CHEM, V263, P11768; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORTON RE, 1982, J LIPID RES, V23, P1058; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; SAMMETT D, 1985, J BIOL CHEM, V260, P6687; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCHECHTER I, 1971, EUR J BIOCHEM, V18, P21; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SWENSON TL, 1988, J BIOL CHEM, V263, P5150; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; WANG S, 1992, J BIOL CHEM, V267, P17487; WANG S, 1991, BIOCHEMISTRY-US, V30, P3484, DOI 10.1021/bi00228a019; WANG XB, 1989, DNA-J MOLEC CELL BIO, V8, P753, DOI 10.1089/dna.1989.8.753; YOUNG JA, 1992, P NATL ACAD SCI USA, V89, P4094	27	58	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1955	1959						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678413				2022-12-25	WOS:A1993KH62000070
J	MINNING, DM; KLOEK, AP; YANG, J; MATHEWS, FS; GOLDBERG, DE				MINNING, DM; KLOEK, AP; YANG, J; MATHEWS, FS; GOLDBERG, DE			SUBUNIT INTERACTIONS IN ASCARIS HEMOGLOBIN OCTAMER FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUUM; SEQUENCE	The oxygen-avid, perienteric hemoglobin of Ascaris is a homooctamer. Each subunit contains two tandem globin domains that are highly homologous with the exception of a charged COOH-terminal extension, In solution, recombinant domain one (Hi) exists as a monomer, whereas recombinant domain two with the COOH-terminal tail (D2) is primarily an octamer, To examine the role of the COOH-terminal extension in Ascaris hemoglobin multimer formation, we attached the tail to the monomeric, heme-containing proteins, myoglobin and D1; neither construct was capable of multimer formation. Additionally, we removed the tail from both full-length Ascaris hemoglobin and D2. This substantially decreased, but did not eliminate, multimerization, We further characterized subunit interactions by disrupting full-length hemoglobin multimers with the chaotropic salt, NaSCN, which yielded intermediate oligomers, In solution, D2 demonstrated a greater propensity to dissociate than full-length hemoglobin, indicating that D1 contributes to octamer stability, D1 formed a weak dimer in its crystal; thus, we analyzed interactions along the subunit interface, Hydrogen bonds as well as hydrophobic and electrostatic forces appeared to contribute to dimer formation, Amino acid substitutions along this interface in D2 are predicted to enhance subunit interactions for that domain, Our studies reveal that the COOH-terminal tail is necessary, but not sufficient, for efficient octamer formation. Other regions, possibly within the E- and F-helices and AB loops of both domains, appear to be important for Ascaris hemoglobin octamer formation.	WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DARAWSHE S, 1987, BIOCHEM J, V242, P689, DOI 10.1042/bj2420689; DARAWSHE S, 1991, EUR J BIOCHEM, V201, P169, DOI 10.1111/j.1432-1033.1991.tb16270.x; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P255, DOI 10.1098/rspb.1949.0024; DEBAERE I, 1992, P NATL ACAD SCI USA, V89, P4638, DOI 10.1073/pnas.89.10.4638; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; KLOEK AP, 1993, J BIOL CHEM, V268, P17669; MORRISON HG, 1993, BIOTECHNIQUES, V14, P454; PERUTZ MF, 1993, CURR BIOL, V3, P249, DOI 10.1016/0960-9822(93)90174-M; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224	12	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22248	22253		10.1074/jbc.270.38.22248	http://dx.doi.org/10.1074/jbc.270.38.22248			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673204	hybrid			2022-12-25	WOS:A1995RW31400030
J	SUGUMARAN, G; KATSMAN, M; DRAKE, RR				SUGUMARAN, G; KATSMAN, M; DRAKE, RR			PURIFICATION, PHOTOAFFINITY-LABELING, AND CHARACTERIZATION OF A SINGLE ENZYME FOR 6-SULFATION OF BOTH CHONDROITIN SULFATE AND KERATAN SULFATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSAMINOGLYCAN SULFOTRANSFERASE ACTIVITIES; CHICK-EMBRYO CHONDROCYTES; MOUSE MASTOCYTOMA-CELLS; ANIMAL SERA; 6-SULFOTRANSFERASE; BIOSYNTHESIS; CARTILAGE; 4-SULFATE; 4-SULFOTRANSFERASE; PROTEOCHONDROITIN	A soluble sulfotransferase that could 6-sulfate both chondroitin sulfate and corneal keratan sulfate was purified 27,500-fold using a sequence of affinity chromatographic steps with heparin-Sepharose, wheat germ agglutinin-agarose, and 3',5'-ADP-agarose. The essentially pure enzyme had a specific activity 40 times greater than the most purified chondroitin 6-sulfotransferase previously reported and exhibited a single sharp Coomassie Blue-stained and a heavy silver-stained protein band of 75 kDa on SDS-polyacrylamide gel electrophoresis, Chromatography of the purified enzyme on Sephacryl demonstrated a size of 150 kDa, which indicated that the native enzyme exists as a dimer, In addition to B-sulfation of nonsulfated GalNAc, the purified serum enzyme had the ability to sulfate GalNAc 4-sulfate residues to give GalNAc 4,6-disulfate residues, The purified enzyme exhibited a K-m of 40 mu M for adenosine 3'-phosphate 5'-phosphosulfate when either chondroitin sulfate or corneal keratan sulfate were used as the accepters. Use of both chondroitin sulfate and keratan sulfate in the same experiment demonstrated mutual competition, establishing that the sulfation of these substrates is by the same enzyme, Photoaffinity labeling of the purified enzyme with 2-azidoadenosine 3',5'-di[5'-P-32]phosphate occurred only with the 75-kDa protein, confirming that this is the chondroitin 6-sulfotransferase/keratan sulfotransferase.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, BOSTON, MA 02115 USA; UNIV ARKANSAS MED SCI HOSP, DEPT BIOCHEM & MOLEC BIOL, LITTLE ROCK, AR 72205 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Arkansas System; University of Arkansas Medical Sciences	SUGUMARAN, G (corresponding author), EDITH NOURSE ROGERS MEM VET ADM HOSP, BLDG 70, 200 SPRINGS RD, BEDFORD, MA 01730 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041649] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-41649] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRANDAN E, 1988, J BIOL CHEM, V263, P2417; DELUCA S, 1968, J BIOL CHEM, V243, P2725; FALTYNEK CR, 1978, J BIOL CHEM, V253, P7646; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HABUCHI O, 1971, J BIOL CHEM, V246, P7357; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HABUCHI O, 1982, BIOCHIM BIOPHYS ACTA, V717, P414, DOI 10.1016/0304-4165(82)90282-3; HABUCHI O, 1985, J BIOL CHEM, V260, P3102; HABUCHI O, 1991, BIOCHIM BIOPHYS ACTA, V1133, P9; INOUE H, 1986, J BIOL CHEM, V261, P4470; INOUE H, 1986, J BIOL CHEM, V261, P4460; KELLER R, 1983, H-S Z PHYSIOL CHEM, V364, P239, DOI 10.1515/bchm2.1983.364.1.239; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; MALMSTRO.A, 1971, EUR J BIOCHEM, V18, P431, DOI 10.1111/j.1432-1033.1971.tb01260.x; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; MOMBURG M, 1972, H-S Z PHYSIOL CHEM, V353, P1351, DOI 10.1515/bchm2.1972.353.2.1351; MOURAO PAS, 1983, MOL CELL BIOCHEM, V60, P49; NAKANISHI Y, 1981, J BIOL CHEM, V256, P5443; NAKAZAWA K, 1975, J BIOL CHEM, V250, P912; OTTERNESS DM, 1991, MOL PHARMACOL, V39, P34; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RADOMINSKA A, 1994, METHOD ENZYMOL, V230, P330; RUTER ER, 1984, J BIOL CHEM, V259, P1771; SAITO H, 1968, J BIOL CHEM, V243, P1536; SHAKLEE PN, 1986, BIOCHEM J, V235, P225, DOI 10.1042/bj2350225; SILBERT JE, 1980, BIOCHEM J, V190, P307, DOI 10.1042/bj1900307; SUGAHARA K, 1989, J BIOCHEM-TOKYO, V106, P910, DOI 10.1093/oxfordjournals.jbchem.a122951; SUGAHARA K, 1987, ANAL BIOCHEM, V166, P404, DOI 10.1016/0003-2697(87)90591-4; SUGAHARA K, 1987, ARCH BIOCHEM BIOPHYS, V258, P391, DOI 10.1016/0003-9861(87)90360-2; SUGUMARAN G, 1991, J BIOL CHEM, V266, P9565; SUGUMARAN G, 1986, J BIOL CHEM, V261, P2659; SUGUMARAN G, 1990, J BIOL CHEM, V265, P18284; SUGUMARAN G, 1989, METHOD ENZYMOL, V179, P422; SUZUKI S, 1968, J BIOL CHEM, V243, P1543; SYLVERS LA, 1989, FEBS LETT, V245, P9, DOI 10.1016/0014-5793(89)80180-2; WLAD H, 1994, J BIOL CHEM, V269, P24538	36	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22483	22487		10.1074/jbc.270.38.22483	http://dx.doi.org/10.1074/jbc.270.38.22483			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673238	hybrid			2022-12-25	WOS:A1995RW31400067
J	ASAHI, M; FUJII, J; SUZUKI, K; SEO, HG; KUZUYA, T; HORI, M; TADA, M; FUJII, S; TANIGUCHI, N				ASAHI, M; FUJII, J; SUZUKI, K; SEO, HG; KUZUYA, T; HORI, M; TADA, M; FUJII, S; TANIGUCHI, N			INACTIVATION OF GLUTATHIONE-PEROXIDASE BY NITRIC-OXIDE - IMPLICATION FOR CYTOTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENT RAT-LIVER; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ADP-RIBOSYLATION; S-NITROSYLATION; APOPTOSIS; DEATH	S-nitro-N-acetyl-DL-penicillamine (SNAP), a nitric oxide (NO) donor, inactivated bovine glutathione peroxidase (GPx) in a dose- and time-dependent manner. The IC50 of SNAP for GPx was 2 mu M at 1 h of incubation and was 20% of the IC50 for another thiol enzyme, glyceraldehyde-3-phosphate dehydrogenase, in which a specific cysteine residue is known to be nitrosylated, Incubation of the inactivated GPx with 5 mM dithiothreitol within 1 h restored about 50% of activity of the start of the SNAP incubation. A longer exposure to NO donors, however, irreversibly inactivated the enzyme, The similarity of the inactivation with SNAP and reactivation with dithiothreitol of GPx to that of glyceraldehyde-3-phosphate dehydrogenase, suggested that NO released from SNAP modified a cysteine-like essential residue on GPx, When U937 cells were incubated with 100 mu M SNAP for 1 h, a significant decrease in GPx activity was observed although the change was less dramatic than that with the purified enzyme, and intracellular peroxide levels increased as judged by flow cytometric analysis using a peroxide-sensitive dye, Other major antioxidative enzymes, copper/zinc superoxide dismutase, manganese superoxide dismutase, and catalase, were not affected by SNAP, which suggested that the increased accumulation of peroxides in SNAP-treated cells was due to inhibition of GPx activity by NO. Moreover, stimulation with lipopolysaccharide significantly decreased intracellular GPx activity in RAW 264.7 cells, and this effect was blocked by NO synthase inhibitor N-omega-methyl-L-arginine. This indicated that GPx was also inactivated by endogenous NO, This mechanism may at least in part explain the cytotoxic effects of NO on cells and NO-induced apoptotic cell death.	OSAKA UNIV, SCH MED, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT INTERNAL MED 1, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT PATHOPHYSIOL, SUITA, OSAKA 565, JAPAN; KANSAI MED UNIV, CHEM LAB, HIRAKATA, OSAKA 573, JAPAN	Osaka University; Osaka University; Osaka University; Kansai Medical University			Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				Aebi H., 1974, METHODS ENZYMATIC AN, P673, DOI [10.1016/B978-0-12-091302-2.50032-3, DOI 10.1016/B978-0-12-091302-2.50032-3]; AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; ALBINA JE, 1993, J IMMUNOL, V150, P5080; AMSTAD P, 1994, J BIOL CHEM, V269, P1606; BASS DA, 1983, J IMMUNOL, V130, P1910; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; KORSMEYER SJ, 1992, BLOOD, V80, P879; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Matsuda Y, 1991, Protein Expr Purif, V2, P170, DOI 10.1016/1046-5928(91)90067-S; MONCADA S, 1991, PHARMACOL REV, V43, P109; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SANDSTROM PA, 1994, J BIOL CHEM, V269, P798; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOUTHAM E, 1991, NEUROSCI LETT, V130, P107, DOI 10.1016/0304-3940(91)90239-P; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SUEMIZU H, 1992, HYBRIDOMA, V11, P795, DOI 10.1089/hyb.1992.11.795; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; YOSHIMURA S, 1988, BIOCHEM BIOPH RES CO, V154, P1024, DOI 10.1016/0006-291X(88)90242-2; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382	31	276	285	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21035	21039		10.1074/jbc.270.36.21035	http://dx.doi.org/10.1074/jbc.270.36.21035			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673130	hybrid			2022-12-25	WOS:A1995RU05400027
J	FIRE, E; GUTMAN, O; ROTH, MG; HENIS, YI				FIRE, E; GUTMAN, O; ROTH, MG; HENIS, YI			DYNAMIC OR STABLE INTERACTIONS OF INFLUENZA HEMAGGLUTININ MUTANTS WITH COATED PITS - DEPENDENCE ON THE INTERNALIZATION SIGNAL BUT NOT ON AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE PHOTOBLEACHING RECOVERY; RECEPTOR-MEDIATED ENDOCYTOSIS; MEMBRANE-PROTEIN TRAFFICKING; LYSOSOMAL ACID-PHOSPHATASE; LOW-DENSITY LIPOPROTEIN; CYTOPLASMIC DOMAIN; VIRUS HEMAGGLUTININ; ASIALOGLYCOPROTEIN RECEPTOR; LATERAL MOBILITY; INVITRO BINDING	Measurements of the lateral mobility of native and mutated membrane proteins, combined with treatments that alter clathrin lattice structure, are capable of characterizing their interactions with coated pits in live cells (Fire, E., Zwart, D. E., Roth, M. G., and Henis, Y. I. (1991) J. Cell Biol. 115, 1585-1594). To explore the dependence of these interactions on the internalization signal and the aggregation state of the protein, we have extended this approach to investigate the interactions between coated pits and several influenza hemagglutinin (HA) mutants, which differ in the internalization signals in their short cytoplasmic tails. The lack of internalization signals in the trimeric wild-type HA enables a direct comparison between specific internalization signals introduced singly in each mutant. We have selected for these studies HA mutants that showed different internalization rates and varied in their tendency to aggregate into complexes larger than trimers. Our results indicate that the mode of interaction with coated pits (transient association-dissociation versus stable entrapment) depends on the internalization signal and affects the internalization efficiency. Mutants that contain a strong internalization signal and undergo fast endocytosis were entrapped in coated pits for the entire duration of the lateral mobility measurement, suggesting stable association with (slow dissociation from) coated pits. A mutant with a suboptimal internalization signal, which was internalized 10-fold slower, exhibited transient interactions with coated pits. Both types of interactions disappeared or were significantly reduced upon disruption of the clathrin lattices under hypertonic conditions, and were modulated following the ''freezing'' of coated pits by cytosol acidification. Unlike the dependence on the cytoplasmic internalization signal, the interactions with coated pits did not depend on the aggregation state (measured by sucrose gradient centrifugation after solubilization in n-octylglucoside) of the mutants.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL; UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA	Tel Aviv University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Roth, Michael/0000-0002-9056-332X; Henis, Yoav/0000-0002-1408-3877	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARAK LS, 1981, J CELL BIOL, V90, P595, DOI 10.1083/jcb.90.3.595; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BRANDTZAEG P, 1973, SCAND J IMMUNOL, V2, P273, DOI 10.1111/j.1365-3083.1973.tb02037.x; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DOYLE C, 1985, J CELL BIOL, V100, P704, DOI 10.1083/jcb.100.3.704; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; ELSON EL, 1979, J SUPRAMOL STR CELL, V12, P481, DOI 10.1002/jss.400120408; FIRE E, 1991, J CELL BIOL, V115, P1585, DOI 10.1083/jcb.115.6.1585; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; HENIS YI, 1985, EXP CELL RES, V160, P514, DOI 10.1016/0014-4827(85)90198-3; HENIS YI, 1983, BIOCHIM BIOPHYS ACTA, V762, P281, DOI 10.1016/0167-4889(83)90082-4; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KATZIR Z, 1994, J BIOL CHEM, V269, P21568; KOPPEL DE, 1976, BIOPHYS J, V16, P1315, DOI 10.1016/S0006-3495(76)85776-1; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LAZAROVITS J, 1990, J BIOL CHEM, V265, P4760; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; NAIM HY, 1993, J VIROL, V67, P4831, DOI 10.1128/JVI.67.8.4831-4841.1993; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; PEARSE BMF, 1987, ANNU REV BIOPHYS BIO, V16, P49, DOI 10.1146/annurev.bb.16.060187.000405; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PETERSEN NO, 1986, HDB EXPT IMMUNOLOGY; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; ROTH MG, 1993, ENDOSOMES LYSOSOMES, P19; SAFFMAN PG, 1975, P NATL ACAD SCI USA, V72, P3111, DOI 10.1073/pnas.72.8.3111; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ZWART DE, 1995, IN PRESS J BIOL CHEM	48	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21075	21081		10.1074/jbc.270.36.21075	http://dx.doi.org/10.1074/jbc.270.36.21075			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673136	hybrid			2022-12-25	WOS:A1995RU05400034
J	SCHWARZMANN, G; HOFMANN, P; PUTZ, T; ALBRECHT, B				SCHWARZMANN, G; HOFMANN, P; PUTZ, T; ALBRECHT, B			DEMONSTRATION OF DIRECT GLYCOSYLATION OF NONDEGRADABLE GLUCOSYLCERAMIDE ANALOGS IN CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAUCHER DISEASE; INTRACELLULAR-TRANSPORT; ACTIVATOR PROTEIN; HUMAN-FIBROBLASTS; PURIFICATION; GLYCOSPHINGOLIPIDS; GLUCOCEREBROSIDASE; GANGLIOSIDES; BIOSYNTHESIS; DEGRADATION	After uptake by various cells (human skin fibroblasts, rat neuroblastoma B 104, human neuroblastoma SHSY5Y, murine cerebellar cells), a radioactive and a fluorescent analog of a nondegradable glucosylceramide with sulfur in the glycosidic link were glycosylated to a cell-specific pattern of glycolipid analogs, These results, for the first time, show that a glucosylceramide analog can be conveyed from the plasma membrane of cultured cells to those Golgi compartments that function in the early glycosylation steps of glycolipids, This observation is further confirmed by the fact that the cationic ionophore monensin, known to impede membrane flow from proximal to distal Golgi cisternae, inhibited the formation of complex ganglioside analogs but not those of lactosylceramide, sialyl lactosylceramide (G(M3)), and disialyl lactosylceramide (G(D3)).			SCHWARZMANN, G (corresponding author), UNIV BONN,INST ORGAN CHEM & BIOCHEM,GERHARD DOMAGK STR 1,D-53121 BONN,GERMANY.							AERTS JMFG, 1985, EUR J BIOCHEM, V150, P565, DOI 10.1111/j.1432-1033.1985.tb09058.x; ALBRECHT B, 1995, IN PRESS CARBOHYDR R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; CONZELMANN E, 1982, EUR J BIOCHEM, V123, P455, DOI 10.1111/j.1432-1033.1982.tb19789.x; DEAN KJ, 1979, J BIOL CHEM, V254, P9994; EGGE H, 1987, MASS SPECTROM REV, V6, P331, DOI 10.1002/mas.1280060302; FENDERSON BA, 1985, J EXP MED, V160, P1591; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Hinsberg O, 1908, BER DTSCH CHEM GES, V41, P2836, DOI 10.1002/cber.190804102232; KAARIAINEN L, 1980, J CELL BIOL, V87, P783, DOI 10.1083/jcb.87.3.783; KLIMA H, 1993, BIOCHEM J, V292, P571, DOI 10.1042/bj2920571; MILLERPRODRAZA H, 1984, BIOCHIM BIOPHYS ACTA, V804, P44, DOI 10.1016/0167-4889(84)90097-1; OLAH GA, 1979, SYNTHESIS-STUTTGART, P61; REBHAN M, 1994, NEUROREPORT, V5, P941, DOI 10.1097/00001756-199404000-00022; SAITO M, 1985, J BIOL CHEM, V260, P2295; SCHWARZMANN G, 1987, METHOD ENZYMOL, V138, P319; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TRENKNER E, 1977, J CELL BIOL, V75, P915, DOI 10.1083/jcb.75.3.915; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VANECHTEN G, 1989, J NEUROCHEM, V52, P207; VANWEELY S, 1991, BIOCHIM BIOPHYS ACTA, V1096, P301, DOI 10.1016/0925-4439(91)90066-I; VANWEELY S, 1993, BIOCHIM BIOPHYS ACTA, V1181, P55, DOI 10.1016/0925-4439(93)90090-N; WEITZ G, 1983, H-S Z PHYSIOL CHEM, V364, P863, DOI 10.1515/bchm2.1983.364.2.863; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; ZSCHOCHE A, 1994, EUR J BIOCHEM, V222, P83, DOI 10.1111/j.1432-1033.1994.tb18844.x	28	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21271	21276		10.1074/jbc.270.36.21271	http://dx.doi.org/10.1074/jbc.270.36.21271			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673162	hybrid			2022-12-25	WOS:A1995RU05400062
J	SHEN, WJ; KIM, HS; TSAI, SY				SHEN, WJ; KIM, HS; TSAI, SY			STIMULATION OF HUMAN INSULIN-RECEPTOR GENE-EXPRESSION BY RETINOBLASTOMA GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; TRANSCRIPTION FACTOR; CARCINOMA-CELLS; SUSCEPTIBILITY GENE; FUNCTIONAL-ANALYSIS; TUMOR SUPPRESSOR; PROMOTER REGION; FACTOR-BINDING; PROTEIN; GROWTH	Multiple cis-acting elements have been defined to be important for the transcriptional regulation of the human insulin receptor (hIR) gene expression. We report here that one of these elements also mediated the stimulation of hIR promoter activity by the retinoblastoma gene product (Rb). The cis-element responsible for Rb stimulation was localized to the GA and GC boxes situated between -643 to -607 of the hIR gene. We have previously demonstrated that these GA and GC boxes bind Sp1 with high affinity and are responsible for E1a activation of hIR promoter activity. Mutation of these sequences completely abolished Rb-dependent enhancement of hIR promoter activity. In addition, we localized three regions in the N-terminal domain of Rb to be involved in stimulation of hIR promoter activity. Our results represent one of the first studies to demonstrate a functional importance assigned to the multiple phosphorylation sites in the N terminus of Rb. Finally, the mechanism by which Rb activates the hIR promoter are presented.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044988] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44988] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARAKI E, 1991, J BIOL CHEM, V266, P3944; ARAKI E, 1987, J BIOL CHEM, V262, P16186; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAMERON KE, 1992, J BIOL CHEM, V267, P17375; CHELLAPPAN SP, 1991, CELL, V65, P1058; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CUATRECASAS P, 1972, J BIOL CHEM, V247, P1980; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAHN CR, 1985, ANNU REV MED, V36, P429; KARANTZA V, 1993, MOL CELL BIOL, V13, P6640, DOI 10.1128/MCB.13.11.6640; KIM HS, 1994, MOL ENDOCRINOL, V9, P178; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOLTERMAN OG, 1981, J CLIN INVEST, V68, P957, DOI 10.1172/JCI110350; LEE JK, 1992, J BIOL CHEM, V267, P4638; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; MCKEON C, 1991, BIOCHEM BIOPH RES CO, V174, P721, DOI 10.1016/0006-291X(91)91477-T; MCKEON C, 1990, MOL ENDOCRINOL, V4, P647, DOI 10.1210/mend-4-4-647; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; STRAUS DS, 1984, ENDOCR REV, V5, P356, DOI 10.1210/edrv-5-2-356; SUMEGI J, 1990, CELL GROWTH DIFFER, V2, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1992, CANCER SURV, V12, P43; WHYTE P, 1988, NATURE, V34, P471; XU J, 1993, J BIOL CHEM, V268, P16065; YU DH, 1992, J BIOL CHEM, V267, P10203	58	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20525	20529		10.1074/jbc.270.35.20525	http://dx.doi.org/10.1074/jbc.270.35.20525			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657628	hybrid			2022-12-25	WOS:A1995RR58400046
J	CAMERON, HS; SZCZEPANIAK, D; WESTON, BW				CAMERON, HS; SZCZEPANIAK, D; WESTON, BW			EXPRESSION OF HUMAN-CHROMOSOME 19P ALPHA(1,3)-FUCOSYL-TRANSFERASE GENES IN NORMAL-TISSUES - ALTERNATIVE SPLICING, POLYADENYLATION, AND ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP ANTIGENS; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; HUMAN-PAROTID SALIVA; SIALYL LEWIS-X; FUCOSYL-TRANSFERASE; EMBRYONIC ANTIGEN; E-SELECTIN; DETERMINES EXPRESSION; MOLECULAR-CLONING; CELL-ADHESION	The human alpha(1,3)-fucosyltransferase genes FUT3, FUT5, and FUT6 form a cluster on chromosome 19p13.3. Expression was studied using reverse transcriptase-polymerase chain reaction, rapid amplification of cDNA ends, and Northern analyses, FUT3 and FUT6 were expressed at high levels, while FUT5 expression was lower and restricted to fewer cell types. Alternatively spliced transcripts were identified for FUT3 and FUT6 in kidney, Liver, and colon. A 2.37-kilobase pair (kb) FUT3 transcript, detected at high levels in kidney and colon, was absent in liver. FUT6 expression was characterized by a 3.5-kb transcript present in kidney and liver, and a 2.5-kb transcript in colon and liver. Two polyadenylation sites were shown for FUT5, but absence of consensus sequences suggests reduced efficiency for cleavage and polyadenylation. Two polyadenylation sites were also shown for FUT6, with the alternatively spliced downstream signal in tissues expressing high levels of FUT6. In these tissues, additional splicing results in isoforms with catalytic domain deletions, No detectable alpha(1,3)- or alpha(1,4)-fucosyltransferase activity was found in assays of cells transfected with FUT6 isoform cDNAs, Thus, tissue-specific post-transcriptional modifications are associated with expression patterns of FUT3, FUT5, and FUT6.	UNIV N CAROLINA, DEPT PEDIAT, DIV PEDIAT HEMATOL ONCOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CTR THROMBOSIS & HEMOSTASIS, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			/L-2667-2019		NATIONAL CANCER INSTITUTE [K08CA001758] Funding Source: NIH RePORTER; NCI NIH HHS [CA01758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BALL GE, 1992, J AM CHEM SOC, V114, P5449, DOI 10.1021/ja00039a080; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOULARAND S, 1995, J BIOL CHEM, V270, P3748, DOI 10.1074/jbc.270.8.3748; BURCH JBE, 1994, NUCLEIC ACIDS RES, V22, P4733, DOI 10.1093/nar/22.22.4733; CANDELIER JJ, 1993, LAB INVEST, V69, P449; DOHI T, 1994, CANCER, V73, P1552, DOI 10.1002/1097-0142(19940315)73:6<1552::AID-CNCR2820730605>3.0.CO;2-6; DOMINSKI Z, 1994, J BIOL CHEM, V269, P23590; FEIZI T, 1987, BIOCHEM J, V245, P1; FLEMING S, 1986, HISTOCHEM J, V18, P61, DOI 10.1007/BF01675358; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; ITZKOWITZ SH, 1986, CANCER RES, V46, P2627; JEZEQUELCUER M, 1993, BIOCHIM BIOPHYS ACTA, V1157, P252, DOI 10.1016/0304-4165(93)90107-J; JEZEQUELCUER M, 1992, LIVER, V12, P140; JOHNSON PH, 1981, BIOCHEM BIOPH RES CO, V100, P1611, DOI 10.1016/0006-291X(81)90703-8; KAN JLC, 1995, J BIOL CHEM, V270, P1823, DOI 10.1074/jbc.270.4.1823; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUIJPERS TW, 1993, BLOOD, V81, P873; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LANGKILDE NC, 1991, BRIT J HAEMATOL, V79, P493, DOI 10.1111/j.1365-2141.1991.tb08061.x; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEFF SE, 1987, CELL, V48, P517, DOI 10.1016/0092-8674(87)90202-9; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; MANDEL U, 1991, VOX SANG, V61, P205, DOI 10.1111/j.1423-0410.1991.tb00947.x; MCCURLEY RS, 1995, GENOMICS, V26, P142, DOI 10.1016/0888-7543(95)80094-3; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MESSNER HA, 1981, BLOOD, V58, P402; MOLLICONE R, 1992, CARBOHYD RES, V228, P265, DOI 10.1016/S0008-6215(00)90564-0; MOLLICONE R, 1994, TRANSFUS CLIN BIOL, V1, P91, DOI 10.1016/S1246-7820(94)80002-2; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; NAH HD, 1994, J BIOL CHEM, V269, P16443; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; OKADA Y, 1990, J HEPATOL, V10, P1, DOI 10.1016/0168-8278(90)90065-Y; OKADA Y, 1994, CANCER, V73, P1811, DOI 10.1002/1097-0142(19940401)73:7<1811::AID-CNCR2820730707>3.0.CO;2-4; ORNTOFT TF, 1991, BLOOD, V77, P1389; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PENG SB, 1994, J BIOL CHEM, V269, P17262; PENNINGTON JE, 1985, J EMBRYOL EXP MORPH, V90, P335; PETERSON ML, 1989, MOL CELL BIOL, V9, P726, DOI 10.1128/MCB.9.2.726; SAKAMOTO J, 1986, CANCER RES, V46, P1553; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SASAKI M, 1994, HEPATOLOGY, V19, P138, DOI 10.1016/0270-9139(94)90065-5; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; TAMAGAWA H, 1987, J DENT RES, V66, P756, DOI 10.1177/00220345870660031001; TAMAGAWA H, 1987, J DENT RES, V66, P72, DOI 10.1177/00220345870660011601; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; YAGO K, 1993, CANCER RES, V53, P5559	60	62	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20112	20122		10.1074/jbc.270.34.20112	http://dx.doi.org/10.1074/jbc.270.34.20112			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650030	hybrid			2022-12-25	WOS:A1995RQ99100066
J	WERNERFELMAYER, G; WERNER, ER; FUCHS, D; HAUSEN, A; REIBNEGGER, G; SCHMIDT, K; WEISS, G; WACHTER, H				WERNERFELMAYER, G; WERNER, ER; FUCHS, D; HAUSEN, A; REIBNEGGER, G; SCHMIDT, K; WEISS, G; WACHTER, H			PTERIDINE BIOSYNTHESIS IN HUMAN ENDOTHELIAL-CELLS - IMPACT ON NITRIC OXIDE-MEDIATED FORMATION OF CYCLIC-GMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; RELAXING FACTOR; L-ARGININE; INTERFERON-GAMMA; MACROPHAGE OXIDATION; GTP-CYCLOHYDROLASE; NITROGEN-OXIDES; SYNTHASE; TETRAHYDROBIOPTERIN; PURIFICATION	Stimulation of nitric oxide (NO) synthase in endothelial cells by Ca2+ influx leads to increased intracellular levels of cGMP. NO synthase from various sources is known to use tetrahydrobiopterin, flavins, and NADPH as cofactors. We studied the effect of interferon-gamma, tumor necrosis factor-alpha, and lipopolysaccharide on tetrahydrobiopterin biosynthetic activities in human umbilical vein endothelial cells (HUVEC). These stimuli led to an up to 40-fold increase of GTP cyclohydrolase I (EC 3.5.4.16) activity and to increased accumulation of neopterin and tetrahydrobiopterin in HUVEC. Further enzyme activities of tetrahydrobiopterin biosynthesis, i.e. 6-pyruvoyltetrahydropterin synthase and sepiapterin reductase (EC 1.1.1.153), remained unchanged. NO synthase activity in protein fractions from homogenates of cells treated with interferon-gamma plus tumor necrosis factor-alpha was not influenced as compared with untreated controls. However, interferon-gamma alone or in combination with tumor necrosis factor-alpha significantly increased intracellular cGMP formation in intact HUVEC by 50 and 80%, respectively. These stimuli increased intracellular tetrahydrobiopterin concentrations up to 14-fold. NO-triggered cGMP formation was similarity increased by incubation of otherwise untreated cells with sepiapterin, leading to elevated intracellular tetrahydrobiopterin levels. Thus, cytokines indirectly stimulate the activity of constitutive NO synthase in HUVEC by upregulating production of the cofactor tetrahydrobiopterin.	UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, FRITZ PREGL STR 3, A-6020 INNSBRUCK, AUSTRIA; GRAZ UNIV, INST PHARMACOL & TOXICOL, A-8010 GRAZ, AUSTRIA	University of Innsbruck; University of Graz			Fuchs, Dietmar/AAL-8011-2021; Reibnegger, Gilbert/H-5742-2012	Fuchs, Dietmar/0000-0003-1627-9563; Reibnegger, Gilbert/0000-0001-7202-2426; Werner-Felmayer, Gabriele/0000-0002-2340-8063; Werner, Ernst R./0000-0003-1948-3391				ANDERT SE, 1992, CLIN EXP IMMUNOL, V88, P555; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RR, 1989, CANCER RES, V49, P4941; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; DRAPIER JC, 1991, RES IMMUNOL, V142, P553, DOI 10.1016/0923-2494(91)90100-W; EVANS T, 1992, P NATL ACAD SCI USA, V89, P5361, DOI 10.1073/pnas.89.12.5361; FORSTERMANN U, 1986, CIRC RES, V58, P531, DOI 10.1161/01.RES.58.4.531; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; GAL EM, 1978, NEUROCHEM RES, V3, P69, DOI 10.1007/BF00964361; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HOLLOWAY JH, 1960, ANAL CHEM, V32, P249, DOI 10.1021/ac60158a033; IGNARRO LJ, 1986, J PHARMACOL EXP THER, V237, P893; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; KLATT P, 1992, FEBS LETT, V305, P160, DOI 10.1016/0014-5793(92)80886-L; KWON NS, 1989, J BIOL CHEM, V264, P20496; LAMAS S, 1991, AM J PHYSIOL, V261, pC634, DOI 10.1152/ajpcell.1991.261.4.C634; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MITCHELL JA, 1991, BIOCHEM BIOPH RES CO, V176, P1417, DOI 10.1016/0006-291X(91)90444-C; MONCADA S, 1991, PHARMACOL REV, V43, P109; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SCHMIDT K, 1992, BIOCHEM J, V281, P297, DOI 10.1042/bj2810297; SCHMIDT K, 1989, EUR J PHARMACOL, V170, P157, DOI 10.1016/0014-2999(89)90536-0; STROHMAIER W, 1987, CRIT CARE MED, V15, P757, DOI 10.1097/00003246-198708000-00009; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; VIVEROS OH, 1981, SCIENCE, V213, P349, DOI 10.1126/science.7017928; Wachter H, 1992, NEOPTERIN BIOCH METH, V10, P289; WERNER ER, 1987, CLIN CHEM, V33, P2028; WERNER ER, 1991, BIOCHEM J, V280, P709, DOI 10.1042/bj2800709; WERNER ER, 1990, J BIOL CHEM, V265, P3189; WERNER ER, 1989, BIOCHEM J, V262, P891; WERNERFELMAYER G, 1990, CANCER RES, V50, P2863; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; YIM JJ, 1976, J BIOL CHEM, V251, P5087; YUI Y, 1991, J BIOL CHEM, V266, P12544; YUI Y, 1991, J BIOL CHEM, V266, P3369; ZIEGLER I, 1990, J BIOL CHEM, V265, P17026	50	250	252	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1842	1846						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678411				2022-12-25	WOS:A1993KH62000054
J	BERTHIAUME, L; RESH, MD				BERTHIAUME, L; RESH, MD			BIOCHEMICAL-CHARACTERIZATION OF A PALMITOYL ACYLTRANSFERASE ACTIVITY THAT PALMITOYLATES MYRISTOYLATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVERLAP EXTENSION; MYRISTYLATION; PURIFICATION; SYSTEM	Dynamic regulation of signal transduction by revers reversible palmitoylation-depalmitoylation cycles has been recently described, However, further understanding of fatty acylation reactions has been hampered by our lack of knowledge about the specific transferases and thio esterases involved. Here, we describe an assay for the palmitoyl acyltransferase (PAT) that palmitoylates ''myrGlyCys'' containing members of the Src family of protein tyrosine kinases (PTKs), Since N-myristoylation of Fyn PTK, a member of the Src family, has been shown to be a prerequisite for palmitoylation, a new single plasmid vector that allows overexpression of myristoylated Fyn substrate in Escherichia coli was developed, Purified myristoylated protein substrates were incubated with [I-125]iodopalmitoyl CoA, a palmitoyl CoA analog, in the presence of bovine brain lysates, Transfer of radiolabel to the Fyn substrate was detected by SDS-polyacrylamide gel electrophoresis and autoradiography. This assay was used to partially purify and characterize PAT activity from bovine brain. Here, we demonstrate that PAT is a membrane-bound enzyme, which palmitoylates myristoylated Fyn substrates containing a cysteine residue in position three. The PAT activity attached palmitate to Fyn proteins via a thioester Linkage and exhibited a fatty acyl CoA preference for long chain fatty acids, It is likely that palmitoylation of Fyn and other Src family members by PAT regulates PTK localization and signaling functions.	MEM SLOAN KETTERING CANC CTR,DEPT GENET & CELL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center				Resh, Marilyn/0000-0001-6118-9466; Berthiaume, Luc/0000-0003-0926-059X	NATIONAL CANCER INSTITUTE [R01CA052405] Funding Source: NIH RePORTER; NCI NIH HHS [CA52405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; BERTHIAUME L, 1994, J BIOL CHEM, V269, P6498; BERTHIAUME L, 1995, METHOD ENZYMOL, V250, P454; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; DASILVA AM, 1990, J CELL BIOL, V111, P401, DOI 10.1083/jcb.111.2.401; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; Fleischer S, 1974, Methods Enzymol, V31, P3; GUTIERREZ L, 1991, BIOCHIM BIOPHYS ACTA, V1078, P147, DOI 10.1016/0167-4838(91)99003-B; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCILHINNEY RAJ, 1992, LIPID MODIFICATION P, P15; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PESECKIS SM, 1994, J BIOL CHEM, V269, P30888; PESECKIS SM, 1993, J BIOL CHEM, V268, P5107; QUESNEL S, 1994, BIOCHEMISTRY-US, V33, P13340, DOI 10.1021/bi00249a021; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESINGER MJ, 1993, LIPID MODIFICATION P, P1; SCHONER BE, 1990, METHOD ENZYMOL, V185, P94; SCHWARZ H, 1992, BIOTECHNIQUES, V13, P205; SILVERMAN L, 1993, CELL GROWTH DIFFER, V4, P475; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	35	129	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22399	22405		10.1074/jbc.270.38.22399	http://dx.doi.org/10.1074/jbc.270.38.22399			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673226	hybrid			2022-12-25	WOS:A1995RW31400053
J	PANDEY, A; DUAN, H; DIFIORE, PP; DIXIT, V				PANDEY, A; DUAN, H; DIFIORE, PP; DIXIT, V			THE RET RECEPTOR PROTEIN-TYROSINE KINASE ASSOCIATES WITH THE SH2-CONTAINING ADAPTER PROTEIN GRB10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ZINC FINGER PROTEIN; TRANSFORMING GENE; ACTIVATION; CARCINOMAS; ONCOGENE; ENCODES; SUBUNIT; FUSION; ALPHA	Ret is a receptor protein tyrosine kinase that has been implicated in the development of the enteric nervous, endocrine, and renal systems, Mutations associated with multiple endocrine neoplasia types 2A and 2B (MEN 2A and 2B) have been shown to activate the intrinsic kinase and transforming ability of ret (Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, IM. H., and Paolo DiFiore, P. (1995) Science 267, 381-383), Using the cytoplasmic domain of Ret as bait in a yeast two-hybrid screen of a mouse embryonic library, it was discovered that the src homology 2 (SH2) domain containing protein Grb10 bound Ret, Grb10 belongs to an emerging family of SH2 containing adapter proteins, the prototypical member being Grb7. Using glutathione S-transferase fusion proteins, it was demonstrated that the SH2 domain of Grb10 specifically interacted with Ret, Additionally, using an EGFR/Ret chimera, it was shown that Grb10 bound Ret in an activation dependent manner in vivo. This is the first description of a receptor protein tyrosine kinase that utilizes Grb10 as a signaling intermediate.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; EUROPEAN INST ONCOL, I-20141 MILAN, ITALY	University of Michigan System; University of Michigan; IRCCS European Institute of Oncology (IEO)			Di Fiore, Pier Paolo/K-2130-2012; Pandey, Akhilesh/B-4127-2009	Di Fiore, Pier Paolo/0000-0002-2252-0950; Pandey, Akhilesh/0000-0001-9943-6127	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39255] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASAI N, 1995, MOL CELL BIOL, V15, P1613; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HU HM, 1994, J BIOL CHEM, V269, P30069; IWAMOTO T, 1993, ONCOGENE, V8, P1087; LAHERTY CD, 1993, J BIOL CHEM, V268, P5032; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; OOI J, 1995, ONCOGENE, V10, P1621; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PANDEY A, 1994, J BIOL CHEM, V269, P30154; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559; ZHU GC, 1993, J BIOL CHEM, V268, P1775	33	106	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21461	21463		10.1074/jbc.270.37.21461	http://dx.doi.org/10.1074/jbc.270.37.21461			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665556	hybrid			2022-12-25	WOS:A1995RU75700009
J	SHIEH, SY; STELLRECHT, CMM; TSAI, MJ				SHIEH, SY; STELLRECHT, CMM; TSAI, MJ			MOLECULAR CHARACTERIZATION OF THE RAT INSULIN ENHANCER-BINDING COMPLEX 3B2 - CLONING OF A BINDING-FACTOR WITH PUTATIVE HELICASE MOTIFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; PANCREATIC ALPHA-CELLS; RICH ACTIVATION MOTIF; TRANSCRIPTION FACTOR; BETA-CELLS; II GENE; 5'-FLANKING REGION; DNA; PROTEIN; SEQUENCES	Cell-specific expression of the rat insulin II gene is in part mediated through an element located in the 5'-flanking region, The element, termed RIPE3b (-126 to -101), confers P-cell-specific expression in conjunction with an adjacent element RTPE3a (-110 to -86), Here we report the characterization of one of the RIPE3b-binding complexes, 3b2. UV cross-linking analysis demonstrated that it is composed of at least three polypeptides: p58, p62, and p110. Furthermore, a cDNA was isolated via expression screening for binding to RIPE3b. Sequence analysis reveals that the encoded protein, designated Rip-1, possessed putative helicase motifs and a potential transcription activation domain, Overexpression of Rip-1 in cells greatly enhances the 3b2 binding complex, suggesting that Rip-1 is involved in the binding of 3b2.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine			Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD017379, R01HD017379] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17379] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FUKITA Y, 1993, J BIOL CHEM, V268, P17463; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HWUNG YP, 1990, MOL CELL BIOL, V10, P1784, DOI 10.1128/MCB.10.4.1784; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KERR D, 1991, J BIOL CHEM, V266, P15876; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MIZUTA TR, 1993, NUCLEIC ACIDS RES, V21, P1761, DOI 10.1093/nar/21.8.1761; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAYA FJ, 1995, GENE DEV, V8, P1009; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OHLSSON H, 1988, P NATL ACAD SCI USA, V85, P4228, DOI 10.1073/pnas.85.12.4228; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; PEYTON M, 1994, J BIOL CHEM, V269, P25936; PHILIPPE J, 1991, ENDOCR REV, V12, P252, DOI 10.1210/edrv-12-3-252; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Sambrook J, 1989, MOL CLONING LABORATO; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SHIASAKI Y, 1990, BIOCHEM BIOPH RES CO, V170, P314; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; STELLRECHT CMM, 1993, J BIOL CHEM, V268, P4078; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; WU KJ, 1991, MOL CELL BIOL, V11, P4423, DOI 10.1128/MCB.11.9.4423	47	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21503	21508		10.1074/jbc.270.37.21503	http://dx.doi.org/10.1074/jbc.270.37.21503			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665561	hybrid			2022-12-25	WOS:A1995RU75700016
J	PHILIPHOLLINGSWORTH, S; ORGAMBIDE, GG; BRADFORD, JJ; SMITH, DK; HOLLINGSWORTH, RI; DAZZO, FB				PHILIPHOLLINGSWORTH, S; ORGAMBIDE, GG; BRADFORD, JJ; SMITH, DK; HOLLINGSWORTH, RI; DAZZO, FB			MUTATION OR INCREASED COPY NUMBER OF NODE HAS NO EFFECT ON THE SPECTRUM OF CHITOLIPOOLIGOSACCHARIDE NOD FACTORS MADE BY RHIZOBIUM-LEGUMINOSARUM BV TRIFOLII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-SPECIFIC NODULATION; WHITE CLOVER; MELILOTI; GENES; ACID; LIPOOLIGOSACCHARIDES; LIPOPOLYSACCHARIDE; RECOGNITION; EXPRESSION; SYMBIOSIS	The bacterial gene nodE is the key determinant of host specificity in the Rhizobium leguminosarum-legume symbiosis and has been proposed to determine unique polyunsaturated fatty acyl moieties in chitolipooligosaccharides (CLOS) made by the bacterial symbiont, We evaluated nodE function by examining CLOS structures made by wild-type R, leguminosarum by. trifolii ANU843, an isogenic nodE::Tn5 mutant, and a recombinant strain containing multiple copies of the pSym nod region of ANU843, H-1-NMR, electrospray ionization mass spectrometry, fast atom bombardment mass spectrometry, flame ionization detection-gas chromatography, gas chromatography/mass spectrometry, and high performance liquid chromatography/UV photodiode array analyses revealed that these bacterial strains made the same spectrum of CLOS species. We also found that ions in the mass spectra which were originally assigned to nodE-dependent CLOS species containing unique polyunsaturated fatty acids (Spaink, H, P., Bloemberg, G, V,, van Brussel, A A, N., Lugtenberg, B, J, J,, van der Drift, K.M.G.M., Haverkamp, J,, and Thomas-Gates, J, E, (1995) Mol, Plant-Microbe Interact, 8, 155-164) were actually due to sodium adducts of the major nodE-independent CLOS species, No evidence for nodE-dependent CLOSs was found for these strains. These results indicate a need to revise the current model to explain how nodE determines host range in the R, leguminosarum-legume symbiosis.	MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT CHEM,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University; Michigan State University; Michigan State University					NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004750] Funding Source: NIH RePORTER; NCRR NIH HHS [1-S10-RR04750] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CARLSON RW, 1994, MOL PLANT MICROBE IN, V7, P684, DOI 10.1094/MPMI-7-0684; CEDERGREN RA, 1995, BIOCHEMISTRY-US, V34, P4467, DOI 10.1021/bi00013a040; Dazzo F. B., 1982, Experimental microbial ecology, P431; DAZZO FB, 1979, CURR MICROBIOL, V2, P15, DOI 10.1007/BF02601726; DEMONT N, 1993, J BIOL CHEM, V268, P20134; DENARIE J, 1992, ANNU REV MICROBIOL, V46, P497, DOI 10.1146/annurev.mi.46.100192.002433; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; DJORDJEVIC MA, 1985, MOL GEN GENET, V200, P463, DOI 10.1007/BF00425732; DJORDJEVIC MA, 1991, AUST J PLANT PHYSIOL, V18, P543, DOI 10.1071/PP9910543; DJORDJEVIC MA, 1982, J BACTERIOL, V151, P560, DOI 10.1128/JB.151.2.560-568.1982; ESPUNY MR, 1987, J APPL BACTERIOL, V63, P13, DOI 10.1111/j.1365-2672.1987.tb02412.x; FISHER RF, 1985, APPL ENVIRON MICROB, V49, P1432, DOI 10.1128/AEM.49.6.1432-1435.1985; HIRSCH AM, 1992, NEW PHYTOL, V122, P211, DOI 10.1111/j.1469-8137.1992.tb04227.x; HOLLINGSWORTH RI, 1988, J MICROBIOL METH, V7, P295, DOI 10.1016/0167-7012(88)90024-3; HOLLINGSWORTH RI, 1989, J BIOL CHEM, V264, P9300; HRABAK EM, 1981, J BACTERIOL, V148, P697, DOI 10.1128/JB.148.2.697-711.1981; HUNTER SW, 1985, BIOCHEMISTRY-US, V24, P2798, DOI 10.1021/bi00332a030; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; MARIN LML, 1992, BIOCHEMISTRY-US, V31, P11106, DOI 10.1021/bi00160a021; MCKAY IA, 1993, APPL ENVIRON MICROB, V59, P3385, DOI 10.1128/AEM.59.10.3385-3392.1993; ORGAMBIDE GG, 1992, CARBOHYD RES, V233, P151, DOI 10.1016/S0008-6215(00)90927-3; ORGAMBIDE GG, 1995, BIOCHEMISTRY-US, V34, P3832, DOI 10.1021/bi00011a041; ORGAMBIDE GG, 1993, LIPIDS, V28, P975, DOI 10.1007/BF02537117; OSTERHOUT GJ, 1991, J CLIN MICROBIOL, V29, P1822, DOI 10.1128/JCM.29.9.1822-1830.1991; PETERS NK, 1985, SCIENCE, V233, P977; POUPOT R, 1995, J BIOL CHEM, V270, P6050, DOI 10.1074/jbc.270.11.6050; PRICE NPJ, 1992, MOL MICROBIOL, V6, P3575, DOI 10.1111/j.1365-2958.1992.tb01793.x; REDMOND JW, 1986, NATURE, V323, P632, DOI 10.1038/323632a0; ROLFE B, 1982, PLANT SCI LETT, V19, P277; SALZWEDEL JL, 1993, MOL PLANT MICROBE IN, V6, P127, DOI 10.1094/MPMI-6-127; SCHOFIELD PR, 1984, PLANT MOL BIOL, V3, P3, DOI 10.1007/BF00023410; SCHULTZE M, 1992, P NATL ACAD SCI USA, V89, P192, DOI 10.1073/pnas.89.1.192; SPAINK HP, 1989, EMBO J, V8, P2811, DOI 10.1002/j.1460-2075.1989.tb08427.x; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; SPAINK HP, 1995, MOL PLANT MICROBE IN, V8, P155, DOI 10.1094/MPMI-8-0155; TRUCHET G, 1989, PROTOPLASMA, V149, P82, DOI 10.1007/BF01322980; Williams D.H., 1966, SPECTROSCOPIC METHOD, P6	37	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20968	20977		10.1074/jbc.270.36.20968	http://dx.doi.org/10.1074/jbc.270.36.20968			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673121	hybrid			2022-12-25	WOS:A1995RU05400018
J	SVENSSON, L; HEINEGARD, D; OLDBERG, A				SVENSSON, L; HEINEGARD, D; OLDBERG, A			DECORIN-BINDING SITES FOR COLLAGEN TYPE-I ARE MAINLY LOCATED IN LEUCINE-RICH REPEATS 4-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOGLYCAN-II; CORE PROTEIN; FIBROMODULIN; EXPRESSION; CDNA; CARTILAGE; SEQUENCE; BIGLYCAN; HOMOLOGY; BONE	Decorin and biglycan are structurally related interstitial proteoglycans synthesized in connective tissues like skin, tendon, and cartilage. Despite the conspicuous sequence similarities, where about 55% of the amino acid residues in decorin and biglycan are located in identical positions, the two proteoglycans show differences in their interaction with collagen. Decorin binds to collagen type I, whereas biglycan in several assay systems shows no affinity for this collagen type. Here we have made use of these structural similarities and affinity differences in studies of the collagen binding properties of decorin. Recombinant biglycan/decorin chimeras were produced in mammalian cells and analyzed for their capacity to bind collagen. In the chimeras, biglycan contributes sequences crucial for synthesis and export from the mammalian cells, and decorin provides potential collagen-binding properties. By using this approach we show that decorin binds to the collagen primarily via leucine-rich repeats 4-5 composed of some 40 amino acid residues. Proteoglycan chimeras containing decorin sequences from the N terminus to leucine-rich repeat 3 or sequences from leucine rich repeat 6 to the C terminus do not show any detectable binding to collagen. A proteoglycan chimera containing decorin leucine rich repeats 4-5 flanked by biglycan sequences binds to collagen. However, this chimera binds to collagen with somewhat lower affinity than wild type decorin, suggesting that additional low affinity binding sites may be located in other parts of decorin. Alternatively, the conformation of the collagen binding leucine-rich repeats 4-5 are different in decorin and in the biglycan/decorin chimera, leading to a lower collagen affinity for the latter.	LUND UNIV, DEPT CELL & MOLEC BIOL, S-22100 LUND, SWEDEN	Lund University								ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEINEGARD D, 1981, BIOCHEM J, V197, P355, DOI 10.1042/bj1970355; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; YOUNG JM, 1988, GENE, V62, P171, DOI 10.1016/0378-1119(88)90556-2	20	197	201	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20712	20716		10.1074/jbc.270.35.20712	http://dx.doi.org/10.1074/jbc.270.35.20712			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657652	hybrid			2022-12-25	WOS:A1995RR58400072
J	VAGNER, S; WAYSBORT, A; MARENDA, M; GENSAC, MC; AMALRIC, F; PRATS, AC				VAGNER, S; WAYSBORT, A; MARENDA, M; GENSAC, MC; AMALRIC, F; PRATS, AC			ALTERNATIVE TRANSLATION INITIATION OF THE MOLONEY MURINE LEUKEMIA-VIRUS MESSENGER-RNA CONTROLLED BY INTERNAL RIBOSOME ENTRY INVOLVING THE P57/PTB SPLICING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' NONCODING REGION; HUMAN RHINOVIRUS RNA; MESSENGER-RNA; PROTEIN-SYNTHESIS; PICORNAVIRUS RNA; CIS ELEMENTS; NONTRANSLATED REGION; INVITRO TRANSLATION; SECONDARY STRUCTURE; BINDING PROTEIN	Moloney murine leukemia virus (Mo-MuLV) genomic mRNA codes for two gag precursors by alternative initiations of translation. An AUG codon governs the synthesis of the retroviral capsid proteins precursor, whereas a CUG codon directs the synthesis of a glycosylated cell surface antigen, the gross cell surface antigen. Control of the relative synthesis of the two precursors is crucial for MuLV infectivity and pathology. Furthermore, the MuLV mRNA leader sequence is very long and should inhibit translation according to the classical scanning model. This suggests a different translation initiation mechanism allowing gag efficient expression. We demonstrate, by using bicistronic vectors expressed in COS-7 cells, that the Mo-MuLV mRNA leader drives translation initiation by internal ribosome entry. We have localized the internal ribosome entry site (IRES) between the two initiation codons. This 126 nucleotide long IRES implies an oligopyrimidine tract located 45 nucleotides upstream of AUG codon. UV crosslinking and affinity chromatography experiments show that the PTB/p57 splicing factor specifically interacts with this oligopyrimidine tract. The MuLV IRES controls alternative translation initiation by activating the capsid protein precursor expression. This gag translational enhancer could exist in other retroviruses.	CHU RANGUEIL, INST LOUIS BUGNARD,INSERM,U397, UNITE ENDOCRINOL & COMMUN CELLULAIRE, F-31054 TOULOUSE, FRANCE; CNRS, BIOL MOLEC EUCARYOTES LAB, F-31062 TOULOUSE, FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)			Prats, Anne-Catherine/E-5051-2016; Vagner, Stephan/G-3664-2013	Prats, Anne-Catherine/0000-0002-5282-3776; vagner, stephan/0000-0003-1452-7164; MARENDA, MARC/0000-0001-6778-1110				AGOL VI, 1991, ADV VIRUS RES, V40, P103; ANGEL RMD, 1989, P NATL ACAD SCI USA, V86, P8292; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; BELSHAM GJ, 1992, EMBO J, V11, P1105, DOI 10.1002/j.1460-2075.1992.tb05150.x; BELSHAM GJ, 1990, J VIROL, V64, P5389, DOI 10.1128/JVI.64.11.5389-5395.1990; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; BORMAN A, 1992, VIROLOGY, V188, P685, DOI 10.1016/0042-6822(92)90523-R; BORMAN A, 1993, J GEN VIROL, V74, P1775, DOI 10.1099/0022-1317-74-9-1775; BOROVJAGIN A, 1994, FEBS LETT, V351, P299, DOI 10.1016/0014-5793(94)00848-5; CORBIN A, 1994, J VIROL, V68, P3857, DOI 10.1128/JVI.68.6.3857-3867.1994; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; EDWARDS SA, 1979, J VIROL, V30, P551, DOI 10.1128/JVI.30.2.551-563.1979; GLASS MJ, 1993, VIROLOGY, V193, P842, DOI 10.1006/viro.1993.1193; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; JACKSON RJ, 1988, NATURE, V334, P292, DOI 10.1038/334292a0; JACKSON RJ, 1991, NATURE, V353, P14, DOI 10.1038/353014a0; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KAMINSKI A, 1994, EMBO J, V13, P1673, DOI 10.1002/j.1460-2075.1994.tb06431.x; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MEEROVITCH K, 1991, J VIROL, V65, P5895, DOI 10.1128/JVI.65.11.5895-5901.1991; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; MOUGEL M, 1993, NUCLEIC ACIDS RES, V21, P4677, DOI 10.1093/nar/21.20.4677; MURTI KG, 1981, J VIROL, V37, P411, DOI 10.1128/JVI.37.1.411-419.1981; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; PILIPENKO EV, 1994, J MOL BIOL, V241, P398, DOI 10.1006/jmbi.1994.1516; PILLEMER EA, 1986, J VIROL, V57, P413, DOI 10.1128/JVI.57.2.413-421.1986; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS AC, 1990, J VIROL, V64, P774, DOI 10.1128/JVI.64.2.774-783.1990; PRATS AC, 1989, J MOL BIOL, V205, P363, DOI 10.1016/0022-2836(89)90347-1; PRATS AC, 1988, THESIS U P SABATIER; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; THOMAS AAM, 1992, EUR J BIOCHEM, V207, P471, DOI 10.1111/j.1432-1033.1992.tb17073.x; TOYODA H, 1994, ARCH VIROL, V138, P1, DOI 10.1007/BF01310034; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WEISS R, 1984, RNA TUMOR VIRUSES; WITHERELL GW, 1994, J VIROL, V68, P3183, DOI 10.1128/JVI.68.5.3183-3192.1994	49	97	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20376	20383		10.1074/jbc.270.35.20376	http://dx.doi.org/10.1074/jbc.270.35.20376			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657611	hybrid			2022-12-25	WOS:A1995RR58400024
J	AZROLAN, N; ODAKA, H; BRESLOW, JL; FISHER, EA				AZROLAN, N; ODAKA, H; BRESLOW, JL; FISHER, EA			DIETARY-FAT ELEVATES HEPATIC APOA-I PRODUCTION BY INCREASING THE FRACTION OF APOLIPOPROTEIN-A-I MESSENGER-RNA IN THE TRANSLATING POOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; MESSENGER-RNA; PROTEIN-SYNTHESIS; TRANSPORT RATES; GENE-REGULATION; PLASMA-LEVELS; APOPROTEIN-B; CHOLESTEROL; POLYSOMES; EXPRESSION	Elevated plasma high density lipoprotein cholesterol (HDL-C) levels are associated with a decreased risk for coronary heart disease, Ironically, diets enriched in saturated fat and cholesterol (HF/HC diets), which tend to accelerate atherosclerotic processes by increasing LDL cholesterol levels, also raise HDL-C, We have recently reported, using a human apoA-I (hapoA-1) transgenic mouse model, that the elevation of HDL-C by a HF/HC diet is attributable, in part, to an increase in the hepatic production of hapoA-1, To further define the hepatocellular processes associated with this induction, we have prepared primary hepatocytes from hapoA-1 transgenic mice. Rates of hapoA-1 secretion were 40% greater from cells prepared from animals fed the HF/HC relative to a low fat-low cholesterol (LF/LC) control diet, The abundance of hapoA-1 mRNA in these cells was similar between hepatocytes prepared from the HF/HC and LF/LC diet fed animals, suggesting a post-transcriptional mechanism that does not involve mRNA stability, Inhibition of secretion using brefeldin A revealed an increase in cellular hapoA-1 accumulation, Thus, the HF/HC diet apparently affects hepatic hapoA-1 production via a mechanism that is manifest prior to the exit of newly synthesized hapoA-1 from the Golgi, Pulse-chase experiments revealed a 39% greater peak hapoA-1 synthesis, with no difference in the degradation of total labeled hapoA-1 protein, as a result of the HF/HC diet feeding, Finally, resolution of liver S10 extracts via sucrose density sedimentation and metrizamide density equilibrium gradient centrifugation analyses both revealed similar increases (31 and 24%, respectively) in the relative percentage of hapoA-1 mRNA associated with the translating polysomal fractions as a result of the HF/HC feeding, Together, these data suggest that the HF/HC diet affects hepatic hapoA-1 production via a specific modulation in the relative amount of hapoA-1 mRNA in the polysomal pool, These observations provide an opportunity to explore a new mechanism regulating apoA-1 production and might lead to the development of novel therapies to elevate plasma HDL-C levels.	ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021; MED COLL PENN,PHILADELPHIA,PA 19129	Rockefeller University; Drexel University			Breslow, Jan L/B-7544-2008	Fisher, Edward/0000-0001-9802-143X	NHLBI NIH HHS [HL33714, HL32435, HL22633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032435, R01HL033714, P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZROLAN N, 1990, J LIPID RES, V31, P1141; BERGMANN JE, 1979, J BIOL CHEM, V254, P1927; BRINTON EA, 1990, J CLIN INVEST, V85, P144, DOI 10.1172/JCI114405; BRINTON EA, 1994, ARTERIOSCLER THROMB, V14, P707, DOI 10.1161/01.ATV.14.5.707; CHEN XL, 1993, J BIOL CHEM, V268, P21007; DIXON JL, 1993, J LIPID RES, V34, P167; DWORKIN MB, 1985, P NATL ACAD SCI USA, V82, P7636, DOI 10.1073/pnas.82.22.7636; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GO MF, 1988, J CLIN INVEST, V81, P1615, DOI 10.1172/JCI113496; HAYEK T, 1993, J CLIN INVEST, V91, P1665, DOI 10.1172/JCI116375; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MELEFORS O, 1993, BIOESSAYS, V15, P85, DOI 10.1002/bies.950150203; Munro HN, 1989, CURR OPIN CELL BIOL, V1, P1154, DOI 10.1016/S0955-0674(89)80066-3; NELSON EM, 1987, J BIOL CHEM, V262, P11501; ORCI L, 1991, CELL, V64, P1183; REA TJ, 1994, J LIPID RES, V35, P1274; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; RYZANOV AG, 1991, FEBS LETT, V285, P170; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; WALSH A, 1993, J LIPID RES, V34, P617; WALSH A, 1989, J BIOL CHEM, V264, P6488; WANG HX, 1993, J CLIN INVEST, V91, P1380, DOI 10.1172/JCI116340; WANG HX, 1994, J BIOL CHEM, V269, P18514; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134	29	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19833	19838		10.1074/jbc.270.34.19833	http://dx.doi.org/10.1074/jbc.270.34.19833			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649994	hybrid			2022-12-25	WOS:A1995RQ99100026
J	SACCO, PA; MCGRANAHAN, TM; WHEELOCK, MJ; JOHNSON, KR				SACCO, PA; MCGRANAHAN, TM; WHEELOCK, MJ; JOHNSON, KR			IDENTIFICATION OF PLAKOGLOBIN DOMAINS REQUIRED FOR ASSOCIATION WITH N-CADHERIN AND ALPHA-CATENIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL PLAQUE PROTEIN; CELL-ADHESION MOLECULES; AMINO-ACID-SEQUENCE; BETA-CATENIN; EPITHELIAL-CELLS; CYTOPLASMIC DOMAIN; UVOMORULIN; DROSOPHILA; DISTINCT; HOMOLOG	Cadherins are calcium-dependent, cell surface glycoproteins involved in cell cell adhesion. To function in cell-cell adhesion, the transmembrane cadherin molecule must be associated with the cytoskeleton via cytoplasmic proteins known as catenins. Three catenins, alpha-catenin, beta-catenin, and gamma-catenin (also known as plakoglobin), have been identified, The domain of the cadherin molecule important for its interaction with the catenins has been mapped to the COOH-terminal 70 amino acids, but less is known about regions of the catenins that allow them to associate with one another or with the cadherin molecule, In this study we have transfected carboxyl-terminal deletions of plakoglobin into the human fibrosarcoma HT-1080 and used immunofluorescence localization and co-immunoprecipitation to map the regions of plakoglobin that allow it to associate with N-cadherin and with alpha-catenin. Plakoglobin is an armadillo family member containing 13 weakly similar internal repeats. These data show that the alpha-catenin-binding region maps within the first repeat and the N-cadherin binding region maps within repeats 7 and 8.	UNIV TOLEDO,DEPT BIOL,TOLEDO,OH 43606	University System of Ohio; University of Toledo					NIGMS NIH HHS [GM51188] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; FOUQUET B, 1992, DIFFERENTIATION, V51, P187, DOI 10.1111/j.1432-0436.1992.tb00695.x; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Geiger B., 1985, CELL CONTACT ADHESIO, P461; Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HIRT RP, 1992, GENE, V111, P199, DOI 10.1016/0378-1119(92)90687-K; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; JOHNSON KR, 1993, EXP CELL RES, V207, P252, DOI 10.1006/excr.1993.1191; KAPPRELL HP, 1987, EUR J BIOCHEM, V166, P505, DOI 10.1111/j.1432-1033.1987.tb13543.x; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KORMAN NJ, 1989, NEW ENGL J MED, V321, P631, DOI 10.1056/NEJM198909073211002; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Magee AI, 1991, CURR OPIN CELL BIOL, V3, P854, DOI 10.1016/0955-0674(91)90060-C; MATHUR M, 1994, J BIOL CHEM, V269, P14075; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PIEPENHAGEN PA, 1993, J CELL SCI, V104, P751; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; REID RA, 1990, NUCLEIC ACIDS RES, V18, P5896, DOI 10.1093/nar/18.19.5896; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SHORE EM, 1991, J BIOL CHEM, V266, P19672; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049	41	132	133	4	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20201	20206		10.1074/jbc.270.34.20201	http://dx.doi.org/10.1074/jbc.270.34.20201			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650039	hybrid			2022-12-25	WOS:A1995RQ99100077
J	YUK, MH; LODISH, HF				YUK, MH; LODISH, HF			ENHANCED FOLDING AND PROCESSING OF A DISULFIDE MUTANT OF THE HUMAN ASIALOGLYCOPROTEIN RECEPTOR H2B SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEPATOMA-CELLS; ENDOPLASMIC-RETICULUM; PROTEIN-DEGRADATION; BINDING PROTEINS; BOND FORMATION; PRE-GOLGI; SEQUENCE; CALCIUM; POLYPEPTIDES; SECRETION	Unfolded forms of the H2b subunit of the human asialoglycoprotein receptor, a galactose-specific C-type lectin, are degraded in the endoplasmic reticulum (ER), whereas folded forms of the protein can mature to the cell surface (Wikstrom, L., and Lodish, H. F. (1993) J. Biol. Chem. 268, 14412-14416). There are eight cysteines in the exoplasmic domain of the protein, forming four disulfide bonds in the folded protein. We have constructed double cysteine to alanine mutants for each of the four disulfide bonds and examined the folding and metabolic fate of each of the mutants in transfected 3T3 fibroblasts. We find that mutation of the two cysteines nearest to the transmembrane region (C1) does not prevent proper folding of the protein, whereas mutations of the other three disulfides prevent proper folding of the protein and all of the mutant proteins are degraded in the ER, A normal (similar to 20%) fraction of the C1 mutant protein exits the endoplasmic reticulum and is processed in the Golgi complex, and it does so at a faster rate compared to the wild-type. Furthermore, the folded form of this mutant protein is more resistant to unfolding by dithiothreitol than the wild-type. The CI mutant protein is expressed on the cell surface and can form a functional receptor with the H1 subunit with similar binding affinities for natural ligands as that of the wild-type receptor. The same fraction of newly made mutant and wild-type proteins (similar to 80%) remain in the ER, but the mutant protein is degraded more quickly. Thus, the presence of the C1 disulfide bond in the wild-type receptor both reduces the rate of protein folding and exit to the Golgi and slows the rate of ER degradation of the portion (similar to 80%) of the receptor that never folds properly.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)								AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BISCHOFF J, 1987, J BIOL CHEM, V262, P11825; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FUHLENDORFF J, 1987, BIOCHEMISTRY-US, V26, P6757, DOI 10.1021/bi00395a027; GIGA Y, 1987, J BIOL CHEM, V262, P6197; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; HUTH JR, 1992, J BIOL CHEM, V267, P8570; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KAJI EH, 1993, J BIOL CHEM, V268, P22188; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LODISH HF, 1993, J BIOL CHEM, V268, P20598; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; NG NFL, 1992, J BIOL CHEM, V267, P16069; OMURA F, 1992, EUR J BIOCHEM, V205, P551, DOI 10.1111/j.1432-1033.1992.tb16812.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P158; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; SPIESS M, 1985, J BIOL CHEM, V260, P1979; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TAKEZAWA R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P220, DOI 10.1016/0167-4781(93)90300-3; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WIKSTROM L, 1993, J BIOL CHEM, V268, P14412; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; YOUNG J, 1993, J BIOL CHEM, V268, P19810; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735	41	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20169	20176		10.1074/jbc.270.34.20169	http://dx.doi.org/10.1074/jbc.270.34.20169			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650036	hybrid			2022-12-25	WOS:A1995RQ99100073
J	URBATSCH, IL; SANKARAN, B; WEBER, J; SENIOR, AE				URBATSCH, IL; SANKARAN, B; WEBER, J; SENIOR, AE			P-GLYCOPROTEIN IS STABLY INHIBITED BY VANADATE-INDUCED TRAPPING OF NUCLEOTIDE AT A SINGLE CATALYTIC SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; ADENOSINE-TRIPHOSPHATASE; ESCHERICHIA-COLI; ATP HYDROLYSIS; GIZZARD MYOSIN; RECONSTITUTION; SUBFRAGMENT-1; PURIFICATION; DIPHOSPHATE; BINDING	P-glycoprotein (Pgp or multidrug-resistance protein) shows drug-stimulated ATPase activity, The catalytic sites are known to be of low affinity and specificity for nucleotides, From the sequence, two nucleotide sites are predicted per Pgp molecule. Using plasma membranes from a multidrug-resistant Chinese hamster ovary cell line, which are highly enriched in Pgp, we show that vanadate-induced trapping of nucleotide at a single catalytic site produces stably inhibited Pgp, with t(1/2) for reactivation of ATPase activity of 84 min at 37 degrees C and >30 h at 4 degrees C. Reactivation of ATPase correlated with release of trapped nucleotide. Concentrations of MgATP and MgADP required to produce 50% inhibition were 9 and 15 mu M, respectively, thus the apparent affinity for nucleotide is greatly increased by vanadate-trapping. The trapped nucleotide species was ADP, Divalent cation was required, with magnesium, manganese, and cobalt all effective; cobalt yielded a very stable inhibited species, t(1/2) at 37 degrees C = 18 h, No photocleavage of Pgp was observed after vanadate trapping with MgATP, nor was UV-induced photolabeling of Pgp by trapped adenine nucleotide observed, Vanadate-trapping with 8-azido-ATP followed by UV irradiation caused permanent inactivation and specific labeling of Pgp, Vanadate-induced inhibition was also shown with pure, reconstituted Pgp, with similar characteristics to those in plasma membranes, Vanadate trapping overcomes technical difficulties posed by lack of high affinity nucleotide-binding site(s) or a covalent enzyme-phosphate catalytic intermediate in Pgp. The finding that vanadate trapping of nucleotide at just one site/Pgp is sufficient to give full inhibition of ATPase activity shows that the two pre dieted nucleotide sites can not function independently as catalytic sites.			URBATSCH, IL (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642, USA.				NIGMS NIH HHS [GM50156] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050156] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; CREMO CR, 1989, J BIOL CHEM, V264, P6608; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P7982, DOI 10.1021/bi00486a029; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GARABEDIAN TE, 1991, BIOCHEMISTRY-US, V30, P10126, DOI 10.1021/bi00106a008; GARABEDIAN TE, 1990, J BIOL CHEM, V265, P22547; GIBBONS IR, 1987, J BIOL CHEM, V265, P2780; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gros P, 1993, Int Rev Cytol, V137C, P169; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENEFSKY HS, 1986, METHOD ENZYMOL, V126, P608; RINGEL I, 1990, BIOCHEMISTRY-US, V29, P9091, DOI 10.1021/bi00490a029; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; WOLODKO WT, 1983, J BIOL CHEM, V258, P4116; YOUNT RG, 1992, PHILOS T ROY SOC B, V336, P55, DOI 10.1098/rstb.1992.0044	26	364	367	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19383	19390		10.1074/jbc.270.33.19383	http://dx.doi.org/10.1074/jbc.270.33.19383			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642618	hybrid			2022-12-25	WOS:A1995RP70300032
J	KHANNA, KK; BEAMISH, H; YAN, J; HOBSON, K; WILLIAMS, R; DUNN, I; LAVIN, MF				KHANNA, KK; BEAMISH, H; YAN, J; HOBSON, K; WILLIAMS, R; DUNN, I; LAVIN, MF			NATURE OF G1/S CELL-CYCLE CHECKPOINT DEFECT IN ATAXIA-TELANGIECTASIA	ONCOGENE			English	Article						ATAXIA-TELANGIECTASIA; CELL CYCLE; P53; CYCLIN-DEPENDENT-KINASE; P53/WAF1; RETINOBLASTOMA PROTEIN	IONIZING-RADIATION; DNA-DAMAGE; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; P53 PROTEIN; TYROSINE PHOSPHORYLATION; MAMMALIAN-CELLS; CDK2 ACTIVITY; EXPRESSION; INDUCTION	We have previously demonstrated that cells from patients with ataxia-telangiectasia (A-T) fail to show initial delay at several cell cycle checkpoints post-irradiation. In addition a defect in the induction of p53 by ionizing radiation was evident. We demonstrate here that the radiation signal transduction pathway operating through p53, its target gene WAF1, cyclin-dependent kinases and the retinoblastoma (Rb) protein is defective in A-T cells. The defective p53 induction after ionizing radiation, observed previously in A-T cells, was also reflected at the functional level using p53-DNA binding activity, transactivation and transfection with wild type p53. Correction of the defect at the G1/S checkpoint was observed when wild type p53 was constitutively expressed in A-T cells. Exposure of control cells to radiation gave rise to p53 induction and as a consequence increased expression of WAF1 mRNA and protein, but A-T cells were defective in this response. As expected the WAF1 response in irradiated control cells resulted in an inhibition of cyclin-dependent kinase activity including cyclin E-cdk2, which plays an important role in the transition from G1 to S phase. No inhibition of cyclin-dependent kinase activity was observed in A-T cells correlating with the delayed WAF1 response. On the contrary an enhancement of cyclin-dependent kinase activity was seen in A-T cells post-irradiation. An accumulation of the hypophosphorylated form of Rb protein occurred in irradiated control cells compatible with the G1/S phase delay observed in these cells after exposure to radiation. In unirradiated A-T cells the amount of Rb protein was much higher compared to controls and it was mainly in the hyperphosphorylated (functionally inactive) form. In addition, accumulation of the hypophosphorylated form of Rb in A-T cells postirradiation was defective, consistent with the lack of cell cycle arrest. Thus the failure of the G1/S checkpoint in A-T cells after exposure to ionizing radiation is consistent with a defective radiation signal transduction pathway operating through p53.	QUEENSLAND INST MED RES, QUEENSLAND CANC FUND RES UNIT, BANCROFT CTR, BRISBANE, QLD 4029, AUSTRALIA; MED SCH HERSTON, DEPT PATHOL, QUEENSLAND CANC FUND RES UNIT, HERSTON, QLD 4006, AUSTRALIA; UNIV QUEENSLAND, ROYAL BRISBANE HOSP, DEPT SURG, HERSTON, QLD 4029, AUSTRALIA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland			Lavin, Martin F/F-5961-2014; Yan, Jun/F-1224-2010	Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381; Yan, Jun/0000-0001-9617-0335				BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BELT PBGM, 1989, GENE, V84, P407, DOI 10.1016/0378-1119(89)90515-5; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN P, 1983, THESIS U QUEENSLAND; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAN SJ, 1994, CANCER RES, V54, P5824; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALL FL, 1993, ONCOGENE, V8, P1377; HANAWALT PC, 1986, TRENDS GENET, V2, P124, DOI 10.1016/0168-9525(86)90201-5; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HONG JH, 1994, RADIAT RES, V140, P17, DOI 10.2307/3578563; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KHANNA KK, 1993, ONCOGENE, V8, P3307; KHARBANDA S, 1994, CANCER RES, V54, P1412; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS151; LAVIN MF, 1992, CELL BIOL, V77, P235; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI Y, 1994, ONCOGENE, V9, P2261; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MICHIELI P, 1994, CANCER RES, V54, P3391; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; NEVINS JR, 1992, SCIENCE, V258, P424; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PRICE BD, 1994, CANCER RES, V54, P896; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; PRICE BD, 1993, ONCOGENE, V8, P3055; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	59	110	110	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					609	618						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651723				2022-12-25	WOS:A1995RQ46900001
J	MACHIDE, M; MANO, H; TODOKORO, K				MACHIDE, M; MANO, H; TODOKORO, K			INTERLEUKIN-3 AND ERYTHROPOIETIN INDUCE ASSOCIATION OF VAV WITH TEC KINASE THROUGH TEC HOMOLOGY DOMAIN	ONCOGENE			English	Article						TEC KINASE; VAV; ERYTHROPOIETIN; IL3; SIGNAL TRANSDUCTION	TYROSINE-PHOSPHORYLATED PROTEIN; HEMATOPOIETIC-CELLS; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; SH2 DOMAIN; RECEPTOR; GRB2; ACTIVATION; GENE; RAS	Although hematopoietic cytokine receptors lack tyrosine kinase domains, the binding of their ligands to the receptors induce rapid tyrosine phosphorylation of various cellular target proteins. The specific tyrosine kinases which phosphorylate these substrates, however, have not been identified, other than that JAK kinases which phosphorylate STAT proteins and the receptors. We found that the c-vav proto-oncogene product, Vav, is rapidly and transiently tyrosine-phosphorylated in response to erythropoietin and IL3 stimulations and that Tec kinase is also transiently activated by these cytokines. Immunoprecipitation experiments demonstrated that Tec kinase binds to Vav upon these cytokine stimulations and that Grb2 constitutively associates with Vav. In vitro binding assays showed that erythropoietin and IL3 stimulation induce the specific binding of Vav to Tec kinase through Tec homology domains. We therefore concluded that Tec kinase is one of the key enzymes in Epo and IL3 receptor-mediated signaling pathways and that Vav plays an important role in the cytokine receptor-mediated signal transduction.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; KYOTO UNIV,DEPT ZOOL,SAKYO KU,KYOTO,JAPAN; JICHI MED SCH,DEPT MOLEC BIOL,MINAMI KAWACHI,TOCHIGI,JAPAN	RIKEN; Kyoto University; Jichi Medical University								ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; GOLDWASSER E, 1990, PEPTIDE GROWTH FACTO, V1, P747; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GULBINS E, 1994, J IMMUNOL, V152, P2123; IHLE JN, 1994, P SOC EXP BIOL MED, V206, P268; ISFORT R, 1988, J BIOL CHEM, V263, P19203; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOCH CA, 1991, SCIENCE, V252, P688; KURAMOCHI S, 1991, BIOCHEM BIOPH RES CO, V181, P1103, DOI 10.1016/0006-291X(91)92052-L; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1995, BLOOD, V85, P343; MANO H, 1993, ONCOGENE, V8, P417; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; QUELLE FW, 1991, J BIOL CHEM, V266, P609; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REN HY, 1994, J BIOL CHEM, V269, P19633; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH DB, 1989, GENE, V67, P31; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TODOKORO K, 1994, BIOCHEM BIOPH RES CO, V202, P1912; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	57	88	88	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					619	625						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651724				2022-12-25	WOS:A1995RQ46900002
J	PRYOR, WA; UPPU, RM				PRYOR, WA; UPPU, RM			A KINETIC-MODEL FOR THE COMPETITIVE REACTIONS OF OZONE WITH AMINO-ACID-RESIDUES IN PROTEINS IN REVERSE MICELLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; HYDROGEN-PEROXIDE; OXIDATIVE DAMAGE; IN-VITRO; OZONATION; EXPOSURE; PHOSPHATIDYLCHOLINE; PRODUCTS; TRYPTOPHAN; LYSOZYME	Lysozyme and 10 other proteins are solubilized in reverse micelles formed by 0.1 M sodium di-2-ethylhexylsulfosuccinate and 2.0-2.5 M water (pH 7.4) in isooctane solvent. Exposure of the protein-containing reverse micellar solutions to ozone causes oxidative damage to the proteins, as assessed by the oxidation of tryptophan residues. The oxidation product of the protein-bound tryptophan has a molar absorption coefficient of 3275 +/- 81 M-1 cm-1 (mean +/- S.D., n = 6) at 320 nm. The product is suggested to be a Criegee ozonide or a tautomer of the Criegee ozonide and not N-formylkynurenine. Ozonation of lysozyme in reverse micelles results in the formation of hydrogen peroxide in yields of only approximately 0.07 mol/mol of tryptophan residues oxidized. The recovery of hydrogen peroxide added as an internal standard to the lysozyme-containing reverse micellar solutions ranges from 84 to 88%, whether or not the samples are subjected to ozonation. This suggests that hydrogen peroxide is neither destroyed during the process of ozonation nor consumed by the protein to a significant extent in an adventitious reaction. A kinetic model for the overall reaction of ozone with the proteins is developed, taking into account the concentrations and the reactivities of individual amino acid residues toward ozone. The model predicts the fractional reaction of ozone with tryptophan residues in the proteins, despite differences in amino acid composition, molecular weight, and tertiary structures. The lack of influence of protein structure is confirmed further by the observation that the native lysozyme (with and without external S-carboxymethylcysteine) and S-carboxymethylated lysozyme give identical values of the fractional reaction of ozone with tryptophan residues. The kinetic equations for the competitive reactions of ozone with amino acid residues in proteins, with some minor modifications, are applicable to ozonations on complex mixtures of lipids, proteins, and antioxidants.			PRYOR, WA (corresponding author), LOUISIANA STATE UNIV, INST BIODYNAM, 711 CHOPPIN HALL, BATON ROUGE, LA 70803 USA.							BACHMANN PA, 1990, J AM CHEM SOC, V112, P8200, DOI 10.1021/ja00178a073; BADER H, 1981, WATER RES, V15, P449, DOI 10.1016/0043-1354(81)90054-3; BAILEY PS, 1958, CHEM REV, V58, P925, DOI 10.1021/cr50023a005; BAILEY PS, 1982, OZONATION ORGANIC CH, V2, P111; BANERJEE SK, 1992, ARCH BIOCHEM BIOPHYS, V295, P84, DOI 10.1016/0003-9861(92)90491-E; Blow D. M., 1971, ENZYMES, VIII, P185, DOI DOI 10.1016/S1874-6047(08)60397-2; CHAN PC, 1977, J BIOL CHEM, V252, P8537; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; CROSS CE, 1992, FEBS LETT, V298, P269, DOI 10.1016/0014-5793(92)80074-Q; CROSS CE, 1992, FREE RADICAL RES COM, V15, P347, DOI 10.3109/10715769209049150; CUETO R, 1992, BIOCHEM BIOPH RES CO, V188, P129, DOI 10.1016/0006-291X(92)92359-6; DAGLIESH CE, 1952, J CHEM SOC, V29, P137; DAYHOFF MO, 1973, ATLAS PROTEIN SEQUEN, V5; DAYHOFF MO, 1976, ATLAS PROTEIN SEQ S2, V5; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V0005; DAYHOFF MO, 1969, ATLAS PROTEIN SEQUEN, V4; DOOLEY MM, 1982, ARCH BIOCHEM BIOPHYS, V218, P459, DOI 10.1016/0003-9861(82)90368-X; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FREEMAN BA, 1979, ARCH BIOCHEM BIOPHYS, V197, P264, DOI 10.1016/0003-9861(79)90244-3; FREEMAN BA, 1979, ASSESSING TOXIC EFFE, P151; GIAMALVA DH, 1986, J AM CHEM SOC, V108, P6646, DOI 10.1021/ja00281a033; GIAMALVA DH, 1988, CHEM RES TOXICOL, V1, P144, DOI 10.1021/tx00003a002; GIESE AC, 1952, ARCH BIOCHEM BIOPHYS, V40, P71, DOI 10.1016/0003-9861(52)90075-1; GOLDSTEIN BD, 1975, ENVIRON RES, V9, P179, DOI 10.1016/0013-9351(75)90062-6; HOIGNE J, 1983, WATER RES, V17, P185, DOI 10.1016/0043-1354(83)90099-4; JOHNSON DA, 1980, AM REV RESPIR DIS, V121, P1031; KABANOV AV, 1989, ANAL BIOCHEM, V181, P145, DOI 10.1016/0003-2697(89)90408-9; KABANOV AV, 1991, FEBS LETT, V278, P143, DOI 10.1016/0014-5793(91)80103-A; KNIGHT KL, 1984, ARCH BIOCHEM BIOPHYS, V229, P259, DOI 10.1016/0003-9861(84)90152-8; KONINGS AWT, 1980, RADIAT RES, V81, P200, DOI 10.2307/3575396; KURODA M, 1975, J BIOCHEM-TOKYO, V78, P641, DOI 10.1093/oxfordjournals.jbchem.a130951; LAI CC, 1990, CHEM RES TOXICOL, V3, P517, DOI 10.1021/tx00018a005; LEH F, 1978, ENVIRON RES, V16, P179, DOI 10.1016/0013-9351(78)90154-8; LEH F, 1974, ACS SYM SER, V3, P22; LEVASHOV AV, 1982, J COLLOID INTERF SCI, V88, P444, DOI 10.1016/0021-9797(82)90273-9; MACGILLIVRAY RTA, 1982, P NATL ACAD SCI-BIOL, V79, P2504, DOI 10.1073/pnas.79.8.2504; MAKINO K, 1959, BIOCHIM BIOPHYS ACTA, V31, P301, DOI 10.1016/0006-3002(59)90001-0; MEINERS BA, 1977, ENVIRON RES, V14, P99, DOI 10.1016/0013-9351(77)90072-X; MUDD JB, 1969, ATMOS ENVIRON, V3, P669, DOI 10.1016/0004-6981(69)90024-9; NYMAN PO, 1964, BIOCHIM BIOPHYS ACTA, V85, P141, DOI 10.1016/0926-6569(64)90174-9; OOSTING RS, 1992, AM J PHYSIOL, V262, pL63, DOI 10.1152/ajplung.1992.262.1.L63; PAULS KP, 1980, NATURE, V283, P504, DOI 10.1038/283504a0; PREVIERO A, 1967, J MOL BIOL, V24, P261, DOI 10.1016/0022-2836(67)90331-2; PREVIERO A, 1964, GAZZ CHIM ITAL, V94, P630; PRYOR WA, 1992, CHEM RES TOXICOL, V5, P505, DOI 10.1021/tx00028a008; PRYOR WA, 1991, CHEM RES TOXICOL, V4, P341, DOI 10.1021/tx00021a014; PRYOR WA, 1991, CHEM-BIOL INTERACT, V79, P41, DOI 10.1016/0009-2797(91)90051-8; PRYOR WA, 1984, J AM CHEM SOC, V106, P7094, DOI 10.1021/ja00335a038; PRYOR WA, 1992, BIOCHEM BIOPH RES CO, V188, P618, DOI 10.1016/0006-291X(92)91101-U; PRYOR WA, 1985, J AM CHEM SOC, V107, P2793, DOI 10.1021/ja00295a036; PRYOR WA, 1983, J AM CHEM SOC, V105, P6858, DOI 10.1021/ja00361a019; RABINOWITZ JL, 1988, EXP LUNG RES, V14, P477, DOI 10.3109/01902148809087822; RAZUMOVSKII SD, 1971, IAN SSSR KH, V4, P686; SAKIYAMA F, 1978, CHEM LETT, P893, DOI 10.1246/cl.1978.893; SANTROCK J, 1992, CHEM RES TOXICOL, V5, P134, DOI 10.1021/tx00025a023; SQUADRITO GL, 1992, LIPIDS, V27, P955, DOI 10.1007/BF02535571; SRISANKAR EV, 1979, ARCH ENVIRON HEALTH, V34, P346, DOI 10.1080/00039896.1979.10667429; TEIGE B, 1974, CHEM PHYS LIPIDS, V12, P153, DOI 10.1016/0009-3084(74)90071-1; TODD GW, 1958, PHYSIOL PLANTARUM, V11, P457, DOI 10.1111/j.1399-3054.1958.tb08242.x; UPPU RM, 1992, BIOCHEM BIOPH RES CO, V187, P473, DOI 10.1016/S0006-291X(05)81518-9; VERWEIJ H, 1979, CHEMOSPHERE, V8, P443, DOI 10.1016/0045-6535(79)90004-3; Walsh K. A., 1970, METHODS ENZYMOL, V19, P41	62	63	67	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3120	3126						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679107				2022-12-25	WOS:A1993KM16100019
J	HORIE, M; BROXMEYER, HE				HORIE, M; BROXMEYER, HE			INVOLVEMENT OF IMMEDIATE-EARLY GENE-EXPRESSION IN THE SYNERGISTIC EFFECTS OF STEEL FACTOR IN COMBINATION WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR OR INTERLEUKIN-3 ON PROLIFERATION OF A HUMAN FACTOR-DEPENDENT CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-KIT PROTOONCOGENE; WILMS-TUMOR LOCUS; GROWTH-FACTOR; MOLECULAR-CLONING; FOS GENE; TRANSCRIPTIONAL ACTIVATION; 3RD MEMBER; 3T3 CELLS; GM-CSF; JUN-D	Steel factor (SLF) synergizes with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-3 (IL-3) to stimulate proliferation of human factor-dependent cell line, MO7e. To elucidate molecular mechanisms underlying this synergism, induction of immediate-early genes was studied. Treatment of MO7e cells with SLF, GM-CSF, and IL-3 induced/enhanced expression of c-fos, junB, egr-1, and c-myc genes. SLF treatment of MO7e cells led to higher expression of c-fos, junB, and egr-1 genes than did treatment with GM-CSF or IL-3. However, GM-CSF and IL-3 had more prolonged effects on enhancement of the c-myc gene than SLF. Using optimal dosages for cell proliferation, induction of c-fos and junB was greater than additive with SLF plus GM-CSF or IL-3, as compared with each factor alone. Using suboptimal amounts of SLF with optimal GM-CSF or IL-3, induction of c-fos,junB, egr-1, and c-myc genes was greater than additive. De novo protein synthesis was not required for greater induction of these immediate-early genes by the combination of SLF plus GM-CSF. Based on nuclear run-on and actinomycin D experiments, the data suggest that the synergistic effects of SLF plus GM-CSF on the induction of immediate-early genes may be mediated in part at the level of transcription and mRNA stabilization for c-fos, at the level of mRNA stabilization for junB, and at the level of transcription for egr-1.	INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,975 W WALNUT ST,IB501,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MICROBIOL IMMUNOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NCI NIH HHS [R37CA36464] Funding Source: Medline; NHLBI NIH HHS [R01HL49202, R01HL46549] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036464] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049202, R01HL046549] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDERSON DM, 1991, CELL GROWTH DIFFER, V2, P373; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BOSWELL HS, 1990, EXP HEMATOL, V18, P794; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; BROXMEYER HE, 1991, BLOOD, V77, P2142; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOU CC, 1987, P NATL ACAD SCI USA, V84, P2575, DOI 10.1073/pnas.84.9.2575; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DATTA R, 1991, CELL GROWTH DIFFER, V2, P43; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAMILTON JA, 1989, J CELL PHYSIOL, V141, P618, DOI 10.1002/jcp.1041410321; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KUJUBU DA, 1987, ONCOGENE, V1, P257; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LIM RW, 1987, ONCOGENE, V1, P263; LITZJACKSON S, 1992, BLOOD, V79, P2404; LIU JW, 1991, J BIOL CHEM, V266, P5929; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NAKAMURA T, 1991, CELL GROWTH DIFFER, V2, P267; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; ORLOFSKY A, 1987, EMBO J, V6, P2947, DOI 10.1002/j.1460-2075.1987.tb02599.x; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHABO Y, 1990, LEUKEMIA, V4, P797; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	52	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					968	973						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678261				2022-12-25	WOS:A1993KG07700034
J	JACKSON, DA; NATHANSON, NM				JACKSON, DA; NATHANSON, NM			SUBTYPE-SPECIFIC REGULATION OF MUSCARINIC RECEPTOR EXPRESSION AND FUNCTION BY HETEROLOGOUS RECEPTOR ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; EMBRYONIC CHICK HEART; CYCLIC-AMP FORMATION; ACETYLCHOLINE-RECEPTOR; PHOSPHATIDYLINOSITOL TURNOVER; CELLS; AGONISTS; CLONING; GENE; ANTAGONISTS	Incubation of cultured embryonic chicken heart cells with the beta-adrenergic agonist isoproterenol resulted in a dose-dependent increase in the number of mAChR on the surface of intact cells. The isoproterenol-mediated increase in mAChR number was time dependent and reached a maximum by 48 h. Chick heart cells treated with isoproterenol exhibited a greater than 6-fold increase in the sensitivity for carbachol-mediated inhibition of adenylyl cyclase activity as compared to control. Stimulation of cultured heart cells for 24 h with isoproterenol resulted in a 25-35% increase in cm2 mRNA levels as compared to control cm2 mRNA levels. In contrast, the level of cm4 mRNA was not significantly affected by isoproterenol treatment. cm2 mRNA levels were maximally elevated by 15 h following isoproterenol stimulation and remained elevated for up to 72 h. Incubation of cells with isoproterenol in the presence of Rp-cAMP, an inhibitor of cAMP-dependent protein kinase, blocked the increase in the level of cm2 mRNA. Thus, prolonged activation of beta-adrenergic receptors results in an increase in mAChR number and muscarinic responsiveness in chick heart cells due to a cAMP-dependent protein kinase mediated increase in cm2 mRNA levels.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL 30639] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030639] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BRAUN T, 1987, BIOCHEM BIOPH RES CO, V149, P125, DOI 10.1016/0006-291X(87)91613-5; BROWN JH, 1984, FED PROC, V43, P2613; BROWN JH, 1984, J BIOL CHEM, V259, P3777; FISHMAN WH, 1987, AM J CARDIOL, V59, pF26; GADBUT AP, 1994, J BIOL CHEM, V41, P25823; GALPER JB, 1982, J GEN PHYSIOL, V80, P231, DOI 10.1085/jgp.80.2.231; GALPER JB, 1980, J BIOL CHEM, V255, P9571; HABECKER BA, 1993, BIOCHEMISTRY-US, V32, P4986, DOI 10.1021/bi00070a003; HABECKER BA, 1992, P NATL ACAD SCI USA, V89, P5035, DOI 10.1073/pnas.89.11.5035; HALVORSEN SW, 1981, J BIOL CHEM, V256, P7941; HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4; HIRASAWA K, 1985, ANNU REV PHARMACOL, V25, P147, DOI 10.1146/annurev.pharmtox.25.1.147; HUNTER DD, 1986, J NEUROSCI, V6, P3739; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; MARGUETANT R, 1992, J MOL CELL CARDIOL, V24, P535; MOTOMURA S, 1990, BRIT J CLIN PHARMACO, V30, pS112, DOI 10.1111/j.1365-2125.1990.tb05478.x; NATHANSON NM, 1978, P NATL ACAD SCI USA, V75, P1788, DOI 10.1073/pnas.75.4.1788; NATHANSON NM, 1983, J NEUROCHEM, V41, P1545, DOI 10.1111/j.1471-4159.1983.tb00862.x; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; ORELLANA SA, 1985, BIOCHEM PHARMACOL, V34, P1321, DOI 10.1016/0006-2952(85)90512-X; PEPPEL K, 1990, BIOTECHNIQUES, V9, P711; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PORT JD, 1992, J PHARMACOL EXP THER, V262, P217; PRICHARD BNC, 1983, J CARDIOVASC PHARM, V5, pS56, DOI 10.1097/00005344-198300051-00009; REITHMANN C, 1992, N-S ARCH PHARMACOL, V345, P530; RENAUD JF, 1980, DEV BIOL, V78, P184, DOI 10.1016/0012-1606(80)90328-0; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SUBERS EM, 1988, J MOL CELL CARDIOL, V20, P131, DOI 10.1016/S0022-2828(88)80026-9; TIETJE KM, 1991, J BIOL CHEM, V266, P17382; TIETJE KM, 1990, J BIOL CHEM, V265, P2828	35	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22374	22377		10.1074/jbc.270.38.22374	http://dx.doi.org/10.1074/jbc.270.38.22374			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673222	hybrid			2022-12-25	WOS:A1995RW31400049
J	LAMPHEAR, BJ; KIRCHWEGER, R; SKERN, T; RHOADS, RE				LAMPHEAR, BJ; KIRCHWEGER, R; SKERN, T; RHOADS, RE			MAPPING OF FUNCTIONAL DOMAINS IN EUKARYOTIC PROTEIN-SYNTHESIS INITIATION-FACTOR 4G (EIF4G) WITH PICORNAVIRAL PROTEASES - IMPLICATIONS FOR CAP-DEPENDENT AND CAP-INDEPENDENT TRANSLATIONAL INITIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED HELA-CELLS; MESSENGER-RNA TRANSLATION; BINDING-PROTEIN; FACTOR-III; POLIOVIRUS INFECTION; P220 COMPONENT; INTERNAL INITIATION; COMPLEX; CLEAVAGE; VIRUS	Cap-dependent binding of mRNA to the 40 S ribosomal subunit during translational initiation requires the association of eukaryotic initiation factor 4G (eIF4G; formerly eIF-4 gamma and p220) with other initiation factors, notably eIF4E, eIF4A, and eIF3. Infection of cells by picornaviruses results in proteolytic cleavage of eIF4G and generation of a cap-independent translational state. Rhinovirus 2A protease and foot-and-mouth-disease virus L protease were used to analyze the association of eIF4G with eIF4A, eIF4E, and eIF3. Both proteases bisect eIF4G into N- and C-terminal fragments termed cp(N) and cp(C). cp(N) was shown to contain the eIF4E-binding site, as judged by retention on m(7)GTP-Sepharose, whereas cp(C) was bound to eIF3 and eIF4A, based on ultracentrifugal co-sedimentation. Further proteolysis of cp(N) by L protease produced an 18-kDa polypeptide termed cp(N2) which retained eIF4E binding activity and corresponded to amino acid residues 319-479 of rabbit eIF4G. Further proteolysis of cp(C) yielded several smaller fragments. cp(C2) (similar to 887-1402) contained the eIF4A binding site, whereas cp(C3) (similar to 480-886) contained the eIF3 binding site. These results suggest that cleavage by picornaviral proteases at residues 479-486 separates eIF4G into two domains, one required for recruiting capped mRNAs and one for attaching mRNA to the ribosome and directing helicase activity. Only the latter would appear to be necessary for internal initiation of picornaviral RNAs.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, SHREVEPORT, LA 71130 USA; UNIV VIENNA, FAK MED, INST BIOCHEM, A-1030 VIENNA, AUSTRIA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Vienna			Skern, Tim/AAC-1732-2022	Skern, Tim/0000-0001-8865-5500	NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON SD, 1968, ARCH BIOCHEM BIOPHYS, V125, P671, DOI 10.1016/0003-9861(68)90625-5; ANTHONY DD, 1991, J BIOL CHEM, V266, P10218; ARGOS P, 1984, NUCLEIC ACIDS RES, V12, P7251, DOI 10.1093/nar/12.18.7251; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BENNE R, 1978, J BIOL CHEM, V253, P3078; BERNSTEIN HD, 1985, MOL CELL BIOL, V5, P2913, DOI 10.1128/MCB.5.11.2913; BONNEAU AM, 1987, J VIROL, V61, P986, DOI 10.1128/JVI.61.4.986-991.1987; BUCKLEY B, 1986, VIROLOGY, V152, P497, DOI 10.1016/0042-6822(86)90155-8; BUCKLEY B, 1987, J BIOL CHEM, V262, P13599; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN R, 1983, J BIOL CHEM, V258, P7236; EDERY I, 1983, J BIOL CHEM, V258, P1398; ETCHISON D, 1985, J VIROL, V54, P634, DOI 10.1128/JVI.54.2.634-638.1985; ETCHISON D, 1984, J VIROL, V51, P832, DOI 10.1128/JVI.51.3.832-837.1984; ETCHISON D, 1990, J BIOL CHEM, V265, P7492; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6; GORBALENYA AE, 1986, FEBS LETT, V194, P253, DOI 10.1016/0014-5793(86)80095-3; GOSS DJ, 1990, BIOCHEMISTRY-US, V29, P5008, DOI 10.1021/bi00473a002; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HAMBIDGE SJ, 1992, P NATL ACAD SCI USA, V89, P10272, DOI 10.1073/pnas.89.21.10272; HANSEN J, 1982, J VIROL, V42, P200, DOI 10.1128/JVI.42.1.200-207.1982; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JACKSON RJ, 1994, MOL BIOL REP, V19, P147, DOI 10.1007/BF00986957; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JOSHI B, 1994, J BIOL CHEM, V269, P2048; KIRCHWEGER R, 1994, J VIROL, V68, P5677, DOI 10.1128/JVI.68.9.5677-5684.1994; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LEE KAW, 1985, J VIROL, V54, P515, DOI 10.1128/JVI.54.2.515-524.1985; LEE KAW, 1982, P NATL ACAD SCI-BIOL, V79, P3447, DOI 10.1073/pnas.79.11.3447; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; LLOYD RE, 1987, J VIROL, V61, P2480, DOI 10.1128/JVI.61.8.2480-2488.1987; LLOYD RE, 1986, VIROLOGY, V150, P299, DOI 10.1016/0042-6822(86)90291-6; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PEREZ L, 1992, VIROLOGY, V189, P178, DOI 10.1016/0042-6822(92)90693-J; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUECKERT R R, 1990, P507; SCHEPER GC, 1992, J BIOL CHEM, V267, P7269; SEAL SN, 1983, J BIOL CHEM, V258, P859; SOMMERGRUBER W, 1994, VIROLOGY, V198, P741, DOI 10.1006/viro.1994.1089; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; TAHARA SM, 1981, J BIOL CHEM, V256, P7691; TIMMER RT, 1993, J BIOL CHEM, V268, P9504; TRACHSEL H, 1980, P NATL ACAD SCI-BIOL, V77, P770, DOI 10.1073/pnas.77.2.770; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; Trachsel H., 1991, TRANSLATION EUKARYOT; VANHEUGTEN HAA, 1991, J BIOL CHEM, V266, P7279; WHETTER LE, 1994, J VIROL, V68, P5253, DOI 10.1128/JVI.68.8.5253-5263.1994; WYCKOFF EE, 1990, P NATL ACAD SCI USA, V87, P9529, DOI 10.1073/pnas.87.24.9529; WYCKOFF EE, 1990, BIOCHEMISTRY-US, V29, P10055, DOI 10.1021/bi00495a007; WYCKOFF EE, 1992, J VIROL, V66, P2943, DOI 10.1128/JVI.66.5.2943-2951.1992; YAN RQ, 1992, J BIOL CHEM, V267, P23226	65	478	485	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21975	21983		10.1074/jbc.270.37.21975	http://dx.doi.org/10.1074/jbc.270.37.21975			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665619	hybrid			2022-12-25	WOS:A1995RU75700083
J	WERA, S; FERNANDEZ, A; LAMB, NJC; TUROWSKI, P; HEMMINGSMIESZCZAK, M; MAYERJAEKEL, RE; HEMMINGS, BA				WERA, S; FERNANDEZ, A; LAMB, NJC; TUROWSKI, P; HEMMINGSMIESZCZAK, M; MAYERJAEKEL, RE; HEMMINGS, BA			DEREGULATION OF TRANSLATIONAL CONTROL OF THE 65-KDA REGULATORY SUBUNIT (PR65-ALPHA) OF PROTEIN PHOSPHATASE 2A LEADS TO MULTINUCLEATED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA SECONDARY STRUCTURE; MOLECULAR-CLONING; CATALYTIC SUBUNIT; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; EUKARYOTIC RIBOSOMES; MAMMALIAN-CELLS; EXPRESSION; INITIATION; SEQUENCE	Efficient translation of the mRNA encoding the 65-kDa regulatory subunit (PR65 alpha) of protein phosphatase 2A (PP2A) is prevented by an out of frame upstream AUG and a stable stem-loop structure (Delta G = -55.9 kcal/mol) in the 5'-untranslated region (5'-UTR). Deletion of the 5'-UTR allows efficient translation of the PR65 alpha message in vitro and overexpression in COS-1 cells. Insertion of the 5'-UTR into the beta-galactosidase leader sequence dramatically inhibits translation of the beta-galactosidase message in vitro and in vivo, confirming that this sequence functions as a potent translation regulatory sequence. Cells transfected or microinjected with a PR65 alpha expression vector lacking the 5'-UTR, express high levels of PR65 alpha, accumulating in both nucleus and cytoplasm, PR65 alpha overexpressing rat embryo fibroblasts (REF-52 cells) become multinucleated. These data and previous results (Mayer-Jaekel, R. E., Ohkura, H., Gomes, R., Sunkel, C. E., Baumgartner, S., Hemmings, B. A., and Glover, D. M. (1993) Cell 72, 621-633) suggest that PP2A participates in the regulation of both mitosis and cytokinesis.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; INSERM, CNRS, CTR RECH BIOCHIM MACROMOLEC, DEPT CELL BIOL, F-34033 MONTPELLIER, FRANCE	Friedrich Miescher Institute for Biomedical Research; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier								ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORNICKI P, 1989, J BIOMOL STRUCT DYN, V6, P971, DOI 10.1080/07391102.1989.10506525; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; KHEWGOODALL Y, 1991, BIOCHEMISTRY-US, V30, P89, DOI 10.1021/bi00215a014; KIEHART DP, 1982, J CELL BIOL, V94, P165, DOI 10.1083/jcb.94.1.165; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MAYER RE, 1991, ADV PROTEIN PHOSPHAT, V6, P265; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MAYERJAEKEL RE, 1992, MOL BIOL CELL, V3, P287, DOI 10.1091/mbc.3.3.287; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; SAGLIOCCO FA, 1993, J BIOL CHEM, V268, P26522; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	44	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21374	21381		10.1074/jbc.270.36.21374	http://dx.doi.org/10.1074/jbc.270.36.21374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673173	hybrid			2022-12-25	WOS:A1995RU05400077
J	HSIUNG, YC; ELSEA, SH; OSHEROFF, N; NITISS, JL				HSIUNG, YC; ELSEA, SH; OSHEROFF, N; NITISS, JL			A MUTATION IN YEAST TOP2 HOMOLOGOUS TO A QUINOLONE-RESISTANT MUTATION IN BACTERIA - MUTATION OF THE AMINO-ACID HOMOLOGOUS TO SER(83) OF ESCHERICHIA-COLI GYRA ALTERS SENSITIVITY TO EUKARYOTIC TOPOISOMERASE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED DNA CLEAVAGE; ANTITUMOR DRUGS; ENZYME; COMPLEX; CELLS; SITE; FLUOROQUINOLONES; ENHANCEMENT; BINDING; SHARE	In prokaryotic type II topoisomerases (DNA gyrases), mutations that result in resistance to quinolones frequently occur at Ser(83) or Ser(84) of the gyrA subunit. Mutations to Trp, Ala, and Leu have been identified, all of which confer high levels of quinolone resistance. Extensive segments of DNA gyrase are homologous to eukaryotic topoisomerase II, and Ser(741) of yeast TOP2 is homologous to Ser(83) of prokaryotic DNA gyrA. Introduction of the Ser(741) --> Trp mutation into yeast TOP2 confers resistance to 6,8-difluoro 7-(4'-hydroxyphenyl)-1-cyclopropyl-4-quinolone-3 carboxylic acid (CP 115,953), a fluoroquinolone with substantial activity against eukaryotic topoisomerase II, whereas changing Ser(741) to either Leu or Ala does not change sensitivity to quinolones. Interestingly, Ser(741) --> Trp in the yeast TOP2 also confers hypersensitivity to etoposide. Sensitivity to intercalating anti topoisomerase II agents such as amsacrine is not changed by any of the three mutations. The topoisomerase II protein carrying the Ser(741) --> Trp mutation was overexpressed and purified. The purified mutant enzyme had enhanced levels of etoposide stabilized covalent complex as compared with the wild type enzyme and reduced cleavage with CP-115,953. Unlike the wild type enzyme, etoposide-stabilized cleavage is not readily reversible by heat. We suggest that Ser(741) is near a binding site for both quinolones and etoposide and that the Ser(741) --> Trp mutation leads to a more stable ternary complex between etoposide, DNA, and the mutant enzyme.	ST JUDE CHILDRENS RES HOSP, DEPT MOLEC PHARMACOL, MEMPHIS, TN 38101 USA; CHILDRENS HOSP LOS ANGELES, DIV HEMATOL ONCOL, DEV THERAPEUT SECT, LOS ANGELES, CA 90027 USA; UNIV SO CALIF, SCH MED, DEPT BIOCHEM & MOLEC BIOL, LOS ANGELES, CA 90089 USA; VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA	St Jude Children's Research Hospital; Children's Hospital Los Angeles; University of Southern California; Vanderbilt University; Vanderbilt University			Nitiss, John/E-9974-2010	Elsea, Sarah/0000-0002-1400-8519; Nitiss, John/0000-0002-1013-4972	NATIONAL CANCER INSTITUTE [T32CA009582, R01CA052814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09582, CA52814] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck W T, 1991, Semin Cancer Biol, V2, P235; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; ELSEA SH, 1993, ANTIMICROB AGENTS CH, V37, P2179, DOI 10.1128/AAC.37.10.2179; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; ELSEA SH, 1992, J BIOL CHEM, V267, P13150; GIAEVER G, 1986, J BIOL CHEM, V261, P2448; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HSIUNG YH, 1989, J BIOL CHEM, V264, P9713; JANNATIPOUR M, 1993, J BIOL CHEM, V268, P18586; KAWADA SZ, 1991, CANCER RES, V51, P2922; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE MP, 1992, NUCLEIC ACIDS RES, V20, P5027, DOI 10.1093/nar/20.19.5027; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LIU YX, 1994, CANCER RES, V54, P2943; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; Neu H C, 1994, Adv Pharmacol, V29A, P227; Nitiss J L, 1994, Adv Pharmacol, V29A, P103; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; ROBINSON MJ, 1992, ANTIMICROB AGENTS CH, V36, P751, DOI 10.1128/AAC.36.4.751; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHILD D, 1983, CURR GENET, V7, P85, DOI 10.1007/BF00365631; Sherman F, 1979, METHODS YEAST GENETI; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WILLMOTT CJR, 1993, ANTIMICROB AGENTS CH, V37, P126, DOI 10.1128/AAC.37.1.126; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	34	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20359	20364		10.1074/jbc.270.35.20359	http://dx.doi.org/10.1074/jbc.270.35.20359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657608	hybrid			2022-12-25	WOS:A1995RR58400021
J	ULLU, E; TSCHUDI, C				ULLU, E; TSCHUDI, C			ACCURATE MODIFICATION OF THE TRYPANOSOME SPLICED LEADER CAP STRUCTURE IN A HOMOLOGOUS CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; M3G CAP; BRUCEI; TRANSCRIPTION; REQUIREMENT; METHYLATION; TRANSPORT; INVITRO; SIGNAL; INVIVO	During RNA maturation in trypanosomatid protozoa, trans-splicing transfers the spliced leader (SL) sequence and its cap from the SL RNA to the 5' end of all mRNAs. In Trypanosoma brucei and Crithidia fasciculata the SL RNA has an unusual cap structure with four methylated nucleotides following the 7-methylguanosine residue (cap 4). Since modification of the 5' end of the SL RNA is a pre-requisite for trans-splicing activity in T. brucei, we have begun to characterize the enzyme(s) involved in this process. Here we report the development of a T. brucei cell-free system for modification of the cap of the SL RNA. Analysis of the nucleotide composition of the in vitro generated cap structure by two-dimensional thin layer chromatography established that the in vitro reaction is accurate. Cap 4 formation requires the SL RNA to be in a ribonucleoprotein particle and can be inhibited by annealing a complementary 2'-O-methyl RNA oligonucleotide to nucleotides 7-18 of the SL RNA. Methylation of the 5' end of the SL RNA is also required for trans-splicing in T. cruzi and Leishmania amazonensis and cell-free extracts from C. fasciculata and L. amazonensis are capable of modifying the cap structure on the T. brucei SL ribonucleoprotein particle.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520	Yale University; Yale University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028798, R37AI028798] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28798] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASTROM SU, 1994, CELL, V79, P535, DOI 10.1016/0092-8674(94)90262-3; BANGS JD, 1992, J BIOL CHEM, V267, P9805; CROSS M, 1991, MOL CELL BIOL, V11, P5516, DOI 10.1128/MCB.11.11.5516; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; FREISTADT MS, 1987, NUCLEIC ACIDS RES, V15, P9861, DOI 10.1093/nar/15.23.9861; FREISTADT MS, 1988, J BIOL CHEM, V263, P15071; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HARRIS KA, 1995, RNA, V1, P351; HUANG J, 1991, EMBO J, V10, P3877, DOI 10.1002/j.1460-2075.1991.tb04957.x; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; LAIRD PW, 1987, EMBO J, V6, P1055, DOI 10.1002/j.1460-2075.1987.tb04858.x; MCNALLY KP, 1992, MOL CELL BIOL, V12, P4844, DOI 10.1128/MCB.12.11.4844; PATTON JR, 1991, MOL CELL BIOL, V11, P5998, DOI 10.1128/MCB.11.12.5998; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; PLESSEL G, 1994, MOL CELL BIOL, V14, P4160, DOI 10.1128/MCB.14.6.4160; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SINGH R, 1990, MOL CELL BIOL, V10, P939, DOI 10.1128/MCB.10.3.939; SIRUMCONNOLLY K, 1993, SCIENCE, V262, P1886, DOI 10.1126/science.8266080; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; ULLU E, 1990, NUCLEIC ACIDS RES, V18, P3319, DOI 10.1093/nar/18.11.3319; ULLU E, 1993, J BIOL CHEM, V268, P13068	26	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20365	20369		10.1074/jbc.270.35.20365	http://dx.doi.org/10.1074/jbc.270.35.20365			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657609	hybrid			2022-12-25	WOS:A1995RR58400022
J	MURAI, N; TAGUCHI, H; YOSHIDA, M				MURAI, N; TAGUCHI, H; YOSHIDA, M			KINETIC-ANALYSIS OF INTERACTIONS BETWEEN GROEL AND REDUCED ALPHA-LACTALBUMIN - EFFECT OF GROES AND NUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; ESCHERICHIA-COLI; CHAPERONIN GROE; HYDROLYSIS; ABSENCE; BARNASE; BINDING; CELL; ATP	The real-time analysis of the association and dissociation of chaperonin with respect to its substrate protein was carried out using the BIAcore(TM) system, We immobilized alpha-lactalbumin (LA) as a substrate protein on the sensor chip and the GroEL solution was passed over it. Whereas GroEL did not bind to the immobilized native LA, it associated with the immobilized Ca2+-depleted, disulfide bond-reduced form of LA (rLA) rapidly (k(on) = 1.96 x 10(5) M(-1) s(-1)) and dissociated extremely slowly (k(off) = 2.08 x 10(-4) s(-1)), giving a low dissociation constant (K-D = 1.06 nM). MgATP greatly accelerated the dissociation (k(off) = 0.15 +/- 0.02 s(-1)). The K-D value remained almost unchanged when GroES and/or 10 mu M ADP was included in the GroEL solution, However, when 1 mM ADP was included, the K-D value of GroEL increased by 2 orders of magnitude solely due to the change in k(off). When GroES and 1 mM ADP were included, no interaction with rLA was detected due to changes in both k(on) and k(off). These results indicate that GroEL/ES has high and low affinity ADP binding sites and that occupation of the low affinity sites by ADP was responsible for the loss of ability to interact with the substrate protein, The effect of excess GroES on the preformed GroEL rLA and GroELIES rLA complexes was also examined. With increasing GroES, the dissociation of GroEL and GroEL/ES from rLA was accelerated, and thus the possibility is suggested that the substrate protein and GroES compete for the same site on GroEL.	TOKYO INST TECHNOL,RESOURCES UTILIZAT RES LAB,YOKOHAMA,KANAGAWA 226,JAPAN	Tokyo Institute of Technology			Taguchi, Hideki/B-6946-2009; taguchi, hideki/AAM-2663-2021; MURAI, NORIYUKI/V-5747-2018	Taguchi, Hideki/0000-0002-6612-9339; taguchi, hideki/0000-0002-6612-9339; MURAI, NORIYUKI/0000-0002-1552-5104				AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHAIKEN I, 1991, ANAL BIOCHEM, V201, P197; CULLEN DC, 1988, BIOSENSORS, V3, P211; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FARGERSTAM LG, 1992, J CHROMATOGR, V597, P397; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRANZOW R, 1992, BIO-TECHNOL, V10, P390, DOI 10.1038/nbt0492-390; GRAY TE, 1993, EMBO J, V12, P4145, DOI 10.1002/j.1460-2075.1993.tb06098.x; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HIRAOKA Y, 1980, BIOCHEM BIOPH RES CO, V95, P1098, DOI 10.1016/0006-291X(80)91585-5; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KUBO T, 1993, J BIOL CHEM, V268, P19346; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LIEDBERG B, 1983, SENSOR ACTUATOR, V4, P299, DOI 10.1016/0250-6874(83)85036-7; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MAKINO Y, 1993, FEBS LETT, V336, P363, DOI 10.1016/0014-5793(93)80838-L; MARTIN J, 1991, NATURE, V352, P39; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; OKAZAKI A, 1994, NAT STRUCT BIOL, V1, P439, DOI 10.1038/nsb0794-439; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; TAGUCHI H, 1995, FEBS LETT, V359, P159; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; VIITANEN PV, 1992, PROTEIN SCI, V1, P361; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YUTANI K, 1992, J MOL BIOL, V228, P347, DOI 10.1016/0022-2836(92)90824-4; ZHAN R, 1994, J MOL BIOL, V242, P150	40	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19957	19963		10.1074/jbc.270.34.19957	http://dx.doi.org/10.1074/jbc.270.34.19957			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650011	hybrid			2022-12-25	WOS:A1995RQ99100044
J	SERRA, EC; KRAPP, AR; OTTADO, J; FELDMAN, MF; CECCARELLI, EA; CARRILLO, N				SERRA, EC; KRAPP, AR; OTTADO, J; FELDMAN, MF; CECCARELLI, EA; CARRILLO, N			THE PRECURSOR OF PEA FERREDOXIN-NADP(+) REDUCTASE SYNTHESIZED IN ESCHERICHIA-COLI CONTAINS BOUND FAD AND IS TRANSPORTED INTO CHLOROPLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; NADP+ OXIDOREDUCTASE; COMPETENT PRECURSOR; SPINACH FERREDOXIN; STEP PURIFICATION; PROTEIN IMPORT; SMALL SUBUNIT; TRANSLOCATION; CARBOXYLASE; BINDING	The precursor of the chloroplast flavoprotein ferredoxin-NADP(+) reductase hom pea was expressed in Escherichia coli as a carboxyl-terminal fusion to glutathione S-transferase. The fused protein was soluble, and the precursor could be purified in a few steps involving affinity chromatography on glutathione-agarose, cleavage of the transferase portion by protease Xa, and ion exchange chromatography on DEAE-cellulose. The purified prereductase contained bound FAD but displayed marginally low levels of activity, Removal of the transit peptide by limited proteolysis rendered a functional protease-resistant core exhibiting enzymatic activity, The FAD-containing precursor expressed in E. coli was readily transported into isolated pea chloroplasts and was processed to the mature size, both inside the plastid and by incubation with stromal extracts in a plastid-free reaction. import was dependent on the presence of ATP and was stimulated severalfold by the addition of plant leaf extracts.	UNIV NACL ROSARIO,FAC CIENCIAS BIOQUIM & FARMACEUT,DEPT CIENCIAS BIOL,MOLEC BIOL SECT,RA-2000 ROSARIO,ARGENTINA	National University of Rosario			Feldman, Mario/A-2637-2014; Ceccarelli, Eduardo A./M-8699-2014; Ceccarelli, Eduardo A./V-2600-2019	Feldman, Mario/0000-0003-4497-0976; Ceccarelli, Eduardo A./0000-0001-5776-3306; Ceccarelli, Eduardo A./0000-0001-5776-3306				ALTIERI F, 1989, J BIOL CHEM, V264, P4782; AMERICA T, 1994, PLANT MOL BIOL, V24, P283, DOI 10.1007/BF00020168; ARCHER EK, 1993, PLANT MOL BIOL, V23, P1105, DOI 10.1007/BF00042345; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bar-Nun S, 1980, METHOD ENZYMOL, V69, P363; CARRILLO N, 1985, EUR J BIOCHEM, V150, P469, DOI 10.1111/j.1432-1033.1985.tb09045.x; Carrillo N, 1987, TOPICS PHOTOSYNTHESI, V8, P527; CECCARELLI EA, 1991, J BIOL CHEM, V266, P14283; CHOI SY, 1986, EUR J BIOCHEM, V161, P289, DOI 10.1111/j.1432-1033.1986.tb10445.x; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DELLACIOPPA G, 1986, P NATL ACAD SCI USA, V83, P6873, DOI 10.1073/pnas.83.18.6873; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EVANS A, 1992, PROTEIN EXPRES PURIF, V3, P178, DOI 10.1016/1046-5928(92)90013-M; FELIPO V, 1983, EUR J BIOCHEM, V133, P641, DOI 10.1111/j.1432-1033.1983.tb07511.x; FERNANDEZ MD, 1991, J BIOL CHEM, V266, P7220; GADDA G, 1990, J BIOL CHEM, V265, P11955; GROSSMAN AR, 1982, J BIOL CHEM, V257, P1558; JENG JJ, 1991, ARCH BIOCHEM BIOPHYS, V289, P214, DOI 10.1016/0003-9861(91)90464-T; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; NAGAO M, 1992, J BIOL CHEM, V267, P17925; NAKANO H, 1994, NUCLEIC ACIDS RES, V22, P543, DOI 10.1093/nar/22.3.543; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; OBLONG JE, 1992, J BIOL CHEM, V267, P14328; ORELLANO EG, 1993, J BIOL CHEM, V268, P19267; OTTADO J, 1994, EUR J BIOCHEM, V225, P677, DOI 10.1111/j.1432-1033.1994.00677.x; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; PILON M, 1990, J BIOL CHEM, V265, P3358; PILON M, 1992, J BIOL CHEM, V267, P19907; ROBINSON KM, 1994, EUR J BIOCHEM, V222, P983, DOI 10.1111/j.1432-1033.1994.tb18949.x; ROBINSON SP, 1979, ARCH BIOCHEM BIOPHYS, V196, P319, DOI 10.1016/0003-9861(79)90584-8; SCHREIER PH, 1988, PLANT MOL BIOL MANUA, P1; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SERRA EC, 1993, PROTEIN EXPRES PURIF, V4, P539, DOI 10.1006/prep.1993.1071; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLL J, 1993, PHYSIOL PLANTARUM, V87, P433, DOI 10.1111/j.1399-3054.1993.tb01752.x; TARONI F, 1991, J BIOL CHEM, V266, P13267; VALLEJOS RH, 1984, J BIOL CHEM, V259, P8048; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; YUAN JG, 1994, J BIOL CHEM, V269, P18463	45	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19930	19935		10.1074/jbc.270.34.19930	http://dx.doi.org/10.1074/jbc.270.34.19930			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650008	hybrid			2022-12-25	WOS:A1995RQ99100040
J	KENNEDY, MW; BRITTON, C; PRICE, NC; KELLY, SM; COOPER, A				KENNEDY, MW; BRITTON, C; PRICE, NC; KELLY, SM; COOPER, A			THE DVA-1 POLYPROTEIN OF THE PARASITIC NEMATODE DICTYOCAULUS-VIVIPARUS - A SMALL HELIX-RICH LIPID-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID ANALOG; PHOSPHOGLYCERATE MUTASE; 3-DIMENSIONAL STRUCTURE; DIROFILARIA-IMMITIS; MAJOR ALLERGEN; ASCARIS; ANTIGENS; ALBUMIN	DNA encoding a single unit of the DvA-1 polyprotein of the parasitic nematode Dictyocaulus viviparus was isolated and the polypeptide (''rDvA-1L'') expressed in Escherichia coli, to give a protein showing high binding affinity for fatty acids and retinoids, Fluorescent fatty acid probes show substantial changes in emission spectrum in the presence of rDvA-1L, which can be reversed by fatty acids (oleic, palmitic, stearic, arachidonic) and retinoids, but not by tryptophan, squalene, or cholesterol. Moreover, changes in intrinsic fluorescence of retinol or retinoic acid confirm a retinoid binding activity, Fluorescence titration experiments indicate stoichiometric binding to a single protein site per monomer unit with affinities (K-d) in the range 3 x 10(-8) M for 11-((5-dimethylaminonaphthalene-1-sulfonyl)amino)undecanoic acid, and, by competition, 5 x 10(-8) RI for oleic acid, The extreme blue shift of bound fluorescent fatty acid suggests an unusually low polarity for the protein binding site. The emission spectrum of the single tryptophan of rDvA-1L indicates that it is deeply buried in a nonpolar environment, and its spectrum is unaffected by ligand binding, Far UV circular dichroism of rDvA-1L reveals a high alpha-helix content (53%). Differential scanning calorimetry studies indicate that rDvA-1L is highly stable (T-m approximate to 98 degrees C), refolding efficiently following thermal denaturation, DvA-1 therefore represents an example of a new class of lipid binding protein, and is the first product of a polyprotein with this activity to be described.	UNIV GLASGOW,WELCOME LABS EXPTL PARASITOL,GLASGOW G12 8QQ,LANARK,SCOTLAND; UNIV GLASGOW,DEPT CHEM,GLASGOW G12 8QQ,LANARK,SCOTLAND; UNIV STIRLING,DEPT BIOL & MOLEC SCI,STIRLING FK9 4LA,SCOTLAND	University of Glasgow; University of Glasgow; University of Stirling			Kelly, Sharon/K-4611-2013; Cooper, Alan/F-7813-2011	Cooper, Alan/0000-0001-6709-7343; Kelly, Sharon/0000-0002-3516-1387; Britton, Collette/0000-0002-5165-312X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BRITTON C, 1995, IN PRESS MOL BIOCH P; CHRISTIE JF, 1990, IMMUNOLOGY, V69, P596; Cooper A, 1994, Methods Mol Biol, V22, P109; CULPEPPER J, 1992, MOL BIOCHEM PARASIT, V54, P51, DOI 10.1016/0166-6851(92)90094-Z; EFTINK MR, 1984, BIOCHEMISTRY-US, V23, P3891, DOI 10.1021/bi00312a016; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; FRAPIN D, 1993, J PROTEIN CHEM, V12, P443, DOI 10.1007/BF01025044; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLATZ JFC, 1990, MOL CELL BIOCHEM, V98, P237, DOI 10.1007/BF00231390; HAUGHLAND RP, 1992, HDB FLUORESCENT PROB; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; JOHNSON CM, 1987, BIOCHEM J, V245, P525, DOI 10.1042/bj2450525; KENNEDY MW, 1986, IMMUNOLOGY, V58, P515; KRAGELUND BB, 1993, J MOL BIOL, V230, P1260, DOI 10.1006/jmbi.1993.1240; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; MACGREGOR RB, 1986, NATURE, V319, P70, DOI 10.1038/319070a0; MCREYNOLDS LA, 1993, PARASITOL TODAY, V9, P403, DOI 10.1016/0169-4758(93)90046-I; MOORE JD, 1993, BIOCHEM J, V295, P277, DOI 10.1042/bj2950277; Nozaki Y, 1972, Methods Enzymol, V26, P43; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; POOLE CB, 1992, P NATL ACAD SCI USA, V89, P5986, DOI 10.1073/pnas.89.13.5986; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SACCHETTINI JC, 1989, J MOL BIOL, V208, P827; SPENCE HJ, 1993, MOL BIOCHEM PARASIT, V7, P339; THUMSER AEA, 1994, BIOCHEM J, V297, P103, DOI 10.1042/bj2970103; TOMLINSON LA, 1989, J IMMUNOL, V143, P2349; TWEEDIE S, 1993, EXP PARASITOL, V76, P156, DOI 10.1006/expr.1993.1018; WHITE MF, 1993, BIOCHEM J, V295, P743, DOI 10.1042/bj2950743; WILKINSON TCI, 1986, BIOCHEM J, V238, P419, DOI 10.1042/bj2380419; WILTON DC, 1990, BIOCHEM J, V270, P163, DOI 10.1042/bj2700163; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	33	36	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19277	19281		10.1074/jbc.270.33.19277	http://dx.doi.org/10.1074/jbc.270.33.19277			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642601				2022-12-25	WOS:A1995RP70300015
J	SHA, M; FERREDAMARE, AR; BURLEY, SK; GOSS, DJ				SHA, M; FERREDAMARE, AR; BURLEY, SK; GOSS, DJ			ANTI-COOPERATIVE BIPHASIC EQUILIBRIUM BINDING OF TRANSCRIPTION FACTOR UPSTREAM STIMULATORY FACTOR TO ITS COGNATE DNA MONITORED BY PROTEIN FLUORESCENCE CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; SYNTHESIS INITIATION FACTOR-4E; FACTOR USF; COMPONENT; ELEMENT; REGION; RNA	Upstream stimulatory factor USF is a human transcriptional activation factor, which uses a basic/helix-loop-helix/leucine zipper (b/HLH/Z) motif to homodimerize and recognize specific sequences in the promoter region of both nuclear and viral genes transcribed by RNA polymerase II, Steady state fluorescence spectroscopy demonstrated that the basic/helix-loop-helix/leucine zipper domain of USF binds its DNA targets with high affinity and specificity, whereas removal of the leucine zipper yielding the basic/helix-loop-helix minimal DNA binding region reduces both affinity and specificity. Stopped flow method provided kinetic evidence for a two-step binding process involving rapid formation of a protein-DNA intermediate followed by a slow isomerization step, which is consistent with the basic region undergoing a random coil to a-helix folding transition on specific DNA recognition. The leucine zipper is also necessary for USF to function as a bivalent homotetramer, capable of binding two distinct recognition sites simultaneously and mediating DNA looping under physiologic conditions. Titration studies revealed that the first binding event has a equilibrium constant K-eq = (2.2 +/- 2.0) x 10(9) M(-1) for major late promoter DNA, whereas the second binding event occurs with a remarkably reduced affinity, K-eq = (1.2 +/- 0.8) x 10(8) M(-1). This anticooperative feature of DNA binding by the homotetramer suggests that USF stimulates transcription by mediating DNA looping between nearby recognition sites located in class II nuclear and viral gene promoters,	CUNY HUNTER COLL,DEPT CHEM,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOLEC BIOPHYS LABS,NEW YORK,NY 10021	City University of New York (CUNY) System; Hunter College (CUNY); Howard Hughes Medical Institute; Rockefeller University				Burley, Stephen K./0000-0002-2487-9713				BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BRUN F, 1975, BIOCHEMISTRY-US, V14, P558, DOI 10.1021/bi00674a015; BUNGERT J, 1992, J MOL BIOL, V223, P885, DOI 10.1016/0022-2836(92)90250-N; CARBERRY SE, 1989, BIOCHEMISTRY-US, V28, P8078, DOI 10.1021/bi00446a017; CARBERRY SE, 1990, BIOCHEMISTRY-US, V29, P3337, DOI 10.1021/bi00465a027; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GARLAND DL, 1978, BIOCHEMISTRY-US, V17, P4266, DOI 10.1021/bi00613a024; ISHIDA T, 1983, BIOCHEM BIOPH RES CO, V115, P849, DOI 10.1016/S0006-291X(83)80012-6; LAWACZECK R, 1974, BIOPOLYMERS, V13, P2003, DOI 10.1002/bip.1974.360131006; LESHKOWITZ D, 1992, DNA CELL BIOL, V11, P549, DOI 10.1089/dna.1992.11.549; MARTIN KA, 1994, GENE, V142, P275, DOI 10.1016/0378-1119(94)90274-7; MEISTERERNST M, 1985, P NATL ACAD SCI USA, V87, P9153; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; OLSEN K, 1993, BIOCHEMISTRY-US, V32, P9686, DOI 10.1021/bi00088a021; READ ML, 1993, BIOCHEM J, V295, P233, DOI 10.1042/bj2950233; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHA M, 1994, J BIOL CHEM, V269, P14872	21	21	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19325	19329		10.1074/jbc.270.33.19325	http://dx.doi.org/10.1074/jbc.270.33.19325			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642609	hybrid			2022-12-25	WOS:A1995RP70300023
J	SUZUKI, K; YAMAGUCHI, T; TANAKA, T; KAWANISHI, T; NISHIMAKIMOGAMI, T; YAMAMOTO, K; TSUJI, T; IRIMURA, T; HAYAKAWA, T; TAKAHASHI, A				SUZUKI, K; YAMAGUCHI, T; TANAKA, T; KAWANISHI, T; NISHIMAKIMOGAMI, T; YAMAMOTO, K; TSUJI, T; IRIMURA, T; HAYAKAWA, T; TAKAHASHI, A			ACTIVATION INDUCES DEPHOSPHORYLATION OF COFILIN AND ITS TRANSLOCATION TO PLASMA-MEMBRANES IN NEUTROPHIL-LIKE DIFFERENTIATED HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; PROTEIN-KINASE-C; NADPH OXIDASE; SUPEROXIDE GENERATION; GUANINE-NUCLEOTIDES; PHOSPHORYLATION; ACTIN; COMPONENTS; STAUROSPORINE	We suggested that a cytosolic 21-kDa phosphoprotein played an important role in opsonized zymosan-triggered activation of superoxide-generating enzyme in neutrophil-like HL-60 cells through dephosphorylation (Suzubi, K., Yamaguchi, T., Oshizawa, T., Yamamoto, Y., Nishimaki-Mogami, T., Hayakawa, T., and Takahashi, A (1995) Biochim, Biophys, Acta 1266, 261-267). In the present study, we characterized the phosphoprotein and studied changes in its localization upon activation of phagocytes. The 21-kDa phosphoprotein was rapidly dephosphorylated upon activation not only with opsonized zymosan but also with formyl-Met-Leu-Phe and arachidonic acid. The peptide fragments derived from the 21-kDa phosphoprotein were found to have the same amino acid sequences as those of cofilin, an actin-binding protein. The phosphoprotein reacted exclusively with anti cofilin antibody on two dimensional immunoblots. Accordingly, together with its apparent molecular weight, isoelectric point, and detection of phosphoserine as a phosphoamino acid, we concluded that the 21-kDa phosphoprotein was a phosphorylated form of cofilin. The amount of cofilin in membranous fractions was increased upon activation. Furthermore, confocal laser scanning microscopy showed that cofilin existed diffusely in the cytosol and nuclear region of the resting cells, while in the activated cells, it was accumulated at the plasma membrane area, forming ruffles or endocytic vesicles on which O-2(radical) (anion) should be produced. These results suggested that in resting cells cofilin exists as a soluble phosphoprotein in the cytosol and nuclei, while upon stimulation a large portion of cofilin is dephosphorylated and translocated to the plasma membrane regions.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	SUZUKI, K (corresponding author), NATL INST HLTH SCI,SETAGAYA KU,18-1 KAMIYOGA 1 CHOME,TOKYO 158,JAPAN.		Kawanishi, Tetsuya/V-3860-2019					ABE H, 1989, J BIOCHEM-TOKYO, V106, P696, DOI 10.1093/oxfordjournals.jbchem.a122919; ANDREWS PC, 1983, BLOOD, V61, P333; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BADWEY JA, 1989, BIOCHEM BIOPH RES CO, V158, P1029, DOI 10.1016/0006-291X(89)92825-8; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; DEWALD B, 1989, BIOCHEM J, V264, P879, DOI 10.1042/bj2640879; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; GOLDSCHMIDTCLER.PJ, 1991, SCIENCE, V251, P1231; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; KONAMI Y, 1992, J BIOCHEM-TOKYO, V112, P366, DOI 10.1093/oxfordjournals.jbchem.a123907; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; OGAWA K, 1990, NUCLEIC ACIDS RES, V18, P7169, DOI 10.1093/nar/18.23.7169; OHTA Y, 1989, J BIOL CHEM, V264, P16143; ONO S, 1994, J BIOL CHEM, V269, P15280; PARK JW, 1992, J BIOL CHEM, V267, P19901; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; RETROSEN D, 1990, J BIOL CHEM, V265, P19910; ROBINSON JM, 1990, BIOCHIM BIOPHYS ACTA, V1055, P55, DOI 10.1016/0167-4889(90)90090-Z; ROSALES C, 1994, NEUTROPHIL, P23; SAITO T, 1994, EXP CELL RES, V212, P49, DOI 10.1006/excr.1994.1117; SAMSTAG Y, 1994, P NATL ACAD SCI USA, V91, P4494, DOI 10.1073/pnas.91.10.4494; SEIFERT R, 1987, EUR J BIOCHEM, V162, P563, DOI 10.1111/j.1432-1033.1987.tb10676.x; SMITH RM, 1991, BLOOD, V77, P673; SUZUKI K, 1995, BBA-MOL CELL RES, V1266, P261, DOI 10.1016/0167-4889(95)00029-R; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382	42	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19551	19556		10.1074/jbc.270.33.19551	http://dx.doi.org/10.1074/jbc.270.33.19551			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642640	hybrid			2022-12-25	WOS:A1995RP70300056
J	POLLOCK, PM; YU, F; QIU, L; PARSONS, PG; HAYWARD, NK				POLLOCK, PM; YU, F; QIU, L; PARSONS, PG; HAYWARD, NK			EVIDENCE FOR UV INDUCTION OF CDKN2 MUTATIONS IN MELANOMA CELL-LINES	ONCOGENE			English	Article						CDKN2 GENE; DIPYRIMIDINE; MELANOMA; TANDEM MUTATION; UV RADIATION	FAMILIAL MELANOMA; P53 MUTATIONS; STRAND BIAS; GENE; SKIN; SPECIFICITY; REPAIR; LOCUS; ASSIGNMENT; HOTSPOTS	The CDKN2 gene, encoding the cyclin dependent kinase inhibitor p16, is a tumour suppressor gene involved in melanoma and maps to chromosome band 9p22. Mutations or interstitial deletions of this gene have been found both in the germline of familial melanoma cases and somatically in melanoma cell lines. Previous mutation analyses of melanoma cell lines have indicated a high frequency of C:G to T:A transitions, with all of these mutations occurring at dipyrimidine sites. Including three melanoma cell lines carrying tandem CC to TT mutations, the spectrum of mutations so far reported indicates a possible role for u.v. radiation in the mutagenesis of this gene in some tumours. To further examine this hypothesis we have characterised mutations of the CDKN2 gene in 30 melanoma cell lines. Nineteen lines carried complete or partial homozygous deletions of the gene. Of the remaining cell lines, eight were shown by direct sequencing of PCR products from exon 1 and exon 2 to carry a total of nine different mutations of CDKN2. Two cell lines carried tandem CC to TT mutations and a high rate of C:G to T:A transitions was observed. This study provides further evidence for the role of u.v. light in the genesis of melanoma, with one target being the CDKN2 tumour suppressor gene.	QUEENSLAND INST MED RES,QUEENSLAND CANC FUND RES LABS,JOINT EXPTL ONCOL PROGRAM,HERSTON,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute			Parsons, Peter G/H-8163-2015; hayward, nicholas k/C-1367-2015; hayward, nick/AAV-8802-2020	Parsons, Peter G/0000-0002-0473-3346; hayward, nicholas k/0000-0003-4760-1033; Pollock, Pamela/0000-0001-8420-1026				AIRNS P, 1994, SCIENCE, V265, P415; ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CHENG JQ, 1994, CANCER RES, V54, P5547; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FRANKLIN WA, 1985, NUCLEIC ACIDS RES, V13, P5317, DOI 10.1093/nar/13.14.5317; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; GRUIS NA, 1993, MELANOMA RES, V3, P271; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; ISSHIKI K, 1994, ONCOGENE, V9, P1649; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAMB A, 1995, SCIENCE, V267, P16, DOI 10.1126/science.267.5194.16; KANJILAL S, 1993, CANCER RES, V53, P2961; KRESS S, 1992, CANCER RES, V52, P6400; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; LIU QY, 1995, ONCOGENE, V10, P619; MAESTRO R, 1995, SCIENCE, V267, P15, DOI 10.1126/science.7809600; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MORI T, 1994, CANCER RES, V54, P3396; MURTY VVVS, 1992, GENOMICS, V13, P227, DOI 10.1016/0888-7543(92)90228-K; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; NOBORI T, 1964, NATURE, V368, P753; OHTA M, 1994, CANCER RES, V54, P5269; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; WALKER GJ, 1994, ONCOGENE, V9, P819; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	39	109	110	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					663	668						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651729				2022-12-25	WOS:A1995RQ46900007
J	AKASHI, M; HACHIYA, M; OSAWA, Y; SPIRIN, K; SUZUKI, G; KOEFFLER, HP				AKASHI, M; HACHIYA, M; OSAWA, Y; SPIRIN, K; SUZUKI, G; KOEFFLER, HP			IRRADIATION INDUCES WAF1 EXPRESSION THROUGH A P53-INDEPENDENT PATHWAY IN KG-1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; FACTOR GENE-EXPRESSION; LONG TERMINAL REPEAT; FACTOR-KAPPA-B; WILD-TYPE P53; IONIZING-RADIATION; FREQUENT MUTATIONS; OXYGEN RADICALS; SUPPRESSOR GENE	WAF1 binds to cyclin-Cdk complexes and inhibits their activity, causing cell cycle arrest. Previous studies have shown that expression of WAF1 is induced through the p53-dependent pathway; WAF1 is induced in cells with functional p53 but not in cells with either mutant p53 or no p53. Human myeloblastic leukemia cells KG-1 had no constitutive expression of p53, and irradiation did not induce p53. However, irradiation increased WAF1 expression in KG-1 cells and other cell lines containing mutant p53. The KG-1 cells constitutively produced low levels of tumor necrosis factor (TNF); irradiation markedly increased the production of TNF. Notably, induction of WAF1 mRNA by irradiation was blocked by anti-TNF antibody, Furthermore, exogenously added TNF increased levels of WAF1 mRNA in these cells. Irradiation increased the rate of WAF1 transcription 3-fold, and the half-life (t(1/2)) of WAF1 mRNA in these cells increased from <1 h in unirradiated cells to >4 h in irradiated cells. These findings indicate that increased levels of WAF1 transcripts occur, at least in part, through a pathway of TNF production and that the increase in WAF1 mRNA observed after irradiation is regulated by both transcriptional and posttranscriptional mechanisms. Our present study strongly suggests that an alternative pathway of induction of WAF1 occurs independent of activation by p53.	UNIV CALIF LOS ANGELES, SCH MED, CEDARS SINAI RES INST, LOS ANGELES, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	AKASHI, M (corresponding author), NATL INST RADIOL SCI, DIV RADIAT HLTH, INAGE KU, 4-9-1 ANAGAWA, CHIBA 263, JAPAN.				NCI NIH HHS [CA43277, CA33936, CA26038] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026038, U01CA043277, R01CA033936] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P986, DOI 10.1016/0006-291X(92)92301-D; AKASHI M, 1989, BLOOD, V74, P2383; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BRACH MA, 1993, J BIOL CHEM, V268, P8466; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CAVARD C, 1990, J CLIN INVEST, V86, P1369, DOI 10.1172/JCI114849; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; CLARK IA, 1985, MED RES REV, V5, P297, DOI 10.1002/med.2610050303; CLEMENS MJ, 1984, TRANSCRIPTION TRANSL, P211; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DENEKAMP J, 1986, INT J RADIAT BIOL, V49, P357, DOI 10.1080/09553008514552591; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI 10.1016/S0065-2776(08)60642-2; DOROSHOW JH, 1986, P NATL ACAD SCI USA, V83, P4514, DOI 10.1073/pnas.83.12.4514; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; HACHIYA M, 1994, EXP CELL RES, V214, P343, DOI 10.1006/excr.1994.1266; HALL EJ, 1988, RADIOBIOLOGY RADIOLO, P10; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HALLAHAN DE, 1991, CANCER RES, V51, P4565; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; KASTAN M, CANCER RES, V51, P6304; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P4279; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; LIN CS, 1990, P NATL ACAD SCI USA, V87, P36, DOI 10.1073/pnas.87.1.36; MALTER JS, 1991, J BIOL CHEM, V266, P3167; Maniatis T, 1982, MOL CLONING LABORATO, P194; MARX J, 1993, SCIENCE, V262, P1644, DOI 10.1126/science.8259506; MICHIELI P, 1994, CANCER RES, V54, P3391; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCOTT MD, 1989, J BIOL CHEM, V264, P2498; SHERMAN ML, 1991, J CLIN INVEST, V87, P1794, DOI 10.1172/JCI115199; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WITTE L, 1989, CANCER RES, V49, P5066; WOLOSCHAK GE, 1990, CANCER RES, V50, P339; XLONG Y, 1993, NATURE, V366, P701; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	79	85	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19181	19187		10.1074/jbc.270.32.19181	http://dx.doi.org/10.1074/jbc.270.32.19181			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642586				2022-12-25	WOS:A1995RN95400074
J	VOLKMANN, S; WOHRL, BM; TISDALE, M; MOELLING, K				VOLKMANN, S; WOHRL, BM; TISDALE, M; MOELLING, K			ENZYMATIC ANALYSIS OF 2 HIV-1 REVERSE-TRANSCRIPTASE MUTANTS WITH MUTATIONS IN CARBOXYL-TERMINAL AMINO-ACID-RESIDUES CONSERVED AMONG RETROVIRAL RIBONUCLEASES-H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DEPENDENT DNA-POLYMERASE; RNASE-H; ESCHERICHIA-COLI; DOMAIN-STRUCTURE; PRIMER; ENDONUCLEASE; MUTAGENESIS; EXONUCLEASE; MECHANISM	The reverse transcriptase (RT) of HIV-1 has been mutagenized within the carboxyl-terminal domain which harbors the RNase H. Two amino acids highly conserved among all 14 known RT sequences but not in the bacterial RNase H have been mutagenized resulting in the mutant proteins N494D and Q475E. They were expressed as recombinant proteins, purified, and analyzed for their in vitro properties in comparison to the p66 homodimeric wild-type and a previously described H539N mutant. The N494D mutant closely resembles the wild-type RNase H, exhibits art endonuclease activity and a processive RNase H activity, gives rise to small RNA hydrolysis products, and acts in concert with the RT. The Q475E mutant is more defective and resembles the H539N mutant, exhibits a retarded endonuclease activity and an impaired 3' --> 5' processive RNA cleavage activity, gives rise to predominantly larger RNA hydrolysis products, is less processive in the presence of competitor substrate, and is defective in its ability to hydrolyze the polypurine tract and homopolymeric hybrids. Short homopolymeric stretches cause a pausing of the RT of wild-type and mutants which results in a coordinated action of the RNase H. Pausing of the RT correlates with RNase H cleavages about 20 nucleotides behind the point of synthesis. The defects of the mutant enzymes can be interpreted on the basis of the known crystallography data.	MAX PLANCK INST MOLEC GENET, ABT SCHUSTER, IHNESTR 73, W-1000 BERLIN 33, GERMANY; WELLCOME RES LABS, DEPT MOLEC SCI, BECKENHAM BR3 3BS, KENT, ENGLAND	Max Planck Society; GlaxoSmithKline; Wellcome Research Laboratories								BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BECERRA SP, 1990, FEBS LETT, V270, P76, DOI 10.1016/0014-5793(90)81238-J; BENARTZI H, 1992, P NATL ACAD SCI USA, V89, P927, DOI 10.1073/pnas.89.3.927; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; CROUCH R J, 1990, New Biologist, V2, P771; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; DUDDING LR, 1990, BIOCHEM BIOPH RES CO, V167, P244, DOI 10.1016/0006-291X(90)91757-J; DUDDING LR, 1991, BIOCHEMISTRY-US, V30, P10498, DOI 10.1021/bi00107a019; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; HUBER HE, 1990, J BIOL CHEM, V265, P10565; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRUG MS, 1989, P NATL ACAD SCI USA, V86, P3539, DOI 10.1073/pnas.86.10.3539; KRUG MS, 1991, BIOCHEMISTRY-US, V30, P10614, DOI 10.1021/bi00108a003; LAI MHT, 1978, J VIROL, V25, P652, DOI 10.1128/JVI.25.2.652-663.1978; LORI F, 1988, AIDS RES HUM RETROV, V4, P393, DOI 10.1089/aid.1988.4.393; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; MANIATIS T, 1982, MOL CLONING LABORATO, V28, P9088; MIZRAHI V, 1989, BIOCHEMISTRY-US, V28, P9088, DOI 10.1021/bi00449a020; MIZRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359, DOI 10.1093/nar/18.18.5359; MOELLING K, 1992, MED MICROBIOL LETT, V1, P71; MOLLING K, 1971, NATURE-NEW BIOL, V234, P240, DOI 10.1038/newbio234240a0; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; OYAMA F, 1989, J BIOL CHEM, V264, P18808; PAINTER GR, 1990, J CELL BIOCHEM     S, V14, P109; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SCHATZ O, 1989, GENE REGULATION AIDS, P293; STARNES MC, 1989, J BIOL CHEM, V264, P7073; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; TISDALE M, 1989, J ANTIMICROBIOL SA47, V23, pS4; VARMUS H, 1987, SCI AM, V257, P56, DOI 10.1038/scientificamerican0987-56; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WATSON KF, 1979, BIOCHEMISTRY-US, V18, P3210, DOI 10.1021/bi00582a004; WINTERSBERGER U, 1990, PHARMACOL THERAPEUT, V48, P259, DOI 10.1016/0163-7258(90)90083-E; WOHRL BM, 1991, J MOL BIOL, V220, P801, DOI 10.1016/0022-2836(91)90119-Q; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	50	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2674	2683						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679100				2022-12-25	WOS:A1993KK81500063
J	PETRONILLI, V; COLA, C; BERNARDI, P				PETRONILLI, V; COLA, C; BERNARDI, P			MODULATION OF THE MITOCHONDRIAL CYCLOSPORINE A-SENSITIVE PERMEABILITY TRANSITION PORE .2. THE MINIMAL REQUIREMENTS FOR PORE INDUCTION UNDERSCORE A KEY ROLE FOR TRANSMEMBRANE ELECTRICAL POTENTIAL, MATRIX PH, AND MATRIX CA2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CA-2+-INDUCED MEMBRANE TRANSITION; HEART-MITOCHONDRIA; OXIDATIVE STRESS; N-ETHYLMALEIMIDE; CA-2+-DEPENDENT PORE; CALCIUM FLUXES; CA-2+ RELEASE; RUTHENIUM RED; INHIBITION	This paper reports an investigation on the minimal requirements for induction of the mitochondrial cyclosporin A-sensitive permeability transition pore (MTP). Energized rat liver mitochondria incubated in sucrose medium take up a Ca2+ pulse but do not show activation of the MTP upon addition of fully uncoupling concentrations of carbonyl cyanide-p-trifluoromethoxyphenyl hydrazone (FCCP). Yet, addition of ruthenium red immediately prior to FCCP or inclusion of acetate or low concentrations of phosphate in the incubation medium restore the ability of FCCP to trigger MTP opening. Since ruthenium red, phosphate, or acetate do not induce the MTP per se, they must act upon some additional factor(s) that counteract the increase of pore ''open'' probability induced by membrane depolarization (Bernardi, P. (1992) J. Biol. Chem. 267, 8834-8839). We show that two key factors determining the overall probability of pore opening are matrix pH and matrix [Ca2+] when the membrane is depolarized. Indeed, in the absence of ruthenium red, phosphate, or acetate the addition of FCCP is followed by fast Ca2+ efflux on the uniporter mirrored by intense matrix acidification following compensatory H+ influx via FCCP. Ruthenium red prevents both Ca2+ efflux and matrix acidification, acetate mainly prevents matrix acidification, and phosphate both slows down Ca2+ efflux and prevents matrix acidification. Taken together, our data indicate that membrane depolarization is both necessary and sufficient to trigger MTP opening when matrix acidification and rapid Ca2+ efflux are prevented. Thus, the wide variety of MTP ''inducing agents'' may largely reflect the wide variety of the possible combinatorial effects on the minimal requirements for MTP operation.	UNIV PADUA, SCH MED, DEPT BIOMED SCI, BIOPHYS & MEMBRANE BIOL LAB, I-35121 PADUA, ITALY	University of Padua	PETRONILLI, V (corresponding author), UNIV PADUA, SCH MED, CNR, STUDY PHYSIOL MITOCHONDRIA UNIT, VIA TRIESTE 75, I-35121 PADUA, ITALY.		Bernardi, Paolo/C-3656-2008; Petronilli, Valeria/C-3558-2015	Bernardi, Paolo/0000-0001-9187-3736; Petronilli, Valeria/0000-0003-4026-6404				AZZONE GF, 1976, BIOCHIM BIOPHYS ACTA, V459, P96; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BERNARDI P, 1979, EUR J BIOCHEM, V102, P555, DOI 10.1111/j.1432-1033.1979.tb04272.x; BERNARDI P, 1984, BIOCHEMISTRY-US, V23, P1645, DOI 10.1021/bi00303a010; BERNARDI P, 1983, BIOCHIM BIOPHYS ACTA, V724, P212, DOI 10.1016/0005-2728(83)90140-8; BERNARDI P, 1992, MECHANICS SWELLING C, P357; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V943, P245, DOI 10.1016/0005-2736(88)90556-1; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; CROMPTON M, 1988, BIOCHEM J, V255, P357; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GARLID KD, 1986, J BIOL CHEM, V261, P1529; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HARRIS EJ, 1977, FEBS LETT, V79, P284, DOI 10.1016/0014-5793(77)80804-1; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; IGVABVOA U, 1991, BIOCHIM BIOPHYS ACTA, V1059, P339; JUNG DW, 1990, BIOCHEMISTRY-US, V29, P4121, DOI 10.1021/bi00469a015; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; MASSARI S, 1972, BIOCHIM BIOPHYS ACTA, V238, P23, DOI 10.1016/0005-2728(72)90094-1; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; PFEIFFER DR, 1979, J BIOL CHEM, V254, P1485; PFEIFFER DR, 1978, J BIOL CHEM, V253, P4165; POZZAN M, 1981, FEBS LETT, V127, P263; SCHLEGEL J, 1992, BIOCHEM J, V285, P65, DOI 10.1042/bj2850065; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1991, J BIOL CHEM, V266, P3376; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004	33	217	221	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1011	1016						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678245				2022-12-25	WOS:A1993KG07700040
J	SCHUMACHER, R; SOOS, MA; SCHLESSINGER, J; BRANDENBURG, D; SIDDLE, K; ULLRICH, A				SCHUMACHER, R; SOOS, MA; SCHLESSINGER, J; BRANDENBURG, D; SIDDLE, K; ULLRICH, A			SIGNALING-COMPETENT RECEPTOR CHIMERAS ALLOW MAPPING OF MAJOR INSULIN-RECEPTOR BINDING DOMAIN DETERMINANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; TYROSINE KINASE-ACTIVITY; AMINO-ACID-SEQUENCE; MONOCLONAL-ANTIBODIES; TERTIARY STRUCTURE; ALPHA-SUBUNIT; EGF-RECEPTOR; SITE; SPECIFICITY; DNA	Chimeric receptors were generated in which structurally defined subdomains of the insulin receptor (IR) and insulin growth factor-I receptor (IGF-1R) alpha-subunits were exchanged between their respective receptor backbone structures. Upon expression in human fibroblasts, nine IR/IGF-1R chimeras were transported to the cell surface, where they formed binding sites with differential properties. One IGF-1R/IR chimera (C3') exhibited to some extent high insulin specificity, demonstrating the presence of major insulin binding determinants within the amino acid 325-524 region of the IR alpha-subunit. Complementation of this region with subdomain 1 (amino acids 1-137) reconstituted full insulin binding potential within an IGF-1R framework. In addition, both the IGF-1R/IR C3' chimera and another chimera (C13') displayed high affinity binding properties for IGF-1, which suggests distinct locations for major insulin and IGF-1 binding determinants in their respective receptors, in agreement with our previous findings (Schumacher, R., Mosthaf, L., Schlessinger, J., Brandenburg, D., and Ullrich, A. (1991) J. Biol. Chem. 266, 19288-19295). The binding characteristics of all receptor chimeras correlated directly with the ability of the ligands to regulate their tyrosine kinase activity in intact cells. These results demonstrate direct coupling of ligand binding affinity and capacity for tyrosine kinase activation.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY; DEUTSCH WOLFORSCHUNGINST,W-5100 AACHEN,GERMANY; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; UNIV CAMBRIDGE,ADDENBROOKES HOSP,CAMBRIDGE CB2 2QR,ENGLAND	Max Planck Society; New York University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge								ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BLUNDELL TL, 1978, P NATL ACAD SCI USA, V75, P180, DOI 10.1073/pnas.75.1.180; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DINTZIS SM, 1990, EMBO J, V9, P77, DOI 10.1002/j.1460-2075.1990.tb08082.x; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Ellis L, 1988, J Mol Recognit, V1, P25, DOI 10.1002/jmr.300010106; FABRY M, 1992, J BIOL CHEM, V267, P8950; FENDLY BM, 1990, CANCER RES, V50, P1550; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; RAFAELOFF R, 1989, J BIOL CHEM, V264, P15900; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; RINDERKNECHT E, 1978, J BIOL CHEM, V253, P2769; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, pA660; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SOOS MA, 1992, J BIOL CHEM, V267, P12955; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; YIP CC, 1992, J CELL BIOCHEM, V48, P19, DOI 10.1002/jcb.240480105; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; YIP CC, 1991, BIOCHEMISTRY-US, V30, P695, DOI 10.1021/bi00217a016; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	44	109	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1087	1094						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678247				2022-12-25	WOS:A1993KG07700051
J	BROCK, TG; MCNISH, RW; PETERSGOLDEN, M				BROCK, TG; MCNISH, RW; PETERSGOLDEN, M			TRANSLOCATION AND LEUKOTRIENE SYNTHETIC CAPACITY OF NUCLEAR 5-LIPOXYGENASE IN RAT BASOPHILIC LEUKEMIA-CELLS AND ALVEOLAR MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ASSOCIATION; ARACHIDONIC-ACID; HUMAN-LEUKOCYTES; PROTEIN; INHIBITION; STIMULATION; CALCIUM; ENZYME	Leukotriene (LT) synthesis involves the translocation of enzymatically active 5-lipoxygenase (5-LO) from a soluble site to a bound site, where it interacts with 5-lipoxygenase-activating protein (FLAP). In human polymorphonuclear leukocytes (PMNs), 5-LO moves from the cytosol to the nuclear envelope (NE) to interact with FLAP. However, 5-LO has recently been found within the nucleus, as well as the cytosol, of rat basophilic leukemia (RBL) cells and alveolar macrophages (AMs). To assess whether nuclear 5-LO can contribute to LT synthesis in these cells, we investigated whether this enzyme pool 1) translocates upon cell activation, 2) colocalizes with FLAP, and 3) is enzymatically active. By cell fractionation followed by immunoblotting, both cytosolic and nuclear soluble 5-LO decreased dramatically in RBL cells following activation with the calcium ionophore A23187. Concurrently, 5-LO increased in the pelletable nuclear pool, where FLAP was also detected. The loss of both cytosolic and nuclear soluble 5-LO, with concomitant increase exclusively at the NE, as well as co-localization with FLAP, were confirmed by indirect immunofluorescent and confocal microscopy. In AMs, the nuclear soluble pool of 5-LO moved to the NE, where FLAP was also found; however, the cytosolic 5-LO pool did not translocate. Application of these methods to PMNs confirmed that cytosolic 5-LO moved to the nuclear envelope and co-localized with FLAP. By cell-free assay, nuclear soluble proteins from both RBL cells and AMs, but not PMNs, were able to generate 5-LO products from arachidonate, and this was inhibited by the direct 5-LO inhibitor zileuton. Cytosolic proteins from all cell types also showed cell-free 5-LO activity. These results demonstrate three distinct patterns of 5-LO translocation that are specific for each cell type: translocation of only a cytosolic pool in PMNs, of only a nuclear pool in AMs, and of both cytosolic and nuclear pools in RBL cells. By virtue of its enzymatic activity and ability to translocate, nuclear 5-LO has the potential to contribute to LT synthesis in RBL cells and AMs. Finally, these results provide a foundation for considering the individual functions of discrete pools of 5-LO in future studies.			BROCK, TG (corresponding author), UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV PULM & CRIT CARE MED,ANN ARBOR,MI 48109, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL046487, R01HL047391, T32HL007749] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07749, P50 HL46487, R01 HL47391] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; BROCK TG, 1994, J BIOL CHEM, V269, P22059; CAPRIOTTI AM, 1988, J BIOL CHEM, V263, P10029; COFFEY M, 1992, J BIOL CHEM, V267, P570; COFFEY MJ, 1994, AM J RESP CELL MOL, V11, P153, DOI 10.1165/ajrcmb.11.2.8049076; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; GUIDOT DM, 1994, P NATL ACAD SCI USA, V91, P8156, DOI 10.1073/pnas.91.17.8156; HATZELMANN A, 1994, BIOCHEM PHARMACOL, V48, P31, DOI 10.1016/0006-2952(94)90220-8; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; KARGMAN S, 1992, J CELL BIOL, V119, P1701, DOI 10.1083/jcb.119.6.1701; KARGMAN S, 1991, J BIOL CHEM, V266, P23745; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MALAVIYA R, 1993, J BIOL CHEM, V268, P4939; MANCINI JA, 1992, MOL PHARMACOL, V41, P267; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; PERCIVAL MD, 1992, EUR J BIOCHEM, V210, P109, DOI 10.1111/j.1432-1033.1992.tb17397.x; PETERSGOLDEN M, 1990, J IMMUNOL, V144, P263; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; REID GK, 1990, J BIOL CHEM, V265, P19818; ROTMAN EI, 1992, BIOCHEM J, V282, P487, DOI 10.1042/bj2820487; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SOLIVEN B, 1993, AM J PHYSIOL, V264, pC632, DOI 10.1152/ajpcell.1993.264.3.C632; STEINHILBER D, 1993, BIOCHIM BIOPHYS ACTA, V1178, P1, DOI 10.1016/0167-4889(93)90104-W; WONG A, 1988, BIOCHEMISTRY-US, V27, P6763, DOI 10.1021/bi00418a018; WONG A, 1991, BIOCHEMISTRY-US, V30, P9346, DOI 10.1021/bi00102a030; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	33	120	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21652	21658		10.1074/jbc.270.37.21652	http://dx.doi.org/10.1074/jbc.270.37.21652			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665580	hybrid			2022-12-25	WOS:A1995RU75700037
J	AKOPIAN, AN; WOOD, JN				AKOPIAN, AN; WOOD, JN			PERIPHERAL NERVOUS SYSTEM-SPECIFIC GENES IDENTIFIED BY SUBTRACTIVE CDNA CLONING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL-ROOT GANGLIA; MUSCLE C-PROTEIN; MOLECULAR-CLONING; SPINAL-CORD; NEURONS; RAT; HYBRIDIZATION; PURIFICATION; MEMBRANE; COMPLEX	An improved method for constructing and screening subtractive cDNA libraries has been used to identify 46 mRNA transcripts that are expressed selectively in neonatal rat dorsal root ganglia (DRG) as judged by Northern blots and in situ hybridization. Sequence analysis demonstrates that both known (e.g. peripherin, calcitonin gene-related peptide, myelin PO) and novel identifiable transcripts (e.g. C-protein-like, synuclein-like, villin-like) are present in the library. Half of the transcripts (23) are undetectable in liver, kidney, heart, spleen, cerebellum, and cerebral cortex, Of the DRG-specific transcripts, 12 contain putative open reading frames that show no identity with known proteins. The construction of such a subtractive library thus provides us with both known and novel markers, and identifies new predicted DRG-specific proteins. In addition, the DRG-specific clones provide probes to define the regulatory elements that specify peripheral nervous-system-specific gene expression.			AKOPIAN, AN (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anderson David J., 1993, Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie, V316, P1082; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; FURST DO, 1992, J CELL SCI, V102, P769; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GHYSEN A, 1993, BIOESSAYS, V15, P293, DOI 10.1002/bies.950150502; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jan Yuh Nung, 1994, Current Opinion in Neurobiology, V4, P8, DOI 10.1016/0959-4388(94)90025-6; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KOJIMA T, 1990, J BIOCHEM-TOKYO, V107, P470, DOI 10.1093/oxfordjournals.jbchem.a123069; KORNEEV S, 1994, PROG NEUROBIOL, V42, P339, DOI 10.1016/0301-0082(94)90074-4; KRISTAL SM, 1983, NEUROSCI LETT, V35, P41; LEBEAU MC, 1991, NUCLEIC ACIDS RES, V19, P1337, DOI 10.1093/nar/19.6.1337; LEMKE G, 1985, CELL, V40, P501, DOI 10.1016/0092-8674(85)90198-9; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; MAYEUX V, 1993, DEV BRAIN RES, V71, P201, DOI 10.1016/0165-3806(93)90172-7; NAKAJO S, 1993, EUR J BIOCHEM, V217, P57; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; OTTO JJ, 1994, CURR OPIN CELL BIOL, V6, P105, DOI 10.1016/0955-0674(94)90123-6; ROISEN FJ, 1983, J MUSCLE RES CELL M, V4, P163, DOI 10.1007/BF00712028; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCOTT SA, 1993, SENSORY NEURONS; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; TAJBAKHSH S, 1994, NEURON, V13, P813, DOI 10.1016/0896-6273(94)90248-8; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WIELAND I, 1990, P NATL ACAD SCI USA, V87, P2720, DOI 10.1073/pnas.87.7.2720; ZHANG JH, 1990, J COMP NEUROL, V302, P715, DOI 10.1002/cne.903020404	35	85	91	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21264	21270		10.1074/jbc.270.36.21264	http://dx.doi.org/10.1074/jbc.270.36.21264			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673161	hybrid			2022-12-25	WOS:A1995RU05400061
J	HIDALGO, E; BOLLINGER, JM; BRADLEY, TM; WALSH, CT; DEMPLE, B				HIDALGO, E; BOLLINGER, JM; BRADLEY, TM; WALSH, CT; DEMPLE, B			BINUCLEAR [2FE-2S] CLUSTERS IN THE ESCHERICHIA-COLI SOXR PROTEIN AND ROLE OF THE METAL CENTERS IN TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEINS; NITRIC-OXIDE; NUCLEASE ACTIVITY; STRESS REGULON; SUPEROXIDE; ACTIVATION; DNA; GENES; MERR; MACROPHAGES	SoxR protein of Escherichia coli is activated by super oxide-generating agents or nitric oxide as a powerful transcription activator of the soxS gene, whose product activates similar to 10 other promoters, SoxR contains non heme iron essential for abortive initiation of transcription in vitro, Here we show that this metal dependence extends to full-length transcription in vitro, In the presence off. coli sigma(70) RNA polymerase, iron-containing SoxR mediates open complex formation at the soxS promoter, as determined using footprinting with Cu-5-phenyl-1,10-phenanthroline. We investigated the nature of the SoxR iron center by chemical analyses and electron paramagnetic resonance spectroscopy. Dithionite-reduced Fe-SoxR exhibited an almost axial paramagnetic signature with g values of 2.01 and 1.93 observable up to 100 g. These features, together with quantitation of spin, iron, and S2-, and hydrodynamic evidence that SoxR is a homodimer in solution, indicate that (SoxR)(2) contains two [2Fe-2S] clusters. Treatment of Fe-SoxR with high concentrations of dithiothreitol caused subtle changes in the visible absorption spectrum and blocked transcriptional activity without generating reduced [2Fe-2S] centers, but was also associated with the loss of iron from the protein, However, lowering the thiol concentration by dilution allowed spontaneous regeneration of active Fe-SoxR.	HARVARD UNIV, SCH PUBL HLTH, DEPT MOLEC & CELLULAR TOXICOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School			Bollinger, Joseph/C-1425-2016; Hidalgo, Elena/K-2919-2014	Hidalgo, Elena/0000-0002-3768-6785	NCI NIH HHS [CA37831] Funding Source: Medline; NIGMS NIH HHS [GM20011, GM15477] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020011, R37GM020011] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; Freifelder D, 1973, Methods Enzymol, V27, P140; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GONZALEZFLECHA B, 1994, J BACTERIOL, V176, P2293; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; GREEN J, 1993, FEBS LETT, V329, P55, DOI 10.1016/0014-5793(93)80192-W; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HIDALGO E, 1994, ENCY INORGANIC CHEM, V4, P1896; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; MALMSTRO.BG, 1970, BIOCHIM BIOPHYS ACTA, V205, P48, DOI 10.1016/0005-2728(70)90060-5; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; NUNOSHIBA T, 1995, INFECT IMMUN, V63, P794, DOI 10.1128/IAI.63.3.794-798.1995; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; ORMEJOHNSON WH, 1982, IRON SULFUR PROTEINS, P67; RUSSELL DR, 1981, NUCLEIC ACIDS RES, V9, P2517, DOI 10.1093/nar/9.11.2517; Sambrook J, 1989, MOL CLONING LABORATO; Sies H., 1991, OXIDATIVE STRESS OXI, pxv; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; THEDERAHN T, 1990, BIOCHEM BIOPH RES CO, V168, P756, DOI 10.1016/0006-291X(90)92386-E; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; WU J, 1992, J BACTERIOL, V174, P3915, DOI 10.1128/jb.174.12.3915-3920.1992	41	147	153	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20908	20914		10.1074/jbc.270.36.20908	http://dx.doi.org/10.1074/jbc.270.36.20908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673113	hybrid			2022-12-25	WOS:A1995RU05400010
J	BETTICHER, DC; THATCHER, N; ALTERMATT, HJ; HOBAN, P; RYDER, WDJ; HEIGHWAY, J				BETTICHER, DC; THATCHER, N; ALTERMATT, HJ; HOBAN, P; RYDER, WDJ; HEIGHWAY, J			ALTERNATE SPLICING PRODUCES A NOVEL CYCLIN D1 TRANSCRIPT	ONCOGENE			English	Article						CCND1; CYCLIN D1; SPLICING; POLYMORPHISM	MESSENGER-RNA; RETINOBLASTOMA PROTEIN; FIBROBLASTS; GENE; DNA	Using Northern blotting and PCR analysis of cDNA derived from a range of cell lines and tissues, alternate splicing of the cyclin D1 gene (CCND1) mRNA has been demonstrated, The variant transcript shows no splicing at the downstream exon 4 boundary, encoding a protein with an altered carboxy-terminal domain, Investigation of mRNA extracted from mononuclear cells, lung tumour and normal tissue suggests that both transcripts are invariably expressed. However, splicing to produce the two forms of mRNA is modulated, in the heterozygote, by a frequent A/G polymorphism located within the splice donor region of exon 4. Preliminary analysis of patients with resectable non-small cell lung cancer suggests that genotype is associated with shortened event free survival and greater risk of local relapse.	CHRISTIE HOSP NHS TRUST, PATERSON INST CANC RES, CANC RES CAMPAIGN, DEPT CANC GENET, MANCHESTER M20 9BX, LANCS, ENGLAND; UNIV HOSP BERN, INST PATHOL, BERN, SWITZERLAND; CHRISTIE HOSP NHS TRUST, CANC RES CAMPAIGN, DEPT MED ONCOL, BERN, SWITZERLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Bern; University Hospital of Bern			Betticher, Daniel C/G-5849-2013					AKIYAMA N, 1994, CANCER RES, V54, P377; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; COX DR, 1972, J R STAT SOC B, V34, P187; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HODGES D, 1994, ADV GENET, V31, P207, DOI 10.1016/S0065-2660(08)60399-5; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JAKOBSEN KS, 1990, NUCLEIC ACIDS RES, V18, P3669, DOI 10.1093/nar/18.12.3669; JARES P, 1994, CANCER RES, V54, P4813; Kay R, 1983, Stat Med, V2, P41, DOI 10.1002/sim.4780020106; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOVEC H, 1994, ONCOGENE, V9, P323; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MICHALIDES R, 1995, CANCER RES, V55, P975; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Nelson W., 1969, J QUAL TECHNOL, V1, P27, DOI DOI 10.1080/00224065.1969.11980344; OHNO K, 1988, J BIOL CHEM, V263, P18563; PINES J, 1993, BIOCHEM SOC T, V21, P921, DOI 10.1042/bst0210921; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; VIDAUD M, 1989, P NATL ACAD SCI USA, V86, P1041, DOI 10.1073/pnas.86.3.1041; WATTS CKW, 1994, BREAST CANCER RES TR, V31, P95, DOI 10.1007/BF00689680; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; 1987, MANUAL STAGING CANCE; 1981, HISTOLOGICAL TYPING	39	368	375	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					1005	1011						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675441				2022-12-25	WOS:A1995RU79800024
J	CHADENEAU, C; SIEGEL, P; HARLEY, CB; MULLER, WJ; BACCHETTI, S				CHADENEAU, C; SIEGEL, P; HARLEY, CB; MULLER, WJ; BACCHETTI, S			TELOMERASE ACTIVITY IN NORMAL AND MALIGNANT MURINE TISSUES	ONCOGENE			English	Article						TELOMERASE; MAMMARY TUMORIGENESIS; MOUSE TISSUES; PROLIFERATIVE LIFE-SPAN	HUMAN FIBROBLASTS; SENESCENCE; IDENTIFICATION; CELLS; MOUSE; MICE	Telomere shortening may contribute to the limited lifespan of somatic cells and telomerase, the enzyme that elongates telomeric DNA and maintains telomere length, may be essential for unlimited cell proliferation irt vivo and in vitro. Telomerase is not expressed in most human somatic cells but is a nearly ubiquitous tumour marker, being activated in malignant cells from many cancers, Inhibition of telomerase may lead to telomere shortening and eventually limit the proliferative capacity of malignant cells and hence be of therapeutic value, With the intent of characterizing an animal model for inhibition studies, we investigated telomerase activity during mammary tumorigenesis in transgenic mice overexpressing the neu gene, We detected activity in primary mammary tumours and lung metastases but also in normal mammary glands and other organs, Activity Tvas elevated in tumors versus normal tissues and was enhanced by short-term culturing of normal cells, Telomerase activity was also present in somatic tissues from the non-transgenic parental strain and the outbred Mus spretus strain, As we recently detected telomerase activity in normal human hemopoietic tissues, mouse models of tumorigenesis may provide useful experimental systems for assessing the outcome of in vivo inhibition of telomerase in both malignant and normal cells.	MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8N 3Z5,CANADA; MCMASTER UNIV,DEPT BIOL,HAMILTON,ON L8N 3Z5,CANADA; GERON CORP,MENLO PK,CA 94025	McMaster University; McMaster University; Geron Corporation			Chadeneau, Corinne/AAT-6790-2021	Chadeneau, Corinne/0000-0001-8808-1738				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BACCHETTI S, 1995, IN PRESS INT J ONC, V7; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CHADENEAU C, 1995, CANCER RES, V55, P2533; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; COUNTER CM, 1995, BLOOD, V9, P2315; COUNTER CM, 1994, EMBO J, V91, P2900; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GREIDER CW, 1990, BIOESSAYS, V12, P363, DOI 10.1002/bies.950120803; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HIRTE HW, 1994, CANCER, V74, P900, DOI 10.1002/1097-0142(19940801)74:3<900::AID-CNCR2820740317>3.0.CO;2-N; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; NEWBOLD RF, 1993, TOXICOL LETT, V67, P211, DOI 10.1016/0378-4274(93)90057-5; NILSSON P, 1994, ONCOGENE, V9, P3043; NOWELL PC, 1986, CANCER RES, V46, P2203; OHTOSHI T, 1991, AM J RESP CELL MOL, V4, P255, DOI 10.1165/ajrcmb/4.3.255; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	37	133	139	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					893	898						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675448				2022-12-25	WOS:A1995RU79800010
J	COSOWSKY, L; RAO, SNV; MACDONALD, GJ; PAPKOFF, H; CAMPBELL, RK; MOYLE, WR				COSOWSKY, L; RAO, SNV; MACDONALD, GJ; PAPKOFF, H; CAMPBELL, RK; MOYLE, WR			THE GROOVE BETWEEN THE ALPHA-SUBUNIT AND BETA-SUBUNIT OF HORMONES WITH LUTROPIN (LH) ACTIVITY APPEARS TO CONTACT THE LH RECEPTOR, AND ITS CONFORMATION IS CHANGED DURING HORMONE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; HUMAN CHORIOGONADOTROPIN-BETA; FOLLICLE-STIMULATING-HORMONE; LUTEINIZING-HORMONE; MONOCLONAL-ANTIBODIES; NUCLEOTIDE-SEQUENCE; PITUITARY GONADOTROPINS; GLYCOPROTEIN HORMONES; SYNTHETIC PEPTIDES; CDNA	Gonadotropins are heterodimeric glycoprotein hormones that control vertebrate fertility through their actions on gonadal lutropin (luteinizing hormone, LH) and follitropin (follicle-stimulating hormone, FSH) receptors, The beta-subunits of these hormones control receptor binding specificity; however, the region of the beta-subunit that contacts the receptor has not been identified, By a process of elimination we show this contact to be the portions of beta-subunit loops one and three found in a hormone groove created by the juxtaposition of the alpha- and beta-subunits. Most other regions of the beta-subunit can be recognized by antibodies that bind to human chorionic hormone (hCG)-receptor complexes or replaced without disrupting hormone function, Using a series of bovine LH/hCG and human FSH/hCG beta-subunit chimeras we identified key hCG beta-subunit residues in the epitopes of two antibodies that bind to hCG-receptor complexes, These epitopes include the surfaces of beta-subunit loops one and three near residue 74 on the outside of the hormone groove and parts of the C-terminal end of the ''seat belt'' that holds the two subunits together, The antibody that recognized residue 74 bound to receptor complexes containing most mammalian lutropins better than to the free hormones, an indication that the outside surface of the beta-subunit groove is altered during hormone binding, This region of the beta-subunit is furthest from the alpha-subunit and is recognized equally well in the free beta-subunit and in the heterodimer, Thus, the receptor associated increase in antibody binding appears due to an interaction of this portion of the beta-subunit with the receptor and not to an effect of the receptor on the relative positions of the alpha- and beta-subunits, Unlike most previous studies designed to identify portions of the beta-subunit likely to contact the LH receptor, this indirect approach provides data that are more easily interpreted because it does not rely on the use of mutations that disrupt hormone function, The approach described here should be valuable for studying the receptor interactions of other complex ligands.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT OBSTET GYNECOL, PISCATAWAY, NJ 08854 USA; UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT NEUROSCI & CELL BIOL, PISCATAWAY, NJ 08854 USA; UNIV CALIF DAVIS, DEPT ANIM SCI, DAVIS, CA 95616 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California Davis			Campbell, Robert/G-4112-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD014907, R01HD024650, R01HD005722, R37HD014907] Funding Source: NIH RePORTER; NICHD NIH HHS [HD05722, HD14907, HD24650] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BIDART JM, 1989, ENDOCRINOLOGY, V124, P923, DOI 10.1210/endo-124-2-923; BOUSFIELD GR, 1988, J BIOL CHEM, V263, P12602; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHARLESWORTH MC, 1991, ENDOCRINOLOGY, V128, P2907, DOI 10.1210/endo-128-6-2907; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN F, 1991, J BIOL CHEM, V266, P19357; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; CHEN F, 1991, BIOCHEMISTRY-US, V30, P10171, DOI 10.1021/bi00106a014; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COLOMA TAS, 1990, BIOCHEMISTRY-US, V29, P1194, DOI 10.1021/bi00457a015; CRAWFORD RJ, 1986, GENE, V46, P161, DOI 10.1016/0378-1119(86)90400-2; CRUZ RI, 1987, J CLIN ENDOCR METAB, V64, P433, DOI 10.1210/jcem-64-3-433; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DANGELOBERNARD G, 1990, NUCLEIC ACIDS RES, V18, P2175, DOI 10.1093/nar/18.8.2175; Gordon WL, 1985, LUTEINIZING HORMONE, P173; HAGEVANNOORT M, 1992, P NATL ACAD SCI USA, V89, P3922, DOI 10.1073/pnas.89.9.3922; HAGEVANNOORT M, 1993, P NATL ACAD SCI USA, V90, P12056; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG JN, 1993, J BIOL CHEM, V268, P9311; JAMESON L, 1984, J BIOL CHEM, V259, P5474; KATO Y, 1989, MOL CELL ENDOCRINOL, V62, P47, DOI 10.1016/0303-7207(89)90112-3; KEUTMANN HT, 1987, P NATL ACAD SCI USA, V84, P2038, DOI 10.1073/pnas.84.7.2038; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LICHT P, 1979, J ENDOCRINOL, V83, P311, DOI 10.1677/joe.0.0830311; LIU C, 1993, J BIOL CHEM, V268, P21613; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; Maniatis T, 1989, MOL CLONING; MATSUI T, 1991, BIOCHEM BIOPH RES CO, V174, P940, DOI 10.1016/0006-291X(91)91509-B; MATTERI RL, 1987, DOMEST ANIM ENDOCRIN, V4, P157, DOI 10.1016/0739-7240(87)90011-7; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MAURER RA, 1985, J BIOL CHEM, V260, P4684; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1987, J BIOL CHEM, V262, P16920; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; MOYLE WR, 1988, J RECEPTOR RES, V8, P419, DOI 10.3109/10799898809049002; MOYLE WR, 1988, ICSU SHORT REP, V8, P116; NOCE T, 1989, J MOL ENDOCRINOL, V3, P129, DOI 10.1677/jme.0.0030129; PAPKOFF H, 1982, GEN COMP ENDOCR, V48, P181, DOI 10.1016/0016-6480(82)90016-8; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; ROSER JF, 1984, BIOL REPROD, V30, P1253, DOI 10.1095/biolreprod30.5.1253; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SANTACOLOMA TA, 1991, MOL CELL ENDOCRINOL, V78, P197, DOI 10.1016/0303-7207(91)90123-A; Segaloff D L, 1990, Recent Prog Horm Res, V46, P261; SHERMAN GB, 1992, MOL ENDOCRINOL, V6, P951, DOI 10.1210/me.6.6.951; SMITH PL, 1993, J BIOL CHEM, V268, P795; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; WEINER RS, 1992, MOL CELL ENDOCRINOL, V85, P41, DOI 10.1016/0303-7207(92)90123-N; WEISS J, 1992, NEW ENGL J MED, V326, P179, DOI 10.1056/NEJM199201163260306; WOLF DL, 1987, NUCLEIC ACIDS RES, V15, P10602, DOI 10.1093/nar/15.24.10602; XIA H, 1993, J MOL ENDOCRINOL, V10, P337, DOI 10.1677/jme.0.0100337	54	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20011	20019		10.1074/jbc.270.34.20011	http://dx.doi.org/10.1074/jbc.270.34.20011			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650019	hybrid			2022-12-25	WOS:A1995RQ99100052
J	COX, KH; ADAIRKIRK, TL; COX, JV				COX, KH; ADAIRKIRK, TL; COX, JV			4 VARIANT CHICKEN ERYTHROID AE1 ANION-EXCHANGERS - ROLE OF THE ALTERNATIVE N-TERMINAL SEQUENCES IN INTRACELLULAR TARGETING IN TRANSFECTED HUMAN ERYTHROLEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYRIN-BINDING SITE; TRANSCRIPTIONAL INITIATION; ENDOPLASMIC-RETICULUM; CYTOPLASMIC DOMAIN; MESSENGER-RNAS; BAND-3; PROTEIN; GENE; ORGANIZATION; LOCALIZATION	Four variant AE1 anion exchangers with predicted molecular masses of similar to 99, similar to 102, similar to 104, and similar to 108 kDa are expressed in chicken erythroid cells. These variant polypeptides differ in sequence only at the N terminus of their cytoplasmic domains, Molecular analyses have shown that transcripts derived from both of the erythroid-specific promoters, P1 and P2, encode all four of these AE1 anion exchanger variants. However, quantitative RNase protection analyses have shown that the transcripts derived from the P1 promoter are much more prevalent than those derived from the P2 promoter, Reverse transcriptase polymerase chain reaction studies have indicated that the extensive diversity in the transcripts derived from the AE1 gene occurs both in primitive and definitive lineage erythroid cells, Transient transfection analyses using human erythroleukemia cells have investigated the functional significance of the alternative sequences at the N terminus of these variant exchangers, These studies have shown that the erythroid AE1 variants are sorted to different membrane compartments in these cells, The similar to 99- and similar to 102-kDa variants are primarily sorted to the plasma membrane, whereas the similar to 108-kDa variant is retained in a perinuclear compartment. These results suggest that the alternative N-terminal cytoplasmic sequences of these polypeptides may serve as signals to direct these variant transporters to different membrane compartments within cells.	UNIV TENNESSEE,CTR HLTH SCI,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center								ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; BECK KA, 1994, J CELL BIOL, V127, P707, DOI 10.1083/jcb.127.3.707; BECK KA, 1993, J CELL BIOL, V5, pA240; BENNETT V, 1980, NATURE, V280, P468; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; BRUNS GAP, 1973, PHILOS T ROY SOC B, V266, P225, DOI 10.1098/rstb.1973.0050; COX KH, 1995, AM J PHYSIOL-RENAL, V268, pF503, DOI 10.1152/ajprenal.1995.268.3.F503; DAVIS L, 1989, J BIOL CHEM, V264, P9665; GABATHULER R, 1990, J CELL BIOL, V111, P1803, DOI 10.1083/jcb.111.5.1803; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KELLOKUMPU S, 1988, SCIENCE, V264, P1308; KIM HRC, 1988, MOL CELL BIOL, V8, P4416, DOI 10.1128/MCB.8.10.4416; KIM HRC, 1989, MOL CELL BIOL, V9, P5198, DOI 10.1128/MCB.9.11.5198; Knauf P.A, 1979, CURR TOP MEMBR TRANS, V12, P249, DOI 10.1016/S0070-2161(08)60259-2; KOLLERTJONS A, 1993, AM J PHYSIOL, V265, pF813, DOI 10.1152/ajprenal.1993.265.6.F813; KOPITO RR, 1987, P NATL ACAD SCI USA, V84, P7149, DOI 10.1073/pnas.84.20.7149; KORSGREN C, 1988, J BIOL CHEM, V263, P10212; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUDRYCKI KE, 1993, AM J PHYSIOL, V264, pF540, DOI 10.1152/ajprenal.1993.264.3.F540; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; KWIATKOWSKI DJ, 1988, J CELL BIOL, V106, P375, DOI 10.1083/jcb.106.2.375; LINN SC, 1992, J BIOL CHEM, V267, P7927; MORGANS CW, 1993, J CELL SCI, V105, P1137; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; Sambrook J, 1989, MOL CLONING LABORATO; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; WONG SH, 1993, J BIOL CHEM, V268, P22853	31	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19752	19760		10.1074/jbc.270.34.19752	http://dx.doi.org/10.1074/jbc.270.34.19752			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649985	hybrid			2022-12-25	WOS:A1995RQ99100015
J	JUUL, B; TURC, H; DURAND, ML; DEGRACIA, AG; DENOROY, L; MOLLER, JV; CHAMPEIL, P; LEMAIRE, M				JUUL, B; TURC, H; DURAND, ML; DEGRACIA, AG; DENOROY, L; MOLLER, JV; CHAMPEIL, P; LEMAIRE, M			DO TRANSMEMBRANE SEGMENTS IN PROTEOLYZED SARCOPLASMIC-RETICULUM CA2+-ATPASE RETAIN THEIR FUNCTIONAL CA2+ BINDING-PROPERTIES AFTER REMOVAL OF CYTOPLASMIC FRAGMENTS BY PROTEINASE-K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; EXTENSIVE TRYPTIC DIGESTION; CHARGED AMINO-ACIDS; TRANSPORT SITES; BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; MEMBRANE-PROTEINS; CATION OCCLUSION; CALCIUM-BINDING; CONFORMATIONAL-CHANGES	The present study was undertaken to investigate the Ca2+ binding properties of sarcoplasmic reticulum Ca2+-ATPase after removal of the cytoplasmic regions by treatment with proteinase K. One of the proteolysis cleavage sites (at the end of M6) was found unexpectedly close to the predicted membrane-water interphase, but otherwise the cleavage pattern was consistent with the presence of 10 transmembrane ATPase segments, C-terminal membranous peptides containing the putative transmembrane segments M7 to M10 accumulated after prolonged proteolysis, as well as large water-soluble fragments containing most of the phosphorylation and ATP-binding domain. Ca2+ binding was intact after cleavage of the polypeptide chain in the N-terminal region, but cuts at other locations disrupted the high affinity binding and sequential dissociation properties characteristic of native sarcoplasmic reticulum, leaving the translocation sites with only weak affinity for Ca2+ High affinity Ca2+ binding could only be maintained when proteolysis and subsequent manipulations took place in the presence of a Ca2+ concentration high enough to ensure permanent occupation of the binding sites with Ca2+. We conclude that in the absence of Ca2+ the complex of membrane-spanning segments in proteolyzed Ca2+-ATPase is labile, probably because of relatively free movement or rearrangement of individual segments. Our study, which is discussed in relation to results obtained on Na+,K+-ATPase and H+,K+-ATPase, emphasizes the importance of the cytosolic segments of the main polypeptide chain in exerting constraints on the intramembranous domain of a P-type ATPase.	CTR ETUD SACLAY, CEA,DEPT BIOL CELLULAIRE & MOLEC, BIOPHYS PROT & MEMBRANES SECT,CNRS, URA 1290, F-91191 GIF SUR YVETTE, FRANCE; AARHUS UNIV, DEPT BIOPHYS, DK-8000 AARHUS C, DENMARK; CNRS, SERV CENT ANALYSE, F-69390 VERNAISON, FRANCE	CEA; Centre National de la Recherche Scientifique (CNRS); Aarhus University; Centre National de la Recherche Scientifique (CNRS)								ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1994, FEBS LETT, V354, P93, DOI 10.1016/0014-5793(94)01100-1; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BIBI E, 1992, P NATL ACAD SCI USA, V89, P1524, DOI 10.1073/pnas.89.5.1524; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; COPE DL, 1994, BIOCHEM J, V300, P291, DOI 10.1042/bj3000291; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DEFORESTA B, 1990, EUR J BIOCHEM, V194, P383; DEFORESTA B, 1994, EUR J BIOCHEM, V223, P359; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; DUPONT Y, 1976, BIOCHEM BIOPH RES CO, V71, P544, DOI 10.1016/0006-291X(76)90821-4; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; ENOUF J, 1988, J BIOL CHEM, V263, P13922; ESMANN M, 1992, BIOCHIM BIOPHYS ACTA, V1108, P247, DOI 10.1016/0005-2736(92)90032-H; FAMBROUGH DM, 1994, CURR TOP MEMBR, V41, P45, DOI 10.1016/S0070-2161(08)60453-0; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; FORGE V, 1993, J BIOL CHEM, V268, P10953; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; GARRIGOS M, 1991, ANAL BIOCHEM, V194, P82, DOI 10.1016/0003-2697(91)90154-L; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HALTIA T, 1995, BBA-BIOENERGETICS, V1228, P1, DOI 10.1016/0005-2728(94)00161-W; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1980, J BIOL CHEM, V255, P3025; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P6144, DOI 10.1021/bi00141a027; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeGendre N., 1989, PRACTICAL GUIDE PROT, P52; LEMAIRE M, 1993, ANAL BIOCHEM, V214, P50, DOI 10.1006/abio.1993.1455; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LONDON E, 1978, ANAL BIOCHEM, V88, P203, DOI 10.1016/0003-2697(78)90412-8; LOO TW, 1994, J BIOL CHEM, V269, P7750; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; MATA AM, 1992, BIOCHEM J, V286, P567, DOI 10.1042/bj2860567; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MEIS LD, 1971, J BIOL CHEM, V246, P4759; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MERINO JM, 1994, FEBS LETT, V343, P155, DOI 10.1016/0014-5793(94)80309-9; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; MOLLER JV, 1993, SODIUM PUMP, P131; NING G, 1993, FEBS LETT, V330, P19, DOI 10.1016/0014-5793(93)80910-M; OR E, 1993, J BIOL CHEM, V268, P16929; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; OVCHINNIKOV YA, 1987, TRENDS BIOCHEM SCI, V12, P434, DOI 10.1016/0968-0004(87)90210-6; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; POPOT JL, 1993, CURR OPIN STRUC BIOL, V3, P532, DOI 10.1016/0959-440X(93)90079-Z; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; RABON EC, 1993, J BIOL CHEM, V268, P8012; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMALZING G, 1992, J BIOL CHEM, V267, P20212; SCHMALZING G, 1994, CELL PHYSIOL BIOCHEM, V4, P96, DOI 10.1159/000154715; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; SHIN JM, 1994, J BIOL CHEM, V269, P22533; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; SUMBILLA C, 1991, J BIOL CHEM, V266, P12682; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; WEBER K, 1969, J BIOL CHEM, V244, P4406; YAMAGUCHI M, 1988, METHOD ENZYMOL, V157, P233; YAMANAKA N, 1976, BIOCHIM BIOPHYS ACTA, V426, P132, DOI 10.1016/0005-2736(76)90435-1	78	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20123	20134		10.1074/jbc.270.34.20123	http://dx.doi.org/10.1074/jbc.270.34.20123			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650031	hybrid			2022-12-25	WOS:A1995RQ99100067
J	YANO, M; ELHAYEK, R; IKEMOTO, N				YANO, M; ELHAYEK, R; IKEMOTO, N			ROLE OF CALCIUM FEEDBACK IN EXCITATION-CONTRACTION COUPLING IN ISOLATED TRIADS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FROG SKELETAL-MUSCLE; CUT TWITCH FIBERS; SARCOPLASMIC-RETICULUM; CHARGE MOVEMENT; HUMP COMPONENT; CA-2+ RELEASE; FOOT PROTEIN; FURA-2; DEPOLARIZATION; INACTIVATION	There is a considerable controversy in the literature concerning the effects of higher concentrations of calcium chelators (e.g. BAPTA (1,2-bis(o-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid) or fura-2) on the intracellular Ca2+ transients in muscle, We induced calcium release from sarcoplasmic reticulum (SR) in the triad preparation by chemical depolarization of the T-tubule in the presence of various concentrations of BAPTA-calcium buffer ([Ca2+] = 0.1 mu M) and investigated the effects of the BAPTA concentration on the time courses of conformational changes in the junctional foot protein (JFP) and calcium release hem SR Upon stimulation, the JFP underwent biphasic conformational changes, as determined by stopped-now fluorometry of the JFP-bound conformational probe, The first phase of protein conformational change, which preceded calcium release from SR, was virtually unaffected by the BAPTA concentration However, the magnitude of the second phase increased in an inversely proportional fashion to the BAPTA concentration, An abrupt increase in [Ca2+] from 0.1 mu M up to 1.0 mu M (Delta Ca2+), concurrently with T-tubule depolarization, produced biphasic protein conformational changes: a Delta Ca2+-independent first phase and a Delta Ca2+ dependent second phase, Similar Ca2+ jump experiments under non-depolarizing conditions produced a slow monophasic conformational change equivalent to the second phase described above, These results suggest that the first phase of protein conformational change represents the activation of JFP by T-tubule depolarization to induce calcium release, and the second phase the secondary activation by the released Ca2+, Activation of the JFP by the released Ca2+ resulted in an acceleration of both (i) the rate of initial calcium release, and (ii) the subsequent attenuation of calcium release, The acceleration of both was suppressed by higher concentrations of BAPTA These results provide a reasonable explanation for both of the apparently contradictory views in the Literature; high concentrations of calcium buffer (a) suppress the initial activation and (b) prevent the subsequent attenuation of calcium release.	BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School					NIAMS NIH HHS [AR 16822] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON K, 1995, J GEN PHYSIOL, V105, P363, DOI 10.1085/jgp.105.3.363; BAYLOR SM, 1983, J PHYSIOL-LONDON, V344, P625, DOI 10.1113/jphysiol.1983.sp014959; CSERNOCH L, 1992, ADV EXP MED BIOL, V311, P137; CSERNOCH L, 1991, J GEN PHYSIOL, V97, P845, DOI 10.1085/jgp.97.5.845; CSERNOCH L, 1993, J GEN PHYSIOL, V101, P297, DOI 10.1085/jgp.101.2.297; ELHAYEK R, 1995, J BIOL CHEM, V270, P15634, DOI 10.1074/jbc.270.26.15634; FILL M, 1990, BIOPHYS J, V57, P471, DOI 10.1016/S0006-3495(90)82563-7; GARCIA J, 1991, J GEN PHYSIOL, V97, P885, DOI 10.1085/jgp.97.5.885; HOLLINGWORTH S, 1992, BIOPHYS J, V63, P224, DOI 10.1016/S0006-3495(92)81599-0; IKEMOTO N, 1989, J BIOENERG BIOMEMBR, V21, P247, DOI 10.1007/BF00812071; IKEMOTO N, 1994, BIOCHEMISTRY-US, V33, P10961, DOI 10.1021/bi00202a015; IKEMOTO N, 1988, METHOD ENZYMOL, V157, P469; JACQUEMOND V, 1991, BIOPHYS J, V60, P867, DOI 10.1016/S0006-3495(91)82120-8; JONG DS, 1993, J GEN PHYSIOL, V102, P333, DOI 10.1085/jgp.102.2.333; KANG JJ, 1992, BIOCHEMISTRY-US, V31, P3288, DOI 10.1021/bi00127a034; KIRINO Y, 1983, J BIOCHEM-TOKYO, V94, P1111, DOI 10.1093/oxfordjournals.jbchem.a134454; LATTANZIO FA, 1991, BIOCHEM BIOPH RES CO, V177, P184, DOI 10.1016/0006-291X(91)91966-G; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; NAGASAKI K, 1983, J BIOCHEM-TOKYO, V94, P1101, DOI 10.1093/oxfordjournals.jbchem.a134453; OHKUSA T, 1991, J BIOCHEM-TOKYO, V109, P609, DOI 10.1093/oxfordjournals.jbchem.a123428; PALADE P, 1987, J BIOL CHEM, V262, P6149; PAPE PC, 1993, J GEN PHYSIOL, V102, P295, DOI 10.1085/jgp.102.2.295; PIZARRO G, 1991, J GEN PHYSIOL, V97, P913, DOI 10.1085/jgp.97.5.913; PIZARRO G, 1992, J PHYSIOL-LONDON, V457, P525, DOI 10.1113/jphysiol.1992.sp019392; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; RIOS E, 1993, J GEN PHYSIOL, V102, P449, DOI 10.1085/jgp.102.3.449; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; RIOS E, 1988, NEWS PHYSIOL SCI, V3, P223, DOI 10.1152/physiologyonline.1988.3.6.223; SCHNEIDER MF, 1987, J PHYSIOL-LONDON, V392, P167, DOI 10.1113/jphysiol.1987.sp016775; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SCHNEIDER MF, 1988, J PHYSIOL-LONDON, V405, P727, DOI 10.1113/jphysiol.1988.sp017358; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; SHIROKOVA N, 1994, J GEN PHYSIOL, V104, P449, DOI 10.1085/jgp.104.3.449; SIMON BJ, 1991, J GEN PHYSIOL, V97, P437, DOI 10.1085/jgp.97.3.437; SIMON BJ, 1992, BIOPHYS J, V61, P1109, DOI 10.1016/S0006-3495(92)81920-3; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; SZUCS G, 1991, J GEN PHYSIOL, V97, P897, DOI 10.1085/jgp.97.5.897; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; YANO M, 1995, J BIOL CHEM, V270, P3017, DOI 10.1074/jbc.270.7.3017; YANO M, 1994, FEBS LETT, V351, P349, DOI 10.1016/0014-5793(94)00869-8	42	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19936	19942		10.1074/jbc.270.34.19936	http://dx.doi.org/10.1074/jbc.270.34.19936			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650009	hybrid			2022-12-25	WOS:A1995RQ99100041
J	BOAM, DSW; DAVIDSON, I; CHAMBON, P				BOAM, DSW; DAVIDSON, I; CHAMBON, P			A TATA-LESS PROMOTER CONTAINING BINDING-SITES FOR UBIQUITOUS TRANSCRIPTION FACTORS MEDIATES CELL-TYPE-SPECIFIC REGULATION OF THE GENE FOR TRANSCRIPTION ENHANCER FACTOR-I (TEF-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I TEF-1; SV40 ENHANCER; AUTO-REGULATION; RECEPTOR GENE; DNA; EXPRESSION; SEQUENCE; INITIATOR; PROTEINS; ELEMENTS	TEF-1 is a tissue-specific human transcription factor which binds to and activates transcription from the SV40 early promoter and the HPV-16 E6/E7 promoter and may be involved in regulation of muscle-specific and placenta-specific gene expression, To investigate the mechanism of its tissue-specific expression, we have isolated up to 3 kilobase pairs of 8'-flanking DNA and characterized the promoter of the gene for TEF-1, Multiple transcription start sites centering on a motif similar to the initiator element (Inr) were identified. A minimal promoter, which contains no recognizable TATA element but contains an Inr, delimited at -137 base pairs had full transcriptional activity both in vivo in HeLa cells and in vitro in HeLa cell extracts, This promoter is also highly active in vitro in lymphoid cell extracts, but not in vivo in lymphoid cell lines, which do not express the endogenous TEF-1 gene. The minimal promoter, which is sufficient to direct tissue-specific expression of the TEF-1 gene in vivo, contains multiple sites which bind the ubiquitous transcription factors Sp1 and ATF-1. Mutation of the Inr completely abolished transcription from the major start site while transcription from the minor sites was slightly augmented. Inactivation of the proximal Sp1 site abolished transcription from the principle start site and increased transcription from a 5' minor start site. Insertion of a TATA box element did not qualitatively alter the pattern of start site usage which seemed to be dependent upon integrity of the upstream Sp1 site. These observations suggest a ''cross-talk'' between the Inr and a proximal element to fix transcription start sites, which is independent of spacing and the presence of a TATA element.	INST GENET & BIOL MOLEC & CELLULAIRE, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)				Davidson, Irwin/0000-0001-5533-1171				BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; BONNEROT C, 1991, NUCLEIC ACIDS RES, V19, P7251, DOI 10.1093/nar/19.25.7251; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CHAUDHARY S, 1994, MOL CELL BIOL, V14, P5290, DOI 10.1128/MCB.14.8.5290; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; KUNKEL TA, 1985, METHOD ENZYMOL, V154, P387; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MAXAM A, 1978, METHOD ENZYMOL, V65, P499; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORIOKA H, 1988, MOL CELL BIOL, V8, P3542, DOI 10.1128/MCB.8.8.3542; NOMIYAMA H, 1987, P NATL ACAD SCI USA, V84, P7881, DOI 10.1073/pnas.84.22.7881; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	46	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19487	19494		10.1074/jbc.270.33.19487	http://dx.doi.org/10.1074/jbc.270.33.19487			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642633	hybrid			2022-12-25	WOS:A1995RP70300047
J	WAWRZYNOW, A; BANECKI, B; WALL, D; LIBEREK, K; GEORGOPOULOS, C; ZYLICZ, M				WAWRZYNOW, A; BANECKI, B; WALL, D; LIBEREK, K; GEORGOPOULOS, C; ZYLICZ, M			ATP HYDROLYSIS IS REQUIRED FOR THE DNAJ-DEPENDENT ACTIVATION OF DNAK CHAPERONE FOR BINDING TO BOTH NATIVE AND DENATURED PROTEIN SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI DNAJ; LAMBDA-P-PROTEIN; REPLICATION PROTEIN; GRPE; PURIFICATION; HOMOLOG; COMPLEX	Using two independent experimental approaches to monitor protein-protein interactions (enzyme-linked immunosorbent assay and size exclusion high performance liquid chromatography) we describe a general mechanism by which DnaJ modulates the binding of the DnaK chaperone to various native protein substrates, e.g. lambda P, lambda O, sigma(32), P1, RepA, as well as permanently denatured alpha-carboxymethylated lactalbumin, The presence of DnaJ promotes the DnaK for efficient DnaK-substrate complex formation, ATP hydrolysis is absolutely required for such DnaJ-dependent activation of DnaK for binding to both native and denatured protein substrates. Although ADP can stabilize such an activated DnaK-protein complex, it cannot substitute for ATP in the activation reaction, Ln the presence of DnaJ and ATP, DnaK possesses the affinity to different substrates which correlates well with the affinity of DnaJ alone for these protein substrates, Only when the affinity of the DnaJ chaperone for its protein substrate is relatively high (e.g. sigma(32), RepA) can a tertiary complex DnaK-substrate-DnaJ be detected. In the case that DnaJ binds weakly to its substrate (lambda P, alpha-carboxymethylated lactalbumin), DnaJ is only transiently associated with the DnaK-substrate complex, but the DnaK activation reaction still occurs, albeit less efficiently,	UNIV UTAH,MED CTR,DEPT CELLULAR VIRAL & MOLEC BIOL,SALT LAKE CITY,UT 84132; CTR MED UNIV GENEVA,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND	Utah System of Higher Education; University of Utah; University of Geneva	WAWRZYNOW, A (corresponding author), UNIV GDANSK,DEPT MOLEC BIOL,DIV BIOPHYS,24 KLADKI,PL-80822 GDANSK,POLAND.		Liberek, Krzysztof/F-5812-2011	Zylicz, Alicja/0000-0003-4174-3073; Liberek, Krzysztof/0000-0002-7532-9279; Wall, Daniel/0000-0002-0273-1371				BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; CYR DM, 1994, J BIOL CHEM, V269, P9798; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; LIBEREK K, 1993, P NATL ACAD SCI USA, V90, P11019, DOI 10.1073/pnas.90.23.11019; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PANAGIOTIDIS CA, 1994, J BIOL CHEM, V269, P16643; PRASAD K, 1994, J BIOL CHEM, V269, P6931; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHERMAN MY, 1993, P NATL ACAD SCI USA, V90, P8648, DOI 10.1073/pnas.90.18.8648; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WICKNER S, 1992, NATURE, V350, P165; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431; [No title captured]	30	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19307	19311		10.1074/jbc.270.33.19307	http://dx.doi.org/10.1074/jbc.270.33.19307			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642606	hybrid			2022-12-25	WOS:A1995RP70300020
J	POSAS, F; CLOTET, J; MUNS, MT; COROMINAS, J; CASAMAYOR, A; ARINO, J				POSAS, F; CLOTET, J; MUNS, MT; COROMINAS, J; CASAMAYOR, A; ARINO, J			THE GENE PPG ENCODES A NOVEL YEAST PROTEIN PHOSPHATASE INVOLVED IN GLYCOGEN ACCUMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; SYNTHASE; TYPE-1; PHOSPHORYLASE; PURIFICATION; KINASES; TRANSFORMATION; METABOLISM; DISTINCT	Degenerate oligonucleotides were used to selectively amplify yeast genomic sequences related to Ser/Thr protein phosphatases. Among the sequences obtained, clone ST4-2 was found to code for a novel sequence related to previously known phosphatases. A size-selected yeast genomic library was constructed and screened using clone ST4-2 as probe, and one positive clone, named PPG, was isolated. DNA sequencing of a 1.8-kilobase pair fragment of this clone revealed an open reading frame of 1104 base pairs which codes for a 368-amino acid protein. On the basis of its amino acid sequence, the product of gene PPG would be an acidic protein, structurally more related to type 2A than to type 1 or 2B phosphatases, and is characterized by an extension of about 50 amino acids at the carboxyl terminus. The gene, which is located in chromosome XIV, is expressed as a 1.3-kilobase mRNA and is not essential for growth. Haploid mutants carrying a disrupted copy of the gene were able to grow in glucose as well as in other carbon sources, but they accumulated less glycogen than the wild type strain. However, the state of activation of glycogen synthase was essentially identical in wild type and mutant cells. The finding that, in early exponential phase, mutant cells contain higher levels of glycogen phosphorylase a, in addition to a lower amount of total glycogen synthase activity observed in medium-late exponential phase, could account for the difference found in glycogen accumulation.	UNIV AUTONOMA BARCELONA,FAC VET,DEPT BIOQUIM & BIOL MOLEC,E-08193 BARCELONA,SPAIN	Autonomous University of Barcelona			Posas, Francesc/K-1364-2013; Casamayor, Antonio/A-3190-2012; Arino, Joaquin/D-3756-2011	Posas, Francesc/0000-0002-4164-7076; Casamayor, Antonio/0000-0003-2788-7329; Arino, Joaquin/0000-0002-6774-2987; Arino Carmona, Joaquin/0000-0002-0390-4270				ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; CARABAZA A, 1990, BIOCHEM J, V268, P401, DOI 10.1042/bj2680401; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FENG ZH, 1991, J BIOL CHEM, V266, P23796; FERNANDEZBANARES I, 1991, FEBS LETT, V290, P38, DOI 10.1016/0014-5793(91)81220-3; FOSSET M, 1971, BIOCHEMISTRY-US, V10, P4105, DOI 10.1021/bi00798a015; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; HOEKSTRA MF, 1991, TRENDS GENET, V7, P293, DOI 10.1016/0168-9525(91)90178-S; HOEKSTRA MF, 1991, TRENDS GENET, V7, P256, DOI 10.1016/0168-9525(91)90161-I; HWANG PK, 1989, MOL CELL BIOL, V9, P1659, DOI 10.1128/MCB.9.4.1659; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LAYNE E, 1957, METHOD ENZYMOL, V3, P450; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; MISHRA C, 1983, FEMS MICROBIOL LETT, V18, P25; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PENG ZY, 1991, J BIOL CHEM, V266, P10925; PENG ZY, 1990, J BIOL CHEM, V265, P13871; POSAS F, 1992, J BIOL CHEM, V267, P11734; POSAS F, 1991, FEBS LETT, V279, P341, DOI 10.1016/0014-5793(91)80183-4; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; ROTHMANDENES LB, 1971, BIOCHEMISTRY-US, V10, P1236; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; ROWEN DW, 1992, MOL CELL BIOL, V12, P22, DOI 10.1128/MCB.12.1.22; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; WINGENDERDRISSEN R, 1983, BIOCHIM BIOPHYS ACTA, V743, P343, DOI 10.1016/0167-4838(83)90392-8	38	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1349	1354						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678255				2022-12-25	WOS:A1993KG07700088
J	HATTORI, K; HATTORI, M; ADACHI, H; TSUJIMOTO, M; ARAI, H; INOUE, K				HATTORI, K; HATTORI, M; ADACHI, H; TSUJIMOTO, M; ARAI, H; INOUE, K			PURIFICATION AND CHARACTERIZATION OF PLATELET-ACTIVATING-FACTOR ACETYLHYDROLASE-II FROM BOVINE LIVER CYTOSOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA; FACTOR 1-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; HUMAN ERYTHROCYTES; ENDOTHELIAL-CELLS; DIFFERENTIATION; PAF; PHOSPHATIDYLCHOLINE; HYDROLYSIS; THROMBIN	Platelet-activating factor (PAF) acetylhydrolase, which inactivates PAF by removing the acetyl group at the sn-2 position, is distributed widely in plasma and tissues. In a previous study, we demonstrated that the PAF acetylhydrolase activity present in the soluble fraction of bovine brain cortex could be separated chromatographically into three peaks (tentatively designated isoforms Ia, Ib, and II) (Hattori, M., Arai, H., and Inoue, a (1993) J. Biol. Chem, 268, 18748-18753). In this study, these three isoforms were also detected in kidney and Liver cytosols, although their relative activity ratios in these tissues differed. In particular, isoform II was responsible for the majority of the bovine liver PAF acetylhydrolase activity. We purified isoform II from bovine Liver cytosol to near homogeneity and demonstrated that it is a single 40-kDa polypeptide. This enzyme was inactivated by diisopropyl fluorophosphate and 5,5'-dithiobis(2-nitrobenzoic acid), suggesting that both serine and cysteine residues are required for the enzyme activity, and [H-3]diisopropyl fluorophosphate labeled only the 80-kDa polypeptide, confirming the enzyme's identity. Isoform II showed a comparatively broader substrate specificity than isoform Ib. Isoform II hydrolyzed propionyl and butyroyl moieties at the sn-2 position approximately half as effectively as it did PAF, whereas isoform Ib hardly hydrolyzed these substrates. Taken together with previous data, the current findings indicate that tissue cytosol contains at least two types of PAF acetylhydrolase with respect to polypeptide composition, substrate specificity, and tissue distribution and suggest that these two enzymes may share distinct physiological functions in tissues.	UNIV TOKYO, FAC PHARMACEUT SCI, DEPT HLTH CHEM, BUNKYO KU, TOKYO 113, JAPAN; SUNTORY INST BIOMED RES, OSAKA 618, JAPAN	University of Tokyo; Suntory Holdings Ltd			Hattori, Mitsuharu/F-3859-2010	Hattori, Mitsuharu/0000-0002-0503-4969				AARSMAN AJ, 1991, EUR J BIOCHEM, V200, P187, DOI 10.1111/j.1432-1033.1991.tb21066.x; BLANK ML, 1981, J BIOL CHEM, V256, P175; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; ELSTAD MR, 1989, J BIOL CHEM, V264, P8467; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; GUOTA CM, 1977, P NATL ACAD SCI USA, V74, P4315; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; LEE TC, 1982, BIOCHEM BIOPH RES CO, V105, P1303, DOI 10.1016/0006-291X(82)90928-7; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; NIJSSEN JG, 1986, BIOCHIM BIOPHYS ACTA, V876, P611, DOI 10.1016/0005-2760(86)90050-0; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SHUKLA SD, 1991, LIPIDS, V26, P1028, DOI 10.1007/BF02536496; SISSON JH, 1987, J IMMUNOL, V138, P3918; SNYDER F, 1995, BIOCHEM J, V305, P689, DOI 10.1042/bj3050689; SNYDER F, 1995, BBA-LIPID LIPID MET, V1254, P231, DOI 10.1016/0005-2760(94)00192-2; SNYDER F, 1987, PLATELET ACTIVATING; STAFFORINI DM, 1991, LIPIDS, V26, P979, DOI 10.1007/BF02536488; STAFFORINI DM, 1993, J BIOL CHEM, V268, P3857; STAFFORINI DM, 1991, METHOD ENZYMOL, V197, P411; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STEINBRECHER UP, 1989, J LIPID RES, V30, P305; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TOUQUI L, 1985, BIOCHEM J, V229, P811, DOI 10.1042/bj2290811; YANOSHITA R, 1988, J BIOCHEM-TOKYO, V103, P815, DOI 10.1093/oxfordjournals.jbchem.a122352	31	93	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22308	22313		10.1074/jbc.270.38.22308	http://dx.doi.org/10.1074/jbc.270.38.22308			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673213	hybrid			2022-12-25	WOS:A1995RW31400040
J	INOUE, A; TORIGOE, T; SOGAHATA, K; KAMIGUCHI, K; TAKAHASHI, S; SAWADA, Y; SAIJO, M; TAYA, Y; ISHII, S; SATO, N; KIKUCHI, K				INOUE, A; TORIGOE, T; SOGAHATA, K; KAMIGUCHI, K; TAKAHASHI, S; SAWADA, Y; SAIJO, M; TAYA, Y; ISHII, S; SATO, N; KIKUCHI, K			70-KDA HEAT-SHOCK COGNATE PROTEIN INTERACTS DIRECTLY WITH THE N-TERMINAL REGION OF THE RETINOBLASTOMA GENE-PRODUCT PRB - IDENTIFICATION OF A NOVEL REGION OF PRB-MEDIATING PROTEIN-INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; E2F TRANSCRIPTION FACTOR; LARGE T-ANTIGEN; ESCHERICHIA-COLI; RB PROTEIN; CELL-CYCLE; BINDING; P53; TRANSFORMATION; MUTATIONS	Retinoblastoma protein (pRb) functions as a tumor suppressor, and certain proteins are known to bind to pRb in the C-terminal region. Although the N-terminal region of pRb may also mediate interaction with some proteins, no such protein has been identified yet. We demonstrated previously the in vivo protein association between pRb and 73-kDa heat shock cognate protein (hsc73) in certain human tumor cell lines. In this report we analyzed the interaction between these two proteins in vitro, Our data showed that hsc73 interacts with the novel N-terminal region of pRb; that is, pRb binds directly to hsc73 and dissociates from hsc73 in an ATP-dependent manner. By using deletion mutants of cDNA encoding pRb, the hsc73 binding site of pRb was determined to be located in the region (residues 301-372) outside the so-called A pocket (residues 373-579) of this tumor suppressor protein. This finding was compatible with the fact that the adenovirus E1A oncoprotein, which is known to bind to the E2F binding pocket region of pRb, could not compete with hsc73 for the binding, Furthermore, phosphorylation of pRb by cyclin-dependent kinase inhibited the binding of pRb to hsc73. These data suggest that hsc73 may act exclusively as the molecular chaperone for nonphosphorylated pRb. As a result, hsc73 may function as a molecular stabilizer of nonphosphorylated pRb.	SAPPORO MED UNIV,SCH MED,DEPT PATHOL,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN; SAPPORO MED UNIV,SCH MED,DEPT BIOL MOLEC,SAPPORO,HOKKAIDO 060,JAPAN; SAPPORO MED UNIV,SCH MED,DEPT ORTHOPED,SAPPORO,HOKKAIDO 060,JAPAN; NATL CANC CTR,RES INST,DIV BIOL,TOKYO 104,JAPAN	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; National Cancer Center - Japan								BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHO JM, 1991, CANCER RES, V51, P4250; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARA I, 1991, MICROBIOL IMMUNOL, V35, P995, DOI 10.1111/j.1348-0421.1991.tb01621.x; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LAM KT, 1992, BIOCHEM BIOPH RES CO, V184, P167, DOI 10.1016/0006-291X(92)91174-O; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEHMAN TA, 1991, CANCER RES, V51, P4090; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; NEVINS JR, 1992, SCIENCE, V258, P424; NIHEI T, 1993, CANCER RES, V53, P1702; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DB, 1986, P NATL ACAD SCI USA, V83, P8703, DOI 10.1073/pnas.83.22.8703; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TAYA Y, 1990, GENETIC BASIS FOR CARCINOGENESIS, P171; WEINBERG RA, 1992, CANCER SURV, V12, P43; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHITE E, 1988, J VIROL, V62, P4153, DOI 10.1128/JVI.62.11.4153-4166.1988; YATSUNAMI J, 1993, CANCER RES, V53, P239; YEHIELY F, 1992, CELL GROWTH DIFFER, V3, P803	41	40	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22571	22576		10.1074/jbc.270.38.22571	http://dx.doi.org/10.1074/jbc.270.38.22571			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673249	hybrid			2022-12-25	WOS:A1995RW31400079
J	WAGNER, PD; VU, ND				WAGNER, PD; VU, ND			PHOSPHORYLATION OF ATP-CITRATE LYASE BY NUCLEOSIDE DIPHOSPHATE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; TUMOR-METASTASIS; SEQUENCE-ANALYSIS; BINDING PROTEINS; MELANOMA-CELLS; BREAST-CANCER; NM23; EXPRESSION; GENE; AUTOPHOSPHORYLATION	Rat liver nucleoside diphosphate kinase (NDPK) and PC12 cell cytosol were used to determine whether NDPK could function as a protein kinase. NDPK was phosphorylated on its catalytic histidine using [gamma-P-32]ATP, and the phosphorylated NDPK separated from [gamma-P-32]ATP, The addition of phosphorylated NDPK to dialyzed PC12 cell cytosol resulted in the phosphorylation of a protein with a subunit molecular mass of about 120 kDa, This phosphorylation appeared to occur by a direct transfer of a phosphoryl group from the catalytic histidine of NDPK to a histidine on the 120-kDa protein. The 120-kDa protein was partially purified and shown by peptide sequencing to be ATP-citrate lyase, ATP-citrate lyase is the primary source of cytosolic acetyl-CoA. NDPK phosphorylated the histidine at the catalytic site of ATP-citrate lyase, This histidine can also be phosphorylated by ATP, and its phosphorylation is the first step in the conversion of citrate and CoA to oxaloacetate and acetyl-CoA by ATP-citrate lyase. The level of phosphorylation of PC12 cell ATP-citrate lyase by phosphorylated NDPK was comparable with that by ATP. Thus, in addition to its nucleoside diphosphate kinase activity, NDPK can function as a protein kinase.			WAGNER, PD (corresponding author), NCI, BIOCHEM LAB, BLDG 37, RM 4C24, 37 CONVENT DR MSC 4255, BETHESDA, MD 20892 USA.							AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; BAGGETTO LG, 1992, BIOCHIMIE, V74, P959, DOI 10.1016/0300-9084(92)90016-8; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOMINAAR AA, 1994, FEBS LETT, V353, P5, DOI 10.1016/0014-5793(94)00997-X; BRIDGER WA, 1984, CURR TOP CELL REGUL, V24, P345; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BUCZYNSKI G, 1990, BIOCHIM BIOPHYS ACTA, V1041, P296, DOI 10.1016/0167-4838(90)90288-Q; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; ELSHOURBAGY NA, 1990, J BIOL CHEM, V265, P1430; FRANCIS B, 1989, MOL CARCINOGEN, V2, P168, DOI 10.1002/mc.2940020310; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; INOUE H, 1967, BIOCHEM BIOPH RES CO, V26, P602, DOI 10.1016/0006-291X(67)90108-8; KADRMAS EF, 1991, BIOCHIM BIOPHYS ACTA, V1074, P339, DOI 10.1016/0304-4165(91)90083-S; KAVANAUGHBLACK A, 1994, P NATL ACAD SCI USA, V91, P5883, DOI 10.1073/pnas.91.13.5883; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIMURA N, 1988, J BIOL CHEM, V263, P4647; KIMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P99, DOI 10.1016/0006-291X(90)91680-Q; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LINN TC, 1979, J BIOL CHEM, V254, P1691; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MELKI R, 1992, BIOCHEM BIOPH RES CO, V187, P65, DOI 10.1016/S0006-291X(05)81459-7; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; MUNOZDORADO J, 1993, J BACTERIOL, V175, P1176; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; OHTSUKI K, 1986, BIOCHIM BIOPHYS ACTA, V882, P322, DOI 10.1016/0304-4165(86)90254-0; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SINGH M, 1976, J BIOL CHEM, V251, P5242; SJOBERG ER, 1993, J BIOL CHEM, V268, P10185; SRERE PA, 1975, ADV ENZYMOLOGY, V43, P85; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; VU ND, 1993, BIOCHEM J, V296, P169, DOI 10.1042/bj2960169; WAGNER PD, 1989, J BIOL CHEM, V264, P19614; WEI YF, 1991, METHOD ENZYMOL, V200, P388; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; WELLS TNC, 1991, EUR J BIOCHEM, V199, P163, DOI 10.1111/j.1432-1033.1991.tb16105.x; WILLIAMS SP, 1985, BIOCHEMISTRY-US, V24, P5527, DOI 10.1021/bi00341a037	56	162	164	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21758	21764		10.1074/jbc.270.37.21758	http://dx.doi.org/10.1074/jbc.270.37.21758			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665595	hybrid			2022-12-25	WOS:A1995RU75700054
J	BENNER, GE; DENNIS, PB; MASARACCHIA, RA				BENNER, GE; DENNIS, PB; MASARACCHIA, RA			ACTIVATION OF AN S6/H4 KINASE (PAK-65) FROM HUMAN PLACENTA BY INTRAMOLECULAR AND INTERMOLECULAR AUTOPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; PURIFICATION; CLEAVAGE	The S6/H4 kinase purified from human placenta catalyzes phosphorylation of the S6 ribosomal protein, histone H4, and myelin basic protein. In vitro activation of the p60 S6/H4 kinase requires removal of an autoinhibitory domain by mild trypsin digestion and autophosphorylation of the catalytic domain (p40 S6/H4 kinase). The two autophosphorylation/autoactivation sites contain the sequences SSMVGTPY (site 1) and SVIDPVPAPVGD-SHVDGAAK (site 2). These sequences identify S6/H4 kinase as the rac-activated PAK65 (Martin, G. A., Bollag, G., McCormick, F. and Abo, A. (1995) EMBO J. 14, 1971-1978). Site 1 phosphorylation is most rapid, but activation does not occur until site 2 is autophosphorylated. The site 1 phosphorylation occurs by an intramolecular mechanism whereas site 2 autophosphorylation occurs by an intermolecular mechanism. A model is proposed in which phosphorylation of sites 1 and 2 occurs sequentially. The model proposes that trypsin treatment of the inactive holoenzyme removes an inhibitory rac-binding domain which blocks MgATP access to the catalytic site. The pseudosubstrate domain at site 1 is autophosphorylated and subsequent bimolecular autophosphorylation at site 2 fully opens the catalytic site. Phosphorylation by a regulatory protein kinase may occur at site 2 in vivo.	UNIV N TEXAS, DEPT BIOL SCI, DIV MOLEC BIOL & BIOCHEM, DENTON, TX 76203 USA	University of North Texas System; University of North Texas Denton					PHS HHS [32350] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRANDON SD, 1991, J BIOL CHEM, V266, P380; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DELAHOUSSAYE BA, 1983, J BIOL CHEM, V258, P4272; DENNIS PB, 1993, J BIOL CHEM, V268, P19833; ECKOLS TK, 1983, EUR J BIOCHEM, V134, P249, DOI 10.1111/j.1432-1033.1983.tb07558.x; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GUO H, 1993, J BIOL CHEM, V268, P11193; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; JUHL H, 1983, METHOD ENZYMOL, V99, P37; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG SD, 1987, J BIOL CHEM, V262, P9421; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	25	61	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21121	21128		10.1074/jbc.270.36.21121	http://dx.doi.org/10.1074/jbc.270.36.21121			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673144	hybrid, Green Published			2022-12-25	WOS:A1995RU05400042
J	BERTELOOT, A; STDENIS, JF; VANDEWERVE, G				BERTELOOT, A; STDENIS, JF; VANDEWERVE, G			EVIDENCE FOR A MEMBRANE EXCHANGEABLE GLUCOSE POOL IN THE FUNCTIONING OF RAT-LIVER GLUCOSE-6-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE-DISEASE TYPE-1A; MICROSOMAL GLUCOSE-6-PHOSPHATASE; TRANSPORT PROTEIN; SYSTEM; IDENTIFICATION; PYROPHOSPHATE; PHOSPHATE; GENE	We have investigated the kinetics of tracer uptake into rat liver microsomes in relation to [C-14]glucose 6-phosphate (Glu-6-P) hydrolysis by glucose 6-phosphatase (Glu-6-Pase). 1) The steady-state levels of intravesicular tracer accumulated during the rapid (AMP(1)) and slow (AMP(2)) phases of uptake both demonstrate Michaelis-Menten kinetics relative to outside Glu-6-P concentrations with K-m values similar to those observed for the initial burst (V-i) and steady-state (V-ss) rates of Glu-6-P hydrolysis. 2) The AMP(1)/AMP(2) ratio is constant (mean value = 0.105 +/- 0.018) over the whole range of outside Glu-6-P concentrations and is equal to the AMP(1max)/AMP(2max) ratio (0.109 +/- 0.032), 3) Linear relationships are observed between the initial rates of glucose transport during the slow uptake phase (V-a2) and [AMP(1)], and between [V-ss] and [AMP(2)]. 4) The value of V-ss max exceeds by more than 10-fold that of V-a2 max. 5) It is concluded that the substrate transport model is incompatible with those results and that AMP, represents a membrane exchangeable glucose pool. 6) We propose a new version of the conformational model in which the catalytic site lies deep within a hydrophilic pocket of an intrinsic membrane protein and communicates with the extra- and intravesicular spaces through channels with different glucose permeabilities.	UNIV MONTREAL,DEPT NUTR,ENDOCRINOL METAB LAB,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,DEPT BIOCHEM,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,GRP RECH TRANSPORT MEMBRANAIRE,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,DEPT PHYSIOL,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal								ARION WJ, 1980, J BIOL CHEM, V255, P396; BERTELOOT A, 1991, J BIOL CHEM, V266, P5497; BURCHELL A, 1990, FASEB J, V4, P2978, DOI 10.1096/fasebj.4.12.2168325; BURCHELL A, 1994, BIOCHEM SOC T, V22, P658, DOI 10.1042/bst0220658; LEI KJ, 1995, J CLIN INVEST, V95, P234, DOI 10.1172/JCI117645; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; NORDLIE RC, 1982, METHOD ENZYMOL, V87, P319; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; ROMANELLI A, 1994, BIOCHEM BIOPH RES CO, V200, P1491, DOI 10.1006/bbrc.1994.1619; SCHULZE HU, 1986, J BIOL CHEM, V261, P6571; SCHULZE HU, 1980, EUR J BIOCHEM, V106, P505, DOI 10.1111/j.1432-1033.1980.tb04597.x; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; STDENIS JF, 1995, J BIOL CHEM, V270, P21092, DOI 10.1074/jbc.270.36.21092; STDENIS JF, 1994, J CLIN ENDOCR METAB, V79, P955, DOI 10.1210/jc.79.4.955; STDENIS JF, 1995, BIOCHEM J, V310, P221, DOI 10.1042/bj3100221; VIDAL H, 1992, FEBS LETT, V302, P197, DOI 10.1016/0014-5793(92)80439-N; WADDELL ID, 1988, FEBS LETT, V229, P179, DOI 10.1016/0014-5793(88)80822-6; WADDELL ID, 1991, BIOCHEM J, V275, P363, DOI 10.1042/bj2750363; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173; WOHLHUETER RM, 1980, INT REV CYTOL, V64, P171, DOI 10.1016/S0074-7696(08)60238-7	20	26	26	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21098	21102		10.1074/jbc.270.36.21098	http://dx.doi.org/10.1074/jbc.270.36.21098			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673140	hybrid			2022-12-25	WOS:A1995RU05400038
J	ENGELENDER, S; WOLOSKER, H; DEMEIS, L				ENGELENDER, S; WOLOSKER, H; DEMEIS, L			THE CA2+-ATPASE ISOFORMS OF PLATELETS ARE LOCATED IN DISTINCT FUNCTIONAL CA2+ POOLS AND ARE UNCOUPLED BY A MECHANISM DIFFERENT FROM THAT OF SKELETAL-MUSCLE CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; HUMAN-BLOOD PLATELETS; TRANSMEMBRANE CHANNEL; HYDROPHOBIC MOLECULES; CALCIUM RELEASE; ATP SYNTHESIS; CA-2+ ATPASE; TRANSPORT; VESICLES; MEMBRANE	Vesicles derived from the dense tubular system of platelets possess a Ca2+-ATPase that can use either ATP or acetyl phosphate as a substrate. In the presence of phosphate as a precipitating anion, the maximum amount of Ca2+ accumulated by the vesicles with the use of acetyl phosphate was only one-third of that accumulated with the use of ATP. Vesicles derived from the sarcoplasmic reticulum of skeletal muscle accumulated equal amounts of Ca2+ regardless of the substrate used. When acetyl phosphate was used in platelet vesicles, the transport of Ca2+ was inhibited by Na+, Li+, and K+; in sarcoplasmic reticulum vesicles, only Na+ caused inhibition. When ATP was used as substrate, the different monovalent cation had no effect on either sarcoplasmic reticulum or platelet vesicles. The catalytic cycle of the Ca2+-ATPase is reversed when a Ca2+ gradient is formed across the vesicle membrane, The stoichiometry between active Ca2+ efflux and ATP synthesis was one in platelet vesicles and two in sarcoplasmic reticulum vesicles. The coupling between ATP synthesis and Ca2+ efflux in sarcoplasmic reticulum vesicles was abolished by arsenate regardless of whether the vesicles were loaded with Ca2+ using acetyl phosphate or ATP. In platelets, uncoupling was observed only when the vesicles were loaded using acetyl phosphate. In both sarcoplasmic reticulum and platelet vesicles, the effect of arsenate was antagonized by thapsigargin (2 mu M), micromolar Ca2+ concentrations, P-i (5-20 mM), and MgATP (10-100 mu M). Trifluoperazine also uncoupled the platelet Ca2+ pump but, different from arsenate, this drug was effective in vesicles that were loaded using either ATP or acetyl phosphate. Trifluoperazine enhanced Ca2+ efflux from both sarcoplasmic reticulum and platelet vesicles; thapsigargin, Ca2+, Mg2+, or K+ antagonized this effect in sarcoplasmic reticulum but not in platelet vesicles. The data indicate that the Ca2+-transport isoforms found in sarcoplasmic reticulum and in platelets have different kinetic properties.	FED UNIV RIO DE JANEIRO, DEPT BIOQUIM, INST CIENCIAS BIOMED, BR-21941590 RIO DE JANEIRO, BRAZIL					Wolosker, Herman/0000-0001-5508-9194; Engelender, Simone/0000-0001-7401-6855				ADUNYAH SE, 1986, J BIOL CHEM, V261, P3071; ALVES EW, 1987, EUR J BIOCHEM, V166, P647, DOI 10.1111/j.1432-1033.1987.tb13562.x; BARLOGIE B, 1971, FEBS LETT, V12, P267, DOI 10.1016/0014-5793(71)80194-1; BENECH JC, 1995, BIOCHEM J, V306, P35, DOI 10.1042/bj3060035; BOBE R, 1994, J BIOL CHEM, V269, P1417; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; BURK SE, 1989, J BIOL CHEM, V264, P18561; CARDOSO CM, 1993, BIOCHEM J, V296, P49, DOI 10.1042/bj2960049; CHIESI M, 1979, J BIOL CHEM, V254, P370; CUTLER L, 1978, J GEN PHYSIOL, V61, P463; DEAN WL, 1982, J BIOL CHEM, V257, P4390; DEAN WL, 1983, J BIOL CHEM, V259, P7343; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1992, FEBS LETT, V299, P33, DOI 10.1016/0014-5793(92)80093-V; DEMEIS L, 1990, J BIOL CHEM, V265, P18848; DEMEIS L, 1988, EUR J BIOCHEM, V171, P343; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1988, METHOD ENZYMOL, V157, P190; DEMEIS L, 1981, TRANSPORT LIFE SCI, V2; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; ENOUF J, 1989, BIOCHEM J, V263, P547, DOI 10.1042/bj2630547; ENOUF J, 1992, BIOCHEM J, V286, P135, DOI 10.1042/bj2860135; ENYEDI A, 1986, J BIOL CHEM, V261, P9558; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FISCHER TH, 1987, BIOCHEMISTRY-US, V26, P8024, DOI 10.1021/bi00398a070; GOSH TK, 1988, J BIOL CHEM, V263, P11075; HASSELBACH W, 1972, FEBS LETT, V20, P311, DOI 10.1016/0014-5793(72)80094-2; INESI G, 1989, J BIOL CHEM, V264, P5929; JAVORS MA, 1982, BIOCHIM BIOPHYS ACTA, V691, P220, DOI 10.1016/0005-2736(82)90410-2; KASERGLANZMANN R, 1978, BIOCHIM BIOPHYS ACTA, V512, P1, DOI 10.1016/0005-2736(78)90213-4; LEPEUCH CJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P456, DOI 10.1016/0005-2736(83)90041-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1989, J BIOL CHEM, V264, P7059; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAKINOSE M, 1971, FEBS LETT, V12, P271, DOI 10.1016/0014-5793(71)80196-5; MENASHI S, 1982, FEBS LETT, V140, P298, DOI 10.1016/0014-5793(82)80918-6; PICK U, 1982, EUR J BIOCHEM, V131, P393; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SAXENA S P, 1991, FASEB Journal, V5, pA902; SCHWARTZENBACH G, 1957, HELV CHIM ACTA, V40, P1186; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; WHITE GC, 1982, BIOCHEM BIOPH RES CO, V104, P1066, DOI 10.1016/0006-291X(82)91358-4; WOLOSKER H, 1994, AM J PHYSIOL, V266, pC1376, DOI 10.1152/ajpcell.1994.266.5.C1376; WOLOSKER H, 1990, EUR J BIOCHEM, V193, P873, DOI 10.1111/j.1432-1033.1990.tb19411.x; WOLOSKER H, 1992, J BIOL CHEM, V267, P5785; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; WUYTACK F, 1994, J BIOL CHEM, V269, P1410	48	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21050	21055		10.1074/jbc.270.36.21050	http://dx.doi.org/10.1074/jbc.270.36.21050			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673132	hybrid			2022-12-25	WOS:A1995RU05400030
J	GERGEL, D; MISIK, V; ONDRIAS, K; CEDERBAUM, AI				GERGEL, D; MISIK, V; ONDRIAS, K; CEDERBAUM, AI			INCREASED CYTOTOXICITY OF 3-MORPHOLINOSYDNONIMINE TO HEPG2 CELLS IN THE PRESENCE OF SUPEROXIDE-DISMUTASE - ROLE OF HYDROGEN-PEROXIDE AND IRON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; LIPID-PEROXIDATION; CYTO-TOXICITY; FREE-RADICALS; URIC-ACID; PEROXYNITRITE; HYDROXYL; COMPLEXES; OXYGEN; CARDIOPROTECTION	3-Morpholinosydnonimine (SIN-1) is widely used to generate nitric oxide (NOx.) and superoxide radical (Oa. The effect of SOD on the toxicity of SIN-1 is complex, depending on what is the ultimate species responsible for toxicity. SIN-1 (<1 mM) was only slightly toxic to HepG2 cells, Copper,zinc superoxide dismutase (Cu,Zn-SOD) or manganese superoxide dismutase (Mn-SOD) increased the toxicity of SIN-1. Catalase abolished, while sodium azide potentiated, this toxicity, suggesting a key role for H2O2 in the overall mechanism. Depletion of GSH from the HepG2 cells also potentiated the toxicity of SIN-1 plus SOD, Although Me(2)SO, sodium formate, and mannitol had no protective effect, iron chelators, thiourea and urate protected the cells against the SIN-1 plus Cu,Zn-SOD-mediated cytotoxicity. The cytotoxic effect of Cu,Zn-SOD but not Mn-SOD, showed a biphasic dose response being most pronounced at lower concentrations (10-100 units/ml). In the presence of SIN-1, Mn-SOD increased accumulation of H2O2 in a concentration-dependent manner. In contrast, Cu,Zn-SOD increased H2O2 accumulation from SIN-1 at low but not high concentrations of the enzyme, suggesting that high concentrations of the Cu,Zn-SOD interacted with the H2O2. EPR spin trapping studies demonstrated the formation of hydroxyl radical from the decomposition of H2O2 by high concentrations of the Cu,Zn-SOD. The cytotoxic effect of the NO donors SNAP and DEA/NO was only slightly enhanced by SOD; catalase had no effect, Thus, the oxidants responsible for the toxicity of SIN-1 and SNAP or DEA\NO to HepG2 cells under these conditions are different, with H2O2 derived from O-2-radical-anion dismutation playing a major role with SIN-1, These results suggest that the potentiation of SIN-1 toxicity by SOD is due to enhanced production of H2O2, followed by site-specific damage of critical cellular sites by a transition metal-catalyzed reaction, These results also emphasize that the role of SOD as a protectant against oxidant damage is complex and dependent, in part, on the subsequent fate and reactivity of the generated H2O2.	CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029; NCI,BETHESDA,MD 20892	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Ondrias, Karol/0000-0001-8329-3563	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R56AA003312, R01AA009460, R01AA003312] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-09460, AA-03312] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ASSREUY J, 1994, EUR J IMMUNOL, V24, P672, DOI 10.1002/eji.1830240328; AUGUSTO O, 1994, ARCH BIOCHEM BIOPHYS, V310, P118, DOI 10.1006/abbi.1994.1147; BARNIER M, 1989, AM J PHYSIOL, V256, pH1344; BECKMAN JS, 1990, P NATL ACAD SCI USA, V84, P1620; BRITIGAN BE, 1987, J LEUKOCYTE BIOL, V41, P349, DOI 10.1002/jlb.41.4.349; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; CEDERBAUM AI, 1979, BIOCHEMISTRY-US, V18, P1187, DOI 10.1021/bi00574a011; CROW JP, 1994, FREE RADICAL BIO MED, V16, P331, DOI 10.1016/0891-5849(94)90034-5; DARLEYUSMAR VM, 1992, FREE RADICAL RES COM, V14, P19; DAVIES KJA, 1986, BIOCHEM J, V235, P747, DOI 10.1042/bj2350747; DEGROOT H, 1992, FEBS LETT, V315, P139; DIMASCIO P, 1994, FEBS LETT, V335, P287; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; ELROYSTEIN O, 1988, CELL, V52, P259, DOI 10.1016/0092-8674(88)90515-6; FEELISCH M, 1989, J CARDIOVASC PHA S11, V14, P313; FOSSATI P, 1980, CLIN CHEM, V26, P227; FUNG KP, 1994, LIFE SCI, V54, pPL491, DOI 10.1016/0024-3205(94)00722-5; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; GUTTERIDGE JMC, 1984, BIOCHEM J, V224, P761, DOI 10.1042/bj2240761; HADDAD IY, 1994, AM J PHYSIOL, V264, pL242; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HERSHKO C, 1988, CRIT REV CLIN LAB SC, V76, P303; Hildebrandt A G, 1978, Methods Enzymol, V52, P342; HOGG N, 1992, BIOCHEM J, V28, P419; HORTON RA, 1994, BIOCHEM J, V299, P735, DOI 10.1042/bj2990735; ILAN YA, 1977, BIOCHIM BIOPHYS ACTA, V498, P386, DOI 10.1016/0304-4165(77)90277-X; IOANNIDIS I, 1993, BIOCHEM J, V296, P341, DOI 10.1042/bj2960341; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KING PA, 1992, J AM CHEM SOC, V114, P5430, DOI 10.1021/ja00039a068; KRONCKE KD, 1993, BIOCHIM BIOPHYS ACTA, V1182, P221, DOI 10.1016/0925-4439(93)90144-P; KUKIELKA E, 1989, ARCH BIOCHEM BIOPHYS, V275, P540, DOI 10.1016/0003-9861(89)90400-1; LAFONCAZAL M, 1993, NEUROPHARMACOLOGY, V32, P1259, DOI 10.1016/0028-3908(93)90020-4; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MAO GD, 1993, J BIOL CHEM, V268, P416; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1988, FREE RADICAL BIO MED, V5, P363, DOI 10.1016/0891-5849(88)90109-8; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOORHOUSE CP, 1985, BIOCHIM BIOPHYS ACTA, V843, P261, DOI 10.1016/0304-4165(85)90147-3; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NELSON SK, 1994, FREE RADICAL BIO MED, V16, P195, DOI 10.1016/0891-5849(94)90143-0; NORONHADUTRA AA, 1993, FEBS LETT, V321, P59, DOI 10.1016/0014-5793(93)80621-Z; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P465, DOI 10.1016/0891-5849(90)90123-Z; OURY TD, 1992, P NATL ACAD SCI USA, V89, P9715, DOI 10.1073/pnas.89.20.9715; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; ROSEN GM, 1984, P NATL ACAD SCI USA, V81, P7268; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SCHULZ W, 1991, BASIC RES CARDIOL, V86, P233; SCOTT MD, 1989, J BIOL CHEM, V264, P2498; SCOTT MD, 1987, J BIOL CHEM, V262, P3640; SIEGFRIED MR, 1992, J PHARMACOL EXP THER, V260, P668; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STIEF CG, 1992, J UROLOGY, V148, P1437, DOI 10.1016/S0022-5347(17)36931-8; WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003; WINK DA, 1994, NEUROBIOLOGY NO OH, P765; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006	61	59	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20922	20929		10.1074/jbc.270.36.20922	http://dx.doi.org/10.1074/jbc.270.36.20922			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673115	hybrid			2022-12-25	WOS:A1995RU05400012
J	KOTENKO, SV; IZOTOVA, LS; POLLACK, BP; MARIANO, TM; DONNELLY, RJ; MUTUKUMARAN, G; COOK, JR; GAROTTA, G; SILVENNOINEN, O; IHLE, JN; PESTKA, S				KOTENKO, SV; IZOTOVA, LS; POLLACK, BP; MARIANO, TM; DONNELLY, RJ; MUTUKUMARAN, G; COOK, JR; GAROTTA, G; SILVENNOINEN, O; IHLE, JN; PESTKA, S			INTERACTION BETWEEN THE COMPONENTS OF THE INTERFERON-GAMMA RECEPTOR COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY FACTOR; SIGNAL-TRANSDUCTION; EXTRACELLULAR DOMAIN; GENE; IDENTIFICATION; PROTEINS; CHROMOSOME-21; INDUCTION; SYSTEM; CELLS	Interferon gamma (IFN-gamma) signals through a multimeric receptor complex consisting of two different chains: the IFN-gamma receptor binding subunit (IFN-gamma R, IFN-gamma R1), and a transmembrane accessory factor (AF-1, IFN-gamma R2) necessary for signal transduction. Using cell lines expressing different cloned components of the IFN-gamma receptor complex, we examined the function of the receptor components in signal transduction upon IFN-gamma treatment. A specific IFN-gamma R2:IFN-gamma cross-linked complex was observed in cells expressing both IFN-gamma R1 and IFN-gamma R2 indicating that IFN-gamma R2 (AF-1) interacts with IFN-gamma and is closely associated with IFN-gamma R1. We show that the intracellular domain of IFN-gamma R2 is necessary for signaling. Cells coexpressing IFN-gamma R1 and truncated IFN-gamma R2, lacking the COOH-terminal 51 amino acids (residues 286-337), or cells expressing IFN-gamma R1 alone were unresponsive to IFN-gamma treatment as measured by MHC class I antigen induction. Jak1, Jak2, and Stat1 alpha were activated, and IFN-gamma R1 was phosphorylated only in cells expressing both IFN-gamma R1 and IFN-gamma R2. Jak2 kinase was shown to associate with the intracellular domain of the LFN-gamma R2.	HUMAN GENOME SCI, ROCKVILLE, MD 20850 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	GlaxoSmithKline; Human Genome Sciences Inc; St Jude Children's Research Hospital	KOTENKO, SV (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT MOLEC GENET & MICROBIOL, PISCATAWAY, NJ 08854 USA.				NCI NIH HHS [P30 CA21765, R01 CA46465] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA046465] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P781, DOI 10.1111/j.1432-1033.1992.tb17248.x; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; HIBINO Y, 1991, J BIOL CHEM, V266, P6948; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KALINA U, 1993, J VIROL, V67, P1702, DOI 10.1128/JVI.67.3.1702-1706.1993; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARIANO TM, 1987, J BIOL CHEM, V262, P5812; MARIANO TM, 1991, CYTOKINES PRACTICAL, P95; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; REHBERG E, 1982, J BIOL CHEM, V257, P1497; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Sambrook J, 1989, MOL CLONING LABORATO; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	47	137	147	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20915	20921		10.1074/jbc.270.36.20915	http://dx.doi.org/10.1074/jbc.270.36.20915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673114	hybrid			2022-12-25	WOS:A1995RU05400011
J	SCHWERK, C; KLOTZBUCHER, M; SACHS, M; ULBER, V; KLEINHITPASS, L				SCHWERK, C; KLOTZBUCHER, M; SACHS, M; ULBER, V; KLEINHITPASS, L			IDENTIFICATION OF A TRANSACTIVATION FUNCTION IN THE PROGESTERONE-RECEPTOR THAT INTERACTS WITH THE TAF(II)110 SUBUNIT OF THE TFIID COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING-PROTEIN; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR; MOLECULAR-CLONING; RNA-POLYMERASE; ESTROGEN; COACTIVATORS; SUPERFAMILY; EXPRESSION	Transcriptional activation of target genes by the human progesterone receptor is thought to involve direct or indirect protein-protein interactions between the progesterone receptor and general transcription factors. A key role in transcription plays the general transcription factor TFIID, a multiprotein complex consisting of the TATA-binding protein and several tightly associated factors (TAFs). TAFs have been shown to be required for activated transcription and are, thus, potential targets of activator proteins. Using in vitro interaction assays, we could identify specific interactions between the progesterone receptor and the TATA-binding protein-associated factor dTAF(II)110. The dTAF(II)110 domain responsible for the interaction is distinct from that reported to suffice for binding to Sp1. Somewhat surprisingly, deletion analysis indicated that the previously identified activation functions 1 and 2 of the progesterone receptor are not required for this interaction but pointed to an important role of the DNA binding domain. In cotransfection experiments and an in vitro transcription assay, the DNA binding domain of the progesterone receptor displayed significant activation potential. These findings, taken together, suggest that an interaction between the progesterone receptor and TAF(II)110 may represent an important step in the mechanism of activation.	UNIV ESSEN GESAMTHSCH KLINIKUM,INST ZELLBIOL TUMORFORSCH,D-45122 ESSEN,GERMANY	University of Duisburg Essen			Schwerk, Christian/GNP-5375-2022					BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; DOBBELING U, 1988, EMBO J, V7, P2495, DOI 10.1002/j.1460-2075.1988.tb03096.x; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KLEINHITPASS L, 1991, NUCLEIC ACIDS RES, V19, P1227, DOI 10.1093/nar/19.6.1227; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MCEWAN IJ, 1994, J BIOL CHEM, V269, P25629; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MEYER ME, 1992, J BIOL CHEM, V267, P10882; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; NARDULLI AM, 1991, J BIOL CHEM, V266, P24070; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PFITZNER E, 1993, MOL ENDOCRINOL, V7, P1061, DOI 10.1210/me.7.8.1061; Sambrook J, 1989, MOL CLONING LABORATO; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TONG X, 1995, J VIROL, V69, P585, DOI 10.1128/JVI.69.1.585-588.1995; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VASSEN L, 1994, CELL CULTURE PHARM R, V11, P267; VONSTRANDMANN EP, 1995, DEVELOPMENT, V121, P1217; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOKIMORI K, 1993, GENE DEV, V7, P2587; ZAPP D, 1993, MOL CELL BIOL, V13, P6416, DOI 10.1128/MCB.13.10.6416; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	53	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21331	21338		10.1074/jbc.270.36.21331	http://dx.doi.org/10.1074/jbc.270.36.21331			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673170	hybrid			2022-12-25	WOS:A1995RU05400071
J	SUN, ZM; MEANS, AR				SUN, ZM; MEANS, AR			AN INTRON FACILITATES ACTIVATION OF THE CALSPERMIN GENE BY THE TESTIS-SPECIFIC TRANSCRIPTION FACTOR CREM-TAU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; CALMODULIN-BINDING PROTEIN; SV40 ENHANCER; SEQUENCE; EXPRESSION; ELEMENTS	Calspermin is a high affinity Ca2+/calmodulin binding protein that is found only in postmeiotic male germ cells, Our previous studies have shown that the calspermin transcript is produced by utilization of a testis-specific promoter located within an intron of the calmodulin kinase IV gene. This promoter contains two cAMP response element-like motifs that bind the testis-specific transcription factor CREM tau. This interaction is required for transcriptional activation. Here we describe a novel regulatory element, the 111-base pair first intron of the calspermin gene, which is also required for enhancement of transcription by CREM tau via the cAMP response element motifs, Deletion or inversion of this intron results in loss of CREM tau-mediated stimulation of transcription. However, CREM tau stimulates calspermin promoter activity when the intron is moved upstream of the promoter but only when inserted in the proper orientation. Footprint, linker scanning, and deletion analyses were used to identify regulatory elements in the intron. We suggest that the intron functions as an orientation-dependent but position-independent regulatory element to activate the calspermin promoter by facilitating the stimulatory effect of CREM tau on transcription.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University					NICHD NIH HHS [HD-07503] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BORNSTEIN P, 1988, MOL CELL BIOL, V8, P4851, DOI 10.1128/MCB.8.11.4851; BROOKS AR, 1994, MOL CELL BIOL, V14, P2243, DOI 10.1128/MCB.14.4.2243; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; GOOMER RS, 1994, P NATL ACAD SCI USA, V91, P7985, DOI 10.1073/pnas.91.17.7985; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; IMAI E, 1993, J BIOL CHEM, V268, P5353; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; LEFRANC G, 1990, BIOCHIMIE, V72, P7, DOI 10.1016/0300-9084(90)90167-F; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MEANS AR, 1993, RECENT PROG HORM RES, V48, P79; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS BJ, 1992, J HYPERTENS, V10, P337, DOI 10.1097/00004872-199204000-00003; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; ONO T, 1989, J BIOL CHEM, V264, P2081; PETERLIN BM, 1991, RES IMMUNOL, V142, P393, DOI 10.1016/0923-2494(91)90037-J; SCHIRM S, 1987, GENE DEV, V1, P65, DOI 10.1101/gad.1.1.65; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561	22	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20962	20967		10.1074/jbc.270.36.20962	http://dx.doi.org/10.1074/jbc.270.36.20962			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673120	hybrid			2022-12-25	WOS:A1995RU05400017
J	PELICCI, G; LANFRANCONE, L; SALCINI, AE; ROMANO, A; MELE, S; BORRELLO, MG; SEGATTO, O; DIFIORE, PP; PELICCI, PG				PELICCI, G; LANFRANCONE, L; SALCINI, AE; ROMANO, A; MELE, S; BORRELLO, MG; SEGATTO, O; DIFIORE, PP; PELICCI, PG			CONSTITUTIVE PHOSPHORYLATION OF SHC PROTEINS IN HUMAN TUMORS	ONCOGENE			English	Article						SHC PHOSPHORYLATION; HUMAN TUMORS	GUANINE-NUCLEOTIDE EXCHANGE; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; SIGNAL TRANSDUCTION; ADAPTER PROTEIN; SEVENLESS GENE; V-SRC; RAS; GRB2; IDENTIFICATION	The She gene encodes three overlapping proteins which all contain a carboxy-terminal SH2 domain. She proteins are ubiquitously expressed and are downstream targets and effecters of activated tyrosine kinases (TK). We investigated tyrosine-phosphorylation of She proteins in normal and transformed cells. In tumor cells with known TK gene alterations She proteins were constitutively phosphorylated and complexed with the activated TK. No constitutive She phosphorylation was found in primary cell cultures and normal tissues, In 14 of 27 tumor cell lines with no reported TK alterations, She proteins were constitutively phosphorylated and formed stable complexes with novel tyrosine-phosphorylated polypeptides. Ten distinct She-associated phosphoproteins were identified with molecular weights ranging from 30 to 200 kDa. In a subset of carcinoma cell lines, phosphorylated She proteins complexed with a p175 phosphoprotein that was identified as the constitutively activated EGFR. In one glioblastoma cell line, a Shc-associated p190 was identified as the activated PDGFR. In 13 of 14 acute leukemia samples phosphorylated She proteins were constitutively complexed with a p140 phosphoprotein. Some of the She-associated phosphoproteins (EGFR, PDGFR, erbB-2, Met, bcr-abl, H4-ret) bound both the Shc- and Grb2-SH2 domains in vitro; others (p175; p70-p80) only the Shc-SH2 domain and yet others (p140) only the Grb2-SH3 domains. These results indicate that She proteins are common substrates of constitutively activated TKs and that the analysis of She phosphorylation allow the identification of tumors with constitutive TK activation.	UNIV PERUGIA,IST MED INTERNA & SCI ONCOL,I-06100 PERUGIA,ITALY; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892; IST NAZL TUMORI,MILAN,ITALY; IST REGINA ELENA,ROME,ITALY; FAC MED & CHIRURG BARI,IST MICROBIOL,BARI,ITALY; EUROPEAN INST ONCOL,MILAN,ITALY	University of Perugia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita degli Studi di Bari Aldo Moro; IRCCS European Institute of Oncology (IEO)			Borrello, Maria Grazia/C-3161-2017; Pelicci, Pier Giuseppe/AAL-6572-2020; Salcini, Anna Elisabetta/G-4472-2017; Di Fiore, Pier Paolo/K-2130-2012; Lanfrancone, Luisa/AAC-8671-2019; Pelicci, Giuliana/AAA-8921-2022	Borrello, Maria Grazia/0000-0002-6854-2848; Di Fiore, Pier Paolo/0000-0002-2252-0950; Lanfrancone, Luisa/0000-0002-4523-3815; Pelicci, Giuliana/0000-0003-0986-8255; Salcini, Anna Elisabetta/0000-0001-5828-2512; Segatto, Oreste/0000-0003-2561-1142				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALDARI CT, 1995, ONCOGENE, V10, P1141; BATZER LN, 1993, NATURE, V363, P85; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CROWE AJ, 1994, ONCOGENE, V9, P537; DAMEN JE, 1993, BLOOD, V82, P2996; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DILWORTH S, 1994, NATURE, V267, P87; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; JHIANG SM, 1992, ONCOGENE, V7, P1331; KAMPS MP, 1988, ONCOGENE, V2, P305; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATOSKOVA B, 1995, IN PRESS MOL CELL BI; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PELICCI G, 1995, IN PRESS ONCOGENE; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RODRIGUES CA, 1994, CURR OPIN GENE DEV, V4, P15; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SEGATTO O, 1993, ONCOGENE, V8, P2105; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STEPHENS RM, 1994, NEURON, V12, P1; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	50	120	124	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					899	907						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675449				2022-12-25	WOS:A1995RU79800011
J	WHITAKER, NJ; BRYAN, TM; BONNEFIN, P; CHANG, ACM; MUSGROVE, EA; BRAITHWAITE, AW; REDDEL, RR				WHITAKER, NJ; BRYAN, TM; BONNEFIN, P; CHANG, ACM; MUSGROVE, EA; BRAITHWAITE, AW; REDDEL, RR			INVOLVEMENT OF RB-1, P53, P16(INK4) AND TELOMERASE IN IMMORTALIZATION OF HUMAN-CELLS	ONCOGENE			English	Article						SENESCENCE; IMMORTALIZATION; RB-1; P53; P16(INK4); TELOMERASE	RETINOBLASTOMA PROTEIN; MONOCLONAL-ANTIBODY; LIFE-SPAN; WILD-TYPE; LINES; IDENTIFICATION; MUTATIONS; CYCLINS; PHOSPHORYLATION; EXPRESSION	Involvement of the retinoblastoma susceptibility (RB-1), p16(INK4), p53 and telomerase genes in immortalisation was examined by determining their status in 15 human cell lines representing four immortalisation complementation groups, No abnormalities of RB-1, p53 and p16(INK4) were detected in cell lines containing DNA tumour virus proteins known to bind to the protein products of the RB-1 and p53 genes, In contrast, in all other cell lines from each of the four groups either RB-1 was mutant or p16(INK4) protein was undetectable and there were cell lines containing p53 mutations in three of Telomerase activity was detected in 12/15 lines, including some of the virally immortalised lines and in some lines from each group, Since none of these changes correlated with complementation group, other genetic changes must be required for immortalisation.	CHILDRENS MED RES INST,WESTMEAD,NSW 2145,AUSTRALIA; ST VINCENTS HOSP,GARVAN INST MED RES,DIV CANC BIOL,SYDNEY,NSW 2010,AUSTRALIA; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 2601,AUSTRALIA	Children's Medical Research Institute - Australia; Garvan Institute of Medical Research; St Vincents Hospital Sydney; Australian National University; John Curtin School of Medical Research			Bryan, Tracy M/B-8468-2014; Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107; Bryan, Tracy/0000-0002-7990-5501				BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BUNN CL, 1980, EXP CELL RES, V127, P385, DOI 10.1016/0014-4827(80)90443-7; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DESILVA R, 1994, EXP CELL RES, V213, P418, DOI 10.1006/excr.1994.1218; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARLEY CB, 1992, EXP GERONTOL, V256, P271; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HE J, 1994, CANCER RES, V54, P5804; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LEHMAN TA, 1991, CANCER RES, V51, P4090; MILNER J, 1987, ONCOGENE, V1, P453; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MUGGLETONHARRIS AL, 1980, SOMAT CELL GENET, V6, P689, DOI 10.1007/BF01538968; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; REDDEL RR, 1995, INT J CANCER, V61, P199; ROMANO JW, 1989, ONCOGENE, V4, P1483; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHARMA S, 1993, CELL GROWTH DIFFER, V4, P861; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WHITAKER NJ, 1992, J VIROL, V66, P1202, DOI 10.1128/JVI.66.2.1202-1206.1992; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; XU HJ, 1989, ONCOGENE, V4, P807	41	81	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					971	976						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675456				2022-12-25	WOS:A1995RU79800018
J	GALISTEO, ML; DIKIC, I; BATZER, AG; LANGDON, WY; SCHLESSINGER, J				GALISTEO, ML; DIKIC, I; BATZER, AG; LANGDON, WY; SCHLESSINGER, J			TYROSINE PHOSPHORYLATION OF THE C-CBL PROTOONCOGENE PROTEIN PRODUCT AND ASSOCIATION WITH EPIDERMAL GROWTH-FACTOR (EGF) RECEPTOR UPON EGF STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							V-CBL; BINDING-SITE; DOMAIN; TRUNCATION; KINASES; GRB2; SH2	The murine retroviral oncogene v-cbl induces pre-B cell lymphomas and myelogenous leukemias. The protein product of the mammalian c-cbl proto-oncogene is a widely expressed cytoplasmic 120-kDa protein (p120(cbl)) whose normal cellular function has not been deter mined. Here we show that upon stimulation of human epidermal growth factor (EGF) receptor, p120(cbl) becomes strongly tyrosine-phosphorylated and associates with activated EGF receptor in vivo. A GST fusion protein containing amino acids 1-486 of p120(cbl), including a region highly conserved in nematodes, binds directly to the autophosphorylated carboxyl-terminal tail of the EGF receptor. Platelet derived growth factor (PDGF), fibroblast growth factor (FGF), or nerve growth factor (NGF) stimulation also results in tyrosine phosphorylation of p120(cbl). Recent genetic studies in Caenorhabditis elegans indicate that Sli-1, a p120(cbl) homologue, plays a negative regulatory role in control of the Ras signaling pathway initiated by the C. elegans EGF receptor homologue. Our results indicate that p120(cbl) is involved in an early step in the EGF signaling pathway that is conserved from nematodes to mammals.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; UNIV WESTERN AUSTRALIA,DEPT BIOCHEM,NEDLANDS,WA 6009,AUSTRALIA	New York University; University of Western Australia			Dikic, Ivan/O-4650-2015	Dikic, Ivan/0000-0001-8156-9511				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI NX, 1994, ONCOGENE, V9, P3457; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; PAWSON T, 1994, CURR BIOL, V3, P434; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RON D, 1992, BIOTECHNIQUES, V13, P866; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; YOON CH, 1995, IN PRESS SCIENCE	27	180	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20242	20245		10.1074/jbc.270.35.20242	http://dx.doi.org/10.1074/jbc.270.35.20242			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657591	hybrid			2022-12-25	WOS:A1995RR58400003
J	SPRECHER, H; BARR, HM; SLOTKY, JI; TZUKERMAN, M; EYTAN, GD; ASSARAF, YG				SPRECHER, H; BARR, HM; SLOTKY, JI; TZUKERMAN, M; EYTAN, GD; ASSARAF, YG			ALTERATION OF MITOCHONDRIAL GENE-EXPRESSION AND DISRUPTION OF RESPIRATORY-FUNCTION BY THE LIPOPHILIC ANTIFOLATE PYRIMETHAMINE IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; HAMSTER OVARY CELLS; DIHYDROFOLATE-REDUCTASE; HELA-CELLS; FLOW-CYTOMETRY; METHOTREXATE; RESISTANCE; DRUG; TRANSPORT; ACID	To clone the mammalian gene(s) associated with a novel lipophilic antifolate resistance provoked by the antiparasitic drug pyrimethamine (Assaraf, Y. G., and Slotky, J. I. (1993) J. Biol. Chem. 268, 4556-4566), differential screening of a cDNA library from pyrimethamine-resistant (Pyr(R100)) cells was used. This library was screened with total cDNA from wild-type and Pyr(R100) cells. Surprisingly, several differentially overexpressed cDNA clones were isolated from Pyr(R100) cells, many of which mapped to the mitochondrial genome. Several lines of evidence establish mitochondria as a new target for the cytotoxic activity of pyrimethamine. (a) At greater than or equal to 10 mu M, pyrimethamine inhibited mitochondrial respiration in viable wild-type cells. (b) Electron microscopy revealed degenerated mitochondrial membrane cristae in Pyr(R100) cells. (c) Some mitochondrially encoded transcripts were prominently elevated, whereas the normally stable 12 S/16 S rRNA was decreased in Pyr(R100) cells. (d) Metabolic pulse chase labeling suggested an increased turnover rate of mitochondrially synthesized proteins in Pyr(R100) cells. (e) The specific activity of the key respiratory enzymatic complex cytochrome c oxidase was reduced by 6-fold in Pyr(R100) cells. (f) Consequently, the rate of respiration in intact Pyr(P100) cells was reduced by 3-fold. We conclude that pyrimethamine and possibly lipophilic analogues of methotrexate possess a folinic acid nonrescuable toxicity involving disruption of mitochondrial inner membrane structure and respiratory function, thereby establishing a new organellar target for the cytotoxic effect elicited by lipid-soluble antifolates.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL	Technion Israel Institute of Technology				Assaraf, Yehuda G./0000-0001-6692-8221				ALT FW, 1978, J BIOL CHEM, V253, P1357; ASSARAF YG, 1987, P NATL ACAD SCI USA, V84, P7154, DOI 10.1073/pnas.84.20.7154; ASSARAF YG, 1989, J BIOL CHEM, V264, P18326; ASSARAF YG, 1993, J BIOL CHEM, V268, P4556; ASSARAF YG, 1993, ANTI-CANCER DRUG, V4, P535, DOI 10.1097/00001813-199310000-00002; BEREITERHAHN J, 1976, BIOCHIM BIOPHYS ACTA, V423, P1, DOI 10.1016/0005-2728(76)90096-7; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NG, 1994, MOL CELL BIOL, V14, P1045, DOI 10.1128/MCB.14.2.1045; CAVALLITO JC, 1978, DRUG METAB DISPOS, V6, P329; CHABNER BA, 1990, CANCER CHEMOTHERAPY; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CONOVER TE, 1981, J BIOL CHEM, V256, P402; COWAN KH, 1984, J BIOL CHEM, V259, P793; DAGA A, 1993, J BIOL CHEM, V268, P8123; DUCH DS, 1982, CANCER RES, V42, P3987; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ERBRICH U, 1982, HISTOCHEMISTRY, V74, P1, DOI 10.1007/BF00495046; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREI E, 1984, P NATL ACAD SCI-BIOL, V81, P2873, DOI 10.1073/pnas.81.9.2873; GILMAN AG, 1990, PHARMACOL BASIS THER, P985; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V6, P385; HABER DA, 1981, J BIOL CHEM, V256, P9501; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; LEWIS LD, 1992, ANTIMICROB AGENTS CH, V36, P2061, DOI 10.1128/AAC.36.9.2061; LIN JT, 1987, J CLIN ONCOL, V5, P2032, DOI 10.1200/JCO.1987.5.12.2032; LOU J, 1994, J INTERFERON RES, V14, P33, DOI 10.1089/jir.1994.14.33; LU X, 1992, CANCER RES, V52, P3718; MALCZEWSKI RM, 1984, J BIOL CHEM, V259, P1103; MELERA PW, 1988, J BIOL CHEM, V263, P1978; MUUS P, 1991, BRIT J CANCER, V64, P29, DOI 10.1038/bjc.1991.234; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; NAKASHIMA RA, 1984, CANCER RES, V44, P5702; NARDELLI M, 1994, FEBS LETT, V344, P10, DOI 10.1016/0014-5793(94)00342-4; PIZZORNO G, 1988, CANCER RES, V48, P2149; RAGO RP, 1994, CANCER, V73, P1954, DOI 10.1002/1097-0142(19940401)73:7<1954::AID-CNCR2820730729>3.0.CO;2-H; RAIKHINSTEIN M, 1993, P NATL ACAD SCI USA, V90, P10509, DOI 10.1073/pnas.90.22.10509; ROOS DS, 1987, P NATL ACAD SCI USA, V84, P4860, DOI 10.1073/pnas.84.14.4860; ROTTELE J, 1993, CELL MOL BIOL, V39, P739; SCNEIDER K, 1994, HISTOCHEMISTRY, V101, P135; SHARMA RC, 1991, CANCER RES, V51, P2949; SHARP MGF, 1992, J PATHOL, V168, P163, DOI 10.1002/path.1711680203; SIMON SM, 1994, P NATL ACAD SCI USA, V91, P3497, DOI 10.1073/pnas.91.9.3497; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SRIMATKANDADA S, 1989, J BIOL CHEM, V264, P3524; WHITFIELD CD, 1990, J BIOL CHEM, V265, P18852	49	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20668	20676		10.1074/jbc.270.35.20668	http://dx.doi.org/10.1074/jbc.270.35.20668			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657646	hybrid			2022-12-25	WOS:A1995RR58400066
J	KIRKPATRICK, RB; GANGULY, S; ANGELICHIO, M; GRIEGO, S; SHATZMAN, A; SILVERMAN, C; ROSENBERG, M				KIRKPATRICK, RB; GANGULY, S; ANGELICHIO, M; GRIEGO, S; SHATZMAN, A; SILVERMAN, C; ROSENBERG, M			HEAVY-CHAIN DIMERS AS WELL AS COMPLETE ANTIBODIES ARE EFFICIENTLY FORMED AND SECRETED FROM DROSOPHILA VIA A BIP-MEDIATED PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; LUMINAL ER PROTEINS; BINDING-PROTEIN; IMMUNOGLOBULIN SUPERFAMILY; GENE; EXPRESSION; MELANOGASTER; COMPARTMENT; ENCODES; MEMBER	We have constructed a stable Drosophila cell line coexpressing heavy chain (HC) and Light chain (LC) immunoglobulins of a humanized monoclonal antibody (mAb) that recognizes the F antigen of respiratory syncytial virus Tempest, P. R, Bremmer, P., Lambert, M., Taylor, G., Furze, J. M, Carr, F. J., and Harris, W. J. (1991) Bio/Technology 9, 266-271. These cells efficiently secrete antibody with substrate binding activity indistinguishable from that produced from vertebrate cell lines. Significantly, the Drosophila homologue of the immunoglobulin binding chaperone protein (BiP), hsc72, was found to interact specifically with the immunoglobulin HC in an ATP-dependent fashion, similar to the BiP-HC interaction known to occur in vertebrate cells. This is, in fact, the first substrate ever shown to interact specifically with Drosophila hsc72. Most surprisingly, expression of heavy chains in the absence of LC led to the efficient secretion of heavy chain dimers. Moreover, this secretion occurred in association with hsc72. This dramatically contrasts with what is seen in vertebrate cells where in the absence of LC, HC remains sequestered inside the cell in stable association with BiP. Our results clearly suggest that Drosophila Hip can substitute for its mammalian counterpart and chaperone the secretion of active IgG. However, the finding that Drosophila Hip can also uniquely chaperone heavy chain dimers indicates mechanistic differences that may relate to the evolved need for retaining immature IgGs in vertebrates.	SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC VIROL & HOST DEF,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline	KIRKPATRICK, RB (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,709 SWEDELAND RD,KING OF PRUSSIA,PA 19406, USA.							ANGELICHIO ML, 1991, NUCLEIC ACIDS RES, V19, P5037, DOI 10.1093/nar/19.18.5037; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BOLE DG, 1986, J CELL BIOL, V102, P1588; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; CARAYANNOPOULOS L, 1994, P NATL ACAD SCI USA, V91, P8348, DOI 10.1073/pnas.91.18.8348; DACKOWSKI W, 1981, P NATL ACAD SCI-BIOL, V78, P7091, DOI 10.1073/pnas.78.11.7091; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; FRANKLIN EC, 1975, CONT TOPICS MOL IMMU, P89; GARBE JC, 1993, DEVELOPMENT, V119, P1237; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V365, P33; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAAS IG, 1988, P NATL ACAD SCI USA, V85, P2250, DOI 10.1073/pnas.85.7.2250; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; JOHANSEN H, 1989, GENE DEV, V3, P882, DOI 10.1101/gad.3.6.882; KANIA A, 1993, NEURON, V11, P673, DOI 10.1016/0896-6273(93)90078-6; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MAINS PE, 1982, J BIOL CHEM, V258, P5027; MARCHALONIS JJ, 1994, PRIMORDIAL IMMUNITY, P1; MARONI G, 1986, GENETICS, V112, P493; MCCUNE JM, 1981, J IMMUNOL, V127, P2609; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MORRISON SL, 1975, J IMMUNOL, V114, P655; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; RUBIN DM, 1993, GENE, V128, P155, DOI 10.1016/0378-1119(93)90558-K; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SEEGER MA, 1988, CELL, V55, P589, DOI 10.1016/0092-8674(88)90217-6; SELIGMANN M, 1979, IMMUNOL REV, V48, P145, DOI 10.1111/j.1600-065X.1979.tb00302.x; SHIELDS G, 1977, DROSOPHILA INF SERVI, V52, P161; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; TEMPEST PR, 1991, BIO-TECHNOL, V9, P266, DOI 10.1038/nbt0391-266; VANDERSTRATEN A, 1989, CURR METHODS MOL BIO, V1, P1; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	41	69	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19800	19805		10.1074/jbc.270.34.19800	http://dx.doi.org/10.1074/jbc.270.34.19800			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649989	hybrid			2022-12-25	WOS:A1995RQ99100021
J	PTASZNIK, A; TRAYNORKAPLAN, A; BOKOCH, GM				PTASZNIK, A; TRAYNORKAPLAN, A; BOKOCH, GM			G-PROTEIN-COUPLED CHEMOATTRACTANT RECEPTORS REGULATE LYN TYROSINE KINASE-CENTER-DOT-SHC ADAPTER PROTEIN SIGNALING COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 3-KINASE; HUMAN NEUTROPHILS; ACTIVATED NEUTROPHILS; SUPEROXIDE PRODUCTION; PHOSPHORYLATION; ASSOCIATION; TRANSDUCTION; STIMULATION; PATHWAY	Receptors for chemoattractants that direct the migration of phagocytic leukocytes to sites of injury/infection also modulate many other leukocyte functions that are critical to the inflammatory response, These chemoattractant receptors, members of the G protein-coupled heptahelical receptor family, have been classically linked to cell activation via phospholipase C, calcium, and protein kinase C. We show here that activation of the N-formyl peptide chemoattractant receptor stimulates an additional protein kinase C-independent pathway through the Src-related tyrosine kinase, Lyn, in human neutrophils. We demonstrate that activation of Lyn is associated with binding to the She adapter protein, which becomes phosphorylated on tyrosine residues. This interaction appears to be mediated via the She SH2 domain, Complexes of phosphorylated Lyn and She with phosphatidylinositol 3-kinase are rapidly formed in stimulated neutrophils, correlating with phosphatidylinositol 1,4,5-trisphosphate formation and cell activation. This signaling pathway involving a Src-related kinase and the She adapter protein provides a potential mechanism linking chemoattractant receptors to downstream events involving Rac activation and NADPH oxidase, Regulation of She by G protein-coupled receptors may also allow these receptors to modulate the activity of the Ras/mitogen-activated protein kinase cascade.	Scripps Res Inst, DEPT IMMUNOL IMM14, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT MED, SAN DIEGO, CA 92103 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego					NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIGMS NIH HHS [GM39434] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; BOKOCH GM, 1991, CURRENT TOPICS MEMBR, P65; BOLEN JB, 1993, ONCOGENE, V8, P2025; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; CAMBIER JC, 1994, CURR OPIN GENET DEV, V4, P55, DOI 10.1016/0959-437X(94)90091-4; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; DOBOS GJ, 1992, J IMMUNOL, V149, P609; DORSEUIL O, 1995, IN PRESS J LEUKOCYTE; EBERLE M, 1990, J BIOL CHEM, V265, P16726; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOMEZCAMBRONERO J, 1989, BIOCHEM BIOPH RES CO, V162, P1478, DOI 10.1016/0006-291X(89)90841-3; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KUSUNOKI T, 1992, BIOCHEM BIOPH RES CO, V183, P789, DOI 10.1016/0006-291X(92)90552-V; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NACCACHE PH, 1990, BLOOD, V76, P2098; NOBES CD, 1995, J CELL SCI, V108, P225; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; OKADA T, 1994, J BIOL CHEM, V269, P3563; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHREIBER RE, 1993, J LEUKOCYTE BIOL, V53, P470, DOI 10.1002/jlb.53.4.470; SNYDERMAN R, 1988, INFLAMMATION BASIC P, P309; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; TORRES M, 1993, J IMMUNOL, V150, P1563; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VLAHOS CJ, 1992, FEBS LETT, V309, P242, DOI 10.1016/0014-5793(92)80781-B; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	48	168	169	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19969	19973		10.1074/jbc.270.34.19969	http://dx.doi.org/10.1074/jbc.270.34.19969			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650013	hybrid			2022-12-25	WOS:A1995RQ99100046
J	RUBINCHIK, S; PARRIS, W; GOLD, M				RUBINCHIK, S; PARRIS, W; GOLD, M			THE IN-VITRO TRANSLOCASE ACTIVITY OF LAMBDA-TERMINASE AND ITS SUBUNITS - KINETIC AND BIOCHEMICAL-ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; DNA PACKAGING ENZYME; BACTERIOPHAGE-LAMBDA; COS DNA; ESCHERICHIA-COLI; ATPASE ACTIVITY; GENE PRODUCTS; EARLY EVENTS; INVITRO; SYSTEM	The terminase holoenzyme of bacteriophage lambda is a multifunctional protein composed of two subunits, gpNu1 and gpA In vitro, under certain conditions, terminase can render DNAs from various sources, of varying lengths and termini, resistant to degradation by high concentrations of DNase I. This reaction is completely dependent on the presence of terminase, proheads, a hydrolyzable triphosphate, and a divalent metal ion, and we propose that it is the result of translocation of DNA into proheads by terminase. This reaction is stoichiometric with respect to terminase, DNA, and proheads and can be supported by all deoxyriboand ribonucleoside triphosphates, but not by the corresponding diphosphates or nonhydrolyzable ATP analogs. Mg2+ and Ca2+ promote the reaction, but Mn2+ and Zn2+ do not. In the absence of spermidine, translocase activity is low, but addition of the Escherichia coli protein integration host factor (IHF) promotes specific translocation of only those DNA fragments containing the terminase-binding site, cosB. When spermidine is present, nonspecific translocation of DNA from any source is stimulated. Under these conditions IHF no longer promotes specificity, but translocation of only cosB-containing DNA fragments can be restored by addition of small amounts of a dialyzed and RNase-treated E. coli extract, suggesting that additional host factor(s) may be involved in determination of packaging specificity. To a limited extent, gpA alone can promote translocation, but gpNu1, which has no translocase activity on its own, must be added to approach the holoenzyme-like activity levels. Formation of viable phage cannot be accomplished by gpA in the absence of gpNu1.	UNIV TORONTO,FAC MED,DEPT MED & MOLEC GENET,TORONTO,ON M5S 1A8,CANADA	University of Toronto								BECKER A, 1977, VIROLOGY, V78, P291, DOI 10.1016/0042-6822(77)90100-3; BECKER A, 1990, J BACTERIOL, V172, P2819, DOI 10.1128/jb.172.6.2819-2824.1990; BEHNISCH W, 1985, VIROLOGY, V144, P310, DOI 10.1016/0042-6822(85)90273-9; BLACK LW, 1988, BACTERIOPHAGES, V2, P321; CAMPBELL A, 1961, VIROLOGY, V14, P22, DOI 10.1016/0042-6822(61)90128-3; CASJENS S, 1985, VIRUS STRUCTURE ASSE, P76; CUE D, 1993, P NATL ACAD SCI USA, V90, P9290, DOI 10.1073/pnas.90.20.9290; EARNSHAW WC, 1980, CELL, V21, P319, DOI 10.1016/0092-8674(80)90468-7; FEISS M, 1986, TRENDS GENET, V2, P100, DOI 10.1016/0168-9525(86)90193-9; FEISS M, 1983, GENE, V24, P207, DOI 10.1016/0378-1119(83)90081-1; Georgopoulos C., 1983, LAMBDA 2, P279; GOLD M, 1983, J BIOL CHEM, V258, P4619; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; GUO PX, 1986, P NATL ACAD SCI USA, V83, P3505, DOI 10.1073/pnas.83.10.3505; HAMADA K, 1986, VIROLOGY, V151, P110, DOI 10.1016/0042-6822(86)90108-X; HASHIMOTO C, 1988, VIROLOGY, V166, P432, DOI 10.1016/0042-6822(88)90514-4; HIGGINS RR, 1988, CELL, V54, P765, DOI 10.1016/S0092-8674(88)91021-5; HOHN B, 1983, P NATL ACAD SCI-BIOL, V80, P7456, DOI 10.1073/pnas.80.24.7456; KOSTURKO LD, 1989, NUCLEIC ACIDS RES, V17, P317, DOI 10.1093/nar/17.1.317; LOW B, 1968, P NATL ACAD SCI USA, V60, P160, DOI 10.1073/pnas.60.1.160; MIWA T, 1983, GENE, V24, P199; MIWA T, 1982, GENE, V20, P265; MORITA M, 1993, VIROLOGY, V193, P748, DOI 10.1006/viro.1993.1183; MURIALDO H, 1991, ANNU REV BIOCHEM, V60, P125; MURIALDO H, 1988, MOL GEN GENET, V213, P42, DOI 10.1007/BF00333396; MURIALDO H, 1972, VIROLOGY, V48, P785, DOI 10.1016/0042-6822(72)90162-6; PARRIS W, 1994, J BIOL CHEM, V269, P13564; PERUCCHETTI R, 1988, VIROLOGY, V165, P103, DOI 10.1016/0042-6822(88)90663-0; PTASHNE M, 1967, P NATL ACAD SCI USA, V57, P306, DOI 10.1073/pnas.57.2.306; RAO VB, 1988, J MOL BIOL, V200, P475, DOI 10.1016/0022-2836(88)90537-2; ROSENBERG SM, 1985, GENE, V38, P165, DOI 10.1016/0378-1119(85)90215-X; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13586; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13575; SHIBATA H, 1987, VIROLOGY, V159, P250, DOI 10.1016/0042-6822(87)90462-4; SHINDER G, 1988, J VIROL, V62, P387, DOI 10.1128/JVI.62.2.387-392.1988; SHINDER G, 1989, NUCLEIC ACIDS RES, V17, P2005, DOI 10.1093/nar/17.5.2005; SON M, 1992, VIROLOGY, V190, P824, DOI 10.1016/0042-6822(92)90920-K; STERNBERG N, 1977, J MOL BIOL, V117, P733, DOI 10.1016/0022-2836(77)90067-5; STERNBERG N, 1977, GENE, V1, P255, DOI 10.1016/0378-1119(77)90049-X; TOMKA MA, 1993, BIOCHEMISTRY-US, V32, P11992, DOI 10.1021/bi00096a008; TOMKA MA, 1993, J BIOL CHEM, V268, P3056; XU SY, 1991, J MOL BIOL, V220, P293, DOI 10.1016/0022-2836(91)90014-W; YANOFSKY C, 1966, J MOL BIOL, V21, P313, DOI 10.1016/0022-2836(66)90102-1	43	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20059	20066		10.1074/jbc.270.34.20059	http://dx.doi.org/10.1074/jbc.270.34.20059			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650023	hybrid			2022-12-25	WOS:A1995RQ99100058
J	BANDYOPADHYAY, SK; LEONARD, GT; BANDYOPADHYAY, T; STARK, GR; SEN, GC				BANDYOPADHYAY, SK; LEONARD, GT; BANDYOPADHYAY, T; STARK, GR; SEN, GC			TRANSCRIPTIONAL INDUCTION BY DOUBLE-STRANDED-RNA IS MEDIATED BY INTERFERON-STIMULATED RESPONSE ELEMENTS WITHOUT ACTIVATION OF INTERFERON-STIMULATED GENE FACTOR-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SIGNAL-TRANSDUCTION; INDUCIBLE GENES; MESSENGER-RNA; HUMAN-CELLS; IFN-BETA; EXPRESSION; IRF-1; BINDING; PROTEIN; ALPHA	Many genes induced by type I interferons (IFNs) are also induced by double stranded (ds) RNA. In this study, we investigated the mechanism of this induction process. Using cell lines from which the type I IFN genes have been deleted, we established that induction by dsRNA of the IFN-inducible 561 gene is direct and not mediated by the intermediate synthesis of IFN. Unlike 561 mRNA, the IFN-inducible 6-16 mRNA was induced poorly by dsRNA. Transfection studies demonstrated that the sequence difference between the core IFN-stimulated response elements (ISREs) of these two genes is not responsible for their differential inducibility by dsRNA. A point mutation in the 561 ISRE that abolished its response to IFN-alpha also made it unresponsive to dsRNA, thus demonstrating that the ISRE is the relevant cis acting element for dsRNA signaling. The roles of different known ISRE-binding protein and tyrosine kinases in transducing the signal elicited by dsRNA were evaluated in genetically altered cell lines, dsRNA failed to induce 561 mRNA in cells expressing an antisense RNA for interferon regulatory factor 1, whereas it was induced strongly in cells expressing the corresponding sense mRNA, 561 mRNA was also induced strongly by dsRNA, but not by IFN-alpha, in mutant cell lines that do not express functional tyrosine kinases Tyk2 or JAK1 or ISRE binding protein, p48, or STATE, all of which are required for LFN-alpha signaling. However, in cells devoid of functional STAT1, which is also required for IFN-alpha signaling, the induction of 561 mRNA by dsRNA was very low. Expression of transfected STAT1 alpha protein, but not of STAT1 beta protein, in these cells greatly enhanced the dsRNA inducibility of the 561 gene. These studies indicate that the major ISRE-mediated signaling pathway used by dsRNA requires interferon regulatory factor 1 and STAT1 alpha. This pathway, however, does not require the other known cytoplasmic components used for IFN-alpha signaling.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Case Western Reserve University			Li, Chia Cheng/D-9906-2015		NATIONAL CANCER INSTITUTE [P01CA062220, R01CA068782] Funding Source: NIH RePORTER; NCI NIH HHS [CA-62220, CA-68782] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANDYOPADHYAY SK, 1992, J BIOL CHEM, V267, P6389; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DALY C, 1993, MOL CELL BIOL, V13, P3756, DOI 10.1128/MCB.13.6.3756; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Demaeyer E., 1988, INTERFERONS OTHER RE; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; HAINES DS, 1991, J CELL BIOCHEM, V46, P9, DOI 10.1002/jcb.240460104; KALVAKOLANU DVR, 1991, J BIOL CHEM, V266, P873; KUSARI J, 1986, MOL CELL BIOL, V6, P2062, DOI 10.1128/MCB.6.6.2062; KUSARI J, 1987, MOL CELL BIOL, V7, P528, DOI 10.1128/MCB.7.1.528; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEMET S, 1991, J INTERFERON RES, V11, P131, DOI 10.1089/jir.1991.11.131; MIYAKOSHI J, 1990, CANCER RES, V50, P278; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PARRINGTON J, 1994, EUR J BIOCHEM, V214, P617; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SAMBROOK J, 1989, MOL CLONING LABORATO, P1639; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; TIWARI RK, 1987, EMBO J, V6, P3373, DOI 10.1002/j.1460-2075.1987.tb02659.x; TIWARI RK, 1988, MOL CELL BIOL, V8, P4278; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WATHELET MG, 1987, EUR J BIOCHEM, V169, P313, DOI 10.1111/j.1432-1033.1987.tb13614.x; WATHELET MG, 1992, EUR J BIOCHEM, V206, P901, DOI 10.1111/j.1432-1033.1992.tb16999.x	35	117	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19624	19629		10.1074/jbc.270.33.19624	http://dx.doi.org/10.1074/jbc.270.33.19624			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642650	hybrid			2022-12-25	WOS:A1995RP70300066
J	MAXWELL, SE; RAMALINGAM, S; GERBER, LD; BRINK, L; UDENFRIEND, S				MAXWELL, SE; RAMALINGAM, S; GERBER, LD; BRINK, L; UDENFRIEND, S			AN ACTIVE CARBONYL FORMED DURING GLYCOSYLPHOSPHATIDYLINOSITOL ADDITION TO A PROTEIN IS EVIDENCE OF CATALYSIS BY A TRANSAMIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(PI-G)-ANCHORED MEMBRANE-PROTEINS; TERMINAL SIGNAL PEPTIDE; PLACENTAL ALKALINE-PHOSPHATASE; ACID-REQUIREMENTS ADJACENT; DECAY-ACCELERATING FACTOR; CLEAVAGE ATTACHMENT SITE; CELL-FREE SYSTEMS; PHOSPHOLIPASE-C; PI-G; BACILLUS-CEREUS	Glycosylphosphatidylinositol (GPI) substitution is now recognized to be a ubiquitous method of anchoring a protein to membranes in eukaryotes. The structure of GPI and its biosynthetic pathways are known and the signals in a nascent protein for GPI addition have been elucidated. The enzyme(s) responsible for GPI addition with release of a COOH-terminal signal peptide has been considered to be a transamidase but has yet to be isolated, and evidence that it is a transamidase is indirect. The experiments reported here show that hydrazine and hydroxylamine, in the presence of rough microsomal membranes, catalyze the conversion of the pro form of the engineered protein miniplacental alkaline phosphatase (prominiPLAP) to mature forms from which the COOH-terminal signal peptide has been cleaved, apparently at the same site but without the addition of GPI. The products, presumably the hydrazide or hydroxamate of miniPLAP, have yet to be characterized definitively. However, our demonstration of enzyme-catalyzed cleavage of the signal peptide in the presence of the small nucleophiles, even in the absence of an energy source, is evidence of an activated carbonyl intermediate which is the hallmark of a transamidase.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110	Roche Holding								AMTHAUER R, 1992, P NATL ACAD SCI USA, V89, P6124, DOI 10.1073/pnas.89.13.6124; BAILEY CA, 1989, P NATL ACAD SCI USA, V86, P22, DOI 10.1073/pnas.86.1.22; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUCHANAN JM, 1973, ADV ENZYMOL RAMB, V39, P91; CARAS IW, 1989, J CELL BIOL, V108, P1387, DOI 10.1083/jcb.108.4.1387; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DAVITZ MA, 1986, J EXP MED, V163, P1150, DOI 10.1084/jem.163.5.1150; DOERING TL, 1990, J BIOL CHEM, V265, P611; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1993, LIPID MODIFICATIONS, P83; GERBER LD, 1992, J BIOL CHEM, V267, P12168; HERELD D, 1988, POST TRANSLATIONAL M, P9; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; IKEZAWA H, 1976, BIOCHIM BIOPHYS ACTA, V450, P154; KAMITANI T, 1993, J BIOL CHEM, V268, P20733; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P4982, DOI 10.1073/pnas.89.11.4982; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P1350, DOI 10.1073/pnas.89.4.1350; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; KODUKULA K, 1995, METHOD ENZYMOL, V250, P536; LAZAR DF, 1994, P NATL ACAD SCI USA, V91, P9665, DOI 10.1073/pnas.91.21.9665; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; LOW MG, 1977, BIOCHEM J, V167, P281, DOI 10.1042/bj1670281; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW MG, 1985, NATURE, V318, P62, DOI 10.1038/318062a0; LOW MG, 1977, FEBS LETT, V82, P143, DOI 10.1016/0014-5793(77)80905-8; MAXWELL SE, 1995, P NATL ACAD SCI USA, V92, P1550, DOI 10.1073/pnas.92.5.1550; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MCCOMB RB, 1972, CLIN CHEM, V18, P97; MEDOF ME, 1986, BIOCHEMISTRY-US, V25, P6740, DOI 10.1021/bi00370a003; MEDOF ME, 1988, CYTOLYTIC LYMPHOCYTE, P57; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MORAN P, 1991, J BIOL CHEM, V266, P1250; MORAN P, 1994, J CELL BIOL, V125, P333, DOI 10.1083/jcb.125.2.333; SUNDLER R, 1978, J BIOL CHEM, V253, P4175; TAGUCHI R, 1980, BIOCHIM BIOPHYS ACTA, V619, P48; TATE SS, 1974, P NATL ACAD SCI USA, V71, P3320; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; WELLNER VP, 1966, BIOCHEMISTRY-US, V5, P872, DOI 10.1021/bi00867a010	43	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19576	19582		10.1074/jbc.270.33.19576	http://dx.doi.org/10.1074/jbc.270.33.19576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642644				2022-12-25	WOS:A1995RP70300060
J	MILOSO, M; MAZZOTTI, M; VASS, WC; BEGUINOT, L				MILOSO, M; MAZZOTTI, M; VASS, WC; BEGUINOT, L			SHC AND GRB-2 ARE CONSTITUTIVELY ACTIVATED BY AN EPIDERMAL GROWTH-FACTOR RECEPTOR WITH A POINT MUTATION IN THE TRANSMEMBRANE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EGF RECEPTOR; AUTOPHOSPHORYLATION SITES; SIGNAL TRANSDUCTION; ONCOGENIC FORMS; PHOSPHORYLATION; TRANSFORMATION; SUBSTITUTION; GENE	A single point mutation, Glu(627) --> Val, equivalent to the activating mutation in the Neu oncogene, was inserted in the transmembrane domain of the human epidermal growth factor (EGF) receptor. Unlike the wild type, Glu(627)-EGF receptor, transfected in NIH3T3 cells, gave rise to focal transformation and growth in agar even in the absence of EGF. Constitutive activity of mutant EGF receptor amounted to 20% of that of wild type receptor stimulated by EGF. In addition, the mutant receptor was more sensitive to EGF, reaching maximum transforming activity at 5 ng/ml EGF, NIH3T3 cells expressing Glu(627)-EGF receptor showed a transformed phenotype and were not arrested in G(0) upon serum deprivation, The mutant receptor was constitutively autophosphorylated. and several other cellular proteins were phosphorylated on tyrosine in absence of the ligand. Among these, the SHC adaptor protein was phosphorylated in absence of EGF, the other adaptor, GRB-2, was constitutively associated with the Glu(627)-EGF receptor in vivo and in vitro, and mitogen-activated protein kinase was constitutively phosphorylated. In contrast, other EGF receptor substrates, like phospholipase C gamma, were not phosphorylated in absence of EGF. The mutant receptor showed a higher sensitivity to cleavage by calpain both in absence and presence of EGF, appeared as a 170- and 150-kDa doublet in cell extracts, and a specific calpain inhibitor blocked the appearance of the 150-kDa form. Since the calpain cleavage site is located in the receptor cytoplasmic tail, this finding suggests that the Glu(627) mutation induces a slightly different conformation in the EGF receptor intracellular domain. In conclusion, our data show that a point mutation in the EGF receptor transmembrane domain was able to constitutively activate the receptor and to induce transformation via constitutive activation of the Ras pathway.	HOSP SAN RAFFAELE,DIBIT,MOLEC ONCOL LAB,I-20132 MILAN,ITALY; HOSP SAN RAFFAELE,CNR,IST NEUROSCI & BIOIMMAGINI,I-20132 MILAN,ITALY; NIH,MOLEC ONCOL LAB,BETHESDA,MD 20892	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; National Institutes of Health (NIH) - USA			Miloso, Mariarosaria/AAC-7373-2021					ALVAREZ CV, 1995, J BIOL CHEM, V270, P16271, DOI 10.1074/jbc.270.27.16271; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P488; BEGUINOT L, 1986, J BIOL CHEM, V261, P1801; BERTICS PJ, 1987, J BIOL CHEM, V263, P3610; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CARPENTER G, 1990, J BIOL CHEM, V265, P616; CARPENTER G, 1993, FORUM, V3, P613; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; GULLICK WJ, 1992, EMBO J, V11, P43, DOI 10.1002/j.1460-2075.1992.tb05025.x; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HELIN K, 1991, ONCOGENE, V6, P3610; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LONGO N, 1992, J BIOL CHEM, V267, P12416; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; ROUSSEL MF, CELL, V55, P979; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SOLER C, 1994, ONCOGENE, V9, P2207; SOLER C, 1994, J BIOL CHEM, V269, P12320; SOLER C, 1993, J BIOL CHEM, V268, P22010; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P23453; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WOOLWORD JM, 1988, CELL, V5, P965; YAMADA K, 1992, J BIOL CHEM, V267, P12452; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	41	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19557	19562		10.1074/jbc.270.33.19557	http://dx.doi.org/10.1074/jbc.270.33.19557			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642641	hybrid			2022-12-25	WOS:A1995RP70300057
J	MANO, H; MANO, K; TANG, B; KOEHLER, M; YI, T; GILBERT, DJ; JENKINS, NA; COPELAND, NG; IHLE, JN				MANO, H; MANO, K; TANG, B; KOEHLER, M; YI, T; GILBERT, DJ; JENKINS, NA; COPELAND, NG; IHLE, JN			EXPRESSION OF A NOVEL FORM OF TEC KINASE IN HEMATOPOIETIC-CELLS AND MAPPING OF THE GENE TO CHROMOSOME-5 NEAR KIT	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; AMINO-TERMINAL DOMAIN; SENSITIVE V-ABL; SIGNAL TRANSDUCTION; C-ABL; DEVELOPMENTAL EXPRESSION; CYTOPLASMIC DOMAINS; ANTIGEN RECEPTOR; MESSENGER-RNA; MYELOID CELLS	The Tec kinase was initially identified as a novel cytoplasmic protein tyrosine kinase that is preferentially expressed in the liver and is highly homologous to the Drosophila Dsrc28C src-related tyrosine kinase. In screening of interleukin 3 (IL-3)-dependent myeloid leukemia cells for protein tyrosine kinases, we observed that all cell lines examined expressed high levels of Tec transcripts. However, characterization of Tec cDNAs indicated that they differed significantly from the published sequence. Most strikingly, an insertion of 41 bp in the 5' region affects the initiation codon and results in replacing the published 13 amino acid amino-terminal sequences with 94 amino acids. Using polymerase chain reaction (PCR) analysis, only the form containing the insertion was detected in hematopoietic cells. In addition, we found an in-frame insertion of 66 bp that introduces an additional 22 amino acids into the SH3 domain. This insertion restores conserved SH3 sequences that are found in the src gene family and in the Dsrc28C gene. By PCR analysis, approximately equal levels of Tec transcripts containing the intact SH3 domain and containing the 22 amino acid deletion were found in hematopoietic cells. Lastly, by interspecies backcross analysis, we show that the Tec gene is tightly linked to the c-Kit gene on mouse chromosome 5.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA; NCI, FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM, MAMMALIAN GENET LAB, FREDERICK, MD 21702 USA	St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74101, P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [DK42932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BERNARDS A, 1988, ONCOGENE, V2, P297; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEGIORGI L, 1981, NATURE, V292, P545, DOI 10.1038/292545a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Green EL, 1981, GENETICS PROBABILITY, P77; Green MC., 1989, GENETIC VARIANTS STR, P12; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; IHLE JN, 1989, INT J CELL CLONING, V7, P68, DOI 10.1002/stem.5530070202; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; IHLE JN, 1990, PEPTIDE GROWTH FACTO; ISFORT R, 1988, J BIOL CHEM, V263, P19203; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KANAKURA Y, 1990, BLOOD, V76, P706; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; MANO H, 1990, ONCOGENE, V5, P1781; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VINCENT WS, 1989, GENE DEV, V3, P334, DOI 10.1101/gad.3.3.334; WADSWORTH SC, 1990, DEV BIOL, V138, P296, DOI 10.1016/0012-1606(90)90198-R; WILKS AF, 1988, ONCOGENE, V3, P289; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	63	161	168	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					417	424						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	7678927				2022-12-25	WOS:A1993KN00600021
J	MYERS, RL; PAYSON, RA; CHOTANI, MA; DEAVEN, LL; CHIU, IM				MYERS, RL; PAYSON, RA; CHOTANI, MA; DEAVEN, LL; CHIU, IM			GENE STRUCTURE AND DIFFERENTIAL EXPRESSION OF ACIDIC FIBROBLAST GROWTH-FACTOR MESSENGER-RNA - IDENTIFICATION AND DISTRIBUTION OF 4 DIFFERENT TRANSCRIPTS	ONCOGENE			English	Article							SMOOTH-MUSCLE CELLS; FACTOR-II GENE; FACTOR FAMILY; HUMAN GLIOMAS; TISSUES; MENINGIOMAS; PROMOTERS; SEQUENCE; CULTURE; CLASS-1	We have isolated four cDNA clones coding for human acidic fibroblast growth factor (aFGF) containing alternative 5' untranslated exons. Using RNAase protection analyses, we demonstrated the presence of at least four upstream, untranslated exons that are alternatively spliced to the first protein-coding exon. We designate these four untranslated exons, - 1A, - 1B, - 1C and - 1D. Splicing of these exons to the first coding exon will generate mRNA 1.A, 1.B, 1.C and 1.D respectively. Expression of these transcripts is regulated in a tissue-specific manner, as the major aFGF transcript in human brain frontal cortex differs from that in kidney. Furthermore, the pattern of aFGF transcripts in several glioblastoma cell fines tested is different from that in normal brain tissue. We isolated nine overlapping genomic clones containing these four upstream, untranslated exons. These four exons were localized on these clones by Southern hybridization and nucleotide sequence analysis. The overlapping clones are shown to be contiguous with our previously isolated genomic clones that contain the three aFGF-coding exons. The sizes of the four introns are 82.9, 71.1, 29.3 and 6.9 kbp. The transcriptional start sites of the two most upstream exons (- 1A and - 1B) have been mapped using RNAase protection and primer extension analyses. The sequences upstream of the start sites for aFGF 1.B mRNA do not contain a consensus TATA box. In contrast, the canonical CCAAT and TATA sequences are located at the proper distances from the transcription start site of aFGF 1.A mRNA.	OHIO STATE UNIV, DEPT INTERNAL MED, DAVIS MED RES CTR, 480 W 9TH AVE, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR COMPREHENS CANC, COLUMBUS, OH 43210 USA; LOS ALAMOS NATL LAB, CTR HUMAN GENOME STUDIES, LOS ALAMOS, NM 87545 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; United States Department of Energy (DOE); Los Alamos National Laboratory			Chiu, Ing-Ming/B-1534-2008; Chotani, Maqsood/E-2891-2011		NATIONAL CANCER INSTITUTE [T32CA009338, P30CA016058, R01CA045611] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16058, T32 CA09338, R01 CA45611] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALTERIO J, 1990, BIOCHEM BIOPH RES CO, V166, P1205, DOI 10.1016/0006-291X(90)90994-X; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BUNNAG P, 1991, IN VITRO CELL DEV B, V27, P89; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU IM, 1990, FID RES FDN, V3, P57; CHIU IM, 1990, ONCOGENE, V5, P755; CHIU IM, 1989, MOL CHEM NEUROPATHOL, V10, P37, DOI 10.1007/BF02969485; COOK PW, 1990, MOL ENDOCRINOL, V4, P1377, DOI 10.1210/mend-4-9-1377; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CRUMLEY G, 1990, BIOCHEM BIOPH RES CO, V171, P7, DOI 10.1016/0006-291X(90)91348-V; DEPAGTERHOLTHUIZEN P, 1987, FEBS LETT, V214, P259, DOI 10.1016/0014-5793(87)80066-2; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GOSPODAROWICZ D, 1987, METHOD ENZYMOL, V147, P106; GROSS JL, 1990, J NEUROSCI RES, V27, P689, DOI 10.1002/jnr.490270429; HALL JA, 1990, J CELL BIOCHEM, V43, P17, DOI 10.1002/jcb.240430103; HALLEY C, 1988, NUCLEIC ACIDS RES, V16, P10913, DOI 10.1093/nar/16.22.10913; HARRIS SE, 1991, MOLECULAR AND CELLULAR BIOLOGY OF PROSTATE CANCER, P315; KOZAK M, 1988, J CELL BIOL, V107, P1, DOI 10.1083/jcb.107.1.1; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; MARICS I, 1989, ONCOGENE, V4, P335; MORRISON RS, 1981, P NATL ACAD SCI-BIOL, V78, P7205, DOI 10.1073/pnas.78.11.7205; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUSSELL DS, 1963, PATHOLOGY NERVOUS SY, P93; Sambrook J, 1989, MOL CLONING LABORATO; SOARES MB, 1986, J MOL BIOL, V192, P737, DOI 10.1016/0022-2836(86)90025-2; TAKAHASHI JA, 1991, BIOCHEM BIOPH RES CO, V177, P1, DOI 10.1016/0006-291X(91)91939-A; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; VANDEWINKEL JGJ, 1991, J BIOL CHEM, V266, P13449; WANG WP, 1991, ONCOGENE, V6, P1521; WANG WP, 1991, DNA CELL BIOL, V10, P771, DOI 10.1089/dna.1991.10.771; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; Weich HA, 1990, GROWTH FACTORS, V2, P313, DOI 10.3109/08977199009078019; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WINKLES JA, 1987, P NATL ACAD SCI USA, V84, P7124, DOI 10.1073/pnas.84.20.7124; WINKLES JA, 1991, CELL GROWTH DIFFER, V2, P531; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YOUNG RA, 1981, CELL, V23, P451, DOI 10.1016/0092-8674(81)90140-9; ZAGZAG D, 1990, CANCER RES, V50, P7393; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	48	56	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					341	349						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	7678925				2022-12-25	WOS:A1993KN00600013
J	SELVA, E; RADEN, DL; DAVIS, RJ				SELVA, E; RADEN, DL; DAVIS, RJ			MITOGEN-ACTIVATED PROTEIN-KINASE STIMULATION BY A TYROSINE KINASE-NEGATIVE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; EGF RECEPTOR; CELLS; PHOSPHORYLATION; SITE	Mutation of the epidermal growth factor receptor (EGF-R) within the ATP binding subdomain results in a receptor that lacks tyrosine kinase activity and is defective in signal transduction. However, this kinase-negative EGF-R is able to activate MAP kinase (Campos-Gonzalez, R., and Glenny, J. R. (1992) J. Biol. Chem. 267, 14535-14538). This observation suggests that signal initiation by the EGF-R can occur by a mechanism that is independent of the receptor tyrosine kinase activity. Here, we report that the kinase-negative EGF-R is phosphorylated on tyrosine in EGF-treated cells. The mechanism of tyrosine phosphorylation can be accounted for by the action of EGF to stimulate a protein kinase activity that is associated with the kinase-negative EGF-R. This protein kinase activity is not intrinsic to the receptor and can be separated from the EGF-R by incubation with 0.5 M NaCl. MAP kinase activation by the kinase-negative EGF-R may therefore occur by a mechanism that requires a receptor-associated tyrosine kinase. Thus, it is unnecessary to propose a novel kinase-independent mechanism of signal initiation to account for MAP kinase activation by the kinase-negative EGF-R.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NCI NIH HHS [CA58396] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; LEISTER KJ, 1989, P NATL ACAD SCI USA, V86, P783, DOI 10.1073/pnas.86.3.783; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; NORTHWOOD IC, 1990, P NATL ACAD SCI USA, V87, P6107, DOI 10.1073/pnas.87.16.6107; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	20	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2250	2254						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678418				2022-12-25	WOS:A1993KH62000112
J	CARDOZO, C; ELEUTERI, AM; ORLOWSKI, M				CARDOZO, C; ELEUTERI, AM; ORLOWSKI, M			DIFFERENCES IN CATALYTIC ACTIVITIES AND SUBUNIT PATTERN OF MULTICATALYTIC PROTEINASE COMPLEXES (PROTEASOMES) ISOLATED FROM BOVINE PITUITARY, LUNG, AND LIVER - CHANGES IN LMP7 AND THE COMPONENT NECESSARY FOR EXPRESSION OF THE CHYMOTRYPSIN-LIKE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; SENSITIVE NEUTRAL ENDOPEPTIDASE; CLASS-II REGION; CDNA CLONING; LINKED LMP; HUMAN MHC; UBIQUITIN; GENE; SPECIFICITY; PROTEOLYSIS	Polyacrylamide gel electrophoresis and high performance liquid chromatography of multicatalytic proteinase complexes (MPC) isolated from bovine pituitary, lung and liver showed marked differences in the pattern of subunits, The concentrations of LMP7 in the lung and liver were 10 and 5 times, respectively, greater than those in the pituitary, whereas the chymotrypsin-like activity and the amount of a subunit (BO2), necessary for its expression, were markedly decreased in the lung and moderately decreased in the liver, Lower trypsinlike, small neutral amino acid preferring, and peptidyl-glutamyl-peptide hydrolyzing activities were also found in the lung and liver. The activity of the branched chain amino acid preferring component (BrAAP), predominantly latent in the pituitary, was highly activated in the lung and liver, as evidenced by a greatly decreased IT, and a 20-fold increase of the specificity constant V-max/K-m, indicating facilitated substrate access to its active site and increased affinity toward substrates with branched chain amino acids in the P-1 position, It is suggested that overexpression of LMP7 in the lung is related to increased exposure of the airways to foreign antigens, The possible association between amounts of LMP7 and the activation of the BrAAP component needs further examination.	CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029; UNIV CAMERINO,I-62032 CAMERINO,ITALY	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Camerino			Cardozo, Christopher/R-6021-2019	Cardozo, Christopher/0000-0003-4013-2537; Eleuteri, Anna Maria/0000-0003-0461-1346	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025377] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO8 HL02835] Funding Source: Medline; NIDDK NIH HHS [DK 25377] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKI M, 1992, FEBS LETT, V301, P65, DOI 10.1016/0014-5793(92)80211-X; AKIYAMA K, 1994, FEBS LETT, V343, P85, DOI 10.1016/0014-5793(94)80612-8; AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; AMSTERDAM A, 1993, P NATL ACAD SCI USA, V90, P99, DOI 10.1073/pnas.90.1.99; ARRIBAS J, 1990, J BIOL CHEM, V265, P13696; BELICH MP, 1994, CURR BIOL, V4, P769, DOI 10.1016/S0960-9822(00)00174-3; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; BURNETTE WN, 1991, ANAL BIOCHEM, V112, P195; CARDOZO C, 1992, BIOCHEMISTRY-US, V31, P7373, DOI 10.1021/bi00147a023; CARDOZO C, 1994, BIOCHEMISTRY-US, V33, P6483, DOI 10.1021/bi00187a014; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DJABALLAH H, 1992, EUR J BIOCHEM, V209, P629, DOI 10.1111/j.1432-1033.1992.tb17329.x; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; ELLIOTT T, 1993, CURR BIOL, V3, P854, DOI 10.1016/0960-9822(93)90219-E; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; Falk K, 1993, Semin Immunol, V5, P81, DOI 10.1006/smim.1993.1012; FRIEDMAN H, 1994, P NATL ACAD SCI USA, V91, P2031, DOI 10.1073/pnas.91.6.2031; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GLYNNE R, 1993, EUR J IMMUNOL, V23, P860, DOI 10.1002/eji.1830230414; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4601; HOUGH R, 1987, J BIOL CHEM, V262, P8303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; ORLOWSKI M, 1991, BIOCHEMISTRY-US, V30, P5999, DOI 10.1021/bi00238a025; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; ORLOWSKI M, 1981, BIOCHEM BIOPH RES CO, V101, P814; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SATO S, 1990, BIOCHIM BIOPHYS ACTA, V1041, P269, DOI 10.1016/0167-4838(90)90283-L; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SHIVANANDAPPA T, 1991, CURR EYE RES, V10, P871, DOI 10.3109/02713689109013883; TAMURA T, 1990, FEBS LETT, V264, P91, DOI 10.1016/0014-5793(90)80773-C; TANAKA K, 1994, J LEUKOCYTE BIOL, V56, P571, DOI 10.1002/jlb.56.5.571; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USTRELL V, 1995, P NATL ACAD SCI USA, V92, P584, DOI 10.1073/pnas.92.2.584; WAGNER BJ, 1991, CURR EYE RES, V10, P485, DOI 10.3109/02713689109001756; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YU B, 1993, J BIOL CHEM, V268, P2029	56	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22645	22651		10.1074/jbc.270.38.22645	http://dx.doi.org/10.1074/jbc.270.38.22645			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673255	hybrid			2022-12-25	WOS:A1995RW31400089
J	DASGUPTA, M; BLUMENTHAL, DK				DASGUPTA, M; BLUMENTHAL, DK			CHARACTERIZATION OF THE REGULATORY DOMAIN OF THE GAMMA-SUBUNIT OF PHOSPHORYLASE-KINASE - THE 2 NONCONTIGUOUS CALMODULIN-BINDING SUBDOMAINS ARE ALSO AUTOINHIBITORY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; SEPHAROSE AFFINITY-CHROMATOGRAPHY; GLYCOGEN-PHOSPHORYLASE; CATALYTIC SUBUNIT; PROTEIN-KINASES; PURIFICATION; SPECIFICITY; ACTIVATION; COMPLEXES; ALPHA	Phosphorylase kinase is a multimeric protein kinase (alpha(4) beta(4) gamma(4) delta(4)) whose enzymatic activity is conferred by its gamma-subunit. A library of 18 overlapping synthetic peptides spanning residues 277-386 of the gamma-subunit has been prepared to use in identifying important regulatory structures in the protein. In the present study, the library was screened to identify regions that might function as autoinhibitory domains, Peptides from two distinct regions were found to inhibit the Ca2+-activated holoenzyme. The same regions were previously found to bind calmodulin (i.e. the delta-subunit; Dasgupta, M. Honeycutt, T., and Blumenthal, D. K. (1989) J. Biol. Chem. 264, 17156-17163). The most potent substrate antagonist peptides were PhK13 (residues 302-326; K-i = 300 nM) and PhK5 (residues 342-366; K-i = 20 mu M). Both peptides inhibited the holoenzyme competitively with respect to phosphorylase b and noncompetitively with respect to Mg . ATP. When the pattern of inhibition with both peptides present was analyzed, inhibition was observed to be synergistic and modestly cooperative indicating that the two peptides can simultaneously occupy the protein substrate-binding site(s), These data are consistent with a model in which the regions of the gamma-subunit represented by PhK5 and PhK13 work in concert as regulatory subdomains that transduce Ca2+-induced conformational changes in the delta-subunit to the catalytic gamma-subunit through a pseudosubstrate autoinhibitory mechanism.	UNIV UTAH, DEPT PHARMACOL & TOXICOL, SALT LAKE CITY, UT 84112 USA; UNIV TEXAS, CTR HLTH, DEPT BIOCHEM, TYLER, TX 75710 USA	Utah System of Higher Education; University of Utah; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)				Blumenthal, Donald/0000-0002-8614-1167; /0000-0002-7260-3746	NIGMS NIH HHS [GM39290] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039290] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMENTHAL DK, 1987, METHOD ENZYMOL, V139, P115; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN KFJ, 1982, J BIOL CHEM, V257, P5948; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; Corbin J D, 1974, Methods Enzymol, V38, P287; COX S, 1992, PROTEIN ENG, V5, P811, DOI 10.1093/protein/5.8.811; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; FARRAR YJK, 1991, BIOCHEMISTRY-US, V30, P10274, DOI 10.1021/bi00106a027; GEUSS U, 1985, EUR J BIOCHEM, V153, P327, DOI 10.1111/j.1432-1033.1985.tb09305.x; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRAVES DJ, 1983, METHOD ENZYMOL, V99, P268; HARRIS WR, 1990, J BIOL CHEM, V265, P11740; HUANG CYF, 1995, J BIOL CHEM, V270, P7183, DOI 10.1074/jbc.270.13.7183; HUANG CYF, 1993, MOL CELL BIOCHEM, V128, P7, DOI 10.1007/BF01076753; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; KASTENSCHMIDT LL, 1968, BIOCHEMISTRY-US, V7, P3590, DOI 10.1021/bi00850a037; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KENNELLY PJ, 1987, J BIOL CHEM, V262, P11958; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; KREBS EG, 1956, BIOCHIM BIOPHYS ACTA, V20, P150, DOI 10.1016/0006-3002(56)90273-6; NEWSHOLME P, 1992, J BIOL CHEM, V267, P810; PICKETTGIES CR, 1985, ENZYMES, P395; REIMANN EM, 1984, BIOCHEMISTRY-US, V23, P4185, DOI 10.1021/bi00313a027; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SANCHEZ VE, 1993, J BIOL CHEM, V268, P17889; SEGEL IH, 1974, ENZYME KINETICS; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; TABATABAI LB, 1978, J BIOL CHEM, V253, P2196; TAKIO K, 1985, BIOCHEMISTRY-US, V24, P6028, DOI 10.1021/bi00343a002; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; YAZAWA M, 1978, J BIOCHEM-TOKYO, V84, P1259, DOI 10.1093/oxfordjournals.jbchem.a132244	32	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22283	22289		10.1074/jbc.270.38.22283	http://dx.doi.org/10.1074/jbc.270.38.22283			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673209	hybrid			2022-12-25	WOS:A1995RW31400036
J	LLOYD, QP; KUHN, MA; GAY, CV				LLOYD, QP; KUHN, MA; GAY, CV			CHARACTERIZATION OF CALCIUM TRANSLOCATION ACROSS THE PLASMA-MEMBRANE OF PRIMARY OSTEOBLASTS USING A LIPOPHILIC CALCIUM-SENSITIVE FLUORESCENT DYE, CALCIUM-GREEN-C-18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE; INTRACELLULAR CALCIUM; CYTOSOLIC CALCIUM; ATPASE ACTIVITY; CA++-ATPASE; CELLS; INHIBITION; CALMODULIN; TRANSPORT; VESICLES	The synthesis of Calcium Green C-18, a lipophilic fluorescent calcium-sensitive dye, and its use as a monitor of Ca2+ efflux from cells is described, This indicator consists of a Calcium Green-1 molecule conjugated to a lipophilic 18-carbon alkyl chain which will intercalate into cell membranes, The K-d of the indicator for Ca2+ in aqueous solution (pH 7.2, 22 degrees C, ionic strength 0.1 M) is 0.23 +/- 0.04 mu M and in the presence of liposomes is 0.062 +/- 0.007 mu M. Due to its high negativity, the calcium chelating fluorophore faces the cell exterior, when loaded under a defined set of conditions. The dye was found largely on the surface of the cells when loaded at a concentration of 5 mu M for 10 min at 37 degrees C, Five minutes after introduction of EGTA, 83-95% fluorescence disappeared, indicating that most of the fluorophore was on the cell surface, Photobleaching was minimal (3-13%), th confocal laser scanning microscope was used to detect and quantify fluorescence. Internalized dye was apparent in cells loaded for longer times (30-60 min) and in membrane-impaired cells, as shown by uptake of propidium iodide, Under defined confocal laser scanning microscope settings, a transient fluorescence at the periphery of similar to 30% of the cells was observed following 10(-8) M parathyroid hormone treatment, indicating the presence of outwardly directed calcium transport across the plasma membrane, Calcium efflux usually lasted 7-10 min, peaking at around 2-3 min, Changes in cell shape were also observed, Calcium efflux was shown to be sensitive to (a) 10 mu M quercetin and 10 mu M vanadate, partially specific inhibitors of plasma membrane Ca2+ ATPase, to (b) 0.1 mM trifluoperazine, an agent which renders calmodulin ineffective, and to (c) 10 mM neomycin sulfate, which blocks release of Ca2+ from intracellular stores, Thapsigargin (5 mu M), an inhibitor of Ca2+-ATPase of the endoplasmic reticulum, prolonged fluorescence, These observations indicate that cell surface fluorescence was due to the capture of Ca2+ by Calcium Green C-18 after Ca2+ had been translocated across osteoblast plasma membranes, Involvement of the plasma membrane Ca2+-ATPase, known to be present in osteoblasts in substantial amounts, is implicated.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, DEPT POULTRY SCI, UNIVERSITY PK, PA 16802 USA; MOLEC PROBES INC, EUGENE, OR 97402 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIDCR NIH HHS [DE09459] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009459] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKISAKA T, 1988, J BONE MINER RES, V3, P19; ALI NN, 1990, J BONE MINER RES, V5, P115; BIDWELL JP, 1991, ENDOCRINOLOGY, V129, P2993, DOI 10.1210/endo-129-6-2993; BLATTER LA, 1990, BIOPHYS J, V58, P1491, DOI 10.1016/S0006-3495(90)82494-2; BOND GH, 1980, BIOCHIM BIOPHYS ACTA, V600, P781, DOI 10.1016/0005-2736(80)90480-0; CARAFOLI E, 1990, PROG CLIN BIOL RES, V332, P181; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CARIDE AJ, 1983, BIOCHIM BIOPHYS ACTA, V734, P363, DOI 10.1016/0005-2736(83)90136-0; CIVITELLI R, 1989, ENDOCRINOLOGY, V125, P1204, DOI 10.1210/endo-125-3-1204; EBERHARD M, 1991, BIOCHEM BIOPH RES CO, V180, P209, DOI 10.1016/S0006-291X(05)81278-1; EGAN JJ, 1991, J CELL BIOCHEM, V45, P101, DOI 10.1002/jcb.240450117; ETTER EF, 1994, J BIOL CHEM, V269, P10141; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; GARRAHAN PJ, 1990, INTRACELLULAR CALCIU, P271; GAY CV, 1995, COMP BIOCHEM PHYS A, V111, P257, DOI 10.1016/0300-9629(95)00004-Q; GAY CV, 1994, IN VITRO CELL DEV-AN, V30A, P379, DOI 10.1007/BF02634358; GIRARD S, 1992, BIOPHYS J, V61, P509, DOI 10.1016/S0006-3495(92)81855-6; HAUGLAND R, 1993, FLUORESCENT LUMINESC, P34; HAUGLAND RP, 1992, HDB FLUORESCENT PROB, P113; KRAUSFRIEDMANN N, 1982, EUR J BIOCHEM, V129, P7, DOI 10.1111/j.1432-1033.1982.tb07014.x; KRIEGER NS, 1992, J BONE MINER RES, V7, P1105; KUMAR R, 1993, J BONE MINER RES, V8, P505; KURIKI Y, 1976, BIOCHEMISTRY-US, V15, P4951, DOI 10.1021/bi00668a001; LOWIK CWGM, 1985, CELL CALCIUM, V6, P311, DOI 10.1016/0143-4160(85)90002-8; LUTHRA MG, 1982, BIOCHIM BIOPHYS ACTA, V692, P271, DOI 10.1016/0005-2736(82)90531-4; LYTTON J, 1991, J BIOL CHEM, V266, P17067; NIGGLI V, 1981, J BIOL CHEM, V256, P395; OCHS DL, 1983, J BIOL CHEM, V258, P116; PETHIG R, 1989, CELL CALCIUM, V10, P491, DOI 10.1016/0143-4160(89)90026-2; Philipson K D, 1993, Int Rev Cytol, V137C, P199; REID IR, 1987, AM J PHYSIOL, V253, pE45, DOI 10.1152/ajpendo.1987.253.1.E45; RIBEIRO CP, 1992, AM J PHYSIOL, V262, pF209, DOI 10.1152/ajprenal.1992.262.2.F209; SASAKI T, 1987, CELL TISSUE RES, V248, P103, DOI 10.1007/BF01239969; SHORT CL, 1994, J BONE MINER RES, V9, P1159; TAKUMA T, 1985, BIOCHEM J, V227, P239, DOI 10.1042/bj2270239; THASTRUP O, 1987, BIOCHEM BIOPH RES CO, V142, P654, DOI 10.1016/0006-291X(87)91464-1; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; VANLEEUWEN JPTM, 1988, BONE MINER, V4, P177; WUTHRICH A, 1980, CELL CALCIUM, V1, P21, DOI 10.1016/0143-4160(80)90010-X; YAMAGUCHI DT, 1991, CELL CALCIUM, V12, P609, DOI 10.1016/0143-4160(91)90058-M	40	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22445	22451		10.1074/jbc.270.38.22445	http://dx.doi.org/10.1074/jbc.270.38.22445			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673232	hybrid			2022-12-25	WOS:A1995RW31400061
J	GOLDSMITH, MA; LAI, SY; XU, W; AMARAL, MC; KUCZEK, ES; PARENT, LJ; MILLS, GB; TARR, KL; LONGMORE, GD; GREENE, WC				GOLDSMITH, MA; LAI, SY; XU, W; AMARAL, MC; KUCZEK, ES; PARENT, LJ; MILLS, GB; TARR, KL; LONGMORE, GD; GREENE, WC			GROWTH SIGNAL-TRANSDUCTION BY THE HUMAN INTERLEUKIN-2 RECEPTOR REQUIRES CYTOPLASMIC TYROSINES OF THE BETA-CHAIN AND NONTYROSINE RESIDUES OF THE GAMMA(C) CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IL-2 RECEPTOR; KINASE-ACTIVITY; ACTIVATION; BINDING; DOMAIN; REGION; PHOSPHORYLATION; PROTEIN; COMPLEX; ANTIGEN	To evaluate the possible role for receptor-based tyrosine phosphorylation in growth signaling induced by interleukin-2 (IL-2), a series of substitution tyrosine mutants of the IL-2 receptor beta and gamma(c) chains was prepared and analyzed. Concurrent mutation of all six of the cytoplasmic tyrosines present in the beta chain markedly inhibited IL-2-induced growth signaling in both pro-B and T cell lines. Growth signaling in a pro-B cell line was substantially reconstituted when either of the two distal tyrosines (Tyr-392, Tyr-510) was selectively restored in the tyrosine-negative beta mutant, whereas reconstitution of the proximal tyrosines (Tyr-338, Tyr-355, Tyr-358, Tyr-361) did not restore this signaling function. Furthermore, at least one of the two cytoplasmic tyrosines that is required for beta chain function was found to serve as a phosphate acceptor site upon induction with IL-2. Studies employing a chimeric receptor system revealed that tyrosine residues of the beta chain likewise were important for growth signaling in T cells. In contrast, although the gamma(c) subunit is a target for tyrosine phosphorylation in vivo, concurrent substitution of all four cytoplasmic tyrosines of this chain produced no significant effect on growth signaling by chimeric IL-2 receptors. However, deletion of either the Box 1, Box 2, or intervening (V-Box) regions of gamma(c) abrogated receptor function. Therefore, tyrosine residues of beta but not of gamma(c) appear to play a pivotal role in regulating growth signal transduction through the IL-2 receptor, either by influencing cytoplasmic domain folding or by serving as sites for phosphorylation and subsequent association with signaling intermediates. These findings thus highlight a fundamental difference in the structural requirements for IL-2R beta and gamma(c) in receptor-mediated signal transduction.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94141; PENN STATE UNIV,COLL MED,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033; TORONTO GEN HOSP,TORONTO,ON M4X 1K9,CANADA; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Washington University (WUSTL); Washington University (WUSTL)	GOLDSMITH, MA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,GLADSTONE INST VIROL & IMMUNOL,SAN FRANCISCO,CA 94141, USA.			Lai, Stephen/0000-0001-8301-7286; Parent, Leslie/0000-0002-0431-9049; Kuczek, Elizabeth/0000-0002-5412-5509				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARUFFO A, 1991, CURRENT PROTOCOLS MO; ASAO H, 1990, J EXP MED, V171, P2183; ASAO H, 1992, FEBS LETT, V304, P141, DOI 10.1016/0014-5793(92)80605-G; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BURNS LA, 1993, J BIOL CHEM, V268, P17659; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FUNG MR, 1991, J IMMUNOL, V147, P1253; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GARCIA GG, 1992, BIOCHEM J, V285, P851, DOI 10.1042/bj2850851; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; GOLDSMITH MA, 1994, CYTOKINE HDB, P57; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; ISHII N, 1994, J IMMUNOL, V153, P1310; KAWAHARA A, 1994, MOL CELL BIOL, V4, P5433; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MERIDA I, 1991, J IMMUNOL, V147, P2202; MICHIEL DF, 1991, CYTOKINE, V3, P428, DOI 10.1016/1043-4666(91)90047-H; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SELDIN DC, 1994, P NATL ACAD SCI USA, V91, P2140, DOI 10.1073/pnas.91.6.2140; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TRUITT KE, 1994, J BIOL CHEM, V269, P5937; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	60	61	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21729	21737		10.1074/jbc.270.37.21729	http://dx.doi.org/10.1074/jbc.270.37.21729			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665592	hybrid			2022-12-25	WOS:A1995RU75700050
J	LOPEZCABRERA, M; MUNOZ, E; BLAZQUEZ, MV; URSA, MA; SANTIS, AG; SANCHEZMADRID, F				LOPEZCABRERA, M; MUNOZ, E; BLAZQUEZ, MV; URSA, MA; SANTIS, AG; SANCHEZMADRID, F			TRANSCRIPTIONAL REGULATION OF THE GENE ENCODING THE HUMAN C-TYPE LECTIN LEUKOCYTE RECEPTOR AIM/CD69 AND FUNCTIONAL-CHARACTERIZATION OF ITS TUMOR NECROSIS FACTOR-ALPHA-RESPONSIVE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; T-CELL ACTIVATION; NATURAL-KILLER-CELLS; LYMPHOCYTE-ACTIVATION; INDUCER MOLECULE; ANTIGEN CD69; EXPRESSION; PROLIFERATION; BINDING; ANTIBODIES	The human activation antigen CD69 is a member of the C-type animal lectin superfamily that functions as a signal-transmitting receptor. Although the expression of CD69 can be induced in vitro on cells of most hematopoietic lineages with a wide variety of stimuli, in vivo it is mainly expressed by T-lymphocytes located in the inflammatory infiltrates of several human diseases. To elucidate the mechanisms that regulate the constitutive and inducible expression of CD69 by leukocytes, we isolated the promoter region of the CD69 gene and carried out its functional characterization. Sequence analysis of the 5'-flanking region of the CD69 gene revealed the presence of a potential TATA element 30 base pairs upstream of the major transcription initiation site and several putative binding sequences for inducible transcription factors (NF-kappa B, Egr-1, AP-1), which might mediate the inducible expression of this gene, Transient expression of CD69 promoter-based reporter gene constructs in K562 cells indicated that the proximal promoter region spanning positions -78 to +16 contained the cis-acting sequences necessary for basal and phorbol 12-myristate 13-acetate-inducible transcription of the CD69 gene. Removal of the upstream sequences located between positions -78 and -38 resulted in decreased promoter strength and abolished the response to phorbol 12-myristate 13-acetate. We also found that tumor necrosis factor-alpha (TNF-alpha) is capable of inducing the surface expression of the CD69 molecule as well as the promoter activity of fusion plasmids that contain 5'-flanking sequences of the CD69 gene, suggesting that this cytokine may regulate in vivo the expression of CD69. In addition, cotransfection experiments demonstrated that the CD69 gene promoter can be activated by the NF-kappa B/Rel family members c-Rel and RelA. The deletion of the sequence spanning positions -255 to -170 abolished both the response to TNF-alpha and the transactivation by NF-kappa B. These results indicate that the NF-kappa B-binding site located at position -223 is necessary for the TNF-alpha-induced expression of the CD69 gene. Mobility shift assays showed that the two NF-kappa B motifs located in the proximal promoter region (positions -223 and -160) bind various NF-kappa B-related complexes, in eluding the heterodimers p50/RelA and p50/c-Rel and homodimers of p50 (KBF-1) and RelA. Our findings help to explain the regulated synthesis of CD69 in vivo and suggest that TNF-alpha has a key role in the expression of this molecule at sites of chronic inflammation.	UNIV AUTONOMA MADRID,HOSP PRINCESA,SERV IMMUNOL,E-28006 MADRID,SPAIN; UNIV AUTONOMA MADRID,HOSP PRINCESA,UNIDAD BIOL MOLEC,E-28006 MADRID,SPAIN; UNIV CORDOBA,FAC MED,DEPT FISIOL & INMUNOL,E-14004 CORDOBA,SPAIN	Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Hospital de La Princesa; Universidad de Cordoba			Munoz, Eduardo/I-5225-2012; Cabrera, Manuel López/AAA-5463-2019; Sanchez-Madrid, Francisco/M-7889-2016	Munoz, Eduardo/0000-0001-8478-5842; Sanchez-Madrid, Francisco/0000-0001-5303-0762; Lopez Cabrera, Manuel/0000-0002-0976-9719				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; CEBRIAN M, 1988, J EXP MED, V168, P1621, DOI 10.1084/jem.168.5.1621; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GARCIAMONZON C, 1990, GASTROENTEROLOGY, V98, P1029, DOI 10.1016/0016-5085(90)90030-5; GHOSH D, 1991, TRENDS BIOCHEM SCI, V16, P445, DOI 10.1016/0968-0004(91)90173-S; GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841; HAMANN J, 1993, J IMMUNOL, V150, P4920; HARA T, 1986, J EXP MED, V164, P1988, DOI 10.1084/jem.164.6.1988; HARTNELL A, 1993, IMMUNOLOGY, V80, P281; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; LANIER LL, 1988, J EXP MED, V167, P1572, DOI 10.1084/jem.167.5.1572; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537; MCMAHON SB, 1995, J EXP MED, V181, P417, DOI 10.1084/jem.181.1.417; MORETTA A, 1991, J EXP MED, V174, P1393, DOI 10.1084/jem.174.6.1393; NAKAMURA S, 1989, J EXP MED, V169, P677, DOI 10.1084/jem.169.3.677; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUEDA A, 1993, J BIOL CHEM, V268, P19305; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; SANCHEZMATEOS P, 1991, EUR J IMMUNOL, V21, P2317, DOI 10.1002/eji.1830211005; SANCHEZMATEOS P, 1989, IMMUNOLOGY, V68, P72; SANTIS AG, 1992, EUR J IMMUNOL, V22, P1253, DOI 10.1002/eji.1830220521; SANTIS AG, 1994, EUR J IMMUNOL, V24, P1692, DOI 10.1002/eji.1830240735; SANTIS AG, 1995, IN PRESS EUR J IMMUN; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TESTI R, 1990, J EXP MED, V172, P701, DOI 10.1084/jem.172.3.701; TESTI R, 1989, J IMMUNOL, V143, P1123; TUGORES A, 1992, J IMMUNOL, V148, P2300; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; YOKOYAMA WM, 1993, CURR OPIN IMMUNOL, V5, P67, DOI 10.1016/0952-7915(93)90083-5; ZIEGLER SF, 1994, J IMMUNOL, V152, P1228; ZIEGLER SF, 1993, EUR J IMMUNOL, V23, P1643, DOI 10.1002/eji.1830230737	38	103	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21545	21551		10.1074/jbc.270.37.21545	http://dx.doi.org/10.1074/jbc.270.37.21545			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665567	hybrid			2022-12-25	WOS:A1995RU75700022
J	HACKETT, RH; WANG, YD; LARNER, AC				HACKETT, RH; WANG, YD; LARNER, AC			MAPPING OF THE CYTOPLASMIC DOMAIN OF THE HUMAN GROWTH-HORMONE RECEPTOR REQUIRED FOR THE ACTIVATION OF JAK2 AND STAT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; DNA-BINDING FACTOR; TYROSINE KINASE; SIGNAL-TRANSDUCTION; INTERFERON-ALPHA/BETA; CYTOKINE RECEPTORS; INVITRO ACTIVATION; PHOSPHORYLATION; PHOSPHATASE; PROMOTER	Incubation of cells with growth hormone (GH) stimulates both tyrosine phosphorylation of the Jak2 tyrosine kinase and, in some cells, the transcription factor Stat1 alpha (1-4). When the promyeloid cell line FDC-P1 is transfected with the human growth hormone receptor, these cells can grow in the presence of GH and in the absence of interleukin-3. Growth hormone treatment of cells expressing the human growth hormone receptor did not activate Stat1 alpha. However, a complex is present in extracts prepared from growth hormone treated cells that binds to the gamma response region, an enhancer present in the promoter of the high affinity Fc gamma R1 receptor to which cytokine-activated Stat complexes bind. When truncations of the cytoplasmic domain of the receptor are expressed in FDC-P1 cells only the membrane-proximal 80 amino acids (containing box 1 and box 2) are required for activation of both a GH-stimulated binding activity (GHSF) and tyrosine phosphorylation of Jak2. Activation of GHSF can be inhibited in a cell-free system by the addition of a glutathione S-transferase fusion protein containing these SO amino acids. Replacement of the one tyrosine in this region of the receptor with a phenylalanine does not alter the activation of either GHSF or Jak2, suggesting that tyrosine phosphorylation of the receptor is not required for GH activation of GHSF. Moreover, a cell line expressing a receptor with only the 54 membrane-proximal amino acids of the intracellular domain (including box 1) shows constitutively tyrosine phosphorylated Jak2 as well as GHSF binding. With this truncated receptor, there is little if any additional GH-induced tyrosine phosphorylation of Jak2 or induced binding to the gamma response region. These results define the importance of the membrane-proximal 80 amino acids of the GH receptor (with the conserved box 1 and box 2 domains) with regard to GH activation of both Jak2 and Stat(s). They also suggest that within these domains there may be positive and negative elements that regulate Jak2 function.	CTR BIOL EVALUAT & RES, DIV CYTOKINE BIOL, BETHESDA, MD 20892 USA; GENENTECH INC, DEPT MOLEC BIOL, S SAN FRANCISCO, CA 94080 USA	US Food & Drug Administration (FDA); Roche Holding; Genentech								ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLOSI P, 1993, J BIOL CHEM, V268, P12617; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DAVID M, 1993, J BIOL CHEM, V268, P6593; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; HE TC, 1994, J BIOL CHEM, V269, P18291; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1993, BLOOD, V82, P1960; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; SILVA CM, 1994, J BIOL CHEM, V269, P27532; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; STRED SE, 1992, ENDOCRINOLOGY, V130, P1626, DOI 10.1210/en.130.3.1626; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WANG XZ, 1994, P NATL ACAD SCI USA, V91, P1391, DOI 10.1073/pnas.91.4.1391; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	42	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21326	21330		10.1074/jbc.270.36.21326	http://dx.doi.org/10.1074/jbc.270.36.21326			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673169	hybrid			2022-12-25	WOS:A1995RU05400070
J	HAMANAKA, R; SMITH, MR; OCONNOR, PM; MALOID, S; MIHALIC, K; SPIVAK, JL; LONGO, DL; FERRIS, DK				HAMANAKA, R; SMITH, MR; OCONNOR, PM; MALOID, S; MIHALIC, K; SPIVAK, JL; LONGO, DL; FERRIS, DK			POLO-LIKE KINASE IS A CELL-CYCLE-REGULATED KINASE ACTIVATED DURING MITOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; CDC2 PROTEIN-KINASE; PHOSPHORYLATION SITES; DEPENDENT KINASES; MESSENGER-RNA; IDENTIFICATION; DROSOPHILA; DEPHOSPHORYLATION; CHECKPOINTS; DIVISION	Previously, we demonstrated that expression of polo-like kinase (PLK) is required for cellular DNA synthesis and that overexpression of PLK is sufficient to induce DNA synthesis. We now report that the endogenous levels of PLK, its phosphorylation status, and protein kinase activity are tightly regulated during cell cycle progression. PLK protein is low in G(1), accumulates during S and G(2)M, and is rapidly reduced after mitosis. During mitosis, PLK is phosphorylated on serine, and its serine threonine kinase function is activated at a time close to that of p34(cdc2). The phosphorylated form of PLK migrates with reduced mobility on SDS-polyacrylamide gel electrophoresis, and dephosphorylation by purified protein phosphatase 2A converts it to the more rapidly migrating form and reduces the total amount of PLK kinase activity. Purified p34(cdc2)-cyclin B complex can phosphorylate PLK protein in vitro but causes little increase in PLK kinase activity.	NCI,FREDERICK CANC RES & DEV CTR,DIV CANC TREATMENT,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702; NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,MOLEC PHARMACOL LAB,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DIV HEMATOL,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University			Longo, Dan L./F-6022-2011					BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HANKS S, 1991, METHOD ENZYMOL, V200, P3862; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1973, GENETICS, V74, P267; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; KATO J, 1993, GENE DEV, V7, P331; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KREK W, 1992, NEW BIOL, V4, P323; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NIGG EA, 1991, SEMIN CELL BIOL, V2, P251; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PINES J, 1990, New Biologist, V2, P389; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SUNKEL CE, 1988, J CELL SCI, V89, P25; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U	41	160	172	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21086	21091		10.1074/jbc.270.36.21086	http://dx.doi.org/10.1074/jbc.270.36.21086			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673138	hybrid			2022-12-25	WOS:A1995RU05400036
J	RAIMO, G; MASULLO, M; BOCCHINI, V				RAIMO, G; MASULLO, M; BOCCHINI, V			STUDIES ON THE POLYPEPTIDE ELONGATION-FACTOR-2 FROM SULFOLOBUS-SOLFATARICUS - INTERACTION WITH GUANOSINE NUCLEOTIDES AND GTPASE ACTIVITY STIMULATED BY RIBOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II; ARCHAEBACTERIAL RIBOSOMES; STRUCTURAL-PROPERTIES; PROTEIN-SYNTHESIS; BINDING	The elongation factor 2 from the thermoacidophilic archaeon Sulfolobus solfataricus (SsEF-2) binds [H-3]GDP at 1:1 molar ratio. The bound [H-3]GDP is displaced by GTP or its nonhydrolyzable analogue guanyl-5'-yl imidodiphosphate (Gpp(NH)p) but not by ATP, thus indicating that only the two guanosine nucleotides compete for the same binding site. The affinity of SsEF-2 for [H-3]GDP is higher than that for GTP and Gpp(NH)p. On the contrary, in the presence of ribosomes the affinity of SsEF-2 for GDP is lower than that for Gpp(NH)p. SsEF-2 is endowed with an intrinsic hardly detectable GTPase activity that is stimulated by ribosomes up to 2000-fold. The ribosome-stimulated SsEF-2 GTPase (GTPase(r)) reaches a maximum at pH 7.8 and is not affected by ATP but is competitively inhibited by either GDP or Gpp(NH)p. Both K-m for [gamma-P-32]GTP and k(cat) of GTPase(r) increase with increasing temperature, and the highest catalytic efficiency is reached at 80 degrees C. The ADP-ribosylation of SsEF-2 does not significantly affect either the binding of GDP and GTP or the kinetics of the GTPase(r). A hypothesis on the stimulation by ribosome of SsEF-2 GTPase is proposed.	UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOCHIM & BIOTECNOL MED,I-80131 NAPLES,ITALY	University of Naples Federico II			Raimo, Gennaro/F-4651-2012; Masullo, Mariorosario/H-4884-2016	Masullo, Mariorosario/0000-0003-4485-7383; Raimo, Gennaro/0000-0003-0365-7430				ARAI N, 1977, J BIOCHEM-TOKYO, V82, P687, DOI 10.1093/oxfordjournals.jbchem.a131744; BEAUCLERK AAD, 1985, EUR J BIOCHEM, V151, P245, DOI 10.1111/j.1432-1033.1985.tb09095.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMMARANO P, 1985, EMBO J, V4, P811, DOI 10.1002/j.1460-2075.1985.tb03702.x; DEVENDITTIS E, 1986, J BIOL CHEM, V261, P4445; DEVENDITTIS E, 1993, GENE, V136, P41; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; Klink F., 1985, BACTERIA, V8, P379; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASULLO M, 1991, EUR J BIOCHEM, V199, P529, DOI 10.1111/j.1432-1033.1991.tb16151.x; MASULLO M, 1989, BIOCHEM J, V261, P725, DOI 10.1042/bj2610725; MASULLO M, 1994, J BIOL CHEM, V239, P20376; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; MIZUMOTO K, 1974, J BIOCHEM-TOKYO, V76, P1269, DOI 10.1093/oxfordjournals.jbchem.a130680; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; NURTEN R, 1980, EUR J BIOCHEM, V103, P551, DOI 10.1111/j.1432-1033.1980.tb05979.x; NYGARD O, 1990, J BIOL CHEM, V265, P6030; PARMEGGIANI A, 1981, MOL CELL BIOCHEM, V35, P129, DOI 10.1007/BF02357085; RAIMO G, 1992, BIOCHIM BIOPHYS ACTA, V1132, P127, DOI 10.1016/0167-4781(92)90002-H; RAIMO G, 1993, ITAL J BIOCHEM, V42, P11; ROHRBACH MS, 1976, BIOCHEMISTRY-US, V15, P4565, DOI 10.1021/bi00666a003; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x	22	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21082	21085		10.1074/jbc.270.36.21082	http://dx.doi.org/10.1074/jbc.270.36.21082			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673137	hybrid			2022-12-25	WOS:A1995RU05400035
J	WATERS, SB; HOLT, KH; ROSS, SE; SYU, LJ; GUAN, KL; SALTIEL, AR; KORETZKY, GA; PESSIN, JE				WATERS, SB; HOLT, KH; ROSS, SE; SYU, LJ; GUAN, KL; SALTIEL, AR; KORETZKY, GA; PESSIN, JE			DESENSITIZATION OF RAS ACTIVATION BY A FEEDBACK DISASSOCIATION OF THE SOS-GRB2 COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL GROWTH-FACTOR; PROTEIN; KINASES; P21RAS; RECEPTOR; EXCHANGE; INSULIN; RAF-1	Activation of Ras by the exchange of bound GDP for GTP is predominantly catalyzed by the guanylnucleotide exchange factor SOS. Receptor tyrosine kinases increase Ras-GTP loading by targeting SOS to the plasma membrane location of Ras through the small adaptor protein Grb2. However, despite the continuous stimulation of receptor tyrosine kinase activity, Ras activation is transient and, in the case of insulin, begins returning to the GDP-bound state within 5 min. We report here that the cascade of serine kinases activated directly by Ras results in a mitogen-activated protein kinase kinase (MEK)-dependent phosphorylation of SOS and subsequent disassociation. of the Grb2-SOS complex, thereby interrupting the ability of SOS to catalyze nucleotide exchange on Ras. These data demonstrate a molecular feedback mechanism accounting for the desensitization of Ras-GTP loading following insulin stimulation.	UNIV IOWA,DEPT PHYSIOL,IOWA CITY,IA 52242; UNIV IOWA,DEPT MED,IOWA CITY,IA 52242; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48104	University of Iowa; University of Iowa; Pfizer; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019; Koretzky, Gary/AAU-5381-2021	Saltiel, Alan/0000-0002-9726-9828				ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; DUDLEY DT, 1995, IN PRESS P NATL ACAD; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; UEKI K, 1994, J BIOL CHEM, V269, P15756; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	20	135	138	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20883	20886		10.1074/jbc.270.36.20883	http://dx.doi.org/10.1074/jbc.270.36.20883			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673108	hybrid			2022-12-25	WOS:A1995RU05400004
J	BREUER, O; BJORKHEM, I				BREUER, O; BJORKHEM, I			USE OF AN O-18(2) INHALATION TECHNIQUE AND MASS ISOTOPOMER DISTRIBUTION ANALYSIS TO STUDY OXYGENATION OF CHOLESTEROL IN RAT - EVIDENCE FOR IN-VIVO FORMATION OF 7-OXOCHOLESTEROL, 7-BETA-HYDROXYCHOLESTEROL, 24-HYDROXYCHOLESTEROL, AND 24-HYDROXYCHOLESTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; STEROL SYNTHESIS; 25-HYDROXYCHOLESTEROL; DERIVATIVES; INHIBITION; REDUCTASE; MECHANISM; INVIVO; CELLS	Cholesterol oxidation products (oxysterols) have been detected in many different tissues, often at concentrations 10(3) to 10(4) times lower than cholesterol. This constitutes a considerable risk of quantitation errors, since even a minor oxidation of cholesterol during sample processing would yield a substantial increase of oxysterol levels. It has therefore been suggested that some of the oxysterols do not occur in vivo and their detection in tissues merely are artifacts produced in vitro. In the present work, an O-18(2), inhalation technique was developed in order to clarify which oxysterols are produced in vivo, Rats were exposed for 3 h to an atmosphere with a composition similar to normal air, except that it contained O-18(2), instead of O-16(2). Control rats were kept in O-16(2)-containing atmosphere throughout the experiment. The O-18(2) enrichment of oxysterols in plasma and liver was determined by gas/liquid chromatography-mass spectrometry and mass isotopomer distribution analysis. In vivo formation of oxysterols, indicated by enrichment in O-18(2), was established for cholest-5-ene-3 beta,7 alpha-diol, cholest-5-ene-3 beta,7 beta-diol, 7-oxocholesterol, cholest-5-ene-3 beta,24-diol, cholest-5-ene-3 beta,25-diol, and cholest-5-ene-3 beta,27-diol. Additionally, it seems likely that cholest-5-ene-3 beta,4 beta-diol is formed in vivo. The O-18(2) labeling pattern suggests that there is incomplete equilibration between the liver and plasma pools of cholest-5-ene-3 beta,27-diol. No evidence for the in vivo formation of 5,6-oxygenated oxysterols was obtained.			BREUER, O (corresponding author), KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT MED LAB SCI & TECHNOL,DIV CLIN CHEM,S-14186 HUDDINGE,SWEDEN.			Bjorkhem, Ingemar/0000-0001-6087-9190; Bjorkhem, Ingemar/0000-0002-0575-9425				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BJORKHEM I, 1987, J LIPID RES, V28, P889; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1979, J BIOL CHEM, V254, P5252; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; BJORKHEM I, 1974, J BIOL CHEM, V249, P2528; BROWN MS, 1975, J BIOL CHEM, V250, P4025; CHANG TY, 1980, J BIOL CHEM, V255, P7787; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; ERICKSON SK, 1978, J BIOL CHEM, V253, P4159; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Halliwell B., 1989, FREE RADICAL BIO MED, P214; JOHANSSON G, 1971, EUR J BIOCHEM, V21, P68, DOI 10.1111/j.1432-1033.1971.tb01441.x; JOHNSON KA, 1994, J LIPID RES, V35, P2241; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KANDUTSCH AA, 1974, J BIOL CHEM, V249, P6057; KANDUTSCH AA, 1978, LIPIDS, V13, P704, DOI 10.1007/BF02533749; KUDO K, 1989, J LIPID RES, V30, P1097; LUND E, 1992, J BIOL CHEM, V267, P12462; LUND E, 1993, BIOCHIM BIOPHYS ACTA, V1166, P177, DOI 10.1016/0005-2760(93)90094-P; MAYEVSKY A, 1973, BIOCHEM BIOPH RES CO, V51, P746, DOI 10.1016/0006-291X(73)91379-X; REISS AB, 1994, J LIPID RES, V35, P1026; ROSENBLATT J, 1992, AM J PHYSIOL, V263, pE584, DOI 10.1152/ajpendo.1992.263.3.E584; Smith, 1981, CHOLESTEROL AUTOXIDA; SMITH LL, 1989, FREE RADICAL BIO MED, V7, P285, DOI 10.1016/0891-5849(89)90136-6; SMITH LL, 1987, CHEM PHYS LIPIDS, V44, P87, DOI 10.1016/0009-3084(87)90046-6; SMITH LL, 1967, J CHROMATOGR, V26, P509, DOI 10.1016/S0021-9673(01)98913-7; TENG JI, 1976, BIOORG CHEM, V5, P99, DOI 10.1016/0045-2068(76)90017-1; WATSON KE, 1994, J CLIN INVEST, V93, P2106, DOI 10.1172/JCI117205	30	73	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20278	20284		10.1074/jbc.270.35.20278	http://dx.doi.org/10.1074/jbc.270.35.20278			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657597	hybrid			2022-12-25	WOS:A1995RR58400010
J	MAEDA, M; TAFT, CS; BUSH, EW; HOLDER, E; BAILEY, WM; NEVILLE, H; PERRYMAN, MB; BIES, RD				MAEDA, M; TAFT, CS; BUSH, EW; HOLDER, E; BAILEY, WM; NEVILLE, H; PERRYMAN, MB; BIES, RD			IDENTIFICATION, TISSUE-SPECIFIC EXPRESSION, AND SUBCELLULAR-LOCALIZATION OF THE 80-KDA AND 71-KDA FORMS OF MYOTONIC-DYSTROPHY KINASE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							UNSTABLE CTG REPEAT; MESSENGER-RNA; MUSCULAR-DYSTROPHY; TRIPLET REPEAT; GENE; TRANSCRIPT; ANTIBODIES; DROSOPHILA; EXPANSION; MUTATION	The protein product of the myotonic dystrophy (DM) gene is a putative serine-threonine protein kinase (DM kinase). Previous reports have characterized the DM gene product as various 50-62-kDa proteins. The predicted protein size from DM cDNA sequence is 69 kDa. We therefore expressed a full-length recombinant human DM kinase protein and compared its size and expression to heart, cardiac Purkinje fibers, and skeletal muscle from normal and DM subjects. Recombinantly expressed DM kinase and endogenous DM kinase in human heart, displayed two immunoreactive DM kinase proteins with apparent molecular sizes of 71 and 80 kDa, suggesting that these prior reports are incorrect. In cardiac Purkinje fibers the 71-kDa protein was the major form, and in skeletal muscle the 80-kDa protein was the major form. Immunostaining showed DM kinase localized to neuromuscular junctions in skeletal muscle and intercalated discs in heart and Purkinje fibers. DM subjects showed low abundance of DM kinase in heart and skeletal muscle, suggesting haplotype insufficiency as a potential mechanism for disease expression. These studies describe differential expression of two protein forms of DM kinase, which are localized to specialized cellular structures associated with impulse transmission.	UNIV COLORADO,HLTH SCI CTR,DIV CARDIOL,TEMPLE HOYNE BUELL LABS,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DIV NEUROMUSCULAR,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DENVER GEN HOSP,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NHLBI NIH HHS [R01HL50715] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050715] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNANE D, 1994, CIRCULATION, V90, P2629, DOI 10.1161/01.CIR.90.6.2629; ASTROW SH, 1992, J NEUROSCI, V12, P1605; BARBAS JA, 1991, GENE DEV, V5, P132, DOI 10.1101/gad.5.1.132; BIES RD, 1992, CIRCULATION, V86, P147, DOI 10.1161/01.CIR.86.1.147; BREWSTER BS, 1993, BIOCHEM BIOPH RES CO, V194, P1256, DOI 10.1006/bbrc.1993.1958; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; DUNNE PW, 1994, BIOCHEMISTRY-US, V33, P10809, DOI 10.1021/bi00201a031; Engel AG, 1994, MYOLOGY, P1192; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GEIGER B, 1990, J CELL SCI, V97, P607; GREEN CR, 1983, TISSUE CELL, V15, P17, DOI 10.1016/0040-8166(83)90030-7; HARLEY HG, 1993, AM J HUM GENET, V52, P1164; HOFMANNRADVANYI H, 1993, HUM MOL GENET, V2, P1263, DOI 10.1093/hmg/2.8.1263; HUNTER A, 1992, J MED GENET, V29, P774, DOI 10.1136/jmg.29.11.774; KOGA R, 1994, BIOCHEM BIOPH RES CO, V202, P577, DOI 10.1006/bbrc.1994.1967; LEGATO MJ, 1973, MYOCARDIAL CELL CLIN, P131; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; MELACINI P, 1995, J AM COLL CARDIOL, V25, P239, DOI 10.1016/0735-1097(94)00351-P; OHIENDIECH K, 1991, NEURON, V7, P499; PERRYMAN MB, 1993, TRENDS CARDIOVAS MED, V3, P82, DOI 10.1016/1050-1738(93)90028-5; PONS F, 1994, CIRCULATION, V90, P369, DOI 10.1161/01.CIR.90.1.369; PRYSTOWSKY EN, 1979, CIRCULATION, V60, P1360, DOI 10.1161/01.CIR.60.6.1360; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; SOMMER JR, 1968, J CELL BIOL, V37, P570, DOI 10.1083/jcb.37.2.570; VANDERVEN PFM, 1993, HUM MOL GENET, V2, P1889; WARMKE JW, 1989, GENETICS, V122, P139	29	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20246	20249		10.1074/jbc.270.35.20246	http://dx.doi.org/10.1074/jbc.270.35.20246			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657592	hybrid			2022-12-25	WOS:A1995RR58400004
J	DOUVILLE, K; PRICE, A; EICHLER, J; ECONOMOU, A; WICKNER, W				DOUVILLE, K; PRICE, A; EICHLER, J; ECONOMOU, A; WICKNER, W			SECYEG AND SECA ARE THE STOICHIOMETRIC COMPONENTS OF PREPROTEIN TRANSLOCASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI PLASMA-MEMBRANE; PRECURSOR PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL RECOGNITION PARTICLE; ESCHERICHIA-COLI; CYTOPLASMIC MEMBRANE; TRIGGER FACTOR; ACIDIC PHOSPHOLIPIDS; INNER MEMBRANE; COAT PROTEIN	The transport of large preproteins across the Escherichia coli plasma membrane is catalyzed by preprotein translocase, comprised of the peripherally bound SecA subunit and an integrally bound heterotrimeric domain consisting of the SecY, SecE, and SecG subunits. me have now placed the secY, secE, and secG genes under the control of an arabinose-inducible promoter on a multicopy plasmid. Upon induction, all three of the proteins are strongly overexpressed and recovered in the plasma membrane fraction. These membranes show a strong enhancement of 1) translocation ATPase activity, 2) preprotein translocation, 3) capacity for SecA binding, and 4) formation of the membrane-inserted form of Seek These data establish that SecY, SecE, and SecG constitute the integral membrane domain of preprotein translocase.	DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; UNIV CRETE, DEPT BIOL, GR-71110 IRAKLION, GREECE	Dartmouth College; University of Crete			Economou, Anastassios/P-8292-2017; EICHLER, JERRY/F-2351-2012	Economou, Anastassios/0000-0002-1770-507X; EICHLER, JERRY/0000-0001-9409-8026				AKIYAMA Y, 1994, J BIOL CHEM, V269, P5225; ARKOWITZ RA, 1994, EMBO J, V13, P954, DOI 10.1002/j.1460-2075.1994.tb06340.x; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BASSILANA M, 1993, BIOCHEMISTRY-US, V32, P2626, DOI 10.1021/bi00061a021; BASSILANA M, 1992, J BIOL CHEM, V267, P25246; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DOUVILLE K, 1994, J BIOL CHEM, V269, P18705; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HABERLAND ME, 1989, J IMMUNOL, V142, P855; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; ITO K, 1992, MOL MICROBIOL, V6, P2423; ITO K, 1980, J BIOL CHEM, V255, P2123; JOLY JC, 1994, P NATL ACAD SCI USA, V91, P4703, DOI 10.1073/pnas.91.11.4703; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KIM YJ, 1994, FEBS LETT, V339, P175, DOI 10.1016/0014-5793(94)80410-9; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY CK, 1994, P NATL ACAD SCI USA, V91, P2557, DOI 10.1073/pnas.91.7.2557; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RANDALL LL, 1994, PHOSPHATE IN MICROORGANISMS, P251; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RENSING SA, 1994, MOL PHYLOGENET EVOL, V3, P187, DOI 10.1006/mpev.1994.1021; Sambrook J, 1989, MOL CLONING LABORATO; SCARAMUZZI CD, 1992, FEBS LETT, V304, P119, DOI 10.1016/0014-5793(92)80601-C; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHLENSTEDT G, 1987, EMBO J, V6, P699, DOI 10.1002/j.1460-2075.1987.tb04810.x; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0	65	114	116	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20106	20111		10.1074/jbc.270.34.20106	http://dx.doi.org/10.1074/jbc.270.34.20106			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650029	hybrid			2022-12-25	WOS:A1995RQ99100065
J	HSU, HY; NICHOLSON, AC; POMERANTZ, KB; KANER, RJ; HAJJAR, DP				HSU, HY; NICHOLSON, AC; POMERANTZ, KB; KANER, RJ; HAJJAR, DP			ALTERED CHOLESTEROL TRAFFICKING IN HERPESVIRUS-INFECTED ARTERIAL CELLS - EVIDENCE FOR VIRAL PROTEIN KINASE-MEDIATED CHOLESTEROL ACCUMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; SIMPLEX VIRUS-INFECTION; RECEPTOR GENE; GROWTH-FACTOR; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; CULTURED FIBROBLASTS; CYTOKINE REGULATION; LIPID-ACCUMULATION; TRANSFORMED-CELLS	Herpesvirus infection of arterial smooth muscle cells has been shown to cause cholesteryl ester (CE) accumulation. However, the effects of human herpes simplex virus type 1 (HSV-1) infection on cholesterol binding and internalization, intracellular metabolism, and efflux have not been evaluated. In addition, the effects of viral infection on signal transduction pathways that impact upon cholesterol metabolism have not been studied. We show in studies reported herein that HSV-1 infection of arterial smooth muscle cells enhances low density lipoprotein (LDL) binding and uptake which parallels an increase in LDL receptor steady state mRNA levels and transcription of the LDL receptor gene. HSV-1 also increases CE synthesis and 5-hydroxy-3-methylglutaryl-CoA reductase activity but concomitantly reduces CE hydrolysis and cholesterol efflux. Interestingly, this viral infection was associated with a time-dependent decrease in protein kinase A activity and an increase in viral-induced protein kinase (VPK) activity commensurate with the accumulation of esterified cholesterol. The relationship between increased VPK activity and alterations in CE accumulation in virally infected cells was explored using an HSV-1 VPK- mutant in which the portion of the HSV-1 genome encoding VPK had been deleted. Cholesteryl ester accumulation was significantly increased (>50-fold) in HSV-1-infected cells compared to uninfected cells. However, the HSV-1 VPK- mutant had no significant effect on CE accumulation. The relationship between VPK activity and these alterations in cholesterol metabolism was further supported by the observation that staurosporine and calphostin C (protein kinase inhibitors) reduced protein kinase activity in HSV-l-infected cells. These results suggest several potential mechanisms by which alterations in kinase activities in response to HSV-1 infection of vascular cells may alter cholesterol trafficking processes that eventually lead to CE accumulation.	CORNELL UNIV, COLL MED, DEPT BIOCHEM, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT PATHOL, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT MED, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT MED, NEW YORK, NY 10021 USA	Cornell University; Cornell University; Cornell University; Memorial Sloan Kettering Cancer Center				Pomerantz, Kenneth/0000-0001-9443-5301	NHLBI NIH HHS [HL-45343, HL-07423, HL-46403] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403, R01HL045343, T32HL007423] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albrecht T, 1989, Subcell Biochem, V15, P157; AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; Battey, 1986, BASIC METHODS MOL BI; BEG ZH, 1987, METABOLISM, V36, P900, DOI 10.1016/0026-0495(87)90101-6; BENDITT EP, 1983, P NATL ACAD SCI-BIOL, V80, P6386, DOI 10.1073/pnas.80.20.6386; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1974, P NATL ACAD SCI USA, V71, P788, DOI 10.1073/pnas.71.3.788; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JK, 1988, IN VITRO CELL DEV B, V24, P199; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN DI, 1992, SCIENCE, V256, P542, DOI 10.1126/science.1570514; COLBRAN RJ, 1986, FEBS LETT, V201, P257, DOI 10.1016/0014-5793(86)80619-6; CUNNINGHAM C, 1992, J GEN VIROL, V73, P303, DOI 10.1099/0022-1317-73-2-303; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ETINGIN OR, 1990, J LIPID RES, V31, P299; EVERETT RD, 1985, EMBO J, V4, P1973, DOI 10.1002/j.1460-2075.1985.tb03880.x; GARCIN D, 1990, EUR J BIOCHEM, V194, P279, DOI 10.1111/j.1432-1033.1990.tb19454.x; GHOSH S, 1989, LIPIDS, V24, P733, DOI 10.1007/BF02535213; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GROVE RI, 1991, J LIPID RES, V32, P1889; HAJJAR DP, 1980, AM J PATHOL, V100, P683; HAJJAR DP, 1992, FASEB J, V6, P2933, DOI 10.1096/fasebj.6.11.1644257; HAJJAR DP, 1982, J CLIN INVEST, V70, P479, DOI 10.1172/JCI110639; HAJJAR DP, 1991, AM J PATHOL, V139, P1195; HAJJAR DP, 1987, J CLIN INVEST, V80, P1317, DOI 10.1172/JCI113208; HAJJAR DP, 1983, J LIPID RES, V24, P1176; HAJJAR DP, 1985, J BIOL CHEM, V260, P6124; HAJJAR DP, 1986, ARCH BIOCHEM BIOPHYS, V247, P49, DOI 10.1016/0003-9861(86)90531-X; HALEY NJ, 1980, J LIPID RES, V21, P961; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HOKLAND BM, 1993, J BIOL CHEM, V268, P25343; HSU HY, 1994, J BIOL CHEM, V269, P9213; KEMP LM, 1986, NUCLEIC ACIDS RES, V14, P9261, DOI 10.1093/nar/14.23.9261; LANGELAND N, 1986, BIOCHEM J, V237, P707, DOI 10.1042/bj2370707; LEADER DP, 1988, TRENDS BIOCHEM SCI, V13, P244, DOI 10.1016/0968-0004(88)90157-0; LENG L, 1993, CANCER RES, V53, P5554; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNAB JCM, 1985, EMBO J, V4, P3223, DOI 10.1002/j.1460-2075.1985.tb04069.x; MAZZONE T, 1989, J BIOL CHEM, V264, P1787; MELNICK JL, 1983, LANCET, V2, P644; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MIDDLETON B, 1992, BIOCHEM J, V282, P853, DOI 10.1042/bj2820853; MOORBY CD, 1992, ATHEROSCLEROSIS, V97, P21, DOI 10.1016/0021-9150(92)90047-K; NICHOLSON AC, 1992, J BIOL CHEM, V267, P25982; OFFORD EA, 1989, J VIROL, V63, P2388, DOI 10.1128/JVI.63.5.2388-2391.1989; POMERANTZ KB, 1990, BIOCHEMISTRY-US, V29, P1892, DOI 10.1021/bi00459a033; PURVES FC, 1992, J VIROL, V66, P4295, DOI 10.1128/JVI.66.7.4295-4303.1992; PURVES FC, 1991, J VIROL, V65, P5757, DOI 10.1128/JVI.65.11.5757-5764.1991; PURVES FC, 1992, P NATL ACAD SCI USA, V89, P7310, DOI 10.1073/pnas.89.16.7310; PURVES FC, 1986, J GEN VIROL, V67, P1049, DOI 10.1099/0022-1317-67-6-1049; PURVES FC, 1987, J VIROL, V61, P2896, DOI 10.1128/JVI.61.9.2896-2901.1987; SMITH JR, 1988, J BIOL CHEM, V263, P18480; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; STOUT RW, 1983, ATHEROSCLEROSIS, V46, P13, DOI 10.1016/0021-9150(83)90159-4; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUGDEN PH, 1976, BIOCHEM J, V159, P423, DOI 10.1042/bj1590423	62	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19630	19637		10.1074/jbc.270.33.19630	http://dx.doi.org/10.1074/jbc.270.33.19630			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642651	hybrid			2022-12-25	WOS:A1995RP70300067
J	NAKAI, H; KRUKLITIS, R				NAKAI, H; KRUKLITIS, R			DISASSEMBLY OF THE BACTERIOPHAGE-MU TRANSPOSASE FOR THE INITIATION OF MU DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVITRO TRANSPOSITION; ESCHERICHIA-COLI; B-PROTEIN; PHAGE-MU; ENZYMATIC REPLICATION; STRAND CLEAVAGE; COMPLEXES; TRANSPOSOSOMES; AMPLIFICATION; PURIFICATION	Upon catalyzing strand transfer, the Mu transposase (MuA) remains tightly bound to the resulting transposition intermediate, the strand transfer complex (STC), and poses an impediment to host replication proteins. Additional host factors, which can be resolved into two fractions (Mu Replication Factor alpha and beta; MRF alpha and MRF beta), are required to disassemble the MuA complex and initiate DNA synthesis. MRF alpha modifies the protein content of the STC, removing MuA from the DNA in the process. The MRF beta promotes initiation of Mu DNA synthesis on the STC altered by the MRF alpha. These host factors cannot promote initiation of Mu DNA synthesis if the STC is damaged by partial proteolysis. Moreover, the mutant protein MuA211 cannot be removed from the STC by MRF alpha, blocking initiation of DNA synthesis. These results indicate that MuA in the STC plays a critical function in beginning a sequence of events leading to the establishment of a Mu replication fork.			NAKAI, H (corresponding author), GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007, USA.				NIGMS NIH HHS [GM49649] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049649] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CRAIGIE R, 1985, J BIOL CHEM, V260, P1832; CRAIGIE R, 1994, CELL, V39, P387; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; HARSHEY RM, 1986, J GENET, V65, P159, DOI 10.1007/BF02931149; KOCH C, 1987, PHAGE MU, P75; KRUKLITIS R, 1994, J BIOL CHEM, V269, P16469; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEUNG PC, 1991, J MOL BIOL, V219, P189, DOI 10.1016/0022-2836(91)90561-J; MAKI H, 1988, J BIOL CHEM, V263, P6570; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAI H, 1993, J BIOL CHEM, V268, P23997; RESIBOIS A, 1984, PROTEINS INVOLVED DN, P69; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; TOUSSAINT A, 1974, MOL GEN GENET, V131, P209, DOI 10.1007/BF00267960; TOUSSAINT A, 1983, MOBILE GENETIC ELEME, P105; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9	34	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19591	19598		10.1074/jbc.270.33.19591	http://dx.doi.org/10.1074/jbc.270.33.19591			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642646	hybrid			2022-12-25	WOS:A1995RP70300062
J	YOSHIMURA, K; CHU, CS; CRYSTAL, RG				YOSHIMURA, K; CHU, CS; CRYSTAL, RG			ALTERNATIVE SPLICING OF INTRON-23 OF THE HUMAN CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE RESULTING IN A NOVEL EXON AND TRANSCRIPT CODING FOR A SHORTENED INTRACYTOPLASMIC-C TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL; EPITHELIAL-CELLS; DNA; EXPRESSION; IDENTIFICATION; CFTR; SEQUENCES; FRAGMENTS; MUTATIONS; INVITRO	The cystic fibrosis transmembrane conductance regulator (CFTR) gene, the gene responsible for the lethal hereditary disorder cystic fibrosis, codes for a membrane protein functioning as a cAMP-regulated Cl- channel. Evaluation of human CFTR mRNA transcripts from epithelial and nonepithelial cells demonstrated a CFTR cDNA containing a 260-base pair (bp) insertion between the known CFTR exons 23 and 24, introducing a premature stop codon that would result in a CFTR protein shortened by 61 amino acids at the carboxyl terminus compared to that expected from the normal reported human CFTR coding sequences. Sequence analysis of intron 23 of the CFTR gene demonstrated that the 260-bp insertion (named exon 24a), a part of the reported intron 23 and located consecutive to exon 24, is likely generated by an alternative splice acceptor site. The exon 24a+ CFTR mRNA transcripts represented 3-16% of the total CFTR transcripts in epithelial and nonepithelial cells. These observations suggest an unexpected plasticity of expression of the CFTR gene, where alternative splicing of precursor CFTR mRNA transcripts permits the use of an alternative exon derived from a genomic segment previously believed to function as an intron.			YOSHIMURA, K (corresponding author), NHLBI, PULM BRANCH, BETHESDA, MD 20892 USA.							ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BARGON J, 1992, MOL CELL BIOL, V12, P1872, DOI 10.1128/MCB.12.4.1872; BARGON J, 1992, J BIOL CHEM, V267, P16056; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1991, J BIOL CHEM, V266, P19142; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BOYUM A, 1976, SCAND J IMMUNOL, P9, DOI 10.1111/j.1365-3083.1976.tb03851.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU JL, 1991, J BIOL CHEM, V266, P24471; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CHU CS, 1992, J CLIN INVEST, V90, P785, DOI 10.1172/JCI115952; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KINNIBURGH AJ, 1979, CELL, V17, P915, DOI 10.1016/0092-8674(79)90331-3; KOBAYASHI K, 1990, AM J HUM GENET, V47, P611; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PAWLAK A, 1990, J BIOL CHEM, V265, P3256; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALTINI C, 1984, AM REV RESPIR DIS, V130, P650; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	41	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					686	690						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678008				2022-12-25	WOS:A1993KE60300103
J	MACAULEY, A; OKADA, M; NADA, S; NAKAGAWA, H; COOPER, JA				MACAULEY, A; OKADA, M; NADA, S; NAKAGAWA, H; COOPER, JA			PHOSPHORYLATION OF SRC MUTANTS AT TYR-527 IN FIBROBLASTS DOES NOT CORRELATE WITH INVITRO PHOSPHORYLATION BY CSK	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; MIDDLE-T-ANTIGEN; CARBOXY TERMINUS; REGULATORY DOMAIN; PP60C-SRC; ACTIVATION; P60C-SRC; BINDING; TRANSFORMATION; P56LCK	In normal fibroblasts, the product of the cellular src gene, p60c-src or Src, is repressed by phosphorylation at its C-terminal tyrosine residue, Tyr 527. Mutations in Src that prevent phosphorylation cause enzymatic activation and malignant transformation. The tyrosine kinases that phosphorylate Src at Tyr 527 in vivo have not been identified, but a tyrosine kinase known as CSK is an excellent candidate. CSK has the unusual ability to phosphorylate Src in vitro only at Tyr 527. To examine whether CSK has the appropriate sequence specificy to explain the phosphorylation of Src at Tyr 527 in fibroblasts, we have made use of a set of C-terminal substitution mutants of Src. These mutants were previously characterized for their levels of Tyr 527 phosphorylation when expressed in Rat2 fibroblasts. The ability of CSK to phosphorylate selected mutants has now been tested, using both in vitro phosphorylation assays and co-expression of CSK with the Src mutants in a heterologous organism, Saccharomyces cerevisiae. We also tested whether the mutant Src molecules could autophosphorylate at Tyr 527, by examining the phosphorylation state of catalytically active forms expressed in the absence of CSK in yeast cells. The results show that CSK has strict sequence specificity for the normal Src sequence, although it can also phosphorylate the Lck sequence. The other mutant Src molecules tested were not phosphorylated by CSK, even though some of these mutants are highly phosphorylated at Tyr 527 in Rat 2 cells. All the mutants that are phosphorylated at Tyr 527 in Rat2 cells are also able to autophosphorylate at Tyr 527. The results suggest that CSK, autophosphorylation, and phosphorylation by kinases other than CSK, may all contribution to repressing Src catalytic activity in fibroblasts.	OSAKA UNIV,DIV PROT METAB,SUITA,OSAKA 565,JAPAN	Osaka University	COOPER, JA (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.				NCI NIH HHS [CA-41072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA041072, R01CA041072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COBB BS, 1991, MOL CELL BIOL, V11, P5832, DOI 10.1128/MCB.11.12.5832; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1987, ONCOGENE RES, V1, P297; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4243; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MACAULEY A, 1988, MOL CELL BIOL, V8, P3560, DOI 10.1128/MCB.8.8.3560; MACAULEY A, 1990, New Biologist, V2, P828; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARTANEN J, 1991, ONCOGENE, V6, P2013; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; WILKERSON VW, 1985, J VIROL, V55, P314, DOI 10.1128/JVI.55.2.314-321.1985; YACIUK P, 1988, ONCOGENE RES, V3, P207	39	35	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					117	124						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	7678701				2022-12-25	WOS:A1993KN00500014
J	DUNCAN, PI; HOWELL, BW; MARIUS, RM; DRMANIC, S; DOUVILLE, EMJ; BELL, JC				DUNCAN, PI; HOWELL, BW; MARIUS, RM; DRMANIC, S; DOUVILLE, EMJ; BELL, JC			ALTERNATIVE SPLICING OF STY, A NUCLEAR DUAL-SPECIFICITY KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TYROSINE KINASE; SIGNAL TRANSDUCTION; SKELETAL-MUSCLE; MESSENGER-RNA; RECEPTOR; THREONINE; GENE; PHOSPHOTYROSINE; VARIANTS	The LAMMER subfamily of kinases has been conserved throughout evolution, and its members are thought to play important roles in the regulation of cellular growth and differentiation programs. STY is a murine LAMMER kinase which has been implicated in the control of PC12 cell differentiation. Multiple transcripts are derived from the Sty gene, and their relative abundance is developmentally regulated, Alternative splicing of the primary Sty transcript generates mRNAs encoding full-length catalytically active (STY) and truncated, kinase-deficient polypeptides. Both STY and its truncated isoform, STYT, are localized in the nucleus and are capable of heterodimerizing. We also demonstrate that STY functions as a dual specificity kinase in mammalian cells.	OTTAWA REG CANC CTR,CANC RES GRP,OTTAWA,ON K1H 8L6,CANADA	University of Ottawa; Ottawa Hospital Research Institute				Howell, Brian/0000-0002-0204-0773				BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENDER J, 1994, P NATL ACAD SCI USA, V91, P12105, DOI 10.1073/pnas.91.25.12105; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DORAI T, 1990, MOL CELL BIOL, V10, P4068, DOI 10.1128/MCB.10.8.4068; DOUVILLE E, 1994, CANCER METAST REV, V13, P1, DOI 10.1007/BF00690414; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; HANES J, 1994, J MOL BIOL, V244, P665, DOI 10.1006/jmbi.1994.1763; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LEWIN B, 1987, GENES; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MYERS MP, 1994, MOL CELL BIOL, V14, P6954, DOI 10.1128/MCB.14.10.6954; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; QIAN LA, 1993, MOL CELL BIOL, V13, P1686, DOI 10.1128/MCB.13.3.1686; RABINOW L, 1989, EMBO J, V8, P879, DOI 10.1002/j.1460-2075.1989.tb03449.x; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT REM, 1990, MOL ENDOCRINOL, V4, P812, DOI 10.1210/mend-4-6-812; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YUN B, 1994, GENE DEV, V8, P1160, DOI 10.1101/gad.8.10.1160	32	61	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21524	21531		10.1074/jbc.270.37.21524	http://dx.doi.org/10.1074/jbc.270.37.21524			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665564	hybrid			2022-12-25	WOS:A1995RU75700019
J	KOJIMA, T; OHEDA, M; HATTORI, K; TANIGUCHI, Y; TAMURA, M; OCHI, N; YAMAGUCHI, N				KOJIMA, T; OHEDA, M; HATTORI, K; TANIGUCHI, Y; TAMURA, M; OCHI, N; YAMAGUCHI, N			MOLECULAR-CLONING AND EXPRESSION OF MEGAKARYOCYTE POTENTIATING FACTOR CDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE SECRETORY PATHWAY; HUMAN INTERFERON-GAMMA; AMINO-ACID-SEQUENCE; GROWTH-FACTOR; PRECURSOR; PROTEIN; CELLS	The human megakaryocyte potentiating factor (hMPF) has been previously purified from a culture supernatant of human pancreatic cancer cells HPC-Y5 (Yamaguchi, N., Hattori, K., Oh-eda, M., Kojima, T., Imai, N., and Ochi, N. (1994) J. Biol. Chem. 269, 805-808). We have now isolated hMPF cDNA from a HPC-Y5 cDNA library using polymerase chain reaction and plaque hybridization methods. The hMPF cDNA encodes a polypeptide consisting of 622 amino acids, including a signal peptide of 33 amino acids, and with a deduced molecular mass of 68 kDa, although HPC-Y5 cells secrete a 33-kDa form of hMPF. Human MPF does not show any significant homology with other previously described sequences. The cDNA was expressed in COS-7 and Chinese hamster ovary (CHO) cells, and megakaryocyte potentiating activity was detected in their culture supernatant. The COS-7 cells secreted only a 33-kDa recombinant hMPF, whereas an additional 30-kDa form was detected in the culture medium of CHO cells. The 33-kDa rhMPF purified from CHO cells showed megakaryocyte potentiating activity, but not the purified 30-kDa rhMPF. The difference in structure and activity between the 33- and 30-kDa forms of hMPF was ascribed to the existence in the 33-kDa form of the C-terminal 25 amino acid residues.	KYOTO PREFECTURAL UNIV MED,NEUROL DIS & GERIAT RES INST,DEPT CELL BIOL,KAMIGYO KU,KYOTO 602,JAPAN; CHUGAI PHARMACEUT CO LTD,FUJI GOTEMBA RES LABS,SHIZUOKA 412,JAPAN	Kyoto Prefectural University of Medicine; Chugai Pharmaceutical Co., Ltd.; Roche Holding								BENDIG MM, 1992, Patent No. 19759; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; GORDON MS, 1992, BLOOD, V80, P302; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HATTORI M, 1993, J BIOL CHEM, V268, P22414; LEVY WP, 1981, P NATL ACAD SCI-BIOL, V78, P6186, DOI 10.1073/pnas.78.10.6186; METCALF D, 1975, P NATL ACAD SCI USA, V72, P1744, DOI 10.1073/pnas.72.5.1744; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PAN YCE, 1987, EUR J BIOCHEM, V166, P145, DOI 10.1111/j.1432-1033.1987.tb13494.x; RINDERKNECHT E, 1984, J BIOL CHEM, V259, P6790; SCOTT J, 1983, NATURE, V302, P538, DOI 10.1038/302538a0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHORTLE D, 1989, BIOCHEMISTRY-US, V28, P936, DOI 10.1021/bi00429a003; SLODOWSKI O, 1991, EUR J BIOCHEM, V202, P1133, DOI 10.1111/j.1432-1033.1991.tb16481.x; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; WATANABE T, 1993, FEBS LETT, V320, P215, DOI 10.1016/0014-5793(93)80589-M; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WILLIAMS N, 1981, BLOOD, V57, P157; WILLIAMS N, 1982, J CELL PHYSIOL, V110, P101, DOI 10.1002/jcp.1041100116; YAMAGUCHI N, 1994, J BIOL CHEM, V269, P805; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	24	97	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21984	21990		10.1074/jbc.270.37.21984	http://dx.doi.org/10.1074/jbc.270.37.21984			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665620	hybrid			2022-12-25	WOS:A1995RU75700084
J	OSHIMA, H; SZAPARY, D; SIMONS, SS				OSHIMA, H; SZAPARY, D; SIMONS, SS			THE FACTOR-BINDING TO THE GLUCOCORTICOID MODULATORY ELEMENT OF THE TYROSINE AMINOTRANSFERASE GENE IS A NOVEL AND UBIQUITOUS HETEROMERIC COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-A; TISSUE-SPECIFIC EXTINGUISHER; SEQUENCE-SPECIFIC BINDING; HEPATOMA-CELL LINES; TRANSCRIPTION FACTOR; AGONIST ACTIVITY; PROGESTERONE-RECEPTOR; DNA-BINDING; DEXAMETHASONE 21-MESYLATE; RESPONSIVE ELEMENTS	Glucocorticoid induction of the tyrosine aminotransferase gene deviates from that of many glucocorticoid-responsive genes by having a lower EC(50) and displaying more agonist activity with a given antiglucocorticoid. A cis acting element, located 3646 base pairs upstream of the start of tyrosine aminotransferase gene transcription, has been found to be sufficient to reproduce these variations with heterologous genes and promoters (Oshima, H., and Simons, S. S., Jr. (1992) Mol. Endocrinol. 6, 416-428). This element has been called a glucocorticoid modulatory element, or GME. Others have called this sequence a cyclic AMP-responsive element (CRE) due to the binding of the cyclic AMP response element binding protein (CREB). We now report the partial purification and characterization of two new proteins (GMEB1 and -2) of 88 and 67 kDa that bind to the GME/ CRE as a heteromeric complex. This purification was followed by the formation of a previously characterized, biologically relevant band in gel shift assays. By several biochemical criteria, the GMEBs differed from many of the previously described CREB/CREM/ATF family members. Partial peptide sequencing revealed that the sequences of these two proteins have not yet been described. Size exclusion chromatography and molecular weight measurements of the gel-shifted band demonstrated that the GMEBs bound to the GME as a macromolecular complex of about 550 kDa that could be dissociated by deoxycholate. Similar experiments showed that CREB bound to the GME as heteromeric complexes of about 310 and 360 kDa. As determined from gel shift assays, GMEB1 and -2 are not restricted to rat liver cells but appear to be ubiquitous. Thus, these novel GMEBs may participate in a similar modulation of other glucocorticoid-inducible genes in a variety of cells.	NIDDK,CELLULAR & MOLEC BIOL LAB,STEROID HORMONES SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; CHANDRAN UR, 1992, MOL ENDOCRINOL, V6, P837, DOI 10.1210/me.6.5.837; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COONEY AJ, 1993, TRANSCRIPTION FACTOR, P49; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HARRISON SC, 1991, NATURE, V358, P715; HEINRICHS AAJ, 1993, BIOCHEMISTRY-US, V32, P11436, DOI 10.1021/bi00093a022; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KAZMI SMI, 1993, ENDOCRINOLOGY, V133, P1230, DOI 10.1210/en.133.3.1230; KUPFER SR, 1993, J BIOL CHEM, V268, P17519; LALLI E, 1994, J BIOL CHEM, V269, P17359; Maniatis T, 1989, DECONTAMINATION DILU; MARODER M, 1993, MOL ENDOCRINOL, V7, P570, DOI 10.1210/me.7.4.570; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MERCIER L, 1983, ENDOCRINOLOGY, V112, P601, DOI 10.1210/endo-112-2-601; MERCIER L, 1986, J STEROID BIOCHEM, V25, P11, DOI 10.1016/0022-4731(86)90275-X; MILLER PA, 1988, ENDOCRINOLOGY, V122, P2990, DOI 10.1210/endo-122-6-2990; MIYASHITA Y, 1993, J STEROID BIOCHEM, V46, P309, DOI 10.1016/0960-0760(93)90220-Q; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NING YM, 1993, J BIOL CHEM, V268, P6073; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; OSHIMA H, 1993, J BIOL CHEM, V268, P26858; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; OSHIMA H, 1992, ENDOCRINOLOGY, V130, P2106, DOI 10.1210/en.130.4.2106; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; REICHMAN ME, 1984, BIOCHEMISTRY-US, V23, P5376, DOI 10.1021/bi00317a042; REIK A, 1994, MOL ENDOCRINOL, V8, P490, DOI 10.1210/me.8.4.490; SANCHEZ ER, 1994, MOL ENDOCRINOL, V8, P408, DOI 10.1210/me.8.4.408; SARTORIUS CA, 1993, J BIOL CHEM, V268, P9262; SHEPARD AR, 1994, J BIOL CHEM, V269, P1804; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; SIMONS SS, 1988, J STEROID BIOCHEM, V31, P1, DOI 10.1016/0022-4731(88)90198-7; SIMONS SS, 1987, J BIOL CHEM, V262, P9669; SIMONS SS, 1989, CANCER RES, V49, pS2244; SIMONS SS, 1987, STEROID STEROL HORMO, P251; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; SZAPARY D, 1992, ENDOCRINOLOGY, V130, P3492, DOI 10.1210/en.130.6.3492; WASNER G, 1988, MOL ENDOCRINOL, V2, P1009, DOI 10.1210/mend-2-11-1009; WASNER G, 1987, MOL ENDOCRINOL, V1, P109, DOI 10.1210/mend-1-1-109; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437	53	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21893	21901		10.1074/jbc.270.37.21893	http://dx.doi.org/10.1074/jbc.270.37.21893			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665613	hybrid			2022-12-25	WOS:A1995RU75700073
J	TAIT, JF; ENGELHARDT, S; SMITH, C; FUJIKAWA, K				TAIT, JF; ENGELHARDT, S; SMITH, C; FUJIKAWA, K			PROUROKINASE-ANNEXIN-V CHIMERAS - CONSTRUCTION, EXPRESSION, AND CHARACTERIZATION OF RECOMBINANT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL ANTICOAGULANT PROTEIN; SINGLE-CHAIN UROKINASE; ESCHERICHIA-COLI; PLASMINOGEN-ACTIVATOR; PLATELET-AGGREGATION; PHOSPHOLIPID BINDING; CLOT LYSIS; PHOSPHATIDYLSERINE; EXPOSURE; CONJUGATION	Annexin V is a human protein that binds with high affinity to the abundant phosphatidylserine molecules exposed on activated platelets and accumulates selectively in thrombi after intravenous administration in animal models of arterial thrombosis. We designed two chimeras that use annexin V as a means to target thrombolytic agents to platelet-containing thrombi: prourokinase (1-411)-annexin V (1-320); and prourokinase (144-411)-annexin V (1-320) (amino acid numbers of parent proteins given in parentheses). Chimeras were produced by cytoplasmic expression in Escherichia coli, refolded, and purified in single-chain form. Both chimeras had the same specific activity as annexin V in binding to cell membranes containing exposed phosphatidylserine. After activation with plasmin, both chimeras had specific amidolytic activity similar to that of urokinase. Both chimeras activated plasminogen in vitro with kinetic parameters similar to those for urokinase, and both showed full activity compared to urokinase in an assay of clot lysis in vitro. This study shows the feasibility of producing chimeric plasminogen activators in which annexin V provides the thrombus-targeting component; although not yet tested in vivo, such chimeras may have advantages over antibody-based targeting agents.	UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	TAIT, JF (corresponding author), UNIV WASHINGTON, DEPT LAB MED, HLTH SCI RM NW-120, BOX 357110, SEATTLE, WA 98195 USA.				NHLBI NIH HHS [HL-47151] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047151] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON HV, 1993, NEW ENGL J MED, V329, P703; ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BEVERS EM, 1991, BLOOD REV, V5, P147; BODE C, 1985, SCIENCE, V229, P765, DOI 10.1126/science.4023710; BODE C, 1991, CIRCULATION, V84, P805, DOI 10.1161/01.CIR.84.2.805; BODE C, 1990, CIRCULATION, V81, P1974, DOI 10.1161/01.CIR.81.6.1974; COLLEN D, 1993, LANCET, V342, P34, DOI 10.1016/0140-6736(93)91888-S; CONCHA NO, 1993, SCIENCE, V261, P1321, DOI 10.1126/science.8362244; COOKSON BT, 1994, GENOMICS, V20, P463, DOI 10.1006/geno.1994.1201; DEBONO D, 1994, HAEMOSTASIS THROMBOS, P1459; DEWERCHIN M, 1991, BLOOD, V78, P1005; FADOK VA, 1992, J IMMUNOL, V148, P2207; FLAHERTY MJ, 1990, J LAB CLIN MED, V115, P174; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P8087, DOI 10.1021/bi00399a011; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P5572, DOI 10.1021/bi00391a053; HOLMES WE, 1985, BIO-TECHNOL, V3, P923, DOI 10.1038/nbt1085-923; HOLVOET P, 1993, BLOOD, V81, P696; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; IWASAKI A, 1987, J BIOCHEM, V102, P1261, DOI 10.1093/oxfordjournals.jbchem.a122165; LIJNEN HR, 1994, HAEMOSTASIS THROMBOS, P625; MEERS P, 1991, BIOCHEMISTRY-US, V30, P2903, DOI 10.1021/bi00225a025; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; ORSINI G, 1991, EUR J BIOCHEM, V195, P691, DOI 10.1111/j.1432-1033.1991.tb15755.x; RAO LVM, 1992, THROMB RES, V67, P517, DOI 10.1016/0049-3848(92)90013-Z; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RUNGE MS, 1991, P NATL ACAD SCI USA, V88, P10337, DOI 10.1073/pnas.88.22.10337; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; Sambrook J, 1989, MOL CLONING LABORATO; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; STRATTON JR, 1995, IN PRESS CIRCULATION; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGIMURA M, 1994, BLOOD COAGUL FIBRIN, V5, P365; TAIT JF, 1994, THROMB RES, V75, P491, DOI 10.1016/0049-3848(94)90224-0; TAIT JF, 1989, J BIOL CHEM, V264, P7944; TAIT JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P187, DOI 10.1016/0003-9861(92)90111-9; TAIT JF, 1994, J LAB CLIN MED, V123, P741; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; THIAGARAJAN P, 1991, J BIOL CHEM, V266, P24302; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281; WINKLER ME, 1986, BIOCHEMISTRY-US, V25, P4041, DOI 10.1021/bi00362a008	41	56	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21594	21599		10.1074/jbc.270.37.21594	http://dx.doi.org/10.1074/jbc.270.37.21594			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665573	hybrid			2022-12-25	WOS:A1995RU75700028
J	HOWARD, PW; MAURER, RA				HOWARD, PW; MAURER, RA			A COMPOSITE ETS/PIT-1 BINDING-SITE IN THE PROLACTIN GENE CAN MEDIATE TRANSCRIPTIONAL RESPONSES TO MULTIPLE SIGNAL-TRANSDUCTION PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; PROTEIN-KINASE-C; CELL-SPECIFIC EXPRESSION; RAT GROWTH-HORMONE; SYNERGISTIC INTERACTIONS; PROXIMAL REGION; PHORBOL ESTER; FACTOR PIT-1; PITUITARY; PROMOTER	Binding sites for the tissue-specific transcription factor, Pit-1, are required for basal and hormonally induced prolactin gene transcription, Although Pit-1 is phosphorylated in response to several signaling pathways, the mechanism by which Pit-1 contributes to hormonal induction of gene transcription has not been defined, Recent reports suggest that phosphorylation of Pit-1 may not be required for hormonal regulation of the prolactin promoter, Analysis of the contribution of individual Pit-1 binding sites has been complicated due to the fact that some of the elements appear to be redundant, To better understand the role of Pit-1 sites in mediating hormonal regulation of the prolactin gene, we have performed enhancer tests using the three most proximal Pit-1 binding sites of the rat prolactin gene which are designated the 1P, 2P, and 3P sites. The results demonstrate that multimers of the 3P Pit-1 binding site are much more responsive to several hormonal and intracellular signaling pathways than multimers of the 1P or 2P sites. The 3P DNA element was found to contain a consensus binding site for the Ets family of proteins. Mutation of the Ets binding site greatly decreased the ability of epidermal growth factor, phorbol esters, Ras, or the Raf kinase to induce reporter gene activity, Mutation of the Ets site had little effect on basal enhancer activity, In contrast, mutation of the consensus Pit-1 binding site in the 3P element essentially abolished all basal enhancer activity, Overexpression of Ets-1 in GH(3) pituitary cells enhanced both basal and Ras induced activity from the 3P enhancer, These data describe a composite element in the prolactin gene containing binding sites for two different factors and the studies suggest a mechanism by which Ets proteins and Pit-1 functionally cooperate to permit transcriptional regulation by different signaling pathways.	OREGON HLTH SCI UNIV,DEPT DEV & CELL BIOL,PORTLAND,OR 97201; UNIV IOWA,MOLEC BIOL PHD PROGRAM,IOWA CITY,IA 52242	Oregon Health & Science University; University of Iowa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040339] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40339] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CAMPER SA, 1985, J BIOL CHEM, V260, P2246; CAROLL MP, 1994, J BIOL CHEM, V269, P1249; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; DEMDEN MC, 1992, MOL ENDOCRINOL, V6, P581, DOI 10.1210/me.6.4.581; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; ELSHOLTZ HP, 1990, GENE DEV, V4, P43, DOI 10.1101/gad.4.1.43; ERNST P, 1993, MOL CELL BIOL, V13, P2982, DOI 10.1128/MCB.13.5.2982; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEARON CW, 1985, J BIOL CHEM, V260, P8366; FISCHBERG DJ, 1994, MOL ENDOCRINOL, V8, P1566, DOI 10.1210/me.8.11.1566; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUTIERREZHARTMA.A, 1994, MOL ENDOCRINOL, V8, P1447; GUTIERREZHARTMANN, 1987, P NATL ACAD SCI USA, V84, P5211; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOGGARD N, 1991, MOL ENDOCRINOL, V5, P1748, DOI 10.1210/mend-5-11-1748; HOWARD PW, 1994, J BIOL CHEM, V269, P28662; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KEECH CA, 1992, MOL ENDOCRINOL, V6, P2059, DOI 10.1210/me.6.12.2059; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KIM KE, 1988, MOL ENDOCRINOL, V3, P1374; KIM MK, 1993, J BIOL CHEM, V268, P23366; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MURDOCH GH, 1985, J BIOL CHEM, V260, P1852; MURDOCH GH, 1983, J BIOL CHEM, V258, P5329; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SHEPARD AR, 1994, J BIOL CHEM, V269, P1804; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STANLEY F, 1988, J BIOL CHEM, V263, P13444; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; SUPOWIT SC, 1984, P NATL ACAD SCI-BIOL, V81, P2975, DOI 10.1073/pnas.81.10.2975; VOSS JW, 1993, MOL ENDOCRINOL, V7, P1551, DOI 10.1210/me.7.12.1551; VOSS JWL, 1992, GENE DEV, V5, P1309; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; YAN GZ, 1991, MOL ENDOCRINOL, V5, P535, DOI 10.1210/mend-5-4-535; YAN GZ, 1991, MOL ENDOCRINOL, V5, P1488, DOI 10.1210/mend-5-10-1488	73	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20930	20936		10.1074/jbc.270.36.20930	http://dx.doi.org/10.1074/jbc.270.36.20930			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673116	hybrid			2022-12-25	WOS:A1995RU05400013
J	IMAGAWA, M; ISHIKAWA, Y; SHIMANO, H; OSADA, S; NISHIHARA, T				IMAGAWA, M; ISHIKAWA, Y; SHIMANO, H; OSADA, S; NISHIHARA, T			CTG TRIPLET REPEAT IN MOUSE GROWTH-INHIBITORY FACTOR METALLOTHIONEIN-III GENE PROMOTER REPRESSES THE TRANSCRIPTIONAL ACTIVITY OF THE HETEROLOGOUS PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALZHEIMERS-DISEASE; MYOTONIC-DYSTROPHY; MOLECULAR-CLONING; MAMMALIAN-CELLS; MESSENGER-RNA; FACTOR CDNA; EXPRESSION; PROTEIN; BRAIN; DNA	Growth inhibitory factor/metallothionein III (GIF/MT-III) is expressed specifically in brain, and neither mRNA nor protein is detected in other organs, This tissue-specific expression might be regulated by negative elements as well as positive elements, such as tissue-specific enhancers, To investigate the repression mechanisms of this gene in organs other than the brain, transfection experiments were performed by using various deletion mutants, Interestingly, a 25 x CTG repeat in the promoter region seemed to contribute to the repression activity, Moreover, the repression activity of this 25 x CTG repeat was also observed in various promoters and in a direction and position independent manner, indicating that this element could act as a silencer. However, no binding protein was detected by gel-shift and footprint analyses. These results strongly suggest that the CTG repeat functions as a negative element, and that this effect is caused by unknown mechanisms, rather than by interactions between specific cis-elements and specific trans-acting factors as reported previously, It is also possible that the CTG repeat functions as a general silencer in many genes.			IMAGAWA, M (corresponding author), OSAKA UNIV,FAC PHARMACEUT SCI,DEPT ENVIRONM BIOCHEM,1-6 YAMADA OKA,SUITA,OSAKA 565,JAPAN.		Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020	Shimano, Hitoshi/0000-0002-5562-5572; 				ASHALL F, 1994, TRENDS BIOCHEM SCI, V19, P42, DOI 10.1016/0968-0004(94)90173-2; CAHILL MA, 1994, FEBS LETT, V344, P105, DOI 10.1016/0014-5793(94)00320-3; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Erlich H.A., 1989, PCR TECHNOLOGY; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; HAMER DH, 1986, ANN REV BIOCH, V56, P913; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLTZMAN DM, 1991, TRENDS BIOCHEM SCI, V16, P140, DOI 10.1016/0968-0004(91)90056-2; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KOBAYASHI H, 1993, MOL BRAIN RES, V19, P188, DOI 10.1016/0169-328X(93)90025-K; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MANDELKOW EM, 1993, TRENDS BIOCHEM SCI, V18, P480, DOI 10.1016/0968-0004(93)90011-B; MARTIN JB, 1993, SCIENCE, V262, P674, DOI 10.1126/science.8235586; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; ROSS CA, 1993, TRENDS NEUROSCI, V16, P254, DOI 10.1016/0166-2236(93)90175-L; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; Sambrook J, 1989, MOL CLONING LABORATO; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TSUJI S, 1992, EMBO J, V11, P4843, DOI 10.1002/j.1460-2075.1992.tb05590.x; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2	26	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20898	20900		10.1074/jbc.270.36.20898	http://dx.doi.org/10.1074/jbc.270.36.20898			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673112	hybrid			2022-12-25	WOS:A1995RU05400008
J	MCALISTERHENN, L; STEFFAN, JS; MINARD, KI; ANDERSON, SL				MCALISTERHENN, L; STEFFAN, JS; MINARD, KI; ANDERSON, SL			EXPRESSION AND FUNCTION OF A MISLOCALIZED FORM OF PEROXISOMAL MALATE-DEHYDROGENASE (MDH3) IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; ISOCITRATE DEHYDROGENASE; CITRATE SYNTHASE; MITOCHONDRIAL; GENE; INACTIVATION; DISRUPTION; GLUCOSE; DNA	The malate dehydrogenase isozyme MDH3 of Saccharomyces cerevisiae was found to be localized to peroxisomes by cellular fractionation and density gradient centrifugation. However, unlike other yeast peroxisomal enzymes that function in the glyoxylate pathway, MDH3 was found to be refractory to catabolite inactivation, i.e. to rapid inactivation and degradation following glucose addition. To examine the structural requirements for organellar localization, the Ser-Lys-Leu carboxyl-terminal tripeptide, a common motif for localization of peroxisomal proteins, was removed by mutagenesis of the MDH3 gene. This resulted in cytosolic localization of MDH3 in yeast transformants. To examine structural requirements for catabolite inactivation, a 12-residue amino-terminal extension from the yeast cytosolic MDH2 isozyme was added to the amino termini of the peroxisomal and mislocalized ''cytosolic'' forms of MDH3. This extension was previously shown to be essential for catabolite inactivation of MDH2 but failed to confer this property to MDH3. The mislocalized cytosolic forms of MDH3 were found to be catalytically active and competent for metabolic functions normally provided by MDH2.	UNIV CALIF IRVINE,SCH MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine	MCALISTERHENN, L (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284, USA.				NIGMS NIH HHS [GM33218] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033218] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRKTOFT JJ, 1982, P NATL ACAD SCI-BIOL, V79, P6166, DOI 10.1073/pnas.79.20.6166; BOTSTEIN D, 1979, GENE, V8, P12; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANTRENNE H, 1955, BIOCHIM BIOPHYS ACTA, V16, P410, DOI 10.1016/0006-3002(55)90246-8; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DAUM G, 1982, J BIOL CHEM, V257, P3028; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; GANCEDO C, 1976, ARCH MICROBIOL, V109, P221, DOI 10.1007/BF00446632; GIETL C, 1994, P NATL ACAD SCI USA, V91, P3151, DOI 10.1073/pnas.91.8.3151; GIETL C, 1990, P NATL ACAD SCI USA, V87, P5773, DOI 10.1073/pnas.87.15.5773; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; LOPEZBOADO YS, 1987, ARCH MICROBIOL, V147, P231, DOI 10.1007/BF00463480; Maniatis T., 1982, MOL CLONING; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; MCCAMMON MT, 1990, J BACTERIOL, V172, P5816, DOI 10.1128/jb.172.10.5816-5827.1990; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; MINARD KI, 1992, J BIOL CHEM, V267, P17458; MINARD KI, 1991, MOL CELL BIOL, V11, P370, DOI 10.1128/MCB.11.1.370; PURDUE PE, 1994, J BIOL CHEM, V269, P30065; RODERICK SL, 1986, J BIOL CHEM, V261, P9461; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH KK, 1992, MOL CELL BIOL, V12, P5593, DOI 10.1128/MCB.12.12.5593; Singh N., 1993, Molecular Biology of the Cell, V4, p106A; Srere P. A., 1972, ENERGY METABOLISM RE, P79; STEFFAN JS, 1992, J BIOL CHEM, V267, P24708; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; THOMPSON LM, 1989, J BIOL CHEM, V264, P12091; THOMPSON LM, 1988, BIOCHEMISTRY-US, V27, P8393, DOI 10.1021/bi00422a015; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	34	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21220	21225		10.1074/jbc.270.36.21220	http://dx.doi.org/10.1074/jbc.270.36.21220			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673155	hybrid			2022-12-25	WOS:A1995RU05400055
J	TOURKINE, N; SCHINDLER, C; LAROSE, M; HOUDEBINE, LM				TOURKINE, N; SCHINDLER, C; LAROSE, M; HOUDEBINE, LM			ACTIVATION OF STAT FACTORS BY PROLACTIN, INTERFERON-GAMMA, GROWTH-HORMONES, AND A TYROSINE PHOSPHATASE INHIBITOR IN RABBIT PRIMARY MAMMARY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; SIGNAL-TRANSDUCTION PATHWAY; CASEIN GENE PROMOTER; BETA-CASEIN; EXTRACELLULAR-MATRIX; NUCLEAR FACTOR; KINASE-C; TRANSCRIPTION FACTOR; LACTOGENIC HORMONES; RECEPTOR	In numerous studies on mammary epithelial cell lines multiple factors, added to the medium or contained in the serum, were required for casein gene expression. It has been shown in these systems that the mammary gland factor (MGF) is implicated in the activation of the beta-casein gene promoter. In the present study, we determined the relationship between known agents that affect casein gene expression and MGF activity using the properties of rabbit primary mammary epithelial cells to respond to PRL alone, when cultured in chemically defined medium. We demonstrate that MGF is rapidly activated by PRL alone or by human growth hormone, a natural ligand of many PRL receptors (PRL-Rs), in the cytoplasm and accumulated in the nucleus, The MGF activation by PRL occurred in the absence of endogenous extracellular matrix, a condition where casein synthesis is known to be markedly reduced. Different inhibitors of protein-tyrosine kinases, which have been shown to reduce casein mRNA synthesis, but not of protein kinase C, decrease the MGF activity. A tyrosine phosphatase inhibitor, sodium pervanadate, induced two GAS-binding complexes related to MGF and STAT1. Our data show that MGF is a latent cytoplasmic factor rapidly activated in mammary epithelial cells, by a mechanism involving a tyrosine kinase and a tyrosine phosphatase.	INRA, UNITE DIFFERENCIAT CELLULAIRE, F-78352 JOUY EN JOSAS, FRANCE; COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Columbia University								AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALTIOK S, 1993, MOL CELL BIOL, V13, P7303, DOI 10.1128/MCB.13.12.7303; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAYATSARMADI M, 1993, MOL CELL ENDOCRINOL, V92, P127, DOI 10.1016/0303-7207(93)90083-V; BAYATSARMADI M, IN PRESS INT J BIOCH; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLUM JL, 1988, J CELL PHYSIOL, V135, P13, DOI 10.1002/jcp.1041350103; CAHOREAU C, 1992, BIOCHIMIE, V74, P1053, DOI 10.1016/0300-9084(92)90003-W; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CAULFIELD JJ, 1986, J ENDOCRINOL, V109, P29, DOI 10.1677/joe.0.1090029; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DJIANE J, 1982, ENDOCRINOLOGY, V110, P791, DOI 10.1210/endo-110-3-791; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; GERTLER A, 1983, MOL CELL ENDOCRINOL, V33, P169, DOI 10.1016/0303-7207(83)90165-X; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HOUDEBINE LM, 1990, REPROD NUTR DEV, V30, P431, DOI 10.1051/rnd:19900317; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MITEV V, 1995, IN PRESS REPROD NUTR, V35; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; NICOLL CS, 1980, FED PROC, V39, P2563; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PUISSANT C, 1991, CELL BIOL INT REP, V15, P121, DOI 10.1016/0309-1651(91)90103-P; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUI H, 1992, J BIOL CHEM, V267, P24076; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL DH, 1989, TRENDS PHARMACOL SCI, V10, P40, DOI 10.1016/0165-6147(89)90106-5; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; SCHMITT-NEY M, 1992, MOL ENDOCRINOL, V6, P1988, DOI 10.1210/me.6.12.1988; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SLIVA D, 1994, J BIOL CHEM, V269, P26208; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STANDKE GJR, 1994, MOL ENDOCRINOL, V8, P469, DOI 10.1210/me.8.4.469; TERNYNCK T, 1987, TECHNIQUES IMMUNOENZ, P14; THEPOT D, 1991, GENE, V97, P301, DOI 10.1016/0378-1119(91)90067-L; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOURKINE N, 1989, ONCOGENE, V4, P973; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	78	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20952	20961		10.1074/jbc.270.36.20952	http://dx.doi.org/10.1074/jbc.270.36.20952			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673119	hybrid			2022-12-25	WOS:A1995RU05400016
J	CAMUS, C; HERMANNLEDENMAT, S; JACQUET, M				CAMUS, C; HERMANNLEDENMAT, S; JACQUET, M			IDENTIFICATION OF GUANINE EXCHANGE FACTOR KEY RESIDUES INVOLVED IN EXCHANGE ACTIVITY AND RAS INTERACTION	ONCOGENE			English	Article						RAS EXCHANGE FACTOR; HUMAN; SACCHAROMYCES CEREVISIAE; ALAMINE SCANNING; 2-HYBRID	SACCHAROMYCES-CEREVISIAE CDC25; NUCLEOTIDE-RELEASING FACTOR; GENE-PRODUCT; SCANNING MUTAGENESIS; SIGNAL TRANSDUCTION; PROTEIN-KINASE; YEAST; RECEPTOR; GRB2; DNA	We have carried out a functional analysis of the human HGRF55 exchange factor in the yeast Saccharomyces cerevisiae. Twelve residues conserved among most of all known guanine exchange factors (GEFs) have been independently changed to alanine. Taking advantage of the ability of Hgrf55p to replace the yeast Cdc25p exchange factor, and using the two-hybrid system with RAS2(ala22) allele, we have identified key residues for the interaction with Pas and/or its activation. Substitution of arginine 392 to alanine leads to a complete loss of interaction with Ras, though the protein remains stable. Substitution of Asp266 or Arg359 to alanine results in inactive proteins at 39 degrees C, still able however to interact with Ras. The other charged-to-alanine substitutions led to no detectable phenotype when present alone but most of them dramatically increased the temperature sensitive phenotype observed with [Asp266Ala] substitution. Surprisingly, the cysteine to alanine substitution in the highly conserved PCVPF/Y motif proved to be without effect, suggesting that the sulfhydryl group is not essential for stability or interaction with Ras.	UNIV PARIS 11, INST GENET & MICROBIOL,INFORMAT GENET & DEV LAB, CNRS,URA 1354, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Camus, Christelle/A-3141-2009	Camus, Christelle/0000-0001-6590-1713				BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CAMONIS JH, 1988, MOL CELL BIOL, V8, P2980, DOI 10.1128/MCB.8.7.2980; CAMONIS JH, 1990, GENE, V86, P263, DOI 10.1016/0378-1119(90)90288-3; CAMUS C, 1994, MOL GEN GENET, V245, P167, DOI 10.1007/BF00283264; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHEN LP, 1993, DEV GENET, V14, P339, DOI 10.1002/dvg.1020140503; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; COCCETTI P, 1995, BIOCHEM BIOPH RES CO, V206, P253, DOI 10.1006/bbrc.1995.1035; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GARREAU H, 1990, FEBS LETT, V269, P53, DOI 10.1016/0014-5793(90)81117-7; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HOWE LR, 1993, ONCOGENE, V8, P2583; JANIN J, 1979, NATURE, V277, P491, DOI 10.1038/277491a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Miller JH., 1972, EXPT MOL GENETICS; MIRISOLA MG, 1994, J BIOL CHEM, V269, P15740; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NASMYTH K, 1985, CELL, V42, P213, DOI 10.1016/S0092-8674(85)80117-3; PARK WM, 1994, MOL CELL BIOL, V14, P8117, DOI 10.1128/MCB.14.12.8117; PART D, 1985, CELL DIFFER DEV, V17, P221, DOI 10.1016/0045-6039(85)90496-8; PETITJEAN A, 1990, GENETICS, V124, P797; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIKORSKI RS, 1989, GENETICS, V122, P19; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; VANAELST L, 1990, EUR J BIOCHEM, V193, P675; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WEI W, 1994, GENE, V151, P279, DOI 10.1016/0378-1119(94)90671-8	47	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					951	959						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675454				2022-12-25	WOS:A1995RU79800016
J	SACHDEV, S; ROTTJAKOB, EM; DIEHL, JA; HANNINK, M				SACHDEV, S; ROTTJAKOB, EM; DIEHL, JA; HANNINK, M			I-KAPPA-B-ALPHA-MEDIATED INHIBITION OF NUCLEAR TRANSPORT AND DNA-BINDING BY REL PROTEINS ARE SEPARABLE FUNCTIONS - PHOSPHORYLATION OF C-TERMINAL SERINE RESIDUES OF I-KAPPA-B-ALPHA IS SPECIFICALLY REQUIRED FOR INHIBITION OF DNA-BINDING	ONCOGENE			English	Article						I-KAPPA-B; NF-KAPPA-B; REL; TRANSCRIPTIONAL REGULATION; PHOSPHORYLATION	TRANSCRIPTION FACTORS; ACTIVATION; CELLS; GENE; TRANSFORMATION; EXPRESSION; MECHANISM; ONCOGENE; ENCODES; BETA	I kappa B-alpha inhibits both DNA-binding and nuclear translocation of dimeric Rel complexes that contain either the RelA or c-Rel proteins. These inhibitory functions of I kappa B-alpha proteins are regulated by both constitutive and inducible phosphorylation. We have mapped the constitutive phosphorylation sites of p40, the avian I kappa B-alpha protein, to a C-terminal acidic serine-rich region that contains four serine residues. Deletions or point mutations that significantly alter the overall negatively charged character of this region abolish association of p40 with Rel proteins in vitro. Serine-to-alanine amino acid substitutions in this region modulate the association of p40 with Rel proteins in vitro and abolish p40-mediated inhibition of DNA-binding by c-Rel. Substitution of aspartic acid residues for the phosphorylated serine residues has no effect on p40-mediated inhibition of DNA-binding. In contrast, the C-terminal acidic serine-rich region is not required for p40-mediated inhibition of nuclear translocation of Rel proteins. Our results demonstrate that p40-mediated inhibition of nuclear translocation and inhibition of DNA-binding by Rel proteins are separable functions. Our results suggest that the phosphorylation status of C-terminal serine residues of I kappa B-alpha proteins will be an important aspect of the autoregulatory feedback loop that enforces temporal control of Rel-regulated gene expression.	UNIV MISSOURI, DEPT BIOCHEM, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia					NCI NIH HHS [CA55027] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055027] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P21; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DIEHL JA, 1995, J BIOL CHEM, V270, P2703, DOI 10.1074/jbc.270.6.2703; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; ERNST MK, 1995, MOL CELL BIOL, V15, P872; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KOONG AC, 1994, CANCER RES, V54, P1425; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LINK E, 1992, J BIOL CHEM, V267, P239; MOSIALOS G, 1994, MOL CELL BIOL, V91, P12740; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TZEN CY, 1994, EXP CELL RES, V211, P12, DOI 10.1006/excr.1994.1052; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	41	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					811	823						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675442				2022-12-25	WOS:A1995RU79800001
J	SIMPSON, JC; DASCHER, C; ROBERTS, LM; LORD, JM; BALCH, WE				SIMPSON, JC; DASCHER, C; ROBERTS, LM; LORD, JM; BALCH, WE			RICIN CYTOTOXICITY IS SENSITIVE TO RECYCLING BETWEEN THE ENDOPLASMIC-RETICULUM AND THE GOLGI-COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; CELLS; TOXIN; INHIBITION; PROTEINS; SEQUENCE; RECEPTOR; PATHWAY; NETWORK	Cytotoxic proteins that kill mammalian cells by catalytically inhibiting protein synthesis must enter the cytosol in order to reach their substrates. With the exception of diphtheria toxin, which enters the cytosol from acidified endosomes, the intracellular site of translocation of other toxins including ricin, Escherichia coli Shiga-like toxin-1, and Pseudomonas exotoxin A is likely to involve early compartments of the secretory pathway. We have used a molecular approach to identify the site and mechanism of toxin delivery to the cytosol by transiently expressing mutant GTPases that inhibit the assembly of biochemical complexes mediating anterograde and retrograde transport in the exocytic and endocytic pathways, The results provide evidence to suggest that receptors actively recycling between the endoplasmic reticulum and terminal Golgi compartments are essential for toxin translocation to the cytosol from the endoplasmic reticulum, The rapid kinetics of intoxication demonstrate a substantial level of bidirectional membrane flow and sorting through the early secretory pathway.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	SIMPSON, JC (corresponding author), UNIV WARWICK, DEPT BIOL SCI, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND.			Simpson, Jeremy/0000-0002-7956-7805	NIGMS NIH HHS [GM42336] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGENT RH, 1994, J BIOL CHEM, V269, P26705; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; EIKLID K, 1983, INFECT IMMUN, V42, P771, DOI 10.1128/IAI.42.2.771-777.1983; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KREIS TE, 1994, CURR OPIN CELL BIOL, V6, P533, DOI 10.1016/0955-0674(94)90073-6; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LAFAY F, 1974, J VIROL, V14, P1220, DOI 10.1128/JVI.14.5.1220-1228.1974; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LORD JM, 1994, FASEB J, V8, P201, DOI 10.1096/fasebj.8.2.8119491; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; NEWTON DL, 1992, J BIOL CHEM, V267, P11917; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OKA T, 1994, J CELL BIOL, V124, P425, DOI 10.1083/jcb.124.4.425; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PETER F, 1992, J BIOL CHEM, V267, P10631; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SANDVIG K, 1994, J CELL BIOL, V126, P53, DOI 10.1083/jcb.126.1.53; SANDVIG K, 1994, FEBS LETT, V346, P99, DOI 10.1016/0014-5793(94)00281-9; Schmid SL, 1993, CURR OPIN CELL BIOL, V5, P621, DOI 10.1016/0955-0674(93)90131-9; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; WALES R, 1993, J BIOL CHEM, V268, P23986; WILSON BS, 1994, J CELL BIOL, V125, P557, DOI 10.1083/jcb.125.3.557; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z	40	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20078	20083		10.1074/jbc.270.34.20078	http://dx.doi.org/10.1074/jbc.270.34.20078			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650025	hybrid			2022-12-25	WOS:A1995RQ99100061
J	IYPE, LE; INMAN, RB; COX, MM				IYPE, LE; INMAN, RB; COX, MM			BLOCKED RECA PROTEIN-MEDIATED DNA STRAND EXCHANGE-REACTIONS ARE REVERSED BY THE RUVA AND RUVB PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RUVA; HOLLIDAY JUNCTIONS; BRANCH MIGRATION; 3-STRANDED DNA; CONJUGATIONAL RECOMBINATION; NUCLEOSIDE TRIPHOSPHATE; PARTIAL DENATURATION; ATP HYDROLYSIS; M13 VECTORS; REPAIR	RecA protein is unable to complete a DNA strand exchange reaction between a circular single-stranded DNA and a linear duplex DNA substrate with heterologous sequences of 375 base pairs at the distal end. Instead, it generates a branched intermediate in which strand exchange has proceeded up to the homology/heterology junction, Addition of the RuvA and RuvB proteins to these stalled intermediates leads to the rapid conversion of intermediates back to the original substrates, The reversal reaction is initiated at the branch, and the hybrid DNA is unwound in the direction opposite to that of the RecA reaction that created it, Under optimal conditions the rate of the reaction exhibits only a modest dependence on the length of hybrid DNA that must be unwound. Products of the reversal reaction are detected within minutes after addition of RuvAB, and appear with an apparent first order progress curve exhibiting a t(1/2) in the range of 6-12 min under optimal conditions. Few molecules that have undergone only partial reversal are detected, This suggests that the assembly or activation of RuvAB on the branched substrate is rate-limiting, while any migration of RuvAB on the DNA to effect unwinding of the hybrid DNA (and reformation of substrate DNA) is very fast. The results are discussed in the context of the role of RuvA and RuvB proteins in recombinational DNA repair. We suggest that one function of the RuvAB proteins is to act as an antirecombinase, to eliminate intragenomic crossovers between homologous segments of the bacterial chromosome that might otherwise lead to deleterious inversions or deletions.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM14711] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014711] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1994, P NATL ACAD SCI USA, V91, P9901, DOI 10.1073/pnas.91.21.9901; BEDALE WA, 1991, J BIOL CHEM, V266, P6499; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Davis R., 1980, ADV BACTERIAL GENETI; DUNDERDALE HJ, 1994, CURR OPIN GENET DEV, V4, P221, DOI 10.1016/S0959-437X(05)80048-6; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; IYPE LE, 1994, J BIOL CHEM, V269, P24967; JAIN SK, 1992, J BIOL CHEM, V267, P4215; JAIN SK, 1994, J BIOL CHEM, V269, P20653; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1987, J GEN MICROBIOL, V133, P2531; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; LUISIDELUCA C, 1989, GENETICS, V122, P269; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MULLER B, 1993, J BIOL CHEM, V268, P17179; MULLER B, 1994, EXPERIENTIA, V50, P216; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; Ochman H, 1987, ESCHERICHIA COLI SAL, P1649; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SEGALL A, 1988, SCIENCE, V241, P1314, DOI 10.1126/science.3045970; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; STASIAK A, 1992, MOL MICROBIOL, V6, P3267, DOI 10.1111/j.1365-2958.1992.tb02194.x; STASIAK A, 1994, EXPERIENTIA, V50, P192, DOI 10.1007/BF01924002; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WEST SC, 1992, MOL MICROBIOL, V6, P2755, DOI 10.1111/j.1365-2958.1992.tb01454.x; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WEST SC, 1993, COLD SPRING HARB SYM, V58, P525, DOI 10.1101/SQB.1993.058.01.059; WHITBY MC, 1993, CELL, V75, P341, DOI 10.1016/0092-8674(93)80075-P; WHITBY MC, 1994, EMBO J, V13, P5220, DOI 10.1002/j.1460-2075.1994.tb06853.x	54	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19473	19480		10.1074/jbc.270.33.19473	http://dx.doi.org/10.1074/jbc.270.33.19473			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642631	hybrid			2022-12-25	WOS:A1995RP70300045
J	LOO, TW; HO, C; CLARKE, DM				LOO, TW; HO, C; CLARKE, DM			EXPRESSION OF A FUNCTIONALLY ACTIVE HUMAN RENAL SODIUM-CALCIUM EXCHANGER LACKING A SIGNAL SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTES; NA+-CA2+ EXCHANGER; MEMBRANE; PROTEIN; CA; LOCALIZATION; RETICULUM; INVITRO	The Na+-Ca2+ exchanger is an unusual membrane transport protein as it contains an NH2-terminal signal sequence which is co-translationally removed in the endoplasmic reticulum during synthesis, To determine if the signal sequence was essential for biosynthesis, mutations were introduced in the NH2 terminus of the cDNA coding for the human renal Na+-Ca2+ exchanger in order to alter processing of the protein, To prevent cleavage of the signal sequence during biosynthesis, the last residue of the consensus signal sequence, Ala(-1), was changed to Phe. Deletion mutants were also constructed to encode for exchangers which lacked the signal sequence, the signal sequence and the first extracellular loop, or all of the NH2 terminus including the first transmembrane segment of the mature protein. These mutants were expressed in HEK 293 cells and assayed for Na+-Ca2+ exchange activity. Mutants lacking either a signal sequence or containing a noncleavable signal sequence were still targeted to the plasma membrane, where they exhibited Na+-Ca2+ exchange activity. By contrast, the mutants which had more than the signal sequence deleted did not demonstrate any exchange activity. These mutants were, however, still integrated into the membrane and were resistant to alkali extraction, These results show that the signal sequence is not essential for biogenesis of the Na+-Ca2+ exchanger and suggests that the molecule contains one or more internal signal sequences for insertion into the membrane during biosynthesis.	UNIV TORONTO,DEPT MED,MRC,MEMBRANE BIOL GRP,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BERS DM, 1990, AM J PHYSIOL, V258, pC944, DOI 10.1152/ajpcell.1990.258.5.C944; BOURDEAU JE, 1993, J AM SOC NEPHROL, V4, P105; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; FRANK JS, 1992, J CELL BIOL, V117, P337, DOI 10.1083/jcb.117.2.337; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; FULLMER CS, 1987, P NATL ACAD SCI USA, V84, P4772, DOI 10.1073/pnas.84.14.4772; GABELLINI N, 1995, J BIOL CHEM, V270, P6917, DOI 10.1074/jbc.270.12.6917; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HYRSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KOLLING R, 1994, FEBS LETT, V351, P155, DOI 10.1016/0014-5793(94)00825-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1992, J BIOL CHEM, V267, P7828; LI ZP, 1994, J BIOL CHEM, V269, P17434; LOO TW, 1994, AM J PHYSIOL, V267, pF70, DOI 10.1152/ajprenal.1994.267.1.F70; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1994, J BIOL CHEM, V269, P28683; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; NICOLL DA, 1991, ANN NY ACAD SCI, V639, P181, DOI 10.1111/j.1749-6632.1991.tb17305.x; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PARMENTIER M, 1987, EUR J BIOCHEM, V170, P207, DOI 10.1111/j.1432-1033.1987.tb13688.x; PHILIPSON K D, 1992, Current Opinion in Cell Biology, V4, P678, DOI 10.1016/0955-0674(92)90089-U; Philipson K D, 1993, Int Rev Cytol, V137C, P199; REILLY RF, 1993, AM J PHYSIOL, V265, pF327, DOI 10.1152/ajprenal.1993.265.2.F327; REITHMEIER RAF, 1994, CURR OPIN CELL BIOL, V6, P583, DOI 10.1016/0955-0674(94)90080-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKERJANC IS, 1993, FEBS LETT, V336, P168, DOI 10.1016/0014-5793(93)81633-B; TAM LY, 1994, J BIOL CHEM, V269, P32542; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZHANG JT, 1995, J BIOL CHEM, V270, P1742, DOI 10.1074/jbc.270.4.1742	39	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19345	19350		10.1074/jbc.270.33.19345	http://dx.doi.org/10.1074/jbc.270.33.19345			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642612	hybrid			2022-12-25	WOS:A1995RP70300026
J	REIN, T; FORSTER, R; KRAUSE, A; WINNACKER, EL; ZORBAS, H				REIN, T; FORSTER, R; KRAUSE, A; WINNACKER, EL; ZORBAS, H			ORGANIZATION OF THE ALPHA-GLOBIN PROMOTER AND POSSIBLE ROLE OF NUCLEAR FACTOR-I IN AN ALPHA-GLOBIN-INDUCIBLE AND IN A NONINDUCIBLE CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS DNA-REPLICATION; RNA POLYMERASE-II; GENE-TRANSCRIPTION; CHROMATIN STRUCTURE; BINDING PROTEIN; NF-I; ERYTHROID-DIFFERENTIATION; EUKARYOTIC TRANSCRIPTION; METHYLATED CPGS; EXPRESSION	Nuclear factor I (NFI) was suggested to be involved in the expression of the human alpha-globin gene. Two established cell lines, which express alpha-globin differentially, were therefore compared for differences in binding of NFI at the alpha-globin promoter in vivo. HeLa cells, in which alpha-globin is repressed, show a high density promoter occupation with several proteins associated with structurally distorted DNA. Cell line K562, which is inducible for alpha-globin, surprisingly was found to be heterogeneous consisting mainly of cells (similar to 95%) unable to express alpha-globin. However, the promoter of the nonexpressing K562 cells was clearly different from that of HeLa cells, being occupied only at basal transcriptional elements. Therefore, the alpha-globin gene in these K562 cells may not be truly repressed, but in an intermediate state between repression and active transcription. The NFI site of the alpha-globin promoter appeared occupied in HeLa but free of proteins in K562 cells. All cells of both cell lines produce NFI, but the composition and DNA binding affinity of NFI species differ significantly between the two cell fines. Therefore, distinct forms of NFI may repress alpha-globin transcription in HeLa cells. However, NFI is apparently not involved in establishing the latent transcriptional state of the majority of K562 cells.	UNIV MUNICH,INST BIOCHEM,D-81375 MUNICH,GERMANY	University of Munich			Förster, Reinhold/D-6770-2011	Forster, Reinhold/0000-0001-6190-7923; Rein, Theo/0000-0003-2850-4289				ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; APT D, 1993, J VIROL, V67, P4455, DOI 10.1128/JVI.67.8.4455-4463.1993; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BENEZRA R, 1986, CELL, V44, P697, DOI 10.1016/0092-8674(86)90835-4; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1987, EMBO J, V6, P999, DOI 10.1002/j.1460-2075.1987.tb04851.x; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BOSHER J, 1992, J VIROL, V66, P3140, DOI 10.1128/JVI.66.5.3140-3150.1992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CIVELLI O, 1982, J BIOL CHEM, V257, P6783; CLARK L, 1990, J VIROL, V64, P1335, DOI 10.1128/JVI.64.3.1335-1344.1990; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; DEAN DC, 1990, J BIOL CHEM, V265, P3522; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; DEY A, 1992, MOL CELL BIOL, V12, P3590, DOI 10.1128/MCB.12.8.3590; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DUSSERRE Y, 1992, MOL CELL BIOL, V12, P5228, DOI 10.1128/MCB.12.11.5228; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FORSTER R, 1993, BIOCHEM BIOPH RES CO, V196, P1496, DOI 10.1006/bbrc.1993.2421; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GIL G, 1988, J BIOL CHEM, V263, P19009; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRAHAM GH, 1988, EMBO J, V7, P2191; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GRONOSTAJSKI RM, 1984, P NATL ACAD SCI-BIOL, V81, P4013, DOI 10.1073/pnas.81.13.4013; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAY RT, 1985, EMBO J, V4, P421, DOI 10.1002/j.1460-2075.1985.tb03645.x; HENNIGHAUSEN L, 1985, NATURE, V314, P289, DOI 10.1038/314289a0; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JOSEESTANYOL M, 1988, J BIOL CHEM, V263, P10865; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KIM CG, 1990, MOL CELL BIOL, V12, P5985; KNEZETIC JA, 1993, MOL CELL BIOL, V13, P4632, DOI 10.1128/MCB.13.8.4632; KRAUSE A, 1993, HETEROLOGOUS NFI EXP; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MACLEOD K, 1991, MOL CELL BIOL, V11, P4324, DOI 10.1128/MCB.11.9.4324; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MCGHEE JD, 1979, P NATL ACAD SCI USA, V76, P2133, DOI 10.1073/pnas.76.5.2133; MCQUILLAN JJ, 1991, NUCLEIC ACIDS RES, V19, P6627, DOI 10.1093/nar/19.23.6627; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; OVERBEEK PA, 1981, BIOCHIM BIOPHYS ACTA, V656, P195, DOI 10.1016/0005-2787(81)90087-3; PLUMB M, 1991, J VIROL, V65, P1991, DOI 10.1128/JVI.65.4.1991-1999.1991; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROY RJ, 1992, NUCLEIC ACIDS RES, V20, P401, DOI 10.1093/nar/20.3.401; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; RUTHERFORD T, 1981, P NATL ACAD SCI-BIOL, V78, P348, DOI 10.1073/pnas.78.1.348; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SUN JM, 1994, J CELL BIOCHEM, V55, P252, DOI 10.1002/jcb.240550212; TREISMAN R, 1983, P NATL ACAD SCI-BIOL, V80, P7428, DOI 10.1073/pnas.80.24.7428; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; YAGI M, 1986, MOL CELL BIOL, V6, P1108, DOI 10.1128/MCB.6.4.1108; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; ZORBAS H, 1992, J BIOL CHEM, V267, P8478; ZORBAS H, 1989, NUCLEIC ACIDS RES, V19, P7735	87	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19643	19650		10.1074/jbc.270.33.19643	http://dx.doi.org/10.1074/jbc.270.33.19643			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642653				2022-12-25	WOS:A1995RP70300069
J	AZUMA, H; HAYASHI, T; DENT, JA; RUGGERI, ZM; WARE, J				AZUMA, H; HAYASHI, T; DENT, JA; RUGGERI, ZM; WARE, J			DISULFIDE BOND REQUIREMENTS FOR ASSEMBLY OF THE PLATELET GLYCOPROTEIN-IB-BINDING DOMAIN OF VONWILLEBRAND-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIII-RELATED ANTIGEN; RNA-POLYMERASE; EXPRESSION; SECRETION; SITE; IDENTIFICATION; FRAGMENT; CELLS	von Willebrand factor (vWF) is a multimeric glycoprotein of plasma and the subendothelial matrix that interacts with specific platelet receptors to establish platelet adhesion at a site of vascular injury. The vWF domain containing the platelet receptor glycoprotein Ib-binding site can be expressed in heterologous cells as a recombinant homodimeric fragment that mediates platelet-platelet interaction, analogous to multimeric vWF. The recombinant domain, r116, contains 7 Cys residues within its 290-residue monomeric subunit paired in an unidentified intra- and intermolecular disulfide bond arrangement. In this report we define the disulfide bond-dependent framework of r116 that provides the domain with its essential structural features that support dimer formation and the generation of a disulfide bond-dependent epitope. The results demonstrate that a triplet of Cys residues at positions 459, 462, and 464 are essential for efficient dimer formation. An intramolecular Cys509/Cys695 disulfide loop is required for generating a functional dimeric molecule, and monomeric molecules containing a Cys509/Cys695 intramolecular disulfide bond are unable to support ristocetin-mediated platelet aggregation. The disulfide arrangement in r116 is similar, if not identical, to the proposed arrangement within the corresponding region of plasma vWF, and these studies document the inherent Cys-dependent maturation of an isolated vWF domain.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV EXPTL HEMOSTASIS & THROMBOSIS, SBR 8, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050545] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL050545, R01 HL050545-06] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; AZUMA H, 1991, J BIOL CHEM, V266, P12342; BAUMGARTNER HR, 1978, THROMB HAEMOSTASIS, V39, P782; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; FUJIMURA Y, 1991, BLOOD, V77, P113; FUJIMURA Y, 1986, J BIOL CHEM, V261, P381; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; KOUTTS J, 1978, J CLIN INVEST, V62, P1255, DOI 10.1172/JCI109246; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOESBERG C, 1983, BIOCHIM BIOPHYS ACTA, V763, P160, DOI 10.1016/0167-4889(83)90039-3; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; Marston F. A. O., 1987, DNA CLONING, P59; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MOHRI H, 1988, J BIOL CHEM, V263, P17901; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUGGERI ZM, 1981, BLOOD, V57, P1140; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; Sambrook J, 1989, MOL CLONING LABORATO; SHELTONINLOES BB, 1986, BIOCHEMISTRY-US, V25, P3164, DOI 10.1021/bi00359a014; SPORN LA, 1987, BLOOD, V69, P1531; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; STEL HV, 1985, BLOOD, V65, P85; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WARE J, 1991, P NATL ACAD SCI USA, V88, P2946, DOI 10.1073/pnas.88.7.2946; WEISS HJ, 1986, BLOOD, V67, P322	27	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2821	2827						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679102				2022-12-25	WOS:A1993KK81500083
J	SUN, WJ; BARCHI, RL; COHEN, SA				SUN, WJ; BARCHI, RL; COHEN, SA			PROBING SODIUM-CHANNEL CYTOPLASMIC DOMAIN-STRUCTURE - EVIDENCE FOR THE INTERACTION OF THE RSKM1 AMINO AND CARBOXYL TERMINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; MONOCLONAL-ANTIBODIES; FUNCTIONAL RECONSTITUTION; TERTIARY STRUCTURE; LOCALIZATION; INFERENCES; SARCOLEMMA; SEQUENCE; SUBTYPES	Epitopes for monoclonal antibodies directed against the purified adult rat skeletal muscle sodium channel (rSkM1) were localized using channel proteolysis and fusion proteins, The interactions between these and other monoclonal antibodies with site-specific polyclonal antibodies were used to investigate the spatial relationships among rSkM1 cytoplasmic segments. Competition between antibodies for binding was performed using a solution-phase assay in which solubilized channel protein retains many of the biophysical characteristics of the rSkM1 protein in vivo. Our results support a model in which: 1) the amino terminus assumes a rigid structure having a fixed orientation with respect to other intracellular segments; 2) the interdomain 2-3 region is centrally located on the cytoplasmic surface of the channel, extends farther into the cytoplasm, and has an intermediate degree of flexibility; 3) the beginning of the amino terminus and end of the carboxyl terminus specifically interact with each other; and 4) domains 1 and 4 are adjacent. The sequences responsible for the interaction of the amino and carboxyl termini were identified by demonstrating the specific binding of a synthetic peptide encompassing the first 30 residues of the rSkM1 amino terminus to a fusion protein containing the rSkM1 carboxyl terminus.	PHILADELPHIA VET ADM MED CTR,DEPT MED,CARDIOL SECT 111C,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT NEUROSCI,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,INST NEUROL SCI,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania								BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P455, DOI 10.1146/annurev.ne.11.030188.002323; BARCHI RL, 1980, P NATL ACAD SCI-BIOL, V77, P1306, DOI 10.1073/pnas.77.3.1306; BARCHI RL, 1984, J CELL BIOCHEM, V26, P135, DOI 10.1002/jcb.240260302; CASADEI JM, 1987, J NEUROCHEM, V48, P773, DOI 10.1111/j.1471-4159.1987.tb05584.x; CASADEI JM, 1984, P NATL ACAD SCI-BIOL, V81, P6227, DOI 10.1073/pnas.81.19.6227; COHEN SA, 1992, J MEMBRANE BIOL, V128, P219; GORDON RD, 1988, J NEUROSCI, V8, P3742; GORDON RD, 1987, P NATL ACAD SCI USA, V84, P308, DOI 10.1073/pnas.84.1.308; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HAIMOVICH B, 1987, J NEUROSCI, V7, P2957; KRANER S, 1989, J BIOL CHEM, V264, P13273; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; SCHOTLAND DL, 1991, MUSCLE NERVE, V14, P142, DOI 10.1002/mus.880140209; SUN WJ, 1995, ANAL BIOCHEM, V226, P188, DOI 10.1006/abio.1995.1210; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; WEIGELE JB, 1982, P NATL ACAD SCI-BIOL, V79, P3651, DOI 10.1073/pnas.79.11.3651; WILSON JE, 1991, METHOD BIOCHEM ANAL, V35, P215; ZWERLING SJ, 1991, J BIOL CHEM, V266, P4574	21	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22271	22276		10.1074/jbc.270.38.22271	http://dx.doi.org/10.1074/jbc.270.38.22271			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673207	hybrid			2022-12-25	WOS:A1995RW31400034
J	ROWLEY, DR; DANG, TD; LARSEN, M; GERDES, MJ; MCBRIDE, L; LU, B				ROWLEY, DR; DANG, TD; LARSEN, M; GERDES, MJ; MCBRIDE, L; LU, B			PURIFICATION OF A NOVEL PROTEIN (PS20) FROM UROGENITAL SINUS MESENCHYMAL CELLS WITH GROWTH-INHIBITORY PROPERTIES IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMAL-EPITHELIAL INTERACTIONS; RODENT URINARY-BLADDER; FUNCTIONAL CYTODIFFERENTIATION; PROSTATIC DEVELOPMENT; TISSUE RECOMBINANTS; INDUCTION; DIFFERENTIATION; TRACT; DUCT	Our previous studies have characterized mesenchyme-derived proteins to identify biologically active proteins and novel markers for stromal cell paracrine action relative to stromal-epithelial interactions. Previous reports have characterized properties of a growth inhibitory activity (to bladder and prostatic epithelial cells), secreted by U4F fetal rat urogenital sinus mesenchymal cells, not cross-reactive with antibodies to known cytokines, and provisionally termed UGIF. The present study reports the characterization, purification, and biological properties of a 20-21-kDa protein responsible for UGIF activity. The 20-21-kDa protein (termed ps20) was purified to near homogeneity, the amino-terminal sequence was determined, and biological properties were characterized in vitro. Amino-terminal sequence analysis indicated no direct matches or regions of homology with known proteins. Purified ps20 induced a linear and saturable inhibition of [H-3]thymidine incorporation in PC-3 prostatic carcinoma cells (half-maximal activity at 2.6 nM), inhibited cell proliferation (increased population doubling time from 19.8 to 25.8 h), and induced a 210% stimulation in the synthesis of secreted proteins. These data suggest that ps20 may be a candidate paracrine effector protein and may play a role in stromal-epithelial cell interactions in the prostate gland.	BAYLOR COLL MED,CELL & MOLEC BIOL PROGRAM,HOUSTON,TX 77030	Baylor College of Medicine	ROWLEY, DR (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NCI NIH HHS [CA58093] Funding Source: Medline; NIDDK NIH HHS [DK45909] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045909] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHUNG LWK, 1993, SEMIN CANCER BIOL, V4, P183; CHUNG LWK, 1988, BIOL REPROD, V39, P50, DOI 10.1095/biolreprod39.1.50; COOKE PS, 1986, P NATL ACAD SCI USA, V83, P2109, DOI 10.1073/pnas.83.7.2109; CUNHA GR, 1976, INT REV CYTOL, V47, P137, DOI 10.1016/S0074-7696(08)60088-1; CUNHA GR, 1983, J CELL BIOL, V96, P1662, DOI 10.1083/jcb.96.6.1662; CUNHA GR, 1972, ANAT REC, V172, P179, DOI 10.1002/ar.1091720206; CUNHA GR, 1992, J ANDROL, V13, P465; CUNHA GR, 1980, BIOL REPROD, V22, P19, DOI 10.1095/biolreprod22.1.19; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; DREWS U, 1977, CELL, V10, P401, DOI 10.1016/0092-8674(77)90027-7; FUJII H, 1982, J UROLOGY, V128, P858, DOI 10.1016/S0022-5347(17)53221-8; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAYASHI N, 1991, CANCER RES, V51, P4924; HIGGINS SJ, 1989, DEVELOPMENT, V106, P219; HIGGINS SJ, 1989, DEVELOPMENT, V106, P235; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; LACROIX B, 1985, BIOL CELL, V54, P235, DOI 10.1111/j.1768-322X.1985.tb00399.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGRATH CM, 1983, CANCER RES, V43, P1355; NEUBAUER BL, 1983, J CELL BIOL, V96, P1671, DOI 10.1083/jcb.96.6.1671; PRINS GS, 1995, ENDOCRINOLOGY, V136, P1303, DOI 10.1210/en.136.3.1303; PRINS GS, 1991, ENDOCRINOLOGY, V129, P3187, DOI 10.1210/endo-129-6-3187; PRINS GS, 1992, ENDOCRINOLOGY, V130, P3066, DOI 10.1210/en.130.5.3066; ROWLEY DR, 1995, CANCER RES, V55, P781; ROWLEY DR, 1992, IN VITRO CELL DEV-AN, V28A, P29; ROWLEY DR, 1987, CANCER RES, V47, P2955; ROWLEY DR, 1992, ENDOCRINOLOGY, V130, P471; SMITH BT, 1983, P NATL ACAD SCI-BIOL, V80, P1951, DOI 10.1073/pnas.80.7.1951	28	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					22058	22065		10.1074/jbc.270.37.22058	http://dx.doi.org/10.1074/jbc.270.37.22058			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665628	hybrid			2022-12-25	WOS:A1995RU75700094
J	KITAMURA, K; MAITI, A; NG, DHW; JOHNSON, P; MAIZEL, AL; TAKEDA, A				KITAMURA, K; MAITI, A; NG, DHW; JOHNSON, P; MAIZEL, AL; TAKEDA, A			CHARACTERIZATION OF THE INTERACTION BETWEEN CD45 AND CD45-AP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; HUMAN LYMPHOCYTES-T; TYROSINE PROTEIN-KINASE; PHOSPHOTYROSINE PHOSPHATASE; MONOCLONAL-ANTIBODIES; MEMBRANE-PROTEINS; MESSENGER-RNA; PHOSPHORYLATION; SURFACE; CDNA	CD45, a leukocyte-specific transmembrane protein tyrosine phosphatase, is required for critical signal transduction pathways in immune responses. To elucidate the molecular interactions of CD45 with other proteins involved in CD45-mediated signal transduction path ways, we have recently cloned a 30 kDa phosphorylated protein, CD45-AP, which specifically associates with CD45. Binding analysis employing several deleted or chimeric forms of CD45-AP and CD45 demonstrated that the potential transmembrane segment of CD45-AP bound to the transmembrane portion of CD45. CD45-AP was found in particulate fractions of lymphocytes along with CD45, indicating that it is likely to be a transmembrane protein. In addition, CD45-AP was resistant to proteolysis by tosylphenylalanyl chloromethyl ketone-treated trypsin applied to intact cells. This is consistent with the most likely membrane orientation of CD45-AP predicted from the amino acid sequence, that is, only a short amino-terminal segment of CD45-AP is extracellular. We propose that CD45-AP interacts with CD45 at the plasma membrane and that the bulk of CD45-AP located in the cytoplasm act as an adapter which directs the interaction between CD45 and other molecules involved in CD45-mediated signal transduction pathways.	BROWN UNIV,ROGER WILLIAMS MED CTR,DEPT PATHOL,PROVIDENCE,RI 02908; UNIV BRITISH COLUMBIA,DEPT MICROBIOL & IMMUNOL,VANCOUVER,BC V6T 1Z3,CANADA	Brown University; Roger Williams Medical Center; University of British Columbia			Johnson, Pauline/G-9659-2019	Johnson, Pauline/0000-0001-7367-4653	NCI NIH HHS [CA 45148] Funding Source: Medline; NIGMS NIH HHS [GM 48188] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA045148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048188] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL GM, 1993, J IMMUNOL, V151, P3646; BERGER SA, 1994, J EXP MED, V180, P471, DOI 10.1084/jem.180.2.471; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BROWN VK, 1994, J BIOL CHEM, V269, P17238; CHUI D, 1994, EMBO J, V13, P798, DOI 10.1002/j.1460-2075.1994.tb06322.x; CIKES M, 1973, J NATL CANCER I, V50, P347, DOI 10.1093/jnci/50.2.347; DIANZANI U, 1992, EUR J IMMUNOL, V22, P365, DOI 10.1002/eji.1830220212; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIGH S, 1987, BIOCHEM J, V243, P277, DOI 10.1042/bj2430277; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LESLEY J, 1984, CELL IMMUNOL, V83, P14, DOI 10.1016/0008-8749(84)90220-X; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P2155; MITTLER RS, 1991, J IMMUNOL, V147, P3434; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; NG DHW, 1995, BIOCHEM BIOPH RES CO, V206, P302, DOI 10.1006/bbrc.1995.1042; NOTTENBURG C, 1989, P NATL ACAD SCI USA, V86, P8521, DOI 10.1073/pnas.86.21.8521; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PERSCHL A, 1995, J CELL SCI, V108, P1033; RADKE K, 1983, J CELL BIOL, V97, P1601, DOI 10.1083/jcb.97.5.1601; RANKIN BM, 1993, J IMMUNOL, V150, P605; SAGA Y, 1986, P NATL ACAD SCI USA, V83, P6940, DOI 10.1073/pnas.83.18.6940; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SGROI D, 1993, J BIOL CHEM, V268, P7011; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STUDIER FW, 1990, METHOD ENZYMOL, V185, P6; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TAKEDA A, 1994, J BIOL CHEM, V269, P2357; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085	44	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21151	21157		10.1074/jbc.270.36.21151	http://dx.doi.org/10.1074/jbc.270.36.21151			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673147	hybrid			2022-12-25	WOS:A1995RU05400046
J	PEARCE, DA; SHERMAN, F				PEARCE, DA; SHERMAN, F			DEGRADATION OF CYTOCHROME-OXIDASE SUBUNITS IN MUTANTS OF YEAST LACKING CYTOCHROME-C AND SUPPRESSION OF THE DEGRADATION BY MUTATION OF YME1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; HEME LYASE; NUCLEAR MUTATIONS; GENE; PROTEIN; MITOCHONDRIA; IMPORT; IDENTIFICATION; DENITRIFICANS; DEFICIENT	We have confirmed by spectral analysis that cytochrome oxidase is not present in strains of the yeast Saccharomyces cerevisiae having a primary deficiency in cytochrome c, and we have demonstrated by immunological procedures that such strains lack the mitochondrially encoded subunits I, II, and III of cytochrome oxidase. Furthermore, pulse-chase experiments demonstrated that subunit II is rapidly degraded in vivo. This degradation can be at least partially suppressed by disruption of the nuclear gene YME1, which encodes a putative ATP-Zn2+-dependent protease. We suggest that the cytochrome oxidase subunits are not properly assembled in the absence of cytochrome c, and that Yme1 and possibly other proteases degrade the unassembled mitochondrial-encoded subunits of cytochrome oxidase.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012702] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 12702] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGELER R, 1990, J BIOL CHEM, V265, P16389; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BOTTORFF DA, 1994, CURR GENET, V26, P329, DOI 10.1007/BF00310497; COOPER CE, 1991, BIOCHEM CELL BIOL, V69, P586, DOI 10.1139/o91-089; DOWHAN W, 1985, EMBO J, V4, P179, DOI 10.1002/j.1460-2075.1985.tb02334.x; DOWNIE JA, 1977, J MOL BIOL, V113, P364; DRYGAS ME, 1989, J BIOL CHEM, V264, P17897; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; GEIER BM, 1995, EUR J BIOCHEM, V227, P296, DOI 10.1111/j.1432-1033.1995.tb20388.x; GUELIN E, 1994, YEAST, V10, P1389, DOI 10.1002/yea.320101016; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HICKEY DR, 1991, GENE, V105, P73, DOI 10.1016/0378-1119(91)90515-D; KADENBACH B, 1981, FEBS LETT, V135, P1, DOI 10.1016/0014-5793(81)80932-5; MCEWEN JE, 1993, CURR GENET, V23, P9, DOI 10.1007/BF00336742; NAKAI T, 1994, J BIOCHEM-TOKYO, V116, P752, DOI 10.1093/oxfordjournals.jbchem.a124592; NARGANG FE, 1988, J BIOL CHEM, V263, P9388; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; PATTERSON TE, 1987, CYTOCHROME SYSTEMS M, P253; PEARCE DA, 1995, P NATL ACAD SCI USA, V92, P3735, DOI 10.1073/pnas.92.9.3735; REID GA, 1983, METHOD ENZYMOL, V97, P324; REILLY C, 1965, BIOCHIM BIOPHYS ACTA, V95, P640, DOI 10.1016/0005-2787(65)90518-6; Sambrook J, 1989, MOL CLONING LABORATO; SCHAEFER PW, 1987, ENVIRON ENTOMOL, V16, P368, DOI 10.1093/ee/16.2.368; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; SHERMAN F, 1966, P NATL ACAD SCI USA, V55, P1498, DOI 10.1073/pnas.55.6.1498; SHERMAN F, 1965, J MOL BIOL, V13, P21, DOI 10.1016/S0022-2836(65)80077-8; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; TAANMAN JW, 1993, J BIOL CHEM, V268, P18754; TAUER R, 1994, FEBS LETT, V353, P197, DOI 10.1016/0014-5793(94)01045-5; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; THORSNESS PE, 1993, GENETICS, V134, P21; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; VANDYCK L, 1994, J BIOL CHEM, V269, P238; WEBER ER, 1995, GENETICS, V140, P435; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WRIGHT RM, 1986, J BIOL CHEM, V261, P7183; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; YAMAMOTO T, 1992, GENETICS, V131, P811	43	96	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20879	20882		10.1074/jbc.270.36.20879	http://dx.doi.org/10.1074/jbc.270.36.20879			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673107	hybrid			2022-12-25	WOS:A1995RU05400003
J	SCHISCHMANOFF, PO; WINARDI, R; DISCHER, DE; PARRA, MK; BICKNESE, SE; WITKOWSKA, HE; CONBOY, JG; MOHANDAS, N				SCHISCHMANOFF, PO; WINARDI, R; DISCHER, DE; PARRA, MK; BICKNESE, SE; WITKOWSKA, HE; CONBOY, JG; MOHANDAS, N			DEFINING OF THE MINIMAL DOMAIN OF PROTEIN-4.1 INVOLVED IN SPECTRIN-ACTIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; GLUTATHIONE-S-TRANSFERASE; BETA-SPECTRIN; MEMBRANE SKELETON; ESCHERICHIA-COLI; PEPTIDE-FRAGMENTS; COMPLEX; PHOSPHORYLATION; ASSOCIATIONS; ISOFORMS	The spectrin-actin-binding domain of protein 4.1 is encoded by a 21-amino acid alternative exon and a 59-amino acid constitutive exon, To characterize the minimal domain active for interactions with spectrin and actin, we functionally characterized recombinant 4.1 peptides containing the 21-amino acid cassette plus varying portions of the 59-amino acid cassette (designated 21.10 to 21.59). Peptide 21.43 was shown fully functional in binary interactions with spectrin (by cosedimentation and coimmunoprecipitation experiments) and in ternary complex formation with spectrin and actin (by an in vitro gelation assay), Further truncation produced peptides incapable of binary interactions but fully competent for ternary complex formation (peptides 21.36 and 21.31), shorter peptides with reduced ternary complex activity and altered kinetics (21.26 and 0.59), and inactive peptides (21.20 and 21.10), Binding studies and circular dichroism experiments suggested that residues 37-43 of the constitutive domain were directly involved in spectrin binding. These data indicate that 4.1-spectrin binary interaction requires the 21-amino acid alternative cassette plus the 43 N-terminal residues of the constitutive domain, Moreover, the existence of two possible ternary complex assembly pathways is suggested: one initiated by 4.1-spectrin interactions, and a second by 4.1-actin interactions, The latter may require a putative actin binding motif within the 26 N-terminal residues of the constitutive domain.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV LIFE SCI,BERKELEY,CA 94720; UNIV CALIF BERKELEY & SAN FRANCISCO,JOINT GRAD GRP BIOENGN,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; CHILDRENS HOSP OAKLAND,RES INST,OAKLAND,CA 94609	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California San Francisco; University of California System; University of California San Francisco; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland				discher, dennis/0000-0001-6163-2229	NCRR NIH HHS [RR 06506-01] Funding Source: Medline; NIDDK NIH HHS [DK 26263, DK 32094] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094, R37DK026263, R01DK026263] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER PS, 1990, EUR J BIOCHEM, V193, P827, DOI 10.1111/j.1432-1033.1990.tb19406.x; BRENNER SL, 1980, J BIOL CHEM, V255, P1670; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; CHASIS JA, 1989, BLOOD, V74, P1112, DOI 10.1182/blood.V74.3.1112.1112; COHEN CM, 1984, BIOCHEMISTRY-US, V23, P6091, DOI 10.1021/bi00320a029; COHEN CM, 1980, CELL, V21, P875, DOI 10.1016/0092-8674(80)90451-1; COHEN CM, 1984, BIOCHEMISTRY-US, V23, P4488, DOI 10.1021/bi00314a039; COLEMAN TR, 1987, J CELL BIOL, V104, P519, DOI 10.1083/jcb.104.3.519; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062, DOI 10.1073/pnas.85.23.9062; CORREAS I, 1986, J BIOL CHEM, V261, P3362; CORREAS I, 1986, J BIOL CHEM, V261, P3310; DISCHER D, 1993, J BIOL CHEM, V268, P7186; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; EDER PS, 1986, BIOCHEMISTRY-US, V25, P1764, DOI 10.1021/bi00355a047; ELZINGER M, 1983, P NATL ACAD SCI USA, V70, P2687; FOWLER V, 1980, J CELL BIOL, V85, P361, DOI 10.1083/jcb.85.2.361; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEMMING NJ, 1994, BIOCHEM J, V299, P191, DOI 10.1042/bj2990191; HORNE WC, 1990, BIOCHIM BIOPHYS ACTA, V1055, P87, DOI 10.1016/0167-4889(90)90095-U; HORNE WC, 1993, BLOOD, V82, P2558; HUANG JP, 1993, J BIOL CHEM, V268, P3758; KAM Z, 1977, BIOCHEMISTRY-US, V16, P5568, DOI 10.1021/bi00644a028; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING E, 1988, J BIOL CHEM, V263, P2209; LIU SC, 1992, SEMIN HEMATOL, V29, P231; LORENZO F, 1994, J CLIN INVEST, V94, P1651, DOI 10.1172/JCI117508; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; MAYS KT, 1992, BLOOD S1, V80, pA273; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; OHANIAN V, 1984, BIOCHEMISTRY-US, V23, P4416, DOI 10.1021/bi00314a027; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PFUHL M, 1994, EMBO J, V13, P1782, DOI 10.1002/j.1460-2075.1994.tb06446.x; PODGORSKI A, 1985, BIOCHEMISTRY-US, V24, P7871, DOI 10.1021/bi00348a004; REID ME, 1990, BLOOD, V75, P2229; RIZO J, 1993, BIOCHEMISTRY-US, V32, P4881, DOI 10.1021/bi00069a025; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUBRAHMANYAM G, 1991, P NATL ACAD SCI USA, V88, P5222, DOI 10.1073/pnas.88.12.5222; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; TANG TK, 1990, J CELL BIOL, V110, P617, DOI 10.1083/jcb.110.3.617; TYLER JM, 1980, J BIOL CHEM, V255, P7034; UNGEWICKELL E, 1979, NATURE, V280, P811, DOI 10.1038/280811a0; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WOLFE LC, 1982, NEW ENGL J MED, V307, P1367, DOI 10.1056/NEJM198211253072203; WU CSC, 1983, BIOCHIM BIOPHYS ACTA, V746, P72, DOI 10.1016/0167-4838(83)90012-2	52	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21243	21250		10.1074/jbc.270.36.21243	http://dx.doi.org/10.1074/jbc.270.36.21243			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673158	hybrid			2022-12-25	WOS:A1995RU05400058
J	GARCIACUELLAR, MP; ESTEBAN, LM; FUJIMURA, T; RODRIGUEZCOUSINO, N; ESTEBAN, R				GARCIACUELLAR, MP; ESTEBAN, LM; FUJIMURA, T; RODRIGUEZCOUSINO, N; ESTEBAN, R			YEAST VIRAL 20S RNA IS ASSOCIATED WITH ITS COGNATE RNA-DEPENDENT RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; SACCHAROMYCES-CEREVISIAE; IDENTIFICATION; GENES; REPLICATION; SPORULATION; EXPRESSION; REPLICON; FORM	Most Saccharomyces cerevisiae strains carry in their cytoplasm 20 S RNA, a Linear single-stranded RNA molecule of 2.5 kilobases in size. 20 S RNA copy number is greatly induced in stress conditions such as starvation, with up to 100,000 copies per cell. 20 S RNA has coding capacity for a protein of 91 kDa (p91) with sequences diagnostic of RNA-dependent RNA polymerases of (+) strand and double-stranded RNA viruses. We detected p91 in 20 S RNA-carrying strains with specific antisera. The amount of p91 in growing cells is higher than that of stationary cells and similar to the one in 20 S RNA-induced cells. Although 20 S RNA is not encapsidated into viral particles, p91 non-covalently forms a ribonucleoprotein complex with 20 S RNA. This suggests a role of p91 in the RNA to RNA synthesis processes required for 20 S RNA replication. Although the strain analyzed also harbors 23 S RNA, a closely related single-stranded RNA, 23 S RNA is not associated with p91 but with its putative RNA polymerase, p104. Similarly, 20 S RNA is not associated with p104 but with p91. These results suggest that 20 S RNA and 23 S RNA replicate independently using their respective cognate RNA polymerases.	UNIV SALAMANCA,CONSEJO SUPER INVEST CIENTIFICAS,DEPT GENET & MICROBIOL,INST MICROBIOL BIOQUIM,E-37071 SALAMANCA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca			Fujimura, Tsutomu/K-5807-2014; Rodríguez-Cousiño, Nieves/K-6465-2014; Esteban, Rosa/K-4356-2014	Fujimura, Tsutomu/0000-0002-9457-6769; Rodríguez-Cousiño, Nieves/0000-0002-6458-3677; Esteban, Rosa/0000-0001-6804-7209				ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BEALL JA, 1986, J IMMUNOL METHODS, V86, P217, DOI 10.1016/0022-1759(86)90456-4; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; ESTEBAN LM, 1994, J BIOL CHEM, V269, P29771; ESTEBAN LM, 1992, J BIOL CHEM, V287, P10874; ESTEBAN R, 1993, PROG NUCLEIC ACID RE, V46, P155, DOI 10.1016/S0079-6603(08)61021-1; FRIED HM, 1978, P NATL ACAD SCI USA, V75, P4224, DOI 10.1073/pnas.75.9.4224; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; GARVIK B, 1978, J BACTERIOL, V134, P261, DOI 10.1128/JB.134.1.261-269.1978; KADOWAKI K, 1971, J BACTERIOL, V105, P831, DOI 10.1128/JB.105.3.831-836.1971; KADOWAKI K, 1971, J BACTERIOL, V105, P826, DOI 10.1128/JB.105.3.826-830.1971; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; MATSUMOTO Y, 1991, J BIOL CHEM, V266, P12779; Matthews REF., 2002, PLANT VIROLOGY; MEYER F, 1981, J MOL BIOL, V153, P631, DOI 10.1016/0022-2836(81)90411-3; Mortimer R K, 1975, Methods Cell Biol, V11, P221, DOI 10.1016/S0091-679X(08)60325-8; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; POLASHOCK JJ, 1994, P NATL ACAD SCI USA, V91, P8680, DOI 10.1073/pnas.91.18.8680; RODRIGUEZCOUSINO N, 1992, NUCLEIC ACIDS RES, V20, P2761, DOI 10.1093/nar/20.11.2761; RODRIGUEZCOUSINO N, 1991, J BIOL CHEM, V266, P12772; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WEJKSNORA PJ, 1978, J BACTERIOL, V134, P246, DOI 10.1128/JB.134.1.246-260.1978; WESOLOWSKI M, 1984, MOL CELL BIOL, V4, P181, DOI 10.1128/MCB.4.1.181; WICKNER RB, 1978, GENETICS, V88, P419; WIDNER WR, 1991, MOL CELL BIOL, V11, P2905, DOI 10.1128/MCB.11.5.2905	32	16	17	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20084	20089		10.1074/jbc.270.34.20084	http://dx.doi.org/10.1074/jbc.270.34.20084			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650026	hybrid			2022-12-25	WOS:A1995RQ99100062
J	JOSEPH, M; NAGARAJ, R				JOSEPH, M; NAGARAJ, R			CONFORMATIONS OF PEPTIDES CORRESPONDING TO FATTY ACYLATION SITES IN PROTEINS - A CIRCULAR-DICHROISM STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNALIZATION SIGNAL; COMPLETE SEQUENCE; WATER SOLUTION; BETA-TURNS; FRAGMENTS; INITIATION; VIRUS; ACID; MYRISTYLATION; TYROSINE	Fatty acid acylation is a posttranslational modification found in membrane proteins that have hydrophobic sequences serving as transmembrane segments as well as those that do not have them. The fatty acids myristate and palmitate are linked through an amide bond to N-terminal glycine and SH of cysteine via a thioester bond, respectively. In order to elucidate whether or how fatty acid acylation would modulate peptide structure, especially in hydrophobic environment, we have carried out circular dichroism studies on synthetic peptides both hydrophobic and hydrophilic in nature, corresponding to fatty acylation sites and their fatty acyl derivatives. The hydrophilic peptides were similar to 12 residues in length as studies on proteins modified by site directed mutagenesis indicated that a peptide segment of similar to 12 residues is sufficient to direct acylation as well as membrane association, especially when the fatty acid is myristic acid. The peptide corresponding to a transmembrane segment composed of 31 residues as well as its palmitoyl derivative was found to adopt alpha-helical structure. Acylation appeared to favor increased partitioning into micelles even in the case of a hydrophobic peptide. The hydrophilic peptides and their myristoyl or palmitoyl derivatives showed very little ordered structure in micelles. Our results suggest that the myristoyl and the palmitoyl moieties do not have the ability to ''force'' a hydrophilic peptide segment into a hydrophobic micellar environment. Thus, the mere presence of a fatty acid moiety may not be sufficient for membrane binding and recycling as is assumed especially in proteins in which no hydrophobic segment is present.	CTR CELLULAR & MOLEC BIOL,HYDERABAD 500007,ANDHRA PRADESH,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)								Atherton E., 1990, SOLID PHASE PEPTIDE; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BRAHMACHARI SK, 1981, J AM CHEM SOC, V103, P1703, DOI 10.1021/ja00397a020; BRAHMACHARI SK, 1982, BIOPOLYMERS, V21, P1107, DOI 10.1002/bip.360210608; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DYSON HJ, 1992, J MOL BIOL, V226, P819, DOI 10.1016/0022-2836(92)90634-V; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GILLEN MF, 1975, CAN J CHEM, V53, P2351, DOI 10.1139/v75-329; GISIN BF, 1973, HELV CHIM ACTA, V56, P1476, DOI 10.1002/hlca.19730560503; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOSEPH M, 1993, BIOORG MED CHEM LETT, V3, P1025, DOI 10.1016/S0960-894X(00)80280-2; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KEMMINK J, 1993, J MOL BIOL, V234, P861, DOI 10.1006/jmbi.1993.1631; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; RENIL M, 1994, TETRAHEDRON, V50, P6681, DOI 10.1016/S0040-4020(01)89696-4; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; Stewart JM, 1984, SOLID PHASE PEPTIDE; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Woody R. W., 1992, ADV BIOPHYS CHEM, V2, P37; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	37	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19439	19445		10.1074/jbc.270.33.19439	http://dx.doi.org/10.1074/jbc.270.33.19439			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642626	hybrid			2022-12-25	WOS:A1995RP70300040
J	FOROUGH, R; ZHAN, X; MACPHEE, M; FRIEDMAN, S; ENGLEKA, KA; SAYERS, T; WILTROUT, RH; MACIAG, T				FOROUGH, R; ZHAN, X; MACPHEE, M; FRIEDMAN, S; ENGLEKA, KA; SAYERS, T; WILTROUT, RH; MACIAG, T			DIFFERENTIAL TRANSFORMING ABILITIES OF NON-SECRETED AND SECRETED FORMS OF HUMAN FIBROBLAST GROWTH FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL GROWTH; ENDOTHELIAL-CELLS; GENE; STIMULATION; EXPRESSION; SEQUENCE; SIGNAL; PHOSPHORYLATION; TUMORIGENESIS	Fibroblast growth factor (FGF)-1(1-154), the precursor for acidic FGF-1(21-154), is a potent angiogenic polypeptide, the structure of which lacks a signal peptide sequence for secretion. To investigate the biological significance of this structural feature, we have attempted forced secretion of FGF-1 through fusion of the entire FGF-1 coding frame with the signal peptide (sp) from the hst/KS3 gene, a secretory member of the heparin-binding growth factor family. We also studied the transforming ability of the signal-less forms of FGF-1 comprising FGF1-154 and FGF-1(21-154). The presence of a soluble and biologically active form of FGF-1 was readily detected in the conditioned medium of NIH 3T3 cells transfected with sp-hst/KS3:FGF-1(1-154) as demonstrated by Western blot analysis and DNA synthesis assays, whereas sp-hst/KS3:FGF-1(21-154) was not detectable in conditioned medium even though the protein was detected in cellular extracts. The secreted form of sp-hst/KS3:FGF-1(1-154) stimulated the proliferation of human umbilical vein endothelial cells in vitro and was able to induce receptor-mediated tyrosine phosphorylation. Furthermore, the forced secretion of biologically active FGF-1 resulted in NIH 3T3 cell transformation as demonstrated by altered morphology in vitro, the formation of discrete colonies in soft agarose, growth under serum-free conditions, and ability to rapidly form highly vascular tumors in vivo. Interestingly, sp-hst/KS3:FGF-1(21-154) also mediated the transition to a transformed phenotype despite the inability to detect extracellular FGF-1 in the media conditioned by these NIH 3T3 cell transfectants. Although the transfection of FGF-1(21-154) yielded similar NIH 3T3 cell morphologic changes, these transfectants did not grow under serum-free conditions or yield colonies in soft agarose, and formed tumors in vivo with delayed kinetics. Furthermore, the FGF-1(1-154) NIH 3T3 cell transfectants did not exhibit morphologic changes, and this may be due to the inability of mRNA to express protein. These data suggest that although non-sp forms of FGF-1 may alter the monolayer phenotype of NIH 3T3 cells in vitro, the ability of FGF-1 to transform NIH 3T3 cells requires the function of a sp-directed secretory pathway and suggests that this pathway increases tumorigenicity in vivo.	AMER RED CROSS, JEROME H HOLLAND LAB BIOMED SCI, DEPT MOLEC BIOL, 15601 CRABBS BRANCH WAY, ROCKVILLE, MD 20855 USA; NCI, FREDERICK CANC RES & DEV CTR, EXPTL IMMUNOL LAB, EXPTL THERAPEUT SECT, FREDERICK, MD 21702 USA; PRI DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA				Sayers, Thomas J/G-4859-2015		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL044336, R01HL032348] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline; NHLBI NIH HHS [HL32348, HL44336] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLAM SB, 1988, ONCOGENE, V3, P129; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BUNNAG P, 1991, IN VITRO CELL DEV B, V27, P89; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DAVIET I, 1990, FEBS LETT, V259, P315, DOI 10.1016/0014-5793(90)80035-H; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FOROUGH R, 1991, BIOCHIM BIOPHYS ACTA, V1090, P293, DOI 10.1016/0167-4781(91)90192-O; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GAY CG, 1990, J BIOL CHEM, V265, P3284; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUANG JS, 1986, J BIOL CHEM, V261, P1600; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; KOZAK M, 1986, IN TRANSLATIONAL CON; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARICS I, 1989, ONCOGENE, V4, P335; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MOSCAT J, 1988, P NATL ACAD SCI USA, V85, P659, DOI 10.1073/pnas.85.3.659; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; THOMPSON JA, 1989, P NATL ACAD SCI USA, V86, P7928, DOI 10.1073/pnas.86.20.7928; THOMPSON JA, 1988, SCIENCE, V241, P1349, DOI 10.1126/science.2457952; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	41	104	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2960	2968						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679105				2022-12-25	WOS:A1993KK81500103
J	STEINERT, PM; PARRY, DAD				STEINERT, PM; PARRY, DAD			THE CONSERVED H1 DOMAIN OF THE TYPE-II KERATIN-1 CHAIN PLAYS AN ESSENTIAL ROLE IN THE ALIGNMENT OF NEAREST NEIGHBOR MOLECULES IN MOUSE AND HUMAN KERATIN-1/KERATIN-10 INTERMEDIATE FILAMENTS AT THE 2-MOLECULE TO 4-MOLECULE LEVEL OF STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSION ELECTRON-MICROSCOPY; BOVINE EPIDERMAL KERATIN; COILED-COIL MOLECULES; AMINO-ACID SEQUENCES; ALPHA-KERATIN; INVITRO; CELLS; VIMENTIN; PROTEIN; EXPRESSION	A number of fundamental questions pertaining to the registration and packing of the constituent coiled-coil molecules in keratin intermediate filaments, and to the regions of the sequences that are responsible for these levels of organization, remain to be elucidated. In this study, small assembly-competent oligomers of mouse and human keratin 1/keratin 10 keratin filaments were cross-linked by the formation of disulfide bonds catalyzed by the copper-phenanthroline reaction. By isolation and characterization of cross-linked peptides, it has been possible to establish two major modes of molecule alignment: an antiparallel arrangement of half-staggered molecules with their 2B segments overlapping and an antiparallel arrangement of molecules in close axial registration. These data confirm earlier models based on theoretical considerations (Crewther, W. G., Dowling, L. M., Steinert, P. M., and Parry, D. A. D. (1983) Int. J. Biol. Macromol. 5, 267-274). Interestingly, these models place the conserved H1 and H2 end domain segments, which flank the ends of the rod domains of the type II keratin 1 chain, in alignment with either the ends of the rod domains and/or with the L2 segment near the center of the rod domains, of the nearest neighbor molecules. Competition experiments with synthetic peptides suggest that the conserved H1 (and possibly H2) subdomain sequences unique to type II keratin chains play pivotal roles in the registration of neighboring molecules in keratin filaments. The data thus afford a molecular explanation for why keratin filaments require a type II chain for assembly in vivo and in vitro.	MASSEY UNIV,DEPT PHYS & BIOPHYS,PALMERSTON NORTH,NEW ZEALAND	Massey University	STEINERT, PM (corresponding author), NIAMSD,SKIN BIOL BRANCH,BLDG 6,RM 425,BETHESDA,MD 20892, USA.							AEBI U, 1983, J CELL BIOL, V97, P1131, DOI 10.1083/jcb.97.4.1131; BAIRD PA, 1976, J BIOL CHEM, V251, P9653; CHIPEV CC, 1992, CELL, V70, P821, DOI 10.1016/0092-8674(92)90315-4; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COMPTON JG, 1992, NAT GENET, V1, P301, DOI 10.1038/ng0792-301; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; CREWTHER WG, 1983, INT J BIOL MACROMOL, V5, P267, DOI 10.1016/0141-8130(83)90040-5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENGEL A, 1985, J ULTRA MOL STRUCT R, V90, P323, DOI 10.1016/S0022-5320(85)80010-1; Fraser R.D.B., 1990, CELLULAR MOL BIOL IN, P205; FRASER RDB, 1985, INT J BIOL MACROMOL, V7, P258, DOI 10.1016/0141-8130(85)90024-8; FRASER RDB, 1983, BIOSCIENCE REP, V3, P517, DOI 10.1007/BF01120695; FRASER RDB, 1986, P NATL ACAD SCI USA, V83, P1179, DOI 10.1073/pnas.83.5.1179; FRASER RDB, 1988, INT J BIOL MACROMOL, V10, P106, DOI 10.1016/0141-8130(88)90017-7; GEISLER N, 1985, J MOL BIOL, V182, P173, DOI 10.1016/0022-2836(85)90035-X; GEISLER N, 1992, EUR J BIOCHEM, V206, P841, DOI 10.1111/j.1432-1033.1992.tb16992.x; HATZFELD M, 1990, J CELL SCI, V97, P317; HATZFELD M, 1992, J CELL BIOL, V116, P157, DOI 10.1083/jcb.116.1.157; HATZFELD M, 1985, J CELL BIOL, V101, P1826, DOI 10.1083/jcb.101.5.1826; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; HOHL D, 1991, J BIOL CHEM, V266, P6626; IP W, 1985, J MOL BIOL, V183, P365, DOI 10.1016/0022-2836(85)90007-5; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; MACK JW, 1988, BIOCHEMISTRY-US, V27, P5418, DOI 10.1021/bi00415a006; MACK JW, 1991, J INVEST DERMATOL, V96, pA615; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; PARRY DAD, 1977, J MOL BIOL, V113, P449, DOI 10.1016/0022-2836(77)90153-X; PARRY DAD, 1985, BIOCHEM BIOPH RES CO, V127, P1012, DOI 10.1016/S0006-291X(85)80045-0; POTSCHKA M, 1990, EUR J CEL LBIOL, V190, P505; QUINLAN RA, 1982, P NATL ACAD SCI-BIOL, V79, P3452, DOI 10.1073/pnas.79.11.3452; QUINLAN RA, 1984, J MOL BIOL, V178, P365, DOI 10.1016/0022-2836(84)90149-9; QUINLAN RA, 1985, ANN NY ACAD SCI, V455; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; SOELLNER P, 1985, P NATL ACAD SCI USA, V82, P7929, DOI 10.1073/pnas.82.23.7929; SPARROW LG, 1989, BIOL WOOL HAIR, P145; STEINERT P, 1978, SCIENCE, V200, P1491, DOI 10.1126/science.566466; STEINERT P, 1982, METHOD CELL BIOL, V24, P399; STEINERT PM, 1975, BIOCHEM J, V149, P39, DOI 10.1042/bj1490039; STEINERT PM, 1985, J BIOL CHEM, V260, P7142; STEINERT PM, 1976, J MOL BIOL, V108, P547, DOI 10.1016/S0022-2836(76)80136-2; STEINERT PM, 1985, ANNU REV CELL BIOL, V1, P41; STEINERT PM, 1991, J STRUCT BIOL, V107, P175, DOI 10.1016/1047-8477(91)90020-W; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STEINERT PM, 1988, J BIOL CHEM, V263, P13333; STEINERT PM, 1991, J STRUCT BIOL, V107, P157, DOI 10.1016/1047-8477(91)90019-S; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1991, INT J BIOL MACROMOL, V13, P130, DOI 10.1016/0141-8130(91)90037-U; STEINERT PM, 1983, NATURE, V302, P794, DOI 10.1038/302794a0; STEINERT PM, 1984, P NATL ACAD SCI-BIOL, V81, P5709, DOI 10.1073/pnas.81.18.5709; STEINERT PM, 1975, BIOCHEM J, V151, P603, DOI 10.1042/bj1510603; STEINERT PM, 1993, IN PRESS J MOL BIOL; STEVEN AC, 1985, ANN NY ACAD SCI, V455, P371, DOI 10.1111/j.1749-6632.1985.tb50423.x; STEVEN AC, 1982, P NATL ACAD SCI-BIOL, V79, P3101, DOI 10.1073/pnas.79.10.3101; STEVEN AC, 1983, J BIOL CHEM, V258, P8323; STEWART M, 1989, J CELL BIOL, V109, P225, DOI 10.1083/jcb.109.1.225; SUN TT, 1984, CANCER CELL TRANSFOR, P167; WHITMANAYNARDI M, 1984, J CELL BIOL, V98, P1407; ZHOU XM, 1988, J BIOL CHEM, V263, P15584	61	99	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2878	2887						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679103				2022-12-25	WOS:A1993KK81500091
J	LORSBACH, RB; MURPHY, WJ; LOWENSTEIN, CJ; SNYDER, SH; RUSSELL, SW				LORSBACH, RB; MURPHY, WJ; LOWENSTEIN, CJ; SNYDER, SH; RUSSELL, SW			EXPRESSION OF THE NITRIC-OXIDE SYNTHASE GENE IN MOUSE MACROPHAGES ACTIVATED FOR TUMOR-CELL KILLING - MOLECULAR-BASIS FOR THE SYNERGY BETWEEN INTERFERON-GAMMA AND LIPOPOLYSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-MAJOR AMASTIGOTES; NECROSIS FACTOR CACHECTIN; L-ARGININE; MURINE MACROPHAGES; IFN-GAMMA; PERITONEAL-MACROPHAGES; EFFECTOR MECHANISM; FACTOR-ALPHA; INDUCTION; NITRATE	Macrophages can become activated to kill both tumor cells and a variety of microbes. Results here show that synthesis of nitric oxide (NO), a mediator of many macrophage cytotoxic functions, was greatly increased when cells of the mouse macrophage cell line RAW 264.7 were costimulated with bacterial lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma), compared to LPS alone. This increase paralleled increases in cytotoxicity. Northern analysis showed that increased production of NO was preceded by markedly enhanced expression of mRNA for the inducible form of macrophage NO synthase (mac-NOS), which catalyzes the synthesis of NO. Cycloheximide inhibited the induction of mac-NOS mRNA by IFN-gamma and LPS, indicating that expression of this mRNA required de novo protein synthesis. Elevated expression of mac-NOS mRNA was not due to an increase in its stability. Rather, the combination of IFN-gamma and LPS induced a much higher rate of transcription of the mac-NOS gene than did stimulation with LPS alone. These results provide one explanation of why priming and triggering stimuli, such as IFN-gamma and LPS, respectively, synergistically activate macrophages and may be applicable to explaining how IFN-gamma augments NO-dependent microbicidal activity in macrophages as well.	UNIV KANSAS,MED CTR,CTR CANC,WILKINSON LAB,KANSAS CITY,KS 66160; UNIV KANSAS,MED CTR,DEPT PATHOL & ONCOL,KANSAS CITY,KS 66160; UNIV KANSAS,MED CTR,DEPT MICROBIOL MICROBIAL GENET & IMMUNOL,KANSAS CITY,KS 66160; JOHNS HOPKINS UNIV,SCH MED,DEPT CARDIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Johns Hopkins University; Johns Hopkins University				Lowenstein, Charles/0000-0003-0485-7514	NCI NIH HHS [R01 CA31199, P01 CA54474] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA054474, R01CA031199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS LB, 1991, J IMMUNOL, V147, P1642; ADAMS LB, 1990, J IMMUNOL, V144, P2725; ALLEN RW, 1987, J BIOL CHEM, V262, P649; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BURCHETT SK, 1988, J IMMUNOL, V140, P3473; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; COWLEY BD, 1989, J BIOL CHEM, V264, P8389; DESCOTEAUX A, 1990, J IMMUNOL, V145, P846; DING AH, 1988, J IMMUNOL, V141, P2407; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREEN SJ, 1990, J IMMUNOL, V145, P4290; GREEN SJ, 1990, J IMMUNOL, V144, P278; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIBBS JB, 1977, SCIENCE, V197, P279, DOI 10.1126/science.327547; KELLER R, 1990, CANCER RES, V50, P1421; LEVIN J, 1970, J LAB CLIN MED, V75, P903; LIEW FY, 1990, J IMMUNOL, V145, P4306; LORSBACH RB, 1992, INFECT IMMUN, V60, P2133, DOI 10.1128/IAI.60.5.2133-2135.1992; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MACKAY RJ, 1986, J IMMUNOL, V137, P1392; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MELLOUK S, 1991, J IMMUNOL, V146, P3971; MORRISON DC, 1975, J BIOL CHEM, V250, P2911; MURRAY HW, 1985, J IMMUNOL, V134, P1619; PACE JL, 1981, J IMMUNOL, V126, P1863; PACE JL, 1983, P NATL ACAD SCI-BIOL, V80, P3782, DOI 10.1073/pnas.80.12.3782; PACE JL, 1985, J IMMUNOL, V134, P977; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; RUCO LP, 1978, J IMMUNOL, V121, P2035; RUSSELL SW, 1977, J EXP MED, V146, P1511, DOI 10.1084/jem.146.6.1511; RUSSELL SW, 1980, J RETICULOENDOTH SOC, V27, P607; Sambrook J, 1989, MOL CLONING LABORATO; STEEG PS, 1982, J EXP MED, V156, P1780, DOI 10.1084/jem.156.6.1780; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1987, J IMMUNOL, V139, P518; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TANNENBAUM CS, 1988, J IMMUNOL, V140, P3640; UCLA C, 1990, J CLIN INVEST, V85, P185, DOI 10.1172/JCI114411; WYNN TA, 1991, J IMMUNOL, V147, P4384; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	47	627	643	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1908	1913						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678412				2022-12-25	WOS:A1993KH62000063
J	TSURUOKA, T; TSUJI, T; NOJIRI, H; HOLMES, EH; HAKOMORI, S				TSURUOKA, T; TSUJI, T; NOJIRI, H; HOLMES, EH; HAKOMORI, S			SELECTION OF A MUTANT-CELL LINE BASED ON DIFFERENTIAL EXPRESSION OF GLYCOSPHINGOLIPID, UTILIZING ANTI-LACTOSYLCERAMIDE ANTIBODY AND COMPLEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINIDE 3-ALPHA-L-FUCOSYLTRANSFERASE; RESISTANT MELANOMA CLONE; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODY; RAT-LIVER; GANGLIOSIDE; GLYCOPROTEINS; INDUCTION; VARIANTS; GM3	A mouse mammary carcinoma mutant cell line showing a characteristic alteration of glycosphingolipid (GSL) composition, but with unchanged protein glycosylation pattern, was isolated. Parent cell line FM3A/F28-7 is characterized by the predominance of lactosylceramide (LacCer) and virtual absence of more complex GSLs. Mutant cell line FUA169 was isolated after treatment of F28-7 cells with the mutagen N-methyl-N'-nitro-N-nitrosoguanidine and incubation with anti-LacCer monoclonal antibody T5A7 and complement. FUA169 cells were characterized by a dramatic reduction in LacCer and by the presence of a major ganglioside identified as G(M3). They also showed high activity of CMP-sialic acid:LacCer 2,3-sialosyltransferase, whereas F28-7 cells had no detectable activity of this enzyme. In contrast to the difference in GSL pattern, F28-7 and FUA169 showed identical protein glycosylation patterns, as evidenced by ''Western blotting'' with various lectins and surface labeling with galactose oxidase/(NaBH4)-H-3 and periodate/(NaBH4)-H-3. Thus, FUA169 is identified as a glycosylation mutant with regard to G(M3) expression and will be useful for studies of the functional role of G(M3). Growth of FUA169 cells, relative to F28-7 cells, showed greater temperature sensitivity and greater inhibitability based on restriction of growth factors, particularly insulin.	BIOMEMBRANE INST,201 ELLIOT AVE W,SEATTLE,WA 98119; FRED HUTCHINSON CANC RES CTR,DEPT BIOCHEM ONCOL MEMBRANE RES,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98119; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98119; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98119	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL CANCER INSTITUTE [R35CA042505, R01CA020026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023100] Funding Source: NIH RePORTER; NCI NIH HHS [CA42505, CA20026] Funding Source: Medline; NIGMS NIH HHS [GM23100] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYUSAWA D, 1980, SOMAT CELL GENET, V6, P261, DOI 10.1007/BF01538800; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CAMPBELL C, 1983, CELL, V35, P303, DOI 10.1016/0092-8674(83)90233-7; CAMPBELL C, 1984, J BIOL CHEM, V259, P1208; DEN H, 1971, J BIOL CHEM, V246, P2721; FINNE J, 1980, CANCER RES, V40, P2580; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; GOTTLIEB C, 1976, J BIOL CHEM, V251, P7761; GOTTLIEB C, 1974, P NATL ACAD SCI USA, V71, P1078, DOI 10.1073/pnas.71.4.1078; HAKOMORI S, 1984, MONOCLONAL ANTIBODIE, P67; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HAKOMORI SI, 1983, SPHINGOLIPID BIOCH, P1; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; HOLMES EH, 1983, J BIOL CHEM, V258, P3706; HYMAN R, 1974, JNCI-J NATL CANCER I, V52, P963, DOI 10.1093/jnci/52.3.963; KANNAGI R, 1982, J BIOL CHEM, V257, P4438; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; MEAGER A, 1975, NATURE, V257, P137, DOI 10.1038/257137a0; NAOI M, 1974, ANAL BIOCHEM, V58, P571, DOI 10.1016/0003-2697(74)90226-7; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; PRIEELS JP, 1983, EUR J BIOCHEM, V130, P347, DOI 10.1111/j.1432-1033.1983.tb07159.x; SCHENGRUND CL, 1973, J BIOL CHEM, V248, P4424; SENN HJ, 1981, EUR J BIOCHEM, V120, P59, DOI 10.1111/j.1432-1033.1981.tb05670.x; SWEELEY CC, 1985, ANNU REV BIOCHEM, V54, P765, DOI 10.1146/annurev.biochem.54.1.765; SYMINGTON FW, 1984, J BIOL CHEM, V259, P6008; TAO TW, 1977, NATURE, V270, P437, DOI 10.1038/270437a0; WATANABE K, 1981, J LIPID RES, V22, P1020; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; WRIGHT JA, 1973, J CELL BIOL, V56, P666, DOI 10.1083/jcb.56.3.666; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	32	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2211	2216						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678417				2022-12-25	WOS:A1993KH62000106
J	HOCKERMAN, GH; JOHNSON, BD; SCHEUER, T; CATTERALL, WA				HOCKERMAN, GH; JOHNSON, BD; SCHEUER, T; CATTERALL, WA			MOLECULAR DETERMINANTS OF HIGH-AFFINITY PHENYLALKYLAMINE BLOCK OF L-TYPE CALCIUM CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SKELETAL-MUSCLE; ALPHA-1 SUBUNIT; RECEPTOR; EXPRESSION; CLONING; D600; SITE	The high affinity phenylalkylamine (-)D888 blocks ion currents through L-type Ca2+ channels containing the alpha(1C) subunit with an apparent K-d of 50 nM, but N-type Ca2+ channels in the pheochromocytoma cell line PC12 are blocked with a 100-fold higher K-d value of 5 mu M. L-type Ca2+ channels containing alpha(1C) subunits with the site-directed mutations Y1463A, A1467S, or I1470A in the putative transmembrane segment S6 in domain IV (IVS6) were 6-12 times less sensitive to block. by (-)D888 than control alpha(1C). Ca2+ channels containing paired combinations of these mutations were even less sensitive to block by (-)D888 than the single mutants, and channels containing all three mutations were > 100 times less sensitive to (-)D888 block, similar to N-type Ca2+ channels, In addition, the Y1463A mutant and all combination mutants including the Y1463A mutation had altered ion selectivity, suggesting that Tyr-1463 faces the pore and is involved in ion permeation. Since these three critical amino acid residues are aligned on the same face of the putative IVS6 alpha-helix, we propose that they contribute to a receptor site in the pore that confers a high affinity block of L-type channels by (-)D888.			HOCKERMAN, GH (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.				NHLBI NIH HHS [P01 HL44948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; CATTERALL WA, 1994, CURR OPIN CELL BIOL, V6, P607, DOI 10.1016/0955-0674(94)90083-3; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; EHARA T, 1978, J PHARMACOL EXP THER, V207, P49; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; ERDMANN R, 1989, J PHYSIOL-LONDON, V413, P521, DOI 10.1113/jphysiol.1989.sp017667; Fleckenstein A, 1980, Eur Heart J, V1, P15; GOLL A, 1984, FEBS LETT, V176, P371, DOI 10.1016/0014-5793(84)81199-0; GRANTHAM CJ, 1984, BRIT J PHARMACOL, V111, P483; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HESCHELER J, 1982, PFLUG ARCH EUR J PHY, V393, P287, DOI 10.1007/BF00581411; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MARGOLSKEE RF, 1994, BIOTECHNIQUES, V15, P906; MCDONALD TF, 1984, J PHYSIOL-LONDON, V352, P217, DOI 10.1113/jphysiol.1984.sp015288; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; SHIEH CC, 1994, BIOPHYS J, V67, P2316, DOI 10.1016/S0006-3495(94)80718-0; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; STRIESSNIG J, 1987, FEBS LETT, V212, P247, DOI 10.1016/0014-5793(87)81354-6; TAGLIALATELA M, 1994, J BIOL CHEM, V269, P13867; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0	25	113	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22119	22122		10.1074/jbc.270.38.22119	http://dx.doi.org/10.1074/jbc.270.38.22119			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673189	hybrid			2022-12-25	WOS:A1995RW31400012
J	HOPKINS, C; GRILLEY, M; MILLER, C; SHON, KJ; CRUZ, LJ; GRAY, WR; DYKERT, J; RIVIER, J; YOSHIKAMI, D; OLIVERA, BM				HOPKINS, C; GRILLEY, M; MILLER, C; SHON, KJ; CRUZ, LJ; GRAY, WR; DYKERT, J; RIVIER, J; YOSHIKAMI, D; OLIVERA, BM			A NEW FAMILY OF CONUS PEPTIDES TARGETED TO THE NICOTINIC ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEOGRAPHUS VENOM; ALPHA-CONOTOXIN; OMEGA-CONOTOXIN; PURIFICATION; SPECTROSCOPY; CHANNELS	In this work, a new family of Conus peptides, the alpha A-conotoxins, which target the nicotinic acetylcholine receptor, is defined, The first members of this family have been characterized from the eastern Pacific species, Conus purpurascens (the purple cone); three peptides that cause paralysis in fish were purified and characterized from milked venom, The sequence and disulfide bonding pattern of one of these, alpha A-conotoxin PIVA, is as follows: [GRAPHICS] where O represents trans 4-hydroxyproline. The two other peptides purified from C. purpurascens venom are the under-hydroxylated derivatives, [Pro(13)]alpha A-conotoxin PIVA and [Pro(7,13)]alpha A-conotoxin PNA. The peptides have been chemically synthesized in a biologically active form, Both electrophysiological experiments and competition binding with alpha-bungarotoxin demonstrate that alpha A-PIVA acts as an antagonist of the nicotinic acetylcholine receptor at the postsynaptic membrane.	UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112; SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037; UNIV PHILIPPINES,INST MARINE SCI,QUEZON 1101,PHILIPPINES	Utah System of Higher Education; University of Utah; Salk Institute; University of the Philippines System; University of the Philippines Diliman				Hopkins, Chris/0000-0002-6981-6329	NIGMS NIH HHS [P01 GM 28677] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028677] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRUZ LJ, 1983, NRCP SALIGANG SALIKS, V2, P118; FAINZILBER M, 1994, J BIOL CHEM, V269, P2574; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GRAY WR, 1993, PROTEIN SCI, V2, P1749, DOI 10.1002/pro.5560021018; GRAY WR, 1981, J BIOL CHEM, V256, P4734; KOBAYASHI Y, 1989, BIOCHEMISTRY-US, V28, P4853, DOI 10.1021/bi00437a050; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; MYERS RA, 1993, CHEM REV, V93, P1923, DOI 10.1021/cr00021a013; MYERS RA, 1989, J NEUROSCI, V15, P678; OLIVERA BM, 1984, BIOCHEMISTRY-US, V23, P5087, DOI 10.1021/bi00317a001; PARDI A, 1989, BIOCHEMISTRY-US, V28, P5494, DOI 10.1021/bi00439a026; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; RIVIER J, 1987, J BIOL CHEM, V262, P1194; RIVIER J, 1984, J CHROMATOGR, V288, P303, DOI 10.1016/S0021-9673(01)93709-4; YOSHIKAMI D, 1989, ANN NY ACAD SCI, V560, P230, DOI 10.1111/j.1749-6632.1989.tb24100.x; ZAFARALLA GC, 1988, BIOCHEMISTRY-US, V27, P7102, DOI 10.1021/bi00418a065	17	123	129	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22361	22367		10.1074/jbc.270.38.22361	http://dx.doi.org/10.1074/jbc.270.38.22361			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673220	hybrid			2022-12-25	WOS:A1995RW31400047
J	KUROKI, J; HOSOYA, T; ITAKURA, M; HIROSE, S; TAMECHIKA, I; YOSHIMOTO, T; GHONEIM, MA; NARA, K; KATO, A; SUZUKI, Y; FURUKAWA, M; TACHIBANA, S				KUROKI, J; HOSOYA, T; ITAKURA, M; HIROSE, S; TAMECHIKA, I; YOSHIMOTO, T; GHONEIM, MA; NARA, K; KATO, A; SUZUKI, Y; FURUKAWA, M; TACHIBANA, S			CLONING, CHARACTERIZATION, AND TISSUE DISTRIBUTION OF PORCINE SPAI, A PROTEIN WITH A TRANSGLUTAMINASE SUBSTRATE DOMAIN AND THE WAP MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NUCLEOTIDE-SEQUENCE; 4-DISULFIDE CORE; POTENT INHIBITOR; CROSS-LINKING; K+-ATPASE; CDNA; GENE; PEPTIDE; VASOPRESSIN	The primary and gene structures and tissue distribution of porcine SPAI-2, a protein that belongs to the WAP protein superfamily and has a sodium-potassium ATPase inhibitory activity, were determined by molecular cloning and Northern analysis. A full-length cDNA clone was isolated from a porcine duodenum cDNA Library. The cDNA insert encoded a polypeptide of 187 amino acids, which is composed of three domains: a hydrophobic presequence of 21 amino acids, a prosegment of 105 amino acids ending with Asp(126), and the mature SPAI-2 sequence of 61 amino acids beginning with pro(127). The prosegment contained 16 repeats of a hexapeptide that is highly homologous to the repetitive sequence found in the transglutaminase domain of the human elafin, an elastase-specific inhibitor that also belongs to the WAP superfamily, The repetitive sequence was demonstrated to be a good substrate of transglutaminase using a recombinant preparation produced in Escherichia coli. A porcine genomic Library was then screened for the SPAI gene. Characterization and sequencing of positive clones indicated that the gene is similar to the elafin gene, having 3 exons encoding the 5'-untranslated region and signal sequence, proSPAI, and 3'-untranslated region, respectively. Northern blot analysis revealed intestine-specific expression of SPAI mRNA; the message was especially abundant in the small intestine, ProSPAI was also found in the circulation. The similarity of proSPAI to elafin in the domain structure, the acid-labile nature of the cleavage site (Asp(126)-pro(127)), and the fact that the major form of SPAI in the plasma is proSPAI strongly suggest that proSPAI is not the precursor but rather it is the native form of SPAI. Like elafin, therefore, SPAI appears to be a new type of biologically active substance with a transglutaminase substrate domain that acts as an anchoring sequence.	TOKYO INST TECHNOL,DEPT BIOL SCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN; EISAI & CO LTD,TSUKUBA RES LABS,TSUKUBA,IBARAKI 30026,JAPAN	Tokyo Institute of Technology; Eisai Co Ltd			Kato, Akira/E-6328-2010	Kato, Akira/0000-0002-9083-1443; ghoneim, magdy/0000-0003-0185-3024				ARAKI K, 1989, BIOCHEM BIOPH RES CO, V164, P496, DOI 10.1016/0006-291X(89)91747-6; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BEG OU, 1986, EUR J BIOCHEM, V159, P195, DOI 10.1111/j.1432-1033.1986.tb09852.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUTO MA, 1992, INFECT IMMUN, V60, P5042, DOI 10.1128/IAI.60.12.5042-5047.1992; DANDEKAR AM, 1982, P NATL ACAD SCI-BIOL, V79, P3987, DOI 10.1073/pnas.79.13.3987; DRENTH J, 1980, J BIOL CHEM, V255, P2652; DRENTH J, 1981, J BIOL CHEM, V256, P2601; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; FAZAL A, 1989, FEBS LETT, V257, P260, DOI 10.1016/0014-5793(89)81548-0; FIETZ MJ, 1990, J CELL BIOL, V110, P427, DOI 10.1083/jcb.110.2.427; GOODFRIEND L, 1985, MOL IMMUNOL, V22, P899, DOI 10.1016/0161-5890(85)90076-8; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HEINZEL R, 1986, EUR J BIOCHEM, V160, P61, DOI 10.1111/j.1432-1033.1986.tb09940.x; HENNIGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P2677, DOI 10.1093/nar/10.8.2677; HENNINGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P3733, DOI 10.1093/nar/10.12.3733; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; ISHIZUKA N, 1991, BIOCHIM BIOPHYS ACTA, V1069, P259, DOI 10.1016/0005-2736(91)90133-S; IVELL R, 1984, P NATL ACAD SCI-BIOL, V81, P2006, DOI 10.1073/pnas.81.7.2006; KATO I, 1979, FED PROC, V38, P832; KIRCHHOFF C, 1991, BIOL REPROD, V45, P350, DOI 10.1095/biolreprod45.2.350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landon, 1977, Methods Enzymol, V47, P145; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; MOORE JT, 1987, P NATL ACAD SCI USA, V84, P6712, DOI 10.1073/pnas.84.19.6712; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; RUPPERT S, 1984, NATURE, V308, P554, DOI 10.1038/308554a0; SAHEKI T, 1992, BIOCHEM BIOPH RES CO, V185, P240, DOI 10.1016/S0006-291X(05)80981-7; SAUSVILLE E, 1985, J BIOL CHEM, V260, P236; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; STETLER G, 1986, NUCLEIC ACIDS RES, V14, P7883, DOI 10.1093/nar/14.20.7883; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; WIEDOW O, 1990, J BIOL CHEM, V265, P14791	36	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22428	22433		10.1074/jbc.270.38.22428	http://dx.doi.org/10.1074/jbc.270.38.22428			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673229	hybrid			2022-12-25	WOS:A1995RW31400058
J	CHOI, ME; BALLERMANN, BJ				CHOI, ME; BALLERMANN, BJ			INHIBITION OF CAPILLARY MORPHOGENESIS AND ASSOCIATED APOPTOSIS BY DOMINANT-NEGATIVE MUTANT TRANSFORMING GROWTH-FACTOR-BETA RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; DEVELOPMENTAL EXPRESSION; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; FORMATION INVITRO; II RECEPTOR; ANGIOGENESIS; PROLIFERATION; FACTOR-BETA-1; ACTIVATION	Transforming growth factor-beta 1 (TGF-beta 1) induces angiogenesis in vivo and capillary morphogenesis in vitro. Two receptor serine/threonine kinases (types I and II) have been identified as signal transducing TGF-beta receptors. We explored the possibility of inhibiting TGF-beta-mediated events in glomerular capillary endothelial cells using a TGF-beta type II receptor (TPR-II) transdominant negative mutant. A mutant TGF-beta type II receptor (T beta R-IIM), lacking the cytoplasmic serine/threonine kinase domain, was produced by polymerase chain reaction using rat T beta R-II cDNA as template. Since T beta R-II and TGF-beta type I receptor (T beta R-I) heterodimerize for signal transduction, the mutant receptor competes for binding to wild-type T beta R-I, hence acting in a dominant negative fashion. Glomerular capillary endothelial cells were stably transfected with T beta R-IIM, and four independent clones were expanded. That the T beta R-IIM mRNA was expressed was shown by reverse transcriptase-polymerase chain reaction. RNase protection assay, and Northern analysis. Presence of cell surface T beta R-IIM protein was shown by affinity cross-linking with I-125-TGF-beta 1. In wild-type endothelial cells, TGF-beta 1 (2 ng/ml) significantly inhibited [H-3]thymidine incorporation to 63 +/- 10% of control (n = 4). In transfected endothelial cells carrying T beta R-IIM, TGF-beta 1 stimulated [H-3]thymidine incorporation to 131 +/- 9% of control (n = 4, p < 0.005). Also, in wild-type endothelial cells, endogenous and exogenous TGF-beta 1 induced apoptosis and associated capillary formation. Both apoptosis and capillary formation were uniformly and entirely absent in transfected endothelial. cells carrying T beta R-IIM. This represents the first demonstration that capillary morphogenesis in vitro is associated with apoptosis, and that interference with T beta R-II signaling inhibits this process in glomerular capillary endothelial cells.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	Johns Hopkins University	CHOI, ME (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DIV NEPHROL,BALTIMORE,MD 21205, USA.		Ballermann, Barbara J/G-5349-2016	Ballermann, Barbara J/0000-0002-8220-6381	NIDDK NIH HHS [5-K12-DK0129809] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JC, 1993, DEVELOPMENT, V117, P183; BALLERMANN BJ, 1989, AM J PHYSIOL, V256, pC182, DOI 10.1152/ajpcell.1989.256.1.C182; BRAND T, 1993, J BIOL CHEM, V268, P11500; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHOI ME, 1993, KIDNEY INT, V44, P948, DOI 10.1038/ki.1993.336; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FOLKMAN J, 1987, SCIENCE, V235, P42; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GEISER AG, 1992, J BIOL CHEM, V267, P2588; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; NGUYEN M, 1992, J BIOL CHEM, V267, P26157; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SANDBERG M, 1988, DEVELOPMENT, V102, P461; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WISEMAN DM, 1988, BIOCHEM BIOPH RES CO, V157, P793, DOI 10.1016/S0006-291X(88)80319-X; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731; ZENTELLA A, 1992, P NATL ACAD SCI USA, V89, P5176, DOI 10.1073/pnas.89.11.5176	41	121	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21144	21150		10.1074/jbc.270.36.21144	http://dx.doi.org/10.1074/jbc.270.36.21144			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673146	hybrid			2022-12-25	WOS:A1995RU05400045
J	FIRTH, JD; EBERT, BL; RATCLIFFE, PJ				FIRTH, JD; EBERT, BL; RATCLIFFE, PJ			HYPOXIC REGULATION OF LACTATE-DEHYDROGENASE-A - INTERACTION BETWEEN HYPOXIA-INDUCIBLE FACTOR-1 AND CAMP RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; GLUCAGON-DEPENDENT ACTIVATION; RAT HEPATOCYTE CULTURES; HEME PROTEIN; TRANSCRIPTIONAL ENHANCER; FUNCTIONAL-ANALYSIS; OXYGEN SENSOR; CYCLIC-AMP; FACTOR-I	The oxygen-regulated control system responsible for the induction of erythropoietin (Epo) by hypoxia is present in most (if not all) cells and operates on other genes, including those involved in energy metabolism. To understand the organization of cis-acting sequences that are responsible for oxygen-regulated gene expression, we have studied the 5' flanking region of the mouse gene encoding the hypoxically inducible enzyme lactate dehydrogenase A (LDH). Deletional and mutational analysis of the function of mouse LDH-reporter fusion gene constructs in transient transfection assays defined three domains, between -41 and -84 base pairs up stream of the transcription initiation site, which were crucial for oxygen-regulated expression, The most important of these, although not capable of driving hypoxic induction in isolation, had the consensus of a hypoxia-inducible factor 1 (HIF-1) site, and cross-competed for the binding of HIF-1 with functionally active Epo and phosphoglycerate kinase-1 sequences. The second domain was positioned close to the HIF-1 site, in an analogous position to one of the critical regions in the Epo 3' hypoxic enhancer, The third domain had the motif of a cAMP response element (CRE), Activation of cAMP by forskolin had no effect on the level of LDH mRNA in normoxia, but produced a magnified response to hypoxia that was dependent upon the integrity of the CRE, indicating an interaction between inducible factors binding the HIF-1 and CRE sites.			FIRTH, JD (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,ERYTHROPOIETIN GRP,RM 420,OXFORD OX3 9DU,ENGLAND.			Ratcliffe, Peter/0000-0002-2853-806X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BECK I, 1993, BLOOD, V82, P704; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GORLACH A, 1994, FEBS LETT, V348, P216, DOI 10.1016/0014-5793(94)00607-5; JUNGMANN RA, 1982, J BIOL CHEM, V258, P5312; KIETZMANN T, 1992, FEBS LETT, V311, P251, DOI 10.1016/0014-5793(92)81113-Z; KIETZMANN T, 1993, BIOCHEM BIOPH RES CO, V195, P792, DOI 10.1006/bbrc.1993.2115; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; LOIKE JD, 1992, AM J PHYSIOL, V263, pC326, DOI 10.1152/ajpcell.1992.263.2.C326; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MARKERT CL, 1975, SCIENCE, V189, P102, DOI 10.1126/science.1138367; MARTI HH, 1994, PFLUG ARCH EUR J PHY, V429, P216, DOI 10.1007/BF00374315; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MILES MF, 1981, J BIOL CHEM, V256, P2545; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; ROBIN ED, 1984, J CELL PHYSIOL, V118, P287, DOI 10.1002/jcp.1041180311; RODGERS GM, 1972, P SOC EXP BIOL MED, V140, P977; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHORT S, 1991, J BIOL CHEM, V266, P22164; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WEBSTER KA, 1987, MOL CELL BIOCHEM, V77, P19; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; WOLFLE D, 1985, EUR J BIOCHEM, V151, P299, DOI 10.1111/j.1432-1033.1985.tb09100.x	34	392	401	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21021	21027		10.1074/jbc.270.36.21021	http://dx.doi.org/10.1074/jbc.270.36.21021			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673128	hybrid			2022-12-25	WOS:A1995RU05400025
J	HULETT, MD; WITORT, E; BRINKWORTH, RI; MCKENZIE, IFC; HOGARTH, PM				HULETT, MD; WITORT, E; BRINKWORTH, RI; MCKENZIE, IFC; HOGARTH, PM			MULTIPLE REGIONS OF HUMAN FC-GAMMA-RII (CD32) CONTRIBUTE TO THE BINDING OF IGG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER CELLS; EPSILON-RI; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; ALPHA-SUBUNIT; RECEPTOR; EXPRESSION; IDENTIFICATION; POLYMORPHISM; ANTIGEN	The low affinity receptor for IgG, Fc gamma RII (CD32), has a wide distribution on hematopoietic cells where it is responsible for a diverse range of cellular responses crucial for immune regulation and resistance to infection. Fc gamma RII is a member of the immunoglobulin superfamily, containing an extracellular region of two Ig-like domains. The IgG binding site of human Fc gamma RII has been localized to an 8-amino acid segment of the second extracellular domain, Asn(154)-Ser(161). In this study, evidence is presented to suggest that domain 1 and two additional regions of domain 2 also contribute to the binding of IgG by Fc gamma RII. Chimeric receptors generated by exchanging the extracellular domains and segments of domain 2 between Fc gamma RII and the structurally related Fc epsilon RI alpha chain were used to demonstrate that substitution of domain 1 in its entirety or the domain 2 regions encompassing residues Ser(109)-Val(116) and Ser(130)-Thr(135) resulted in a loss of the ability of these receptors to bind hIgG1 in dimeric form. Site-directed mutagenesis performed on individual residues within and flanking the Ser(109)-Val(116) and Ser(130)-Thr(135) domain 2 segments indicated that substitution of Lys(113), Pro(114), Leu(115), Val(116), Phe(129) and His(131) profoundly decreased the binding of hIgG1, whereas substitution of Asp(133) and Pro(134) increased binding. These findings suggest that not only is domain 1 contributing to the affinity of IgG binding by Fc gamma RII but, importantly, that the domain 2 regions Ser(109)-Val(116) and Phe(129)-Thr(135) also play key roles in the binding of hIgG1. The location of these binding regions on a molecular model of the entire extracellular region of Fc gamma RII indicates that they comprise loops that are juxtaposed in domain 2 at the interface with domain 1, with the putative crucial binding residues forming a hydrophobic pocket surrounded by a wall of predominantly aromatic and basic residues.	AUSTIN HOSP,AUSTIN RES INST,HEIDELBERG,VIC 3084,AUSTRALIA; UNIV QUEENSLAND,CTR DRUG DESIGN & DEV,BRISBANE,QLD 4072,AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Queensland			Hulett, Mark D/C-4160-2012	Hogarth, Mark/0000-0002-0360-7890; Hulett, Mark/0000-0003-2072-5968				ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FARBER DL, 1993, J IMMUNOL, V1504, P4364; GOSSELIN EJ, 1990, J IMMUNOL, V144, P1817; GRAZIANO RF, 1987, J IMMUNOL, V139, P3536; HARLOW E, 1988, ANTIBODIES LABORATOR, P328; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; HIBBS ML, 1985, IMMUNOGENETICS, V22, P335, DOI 10.1007/BF00430917; HIBBS ML, 1994, J IMMUNOL, V152, P4466; HOGARTH PM, 1992, IMMUNOL REV, V125, P21, DOI 10.1111/j.1600-065X.1992.tb00623.x; HORTON RM, 1988, GENE AMST, V77, P61; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; HULETT MD, 1994, J BIOL CHEM, V269, P15287; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; IERINO FL, 1993, J IMMUNOL, V150, P1794; LAH M, 1990, IMMUNOGENETICS, V31, P202, DOI 10.1007/BF00211557; LOPEZ AF, 1983, IMMUNOLOGY, V48, P503; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MALLAMACI MA, 1993, J BIOL CHEM, V268, P22076; PARISH CR, 1974, PROC R SOC SER B-BIO, V187, P47, DOI 10.1098/rspb.1974.0060; PIETERSZ GA, CANCER RES, V48, P4469; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; RIGLEY KP, 1989, EUR J IMMUNOL, V19, P481, DOI 10.1002/eji.1830190311; RISKE F, 1991, J BIOL CHEM, V266, P11245; ROBINSON MW, 1993, J IBOL CHEM, V268, P12736; Sambrook J, 1989, MOL CLONING LABORATO; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; STENGELIN S, 1988, EMBO J, V7, P1053, DOI 10.1002/j.1460-2075.1988.tb02913.x; STUART SG, 1987, J EXP MED, V166, P1668, DOI 10.1084/jem.166.6.1668; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; TATE BJ, 1992, IMMUNOL CELL BIOL, V70, P79, DOI 10.1038/icb.1992.12; TAX WJM, 1983, NATURE, V304, P445, DOI 10.1038/304445a0; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WARMERDAM PAM, 1991, J IMMUNOL, V147, P1338; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	43	57	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21188	21194		10.1074/jbc.270.36.21188	http://dx.doi.org/10.1074/jbc.270.36.21188			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673151	hybrid			2022-12-25	WOS:A1995RU05400051
J	SASAKI, H; NAGURA, K; ISHINO, M; TOBIOKA, H; KOTANI, K; SASAKI, T				SASAKI, H; NAGURA, K; ISHINO, M; TOBIOKA, H; KOTANI, K; SASAKI, T			CLONING AND CHARACTERIZATION OF CELL-ADHESION KINASE-BETA, A NOVEL PROTEIN-TYROSINE KINASE OF THE FOCAL ADHESION KINASE SUBFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION; PP125(FAK); EXPRESSION; IDENTIFICATION; ACTIVATION; RECEPTORS; TRANSFORMATION; CONSTRUCTION; LYMPHOCYTE; EFFICIENT	A second protein-tyrosine kinase (PTK) of the focal adhesion kinase (FAK) subfamily, cell adhesion kinase beta (CAK beta), was identified by cDNA cloning. The rat CAK beta is a 115.7-kDa PTK that contains N- and C-terminal domains of 418 and 330 amino acid residues besides the central kinase domain, The rat CAK beta has a homology with mouse FAK over their entire lengths except for the extreme N-terminal 88 residues and shares 45% overall sequence identity (60% identical in the catalytic domain), which indicates that CAK beta is a protein structurally related to but different from FAK. The CAK beta gene is less evenly expressed in a variety of rat organs than the FAK gene, Anti-CAK beta antibody immunoprecipitated a 113-kDa protein from rat brain, 3Y1 fibroblasts, and COS-7 cells transfected with CAK beta cDNA, The tyrosine-phosphorylated state of CAK beta was not reduced on trypsinization, nor enhanced in response to plating 3Y1 cells onto fibronectin, CAK beta localized to sites of cell-to-cell contact in COS-7 transfected with CAK beta cDNA, in which FAK was found at the bottom of the cells. Thus, CAK beta is a PTK possibly participating in the signal transduction regulated by cell-to-cell contacts.	SAPPORO MED UNIV, SCH MED, CANC RES INST, DEPT BIOCHEM, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN; SAPPORO MED UNIV, SCH MED, DEPT PATHOL, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN	Sapporo Medical University; Sapporo Medical University								AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASEGAWASASAKI H, 1988, J BIOL CHEM, V263, P12970; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MURAKAMI T, 1993, BIOIMAGES, V1, P1; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; RANKIN S, 1994, J BIOL CHEM, V269, P704; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA H, 1988, J CELL PHYSIOL, V136, P421, DOI 10.1002/jcp.1041360305; TANIGUCHI T, 1994, ONCOGENE, V9, P861; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; YAGIHASHI A, 1988, CANCER RES, V48, P2798; YAMASHITA Y, 1991, FEBS LETT, V288, P46, DOI 10.1016/0014-5793(91)81000-X; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHANG C, 1994, J BIOL CHEM, V269, P25247; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	349	363	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21206	21219		10.1074/jbc.270.36.21206	http://dx.doi.org/10.1074/jbc.270.36.21206			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673154	hybrid			2022-12-25	WOS:A1995RU05400054
J	RAO, S; ORR, GA; CHAUDHARY, AG; KINGSTON, DGI; HORWITZ, SB				RAO, S; ORR, GA; CHAUDHARY, AG; KINGSTON, DGI; HORWITZ, SB			CHARACTERIZATION OF THE TAXOL BINDING-SITE ON THE MICROTUBULE - 2-(M-AZIDOBENZOYL)TAXOL PHOTOLABELS A PEPTIDE (AMINO-ACIDS 217-231) OF BETA-TUBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POLYACRYLAMIDE-GEL ELECTROPHORESIS; ASSEMBLY INVITRO; PROTEINS; IDENTIFICATION; COLCHICINE; MECHANISM; CLEAVAGE; ABSENCE; AGENT	Photoaffinity labeling methods are being used to define the molecular contacts between taxol and its target protein, tubulin. Our laboratory has demonstrated previously that [H-3]3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin (Rao, S., Krauss, N. E., Heerding, J. M., Swindell, C. S., Ringel, I., Orr, G. A., and Horwitz, S. B. (1994) J. Biol. Chem. 269, 3132-3134). The interaction of a second photoaffinity analogue of taxol, [H-3]2-(m-azidobenzoyl)taxol, with tubulin has been investigated. This analogue specifically photolabels beta-tubulin and the photolabeling is competed by both taxol and unlabeled 2-(m-azidobenzoyl)taxol indicating a common binding domain. To identify the site(s) of photoincorporation, [H-3]2-(m-azidobenzoyl)taxol-photolabeled beta-tubulin was subjected to sequential cyanogen bromide and tryptic digestions. Radiolabeled peptides were purified by reverse phase high performance liquid chromatography, and amino acid sequencing studies identified a peptide containing amino acid residues 217-231 of beta-tubulin as the major photolabeled domain.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461; VIRGINIA POLYTECH INST & STATE UNIV,DEPT CHEM,BLACKSBURG,VA 24061	Yeshiva University; Albert Einstein College of Medicine; Virginia Polytechnic Institute & State University			Kingston, David G. I./B-4272-2009	Kingston, David G. I./0000-0001-8944-246X	NCI NIH HHS [CA13330, CA56677, CA39821] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056677, R35CA039821, P30CA013330] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL HM, 1969, J ORG CHEM, V34, P3923, DOI 10.1021/jo01264a038; CHUDHARY AG, 1994, J AM CHEM SOC, V116, P4097; DERRY WB, 1995, BIOCHEMISTRY-US, V34, P2203, DOI 10.1021/bi00007a014; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; GROVER S, 1995, BIOCHEMISTRY-US, V34, P3927, DOI 10.1021/bi00012a009; GURD FRN, 1967, METHOD ENZYMOL, V11, P532; HALL JL, 1983, MOL CELL BIOL, V3, P854, DOI 10.1128/MCB.3.5.854; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; HORWITZ SB, 1982, COLD SPRING HARB SYM, V46, P219; JAYARAM B, 1994, J BIOL CHEM, V269, P3233; KINGSTON DGI, 1994, TRENDS BIOTECHNOL, V12, P222, DOI 10.1016/0167-7799(94)90120-1; KUMAR N, 1981, J BIOL CHEM, V256, P435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MGS, 1984, NUCLEIC ACIDS RES, V12, P5823, DOI 10.1093/nar/12.14.5823; LITTLE M, 1987, BIOCHIM BIOPHYS ACTA, V912, P28, DOI 10.1016/0167-4838(87)90243-3; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; PARNESS J, 1982, BIOCHEM BIOPH RES CO, V105, P1082, DOI 10.1016/0006-291X(82)91080-4; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1992, J NATL CANCER I, V84, P785, DOI 10.1093/jnci/84.10.785; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIFF PB, 1981, BIOCHEMISTRY-US, V20, P3247, DOI 10.1021/bi00514a041; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SONDEREGGER P, 1982, ANAL BIOCHEM, V122, P298, DOI 10.1016/0003-2697(82)90285-8; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; WILSON L, 1973, J CELL BIOL, V58, P709, DOI 10.1083/jcb.58.3.709; Wilson Leslie, 1994, V13, P59	32	218	233	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20235	20238		10.1074/jbc.270.35.20235	http://dx.doi.org/10.1074/jbc.270.35.20235			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657589	hybrid			2022-12-25	WOS:A1995RR58400001
J	COTTRELL, TJ; HARRIS, LJ; TANAKA, T; YADA, RY				COTTRELL, TJ; HARRIS, LJ; TANAKA, T; YADA, RY			THE SOLE LYSINE RESIDUE IN PORCINE PEPSIN WORKS AS A KEY RESIDUE FOR CATALYSIS AND CONFORMATIONAL FLEXIBILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ASPARTIC PROTEINASES; ACTIVE-SITE; CHYMOSIN; RESOLUTION; INCLUSION; EFFICIENT; REVEALS	Pepsin contains a single lysine residue which protrudes from the enzyme's surface, behind the active site cleft, on the C-terminal domain. Mutations of pepsin by site-directed mutagenesis of the Lys-319 residue were generated to study the structure-function relationships. Kinetic parameters, pH activity profiles, along with conformational analysis using circular dichroism (CD), and molecular modelling were examined for the wild-type (non-mutant) and mutant enzymes. The pepsin mutations, Lys-319 --> Met and Lys-319 --> Glu, resulted in a progressive increase in the K-m and similar decrease in k(cat), respectively, as well as being denatured at a lower pH than the wild-type pepsin. CD analysis indicated that mutations at Lys-319 resulted in changes in secondary structure fractions which were reflected in changes in enzymatic activity as compared to the wild-type pepsin, i.e. kinetic data and pH denaturation study. Molecular modelling of mutant enzymes indicated differences in flexibility in the flap loop region of the active site, the region around the entrance of the active site cleft, subsite regions for peptide binding, and in the subdomains of the C-terminal domain when compared to the wildtype enzyme. The results suggest that Lys-319, which is distal to the active site, is important to the flexibility/stability of the enzyme, as well as to its catalytic machinery.	UNIV GUELPH, DEPT FOOD SCI, GUELPH, ON N1G 2W1, CANADA	University of Guelph			Tanaka, Takuji/AAN-8462-2020; Harris, Linda J/B-5030-2011; Yada, Rickey Y/A-8289-2013	Harris, Linda J/0000-0002-1911-752X; Yada, Rickey/0000-0002-8648-2156				ABADZAPATERO C, 1990, PROTEINS, V8, P62, DOI 10.1002/prot.340080109; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN LQ, 1992, ACTA CRYSTALLOGR B, V48, P476, DOI 10.1107/S0108768192001939; CONRAD M, 1979, B MATH BIOL, V41, P387, DOI 10.1016/S0092-8240(79)90019-3; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P26; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; ENGLARD S, 1990, METHOD ENZYMOL, V182, P285; FUSEK M, 1990, J BIOL CHEM, V265, P1496; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN XL, 1989, J BIOL CHEM, V264, P4482; LIN XL, 1992, J BIOL CHEM, V267, P17257; LIN XL, 1993, PROTEIN SCI, V2, P1383, DOI 10.1002/pro.5560020903; Northrop JH, 1930, J GEN PHYSIOL, V13, P739, DOI 10.1085/jgp.13.6.739; PEARL L, 1984, FEBS LETT, V174, P96, DOI 10.1016/0014-5793(84)81085-6; PITTS JE, 1992, SCAND J CLIN LAB INV, V52, P39, DOI 10.3109/00365519209104653; RYLE AP, 1966, BIOCHEM J, V98, P485, DOI 10.1042/bj0980485; Sambrook J, 1989, MOL CLONING LABORATO; SUZUKI J, 1990, PROTEIN ENG, V4, P69, DOI 10.1093/protein/4.1.69; SUZUKI J, 1989, PROTEIN ENG, V2, P563, DOI 10.1093/protein/2.7.563; TICHY PJ, 1993, PROTEIN EXPRES PURIF, V4, P59, DOI 10.1006/prep.1993.1009; VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98; WILLIAMS RJP, 1993, TRENDS BIOCHEM SCI, V18, P115, DOI 10.1016/0968-0004(93)90015-F; YADA RY, 1986, J FOOD BIOCHEM, V10, P155, DOI 10.1111/j.1745-4514.1986.tb00098.x; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	26	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19974	19978		10.1074/jbc.270.34.19974	http://dx.doi.org/10.1074/jbc.270.34.19974			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650014	hybrid			2022-12-25	WOS:A1995RQ99100047
J	HERSHENSON, MB; CHAO, TSO; ABE, MK; GOMES, I; KELLEHER, MD; SOLWAY, J; ROSNER, MR				HERSHENSON, MB; CHAO, TSO; ABE, MK; GOMES, I; KELLEHER, MD; SOLWAY, J; ROSNER, MR			HISTAMINE ANTAGONIZES SEROTONIN AND GROWTH FACTOR-INDUCED MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION IN BOVINE TRACHEAL SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; PATHWAYS; ASTHMA; RAF; BRONCHOCONSTRICTION; PHOSPHORYLATION; STIMULATION; INHIBITION; CAMP	We examined the effects of the bronchoconstrictor agonists serotonin (5-hydroxytryptamine; 5-HT) and histamine on mitogen-activated protein (MAP) kinase activation in cultured bovine tracheal myocytes, Kinase renaturation assays demonstrated activation of the 42-and 44-kDa MAP kinases within 2 min of 5-HT exposure, MAP kinase activation was mimicked by alpha-methyl-5-HT and reduced by pretreatment with either phorbol 12,13-dibutyrate or forskolin, suggesting activation of the 5-HT, receptor, protein kinase C, and Raf-1, respectively, Raf-1 activation was confirmed by measurement of Raf-1 activity, and the requirement of Raf-1 for 5-HT-induced MAP binase activation was demonstrated by transient transfection of cells with a dominant-negative allele of Raf-1, Histamine pretreatment significantly inhibited 5-HT and insulin-derived growth factor-1-induced MAP kinase activation, Attenuation of MAP kinase activation was reversed by cimetidine, mimicked by forskolin, and accompanied by cAMP accumulation and inhibition of Raf-1, suggesting activation of the H-2 receptor and cAMP-dependent protein kinase A. However, histamine treatment inhibited Raf-1 but not MAP kinase activation following treatment with either platelet-derived growth factor or epidermal growth factor, implying a Raf-1-independent MAP kinase activation pathway, In summary, our data suggest a model whereby 5-HT activates MAP kinase via a protein kinase C/Raf-1 pathway, and histamine attenuates MAP kinase activation by serotonin via activation of cAMP-dependent protein kinase A and inhibition of Raf-1.	UNIV CHICAGO,BEN MAY INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago; University of Chicago			Solway, Julian/B-1116-2008	Solway, Julian/0000-0002-0898-8530	NATIONAL CANCER INSTITUTE [R01CA035541] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054685] Funding Source: NIH RePORTER; NCI NIH HHS [CA35541] Funding Source: Medline; NHLBI NIH HHS [HL02731, HL54685] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE MK, 1994, AM J RESP CELL MOL, V11, P577, DOI 10.1165/ajrcmb.11.5.7946386; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BUCKNER CK, 1991, J PHARMACOL EXP THER, V257, P26; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; FLORIO C, 1992, AM J RESP CELL MOL, V7, P582, DOI 10.1165/ajrcmb/7.6.582; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HARTMANN T, 1992, AM J PHYSIOL, V262, pL528, DOI 10.1152/ajplung.1992.262.5.L528; HERSHENSON MB, 1994, AM J RESP CELL MOL, V11, P296, DOI 10.1165/ajrcmb.11.3.8086167; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JOHNSON DE, 1989, AM REV RESPIR DIS, V140, P1807, DOI 10.1164/ajrccm/140.6.1807; KAO LC, 1984, PEDIATRICS, V73, P509; KELLEHER MD, 1995, IN PRESS AM J PHYSL; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOTLIKOFF MI, 1987, AM J PHYSIOL, V253, pC561, DOI 10.1152/ajpcell.1987.253.4.C561; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MARGRAF LR, 1992, AM REV RESPIR DIS, V143, P391; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; NEMECEK GM, 1986, P NATL ACAD SCI USA, V83, P674, DOI 10.1073/pnas.83.3.674; PANETTIERI R, 1994, AM J RESP CRIT CARE, V149, pA303; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; RUSSELL M, 1994, MOL CELL BIOL, V14, P2343, DOI 10.1128/MCB.14.4.2343; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; STURGILL TW, 1986, BIOCHEM BIOPH RES CO, V134, P565, DOI 10.1016/S0006-291X(86)80457-0; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	37	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19908	19913		10.1074/jbc.270.34.19908	http://dx.doi.org/10.1074/jbc.270.34.19908			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650005	hybrid			2022-12-25	WOS:A1995RQ99100037
J	UENO, H; HIRANO, N; KOZUTSUMI, H; SASAKI, K; TANAKA, T; YAZAKI, Y; HIRAI, H				UENO, H; HIRANO, N; KOZUTSUMI, H; SASAKI, K; TANAKA, T; YAZAKI, Y; HIRAI, H			AN EPIDERMAL GROWTH-FACTOR RECEPTOR-LEUKOCYTE TYROSINE KINASE CHIMERIC RECEPTOR GENERATES LIGAND-DEPENDENT GROWTH SIGNALS THROUGH THE RAS SIGNALING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; INSULIN-RECEPTOR; EXTRACELLULAR DOMAIN; SH3 DOMAINS; HUMAN LTK; PROTEIN; GRB2; CELLS; ASSOCIATION; PHOSPHORYLATION	Leukocyte tyrosine kinase (LTK) is a receptor tyrosine kinase that belongs to the insulin receptor family. LTR is mainly expressed in pre B cells and brain, Previously we cloned the full-length cDNA of human LTR, but no ligands have so far been identified, and hence, very little is known about the physiological role of LTK. To analyze the function of the LTK kinase, we constructed chimeric receptors composed of the extracellular domain of epidermal growth factor receptor and the transmembrane and the cytoplasmic domains of LTK and established cell lines that stably express these chimeric molecules. When cultured in medium containing EGF, growth of these cell lines was stimulated, and these fusion proteins became autophosphorylated and associated with She in uiuo in a ligand-dependent manner, By treatment with EGF, She was associated with the Grb2/Ash-Sos complex, Our analyses demonstrate that LTK associates with Grb2/Ash through an internal adaptor, Shc, depending on a ligand stimulation, The LTK binding site for She was tyrosine 862 at the carboxyl-terminal domain and to a lesser extent tyrosine 485 at the juxtamembrane domain, Both of them are located in NP/AXY motif which is consistent with binding sites for She. These findings demonstrate that LTR can activate the Ras pathway in a ligand dependent manner and that at least one of the functions of this kinase is involved in the cell growth.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo			Tanaka, Tomoyuki U/A-4775-2008					BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; HAASE VH, 1991, ONCOGENE, V6, P2319; HERBST R, 1991, J BIOL CHEM, V266, P19908; KOZUTSUMI H, 1994, ONCOGENE, V9, P2991; KOZUTSUMI H, 1993, BIOCHEM BIOPH RES CO, V190, P674, DOI 10.1006/bbrc.1993.1101; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARU Y, 1990, ONCOGENE RES, V5, P199; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PANDIELLA A, 1989, ONCOGENE, V4, P1299; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SNIJDERS AJ, 1993, ONCOGENE, V8, P27; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20135	20142		10.1074/jbc.270.34.20135	http://dx.doi.org/10.1074/jbc.270.34.20135			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650032	hybrid			2022-12-25	WOS:A1995RQ99100068
J	KOTANIDES, H; MOCZYGEMBA, M; WHITE, MF; REICH, NC				KOTANIDES, H; MOCZYGEMBA, M; WHITE, MF; REICH, NC			CHARACTERIZATION OF THE INTERLEUKIN-4 NUCLEAR ACTIVATED FACTOR/STAT AND ITS ACTIVATION INDEPENDENT OF THE INSULIN-RECEPTOR SUBSTRATE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; GAMMA-CHAIN; MAP KINASE; IL-4; EXPRESSION; DISTINCT; IDENTIFICATION; LYMPHOKINE; ELEMENTS	The activation of a latent DNA binding factor by interleukin-4 (IL-4), the IL-4 nuclear activated factor (IL-4 NAF), occurs within minutes of IL-4 binding to its receptor. Molecular characterization of IL-4 NAF by ultraviolet light cross-linking experiments revealed a single protein of 120-130 kDa in contact with the DNA target site. Glycerol gradient sedimentation analysis indicated a molecular mass of IL-4 NAF consistent with a monomer that is capable of binding DNA. The IL-4 NAF target site is a palindromic sequence that is also recognized by the interferon-induced transcription factor, p91/STAT1 alpha. However, IL-4 NAF and p91/STAT1 alpha display distinguishable DNA binding specificities that may generate one level of specificity in the expression of target genes. Previous studies suggested the involvement of the insulin receptor substrate-1 (IRS-1) in the IL-4 signal transduction pathway. Although IRS-1 is involved in the stimulation of mitogenesis, our results demonstrate that activation of IL-4 NAF is independent of IRS-signaling proteins. The results of this study indicate that IL-4 stimulates bifurcating signal pathways that can direct mitogenesis via the IRS-signaling proteins and specific gene expression via the IL-4 NAF.	SUNY STONY BROOK, GRAD PROGRAM MOLEC & CELLULAR BIOL, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA; JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02215 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Harvard Medical School; Harvard University; Joslin Diabetes Center, Inc.								Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALY C, 1994, TRENDS ENDOCRIN MET, V5, P159, DOI 10.1016/1043-2760(94)90013-2; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MONROE JG, 1988, CLIN IMMUNOL IMMUNOP, V49, P292, DOI 10.1016/0090-1229(88)90119-5; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; OKUDA K, 1992, BLOOD, V79, P2880; PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476; PAUL WE, 1991, BLOOD, V77, P1859; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SUTER U, 1989, J IMMUNOL, V143, P3087; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WHITE MF, 1994, J BIOL CHEM, V269, P1; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X	39	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19481	19486		10.1074/jbc.270.33.19481	http://dx.doi.org/10.1074/jbc.270.33.19481			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642632	hybrid			2022-12-25	WOS:A1995RP70300046
J	GOGA, A; LIU, X; HAMBUCH, TM; SENECHAL, K; MAJOR, E; BERK, AJ; WITTE, ON; SAWYERS, CL				GOGA, A; LIU, X; HAMBUCH, TM; SENECHAL, K; MAJOR, E; BERK, AJ; WITTE, ON; SAWYERS, CL			P53 DEPENDENT GROWTH SUPPRESSION BY THE C-ABL NUCLEAR TYROSINE KINASE	ONCOGENE			English	Article						CELL CYCLE; GROWTH ARREST; ONCOGENE; TUMOR; SUPPRESSOR GENES	TATA-BINDING PROTEIN; CELL-CYCLE ARREST; WILD-TYPE P53; RETINOBLASTOMA PROTEIN; P53-DEFICIENT MICE; ACTIVATION DOMAIN; GENE-PRODUCT; MUTATION; DNA; PHOSPHORYLATION	Growth suppression by the Rb and p53 tumor suppressor proteins is mediated through effects on cell cycle regulatory proteins at the G1/S transition. Because overexpression of c-Abl induces G1 arrest in fibroblasts, we reasoned that c-Abl may also affect cell cycle proteins which regulate G1. We used fibroblasts containing disruptions of the Rb or p53 genes to genetically test the role of these proteins in c-Abl growth suppression. We find that c-Abl requires p53 but not Rb to suppress growth, c-Abl binds p53 in vitro and enhances p53 dependent transcription from a promoter containing p53 DNA binding sites. An Abl mutant which no longer binds p53 does not enhance p53 transcriptional activity and fails to suppress growth. These findings provide a novel link between a growth inhibitory tyrosine kinase and the p53 tumor suppressor protein.	UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles			BERK, ARNOLD/AAF-7052-2020; Sawyers, Charles/G-5327-2016					AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MATTIONI T, 1995, ONCOGENE, V10, P1325; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; NEVINS JR, 1992, SCIENCE, V258, P424; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SAWYERS CL, 1992, CANCER SURV, V15, P37; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SERRANO M, 1993, NATURE, V16, P704; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TSUKADA T, 1993, ONCOGENE, V8, P3313; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190	63	127	132	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					791	799						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651743				2022-12-25	WOS:A1995RQ46900023
J	KARP, SJ; MASU, M; EKI, T; OZAWA, K; NAKANISHI, S				KARP, SJ; MASU, M; EKI, T; OZAWA, K; NAKANISHI, S			MOLECULAR-CLONING AND CHROMOSOMAL LOCALIZATION OF THE KEY SUBUNIT OF THE HUMAN N-METHYL-D-ASPARTATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID RECEPTORS; CA2+ PERMEABILITY; XENOPUS OOCYTES; CHANNELS; ANTAGONISTS; EXPRESSION; SEQUENCE; GENES	A complementary DNA encoding the key subunit of the human N-methyl-D-aspartate (NMDA) receptor (NMDAR1) has been cloned using a probe derived from the rat NMDAR1 cDNA. The cDNA encodes a 938-amino acid protein, which shows 99% amino acid homology with the rat counterpart. Of the 7 of 938 amino acids which are different, three occur in the region of the signal peptide and the others in the extracellular amino-terminal domain preceding the 4 putative transmembrane segments. Expression in Xenopus oocytes demonstrated that the single protein encoded by the cloned cDNA possesses the electrophysiological and pharmacological properties characteristic of the NMDA receptor, including Ca2+ permeability, voltage-dependent Mg2+ block, and inhibition by selective antagonists such as Zn2+ and channel blockers. The high evolutionary conservation in the structure and properties of NMDAR1 argues strongly for the importance of this receptor in functions of glutamate neurotransmission. RNA blot analysis showed abundant expression of mRNA whose size is about 4.5 and 4.8 kilonucleotides. The human gene encoding the NMDAR1 subunit has been mapped to chromosome 9q34.3 by the analyses of blot hybridization of a DNA panel of human/hamster somatic cell hybrids and fluorescence in situ hybridization of human chromosomes.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,GENE BANK,TSUKUBA,IBARAKI 305,JAPAN	RIKEN	KARP, SJ (corresponding author), KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN.							BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DAVISSON MT, 1991, CYTOGENET CELL GENET, V58, P1152, DOI 10.1159/000133726; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; ISHII T, 1993, IN PRESS J BIOL CHEM, V268; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LEONARD JP, 1990, NEURON, V4, P53, DOI 10.1016/0896-6273(90)90443-J; LODGE D, 1990, TRENDS PHARMACOL SCI, V11, P81, DOI 10.1016/0165-6147(90)90323-Z; MACDONALD JF, 1990, TRENDS PHARMACOL SCI, V11, P167, DOI 10.1016/0165-6147(90)90070-O; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MISHINA M, 1991, BIOCHEM BIOPH RES CO, V180, P813, DOI 10.1016/S0006-291X(05)81137-4; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; OZAWA K, 1992, GENOMICS, V12, P214, DOI 10.1016/0888-7543(92)90368-3; POVEY S, 1991, CYTOGENET CELL GENET, V58, P403, DOI 10.1159/000133169; PUCKETT C, 1991, P NATL ACAD SCI USA, V88, P7557, DOI 10.1073/pnas.88.17.7557; SAKURADA K, 1993, IN PRESS J BIOL CHEM, V268; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SCHOFIELD PR, 1989, FEBS LETT, V244, P361, DOI 10.1016/0014-5793(89)80563-0; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A	33	102	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3728	3733						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679115				2022-12-25	WOS:A1993KM16100106
J	JOHNSON, GR; KANNAN, B; SHOYAB, M; STROMBERG, K				JOHNSON, GR; KANNAN, B; SHOYAB, M; STROMBERG, K			AMPHIREGULIN INDUCES TYROSINE PHOSPHORYLATION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR AND P185(ERBB2) - EVIDENCE THAT AMPHIREGULIN ACTS EXCLUSIVELY THROUGH THE EPIDERMAL GROWTH-FACTOR RECEPTOR AT THE SURFACE OF HUMAN EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-RECEPTOR; HUMAN-BREAST; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; NEU ONCOGENE; A431 CELLS; PROTEIN; GENE; LINE	The COOH-terminal half of the amphiregulin (AR) molecule has sequence homology to epidermal growth factor (EGF). The ability of AR to elicit in vivo phosphorylation of the EGF receptor (EGFR) and p185erbB2 was studied in four human epithelial cell lines which expressed either or both of the receptor tyrosine kinases. AR induced the phosphorylation of the EGFR and p185erbB2, and phosphoamino acid analysis revealed enhanced phosphorylation of tyrosine residues in both receptor proteins. A monoclonal antibody (mAb) which binds to the extracellular domain of the EGFR blocked the phosphorylation of the EGFR and p185erbB2 as well as AR-induced mitogenesis indicating that the EGFR mediated these responses. In MDA-MB-453 cells which lack EGFRs, AR did not induce phosphorylation of p185erbB2, did not affect proliferation, and had no detectable effect on the phosphorylation of cellular proteins isolated using an anti-phosphotyrosine mAb. Qualitatively, in vivo phosphorylations induced by AR and EGF were found to be indistinguishable as demonstrated by analysis of cellular P-32-labeled proteins isolated with the anti-phosphotyrosine mAb. Moreover, in the presence of the anti-EGFR mAb, AR had no effect on the proliferation of cells. These results provide strong evidence that the EGFR is the sole cell surface mediator of the action of AR in human epithelial cells.	BRISTOL MYERS SQUIBB, PHARMACEUT RES INST, SEATTLE, WA 98121 USA	Bristol-Myers Squibb	JOHNSON, GR (corresponding author), US FDA, DIV CYTOKINE BIOL,CELL BIOL LAB,HFM-511,BLDG 29A, 8800 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BACCARINI M, 1991, J BIOL CHEM, V266, P10941; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; COCHET C, 1984, J BIOL CHEM, V259, P2553; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; FRACKELTON AR, 1991, METHOD ENZYMOL, V201, P79; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; HANCOCK MC, 1991, CANCER RES, V51, P4575; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; JOHNSON GR, 1991, BIOCHEM BIOPH RES CO, V180, P481, DOI 10.1016/S0006-291X(05)81090-3; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LICHTNER RB, 1992, J BIOL CHEM, V267, P11872; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; REYNOLDS FH, 1981, NATURE, V292, P259, DOI 10.1038/292259a0; SAEKI T, 1992, CANCER RES, V52, P3467; SATO JD, 1987, METHOD ENZYMOL, V146, P63; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SOULE HD, 1990, CANCER RES, V50, P6075; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STROMBERG K, 1992, CANCER RES, V52, P341; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	60	136	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2924	2931						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679104				2022-12-25	WOS:A1993KK81500098
J	LOPEZCABRERA, M; NUEDA, A; VARA, A; GARCIAAGUILAR, J; TUGORES, A; CORBI, AL				LOPEZCABRERA, M; NUEDA, A; VARA, A; GARCIAAGUILAR, J; TUGORES, A; CORBI, AL			CHARACTERIZATION OF THE P150,95 LEUKOCYTE INTEGRIN ALPHA-SUBUNIT (CD11C) GENE PROMOTER - IDENTIFICATION OF CIS-ACTING ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIRY-CELL LEUKEMIA; REGULATED EXPRESSION; MONOCLONAL-ANTIBODIES; GLYCOPROTEIN FAMILY; MAMMALIAN-CELLS; ADHESION; TRANSCRIPTION; MAC-1; RECEPTOR; LFA-1	The leukocyte integrin p150,95 (CD11c/CD18) is involved in a number of cell-cell and cell-extracellular matrix interactions and mediates signal transduction into the cytoplasm. p150,95 is expressed on cells of the myeloid lineage as well as on certain activated T and B lymphocytes, and its expression is regulated during cell activation and differentiation. Since CD18 is expressed on all leukocyte lineages, the restricted expression of p150,95 must be controlled at the level of CD11c gene transcription. To understand the mechanisms that direct the constitutive and regulated leukocyte expression of p150,95 we have structurally characterized the CD11c promoter region and initiated its functional dissection. The CD11c promoter lacks TATA- and CCAAT-boxes, directs the synthesis of transcripts with heterogeneous 5'-ends, and contains an initiator-like sequence at the major transcription initiation site. Several putative binding sequences for ubiquitous (Sp1, AP-1, AP-2, and NF-kB) and leukocyte-specific (PU.1) transcription factors have been identified in the proximal region of the CD11c promoter which may participate in the regulation of the expression of p150,95. Transient expression of CD11c-based reporter gene constructs indicates that the CD11c promoter dictates the tissue-specific expression of p150,95 and that sequences contained within 160 base pairs 5' from the major transcriptional start site are involved in the tissue-specific and regulated expression of p150,95. DNase I protection analysis on the promoter region spanning from -160 to +40 revealed four regions of DNA-protein interactions (FPI-FPIV), two of which (FPIII and FPIV) correlate with the cell type-specific and regulated expression of the CD11c gene.	HOSP PRINCESA DIEGO LEON 62, UNIDAD BIOL MOLEC, PLANTA 9, E-28006 MADRID, SPAIN; HOSP PRINCESA, SERV INMUNOL, E-28006 MADRID, SPAIN	Hospital de La Princesa			Corbí, Angel L./ABC-8146-2020; Tugores, Antonio/AAE-7939-2021; Cabrera, Manuel López/AAA-5463-2019; Corbi, Angel/B-7194-2011	Corbí, Angel L./0000-0003-1980-5733; Corbi, Angel/0000-0003-1980-5733; Lopez Cabrera, Manuel/0000-0002-0976-9719; Nueda, Arsenio/0000-0001-8373-500X; Tugores, Antonio/0000-0002-1849-9239				AGURA ED, 1992, BLOOD, V79, P602; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANDERSON DC, 1986, J IMMUNOL, V137, P15; BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J EXP MED, V167, P1597, DOI 10.1084/jem.167.5.1597; CORBI AL, 1990, J BIOL CHEM, V265, P2782; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUITS AJ, 1991, SCAND J IMMUNOL, V33, P151, DOI 10.1111/j.1365-3083.1991.tb03745.x; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANSON CA, 1990, BLOOD, V76, P2360; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HICKSTEIN DD, 1992, P NATL ACAD SCI USA, V89, P2105, DOI 10.1073/pnas.89.6.2105; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KEIZER GD, 1987, EUR J IMMUNOL, V17, P1317, DOI 10.1002/eji.1830170915; KEIZER GD, 1987, J IMMUNOL, V138, P3130; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUDO S, 1991, J BIOL CHEM, V266, P8483; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEBEAU MM, 1985, NATURE, V313, P709, DOI 10.1038/313709a0; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; MILLER LJ, 1986, J IMMUNOL, V137, P2891; PAHL HL, 1992, BLOOD, V79, P865; POSTIGO AA, 1991, J EXP MED, V174, P1313, DOI 10.1084/jem.174.6.1313; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSMARIN AG, 1992, BLOOD, V79, P2598; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTING R, 1985, BLOOD, V65, P974; SHELLEY CS, 1991, P NATL ACAD SCI USA, V88, P10525, DOI 10.1073/pnas.88.23.10525; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STACKER SA, 1991, J IMMUNOL, V146, P648; UZAN G, 1991, J BIOL CHEM, V266, P8932	41	63	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1187	1193						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678251				2022-12-25	WOS:A1993KG07700064
J	WILLIAMSON, RA; YEA, CM; ROBSON, PA; CURNOCK, AP; GADHER, S; HAMBLETON, AB; WOODWARD, K; BRUNEAU, JM; HAMBLETON, P; MOSS, D; THOMSON, TA; SPINELLAJAEGLE, S; MORAND, P; COURTIN, O; SAUTES, C; WESTWOOD, R; HERCEND, T; KUO, EA; RUUTH, E				WILLIAMSON, RA; YEA, CM; ROBSON, PA; CURNOCK, AP; GADHER, S; HAMBLETON, AB; WOODWARD, K; BRUNEAU, JM; HAMBLETON, P; MOSS, D; THOMSON, TA; SPINELLAJAEGLE, S; MORAND, P; COURTIN, O; SAUTES, C; WESTWOOD, R; HERCEND, T; KUO, EA; RUUTH, E			DIHYDROOROTATE DEHYDROGENASE IS A HIGH-AFFINITY BINDING-PROTEIN FOR A77-1726 AND MEDIATOR OF A RANGE OF BIOLOGICAL EFFECTS OF THE IMMUNOMODULATORY COMPOUND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIMIDINE NUCLEOTIDE BIOSYNTHESIS; HWA-486; PURIFICATION; LEFLUNOMIDE; INHIBITION; DETERGENT; RECEPTOR	A protein with high affinity (K-d 12 nM) for the immunomodulatory compound A77 1726 has been isolated from mouse spleen and identified as the mitochondrial enzyme dihydroorotate dehydrogenase (EC 1.3.3.1), The purified protein had a pi 9.6-9.8 and a subunit M(r) of 43,000, Peptides derived from the mouse protein displayed high microsequence similarity to human and rat dihydroorotate dehydrogenase with, respectively, 35 and 39 out of 43 identified amino acids identical. Dihydroorotate dehydrogenase catalyzes the fourth step in de novo pyrimidine biosynthesis. The in vitro antiproliferative effects of A77 1726 are mediated by enzyme inhibition and can be overcome by addition of exogenous uridine, The rank order of potency of A77 1726 and its analogues in binding or enzyme inhibition was similar to that for inhibition of the mouse delayed type hypersensitivity response. It is proposed that inhibition of dihydroorotate dehydrogenase is an in vivo mechanism of action of the A77 1726 class of compounds. This was confirmed using uridine to counteract inhibition of the murine acute graft versus host response.	ROUSSEL UCLAF, DEPT TOXICOL, F-93235 PARIS, FRANCE; INST CURIE, INSERM, U255, F-75231 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	WILLIAMSON, RA (corresponding author), HOECHST ROUSSEL PHARMACEUT PROPRIETARY LTD, IMMUNOL DOMAIN, SWINDON SN3 5BZ, WILTS, ENGLAND.		Morand, Philippe/C-1213-2016	Morand, Philippe/0000-0003-0306-8759; sautes-fridman, catherine/0000-0003-1735-8722				BARTLETT RR, 1985, INT J IMMUNOPHARMACO, V7, P7, DOI 10.1016/0192-0561(85)90003-7; BARTLETT RR, 1989, THERAPEUTIC APPROACHES TO INFLAMMATORY DISEASES, P215; BARTLETT RR, 1991, AGENTS ACTIONS, V32, P10, DOI 10.1007/BF01983301; CHEN SF, 1986, CANCER RES, V46, P5014; CHERWINSKI HM, 1995, J PHARMACOL EXP THER, V272, P460; DEGRIP WJ, 1979, CHEM PHYS LIPIDS, V23, P321, DOI 10.1016/0009-3084(79)90010-0; DOMLJAN Z, 1994, ARTHRITIS RHEUM S, V36, pS56; HINES V, 1986, J BIOL CHEM, V261, P1386; Hulme E. C., 1992, RECEPTOR LIGAND INTE, P63; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; KEANA JFW, 1978, MEMBRANE BIOCHEM, V1, P323, DOI 10.3109/09687687809063854; KEPPLER D, 1982, METABOLIC COMPARTMEN, P147; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKASCHUS G, 1992, BIOCHEM PHARMACOL, V43, P1025, DOI 10.1016/0006-2952(92)90609-M; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MATTAR T, 1993, FEBS LETT, V334, P161, DOI 10.1016/0014-5793(93)81704-4; MCCHESNEY LP, 1994, TRANSPLANTATION, V57, P1717, DOI 10.1097/00007890-199457120-00005; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MINET M, 1992, GENE, V121, P393, DOI 10.1016/0378-1119(92)90150-N; POPOVIC S, 1986, AGENTS ACTIONS, V19, P313, DOI 10.1007/BF01971235; ROUDEBUSH RE, 1992, AGENTS ACTIONS, V35, P260, DOI 10.1007/BF01997509; TARAYRE JP, 1990, ARZNEIMITTEL-FORSCH, V40-2, P1125; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILLIAMSON RA, 1990, J NEUROCHEM, V55, P1357, DOI 10.1111/j.1471-4159.1990.tb03147.x	24	184	194	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22467	22472		10.1074/jbc.270.38.22467	http://dx.doi.org/10.1074/jbc.270.38.22467			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673235	hybrid			2022-12-25	WOS:A1995RW31400064
J	MICHAELY, P; BENNETT, V				MICHAELY, P; BENNETT, V			THE ANK REPEATS OF ERYTHROCYTE ANKYRIN FORM 2 DISTINCT BUT COOPERATIVE BINDING-SITES FOR THE ERYTHROCYTE ANION-EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; HEREDITARY SPHEROCYTOSIS; MEMBRANE-SKELETON; BAND-3; SPECTRIN; PROTEIN; ASSOCIATION; PHOSPHORYLATION; EXPRESSION; DELETION	The 24 ANK repeats of the membrane-binding domain of ankyrin form four folded subdomains of six ANK repeats each. These four repeat subdomains mediate interactions with at least seven different families of membrane proteins. In the erythrocyte, the main membrane target of ankyrin is the Cl-/HCO3- anion exchanger. This report presents the first evidence that ankyrin contains two separate binding sites for anion exchanger dimers. One site utilizes repeat subdomain two (repeats 7-12) while the other requires both repeat subdomains three and four (repeats 13-24). The two sites are positively coupled with a Hill coefficient of 1.4. Since the anion exchanger exists as a dimer in the membrane, the presence of two binding sites on ankyrin allows ankyrin to interact with four anion exchangers simultaneously. These findings provide a direct demonstration of the versatility of ANK repeats in protein recognition, and have important implications for the organization of ankyrin-linked integral membrane proteins in erythrocytes as well as other cells.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University	MICHAELY, P (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.							BENNETT V, 1982, BIOCHIM BIOPHYS ACTA, V689, P475, DOI 10.1016/0005-2736(82)90305-4; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1979, NATURE, V281, P597, DOI 10.1038/281597a0; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CIANCI CD, 1988, J CELL BIOCHEM, V37, P301, DOI 10.1002/jcb.240370305; COETZER TL, 1988, NEW ENGL J MED, V318, P230, DOI 10.1056/NEJM198801283180407; COSTA FF, 1990, NEW ENGL J MED, V323, P1046, DOI 10.1056/NEJM199010113231507; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; DAVIS L, 1989, J BIOL CHEM, V264, P9665; DAVIS LH, 1992, J BIOL CHEM, V267, P18966; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; DING Y, 1994, J BIOL CHEM, V269, P32201; HALL TG, 1987, J BIOL CHEM, V262, P10537; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; JAROLIM P, 1992, J CLIN INVEST, V93, P121; JENNINGS ML, 1984, J MEMBRANE BIOL, V80, P105, DOI 10.1007/BF01868768; KANNAN R, 1988, J BIOL CHEM, V263, P13766; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; NIGG E, 1979, NATURE, V277, P493, DOI 10.1038/277493a0; NIGG EA, 1980, P NATL ACAD SCI-BIOL, V77, P4702, DOI 10.1073/pnas.77.8.4702; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; PINDER JC, 1995, BLOOD, V85, P2951, DOI 10.1182/blood.V85.10.2951.bloodjournal85102951; SOONG CJ, 1987, ARCH BIOCHEM BIOPHYS, V254, P509, DOI 10.1016/0003-9861(87)90131-7; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANNER MJA, 1991, BLOOD, V78, P2785; THEVENIN B, 1990, J BIOL CHEM, V285, P16166; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913; WEAVER DC, 1984, J BIOL CHEM, V259, P6170; WEINSTEIN RS, 1980, MEMBRANE TRANSPORT E, P35; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893	40	104	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					22050	22057		10.1074/jbc.270.37.22050	http://dx.doi.org/10.1074/jbc.270.37.22050			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665627	hybrid			2022-12-25	WOS:A1995RU75700093
J	STREULI, CH; EDWARDS, GM; DELCOMMENNE, M; WHITELAW, CBA; BURDON, TG; SCHINDLER, C; WATSON, CJ				STREULI, CH; EDWARDS, GM; DELCOMMENNE, M; WHITELAW, CBA; BURDON, TG; SCHINDLER, C; WATSON, CJ			STAT5 AS A TARGET FOR REGULATION BY EXTRACELLULAR-MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED BASEMENT-MEMBRANE; CASEIN GENE-EXPRESSION; BETA-CASEIN; MAMMARY; DIFFERENTIATION; COMPONENTS; CELLS	Transcription of tissue-specific genes in mammary gland requires signals from both prolactin and basement membrane. Here we address the mechanism by which this specialized extracellular matrix regulates transcription. Using mammary cell cultures derived from transgenic mice harboring the ovine beta-lactoglobulin gene, we show that either a basement membrane extract, or purified laminin-1, induced high levels of beta-lactoglobulin synthesis. It is known that prolactin signals through Stat5 (signal transducer and activator of transcription). This transcription factor interacts with gamma-interferon activation site-related motifs within the beta-lactoglobulin promoter, which we show are required for matrix dependence of beta-lactoglobulin expression. The DNA binding activity of Stat5 was present only in extracts of mammary cells cultured on basement membrane, indicating that the activation state of Stat5 is regulated by the type of substratum the cell encounters. Thus, basement membrane controls transcription of milk protein genes through the Stat5-mediated prolactin signaling pathway, providing a molecular explanation for previous studies implicating extracellular matrix in the control of mammary differentiation.	UNIV MANCHESTER,SCH BIOL SCI,MANCHESTER M13 9PT,LANCS,ENGLAND; ROSLIN INST EDINBURGH,ROSLIN EH25 9PS,MIDLOTHIAN,SCOTLAND; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	University of Manchester; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; Columbia University			watson, Christine J/B-1431-2012	Whitelaw, Bruce/0000-0002-2918-1605	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BRISCOE J, 1994, CURR BIOL, V4, P1033, DOI 10.1016/S0960-9822(00)00236-0; BURDON TG, 1994, MOL ENDOCRINOL, V8, P1528, DOI 10.1210/me.8.11.1528; BURDON TG, 1994, FEBS LETT, V350, P177, DOI 10.1016/0014-5793(94)00757-8; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CHEN QM, 1994, J BIOL CHEM, V269, P26602; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GILMOUR KC, 1994, P NATL ACAD SCI USA, V91, P6850, DOI 10.1073/pnas.91.15.6850; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LI ML, 1987, P NATL ACAD SCI USA, V84, P136, DOI 10.1073/pnas.84.1.136; LI S, 1995, MOL CELL BIOL, V15, P2063; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; RUI H, 1994, J BIOL CHEM, V269, P5364; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591; STREULI CH, 1990, J CELL BIOL, V110, P1405; STREULI CH, 1993, J CELL BIOL, V120, P253, DOI 10.1083/jcb.120.1.253; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; STREULI CH, 1995, IN PRESS LAMININS; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WATSON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603, DOI 10.1093/nar/19.23.6603; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; WHITELAW CBA, 1992, BIOCHEM J, V286, P31, DOI 10.1042/bj2860031; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	42	140	144	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21639	21644		10.1074/jbc.270.37.21639	http://dx.doi.org/10.1074/jbc.270.37.21639			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665578	hybrid			2022-12-25	WOS:A1995RU75700035
J	LORENZ, MW; KELLNER, R; HOFFMANN, KH				LORENZ, MW; KELLNER, R; HOFFMANN, KH			A FAMILY OF NEUROPEPTIDES THAT INHIBIT JUVENILE-HORMONE BIOSYNTHESIS IN THE CRICKET, GRYLLUS-BIMACULATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COCKROACH DIPLOPTERA-PUNCTATA; CORPORA ALLATA; ALLATOSTATIN; IDENTIFICATION; SEQUENCE	Four nonapeptides that inhibit juvenile hormone synthesis have been isolated by four high performance liquid chromatographic steps from extracts of the brain of the field cricket, Gryllus bimaculatus. The primary structures of these peptides were assigned by Edman degradation and mass spectrometry as Gly-Trp-Gln-Asp-Leu-Asn-Gly-Gly-Trp-NH2 (Grb-AST B1), Gly-Trp-Arg-Asp-Leu-Asn-Gly-Gly-Trp-NH2 (Grb-AST B2), Ala-Trp-Arg-Asp-Leu-Ser-Gly-Gly-Trp-NH2 (Grb-AST B3), and Ala-Trp-Glu-Arg-Phe-His-Gly-Ser-Trp-NH2 (Grb-AST B4). Each of the peptides shows high sequence similarity to the locustamyoinhibiting peptide (Lom-MIP), but is structurally different from all the allatostatins so far identified. The synthetic allatostatins Grb-AST B1-4 are potent inhibitors (50% inhibition at 10(-8) to 7 x 10(-8) M) of juvenile hormone III biosynthesis by corpora allata from 3 day-old virgin females of G. bimaculatus using an in vitro bioassay. At 10(-7) M, Grb-AST B1 also strongly inhibits juvenile hormone III biosynthesis by corpora allata from 2-day-old adult males and 1-day-old (males and females) and 4-day-old (females) last instar larvae of G. bimaculatus. The inhibitory effect of Grb-AST B1 was also evident on corpora allata from a related species, Acheta domesticus, Inhibition of juvenile hormone synthesis by Grb-AST B1-4 is reversible.	UNIV BAYREUTH,LEHRSTUHL TIEROKOL 1,D-95440 BAYREUTH,GERMANY; UNIV MAINZ,INST PHYSIOL CHEM & PATHOBIOCHEM,D-55099 MAINZ,GERMANY	University of Bayreuth; Johannes Gutenberg University of Mainz			Lorenz, Matthias/C-4106-2011	Hoffmann, Klaus H./0000-0002-7942-9779				Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; BELLES X, 1994, REGUL PEPTIDES, V53, P237, DOI 10.1016/0167-0115(94)90172-4; DONLY BC, 1993, P NATL ACAD SCI USA, V90, P8807, DOI 10.1073/pnas.90.19.8807; DUVE H, 1993, P NATL ACAD SCI USA, V90, P2456, DOI 10.1073/pnas.90.6.2456; DUVE H, 1994, J BIOL CHEM, V269, P21059; DUVE H, 1994, CELL TISSUE RES, V276, P367, DOI 10.1007/BF00306122; FEYEREISEN R, 1981, ANAL BIOCHEM, V111, P372, DOI 10.1016/0003-2697(81)90575-3; GADE G, 1987, PHYSIOL ENTOMOL, V12, P309, DOI 10.1111/j.1365-3032.1987.tb00755.x; GERSTENLAUER B, 1995, EUR J ENTOMOL, V92, P81; HAYES TK, 1994, PEPTIDES, V15, P1165, DOI 10.1016/0196-9781(94)90138-4; KRAMER SJ, 1991, P NATL ACAD SCI USA, V88, P9458, DOI 10.1073/pnas.88.21.9458; LORENZ MW, 1995, REGUL PEPTIDES, V57, P227, DOI 10.1016/0167-0115(95)00036-B; NEUHAUSER T, 1994, J COMP PHYSIOL B, V164, P23, DOI 10.1007/BF00714567; PRATT GE, 1989, BIOCHEM BIOPH RES CO, V163, P1243, DOI 10.1016/0006-291X(89)91111-X; PRATT GE, 1991, P NATL ACAD SCI USA, V88, P2412, DOI 10.1073/pnas.88.6.2412; PRATT GE, 1990, MOL CELL ENDOCRINOL, V70, P185, DOI 10.1016/0303-7207(90)90158-5; PRATT GE, 1974, LIFE SCI, V14, P575, DOI 10.1016/0024-3205(74)90372-5; RAINA AK, 1988, INSECT BIOCHEM, V18, P785, DOI 10.1016/0020-1790(88)90101-1; REICHWALD K, 1994, P NATL ACAD SCI USA, V91, P11894, DOI 10.1073/pnas.91.25.11894; SCHOOFS L, 1991, REGUL PEPTIDES, V36, P111, DOI 10.1016/0167-0115(91)90199-Q; SMART D, 1994, J COMP NEUROL, V347, P426, DOI 10.1002/cne.903470308; SMIT AB, 1992, J NEUROSCI, V12, P1709; STAY B, 1994, ADV INSECT PHYSIOL, V25, P267; TOBVE SS, 1974, BIOCHEM J, V14, P4107; WEAVER RJ, 1994, COMP BIOCHEM PHYS C, V107, P119, DOI 10.1016/1367-8280(94)90018-3; WEAVER RJ, 1991, J INSECT PHYSIOL, V37, P111, DOI 10.1016/0022-1910(91)90096-I; WOODHEAD AP, 1994, INSECT BIOCHEM MOLEC, V24, P257, DOI 10.1016/0965-1748(94)90005-1; WOODHEAD AP, 1992, ARCH INSECT BIOCHEM, V20, P253, DOI 10.1002/arch.940200403; WOODHEAD AP, 1989, P NATL ACAD SCI USA, V80, P5997	29	163	173	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21103	21108		10.1074/jbc.270.36.21103	http://dx.doi.org/10.1074/jbc.270.36.21103			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673141	hybrid			2022-12-25	WOS:A1995RU05400039
J	MAGGIRWAR, SB; HARHAJ, E; SUN, SC				MAGGIRWAR, SB; HARHAJ, E; SUN, SC			ACTIVATION OF NF-KAPPA-B/REL BY TAX INVOLVES DEGRADATION OF I-KAPPA-B-ALPHA AND IS BLOCKED BY A PROTEASOME INHIBITOR	ONCOGENE			English	Note						TAX; HTLV-I; NF-KAPPA-B; I-KAPPA-B-ALPHA; PROTEIN PHOSPHORYLATION; PROTEASOME INHIBITOR	T-CELL LEUKEMIA; VIRUS TYPE-I; RECEPTOR GENE-EXPRESSION; HTLV-I; TRANSCRIPTION FACTOR; NUCLEAR-LOCALIZATION; PRECURSOR P105; DNA-BINDING; C-REL; PROTEINS	The tax gene product of the human T-cell leukemia virus type I (HTLV-I) induces the nuclear expression and biological function of the NF-kappa B/Rel family of host transcription factors although the underlying mechanism remains unclear, In the present study, we demonstrate that Tax-mediated activation of NF-kappa B/Rel can be inhibited by a proteasome inhibitor, suggesting the involvement of proteolytic reactions in this Tax-specific activation pathway. Transient transfection and reporter gene assays have revealed that Tax overrides the inhibitory function of I kappa B alpha in both F9 embryonal cells and Jurkat T cells. Moreover, Tax-mediated inactivation of I kappa B alpha requires a 16 amino acid sequence element located at the N-terminal region (amino acid 21-36) of I kappa B alpha, which is also required for tumor necrosis factor alpha-induced degradation of this inhibitory protein. We further demonstrate that the proteasome inhibitor also blocks the degradation of I kappa B alpha observed in HTLV-I-infected T cells. Interestingly, inhibition of I kappa B alpha degradation in these cells led to the accumulation of a phosphorylated form of I kappa B alpha. Together, these studies suggest that Tax activation of NF-kappa B/Rel may involve induction of phosphorylation and subsequent proteasome-mediated degradation of the inhibitor I kappa B alpha.	PENN STATE UNIV,COLL MED,MILTON S HERSHEY MED CTR,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health								ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1990, MOL ASPECTS CELLULAR, P409; BALLARD D W, 1989, New Biologist, V1, P83; BALLARD DW, 1986, SCIENCE, V241, P1652; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CRENON I, 1993, ONCOGENE, V8, P867; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GESSAIN A, 1985, LANCET, V2, P407; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HIRAI H, 1992, ONCOGENE, V7, P1737; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MUNOZ E, 1994, J VIROL, V68, P8035; NAUMANN M, 1993, ONCOGENE, V8, P2275; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OSAME M, 1986, LANCET, V1, P1031; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1046; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WATANABE M, 1993, ONCOGENE, V8, P2949; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	57	49	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					993	998						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675460				2022-12-25	WOS:A1995RU79800022
J	FRANTZ, JD; GILBERT, W				FRANTZ, JD; GILBERT, W			A NOVEL YEAST GENE-PRODUCT, G4P1, WITH A SPECIFIC AFFINITY FOR QUADRUPLEX NUCLEIC-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TELOMERIC DNA; GENOMIC RNA; DIMERIZATION; MUTATIONS	G4 nucleic acids are four-stranded helical structures that are formed in vitro by nucleic acids that contain guanine tracts. These structures anneal readily under physiological conditions and are unusually stable once formed. G4 nucleic acids are thought to participate in telomere function, retroviral genome dimerization, chromosome alignment during homologue pairing, and mitotic recombination, although the in vivo demonstration of these structures in any of these situations has not yet been achieved. Here we purify and characterize an activity from yeast, G4p1, which has a high and specific affinity for G4 nucleic acids. G4p1 prefers substrates containing multiple G4 domains, has an equal affinity for parallel and antiparallel G4 structures, and binds equivalently to RNA and DNA in G4 form. The Keg for G4p1 binding to a G4 DNA oligomer is 5.0 x 10(8) M(-1) under near physiological conditions. G4p1 was purified and shown to derive from a 42-kDa protein (p42). We have cloned and sequenced the gene encoding p42 and show it to encode a novel protein with a region significantly homologous to bacterial methionyl-tRNA synthetase dimerization domains, We have reconstituted the G4p1 binding activity with recombinant p42 and present evidence that G4p1 is a homodimer of p42.			FRANTZ, JD (corresponding author), HARVARD UNIV, BIOL LABS, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA.				NIGMS NIH HHS [GM41895] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041895] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CASSIO D, 1971, EUR J BIOCHEM, V20, P283, DOI 10.1111/j.1432-1033.1971.tb01393.x; CHRISTIANSEN J, 1994, NUCLEIC ACIDS RES, V22, P5709, DOI 10.1093/nar/22.25.5709; DAVIS TN, 1987, METHOD ENZYMOL, V139, P248; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FRANTZ JD, 1995, J BIOL CHEM, V270, P9413, DOI 10.1074/jbc.270.16.9413; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; GALLAGHER SR, 1992, CURRENT PROTOCOLS MO, V2; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; KAO J, 1994, J BIOL CHEM, V269, P9774; KIM JM, 1990, GENETICS, V126, P799; LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2; SEN D, 1992, METHOD ENZYMOL, V211, P191; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; Sen D, 1991, CURR OPIN STRUC BIOL, V1, P435, DOI 10.1016/0959-440X(91)90044-T; SMITH DB, 1992, CURRENT PROTOCOLS MO, V2; SNYDER M, 1986, P NATL ACAD SCI USA, V83, P730, DOI 10.1073/pnas.83.3.730; SORGER PK, 1989, PROTEIN FUNCTION PRA, P199; Sundquist W. I., 1991, Nucleic Acids and Molecular Biology, V5, P1; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WILLIAMSON JR, 1994, ANNU REV BIOPH BIOM, V23, P703, DOI 10.1146/annurev.bb.23.060194.003415; WILLIAMSON JR, 1993, CURR OPIN STRUC BIOL, V3, P357, DOI 10.1016/S0959-440X(05)80106-X; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7	25	59	61	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20692	20697		10.1074/jbc.270.35.20692	http://dx.doi.org/10.1074/jbc.270.35.20692			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657649	hybrid			2022-12-25	WOS:A1995RR58400069
J	PREVIS, SF; FERNANDEZ, CA; YANG, DW; SOLOVIEV, MV; DAVID, F; BRUNENGRABER, H				PREVIS, SF; FERNANDEZ, CA; YANG, DW; SOLOVIEV, MV; DAVID, F; BRUNENGRABER, H			LIMITATIONS OF THE MASS ISOTOPOMER DISTRIBUTION ANALYSIS OF GLUCOSE TO STUDY GLUCONEOGENESIS - SUBSTRATE CYCLING BETWEEN GLYCEROL AND TRIOSE PHOSPHATES IN LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STABLE ISOTOPES; BIOSYNTHESIS; HUMANS; INVIVO	Mass isotopomer distribution analysis allows studying the synthesis of polymeric biomolecules from N-15, C-13-, or H-2-labeled monomeric units in the presence of unlabeled polymer, The mass isotopomer distribution of the polymer allows calculation of (i) the enrichment of the monomer and (ii) the dilution of the newly synthesized polymer by unlabeled polymer, We tested the conditions of validity of mass isotopomer distribution analysis of glucose labeled from [U-C-13(3)]lactate, [U-C-13(3)]glycerol, and [2-C-13]glycerol to calculate the fraction of glucose production derived from gluconeogenesis. Experiments were conducted in perfused rat livers, Live rats, and live monkeys, In all cases, [C-13]glycerol yielded labeling patterns of glucose that are incompatible with glucose being formed from a single pool of triose phosphates of constant enrichment, We show evidence that variations in the enrichment of triose phosphates result from (i) the large fractional decrease in physiological glycerol concentration in a single pass through the liver and (ii) the release of unlabeled glycerol by the liver, presumably via lipase activity, This zonation of glycerol metabolism in Liver results in the calculation of artifactually low contributions of gluconeogenesis to glucose production when the latter is labeled from [C-13]glycerol, In contrast, [U-C-13(3)]lactate appears to be a suitable tracer for mass isotopomer distribution analysis of gluconeogenesis in vivo, but not in the perfused liver, In other perfusion experiments with [H-2(5)]glycerol, we showed that the rat liver releases glycerol molecules containing one to four H-2 atoms, This indicates the operation of a substrate cycle between extracellular glycerol and liver triose phosphates, where H-2 is lost in the reversible reactions catalyzed by alpha-glycerophosphate dehydrogenase, triose-phosphate isomerase, and glycolytic enzymes, This substrate cycle presumably involves alpha-glycerophosphate hydrolysis.	CASE WESTERN RESERVE UNIV, DEPT NUTR, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT BIOMED ENGN, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035543] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35543] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Biemann K., 1962, MASS SPECTROMETRY OR, P223; BIRD RB, 1960, TRANSPORT PHENOMENA, P554; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DEBEER LJ, 1982, FEBS LETT, V140, P159, DOI 10.1016/0014-5793(82)80884-3; FERNANDEZ CA, 1994, 1994 P S INT FED AUT, P367; GRUNNET N, 1967, EUR J BIOCHEM, V3, P78, DOI 10.1111/j.1432-1033.1967.tb19500.x; HAUSSINGER D, 1984, TRENDS BIOCHEM SCI, V9, P300, DOI 10.1016/0968-0004(84)90294-9; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; HELLERSTEIN MK, 1991, J CLIN INVEST, V87, P1841, DOI 10.1172/JCI115206; HELLERSTEIN MK, 1991, J BIOL CHEM, V266, P10920; HELLERSTEIN MK, 1991, AM J PHYSIOL, V261, pE479, DOI 10.1152/ajpendo.1991.261.4.E479; HETENYI G, 1982, FED PROC, V41, P104; JUNGERMANN K, 1986, ENZYME, V35, P161, DOI 10.1159/000469338; JUNGERMANN K, 1986, REGULATION HEPATIC M, P211; KELLEHER JK, 1992, AM J PHYSIOL, V262, pE118, DOI 10.1152/ajpendo.1992.262.1.E118; KHARROUBI AT, 1992, AM J PHYSIOL, V263, pE667, DOI 10.1152/ajpendo.1992.263.4.E667; KREBS HA, 1966, BIOCHEM J, V101, P242, DOI 10.1042/bj1010242; LANDAU BR, 1995, AM J PHYSIOL-ENDOC M, V269, pE18, DOI 10.1152/ajpendo.1995.269.1.E18; LANDAU BR, 1995, J CLIN INVEST, V95, P172, DOI 10.1172/JCI117635; LANDAU BR, 1993, ADV EXP MED BIOL, V334, P209; LASDON LS, 1989, GRG USERS GUIDE; LEADLAY PF, 1976, BIOCHEMISTRY-US, V15, P5617, DOI 10.1021/bi00670a029; LEE WNP, 1994, AM J PHYSIOL, V266, pE699, DOI 10.1152/ajpendo.1994.266.5.E699; LEE WNP, 1994, AM J PHYSIOL, V266, pE372, DOI 10.1152/ajpendo.1994.266.3.E372; LEE WP, 1993, DIABETES, V42, pA178; LIN ECC, 1977, ANNU REV BIOCHEM, V46, P765, DOI 10.1146/annurev.bi.46.070177.004001; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; MINASSIAN C, 1994, J BIOL CHEM, V269, P16585; NEESE RA, 1995, J BIOL CHEM, V270, P14452, DOI 10.1074/jbc.270.24.14452; OLSON AC, 1966, BIOCHIM BIOPHYS ACTA, V125, P185, DOI 10.1016/0005-2760(66)90159-7; PERONI O, 1995, IN PRESS AM J PHYSL; PREVIS SF, 1994, ANAL BIOCHEM, V218, P192, DOI 10.1006/abio.1994.1159; ROBINSON J, 1969, BIOCHEM J, V112, P455, DOI 10.1042/bj1120455; ROSE IA, 1962, J BIOL CHEM, V237, P3325; ROSENBLATT J, 1992, AM J PHYSIOL, V263, pE584, DOI 10.1152/ajpendo.1992.263.3.E584; ROSIERS CD, 1991, J BIOL CHEM, V266, P1574; SCRUTTON MC, 1969, METHOD ENZYMOL, V13, P235; SESTOFT L, 1975, BIOCHIM BIOPHYS ACTA, V375, P462, DOI 10.1016/0005-2736(75)90360-0; STRISOWER EH, 1952, J BIOL CHEM, V198, P115; STRONG JM, 1985, J BIOL CHEM, V260, P4276; TURNER SM, 1994, FASEB J, V8, pA956; WINKLER B, 1969, AM J PHYSIOL, V216, P191, DOI 10.1152/ajplegacy.1969.216.1.191	42	78	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19806	19815		10.1074/jbc.270.34.19806	http://dx.doi.org/10.1074/jbc.270.34.19806			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649990	hybrid			2022-12-25	WOS:A1995RQ99100022
J	JEAN, F; BOUDREAULT, A; BASAK, A; SEIDAH, NG; LAZURE, C				JEAN, F; BOUDREAULT, A; BASAK, A; SEIDAH, NG; LAZURE, C			FLUORESCENT PEPTIDYL SUBSTRATES AS AN AID IN STUDYING THE SUBSTRATE-SPECIFICITY OF HUMAN PROHORMONE CONVERTASE PC1 AND HUMAN FURIN AND DESIGNING A POTENT IRREVERSIBLE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILISIN FAMILY; KEX2-LIKE ENDOPROTEASE; ENZYMATIC-PROPERTIES; PROCESSING ENZYMES; CLEAVAGE SITE; PRECURSOR; ENDOPEPTIDASE; PURIFICATION; BIOSYNTHESIS; TRYPSIN	The substrate specificities of two human prohormone convertases, furin and PC1, were examined with a series of 7-amino-4-methylcoumarinamide (MCA) containing peptidyl substrates. Using acetyl-Arg-Ser-lys-Arg-MCA as model, P4 Arg substitution by Lys or Orn resulted for furin in a 538- and a 280-fold lower k(cat)/K-m value, but only in a 14 and 18-fold decrease for PC1, Substitution of P3 Ser by either Pro, Glu, or Lys does not modify significantly the k(cat)/K-m value for PC1, whereas furin activity is seriously impaired by the Glu substitution. Elongating the peptidyl sequence up to the P8 position decreases the k(cat)/K-m value for furin but not for PC1. In both the P3 or P5 Glu substitution, the decrease of k(cat)/K-m was due primarily to lower k(cat) rather than higher K-m, possibly because of the presence of a negatively charged side chain. Finally, an octapeptidyl chloromethane derivative proved to be a potent irreversible inhibitor of either PC1 and furin, The 811-fold difference in the apparent K-app/[I] (1.63 x 10(6) s(-1) M(-1)), and k(cat)/K-m determined with the corresponding peptidyl MCA substrate (2.01 x 10(9) s(-1) M(-1)), supports the proposal that cleavage of the acylenzyme represents the rate-limiting step for PC1 and furin.	UNIV MONTREAL,CLIN RES INST MONTREAL,NEUROPEPTIDE STRUCT & METAB LAB,MONTREAL,PQ H2W 1R7,CANADA; UNIV MONTREAL,CLIN RES INST MONTREAL,JA DE SEVE LAB BIOCHEM NEUROENDOCRINOL,MONTREAL,PQ H2W 1R7,CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				ALARCON C, 1994, BIOCHEM J, V301, P257, DOI 10.1042/bj3010257; ANGLIKER H, 1995, ANAL BIOCHEM, V224, P409, DOI 10.1006/abio.1995.1058; BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BAILYES EM, 1992, BIOCHEM J, V286, P223, DOI 10.1042/bj2860223; BASAK A, 1994, INT J PEPT PROT RES, V44, P253; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRENNER C, 1993, CURR BIOL, V3, P498, DOI 10.1016/0960-9822(93)90040-U; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRISTOL JA, 1993, J BIOL CHEM, V268, P7577; CHAUVET J, 1987, FEBS LETT, V217, P180, DOI 10.1016/0014-5793(87)80659-2; DECROLY E, 1994, J BIOL CHEM, V269, P12240; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; GRAF L, 1988, P NATL ACAD SCI USA, V85, P4961, DOI 10.1073/pnas.85.14.4961; GROSKREUTZ DJ, 1994, J BIOL CHEM, V269, P6241; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HENDY GN, 1995, J BIOL CHEM, V270, P9517, DOI 10.1074/jbc.270.16.9517; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KITZ R, 1962, J BIOL CHEM, V237, P3245; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KREUTTER K, 1994, BIOCHEMISTRY-US, V33, P13792, DOI 10.1021/bi00250a033; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; OHNISHI Y, 1994, J VIROL, V68, P4075, DOI 10.1128/JVI.68.6.4075-4079.1994; POWERS JC, 1977, CHEM BIOCH AMINO ACI, V4, P65; REHEMTULLA A, 1992, BLOOD, V79, P2349; RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6; RUFAUT NW, 1993, J BIOL CHEM, V268, P20291; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1991, ENZYME, V45, P271, DOI 10.1159/000468901; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; SIZONENKO SV, 1991, BIOCHEM J, V278, P621, DOI 10.1042/bj2780621; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; WALKER JA, 1994, J VIROL, V68, P1213, DOI 10.1128/JVI.68.2.1213-1218.1994; WASLEY LC, 1993, J BIOL CHEM, V268, P8458; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; ZIMMERMAN M, 1977, ANAL BIOCHEM, V70, P258	45	76	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19225	19231		10.1074/jbc.270.33.19225	http://dx.doi.org/10.1074/jbc.270.33.19225			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642593	hybrid			2022-12-25	WOS:A1995RP70300007
J	ROHLFS, RJ; HUANG, LX; HILLE, R				ROHLFS, RJ; HUANG, LX; HILLE, R			PROTOTROPIC CONTROL OF INTRAMOLECULAR ELECTRON-TRANSFER IN TRIMETHYLAMINE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND COENZYME; IRON-SULFUR CLUSTER; DIMETHYLAMINE DEHYDROGENASE; METHYLOTROPHIC BACTERIA; PROSTHETIC GROUPS; FLAVOPROTEIN; FLAVIN	The pH dependence of static optical/EPR spectra of trimethylamine dehydrogenase reduced to the level of two equivalents (TMADH(2eq)) has been examined and indicates the existence of three different states for this iron-sulfur flavoprotein, At pH 6, TMADH(2eq) exists principally in a form possessing flavin mononucleotide hydroquinone, with its iron-sulfur center oxidized, At pH 8, the enzyme principally contains flavin mononucleotide semiquinone and reduced iron-sulfur, but despite the proximity of the two centers to one another, their magnetic moments do not interact, At pH 10, TMADH(2eq) exhibits the EPR spectrum that is diagnostic of a previously characterized spin-interacting state in which the magnetic moments of the flavin semiquinone and reduced iron-sulfur center are strongly ferromagnetically coupled, The kinetics of the interconversion of these three states have been investigated using a pH jump technique in both H2O and D2O. The observed kinetics are consistent with a reaction mechanism involving sequential protonation/deprotonation and intramolecular electron transfer events, All reactions studied show a normal solvent kinetic isotope effect, Proton inventory analysis indicates that at least one proton is involved in the reaction between pH 6 and 8, which principally controls intramolecular electron transfer, whereas at least two protons are involved between pH 8 and 10, which principally control formation of the spin-interacting state, The results of these and previous studies indicate that for TMADH(2eq) between pH 10 and 6, at least three protonation/deprotonation events are associated with intramolecular electron transfer and formation of the spin-interacting state, with estimated pK(alpha) values of 6.0, 8.0, and similar to 9.5, These pK(alpha) values are attributed to the flavin hydroquinone, flavin semiquinone, and an undesignated basic group on the protein, respectively.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University								BELLAMY HD, 1988, J BIOL CHEM, V284, P11887; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; DUDLEY KH, 1965, HELV CHIM ACTA, V47, P1354; EHRENBERG A, 1967, EUR J BIOCHEM, V2, P286, DOI 10.1111/j.1432-1033.1967.tb00137.x; Gross P, 1936, T FARADAY SOC, V32, P0879, DOI 10.1039/tf9363200879; GUTFREUND, 1977, ENZYMES PHYSICAL PRI, P173; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; HILLE R, 1986, J BIOL CHEM, V261, P1241; HILLE R, 1991, BIOCHEMISTRY-US, V30, P8521; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; Klinman J P, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P415; LEHMAN TC, 1990, BIOCHEMISTRY-US, V29, P10594, DOI 10.1021/bi00499a004; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; MATHEWS FS, 1987, FLAVINS FLAVOPROTEIN, P663; Orr WJC, 1937, J CHEM SOC, P330, DOI 10.1039/jr9370000330; PALMER G, 1969, J BIOL CHEM, V244, P2614; ROHLFS RJ, 1994, J BIOL CHEM, V269, P30869; ROHLFS RJ, 1991, J BIOL CHEM, V266, P15244; Schowen R. L, 1978, TRANSIT STATES BIOCH, P225; SINGER TP, 1980, FLAVINS FLAVOPROTEIN, P277; STEENKAMP DJ, 1982, BIOCHEM J, V207, P233, DOI 10.1042/bj2070233; STEENKAMP DJ, 1982, BIOCHEM J, V207, P241, DOI 10.1042/bj2070241; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2812; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEENKAMP DJ, 1978, MECHANISMS OXIDIZING, P127; STEVENSON RC, 1986, BIOCHIM BIOPHYS ACTA, V869, P81, DOI 10.1016/0167-4838(86)90313-4; ZEHNDER AJB, 1976, SCIENCE, V194, P1165, DOI 10.1126/science.793008	30	29	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22196	22207		10.1074/jbc.270.38.22196	http://dx.doi.org/10.1074/jbc.270.38.22196			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673198	hybrid			2022-12-25	WOS:A1995RW31400023
J	CARDENAS, ME; LIM, E; HEITMAN, J				CARDENAS, ME; LIM, E; HEITMAN, J			MUTATIONS THAT PERTURB CYCLOPHILIN A LIGAND-BINDING POCKET CONFER CYCLOSPORINE-A RESISTANCE IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; CIS-TRANS-ISOMERIZATION; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; HOMOLOG NINAA; A-BINDING; SIGNAL-TRANSDUCTION; ACTIVE-SITE; CALCINEURIN; PROTEIN	In complex with the peptidyl-prolyl isomerase cyclophilin A, the immunosuppressive antifungal drug cyclosporin A (CsA) inhibits a Ca2+/calmodulin-dependent protein phosphatase, calcineurin, which regulates signal transduction. We isolated and characterized cyclophilin A mutations that confer CsA resistance in a Saccharomyces cerevisiae strain whose growth is CsA-sensitive. Three mutations (G70S, H90Y, and G102A) alter single amino acids conserved between yeast and human cyclophilin A, which structural analyses implicate in CsA binding to human cyclophilin A. By Western analysis, all three mutant proteins are expressed in yeast, In vitro, two purified mutant cyclophilins (G70S, G102A) retain prolyl isomerase activity and have moderately reduced affinity for CsA and calcineurin but, when bound to CsA, do bind and inhibit calcineurin phosphatase activity. In contrast, the purified H90Y mutant cyclophilin is dramatically decreased in prolyl isomerase activity, CsA affinity, and calcineurin binding and inhibition. These studies identify conserved cyclophilin A residues that participate in CsA binding and catalysis.	DUKE UNIV, MED CTR, DEPT GENET, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; Howard Hughes Medical Institute			Heitman, Joseph/ABC-6006-2021		NHLBI NIH HHS [P01 HL50985-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL050985] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BREUDER T, 1994, P NATL ACAD SCI USA, V91, P5372, DOI 10.1073/pnas.91.12.5372; Cardenas Maria E., 1994, Perspectives in Drug Discovery and Design, V2, P103, DOI 10.1007/BF02171739; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLUBB RT, 1994, BIOCHEMISTRY-US, V33, P2761, DOI 10.1021/bi00176a004; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; ETZKORN FA, 1994, BIOCHEMISTRY-US, V33, P2380, DOI 10.1021/bi00175a005; FEJZO J, 1994, BIOCHEMISTRY-US, V33, P5711, DOI 10.1021/bi00185a007; FESIK SW, 1990, SCIENCE, V250, P1406, DOI 10.1126/science.2255910; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FOOR F, 1992, NATURE, V360, P682; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1992, NEW BIOL, V4, P448; Heitman Joseph, 1993, Methods (Orlando), V5, P176, DOI 10.1006/meth.1993.1022; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; KALLEN J, 1992, FEBS LETT, V300, P286, DOI 10.1016/0014-5793(92)80865-E; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KE HM, 1993, P NATL ACAD SCI USA, V90, P11850, DOI 10.1073/pnas.90.24.11850; KE HM, 1992, J MOL BIOL, V228, P539, DOI 10.1016/0022-2836(92)90841-7; KE HM, 1993, P NATL ACAD SCI USA, V90, P3324, DOI 10.1073/pnas.90.8.3324; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MIKOL V, 1994, P NATL ACAD SCI USA, V91, P5183, DOI 10.1073/pnas.91.11.5183; MIKOL V, 1994, PROTEIN ENG, V7, P597, DOI 10.1093/protein/7.5.597; MIKOL V, 1993, J MOL BIOL, V234, P1119, DOI 10.1006/jmbi.1993.1664; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; ONDEK B, 1992, J BIOL CHEM, V267, P16460; PARENT SA, 1993, J GEN MICROBIOL, V139, P2973, DOI 10.1099/00221287-139-12-2973; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIKORSKI RS, 1989, GENETICS, V122, P19; Stamnes MA, 1990, CURR OPIN CELL BIOL, V2, P1104, DOI 10.1016/0955-0674(90)90163-9; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; YE RR, 1992, EUR J BIOCHEM, V204, P713, DOI 10.1111/j.1432-1033.1992.tb16686.x; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	53	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20997	21002		10.1074/jbc.270.36.20997	http://dx.doi.org/10.1074/jbc.270.36.20997			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673124	hybrid			2022-12-25	WOS:A1995RU05400021
J	TOMIC, S; GREISER, U; LAMMERS, R; KHARITONENKOV, A; IMYANITOV, E; ULLRICH, A; BOHMER, FD				TOMIC, S; GREISER, U; LAMMERS, R; KHARITONENKOV, A; IMYANITOV, E; ULLRICH, A; BOHMER, FD			ASSOCIATION OF SH2 DOMAIN PROTEIN-TYROSINE PHOSPHATASES WITH THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN HUMAN TUMOR-CELLS - PHOSPHATIDIC-ACID ACTIVATES RECEPTOR DEPHOSPHORYLATION BY PTP1C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SIGNAL TRANSDUCTION; EXPRESSION; PHOSPHORYLATION; PURIFICATION; KINASES; INSULIN; MITOSIS; BETA; TRANSFORMATION	The SH2 domain protein tyrosine phosphatases (PTPases) PTP1C and PTP1D were found associated with epidermal growth factor (EGF) receptor which was purified from A431 cell. membranes by several steps of chromatography, Both PTPases also associated with the EGF receptor upon exposure of immunoprecipitated receptor to lysates of MCF7 mammary carcinoma cells, The associated PTPases had little activity toward the bound receptor when it was autophosphorylated in vitro, Receptor dephosphorylation could, however, be initiated by treatment of the receptor PTPase complex with phosphatidic acid (PA). When autophosphorylated EGF receptor was exposed to lysates of PTP1C or PTP1D overexpressing 293 cells, the association of PTP1C but not of PTP1D was enhanced in the presence of PA, In intact A431 cells, an association of PTP1C and PTP1D with the EGF receptor was detectable by coimmunoprecipitation experiments, PA treatment reduced the phosphorylation state of ligand activated EGF receptors in A431 cells and in 293 cells overexpressing EGF receptors together with PTP1C but not in 293 cells overexpressing EGF receptors alone or together with PTP1D. We conclude that PTP1C but not PTP1D participates in dephosphorylation of activated EGF receptors, A possible role of PA for physiological modulation of EGF receptor signaling is discussed.	UNIV JENA,FAC MED,GROWTH FACTOR SIGNAL TRANSDUCT RES UNIT,MAX PLANCK SOC,D-07747 JENA,GERMANY; MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	Friedrich Schiller University of Jena; Max Planck Society; Max Planck Society			Imyanitov, Evgeny/ABG-8619-2021					AKIYAMA T, 1985, BIOCHEM BIOPH RES CO, V131, P442, DOI 10.1016/0006-291X(85)91822-4; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOHMER FD, 1993, FEBS LETT, V331, P276, DOI 10.1016/0014-5793(93)80352-U; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; BRAUTIGAN DL, 1981, J BIOL CHEM, V256, P6519; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FAURE R, 1992, J BIOL CHEM, V267, P11215; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; KASZKIN M, 1992, CANCER RES, V52, P5627; KASZKIN M, 1991, CANCER RES, V51, P4328; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOONEY RA, 1992, J BIOL CHEM, V267, P23443; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; POT DA, 1991, J BIOL CHEM, V266, P19688; PUMIGLIA KM, 1992, BIOCHEM J, V286, P441, DOI 10.1042/bj2860441; SCHIEVELLA AR, 1993, CELL GROWTH DIFFER, V4, P239; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TONKS NK, 1988, J BIOL CHEM, V263, P6731; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZANDER NF, 1993, ONCOGENE, V8, P1175; ZHANG WR, 1994, BIOCHEM J, V302, P39, DOI 10.1042/bj3020039; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007	46	133	136	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21277	21284		10.1074/jbc.270.36.21277	http://dx.doi.org/10.1074/jbc.270.36.21277			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673163	hybrid			2022-12-25	WOS:A1995RU05400063
J	WEBER, J; BOWMAN, C; WILKEMOUNTS, S; SENIOR, AE				WEBER, J; BOWMAN, C; WILKEMOUNTS, S; SENIOR, AE			ALPHA-ASPARTATE-261 IS A KEY RESIDUE IN NONCATALYTIC SITES OF ESCHERICHIA-COLI F1-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-BINDING-SITES; DIRECTED MUTAGENESIS; MITOCHONDRIAL F1-ATPASE; CATALYTIC PROPERTIES; ATP BINDING; SYNTHASE; SUBUNIT; F(1)-ATPASE; SPECIFICITY	X-ray structure analysis of the noncatalytic sites of F-1-ATPase revealed that residue alpha-Asp(261) lies close to the Mg of bound Mg-5'-adenylyl-beta,gamma imidodiphosphate. Here, the mutation alpha D261N was generated in Escherichia coli and combined with the alpha R365W mutation, allowing nucleotide binding at F-1 noncatalytic sites to be specifically monitored by tryptophan fluorescence spectroscopy. Purified alpha D261N/alpha R365W F-1-ATPase showed catalytic activity similar to wild-type. An important feature was that, without any resort to nucleotide depletion procedures, the noncatalytic sites in purified native enzyme were already empty. Binding studies with MgATP, MgADP, and the corresponding free nucleotides led to the following conclusions. Residue alpha-Asp(261) interacts with the Mg of Mg-nucleotide in noncatalytic sites and provides a large component of the binding energy (similar to 3 kcal/mol). It is the primary determinant of the preference of noncatalytic sites for Mg-nucleotide. The natural ligands at these sites in wild-type enzyme are the Mg-nucleotides and free nucleotides bind poorly. Under conditions where noncatalytic sites were empty, alpha D261N/alpha R365W F-1 showed significant hydrolysis of MgATP. This establishes unequivocally that occupancy of noncatalytic sites by nucleotide is not required for catalysis.			WEBER, J (corresponding author), UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, BOX 607, ROCHESTER, NY 14642 USA.				NIGMS NIH HHS [GM25349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025349, R01GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALLISON WS, 1992, J BIOENERG BIOMEMBR, V24, P469, DOI 10.1007/BF00762364; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19633; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; COX GB, 1978, BIOCHEM J, V170, P593, DOI 10.1042/bj1700593; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; HARRIS DA, 1993, FEBS LETT, V316, P209, DOI 10.1016/0014-5793(93)81295-B; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; JAULT JM, 1993, J BIOL CHEM, V268, P1558; JOUNOUCHI M, 1993, J BIOCHEM-TOKYO, V1141, P171; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MILGROM YM, 1993, J BIOL CHEM, V268, P23179; MILGROM YM, 1991, J BIOL CHEM, V266, P11551; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; RAO R, 1988, J BIOL CHEM, V263, P15957; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER J, 1994, J BIOL CHEM, V269, P11261; WEBER J, 1993, J BIOL CHEM, V268, P20126; WEBER J, 1995, J BIOL CHEM, V270, P12653, DOI 10.1074/jbc.270.21.12653; WEBER J, 1993, J BIOL CHEM, V268, P6241; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5	26	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21045	21049		10.1074/jbc.270.36.21045	http://dx.doi.org/10.1074/jbc.270.36.21045			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673131	hybrid			2022-12-25	WOS:A1995RU05400029
J	CHEN, JK; CHAO, HH; YANG, VC				CHEN, JK; CHAO, HH; YANG, VC			INHIBITION OF THE GROWTH OF A HUMAN NASOPHARYNGEAL CARCINOMA CELL-LINE BY BFGF IS MEDIATED VIA FGFR-1	FASEB JOURNAL			English	Article						FIBROBLAST GROWTH FACTORS; CARCINOMA CELLS; GROWTH INHIBITION; FGF RECEPTOR SUBTYPES; HEPARIN-LIKE MOLECULES	IMMUNOGLOBULIN DOMAIN; ENDOTHELIAL-CELLS; FACTOR RECEPTOR-1; FIBROBLAST; GENE; EXPRESSION; IDENTIFICATION; SPECIFICITY; CLONING; FAMILY	The growth of CG-1 human nasopharyngeal carcinoma cell line and five of its randomly selected, single cell-derived subline cells is inhibited by bFGF in an autocrine and paracrine manner. In contrast, aFGF, which has a 55% homology in amino acid sequence with bFGF, stimulates cell growth. Basic FGF binds to specific cell surface high-affinity receptor sites with an apparent K-d of 105 pM. Of the two lines examined, the high-affinity binding sites for bFGF are calculated to be 1200 and 2600 per cell. The biological effect of bFGF is conveyed through its binding to the high-affinity receptor sites and the binding is dependent on the presence of cell surface heparin-like molecules, as treatment of cells with heparitinase or sodium chlorate abolishes high-affinity binding and growth inhibition. In contrast, similar treatment has no obvious effect on the growth-stimulatory effect of aFGF. Experimental results are also presented showing that the growth inhibition by bFGF is mediated through type I FGF receptors. These results suggest that bFGF and aFGF act via distinct receptor types to oppositely regulate the growth of CG-1 and subline cells.	TUNGHAI UNIV, INST BIOL GRAD, TAICHUNG 40704, TAIWAN	Tunghai University	CHEN, JK (corresponding author), CHANG GUNG COLL MED & TECHNOL, DEPT PHYSIOL, TAYUAN 333, TAIWAN.							AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BAIRD A, 1986, RECENT PROG HORM RES, V42, P143; BECKER D, 1992, ONCOGENE, V7, P2303; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHANG YS, 1989, CANCER RES, V49, P6752; CHAO HH, 1993, INT J CANCER, V54, P807, DOI 10.1002/ijc.2910540515; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEN JK, 1992, IN VITRO CELL DEV-AN, V28A, P561, DOI 10.1007/BF02631020; CHEN JK, 1994, J CELL PHYSIOL, V160, P401, DOI 10.1002/jcp.1041600302; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EHRLICH R, 1979, J IMMUNOL METHODS, V26, P345, DOI 10.1016/0022-1759(79)90180-7; EISEMANN A, 1991, ONCOGENE, V6, P1195; GLEAVE M, 1991, CANCER RES, V51, P3753; HOSHI H, 1988, IN VITRO CELL DEV B, V24, P309; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAMATA N, 1986, CANCER RES, V46, P1648; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN M, 1992, IN VITRO CELL DEV-AN, V28A, P515; KAWAMOTO T, 1984, J BIOL CHEM, V259, P7761; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; MAIER JAM, 1990, EXP CELL RES, V186, P354, DOI 10.1016/0014-4827(90)90316-3; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; NEW BA, 1992, J CELL PHYSIOL, V150, P320, DOI 10.1002/jcp.1041500215; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; RAZ V, 1991, ONCOGENE, V6, P753; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TORU M, 1992, P NATL ACAD SCI USA, V89, P246; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484	38	5	5	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1995	9	12					1211	1219		10.1096/fasebj.9.12.7672514	http://dx.doi.org/10.1096/fasebj.9.12.7672514			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU816	7672514				2022-12-25	WOS:A1995RU81600011
J	ARRUDA, LK; VAILES, LD; MANN, BJ; SHANNON, J; FOX, JW; VEDVICK, TS; HAYDEN, ML; CHAPMAN, MD				ARRUDA, LK; VAILES, LD; MANN, BJ; SHANNON, J; FOX, JW; VEDVICK, TS; HAYDEN, ML; CHAPMAN, MD			MOLECULAR-CLONING OF A MAJOR COCKROACH (BLATTELLA-GERMANICA) ALLERGEN, BLA-G-2 - SEQUENCE HOMOLOGY TO THE ASPARTIC PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUST MITE ALLERGEN; T-CELL EPITOPES; DER-P-II; HOUSE-DUST; MONOCLONAL-ANTIBODIES; RIBONUCLEIC-ACID; POLLEN ALLERGEN; RISK-FACTORS; CATHEPSIN-D; IDENTIFICATION	Inhalation of allergens produced by the German cockroach (Blattella germanica) elicits IgE antibody formation and the development of asthma in genetically predisposed individuals. We compared the allergenic importance of two cockroach (CR) allergens, Bla g 1 and Bla g 2, and determined the complete amino acid sequence of the major 36-kDa allergen, Bla g 2. A survey of 106 sera from CR allergic patients showed the prevalence of IgE antibodies to Bla gl and Bla g 2 to be 30.2% and 57.6%, respectively. Immediate skin tests on 7 selected patients gave positive reactions using 10(-3) mu g/ml either allergen, whereas controls showed no response to 10 mu g/ml. Natural Bla g 2 was purified and the sequence of the NH2 terminus and tryptic peptides, comprising 36% of the molecule, was determined. The cDNA for Bla g 2 was cloned from a B. germanica expression library and encoded a 24 amino acid signal peptide and a 328-amino acid mature protein, which showed sequence homology to aspartic proteases. Bla g 2 showed the highest degree of identity to mosquito (Aedes aegypti) lysosomal aspartic protease (30.8%), with similar identity to pepsin, cathepsins D and E, renin, and chymosin, Bla g 2 mRNA and protein were detected in B, germanica, but not in Periplaneta americana, the other principal domiciliary CR species in the U. S. High concentrations of Bla g 2 were found in CR digestive organs (esophagus, gut, and proventriculus). The results show that Ela g 2 is a major species-specific allergen of B. germanica and suggest that the allergen functions as a digestive enzyme in the cockroach.	UNIV VIRGINIA, HLTH SCI CTR, CTR ASTHMA & ALLERG DIS, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; SIBIA INC, LA JOLLA, CA 92037 USA	University of Virginia	ARRUDA, LK (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, CTR ASTHMA & ALLERG DIS, DEPT INTERNAL MED, BOX 225, CHARLOTTESVILLE, VA 22908 USA.		Arruda, L. Karla/D-5845-2013	Arruda, L. Karla/0000-0002-7505-210X; Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034607, U01AI034607, R01AI032557] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32557, AI 34607] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARRUDA LK, 1992, J IMMUNOL, V149, P3354; ARRUDA LK, 1995, IN PRESS INT ARCH AL; AZUMA T, 1989, J BIOL CHEM, V264, P16748; BELL WJ, 1981, LABORATORY COCKROACH; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHAPMAN MD, 1993, CLIN EXP ALLERGY, V23, P459, DOI 10.1111/j.1365-2222.1993.tb03230.x; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO WL, 1992, J BIOL CHEM, V267, P21823; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; EBNER C, 1993, J IMMUNOL, V150, P1047; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FOLTMANN B, 1979, J BIOL CHEM, V254, P8447; GEISOW MJ, 1980, ENZYMOLOGY POSTTRANS, P259; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; HELM RM, 1988, INT ARCH ALLER A IMM, V87, P230, DOI 10.1159/000234678; HELM RM, 1995, J ALLERGY CLIN IMMUN, V95, P158; HULETT AC, 1979, ANN ALLERGY, V42, P160; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG BC, 1989, ANN ALLERGY, V63, P207; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V87, P574, DOI 10.1016/0091-6749(91)90017-I; MCKITTRICK FA, 1964, MEMOIR CORNELL U AGR, V389; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; NORMAN PS, 1995, J ALLERGY CLIN IMMUN, V95, P259; OHEHIR RE, 1993, J ALLERGY CLIN IMMUN, V92, P105, DOI 10.1016/0091-6749(93)90044-G; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; RAFNAR T, 1992, J BIOL CHEM, V267, P21119; RUSSELL PJ, 1984, MOL GEN GENET, V196, P275, DOI 10.1007/BF00328060; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SOGAWA K, 1983, J BIOL CHEM, V258, P5306; STANKUS RP, 1990, J ALLERGY CLIN IMMUN, V86, P781, DOI 10.1016/S0091-6749(05)80183-6; SZECSI PB, 1992, SCAND J CLIN LAB INV, V52, P5, DOI 10.3109/00365519209104650; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VANNEERVEN RJJ, 1993, J IMMUNOL, V151, P2326; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225, DOI 10.1016/0161-5890(91)90009-9; WU CH, 1988, J ALLERGY CLIN IMMUN, V82, P727, DOI 10.1016/0091-6749(88)90071-1; WU CH, 1990, CLIN EXP ALLERGY, V20, P675, DOI 10.1111/j.1365-2222.1990.tb02707.x; WU CH, 1995, IN PRESS J ALLERGY C; YSSEL H, 1992, J IMMUNOL, V148, P738; ZWICK H, 1991, J ALLERGY CLIN IMMUN, V87, P626, DOI 10.1016/0091-6749(91)90380-7	52	148	161	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19563	19568		10.1074/jbc.270.33.19563	http://dx.doi.org/10.1074/jbc.270.33.19563			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642642	hybrid			2022-12-25	WOS:A1995RP70300058
J	BARLEV, NA; CANDAU, R; WANG, LA; DARPINO, P; SILVERMAN, N; BERGER, SL				BARLEV, NA; CANDAU, R; WANG, LA; DARPINO, P; SILVERMAN, N; BERGER, SL			CHARACTERIZATION OF PHYSICAL INTERACTIONS OF THE PUTATIVE TRANSCRIPTIONAL ADAPTER, ADA2, WITH ACIDIC ACTIVATION DOMAINS AND TATA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; GLUTATHIONE-S-TRANSFERASE; EARLY GENE-EXPRESSION; FACTOR-TFIIB; FUNCTIONAL DISSECTION; BASAL TRANSCRIPTION; YEAST; VP16; COMPLEX; COACTIVATORS	RNA polymerase II transcription requires functional interactions between activator proteins bound to upstream DNA sites and general factors bound to the core promoter. Accessory transcription factors, such as adaptors and coactivators, have important, but still unclear, roles in the activation process. We tested physical interactions of the putative adaptor ADA2 with activation domains derived from acidic activator proteins and with certain general transcription factors. ADA2 associated with the herpesvirus VP16 and yeast GCN4 activation domains but not with the activation domain of yeast HAP4, which previously was shown to be independent of ADA2 function in vivo and in vitro. Furthermore, the amino terminus of ADA2 directly interacted with the VP16 activation domain, suggesting that ADA2 provides determinants for interaction between activation domains and the adaptor complex. Both TATA-binding protein (TBP) and TFIIB have previously been shown to interact directly with the VP16 activation domain in vitro (Stringer, K. F., Ingles, C. J., and Greenblatt, J. (1990) Nature 345, 783-786; Lin, Y. S., Ha, I., Maldonado, E., Reinberg, D., and Green, M. R. (1991) Nature 353, 569-571). Interestingly, when binding was tested between VP16 and these general factors in yeast nuclear extracts, both factors interacted with VP16, but only the TBP/VP16 association was dependent on ADA2. In addition, ADA2 physically associated with TBP, but not with TFIIB. These results suggest that the role of ADA2 in transcriptional activation is to promote physical interaction between activation domains and TBP.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	The Wistar Institute; Massachusetts Institute of Technology (MIT)			Barlev, Nikolai A/K-5268-2017	Barlev, Nikolai A/0000-0001-7111-2446; Silverman, Neal/0000-0002-4259-456X; Berger, Shelley/0000-0001-5398-4400	NCI NIH HHS [CA10815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PINTO I, 1994, J BIOL CHEM, V269, P30569; POON D, 1993, J BIOL CHEM, V268, P15325; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSE M, 1983, J MOL BIOL, V170, P883, DOI 10.1016/S0022-2836(83)80193-4; ROSE MD, 1988, METHODS YEAST GENETI; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WALKER S, 1993, MOL CELL BIOL, V13, P5233, DOI 10.1128/MCB.13.9.5233; WANG L, 1995, GENE, V158, P163, DOI 10.1016/0378-1119(95)00126-Q; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	73	164	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19337	19344		10.1074/jbc.270.33.19337	http://dx.doi.org/10.1074/jbc.270.33.19337			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642611	hybrid			2022-12-25	WOS:A1995RP70300025
J	GOPAL, D; BURKE, M				GOPAL, D; BURKE, M			FORMATION OF STABLE INHIBITORY COMPLEXES OF MYOSIN SUBFRAGMENT-1 USING FLUOROSCANDIUM ANIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BERYLLIUM FLUORIDE; ADENOSINE-TRIPHOSPHATASE; ALUMINUM FLUORIDE; VANADATE ION; F-19 NMR; F-ACTIN; PHOSPHATE; BINDING; ATPASE; NUCLEOTIDE	Evidence is presented that MgADP can be noncovalently trapped in myosin subfragment 1 in the presence of ScFx resulting in the concomitant loss of ATPase function. The rate of inactivation in the presence of MgCl2 at 25 degrees C is 8.7 M(-1) s(-1) which is too slow for a simple collisional mechanism and suggests that a subsequent slow isomerization step is responsible for formation of a stable ternary complex, S1 . MgADP . ScFx in a manner analogous to that proposed for the Vi stabilized complex by Goodno (Goodno, C. C. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 2620-2624). It is also found that ADP can be trapped in subfragment 1 in the absence of MgCl2 indicating the formation of an S1 . ADP . ScFx complex. The stability of these complexes at 4 degrees C was studied by following the loss of trapped [C-14]ADP with a chase with ADP. The rate of nucleotide loss at 4 degrees C was biphasic for both complexes suggesting that the inhibitory complexes exist in two distinct states as previously proposed for the ternary complex stabilized by Vi (Mihashi, K., Ooi, A., and Hiratsuka, T. (1990) J. Biochem. (Tokyo) 107, 464-469). Formation of these complexes resulted in a marked enhancement of the intrinsic tryptophyl fluorescence suggesting that conformationally they may resemble the steady-state intermediate formed with MgATP. The failure to observe photolysis in the presence of excess Vi at sites associated with the ATP consensus sequence suggests that in these complexes ScFx occupies the site responsible for these cleavage reactions and that it is not displaced by the added Vi.	CASE WESTERN RESERVE UNIV,COLL ARTS & SCI,DEPT BIOL,CLEVELAND,OH 44106	Case Western Reserve University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015319] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15319] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; BECK TW, 1992, BIOPHYS J, V61, pA2506; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; COMBEAU C, 1989, J BIOL CHEM, V264, P19017; CREMO CR, 1989, J BIOL CHEM, V264, P6608; DANTZIG JA, 1992, J PHYSIOL-LONDON, V451, P247, DOI 10.1113/jphysiol.1992.sp019163; GODFREY JE, 1970, BIOCHEMISTRY-US, V9, P886, DOI 10.1021/bi00806a025; GOLDSTEIN G, 1964, ANAL CHEM, V36, P243, DOI 10.1021/ac60207a074; GOODNO CC, 1982, P NATL ACAD SCI-BIOL, V79, P21, DOI 10.1073/pnas.79.1.21; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; HENRY GD, 1993, BIOCHEMISTRY-US, V32, P10451, DOI 10.1021/bi00090a022; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; ISSARTEL JP, 1991, BIOCHEMISTRY-US, V30, P4726, DOI 10.1021/bi00233a013; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST RN, 1973, J AM CHEM SOC, V95, P8762, DOI 10.1021/ja00807a043; LUO Y, 1994, BIOPHYS J, V66, pA79; MARUTA S, 1993, J BIOL CHEM, V268, P7093; MIHASHI K, 1990, J BIOCHEM-TOKYO, V107, P464, DOI 10.1093/oxfordjournals.jbchem.a123068; MOCZ G, 1989, EUR J BIOCHEM, V179, P373, DOI 10.1111/j.1432-1033.1989.tb14563.x; Nowacki W, 1939, Z KRISTALLOGR, V101, P273; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PHAN B, 1992, BIOCHEMISTRY-US, V31, P4787, DOI 10.1021/bi00135a007; RAJASEKHARAN KN, 1987, J BIOL CHEM, V262, P11207; RINGEL I, 1990, BIOCHEMISTRY-US, V29, P9091, DOI 10.1021/bi00490a029; SLEEP JA, 1980, BIOCHEMISTRY-US, V19, P1276, DOI 10.1021/bi00548a002; SMITH SJ, 1990, EUR J BIOCHEM, V193, P69, DOI 10.1111/j.1432-1033.1990.tb19305.x; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Van Eldik R., 1986, INORGANIC HIGH PRESS; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WERBER MM, 1992, BIOCHEMISTRY-US, V31, P7190, DOI 10.1021/bi00146a023; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; [No title captured]	37	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19282	19286		10.1074/jbc.270.33.19282	http://dx.doi.org/10.1074/jbc.270.33.19282			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642602	hybrid			2022-12-25	WOS:A1995RP70300016
J	MASSILLON, D; BOLLEN, M; DEWULF, H; OVERLOOP, K; VANSTAPEL, F; VANHECKE, P; STALMANS, W				MASSILLON, D; BOLLEN, M; DEWULF, H; OVERLOOP, K; VANSTAPEL, F; VANHECKE, P; STALMANS, W			DEMONSTRATION OF A GLYCOGEN/GLUCOSE 1-PHOSPHATE CYCLE IN HEPATOCYTES FROM FASTED RATS - SELECTIVE INACTIVATION OF PHOSPHORYLASE BY 2-DEOXY-2-FLUORO-ALPHA-D-GLUCOPYRANOSYL FLUORIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE PHOSPHATASE-ACTIVITY; GLUCOSE; LIVER; ACTIVATION; MECHANISM; GLUCOSE-6-PHOSPHATE; SPECIFICITY; METABOLITES; SYNTHETASE; SUBSTRATE	In search for a nonmetabolized, superior glucose analogue to study the mechanism of glucose-induced glycogen synthesis, we have tested 2-deoxy-2-fluoro-alpha-D-glucopyranosyl fluoride, which inhibits muscle phosphorylase b 10 fold better than does glucose (Street, I. P., Armstrong, C. R., and Withers, S. G. (1986) Biochemistry 25, 6021-6027), In a gel-filtered liver extract, 0.6 mM analogue and 10 mM glucose equally accelerated the inactivation of phosphorylase and shortened the latency before the activation of glycogen synthase, The analogue was not measurably defluorinated or phosphorylated by intact hepatocytes, as monitored by F-19 NMR. When added to isolated hepatocytes, 10 mM analogue inactivated phosphorylase more extensively than did 50 mM glucose, but unlike glucose, it did not result in the activation of glycogen synthase, Therefore, the binding of glucose to phosphorylase a can account for the inactivation of phosphorylase, but the metabolism of glucose (probably to Glc-6-P) appears to be required to achieve activation of glycogen synthase. The livers of overnight-fasted, anesthetized mice contained appreciable amounts of both phosphorylase a and glycogen synthase a, without net glycogen accumulation, Likewise, hepatocytes isolated from fasted rats and incubated with 10 mM glucose contained 41% of phosphorylase and 32% of glycogen synthase in the a form, and these values remained stable for 1 h, while glycogen accumulated at only 22% of the rate expected from the glycogen synthase activity, The addition of 10 mM analogue decreased phosphorylase a to 10% without significant change in glycogen synthase a (38%), but with a 4-fold increased rate of glycogen accumulation. These findings imply that synthase a is fully active in the liver of the fasted animal and that the absence of net glycogen synthesis is due to continuous glycogenolysis by phosphorylase a.	CATHOLIC UNIV LEUVEN,FAK GENEESKUNDE,AFDELING BIOCHEM,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,FAK GENEESKUNDE,BIOMED NMR EENHEID,B-3000 LOUVAIN,BELGIUM	KU Leuven; KU Leuven				Vanstapel, Florent/0000-0001-6273-856X				ALEMANY S, 1986, FEBS LETT, V198, P194, DOI 10.1016/0014-5793(86)80404-5; BESSELL EM, 1972, BIOCHEM J, V128, P199, DOI 10.1042/bj1280199; BOLLEN M, 1988, BIOCHEM J, V255, P327; BOLLEN M, 1983, BIOCHEM J, V210, P783, DOI 10.1042/bj2100783; CARABAZA A, 1992, FEBS LETT, V296, P211, DOI 10.1016/0014-5793(92)80381-P; CIUDAD CJ, 1986, BIOCHEM BIOPH RES CO, V141, P1195, DOI 10.1016/S0006-291X(86)80171-1; CRISP DM, 1972, BIOCHEM J, V126, P1009, DOI 10.1042/bj1261009; DEWULF H, 1968, EUR J BIOCHEM, V6, P552; DOPERE F, 1980, EUR J BIOCHEM, V104, P137, DOI 10.1111/j.1432-1033.1980.tb04409.x; FEDDERS G, 1994, EUR J BIOCHEM, V219, P1063, DOI 10.1111/j.1432-1033.1994.tb18589.x; GRUNNET N, 1994, ARCH BIOCHEM BIOPHYS, V309, P18, DOI 10.1006/abbi.1994.1077; HALL LD, 1971, CAN J CHEMISTRY, V49, P118, DOI 10.1139/v71-017; HARRIS RA, 1989, J BIOL CHEM, V264, P14674; HUE L, 1975, BIOCHEM J, V152, P105, DOI 10.1042/bj1520105; JUHL H, 1982, BIOCHEM BIOPH RES CO, V106, P210, DOI 10.1016/0006-291X(82)92079-4; KORYTNYK W, 1980, TETRAHEDRON LETT, V21, P1493, DOI 10.1016/S0040-4039(00)92755-2; LAVOIE L, 1991, ENDOCRINOLOGY, V129, P2674, DOI 10.1210/endo-129-5-2674; LIU W, 1991, BIOCHEMISTRY-US, V30, P1419, DOI 10.1021/bi00219a036; MASSILLON D, 1994, BIOCHEM J, V299, P123, DOI 10.1042/bj2990123; MICHAL G, 1984, METHOD ENZYMAT AN, V6, P191; MVUMBI L, 1983, BIOCHEM J, V212, P407, DOI 10.1042/bj2120407; MVUMBI L, 1987, BIOCHEM J, V246, P367, DOI 10.1042/bj2460367; NAKADA T, 1985, BIOCHEM ARCH, V1, P163; STALMANS W, 1974, EUR J BIOCHEM, V41, P127, DOI 10.1111/j.1432-1033.1974.tb03252.x; STALMANS W, 1974, EUR J BIOCHEM, V49, P415, DOI 10.1111/j.1432-1033.1974.tb03847.x; STALMANS W, 1987, Diabetes Metabolism Reviews, V3, P127; STALMANS W, 1976, CURR TOP CELL REGUL, V11, P51; STREET IP, 1986, BIOCHEMISTRY-US, V25, P6021, DOI 10.1021/bi00368a028; TAN AWH, 1982, J BIOL CHEM, V257, P5004; VANDEBROECK A, 1985, EUR J BIOCHEM, V153, P621, DOI 10.1111/j.1432-1033.1985.tb09345.x; VANDEWERVE G, 1984, AM J PHYSIOL, V247, pE241; VANSCHAFTINGEN E, 1993, EUR J BIOCHEM, V218, P745; VILLARPALASI C, 1994, BBA-PROTEIN STRUCT M, V1207, P88, DOI 10.1016/0167-4838(94)90055-8; VILLARPALASI C, 1991, BIOCHIM BIOPHYS ACTA, V1095, P261, DOI 10.1016/0167-4889(91)90109-B; WAJNGOT A, 1991, METABOLISM, V40, P877, DOI 10.1016/0026-0495(91)90019-S; WANG P, 1972, EUR J BIOCHEM, V27, P297, DOI 10.1111/j.1432-1033.1972.tb01839.x; WATSON KA, 1994, BIOCHEMISTRY-US, V33, P5745, DOI 10.1021/bi00185a011; WERA S, 1991, J BIOL CHEM, V266, P339; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; YOUN JH, 1986, J BIOL CHEM, V261, P5960	40	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19351	19356		10.1074/jbc.270.33.19351	http://dx.doi.org/10.1074/jbc.270.33.19351			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642613	hybrid			2022-12-25	WOS:A1995RP70300027
J	POWER, CA; MEYER, A; NEMETH, K; BACON, KB; HOOGEWERF, AJ; PROUDFOOT, AEI; WELLS, TNC				POWER, CA; MEYER, A; NEMETH, K; BACON, KB; HOOGEWERF, AJ; PROUDFOOT, AEI; WELLS, TNC			MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF A NOVEL CC-CHEMOKINE RECEPTOR CDNA FROM A HUMAN BASOPHILIC CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; COUPLED RECEPTORS; PEPTIDE RECEPTOR; T-CELLS; RANTES; FAMILY; ACTIVATION; CYTOKINES; MONOCYTE; SEQUENCE	We report the cloning and characterization of a novel basophil CC chemokine receptor, K5-5, from the human immature basophilic cell line KU-812. The predicted protein sequence of K5-5 shows only 49% identity to the macrophage inflammatory protein-1 alpha/RANTES receptor (CC CKR-1) and 47% identity to monocyte chemotactic protein-1 receptor (b form), suggesting that this cDNA encodes a novel member of the CC chemokine receptor family. Analysis of K5-5 mRNA expression indicates that it is restricted to leukocyte-rich tissues, In addition, we have shown significant levels of K5-5 mRNA in human basophils, which were up-regulated by treatment with interleukin-5. The CC chemokines, macrophage inflammatory protein-1 alpha, RANTES, and monocyte chemotactic protein-1 were able to stimulate a Ca2+-activated chloride channel in Xenopus laevis oocytes injected with R5-5 cRNA, whereas no signal was detected in response to monocyte chemotactic protein-2, macrophage inflammatory protein-1 beta, or the CXC chemokine, interleukin-8. Taken together, these results indicate for the first time the presence of a CC chemokine receptor on basophils, which functions as a ''shared'' CC chemokine receptor and may therefore be implicated in the pathogenesis of basophil-mediated allergic diseases.			POWER, CA (corresponding author), GLAXO INST MOLEC BIOL,14 CHEMIN AULX,CH-1228 PLAN LES OUATES,SWITZERLAND.			Wells, Timothy/0000-0001-9796-847X				ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; ALOUANI S, 1995, EUR J BIOCHEM, V227, P328, DOI 10.1111/j.1432-1033.1995.tb20393.x; AVALOS BR, 1994, BLOOD, V84, P1790, DOI 10.1182/blood.V84.6.1790.bloodjournal8461790; BACON KB, 1994, IMMUNOLOGY, V82, P473; Bertrand D, 1991, METHODS NEUROSCIENCE, V4, P174; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; BISCHOFF SC, 1992, J EXP MED, V175, P1271, DOI 10.1084/jem.175.5.1271; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENBURG JA, 1985, J ALLERGY CLIN IMMUN, V76, P466, DOI 10.1016/0091-6749(85)90728-6; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FREW AJ, 1991, CLIN EXP IMMUNOL, V84, P270; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GAO JL, 1994, J BIOL CHEM, V269, P28539; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GRANT JA, 1986, FASEB J, V45, P2653; HERZOG H, 1993, DNA CELL BIOL, V12, P465, DOI 10.1089/dna.1993.12.465; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRIEGER M, 1992, J IMMUNOL, V149, P2662; KUNA P, 1992, J IMMUNOL, V149, P636; KUNA P, 1993, J IMMUNOL, V150, P1932; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LOETSCHER P, 1994, FASEB J, V8, P1055, DOI 10.1096/fasebj.8.13.7926371; LUSTINARASIMHAN M, 1995, J BIOL CHEM, V270, P2716, DOI 10.1074/jbc.270.6.2716; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MORITA M, 1993, JAP J CLIN EXP MED, V51, P712; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, J BIOL CHEM, V268, P12247; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NICOD LP, 1989, J LEUKOCYTE BIOL, V45, P458, DOI 10.1002/jlb.45.5.458; OTSUKA H, 1986, AM REV RESPIR DIS, V133, P757; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RIMLAND J, 1991, MOL PHARMACOL, V40, P869; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHULTZ P, 1992, BIOCHEM J, V284, P207, DOI 10.1042/bj2840207; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; TURCATTI G, 1993, J RECEPTOR RES, V13, P639, DOI 10.3109/10799899309073684; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; VANRIPER G, 1994, J IMMUNOL, V152, P4055; WANG JM, 1993, J EXP MED, V177, P699, DOI 10.1084/jem.177.3.699; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; Yoshimura T, 1992, Cytokines, V4, P131	51	248	291	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19495	19500		10.1074/jbc.270.33.19495	http://dx.doi.org/10.1074/jbc.270.33.19495			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642634				2022-12-25	WOS:A1995RP70300048
J	FUKAZAWA, T; REEDQUIST, KA; TRUB, T; SOLTOFF, S; PANCHAMOORTHY, G; DRUKER, B; CANTLEY, L; SHOELSON, SE; BAND, H				FUKAZAWA, T; REEDQUIST, KA; TRUB, T; SOLTOFF, S; PANCHAMOORTHY, G; DRUKER, B; CANTLEY, L; SHOELSON, SE; BAND, H			THE SH3 DOMAIN-BINDING T-CELL TYROSYL PHOSPHOPROTEIN P120 - DEMONSTRATION OF ITS IDENTITY WITH THE C-CBL PROTOONCOGENE PRODUCT AND IN-VIVO COMPLEXES WITH FYN, GRB2, AND PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V-CBL; SIGNAL TRANSDUCTION; ANTIGEN RECEPTOR; PROTO-ONCOGENE; TRANSFORMATION; KINASES; CLONING; GENE; RAS; LYMPHOCYTES	Previously, we have identified p120 as a Fyn/Lck SH3 and SH2 domain-binding protein that is tyrosine phosphorylated rapidly after T cell receptor triggering. Here, we used direct protein purification, amino acid sequence analysis, reactivity with antibodies, and two-dimensional gel analyses to identify p120 as the human c-cbl protooncogene product. We demonstrate in, vivo complexes of p120(cbl) with Fyn tyrosine kinase, the adaptor protein Grb2, and the p85 subunit of phosphatidylinositol (PI) 3-kinase, The association of p120(cbl) with Fyn and the p85 subunit of PI 3-kinase (together with PI 3-kinase activity) was markedly increased by T cell activation, consistent with in vitro binding of p120(cbl) to their SH2 as well as SH3 domains, In contrast, a large fraction of p120(cbl) was associated with Grb2 prior to activation, and this association did not change upon T cell activation. In vitro, p120(cbl) interacted with Grb2 exclusively through its SH3 domains, These results demonstrate a novel Grb2-p120(cbl) signaling complex in T cells, distinct from the previously analyzed Grb2-Sos complex. The association of p120(cbl) with ubiquitous signaling proteins strongly suggests a general signal transducing function for this enigmatic protooncogene with established leukemogenic potential but unknown physiological function.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED, DEPT RHEUMATOL & IMMUNOL,LYMPHOCYTE BIOL SECT, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, JOSLIN DIABET CTR,RES DIV, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; OREGON HLTH SCI UNIV, DIV HEMATOL & MED ONCOL, PORTLAND, OR 97201 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Oregon Health & Science University			Fukazawa, Takuya/GLR-7099-2022; Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Druker, Brian/0000-0001-8331-8206	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI028508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NIAID NIH HHS [R29-AI28508] Funding Source: Medline; NIAMS NIH HHS [AR36308] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BAND H, 1987, SCIENCE, V238, P682, DOI 10.1126/science.3672118; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BUDAY L, 1994, J BIOL CHEM, V269, P9019; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DASILVA AJ, 1993, J EXP MED, V178, P2107, DOI 10.1084/jem.178.6.2107; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EISEMAN E, 1992, NATURE, V355, P78; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Harlow E, 1988, ANTIBODIES LABORATOR, P521; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JONES PP, 1984, METHOD ENZYMOL, V108, P452; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MARONEY AC, 1992, ONCOGENE, V7, P1207; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REIF K, 1994, J BIOL CHEM, V269, P14081; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; WRIGHT DD, 1994, MOL CELL BIOL, V14, P2429, DOI 10.1128/MCB.14.4.2429; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	61	194	196	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19141	19150		10.1074/jbc.270.32.19141	http://dx.doi.org/10.1074/jbc.270.32.19141			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642581	hybrid			2022-12-25	WOS:A1995RN95400069
J	UCHIDA, S; SASAKI, S; FURUKAWA, T; HIRAOKA, M; IMAI, T; HIRATA, Y; MARUMO, F				UCHIDA, S; SASAKI, S; FURUKAWA, T; HIRAOKA, M; IMAI, T; HIRATA, Y; MARUMO, F			MOLECULAR-CLONING OF A CHLORIDE CHANNEL THAT IS REGULATED BY DEHYDRATION AND EXPRESSED PREDOMINANTLY IN KIDNEY MEDULLA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							THIN ASCENDING LIMB; FUNCTIONAL EXPRESSION; TRANSPORT INHIBITORS; RECEPTOR SHOWS; CL TRANSPORT; HENLES LOOP; PERMEABILITY; SODIUM	Complementary DNA encoding a rat kidney chloride channel (ClC-K1) was isolated by a polymerase chain reaction (PCR) cloning strategy. We designed degenerate primers, based on the regions where previously cloned chloride channels (ClC-0, -1, and -2) possess significant amino acid identity, and performed reverse transcription PCR with whole kidney mRNA. The 686-amino acid protein encoded by ClC-K1 is about 40% identical to the previously cloned chloride channels and has a similar hydropathy profile. Expression of ClC-K1 in Xenopus oocytes induced Cl- currents that activate instantaneously upon hyperpolarization and depolarization, and displayed a slightly outwardly rectifying current-voltage relationship. The message for ClC-K1 was 2.4 kilobases and was found predominantly in kidney, especially in the inner medulla. Reverse transcription PCR technique using microdissected nephron segments revealed that the main site of expression in kidney was the thin ascending limb of Henle's loop, which has the highest Cl- permeability among the nephron segments and is thought to be involved in a counter-current system for urine concentration in the inner medulla. The abundance of ClC-K1 mRNA in kidney increased about 4-fold as rats became dehydrated by deprivation of water for 5 days. The site of expression and the regulation by dehydration suggest that ClC-K1 function may be important in urinary concentrating mechanisms.	TOKYO MED & DENT UNIV,INST MED RES,DEPT CARDIOVASC DIS,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU)	UCHIDA, S (corresponding author), TOKYO MED & DENT UNIV,DEPT INTERNAL MED 2,1-5-45 YUSHIMA,BUNKYO KU,TOKYO 113,JAPAN.							GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; Higuchi R., 1989, PCR TECHNOLOGY, P61; IMAI M, 1974, J CLIN INVEST, V53, P393, DOI 10.1172/JCI107572; IMAI M, 1987, KIDNEY INT, V31, P565, DOI 10.1038/ki.1987.37; IMAI M, 1976, J CLIN INVEST, V58, P1054, DOI 10.1172/JCI108556; ISOZAKI T, 1991, KIDNEY INT, V40, pS113; ISOZAKI T, 1989, AM J PHYSIOL, V257, pF92, DOI 10.1152/ajprenal.1989.257.1.F92; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KONDO Y, 1987, AM J PHYSIOL, V253, pF1206; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KWON HM, 1992, J BIOL CHEM, V267, P6297; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MOYIYAMA T, 1990, AM J PHYSIOL, V258, pF1470; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; REDHEAD CR, 1992, P NATL ACAD SCI USA, V89, P3716, DOI 10.1073/pnas.89.9.3716; REEVES WB, 1992, ANNU REV PHYSIOL, V54, P29, DOI 10.1146/annurev.physiol.54.1.29; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; UCHIDA S, 1991, J BIOL CHEM, V266, P9605; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; UCHIDA S, 1991, Journal of the American Society of Nephrology, V2, P769; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YOSHITOMI K, 1988, J CLIN INVEST, V82, P866, DOI 10.1172/JCI113691	25	228	232	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3821	3824						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680033				2022-12-25	WOS:A1993KN53300007
J	HILL, KJ; STEVENS, TH				HILL, KJ; STEVENS, TH			VMA22P IS A NOVEL ENDOPLASMIC RETICULUM-ASSOCIATED PROTEIN REQUIRED FOR ASSEMBLY OF THE YEAST VACUOLAR H+-ATPASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE ENCODES; SECRETORY PATHWAY; MEMBRANE GLYCOPROTEIN; PEP4 GENE; SUBUNIT; TRANSPORT; MUTANTS; BIOSYNTHESIS; ENZYME	The Saccharomyces cerevisiae vacuolar H+-ATPase (V-ATPase) is a multi-subunit complex that can be structurally and functionally divided into peripheral (V-1) and integral membrane (V-0) sectors. The vma22-1 mutation was isolated in a screen for mutants defective in V-ATPase function. vma22 Delta cells contain no V-ATPase activity due to a failure to assemble the enzyme complex; V-1 subunits accumulate in the cytosol, and the V-0 100-kDa subunit is rapidly degraded. Turnover of the 100-kDa integral membrane protein was found to occur in the endoplasmic reticulum (ER) of vma22 Delta cells. The product of the VMA22 gene, Vma22p, is a 21-kDa hydrophilic protein that is not a subunit of the V-ATPase but rather is associated with ER membranes. The association of Vma22p with ER membranes was perturbed by mutations in VMA12, a gene that encodes an ER membrane protein (Vma12p) that is also required for V-ATPase assembly. These results indicate that Vma22p, along with Vma21p and Vma12p, form a set of ER proteins required for V-ATPase assembly.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Oregon				Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BELTRAN C, 1992, J BIOL CHEM, V267, P774; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; FOURY F, 1990, J BIOL CHEM, V265, P18554; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1989, J BIOL CHEM, V264, P1775; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; OHYA Y, 1991, J BIOL CHEM, V266, P13971; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PIPER RC, 1994, EUR J CELL BIOL, V65, P305; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Sherman F., 1986, METHODS YEAST GENETI; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	52	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22329	22336		10.1074/jbc.270.38.22329	http://dx.doi.org/10.1074/jbc.270.38.22329			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673216	hybrid			2022-12-25	WOS:A1995RW31400043
J	MARTINEY, JA; CERAMI, A; SLATER, AFG				MARTINEY, JA; CERAMI, A; SLATER, AFG			VERAPAMIL REVERSAL OF CHLOROQUINE RESISTANCE IN THE MALARIA PARASITE PLASMODIUM-FALCIPARUM IS SPECIFIC FOR RESISTANT PARASITES AND INDEPENDENT OF THE WEAK BASE EFFECT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSING DIFFERENT LEVELS; P-GLYCOPROTEIN; HEMOGLOBIN DEGRADATION; EFFLUX; MECHANISM; CULTURE; ACCUMULATION; SENSITIVITY; QUINOLINE; PIGMENT	Verapamil increases the net uptake and cytotoxicity of structurally diverse hydrophobic molecules in many multidrug-resistant mammalian cell lines, This compound has also been reported to reverse chloroquine resistance in the human malaria parasite Plasmodium falciparum (Martin, S. K., Oduola, A. M. J., and Milhous, W. K. (1987) Science 235, 899-901), Although the mechanism of this reversal is unknown, it apparently involves an increase in the amount of chloroquine present in erythrocytes infected with the resistant parasites, Chloroquine is a diprotic weak base that accumulates in acidic organelles as a function of the pH gradient present between the organelle and the external medium, By changing the external medium pH, this property of chloroquine was used to alter the cytotoxicity phenotype of genetically chloroquine-sensitive and -resistant trophozoites, Verapamil was also found to be toxic for malaria trophozoites, although this toxicity was independent of external pH and consistently about 3-4-fold higher against resistant strains, When verapamil was tested for its effects on chloroquine cytotoxicity under conditions of phenotypic reversal, it was still found to exert only a measurable effect on the genetically resistant trophozoites, In short time incubations, verapamil was found to increase net chloroquine accumulation in erythrocytes infected with both chloroquine-sensitive and -resistant organisms, but only to affect the chloroquine susceptibility of the latter, Analysis of our data demonstrates that verapamil works independently of the overall pH gradient concentrating chloroquine into a trophozoite's lysosome, Instead, we propose that it inhibits the activity of a membrane ion channel indirectly responsible for determining chloroquine transit within the parasite's cytoplasm.	KAROLINSKA INST, DIV TOXICOL, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet	MARTINEY, JA (corresponding author), PICOWER INST MED RES, 350 COMMUNITY DR, MANHASSET, NY 11030 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030660] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI-30660-S1, R01-AI-30660-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRAY PG, 1994, MOL BIOCHEM PARASIT, V63, P87, DOI 10.1016/0166-6851(94)90011-6; BRAY PG, 1992, BIOCHEM PHARMACOL, V44, P1317, DOI 10.1016/0006-2952(92)90532-N; BRAY PG, 1992, BIOCHEM PHARMACOL, V43, P1219, DOI 10.1016/0006-2952(92)90495-5; BRAY PG, 1993, FEMS MICROBIOL LETT, V113, P1, DOI 10.1111/j.1574-6968.1993.tb06479.x; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; FOOTE SJ, 1994, ACTA TROP, V56, P157, DOI 10.1016/0001-706X(94)90061-2; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GINSBURG H, 1987, BIOCHEM PHARMACOL, V36, P1567, DOI 10.1016/0006-2952(87)90038-4; GLUZMAN IY, 1987, ANTIMICROB AGENTS CH, V31, P32, DOI 10.1128/AAC.31.1.32; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; JACOBS GH, 1988, AM J TROP MED HYG, V39, P15, DOI 10.4269/ajtmh.1988.39.15; JENSEN JB, 1977, J PARASITOL, V63, P883, DOI 10.2307/3279900; KROGSTAD DJ, 1992, BIOCHEM PHARMACOL, V43, P57, DOI 10.1016/0006-2952(92)90661-2; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LUZ JG, 1994, BIOCHEMISTRY-US, V33, P7239, DOI 10.1021/bi00189a028; MARTIN SK, 1987, SCIENCE, V235, P899, DOI 10.1126/science.3544220; ROEPE PD, 1994, TRENDS PHARMACOL SCI, V15, P445, DOI 10.1016/0165-6147(94)90056-6; ROEPE PD, 1993, BIOCHEMISTRY-US, V32, P11042, DOI 10.1021/bi00092a014; ROEPE PD, 1992, BIOCHEMISTRY-US, V31, P12555, DOI 10.1021/bi00165a003; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; SLATER AFG, 1992, EXP PARASITOL, V74, P362, DOI 10.1016/0014-4894(92)90162-4; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; THEVENOD F, 1994, J BIOL CHEM, V269, P24410; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VALVERDE MA, 1995, FASEB J, V9, P509, DOI 10.1096/fasebj.9.7.7737459; WEI LY, 1994, BIOCHEMISTRY-US, V33, P7229, DOI 10.1021/bi00189a027; WHITE NJ, 1992, J ANTIMICROB CHEMOTH, V30, P571, DOI 10.1093/jac/30.5.571; YAYON A, 1985, P NATL ACAD SCI USA, V82, P2784, DOI 10.1073/pnas.82.9.2784	35	72	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22393	22398		10.1074/jbc.270.38.22393	http://dx.doi.org/10.1074/jbc.270.38.22393			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673225	hybrid			2022-12-25	WOS:A1995RW31400052
J	CARTER, BD; ZIRRGIEBEL, U; BARDE, YA				CARTER, BD; ZIRRGIEBEL, U; BARDE, YA			DIFFERENTIAL REGULATION OF P21(RAS) ACTIVATION IN NEURONS BY NERVE GROWTH-FACTOR AND BRAIN-DERIVED NEUROTROPHIC FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC SENSORY NEURONS; SYMPATHETIC NEURONS; PC12 CELLS; BDNF; SURVIVAL; EXPRESSION; RECEPTORS; NT-3; NGF; SYSTEM	Neurotrophins activate the Trk tyrosine kinase receptors, which subsequently initiate signaling pathways that have yet to be fully resolved, resulting in neuronal survival and differentiation. The ability of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) to activate GTP binding to p2l(ras) was investigated using cultured embryonic chick neurons. In both sympathetic and sensory neurons, the addition of NGF markedly increased the formation of Ras-GTP. The magnitude of the effect was found to depend upon the developmental stage, peaking at embryonic day 11 in sympathetic neurons and at embryonic day 9 in sensory neurons, times when large numbers of neurons depend on NGF for survival. Surprisingly, following the addition of BDNF, no formation of Ras-GTP could be observed in neurons cultured with BDNF. When sensory neurons were cultured with NGF alone, both NGF and BDNF stimulated GTP binding to Ras. In rat cerebellar granule cells, while the acute exposure of these cells to BDNF resulted in the formation Ras-GTP, no response was observed following previous exposure of the cells to BDNF, as was observed with sensory neurons. However, this desensitization was not observed in a transformed cell line expressing TrkB. In neurons, the mechanism underlying the loss of the BDNF response appeared to involve a dramatic loss of binding to cell-surface receptors, as determined by cross-linking with radiolabeled BDNF. Receptor degradation could not account for the desensitization since cell lysates from neurons pretreated with BDNF revealed that the levels of TrkB were comparable to those in untreated cells. These results indicate that in neurons, the pathways activated by NGF and BDNF are differentially regulated and that prolonged exposure to BDNF results in the inability of TrkB to bind its ligand.	MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society	CARTER, BD (corresponding author), MAX PLANCK INST PSYCHIAT,DEPT NEUROBIOCHEM,D-82152 MARTINSRIED,GERMANY.		Barde, Yves/F-6019-2011	Barde, Yves/0000-0002-7627-461X				BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIFFO S, 1995, DEVELOPMENT, V121, P2461; BORASIO GD, 1989, NEURON, V2, P1087; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECHANT G, 1993, J NEUROSCI, V13, P2610, DOI 10.1523/JNEUROSCI.13-06-02610.1993; DECHANT G, 1993, DEVELOPMENT, V119, P545; ERNSBERGER U, 1989, DEV BIOL, V135, P250, DOI 10.1016/0012-1606(89)90177-2; GAESE F, 1994, DEVELOPMENT, V120, P1613; GOTZ R, 1992, EUR J BIOCHEM, V204, P745, DOI 10.1111/j.1432-1033.1992.tb16689.x; HERZOG KH, 1994, DEVELOPMENT, V120, P1643; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KNUSEL B, 1994, J NEUROSCI, V14, P1542, DOI 10.1523/JNEUROSCI.14-03-01542.1994; LEAH J, 1988, INT J DEV NEUROSCI, V6, P403; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MCMAHON SB, 1994, NEURON, V12, P1161, DOI 10.1016/0896-6273(94)90323-9; MILLER FD, 1991, J CELL BIOL, V112, P303, DOI 10.1083/jcb.112.2.303; MUROYA K, 1992, ONCOGENE, V7, P277; NG NFL, 1993, J BIOL CHEM, V268, P25329; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SUDA K, 1978, P NATL ACAD SCI USA, V75, P4042, DOI 10.1073/pnas.75.8.4042; SUTTER A, 1979, J BIOL CHEM, V254, P5972; WIDMER HR, 1993, BRAIN RES, V614, P325, DOI 10.1016/0006-8993(93)91051-S; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	32	88	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21751	21757		10.1074/jbc.270.37.21751	http://dx.doi.org/10.1074/jbc.270.37.21751			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665594	hybrid			2022-12-25	WOS:A1995RU75700053
J	IVESTER, CT; TUXWORTH, WJ; COOPER, G; MCDERMOTT, PJ				IVESTER, CT; TUXWORTH, WJ; COOPER, G; MCDERMOTT, PJ			CONTRACTION ACCELERATES MYOSIN HEAVY-CHAIN SYNTHESIS RATES IN ADULT CARDIOCYTES BY AN INCREASE IN THE RATE OF TRANSLATIONAL INITIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC PERFUSION-PRESSURE; PROTEIN-SYNTHESIS; CARDIAC-HYPERTROPHY; GENE-EXPRESSION; FELINE CARDIOCYTES; SKELETAL-MUSCLE; LOAD REGULATION; MESSENGER-RNAS; HEART-CELLS; OVERLOAD	The purpose of this study was to determine the mechanism by which contraction acutely accelerates the synthesis rate of the contractile protein myosin heavy chain (MHC). Laminin-adherent adult feline cardiocytes were maintained in a serum-free medium and induced to contract at 1 Hz via electrical field stimulation. Electrical stimulation of contraction accelerated rates of MHC synthesis 28%, p < 0.05 by 4 h as determined by incorporation of [H-3]phenylalanine into MHC. MHC mRNA expression as measured by RNase protection was unchanged after 4 h of electrical stimulation. MHC mRNA levels in messenger ribonucleoprotein complexes and translating polysomes were examined by sucrose gradient fractionation. The relative percentage of polysome-bound MHC mRNA was equal at 47% in both electrically stimulated and control cardiocytes. However, electrical stimulation of contraction resulted in a reproducible shift of MHC mRNA from smaller polysomes into larger polysomes, indicating an increased rate of initiation. This shift resulted in significant increases in MHC mRNA levels in the fractions containing the larger polysomes of electrically stimulated cardiocytes as compared with nonstimulated controls. These data indicate that the rate of MHC synthesis is accelerated in contracting cardiocytes via an increase in translational efficiency.	RALPH H JOHNSON DEPT VET AFFAIRS MED CTR, CARDIOL SECT, CHARLESTON, SC 29401 USA; MED UNIV S CAROLINA, GAZES CARDIAC RES INST, DEPT MED, CHARLESTON, SC 29401 USA; MED UNIV S CAROLINA, GAZES CARDIAC RES INST, DEPT PHYSIOL, CHARLESTON, SC 29401 USA; MED UNIV S CAROLINA, GAZES CARDIAC RES INST, DEPT CELL BIOL & ANAT, CHARLESTON, SC 29401 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL48788-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERGER HJ, 1994, AM J PHYSIOL, V266, pH341, DOI 10.1152/ajpheart.1994.266.1.H341; BOHELER KR, 1992, TRENDS CARDIOVAS MED, V2, P176, DOI 10.1016/1050-1738(92)90046-U; BOOTH FW, 1992, AM J PHYSIOL, V262, pR329, DOI 10.1152/ajpregu.1992.262.3.R329; BOOTH FW, 1991, BIOCHEM SOC T, V19, P374, DOI 10.1042/bst0190374; CLARK WA, 1993, CIRC RES, V73, P1163, DOI 10.1161/01.RES.73.6.1163; COOPER G, 1986, CIRC RES, V58, P692, DOI 10.1161/01.RES.58.5.692; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; DELCAYRE C, 1992, AM J PHYSIOL, V263, pH1537, DOI 10.1152/ajpheart.1992.263.5.H1537; DILLMANN WH, 1989, ENDOCR RES, V15, P565, DOI 10.3109/07435808909036352; DOETSCHMAN TC, 1980, DIFFERENTIATION, V16, P149, DOI 10.1111/j.1432-0436.1980.tb01071.x; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; EVERETT AW, 1979, J MOL CELL CARDIOL, V11, P1253, DOI 10.1016/0022-2828(79)90005-1; EVERETT AW, 1977, BIOCHEM J, V166, P315, DOI 10.1042/bj1660315; FAGAN RJ, 1993, MOL CELL ENDOCRINOL, V90, P171, DOI 10.1016/0303-7207(93)90149-E; FAGAN RJ, 1991, J BIOL CHEM, V266, P16518; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; IMAMURA T, 1994, CIRC RES, V75, P418, DOI 10.1161/01.RES.75.3.418; IVESTER CT, 1993, AM J PHYSIOL, V265, pH666; JOHNSON TB, 1994, CIRC RES, V74, P448, DOI 10.1161/01.RES.74.3.448; KATO S, 1995, AM J PHYSIOL-HEART C, V268, pH2495; KENT RL, 1989, CIRC RES, V64, P74, DOI 10.1161/01.RES.64.1.74; KIRA Y, 1984, AM J PHYSIOL, V246, pC247, DOI 10.1152/ajpcell.1984.246.3.C247; KLEIN I, 1992, J CLIN INVEST, V89, P68, DOI 10.1172/JCI115587; KU Z, 1994, AM J PHYSIOL, V267, pC115, DOI 10.1152/ajpcell.1994.267.1.C115; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MARINO TA, 1985, AM J PHYSIOL, V249, pH371, DOI 10.1152/ajpheart.1985.249.2.H371; MOALIC JM, 1984, J MOL CELL CARDIOL, V16, P875, DOI 10.1016/S0022-2828(84)80024-3; MORGAN HE, 1985, BASIC RES CARDIOL, V80, P115; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; MUNRO H. N., 1966, METHOD BIOCHEM ANAL, V14, P113; NAGAI R, 1988, AM J PHYSIOL, V255, pH325, DOI 10.1152/ajpheart.1988.255.2.H325; OJAMAA K, 1994, P NATL ACAD SCI USA, V91, P3468, DOI 10.1073/pnas.91.8.3468; PETERSON MB, 1972, CIRC RES, V31, P317, DOI 10.1161/01.RES.31.3.317; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; SAMAREL AM, 1991, AM J PHYSIOL, V261, pH1067, DOI 10.1152/ajpheart.1991.261.4.H1067; SIEHL D, 1985, AM J PHYSIOL, V248, pC309, DOI 10.1152/ajpcell.1985.248.3.C309; THOMASON DB, 1989, AM J PHYSIOL, V257, pR300, DOI 10.1152/ajpregu.1989.257.2.R300; UMEDA PK, 1987, AM J CARDIOL, V59, pA49, DOI 10.1016/0002-9149(87)90176-7; WIESNER RJ, 1991, AM J PHYSIOL, V260, pL179, DOI 10.1152/ajplung.1991.260.4.L179; WISENBAUGH T, 1984, AM J PHYSIOL, V247, pH146, DOI 10.1152/ajpheart.1984.247.1.H146; YOUNG RB, 1981, EUR J CELL BIOL, V26, P184	41	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21950	21957		10.1074/jbc.270.37.21950	http://dx.doi.org/10.1074/jbc.270.37.21950			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665617	hybrid			2022-12-25	WOS:A1995RU75700080
J	BRINK, S; FISCHER, K; KLOSGEN, RB; FLUGGE, UI				BRINK, S; FISCHER, K; KLOSGEN, RB; FLUGGE, UI			SORTING OF NUCLEAR-ENCODED CHLOROPLAST MEMBRANE-PROTEINS TO THE ENVELOPE AND THE THYLAKOID MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIT PEPTIDE; SPINACH-CHLOROPLASTS; PHOSPHATE TRANSLOCATOR; INTERMEMBRANE SPACE; PRECURSOR PROTEIN; PEA-CHLOROPLASTS; FOREIGN PROTEIN; INNER MEMBRANE; ATP SYNTHASE; IMPORT	The spinach triose phosphate/phosphate translocator and the 37-kDa protein are both integral components of the chloroplast inner envelope membrane. They are synthesized in the cytosol with N-terminal extensions, the transit peptides, that are different in structural terms from those of imported stromal or thylakoid proteins. In order to determine if these N-terminal extensions are essential for the correct localization to the envelope membrane, they were linked to the mature parts of thylakoid membrane proteins, the light-harvesting chlorophyll a/b binding protein and the CF0II-subunit of the thylakoid ATP synthase, respectively. In addition, the transit peptide of the CF0II-subunit that contains signals for the transport across both the envelope and the thylakoid membrane was fused to the mature parts of both envelope membrane proteins. The chimeric proteins were imported into isolated spinach chloroplasts, and the intraorganellar routing of the proteins was analyzed. The results obtained show that the N-terminal extensions of both envelope membrane proteins possess a stroma-targeting function only and that the information for the integration into the envelope membrane is contained in the mature parts of the proteins. At least part of the integration signal is provided by hydrophobic domains in the mature sequences since the removal of such a hydrophobic segment from the 37-kDa protein leads to missorting of the protein to the stroma and the thylakoid membrane.	UNIV COLOGNE,INST BOT,D-50931 COLOGNE,GERMANY; UNIV MUNICH,INST BOT,D-80638 MUNICH,GERMANY	University of Cologne; University of Munich				Brink, Susanne C./0000-0002-3272-9707				ANDREWS J, 1983, PLANT PHYSIOL, V72, P735, DOI 10.1104/pp.72.3.735; AUCHINCLOSS AH, 1992, J BIOL CHEM, V267, P10439; BARTLING D, 1990, BOT MAG TOKYO, V2, P119; BONNER WM, 1974, EUR J BIOCHEM, V46, P84; BRINKS S, 1994, J BIOL CHEM, V269, P16478; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; CLARK SE, 1991, J CELL BIOL, V114, P681, DOI 10.1083/jcb.114.4.681; CLAUSMEYER S, 1993, J BIOL CHEM, V268, P13869; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DRESESWERRINGLOER, 1991, EUR J BIOCHEM, V0195, P00361, DOI 10.1111/j.1432-1033.1991.tb15714.x; FLUGGE UI, 1990, J BIOENERG BIOMEMBR, V22, P769; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GARTNER F, 1995, J BIOL CHEM, V270, P3788; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HENNIG J, 1986, MOL GEN GENET, V203, P117, DOI 10.1007/BF00330392; HERRMANN RG, 1993, FEBS LETT, V326, P192, DOI 10.1016/0014-5793(93)81789-3; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KYTE J, 1982, J MOL BIOL, V257, P105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LI HM, 1992, J BIOL CHEM, V267, P18999; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; MURAKAMI S, 1978, ARCH BIOCHEM BIOPHYS, V185, P30, DOI 10.1016/0003-9861(78)90140-6; MUSGROVE JE, 1989, PLANT PHYSIOL, V90, P1616, DOI 10.1104/pp.90.4.1616; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIER PH, 1985, EMBO J, V4, P25, DOI 10.1002/j.1460-2075.1985.tb02312.x; SOLL J, 1993, PHYSIOL PLANTARUM, V87, P433, DOI 10.1111/j.1399-3054.1993.tb01752.x; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VIITANEN PV, 1988, J BIOL CHEM, V263, P1500; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; WEBER A, 1995, BIOCHEMISTRY-US, V34, P2621, DOI 10.1021/bi00008a028; WEDEL N, 1992, FEBS LETT, V314, P61, DOI 10.1016/0014-5793(92)81462-U; WILLEY DL, 1991, PLANTA, V183, P451, DOI 10.1007/BF00197745	45	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20808	20815		10.1074/jbc.270.35.20808	http://dx.doi.org/10.1074/jbc.270.35.20808			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657665	hybrid			2022-12-25	WOS:A1995RR58400086
J	KHANNA, M; QIN, KN; WANG, RW; CHENG, KC				KHANNA, M; QIN, KN; WANG, RW; CHENG, KC			SUBSTRATE-SPECIFICITY, GENE STRUCTURE, AND TISSUE-SPECIFIC DISTRIBUTION OF MULTIPLE HUMAN 3-ALPHA-HYDROXYSTEROID DEHYDROGENASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDRODIOL DEHYDROGENASE; LIVER CYTOSOL; RAT; REDUCTASE; RECEPTOR; IDENTIFICATION; PURIFICATION; ORGANIZATION; CHLORDECONE; CRYSTALLIN	We have expressed in Escherichia coli functionally active proteins encoded by two human cDNAs that were isolated previously by using rat 3 alpha(-)hydroxysteroid dehydrogenase cDNA as the probe, The expressed proteins catalyzed the interconversion between 5 alpha-dihydrotestosterone and 5 alpha-androstane-3 alpha, 17 beta-diol. Therefore, we name these two enzymes type I and type II 3 alpha-hydroxysteroid dehydrogenases. The type I enzyme has a high affinity for dihydrotestosterone, whereas the type II enzyme has a low affinity for the substrate, The tissue-specific distribution of these two enzymes was determined by reverse transcription polymerase chain reaction using gene-specific oligonucleotide primers, The mRNA transcript of the type I enzyme was found only in the Liver, whereas that of the type II enzyme appeared in the brain, kidney, liver, lung, placenta, and testis, The structure and sequence of the genes encoding these two 3 alpha-hydroxysteroid dehydrogenases were determined by analysis of genomic clones that were isolated from a lambda EMBL3 SP6/T7 library, The genes coding for the type I and type II enzymes were found to span approximately 20 and 16 kilobase pairs, respectively, and to consist of 9 exons of the same sizes and boundaries, The exons range in size from 77 to 223 base pairs (bp), whereas the introns range in size from 375 bp to approximately 6 kilobase pairs. The type I gene contains a TATA box that is located 27 bp upstream of multiple transcription start sites, In contrast, the type II gene contains two tandem AP2 sequences juxtaposed to a single transcription start site.	CORNELL UNIV,COLL MED,DEPT PEDIAT,NEW YORK,NY 10021; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT DRUG METAB,RAHWAY,NJ 07065	Cornell University; Merck & Company					NIDDK NIH HHS [DK-44177] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044177] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHENG KC, 1991, MOL ENDOCRINOL, V5, P823, DOI 10.1210/mend-5-6-823; CHENG KC, 1983, J BIOL CHEM, V258, P1738; CHENG KC, 1991, ARCH BIOCHEM BIOPHYS, V291, P258, DOI 10.1016/0003-9861(91)90132-3; GLATT HR, 1979, NATURE, V277, P319, DOI 10.1038/277319a0; GRAHAM A, 1991, J BIOL CHEM, V266, P6872; IYER RB, 1992, J STEROID BIOCHEM, V43, P343, DOI 10.1016/0960-0760(92)90169-J; KADOR PF, 1982, ENZYMOLOGY CARBONYL, P243; KHANNA M, 1995, GENOMICS, V25, P488; LOU H, 1994, J BIOL CHEM, V269, P8416; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MOLOWA DT, 1986, J TOXICOL ENV HEALTH, V17, P375, DOI 10.1080/15287398609530832; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; PAILHOUX E, 1992, J STEROID BIOCHEM, V42, P561, DOI 10.1016/0960-0760(92)90445-O; PURDY RH, 1991, P NATL ACAD SCI USA, V88, P4553, DOI 10.1073/pnas.88.10.4553; QIN KN, 1994, BIOCHEMISTRY-US, V33, P3223, DOI 10.1021/bi00177a012; QIN KN, 1993, J STEROID BIOCHEM, V46, P673, DOI 10.1016/0960-0760(93)90308-J; QIN KN, 1994, GENE, V149, P357; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Selye H, 1942, ENDOCRINOLOGY, V30, P437, DOI 10.1210/endo-30-3-437; SNYDER M, 1987, METHOD ENZYMOL, V154, P107; STOLZ A, 1987, J CLIN INVEST, V79, P427, DOI 10.1172/JCI112829; TAKIKAWA H, 1990, BIOCHIM BIOPHYS ACTA, V1043, P153, DOI 10.1016/0005-2760(90)90289-A; TOMAREV SI, 1984, FEBS LETT, V171, P297, DOI 10.1016/0014-5793(84)80508-6; TURNER DM, 1989, J PHARMACOL EXP THER, V248, P960; VOGEL K, 1980, J BIOL CHEM, V255, P9621; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; WERMUTH B, 1987, ENZYMOLOGY MOL BIOL, P297; WINTERS CJ, 1990, BIOCHEMISTRY-US, V29, P1080, DOI 10.1021/bi00456a034; WORNER W, 1984, FEBS LETT, V170, P263, DOI 10.1016/0014-5793(84)81325-3; ZANG DE, 1994, J BIOL CHEM, V269, P11425	33	165	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20162	20168		10.1074/jbc.270.34.20162	http://dx.doi.org/10.1074/jbc.270.34.20162			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650035	hybrid			2022-12-25	WOS:A1995RQ99100072
J	LASKY, SR; IWATA, K; ROSMARIN, AG; CAPRIO, DG; MAIZEL, AL				LASKY, SR; IWATA, K; ROSMARIN, AG; CAPRIO, DG; MAIZEL, AL			DIFFERENTIAL REGULATION OF JUND BY DIHYDROXYCHOLECALCIFEROL IN HUMAN CHRONIC MYELOGENOUS LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VITAMIN-D RECEPTOR; THYROID-HORMONE; RESPONSE ELEMENTS; RETINOIC ACID; DNA-BINDING; C-JUN; FOS; AP-1; PROLIFERATION; RICKETS	1,25-Dihydroxyvitamin D-3 inhibits the proliferation of the chronic myelogenous leukemia cell Line RWLeu-4 but not the resistant variant, JMRD(3). Although these cells exhibit no detectable differences in the vitamin D receptor, alterations in the interaction of nuclear extracts with the osteocalcin-1,25-dihydroxyvitamin D-3-response element are noted, It is shown herein that the 1,25-dihydroxyvitamin D, receptor binds to the osteocalcin-1,25-dihydroxyvitamin D-3-response element along with activator protein-1 (AP-I) complexes and that the DNA binding activities of members of the Jun and Fos proto oncogene families, which make up the AP-1 transcription factor, are differentially regulated by 1,25-dihydroxyvitamin D-3. It is shown that JunD DNA binding activity is enhanced by 1,25-dihydroxyvitamin DQ during cell cycle arrest in the sensitive cells but is decreased in the resistant cells. These results suggest that the level of JunD DNA binding activity may be a critical factor in the regulation of proliferation.	BROWN UNIV, MIRIAM HOSP, SCH MED, DIV HEMATOL, PROVIDENCE, RI 02908 USA	Brown University; Lifespan Health Rhode Island; Miriam Hospital	LASKY, SR (corresponding author), ROGER WILLIAMS CANC MED CTR, MED CTR, EXPTL PATHOL SECT, 825 CHALKSTONE AVE, PROVIDENCE, RI 02908 USA.				NCI NIH HHS [CA50558, CA13943, CA45148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050558, P30CA013943, R37CA045148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BEDI A, 1994, BLOOD, V83, P2038; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY MO, 1992, ANN NY ACAD SCI, V660, P124, DOI 10.1111/j.1749-6632.1992.tb21065.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FELDMAN D, 1990, MOL CELL ENDOCRINOL, V72, pC57, DOI 10.1016/0303-7207(90)90137-W; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; KOEFFLER HP, 1985, VITAMIN D MYELOID DI, V29, P409; KOLLA SS, 1994, CANCER RES, V54, P1418; LASKY SR, 1990, CANCER RES, V50, P3087; LASKY SR, 1994, BLOOD, V84, P4283, DOI 10.1182/blood.V84.12.4283.bloodjournal84124283; LIAN JB, 1991, J CELL BIOCHEM, V45, P9, DOI 10.1002/jcb.240450106; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MALLOY PJ, 1989, J CLIN ENDOCR METAB, V68, P263, DOI 10.1210/jcem-68-2-263; MCDONNELL DP, 1988, J STEROID BIOCHEM, V30, P41, DOI 10.1016/0022-4731(88)90074-X; PAPAVASSILIOU AG, 1993, ANTICANCER RES, V13, P2213; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; POLS HAP, 1990, J STEROID BIOCHEM, V37, P873, DOI 10.1016/0960-0760(90)90435-N; RADLERPOHL A, 1993, ANN NY ACAD SCI, V684, P127, DOI 10.1111/j.1749-6632.1993.tb32277.x; RYSECK RP, 1990, ONCOGENE, V5, P1091; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SMETSERS TFCM, 1994, LEUKEMIA, V8, P129; Studzinski George P., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P279; SUDA T, 1990, ANNU REV NUTR, V10, P195, DOI 10.1146/annurev.nu.10.070190.001211; THOMAS M, 1994, LEUKEMIA RES, V18, P401, DOI 10.1016/0145-2126(94)90075-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VEDECKIS WV, 1992, P SOC EXP BIOL MED, V199, P1; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	37	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19676	19679		10.1074/jbc.270.34.19676	http://dx.doi.org/10.1074/jbc.270.34.19676			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649976	hybrid			2022-12-25	WOS:A1995RQ99100003
J	LYKO, F; MARTOGLIO, B; JUNGNICKEL, B; RAPOPORT, TA; DOBBERSTEIN, B				LYKO, F; MARTOGLIO, B; JUNGNICKEL, B; RAPOPORT, TA; DOBBERSTEIN, B			SIGNAL SEQUENCE PROCESSING IN ROUGH MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SEC11 PROTEIN; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; RECOGNITION PARTICLE; ANTIGEN PRESENTATION; PEPTIDE PEPTIDASE; SECRETORY PROTEIN; MESSENGER-RNA; TRANSLOCATION; MEMBRANE	Secretory proteins are synthesized with a signal sequence that is usually cleaved from the nascent protein during the translocation of the polypeptide chain into the lumen of the endoplasmic reticulum. To determine the fate of a cleaved signal sequence, we used a synchronized in vitro translocation system. Fire found that the cleaved signal peptide of preprolactin is further processed close to its COOH terminus. The resulting fragment accumulated in the microsomal fraction and with time was released into the cytosol. Signal sequence cleavage and processing could be reproduced with reconstituted vesicles containing Sec61, signal recognition particle receptor, and signal peptidase complex.	UNIV HEIDELBERG, ZMBH, D-69052 HEIDELBERG, GERMANY; MAX DELBRUCK CTR MOLEC MED, D-10115 BERLIN, GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; Max Delbruck Center for Molecular Medicine								BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHEN LL, 1989, ARCH MICROBIOL, V153, P90, DOI 10.1007/BF00277547; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; GREENBURG G, 1994, J BIOL CHEM, V269, P25354; HABENER JF, 1979, J BIOL CHEM, V254, P596; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; HIGH S, 1993, J BIOL CHEM, V268, P26745; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUSSAIN M, 1982, EUR J BIOCHEM, V129, P233, DOI 10.1111/j.1432-1033.1982.tb07044.x; ICHIHARA S, 1986, J BIOL CHEM, V261, P9405; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MOLLAY C, 1982, P NATL ACAD SCI-BIOL, V79, P2260, DOI 10.1073/pnas.79.7.2260; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; NOVAK P, 1986, J BIOL CHEM, V261, P420; NOVAK P, 1988, J BACTERIOL, V170, P5067, DOI 10.1128/jb.170.11.5067-5075.1988; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; SASAVAGE NL, 1982, J BIOL CHEM, V257, P678; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SUNG M, 1992, J BIOL CHEM, V267, P13154; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973	38	83	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19873	19878		10.1074/jbc.270.34.19873	http://dx.doi.org/10.1074/jbc.270.34.19873			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650000	Green Published, hybrid			2022-12-25	WOS:A1995RQ99100032
J	MACDONALD, MJ				MACDONALD, MJ			FEASIBILITY OF A MITOCHONDRIAL PYRUVATE MALATE SHUTTLE PANCREATIC-ISLETS - FURTHER IMPLICATION OF CYTOSOLIC NADPH IN INSULIN-SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALIC ENZYME-ACTIVITY; BETA-CELL; GLYCERALDEHYDE PHOSPHATE; GLUTAMATE-DEHYDROGENASE; METHYL SUCCINATE; COA CARBOXYLASE; PENTOSE CYCLE; MALONYL-COA; REDOX STATE; RAT ISLETS	Previous studies indicated that in pancreatic islets the amount of glucose-derived pyruvate that enters mitochondrial metabolism via carboxylation is approximately equal to that entering via decarboxylation and that both carboxylation and decarboxylation are correlated with capacitation of glucose metabolism and insulin release. The relatively high rate of carboxylation is consistent with the current study's finding that pyruvate carboxylase is as abundant in pancreatic islets as it is in liver and kidney, Since islets do not contain phosphoenolpyruvate carboxykinase and, therefore, cannot carry out glyconeogenesis from pyruvate, the carboxylase might be present in the islet to participate in novel anaplerotic reactions, This idea was first explored by incubating mitochondria from various tissues with pyruvate, Mitochondria from tissues, such as pancreatic islets, liver, and kidney, in which pyruvate carboxylase is abundant, exported a large amount of malate and little or no citrate, isocitrate, and aspartate to the medium, The amount of malate within the mitochondria was <1% that in the medium, When pancreatic islet mitochondria were incubated with [1-C-14]pyruvate, radioactive carbon appeared in the medium primarily in malate, Very little radioactivity appeared in amino acids, and little or no radioactivity appeared in citrate and isocitrate. Carbon 1 of pyruvate can be incorporated into malate and other citric acid cycle intermediates only via carboxylation, as this carbon would be lost via decarboxylation when pyruvate enters the citric acid cycle as acetyl-CoA via the pyruvate dehydrogenase reaction, The amount of malate formed equaled the (CO2)-C-14, formed and the radioactivity from C-1 of pyruvate recovered in malate slightly exceeded the formation of (CO2)-C-14 in agreement with our previous studies that reported a high rate of carboxylation of pyruvate in intact islets, When intact pancreatic islets were incubated with methyl [U-C-14]succinate as a mitochondrial source of four-carbon dicarboxylic acids, radioactivity appeared in pyruvate and lactate, Taken together with previous studies, the current results suggest that during glucose-induced insulin secretion there is a shuttle operating across the mitochondrial membrane in which glucose-derived pyruvate is taken up by mitochondria and carboxylated to oxaloacetate by pyruvate carboxylase, The oxaloacetate is converted to malate which exits the mitochondrion, where, in the cytosol, it is decarboxylated to pyruvate in the reaction catalyzed by malic enzyme, This pyruvate re-enters mitochondrial pools, Such a cycle produces NADPH in the cytosol, Since it is a cycle, this shuttle can produce far more NADPH than the pentose phosphate pathway, which is known to be a very minor route of glucose metabolism in the islet, If it is accepted that this shuttle is active in the insulin cell, this implicates NADPH regeneration in insulin secretion.			MACDONALD, MJ (corresponding author), UNIV WISCONSIN,SCH MED,CTR CHILDRENS DIABET,RM 3459,1300 UNIV AVE,MADISON,WI 53706, USA.				NIDDK NIH HHS [DK42176, DK28348] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042176, R01DK028348, R55DK028348] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMON HPT, 1985, CELL BIOCHEM FUNCT, V3, P157, DOI 10.1002/cbf.290030302; AMMON HPT, 1980, DIABETES, V29, P830, DOI 10.2337/diabetes.29.10.830; ANJANEYULU K, 1982, BIOCHIMIE, V64, P29, DOI 10.1016/S0300-9084(82)80606-8; ASHCROFT SJ, 1970, BIOCHEM J, V119, P5, DOI 10.1042/bj1190005; ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; ASHCROFT SJH, 1979, BIOCHEM J, V184, P697, DOI 10.1042/bj1840697; BOBYLEVA V, 1993, J BIOENERG BIOMEMBR, V25, P313, DOI 10.1007/BF00762592; BROLIN SE, 1981, ACTA ENDOCRINOL-COP, V96, P93, DOI 10.1530/acta.0.0960093; BRUN T, 1993, J BIOL CHEM, V268, P18905; CHEN SY, 1994, DIABETES, V43, P878, DOI 10.2337/diabetes.43.7.878; COLEMAN DL, 1991, J BIOL CHEM, V266, P21997; COLEMAN DL, 1992, METABOLISM, V41, P1134, DOI 10.1016/0026-0495(92)90299-P; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DAVIS EJ, 1980, EUR J BIOCHEM, V110, P255, DOI 10.1111/j.1432-1033.1980.tb04863.x; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; GIROIX MH, 1985, FEBS LETT, V185, P1, DOI 10.1016/0014-5793(85)80728-6; GRILL V, 1991, ENDOCRINOLOGY, V128, P2195, DOI 10.1210/endo-128-4-2195; GYLFE E, 1976, ACTA DIABETOL LAT, V13, P20, DOI 10.1007/BF02591577; Hansson H.A., 1986, THIOREDOXIN GLUTARED, P177; Hedeskov C J, 1980, Horm Metab Res Suppl, VSuppl 10, P8; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KELLEHER JK, 1985, ANAL BIOCHEM, V151, P55, DOI 10.1016/0003-2697(85)90052-1; KOHNERT KD, 1981, MOL CELL ENDOCRINOL, V22, P305, DOI 10.1016/0303-7207(81)90039-3; LARDY H, 1989, HORMONES, THERMOGENESIS AND OBESITY, P415; LEHNINGER AL, 1993, PRINCIPLES BIOCH, P650; LENZEN S, 1985, J BIOL CHEM, V260, P2629; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH CJ, 1992, AM J PHYSIOL, V262, pE608, DOI 10.1152/ajpendo.1992.262.5.E608; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P201, DOI 10.1006/abbi.1993.1028; MACDONALD MJ, 1990, AM J PHYSIOL, V259, pE548, DOI 10.1152/ajpendo.1990.259.4.E548; MACDONALD MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P128, DOI 10.1006/abbi.1995.1274; MACDONALD MJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P400, DOI 10.1016/0003-9861(89)90123-9; MACDONALD MJ, 1992, HORM METAB RES, V24, P158, DOI 10.1055/s-2007-1003284; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P205, DOI 10.1006/abbi.1993.1413; MACDONALD MJ, 1990, ARCH BIOCHEM BIOPHYS, V279, P104, DOI 10.1016/0003-9861(90)90468-E; MACDONALD MJ, 1985, DIABETES, V34, P246, DOI 10.2337/diabetes.34.3.246; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; MACDONALD MJ, 1988, DIABETES, V37, P997, DOI 10.2337/diabetes.37.7.997; MACDONALD MJ, 1991, ENDOCRINOLOGY, V129, P1370, DOI 10.1210/endo-129-3-1370; MACDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MACDONALD MJ, 1978, BIOCHEM J, V175, P495; MALAISSE WJ, 1978, EUR J BIOCHEM, V87, P121, DOI 10.1111/j.1432-1033.1978.tb12357.x; MALAISSE WJ, 1993, AM J PHYSIOL, V264, pE434, DOI 10.1152/ajpendo.1993.264.3.E434; MALAISSE WJ, 1980, MOL CELL ENDOCRINOL, V20, P171, DOI 10.1016/0303-7207(80)90080-5; MALAISSE WJ, 1985, BIOCHIM BIOPHYS ACTA, V844, P256, DOI 10.1016/0167-4889(85)90098-9; MALAISSE WJ, 1993, AM J PHYSIOL, V264, pE440; MALAISSELAGAE F, 1982, J BIOL CHEM, V257, P3754; MATSCHIN.FM, 1968, DIABETES, V17, P475, DOI 10.2337/diab.17.8.475; McGarry JD., 1992, TXB BIOCH CLIN CORRE, P387; MOLLERING H, 1985, METHOD ENZYMAT AN, V7, P2; PANTEN U, 1975, DIABETOLOGIA, V11, P569, DOI 10.1007/BF01222108; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; PEUHKURINEN KJ, 1984, J MOL CELL CARDIOL, V16, P487, DOI 10.1016/S0022-2828(84)80637-9; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; REINKE LA, 1984, BIOCHEM PHARMACOL, V33, P1315, DOI 10.1016/0006-2952(84)90186-2; SENER A, 1984, BIOCHEM J, V220, P433, DOI 10.1042/bj2200433; SHANK RP, 1985, BRAIN RES, V329, P364, DOI 10.1016/0006-8993(85)90552-9; SHRAGO E, 1986, CLIN ASPECTS HUMAN C, P28; SNYDER PJ, 1979, AM J PHYSIOL, V219, P876; TALJEDAL IB, 1981, DIABETOLOGIA, V21, P1; VANDEWINKEL M, 1983, BIOCHEM BIOPH RES CO, V114, P835, DOI 10.1016/0006-291X(83)90857-4; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; WALTER P, 1966, J BIOL CHEM, V241, P2523; Williamson J. R., 1976, GLUCONEOGENESIS ITS, P165; ZAWALICH WS, 1993, DIABETES, V42, P843, DOI 10.2337/diabetes.42.6.843; ZUHLKE H, 1977, ACTA BIOL MED GER, V36, P1695	69	234	235	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20051	20058						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650022				2022-12-25	WOS:A1995RQ99100057
J	CHIRMULE, N; GOONEWARDENA, H; PAHWA, S; PASIEKA, R; KALYANARAMAN, VS; PAHWA, S				CHIRMULE, N; GOONEWARDENA, H; PAHWA, S; PASIEKA, R; KALYANARAMAN, VS; PAHWA, S			HIV-1 ENVELOPE GLYCOPROTEINS INDUCE ACTIVATION OF ACTIVATED PROTEIN-1 IN CD4+ T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; C-JUN; DNA-BINDING; AIDS PATHOGENESIS; IMMUNE-SYSTEM; AP-1; KINASE; EXPRESSION; MOLECULE; COMPLEX	Activation of CD4 positive T cells is a primary requirement for human immunodeficiency virus (HIV) entry, efficient HIV replication, and progression to AIDS, Utilizing CD4 positive T cell lines and purified T cells from normal individuals, we have demonstrated that native envelope glycoproteins of HIV, gp160, can induce activation of transcription factor, activated protein-1 (AP-1), The stimulatory effects of gp160 are mediated through the CD4 molecule, since treatment of gp160 with soluble CD4-IgG abrogates its activity, and CD4 negative T cell lines fail to be stimulated with gp160. Immunoprecipitation of the gp160-induced nuclear extracts with polyclonal antibodies to Fos and Jun proteins indicates that AP-1 complex is comprised of members of these family of proteins, The gp160-induced AP-1 complex is dependent upon protein tyrosine phosphorylation and is protein synthesis-independent. This stimulation can also be abolished by inhibitors of protein kinase C, but it is unaffected by calcium channel blocker or cyclosporine A, This gp160 treatment adversely affects the functional capabilities of T cells; pretreatment of CD4+ T cells with gp160 for 4 h at 37 degrees C inhibited anti-CD3-induced interleukin-2 secretion, Effects similar to gp160 were seen with anti-CD4 mAb. The aberrant activation of AP-1 by gp160 in CD4 positive T cells could result in up-regulation of cytokines containing AP-1 sites, e.g. interleukin-3 and granulocyte macrophage colony-stimulating factor, and concurrently lead to T cell unresponsiveness by inhibiting interleukin-2 secretion.	ADV BIOSCI LABS INC,KENSINGTON,MD 20872		CHIRMULE, N (corresponding author), N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT PEDIAT,MANHASSET,NY 11030, USA.		Pahwa, Savita/AAA-4900-2019	Pahwa, Savita/0000-0002-4470-4216	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028281] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR 0047] Funding Source: Medline; NIAID NIH HHS [AI 35414, AI 28281] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASCHER MS, 1990, J ACQ IMMUN DEF SYND, V3, P177; BANK I, 1985, J EXP MED, V162, P1294, DOI 10.1084/jem.162.4.1294; BIDDISON WE, 1983, J IMMUNOL, V131, P152; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CAPON DJ, 1991, ANNU REV IMMUNOL, V9, P649, DOI 10.1146/annurev.iy.09.040191.003245; CARREL S, 1991, RES IMMUNOL, V142, P97, DOI 10.1016/0923-2494(91)90017-D; CHIRMULE N, 1990, BLOOD, V75, P152; CHIRMULE N, 1993, J IMMUNOL, V150, P2478; CHIRMULE N, 1994, BIOCHEM BIOPH RES CO, V203, P498, DOI 10.1006/bbrc.1994.2210; COFFER P, 1994, ONCOGENE, V9, P911; CRUIKSHANK WW, 1990, BIOMED PHARMACOTHER, V44, P5, DOI 10.1016/0753-3322(90)90062-E; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GLEICHENHAUS N, 1991, CELL, V64, P511; GOLDMAN F, 1994, J IMMUNOL, V153, P2905; GOWDA SD, 1989, J IMMUNOL, V142, P773; GUBLINS H, 1994, MOL CELL BIOL, V14, P4749; HABESHAW JA, 1990, IMMUNOL TODAY, V11, P418, DOI 10.1016/0167-5699(90)90162-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIVROZ C, 1993, EUR J IMMUNOL, V23, P600, DOI 10.1002/eji.1830230303; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; HSU JC, 1993, CANCER RES, V53, P3789; JAIN J, 1992, J IMMUNOL, V148, P1240; Janeway C A Jr, 1991, Semin Immunol, V3, P153; KALYANARAMAN VS, 1990, AIDS RES HUM RETROV, V6, P371, DOI 10.1089/aid.1990.6.371; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; KRIAKIS JM, 1994, NATURE, V369, P156; LAVIN MF, 1994, ONCOGENE, V9, P2305; LEDBETTER JA, 1993, CURR OPIN IMMUNOL, V5, P334, DOI 10.1016/0952-7915(93)90050-3; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MESSIER H, 1992, J IMMUNOL, V149, P1980; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; OH SK, 1992, J ACQ IMMUN DEF SYND, V5, P251; ORLOFF GM, 1991, AIDS RES HUM RETROV, V7, P587, DOI 10.1089/aid.1991.7.587; OYAIZU N, 1992, J CLIN INVEST, V89, P1807, DOI 10.1172/JCI115785; OYAIZU N, 1994, BLOOD, V84, P2622; OYAIZU N, 1989, P NATL ACAD SCI USA, V87, P2379; PARK JH, 1993, J BIOL CHEM, V268, P6299; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SOULA M, 1992, INT IMMUNOL, V4, P295, DOI 10.1093/intimm/4.2.295; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; THAN S, 1994, BLOOD, V84, P184; VANLINT C, 1991, J VIROL, V65, P7066, DOI 10.1128/JVI.65.12.7066-7072.1991; Veillette A, 1991, Semin Immunol, V3, P143; WEISS A, 1984, J IMMUNOL, V133, P123; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	58	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19364	19369		10.1074/jbc.270.33.19364	http://dx.doi.org/10.1074/jbc.270.33.19364			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642615	hybrid			2022-12-25	WOS:A1995RP70300029
J	MATSUMOTO, R; SALI, A; GHILDYAL, N; KARPLUS, M; STEVENS, RL				MATSUMOTO, R; SALI, A; GHILDYAL, N; KARPLUS, M; STEVENS, RL			PACKAGING OF PROTEASES AND PROTEOGLYCANS IN THE GRANULES OF MAST-CELLS AND OTHER HEMATOPOIETIC-CELLS - A CLUSTER OF HISTIDINES ON MOUSE MAST-CELL PROTEASE-7 REGULATES ITS BINDING TO HEPARIN SERGLYCIN PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE-E-PROTEOGLYCAN; MOLECULAR-CLONING; SERINE PROTEASES; CARBOXYPEPTIDASE-A; NEUTRAL PROTEASES; RAT; GENE; DIFFERENTIATION; IDENTIFICATION; TRANSCRIPTION	Mouse mast cell protease 7 (mMCP-7) is a tryptase stored in the secretory granules of mast cells. At the granule pH of 5.5, mMCP-7 is fully active and is bound to heparin-containing serglycin proteoglycans. To understand the interaction of mMCP-7 with heparin inside and outside the mast cell, this tryptase was first studied by comparative protein modeling. The ''pro'' form of mMCP-7 was then expressed in insect cells and studied by site-directed mutagenesis. Although mMCP-7 lacks known linear sequences of amino acids that interact with heparin, the three-dimensional model of mMCP-7 revealed an area on the surface of the folded protein away from the substrate-binding site that exhibits a strong positive electrostatic potential at the acidic pH of the granule. In agreement with this calculation, recombinant pro-mMCP-7 bound to a heparin-affinity column at pH 5.5 and readily dissociated from the column at pH > 6.5. Site directed mutagenesis confirmed the prediction that the conversion of His residues 8, 68, and 70 in the positively charged region into Glu prevents the binding of pro-mMCP-7 to heparin. Because the binding requires positively charged His residues, native mMCP-7 is able to dissociate from the protease/proteoglycan macromolecular complex when the complex is exocytosed from bone marrow-derived mast cells into a neutral pH environment. Many hematopoietic effector cells store positively charged proteins in granules that contain serglycin proteoglycans. The heparin/mMCP-7 interaction, which depends on the tertiary structure of the tryptase, may be representative of a general control mechanism by which hematopoietic cells maximize storage of properly folded, enzymatically active proteins in their granules.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University					NIAID NIH HHS [AI-23483] Funding Source: Medline; NIAMS NIH HHS [AR-36308, AR-07530] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007530, P60AR036308] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BROOKS BR, 1988, J COMPUT CHEM, V4, P187; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHU W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P83, DOI 10.1016/0167-4838(92)90340-J; DAVIS ME, 1990, COMP PHYS COMMUN, V62, P187; DEYOUNG MB, 1987, ARCH BIOCHEM BIOPHYS, V254, P222, DOI 10.1016/0003-9861(87)90098-1; DIKOV MM, 1994, J BIOL CHEM, V269, P25897; DUBUSKE L, 1984, J IMMUNOL, V133, P1535; Ehrlich P, 1878, THESIS U LEIPZIG GER; EVERITT MT, 1980, FEBS LETT, V110, P292, DOI 10.1016/0014-5793(80)80095-0; GHILDYAL N, 1994, J IMMUNOL, V153, P2624; GOLDSTEIN SM, 1992, J IMMUNOL, V148, P2475; GULLBERG U, 1994, J BIOL CHEM, V269, P25219; GUO NH, 1992, J BIOL CHEM, V267, P19349; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; Jorpes E, 1935, Biochem J, V29, P1817; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAGUNOFF D, 1976, ARCH BIOCHEM BIOPHYS, V173, P554, DOI 10.1016/0003-9861(76)90292-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; MCBRIDE P, 1988, J ALLERGY CLIN IMMUN, V82, P638, DOI 10.1016/0091-6749(88)90977-3; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCNEIL HP, 1992, J IMMUNOL, V149, P2466; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURAKAMI M, 1995, J BIOL CHEM, V270, P2218, DOI 10.1074/jbc.270.5.2218; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PEJLER G, 1994, J BIOL CHEM, V269, P14451; RAVIN E, 1982, J BIOL CHEM, V257, P7229; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; RAZIN E, 1984, J IMMUNOL, V132, P1479; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1994, PROTEIN SCI, V3, P1582, DOI 10.1002/pro.5560030923; SALI A, 1994, PROTEIN STRUCTURE BY DISTANCE ANALYSIS, P64; SALI A, 1993, J BIOL CHEM, V268, P9023; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P363; SCHECHTER NM, 1994, J IMMUNOL, V152, P4062; SCHWARTZ LB, 1981, J IMMUNOL, V126, P2071; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SERAFIN WE, 1987, J IMMUNOL, V139, P3771; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; SHIH HHL, 1985, P NATL ACAD SCI USA, V82, P1697, DOI 10.1073/pnas.82.6.1697; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; Trong H Le, 1989, BIOCHEMISTRY-US, V28, P391, DOI 10.1021/BI00427A054; URATA H, 1993, J BIOL CHEM, V268, P24318; WALTER J, 1982, ACTA CRYSTALLOGR B, V38, P1462, DOI 10.1107/S0567740882006153; YOSHIDA N, 1980, BIOCHEMISTRY-US, V19, P5799, DOI 10.1021/bi00566a021; YURT R, 1977, J EXP MED, V146, P1405, DOI 10.1084/jem.146.5.1405	58	104	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19524	19531		10.1074/jbc.270.33.19524	http://dx.doi.org/10.1074/jbc.270.33.19524			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642636	hybrid			2022-12-25	WOS:A1995RP70300052
J	OKA, S; BRUSES, JL; NELSON, RW; RUTISHAUSER, U				OKA, S; BRUSES, JL; NELSON, RW; RUTISHAUSER, U			PROPERTIES AND DEVELOPMENTAL REGULATION OF POLYSIALYLTRANSFERASE ACTIVITY IN THE CHICKEN-EMBRYO BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYSIALOSYL UNITS; VASE EXON; RAT-BRAIN; BIOSYNTHESIS; ACID; GLUCURONOSYLTRANSFERASE; GLYCOPROTEINS; EXPRESSION; ANTIBODY; NCAM	The properties and developmental regulation of vertebrate polysialyltransferase (PST), an enzyme activity responsible for extension of alpha 2,8-linked sialic acid homopolymers (PSA) associated with the fifth Ig domain of the neural cell adhesion molecule (NCAM), have been studied. The assay for PST used exogenous NCAM as a substrate, with a PSA-specific endoneuraminidase as a control for specificity. Optimal conditions for PST activity at 37 degrees C were found to be pH 6.0 in the presence of divalent cations (Mn2+, 20 mM). The enzyme K-m was found to increase with increasing polymer length, ranging from 0.7 to 0.07 mu M. The developmental regulation both of PST activity and of the addition of PSA to NCAM were studied in chick whole brain, tectum, and cerebellum and found to be precisely coordinated. In each tissue PSA and PST were highest during early stages of morphogenesis, followed by a decrease as development reached completion. The insertion of the VASE exon in the fourth Ig domain of NCAM was also found to parallel closely the developmental down regulation of PSA, and on this basis could be considered a potential determinant in the specific polysialylation of NCAM. However, in direct tests of this hypothesis in transfected cells the presence of VASE did not markedly alter the level of NCAM polysialylation or alter the affinity of PST for the NCAM substrate.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT GENET,CLEVELAND,OH 44106	Case Western Reserve University					NEI NIH HHS [EY06107] Funding Source: Medline; NICHD NIH HHS [HD18369, HD07104] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018369, R37HD018369, T32HD007104] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY006107] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALCARAZ G, 1991, EUR J CELL BIOL, V55, P165; BELLAIRS R, 1995, DEV DYNAM, V202, P333, DOI 10.1002/aja.1002020403; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; DAS KK, 1991, J BIOL CHEM, V266, P5238; DOHERTY P, 1992, NATURE, V356, P791, DOI 10.1038/356791a0; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FINNE J, 1985, J BIOL CHEM, V260, P1265; FREDETTE B, 1993, J CELL BIOL, V123, P1867, DOI 10.1083/jcb.123.6.1867; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; KAWASHIMA C, 1992, GLYCOCONJUGATE J, V9, P307, DOI 10.1007/BF00731091; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; LIVINGSTON B D, 1990, Glycobiology, V1, P39, DOI 10.1093/glycob/1.1.39; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; OKA S, 1992, J BIOL CHEM, V267, P22711; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; RUTISHAUSER U, 1992, DEVELOPMENT, P99; SMALL SJ, 1990, J CELL BIOL, V111, P2089, DOI 10.1083/jcb.111.5.2089; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; WATANABE M, 1986, J CELL BIOL, V103, P1721, DOI 10.1083/jcb.103.5.1721; YANG PF, 1994, J BIOL CHEM, V269, P23039; YOSHIHARA Y, 1991, J CELL BIOL, V115, P731, DOI 10.1083/jcb.115.3.731	26	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19357	19363		10.1074/jbc.270.33.19357	http://dx.doi.org/10.1074/jbc.270.33.19357			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642614				2022-12-25	WOS:A1995RP70300028
J	VENEMA, K; PALMGREN, MG				VENEMA, K; PALMGREN, MG			METABOLIC MODULATION OF TRANSPORT COUPLING RATIO IN YEAST PLASMA-MEMBRANE H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATION STOICHIOMETRY; SARCOPLASMIC-RETICULUM; REGULATORY DOMAIN; H+/ATP STOICHIOMETRY; VOLTAGE-DEPENDENCE; NEUROSPORA-CRASSA; LIPID VESICLES; CALCIUM-PUMP; BINDING; PLANT	The plasma membrane proton pump (H+-ATPase) of yeast energizes solute uptake by secondary transporters and regulates cytoplasmic pH. The addition of glucose to yeast cells stimulates proton efflux mediated by the H+- ATPase. A >50-fold increase in proton extrusion from yeast cells is observed in vivo, whereas the ATPase activity of purified plasma membranes is increased maxi mally 8-fold after glucose treatment (Serrano, R. (1983) FEES Lett. 156, 11-14). The low capacity of yeast cells for proton extrusion in the absence of glucose can be ex plained by the finding that, in H+-ATPase isolated from glucose-starved cells, ATP hydrolysis is essentially uncoupled from proton pumping, The number of protons transported per ATP hydrolyzed is significantly increased after glucose activation, We suggest that intrinsic uncoupling is an important mechanism for regulation of pump activity.	ROYAL VET & AGR UNIV,DEPT PLANT BIOL,DK-1871 FREDERIKSBERG C,DENMARK	University of Copenhagen			Venema, Kees/G-9558-2015; Palmgren, Michael/A-9808-2013	Venema, Kees/0000-0001-5177-6464; Palmgren, Michael/0000-0002-9982-6114				ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; APELL HJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P480, DOI 10.1016/0005-2736(87)90055-1; BAGINSKI ES, 1967, CLIN CHEM, V13, P326; BERBERIAN G, 1993, BIOCHIM BIOPHYS ACTA, V1153, P283, DOI 10.1016/0005-2736(93)90417-X; BLAIR DF, 1986, BIOPHYS J, V50, P713, DOI 10.1016/S0006-3495(86)83511-1; BLAKE MS, 1984, ANAL BIOCHEM, V128, P302; BLATT MR, 1990, J MEMBRANE BIOL, V114, P205, DOI 10.1007/BF01869215; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUER D, 1989, PLANT PHYSIOL, V89, P464, DOI 10.1104/pp.89.2.464; BRISKIN DP, 1991, PLANT PHYSIOL, V95, P242, DOI 10.1104/pp.95.1.242; BRISKIN DP, 1992, J EXP BOT, V43, P269, DOI 10.1093/jxb/43.3.269; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CAPIEAUX E, 1989, J BIOL CHEM, V264, P7437; CAPLAN SR, 1988, ION PUMPS STRUCTURE, P377; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; CID A, 1988, J BIOL CHEM, V263, P14134; DAVIES JM, 1994, P NATL ACAD SCI USA, V91, P8547, DOI 10.1073/pnas.91.18.8547; Dixon M., 1979, ENZYMES, Vthird; DUFOUR JP, 1982, J BIOL CHEM, V257, P9365; FROHLICH O, 1988, J MEMBRANE BIOL, V101, P189, DOI 10.1007/BF01872834; GOORMAGHTIGH E, 1986, J BIOL CHEM, V261, P7466; GRADMANN D, 1978, J MEMBRANE BIOL, V39, P333, DOI 10.1007/BF01869898; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; INESI G, 1989, J BIOL CHEM, V264, P5929; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; KIBAK H, 1993, J BIOL CHEM, V268, P23325; KOLAND JG, 1986, J BIOL CHEM, V261, P5936; KRENN BE, 1993, BIOCHEM J, V294, P705, DOI 10.1042/bj2940705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauger P., 1991, ELECTROGENIC ION PUM; MELTZER S, 1984, J BIOL CHEM, V259, P4244; MONK BC, 1991, J BIOL CHEM, V266, P18097; Morrison J F, 1979, Methods Enzymol, V63, P257; MULLER AWJ, 1993, PHYSIOL CHEM PHYS ME, V25, P95; NAVARRO J, 1984, BIOPHYS J, V46, P709, DOI 10.1016/S0006-3495(84)84069-2; PALMGREN MG, 1991, ANAL BIOCHEM, V192, P316, DOI 10.1016/0003-2697(91)90542-2; PALMGREN MG, 1990, PLANT PHYSIOL, V94, P882, DOI 10.1104/pp.94.3.882; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PERLIN DS, 1986, ARCH BIOCHEM BIOPHYS, V248, P53, DOI 10.1016/0003-9861(86)90400-5; PERLIN DS, 1984, J BIOL CHEM, V259, P7884; PIETROBON D, 1986, BIOCHEMISTRY-US, V25, P767, DOI 10.1021/bi00352a005; PORTILLO F, 1991, FEBS LETT, V287, P71, DOI 10.1016/0014-5793(91)80018-X; PORTILLO F, 1989, FEBS LETT, V247, P381, DOI 10.1016/0014-5793(89)81375-4; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; ROSSIGNOL M, 1982, BIOCHIM BIOPHYS ACTA, V684, P195, DOI 10.1016/0005-2736(82)90005-0; SANDERS D, 1990, ANNU REV PLANT PHYS, V41, P77, DOI 10.1146/annurev.pp.41.060190.000453; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SERRANO R, 1984, CURR TOP CELL REGUL, V23, P87; SOLER F, 1990, EUR J BIOCHEM, V192, P347, DOI 10.1111/j.1432-1033.1990.tb19233.x; STUCKI JW, 1980, EUR J BIOCHEM, V109, P269, DOI 10.1111/j.1432-1033.1980.tb04792.x; TU SI, 1987, ARCH BIOCHEM BIOPHYS, V256, P625, DOI 10.1016/0003-9861(87)90620-5; VANWALRAVEN HS, 1990, BIOCHIM BIOPHYS ACTA, V1015, P425, DOI 10.1016/0005-2728(90)90075-F; VENEMA K, 1993, BIOCHIM BIOPHYS ACTA, V1146, P87, DOI 10.1016/0005-2736(93)90342-W; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; WACH A, 1990, EUR J BIOCHEM, V189, P675, DOI 10.1111/j.1432-1033.1990.tb15536.x; WARNCKE J, 1980, BIOCHIM BIOPHYS ACTA, V591, P224, DOI 10.1016/0005-2728(80)90154-1; WESTERHOFF HV, 1984, TRENDS BIOCHEM SCI, V7, P112; YOSHINORI M, 1988, ION PUMPS STRUCTURE, P387; ZIEGLER W, 1993, GEN PHYSIOL BIOPHYS, V12, P429	60	65	65	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19659	19667		10.1074/jbc.270.33.19659	http://dx.doi.org/10.1074/jbc.270.33.19659			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642655	hybrid			2022-12-25	WOS:A1995RP70300071
J	ZHU, XL; CHANG, KH; HE, DC; MANCINI, MA; BRINKLEY, WR; LEE, WH				ZHU, XL; CHANG, KH; HE, DC; MANCINI, MA; BRINKLEY, WR; LEE, WH			THE C-TERMINUS OF MITOSIN IS ESSENTIAL FOR ITS NUCLEAR-LOCALIZATION, CENTROMERE/KINETOCHORE TARGETING, AND DIMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CENTROMERE; CENP-B; PROTEIN; KINETOCHORE; IDENTIFICATION; SUBUNIT; DOMAINS	Mitosin is a novel 350-kDa nuclear phosphoprotein that dramatically relocates from the evenly nuclear distribution in S phase to the centromere/kinetochore and mitotic apparatus in M phase. The dynamic relocalization of mitosin is accompanied by the phosphorylation of itself, suggesting that mitosin plays a role in mitotic progression. The molecular basis of nuclear localization and targeting of mitosin to the centromere/kinetochore were characterized using a set of epitope-tagged deletion mutants. The data indicate that the extreme C terminus (amino acids 2,487-3,113) of mitosin has both an independent centromere/kinetochore targeting domain and an unusually spaced bipartite nuclear localization signal. Moreover, the same centromere/kinetochore targeting domain was shown to be essential for the ability of mitosin to bind to itself or other putative mitosin-associated proteins through use of the yeast two hybrid system. These results suggest that the C terminus of the mitosin is essential for its role in influencing cell cycle progression.	UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,INST BIOTECHNOL,SAN ANTONIO,TX 78245; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine								BLOOM K, 1993, CELL, V73, P621, DOI 10.1016/0092-8674(93)90242-I; Brinkley B R, 1992, Trends Cell Biol, V2, P15, DOI 10.1016/0962-8924(92)90139-E; CASIANO CA, 1993, J CELL SCI, V106, P1045; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EPSTEIN CJ, 1988, ANNU REV GENET, V22, P51, DOI 10.1146/annurev.ge.22.120188.000411; Forrest D, 1992, CURR OPIN GENET DEV, V2, P19, DOI 10.1016/S0959-437X(05)80316-8; HE D, 1995, IN PRESS INT REV CYT; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; PLUTA AF, 1992, J CELL BIOL, V116, P1081, DOI 10.1083/jcb.116.5.1081; RATTNER JB, 1992, CHROMOSOMA, V101, P259, DOI 10.1007/BF00346003; RATTNER JB, 1993, CELL MOTIL CYTOSKEL, V26, P214, DOI 10.1002/cm.970260305; RATTNER JB, 1988, CHROMOSOMA, V96, P360, DOI 10.1007/BF00330702; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SAITOH H, 1992, CELL, V170, P115; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	21	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19545	19550		10.1074/jbc.270.33.19545	http://dx.doi.org/10.1074/jbc.270.33.19545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642639	hybrid			2022-12-25	WOS:A1995RP70300055
J	CASOLA, S; UNGARO, P; PEDONE, PV; LAZZARO, D; FATTORI, E; CILIBERTO, G; ZARRILLI, R; BRUNI, CB; RICCIO, A				CASOLA, S; UNGARO, P; PEDONE, PV; LAZZARO, D; FATTORI, E; CILIBERTO, G; ZARRILLI, R; BRUNI, CB; RICCIO, A			LOSS OF HETEROZYGOSITY OF IMPRINTED GENES IN SV40 T/T ANTIGEN-INDUCED HEPATOCELLULAR CARCINOMAS	ONCOGENE			English	Article						GENOMIC IMPRINTING; CHROMOSOME IMBALANCES; HEPATOCARCINOGENESIS	GROWTH-FACTOR-II; MOUSE CHROMOSOME-7; TRANSGENIC MICE; WILMS-TUMOR; CANCER; RAT; EXPRESSION; RNA; H19; HEPATOCARCINOGENESIS	Expression of the chromosomally linked Insulin-like Growth Factor II (IGF-II) and H19 genes is regulated by parental imprinting during development, since the maternally inherited IGF-II and the paternally inherited H19 alleles are inactive in fetal tissues. Here we show that expression of IGF-II and H19 genes is activated in transgenic mice during SV40 Tag-induced hepatocarcinogenesis and that imprinting of both genes is conserved in the liver tumors. Allelic imbalances of IGF-II and H19 genes and other chromosome 7 markers were detected in one third (13/39) of the hepatocellular carcinomas analysed. A strong bias on the allele retained in the neoplasms was observed, since underrepresentation or complete loss of maternal chromosome 7 was recognised in 12/13 cases. High levels of IGF-II mRNA were expressed by all carcinomas with relative excess of paternal chromosome 7 alleles and suppressed H19 expression was found in the neoplasms lacking the maternal alleles. Overall the results indicate that expression of imprinted genes is involved in progression of experimental liver tumors and suggest that the murine chromosome 7, whose loss may possibly cause the inactivation of a growth-inhibitory gene, is preferentially retained as paternal copy in the liver tumors because of parental imprinting of IGF-II gene.	UNIV NAPLES FEDERICO II,CTR ENDOCRINOL & ONCOL SPERIMENTALE,CNR,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,I-80131 NAPLES,ITALY; IST RIC BIOL MOLEC P ANGELETTI,DEPT GENET,I-00040 POMEZIA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II			Casola, Stefano/O-3922-2014; Casola, Stefano/AAN-8319-2021; Riccio, Andrea/A-4991-2015; Ciliberto, Gennaro/J-4131-2017; Zarrilli, Raffaele/F-5067-2012; Riccio, Andrea/AAY-7571-2020; Cerrato, Flavia/O-8315-2015	Casola, Stefano/0000-0001-5580-0986; Riccio, Andrea/0000-0001-7990-3576; Ciliberto, Gennaro/0000-0003-2851-8605; Zarrilli, Raffaele/0000-0003-4191-9032; Riccio, Andrea/0000-0001-7990-3576; Cerrato, Flavia/0000-0003-3794-3021; Pedone, Paolo Vincenzo/0000-0002-0828-5843				ALBRECHT S, 1994, CANCER RES, V54, P5041; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; BIRAN H, 1994, TUMOR BIOL, V15, P123, DOI 10.1159/000217882; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; CHIARIOTTI L, 1988, MOL ENDOCRINOL, V2, P1115, DOI 10.1210/mend-2-11-1115; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARK G, 1980, STAINING PROCEDURES; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; FUJIMORI M, 1991, CANCER RES, V51, P89; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HELD WA, 1994, CANCER RES, V54, P6489; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HOLDENER BC, 1993, MAMM GENOME, V4, pS110, DOI 10.1007/BF00360833; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KONDO M, 1995, ONCOGENE, V10, P1193; LITTLE M, 1991, NATURE, V351, P609, DOI 10.1038/351609a0; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NORSTEDT G, 1988, CARCINOGENESIS, V9, P209, DOI 10.1093/carcin/9.2.209; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; PAL N, 1990, ONCOGENE, V5, P1665; PEDONE PV, 1994, J BIOL CHEM, V269, P23970; PEDONE PV, 1994, HUM MOL GENET, V7, P1117; PFEIFER K, 1994, GENE DEV, V8, P1867, DOI 10.1101/gad.8.16.1867; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; RUTHER U, 1993, ONCOGENE, V8, P87; Sambrook J, 1989, MOL CLONING LABORATO; SCHIRMACHER P, 1992, CANCER RES, V52, P2549; SCOTT J, 1985, NATURE, V317, P174; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUNDELIN J, 1985, J BIOL CHEM, V260, P6472; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; UENO T, 1988, CARCINOGENESIS, V9, P1779, DOI 10.1093/carcin/9.10.1779; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; ZARRILLI R, 1992, EUR J BIOCHEM, V209, P445, DOI 10.1111/j.1432-1033.1992.tb17308.x; ZARRILLI R, 1994, MOL CELL ENDOCRINOL, V101, pR1, DOI 10.1016/0303-7207(94)90253-4; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344	56	35	35	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					711	721						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651735				2022-12-25	WOS:A1995RQ46900013
J	TANIGUCHI, T; SCHOFIELD, AE; SCARLETT, JL; MORISON, IM; SULLIVAN, MJ; REEVE, AE				TANIGUCHI, T; SCHOFIELD, AE; SCARLETT, JL; MORISON, IM; SULLIVAN, MJ; REEVE, AE			ALTERED SPECIFICITY OF IGF2 PROMOTER IMPRINTING DURING FETAL DEVELOPMENT AND ONSET OF WILMS-TUMOR	ONCOGENE			English	Article						IMPRINTING; IGF2; PROMOTER; FETAL TISSUE; WILMS TUMOR	GROWTH-FACTOR-II; BECKWITH-WIEDEMANN SYNDROME; FACTOR GENES; RELAXATION	The specificity of IGF2 promoter imprinting was examined in embryonal tissues and Wilms tumour. In several fetal tissues of approximately 12 weeks gestation, IGF2 was found to be monoallelically expressed from all IGF2 promoters i.e. P1, P2, P3 and P4. However, in tissues of slightly older gestation age (15-17 weeks) relaxation of imprinting at the P1 promoter was evident, although the P2-P4 promoters remained imprinted. These data indicate that early in embryogenesis a population of cells exists in which all IGF2 promoters are imprinted, but that as development proceeds the imprinting of the P1 promoter is relaxed. The pattern of IGF2 promoter imprinting was also analysed in Wilms tumour. In some tumours, the pattern of promoter imprinting was identical to that found in early fetal kidney, indicating that this tumour originates within early embryonic kidney tissue. In contrast, in tumours in which relaxation of imprinting had occurred, imprinting relaxation affected all IGF2 promoters. This aberrant pattern of promoter imprinting, which was not detected in fetal kidney, provides further evidence that pathological relaxation of IGF2 imprinting is involved in the genesis of Wilms tumour.	UNIV OTAGO,DEPT BIOCHEM,CANC GENET LAB,DUNEDIN,NEW ZEALAND	University of Otago			Sullivan, Michael/B-5459-2012; Morison, Ian M/A-1236-2008	Morison, Ian M/0000-0003-3616-0025; Sullivan, Michael/0000-0002-8606-5889				ADAMS SM, 1991, FOCUS, V13, P56; BELL GI, 1985, P NATL ACAD SCI USA, V82, P6450, DOI 10.1073/pnas.82.19.6450; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GLENN CC, 1993, HUM MOL GENET, V2, P2001, DOI 10.1093/hmg/2.12.2001; JANSEN M, 1985, FEBS LETT, V179, P243, DOI 10.1016/0014-5793(85)80527-5; Jansen M, 1990, GROWTH FACTORS GENES; LUCASSEN AM, 1993, NAT GENET, V4, P305, DOI 10.1038/ng0793-305; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, HUM MOL GENET, V2, P2163, DOI 10.1093/hmg/2.12.2163; OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REED ML, 1994, NAT GENET, V6, P1; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; SCOTT J, 1985, NATURE, V317, P261; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; WAGSTAFF J, 1993, AM J HUM GENET, V53, P105; WEKSBERG R, 1993, HUM MOL GENET, V2, P549, DOI 10.1093/hmg/2.5.549; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	32	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					751	756						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651739				2022-12-25	WOS:A1995RQ46900017
J	GIANNINI, E; BROUCHON, L; BOULAY, F				GIANNINI, E; BROUCHON, L; BOULAY, F			IDENTIFICATION OF THE MAJOR PHOSPHORYLATION SITES IN HUMAN C5A ANAPHYLATOXIN RECEPTOR IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; FORMYL PEPTIDE RECEPTOR; HUMAN INTERLEUKIN-8 RECEPTOR; DIFFERENTIATED HL-60 CELLS; PLATELET-ACTIVATING-FACTOR; 3RD INTRACELLULAR LOOP; FUNCTIONAL EXPRESSION; POLYMORPHONUCLEAR LEUKOCYTES; CHEMOATTRACTANT RECEPTORS; CHEMOTACTIC RECEPTOR	Interaction of human C5a anaphylatoxin with cell surface receptors mediates cell activation and receptor desensitization, Treatment of differentiated HL60 cells or transiently transfected COS-7 cells with C5a or phorbol 12-myristate 13-acetate (PMA) results in rapid hyperphosphorylation of the C5aR. In an attempt to gain more insight into the function of phosphorylation in the desensitization of C5aR, we have initiated experiments to identify phosphoacceptor sites at the amino acid level after stimulation of cells with either C5a or PMA. In this report we show that C5aR is phosphorylated exclusively on serine residues in both differentiated HL60 and transfected COS-7 cells irrespective of the stimulus used. Peptide mapping after cyanogen bromide cleavage of phosphorylated C5aR indicates that despite the presence of a protein kinase C consensus motif the third cytoplasmic loop is not phosphorylated when cells are challenged with either C5a or PMA. Thus, whether the cells are stimulated with C5a or PMA, the phosphorylation sites appear to be restricted to serine residues in the carboxyl tail. Phosphoamino acid analysis of a series of mutants in which an individual serine residue was replaced by a threonine residue indicates that the C5aR undergoes C5a-dependent phosphorylation to the maximal stoichiometry of 6 mol of PO4/mol of receptor at Ser(314), Ser(317), Ser(327), Ser(332), Ser(334), and Ser(338). Simultaneous substitution of serine residues by alanine at positions 332, 334, and 338 affected neither the binding of C5a nor the cell surface expression of the mutant, but resulted in a dramatic reduction (more than 80%) of both C5a- and PMA-mediated phosphorylation as compared to the wild type receptor. This result suggests that phosphorylation on the segment extending from Ser(332) to Ser(338) is required for the subsequent phosphorylation of the carboxyl-terminal tail of C5aR.	CEN GRENOBLE,DEPT BIOL MOLEC & STRUCT,CEA,BIOCHIM LAB,CNRS,URA 1130,F-38054 GRENOBLE 9,FRANCE	CEA; Centre National de la Recherche Scientifique (CNRS)								ALI H, 1993, J BIOL CHEM, V268, P24247; BOMMAKANTI RK, 1993, J LEUKOCYTE BIOL, V54, P572, DOI 10.1002/jlb.54.6.572; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; CHAPLINSKI TJ, 1982, J CLIN INVEST, V70, P953, DOI 10.1172/JCI110707; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GIANNINI E, 1995, J IMMUNOL, V154, P4055; HAGA T, 1994, J NEUROCHEM, V63, P400; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIPKIN RW, 1995, MOL ENDOCRINOL, V9, P151, DOI 10.1210/me.9.2.151; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921; JESAITIS AJ, 1989, J CELL BIOL, V109, P2783, DOI 10.1083/jcb.109.6.2783; KLOS A, 1994, FEBS LETT, V344, P79, DOI 10.1016/0014-5793(94)00350-5; LAEMMLI UK, 1973, NATURE, V220, P680; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; MCLEISH KR, 1989, MOL PHARMACOL, V36, P384; MCPHAIL LC, 1993, NATURAL IMMUNE SYSTE, P63; MERY L, 1994, J BIOL CHEM, V269, P3457; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PAINTER RG, 1987, J CELL BIOL, V105, P2959, DOI 10.1083/jcb.105.6.2959; PERRET JJ, 1992, BIOCHEM J, V288, P911, DOI 10.1042/bj2880911; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TAKANO T, 1994, J BIOL CHEM, V269, P22453; TARDIF M, 1993, J IMMUNOL, V150, P3534; VANEPPS DE, 1990, J IMMUNOL, V144, P1062; WILDE MW, 1989, J BIOL CHEM, V264, P190; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILTFANG J, 1991, ELECTROPHORESIS, V12, P352, DOI 10.1002/elps.1150120507; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3	49	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19166	19172		10.1074/jbc.270.32.19166	http://dx.doi.org/10.1074/jbc.270.32.19166			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642584	hybrid			2022-12-25	WOS:A1995RN95400072
J	FRETTO, LJ; SNAPE, AJ; TOMLINSON, JE; SEROOGY, JJ; WOLF, DL; LAROCHELLE, WJ; GIESE, NA				FRETTO, LJ; SNAPE, AJ; TOMLINSON, JE; SEROOGY, JJ; WOLF, DL; LAROCHELLE, WJ; GIESE, NA			MECHANISM OF PLATELET-DERIVED GROWTH-FACTOR (PDGF)-AA, (PDGF)-AB, AND (PDGF)-BB BINDING TO ALPHA-PDGF AND BETA-PDGF RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; KINASE ACTIVATION; LIGAND-BINDING; CDNA CLONING; B-PROTEIN; A-CHAIN; EXPRESSION; LOCALIZATION; DIMERIZATION; HETERODIMERS	The biological effects of platelet-derived growth factor (PDGF) are mediated by cell surface alpha and beta PDGF receptors, which, as a result of ligand binding, undergo dimerization in a manner consistent with PDGF being bivalent. In order to directly demonstrate PDGF bivalency and to define the binding of PDGF AB to isolated beta receptor, we developed solid-phase binding assays using purified recombinant extracellular domain of human PDGF receptors. PDGF AA, AB, and BB were prepared from the monomeric chains expressed in Escherichia coli, and each was purified to homogeneity; PDGF AB contained <0.5% of either homodimer. The interactions of these isoforms with immobilized PDGF receptors were examined by several approaches. Scatchard analysis revealed high affinity binding (K(d) = 0.5-1.0 nM) of radiolabeled PDGF AA and AB to alpha receptor and of PDGF BB to both receptor subtypes. Contrary to previous reports, PDGF AB also bound beta receptor with high affinity (K(d) = 0.9 nM). When a B-chain-specific monoclonal antibody that recognizes the putative binding domain of PDGF BB was used for ligand detection, we found that PDGF AB binding to beta receptor occurred exclusively through the B-chain subunit, whereas binding to alpha receptor occurred through either subunit. In addition, site-directed mutagenesis was used to specifically inactivate the B chain of PDGF AB, which eliminated binding to the beta receptor without affecting alpha receptor binding. These results establish that PDGF is bivalent and that monovalent ligand retains high affinity receptor binding.	COR THERAPEUT INC,256 E GRAND AVE,S SAN FRANCISCO,CA 94080; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ESCOBEDO JA, 1988, SCIENCE, V240, P1532, DOI 10.1126/science.2836953; GESUALDO L, 1991, LAB INVEST, V65, P160; GIESE N, 1990, MOL CELL BIOL, V10, P5496, DOI 10.1128/MCB.10.10.5496; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HOPPE J, 1989, BIOCHEMISTRY-US, V28, P2956, DOI 10.1021/bi00433a032; HOPPE J, 1990, EUR J BIOCHEM, V187, P207, DOI 10.1111/j.1432-1033.1990.tb15296.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; JOHNSON RJ, 1992, J EXP MED, V175, P1413, DOI 10.1084/jem.175.5.1413; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SEVERINSSON L, 1989, EUR J BIOCHEM, V182, P679, DOI 10.1111/j.1432-1033.1989.tb14879.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	46	67	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3625	3631						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679113				2022-12-25	WOS:A1993KM16100091
J	HAGLER, J; SHUMAN, S				HAGLER, J; SHUMAN, S			NASCENT RNA CLEAVAGE BY PURIFIED TERNARY COMPLEXES OF VACCINIA RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS EARLY TRANSCRIPTION; ESCHERICHIA-COLI; CHAIN ELONGATION; INITIATION; PROMOTER; PURIFICATION; VIRIONS; ENZYME; VIEW; DNA	Ternary complexes of vaccinia virus RNA polymerase containing 3'-OMeGMP-arrested transcripts were purified by native gel electrophoresis. These complexes resumed elongation in situ when gel slices were incubated with magnesium and NTPs. Elongation occurred in the absence of pyrophosphate, suggesting that the blocking 3'-OMeGMP residue was removed via a novel pathway. We show that purified elongation complexes contain an intrinsic nuclease activity that shortens nascent RNA from the 3'-end. RNA cleavage was absolutely dependent on a divalent cation and was stimulated by CTP. The initial 5' cleavage product remained associated with the ternary complex and could be elongated in the presence of NTPs. Multiple stepwise cleavages generated progressively shorter chains. Purified ternary complexes containing 3'-OH-terminated RNAs also displayed nuclease activity. Involvement of the vaccinia RNA polymerase subunit rpo30 in the transcript-shortening reaction is suggested based on sequence similarity of rpo30 to mammalian protein SII (TFIIS), an extrinsic transcription factor required for nascent RNA cleavage by RNA polymerase II (Reines, D. (1991) J. Biol. Chem. 267, 3795-3800).			HAGLER, J (corresponding author), SLOAN KETTERING INST CANC RES,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM42498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BATEMAN E, 1988, MOL CELL BIOL, V8, P1940, DOI 10.1128/MCB.8.5.1940; BLANK A, 1986, BIOCHEMISTRY-US, V25, P5920, DOI 10.1021/bi00368a013; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; HAGLER J, 1992, P NATL ACAD SCI USA, V89, P10099, DOI 10.1073/pnas.89.21.10099; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HAGLER J, 1992, J VIROL, V66, P2982, DOI 10.1128/JVI.66.5.2982-2989.1992; HAGLER J, 1992, J BIOL CHEM, V267, P7644; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KRAKOW JS, 1969, J BIOL CHEM, V244, P5988; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LIBBY RT, 1989, EMBO J, V8, P3153, DOI 10.1002/j.1460-2075.1989.tb08469.x; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LUO Y, 1991, J BIOL CHEM, V266, P13303; MAITRA U, 1967, J BIOL CHEM, V242, P4897; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MOSS B, 1991, J BIOL CHEM, V266, P1355; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1991, J BIOL CHEM, V266, P10510; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983	32	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2166	2173						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678416				2022-12-25	WOS:A1993KH62000100
J	SANDER, M; CARTER, M; HUANG, SM				SANDER, M; CARTER, M; HUANG, SM			EXPRESSION OF DROSOPHILA RRP1 PROTEIN IN ESCHERICHIA-COLI - ENZYMATIC AND PHYSICAL CHARACTERIZATION OF THE INTACT PROTEIN AND A CARBOXYL-TERMINALLY DELETED EXONUCLEASE-DEFICIENT MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND EXCHANGE; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; REPAIR ENZYMES; RECA PROTEIN; APURINIC ENDONUCLEASE; BRANCH MIGRATION; SEQUENCE; GENE; PURIFICATION	Drosophila Rrp1 protein purified from embryos has four tightly associated enzymatic activities: DNA strand transfer, single-strand DNA renaturation, 3'-exonuclease, and apurinic endonuclease. Copurifying with these activities is a single polypeptide that has an apparent M(r) of 105,000 when estimated by SDS-polyacrylamide gel electrophoresis. To determine if this polypeptide is sufficient for these activities, it has been overexpressed in Escherichia coli. In crude extracts of E. coli cells, an ATP-independent Mg2+-dependent strand transfer activity is observed upon activation of the promoter that drives expression of Rrp1. Rrp1 protein purified from induced E. coli cells has electrophoretic, chromatographic, and enzymatic properties similar to those of Drosophila Rrp1 protein. The carboxyl-terminal region of Rrp1 (amino acids 428-679) is homologous to E. coli exonuclease III. Rrp1 deleted for this region cannot carry out DNA strand transfer, but can renature complementary single-strand DNA. The strand transfer activity of this truncated protein can be restored if DNA 3'-exonuclease is provided in trans by pretreating the double-strand DNA substrate with E. coli exonuclease III. This demonstrates a likely role of the exonuclease in the in vitro DNA strand transfer reaction carried out by Rrp1 protein. Such a role is also suggested by an analysis of the polarity of the strand transfer reaction.			SANDER, M (corresponding author), NIEHS,GENET LAB,POB 12233,RES TRIANGLE PK,NC 27709, USA.							BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK AB, 1991, MOL CELL BIOL, V11, P2576, DOI 10.1128/MCB.11.5.2576; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUTREIX M, 1991, J MOL BIOL, V219, P645, DOI 10.1016/0022-2836(91)90661-O; DYKSTRA CC, 1991, MOL CELL BIOL, V11, P2583, DOI 10.1128/MCB.11.5.2583; EGGLESTON AK, 1991, BIOCHIMIE, V73, P163, DOI 10.1016/0300-9084(91)90199-B; EISEN A, 1988, P NATL ACAD SCI USA, V85, P7481, DOI 10.1073/pnas.85.20.7481; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; HEYER WD, 1988, J BIOL CHEM, V263, P15189; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KONFORTI BB, 1991, J BIOL CHEM, V266, P10112; KONFORTI BB, 1990, J BIOL CHEM, V265, P6916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENHAUPT K, 1989, J BIOL CHEM, V264, P20568; MCCARTHY JG, 1988, P NATL ACAD SCI USA, V85, P5854, DOI 10.1073/pnas.85.16.5854; MOORE SP, 1990, J BIOL CHEM, V265, P11108; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P1087, DOI 10.1093/nar/19.5.1087; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SANDER M, 1991, NUCLEIC ACIDS RES, V19, P4523, DOI 10.1093/nar/19.16.4523; SEKI S, 1991, J BIOL CHEM, V266, P20797; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH GR, 1987, ANNU REV GENET, V21, P179, DOI 10.1146/annurev.genet.21.1.179; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233	36	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2075	2082						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678415				2022-12-25	WOS:A1993KH62000087
J	CARLOS, S; JUTGLAR, L; BORRELL, I; HUNT, DF; AUSIO, J				CARLOS, S; JUTGLAR, L; BORRELL, I; HUNT, DF; AUSIO, J			SEQUENCE AND CHARACTERIZATION OF A SPERM-SPECIFIC HISTONE H1-LIKE PROTEIN OF MYTILUS-CALIFORNIANUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; SECONDARY STRUCTURE; NUCLEOSOMAL ORGANIZATION; NUCLEAR PROTEINS; INFRARED-SPECTRA; CHROMATIN; H-1; H1; MICROHETEROGENEITY; GALLOPROVINCIALIS	The major protein fraction of the protamine-like PL-II* (phi2B) from the sperm of Mytilus californianus has been sequenced and characterized. Immunological and sequence analyses unequivocally show that this protein is indeed a member of the histone H1 family. Along with proteins of the histone H1 class, the protein also shows cross-reactivity and sequence identity, in its NH2-terminal region, with the major protamine-like protein component of Mytilus sperm: PL-III (phi1), of smaller molecular mass. Indeed it is the unusual repetitive sequence motif of the NH2-terminal domain of PL-II* that bestows to this protein its protamine-like nature. Fourier-transform infrared spectroscopy spectroscopy indicates that the protein contains considerable secondary structure: 18% alpha-helix, 21% beta-sheet, 39% turns and bends, 22% random coil. At the higher levels of structure, PL-II* exhibits ionic strength-dependent folding which is indistinguishable from that of histone H5, as monitored by fluorescence anisotropy.	UNIV VICTORIA, DEPT BIOCHEM & MICROBIOL, VICTORIA V8W 3P6, BC, CANADA; CSIC, ESCOLA TECN SUPER ENGN IND, UNIDAD QUIM MACROMOLEC, E-08028 BARCELONA, SPAIN; CTR ENSENANZA TECN SUPER INST QUIM SARRIA, CTR ASOCIADO CSIC, DEPT QUIM ORGAN, E-08017 BARCELONA, SPAIN; UNIV VIRGINIA, DEPT CHEM, CHARLOTTESVILLE, VA 22901 USA	University of Victoria; Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Ramon Llull; Institut Quimic de Sarria; University of Virginia			Hunt, Donald F/I-6936-2012; Borrell, Jose I./M-1646-2013	Hunt, Donald F/0000-0003-2815-6368; Borrell, Jose I./0000-0001-9409-2919				ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ANDO T, 1969, INT J PROT RES, V1, P221; AUSIO J, 1987, BIOCHEMISTRY-US, V26, P975, DOI 10.1021/bi00378a001; AUSIO J, 1988, J BIOL CHEM, V263, P10141; AUSIO J, 1989, EUR J BIOCHEM, V182, P569, DOI 10.1111/j.1432-1033.1989.tb14865.x; AUSIO J, 1988, CELL DIFFER DEV, V23, P175, DOI 10.1016/0045-6039(88)90070-X; AUSIO J, 1982, J BIOL CHEM, V257, P2802; AUSIO J, 1982, BIOCHEMISTRY-US, V21, P5910, DOI 10.1021/bi00266a028; AUSIO J, 1982, EXP CELL RES, V141, P39, DOI 10.1016/0014-4827(82)90065-9; AUSIO J, 1986, COMP BIOCHEM PHYS B, V85, P439, DOI 10.1016/0305-0491(86)90025-8; AUSIO J, 1987, EUR J BIOCHEM, V165, P363, DOI 10.1111/j.1432-1033.1987.tb11449.x; AVRAMOVA Z, 1984, EXP CELL RES, V152, P231, DOI 10.1016/0014-4827(84)90248-9; BLOCH DP, 1969, GENETICS, V61, P93; BRADBURY EM, 1975, EUR J BIOCHEM, V52, P605, DOI 10.1111/j.1432-1033.1975.tb04032.x; BRIAND G, 1980, FEBS LETT, V112, P147, DOI 10.1016/0014-5793(80)80167-0; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CARLOS S, 1993, J BIOL CHEM, V268, P195; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Cohn E. J., 1943, PROTEINS AMINO ACIDS; COLE RD, 1984, ANAL BIOCHEM, V136, P24, DOI 10.1016/0003-2697(84)90303-8; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DOWNING MR, 1976, ANAL BIOCHEM, V74, P298, DOI 10.1016/0003-2697(76)90211-6; GARCIA-RAMIREZ M, 1990, Protein Expression and Purification, V1, P40, DOI 10.1016/1046-5928(90)90043-X; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIANCOTTI V, 1983, EUR J BIOCHEM, V136, P509, DOI 10.1111/j.1432-1033.1983.tb07770.x; HILL CS, 1990, EMBO J, V9, P805, DOI 10.1002/j.1460-2075.1990.tb08177.x; HILL CS, 1989, EMBO J, V8, P2591, DOI 10.1002/j.1460-2075.1989.tb08398.x; HOLLOWAY PW, 1989, BIOCHEMISTRY-US, V28, P931, DOI 10.1021/bi00429a002; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HUNT DF, 1991, TECHNIQUES PROTEIN C, V2, P441; HURLEY CK, 1977, ANAL BIOCHEM, V80, P624, DOI 10.1016/0003-2697(77)90687-X; JOHNS EW, 1964, BIOCHEM J, V92, P55, DOI 10.1042/bj0920055; JUTGLAR L, 1991, J BIOL CHEM, V266, P8184; KMIECIK D, 1985, EUR J BIOCHEM, V150, P359, DOI 10.1111/j.1432-1033.1985.tb09028.x; Koening J. K., 1980, ANAL APPLICATIONS FT, P241; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI ZC, 1988, MOL CELL BIOL, V8, P1842, DOI 10.1128/MCB.8.4.1842; MANTSCH HH, 1986, SPECTROSCOPY BIOL SY, P1; MAYES ELV, 1982, HMG CHROMOSOMAL PROT, P223; MOGENSEN C, 1991, FEBS LETT, V282, P273, DOI 10.1016/0014-5793(91)80493-M; MULLER S, 1989, METHOD ENZYMOL, V170, P251; NAKANO M, 1976, INT J PEPT PROT RES, V8, P565; OKAMOTO Y, 1987, J BIOCHEM-TOKYO, V101, P1017, DOI 10.1093/oxfordjournals.jbchem.a121943; OLIVARES C, 1991, MOL CELL BIOCHEM, V101, P93; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PEPE I, 1990, BIOCHIM BIOPHYS ACTA, V1041, P14, DOI 10.1016/0167-4838(90)90116-W; PHELAN JJ, 1974, J BIOL CHEM, V249, P1099; RISLEY MS, 1990, CHROMOSOMES EUKARYOT, V2, P61; SANDERS MM, 1978, J CELL BIOL, V79, P97, DOI 10.1083/jcb.79.1.97; SHAY CE, 1988, COMP BIOCHEM PHYS B, V91, P69, DOI 10.1016/0305-0491(88)90115-0; SMERDON MJ, 1976, BIOCHEMISTRY-US, V15, P4233, DOI 10.1021/bi00664a016; STRICKLAND WN, 1980, EUR J BIOCHEM, V104, P567, DOI 10.1111/j.1432-1033.1980.tb04460.x; STRICKLAND WN, 1982, BIOCHIM BIOPHYS ACTA, V700, P127, DOI 10.1016/0167-4838(82)90300-4; SUBIRANA JA, 1973, BIOCHIM BIOPHYS ACTA, V317, P364, DOI 10.1016/0005-2795(73)90231-6; SUBIRANA JA, 1990, BIOPOLYMERS, V29, P1351, DOI 10.1002/bip.360291003; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; Susi H., 1972, METHODS ENZYMOL, V26, P445; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; USCHEWA A, 1985, CELL BIOL INT REP, V9, P253, DOI 10.1016/0309-1651(85)90042-6; van Holde KE., 1989, SPRINGER SERIES MOL; VANDERWE.DR, 1974, BIOCHIM BIOPHYS ACTA, V359, P341, DOI 10.1016/0005-2795(74)90233-5; YAGUCHI M, 1979, BIOCHEM BIOPH RES CO, V90, P1400, DOI 10.1016/0006-291X(79)91191-4; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; ZALENSKAYA IA, 1985, FEBS LETT, V188, P243; ZALENSKY AO, 1982, STUD BIOPHYS, V87, P137	66	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					185	194						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7677995				2022-12-25	WOS:A1993KE60300029
J	GREENFEDER, SA; VARNELL, T; POWERS, G; LOMBARDGILLOOLY, K; SHUSTER, D; MCINTYRE, KW; RYAN, DE; LEVIN, W; MADISON, V; JU, G				GREENFEDER, SA; VARNELL, T; POWERS, G; LOMBARDGILLOOLY, K; SHUSTER, D; MCINTYRE, KW; RYAN, DE; LEVIN, W; MADISON, V; JU, G			INSERTION OF A STRUCTURAL DOMAIN OF INTERLEUKIN (IL)-1-BETA CONFERS AGONIST ACTIVITY TO THE IL-1 RECEPTOR ANTAGONIST - IMPLICATIONS FOR IL-1 BIOACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; BIOLOGICAL-ACTIVITY; HUMAN IL-1-BETA; BINDING-SITE; II RECEPTOR; EXPRESSION; PROTEIN; RESOLUTION; INHIBITOR; CLONING	We showed previously that replacement of Lys-145 in the IL-1 receptor antagonist (IL-1ra) with Asp resulted in an analog (IL-1ra K145D) with partial agonist activity. To identify additional amino acids that affect IL-1 bioactivity, we created second site mutations in IL-1ra K145D, Substitutions of single amino acids surrounding position 145 were made; none of these substitutions increased the bioactivity of IL-1ra K145D. However, the insertion of the beta-bulge (QGEESN) of IL-1 beta at the corresponding region of IL-1ra K145D resulted in a 3-4-fold augmentation of bioactivity. An additional increase in agonist activity was observed when the beta-bulge was coexpressed with a second substitution (Kis-54 --> Pro) in IL-1ra K145D, We also show that the bioactivity of both IL-1ra K145D and the triple mutant IL-1ra K145D/H54P/QGEESN is dependent on interaction with the newly cloned IL-1 receptor accessory protein.	HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT INFLAMMAT AUTOIMMUNE DIS,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT CHEM PHYS,NUTLEY,NJ 07110	Roche Holding; Roche Holding								ANTONI G, 1986, J IMMUNOL, V137, P3201; AREND WP, 1994, J IMMUNOL, V153, P4766; AREND WP, 1985, J IMMUNOL, V134, P3868; AURON PE, 1992, BIOCHEMISTRY-US, V31, P6632, DOI 10.1021/bi00144a002; BECKERS W, 1993, J IMMUNOL, V151, P1757; BORASCHI D, 1988, J EXP MED, V168, P675, DOI 10.1084/jem.168.2.675; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CERTA U, 1986, EMBO J, V5, P3051, DOI 10.1002/j.1460-2075.1986.tb04605.x; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; CHIZZONITE R, 1991, J IMMUNOL, V147, P1548; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; DINARELLO CA, 1991, BLOOD, V77, P1627; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; FRASCA D, 1988, J IMMUNOL, V141, P2651; GEHRKE L, 1990, J BIOL CHEM, V265, P5922; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GRUTTER MG, 1994, PROTEIN ENG, V7, P663, DOI 10.1093/protein/7.5.663; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOPKINS SJ, 1989, J IMMUNOL METHODS, V120, P271, DOI 10.1016/0022-1759(89)90252-4; HUANG JJ, 1987, FEBS LETT, V223, P294, DOI 10.1016/0014-5793(87)80307-1; JU G, 1991, P NATL ACAD SCI USA, V88, P2658, DOI 10.1073/pnas.88.7.2658; KAWASHIMA H, 1992, PROTEIN ENG, V5, P171, DOI 10.1093/protein/5.2.171; LABRIOLATOMPKIN.E, 1993, PROTEIN ENG, V8, P535; LABRIOLATOMPKINS E, 1991, P NATL ACAD SCI USA, V88, P11182, DOI 10.1073/pnas.88.24.11182; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAZZEI GJ, 1990, EUR J IMMUNOL, V20, P683, DOI 10.1002/eji.1830200332; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; SIMON PL, 1993, J BIOL CHEM, V268, P9771; SIMONCSITS A, 1994, CYTOKINE, V6, P206, DOI 10.1016/1043-4666(94)90043-4; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; STOCKMAN BJ, 1994, FEBS LETT, V349, P79, DOI 10.1016/0014-5793(94)00643-1; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; VIGERS GPK, 1994, J BIOL CHEM, V269, P12874; WOLFSON AJ, 1993, BIOCHEMISTRY-US, V32, P5327, DOI 10.1021/bi00071a007	44	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22460	22466		10.1074/jbc.270.38.22460	http://dx.doi.org/10.1074/jbc.270.38.22460			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673234	hybrid			2022-12-25	WOS:A1995RW31400063
J	LANDER, HM; OGISTE, JS; TENG, KK; NOVOGRODSKY, A				LANDER, HM; OGISTE, JS; TENG, KK; NOVOGRODSKY, A			P21(RAS) AS A COMMON SIGNALING TARGET OF REACTIVE FREE-RADICALS AND CELLULAR REDOX STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; STIMULATION; CELLS; LYMPHOCYTES; INHIBITION; HEMIN; DNA	Reactive free radicals have been implicated in mediating signal transduction by a variety of stimuli. We have investigated the role of p21(ras) in mediating free radical signaling. Our studies revealed that signaling by oxidative agents which modulate cellular redox status, such as H2O2, hemin, Hg2+, and nitric oxide was prevented in cells in which p21(ras) activity was blocked either through expression of a dominant negative mutant or by treating with a farnesyltransferase inhibitor, as assessed by NF-kappa B binding activity. Furthermore, the NP-kappa B response to these oxidative stress stimuli was found to be enhanced when cells from the human T cell line, Jurkat, were pretreated with L-buthionine-(S,R)-sulfoximine, an inhibitor of glutathione synthesis. We directly assayed p21(ras) and mitogen-activated protein kinase activities in jurkat cells and found both of these signaling molecules to be activated in cells treated with the redox modulating agents. Blocking glutathione synthesis made cells 10- to 100-fold more sensitive to these agents. Finally, using recombinant p21(ras) in vitro, we found that redox modulators directly promoted guanine nucleotide exchange on p21(ras). This study suggests that direct activation of p21(ras) may be a central mechanism by which a variety of redox stress stimuli transmit their signal to the nucleus.	CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY 10021; FELSENSTEIN MED RES CTR,IL-49100 PETAH TIQWA,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,IL-69978 TEL AVIV,ISRAEL	Cornell University; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	LANDER, HM (corresponding author), CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021, USA.			Teng, Kenneth/0000-0002-9392-2172	NIAID NIH HHS [AI37637] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037637] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; AMES BN, 1993, ENVIRON HEALTH PERSP, V101, P35, DOI 10.2307/3431840; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BOS JL, 1989, CANCER RES, V49, P4682; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; LANDER HM, 1993, BIOCHEM J, V291, P281, DOI 10.1042/bj2910281; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANDER HM, 1993, J IMMUNOL, V151, P7182; LANDER HM, 1993, J IMMUNOL, V150, P1509; MUEHLEMATTER D, 1988, CARCINOGENESIS, V9, P239, DOI 10.1093/carcin/9.2.239; REARDON CL, 1987, IMMUNOBIOLOGY, V175, P455, DOI 10.1016/S0171-2985(87)80073-6; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1994, METHOD ENZYMOL, V234, P151; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; STENZEL KH, 1981, J IMMUNOL, V127, P2469; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; WARNER GL, 1986, CELL IMMUNOL, V101, P425, DOI 10.1016/0008-8749(86)90155-3; YAN SD, 1994, J BIOL CHEM, V269, P9889	24	353	357	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21195	21198		10.1074/jbc.270.36.21195	http://dx.doi.org/10.1074/jbc.270.36.21195			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673152	hybrid			2022-12-25	WOS:A1995RU05400052
J	WRIGHT, KL; MOORE, TL; VILEN, BJ; BROWN, AM; TING, JPY				WRIGHT, KL; MOORE, TL; VILEN, BJ; BROWN, AM; TING, JPY			MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II-ASSOCIATED INVARIANT CHAIN GENE-EXPRESSION IS UP-REGULATED BY COOPERATIVE INTERACTIONS OF SP1 AND NF-Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; TRANSCRIPTION FACTOR BINDING; GAMMA-INDUCED EXPRESSION; SERUM RESPONSE ELEMENT; RNA POLYMERASE-II; INTERFERON-GAMMA; SYNERGISTIC ACTIVATION; IFN-GAMMA; BOX-BINDING; CCAAT-BOX	Expression of the major histocompatibility complex (MHC) class II-associated invariant chain (Ii) is required for efficient and complete presentation of antigens by MHC class II molecules and a normal immune response. The Ii gene is generally co-regulated with the MHC class II molecules at the level of transcription and a shared SXY promoter element has been described. This report defines the proximal promoter region of Ii which may regulate Ii transcription distinct from MHC class II, In vivo genomic footprinting identified an occupied, imperfect CCAAT box and an adjacent GC box in the proximal region, These sites are bound in Ii-ositive cell lines and upon interferon-gamma induction of Ii transcription. In contrast, both sites are unoccupied in Ii-egative cell lines and in inducible cell lines prior to interferon-gamma treatment, Together these two sites synergize to stimulate transcription, Independently, the transcription factor NF-Y binds poorly to the imperfect CCAAT box with a rapid off rate, while Sp1 binds to the GC box. Stabilization of NF-Y binding occurs upon Sp1 binding to DNA, In addition, the half-life of Sp1 binding also increased in the presence of NF-Y binding. These findings suggest a mechanism for the complete functional synergy of the GC and CCAAT elements observed in Ii transcription. Furthermore, this report defines a CCAAT box of imperfect sequence which binds NF-Y and activates transcription only when stabilized by an adjacent factor, Sp1.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT MICROBIOL IMMUNOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA48185] Funding Source: Medline; NIAID NIH HHS [AI29564, T32-AI07232] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI029564, R01AI029564, R37AI029564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BARR CL, 1991, J BIOL CHEM, V266, P3475; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BROWN AM, 1993, J BIOL CHEM, V268, P26328; BROWN AM, 1994, MOL CELL BIOL, V14, P2926, DOI 10.1128/MCB.14.5.2926; BROWN AM, 1991, J IMMUNOL, V146, P3183; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COHEN RB, 1986, MOL CELL BIOL, V6, P821, DOI 10.1128/MCB.6.3.821; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CRESSWELL P, 1990, NATURE, V343, P593, DOI 10.1038/343593a0; CRESSWELL P, 1992, CURR OPIN IMMUNOL, V4, P87, DOI 10.1016/0952-7915(92)90131-W; CURRIE RA, 1992, ARCH BIOCHEM BIOPHYS, V298, P630, DOI 10.1016/0003-9861(92)90459-A; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DELVOYE NL, 1993, MOL CELL BIOL, V13, P6969, DOI 10.1128/MCB.13.11.6969; DEPREVAL C, 1985, NATURE, V318, P291, DOI 10.1038/318291a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DOYLE C, 1990, P NATL ACAD SCI USA, V87, P4590, DOI 10.1073/pnas.87.12.4590; EADES AM, 1990, J IMMUNOL, V144, P4399; FABER M, 1990, J BIOL CHEM, V265, P22243; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GROYERSCHWEIZER G, 1992, J STEROID BIOCH MOL, V41, P747; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HOOD L, 1983, ANNU REV IMMUNOL, P529; HOUGHTON AN, 1984, J EXP MED, V160, P255, DOI 10.1084/jem.160.1.255; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; JONES PP, 1978, IMMUNOCHEMISTRY, V16, P51; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; KING DP, 1985, J IMMUNOL, V135, P632; KOCH N, 1984, J IMMUNOL, V132, P1361; KOCH N, 1984, J IMMUNOL, V132, P12; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMB CA, 1992, J IMMUNOL, V148, P3478; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MCGHEE JD, 1981, CELL, V27, P45, DOI 10.1016/0092-8674(81)90359-7; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; MOMBURG F, 1988, CLIN EXP IMMUNOL, V72, P367; MOMBURG F, 1986, J IMMUNOL, V136, P940; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PESSARA U, 1990, MOL CELL BIOL, V10, P4146, DOI 10.1128/MCB.10.8.4146; PETERLIN BM, 1990, IMMUNOL RES, V9, P164, DOI 10.1007/BF02918176; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; POBER JS, 1983, J EXP MED, V157, P1339, DOI 10.1084/jem.157.4.1339; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; RAHMSDORF HJ, 1983, EMBO J, V6, P811; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; SANT AJ, 1994, CURR OPIN IMMUNOL, V6, P57, DOI 10.1016/0952-7915(94)90034-5; SASAKI A, 1990, J NEUROIMMUNOL, V29, P213, DOI 10.1016/0165-5728(90)90164-I; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHERMAN PA, 1989, MOL CELL BIOL, V9, P50, DOI 10.1128/MCB.9.1.50; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TAKIGUCHI M, 1985, EUR J IMMUNOL, V15, P809, DOI 10.1002/eji.1830150813; Teyton L, 1992, Trends Cell Biol, V2, P52, DOI 10.1016/0962-8924(92)90163-H; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; WRIGHT KL, 1992, BIOCHEMISTRY-US, V31, P2812, DOI 10.1021/bi00125a023; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873; ZHU L, 1990, MOL CELL BIOL, V10, P3906, DOI 10.1128/MCB.10.8.3906	90	122	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20978	20986		10.1074/jbc.270.36.20978	http://dx.doi.org/10.1074/jbc.270.36.20978			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673122	hybrid, Green Published			2022-12-25	WOS:A1995RU05400019
J	DAVIE, JR; WYNN, RM; MENG, MS; HUANG, YS; AAHUND, G; CHUANG, DT; LAU, KS				DAVIE, JR; WYNN, RM; MENG, MS; HUANG, YS; AAHUND, G; CHUANG, DT; LAU, KS			EXPRESSION AND CHARACTERIZATION OF BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE KINASE FROM THE RAT - IS IT A HISTIDINE-PROTEIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BOVINE KIDNEY; COMPLEX; PURIFICATION; LIVER; PHOSPHORYLATION; ACTIVATION; ASPARTATE; DOMAINS; BINDING	The recombinant rat branched-chain Lu-ketoacid dehydrogenase kinase has been amplified from rat kidney cDNA, based on the previously reported rat cDNA sequence (Popov, K.M., Zhao, Y., Shimomura, Y., Kuntz, M.J., and Harris, R.A. (1992) J. Biol. Chem. 267, 13127-13130), This kinase was expressed in Escherichia coli as a fusion protein with bacterial maltose-binding protein (MBP), Expression was improved by overexpression of chaperonins GroEL and GroES, The MBP-kinase, when reconstituted with lipoylated recombinant E2 (dihydro lipoyl transacylase), catalyzed phosphorylation of recombinant El (branched-chain alpha-ketoacid decarboxylase) with a K-cat of 28.5 nmol of phosphate/min/nmol of MEP-kinase at 25 degrees C, Recombinant MBP kinase alone demonstrated a slow rate of autophosphorylation with a k(cat) of 3.25 pmol of phosphate/min/nmol of kinase at 25 degrees C, Serine 22 of the kinase was identified as the possible site of autophosphorylation by Edman microsequencing analysis, Autophosphorylated kinase cannot transfer phosphate to E1, indicating that autophosphorylation of kinase is not an intermediate in ATP-dependent phosphorylation of E1, Therefore, despite the reported sequence similarity to prokaryotic histidine protein kinases, the mitochondrial rat branched chain cu-ketoacid dehydrogenase kinase apparently does not phosphorylate E1 via a histidine-mediated phosphotransfer reaction, Significant corrections to the published cDNA sequence of rat branched-chain cu-ketoacid dehydrogenase kinase are included.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Huang, Yi-Shuian/P-2824-2018	Huang, Yi-Shuian/0000-0001-9000-7748; Davie, James/0000-0002-0420-6888; Wynn, Richard/0000-0002-1879-2136	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037373] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-37373] Funding Source: Medline; NIGMS NIH HHS [5-P32 GM-08014] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFTRING RP, 1988, AM J PHYSIOL, V254, pE292, DOI 10.1152/ajpendo.1988.254.3.E292; ALI ST, 1990, BIOCHEM J, V271, P139, DOI 10.1042/bj2710139; BLOCK KP, 1985, BIOCHEM J, V232, P593, DOI 10.1042/bj2320593; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; CHUANG JL, 1994, AM J HUM GENET, V55, P297; CHUANG JL, 1995, J CLIN INVEST, V95, P954, DOI 10.1172/JCI117804; CHUANG JL, 1993, J BIOL CHEM, V268, P8309; COMEAU DE, 1985, J BACTERIOL, V164, P578, DOI 10.1128/JB.164.2.578-584.1985; DAMUNI Z, 1984, P NATL ACAD SCI-BIOL, V81, P4335, DOI 10.1073/pnas.81.14.4335; FONG YL, 1989, J BIOL CHEM, V264, P16759; GOTTFERT M, 1990, P NATL ACAD SCI USA, V87, P2680, DOI 10.1073/pnas.87.7.2680; GRIFFIN TA, 1990, J BIOL CHEM, V265, P12104; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HARRIS RA, 1986, BIOCHEM J, V234, P285, DOI 10.1042/bj2340285; HARRIS RA, 1986, ADV ENZYME REGUL, V25, P219, DOI 10.1016/0065-2571(86)90016-6; LANDGRAF W, 1986, EUR J BIOCHEM, V154, P113, DOI 10.1111/j.1432-1033.1986.tb09365.x; LAU KS, 1990, BIOCHIM BIOPHYS ACTA, V1038, P360, DOI 10.1016/0167-4838(90)90249-F; Lee, 1991, CHEM BIOCH FLAVOENZY, V2, P109; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; MILLER RH, 1988, J BIOL CHEM, V263, P3454; ONO K, 1993, J BIOL CHEM, V268, P26135; PAUL HS, 1982, J BIOL CHEM, V257, P4875; PETTIT FH, 1978, P NATL ACAD SCI USA, V75, P4881, DOI 10.1073/pnas.75.10.4881; POPOV KM, 1992, J BIOL CHEM, V267, P13127; POPOV KM, 1993, J BIOL CHEM, V268, P26602; RADKE GA, 1993, BIOCHEM BIOPH RES CO, V190, P982, DOI 10.1006/bbrc.1993.1146; RORRER K, 1992, J GEN VIROL, V73, P775, DOI 10.1099/0022-1317-73-4-775; SHIMOMURA Y, 1990, ARCH BIOCHEM BIOPHYS, V283, P293, DOI 10.1016/0003-9861(90)90645-F; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; SWANSON RV, 1993, BIOCHEMISTRY-US, V32, P7623, DOI 10.1021/bi00081a004; WEI YF, 1991, METHOD ENZYMOL, V200, P388; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; WYNN RM, 1992, J BIOL CHEM, V267, P12400; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625; ZHAO Y, 1994, J BIOL CHEM, V269, P18583	35	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19861	19867		10.1074/jbc.270.34.19861	http://dx.doi.org/10.1074/jbc.270.34.19861			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649998	hybrid			2022-12-25	WOS:A1995RQ99100030
J	GRYCZYNSKI, Z; LUBKOWSKI, J; BUCCI, E				GRYCZYNSKI, Z; LUBKOWSKI, J; BUCCI, E			HEME-PROTEIN INTERACTIONS IN HORSE HEART MYOGLOBIN AT NEUTRAL PH AND EXPOSED TO ACID INVESTIGATED BY TIME-RESOLVED FLUORESCENCE IN THE PICOSECOND TO NANOSECOND TIME RANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; NUCLEAR MAGNETIC-RESONANCE; LINEAR DICHROISM; ENERGY-TRANSFER; ORIENTATIONAL DISORDER; CIRCULAR-DICHROISM; DECAY KINETICS; TRYPTOPHANS; CHROMOPHORE; RESOLUTION	We measured the steady state and time-resolved emission intensity decay of horse heart myoglobin at various pH values from neutral to pH 4.42. The steady state intensity was reversibly increased with the decreasing pH, almost doubling at pH 4.5, Frequency domain data for emission decay were analyzed separately for each pH and simultaneously by global analyses, The results indicated the presence of four lifetime components, conserved throughout the pH titrations at 40, 116, 1363, and 4822 ps, respectively, The titration affected only their fractional intensitie. Assignments of the lifetimes were based on the Forster theory of radiationless dipole dipole interaction and the atomic coordinates of the system, We assigned the two shorter lifetimes to Trp-14 and Trp-7, respectively, in the presence of normal hemes, The 1363-ps lifetime was assigned to Trp-7 with inverted hemes (i.e. rotated 180 degrees around the alpha-gamma-meso axis of the porphyrin ring). The 4822-ns lifetime was assigned to reversibly heme-dissociated myoglobin, Lorentzian lifetime distributions were narrow for the lifetimes at 40, 116, and 4822 ps, indicating a homogeneous protein structure, Instead the lifetime at 1363 ns had a broad, ps-independent distribution consistent with small angle wobblings of inverted hemes inside the heme pocket, These analyses revealed the presence of three species originating from heme-protein interactions: the native form of crystalline myoglobin, the conformation with disordered hemes, and the reversibly dissociated heme-free myoglobin. There was increased heme inversion and heme dissociability at lower pH, consistent with the titration of the proximal and distal histidines inside the heme pocket.	UNIV MARYLAND,SCH MED,DEPT BIOCHEM,BALTIMORE,MD 21201; UNIV GDANSK,DEPT CHEM,PL-80952 GDANSK,POLAND	University System of Maryland; University of Maryland Baltimore; Fahrenheit Universities; University of Gdansk					NCRR NIH HHS [RR-08119] Funding Source: Medline; NHLBI NIH HHS [R01-HL-1364, P01-HL-48517] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048517] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBINSSON B, 1989, J PHYS CHEM-US, V93, P6646, DOI 10.1021/j100355a016; ALBINSSON B, 1992, J PHYS CHEM-US, V96, P6204, DOI 10.1021/j100194a023; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; AOJULA HS, 1986, BIOCHEM J, V237, P613, DOI 10.1042/bj2370613; BEECHEM JM, 1991, TOPICS FLUORESCENCE, V1, P241; BENESCH RE, 1994, METHOD ENZYMOL, V231, P496; BISMUTO E, 1989, BIOCHEMISTRY-US, V28, P1508, DOI 10.1021/bi00430a013; BISMUTO E, 1994, J MOL BIOL, V241, P103, DOI 10.1006/jmbi.1994.1477; BOTELHO LH, 1978, BIOCHEMISTRY-US, V17, P5197, DOI 10.1021/bi00617a020; BOTELHO LH, 1978, BIOCHEMISTRY-US, V17, P5188, DOI 10.1021/bi00617a019; BUNN HF, 1967, J BIOL CHEM, V243, P465; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; EVANS SV, 1990, J MOL BIOL, V213, P885, DOI 10.1016/S0022-2836(05)80270-0; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; FRAUENFELDER H, 1985, SCIENCE, V229, P337, DOI 10.1126/science.4012322; GRATTON E, 1986, PROGR CHALLENGE NATU; GRYCZYNSKI Z, 1993, BIOPHYS CHEM, V48, P31, DOI 10.1016/0301-4622(93)80039-L; GRYCZYNSKI Z, 1993, PHOTOCHEM PHOTOBIOL, V58, P492, DOI 10.1111/j.1751-1097.1993.tb04920.x; GRYCZYNSKI Z, 1993, BIOPHYS J, V65, P1951, DOI 10.1016/S0006-3495(93)81266-9; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; HARGROVE MS, 1994, BIOCHEMISTRY-US, V30, P11767; HOCHSTRASSER RM, 1984, P NATL ACAD SCI-BIOL, V81, P4399, DOI 10.1073/pnas.81.14.4399; IRACE G, 1986, ARCH BIOCHEM BIOPHYS, V244, P459, DOI 10.1016/0003-9861(86)90614-4; JANES SM, 1987, BIOPHYS J, V51, P653, DOI 10.1016/S0006-3495(87)83390-8; JUE T, 1983, J AM CHEM SOC, V105, P6395; LACZKO G, 1990, REV SCI INSTRUM, V61, P2331, DOI 10.1063/1.1141360; LAKOWICZ JR, 1987, BIOPHYS CHEM, V28, P35, DOI 10.1016/0301-4622(87)80073-X; LAMAR GN, 1984, J AM CHEM SOC, V106, P6395, DOI 10.1021/ja00333a050; LAMAR GN, 1983, J MOL BIOL, V168, P887, DOI 10.1016/S0022-2836(83)80080-1; LIGHT WR, 1987, J BIOL CHEM, V262, P46; LIVINGSTON DJ, 1984, J AM CHEM SOC, V106, P3025, DOI 10.1021/ja00322a043; POSTNIKOVA GB, 1991, EUR J BIOCHEM, V198, P241, DOI 10.1111/j.1432-1033.1991.tb16007.x; SMITH ML, 1991, P NATL ACAD SCI USA, V88, P882, DOI 10.1073/pnas.88.3.882; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; WILLIS KJ, 1990, BIOCHEMISTRY-US, V29, P5270, DOI 10.1021/bi00474a008	36	36	36	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19232	19237		10.1074/jbc.270.33.19232	http://dx.doi.org/10.1074/jbc.270.33.19232			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642594	hybrid			2022-12-25	WOS:A1995RP70300008
J	NAKSHATRI, H; NAKSHATRI, P; CURRIE, RA				NAKSHATRI, H; NAKSHATRI, P; CURRIE, RA			INTERACTION OF OCT-1 WITH TFIIB - IMPLICATIONS FOR A NOVEL RESPONSE ELICITED THROUGH THE PROXIMAL OCTAMER SITE OF THE LIPOPROTEIN-LIPASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TRANSCRIPTION FACTOR-TFIIB; RNA POLYMERASE-II; TATA-BINDING PROTEIN; HEAVY-CHAIN PROMOTER; TYPE-1 TRANSACTIVATOR VMW65; POU-SPECIFIC DOMAIN; NF-KAPPA-B; DNA-BINDING; ACTIVATION DOMAIN; GENE-TRANSCRIPTION	The ubiquitous human POU domain protein, Oct-1, and the related B-cell protein, Oct-2, regulate transcription from a variety of eukaryotic genes by binding to a common cis-acting octamer element, 5'-ATTTGCAT-3'. The binding of Oct-1 and Oct-2 to the functionally important lipoprotein lipase (LPL) promoter octamer site was stimulated by the general transcription factor, TFIIB. Comparative analysis of the LPL, histone H2B (H2B), and herpes simplex virus ICPO gene promoter octamer sites revealed that nucleotide sequences within and flanking the octamer sequence determined the degree of TFII-mediated stimulation of Oct-1 DNA binding. TFIIB was found to decrease the rate of dissociation of Oct-1 from the LPL octamer site, whereas it increased the rate of association, as well as decreased the rate of dissociation, of Oct-1 from the H2B octamer site. A monoclonal antibody against TFIIB immunoprecipitated a ternary complex containing TFIIB, Oct-1, and the LPL and H2B octamer binding sites. TFIIB did not alter the DNase I footprints generated by Oct-1 on the LPL and H2B promoters. However, Oct-1 prevented TATA-binding protein and TFIIB from footprinting the perfect TATA box sequence located 5' of the LPL NF-Y binding site. In transfection experiments, transcription from reporters containing the LPL octamer, and either the SV40 or the yeast transcription factor GAL4-dependent enhancers, initiated at a precise position within the octamer sequence. Transcription from reporters containing the H2B octamer and the SV40 enhancer initiated at several positions within and flanking the octamer site, whereas transcription initiated at a precise position within the octamer from reporters with both the H2B octamer and the GAL4-dependent enhancer. These results suggest that octamers and their flanking sequences play an important role in positioning the site of transcription initiation, and that this could be a function of the interaction of Oct-1 with TFIIB.	PICOWER INST MED RES, GENE REGULAT LAB, MANHASSET, NY 11030 USA	Northwell Health			Currie, Richard/N-6074-2017	Currie, Richard/0000-0002-6528-3326; Nakshatri, Harikrishna/0000-0001-8876-0052	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047272, R01DK047272] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47272] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ARNOSTI DN, 1993, EMBO J, V12, P157, DOI 10.1002/j.1460-2075.1993.tb05641.x; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BANNISTER AJ, 1992, NUCLEIC ACIDS RES, V20, P3523, DOI 10.1093/nar/20.13.3523; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COENJAERTS FEJ, 1994, EMBO J, V13, P5401, DOI 10.1002/j.1460-2075.1994.tb06875.x; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; CURRIE RA, 1992, ARCH BIOCHEM BIOPHYS, V298, P630, DOI 10.1016/0003-9861(92)90459-A; DEEB SS, 1989, BIOCHEMISTRY-US, V28, P4132, DOI 10.1021/bi00436a001; ENERBACK S, 1992, MOL CELL BIOL, V12, P4622, DOI 10.1128/MCB.12.10.4622; Flint S. J, 1981, DNA TUMOR VIRUSES; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HUA XX, 1991, GENE, V107, P247, DOI 10.1016/0378-1119(91)90325-6; ING NH, 1992, J BIOL CHEM, V267, P17617; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEID M, 1994, J BIOL CHEM, V269, P14175; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; PREVIATO L, 1991, J BIOL CHEM, V266, P18958; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; Sambrook J, 1989, MOL CLONING LABORATO; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SEGIL N, 1991, COLD SPRING HARB SYM, V56, P285; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1994, MOL CELL BIOL, V14, P6046, DOI 10.1128/MCB.14.9.6046; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TANUMA Y, 1995, MOL CELL BIOL, V15, P517, DOI 10.1128/MCB.15.1.517; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WALKER S, 1994, CELL, V79, P841, DOI 10.1016/0092-8674(94)90073-6; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; YANG J, 1991, EMBO J, V10, P2291, DOI 10.1002/j.1460-2075.1991.tb07765.x; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	103	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19613	19623		10.1074/jbc.270.33.19613	http://dx.doi.org/10.1074/jbc.270.33.19613			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642649	hybrid, Green Submitted			2022-12-25	WOS:A1995RP70300065
J	RYAN, MG; RATNAM, K; HILLE, R				RYAN, MG; RATNAM, K; HILLE, R			THE MOLYBDENUM CENTERS OF XANTHINE-OXIDASE AND XANTHINE DEHYDROGENASE - DETERMINATION OF THE SPECTRAL CHANGE ASSOCIATED WITH REDUCTION FROM THE MO(VI) TO THE MO(IV) STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HALF-REACTION; MECHANISM; INACTIVATION	The UV-visible absorbance change associated with reduction of the molybdenum centers of xanthine oxidase and xanthine dehydrogenase has been determined using a double-difference technique, At pH 8.5, the Mo(VI) minus Mo(IV) difference spectrum seen with xanthine oxidase exhibits a positive feature at 420 nm, having an extinction change of similar to 3,000 M(-1) cm(-1) as well as evidence for a negative feature below 340 nm, In xanthine oxidase this change is found to exhibit a marked pH dependence, implicating protonation/deprotonation events associated with changes in the molybdenum oxidation state, Application of the double-difference protocol to the respective circular dichroism spectra of xanthine oxidase and xanthine dehydrogenase reveals appreciable CD changes at 420 and 580 nm associated with the reduction of the molybdenum center. The present results demonstrate a direct spectroscopic handle on the molybdenum centers of both xanthine oxidase and xanthine dehydrogenase.			RYAN, MG (corresponding author), OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210, USA.							BASTIAN NR, 1991, J BIOL CHEM, V266, P45; BRAY RC, 1964, J BIOL CHEM, V239, P2667; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; CRAMER SP, 1985, CHEM BIOL MOLYBDENUM, P411; DAVIS MD, 1982, J BIOL CHEM, V257, P4730; DAVIS MD, 1984, J BIOL CHEM, V259, P3526; EDMONDSON D, 1973, J BIOL CHEM, V248, P6135; GUTTERIDGE S, 1980, BIOCHEM J, V189, P615, DOI 10.1042/bj1890615; Hille R., 1985, Metal Ions in Biology, V7, P443; HILLE R, 1987, J BIOL CHEM, V262, P10914; HILLE R, 1994, BBA-BIOENERGETICS, V1184, P143, DOI 10.1016/0005-2728(94)90220-8; HILLE R, 1984, J BIOL CHEM, V259, P1570; HILLE R, 1995, IN PRESS FASEB J; HUNT J, 1994, J BIOL CHEM, V269, P18904; KIM JH, 1993, J BIOL CHEM, V268, P44; KOMAI H, 1969, J BIOL CHEM, V244, P1692; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MCWHIRTER RB, 1991, J BIOL CHEM, V266, P23724; MORRISON M, 1963, J BIOL CHEM, V238, P2847; NISHINO T, 1989, J BIOL CHEM, V264, P6075; OLSON JS, 1974, J BIOL CHEM, V29, P4363; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; STEIFEL EI, 1977, PROG INORG CHEM, V21, P1	25	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19209	19212		10.1074/jbc.270.33.19209	http://dx.doi.org/10.1074/jbc.270.33.19209			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642590				2022-12-25	WOS:A1995RP70300004
J	SUN, Y; HEGAMYER, G; KIM, HT; SITHANANDAM, K; LI, H; WATTS, R; COLBURN, NH				SUN, Y; HEGAMYER, G; KIM, HT; SITHANANDAM, K; LI, H; WATTS, R; COLBURN, NH			MOLECULAR-CLONING OF MOUSE-TISSUE INHIBITOR OF METALLOPROTEINASES-3 AND ITS PROMOTER - SPECIFIC LACK OF EXPRESSION IN NEOPLASTIC JB6 CELLS MAY REFLECT ALTERED GENE METHYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NASOPHARYNGEAL CARCINOMA; POINT MUTATION; MESSENGER-RNA; PHORBOL ESTER; BINDING-SITE; LIVER CELLS; HA-RAS; TRANSFORMATION; P53	Mouse tissue inhibitor of metalloproteinases-3 (mTIMP-3), a gene specifically not expressed in neoplastic JB6 cells, has been isolated recently through the use of the mRNA differential display technique (Sun, Y., Hegamyer, G., and Colburn, N. H. (1994) Cancer Res. 54, 1139-1144). We report here the full-length mTIMP-3 cDNA sequence, the promoter sequence and partial characterization, expression and induction of TIMP-3, and the possible molecular basis for the lack of mTIMP-3 expression in neoplastic JB6 cells. There are three transcripts arising from alternative polyadenylation of mouse TIMP-3 gene, having sizes of 4.6, 2.8, and 2.3 kilobase pairs, respectively. All three TIMP-3 transcripts are expressed in preneoplastic but not neoplastic JB6 cells. Computer analysis of cloned TIMP-3 promoter revealed six AP-1 binding sites, two NF-kappa B sites, a c-Myc site, and two copies of a p53 binding motif separated by eight base pairs with two mismatches at the second motif, along with many other cis elements, TIMP-3 gene expression was inducible by AP-1 and NF-kappa B activators, 12-O-tetradecanoylphorbol-13-acetate, and tumor necrosis factor-alpha only in preneoplastic cells with an induction peak at 2 h post-treatment, suggesting classification of mTIMP-3 as a member of the immediate early gene family. Southern blot, mutational analysis, and transient transcriptional activation experiments revealed that the lack of expression of mTIMP-3 in neoplastic JB6 cells was due neither to gross deletion nor to promoter mutation of the gene, nor was there a lack of transcription factors required for transcriptional activation. Instead, the lack of TIMP-3 expression in neoplastic JB6 cells may reflect an abnormal methylation of the gene. Both hyper- and hypomethylation of the mTIMP-3 gene are associated with complete down-regulation of gene expression in neoplastic JB6 cell lines. Treatment of neoplastic cells with the methylase inhibitor 5-azacytidine caused reexpression of the mTIMP-3 gene in a tumor cell line that showed hypermethylation but not in another that showed hypomethylation of the gene, suggesting a complex role for methylation in the silencing of gene expression.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,CELL BIOL SECT,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,DYN CORP,PROGRAM RESOURCES INC,BIOL CARCINOGENESIS & DEV P,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	SUN, Y (corresponding author), PARKE DAVIS PHARMACEUT RES,DEPT CANC RES,2800 PLYMOUTH RD,ANN ARBOR,MI 48105, USA.							ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTS SS, 1994, DEV DYNAM, V200, P177; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BERNSTEIN LR, 1991, ENVIRON HEALTH PERSP, V93, P111, DOI 10.2307/3431178; BIRKEDALHANSEN H, 1992, CRIT REV ORAL BIOL M, V4, P197; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; DARNELL J, 1990, MOL CELL BIOL, P639; DECLERCK YA, 1994, GENE, V139, P185, DOI 10.1016/0378-1119(94)90753-6; DIBENEDETTI F, 1990, MOL CELL BIOL CYTOKI, P275; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; GALLOWAY DA, 1983, NATURE, V301, P21; Gindhart T D, 1985, Carcinog Compr Surv, V8, P341; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; JONES PA, 1991, CANCER RES, V51, P3617; Jones PA, 1984, DNA METHYLATION BIOC, P165; JONES RH, 1988, CELL, V53, P659, DOI 10.1016/0092-8674(88)90581-8; KHOKHA R, 1989, INVAS METAST, V9, P391; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LECO KJ, 1992, GENE, V117, P209, DOI 10.1016/0378-1119(92)90731-4; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MICHIELI P, 1994, CANCER RES, V54, P3391; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P444; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SILBIGER SM, 1994, GENE, V141, P293, DOI 10.1016/0378-1119(94)90588-6; SUN Y, 1993, CARCINOGENESIS, V14, P1505, DOI 10.1093/carcin/14.8.1505; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; SUN Y, 1995, ONCOGENE, V10, P785; SUN Y, 1994, CANCER RES, V54, P1139; SUN Y, 1989, INT J CANCER, V44, P1028, DOI 10.1002/ijc.2910440615; SUN Y, 1993, BIOTECHNIQUES, V15, P372; SUN Y, 1992, CANCER RES, V52, P1907; SUN Y, 1993, MOL CARCINOGEN, V8, P49, DOI 10.1002/mc.2940080111; SUN Y, 1995, CANCER EPIDEM BIOMAR, V4, P261; SUN Y, 1992, BIOTECHNIQUES, V12, P639; SUN Y, 1995, INT J ONCOL, V6, P465; URIA JA, 1994, CANCER RES, V54, P2091; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WICK M, 1994, J BIOL CHEM, V269, P17953; YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676	59	68	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19312	19319		10.1074/jbc.270.33.19312	http://dx.doi.org/10.1074/jbc.270.33.19312			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642607	hybrid			2022-12-25	WOS:A1995RP70300021
J	XU, X; ZHAO, H; DIAZ, J; MUALLEM, S				XU, X; ZHAO, H; DIAZ, J; MUALLEM, S			REGULATION OF [NA+](I) IN RESTING AND STIMULATED SUBMANDIBULAR SALIVARY DUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MANDIBULAR GLANDS; RAT SUBMAXILLARY GLAND; NA+-H+ EXCHANGE; ELECTROLYTE TRANSPORT; K/H EXCHANGE; ACINAR-CELLS; MAIN DUCT; COTRANSPORT; EPITHELIUM; MECHANISM	In the preceding manuscript (Zhao, H., Xu, X., Diaz, J., and Muallem, S. (1995) J. Biol. Chem. 270, 19599-19605), we described a K-out(+)-dependent H+/HCO3- and Na+ influx pathway in the luminal membrane of salivary duct cells. In the present studies, we further characterized this pathway to show that the K-out(+)-dependent Na+ influx was not mediated by the luminal amiloride-sensitive Na+ channel, the Na+/H+ exchangers, or any electroneutral or conductive Cl--dependent transport pathway. Thus, K+ efflux probably maintained electroneutrality during Na+ influx induced by removal of K-out(+). Accordingly, Na+ influx was largely inhibited by 2.5 mM external Ba2+. The K+ site of the K-out(+)-dependent Na+ influx showed the selectivity sequence Cs+ > K+ > NH4+ >> > Li+ which is different from that of several known K+ channels. More importantly, Na+ influx is 50% inhibited at about 20 mM K-out(+), and significant Na+ influx occurred even at 80 mM K-out(+). This is a critical property for the pathway to play a role in Na+ reabsorption and K+ secretion by the duct. The large Na+ influx in resting duct cells is matched by high activity of the ductal Na+ pump which is about 8-fold faster than that of acinar cells. Stimulation of submandibular ducts with various agonists increased [Na+](i) in an agonist-specific manner. The parasympathetic agonist epinephrine was more effective than isoproterenol and the sympathetic agonist carbachol. The use of various inhibitors of Na+ and K+ transporters suggests that different pathways mediate Na+ influx in stimulated acinar and duct cells of the gland. In duct cells, Na+ influx was inhibited only by extracellular Cs+ and Ba2+. The overall findings support a significant role for the K-out(+)-dependent pathway(s) in Na+ reabsorption and K+ and HCO3- secretion and explain several features of transepithelial electrolyte transport by salivary ducts.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK 36591, DK 38938] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADORANTE JS, 1987, J GEN PHYSIOL, V90, P209, DOI 10.1085/jgp.90.2.209; AUGUSTUS J, 1977, NATURE, V268, P657, DOI 10.1038/268657a0; BIJMAN J, 1983, PFLUG ARCH EUR J PHY, V398, P96, DOI 10.1007/BF00581055; BONANNO JA, 1991, AM J PHYSIOL, V260, pC618, DOI 10.1152/ajpcell.1991.260.3.C618; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; COMPTON JS, 1980, J PHYSIOL-LONDON, V309, P429, DOI 10.1113/jphysiol.1980.sp013518; DINUDOM A, 1993, PFLUG ARCH EUR J PHY, V423, P164, DOI 10.1007/BF00374977; DINUDOM A, 1993, J MEMBRANE BIOL, V135, P289; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GREEN J, 1988, J BIOL CHEM, V263, P5012; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; HOFER AM, 1992, J MEMBRANE BIOL, V126, P245; KNAUF H, 1982, AM J PHYSIOL, V242, pF132, DOI 10.1152/ajprenal.1982.242.2.F132; KNAUF H, 1976, EUR J CLIN INVEST, V6, P43, DOI 10.1111/j.1365-2362.1976.tb00492.x; KNAUF H, 1975, PFLUG ARCH EUR J PHY, V361, P55, DOI 10.1007/BF00587339; KNAUF H, 1972, PFLUG ARCH EUR J PHY, V333, P82, DOI 10.1007/BF00586044; MANGOS JA, 1966, PFLUG ARCH GES PHYS, V291, P99, DOI 10.1007/BF00362655; MARTIN CJ, 1971, PFLUG ARCH EUR J PHY, V327, P303, DOI 10.1007/BF00588450; MUALLEM S, 1990, J BIOL CHEM, V265, P12813; PAULAIS M, 1994, AM J PHYSIOL, V266, pC1594, DOI 10.1152/ajpcell.1994.266.6.C1594; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; ROBERTSON MA, 1994, AM J PHYSIOL, V267, pC146, DOI 10.1152/ajpcell.1994.267.1.C146; SCHNEYER LH, 1969, AM J PHYSIOL, V217, P1324, DOI 10.1152/ajplegacy.1969.217.5.1324; SCHNEYER LH, 1968, AM J PHYSIOL, V215, P664, DOI 10.1152/ajplegacy.1968.215.3.664; WALL SM, 1988, AM J PHYSIOL, V255, pF331, DOI 10.1152/ajprenal.1988.255.2.F331; YOUNG JA, 1967, PFLUG ARCH GES PHYS, V295, P157, DOI 10.1007/BF00362747; YOUNG JA, 1966, PFLUG ARCH GES PHYS, V291, P85, DOI 10.1007/BF00362654; YOUNG JA, 1970, PFLUG ARCH EUR J PHY, V319, P185, DOI 10.1007/BF00586449; ZHANG GH, 1993, AM J PHYSIOL, V264, pC54, DOI 10.1152/ajpcell.1993.264.1.C54; ZHAO H, 1995, J BIOL CHEM, V270, P19599, DOI 10.1074/jbc.270.33.19599; [No title captured]	31	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19606	19612		10.1074/jbc.270.33.19606	http://dx.doi.org/10.1074/jbc.270.33.19606			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642648	hybrid			2022-12-25	WOS:A1995RP70300064
J	YOKOMIZO, A; KOHNO, K; WADA, M; ONO, M; MORROW, CS; COWAN, KH; KUWANO, M				YOKOMIZO, A; KOHNO, K; WADA, M; ONO, M; MORROW, CS; COWAN, KH; KUWANO, M			MARKEDLY DECREASED EXPRESSION OF GLUTATHIONE-S-TRANSFERASE-PI GENE IN HUMAN CANCER CELL-LINES RESISTANT TO BUTHIONINE SULFOXIMINE, AN INHIBITOR OF CELLULAR GLUTATHIONE SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OVARIAN-CANCER; DNA TOPOISOMERASE-II; ELECTROPHILE-RESPONSIVE ELEMENT; YA-SUBUNIT GENE; CHEMICAL CARCINOGENS; NUCLEOTIDE-SEQUENCE; DRUG ACCUMULATION; ALKYLATING-AGENTS; ESCHERICHIA-COLI; MESSENGER-RNA	Buthionine sulfoximine (BSO) is a synthetic amino acid that irreversibly inhibits an enzyme, gamma-glutamyl-cysteine synthetase (gamma-GCS), which is a critical step in glutathione biosynthesis. We isolated three BSO-resist ant sublines, KB/BSO1, KB/BSO2, and KB/BSO3, from human epidermoid cancer KB cells. These cell lines showed 10-to 13-fold higher resistance to BSO, respectively, and had collateral sensitivity to cisplatin, ethacrynic acid, and alkylating agents such as melphalan and nitrosourea. Cellular levels of glutathione S-transferase pi (GST-pi) and its mRNA in BSO-resistant cell lines were less than 10% of the parental cells, Nuclear run-on assay showed that the transcriptional activity of GST-pi was decreased in BSO-resistant cells, and transient transfection of GST-pi promoter-chloramphenicol acetyltransferase constructs revealed that the sequences between -130 and -80 base pairs of the 5'-flanking region were at least partially responsible for the decreased expression of the GST-pi gene. By contrast, gamma-GCS mRNA levels were 3-to 5-fold higher in resistant cell lines than in KB cells, and the gamma-GCS gene was found to be amplified in the BSO-resistant cell lines. GST-pi mRNA levels appeared to be inversely correlated with gamma-GCS mRNA levels in BSO-resistant cells. We further established the transfectants, KB/BSO3-pi 1 and KB/BSO3-pi 2, that overexpressed GST-pi; from KB/BSO3, after introducing a GST-pi expression plasmid. These two transfectants had similar levels in gamma-GCS mRNA, drug sensitivity to alkylating agents, and glutathione content as those of KB cells. These findings suggest that the cellular levels of GST-pi and gamma-GCS might be co-regulated in these novel BSO-resistant cells.	KYUSHU UNIV, SCH MED, DEPT BIOCHEM, FUKUOKA 81282, JAPAN; WAKE FOREST UNIV, MED CTR, DEPT BIOCHEM, WINSTON SALEM, NC 27157 USA; NCI, MED BRANCH, BETHESDA, MD 20892 USA	Kyushu University; Wake Forest University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ABE H, 1994, ANTICANCER RES, V14, P1807; AHOKAS JT, 1985, BIOCHEM PHARMACOL, V34, P2157, DOI 10.1016/0006-2952(85)90411-3; ALIOSMAN F, 1989, CANCER RES, V49, P5258; ARRICK BA, 1984, CANCER RES, V44, P4224; BATIST G, 1986, J BIOL CHEM, V261, P5544; BEHRENS BC, 1987, CANCER RES, V47, P414; BERGELSON S, 1994, CANCER RES, V54, P36; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; CHU G, 1994, J BIOL CHEM, V269, P787; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; FUJII R, 1994, JPN J CANCER RES, V85, P426, DOI 10.1111/j.1349-7006.1994.tb02376.x; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GOODSPEED DC, 1989, GENE, V76, P1, DOI 10.1016/0378-1119(89)90002-4; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN JA, 1984, CANCER RES, V44, P5427; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HAYAKAWA H, 1990, J MOL BIOL, V213, P739, DOI 10.1016/S0022-2836(05)80260-8; ISHIDA K, 1987, NUCLEIC ACIDS RES, V15, P10051, DOI 10.1093/nar/15.23.10051; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; JELINEK J, 1988, CARCINOGENESIS, V9, P81, DOI 10.1093/carcin/9.1.81; KANO T, 1987, CANCER RES, V47, P5626; KATAOKA H, 1986, EMBO J, V5, P3195, DOI 10.1002/j.1460-2075.1986.tb04629.x; KOHNO K, 1990, J BIOL CHEM, V265, P19690; KOHNO K, 1994, J BIOL CHEM, V269, P20503; KOTOH S, 1994, CANCER RES, V54, P3248; LOUIE KG, 1985, CANCER RES, V45, P2110; MATSUO K, 1990, CANCER RES, V50, P5819; MATSUO K, 1993, CANCER RES, V53, P1085; MEISTER A, 1979, CANCER TREAT REP, V63, P1115; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Meister A., 1988, MECHANISMS DRUG RESI, P99; MIYAZAKI M, 1990, BIOCHEM BIOPH RES CO, V166, P1358, DOI 10.1016/0006-291X(90)91016-L; MORIMURA S, 1992, CELL GROWTH DIFFER, V3, P685; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; NAKAGAWA K, 1990, J BIOL CHEM, V265, P4296; NAKAGAWA M, 1993, J UROLOGY, V150, P1970, DOI 10.1016/S0022-5347(17)35948-7; ODWYER PJ, 1992, J NATL CANCER I, V84, P264, DOI 10.1093/jnci/84.4.264; OKUYAMA T, 1994, CANCER, V74, P1230, DOI 10.1002/1097-0142(19940815)74:4<1230::AID-CNCR2820740409>3.0.CO;2-0; ONO M, 1988, MOL CELL BIOL, V8, P4190, DOI 10.1128/MCB.8.10.4190; OZOLS RF, 1987, BIOCHEM PHARMACOL, V36, P147, DOI 10.1016/0006-2952(87)90392-3; OZOLS RF, 1988, MECHANISMS DRUG RESI, P289; RELLESOMFAI S, 1984, BIOCHEM PHARMACOL, V33, P485; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; ROGAN AM, 1984, SCIENCE, V224, P994, DOI 10.1126/science.6372095; SABURI Y, 1989, CANCER RES, V49, P7020; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; Sambrook J, 1989, MOL CLONING LABORATO; SATO K, 1989, ADV CANCER RES, V52, P205; SUZUKAKE K, 1982, BIOCHEM PHARMACOL, V31, P121; TAKANO H, 1991, CANCER RES, V51, P3951; TEW KD, 1994, CANCER RES, V54, P4313; TIMMERBOSSCHA H, 1992, BRIT J CANCER, V66, P227, DOI 10.1038/bjc.1992.249; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	60	33	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19451	19457		10.1074/jbc.270.33.19451	http://dx.doi.org/10.1074/jbc.270.33.19451			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642628	hybrid			2022-12-25	WOS:A1995RP70300042
J	KATO, H; FARIA, TN; STANNARD, B; ROBERTS, CT; LEROITH, D				KATO, H; FARIA, TN; STANNARD, B; ROBERTS, CT; LEROITH, D			ROLE OF TYROSINE KINASE-ACTIVITY IN SIGNAL TRANSDUCTION BY THE INSULIN-LIKE GROWTH FACTOR-I (IGF-I) RECEPTOR - CHARACTERIZATION OF KINASE-DEFICIENT IGF-I RECEPTORS AND THE ACTION OF AN IGF-I-MIMETIC ANTIBODY (ALPHA-IR-3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; ORNITHINE DECARBOXYLASE; MESSENGER-RNA; CELLS; PHOSPHORYLATION; OVEREXPRESSION; REPLACEMENT; BINDING; AUTOPHOSPHORYLATION; EXPRESSION	The insulin-like growth factor-I (IGF-I) receptor is a member of a large family of transmembrane signal transducing molecules. The defining characteristic of this class of receptors is the intrinsic tyrosine kinase activity of the cytoplasmic domain. While it has been demonstrated that this tyrosine kinase activity is necessary for the action of a number of transmembrane tyrosine kinase receptors, no evidence of this type has been adduced to date with respect to the signaling requirement of the IGF-I receptor. We have now shown that stably transfected NIH-3T3 cell lines overexpressing human IGF-I receptors display increased responses to IGF-I and an IGF-I-mimetic antibody, alphaIR-3, in terms of short, intermediate, and long term actions initiated by activation of the IGF-I receptor. These include receptor autophosphorylation, activation of phosphatidylinositol-3-kinase and 2-deoxyglucose uptake, induction of ornithine decarboxylase gene expression, and stimulation of thymidine incorporation. In short term responses, the kinetics seen with alphaIR-3 were slower than those seen with IGF-I. These effects were severely decreased in clones expressing human IGF-I receptors in which the lysine residue in the ATP-binding site of the tyrosine kinase domain had been mutated to alanine or arginine. This was true for both IGF-I and alphaIR-3. These results indicate that, for all parameters tested, the tyrosine kinase activity of the IGF-I receptor is necessary for activation of the IGF-I-stimulated signal transduction cascade. Additionally, the effects of alphaIR-3 also require tyrosine kinase activity.	NIDDKD,DIABET BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772				ADAMO M, 1991, BIOFACTORS, V3, P151; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BRINDLE NPJ, 1990, BIOCHEM J, V268, P615, DOI 10.1042/bj2680615; CHEN SC, 1991, CANCER RES, V51, P1898; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DURONIO V, 1988, RECEPTOR BIOCH MET B, V12, P3; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GHERZI R, 1987, J BIOL CHEM, V262, P16900; GOTTSCHALK WK, 1991, J BIOL CHEM, V266, P8814; HARI J, 1987, J BIOL CHEM, V262, P15341; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HOVIS JG, 1986, J BIOL CHEM, V261, P380; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHANA C, 1985, P NATL ACAD SCI USA, V82, P1673, DOI 10.1073/pnas.82.6.1673; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LOWE WL, 1987, P NATL ACAD SCI USA, V84, P8946, DOI 10.1073/pnas.84.24.8946; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; OEMAR BS, 1991, J BIOL CHEM, V266, P24241; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PONZIO G, 1988, EMBO J, V7, P4111, DOI 10.1002/j.1460-2075.1988.tb03305.x; RAFAELOFF R, 1991, BIOCHEM BIOPH RES CO, V179, P912, DOI 10.1016/0006-291X(91)91905-R; ROTH RA, 1988, COLD SPRING HARB SYM, V53, P3537; ROTH RA, 1991, MODERN CONCEPTS INSU, P505; SIMPSON IA, 1984, SCIENCE, V223, P1301, DOI 10.1126/science.6367041; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STEELEPERKINS G, 1990, BIOCHEM BIOPH RES CO, V171, P1244, DOI 10.1016/0006-291X(90)90819-9; STEELEPERKINS G, 1990, J BIOL CHEM, V265, P9458; SUNG CK, 1989, J BIOL CHEM, V264, P18951; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Ulrich A., 1985, NATURE, V313, P756; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; XIONG LM, 1992, P NATL ACAD SCI USA, V89, P5356, DOI 10.1073/pnas.89.12.5356; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZICK Y, 1984, J BIOL CHEM, V259, P4396	43	247	255	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2655	2661						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679099				2022-12-25	WOS:A1993KK81500060
J	WEBERSCHURHOLZ, S; WISCHMEYER, E; LAURIEN, M; JOCKUSCH, H; SCHURHOLZ, T; LANDRY, DW; ALAWQATI, Q				WEBERSCHURHOLZ, S; WISCHMEYER, E; LAURIEN, M; JOCKUSCH, H; SCHURHOLZ, T; LANDRY, DW; ALAWQATI, Q			INDANYLOXYACETIC ACID-SENSITIVE CHLORIDE CHANNELS FROM OUTER MEMBRANES OF SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER GOLGI MEMBRANES; VOLTAGE DEPENDENCE; ANION CHANNEL; PURIFICATION; CONDUCTANCE; MANNOSIDASE	In mature mammalian muscle, the chloride conductance of the membrane is an important factor in the regulation of excitability. Up to now, no ligand was available for the biochemical characterization of muscle chloride channels. In order to localize and characterize these channels, we have used indanyloxyacetic acid (IAA)-94, a ligand previously used for epithelial Cl- channels (Landry, D. W., Reitman, M., Cragoe, E. J., Jr., and Al-Awqati, Q. (1987) J. Gen. Physiol. 90, 779-798; Landry, D. W., Akabas, M. H., Redhead, C., Edelman, A., Cragoe, E. J., Jr., and Al-Awqati, Q. (1989) Science 244, 1469-1472). IAA induced myotonic responses when microinjected into mature mouse muscle fibers, indicating a blockade of Cl- channels from the cytoplasmic side. Membrane vesicles were prepared from rabbit skeletal muscle and separated by sucrose gradient centrifugation. Fractions obtained (in the order of increasing density) were sarcolemma (SL), T-tubules (TT), sarcoplasmatic reticulum (SR), and triads and mitochondria (TR/M). The fraction enriched for SL was characterized by high specific binding capacity for [H-3]saxitoxin (Na+ channel), whereas TT-rich fractions bound [H-3]PN 200-110 (dihydropyridine receptor) with high specific activity. Upon patch-clamping of lipid supplemented vesicles, IAA-sensitive Cl- channels were found in the SL fraction but not in the SR. Highest specific activities in electrical diffusion potential sensitive Cl-36 transport and [H-3]IAA-94 binding were found in the SL. SL vesicles were solubilized with 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate and subjected to IAA-Sepharose affinity chromatography. Specifically bound protein was eluted with 100 muM IAA-94 and either analyzed by SDS-gel electrophoresis or reconstituted into phospholipid vesicles. The eluate contained four polypeptides (specifically bound, m(app) 110-120 and 60 kDa; unspecifically bound m(app) 67 and 50 kDa) and was highly enriched for IAA-sensitive chloride channels as shown by patch-clamping after reconstitution. The IAA-sensitive 100/280-picosiemens chloride channels of the sarcolemma are likely to be responsible for its major chloride conductance and thereby for the stabilization of resting potential.	UNIV BIELEFELD,DEV BIOL UNIT,W-4800 BIELEFELD 1,GERMANY; UNIV BIELEFELD,DEPT PHYSIOCHEM,W-4800 BIELEFELD 1,GERMANY; COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032	University of Bielefeld; University of Bielefeld; Columbia University			Al-Awqati, Qais/B-2465-2009	Al-Awqati, Qais/0000-0001-7141-1040				BLATZ AL, 1985, BIOPHYS J, V47, P119, DOI 10.1016/S0006-3495(85)83884-4; BLATZ AL, 1986, J PHYSIOL-LONDON, V378, P141, DOI 10.1113/jphysiol.1986.sp016212; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; BROWN GB, 1986, J NEUROSCI, V6, P2064; BURTON F, 1988, MUSCLE NERVE, V11, P1029, DOI 10.1002/mus.880111004; CORREA AM, 1988, BIOPHYS J, V54, P569, DOI 10.1016/S0006-3495(88)82991-6; DULHUNTY A, 1982, J MEMBRANE BIOL, V67, P81, DOI 10.1007/BF01868650; Fleischer S., 1967, METHOD ENZYMOL, V10, P406; HALS GD, 1990, BIOPHYS J, V57, P1037, DOI 10.1016/S0006-3495(90)82622-9; HORGAN DJ, 1988, ARCH BIOCHEM BIOPHYS, V260, P1, DOI 10.1016/0003-9861(88)90417-1; IMAGAWA T, 1987, J BIOL CHEM, V262, P16336; JOCKUSCH H, 1993, IN PRESS J CELL MOTI; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LANDRY DW, 1987, J GEN PHYSIOL, V90, P779, DOI 10.1085/jgp.90.6.779; MEHRKE G, 1988, MUSCLE NERVE, V11, P440, DOI 10.1002/mus.880110505; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; RAN S, 1992, J BIOL CHEM, V267, P3618; REDHEAD CR, 1992, P NATL ACAD SCI USA, V89, P3716, DOI 10.1073/pnas.89.9.3716; RUDEL R, 1985, PHYSIOL REV, V65, P310, DOI 10.1152/physrev.1985.65.2.310; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; WOLL KH, 1987, PFLUG ARCH EUR J PHY, V410, P641, DOI 10.1007/BF00581325	24	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					547	551						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678003				2022-12-25	WOS:A1993KE60300083
J	COLE, PA; GRACE, MR; PHILLIPS, RS; BURN, P; WALSH, CT				COLE, PA; GRACE, MR; PHILLIPS, RS; BURN, P; WALSH, CT			THE ROLE OF THE CATALYTIC BASE IN THE PROTEIN-TYROSINE KINASE-CSK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MECHANISM; SUBUNIT; INHIBITOR; BINDING	A potential distinguishing feature between protein tyrosine kinases and homologous serine/threonine kinases is the function of the catalytic base in these enzymes. In this study, we show that a peptide containing the unnatural amino acid trifluorotyrosine shows remarkably similar efficiency as a substrate of the tyrosine kinase Csk (C-terminal Src kinase) compared with the corresponding tyrosine-containing peptide despite a 4-unit change in the phenolic pK(alpha). These results argue against the importance of early tyrosine deprotonation by a catalytic base in Csk. To further explore the role of the proposed catalytic base, the Csk mutant protein D314E was produced. This mutant displayed a significant reduction in k(cat) (approximately 10(4)) but relatively little effect on substrate K-m values compared with wild-type Csk. Examination of the thio effect (k(cat)-ATP/k(cat)-adenosine 5'-O-(thiotriphosphate)) for D314E Csk led to the suggestion that a role of aspartate 314 may be to enhance the reactivity of the gamma-phosphate of ATP toward electrophilic attack. These results may have significant impact on protein tyrosine kinase inhibitor design.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; UNIV GEORGIA, DEPT CHEM, ATHENS, GA 30602 USA; UNIV GEORGIA, DEPT BIOCHEM & MOLEC BIOL, ATHENS, GA 30602 USA; UNIV GEORGIA, CTR METALLOENZYME STUDIES, ATHENS, GA 30602 USA; HOFFMANN LA ROCHE INC, NUTLEY, NJ 07110 USA	Harvard University; Harvard Medical School; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Roche Holding				Phillips, Robert/0000-0001-8710-562X	NIGMS NIH HHS [GM42588] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1993, J BIOL CHEM, V268, P7747; AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; BENNER SA, 1991, ADV ENZYME REGUL, V31, P121, DOI 10.1016/0065-2571(91)90012-B; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BRUNATI AM, 1992, FEBS LETT, V313, P291, DOI 10.1016/0014-5793(92)81212-5; CHANDLER AJ, 1994, J CHEM SOC PERK T 2, P327, DOI 10.1039/p29940000327; CHEN HY, 1993, BIOCHEMISTRY-US, V32, P11591, DOI 10.1021/bi00094a016; COLE PA, 1994, J BIOL CHEM, V269, P30880; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FILLER R, 1969, J ORG CHEM, V34, P534, DOI 10.1021/jo01255a011; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HEATH DF, 1956, J CHEM SOC, P3796, DOI 10.1039/jr9560003796; HEBEL D, 1992, BIOORG MED CHEM LETT, V2, P41, DOI 10.1016/S0960-894X(00)80651-4; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HERSCHLAG D, 1994, J AM CHEM SOC, V116, P11631, DOI 10.1021/ja00105a001; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Kemp BE, 1990, PEPTIDES PROTEIN PHO; KHAN SA, 1970, J CHEM SOC B, P1172, DOI 10.1039/j29700001172; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; LEE TR, 1994, BIOCHEMISTRY-US, V33, P4245, DOI 10.1021/bi00180a019; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MADHUSUDAN, 1994, PROTEIN SCI, V3, P176; MANTEL M, 1970, P NATL ACAD SCI USA, V65, P660, DOI 10.1073/pnas.65.3.660; MILDVAN AS, 1987, ADV ENZYMOL RAMB, V59, P241; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056; YUAN CJ, 1990, J BIOL CHEM, V265, P16205; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	29	56	57	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22105	22108		10.1074/jbc.270.38.22105	http://dx.doi.org/10.1074/jbc.270.38.22105			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673185	hybrid			2022-12-25	WOS:A1995RW31400008
J	MORIYAMA, Y; YAMAMOTO, A				MORIYAMA, Y; YAMAMOTO, A			VESICULAR L-GLUTAMATE TRANSPORTER IN MICROVESICLES FROM BOVINE PINEAL GLANDS - DRIVING-FORCE, MECHANISM OF CHLORIDE ANION ACTIVATION, AND SUBSTRATE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN SYNAPTIC VESICLES; CHROMAFFIN GRANULE MEMBRANES; PROTON PUMP; BINDING-SITE; AMINO-ACIDS; H+-ATPASE; RAT-BRAIN; SYSTEM; RECONSTITUTION; PURIFICATION	Pinealocytes, endocrine cells that synthesize and secrete melatonin, possess a large number of synaptic-like microvesicles (MVs) containing the L-glutamate transporter (Moriyama, Y., and Yamamoto, A. (1995) FEBS Left., 367, 233-236). In this study, the L-glutamate transporter in MVs isolated from bovine pineal glands was characterized as to its driving force, requirement of anions, and substrate specificity. Upon the addition of ATP, the MVs accumulated L-glutamate. The uptake was significantly dependent on the extravesicular Cl- concentration, being negligible in the absence of Cl- and maximum at 25 mM and decreasing gradually at 20-100 mM. The membrane potential (inside positive) was maximum at 0-10 mM Cl- and then decreased gradually depending on the Cl- concentration, whereas a pH gradient was practically absent without Cl- and increased gradually up to 100 mw Cl-. Ammonium acetate or nigericin plus K+, a dissipator of a pH gradient, had little effect on or was slightly stimulatory toward the uptake, whereas valinomycin plus K+ inhibited both formation of the membrane potential and the glutamate uptake to similar extents. The ATP- and Cl--dependent glutamate uptake was inhibited by fluoride, iodide, or thiocyanate, without vacuolar HC-ATPase being affected. An anion channel blocker, 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid, similarly inhibited the glutamate uptake in a Cl- protectable manner. Furthermore, ATP- and glutamate-dependent acidification of MVs was observed when 4 mM Cl- was present. Among more than 50 kinds of glutamate analogues tested, only a few compounds, including 1-aminocyclohexane-trans-1,3-dicarboxylic acid, caused similar acidification. A good correlation was observed between the acidification and the inhibition of glutamate uptake by glutamate analogues. These results indicated that 1) the major driving force of the glutamate uptake is the membrane potential, 2) Cl- regulates the glutamate uptake, probably via anion-binding site(s) on the transporter, and 3) the transporter shows strict substrate specificity. Hence, the overall properties of the vesicular glutamate transporter in the MVs well matched those of the synaptic vesicle glutamate transporter. We concluded that the vesicular glutamate transporter, being similar if not identical to the neuronal counterpart, operates in endocrine cells.	KANSAI MED UNIV,DEPT PHYSIOL,MORIGUCHI,OSAKA 570,JAPAN	Kansai Medical University	MORIYAMA, Y (corresponding author), HIROSHIMA UNIV,FAC SCI,GRAD DEPT GENE SCI,BIOL MARINE LAB,HIROSHIMA 722,JAPAN.							ANNAERT WG, 1993, J NEUROCHEM, V60, P1746, DOI 10.1111/j.1471-4159.1993.tb13399.x; AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; CIDON S, 1989, J BIOL CHEM, V264, P8281; DEVIES SH, 1993, CELL S, V72, P139; DUNLOP J, 1991, NEUROREPORT, V2, P377, DOI 10.1097/00001756-199107000-00005; EDABI M, 1986, ADV PINEAL RES, P99; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GOVITRAPONG P, 1988, NEUROCHEM INT, V13, P223, DOI 10.1016/0197-0186(88)90058-7; HARTINGER J, 1993, J BIOL CHEM, V268, P23122; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KARASEK M, 1992, MICROSC RES TECHNIQ, V21, P136, DOI 10.1002/jemt.1070210206; KUS L, 1994, J NEUROCHEM, V62, P2241; KUS L, 1993, J PINEAL RES, V14, P39, DOI 10.1111/j.1600-079X.1993.tb00483.x; MALVIN PV, 1993, MAMMALIAN NEUROENDOC, P141; MANDELL JW, 1990, NEURON, V5, P19, DOI 10.1016/0896-6273(90)90030-J; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MAYCOX PR, 1990, TRENDS NEUROSCI, V13, P83, DOI 10.1016/0166-2236(90)90178-D; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MORIYAMA Y, 1995, J BIOL CHEM, V270, P11424, DOI 10.1074/jbc.270.19.11424; MORIYAMA Y, 1995, FEBS LETT, V367, P233, DOI 10.1016/0014-5793(95)00559-R; MORIYAMA Y, 1990, J BIOCHEM, V108, P689, DOI 10.1093/oxfordjournals.jbchem.a123264; MORIYAMA Y, 1992, J EXP BIOL, V172, P171; MORIYAMA Y, 1982, J BIOCHEM-TOKYO, V92, P1333, DOI 10.1093/oxfordjournals.jbchem.a134053; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MORIYAMA Y, 1988, J BIOL CHEM, V263, P8521; NAITO S, 1983, J BIOL CHEM, V258, P696; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; OKANO T, 1994, NATURE, V372, P94, DOI 10.1038/372094a0; OKSCHE A, 1986, PINEAL RETINAL RELAT, P1; REDECKER P, 1993, J NEUROSCI RES, V34, P79, DOI 10.1002/jnr.490340109; REITER RJ, 1981, AM J ANAT, V162, P287, DOI 10.1002/aja.1001620402; ROSETH S, 1995, NEUROSCI LETT, V183, P62, DOI 10.1016/0304-3940(94)11115-Y; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SHIOI J, 1990, BIOCHEM J, V267, P63, DOI 10.1042/bj2670063; TABB JS, 1992, J BIOL CHEM, V267, P15412; TABB JS, 1991, J NEUROSCI, V11, P1822; THOMASREETZ A, 1993, P NATL ACAD SCI USA, V90, P5317, DOI 10.1073/pnas.90.11.5317; TOLL L, 1980, J BIOL CHEM, V255, P1787; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Ueda T, 1986, EXCITATORY AMINO ACI, P173; VANDYKE RW, 1988, J BIOL CHEM, V263, P2603; VANWYK E, 1994, MED SCI RES, V22, P635; WINTER HC, 1993, NEUROCHEM RES, V18, P79, DOI 10.1007/BF00966925; XIE XS, 1989, J BIOL CHEM, V264, P18870	46	83	84	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22314	22320		10.1074/jbc.270.38.22314	http://dx.doi.org/10.1074/jbc.270.38.22314			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673214	hybrid			2022-12-25	WOS:A1995RW31400041
J	RANEY, KD; BENKOVIC, SJ				RANEY, KD; BENKOVIC, SJ			BACTERIOPHAGE-T4 DDA HELICASE TRANSLOCATES IN A UNIDIRECTIONAL FASHION ON SINGLE-STRANDED-DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI REP; GENE-41 PROTEIN; PURIFICATION; REPLICATION; BINDING; OVEREXPRESSION; SEQUENCE	The T4 bacteriophage Dda helicase is believed to be involved in early events in T4 DNA replication and has been shown to stimulate genetic recombination processes in vitro. Dda unwinds double-stranded DNA with 5' to 3' polarity but its ability to translocate on DNA has not been established. The DNA stimulated ATPase activity of Dda helicase has been used to probe translocation on single-strand DNA (ssDNA). Dda exhibits higher ATPase activity in the presence of poly(dT) than oligo(dT)(16), indicating that Dda translocates on ssDNA. Oligonucleotides containing biotin/streptavidin blocks on the 5' or 3' end were used to probe directionality of translocation. The K-act (K-m for DNA) for Dda ATPase activity was reduced in the presence of a streptavidin block. on the 3' end, whereas a streptavidin block on the 5' end had only a small effect on the steady-state ATPase parameters. These results suggest that Dda translocates unidirectionally in a 5' to 3' manner and upon encountering the block remains bound 60 the oligonucleotide rather than sliding off the 3' end. The direction of translocation on ssDNA is consistent with the direction in which Dda unwinds duplex DNA and is not dependent on duplex structure.	PENN STATE UNIV,DEPT CHEM,DAVEY LAB 152,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIEHS NIH HHS [ES05576] Funding Source: Medline; NIGMS NIH HHS [GM13306] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005576] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BARRY J, 1994, J BIOL CHEM, V269, P33063; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; CHAMBERLIN MJ, 1965, FED PROC, V24, P1446; CHAO KL, 1990, J BIOL CHEM, V265, P1067; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; HACKER KJ, 1992, J BIOL CHEM, V267, P20674; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2925; KABOORD BF, 1993, P NATL ACAD SCI USA, V90, P10881, DOI 10.1073/pnas.90.22.10881; KODADEK T, 1987, NATURE, V326, P312, DOI 10.1038/326312a0; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KRELL H, 1979, EUR J BIOCHEM, V93, P387, DOI 10.1111/j.1432-1033.1979.tb12835.x; LIU CC, 1981, J BIOL CHEM, V256, P2813; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MAINE IP, 1994, BIOCHEM BIOPH RES CO, V198, P1070, DOI 10.1006/bbrc.1994.1152; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MATSON SW, 1986, J BIOL CHEM, V261, P169; NOTARNICOLA SM, 1994, J CELL BIOCHEM, V18, P153; PANUSKA JR, 1980, J BIOL CHEM, V225, P5208; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; TSO PO, 1966, BIOCHEMISTRY-US, V5, P4153, DOI 10.1021/bi00876a052; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YANCEYWRONA JE, 1992, NUCLEIC ACIDS RES, V20, P6713, DOI 10.1093/nar/20.24.6713; YOUNG MC, 1994, J MOL BIOL, V235, P1436, DOI 10.1006/jmbi.1994.1099; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100	32	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22236	22242		10.1074/jbc.270.38.22236	http://dx.doi.org/10.1074/jbc.270.38.22236			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673202	hybrid			2022-12-25	WOS:A1995RW31400028
J	WANG, G; GLAZER, PM				WANG, G; GLAZER, PM			ALTERED REPAIR OF TARGETED PSORALEN PHOTOADDUCTS IN THE CONTEXT OF AN OLIGONUCLEOTIDE-MEDIATED TRIPLE-HELIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE-EXTRACTS; FORMING-OLIGONUCLEOTIDES; ESCHERICHIA-COLI; GENE-EXPRESSION; SHUTTLE VECTOR; CROSS-LINKS; DNA; INHIBITION; BINDING; MUTAGENESIS	Oligonucleotides can bind as third strands of DNA in a sequence-specific manner to form triple helices, Psoralen-conjugated, tripler-forming oligonucleotides (TFOs) have been used for the site-specific modification of DNA to inhibit transcription and to target mutations to selected genes. Such strategies, however, must take into account the ability of the cell to repair the triplex-directed lesion, We report experiments showing that the pattern of mutations produced by tripler-targeted psoralen adducts in an SV40 shuttle vector in monkey COS cells can be influenced by the associated third strand, Mutations induced by psoralen adducts in the context of a TFO of length 10 were the same as those generated by isolated adducts but were found to be different from those generated in the presence of a TFO of length 30 at the same target site, In complementary experiments, HeLa whole cell extracts were used to directly assess repair of the TFO-directed psoralen adducts in vitro, Excision of the damaged DNA was inhibited in the context of the 30-mer TFO, but not the 10-mer, These results suggest that an extended triple helix of length 30, which exceeds the typical size of the nucleotide excision repair patch in mammalian cells, can alter repair of an associated psoralen adduct, We present a model correlating these results and proposing that the incision steps in nucleotide excision repair in mammalian cells can be blocked by the presence of a third strand of sufficient length and binding affinity, thereby changing the pattern of mutations, These results may have implications for the use of tripler-forming oligonucleotides for genetic manipulation, and they may lead to the use of such oligonucleotides as tools to probe DNA repair pathways.	YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,NEW HAVEN,CT 06520	Yale University			Glazer, Peter/S-7651-2019	Glazer, Peter/0000-0003-4525-5560	NATIONAL CANCER INSTITUTE [R01CA064186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005775, R01ES005775] Funding Source: NIH RePORTER; NCI NIH HHS [CA64186] Funding Source: Medline; NIEHS NIH HHS [ES05775] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BROITMAN SL, 1987, P NATL ACAD SCI USA, V84, P5120, DOI 10.1073/pnas.84.15.5120; CHENG S, 1991, NUCLEIC ACIDS RES, V19, P657, DOI 10.1093/nar/19.3.657; COLE RS, 1973, P NATL ACAD SCI USA, V70, P1064, DOI 10.1073/pnas.70.4.1064; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DEGOLS G, 1994, J BIOL CHEM, V269, P16933; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; FRANCOIS JC, 1988, NUCLEIC ACIDS RES, V16, P11431, DOI 10.1093/nar/16.24.11431; GASPARRO FP, 1994, NUCLEIC ACIDS RES, V22, P2845, DOI 10.1093/nar/22.14.2845; GLAZER PM, 1986, P NATL ACAD SCI USA, V83, P1041, DOI 10.1073/pnas.83.4.1041; GLAZER PM, 1987, MOL CELL BIOL, V7, P218, DOI 10.1128/MCB.7.1.218; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HAVRE PA, 1993, P NATL ACAD SCI USA, V90, P7879, DOI 10.1073/pnas.90.16.7879; HAVRE PA, 1993, J VIROL, V67, P7324, DOI 10.1128/JVI.67.12.7324-7331.1993; HELENE C, 1991, ANTI-CANCER DRUG DES, V6, P569; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JONES BK, 1990, J BIOL CHEM, V265, P3489; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; PARRIS CN, 1992, GENE, V117, P1, DOI 10.1016/0378-1119(92)90482-5; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; REARDON JT, 1991, NUCLEIC ACIDS RES, V19, P4623, DOI 10.1093/nar/19.17.4623; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SANDOR Z, 1994, NUCLEIC ACIDS RES, V22, P2051, DOI 10.1093/nar/22.11.2051; SLADEK FM, 1989, P NATL ACAD SCI USA, V86, P3982, DOI 10.1073/pnas.86.11.3982; SLADEK FM, 1989, J BIOL CHEM, V264, P6755; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; THOMAS DC, 1988, P NATL ACAD SCI USA, V85, P3723, DOI 10.1073/pnas.85.11.3723; WANG G, 1995, MOL CELL BIOL, V15, P1759; WOOD RD, 1985, J MOL BIOL, V184, P577, DOI 10.1016/0022-2836(85)90304-3; WOOD RD, 1993, COLD SPRING HARB SYM, V58, P625, DOI 10.1101/SQB.1993.058.01.069; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	35	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22595	22601		10.1074/jbc.270.38.22595	http://dx.doi.org/10.1074/jbc.270.38.22595			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673252	hybrid			2022-12-25	WOS:A1995RW31400082
J	YBARRA, J; HOROWITZ, PM				YBARRA, J; HOROWITZ, PM			REFOLDING AND REASSEMBLY OF ACTIVE CHAPERONIN GROEL AFTER DENATURATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE LIVER RHODANESE; CPN60	Conditions are reported that, for the first time, permit the folding and assembly of active chaperonin, GroEL, following denaturation in 8 at urea. The folding could be achieved by dilution or dialysis, and the best yields required the simultaneous presence of ammonium sulfate and the Mg2+ complexes of ATP or ADP, Ammonium sulfate was the key to this particular protocol, since there was a small recovery of oligomer in its presence, but no detectable recovery was induced by ATP or ADP without ammonium sulfate, The refolded/reassembled GroEL could arrest the spontaneous folding of rhodanese, and it could participate in the chaperonin-assisted refolding of rhodanese as effectively as GroEL that had never been unfolded, The results demonstrate that the primary sequence of GroEL contains the information required far its folding, assembly, and function, Thus, in contrast to previous studies, although chaperonins may facilitate GroEL folding, they are not necessary for the acquisition of the functional oligomeric state of this chaperone, This ability to fold denatured GroEL in vitro will facilitate studies of the influences that determine the interesting folding pattern adopted by the native protein.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GOLUBINOFF P, 1989, NATURE, V337, P44; HAYERHARTL MK, 1993, FEBS LETT, V320, P83, DOI 10.1016/0014-5793(93)81663-K; JENKINS AJ, 1986, MOL GEN GENET, V202, P446, DOI 10.1007/BF00333275; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LISSIN NM, 1993, FEBS LETT, V324, P41, DOI 10.1016/0014-5793(93)81528-8; MARUSYK R, 1980, ANAL BIOCHEM, V105, P403, DOI 10.1016/0003-2697(80)90477-7; MENDOZA JA, 1995, BBA-PROTEIN STRUCT M, V1247, P209, DOI 10.1016/0167-4838(94)00231-5; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; MIZOBATA T, 1994, BBA-PROTEIN STRUCT M, V1209, P83, DOI 10.1016/0167-4838(94)90140-6; NEUHOFF V, 1986, ELECTROPHORESIS, V7, P56, DOI 10.1002/elps.1150070110; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; PRICE NC, 1993, BIOCHIM BIOPHYS ACTA, V1161, P52, DOI 10.1016/0167-4838(93)90195-W; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; STANIFORTH RA, 1994, FEBS LETT, V334, P129; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1992, PROTEIN SCI, V1, P363	19	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22113	22115		10.1074/jbc.270.38.22113	http://dx.doi.org/10.1074/jbc.270.38.22113			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673187	hybrid			2022-12-25	WOS:A1995RW31400010
J	FUKUYAMA, K; KUNISHIMA, N; AMADA, F; KUBOTA, T; MATSUBARA, H				FUKUYAMA, K; KUNISHIMA, N; AMADA, F; KUBOTA, T; MATSUBARA, H			CRYSTAL-STRUCTURES OF CYANIDE-BOUND AND TRIIODIDE-BOUND FORMS OF ARTHROMYCES-RAMOSUS PEROXIDASE AT DIFFERENT PH VALUES - PERTURBATIONS OF ACTIVE-SITE RESIDUES AND THEIR IMPLICATION IN ENZYME CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; COPRINUS-CINEREUS PEROXIDASE; X-RAY-DIFFRACTION; LIGNIN PEROXIDASE; CRYSTALLOGRAPHIC REFINEMENT; PHANEROCHAETE-CHRYSOSPORIUM; HORSERADISH-PEROXIDASE; WEISSENBERG CAMERA; RESTING STATE; RESOLUTION	The structures of the cyanide and triiodide complexes of Arthromyces ramosus peroxidase (ARP) at different pH values were investigated by x-ray crystallography in order to examine the behavior of the invariant residues of arginine (Arg-52) and distal histidine (His-56) during the enzyme reaction as well as to provide the structural basis of the active site of peroxidase. The models of the cyanide complexes at pH 7.5, 5.0, and 4.0, respectively, were refined to the R-factors of 17.8, 17.8, and 18.5% using 7.0-1.6-Angstrom resolution data, and those of the triiodide complexes at pH 6.5 and 5.0 refined to 16.9 and 16.8% using 7.0-1.9-Angstrom resolution data. The structures of the cyanide complexes at pH 7.5, 5.0, and 4.0 are identical within experimental error. Cyanide ion bound to the heme in the bent conformation rather than in the tilt conformation. Upon cyanide ion binding, the N-epsilon atom of His-56 moved toward the ion by rotation of the imidazole ring around the C-beta-C-gamma bond, but there was little conformational change in the remaining residues. The distance between the N-epsilon atom of His-56 and the nitrogen atom of the cyanide suggests the presence of a hydrogen bond between them in the pH range investigated. In the triiodide complexes, one of the two triiodides bound to ARP was located at the distal side of the heme. When triiodide bound to ARP, unlike the rearrangement of the distal arginine of cytochrome c peroxidase that occurs on formation of the fluoride complex or compound I, the side chain of Arg-52 moved little. The conformation of the side chain of His-56, however, changed markedly, Conformational flexibility of His-56 appears to be a requisite for proton translocation from one oxygen atom to the other of HOO- by acid-base catalysis to produce compound I. The iron atom in each cyanide complex (low-spin ferric) is located in the heme plane, whereas in each triiodide complex (high-spin ferric) the iron atom is displaced from the plane about 0.2 Angstrom toward the proximal side.			FUKUYAMA, K (corresponding author), OSAKA UNIV,FAC SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN.		Kunishima, Naoki/N-7464-2015; Kubota, Tomomi/J-1492-2018	Kubota, Tomomi/0000-0002-0723-135X; Kunishima, Naoki/0000-0001-9826-9902				AKIMOTO K, 1990, ANAL BIOCHEM, V189, P182, DOI 10.1016/0003-2697(90)90104-H; ALLAIN CC, 1974, CLIN CHEM, V20, P470; BANCI L, 1991, P NATL ACAD SCI USA, V88, P6956, DOI 10.1073/pnas.88.16.6956; BAUNSGAARD L, 1993, EUR J BIOCHEM, V213, P605, DOI 10.1111/j.1432-1033.1993.tb17800.x; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, XPLOR 3 0; DEATHERAGE JF, 1976, J MOL BIOL, V104, P687, DOI 10.1016/0022-2836(76)90129-7; DEROPP JS, 1991, J BIOL CHEM, V266, P15001; EDWARDS SL, 1993, P NATL ACAD SCI USA, V90, P750, DOI 10.1073/pnas.90.2.750; EDWARDS SL, 1990, J BIOL CHEM, V265, P2588; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FULOP V, 1994, STRUCTURE, V2, P201, DOI 10.1016/S0969-2126(00)00021-6; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KUNISHIMA N, 1993, PROTEINS, V15, P216, DOI 10.1002/prot.340150213; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LUKAT GS, 1989, BIOCHEMISTRY-US, V28, P3338, DOI 10.1021/bi00434a032; LUZATTI V, 1952, ACTA CRYSTALLOGR, V5, P802; MORITA Y, 1988, J BIOCHEM-TOKYO, V103, P693, DOI 10.1093/oxfordjournals.jbchem.a122331; NEYA S, 1993, J BIOL CHEM, V268, P8935; PEDERSEN AH, 1994, 13TH INT S LIF SCI K, P24; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PETERSEN JFW, 1994, FEBS LETT, V339, P291, DOI 10.1016/0014-5793(94)80433-8; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; POULOS TL, 1993, J BIOL CHEM, V268, P4429; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SATTERLEE JD, 1991, BIOCHEMISTRY-US, V30, P4398, DOI 10.1021/bi00232a005; SAWAIHATANAKA H, 1995, BIOSCI BIOTECH BIOCH, V59, P1221, DOI 10.1271/bbb.59.1221; STEIGEMANN W, 1974, THESIS TU MUNCHEN; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; THANABAL V, 1988, J AM CHEM SOC, V110, P3027, DOI 10.1021/ja00218a005; VEITCH NC, 1994, EUR J BIOCHEM, V222, P909, DOI 10.1111/j.1432-1033.1994.tb18939.x; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]	38	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21884	21892		10.1074/jbc.270.37.21884	http://dx.doi.org/10.1074/jbc.270.37.21884			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665612	hybrid			2022-12-25	WOS:A1995RU75700072
J	LEE, SH; KIM, DK; DRISSI, R				LEE, SH; KIM, DK; DRISSI, R			HUMAN XERODERMA-PIGMENTOSUM GROUP-A PROTEIN INTERACTS WITH HUMAN REPLICATION PROTEIN-A AND INHIBITS DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; SV40 T-ANTIGEN; A COMPLEMENTING PROTEIN; BINDING-PROTEIN; POLYMERASE-ALPHA; EXCISION REPAIR; DAMAGED DNA; SACCHAROMYCES-CEREVISIAE; LARGE SUBUNIT; INVITRO	Human replication protein A (RPA; also known as human single-stranded DNA binding protein, or HSSB) is a multisubunit complex involved in both DNA replication and repair. While the role of RPA in replication has been well studied, its function in repair is less clear, although it is known to be involved in the early stages of the repair process. We found that RPA interacts with xeroderma pigmentosum group A complementing protein (XPAC), a protein that specifically recognizes UV-damaged DNA. We examined the effect of this XPAC-RPA interaction on in vitro simian virus 40 (SV40) DNA replication catalyzed by the monopolymerase system. XPAC inhibited SV40 DNA replication in vitro, and this inhibition was reversed by the addition of RPA but not by the addition of DNA polymerase alpha-primase complex, SV40 large tumor antigen, or topoisomerase I. This inhibition did not result from an interaction between XPAC and single-stranded DNA (ssDNA), or from competition between RPA and XPAC for DNA binding, because XPAC does not show any ssDNA binding activity and, in fact, stimulates RPA's ssDNA binding activity. Furthermore, XPAC inhibited DNA polymerase alpha activity in the presence of RPA but not in RPA's absence. These results suggest that the inhibitory effect of XPAC on DNA replication probably occurs through its interaction with RPA.	UNIV TENNESSEE, COLL MED, DEPT PATHOL, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	LEE, SH (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, 332 N LAUDERDALE ST, MEMPHIS, TN 38101 USA.				NCI NIH HHS [5P30 CA 21765-16] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KENNY MK, 1990, J BIOL CHEM, V265, P769; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1991, J BIOL CHEM, V266, P594; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MIURA N, 1991, J BIOL CHEM, V266, P19786; MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11008; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WOOD RD, 1993, COLD SPRING HARB SYM, V58, P625, DOI 10.1101/SQB.1993.058.01.069	43	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21800	21805		10.1074/jbc.270.37.21800	http://dx.doi.org/10.1074/jbc.270.37.21800			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665601	hybrid			2022-12-25	WOS:A1995RU75700060
J	SMITH, KE; FISHER, MT				SMITH, KE; FISHER, MT			INTERACTIONS BETWEEN THE GROE CHAPERONINS AND RHODANESE - MULTIPLE INTERMEDIATES AND RELEASE AND REBINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL CAVITY; PROTEINS; POLYPEPTIDE; BINDS; DNAJ	Efficient renaturation of urea-denatured rhodanese using the chaperonin GroE system requires GroEL, GroES, and ATP. At high concentrations this renaturation also requires the substrate thiosulfate to have been present during GroEL-rhodanese complex formation. When thiosulfate is present the GroEL rhodanese complex can be concentrated to greater than 1 mg/ml. rhodanese with little effect on the efficiency of renaturation. However, if complex is formed in the absence of thiosulfate, renaturation of rhodanese in the presence of thiosulfate shows a critical concentration of approximately 0.4 mg/ml, above which renaturation yields drop dramatically, This critical concentration appears to be related to an aggregation event in the refolding of rhodanese. The nucleotide free or ADP-bound form of GroEL also binds to rhodanese that has been either already renatured or never denatured, The bound rhodanese has no activity but can be released from GroEL with ATP recovering 90% of control activity, The data presented herein support a release and rebinding mechanism for the GroE-assisted refolding of rhodanese. It also suggests GroEL binds several protein folding intermediates along the entire refolding pathway.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049309] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49309] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARD DA, 1993, SCIENCE, V260, P1902; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; COHEN BI, 1993, PROTEIN SCI, V2, P2134, DOI 10.1002/pro.5560021213; DADO GP, 1993, J AM CHEM SOC, V115, P12609, DOI 10.1021/ja00079a060; DILL KA, 1993, P NATL ACAD SCI USA, V90, P1942, DOI 10.1073/pnas.90.5.1942; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISHER MT, 1993, J BIOL CHEM, V268, P13777; FISHER MT, 1994, J BIOL CHEM, V269, P29598; FISHER MT, 1994, J BIOL CHEM, V269, P16329; GOLDBERG ME, 1994, PROTEIN SCI, V3, P883; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HARTL FU, 1994, NATURE, V371, P557, DOI 10.1038/371557a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MENDOZOA JA, 1992, J BIOL CHEM, V266, P16973; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; SCMIDT M, 1994, J BIOL CHEM, V269, P10304; TANDON S, 1989, J BIOL CHEM, V264, P9859; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; Westley J, 1981, Methods Enzymol, V77, P285; WIESSMAN JS, 1994, CELL, V78, P693	34	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21517	21523		10.1074/jbc.270.37.21517	http://dx.doi.org/10.1074/jbc.270.37.21517			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665563	hybrid			2022-12-25	WOS:A1995RU75700018
J	LAMBERT, B; JESTIN, JL; BREHIN, P; OLEYKOWSKI, C; YEUNG, AT; MAILLIET, P; PRETOT, C; LEPECQ, JB; JACQUEMINSABLON, A; CHOTTARD, JC				LAMBERT, B; JESTIN, JL; BREHIN, P; OLEYKOWSKI, C; YEUNG, AT; MAILLIET, P; PRETOT, C; LEPECQ, JB; JACQUEMINSABLON, A; CHOTTARD, JC			BINDING OF THE ESCHERICHIA-COLI UVRAB PROTEINS TO THE DNA MONOADDUCTS AND DIADDUCTS OF CIS-[N-2-AMINO-N-2-METHYLAMINO-2,2,1-BICYCLOHEPTANE]DICHLOROPLATINUM(II) AND CISPLATIN - ANALYSIS OF THE FACTORS CONTROLLING RECOGNITION AND PROOF OF MONOADDUCT-MEDIATED UVRB-DNA CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICANCER DRUG CISPLATIN; DAMAGED DNA; PLATINUM COMPLEXES; (A)BC EXCINUCLEASE; EXCISION NUCLEASE; ANTITUMOR AGENTS; ABC EXCINUCLEASE; REPAIR SYNTHESIS; ADDUCTS; INVITRO	The interactions of the Escherichia coli endonuclease UvrAB proteins with the DNA mono- and diadducts of both the cis-racemic exo-[N-2-amino-N-2-methylamino-2,2,1-bicycloheptane]dichloroplatinum(II (complex (1) under bar) and cisplatin (cis-diamminedichloroplatinum(II) (cis-DDP)), have been studied, Complex (1) under bar reacts faster with DNA than cis-DDP and gives monoadducts with a longer lifetime (8 h 20 min chelation t(1/2) compared with 2 h 40 min for cis-DDP), Using pSP65 plasmid [H-3]DNA, the filter binding assay was associated with the analysis of the nucleoprotein complexes to characterize the UvrAB recognition of the platinum adducts and to demonstrate the occurrence of platinum-mediated DNA-protein cross-linking, First, it is shown that the UvrAB proteins recognize the complex (1) under bar mono- and diadducts with a higher affinity than those of cis-DDP. Fifteen times more cis-DDP adducts per plasmid are required than complex (1) under bar adducts, to lead to similar UvrAB binding, However, the UvrAB proteins recognize monoadducts and diadducts of each complex with a similar affinity, Second, it is shown that UvrB is the protein involved in the nucleoprotein complexes formed from mono- and diadducts of complex (1) under bar and cis-DDP, This protein is also partly cross-linked to DNA with a similar efficiency by monoadducts derived from complex (1) under bar and cis-DDP, However, as UvrB has a greater affinity for the DNA adducts of complex (1) under bar than for those of cis-DDP, more UvrB-platinum-DNA cross-links are formed with complex 1 than with cis-DDP, This study, using a bacterial repair system as a model, points to a possible strategy for making new cytotoxic platinum complexes for mammalian cells.	UNIV PARIS 05,CNRS,URA 400,F-75270 PARIS 06,FRANCE; FOX CHASE CANC CTR,PHILADELPHIA,PA 19111; RHONE POULENC RORER SA,CTR RECH VITRY ALFORTVILLE,INST BIOTECHNOL,F-94407 VITRY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Fox Chase Cancer Center; Sanofi-Aventis	LAMBERT, B (corresponding author), INST GUSTAVE ROUSSY,CNRS,URA 147,INSERM,U140,39 RUE CAMILLE DESMOULINS,F-94800 VILLEJUIF,FRANCE.		LAMBERT, Bernard/K-6207-2015		NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA 06927] Funding Source: Medline; NCRR NIH HHS [RR05539] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALAZARD R, 1982, MUTAT RES, V93, P327, DOI 10.1016/0027-5107(82)90148-8; ARIKAN E, 1986, NUCLEIC ACIDS RES, V14, P2637, DOI 10.1093/nar/14.6.2637; BANCROFT DP, 1990, J AM CHEM SOC, V112, P6860, DOI 10.1021/ja00175a020; BAUER W, 1978, BIOCHEMISTRY-US, V17, P1060, DOI 10.1021/bi00599a019; BECK DJ, 1985, NUCLEIC ACIDS RES, V13, P7395, DOI 10.1093/nar/13.20.7395; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BERNGES F, 1991, NUCLEIC ACIDS RES, V19, P1483, DOI 10.1093/nar/19.7.1483; BRABEC V, 1994, BIOCHEMISTRY-US, V33, P1316, DOI 10.1021/bi00172a005; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; CHAO CCK, 1991, MOL CELL BIOL, V11, P2075, DOI 10.1128/MCB.11.4.2075; CHU G, 1990, P NATL ACAD SCI USA, V87, P3324, DOI 10.1073/pnas.87.9.3324; CHU G, 1994, J BIOL CHEM, V269, P787; DJURAN MI, 1991, INORG CHEM, V30, P2648, DOI 10.1021/ic00012a016; DONAHUE BA, 1990, BIOCHEMISTRY-US, V29, P5872, DOI 10.1021/bi00476a032; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EASTMAN A, 1987, CHEM-BIOL INTERACT, V61, P241, DOI 10.1016/0009-2797(87)90004-4; FARRELL N, 1992, CANCER RES, V52, P5065; FILIPSKI J, 1979, SCIENCE, V204, P181, DOI 10.1126/science.571145; GROSSMAN L, 1990, MUTAT RES, V236, P213, DOI 10.1016/0921-8777(90)90006-Q; HANSSON J, 1990, NUCLEIC ACIDS RES, V18, P35, DOI 10.1093/nar/18.1.35; HANSSON J, 1989, NUCLEIC ACIDS RES, V17, P8073, DOI 10.1093/nar/17.20.8073; HEIGERBERNAYS WJ, 1990, BIOCHEMISTRY-US, V29, P8461, DOI 10.1021/bi00488a037; HOLLIS LS, 1989, J MED CHEM, V32, P128, DOI 10.1021/jm00121a024; HOLLIS LS, 1991, CANCER RES, V51, P1866; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; HUSAIN I, 1985, J BACTERIOL, V163, P817, DOI 10.1128/JB.163.3.817-823.1985; JOHNSON NP, 1980, CHEM-BIOL INTERACT, V30, P151, DOI 10.1016/0009-2797(80)90122-2; JONES JC, 1991, J BIOL CHEM, V266, P7101; KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622; KOZELKA J, 1986, INORG CHEM, V25, P1075, DOI 10.1021/ic00228a002; LAMBERT B, 1989, P NATL ACAD SCI USA, V86, P6557, DOI 10.1073/pnas.86.17.6557; LIN JJ, 1992, J BIOL CHEM, V267, P17693; MAILLIET P, 1994, ANTI-CANCER DRUG DES, V10, P51; MARROT L, 1989, BIOCHEMISTRY-US, V28, P1454, DOI 10.1021/bi00430a005; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; PAGE JD, 1990, BIOCHEMISTRY-US, V29, P1016, DOI 10.1021/bi00456a026; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; SEEBERG E, 1990, P NATL ACAD SCI USA, V87, P191, DOI 10.1073/pnas.87.1.191; SEGALBENDIRDJIA.E, 1991, PLATINUM OTHER METAL, P37; TONEY JH, 1989, P NATL ACAD SCI USA, V86, P8328, DOI 10.1073/pnas.86.21.8328; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1991, J BIOL CHEM, V266, P7609; VISSE R, 1994, BIOCHEMISTRY-US, V33, P1804, DOI 10.1021/bi00173a025; VOIGT JM, 1989, J BIOL CHEM, V264, P5172; WALTER RB, 1988, J MOL BIOL, V203, P939, DOI 10.1016/0022-2836(88)90119-2; WOODBURY CP, 1983, BIOCHEMISTRY-US, V22, P4730, DOI 10.1021/bi00289a018; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535	49	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21251	21257		10.1074/jbc.270.36.21251	http://dx.doi.org/10.1074/jbc.270.36.21251			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673159	hybrid			2022-12-25	WOS:A1995RU05400059
J	LAZAR, DF; WIESE, RJ; BRADY, MJ; MASTICK, CC; WATERS, SB; YAMAUCHI, K; PESSIN, JE; CUATRECASAS, P; SALTIEL, AR				LAZAR, DF; WIESE, RJ; BRADY, MJ; MASTICK, CC; WATERS, SB; YAMAUCHI, K; PESSIN, JE; CUATRECASAS, P; SALTIEL, AR			MITOGEN-ACTIVATED PROTEIN-KINASE KINASE INHIBITION DOES NOT BLOCK THE STIMULATION OF GLUCOSE-UTILIZATION BY INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MAP KINASE; SIGNALING PATHWAYS; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; OKADAIC ACID; PHOSPHATASE INHIBITOR; GLYCOGEN-SYNTHASE; PHOSPHORYLATION; RAS	Insulin stimulates the activity of mitogen-activated protein kinase (MAPK) via its upstream activator, MAPK kinase (MEK), a dual specificity kinase that phosphorylates MAPK on threonine and tyrosine. The potential role of MAPK activation in insulin action was investigated with the specific MEK inhibitor PD98059. Insulin stimulation of MAPK activity in 3T3-L1 adipocytes (2.7-fold) and L6 myotubes (1.4-fold) was completely abolished by pretreatment of cells with the MER inhibitor, as was the phosphorylation of MAPK and pp90(Rsk), and the transcriptional activation of c-fos. Insulin receptor autophosphorylation on tyrosine residues and activation of phosphatidylinositol 3'-kinase were unaffected. Pretreatment of cells with PD98059 had no effect on basal and insulin stimulated glucose uptake, lipogenesis, and glycogen synthesis. Glycogen synthase activity in extracts from 3T3-L1 adipocytes and L6 myotubes was increased 3-fold and 1.7-fold, respectively, by insulin. Pretreatment with 10 mu M PD98059 was without effect. Similarly, the 2-fold activation of protein phosphatase 1 by insulin was insensitive to PD98059. These results indicate that stimulation of the MAPK pathway by insulin is not required for many of the metabolic activities of the hormone in cultured fat and muscle cells.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Pfizer; University of Iowa			Saltiel, Alan/L-3632-2019; Mastick, Cynthia/G-9841-2017	Mastick, Cynthia/0000-0003-4769-5412; Saltiel, Alan/0000-0002-9726-9828				BALLOU LM, 1990, NATURE, V349, P348; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CORVERA S, 1991, J BIOL CHEM, V266, P9271; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HESS SL, 1991, J CELL BIOCHEM, V45, P374, DOI 10.1002/jcb.240450411; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAWRENCE JC, 1977, J BIOL CHEM, V252, P444; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; MCCLAIN DA, 1990, DIABETES CARE, V13, P302, DOI 10.2337/diacare.13.3.302; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OHMICHI M, 1992, NEURON, V9, P767; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PANG L, 1993, BIOCHEM BIOPH RES CO, V196, P301, DOI 10.1006/bbrc.1993.2249; PANG L, 1994, J BIOL CHEM, V269, P10604; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; REESJONES R, 1985, J BIOL CHEM, V240, P4461; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; ROLBAND GC, 1993, ENDOCRINOLOGY, V133, P1437, DOI 10.1210/en.133.3.1437; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SALTIEL AR, 1990, DIABETES CARE, V13, P244, DOI 10.2337/diacare.13.3.244; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SRINIVASAN M, 1994, J BIOL CHEM, V269, P12514; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUNG CK, 1991, J CELL BIOCHEM, V48, P1; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TANTI JF, 1991, J BIOL CHEM, V266, P2099; THOMAS G, 1992, BIOCHEM SOC T, V20, P679; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WEISE RJ, 1995, J BIOL CHEM, V270, P3442; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031	62	331	336	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20801	20807		10.1074/jbc.270.35.20801	http://dx.doi.org/10.1074/jbc.270.35.20801			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657664	hybrid			2022-12-25	WOS:A1995RR58400085
J	KUNKEL, T; SPETH, V; BUCHE, C; SCHAFER, E				KUNKEL, T; SPETH, V; BUCHE, C; SCHAFER, E			IN-VIVO CHARACTERIZATION OF PHYTOCHROME-PHYCOCYANOBILIN ADDUCTS IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHALCONE SYNTHASE GENE; AVENA-SATIVA L; ELECTRON-MICROSCOPY; BETA-GLUCURONIDASE; FUSION MARKER; ARABIDOPSIS; EXPRESSION; PROTEIN; INVIVO; APOPHYTOCHROME	The in vivo reconstitution of phycocyanobilin with apophytochrome leads to photoreversible adducts in living yeast cells. Investigations with the rice phytochrome A phycocyanobilin adduct (PHYA*) and the tobacco phytochrome B phycocyanobilin adduct (PHYB*) show that the protein stability in yeast is independent of the form of the photoreceptor. After in vivo assembly and irradiation with red light, 25.6% of the far-red light-absorbing form of PHYB* exhibited dark reversion with a half-life time of approximately 20 min. Control experiments with PHYA* revealed no dark reversion, The data indicate that the molecular basis for this reaction is the formation of heterodimers between the red and the far-red light absorbing form of phytochrome. Electron microscopic in situ localizations and in, vitro sequestering experiments showed that phytochrome A was able to sequester in yeast, On the electron microscopic level, the sequestered areas of phytochrome from etiolated plants and yeast are indistinguishable, The sequestering reaction in yeast is independent of the formation of the far-red light absorbing form of phytochrome, Therefore, we discuss a new model for this reaction in plant. Since it is unlikely that yeast cells contain elements that distinguish between phytochrome A and B, we conclude that sequestering and dark reversion reflect intrinsic properties of phytochrome.	UNIV FREIBURG,INST BIOL 2,D-79104 FREIBURG,GERMANY	University of Freiburg								ABE A, 1988, AGR BIOL CHEM TOKYO, V52, P2035; BORTHWICK HA, 1964, AM NAT, V902, P347; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BROCKMANN J, 1987, PLANT CELL ENVIRON, V10, P105, DOI 10.1111/1365-3040.ep11602037; BUTLER WL, 1963, PLANT PHYSIOL, V38, P514, DOI 10.1104/pp.38.5.514; COLE WJ, 1967, J AM CHEM SOC, V89, P3643, DOI 10.1021/ja00990a055; DEFORCE L, 1991, P NATL ACAD SCI USA, V88, P10392, DOI 10.1073/pnas.88.23.10392; DEHESH K, 1993, PLANT CELL, V5, P1081, DOI 10.1105/tpc.5.9.1081; DONALD RGK, 1990, EMBO J, V9, P1727, DOI 10.1002/j.1460-2075.1990.tb08296.x; FROHNMEYER H, 1992, PLANT J, V2, P899, DOI 10.1111/j.1365-313X.1992.00899.x; GRIMM R, 1986, Z NATURFORSCH C, V41, P988; Gross J, 1984, TECHNIQUES PHOTOMORP, P131; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HILLMAN WS, 1964, AM J BOT, V51, P1102, DOI 10.2307/2439958; HOFMANN E, 1991, PLANTA, V183, P265, DOI 10.1007/BF00197798; JACOBS E, 1986, ANAL BIOCHEM, V155, P583; JEFFERSON RA, 1987, EMBO J, V6, P3901; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; JONES AM, 1986, BIOCHEMISTRY-US, V25, P2987, DOI 10.1021/bi00358a038; KAISER T, 1995, PLANT MOL BIOL, V28, P219, DOI 10.1007/BF00020242; KAISER T, 1995, PLANT MOL BIOL, V28, P231, DOI 10.1007/BF00020243; KAY SA, 1989, NUCLEIC ACIDS RES, V17, P2865, DOI 10.1093/nar/17.7.2865; KEIZER I, 1992, FEMS MICROBIOL LETT, V93, P7, DOI 10.1016/0378-1097(92)90481-3; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KERN R, 1993, PLANT PHYSIOL, V102, P1363, DOI 10.1104/pp.102.4.1363; KUNKEL T, 1993, EUR J BIOCHEM, V215, P587, DOI 10.1111/j.1432-1033.1993.tb18069.x; LI LM, 1994, P NATL ACAD SCI USA, V91, P12535, DOI 10.1073/pnas.91.26.12535; LI LM, 1992, J BIOL CHEM, V267, P19204; MARME D, 1971, PLANTA, V100, P331, DOI 10.1007/BF00385197; MCCURDY DW, 1986, J CELL BIOL, V103, P2541, DOI 10.1083/jcb.103.6.2541; MORISHIMA N, 1990, J BIOL CHEM, V265, P15189; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; PARDEKOOPER M, 1994, PHOTOCHEM PHOTOBIOL, V59, P161; PARKS BM, 1991, PLANT CELL, V3, P1177, DOI 10.1105/tpc.3.11.1177; PIKE CS, 1972, PLANT PHYSIOL, V49, P514, DOI 10.1104/pp.49.4.514; QUAIL PH, 1978, PLANT PHYSIOL, V62, P773, DOI 10.1104/pp.62.5.773; REED JW, 1993, PLANT CELL, V5, P147, DOI 10.1105/tpc.5.2.147; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; RUDIGER W, 1983, P NATL ACAD SCI-BIOL, V80, P6244, DOI 10.1073/pnas.80.20.6244; SCHAFER E, 1974, PLANTA, V116, P257, DOI 10.1007/BF00390231; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SCHULZE-LEFERT P, 1989, EMBO J, V8, P651, DOI 10.1002/j.1460-2075.1989.tb03422.x; SMITH H, 1976, LIGHT PLANT DEV; SOMMERS DE, 1991, PLANT CELL, V3, P1263; SPETH V, 1987, PLANTA, V171, P332, DOI 10.1007/BF00398678; STAIGER D, 1989, P NATL ACAD SCI USA, V86, P6930, DOI 10.1073/pnas.86.18.6930; TOMIZAWA K, 1995, PLANT CELL PHYSIOL, V36, P511, DOI 10.1093/oxfordjournals.pcp.a078787; VIERSTRA RD, 1994, PLANT PHYSIOL, V103, P679; WAHLEITHNER JA, 1991, P NATL ACAD SCI USA, V88, P10387, DOI 10.1073/pnas.88.23.10387; WHITELAM GC, 1994, PLANT CELL ENVIRON, V17, P615, DOI 10.1111/j.1365-3040.1994.tb00153.x	51	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20193	20200		10.1074/jbc.270.34.20193	http://dx.doi.org/10.1074/jbc.270.34.20193			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650038	hybrid			2022-12-25	WOS:A1995RQ99100076
J	SIPOS, G; PUOTI, A; CONZELMANN, A				SIPOS, G; PUOTI, A; CONZELMANN, A			BIOSYNTHESIS OF THE SIDE-CHAIN OF YEAST GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORS IS OPERATED BY NOVEL MANNOSYLTRANSFERASES LOCATED IN THE ENDOPLASMIC-RETICULUM AND THE GOLGI-APPARATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN GLYCOSYLATION; SECRETORY PATHWAY; MEMBRANE ANCHOR; GLYCOPHOSPHATIDYLINOSITOL ANCHORS; GLYCOPROTEIN; MUTANTS; GENE; MEMBER; OLIGOSACCHARIDES	Glycosylphosphatidylinositol (GPI) anchors of the yeast Saccharomyces cerevisiae have been reported to contain three different types of side chains attached to the alpha 1,2-linked mannose of the conserved protein-ethanolamine-PO4-Man alpha 1,2Man alpha 1,6Man alpha 1,4Glc glycan core. The possible side chains are Man alpha 1,2- or Man alpha 1,2Man alpha 1,2- or Man alpha 1,3Man alpha 1,2- (Fankhauser, C., Homan, S. W., Thomas Gates, J. E., McConville, M. J., Desponds, C., Conzelmann, A, and Ferguson, M. A. (1993) J. Biol. Chem. 268, 26365-26374). To determine in what subcellular compartment these side chains are made, we metabolically labeled GPI anchored membrane proteins with myo-[2-H-3]inositol in secretion mutants blocked at various stages of the secretory pathway and analyzed the anchor structure of the labeled glycoproteins. When the exit of vesicles from the endoplasmic reticulum or entry into the cis-Golgi were blocked in sec12 or sec18 cells, all anchors contained a side chain consisting of a single alpha 1,2-linked mannose. GPI proteins trapped in the cis-Golgi of sec7 contained Man alpha 1,3Man alpha 1,2- but no Man alpha 1,2Man alpha 1,2- side chains. Mutants blocked at later stages of the secretory pathway made increased amounts of side chains containing two mannoses. Man alpha 1,2Man alpha 1,2- and Man alpha 1,2Man alpha 1,2- side chains were preferentially associated with ceramide- and diacylglycerol containing GPI anchors, respec tively. Mnn1, mnn2, mnn3, mnn5, and mnt1(= kre2), i.e. mutants which lack or down-regulate 1,2- and 1,3-mannosyltransferases used in the elongation of N . and O-glycans in the Golgi, add the fifth mannose to GPI anchors normally. The same conclusion was reached through the analysis of deletion mutants in KTR1, KTR2, KTR3, KTR4, and YUR1 which all are open reading frames with high homology to MNT1. Mutants deficient in the Golgi elongation of N-glycans such as anp1, van1, mnn9 are deficient in the maturation of the N-glycans of GPI-anchored glycoproteins, but process the GPI anchor side chain normally. Data are consistent with the idea that the fourth mannose is added to proteins as part of the anchor precursor glycolipid in the endoplasmic reticulum, whereas the fifth mannose is added by not yet identified alpha 1,3- and alpha 1,2-mannosyltransferases located in the Golgi apparatus.	UNIV FRIBOURG,INST BIOCHEM,CH-1700 FRIBOURG,SWITZERLAND	University of Fribourg			Puoti, Alessandro/E-5700-2012; Sipos, György/AAC-8267-2019; Sipos, Gyorgy/D-9287-2011; Puoti, Alessandro/ABE-9963-2021	Sipos, György/0000-0002-6666-1384; Puoti, Alessandro/0000-0002-1396-7662				ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; AMTHAUER R, 1992, CLIN CHEM, V38, P2510; ANTALIS C, 1973, J BIOL CHEM, V248, P4655; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BUSSEREAU F, 1993, YEAST, V9, P797, DOI 10.1002/yea.320090714; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; COHEN RE, 1980, J BIOL CHEM, V255, P7700; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; CUNNINGHAM KW, 1989, YEAST, V5, P25, DOI 10.1002/yea.320050105; DEVLIN C, 1990, MOL MICROBIOL, V4, P1993, DOI 10.1111/j.1365-2958.1990.tb02049.x; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; ESMON B, 1981, CELL, V25, P451, DOI 10.1016/0092-8674(81)90063-5; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GEROLD P, 1994, J BIOL CHEM, V269, P2597; GOPAL PK, 1987, P NATL ACAD SCI USA, V84, P8824, DOI 10.1073/pnas.84.24.8824; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HAYNES PA, 1993, EUR J BIOCHEM, V216, P729, DOI 10.1111/j.1432-1033.1993.tb18192.x; HOMANS SW, 1989, BIOCHEMISTRY-US, V28, P2881, DOI 10.1021/bi00433a020; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; LU CF, 1994, MOL CELL BIOL, V14, P4825, DOI 10.1128/MCB.14.7.4825; LUSSIER M, 1993, YEAST, V9, P1057, DOI 10.1002/yea.320091004; MALLET L, 1994, YEAST, V10, P819, DOI 10.1002/yea.320100612; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MULLER G, 1993, J CELL BIOL, V122, P325, DOI 10.1083/jcb.122.2.325; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PUOTI A, 1993, J BIOL CHEM, V268, P7215; PUOTI A, 1991, J BIOL CHEM, V266, P21051; PUOTI A, 1992, J BIOL CHEM, V267, P22673; RASCHKE WC, 1973, J BIOL CHEM, V248, P4660; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; SMITH SW, 1974, J BIOL CHEM, V249, P3395; TSE AGD, 1985, SCIENCE, V230, P1003, DOI 10.1126/science.2865810; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723	43	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19709	19715		10.1074/jbc.270.34.19709	http://dx.doi.org/10.1074/jbc.270.34.19709			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649981	hybrid			2022-12-25	WOS:A1995RQ99100009
J	ZHAO, H; XU, X; DIAZ, J; MUALLEM, S				ZHAO, H; XU, X; DIAZ, J; MUALLEM, S			NA+, K+, AND H+/HCO3- TRANSPORT IN SUBMANDIBULAR SALIVARY DUCTS - MEMBRANE LOCALIZATION OF TRANSPORTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MANDIBULAR GLANDS; RAT SUBMAXILLARY GLAND; GRANULAR DUCTS; ACINAR-CELLS; K/H EXCHANGE; H+ EXCHANGE; MAIN DUCT; RABBIT; STIMULATION; EPITHELIUM	The mechanisms mediating transepithelial ion transport in salivary ducts were characterized and localized by studying the regulation of [Na+](i), [K+]i, and pH(i) in isolated intralobular ducts and perfused main ducts of the submandibular salivary gland. A new procedure was developed for the rapid preparation of intralobular ducts. Measurements of pH(i) revealed the presence of Na+/H+ and Cl-/HCO3- exchange activities in intralobular duct cells. We could not obtain evidence for a coupled K+/H+ exchange activity which was postulated to exist in the luminal membrane of duct cells. Rather, a K-out(+)-dependent pathway which mediates the transport of H+/HCO3- and Na+ was found. This pathway was absent from acinar cells of the same gland and was active in unstimulated duct cells incubated in 5 mM K-out(+). Accordingly, inhibition of the Na+ pump with ouabain resulted in rapid and large Na+ influx in duct but not acinar cells. Perfusion experiments with the experimentally accessible main duct and measurements of pH,were used to provide the first direct localization of ion transporters in salivary ducts. The luminal and basolateral membranes of the duet express separate Na+/H+ and Cl-/HCO3- exchangers. Na+/H+ exchange activity in both membranes was similar, whereas the luminal Cl-/ HCO3- exchange activity was higher than that in the basolateral membrane. The perfused main duct was also used to localize the newly discovered K-out(+)-dependent H+/HCO3- and Na+ transport pathway to the luminal membrane, which suggests that this pathway may play an important role in Na+ reabsorption and K+ and HCO3- secretion by the salivary ductal system.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38938, DK36591] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADORANTE JS, 1987, J GEN PHYSIOL, V90, P209, DOI 10.1085/jgp.90.2.209; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BONANNO JA, 1991, AM J PHYSIOL, V260, pC618, DOI 10.1152/ajpcell.1991.260.3.C618; CASE RM, 1986, EXOCRINE PANCREAS BI, P213; CLARK JD, 1991, AM J PHYSIOL, V261, pC945, DOI 10.1152/ajpcell.1991.261.6.C945; DEHAYE JP, 1991, AM J PHYSIOL, V261, pC490, DOI 10.1152/ajpcell.1991.261.3.C490; DEHAYE JP, 1993, AM J PHYSIOL, V265, pC1356, DOI 10.1152/ajpcell.1993.265.5.C1356; DENNISS AR, 1978, AM J PHYSIOL, V235, pF548, DOI 10.1152/ajprenal.1978.235.6.F548; DENNISS AR, 1978, PFLUG ARCH EUR J PHY, V376, P73, DOI 10.1007/BF00585250; DINUDOM A, 1993, PFLUG ARCH EUR J PHY, V423, P164, DOI 10.1007/BF00374977; DINUDOM A, 1993, CELL CALCIUM, V14, P631, DOI 10.1016/0143-4160(93)90088-N; DINUDOM A, 1993, J MEMBRANE BIOL, V135, P289; GRAY MA, 1993, AM J PHYSIOL, V264, pC591, DOI 10.1152/ajpcell.1993.264.3.C591; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; HOFER AM, 1992, J MEMBRANE BIOL, V126, P245; KNAUF H, 1982, AM J PHYSIOL, V242, pF132, DOI 10.1152/ajprenal.1982.242.2.F132; KNAUF H, 1976, EUR J CLIN INVEST, V6, P43, DOI 10.1111/j.1365-2362.1976.tb00492.x; KNAUF H, 1975, PFLUG ARCH EUR J PHY, V361, P55, DOI 10.1007/BF00587339; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MARTIN CJ, 1973, PFLUG ARCH EUR J PHY, V341, P131, DOI 10.1007/BF00587320; MARTIN CJ, 1971, PFLUG ARCH EUR J PHY, V327, P303, DOI 10.1007/BF00588450; MELVIN JE, 1988, J BIOL CHEM, V263, P19564; MUALLEM S, 1990, J BIOL CHEM, V265, P12806; PAULAIS M, 1994, AM J PHYSIOL, V266, pC1594, DOI 10.1152/ajpcell.1994.266.6.C1594; PORONNIK P, 1993, FEBS LETT, V315, P307, DOI 10.1016/0014-5793(93)81184-2; SCHNEYER LH, 1968, AM J PHYSIOL, V215, P664, DOI 10.1152/ajplegacy.1968.215.3.664; SCHNEYER LH, 1973, AM J PHYSIOL, V224, P136, DOI 10.1152/ajplegacy.1973.224.1.136; SCHNEYER LH, 1977, AM J PHYSIOL, V233, pF22, DOI 10.1152/ajprenal.1977.233.1.F22; SCHNEYER LH, 1976, AM J PHYSIOL, V230, P341, DOI 10.1152/ajplegacy.1976.230.2.341; SCHUSTER VL, 1993, ANNU REV PHYSIOL, V55, P267, DOI 10.1146/annurev.ph.55.030193.001411; STAUFFER PL, 1993, J BIOL CHEM, V268, P19769; THAYSEN JH, 1960, ALKALI METAL IONS BI, P424; TRAYSEN JH, 1954, AM J PHYSIOL, V178, P155; VALDEZ IH, 1991, AM J PHYSIOL, V261, pG359, DOI 10.1152/ajpgi.1991.261.2.G359; XU X, 1995, J BIOL CHEM, V270, P19606, DOI 10.1074/jbc.270.33.19606; YHOUNG JA, 1987, PHYSL GASTROINTESTIN, P773; YOUNG JA, 1970, PFLUG ARCH EUR J PHY, V319, P185, DOI 10.1007/BF00586449; ZHAO H, 1994, J GEN PHYSIOL, V104, P57, DOI 10.1085/jgp.104.1.57	38	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19599	19605		10.1074/jbc.270.33.19599	http://dx.doi.org/10.1074/jbc.270.33.19599			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642647	hybrid			2022-12-25	WOS:A1995RP70300063
J	PIOTROWICZ, RS; WEBER, LA; HICKEY, E; LEVIN, EG				PIOTROWICZ, RS; WEBER, LA; HICKEY, E; LEVIN, EG			ACCELERATED-GROWTH AND SENESCENCE OF ARTERIAL ENDOTHELIAL-CELLS EXPRESSING THE SMALL MOLECULAR-WEIGHT HEAT-SHOCK PROTEIN HSP27	FASEB JOURNAL			English	Article						WILD-TYPE HSP27; MUTANT GENE; ESTRADIOL TREATMENT; CHINESE HAMSTER CELLS	HUMAN-BREAST-CANCER; PHOSPHORYLATION; ORGANIZATION; RESISTANCE; MODULATION; INDUCTION; CARCINOMA; GENE	Bovine arterial endothelial cells were stably transfected with the human wild-type (wt) HSP27 or a mutant gene (mu) encoding a nonphosphorylatable form of the protein. At early passage both cultural and cellular morphology were similar, although the vacuole content in wtHSP27 was much higher than muHSP27 cells. As the cultures aged, wtHSP27 cells became large, polymorphic, highly vacuolated, and reached senescence before muHSP27 transfected cultures, which remained small and polygonal with few detectable vacuoles. Vector control cells showed an intermediate phenotype. Tritiated thymidine incorporation studies were performed with multiple wtHSP27 and muHSP27 clones and the results compared with 11 vector control clones. The results showed an average increase in growth rate for the wtHSP27 cells of 3.0 +/- 0.6 times. The growth rate of eight muHSP27 clones showed a slight decrease. Estradiol treatment of endothelial cells resulted in an increase in both bovine and human HSP27, with peak expression at 100 nM. Treatment of the vector-transfected cells with 100 nM estradiol resulted in a 1.44 +/- 0.18 fold increase in growth rate, which was blocked by expression of muHSP27. These data demonstrate a role for HSP27 in controlling the growth rate of endothelial cells in an estrogen-responsive manner.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA; UNIV NEVADA, RENO, NV 89557 USA	Scripps Research Institute; Nevada System of Higher Education (NSHE); University of Nevada Reno								ADAMS DJ, 1983, CANCER RES, V43, P4297; CHRETIEN P, 1988, J CELL PHYSIOL, V137, P157, DOI 10.1002/jcp.1041370119; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; FAUCHER C, 1993, J BIOL CHEM, V268, P15168; FUQUA SAW, 1989, CANCER RES, V49, P4126; GEIGER B, 1983, DIFFERENTIATION, V23, P189; GUESDON F, 1991, J IMMUNOL, V147, P3402; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HOVER L, 1991, HEAT SHOCK RESPONSE, P41; INGBER DE, 1987, IN VITRO CELL DEV B, V23, P387; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LEVIN EG, 1991, J BIOL CHEM, V266, P174; STEWART AJ, 1992, BRIT J CANCER, V66, P640, DOI 10.1038/bjc.1992.330; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; TORREY RJ, 1994, AM J REPROD IMMUNOL, V27, P171; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	22	35	35	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1995	9	11					1079	1084		10.1096/fasebj.9.11.7649407	http://dx.doi.org/10.1096/fasebj.9.11.7649407			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RP996	7649407				2022-12-25	WOS:A1995RP99600012
J	KAMIMURA, S; GALLIENI, M; ZHONG, M; BERON, T; SLATOPOLSKY, E; DUSSO, A				KAMIMURA, S; GALLIENI, M; ZHONG, M; BERON, T; SLATOPOLSKY, E; DUSSO, A			MICROTUBULES MEDIATE CELLULAR 25-HYDROXYVITAMIN-D-3 TRAFFICKING AND THE GENOMIC RESPONSE TO 1,25-DIHYDROXYVITAMIN-D-3 IN NORMAL HUMAN MONOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRA-RENAL PRODUCTION; VITAMIN-D METABOLISM; INTRACELLULAR-LOCALIZATION; GLUCOCORTICOID RECEPTOR; HORMONE RECEPTORS; MACROPHAGES; CALCITRIOL; BINDING; TRANSLOCATION; LYMPHOCYTES	The genomic actions of 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) are mediated by the intracellular vitamin D receptor (VDR). Although immunocytochemistry has shown that disruption of microtubular assembly prevents nuclear access of the sterol-VDR complex, the role of microtubules in the response to 1,25(OH)(2)D-3 has not been studied in viable cells. Our studies examined this interaction in normal human monocytes. Monocytes convert 25(OR)D-3 to 1,25(OH)(2)D-3 and to 24-hydroxylated metabolites more polar than 1,25(OH)(2)D-3. Microtubule disruption totally abolished the ability of exogenous 1,25(OH)(2)D-3 to suppress its own synthesis and to induce 24-hydroxylase mRNA and activity, without affecting either total 1,25(OH)(2)D-3 uptake or maximal 1,25(OH)(2)D(-)3VDR binding. Thus, intact microtubules are essential for 1,25(OH)(2)D-3-dependent modulation of gene transcription. Interestingly, microtubule disruption also decreased monocyte 1,25(OH)(2)D-3 synthesis, not by decreasing the V-max of monocyte mitochondrial 1 alpha-hydroxylase but through an increase in the K-m for 25(OH)D-3. We examined 25(OH)D-3 transport. Microtubule disruption did not affect total cellular 25(OH)D-3 uptake but reduced its intracellular trafficking to the mitochondria. Thus, microtubules participate in intracellular 25(OH)D-3 transport, and their integrity determines normal 1,25(OH)(2)D-3 synthesis.	WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, DIV RENAL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Dusso, Adriana S/E-8617-2011; Gallieni, Maurizio/H-2895-2019	Gallieni, Maurizio/0000-0002-2011-2160	NIDDK NIH HHS [DK-09976, DK-07126] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK009976, T32DK007126] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JS, 1985, J EXP MED, V161, P755, DOI 10.1084/jem.161.4.755; ADAMS JS, 1994, ENDOCRINOLOGY, V134, P2567, DOI 10.1210/en.134.6.2567; AKNER G, 1990, EUR J CELL BIOL, V53, P390; AMIZUKA N, 1992, ARCH HISTOL CYTOL, V55, P77, DOI 10.1679/aohc.55.77; ANTAKLY T, 1984, ENDOCRINOLOGY, V115, P1984, DOI 10.1210/endo-115-5-1984; BARSHAVIT Z, 1981, CALCIFIED TISSUE INT, V33, P673, DOI 10.1007/BF02409507; BARSONY J, 1990, J CELL BIOL, V111, P2385, DOI 10.1083/jcb.111.6.2385; BARSONY J, 1992, J BIOL CHEM, V267, P24457; BARSONY J, VITAMIN D THERAPEUTI, P345; BHALLA AK, 1986, CELL IMMUNOL, V98, P311, DOI 10.1016/0008-8749(86)90291-1; COHEN MS, 1986, J IMMUNOL, V136, P1049; DIBARTOLOMEIS MJ, 1984, J BIOL CHEM, V259, P159; DUSSO A, 1988, KIDNEY INT, V34, P368, DOI 10.1038/ki.1988.190; DUSSO A, 1989, KIDNEY INT, V35, P860, DOI 10.1038/ki.1989.64; DUSSO A, 1992, J BONE MINER RES, V7, pS151; DUSSO AS, 1991, J CLIN ENDOCR METAB, V72, P157, DOI 10.1210/jcem-72-1-157; ESCOLAR G, 1993, AM J PATHOL, V143, P823; GALLIENI M, 1995, AM J PHYSIOL, V37, pF746; GIBBONS IR, 1988, J BIOL CHEM, V263, P15837; GREEN DE, 1955, J BIOL CHEM, V217, P551; HALLORAN BP, 1984, J CLIN ENDOCR METAB, V59, P1063, DOI 10.1210/jcem-59-6-1063; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; HEWISON M, 1993, CLIN ENDOCRINOL, V39, P663, DOI 10.1111/j.1365-2265.1993.tb02424.x; KEENAN MJ, 1991, INT J BIOCHEM, V23, P1225, DOI 10.1016/0020-711X(91)90220-H; KOREN R, 1986, FEBS LETT, V205, P113, DOI 10.1016/0014-5793(86)80876-6; LAMBERT PW, 1982, J CLIN INVEST, V69, P722, DOI 10.1172/JCI110501; LEPECQ JB, 1966, ANAL BIOCHEM, V17, P100, DOI 10.1016/0003-2697(66)90012-1; PAPAMICHAIL M, 1980, EXP CELL RES, V125, P490, DOI 10.1016/0014-4827(80)90144-5; PIKE JW, 1982, P NATL ACAD SCI-BIOL, V79, P7719, DOI 10.1073/pnas.79.24.7719; PIKE JW, 1982, J BIOL CHEM, V257, P6766; PRATT WB, 1993, J BIOL CHEM, V268, P21455; REINHARDT TA, 1984, J CLIN ENDOCR METAB, V58, P91, DOI 10.1210/jcem-58-1-91; SCHACHTE.H, 1970, J BIOL CHEM, V245, P1090; SHANY S, 1993, J BONE MINER RES, V8, P269; SPAZARY D, 1994, J STEROID BIOCHEM, V51, P143; SPINDLER BJ, 1975, J BIOL CHEM, V250, P4113; STETSON DL, 1983, AM J PHYSIOL, V245, pC113, DOI 10.1152/ajpcell.1983.245.1.C113; TAFT JL, 1986, BIOCHEM BIOPH RES CO, V134, P218, DOI 10.1016/0006-291X(86)90550-4; WALTERS MR, 1985, ENDOCR REV, V6, P512, DOI 10.1210/edrv-6-4-512; WALTERS SN, 1986, ARCH BIOCHEM BIOPHYS, V246, P366, DOI 10.1016/0003-9861(86)90481-9; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	41	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22160	22166		10.1074/jbc.270.38.22160	http://dx.doi.org/10.1074/jbc.270.38.22160			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673194	hybrid			2022-12-25	WOS:A1995RW31400018
J	KING, C; EISENBERG, E; GREENE, L				KING, C; EISENBERG, E; GREENE, L			POLYMERIZATION OF 70-KDA HEAT-SHOCK PROTEIN BY YEAST DNAJ IN ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; PEPTIDE BINDING; COATED VESICLES; TRANSLOCATION; HSP70; HOMOLOG; TEMPERATURES; POLYPEPTIDES	DnaK, the Escherichia coli hsp(70) protein, interacts with DnaJ, a protein cofactor that appears to be involved in presenting protein substrates to DnaK. The yeast DnaJ homolog, YDJ1, has also been shown to interact with yeast hsp70, although the function of this interaction is unknown. In the present study, we investigated the interaction of YDJ1 with both yeast and bovine brain hsp70. We found that, in the presence of ATP, where hsp70 is normally monomeric, YDJ1 induced almost all of the yeast and bovine brain hsp70 to form large polymers, which are readily sedimentable. These polymers were much larger than the dimers and trimers of hsp70, which normally form in the presence of ADP. YDJ1 appeared to be acting catalytically since very little YDJ1 copolymerized with the hsp70, and maximum polymerization occurred at low ratios of YDJ1 to hsp70. The polymerization required ATP and was completely reversed when ATP was replaced by ADP. These data suggest that, in the presence of ATP, YDJ1 may present one hsp70 to another just as under other conditions DnaJ is able to present protein substrates to DnaK.	NHLBI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BAROUCH W, 1993, MOL BIOL CELL, V4, P95; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BRODSKY JL, 1993, J CELL BIOL, V120, P1355; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, J BIOL CHEM, V269, P9798; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAO B, 1993, MOL BIOL CELL, V4, P96; GAO BC, 1991, J BIOL CHEM, V266, P19565; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; GREENE LE, 1990, J BIOL CHEM, V265, P6682; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; LAKEY EK, 1987, P NATL ACAD SCI USA, V84, P1659, DOI 10.1073/pnas.84.6.1659; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MOTOHASHI K, 1994, J BIOL CHEM, V269, P27074; PRASAD K, 1994, J BIOL CHEM, V269, P6931; PRASAD K, 1994, MOL BIOL CELL, V5, P329; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SELL SM, 1990, J BACTERIOL, V172, P4827, DOI 10.1128/jb.172.9.4827-4835.1990; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	43	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22535	22540		10.1074/jbc.270.38.22535	http://dx.doi.org/10.1074/jbc.270.38.22535			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673245	hybrid			2022-12-25	WOS:A1995RW31400074
J	THOMAS, WG; BAKER, KM; MOTEL, TJ; THEKKUMKARA, TJ				THOMAS, WG; BAKER, KM; MOTEL, TJ; THEKKUMKARA, TJ			ANGIOTENSIN-II RECEPTOR ENDOCYTOSIS INVOLVES 2 DISTINCT REGIONS EF THE CYTOPLASMIC TAIL - A ROLE FOR RESIDUES ON THE HYDROPHOBIC FACE OF A PUTATIVE AMPHIPATHIC HELIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MEDIATED ENDOCYTOSIS; POTENTIAL MECHANISM; CARBOXYL-TERMINUS; INTERNALIZATION; PROTEIN; BINDING; SEQUESTRATION; CLATHRIN	Following agonist stimulation, many receptors are rapidly internalized from the plasma membrane via a mechanism which presumably involves recognition motifs within the cytoplasmic domains of the receptor. We have previously demonstrated (Thomas, W. G., Thekkumkara, T. J., Motel, T. J., and Baker, K. M. (1995) J. Biol Chem. 270, 207-213) that truncation of the angiotensin II (AT(1A)) receptor, to remove 45 amino acids from the cytoplasmic tail, markedly reduced agonist stimulated receptor endocytosis. In the present study, we have stably and transiently expressed wild type and carboxyl terminus mutated AT(1A) receptors in Chinese hamster ovary cells to identify regions and specific amino acids important for this process. Wild type AT(1A) receptors rapidly internalized (t(1/2) = 2.5 min; Y-max = 76.4%) after AII stimulation. Using AT(1A) receptor mutants, truncated and deleted at the carboxyl terminus, two distinct regions important for internalization were identified: one membrane proximal site between residues 315-329 and another distal to Lys(333), within the terminal 26 amino acids. Point mutations (Y302A, Y312A, L316F, Y319A, and K325A) were performed to identify residues contributing to the membrane proximal site. Mutation of Y302A, Y312A, and K325A had little effect on the rate (t(1/2) = 4.3, 2.8, and 2.8 min) and maximal amount (Y-max = 81.7, 67.8, and 73.5%) of AII induced internalization. In contrast, L316F and Y319A mutations displayed an approximately 2.5-fold reduction in rate (t(1/2) = 6.1 and 6.2 min) and L316F a decreased maximal level (Y-max 38.1 and 71.4%, respectively) compared to wild type. Interestingly, Leu(316) and Tyr(319) are closely aligned within the hydrophobic aspect of a putative amphipathic helix, possibly representing an internalization motif for the AT(1A) receptor. We conclude that the AT(1A) receptor does not use the NPXXY (NPLFY(302)) motif, first described for the beta(2)-adrenergic receptor, to mediate agonist stimulated endocytosis. Rather, two distinct regions of the carboxyl terminus are utilized: one involving hydrophobic and aromatic residues on a putative alpha-helix and another serine/threonine-rich domain.	WEIS CTR RES, GEISINGER CLIN, DANVILLE, PA 17822 USA				Thomas, Walter/I-2208-2015	Thomas, Walter/0000-0003-0685-2952; Thekkumkara, Thomas/0000-0001-8865-1446	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044883] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44883] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KM, 1993, AM J PHYSIOL, V264, pC179, DOI 10.1152/ajpcell.1993.264.1.C179; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BOOZ GW, 1992, ENDOCRINOLOGY, V130, P3641, DOI 10.1210/en.130.6.3641; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATT KJ, 1993, RENIN ANGIOTENSIN SY, V1; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; CONCHON S, 1994, FEBS LETT, V349, P365, DOI 10.1016/0014-5793(94)00703-9; CROZAT A, 1986, ENDOCRINOLOGY, V118, P2312, DOI 10.1210/endo-118-6-2312; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GREEN SA, 1994, J BIOL CHEM, V269, P26215; GRIENDLING KK, 1987, J BIOL CHEM, V262, P14555; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; HUNYADY L, 1991, J BIOL CHEM, V266, P2783; HUNYADY L, 1994, KIDNEY INT, V46, P1496, DOI 10.1038/ki.1994.428; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PARKER EM, 1995, J BIOL CHEM, V270, P6482, DOI 10.1074/jbc.270.12.6482; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; ROBERTSON JI, 1993, RENIN ANGIOTENSIN SY, V1; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SANDBERG K, 1994, TRENDS ENDOCRIN MET, V5, P28, DOI 10.1016/1043-2760(94)90118-X; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SLICE LW, 1994, J BIOL CHEM, V269, P21755; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SUGIURA N, 1992, J BIOL CHEM, V267, P18067; SWILLENS S, 1992, TRENDS PHARMACOL SCI, V13, P430, DOI 10.1016/0165-6147(92)90139-W; THEKKUMKARA TJ, 1995, MOL CELL BIOCHEM, V146, P79, DOI 10.1007/BF00926885; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; TSUGA H, 1994, J BIOL CHEM, V269, P32522; ULLIAN ME, 1989, J CLIN INVEST, V84, P840, DOI 10.1172/JCI114244; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; WILDE A, 1994, J BIOL CHEM, V269, P7131; YU SS, 1993, J BIOL CHEM, V268, P337	55	106	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22153	22159		10.1074/jbc.270.38.22153	http://dx.doi.org/10.1074/jbc.270.38.22153			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673193	hybrid			2022-12-25	WOS:A1995RW31400017
J	KINGMA, PS; CORBETT, AH; BURCHAM, PC; MARNETT, LJ; OSHEROFF, N				KINGMA, PS; CORBETT, AH; BURCHAM, PC; MARNETT, LJ; OSHEROFF, N			ABASIC SITES STIMULATE DOUBLE-STRANDED DNA CLEAVAGE MEDIATED BY TOPOISOMERASE-II - DNA LESIONS AS ENDOGENOUS TOPOISOMERASE-II POISONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DRUG-INTERACTION DOMAINS; ACUTE MYELOID-LEUKEMIA; DROSOPHILA-MELANOGASTER; ANTINEOPLASTIC DRUGS; ENZYME; RELIGATION; AGENTS; ACID; EPIPODOPHYLLOTOXINS; INHIBITION	Several clinically relevant anticancer drugs induce genomic mutations and cell death by increasing topoisomerase II-mediated DNA breakage. To determine whether endogenous DNA damage also affects this cleavage event, the effects of abasic sites (the most commonly formed spontaneous DNA lesion) on topoisomer ase II activity were investigated. The presence of 3 abasic sites/plasmid stimulated enzyme-mediated DNA breakage >6-fold, primarily by enhancing the forward rate of cleavage, This corresponds to a potency that is >2000-fold higher than that of the anticancer drug, etoposide. These findings suggest that abasic sites represent endogenous topoisomerase II poisons and imply that anticancer drugs mimic the cleavage-enhancing actions of naturally occurring DNA lesions.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,VANDERBILT CANC CTR,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University			Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NATIONAL CANCER INSTITUTE [R35CA047479, T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [CA47479, CA09582] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RD, 1994, MUTAT RES-FUND MOL M, V309, P109, DOI 10.1016/0027-5107(94)90048-5; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CORBETT AH, 1991, J BIOL CHEM, V266, P19666; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; DARPA P, 1990, CANCER RES, V50, P6919; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEVORE R, 1989, ANN INTERN MED, V110, P704, DOI 10.7326/0003-4819-110-9-740; FERGUSON LR, 1994, ENVIRON MOL MUTAGEN, V24, P245, DOI 10.1002/em.2850240402; FREUDENREICH CH, 1994, P NATL ACAD SCI USA, V91, P11007, DOI 10.1073/pnas.91.23.11007; FRIEDBERG EC, 1995, DNA REPAIR; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P14998, DOI 10.1074/jbc.270.25.14998; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; LETEURTRE F, 1994, J BIOL CHEM, V269, P7893; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LLOYD RS, 1980, NUCLEIC ACIDS RES, V8, P5113, DOI 10.1093/nar/8.21.5113; Lloyd RS, 1993, NUCLEASES, P263; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; NETO JBC, 1992, J BIOL CHEM, V267, P19718; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; POMMIER Y, 1993, CANCER CHEMOTH PHARM, V32, P103, DOI 10.1007/BF00685611; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; ROSS JA, 1994, J NATL CANCER I, V86, P1678, DOI 10.1093/jnci/86.22.1678; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SMITH MA, 1994, MED PEDIATR ONCOL, V23, P86, DOI 10.1002/mpo.2950230205; SMITH MA, 1993, J NATL CANCER I, V85, P554, DOI 10.1093/jnci/85.7.554; SORENSEN BS, 1992, J MOL BIOL, V228, P778, DOI 10.1016/0022-2836(92)90863-F; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; ZHANG H, 1990, CANCER CELL-MON REV, V2, P23	42	91	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21441	21444		10.1074/jbc.270.37.21441	http://dx.doi.org/10.1074/jbc.270.37.21441			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665552	hybrid			2022-12-25	WOS:A1995RU75700004
J	LOO, TW; CLARKE, DM				LOO, TW; CLARKE, DM			RAPID PURIFICATION OF HUMAN P-GLYCOPROTEIN MUTANTS EXPRESSED TRANSIENTLY IN HEK-293 CELLS BY NICKEL-CHELATE CHROMATOGRAPHY AND CHARACTERIZATION OF THEIR DRUG-STIMULATED ATPASE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PREDICTED TRANSMEMBRANE DOMAIN; FUNCTIONAL CONSEQUENCES; PROTEIN; MUTATIONS; BINDING	P-glycoprotein containing 10 tandem histidine residues at the COOH end of the molecule was transiently expressed in HEK 293 cells and purified by nickel chelate chromatography. The purified protein had an apparent mass of 170 kDa, and its verapamil-stimulated ATPase activity in the presence of phospholipid was 1.2 mu mol/min/mg of P-glycoprotein. We then characterized P-glycoprotein mutants that exhibited altered drug-resistant phenotypes and analyzed the contribution of the two nucleotide binding folds to drug-stimulated ATPase activity, Mutation of residues in either nucleotide binding fold abolished drug-stimulated ATPase activity. The pattern of drug-stimulated ATPase activities of mutants, which conferred increased relative resistance to colchicine (G141V, G185V, G830V) or decreased relative resistance to all drugs (F978A), correlated with their drug-resistant phenotypes, By contrast, the ATPase activity of mutant F335A was significantly higher than that of wild-type enzyme when assayed in the presence of verapamil (3.4 fold), colchicine (9.1-fold), or vinblastine (3.7-fold), even though it conferred little resistance to vinblastine in transfected cells. These results suggest that both nucleotide-binding domains must be intact to couple drug binding to ATPase activity and that the drug-stimulated ATPase activity profile of a mutant does not always correlate with its drug-resistant phenotype.	UNIV TORONTO,DEPT MED,MRC,MEMBRANE BIOL GRP,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KAJIJI S, 1994, BIOCHEMISTRY-US, V33, P5041, DOI 10.1021/bi00183a006; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1993, J BIOL CHEM, V268, P19965; LOO TW, 1994, J BIOL CHEM, V269, P28683; RAO US, 1995, J BIOL CHEM, V270, P6686; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	20	190	190	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21449	21452		10.1074/jbc.270.37.21449	http://dx.doi.org/10.1074/jbc.270.37.21449			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665554	hybrid			2022-12-25	WOS:A1995RU75700006
J	CHAMBERLIN, SG; SARGOOD, KJ; RICHTER, A; MELLOR, JM; ANDERSON, DW; RICHARDS, NGJ; TURNER, DL; SHARMA, RP; ALEXANDER, P; DAVIES, DE				CHAMBERLIN, SG; SARGOOD, KJ; RICHTER, A; MELLOR, JM; ANDERSON, DW; RICHARDS, NGJ; TURNER, DL; SHARMA, RP; ALEXANDER, P; DAVIES, DE			CONSTRAINED PEPTIDE ANALOGS OF TRANSFORMING GROWTH-FACTOR-ALPHA RESIDUES CYSTEINE-21-32 ARE MITOGENICALLY ACTIVE - USE OF PROLINE MIMETICS TO ENHANCE BIOLOGICAL POTENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING; SYNTHETIC FRAGMENTS; ROTATING-FRAME; SITE; SPECTROSCOPY; EGF	Two proline mimetics, the enantiomers of 2-aza-bicyclo[2,2,1]heptane-3-carboxylic acid, have been incorporated in place of Pro(30) into synthetic peptides based on the B-loop beta-sheet sequence of human transforming growth factor-alpha (TGF-alpha) (residues Cys(21)-Cys(32)). The peptides were further modified by inclusion of an N-terminal phenylalanine and constrained by formation of an intramolecular disulfide bond. While no mitogenic response was observed in the parental NR6 cell line, the peptides stimulated DNA synthesis in NR6/HER cells (NR6 fibroblasts transfected with the human epidermal growth factor receptor). Induction of DNA synthesis was dose dependent, with EC(50) values in the range 130-330 mu M; in the presence of low doses of TGF-alpha, the mitogenic effect of the peptides was additive, up to the plateau response achieved by maximal doses of TGF-alpha alone. These effects are consistent with the peptides acting via the same mechanism as TGF-alpha. Analysis of the structure of the peptides by NMR indicated that the presence of the mimetics significantly increased the propensity of the peptidyl-proline bond to adopt the cis conformation. These data confirm the role of the beta-sheet in receptor activation, and emphasize the importance of presentation of peptides in an appropriate conformation for recognition.	SOUTHAMPTON GEN HOSP,CANC RES CAMPAIGN MEC ONCOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND; UNIV SOUTHAMPTON,DEPT CHEM,SOUTHAMPTON SO17 1BJ,HANTS,ENGLAND; UNIV SOUTHAMPTON,DEPT BIOCHEM,SOUTHAMPTON SO16 7PX,HANTS,ENGLAND; CHEM & BIOL DEF ESTAB,SALISBURY SP4 0JQ,WILTS,ENGLAND	University of Southampton; University of Southampton; University of Southampton			Davies, Donna E/H-2993-2012; Turner, David/B-8267-2009; Turner, David L/B-9061-2011	Turner, David L/0000-0002-3754-6459				ATHERTON E, 1991, PEPTIDES 1990, P243; BAILIE JR, 1994, INT J PEPT PROT RES, V43, P225; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Campbell I D, 1989, Prog Growth Factor Res, V1, P13, DOI 10.1016/0955-2235(89)90038-0; CAMPION SR, 1990, BIOCHEMISTRY-US, V29, P9988, DOI 10.1021/bi00494a032; COWLEY GP, 1986, BRIT J CANCER, V53, P223, DOI 10.1038/bjc.1986.39; DARLAK K, 1988, J CELL BIOCHEM, V36, P341, DOI 10.1002/jcb.240360404; DAVIES DE, 1994, BRIT J CANCER, V70, P263, DOI 10.1038/bjc.1994.290; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; DEFEOJONES D, 1988, MOL CELL BIOL, V8, P2999, DOI 10.1128/MCB.8.8.2999; DEFEOJONES D, 1989, MOL CELL BIOL, V9, P4083, DOI 10.1128/MCB.9.9.4083; DONZEL B, 1972, HELV CHIM ACTA, V55, P947, DOI 10.1002/hlca.19720550321; ENGLER DA, 1992, J BIOL CHEM, V267, P2274; EPSTEIN DA, 1989, J CELL PHYSL, V141, P420; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GOTTLIEB AB, 1988, J EXP MED, V167, P670, DOI 10.1084/jem.167.2.670; Han K H, 1988, J Mol Recognit, V1, P116, DOI 10.1002/jmr.300010304; KATSUURA M, 1989, J BIOCHEM-TOKYO, V106, P87, DOI 10.1093/oxfordjournals.jbchem.a122826; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KOIDE H, 1992, BIOCHIM BIOPHYS ACTA, V1120, P257, DOI 10.1016/0167-4838(92)90245-9; KOMORIYA A, 1984, P NATL ACAD SCI-BIOL, V81, P1351, DOI 10.1073/pnas.81.5.1351; KOPPLE KD, 1988, J AM CHEM SOC, V110, P4168, DOI 10.1021/ja00221a012; LAZAR E, 1988, MOL CELL BIOL, V8, P1247, DOI 10.1128/MCB.8.3.1247; LEE DC, 1991, PEPTIDE GROWTH FACTO, V2, P61; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; MELLOR JM, 1994, IN PRESS TETRAHEDRON; NELSON J, 1991, CARCINOGENESIS, V12, P1823, DOI 10.1093/carcin/12.10.1823; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; RANCE M, 1987, J MAGN RESON, V74, P557, DOI 10.1016/0022-2364(87)90277-0; RICHTER A, 1992, BIOCHEMISTRY-US, V31, P9546, DOI 10.1021/bi00155a006; RICHTER A, 1995, J BIOL CHEM, V270, P1612, DOI 10.1074/jbc.270.4.1612; RICHTER A, 1995, BIOCHEM PHARMACOL, V49, P367, DOI 10.1016/0006-2952(94)00423-J; SCHULTZ G, 1991, J CELL BIOCHEM, V45, P346, DOI 10.1002/jcb.240450407; SCHULZ GE, 1985, PRINCIPLES PROTEIN S; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; TAM JP, 1991, INT J PEPT PROT RES, V38, P204; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WILKS A F, 1990, Progress in Growth Factor Research, V2, P97, DOI 10.1016/0955-2235(90)90026-G	39	7	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21062	21067		10.1074/jbc.270.36.21062	http://dx.doi.org/10.1074/jbc.270.36.21062			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673134	hybrid			2022-12-25	WOS:A1995RU05400032
J	MAXZUD, MK; DANIOTTI, JL; MACCIONI, HJF				MAXZUD, MK; DANIOTTI, JL; MACCIONI, HJF			FUNCTIONAL COUPLING OF GLYCOSYL TRANSFER STEPS FOR SYNTHESIS OF GANGLIOSIDES IN GOLGI MEMBRANES FROM NEURAL RETINA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; BREFELDIN-A; BIOSYNTHESIS; APPARATUS; GLYCOSYLTRANSFERASES; SIALYLTRANSFERASES; GLYCOSPHINGOLIPIDS; OLIGOSACCHARIDES; TRANSLOCATION; TRANSPORT	The synthesis of the oligosaccharide of gangliosides is carried out in the Golgi complex by successive sugar transfers to proper glycolipid accepters, To examine how the product of one glycosylation step couples with the next transfer step, the endogenous gangliosides of Golgi membranes from 14-day-old chick. embryo retina were labeled from CMP-[H-3]NeuAc or UDP-[H-3]GalNAc or UDP-[H-3]Gal in conditions which do not allow vesicular intercompartmental transport, After saturation of the endogenous acceptor capacity, labeling was mostly in the immediate accepters of the corresponding labeled sugars, However, some labeled intermediates progressed to more glycosylated gangliosides if the membranes were incubated in a second step in the presence of the necessary unlabeled sugar nucleotides. This was particularly evident in the case of membranes incubated with UDP-[H-3]Gal, in which most of the [H-3]Gal-labeled lactosylceramide synthesized in the first step was converted to GM3 and GD3, or to GM2 or to GD1a in a second incubation step in the presence of unlabeled CMP-NeuAc alone, or together with UDP-GalNAc, or together with UDP-Gal plus UDP-GalNAc, respectively, Conversion was time dependent and dilution-independent, Since prior reports using brefeldin A indicate that transfer steps catalyzed by GalNAc-T, Gal-T2, and Sial-T4 localize in the trans-Golgi network (TGN), our results lead to the following major conclusions: (a) transfer steps catalyzed by GalNAc-T, Gal-T2, and Sial-T4 colocalize and are functionally coupled in the TGN; (b) proximal Golgi Gal-T1, Sial-T1, and Sial-T2, and their corresponding glycolipid accepters, extend their presence to the TGN, and (c), GalNAc-T and Sial-T2 compete for a common pool of acceptor GM3 in the synthesis of GM2 and GD3.	NATL UNIV CORDOBA,FAC CIENCIAS QUIM,DEPT QUIM BIOL,CONICET,CIQUIBIC,RA-5016 CORDOBA,ARGENTINA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba								ARCE A, 1971, BIOCHEM J, V121, P483, DOI 10.1042/bj1210483; CAPUTTO R, 1974, MOL CELL BIOCHEM, V4, P97, DOI 10.1007/BF01770290; DANIOTTI JL, 1991, J NEUROCHEM, V57, P2054, DOI 10.1111/j.1471-4159.1991.tb06421.x; DANIOTTI JL, 1994, J NEUROCHEM, V62, P1131; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; FRITZ VMR, 1995, IN PRESS J NEUROCHEM; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; HAYES BK, 1993, J BIOL CHEM, V268, P16139; HAYES BK, 1993, J BIOL CHEM, V268, P16155; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; IBER H, 1992, J NEUROCHEM, V58, P1533, DOI 10.1111/j.1471-4159.1992.tb11375.x; JECKEL J, 1992, J CELL BIOL, V29, P75; KLAUSNER RD, 1992, J CELL BIOL, V16, P1071; LANDA CA, 1981, J NEUROCHEM, V37, P813, DOI 10.1111/j.1471-4159.1981.tb04466.x; MACCIONI HJ, 1974, BIOCHEM J, V138, P291, DOI 10.1042/bj1380291; MARTINA JA, 1995, J NEUROCHEM, V64, P1274; MILLERPODRAZA H, 1982, BIOCHEMISTRY-US, V21, P3265, DOI 10.1021/bi00257a003; MILLERPRODRAZA H, 1984, BIOCHIM BIOPHYS ACTA, V804, P44, DOI 10.1016/0167-4889(84)90097-1; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NORES GA, 1994, J CHROMATOGR A, V686, P155, DOI 10.1016/S0021-9673(94)89015-3; PAIEMENT J, 1982, J CELL BIOL, V92, P147, DOI 10.1083/jcb.92.1.147; PANZETTA P, 1987, J NEUROCHEM, V49, P1763, DOI 10.1111/j.1471-4159.1987.tb02434.x; PANZETTA P, 1980, J NEUROCHEM, V35, P100, DOI 10.1111/j.1471-4159.1980.tb12494.x; REINER JM, 1959, BEHAVIOR ENZYME SYST, P89; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SJOBERG ER, 1993, J BIOL CHEM, V268, P10185; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TRINCHERA M, 1990, J BIOL CHEM, V265, P18242; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; WATTENBERG BW, 1990, J CELL BIOL, V111, P421, DOI 10.1083/jcb.111.2.421; YOUNG WW, 1992, J BIOL CHEM, V267, P12011; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838	36	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20207	20214		10.1074/jbc.270.34.20207	http://dx.doi.org/10.1074/jbc.270.34.20207			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650040	hybrid			2022-12-25	WOS:A1995RQ99100078
J	BALLARIN, C; SORGATO, MC				BALLARIN, C; SORGATO, MC			AN ELECTROPHYSIOLOGICAL STUDY OF YEAST MITOCHONDRIA - EVIDENCE FOR 2 INNER MEMBRANE ANION CHANNELS SENSITIVE TO ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTACT MITOCHONDRIA; K+-CHANNEL	The inner membrane of mitochondria from various strains of Saccharomyces cerevisiae has been analyzed with the patch clamp technique for comparison with the better known homologous membrane in mammals (Sorgato, M. C., and Moran, O. (1993) CRC Grit. Rev. Biochem. Mol. Biol. 18, 127-171). Differently than in mammals, the yeast inner membrane was found to harbor essentially two channels with similar anionic selectivity but otherwise different functional behavior. One had a conductance of around 45 picosiemens (in symmetrical 150 mM KCl) and an activity only marginally sensitive to voltage. The other channel was prominent for the higher outwardly rectifying current and for the dependence upon voltage of the open probability that induced rapid closure at physiological (negative) membrane potentials. Particularly interesting was the effect of ATP (Mg2+ free) added on the matrix side of the membrane, In the case of the lower conducting channel, the nucleotide caused an immediate block of activity (IC50, 0.240 mM), whereas it locked the larger conductance in the open state at both positive and negative potentials, In proteoliposomes containing both mitochondrial membranes, the small conductance was clearly evident, whereas a larger channel, cationic and without the voltage dependence typical of that in the native inner membrane, was found.	UNIV PADUA,DIPARTIMENTO CHIM BIOL,I-35121 PADUA,ITALY	University of Padua				BALLARIN, Cristina/0000-0001-7934-7477				BALLARIN C, 1995, BIOENERGETICS PRACTI, P133; BEAVIS AD, 1993, J BIOL CHEM, V268, P997; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; CRIADO M, 1987, FEBS LETT, V224, P172, DOI 10.1016/0014-5793(87)80442-8; DAUM G, 1982, J BIOL CHEM, V257, P3028; GUERIN B, 1994, J BIOL CHEM, V269, P25406; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; KINNALLY KW, 1992, J BIOENERG BIOMEMBR, V24, P99, DOI 10.1007/BF00769536; MANON S, 1993, J BIOENERG BIOMEMBR, V25, P671; MORAN O, 1992, EUR BIOPHYS J BIOPHY, V20, P311, DOI 10.1007/BF00196590; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; PUSCH M, 1994, PHYSIOL REV, V74, P813, DOI 10.1152/physrev.1994.74.4.813; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SORGATO MC, 1993, CRIT REV BIOCHEM MOL, V18, P127; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	18	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19262	19268		10.1074/jbc.270.33.19262	http://dx.doi.org/10.1074/jbc.270.33.19262			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642599	hybrid			2022-12-25	WOS:A1995RP70300013
J	LANEUVILLE, O; BREUER, DK; XU, NX; HUANG, ZH; GAGE, DA; WATSON, JT; LAGARDE, M; DEWITT, DL; SMITH, WL				LANEUVILLE, O; BREUER, DK; XU, NX; HUANG, ZH; GAGE, DA; WATSON, JT; LAGARDE, M; DEWITT, DL; SMITH, WL			FATTY-ACID SUBSTRATE SPECIFICITIES OF HUMAN PROSTAGLANDIN ENDOPEROXIDE-H SYNTHASE-1 AND SYNTHASE-2 - FORMATION OF 12-HYDROXY-(9Z,13E/Z,15Z)-OCTADECATRIENOIC ACIDS FROM ALPHA-LINOLENIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; G/H SYNTHASE; MESSENGER-RNA; COMPLEMENTARY-DNA; BINDING-SITES; HEME-BINDING; CYCLOOXYGENASE; EXPRESSION; CELLS; GENE	Human prostaglandin-endoperoxide H synthase-l and -2 (hPGHS-1 and hPGHS-2) were expressed by transient transfection of COS-1 cells. Microsomes prepared from the transfected cells were used to measure the rates of oxygenation of several 18- and 20-carbon polyunsaturated fatty acid substrates including eicosapentaenoic, arachidonic, dihomo-gamma-linolenic, alpha-linolenic (Delta(9,12,15)), gamma-linolenic, and linoleic acids. Comparisons of k(cat)/K-m values indicate that the order of efficiency of oxygenation is arachidonate > dihomo-gamma-linolenate > linoleate > alpha-linolenate for both isozymes; while the order of efficiency was the same for hPGHS-1 and hPGHS-2, alpha-linoleate was a particularly poor substrate for hPGHS-1. gamma-Linolenate and eicosapentaenoate were poor substrates for both isozymes, but in each case, these two fatty acids were better substrates for hPGHS-2 than hPGHS-1. These studies of substrate specificities are consistent with previous studies of the interactions of PGHS isozymes with nonsteroidal anti-inflammatory drugs that have indicated that the cyclooxygenase active site of PGHS-2 is somewhat larger and more accommodating than that of PGHS-1. The major products formed from linoleate and alpha-linolenate were characterized. 13-Hydroxy-(9Z,11E)-octadecadienoic acid was found to be the main product formed from alpha-linoleate by both isozymes. The major products of oxygenation of alpha-linolenate were determined by mass spectrometry to be 12-hydroxy-(9Z,13E/Z,15Z)-octadecatrieno acids. This result suggests that alpha-linolenate is positioned in the cyclooxygenase active site with a kink in the carbon chain such that hydrogen abstraction occurs from the omega 5-position in contrast to abstraction of the omega 8-hydrogen from other substrates.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; INSA,CHIM BIOL LAB,F-69621 VILLEURBANNE,FRANCE; INSA,INSERM,U352,F-69621 VILLEURBANNE,FRANCE	Michigan State University; Institut National des Sciences Appliquees de Lyon - INSA Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK022042, R37DK022042, R01DK042509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040713] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42509, DK22042] Funding Source: Medline; NIGMS NIH HHS [GM40713] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARNETT J, 1994, BIOCHIM BIOPHYS ACTA, V209, P130; CARTY TJ, 1980, PROSTAGLANDINS, V19, P671, DOI 10.1016/0090-6980(80)90166-5; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DRAFFAN GH, 1968, ORG MASS SPECTROM, V1, P669, DOI 10.1002/oms.1210010508; EGLINTON G, 1968, ORG MASS SPECTROM, V1, P593, DOI 10.1002/oms.1210010413; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GRAFF G, 1982, METHOD ENZYMOL, V86, P386; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAMBERG M, 1967, J BIOL CHEM, V242, P5344; HAMBERG M, 1990, ADV PROSTAGLANDIN TH, V21, P117; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HSI LC, 1994, BIOCHEM BIOPH RES CO, V202, P1592, DOI 10.1006/bbrc.1994.2114; JONES DA, 1993, J BIOL CHEM, V268, P9049; KADUCE TL, 1989, J BIOL CHEM, V264, P6823; KATE M, 1972, TECHNIQUES LIPIDOLOG, P381; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KUHN H, 1990, J BIOL CHEM, V265, P16300; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; LANDS WEM, 1968, BIOCHIM BIOPHYS ACTA, V164, P426, DOI 10.1016/0005-2760(68)90168-9; LANDS WEM, 1973, ADV BIOSCI, V9, P15; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MORITA I, 1993, J BIOL CHEM, V258, P10197; MURPHY RC, 1993, HDB LIPIDS, V7, P173; MUTSAERS JHGM, 1985, EUR J BIOCHEM, V147, P569; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NUGTEREN DH, 1970, BIOCHIM BIOPHYS ACTA, V210, P171, DOI 10.1016/0005-2760(70)90072-X; OHKI S, 1979, J BIOL CHEM, V254, P829; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; OTTO JC, 1993, J BIOL CHEM, V268, P18234; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; PERCIVAL MD, 1994, ARCH BIOCHEM BIOPHYS, V315, P111, DOI 10.1006/abbi.1994.1478; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PILBEAM CC, 1993, J BIOL CHEM, V268, P25643; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; SALMON JA, 1982, METHOD ENZYMOL, V86, P477; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SMITH WL, 1994, MET IONS BIOL SYST, V30, P163; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WILLIS AL, 1987, CRC HDB EICOSANOIDS, P3; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; [No title captured]	69	207	209	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19330	19336		10.1074/jbc.270.33.19330	http://dx.doi.org/10.1074/jbc.270.33.19330			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642610	hybrid			2022-12-25	WOS:A1995RP70300024
J	OHNISHI, J; KIHARA, T; HAMABATA, T; TAKAHASHI, K; TAKAHASHI, T				OHNISHI, J; KIHARA, T; HAMABATA, T; TAKAHASHI, K; TAKAHASHI, T			CLEAVAGE SPECIFICITY OF PORCINE FOLLIPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA KALLIKREIN; TISSUE PLASMINOGEN-ACTIVATOR; FOLLICULAR PLASMINOGEN; FUNCTIONAL-PROPERTIES; RAT OVARY; OVULATION; PROTEINS; CLONING; PURIFICATION; EXPRESSION	Follipsin purified from the follicular fluid of porcine ovaries was studied for its specificity against various synthetic and peptide substrates. The enzyme cleaved only by an endopeptidase activity at the amide and peptide bonds of Arg-X, indicating strict specificity of the S-1 pocket for arginine. The specificity for pocket S-2 appears to favor either hydrophobic or basic side chains. A 10-residue peptide containing a portion of the activation site of human tissue plasminogen activator was synthesized and tested with the enzyme, The peptide was cleaved by follipsin at the Arg-Ile bond, as expected from the specificity deduced above. Furthermore, the enzyme successfully converted single-chain precursor tissue plasminogen activator (sctPA) to its active, two-chain form by cleaving the corresponding peptide bond, Comparison of the rates of single-chain precursor tissue plasminogen activator activation and tissue plasminogen activator peptide hydrolysis revealed that the former is a more efficient substrate than the latter.	HOKKAIDO UNIV, GRAD SCH SCI, DIV BIOL SCI, SAPPORO, HOKKAIDO 060, JAPAN; UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	Hokkaido University; University of Tokyo								ANDREASEN PA, 1984, EMBO J, V3, P51, DOI 10.1002/j.1460-2075.1984.tb01760.x; BEERS WH, 1975, CELL, V6, P387, DOI 10.1016/0092-8674(75)90188-9; BEERS WH, 1975, CELL, V6, P379, DOI 10.1016/0092-8674(75)90187-7; CANIPARI R, 1985, J BIOL CHEM, V260, P5121; COLMAN RW, 1985, BLOOD, V65, P311; ESPEY LL, 1965, AM J PHYSIOL, V208, P208, DOI 10.1152/ajplegacy.1965.208.1.208; ESPEY LL, 1967, AM J PHYSIOL, V212, P1397, DOI 10.1152/ajplegacy.1967.212.6.1397; HAMABATA T, 1994, J BIOL CHEM, V269, P17899; HIRSHFIELD AN, 1991, INT REV CYTOL, V124, P43, DOI 10.1016/s0074-7696(08)61524-7; ICHINOSE A, 1984, FEBS LETT, V175, P412, DOI 10.1016/0014-5793(84)80779-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LIU YX, 1991, EUR J BIOCHEM, V195, P549, DOI 10.1111/j.1432-1033.1991.tb15736.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILWIDSKY A, 1989, FERTIL STERIL, V52, P274; NY T, 1988, DNA-J MOLEC CELL BIO, V7, P671, DOI 10.1089/dna.1988.7.671; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; REICH R, 1985, ENDOCRINOLOGY, V116, P516, DOI 10.1210/endo-116-2-516; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; Rondell P., 1970, Biol. Reprod., V2, P64, DOI 10.1095/biolreprod2.Supplement_2.64; SCHAPIRA M, 1982, J CLIN INVEST, V69, P1199, DOI 10.1172/JCI110557; Schochet SS, 1916, ANAT REC, V10, P447, DOI 10.1002/ar.1090100605; TAIT JF, 1987, J BIOL CHEM, V262, P11651; TAKAHASHI T, 1992, ZOOL SCI, V9, P343; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAFRIRI A, 1989, ENDOCRINOLOGY, V124, P415, DOI 10.1210/endo-124-1-415; VANDERGRAAF F, 1982, J BIOL CHEM, V257, P4300; WALLEN P, 1983, EUR J BIOCHEM, V132, P681, DOI 10.1111/j.1432-1033.1983.tb07418.x	28	9	9	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19391	19394		10.1074/jbc.270.33.19391	http://dx.doi.org/10.1074/jbc.270.33.19391			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642619	hybrid			2022-12-25	WOS:A1995RP70300033
J	BURGESS, TL; ROSS, SL; QIAN, YX; BRANKOW, D; HU, S				BURGESS, TL; ROSS, SL; QIAN, YX; BRANKOW, D; HU, S			BIOSYNTHETIC PROCESSING OF NEU DIFFERENTIATION FACTOR - GLYCOSYLATION, TRAFFICKING, AND REGULATED CLEAVAGE FROM THE CELL-SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-INDUCING ACTIVITY; GLIAL GROWTH-FACTOR; TGF-ALPHA; ACETYLCHOLINE-RECEPTOR; KIT-LIGAND; TRANSMEMBRANE; EXPRESSION; PROTEIN; GENE; AMPLIFICATION	neu differentiation factor (NDF), also known as heregulin, is structurally related to the epidermal growth factor family of growth factors; it stimulates tyrosine phosphorylation of the neu/HER-2 oncogene and causes differentiation of certain human breast cancer cell lines, Alternative splicing of a single gene gives rise to multiple isoforms of NDF/heregulin, as well as the neuronal homologues, designated ARIA (acetylcholine receptor inducing activity) and GGF (glial growth factor); at least 15 structural variants are known. All but two of the NDF/heregulin cDNAs are predicted to encode transmembrane, glycosylated precursors of soluble NDF. In this report we characterized the biosynthetic processing of different NDF isoforms in stably transfected Chinese hamster ovary cells expressing individual NDF isoforms, and in the native cell line Rat 1-EJ, which expresses at least six different NDF isoforms. We found that the precursors for NDF undergo typical glycosyIation and trafficking. A portion of the molecules are proteolyticafly cleaved intracellularly leading to the constitutive secretion of soluble, mature NDF into the culture media, However, a significant portion of the newly synthesized NDF precursor molecules escape intracellufar cleavage and are transported to the cell surface of both transfected and native cells, where they reside as fulllength, transmembrane proteins. Finally we show that these full-length, transmembrane NDF molecules can undergo phorbol ester regulated cleavage from the membrane, releasing the soluble growth factor into the medium.			BURGESS, TL (corresponding author), AMGEN INC,DEPT MAMMALIAN CELL MOLEC BIOL,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.							BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; BERGER MS, 1988, CANCER RES, V48, P1238; Bosenberg MW, 1993, CURR OPIN CELL BIOL, V5, P832, DOI 10.1016/0955-0674(93)90032-L; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; BURGESS TL, 1985, J CELL BIOL, V101, P639, DOI 10.1083/jcb.101.2.639; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CORFAS G, 1993, J NEUROSCI, V13, P2118; DANILENKO DM, 1995, J CLIN INVEST, V95, P842, DOI 10.1172/JCI117734; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GOODEARL ADJ, 1993, J BIOL CHEM, V268, P18095; HAFEN E, 1994, PROG NEUROBIOL, V42, P287, DOI 10.1016/0301-0082(94)90067-1; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; KAUFMAN RJ, 1982, J MOL BIOL, V159, P601, DOI 10.1016/0022-2836(82)90103-6; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMKE GE, 1984, J NEUROSCI, V4, P75; LU HS, 1995, IN PRESS J BIOL CHEM; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TOKSOZ D, 1992, P NATL ACAD SCI USA, V89, P7350, DOI 10.1073/pnas.89.16.7350; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; Ullrich Axel, 1989, SCIENCE, V244, P707, DOI DOI 10.1126/SCIENCE.2470152; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; Woods D F, 1993, J Cell Sci Suppl, V17, P171; YAMAMOTO D, 1994, BIOESSAYS, V16, P237, DOI 10.1002/bies.950160406; YEOMAN LC, 1993, ONCOL RES, V5, P489	49	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	1995	270	32					19188	19196		10.1074/jbc.270.32.19188	http://dx.doi.org/10.1074/jbc.270.32.19188			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RN954	7642587				2022-12-25	WOS:A1995RN95400075
J	POU, S; BHAN, A; BHADTI, VS; WU, SY; HOSMANE, RS; ROSEN, GM				POU, S; BHAN, A; BHADTI, VS; WU, SY; HOSMANE, RS; ROSEN, GM			THE USE OF FLUOROPHORE-CONTAINING SPIN TRAPS AS POTENTIAL PROBES TO LOCALIZE FREE-RADICALS IN CELLS WITH FLUORESCENCE IMAGING METHODS	FASEB JOURNAL			English	Article						HYDROXYL RADICAL; SPIN TRAPS	BIOLOGICAL-SYSTEMS; TRAPPING EVIDENCE; SUPEROXIDE; HYDROXYL	Central to the study of free radical processes is the ability to identify and localize their cellular site of formation. Under the best of experimental conditions, spin trapping/ESR spectroscopy can only characterize intracellular production of specific free radicals and confocal microscopy can only localize the site of their formation. In this article, we report on the development of a fluorophore-containing nitrone, alpha-[4-[5-((2-carboxy)phenyl)-5-hydroxy-4-oxo-3-phenyl)-2-pyrrolin-1-yl]phenyl]-N-(tert-butyl)nitrone sodium salt (4).(3) This nitrone (4) reacts with alpha-hydroxyethyl radical with a second order rate constant of 1.7 x 10(5) M(-1) s(-1) to give a characteristic ESR spectrum. However, we were unable to decrease the fluorescence emission, due in part to the small concentration of nitroxide generated from the reaction of alpha-hydroxyethyl radical with nitrone (4). Using the fluorophore-containing nitroxide (7) as a model, we found that only 12% of the nitroxide needs to be reduced to give an almost 400% increase in the fluorescent emission of (7). Our findings suggest new approaches to the development of various fluorophore-containing nitrones that can both characterize specific free radicals and localize their site of intracellular formation.	UNIV MARYLAND,SCH PHARM,DEPT PHARMACEUT SCI,BALTIMORE,MD 21201; UNIV MARYLAND BALTIMORE CTY,DEPT CHEM & BIOCHEM,CHEM DYNAM LAB,BALTIMORE,MD 21228; VET AFFAIRS MED CTR,BALTIMORE,MD	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore County; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NHLBI NIH HHS [HL-33550] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033550] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCHER SL, 1989, J APPL PHYSIOL, V66, P102, DOI 10.1152/jappl.1989.66.1.102; BLOUGH NV, 1987, J AM CHEM SOC, V110, P1915; BRITIGAN BE, 1990, J BIOL CHEM, V265, P2650; FINKELSTEIN E, 1979, MOL PHARMACOL, V16, P676; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; FINKELSTEIN E, 1985, ADV FREE RADICAL BIO, V1, P345; FOSKETT JK, 1990, NONINVASIVE TECHNIQU; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GERLOCK JL, 1990, FREE RADICAL RES COM, V10, P119, DOI 10.3109/10715769009145941; GREEN SA, 1990, J AM CHEM SOC, V112, P7337, DOI 10.1021/ja00176a038; JANZEN EG, 1971, ACCOUNTS CHEM RES, V4, P31, DOI 10.1021/ar50037a005; JANZEN EG, 1980, FREE RAD BIOL, P116; KIEBER DJ, 1990, FREE RADICAL RES COM, V10, P109, DOI 10.3109/10715769009145940; KUTHAN H, 1982, BIOCHEM J, V203, P551, DOI 10.1042/bj2030551; LEFER AM, 1993, ANNU REV PHARMACOL, V33, P71, DOI 10.1146/annurev.pa.33.040193.000443; MARRIOTT PR, 1980, CAN J CHEM, V58, P803, DOI 10.1139/v80-125; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; POU S, 1994, ANAL BIOCHEM, V217, P76, DOI 10.1006/abio.1994.1085; POU S, 1989, ANAL BIOCHEM, V177, P1, DOI 10.1016/0003-2697(89)90002-X; POYER JL, 1971, J BIOL CHEM, V246, P263; RAMOS CL, 1992, J BIOL CHEM, V267, P8307; SAMUNI A, 1989, FREE RADICAL BIO MED, V6, P141, DOI 10.1016/0891-5849(89)90111-1; TAYLOR DL, 1989, METHODS CELL BIOL, V30	23	24	24	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1995	9	11					1085	1090		10.1096/fasebj.9.11.7649408	http://dx.doi.org/10.1096/fasebj.9.11.7649408			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RP996	7649408				2022-12-25	WOS:A1995RP99600013
J	CHEN, YH; RIBY, J; SRIVASTAVA, P; BARTHOLOMEW, J; DENISON, M; BJELDANES, L				CHEN, YH; RIBY, J; SRIVASTAVA, P; BARTHOLOMEW, J; DENISON, M; BJELDANES, L			REGULATION OF CYP1A1 BY INDOLO[3,2-B]CARBAZOLE IN MURINE HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AH-RECEPTOR; RAT-LIVER; BINDING-SITES; HALF-LIFE; WILD-TYPE; INDUCTION; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; EXPRESSION; GENE; INDOLE-3-CARBINOL	To determine the basis for unexpected differences in CYP1A1 inducing potencies and efficacies for the diet-derived indole derivative, indolo[3,2-b]carbazole (ICZ) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), we conducted a systematic analysis of events involved in the induced expression of CYP1A1 in murine hepatoma-derived cell lines (Hepa-1), In contrast to the effects of TCDD, induction kinetics and CYP1A1 mRNA half-life were dependent on ICZ concentration, and the response from low doses of inducer was transient due to rapid clearance of ICZ, TCDD and ICZ produced the same maximum response (i.e. equal efficacies) from a TCDD-responsive CAT reporter construct in Hepa-1 cells, When measured by the immediate responses associated with CYP1A1 expression, including cellular uptake of inducer, receptor transformation and binding to DRE (gel mobility shift assay), initiation of transcription (nuclear run-on assay), and short-term accumulation of mRNA (Northern blot assay), ICZ also exhibited an efficacy equal to that of TCDD and a potency that corresponds to its receptor affinity, ICZ is a potent and selective noncompetitive inhibitor of ethoxyresorufin O-deethylase activity (K-i = 1.5 nM). Taken together these results indicate that ICZ is a bifunctional modulator of CYP1A1 expression with intrinsic efficacy equal to that of TCDD.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA; LAWRENCE LIVERMORE NATL LAB, DEPT ENVIRONM TOXICOL, DAVIS, CA 95616 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Livermore National Laboratory					NATIONAL CANCER INSTITUTE [R55CA049250] Funding Source: NIH RePORTER; NCI NIH HHS [CA49250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASTROFF B, 1989, TOXICOLOGY, V59, P285, DOI 10.1016/0300-483X(89)90198-4; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BJELDANES LF, 1991, P NATL ACAD SCI USA, V88, P9543, DOI 10.1073/pnas.88.21.9543; BURKE MD, 1974, DRUG METAB DISPOS, V2, P583; CAI YN, 1993, CHEM RES TOXICOL, V6, P872, DOI 10.1021/tx00036a018; CARVER LA, 1994, NUCLEIC ACIDS RES, V22, P3038; CHRISTOU M, 1990, CARCINOGENESIS, V11, P1691, DOI 10.1093/carcin/11.10.1691; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DARGY R, 1989, PHARMACOL TOXICOL, V64, P33, DOI 10.1111/j.1600-0773.1989.tb00596.x; DAUJAT M, 1991, EUR J BIOCHEM, V200, P501, DOI 10.1111/j.1432-1033.1991.tb16211.x; DEKRUIF CA, 1991, CHEM-BIOL INTERACT, V80, P303, DOI 10.1016/0009-2797(91)90090-T; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DURRIN LK, 1989, MOL CELL BIOL, V9, P5733, DOI 10.1128/MCB.9.12.5733; GATTI RA, 1984, BIOTECHNIQUES    MAY, P148; GILLNER M, 1985, MOL PHARMACOL, V28, P357; GILLNER M, 1993, MOL PHARMACOL, V44, P336; GROSE KR, 1992, CHEM RES TOXICOL, V5, P188, DOI 10.1021/tx00026a007; HANKINSON O, 1985, J BIOL CHEM, V260, P1790; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; ISRAEL DI, 1983, J BIOL CHEM, V258, P390; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; KLEMAN MI, 1994, J BIOL CHEM, V269, P5137; KWON CS, 1994, J AGR FOOD CHEM, V42, P2536, DOI 10.1021/jf00047a030; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; LESCA P, 1979, CHEM-BIOL INTERACT, V24, P189, DOI 10.1016/0009-2797(79)90007-3; LESCA P, 1978, BIOCHEM PHARMACOL, V27, P1203, DOI 10.1016/0006-2952(78)90453-7; LIU H, 1994, JNCI-J NATL CANCER I, V86, P1758, DOI 10.1093/jnci/86.23.1758; LUBET RA, 1985, ARCH BIOCHEM BIOPHYS, V238, P43, DOI 10.1016/0003-9861(85)90138-9; MCDANELL R, 1988, FOOD CHEM TOXICOL, V26, P59, DOI 10.1016/0278-6915(88)90042-7; MILLER AG, 1983, J BIOL CHEM, V258, P3523; MURRAY M, 1990, PHARMACOL REV, V42, P85; PASCO DS, 1988, J BIOL CHEM, V263, P8671; PESONEN M, 1991, XENOBIOTICA, V21, P461, DOI 10.3109/00498259109039486; RIDDICK DS, 1994, J BIOL CHEM, V269, P12118; ROBINSON B, 1963, J CHEM SOC, P3097, DOI 10.1039/jr9630003097; SABLE AD, 1989, CARCINOGENESIS, V10, P629; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIESS MH, 1990, FOOD ADDIT CONTAM, V7, pS178, DOI 10.1080/02652039009373876; SILVER G, 1988, J BIOL CHEM, V263, P11802; SPINK DC, 1992, ARCH BIOCHEM BIOPHYS, V293, P342, DOI 10.1016/0003-9861(92)90404-K; TAKAHASHI N, 1995, FOOD CHEM TOXICOL, V33, P111, DOI 10.1016/0278-6915(94)00117-7; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITLOCK JP, 1989, MOL BIOL MED, V6, P169; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; XU LC, 1990, BIOCHEM PHARMACOL, V40, P1399; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019	49	83	84	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22548	22555		10.1074/jbc.270.38.22548	http://dx.doi.org/10.1074/jbc.270.38.22548			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673247	hybrid			2022-12-25	WOS:A1995RW31400076
J	KODURI, RS; TIEN, M				KODURI, RS; TIEN, M			OXIDATION OF GUAIACOL BY LIGNIN PEROXIDASE - ROLE OF VERATRYL ALCOHOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM; DEGRADING BASIDIOMYCETE; MANGANESE PEROXIDASE; HYDROGEN-PEROXIDE; COMPOUND-III; DECOMPOSITION; MECHANISM; ENZYME; BIODEGRADATION; BURDS	We have investigated the Lignin peroxidase-catalyzed oxidation of guaiacol and the role of veratryl alcohol in this reaction by steady-state and pre-steady-state methods. Pre-steady-state kinetic analyses demonstrated that guaiacol is a good substrate for both compounds I and II, the two- and one-electron oxidized enzyme intermediates, respectively, of Lignin peroxidase. The rate constant for the reaction with compound I is 1.2 x 10(6) M(-1) s(-1). The reaction of guaiacol with compound II exhibits a K-d of 64 mu M and a first-order rate constant of 17 s(-1). Oxridation of guaiacol leads to tetraguaiacol formation. This reaction exhibits classical Michaelis-Menten kinetics with a K-m of 160 mu M and a k(cat) of 7.7 s(-1). Veratryl alcohol, a secondary metabolite of ligninolytic fungi, is capable of mediating the oxidation of guaiacol. This was shown by steady-state inhibition studies. Guaiacol completely inhibited the oxidation of veratryl alcohol, whereas veratryl alcohol had no corresponding inhibitory effect on guaiacol oxidation, In fact, at low guaiacol concentrations, veratryl alcohol stimulated the rate of guaiacol oxidation. These results collectively demonstrate that veratryl alcohol can serve as a mediator for phenolic substrates in the lignin peroxidase reaction.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, CTR BIOMOLEC STRUCT & FUNCT, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIEHS NIH HHS [1-P42ES04922-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004922] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARR DP, 1994, ARCH BIOCHEM BIOPHYS, V312, P511, DOI 10.1006/abbi.1994.1339; BARR DP, 1994, ARCH BIOCHEM BIOPHYS, V311, P378, DOI 10.1006/abbi.1994.1251; CAI DY, 1992, J BIOL CHEM, V267, P11149; CANCEL AM, 1993, APPL ENVIRON MICROB, V59, P2909, DOI 10.1128/AEM.59.9.2909-2913.1993; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P416, DOI 10.1016/0003-9861(52)90470-0; CHANCE B, 1955, METHOD ENZYMOL, V2, P764, DOI 10.1016/S0076-6879(55)02300-8; Cleland W W, 1979, Methods Enzymol, V63, P103; GLENN JK, 1983, BIOCHEM BIOPH RES CO, V114, P1077, DOI 10.1016/0006-291X(83)90672-1; HAEMMERLI SD, 1987, FEBS LETT, V220, P149, DOI 10.1016/0014-5793(87)80893-1; HARVEY PJ, 1986, FEBS LETT, V195, P242, DOI 10.1016/0014-5793(86)80168-5; HARVEY PJ, 1990, J BIOTECHNOL, V13, P169, DOI 10.1016/0168-1656(90)90102-H; KHINDARIA A, 1995, BIOCHEMISTRY-US, V34, P6020, DOI 10.1021/bi00018a003; KIRK TK, 1986, BIOCHEM J, V236, P279, DOI 10.1042/bj2360279; KIRK TK, 1986, ENZYME MICROB TECH, V8, P27, DOI 10.1016/0141-0229(86)90006-2; KODURI RS, 1994, BIOCHEMISTRY-US, V33, P4225, DOI 10.1021/bi00180a016; KUAN IC, 1993, J BIOL CHEM, V268, P20064; LUNDQUIST K, 1978, PHYTOCHEMISTRY, V17, P1676, DOI 10.1016/S0031-9422(00)94674-0; Maehly AC, 1954, METHOD BIOCHEM ANAL, P358; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; PASZCZYNSKI A, 1986, ARCH BIOCHEM BIOPHYS, V244, P750, DOI 10.1016/0003-9861(86)90644-2; RENGANATHAN V, 1986, BIOCHEMISTRY-US, V25, P1626, DOI 10.1021/bi00355a027; SANTIMONE M, 1974, CR ACAD SCI D NAT, V279, P951; Segel, 1975, ENZYME KINETICS BEHA, P274; TIEN M, 1986, J BIOL CHEM, V261, P1687; TIEN M, 1983, SCIENCE, V221, P661, DOI 10.1126/science.221.4611.661; TIEN M, 1988, METHOD ENZYMOL, V161, P238; TONON F, 1988, APPL ENVIRON MICROB, V54, P466, DOI 10.1128/AEM.54.2.466-472.1988; VALLI K, 1990, BIOCHEMISTRY-US, V29, P8535, DOI 10.1021/bi00489a005; WARIISHI H, 1990, J BIOL CHEM, V265, P2070; WARIISHI H, 1989, J BIOL CHEM, V264, P3335; WARIISHI H, 1989, FEBS LETT, V243, P165, DOI 10.1016/0014-5793(89)80122-X	31	99	98	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22254	22258		10.1074/jbc.270.38.22254	http://dx.doi.org/10.1074/jbc.270.38.22254			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673205	hybrid			2022-12-25	WOS:A1995RW31400031
J	VANTHOF, R; DEKRUIJFF, B				VANTHOF, R; DEKRUIJFF, B			CHARACTERIZATION OF THE IMPORT PROCESS OF A TRANSIT PEPTIDE INTO CHLOROPLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER ENVELOPE MEMBRANE; PROTEIN IMPORT; SMALL SUBUNIT; FERREDOXIN PRECURSOR; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; SECONDARY STRUCTURE; INVITRO SYNTHESIS; TRANSPORT; BINDING; TRANSLOCATION	In order to get insight into the functioning of transit sequences in chloroplast protein transport, the import of the full-length transit peptide of ferredoxin (trfd) was investigated. trfd rapidly associated with chloroplasts under import conditions and becomes protected against externally added proteases. Import of radiolabeled trfd is inhibited equally efficiently by nonlabeled trfd as well as by the intact precursor of ferredoxin. This strongly suggests that trfd enters the general import pathway of proteins into chloroplasts. trfd import was stimulated by ATP, which is the first demonstration that ATP is involved in membrane translocation of a targeting signal. Imported trfd was membrane-associated but was also partially degraded by internal proteases, most likely present in the stroma, indicating that the membrane-associated fraction of trfd is en route to its functional localization. The degradation products are exported out of the organelle. In contrast to the import of the precursor of ferredoxin, the import of trfd was independent of protease-sensitive components on the chloroplast surface, indicating that the initial binding of precursor proteins may be facilitated by transit sequence-lipid interactions.	UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,INST BIOMEMBRANES,DEPT BIOCHEM MEMBRANES,3584 CH UTRECHT,NETHERLANDS	Utrecht University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULYCHEV A, 1994, FEBS LETT, V356, P204, DOI 10.1016/0014-5793(94)01259-8; CHUPIN V, 1994, FEBS LETT, V350, P104, DOI 10.1016/0014-5793(94)00734-9; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; CORNWELL KL, 1987, PLANT PHYSIOL, V85, P780, DOI 10.1104/pp.85.3.780; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DOBBERSTEIN B, 1977, P NATL ACAD SCI USA, V74, P1082, DOI 10.1073/pnas.74.3.1082; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; FLUGGE UI, 1990, J BIOENERG BIOMEMBR, V22, P769; FRIEDMAN AL, 1989, PLANT PHYSIOL, V89, P993, DOI 10.1104/pp.89.3.993; GASSER SM, 1982, ARCH BIOCHEM BIOPHYS, V277, P368; GUERA A, 1993, PLANT MOL BIOL, V23, P309, DOI 10.1007/BF00029007; HORNIAK L, 1993, FEBS LETT, V334, P241, DOI 10.1016/0014-5793(93)81720-K; HUISMAN JG, 1978, BIOCHEM BIOPH RES CO, V82, P1121, DOI 10.1016/0006-291X(78)90303-0; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; PFISTERER J, 1982, EUR J BIOCHEM, V126, P143, DOI 10.1111/j.1432-1033.1982.tb06758.x; PILON M, 1992, FEBS LETT, V302, P65, DOI 10.1016/0014-5793(92)80286-P; PILON M, 1990, J BIOL CHEM, V265, P3358; PILON M, 1992, J BIOL CHEM, V267, P2548; PILON M, 1992, J BIOL CHEM, V267, P19907; PILON M, 1995, J BIOL CHEM, V270, P3882, DOI 10.1074/jbc.270.8.3882; REIS B, 1978, MOL GEN GENET, V209, P116; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SMEEKENS J, 1989, MOL GEN GENET, V261, P178; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1987, PLANT MOL BIOL, V9, P377, DOI 10.1007/BF00014912; SMEEKENS S, 1985, NUCLEIC ACIDS RES, V13, P3179, DOI 10.1093/nar/13.9.3179; SMITH SM, 1979, NATURE, V278, P662, DOI 10.1038/278662a0; THEG SM, 1989, J BIOL CHEM, V264, P6730; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VANTHOF R, 1995, FEBS LETT, V361, P35, DOI 10.1016/0014-5793(95)00135-V; VANTHOF R, 1993, J BIOL CHEM, V268, P4037; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1991, FEBS LETT, V278, P3335; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WU CB, 1993, J BIOL CHEM, V268, P19384	52	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22368	22373		10.1074/jbc.270.38.22368	http://dx.doi.org/10.1074/jbc.270.38.22368			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673221	hybrid			2022-12-25	WOS:A1995RW31400048
J	DOMANSKI, P; WITTE, M; KELLUM, M; RUBINSTEIN, M; HACKETT, R; PITHA, P; COLAMONICI, OR				DOMANSKI, P; WITTE, M; KELLUM, M; RUBINSTEIN, M; HACKETT, R; PITHA, P; COLAMONICI, OR			CLONING AND EXPRESSION OF A LONG FORM OF THE BETA-SUBUNIT OF THE INTERFERON ALPHA-BETA RECEPTOR THAT IS REQUIRED FOR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CELLS	The interferon alpha beta receptor (IFN alpha R) or type I IFN-R is formed by a 110-kDa alpha subunit or IFNAR and by a beta subunit, which has short and long forms (molecular masses of 55 and 95-100 kDa, respectively). In this report, we demonstrate that the IFN alpha/beta R cDNA recently cloned corresponds to the 55-kDa or short form of the beta subunit, while the 95-100-kDa species reported here corresponds to a longer form of the IFN alpha/beta R cDNA that is probably produced by alternative splicing of the same gene. Stable transfection of the alpha subunit with either form of the beta subunit results in the expression of low and high affinity receptors, while expression of either form of the beta subunit alone only produces low affinity receptors. More important, only expression of the alpha and long form of the human beta subunits in mouse L-929 cells reconstitutes the activation of the Jak kinases and the Stat factors, as well as the antiviral response to human type I IFNs.	UNIV TENNESSEE,DEPT PATHOL,MEMPHIS,TN 38163; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21287; WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL; US FDA,BETHESDA,MD 20892	University of Tennessee System; University of Tennessee Health Science Center; Johns Hopkins University; Weizmann Institute of Science; US Food & Drug Administration (FDA)					NCI NIH HHS [CA55079] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055079] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1995, J BIOL CHEM, V270, P8188, DOI 10.1074/jbc.270.14.8188; COLAMONICI OR, 1994, J BIOL CHEM, V269, P9598; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1994, J BIOL CHEM, V269, P27275; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEVY DE, 1989, GENE DEV, V3, P1203; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PETRICOIN EF, 1992, MOL CELL BIOL, V12, P4486, DOI 10.1128/MCB.12.10.4486; PLATANIAS LC, 1993, J IMMUNOL, V150, P3226; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964	23	234	244	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21606	21611		10.1074/jbc.270.37.21606	http://dx.doi.org/10.1074/jbc.270.37.21606			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665574	hybrid			2022-12-25	WOS:A1995RU75700030
J	EKBERG, K; CHANDRAMOULI, V; KUMARAN, K; SCHUMANN, WC; WAHREN, J; LANDAU, BR				EKBERG, K; CHANDRAMOULI, V; KUMARAN, K; SCHUMANN, WC; WAHREN, J; LANDAU, BR			GLUCONEOGENESIS AND GLUCURONIDATION IN LIVER IN-VIVO AND THE HETEROGENEITY OF HEPATOCYTE FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							60-HOUR FASTED HUMANS; METABOLISM; FRUCTOSE	In order to examine metabolic zonation in human liver, [2-C-14]glycerol, which labels carbons 2 and 5 of glucose-6-P, and [1-C-14]lactate, which labels carbons 3 and 4 of glucose-6-P, in the process of gluconeogenesis, were infused intravenously into healthy subjects who ingested acetaminophen and had fasted 36 h. Distributions of C-14 were determined in glucose in blood and in the glucuronic acid moiety of acetaminophen glucuronide excreted in urine. Ratios of C-14 in carbons 2 and 5 to C-14 in carbons 3 and 4 were significantly higher in blood glucose than in glucuronide. Since glucose and glucuronic acid are formed from glucose-6-P in liver without randomization of carbon, the differences in the ratios indicate that the pool of glucose-6-P in liver is not homogeneous. The glucuronide sampled glucose-6-P with more label from lactate than glycerol compared to the glucose-6-P sampled by the glucose. The apparent explanation is the greater decrease in glycerol compared with lactate concentration as blood streams from the periportal to the perivenous zones of the liver lobule. Glucuronidation is then expressed in humans relatively more in the perivenous than periportal zones and gluconeogenesis from glycerol more in the periportal than perivenous zones.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106; KAROLINSKA HOSP,DEPT CLIN PHYSIOL,S-17671 STOCKHOLM,SWEDEN	Case Western Reserve University; Case Western Reserve University; Karolinska Institutet; Karolinska University Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK014507, R01DK014507] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 14507] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BJORKMAN O, 1980, DIABETES, V29, P610, DOI 10.2337/diab.29.8.610; BJORKMAN O, 1982, DIABETES, V31, P516, DOI 10.2337/diabetes.31.6.516; CERSOSIMO E, 1994, J CLIN INVEST, V93, P2584, DOI 10.1172/JCI117270; Dutton G. J., 1980, GLUCURONIDATION DRUG, P149; HOSTETLER KY, 1969, J BIOL CHEM, V244, P2075; JUNGERMANN K, 1989, PHYSIOL REV, V69, P703; LANDAU BR, 1993, AM J PHYSIOL, V265, pE636, DOI 10.1152/ajpendo.1993.265.4.E636; LANDAU BR, 1995, AM J PHYSIOL-ENDOC M, V269, pE18, DOI 10.1152/ajpendo.1995.269.1.E18; MAGNUSSON I, 1988, P NATL ACAD SCI USA, V85, P4682, DOI 10.1073/pnas.85.13.4682; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; NEESE RA, 1995, J BIOL CHEM, V270, P14452, DOI 10.1074/jbc.270.24.14452; SNEDECOR GW, 1980, STATISTICAL METHODS, P54; WAHREN J, 1977, J CLIN INVEST, V59, P299, DOI 10.1172/JCI108641; WALS PA, 1988, J BIOL CHEM, V263, P4876	14	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21715	21717		10.1074/jbc.270.37.21715	http://dx.doi.org/10.1074/jbc.270.37.21715			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665589	hybrid			2022-12-25	WOS:A1995RU75700047
J	JACKSON, SM; ERICSSON, J; OSBORNE, TF; EDWARDS, PA				JACKSON, SM; ERICSSON, J; OSBORNE, TF; EDWARDS, PA			NF-Y HAS A NOVEL ROLE IN STEROL-DEPENDENT TRANSCRIPTION OF 2 CHOLESTEROGENIC GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LIPOPROTEIN RECEPTOR PROMOTER; MHC CLASS-II; REGULATORY ELEMENT; NUCLEAR-PROTEIN; BINDING; REDUCTASE; SEQUENCE; CLONING	The transcription of farnesyl diphosphate (FPP) synthase is regulated up to 30-fold by the sterol status of the cell. Point mutations in a 6-base pair ATTGGC sequence in the promoter disrupt both sterol-dependent transcription in vivo as well as binding of the transcription factor NF-Y in vitro. Co-transfection of cells with NF YA29, a dominant negative form of NF-Y, and various promoter-reporter genes specifically inhibits the sterol-dependent regulation of FPP synthase and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase. In contrast, NP-YA29 does not affect the regulation of reporter genes under the control of promoters derived from either the HMG-CoA reductase or the low density lipoprotein receptor gene. Transient expression of the 68 kDa transcriptionally active fragment of sterol regulatory element-binding protein in cells stimulates an HMG-CoA synthase-reporter gene over 90-fold. This induction is blocked in cells eo expressing NF-YA29. We hypothesize that NF-Y plays a novel role in sterol-de pendent regulation of two key genes in the cholesterol biosynthetic pathway and that this role requires a specific interaction with the sterol regulatory element-binding protein or related transcription factors.	UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Irvine			Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574	NHLBI NIH HHS [HL48044, HL 30568] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044, P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KIM JB, 1995, MOL CELL BIOL, V15, P2582; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; SPEAR DH, 1994, J BIOL CHEM, V269, P25212; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TRONCHE F, 1991, J MOL BIOL, V221, P31; VALLETT SM, 1994, NUCLEIC ACIDS RES, V22, P5184, DOI 10.1093/nar/22.24.5184; WANG XD, 1993, J BIOL CHEM, V268, P14497; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102	26	105	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21445	21448		10.1074/jbc.270.37.21445	http://dx.doi.org/10.1074/jbc.270.37.21445			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665553	hybrid			2022-12-25	WOS:A1995RU75700005
J	AKOMPONG, T; INMAN, RS; WESSLINGRESNICK, M				AKOMPONG, T; INMAN, RS; WESSLINGRESNICK, M			PHORBOL ESTERS STIMULATE NON-TRANSFERRIN IRON UPTAKE BY K562 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-CELLS; BOUND IRON; DIFFERENTIATION; TRANSPORT; RECEPTORS; RETICULOCYTES; INDUCTION; BINDING; SYSTEM; LINE	Characterization of non-transferrin (non-Tf) iron transport by K562 cells has revealed unique properties relative to iron uptake mechanisms present in other cell types (Inman, R. S., and Wessling-Resnick, M, (1993) J, Biol, Chem, 268, 8521-8528). Since treatment of K562 cells with phorbol esters promotes stable megakaryocytic differentiation, we examined the uptake of non-Tf iron in response to protein kinase C activation, Treatment of K562 cells with phorbol esters increased the cellular uptake of Fe-56 4-6-fold compared with untreated cells. The phorbol ester-induced stimulation of Fe-55 uptake was time and dose-dependent, with significantly enhanced transport observed only after prolonged administration of 50 nM phorbol 12,13-dibutyrate (> 8 h). These effects can be attributed to an increased V-max of transport (14.0 +/- 5 versus 0.6 +/- 0.2 pmol/min/10(6) cells) as well as a 6-fold increase in the apparent K-m (1.2 +/- 0.4 versus 0.2 +/- 0.06 mu M) It is thought that the reduction of Fe3+ to Fe2+ is required as a first step in the uptake mechanism, and the associated ferrireductase activity of K562 cells is also enhanced with phorbol ester treatment by 5-10-fold (337 +/- 53 versus 43 +/- 3 pmol/min/10(6) cells), Bryostatin-1, a protein kinase C activator that fails to induce differentiation of K562 cells, did not promote this effect, indicating that the enhanced transport activity is dependent on the differentiation response, The idea that synthesis of a new class of transporters is responsible for this effect is supported by the observation that actinomycin D blocks up-regulation of non-Tf iron transport. The increased transport and ferrireductase activity induced upon differentiation also correlate with the appearance of saturable iron-binding sites on the surface of K562 cells with K-d similar to 0.4 mu M. These results indicate that non-Tf iron transport activity and the expression of cell surface iron-binding proteins can be controlled by environmental factors that promote megakaryocytic differentiation of K562 cells.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T35DK095737] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK95737] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRON M, 1963, ANAL BIOCHEM, V6, P549, DOI 10.1016/0003-2697(63)90149-0; BARISANI D, 1995, IN PRESS AM J PHYSL; BASSET P, 1986, CANCER RES, V46, P1644; CONRAD ME, 1994, J BIOL CHEM, V269, P7169; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; HO PTC, 1989, CANCER RES, V49, P1989; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HU HYY, 1977, SCIENCE, V197, P559, DOI 10.1126/science.267327; INMAN RS, 1993, J BIOL CHEM, V268, P8521; INMAN RS, 1994, BIOCHEMISTRY-US, V33, P11850, DOI 10.1021/bi00205a022; JORDAN I, 1994, BIOCHEM J, V302, P875, DOI 10.1042/bj3020875; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; KLAUSNER RD, 1984, P NATL ACAD SCI-BIOL, V81, P3005, DOI 10.1073/pnas.81.10.3005; MAY WS, 1984, P NATL ACAD SCI-BIOL, V81, P2016, DOI 10.1073/pnas.81.7.2016; MORGAN EH, 1988, BIOCHIM BIOPHYS ACTA, V943, P428, DOI 10.1016/0005-2736(88)90374-4; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; QIAN ZM, 1991, BIOCHIM BIOPHYS ACTA, V1073, P456, DOI 10.1016/0304-4165(91)90215-3; RANDELL EW, 1994, J BIOL CHEM, V269, P16046; ROVERA G, 1982, ANN NY ACAD SCI, V397, P211, DOI 10.1111/j.1749-6632.1982.tb43428.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHONHORN JE, 1995, J BIOL CHEM, V270, P3698, DOI 10.1074/jbc.270.8.3698; STURROCK A, 1990, J BIOL CHEM, V265, P3139; TEI I, 1982, BIOCHEM BIOPH RES CO, V107, P1419, DOI 10.1016/S0006-291X(82)80157-5; TESTA U, 1984, CANCER RES, V44, P4981; TESTA U, 1982, EXP CELL RES, V140, P251, DOI 10.1016/0014-4827(82)90112-4; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; YEH CJG, 1982, EXP CELL RES, V138, P429, DOI 10.1016/0014-4827(82)90192-6	27	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20937	20941		10.1074/jbc.270.36.20937	http://dx.doi.org/10.1074/jbc.270.36.20937			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673117	hybrid			2022-12-25	WOS:A1995RU05400014
J	THOMMES, P; FARR, CL; MARTON, RF; KAGUNI, LS; COTTERILL, S				THOMMES, P; FARR, CL; MARTON, RF; KAGUNI, LS; COTTERILL, S			MITOCHONDRIAL SINGLE-STRANDED DNA-BINDING PROTEIN FROM DROSOPHILA EMBRYOS - PHYSICAL AND BIOCHEMICAL-CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS; REPLICATION; POLYMERASE; SSB; PURIFICATION; COMPLEXES; CLONING	Using a stringent purification procedure on single-stranded DNA cellulose, we have isolated the mitochondrial single-stranded DNA-binding protein from Drosophila melanogaster embryos. Its identity is demonstrated by amino-terminal sequencing of the homogeneous protein and by its localization to a mitochondrial protein fraction. The mitochondrial protein is immunologically and biochemically distinct from the previously characterized nuclear replication protein A from Drosophila (Mitsis, P. G., Kowalczykowski, S. C., and Lehman, I. R. (1993) Biochemistry 32, 5257-5266; Marton, R. F., Thommes, P., and Cotterill, S. (1994) FEES Lett. 342, 139-144). It consists of a single polypeptide of 18 kDa, which is responsible for the DNA binding activity. Sedimentation analysis suggests that D. melanogaster mitochondrial single stranded DNA-binding protein exists as a homo-oligomer, possibly a tetramer, in solution. The protein binds to DNA in its single-stranded form with a strong preference over double-stranded DNA or RNG and binds to polypyrimidines preferentially over polypurines. Drosophila mitochondrial single-stranded DNA-binding protein exhibits a greater affinity for long oligonucleotides as compared to short ones, yet does not show high cooperativity. Its binding site size, determined by competition studies and by fluorescence quenching, is approximately 17 nucleotides under low salt conditions, and increases in the presence of greater than 150 mM NaCl. The homogeneous protein stimulates the activity of mitochondrial DNA polymerase from D. melanogaster embryos, increasing dramatically the rate of initiation of DNA synthesis on a singly primed DNA template.	MARIE CURIE RES INST,OXTED,SURREY RH8 0TL,ENGLAND; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bradford MM, 1976, ANAL BIOCHEM, V142, P79; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; COX MM, 1982, J BIOL CHEM, V257, P8523; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; GENUARIO R, 1993, CELL MOL BIOL RES, V39, P625; GHRIR R, 1991, ARCH BIOCHEM BIOPHYS, V291, P395, DOI 10.1016/0003-9861(91)90152-9; HOKE GD, 1990, ARCH BIOCHEM BIOPHYS, V282, P116, DOI 10.1016/0003-9861(90)90094-F; KAGUNI J, 1979, J MOL BIOL, V135, P863, DOI 10.1016/0022-2836(79)90516-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMAN TM, 1986, J MOL BIOL, V187, P603, DOI 10.1016/0022-2836(86)90338-4; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MARTON RF, 1994, FEBS LETT, V342, P139, DOI 10.1016/0014-5793(94)80488-5; MEYER RR, 1990, MICROBIOL REV, V54, pP53; MIGNOTTE B, 1985, NUCLEIC ACIDS RES, V13, P1703, DOI 10.1093/nar/13.5.1703; MIGNOTTE B, 1988, EUR J BIOCHEM, V174, P479, DOI 10.1111/j.1432-1033.1988.tb14123.x; PAVCO PA, 1985, J CELL BIOL, V100, P258, DOI 10.1083/jcb.100.1.258; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1981, P NATL ACAD SCI-BIOL, V78, P4274, DOI 10.1073/pnas.78.7.4274; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; THOMMES P, 1993, FEBS LETT, V319, P95, DOI 10.1016/0014-5793(93)80044-U; TIRANTI V, 1991, NUCLEIC ACIDS RES, V19, P4291, DOI 10.1093/nar/19.15.4291; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; VANTUYLE GC, 1985, J CELL BIOL, V100, P251, DOI 10.1083/jcb.100.1.251; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WILLIAMS AJ, 1993, J BIOL CHEM, V268, P24855; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860	28	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21137	21143		10.1074/jbc.270.36.21137	http://dx.doi.org/10.1074/jbc.270.36.21137			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673145	hybrid			2022-12-25	WOS:A1995RU05400044
J	BOUKAMP, P; PETER, W; PASCHEBERG, U; ALTMEIER, S; FASCHING, C; STANBRIDGE, EJ; FUSENIG, NE				BOUKAMP, P; PETER, W; PASCHEBERG, U; ALTMEIER, S; FASCHING, C; STANBRIDGE, EJ; FUSENIG, NE			STEP-WISE PROGRESSION IN HUMAN SKIN CARCINOGENESIS IN-VITRO INVOLVES MUTATIONAL INACTIVATION OF P53, RAS(H) ONCOGENE ACTIVATION AND ADDITIONAL CHROMOSOME LOSS	ONCOGENE			English	Article						RAS-ONCOGENE; HUMAN KERATINOCYTES; MALIGNANT TRANSFORMATION; P53 MUTATION; CHROMOSOME 15	SQUAMOUS-CELL CARCINOMAS; NEOPLASTIC TRANSFORMATION; HUMAN KERATINOCYTES; VIRAL INTEGRATION; FRAGILE SITES; GENE; CANCER; EXPRESSION; LINE; HYBRIDIZATION	Two mechanisms relevant for skin carcinogenesis in man are mutational inactivation of p53 and oncogenic activation of c-ras(H) gene. Previously, we transfected c-ras(H) oncogene into human skin keratinocytes (HaCaT) with u.v.-typic mutations in both p53 alleles, which produced benign and malignant tumorigenic clones, expressing similar amounts of mutant Pas protein, Here we show that neither the ras integration site nor the karyotypic changes affects the formation of the benign or malignant tumorigenic phenotype, From the original malignant HaCaT-ras clone we took single human chromosomes, carrying the c-ras(H) oncogene and transferred them by microcell mediated chromosome transfer into genetically different untransfected nontumorigenic HaCaT cells, This novel approach identified the genetic background of the recipient cell as a critical determinant for the resulting tumor phenotype, Exhibiting similar oncogene expression, microcell hybrids from early passage cells remained nontumorigenic or formed benign tumors, while those with more cytogenetic aberrations (later passages) and loss of >1 copy of chromosome 15 became malignant. Since aberrations in chromosome 15 were also detected in three of five human skin carcinoma lines this study provides evidence that p53 and c-ras(H) mutations are early events of human skin carcinogenesis, while loss of gene(s) on chromosome 15 is a late event.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine	BOUKAMP, P (corresponding author), GERMAN CANC RES CTR,DIV CARCINOGENESIS & DIFFERENTIAT,NEUENHEIMER FELD 280,D-69009 HEIDELBERG,GERMANY.		Pascheberg, Ulrich/GON-9981-2022		NCI NIH HHS [CA19401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA019401, R01CA019401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMBROS PF, 1986, CHROMOSOMA, V94, P11, DOI 10.1007/BF00293525; ANANTHASWAMY HN, 1992, PROG CLIN BIOL RES, V376, P61; BOS JL, 1989, CANCER RES, V49, P4682; BOUKAMP P, 1982, JNCI-J NATL CANCER I, V68, P415; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOUKAMP P, 1994, KERATINOCYTE HDB, P485; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRISSETTE JL, 1993, MOL CARCINOGEN, V7, P21, DOI 10.1002/mc.2940070105; CANNIZZARO LA, 1988, CANCER GENET CYTOGEN, V33, P93, DOI 10.1016/0165-4608(88)90054-4; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; DEAMBROSIS A, 1992, CANCER GENET CYTOGEN, V60, P1, DOI 10.1016/0165-4608(92)90223-U; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P4322; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; FRIEND KK, 1976, SOMAT CELL GENET, V2, P183, DOI 10.1007/BF01542631; FUSENIG NE, 1991, ORAL CANC, P218; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; GAME SM, 1992, INT J CANCER, V52, P461, DOI 10.1002/ijc.2910520322; GANTT R, 1987, CANCER RES, V47, P1390; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDEGENT JE, 1985, J HISTOCHEM CYTOCHEM, V33, P1241, DOI 10.1177/33.12.2415575; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHMAN TA, 1903, CARCINOGENESIS, V14, P833; MCKENNA WG, 1988, SCIENCE, V241, P1325, DOI 10.1126/science.3045971; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; PARSHAD R, 1994, CARCINOGENESIS, V88, P524; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; POPESCU NC, 1990, HUM GENET, V84, P383; QUINN AG, 1994, J INVEST DERMATOL, V102, P300, DOI 10.1111/1523-1747.ep12371786; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; STANBRIDGE EJ, 1992, CANCER SURV, V12, P5; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TILGEN W, 1983, CANCER RES, V43, P5995; VANDERRIET P, 1994, CANCER RES, V54, P25; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	47	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					961	969						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675455				2022-12-25	WOS:A1995RU79800017
J	HERZIG, MCS; LEEBLUNDBERG, LMF				HERZIG, MCS; LEEBLUNDBERG, LMF			THE AGONIST BINDING-SITE ON THE BOVINE BRADYKININ B2 RECEPTOR IS ADJACENT TO A SULFHYDRYL AND IS DIFFERENTIATED FROM THE ANTAGONIST BINDING-SITE BY CHEMICAL CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLIOMA HYBRID-CELLS; SWISS 3T3 CELLS; LIGAND-BINDING; NEURO-BLASTOMA; PHARMACOLOGICAL CHARACTERIZATION; N-ETHYLMALEIMIDE; KININ RECEPTORS; HORMONE BINDING; PHOSPHOLIPASE-C; PROTEINS	Chemical cross-linking was used to analyze the binding sites for the agonist bradykinin (BK) and the antagonists NPC17731 and HOE140 on the bovine B2 bradykinin receptor. [H-3]BK and [H-3]NPC17731 bound with high affinity to the same B2 receptor in bovine myometrial membranes as determined by the total number of specific binding sites and pharmacological specificity of the binding of these two radioligands. Cross-linking experiments were done using a series of bifunctional reagents reactive either primarily to amines (homobifunctional) or reactive to amines in one end and to sulfhydryls in the opposite end (heterobifunctional). All the heterobifunctional reagents plus the homobifunctional arylhalide 1,5-difluoro-2,4-dinitrobenzene were effective in cross-linking the [H-3]BK N terminus specifically to a sulfhydryl in the receptor, and this crosslinking occurred at 5-100 mu M reagent, In contrast, the homobifunctional N-hydroxysuccinimide ester reagents, at less than or equal to 1 mM, were only able to cross-link [H-3]BK to membrane proteins nonspecifically. The sulfhydryl reagents N-ethylnaleimide, iodoacetamide, and phenylarsine oxide blocked cross linking, whereas these re agents did not inhibit reversible specific [H-3]BK binding. Immunoblotting with anti-BK antiserum revealed that low concentrations of BK (5-50 mu M) were cross-linked to a receptor-specific species of 65 kDa. All cross-linking of [H-3]NPC17731 was nonspecific with both homobifunctional and heterobifunctional reagents. The 65 kDa receptor specific species was observed on anti-HOE140 immunoblots, but only when proteins were cross linked with very high concentrations of HOE140 (greater than or equal to 500 nM). Our results provide direct biochemical evidence that the binding site for the agonist BK in the bovine B2 receptor is adjacent to a cysteine and is differentiated from the binding site(s) for the antagonists NPC17731 and HOE140.	UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio					NIGMS NIH HHS [GM41659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041659, R29GM041659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDALLA S, 1993, J BIOL CHEM, V268, P17277; ASANO T, 1986, MOL PHARMACOL, V29, P244; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; BURCH RM, 1993, MOL BIOL PHARM BRADY, P81; BURCH RM, 1993, MOL BIOL PHARM BRADY, P7; DELACADENA RA, 1993, BLOOD, V81, P3313; DERIAN CK, 1986, J BIOL CHEM, V261, P3831; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; EGGERICKX D, 1992, BIOCHEM BIOPH RES CO, V187, P1306, DOI 10.1016/0006-291X(92)90445-Q; ENGELMAN DM, 1980, P NATL ACAD SCI-BIOL, V77, P2023, DOI 10.1073/pnas.77.4.2023; FARMER SG, 1991, IMMUNOPHARMACOLOGY, V22, P1, DOI 10.1016/0162-3109(91)90051-Y; FONG TM, 1992, J BIOL CHEM, V267, P25664; FRASER CM, 1989, J BIOL CHEM, V264, P9266; FREDRICK MJ, 1984, BIOCHEM PHARMACOL, V33, P2887, DOI 10.1016/0006-2952(84)90212-0; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HIGASHIDA H, 1986, P NATL ACAD SCI USA, V83, P942, DOI 10.1073/pnas.83.4.942; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; HONG SL, 1978, J BIOL CHEM, V251, P5814; HOSHINO S, 1990, FEBS LETT, V276, P227, DOI 10.1016/0014-5793(90)80548-W; JI TH, 1983, METHOD ENZYMOL, V91, P580; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KYLE DJ, 1991, J MED CHEM, V34, P2649, DOI 10.1021/jm00112a047; KYLE DJ, 1991, J MED CHEM, V34, P1230, DOI 10.1021/jm00107a052; KYLE DJ, 1991, BRADYKININ ANTAGONIS, P131; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE RTW, 1989, NEUROPEPTIDES, V14, P51, DOI 10.1016/0143-4179(89)90034-6; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P25970; LEEBLUNDBERG LMF, 1990, J BIOL CHEM, V265, P9621; LEEBLUNDBERG LMF, 1993, J BIOL CHEM, V268, P8151; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; MATHIS SA, 1991, BIOCHEM J, V276, P141, DOI 10.1042/bj2760141; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; PROUD D, 1990, J INFECT DIS, V161, P120, DOI 10.1093/infdis/161.1.120; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REGOLI D, 1980, PHARMACOL REV, V32, P1; REISER G, 1982, BRAIN RES, V239, P191, DOI 10.1016/0006-8993(82)90841-1; ROSCHER AA, 1983, J CLIN INVEST, V72, P626, DOI 10.1172/JCI111012; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERANKA LR, 1991, BRADYKININ ANTAGONIS, P191; STEWART JM, 1991, BRADYKININ ANTAGONIS, P51; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TILLY BC, 1987, BIOCHEM J, V244, P129, DOI 10.1042/bj2440129; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROPEA MM, 1992, CAN J PHYSIOL PHARM, V70, P1360, DOI 10.1139/y92-191; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; VAVREK RJ, 1985, PEPTIDES, V6, P161, DOI 10.1016/0196-9781(85)90033-6; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; Weipert J, 1989, Prog Clin Biol Res, V308, P983; WILSON DD, 1989, CIRC SHOCK, V27, P93; Wold F, 1972, Methods Enzymol, V25, P623, DOI 10.1016/S0076-6879(72)25061-3; YANO K, 1984, J BIOL CHEM, V259, P201; YAQOOB M, 1994, J NEUROCHEM, V62, P17	63	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20591	20598		10.1074/jbc.270.35.20591	http://dx.doi.org/10.1074/jbc.270.35.20591			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657637	hybrid			2022-12-25	WOS:A1995RR58400056
J	MATSUNAGA, T; MU, D; PARK, CH; REARDON, JT; SANCAR, A				MATSUNAGA, T; MU, D; PARK, CH; REARDON, JT; SANCAR, A			HUMAN DNA-REPAIR EXCISION NUCLEASE - ANALYSIS OF THE ROLES OF THE SUBUNITS INVOLVED IN DUAL INCISIONS BY USING ANTI-XPG AND ANTI-ERCC1 ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-G; STRANDED-DNA; (A)BC EXCINUCLEASE; ACTIVE-SITE; 5' INCISION; ENDONUCLEASE; COMPLEMENTATION; DEFECTS; BINDING; MUTANTS	Human DNA repair excision nuclease removes DNA damage by incising on both sides of the lesion in a precise manner. The activity requires participation of 16-17 polypeptides. Of these, the XPF . ERCC1 complex and XPG were predicted to carry the nuclease active sites based on studies with the recombinant proteins and the yeast homologs of these proteins. Furthermore, recent work with model (undamaged) substrates have led to predictions of the roles of these proteins in incising 5' or 3' to the lesion. We have used damaged DNA substrates and antibodies to XPG and ERCC1 to test these predictions. Our results reveal that anti-XPG antibodies change the site of 3' incision and at high concentration inhibit the 3' incision without significantly affecting the 5' incision, indicating that XPG makes the 3' incision and further that under this condition 5' incision can occur without 3' incision. In contrast, anti-ERCC1 antibodies inhibit both the 3' and 5' incisions. Using a defined system for excision repair we also demonstrate that the 3' incision can occur without the 5' incision, leading us to conclude that under certain conditions the two incisions can occur independently.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Mu, David/E-8933-2011	Mu, David/0000-0002-7762-0182	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; FRIEDBERG EC, 1995, DNA REPAIR; FUCHS RPP, 1984, J MOL BIOL, V177, P173, DOI 10.1016/0022-2836(84)90063-9; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; HABRAKEN Y, 1994, NATURE, V371, P531, DOI 10.1038/371531a0; HABRAKEN Y, 1994, NUCLEIC ACIDS RES, V22, P3312, DOI 10.1093/nar/22.16.3312; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HABRAKEN Y, 1994, J BIOL CHEM, V269, P31342; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIN JJ, 1992, J BIOL CHEM, V267, P17688; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1993, NUCLEIC ACIDS RES, V21, P5110, DOI 10.1093/nar/21.22.5110; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SUNG P, 1993, J BIOL CHEM, V268, P26391; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; TATEISHI S, 1993, BIOCHEMISTRY-US, V32, P1541, DOI 10.1021/bi00057a019; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; VANDUIN M, 1988, MUTAT RES, V193, P123, DOI 10.1016/0167-8817(88)90042-9	29	174	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20862	20869		10.1074/jbc.270.35.20862	http://dx.doi.org/10.1074/jbc.270.35.20862			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657672	hybrid			2022-12-25	WOS:A1995RR58400093
J	MELCHIORRI, D; REITER, RJ; SEWERYNEK, E; CHEN, LD; NISTICO, G				MELCHIORRI, D; REITER, RJ; SEWERYNEK, E; CHEN, LD; NISTICO, G			MELATONIN REDUCES KAINATE-INDUCED LIPID-PEROXIDATION IN HOMOGENATES OF DIFFERENT BRAIN-REGIONS	FASEB JOURNAL			English	Article						OXIDATIVE STRESS; FREE RADICALS; NEUROPROTECTION; MALONALDEHYDE; EXCITATORY NEUROTRANSMITTER	FREE-RADICAL FORMATION; KAINIC ACID; GLUTAMATE RECEPTOR; OXYGEN RADICALS; AMINO-ACIDS; CELLS; INVITRO; RELEASE; RATS	Melatonin protection against in vitro kainic acid-induced oxidative damage in homogenates from different rat brain regions is shown. Brain-disrupted cell homogenates from cerebral cortex, cerebellum, hippocampus, hypothalamus, and corpus striatum were incubated with kainate (11.7 mM) with or without different concentrations of melatonin (0.1-4 mM). The concentration of malonaldehyde and 4-hydroxyalkenals was measured as an index of Lipid peroxidation. Wistar and Sprague-Dawley rats were used. When administered with kainate, melatonin markedly reduced lipid peroxidation in every brain region of both rat strains. The reduction in lipid peroxidation by melatonin Tvas concentration-dependent and varied from 10% to 100%. The protection conferred by melatonin is likely due, at least in part, to its newly discovered, free radical scavenging ability.	UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284; UNIV ROMA TOR VERGATA,DEPT BIOL,ROME,ITALY	University of Texas System; University of Texas Health San Antonio; University of Rome Tor Vergata								BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BERDICHEVSKY E, 1983, NEUROSCI LETT, V36, P75, DOI 10.1016/0304-3940(83)90489-5; BIZIERE K, 1978, J NEUROCHEM, V31, P513, DOI 10.1111/j.1471-4159.1978.tb02666.x; BONDY SC, 1993, BRAIN RES, V610, P229, DOI 10.1016/0006-8993(93)91405-H; BOSE R, 1992, TOXICOL LETT, V60, P211, DOI 10.1016/0378-4274(92)90276-P; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V66, P289; COYLE JT, 1976, NATURE, V263, P244, DOI 10.1038/263244a0; DYKENS JA, 1987, J NEUROCHEM, V409, P122; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FERKANY JW, 1983, J PHARMACOL EXP THER, V225, P399; GEBICKI JM, 1976, CHEM PHYS LIPIDS, V16, P142, DOI 10.1016/0009-3084(76)90006-2; GIUSTI P, 1995, EXP NEUROL, V131, P39, DOI 10.1016/0014-4886(95)90005-5; HALL JG, 1978, NEUROSCI LETT, V8, P171, DOI 10.1016/0304-3940(78)90192-1; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; Hardeland R., 1993, CHRONOBIOLOGY CHRONO, P113; HICKS M, 1986, FEBS LETT, V199, P92, DOI 10.1016/0014-5793(86)81230-3; KENNAWAY DJ, 1988, J PINEAL RES, V5, P455, DOI 10.1111/j.1600-079X.1988.tb00788.x; Kohler C, 1984, EXCITOTOXINS, P99; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARANI E, 1987, EXPERIENTIA, V43, P305, DOI 10.1007/BF01945560; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Melchiorri Daniela, 1995, Life Sciences, V56, P83, DOI 10.1016/0024-3205(94)00417-Q; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; MORI A, 1994, NEUROCHEM INT, V24, P201, DOI 10.1016/0197-0186(94)90076-0; NARANJORODRIGUE.E, 1994, SOC NEUR ABSTR, V20, P1603; NARANJORODRIGUE.EB, 1991, BRAIN RES BULL, V27, P595; PELLEGRINIGIAMP.DE, 1990, J NEUROSCI, V10, P1035; Pierre C., 1994, LIFE SCI, V55, P271; POEGGELER B, 1994, J PINEAL RES, V17, P1, DOI 10.1111/j.1600-079X.1994.tb00106.x; PUTTFARCKEN PS, 1993, BRAIN RES, V624, P223, DOI 10.1016/0006-8993(93)90081-W; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; REITER RJ, 1994, ANN NY ACAD SCI, V719, P1, DOI 10.1111/j.1749-6632.1994.tb56817.x; SHIDA CS, 1994, J PINEAL RES, V16, P198, DOI 10.1111/j.1600-079X.1994.tb00102.x; SUN AY, 1992, MOL CHEM NEUROPATHOL, V17, P51, DOI 10.1007/BF03159981; TAN DX, 1994, CARCINOGENESIS, V15, P215, DOI 10.1093/carcin/15.2.215; Tan DX, 1993, ENDOCR J, V1, P57	38	164	164	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1995	9	12					1205	1210		10.1096/fasebj.9.12.7672513	http://dx.doi.org/10.1096/fasebj.9.12.7672513			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RU816	7672513				2022-12-25	WOS:A1995RU81600010
J	TSIANG, M; GIBBS, CS; GRIFFIN, LC; DUNN, KE; LEUNG, LLK				TSIANG, M; GIBBS, CS; GRIFFIN, LC; DUNN, KE; LEUNG, LLK			SELECTION OF A SUPPRESSOR MUTATION THAT RESTORES AFFINITY OF AN OLIGONUCLEOTIDE INHIBITOR FOR THROMBIN USING IN-VITRO GENETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; ANION-BINDING EXOSITE; STRANDED-DNA APTAMER; RNA; THROMBOMODULIN; RECOGNITION; SPECIFICITY; QUADRUPLEX; FIBRINOGEN; MOLECULES	The thrombin aptamer is a single-stranded DNA of 15 nucleotides that was identified by the selection of thrombin-binding molecules from a large combinatorial library of oligonucleotides. This prototype aptamer of thrombin has a unique double G-tetrad structure capable of inhibiting thrombin at nanomolar concentrations through binding to a specific region within thrombin exosite I. Substitution of arginine 70 in thrombin exosite I with glutamic acid effectively eliminated binding of the prototype thrombin aptamer, In contrast, aptamers selected against R70E thrombin were able to bind and inhibit both wild-type and R70E thrombins, and displayed potassium-independent inhibition. Aptamers selected against R70E thrombin bound to sites identical or overlapping with that of the prototype thrombin aptamer. These aptamers retained the potential to form double G-tetrad structures; however, these structures would be destabilized by a T --> A substitution, disrupting the T-4-T-13 base pairing found in the prototype. This destabilization appeared to be partially compensated by newly recruited structural elements, Thus, selection against R70E thrombin did not lead to aptamers that bound to alternative sites, but instead to ssDNA structures with a suppressor mutation that accommodated the mutation in thrombin within a double G-tetrad context. These results provide insight into the aptamer-thrombin interaction and suggest that the binding site for the prototype is the dominant aptamorigenic site on thrombin.			TSIANG, M (corresponding author), GILEAD SCI INC,353 LAKESIDE DR,FOSTER CITY,CA 94404, USA.							BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BODE W, 1992, PROTEIN SCI, V1, P426; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; DAVIS S, 1994, J BIOMOL INTERACT AN, V1, P29; EDGINGTON SM, 1993, BIO-TECHNOL, V11, P285, DOI 10.1038/nbt0393-285; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GRIFFIN LC, 1993, GENE, V137, P25, DOI 10.1016/0378-1119(93)90247-Z; GRIFFIN LC, 1993, BLOOD, V81, P3271, DOI 10.1182/blood.V81.12.3271.3271; GRIFFIN LC, 1995, IN PRESS MOL REPERTO; GRIFFIN LC, 1995, IN PRESS METHODS MOL; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; HARDIN CC, 1992, BIOCHEMISTRY-US, V31, P833, DOI 10.1021/bi00118a028; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; KENAN DJ, 1994, TRENDS BIOCHEM SCI, V19, P57, DOI 10.1016/0968-0004(94)90033-7; KUBIK MF, 1994, NUCLEIC ACIDS RES, V22, P2619, DOI 10.1093/nar/22.13.2619; LI WX, 1994, BLOOD, V83, P677, DOI 10.1182/blood.V83.3.677.677; MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745; MUCKE K, 1987, VIROLOGY, V158, P112; OSBORNE RS, 1993, EMBO J, V12, P3391, DOI 10.1002/j.1460-2075.1993.tb06013.x; PABORSKY LR, 1993, J BIOL CHEM, V268, P20808; PADMANABHAN K, 1993, J BIOL CHEM, V268, P17651; RYDEL TJ, 1990, SCIENCE, V249, P7095; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; WANG KY, 1993, BIOCHEMISTRY-US, V32, P11285, DOI 10.1021/bi00093a004; WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; YOUDERIAN P, 1983, CELL, V35, P777, DOI 10.1016/0092-8674(83)90110-1	35	51	53	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19370	19376		10.1074/jbc.270.33.19370	http://dx.doi.org/10.1074/jbc.270.33.19370			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642616	hybrid			2022-12-25	WOS:A1995RP70300030
J	RAMASWAMY, H; SWAMY, CVB; DAS, MR				RAMASWAMY, H; SWAMY, CVB; DAS, MR			PURIFICATION AND CHARACTERIZATION OF A HIGH-MOLECULAR-WEIGHT RIBONUCLEASE FROM HUMAN-MILK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL CATIONIC PROTEIN; AMINO-ACID SEQUENCE; HUMAN-URINE; PANCREATIC RIBONUCLEASE; POLYACRYLAMIDE GELS; NUCLEOTIDE-SEQUENCE; HUMAN LACTOFERRIN; ALLOSTERIC MODEL; CO-OPERATIVITY; HUMAN-SERUM	We have purified a high molecular weight ribonuclease (hmRNase) from human milk by a two-step column chromatographic procedure and characterized the enzyme. The molecular mass of hmRNase is 80 kDa as determined from SDS-polyacrylamide gel electrophoresis. The pH optimum of the enzyme is in the range of 7.5-8.0, similar to other secretory RNases. hmRNase is pyrimidine-specific and cleaves the phosphodiester bond 3' to a pyrimidine residue. It selectively degrades the pyrimidine strand in poly(rA):poly(rU) and poly(dA):poly(rU) double stranded substrates. The extent of degradation for naturally occurring RNAs vary in the order tRNA < rRNA < mRNA at low enzyme concentrations. hmRNase shows allosteric behavior with positive cooperativity in its reaction on polynucleotide substrates. The activity of the enzyme is enhanced in the presence of monoribonucleotides. Antiserum obtained against purified hmRNase did not cross-react with low molecular weight RNase which is also present in milk. In addition, an immunologically cross-reacting species could not be detected in the serum, suggesting the origin of hmRNase in the mammary gland but not blood.	CTR CELLULAR & MOLEC BIOL,HYDERABAD 500007,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)								AKAGI K, 1976, BIOCHIM BIOPHYS ACTA, V442, P368, DOI 10.1016/0005-2787(76)90311-7; BEINTEMA JJ, 1988, BIOCHEMISTRY-US, V27, P4530, DOI 10.1021/bi00412a046; BIENTEMA JJ, 1984, ANAL BIOCHEM, V136, P48; BIENTEMA JJ, 1988, BIOCHEM J, V255, P501; BINGHAM EW, 1964, ARCH BIOCHEM BIOPHYS, V106, P235, DOI 10.1016/0003-9861(64)90182-1; Bittner JJ, 1936, SCIENCE, V84, P162, DOI 10.1126/science.84.2172.162; BLANK A, 1981, BIOCHEMISTRY-US, V20, P2261, DOI 10.1021/bi00511a030; CORBISHLEY TP, 1982, CLIN CHIM ACTA, V124, P225, DOI 10.1016/0009-8981(82)90390-4; COULSON EJ, 1964, ARCH BIOCHEM BIOPHYS, V107, P336, DOI 10.1016/0003-9861(64)90340-6; DALALY BK, 1980, BIOCHIM BIOPHYS ACTA, V615, P381, DOI 10.1016/0005-2744(80)90505-7; DAS MR, 1979, CANCER RES, V39, P5106; DAS MR, 1976, NATURE, V262, P802, DOI 10.1038/262802a0; DIDONATO A, 1987, BIOCHEM J, V241, P435, DOI 10.1042/bj2410435; FURMANSKI P, 1989, J EXP MED, V170, P415, DOI 10.1084/jem.170.2.415; GLAZER AN, 1975, LABORATORY TECHNIQUE, V4, P23; GULLBERG U, 1986, BIOCHEM BIOPH RES CO, V139, P1239, DOI 10.1016/S0006-291X(86)80310-2; IRIE M, 1984, J BIOCHEM-TOKYO, V96, P89, DOI 10.1093/oxfordjournals.jbchem.a134833; JENNESS R, 1970, MILK PROTEINS CHEMIS, V1, P17; JUSSAWALLA DJ, 1970, BRIT J CANCER, V24, P56, DOI 10.1038/bjc.1970.8; KALNITSKY G, 1959, J BIOL CHEM, V234, P1512; KALYANARAMAN S, 1983, MOL BIOL REP, V9, P179, DOI 10.1007/BF00775365; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU DK, 1982, COMP BIOCHEM PHYS B, V71, P535, DOI 10.1016/0305-0491(82)90424-2; LIU DK, 1983, INT J BIOCHEM, V15, P1273, DOI 10.1016/0020-711X(83)90218-5; LIU DK, 1979, BIOCHEM J, V178, P241, DOI 10.1042/bj1780241; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAVROTHALASSITIS GJ, 1984, EUR J BIOCHEM, V142, P481, DOI 10.1111/j.1432-1033.1984.tb08311.x; MCCORMICK JJ, 1974, NATURE, V251, P737, DOI 10.1038/251737a0; MCPHERSON A, 1986, SCIENCE, V232, P765, DOI 10.1126/science.3961503; MIDGLEY JEM, 1965, BIOCHIM BIOPHYS ACTA, V95, P232, DOI 10.1016/0005-2787(65)90488-0; MIZUTA K, 1990, ARCH BIOCHEM BIOPHYS, V281, P144, DOI 10.1016/0003-9861(90)90424-W; MORITA T, 1986, J BIOCHEM-TOKYO, V99, P17, DOI 10.1093/oxfordjournals.jbchem.a135456; NANDI S, 1973, ADV CANCER RES, V17, P353; NEUWELT EA, 1976, J BIOL CHEM, V251, P5752; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OUCHTERLONY O, 1962, PROG ALLERGY, V6, P30, DOI 10.1159/000313795; PAYMASTER JC, 1970, INT J CANCER, V5, P426, DOI 10.1002/ijc.2910050318; PICCOLI R, 1984, J BIOL CHEM, V259, P693; PICCOLI R, 1988, BIOCHEM J, V253, P329, DOI 10.1042/bj2530329; POWELL MJ, 1990, NUCLEIC ACIDS RES, V18, P4013, DOI 10.1093/nar/18.13.4013; RABIN EZ, 1982, BIOCHIM BIOPHYS ACTA, V701, P132, DOI 10.1016/0167-4838(82)90321-1; REY MW, 1990, NUCLEIC ACIDS RES, V18, P5288, DOI 10.1093/nar/18.17.5288; RICHARDS FM, 1971, ENZYMES, V4, P647; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; ROSENBERG HF, 1989, J EXP MED, V170, P163, DOI 10.1084/jem.170.1.163; SAHA BK, 1982, NUCLEIC ACIDS RES, V10, P645, DOI 10.1093/nar/10.2.645; SCHEIT KH, 1979, NATURE, V279, P728, DOI 10.1038/279728a0; SCHMUKLER M, 1975, J BIOL CHEM, V250, P2206; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P3527, DOI 10.1021/bi00360a008; Sierakowska H, 1977, Prog Nucleic Acid Res Mol Biol, V20, P59; SKUP D, 1981, BIOL INTERFERON SYST, P81; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SORRENTINO S, 1988, J BIOL CHEM, V263, P16125; STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031; SUGIYAMA RH, 1981, BIOCHEMISTRY-US, V20, P2268, DOI 10.1021/bi00511a031; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER EJ, 1976, BIOCHEM J, V153, P329, DOI 10.1042/bj1530329; WALKER EJ, 1975, BIOCHEM J, V147, P425, DOI 10.1042/bj1470425; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; YASUDA T, 1990, ARCH BIOCHEM BIOPHYS, V279, P130, DOI 10.1016/0003-9861(90)90472-B	61	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4181	4187						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680036				2022-12-25	WOS:A1993KN53300057
J	JONES, JI; BUSBY, WH; WRIGHT, G; SMITH, CE; KIMACK, NM; CLEMMONS, DR				JONES, JI; BUSBY, WH; WRIGHT, G; SMITH, CE; KIMACK, NM; CLEMMONS, DR			IDENTIFICATION OF THE SITES OF PHOSPHORYLATION IN INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-1 - REGULATION OF ITS AFFINITY BY PHOSPHORYLATION OF SERINE-101	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-I; AMNIOTIC-FLUID; PURIFICATION; INVITRO; PLASMA; FORMS; CELLS; DNA	Serine phosphorylation of insulin-like growth factor binding protein-1 (IGFBP-1) has been shown to alter its affinity for the insulin-like growth factors (IGF-I and IGF-II) and to modify its capacity to modulate cellular responses to the IGFs. Because of this, we determined the sites of serine phosphorylation. Purification of P-32-labeled IGFBP-1 was followed by digestion with trypsin and endoproteinase Glu-C and radiosequencing of labeled peptides. Three serines were found to be phosphorylated, with Ser101, Ser119, and Ser169 containing 70%, 5%, and 25% of the incorporated P-32, respectively. A mutated IGFBP-1, substituting alanine for serine at positions 98 and 101, was expressed in CHO cells. On nondenaturing gels, the wild type protein migrated as five isoforms (one non-phosphorylated and four phosphorylated). However, in the mutated protein, the most rapidly migrating band (a phosphorylated form) was not present. The cells containing the mutated cDNA incorporated 60% less P-32 into immunoprecipitable IGFBP-1. The mutated protein had a 3-fold reduction in affinity for IGF-I compared to the wild type protein. We conclude that Ser101 represents the major site of phosphorylation containing 63% of the total P-32 incorporated and that phosphorylation of Ser101 is important for maintenance of high affinity binding for this growth factor.	UNIV N CAROLINA, SCH MED, DEPT MED, CB 7170 MACNIDER, CHAPEL HILL, NC 27599 USA; MONSANTO CORP RES, CHESTERFIELD, MO 63198 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Monsanto					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG002331, R01AG002331] Funding Source: NIH RePORTER; NIA NIH HHS [AG02331] Funding Source: Medline; NIDDK NIH HHS [DK02024] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAXTER RC, 1991, MODERN CONCEPTS INSU, P371; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; BREWER MT, 1988, BIOCHEM BIOPH RES CO, V152, P1289, DOI 10.1016/S0006-291X(88)80425-X; BURCH WM, 1990, J CLIN ENDOCR METAB, V70, P173, DOI 10.1210/jcem-70-1-173; BUSBY WH, 1988, J BIOL CHEM, V263, P14203; BUSBY WH, 1989, ENDOCRINOLOGY, V125, P773, DOI 10.1210/endo-125-2-773; BUSBY WH, 1988, J CLIN ENDOCR METAB, V67, P1225, DOI 10.1210/jcem-67-6-1225; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; FROST RA, 1991, J BIOL CHEM, V266, P18082; Higuchi R., 1989, PCR TECHNOLOGY, P61; JONES JI, 1991, P NATL ACAD SCI USA, V88, P7481, DOI 10.1073/pnas.88.17.7481; JYUNG RW, 1992, IN PRESS ENDOCRINOLO; LEE YL, 1988, MOL ENDOCRINOL, V2, P404, DOI 10.1210/mend-2-5-404; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MCCUSKER RH, 1992, AUG ANN M AM SOC AN; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMASAKI S, 1990, J BIOL CHEM, V265, P2198; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; SVOBODA ME, 1980, BIOCHEMISTRY-US, V19, P790, DOI 10.1021/bi00545a027	23	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1125	1131						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678248				2022-12-25	WOS:A1993KG07700056
J	GEHRING, MR; CONDON, B; MARGOSIAK, SA; KAN, CC				GEHRING, MR; CONDON, B; MARGOSIAK, SA; KAN, CC			CHARACTERIZATION OF THE PHE-81 AND VAL-82 HUMAN FIBROBLAST COLLAGENASE CATALYTIC DOMAIN PURIFIED FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERSTITIAL COLLAGENASE; PROCOLLAGENASE; ACTIVATION; STROMELYSIN; EXPRESSION; METALLOPROTEINASES; IDENTIFICATION; PURIFICATION; INHIBITORS; POLYMERASE	Soluble recombinant human fibroblast collagenase catalytic domain was highly expressed and purified from Escherichia coli, The expression construct utilized the T7 gene 10 promoter for transcription of a two-cistron messenger RNA which encoded the ubiquitin-collagenase catalytic domain fusion protein as the second cistron. The ubiquitin domain was attached to the collagenase catalytic domain with the linker sequences Gly-Gly-Thr-Gly-Asp-Val-Ala-Gln (wild type) or Gly-Gly-Thr-Gly-Asp-Val-Gly-His (mutant) which served as cleavage sites for in vitro activation. The last four residues of the linker were included based on the crystal structure of human prostromelysin-l catalytic domain. Soluble fusion proteins purified from E. coli retained the proteolytic activity of the collagenase catalytic domain, The collagenase catalytic domain was released by either autoproteolytic or stromelysin-1-catalyzed cleavage, purified to homogeneity, and separately possess Phe-81, Val-82, or Leu-83 as the amino-terminal residue. Very similar K-cat/K-m values were determined for the Phe-81 and Val-82 forms using continuous fluorogenic and chromogenic peptide cleavage assays.	AGOURON PHARMACEUT INC, SAN DIEGO, CA 92121 USA	Pfizer								BLASER J, 1991, EUR J BIOCHEM, V202, P1223, DOI 10.1111/j.1432-1033.1991.tb16494.x; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; DAVIES B, 1993, CANCER RES, V53, P2087; ECKER DJ, 1989, J BIOL CHEM, V264, P7715; GRANT GA, 1987, J BIOL CHEM, V262, P5886; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HORWITZ AL, 1977, P NATL ACAD SCI USA, V74, P897, DOI 10.1073/pnas.74.3.897; KAN CC, 1992, J PROTEIN CHEM, V11, P467, DOI 10.1007/BF01025023; KNAUPER V, 1993, BIOCHEM J, V295, P581; KNAUPER V, 1993, BIOCHEM J, V291, P847; KNAUPER V, 1990, EUR J BIOCHEM, V189, P295, DOI 10.1111/j.1432-1033.1990.tb15489.x; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LEE SC, 1992, J BIOL CHEM, V267, P2849; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; LOWRY CL, 1992, PROTEINS, V12, P42, DOI 10.1002/prot.340120106; MALLYA SK, 1990, BIOCHEMISTRY-US, V29, P10628, DOI 10.1021/bi00499a008; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; MURPHY G, 1992, J BIOL CHEM, V267, P9612; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; SALOWE SP, 1992, BIOCHEMISTRY-US, V31, P4535, DOI 10.1021/bi00134a001; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; TEMPLETON NS, 1990, CANCER RES, V50, P5431; WEINGARTEN H, 1985, ANAL BIOCHEM, V147, P437, DOI 10.1016/0003-2697(85)90294-5; WILLENBROCK F, 1995, FEBS LETT, V358, P189, DOI 10.1016/0014-5793(94)01421-V; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008	33	11	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22507	22513		10.1074/jbc.270.38.22507	http://dx.doi.org/10.1074/jbc.270.38.22507			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673241	hybrid			2022-12-25	WOS:A1995RW31400070
J	GUAN, GM; JIANG, GJ; KOCH, RL; SHECHTER, I				GUAN, GM; JIANG, GJ; KOCH, RL; SHECHTER, I			MOLECULAR-CLONING AND FUNCTIONAL-ANALYSIS OF THE PROMOTER OF THE HUMAN SQUALENE SYNTHASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; STEROL REGULATORY ELEMENT; COENZYME-A REDUCTASE; BINDING PROTEINS; DNA-REPLICATION; TRANSCRIPTION; EXPRESSION; SEQUENCE; REGION; IDENTIFICATION	We have cloned and characterized the 5'-flanking region of the gene encoding human squalene synthase. We report here the promoter activity of successively 5'-truncated sections of a 1 kilobase of this region by fusing it to the coding region of a luciferase reporter gene. DNA segments of 200 base pairs (bp) 5' to the transcription start site, as determined by primer extension analysis, show a strong promoter effect on the expression of the luciferase chimeric gene and a high response to the presence of sterols when transiently transfected into the human hepatoma cell line HepG2 or to the hamster-derived CHO-K1 cells. An approximately 50-fold induction of luciferase activity, in the absence of sterols, was observed in transiently transfected HepG2 cells for fusion constructs containing sections of 200, 459, and 934 bp of the putative human squalene synthase promoter. Loss of promoter activity and response to sterols was localized to a 69-bp section located 131 nucleotides 5' to the transcription start site. Sequence analysis of this region showed that it contained a sterol regulatory element 1 (SRE-1) previously identified in other sterol regulated genes (Smith, J. R., Osborne, T. F., Brown, M. S., Goldstein, J. L., and Gil, G. (1988). J. Biol. Chem. 263, 18480-18487) and two potential NF-1 binding sites. Additional CCAAT box, SRE-1 element, and two Sp1 sites were identified 3' to this section. Sequences within this 69-bp DNA, including the SRE-1 cis-acting element, show strong binding to the purified nuclear transcription factor ADD1 (Tonzonoz, P., Kim, J. B., Graves, R. A., and Spiegelman B. M. (1993) Mol. Cell Biol. 13, 4753-4759) by mobility shift assay and footprinting analyses.	ELEANOR ROOSEVELT INST,BOETTCHER LAB MOLEC GENET,DENVER,CO 80206						NHLBI NIH HHS [HL50628, HL48540] Funding Source: Medline; NIDDK NIH HHS [DK34914] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048540, R01HL050628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034914] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CHAM BE, 1976, J LIPID RES, V17, P176; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FAUST JR, 1979, P NATL ACAD SCI USA, V76, P5018, DOI 10.1073/pnas.76.10.5018; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GIL G, 1986, J BIOL CHEM, V261, P3717; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; JIANG GJ, 1993, J BIOL CHEM, V268, P12818; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAWABE Y, 1994, BIOCHEM BIOPH RES CO, V202, P1460, DOI 10.1006/bbrc.1994.2095; MCKENZIE TL, 1992, J BIOL CHEM, V267, P21368; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; TONZONOZ P, 1993, MOL CELL BIOL, V13, P4753; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YOKOYAMA C, 1993, CELL, V76, P187	32	95	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21958	21965		10.1074/jbc.270.37.21958	http://dx.doi.org/10.1074/jbc.270.37.21958			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665618	hybrid			2022-12-25	WOS:A1995RU75700081
J	LUBYPHELPS, K; HORI, M; PHELPS, JM; WON, D				LUBYPHELPS, K; HORI, M; PHELPS, JM; WON, D			CA2+-REGULATED DYNAMIC COMPARTMENTALIZATION OF CALMODULIN IN LIVING SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; PHOTOBLEACHING RECOVERY; BINDING DOMAIN; F-ACTIN; CALCIUM; DIFFUSION; SEQUENCE; PEPTIDE; CA-2+	A key assumption of most models for calmodulin regulation of smooth and non-muscle contractility is that calmodulin is freely diffusible at resting intracellular concentrations of free Ca2+. However, fluorescence recovery after photobleaching (FRAP) measurements of three different fluorescent analogs of calmodulin in cultured bovine tracheal smooth muscle cells suggest that free calmodulin may be limiting in unstimulated cells, Thirty-seven % of microinjected calmodulin is immobile by FRAP and the fastest recovering component has an effective diffusion coefficient 7-fold slower than a dextran of equivalent size. Combining the FRAP data with extraction data reported in a previous paper (Tansey, M., Luby-Phelps, K., Kamm, K. E., and Stull, J. T. (1994) J. Biol. Chem. 269, 9912-9920), we estimate that at most 5% of total endogenous calmodulin in resting smooth muscle cells is unbound (freely diffusible). Examination of the Ca2+ dependence of calmodulin mobility in permeabilized cells reveals that binding persists even at intracellular Ca2+ concentrations as low as 17 nM. When Ca2+ is elevated to between 450 nM and 3 mu M, some of the bound calmodulin is released, as indicated by an increase in the effective diffusion coefficient and the per cent mobile fraction, At higher Ca2+, calmodulin becomes increasingly immobilized. In about 50% of the cell population, clamping Ca2+ at micromolar levels results in translocation of cytoplasmic calmodulin to the nucleus, The compartmentalization and complex dynamics of calmodulin in living smooth muscle cells have profound implications for understanding how calmodulin regulates contractility in response to extracellular signals.			LUBYPHELPS, K (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA.			Luby-Phelps, Katherine/0000-0002-8378-1409				BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; ELSON EL, 1989, METHOD CELL BIOL, V30, P307; ENYEDI A, 1987, J BIOL CHEM, V262, P6425; GOUGH AH, 1993, J CELL BIOL, V121, P1095, DOI 10.1083/jcb.121.5.1095; HOU L, 1990, BIOPHYS J, V58, P31, DOI 10.1016/S0006-3495(90)82351-1; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KELLER CH, 1982, BIOCHEMISTRY-US, V21, P156, DOI 10.1021/bi00530a027; KEMP BE, 1987, J BIOL CHEM, V262, P2542; LUBYPHELPS K, 1985, J CELL BIOL, V101, P1245, DOI 10.1083/jcb.101.4.1245; LUBYPHELPS K, 1994, COMMENTS MOL CELL BI, V8, P199; MAYR GW, 1983, BIOCHEMISTRY-US, V22, P4316, DOI 10.1021/bi00287a024; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MINTON AP, 1990, INT J BIOCHEM, V22, P1063, DOI 10.1016/0020-711X(90)90102-9; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; NAKANISHI S, 1991, ANAL BIOCHEM, V195, P313, DOI 10.1016/0003-2697(91)90336-R; OLWIN BB, 1984, J BIOL CHEM, V259, P949; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; ONO T, 1992, BRIT J PHARMACOL, V106, P539, DOI 10.1111/j.1476-5381.1992.tb14371.x; PERSECHINI A, 1993, BIOCHIM BIOPHYS ACTA, V1163, P309, DOI 10.1016/0167-4838(93)90167-P; PROVANCE DW, 1993, J CELL SCI, V106, P565; SHMIDT HHHW, 1992, CELL CALCIUM, V13, P427, DOI 10.1016/0143-4160(92)90055-W; SIMON JR, 1988, BIOPHYS J, V54, P801, DOI 10.1016/S0006-3495(88)83018-2; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; VIGERS GPA, 1988, J CELL BIOL, V107, P1011, DOI 10.1083/jcb.107.3.1011; YGUERABIDE J, 1982, BIOPHYS J, V40, P69, DOI 10.1016/S0006-3495(82)84459-7; ZIMPRICH F, 1995, CELL CALCIUM, V17, P233, DOI 10.1016/0143-4160(95)90038-1	31	93	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21532	21538		10.1074/jbc.270.37.21532	http://dx.doi.org/10.1074/jbc.270.37.21532			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665565	hybrid			2022-12-25	WOS:A1995RU75700020
J	WAYMAN, GA; IMPEY, S; STORM, DR				WAYMAN, GA; IMPEY, S; STORM, DR			CA2+ INHIBITION OF TYPE-III ADENYLYL-CYCLASE IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-ACTIVATING PROTEIN; ADP-RIBOSYLATION; WHOLE CELLS; RAT-BRAIN; CALMODULIN; CALCIUM; CLONING; EXPRESSION; STIMULATION; IDENTIFICATION	Type III adenylyl cyclase is stimulated by beta-adrenergic agonists and glucagon in vitro and in vivo, but not by Ca2+ and calmodulin. However, the enzyme is stimulated by Ca2+ and calmodulin in vitro when it is concomitantly activated by the guanyl nucleotide stimulatory protein G(s) (Choi, E. J., Xia, Z., and Storm, D. R. (1992a) Biochemistry 31, 6492-6498). Here, we examined regulation of type III adenylyl cyclase by G(s)-coupled receptors and intracellular Ca2+ in vivo. Surprisingly, intracellular Ca2+ inhibited hormone-stimulated type III adenylyl cyclase activity, Submicromolar concentrations of intracellular free Ca2+, which stimulated type I adenylyl cyclase, inhibited glucagon- or isoproterenol-stimulated type III adenylyl cyclase. Inhibition of type III adenylyl cyclase by intracellular Ca2+ was not mediated by G(i), cAMP-dependent protein kinase, or protein kinase C. However, an inhibitor of CaM kinases antagonized Ca2+ inhibition of the enzyme, and coexpression of constitutively activated CaM kinase II completely inhibited isoproterenol-stimulated type III adenylyl cyclase activity. We propose that Ca2+ inhibition of type III adenylyl cyclase may serve as a regulatory mechanism to attenuate hormone-stimulated cAMP levels in some tissues.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 44948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACSKAI BJ, 1983, SCIENCE, V260, P222; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; DITTMAN AH, 1994, BIOCHEMISTRY-US, V33, P943, DOI 10.1021/bi00170a013; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; IMPEY S, 1994, MOL CELL BIOL, V14, P8272, DOI 10.1128/MCB.14.12.8272; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; MASURE HR, 1984, BIOCHEM J, V218, P691, DOI 10.1042/bj2180691; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Potter J D, 1980, Ann N Y Acad Sci, V356, P220, DOI 10.1111/j.1749-6632.1980.tb29613.x; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SALOMON Y, 1979, ANAL BIOCHEM, V58, P541; SEAMON K, 1981, J BIOL CHEM, V256, P9799; STEER ML, 1975, J BIOL CHEM, V250, P2080; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, J BIOL CHEM, V266, P8595; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; WU ZL, 1993, J BIOL CHEM, V268, P23766; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; XIA ZG, 1992, NEUROSCI LETT, V144, P169, DOI 10.1016/0304-3940(92)90742-P; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	41	118	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21480	21486		10.1074/jbc.270.37.21480	http://dx.doi.org/10.1074/jbc.270.37.21480			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665559	hybrid			2022-12-25	WOS:A1995RU75700013
J	FUKUDA, H; OHTSUBO, E				FUKUDA, H; OHTSUBO, E			LARGE-SCALE PURIFICATION AND CHARACTERIZATION OF TRAI ENDONUCLEASE ENCODED BY SEX FACTOR PLASMID R100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE-I; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; BINDING; ORIT; IDENTIFICATION; DIMERIZATION; CATALYZES; PROTEINS	The TraI protein encoded by plasmid R100 was purified in a large scale by monitoring the strand and site-specific nicking activity at the origin of transfer, oriT, The N-terminal amino acid sequence of the purified protein was identical to that deduced from the DNA sequence of an open reading frame encoding TraI. The TraI protein is a DNA helicase which is highly processive and unwinds DNA in the 5' to 3' direction. The Stokes radius and the sedimentation coefficient for the TraI protein in 200 mM NaCl indicate that the protein is a rod-shaped monomer, whose native molecular weight is 186,000. Chemical cross-linking analysis revealed that there exist more dimers of TraI under the low salt conditions, under which both nicking and unwinding reactions catalyzed by TraI are the most efficient, indicating that the TraI protein is functionally active in a dimer form. TraI hardly introduced a nick into the linearized plasmid DNA and only slightly into the relaxed closed circular DNA, indicating that TraI requires superhelical structure of substrate DNA for the nicking reaction. Deletion analysis in the oriT region revealed that a particular region of 54 base pairs containing oriT is required for the nicking reaction.	UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								ABDELMONEM M, 1983, P NATL ACAD SCI-BIOL, V80, P4659, DOI 10.1073/pnas.80.15.4659; ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P431, DOI 10.1111/j.1432-1033.1976.tb10358.x; ABDELMONEM M, 1977, J MOL BIOL, V110, P867; BENZ I, 1990, EUR J BIOCHEM, V189, P267, DOI 10.1111/j.1432-1033.1990.tb15486.x; BRADSHAW HD, 1990, J BACTERIOL, V172, P4127, DOI 10.1128/jb.172.7.4127-4131.1990; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; INAMOTO S, 1991, J BIOL CHEM, V266, P10086; INAMOTO S, 1990, J GEN APPL MICROBIOL, V36, P287, DOI 10.2323/jgam.36.287; INAMOTO S, 1990, J BIOL CHEM, V265, P6461; INAMOTO S, 1988, J BACTERIOL, V170, P2749, DOI 10.1128/jb.170.6.2749-2757.1988; INAMOTO S, 1994, J BIOCHEM-TOKYO, V116, P834; KUHM B, 1978, J BIOL CHEM, V254, P11343; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LOHMAN TM, 1902, MOL MICROBIOL, V6, P5; MANIATIS T, 1982, MOL CLONING LABORATO, P90; MATSON SW, 1991, J BIOL CHEM, V266, P16232; OHKI M, 1968, COLD SPRING HARB SYM, V33, P651, DOI 10.1101/SQB.1968.033.01.074; OHTSUBO E, 1978, MOL GEN GENET, V159, P131, DOI 10.1007/BF00270886; REYGERS U, 1991, EMBO J, V10, P2689, DOI 10.1002/j.1460-2075.1991.tb07812.x; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; RUPP WD, 1968, COLD SPRING HARB SYM, V33, P647, DOI 10.1101/SQB.1968.033.01.073; SANCAR A, 1979, J BACTERIOL, V137, P692, DOI 10.1128/JB.137.1.692-693.1979; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WONG I, 1992, J BIOL CHEM, V267, P7596; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIOKA Y, 1987, J BACTERIOL, V169, P619, DOI 10.1128/jb.169.2.619-623.1987; YOSHIOKA Y, 1990, J MOL BIOL, V214, P39, DOI 10.1016/0022-2836(90)90145-C	30	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21319	21325		10.1074/jbc.270.36.21319	http://dx.doi.org/10.1074/jbc.270.36.21319			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673168	hybrid			2022-12-25	WOS:A1995RU05400069
J	ISAS, JM; YANNONE, SM; BURGESS, BK				ISAS, JM; YANNONE, SM; BURGESS, BK			AZOTOBACTER-VINELANDII NADPH-FERREDOXIN REDUCTASE CLONING, SEQUENCING, AND OVEREXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; ESCHERICHIA-COLI; ENCODING FLAVODOXIN; CLUSTER; ACTIVATION; MUTAGENESIS; NITROGENASE; RESOLUTION; PROTEIN	Azotobacter vinelandii ferredoxin I (AvFdI) controls the expression of another protein that was originally designated Protein X. Recently we reported that Protein X is a NADPH-specific flavoprotein that binds specifically to FdI (Isas, J. M., and Burgess, B. K. (1994) J. Biol. Chem, 269, 19404-19409), The gene encoding this protein has now been cloned and sequenced, Protein X is 33% identical and has an overall 53% similarity with the fpr gene product from Escherichia coli that encodes NADPH:ferredoxin reductase, On the basis of this similarity and the similarity of the physical properties of the two proteins, we now designate Protein X as A. vinelandii NADPH:ferredoxin reductase and its gene as the fpr gene, The protein has been overexpressed in its native background in A. vinelandii by using the broad host range multicopy plasmid, pKT230. In addition to being regulated by FdI, the fpr gene product is overexpressed when A. vinelandii is grown under N-2-fixing conditions even though the fpr gene is not preceded by a nif specific promoter, By analogy to what is known about fpr expression in E. coli, we propose that FdI may exert its regulatory effect on fpr by interacting with the SoxRS regulon.	UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA	University of California System; University of California Irvine			Yannone, Steven/G-1927-2011		NIGMS NIH HHS [R01-GM45209] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045209] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BENNETT LT, 1988, J BIOL CHEM, V263, P1364; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; BIENERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P331; BLASCHKOWSKI HP, 1982, EUR J BIOCHEM, V123, P563; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; DILLER TC, 1994, J MOL BIOL, V241, P620, DOI 10.1006/jmbi.1994.1535; EMPTAGE MH, 1980, J BIOL CHEM, V255, P1793; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; ISAS JM, 1994, J BIOL CHEM, V269, P19404; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JANSEN T, 1988, CURR GENET, V13, P517, DOI 10.1007/BF02427758; KLUGKIST J, 1986, EUR J BIOCHEM, V155, P41, DOI 10.1111/j.1432-1033.1986.tb09456.x; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; LIOCHEV SI, 1994, P NATL ACAD SCI USA, V91, P1328, DOI 10.1073/pnas.91.4.1328; MANIATIS T, 1982, MOL CLONING LABORATO, P466; MARTIN AE, 1989, J BACTERIOL, V171, P3162, DOI 10.1128/jb.171.6.3162-3167.1989; MERRICK MJ, 1993, CURR PLANT SCI BIOT, V17, P43; MERRITT EA, 1993, ACTA CRYSTALLOGR D, V49, P272, DOI 10.1107/S0907444992007248; MORGAN TV, 1988, J BIOL CHEM, V263, P1370; MORIMYO M, 1988, J BACTERIOL, V170, P2136, DOI 10.1128/jb.170.5.2136-2142.1988; MOSHIRI F, 1991, J BIOL CHEM, V266, P23169; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; STEPHENS PJ, 1991, BIOCHEMISTRY-US, V30, P3200, DOI 10.1021/bi00227a007; STEPHENS PJ, 1985, P NATL ACAD SCI USA, V82, P5661, DOI 10.1073/pnas.82.17.5661; STOUT CD, 1988, J BIOL CHEM, V263, P9256; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; STOUT CD, 1993, J BIOL CHEM, V268, P25920; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1021; THOMSON AJ, 1991, FEBS LETT, V285, P230, DOI 10.1016/0014-5793(91)80807-F; VAZQUEZ A, 1994, PROTEIN EXPRES PURIF, V5, P96, DOI 10.1006/prep.1994.1014; VETTER J, 1971, HOPPESEYLERS Z PHYSL, V352, P443	36	29	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21258	21263		10.1074/jbc.270.36.21258	http://dx.doi.org/10.1074/jbc.270.36.21258			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673160	hybrid			2022-12-25	WOS:A1995RU05400060
J	WITHERS, DJ; BLOOM, SR; ROZENGURT, E				WITHERS, DJ; BLOOM, SR; ROZENGURT, E			DISSOCIATION OF CAMP-STIMULATED MITOGENESIS FROM ACTIVATION OF THE MITOGEN-ACTIVATED PROTEIN-KINASE CASCADE IN SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; GROWTH-FACTOR; CYCLIC-AMP; SIGNAL-TRANSDUCTION; DEPENDENT ACTIVATION; GS-ALPHA; C-FOS; PHOSPHORYLATION; PATHWAY; RAF	Elevation of intracellular cAMP by forskolin, 8-bromoadenosine 3':5'-cyclic monophosphate, and prostaglandin E(1), in synergy with insulin, stimulated DNA synthesis in quiescent Swiss 3T3 cells to the same level achieved by platelet-derived growth factor (PDGF) or bombesin. Both forskolin and 8-bromoadenosine 3':5'-cyclic monophosphate stimulated a significant increase in cell number which, in the presence of insulin, reached the same level achieved with PDGF. Treatment with either PDGF or bombesin caused a marked and persistent stimulation of p42(MAPK) and p44(MAPK). In striking contrast, no activation was seen with mitogenic combinations of cAMP as shown by three different assays. Swiss 3T3 cells stably transfected with a constitutively activated Gs alpha subunit were 100-fold more sensitive to the mitogenic effects of forskolin but in this distinct cellular model forskolin did not activate p42(MAPK). Swiss 3T3 cells stably transfected with interfering mutants of MEK-1 showed a 60% decrease in PDGF-stimulated p42 MAPK activation, but there was no inhibition of the mitogenic effect of forskolin in these cells. Furthermore, the upstream kinases MEK-1/MEK-2 and p74(raf-1) were not activated by mitogenic combinations of cAMP while PDGF caused marked stimulation of their activity. Treatment of 3T3 cells with forskolin attenuated PDGF-stimulated p74(raf-1) and p42(MAPK) activation but enhanced the mitogenic effects of this agent. Mitogenic combinations of cAMP strongly stimulated the phosphorylation and activation of p70(s6k) an effect that was inhibited by rapamycin. This agent markedly inhibited cAMP-stimulated DNA synthesis suggesting a critical role for p70(s6k) in cAMP mitogenic signaling. These results demonstrate that cAMP-induced mitogenesis can be dissociated from activation of the mitogen-activated protein kinase cascade and that this is not an obligatory point of convergence in mitogenic signaling in Swiss 3T3 cells.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; HAMMERSMITH HOSP,DEPT MED,DIV ENDOCRINOL,LONDON W12 0NN,ENGLAND	Cancer Research UK; Imperial College London			Withers, Dominic J/D-7671-2014	Withers, Dominic J/0000-0002-8009-7521				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FAURE M, 1994, J BIOL CHEM, V269, P7851; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; FERRARI S, 1990, P NATL ACAD SCI USA, V89, P7282; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG N, 1994, J BIOL CHEM, V269, P548; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MEHMET H, 1988, ONCOGENE RES, V3, P281; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POSADA J, 1992, MOL BIOL CELL, V3, P383; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1991, ONCOGENE, V6, P495; ROZENGURT E, 1981, P NATL ACAD SCI-BIOL, V78, P4392, DOI 10.1073/pnas.78.7.4392; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; ROZENGURT E, 1983, J CELL PHYSL, V16, P379; SAKURAI T, 1994, J BIOL CHEM, V269, P14118; SETH A, 1991, J BIOL CHEM, V266, P23521; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SPIEGEL AM, 1993, J CLIN INVEST, V92, P1119, DOI 10.1172/JCI116680; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUNIER B, 1995, J BIOL CHEM, V270, P3693; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K	54	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21411	21419		10.1074/jbc.270.36.21411	http://dx.doi.org/10.1074/jbc.270.36.21411			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673177	hybrid			2022-12-25	WOS:A1995RU05400082
J	ZENNARO, MC; KEIGHTLEY, MC; KOTELEVTSEV, Y; CONWAY, GS; SOUBRIER, F; FULLER, PJ				ZENNARO, MC; KEIGHTLEY, MC; KOTELEVTSEV, Y; CONWAY, GS; SOUBRIER, F; FULLER, PJ			HUMAN MINERALOCORTICOID RECEPTOR GENOMIC STRUCTURE AND IDENTIFICATION OF EXPRESSED ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ANDROGEN RECEPTOR; HUMAN GLUCOCORTICOID RECEPTOR; COMPLEMENTARY-DNA; RIBONUCLEIC-ACID; RAT HIPPOCAMPUS; GENE-EXPRESSION; MESSENGER-RNA; TRANSCRIPTION; SUPERFAMILY; PROMOTERS	Most of the known effects of aldosterone are mediated by the mineralocorticoid receptor, an intracellular receptor belonging to the steroid/thyroid hormone/retinoic acid receptor superfamily. We determined the genomic structure of the human MR (hMR) and identified 10 exons in the gene, including two exons (1 alpha and 1 beta) that encode different 5'-untranslated sequence. Expression of the two different hMR variants is under the control of two different promoters that contain no obvious TATA element, but multiple GC boxes. Our results indicate that hMR expression is regulated by alternative promoters perhaps in a tissue- or developmental-specific manner.	COLL FRANCE,INSERM,U36,F-75005 PARIS,FRANCE; PRINCE HENRYS INST MED RES,CLAYTON,VIC 3168,AUSTRALIA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Prince Henry's Institute of Medical Research			Zennaro, Maria-Christina/G-2841-2013; Kotelevtsev, Yuri V/R-1772-2016	Zennaro, Maria-Christina/0000-0001-5449-9191; Keightley, Maria-Cristina/0000-0001-8141-4069; Fuller, Peter/0000-0002-0948-2072; Kotelevtsev, Yuri/0000-0002-7255-7794				ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; AYOUBI TAY, 1994, J BIOL CHEM, V269, P9298; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CASTREN M, 1993, J NEUROENDOCRINOL, V5, P461, DOI 10.1111/j.1365-2826.1993.tb00508.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAIRE M, 1980, J BIOL CHEM, V256, P142; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAN YS, 1989, CYTOGENET CELL GENET, V52, P83, DOI 10.1159/000132846; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FULLER PJ, 1991, FASEB J, V5, P3092, DOI 10.1096/fasebj.5.15.1743440; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; JACKSON SP, 1990, CELL, P155; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KOMESAROFF PA, 1994, J CLIN ENDOCR METAB, V79, P27, DOI 10.1210/jc.79.1.27; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KWAK SP, 1993, ENDOCRINOLOGY, V133, P2344, DOI 10.1210/en.133.5.2344; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; MARVER D, 1985, BIOCHEM ACTION HORM, P385; MEYER AS, 1994, ENDOCRINOLOGY, V134, P1163, DOI 10.1210/en.134.3.1163; MISRAHI M, 1993, BIOCHIM BIOPHYS ACTA, V1216, P289, DOI 10.1016/0167-4781(93)90156-8; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MORRISON N, 1990, HUM GENET, V85, P130; OCHMAN H, 1990, PCR PROTOCOLS GUIDE; PATEL PD, 1989, MOL ENDOCRINOL, V3, P1877, DOI 10.1210/mend-3-11-1877; REUL JMHM, 1989, MOL ENDOCRINOL, V3, P1674, DOI 10.1210/mend-3-10-1674; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STEPHENSON G, 1987, AM J PHYSIOL, V252, pE525, DOI 10.1152/ajpendo.1987.252.4.E525; STRAHLE U, 1992, P NATL ACAD SCI USA, V89, P6731, DOI 10.1073/pnas.89.15.6731; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; TILLEY WD, 1990, J BIOL CHEM, V265, P13776; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; ZENNARO MC, 1994, J CLIN ENDOCR METAB, V79, P32, DOI 10.1210/jc.79.1.32; ZONG J, 1990, MOL CELL BIOL, V10, P5580, DOI 10.1128/MCB.10.10.5580	47	101	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21016	21020		10.1074/jbc.270.36.21016	http://dx.doi.org/10.1074/jbc.270.36.21016			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673127	hybrid			2022-12-25	WOS:A1995RU05400024
J	CORBEIL, HB; WHYTE, P; BRANTON, PE				CORBEIL, HB; WHYTE, P; BRANTON, PE			CHARACTERIZATION OF TRANSCRIPTION FACTOR E2F COMPLEXES DURING MUSCLE AND NEURONAL DIFFERENTIATION	ONCOGENE			English	Article						CELL CYCLE; DIFFERENTIATION E2F; TRANSCRIPTION FACTOR RETINOBLASTOMA	RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; DNA-BINDING ACTIVITY; NERVE GROWTH-FACTOR; CELL-CYCLE; SUSCEPTIBILITY GENE; VIRAL ONCOPROTEINS; PC12 CELLS; P107; FAMILY	The activities of E2F transcription factors are inhibited by interactions with members of the retinoblastoma (RE) tumor suppressor family, p105(RB), p107 and p130, In cycling cells p107 and p130 also interact with heterodimers comprised of Cdk2 and either A or E cyclins. We characterized E2F complexes present in C2C12 and P19 mouse cells induced to differentiate into muscle and neuronal cells, respectively. In both undifferentiated C2C12 and P19 cells, in addition to free species, E2F was found in complexes containing p107 or p130 and Cdk2. No E2F-pRB complexes were detected by electrophoretic mobility shift assays even though such cells were shown to contain pRB and E2F species capable of interacting in vitro. These results suggested that although present, pRB was unable to interact with E2F. Following differentiation of C2C12 cells into myotubes, E2F was present in at least two complexes which contained p130, but not in those containing p107 or Cdk2. Low levels of E2F-pRB complexes were also detected in fully differentiated C2C12 myotubes and in freshly isolated skeletal muscle. In the case of differentiated P19 neuronal cells, E2F was found in complexes containing pRB, p107 and p130. However, such cells may not be representative of fully differentiated neurons, as studies with rodent brain extracts indicated that only pRB-E2F complexes and those recognized by a p130-specific serum were present. These results suggested that in both muscle and neurons, pRB and p130 may play specific roles in the development or maintenance of terminal differentiation.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,HAMILTON,ON L8S 4K1,CANADA	McGill University; McGill University; McMaster University								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V353, P249; BARBEAU D, 1994, ONCOGENE, V9, P359; BOULUKOS KE, 1993, ONCOGENE, V8, P237; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1992, NATURE, V359, P128; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1994, J VIROL, V68, P6697, DOI 10.1128/JVI.68.10.6697-6709.1994; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EGAN C, 1989, ONCOGENE, V4, P383; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1994, FASEB J, V7, P846; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MARUYAMA K, 1987, ONCOGENE, V1, P361; MAYOL X, 1993, ONCOGENE, V8, P2561; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; NEVINS JR, 1992, SCIENCE, V258, P424; PAGANO M, 1992, SCIENCE, V55, P1144; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLACK RS, 1993, ONCOGENE, V8, P1585; SMITH DB, 1988, GENE, V657, P31; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIMAN KG, 1994, FASEB J, V7, P841; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	71	91	91	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					909	920						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675450				2022-12-25	WOS:A1995RU79800012
J	JACOB, ANK; KANDPAL, G; PATANJALI, SR; KANDPAL, RP				JACOB, ANK; KANDPAL, G; PATANJALI, SR; KANDPAL, RP			MOLECULAR-CLONING AND EXPRESSION PATTERN OF GENES FROM A 470 KB REGION NEAR BRCA1 LOCUS ON CHROMOSOME-17Q21	ONCOGENE			English	Note						CDNA; HYBRIDIZATION SELECTION; BRCA1 LOCUS; EXPRESSED SEQUENCES	FAMILIAL BREAST; OVARIAN-CANCER; POLYMORPHISMS; LOCALIZATION; FRAGMENTS; SELECTION; SEQUENCES; LINKAGE; CDNA	We have used direct cDNA selection to isolate expressed sequences from a set of four overlapping YACs, spanning approximately 470 kb of the chromosomal interval 17q21 centromeric to BRCA1 gene. Thirty-eight nonoverlapping unique cDNA fragments were identified in this region. Twenty-two of the selected cDNAs showed complete identity with known genes and expressed sequence tags. Two of these cDNAs shared sequence homology with genes known to encode potential DNA binding motifs and hence could function in transcriptional regulation. The remaining 16 unique cDNA fragments showed no significant similarity to sequences in the databases and could potentially encode novel genes. Northern analysis of the novel cDNAs showed differential expression in various tissues, supporting the transcribed nature of these sequences. Our results place the gene for a G-protein coupled receptor (GPR2) previously mapped to 17q within a 400 kb region on 17q21.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Yale University					NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R29DC001682] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC-01682] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOWCOCK AM, 1993, AM J HUM GENET, V52, P718; BRODY LC, 1995, GENOMICS, V25, P238, DOI 10.1016/0888-7543(95)80131-5; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CROPP CS, 1994, CANCER RES, V54, P2548; EASTON DF, 1993, AM J HUM GENET, V52, P678; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMAN LS, 1995, GENOMICS, V25, P256, DOI 10.1016/0888-7543(95)80133-7; FRIEDMAN LS, 1993, HUM MOL GENET, V2, P821, DOI 10.1093/hmg/2.6.821; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL AP, 1994, SCIENCE, V266, P120; FUTREAL PA, 1994, HUM MOL GENET, V3, P1359, DOI 10.1093/hmg/3.8.1359; FUTREAL PA, 1992, CANCER RES, V52, P2624; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; JACOBS IJ, 1993, CANCER RES, V53, P1218; KRIZMAN DB, 1993, FOCUS, V15, P106; LANDSMAN D, 1989, NUCLEIC ACIDS RES, V17, P2301, DOI 10.1093/nar/17.6.2301; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MARCHESE A, 1994, GENOMICS, V23, P609, DOI 10.1006/geno.1994.1549; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NIKAIDO T, 1990, CLIN EXP IMMUNOL, V79, P209; OSBORNELAWRENCE S, 1995, GENOMICS, V25, P248, DOI 10.1016/0888-7543(95)80132-6; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PATEL K, 1991, NUCLEIC ACIDS RES, V19, P4371, DOI 10.1093/nar/19.16.4371; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P6565; PELTOKETO H, 1992, EUR J BIOCHEM, V209, P459, DOI 10.1111/j.1432-1033.1992.tb17310.x; Sambrook J, 1989, MOL CLONING LABORATO; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SULTSON J, 1992, NATURE, V356, P37; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X; Zhao H. G., 1994, American Journal of Human Genetics, V55, pA252; ZHENG Y, 1991, CELL, V655, P817	35	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					981	986						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675458				2022-12-25	WOS:A1995RU79800020
J	BUHL, AM; OSAWA, S; JOHNSON, GL				BUHL, AM; OSAWA, S; JOHNSON, GL			MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION REQUIRES 2 SIGNAL INPUTS FROM THE HUMAN ANAPHYLATOXIN C5A RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; DEPENDENT ACTIVATION; IN-VITRO; RAF; PATHWAY; CELLS; PHOSPHORYLATION; CAMP; TRANSDUCTION; FIBROBLASTS	The anaphylatoxin C5a receptor activates the Ras/Raf/mitogen-activated protein (MAP) kinase pathway in human neutrophils. The signal pathways involved in Ras/Raf/MAP kinase activation in response to C5a and other chemoattractant receptors is poorly understood. Stimulation of the C5a receptor expressed in HEK293 cells results in modest MAP kinase activation which is inhibited by pertussis toxin-catalyzed ADP-ribosylation of G(i). Coexpression of the C5a receptor and the G(16) alpha subunit (alpha(16)) results in the G(16)-mediated activation of phospholipase C beta and a robust MAP kinase activation. Pertussis toxin treatment of C5a receptor/alpha(16)-cotransfected cells inhibits C5a stimulation of MAP kinase activity approximately 60% relative to the control response. Similarly, the protein kinase C inhibitor, GF109203X inhibits activation of MAP kinase activation in C5a receptor/alpha(16)-cotransfected cells by 60%; the protein kinase C inhibitor does not affect the modest C5a receptor response in the absence of alpha(16) expression. These results demonstrate that two independent signals are required for the maximal activation of MAP kinase by G protein-coupled receptors.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; AARHUS UNIV,DEPT CHEM,DIV BIOSTRUCT CHEM,DK-8000 AARHUS C,DENMARK; UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	National Jewish Health; Aarhus University; University of North Carolina; University of North Carolina Chapel Hill; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; BUHL AM, 1993, FEBS LETT, V323, P132, DOI 10.1016/0014-5793(93)81464-B; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FAURE M, 1994, J BIOL CHEM, V269, P7851; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MITCHELL FM, 1995, IN PRESS J BIOL CHEM, V270; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; RUSSELL M, 1994, MOL CELL BIOL, V14, P2343, DOI 10.1128/MCB.14.4.2343; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	38	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19828	19832		10.1074/jbc.270.34.19828	http://dx.doi.org/10.1074/jbc.270.34.19828			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7649993	hybrid			2022-12-25	WOS:A1995RQ99100025
J	HO, SN; THOMAS, DJ; TIMMERMAN, LA; LI, X; FRANCKE, U; CRABTREE, GR				HO, SN; THOMAS, DJ; TIMMERMAN, LA; LI, X; FRANCKE, U; CRABTREE, GR			NFATC3, A LYMPHOID-SPECIFIC NFATC FAMILY MEMBER THAT IS CALCIUM-REGULATED AND EXHIBITS DISTINCT DNA FINDING SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; PLACENTAL ALKALINE-PHOSPHATASE; CYCLOSPORINE-A; ANTIGEN RECEPTOR; INTERLEUKIN-4 GENE; NUCLEAR FACTOR; TRANSCRIPTION; EXPRESSION; PROMOTER; IDENTIFICATION	Signals transduced by the T cell antigen receptor (TCR) regulate developmental transitions in the thymus and also mediate the immunologic activation of mature, peripheral T cells, In both cases TCR stimulation leads to the assembly of the NFAT transcription complex as a result of the calcium-dependent nuclear translocation of cytosolic subunits, NFATc, and the Ras/protein kinase C-dependent induction of a nuclear subunit, NFATn, To further understand the diverse roles of antigen receptor signaling throughout T cell development, we have identified a new NFATc family member, NFATc3, that is expressed at highest levels in the thymus, NFATc3 is the product of a gene on murine chromosome 8 that is not Linked to the other NFATc genes. NFATc3, like other NFATc family members, contains a conserved rel similarity domain, and also defines a region conserved among NFATc family members, the SP repeat region, characterized by the repeated motif SPxxSPxxSPrx-sxx(D/E)(D/E)swl. NFATc3 activates NFAT site-dependent transcription when overexpressed, yet exhibits a pattern of DNA site specificity distinct hom other NFATc proteins, Additionally, thymic NFATc3 undergoes modifications in response to agents that mimic T cell receptor signaling, including a decrease in apparent molecular mass upon elevation of intracellular calcium that is inhibited by the immunosuppressant FK506, Given the preferential expression of NFATc3 in the thymus, NFATc family members may regulate distinct subsets of genes during T cell development.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University					NCI NIH HHS [CA39612] Funding Source: Medline; NHGRI NIH HHS [HG00298] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA039612, R01CA039612] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ASHTONRICKARDT PG, 1994, IMMUNOL TODAY, V15, P362, DOI 10.1016/0167-5699(94)90174-0; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; CHEN D, 1993, MOL CELL BIOL, V13, P228, DOI 10.1128/MCB.13.1.228; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; CULLEN BR, 1992, METHOD ENZYMOL, V216, P362; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FULEIHAN R, 1994, J CLIN INVEST, V93, P1315, DOI 10.1172/JCI117089; GAO EK, 1988, NATURE, V336, P176, DOI 10.1038/336176a0; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; HADDAD P, 1993, EUR J IMMUNOL, V23, P625, DOI 10.1002/eji.1830230307; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JENKINS MK, 1988, SCIENCE, V241, P1655, DOI 10.1126/science.3262237; LI X, 1995, CYTOGENET CELL GENET, V68, P185, DOI 10.1159/000133910; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LYON MF, 1994, MOUSE GENOME, V91, P21; MATSUDA I, 1994, BIOCHEM BIOPH RES CO, V199, P439, DOI 10.1006/bbrc.1994.1248; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MILATOVICH A, 1991, GENOMICS, V11, P1040, DOI 10.1016/0888-7543(91)90030-I; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NESBITT MN, 1973, CHROMOSOMA, V41, P145, DOI 10.1007/BF00319691; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RIEGEL JS, 1990, J IMMUNOL, V144, P3611; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TSITSIKOV EN, 1994, MOL IMMUNOL, V31, P895, DOI 10.1016/0161-5890(94)90009-4; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; YAMASHITA I, 1993, INT IMMUNOL, V5, P1139, DOI 10.1093/intimm/5.9.1139	43	157	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					19898	19907		10.1074/jbc.270.34.19898	http://dx.doi.org/10.1074/jbc.270.34.19898			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650004	hybrid			2022-12-25	WOS:A1995RQ99100036
J	HORIUCHI, M; KOIKE, G; YAMADA, T; MUKOYAMA, M; NAKAJIMA, M; DZAU, VJ				HORIUCHI, M; KOIKE, G; YAMADA, T; MUKOYAMA, M; NAKAJIMA, M; DZAU, VJ			THE GROWTH-DEPENDENT EXPRESSION OF ANGIOTENSIN-II TYPE-2 RECEPTOR IS REGULATED BY TRANSCRIPTION FACTORS INTERFERON REGULATORY FACTOR-1 AND FACTOR-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENIN GENE-EXPRESSION; IFN-INDUCIBLE GENES; AT2 BINDING-SITES; CELL-GROWTH; R3T3 CELLS; IRF-1; RAT; BETA; SUBTYPES; INHIBITION	Angiotensin II type 2 (AT(2)) receptor is abundantly and widely expressed in fetal tissues but present only in restricted tissues in the adult such as brain and atretic ovary, This receptor is speculated to be involved in tissue growth and/or differentiation. To elucidate the molecular mechanism of growth-regulated AT(2) receptor expression, we cloned the mouse AT(2) receptor genomic DNA and studied its promoter function in mouse fibroblast-derived R3T3 cells, which express AT(2) receptor in the confluent, quiescent state but very low levels of the receptor in actively growing state, Promoter/luciferase reporter deletion analysis of AT(2) receptor in R3T3 cells showed that the putative negative regulatory region is located between the positions -453 and -225, which plays an important role in the transcriptional control of AT(2) receptor gene expression along with the cell growth, We identified the interferon regulatory factor (IRF) binding motif in this region using DNase footprinting analysis and demonstrated that IRF binding oligonucleotide treatment increased the AT(2) receptor expression in growing R3T3 cells but not in confluent cells, Furthermore, by antisense treatment, we demonstrated that IRF-2 attenuated the AT(2) receptor expression in both growing and confluent R3T3 cells, whereas IRF-1 enhanced AT(2) receptor expression in the confluent cells only, Consistent with this result, gel mobility shift assay demonstrated that growing R3T3 cells exhibited only IRF-2 binding, whereas confluent cells exhibited both IRF-1 and IRF-2 binding, Furthermore, we observed using reverse transcription-polymerase chain reaction that the IRF-1 mRNA expression was more abundant in confluent cells than growing cells, whereas IRF-2 expression did not change with R3T3 cell growth, We conclude that, in confluent cells, the enhanced expression of IRF-1 antagonizes the IRF-2 effect and increases the AT(2) receptor expression. We speculate that these transcriptional factors influence cell growth in part by regulating AT(2) receptor expression.	STANFORD UNIV,SCH MED,FALK CARDIOVASC RES CTR,DIV CARDIOVASC MED,STANFORD,CA 94305	Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035610, R01HL046631, R01HL035252, R37HL035610] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35610, HL35252, HL46631] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1987, CELL, V50, P847; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHIU AT, 1989, BIOCHEM BIOPH RES CO, V165, P196, DOI 10.1016/0006-291X(89)91054-1; DAUD AI, 1988, ENDOCRINOLOGY, V122, P2727, DOI 10.1210/endo-122-6-2727; DIGNAM JD, 1993, NUCLEIC ACIDS RES, V11, P1475; DUDLEY DT, 1991, MOL PHARMACOL, V40, P360; DUDLEY DT, 1993, REGUL PEPTIDES, V44, P199, DOI 10.1016/0167-0115(93)90243-2; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HORIUCHI M, 1993, J CLIN INVEST, V92, P1805, DOI 10.1172/JCI116770; HORIUCHI M, 1991, J BIOL CHEM, V266, P16247; ICHIKI T, 1994, BBA-BIOMEMBRANES, V1189, P247, DOI 10.1016/0005-2736(94)90072-8; JANIAK P, 1992, HYPERTENSION, V20, P737, DOI 10.1161/01.HYP.20.6.737; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLAN MA, 1991, P NATL ACAD SCI USA, V88, P11440, DOI 10.1073/pnas.88.24.11440; MIYAMOTO M, 1988, CELL, V54, P9003; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; NAKAJIMA M, 1993, BIOCHEM BIOPH RES CO, V197, P393, DOI 10.1006/bbrc.1993.2492; NAKAMURA M, 1994, HYPERTENSION, V24, P378; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PUCELL AG, 1991, ENDOCRINOLOGY, V128, P1947, DOI 10.1210/endo-128-4-1947; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pH667, DOI 10.1152/ajpheart.1991.261.3.H667; TSUTSUMI K, 1991, ENDOCRINOLOGY, V129, P1075, DOI 10.1210/endo-129-2-1075; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WHITEBREAD S, 1989, BIOCHEM BIOPH RES CO, V163, P284, DOI 10.1016/0006-291X(89)92133-5; YAMADA G, 1990, P NATL ACAD SCI USA, V88, P532; Yamada T., 1995, Journal of Investigative Medicine, V43, p290A	41	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1995	270	34					20225	20230		10.1074/jbc.270.34.20225	http://dx.doi.org/10.1074/jbc.270.34.20225			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RQ991	7650042	hybrid			2022-12-25	WOS:A1995RQ99100080
J	COVARRUBIAS, M; VYAS, TB; ESCOBAR, L; WEI, A				COVARRUBIAS, M; VYAS, TB; ESCOBAR, L; WEI, A			ALCOHOLS INHIBIT A CLONED POTASSIUM CHANNEL AT A DISCRETE SATURABLE SITE - INSIGHTS INTO THE MOLECULAR-BASIS OF GENERAL-ANESTHESIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUID GIANT-AXON; K+ CHANNEL; XENOPUS-OOCYTES; SUBUNIT STOICHIOMETRY; ION CHANNELS; TEA BLOCKADE; RECEPTOR; SHAKER; DROSOPHILA; BINDING	The molecular basis of general anesthetic action on membrane proteins that control ion transport is not yet understood, In a previous report (Covarrubias, M., and Rubin, E. (1993) Proc. Natl. Acad. Sci. 90, 6957-6960), we found that low concentrations of ethanol (17-170 mM) selectively inhibited a noninactivating cloned K+ channel encoded by Drosophila Shaw2. Here, we have conducted equilibrium dose-inhibition experiments, single channel recording, and mutagenesis in vitro to study the mechanism underlying the inhibition of Shaw2 K+ channels by a homologous series of n-alkanols (ethanol to 1-hexanol), The results showed that: (i) these alcohols inhibited Shaw2 whole-cell currents, the equilibrium dose-inhibition relations were hyperbolic, and competition experiments revealed the presence of a discrete site of action, possibly a hydrophobic pocket; (ii) this pocket may be part of the protein because n-alkanol sensitivity can be transferred to novel hybrid K+ channels composed of Shaw2 subunits and homologous ethanol-insensitive subunits; (iii) moreover, a hydrophobic point mutation within a cytoplasmic loop of an ethanol-insensitive K+ channel (human Kv3.4) was sufficient to allow significant inhibition by n-alkanols, with a dose-inhibition relation that closely resembled that of wildtype Shaw2 channels; and (iv) 1-butanol selectively inhibited long duration single channel openings in a manner consistent with a direct effect on channel gating. These results strongly suggest that a discrete site within the ion channel protein is the primary locus of alcohol and general anesthetic action.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)	COVARRUBIAS, M (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,1020 LOCUST ST,JAH 25,PHILADELPHIA,PA 19107, USA.			Covarrubias, Manuel/0000-0002-0881-4143	NIAAA NIH HHS [AA07463, AA07186-07] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186, T32AA007463] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALIFIMOFF JK, 1989, BRIT J PHARMACOL, V96, P9, DOI 10.1111/j.1476-5381.1989.tb11777.x; ANANTHARAM V, 1992, MOL PHARMACOL, V42, P499; Ausubel FM., 2006, ENZYMATIC MANIPULATI; AVEYARD R, 1969, T FARADAY SOC, V65, P2645, DOI 10.1039/tf9696502645; BRAHM J, 1983, J GEN PHYSIOL, V81, P283, DOI 10.1085/jgp.81.2.283; BRAU ME, 1995, J GEN PHYSIOL, V105, P485, DOI 10.1085/jgp.105.4.485; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; COVARRUBIAS M, 1993, P NATL ACAD SCI USA, V90, P6957, DOI 10.1073/pnas.90.15.6957; DIETRICH RA, 1989, PHARMACOL REV, V41, P489; DILGER JP, 1994, ANESTHESIOLOGY, V81, P431, DOI 10.1097/00000542-199408000-00022; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; ELMAGHRABI EA, 1992, P NATL ACAD SCI USA, V89, P4329, DOI 10.1073/pnas.89.10.4329; Franks N P, 1991, Alcohol Alcohol Suppl, V1, P197; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1991, SCIENCE, V254, P427, DOI 10.1126/science.1925602; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; FROEMMEL C, 1984, Journal of Theoretical Biology, V111, P247; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAYDON DA, 1988, J PHYSIOL-LONDON, V402, P363, DOI 10.1113/jphysiol.1988.sp017209; HAYDON DA, 1988, J PHYSIOL-LONDON, V402, P375, DOI 10.1113/jphysiol.1988.sp017210; HAYDON DA, 1983, J PHYSIOL-LONDON, V341, P411, DOI 10.1113/jphysiol.1983.sp014813; HAYDON DA, 1986, J PHYSIOL-LONDON, V373, P311, DOI 10.1113/jphysiol.1986.sp016049; HEIGENBOTHAM L, 1992, NEURON, V8, P483; HERRINGTON J, 1991, J NEUROSCI, V11, P2226; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; Ledwell J. L., 1995, Biophysical Journal, V68, pA32; LI CY, 1994, P NATL ACAD SCI USA, V91, P8200, DOI 10.1073/pnas.91.17.8200; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; MCCORMACK K, 1993, BIOPHYS J, V63, P1740; MCPHEE JC, 1994, P NATL ACAD SCI USA, V91, P12346, DOI 10.1073/pnas.91.25.12346; Meyer H, 1901, ARCH EXP PATHOL PHAR, V46, P338, DOI 10.1007/BF01978064; MILLER KW, 1986, ANN NY ACAD SCI, V492, P71; MOSS GWJ, 1991, P NATL ACAD SCI USA, V88, P134, DOI 10.1073/pnas.88.1.134; MURRELL RD, 1991, J PHYSIOL-LONDON, V437, P431, DOI 10.1113/jphysiol.1991.sp018604; PRESS WH, 1989, NUMERICAL RECIPES PA, P473; RUDY B, 1991, J NEUROSCI RES, V29, P401, DOI 10.1002/jnr.490290316; SINE SM, 1987, BIOPHYS J, V52, P1047; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; SOLC CK, 1988, J NEUROSCI, V8, P2556; STUEHMER W, 1992, METHOD ENZYMOL, V207, P319; Tanford C., 1973, HYDROPHOBIC EFFECT; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; TSUNODA S, 1995, J NEUROSCI, V15, P1741, DOI 10.1523/JNEUROSCI.15-03-01741.1995; WAFFORD KA, 1991, NEURON, V7, P27, DOI 10.1016/0896-6273(91)90071-7; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; WEIGHT FF, 1992, ADV BIOCHEM PSYCHOPH, V47, P335; WEIGHT FF, 1992, INT REV NEUROBIOL, V33, P289, DOI 10.1016/S0074-7742(08)60694-7; WOOD SC, 1995, MOL PHARMACOL, V47, P121; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; ZAGOTTA WN, 1988, J NEUROSCI, V8, P4765; ZORN L, NEUROSCI LETT, V161, P81	59	79	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19408	19416		10.1074/jbc.270.33.19408	http://dx.doi.org/10.1074/jbc.270.33.19408			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642622	hybrid			2022-12-25	WOS:A1995RP70300036
J	MEDHORA, MM; TEITELBAUM, S; CHAPPEL, J; ALVAREZ, J; MIMURA, H; ROSS, FP; HRUSKA, K				MEDHORA, MM; TEITELBAUM, S; CHAPPEL, J; ALVAREZ, J; MIMURA, H; ROSS, FP; HRUSKA, K			1-ALPHA,25-DIHYDROXYVITAMIN-D3 UP-REGULATES EXPRESSION OF THE OSTEOCLAST INTEGRIN ALPHA-V-BETA-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION RECEPTORS; GROWTH FACTOR-BETA; BONE-MARROW-CELLS; VITRONECTIN RECEPTOR; MACROPHAGE DIFFERENTIATION; FIBRONECTIN RECEPTOR; ENDOTHELIAL-CELLS; GENE PROMOTER; 1,25-DIHYDROXYVITAMIN-D3; GLYCOPROTEIN	Osteoclast precursors selectively attach to bone and differentiate into multinucleated cells that function to remodel and resorb it. We have shown previously that attachment of osteoclasts to bone and subsequent resorption are mediated by the integrin alpha(v)beta3. 1Alpha,25-dihydroxyvitamin D3 (1,25-(OH)2D3) enhances osteoclast precursor differentiation in vivo by mechanisms that are still not clearly understood but entail enhanced attachment of cells to bone. This observation raises the possibility that at least one component of vitamin D-induced osteoclast precursor differentiation involves modulation of integrin expression. To test if the steroid modulates the osteoclast integrin alpha(v)beta3 (the vitronectin receptor), we examined the effects of 1,25-(OH)2D3 on transcription of the alpha(v) gene as well as surface expression and function Of alpha(v)beta3, in chicken osteoclast precursors. Treatment of the cells with 1,25-(OH)2D3 led to a progressive dose-dependent increase in steady state alpha(v) mRNA levels with enhanced expression evident within 24 h. The effect was receptor-mediated as indicated by the effects of other vitamin D analogs. The increase in alpha(v) mRNA levels did not reflect decreased message degradation but, as demonstrated by nuclear run-on experiments, was due to accelerated rates of transcription. Most importantly, induction of alpha(v) mRNA by 1,25-(OH)2D3 was mirrored by higher levels of expression of alpha(v)beta3 on the cell surface, as well enhanced attachment to its substrate, vitronectin.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS, DIV RENAL, 216 S KINGSHIGHWAY, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, DEPT PATHOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)				Teitelbaum, Steven/0000-0002-4054-6679	NIAMS NIH HHS [AR32087, AR39561] Funding Source: Medline; NIDDK NIH HHS [DK09976] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087, R01AR039561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK009976] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ JI, 1991, ENDOCRINOLOGY, V128, P2324, DOI 10.1210/endo-128-5-2324; BILLECOCQ A, 1990, P NATL ACAD SCI USA, V87, P6470, DOI 10.1073/pnas.87.16.6470; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BOSSY B, 1990, BIOCHEMISTRY-US, V29, P10191, DOI 10.1021/bi00496a006; BROMMAGE R, 1985, ENDOCR REV, V6, P491, DOI 10.1210/edrv-6-4-491; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DEDHAR S, 1989, J CELL PHYSIOL, V138, P291, DOI 10.1002/jcp.1041380210; DEDHAR S, 1991, J BIOL CHEM, V266, P21846; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; FAMBROUGH DM, 1988, J CELL BIOL, V106, P61, DOI 10.1083/jcb.106.1.61; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HEINO J, 1989, J BIOL CHEM, V264, P380; HOLTROP ME, 1977, CLIN ORTHOP RELAT R, P177; HORTON MA, 1989, J BONE MINER RES, V4, P803; HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNOTZ RA, 1989, J BIOL CHEM, V264, P389; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; KNUDSEN KA, 1985, EXP CELL RES, V157, P218, DOI 10.1016/0014-4827(85)90164-8; KOEFFLER HP, 1984, CANCER RES, V44, P5624; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; MCCARTHY DM, 1983, LEUKEMIA RES, V7, P51, DOI 10.1016/0145-2126(83)90057-7; MERKE J, 1986, J CLIN INVEST, V77, P312, DOI 10.1172/JCI112292; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; ROODMAN GD, 1985, P NATL ACAD SCI USA, V82, P8213, DOI 10.1073/pnas.82.23.8213; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SOKAL RR, 1981, BIOMETRY, P432; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; TINKLER SMB, 1981, J ANAT, V133, P91; UCKER DS, 1984, J BIOL CHEM, V259, P7416	40	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1456	1461						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678259				2022-12-25	WOS:A1993KG07700103
J	SONNENBURG, WK; SEGER, D; BEAVO, JA				SONNENBURG, WK; SEGER, D; BEAVO, JA			MOLECULAR-CLONING OF A CDNA-ENCODING THE 61-KDA CALMODULIN-STIMULATED CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE - TISSUE-SPECIFIC EXPRESSION OF STRUCTURALLY RELATED ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHODIESTERASE; SMOOTH-MUSCLE; BOVINE BRAIN; RAT-BRAIN; INHIBITORS; ACTIVATION; SEQUENCE; ISOZYMES; RECEPTOR; CALCIUM	We have isolated a 2287-bp cDNA encoding the 61-kDa calmodulin-stimulated cyclic nucleotide phosphodiesterase (CaM PDE) from a bovine brain library. A large open reading frame within the cDNA encodes a 530-residue polypeptide which is identical to the sequence of the purified protein previously determined by direct amino acid sequencing. Moreover, COS cells transfected with the cDNA express a cAMP and cGMP hydrolytic activity that is stimulated by calcium and calmodulin, confirming that the cDNA represents a mRNA species encoding a CaM PDE isozyme. RNase protection analyses indicate that either 61-kDa CaM PDE mRNA or structurally related transcripts encoding different CaM PDE isoforms are expressed in a tissue-specific manner. Total RNA isolated from brain (cerebral cortex, basal ganglia, hippocampus, cerebellum, and medulla/spinal cord), heart, aorta, liver, kidney outer medulla, kidney papilla, trachea, and lung completely protected a 410-base antisense riboprobe corresponding to sequence encoding a portion of the catalytic domain. Little or no protection was detected using adrenal cortex, adrenal medulla, liver, kidney cortex, spleen, or T-lymphocyte total RNA. Only brain RNA completely protected a 240-base antisense riboprobe corresponding to the 61-kDa CaM PDE amino terminus encompassing a putative calmodulin-binding domain. However, heart, aorta, liver, kidney, trachea, and lung RNA protected 150 bases of this riboprobe suggesting that these tissues express an isoform structurally related to the 61-kDa CaM PDE. Northern analysis of mRNA isolated from brain, heart, aorta, liver, kidney, lung, and trachea revealed that the cDNA hybridizes with a 3.8- and a 4.4-kb (kilobase) mRNA species. Interestingly, Northern blots of bovine cerebral cortex and heart mRNA probed under stringent conditions with antisense transcripts corresponding to either the 5'- or 3'-untranslated sequence of the 61-kDa CaM PDE cDNA hybridized with only the 4.4-kb mRNA from both tissues. Since different, yet structurally similar CaM PDE isoforms are expressed in brain and in heart, this result, in addition to the RNase protection data, is consistent with the idea that the mRNAs encoding these two CaM PDE isoforms are products of an alternately spliced gene.	UNIV WASHINGTON,DEPT PHARMACOL,SJ-30,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIDDK NIH HHS [DK21023] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIANO MA, 1983, NEUROSCIENCE, V10, P707, DOI 10.1016/0306-4522(83)90212-9; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BODE DC, 1991, CIRC RES, V68, P1070, DOI 10.1161/01.RES.68.4.1070; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; BUXTON ILO, 1985, J BIOL CHEM, V260, P6733; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; CHARBONNEAU H, 1990, CYCLIC NUCLEOTIDE PH, V2, P267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAGIWARA M, 1984, BIOCHEM PHARMACOL, V33, P453, DOI 10.1016/0006-2952(84)90240-5; HANSEN RS, 1986, J BIOL CHEM, V261, P4636; HANSEN RS, 1982, P NATL ACAD SCI-BIOL, V79, P2788, DOI 10.1073/pnas.79.9.2788; HURWITZ RL, 1990, J BIOL CHEM, V265, P8901; KINCAID RL, 1987, P NATL ACAD SCI USA, V84, P1118, DOI 10.1073/pnas.84.4.1118; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRAMER RH, 1988, J NEUROSCI, V8, P1804; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; LORENZ KL, 1983, MOL PHARMACOL, V23, P424; LUDVIG N, 1991, NEUROSCIENCE, V44, P491, DOI 10.1016/0306-4522(91)90072-V; LUGNIER C, 1986, BIOCHEM PHARMACOL, V35, P1743, DOI 10.1016/0006-2952(86)90333-3; MILLERHANCE WC, 1988, J BIOL CHEM, V263, P13979; MIOT F, 1983, FEBS LETT, V151, P273, DOI 10.1016/0014-5793(83)80085-4; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; NOVACK JP, 1991, BIOCHEMISTRY-US, V30, P7940, DOI 10.1021/bi00246a010; ROSSI P, 1988, J BIOL CHEM, V263, P15521; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHARMA RK, 1986, J BIOL CHEM, V261, P14160; SHARMA RK, 1984, J BIOL CHEM, V259, P9248; SHENOLIKAR S, 1985, BIOCHEMISTRY-US, V24, P672, DOI 10.1021/bi00324a020; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH WL, 1989, ADV EXP MED BIOL, V259, P131; SONNENBURG WK, 1991, J BIOL CHEM, V266, P17655; SUMNERS C, 1991, AM J PHYSIOL, V260, pC79, DOI 10.1152/ajpcell.1991.260.1.C79; TANNER LI, 1986, MOL PHARMACOL, V29, P455; TORPHY TJ, 1991, MOL PHARMACOL, V39, P376; WANG JH, 1990, MOL PHARM CELL REGUL, V2, P19; WEISHAAR RE, 1986, BIOCHEM PHARMACOL, V35, P787, DOI 10.1016/0006-2952(86)90247-9	45	82	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					645	652						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678006				2022-12-25	WOS:A1993KE60300097
J	NOHNO, T; ISHIKAWA, T; SAITO, T; HOSOKAWA, K; NOJI, S; WOLSING, DH; ROSENBAUM, JS				NOHNO, T; ISHIKAWA, T; SAITO, T; HOSOKAWA, K; NOJI, S; WOLSING, DH; ROSENBAUM, JS			IDENTIFICATION OF A HUMAN TYPE-II RECEPTOR FOR BONE MORPHOGENETIC PROTEIN-4 THAT FORMS DIFFERENTIAL HETEROMERIC COMPLEXES WITH BONE MORPHOGENETIC PROTEIN TYPE-I RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; SERINE THREONINE KINASE; TGF-BETA; EXPRESSION CLONING; ACTIVIN RECEPTOR; FAMILY; PUNT	Bone morphogenetic proteins (BMPs) comprise the largest subfamily of TGF-beta-related Ligands and are known to bind to type I and type II receptor serine/threonine kinases. Although several mammalian BMP type I receptors have been identified, the mammalian BMP type II receptors have remained elusive. We have isolated a cDNA encoding a novel transmembrane serine/threonine kinase from human skin fibroblasts which we demonstrate here to be a type II receptor that binds BMP-4. This receptor (BRK-3) is distantly related to other known type II receptors and is distinguished from them by an extremely long carboxyl-terminal sequence following the intracellular kinase domain. The BRK-3 gene is widely expressed in a variety of adult tissues. When expressed alone in COS cells, BRK-3 specifically binds BMP-4, but cross-linking of BMP-4 to BRK-3 is undetectable in the absence of either the BRK-1 or BRK-2 BMP type I receptors. Cotransfection of BRK-2 with BRK-3 greatly enhanced affinity labeling of BMP-4 to the type I receptor, in contrast to the affinity labeling pattern observed with the BRK-1 + BRK-3 heteromeric complex. Furthermore, a subpopulation of super-high affinity binding sites is formed in COS cells upon cotransfection only of BRK-2 + BRK-3, suggesting that the different heteromeric BMP receptor complexes have different signaling potential.	PROCTER & GAMBLE CO, MIAMI VALLEY LABS,DIV CORP RES, CINCINNATI, OH 45253 USA; UNIV TOKUSHIMA, FAC ENGN,DEPT BIOL SCI & TECHNOL, TOKUSHIMA 770, JAPAN; Kawasaki Med Sch, DEPT PHARMACOL, KURASHIKI, OKAYAMA 70101, JAPAN; Kawasaki Med Sch, DEPT BIOCHEM, KURASHIKI, OKAYAMA 70101, JAPAN	Procter & Gamble; Tokushima University; Kawasaki Medical School; Kawasaki Medical School			Nohno, Tsutomu/B-6923-2008; Noji, Sumihare/E-3047-2010	Nohno, Tsutomu/0000-0002-0351-5603; 				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BAARENDS WM, 1994, DEVELOPMENT, V120, P189; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU F, 1995, MOL CELL BIOL, V15, P3479; LYONS KM, 1992, CIBA F SYMP, V165, P219; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATSUZAKI K, 1993, J BIOL CHEM, V268, P12719; MATZUK MM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P105, DOI 10.1016/0167-4781(92)90472-C; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MOUSTAKAS A, 1995, J BIOL CHEM, V270, P765, DOI 10.1074/jbc.270.2.765; PANARETTO BA, 1993, REPROD FERT DEVELOP, V5, P345, DOI 10.1071/RD9930345; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; Sambrook J, 1989, MOL CLONING LABORATO; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; Sumitomo S, 1993, DNA Seq, V3, P297, DOI 10.3109/10425179309020827; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAKUMI T, 1995, EXP CELL RES, V216, P208, DOI 10.1006/excr.1995.1026; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	40	200	215	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22522	22526		10.1074/jbc.270.38.22522	http://dx.doi.org/10.1074/jbc.270.38.22522			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673243	hybrid			2022-12-25	WOS:A1995RW31400072
J	SHIMAMOTO, T; TANIMURA, T; YONEDA, Y; KOBAYAKAWA, Y; SUGASAWA, K; HANAOKA, F; OKA, M; OKADA, Y; TANAKA, K; KOHNO, K				SHIMAMOTO, T; TANIMURA, T; YONEDA, Y; KOBAYAKAWA, Y; SUGASAWA, K; HANAOKA, F; OKA, M; OKADA, Y; TANAKA, K; KOHNO, K			EXPRESSION AND FUNCTIONAL ANALYSES OF THE DXPA GENE, THE DROSOPHILA HOMOLOG OF THE HUMAN EXCISION-REPAIR GENE XPA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 CHROMOSOMES; A COMPLEMENTING PROTEIN; HUMAN CELL-EXTRACTS; PIGMENTOSUM GROUP-G; XERODERMA-PIGMENTOSUM; DNA-REPAIR; DAMAGED DNA; MOLECULAR CHARACTERIZATION; YEAST HOMOLOG; CDNA CLONING	Xeroderma pigmentosum (XP) is a human hereditary disease characterized by a defect in DNA repair after exposure to ultraviolet Light. Among the seven groups of XP, group A (XP-A) patients show the most severe deficiency in excision repair and a wide variety of cutaneous and neurological disorders. We have cloned homologs of the human XPA gene from chicken, Xenopus, and Drosophila, and sequence analysis revealed that these genes are highly conserved throughout evolution. Here, we report characterization of the Drosophila homolog of the human XPA gene (Dxpa). The Dxpa gene product shows DNA repair activities in an in vitro repair system, and Dxpa cDNA has been shown to complement a mutant allele of human XP-A cells by transfection. Polytene chromosome in situ hybridization mapped Dxpa to 3F6-8 on the X chromosome, where no mutant defective in excision repair was reported. Northern blot analysis showed that the gene is continuously expressed in all stages of fly development. Interestingly, the Dxpa protein is strongly expressed in the central nervous system and muscles as revealed by immunohistochemical analysis using anti-Dxpa antibodies, consistent with the results obtained in transgenic flies expressing a Dxpa-beta-galactosidase fusion gene driven by the Dxpa promoter.	NARA INST SCI & TECHNOL,RES & EDUC CTR GENET INFORMAT,NARA 63001,JAPAN; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 810,JAPAN; INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN; SENRI LIFE SCI CTR,TOYONAKA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT ANAT & CELL BIOL,SUITA,OSAKA 565,JAPAN	Nara Institute of Science & Technology; Osaka University; Kyushu University; RIKEN; Osaka University								ASAHINA H, 1994, MUTAT RES-DNA REPAIR, V315, P229, DOI 10.1016/0921-8777(94)90034-5; BAKER BS, 1972, GENETICS, V71, P255; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; BOYD JB, 1976, GENETICS, V84, P527; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KOKEN MHM, 1992, NUCLEIC ACIDS RES, V20, P5541, DOI 10.1093/nar/20.21.5541; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MASUTANI C, 1993, J BIOL CHEM, V268, P9105; MIURA N, 1991, J BIOL CHEM, V266, P19786; MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182; MOUNKES LC, 1992, CELL, V71, P925, DOI 10.1016/0092-8674(92)90389-T; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH MS, 1993, P NATL ACAD SCI USA, V90, P6335, DOI 10.1073/pnas.90.13.6335; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SHIMAMOTO T, 1991, BIOCHEM BIOPH RES CO, V181, P1231, DOI 10.1016/0006-291X(91)92070-Z; SUGASAWA K, 1993, J BIOL CHEM, V268, P9098; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TODO T, 1992, MUTAT RES, V273, P85, DOI 10.1016/0921-8777(92)90052-5; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; YAMAMOTO AH, 1990, MUTAT RES, V229, P17, DOI 10.1016/0027-5107(90)90004-N; ZUCKER CS, 1985, CELL, V40, P851	41	18	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22452	22459		10.1074/jbc.270.38.22452	http://dx.doi.org/10.1074/jbc.270.38.22452			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673233	hybrid			2022-12-25	WOS:A1995RW31400062
J	SABATINI, DM; PIERCHALA, BA; BARROW, RK; SCHELL, MJ; SNYDER, SH				SABATINI, DM; PIERCHALA, BA; BARROW, RK; SCHELL, MJ; SNYDER, SH			THE RAPAMYCIN AND FKBP12 TARGET (RAFT) DISPLAYS PHOSPHATIDYLINOSITOL 4-KINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL GROWTH-FACTOR; PHOSPHOINOSITIDE KINASES; MACROLIDES FK-506; CELL-LINE; ACTIVATION; YEAST; 3-KINASE; LYMPHOCYTES; COMPLEXES; RECEPTOR	The immunosuppressant rapamycin prevents cell cycle progression in several mammalian cell lines and the yeast Saccharomyces cerevisiae. In mammalian cells, rapamycin binds to the small FK506-binding protein, FKBP12, allowing the drug-receptor complex to interact with the 289-kDa RAFT1/FRAP proteins. These proteins, along with their yeast homologs, TOR1/DRR1 and TOR2/DRR2, contain a C-terminal domain with amino acid homology to several phosphatidylinositol (PI) 4- and 3-kinases. However, no direct demonstration of kinase activity for this family of proteins has been reported. We now show that RAFT1, immunoprecipitated from rat brain and MG63 and HEK293 cells, contains PI 4-kinase activity and that rapamycin-FKBP12 has no effect on this activity. Thus, it is likely that, in vivo, rapamycin does not directly inhibit the PI 4-kinase activity and affects the RAFT1/FRAP protein through another mechanism.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Johns Hopkins University				Schell, Michael/0000-0003-1553-3582	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R44DA027190, P50DA000266, R43DA027190] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-271-90-7408, DA-00266] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERS MW, 1993, J BIOL CHEM, V268, P22825; Auger K. R., 1990, METHODS INOSITIDE RE, P159; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLACKSTONE CD, 1992, ANN NEUROL, V31, P680, DOI 10.1002/ana.410310620; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHEN YQ, 1994, BIOCHEM BIOPH RES CO, V203, P1, DOI 10.1006/bbrc.1994.2140; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COCHET C, 1991, J BIOL CHEM, V266, P637; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; HEITMAN J, 1994, SCIENCE, V253, P905; JANMEY PA, 1995, CHEM BIOL, V2, P61, DOI 10.1016/1074-5521(95)90276-7; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAM K, 1994, J BIOL CHEM, V269, P20648; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MORICE WG, 1993, J BIOL CHEM, V268, P22737; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; STACK JH, 1994, J BIOL CHEM, V269, P31552; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; WALKER DH, 1987, P NATL ACAD SCI USA, V84, P7513, DOI 10.1073/pnas.84.21.7513; WENG QP, 1995, MOL CELL BIOL, V15, P2833; WONG K, 1994, J BIOL CHEM, V269, P28878; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	47	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20875	20878		10.1074/jbc.270.36.20875	http://dx.doi.org/10.1074/jbc.270.36.20875			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673106	hybrid			2022-12-25	WOS:A1995RU05400002
J	TAKAHASHI, H; IKEDA, T				TAKAHASHI, H; IKEDA, T			MOLECULAR-CLONING AND EXPRESSION OF RAT AND MOUSE B61 GENE - IMPLICATIONS ON ORGANOGENESIS	ONCOGENE			English	Article						B61; ECK; IN SITU HYBRIDIZATION; ORGANOGENESIS	RECEPTOR TYROSINE KINASES; PROTEIN; FAMILY	ECK is a member of EPH receptor protein-tyrosine kinase subfamily and human B61 has been identified as the ligand for ECK recently, In order to better understand the roles of B61-ECK signalling pathway in mammalian development, me have cloned rat and mouse B61 cDNA and examined the expression pattern during rat development, Sequence analysis has revealed that there is a considerable degree of identity among rat, mouse and human B61 (98.0% between rat and mouse, 86.3% between rat and human in amino acid level), Examination of B61 mRNA expression by in situ hybridization analysis revealed tight association of B61 with endothelial cells at an early stage and epithelial cells in various tissues including lung, kidney, intestine, skin at later stage of organogenesis. In the developing skeletal system, B61 is expressed in periosteum, perichondrium and hypertrophic chondrocytes and osteoblasts, In the developing nervous system, expression of B61 is restricted in the neurons of dorsal root ganglia, These expression profiles of B61 in epithelial cells of various organs, developing skeletal system and dorsal. root ganglia match those of ECK, Our data suggest that B61 plays pivotal roles in organogenesis, especially vasculogenesis/angiogenesis and epithelial cell proliferation/differentiation.	SHOWA UNIV,SCH DENT,DEPT ORAL PATHOL,SHINAGAWA KU,TOKYO 142,JAPAN	Showa University	TAKAHASHI, H (corresponding author), MITSUBISHI KASEI INST LIFE SCI,HISTOCHEM LAB,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; GANJU P, 1994, ONCOGENE, V9, P1613; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; IKEDA T, 1992, J CLIN INVEST, V92, P2814; KARPERIEN M, 1994, MECH DEVELOP, V47, P29, DOI 10.1016/0925-4773(94)90093-0; KORHONEN J, 1994, ONCOGENE, V9, P395; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNURCH H, 1993, DEVELOPMENT, V119, P957	15	17	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					879	883						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675446				2022-12-25	WOS:A1995RU79800008
J	BARON, CB; OZAKI, S; WATANABE, Y; HIRATA, M; LABELLE, EF; COBURN, RF				BARON, CB; OZAKI, S; WATANABE, Y; HIRATA, M; LABELLE, EF; COBURN, RF			INOSITOL 1,4,5-TRISPHOSPHATE BINDING TO PORCINE TRACHEAL SMOOTH-MUSCLE ALDOLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOLYTIC-ENZYMES; TRISPHOSPHATE RECEPTOR; COUPLING MECHANISMS; POLYACRYLAMIDE GELS; INTRACELLULAR PH; CALCIUM RELEASE; PROTEINS; CELLS; IDENTIFICATION; PURIFICATION	A cytoskeletal fraction of porcine tracheal smooth muscle (PTSM) was found to contain > 90% of total cellular aldolase (fructose 1,6-bisphosphate aldolase, EC 4.1.2.13) activity. PTSM aldolase was purified by DEAE and inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) affinity chromatography and found to react with an antibody directed against human aldolase C, but not anti aldolase A and B. The molecular mass of native aldolase was about 138 kDa (on Sephacryl S-300); SDS-denatured enzyme was 35 kDa (comigrated with rabbit skeletal muscle aldolase). Total cellular aldolase tetramer (aldolase(4)) content was 34.5 pmol/100 nmol lipid P-i. Ins(1,4,5)P-3) binding activity coeluted with aldolase during Sephacryl 300, DEAE, and Ins(1,4,5)P-3 affinity chromatography. Ins(1,4,5)P-3 bound to purified aldolase (at 0 degrees C) in a dose-dependent manner over the range [Ins(1,4,5)P-3] 20 nM to 20 mu M, with maximal binding of 1 mol of Ins(1,4,5)P-3/mol aldolase, and a K-d of 12-14 mu M. Fru(1,6)P-2 and Fru(2,6)P-2 displaced bound Ins(1,4,5)P-3) with a 50% inhibition at 30 and 170 mu M, respectively. Ins(1,3,4)P-3 (20 mu M) and glyceraldehyde 3-phosphate (2 mM) were also potent inhibitors of Ins(1,4,5)P-3 binding, but not inositol 4-phosphate or inositol 1,4-bisphosphate (20 mu M each). Aldolase-bound Ins(1,4,5)P-3 may play a role in phospholipase C-independent increases in free [Ins(1,4,5)P-3]	BOCKUS RES INST,PHILADELPHIA,PA 19146; EHIME UNIV,FAC ENGN,DEPT APPL CHEM,MATSUYAMA,EHIME 790,JAPAN; KYUSHU UNIV,FAC DENT,DEPT BIOCHEM,FUKUOKA 812,JAPAN	Ehime University; Kyushu University	BARON, CB (corresponding author), UNIV PENN,SCH MED,DEPT PHYSIOL,6085,PHILADELPHIA,PA 19104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050532] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 50532-01] Funding Source: Medline; PHS HHS [R37 H137498-08] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAHAM M, 1985, COMP BIOCHEM PHYS B, V80, P847, DOI 10.1016/0305-0491(85)90473-0; ADAMSON ED, 1976, J EMBRYOL EXP MORPH, V35, P355; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANDRES V, 1990, J BIOL CHEM, V265, P21441; ASKALAN R, 1994, J NEUROCHEM, V63, P1477; BABA K, 1989, J PHYSIOL-LONDON, V412, P23, DOI 10.1113/jphysiol.1989.sp017602; BARON CB, 1989, AM J PHYSIOL, V256, pC375, DOI 10.1152/ajpcell.1989.256.2.C375; BARON CB, 1992, ARCH BIOCHEM BIOPHYS, V292, P382, DOI 10.1016/0003-9861(92)90006-I; BATLLE DC, 1993, AM J PHYSIOL, V264, pC932, DOI 10.1152/ajpcell.1993.264.4.C932; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GSJ, 1991, BIOCHEM J, V273, P541, DOI 10.1042/bj2730541; CARONI P, 1981, J BIOL CHEM, V256, P3263; CHILVERS ER, 1991, BIOCHEM J, V275, P373, DOI 10.1042/bj2750373; COBURN RF, 1990, AM J PHYSIOL, V258, pL119, DOI 10.1152/ajplung.1990.258.4.L119; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; GU H, 1991, AM J PHYSIOL, V261, pC17, DOI 10.1152/ajpcell.1991.261.1.C17; HARDIN CD, 1992, BIOCHIM BIOPHYS ACTA, V1134, P256, DOI 10.1016/0167-4889(92)90184-D; HASHIMOTO T, 1985, BRIT J PHARMACOL, V86, P191, DOI 10.1111/j.1476-5381.1985.tb09449.x; HIRATA M, 1990, BIOCHEM BIOPH RES CO, V168, P379, DOI 10.1016/0006-291X(90)91719-9; HIRATA M, 1994, BIOCHEM BIOPH RES CO, V205, P1563, DOI 10.1006/bbrc.1994.2845; HIRATA M, 1993, METH NEUROSCI, V18, P298; HORSTMAN DA, 1988, J BIOL CHEM, V263, P15297; JONES LR, 1979, J BIOL CHEM, V254, P530; JOSEPH SK, 1989, MOL PHARMACOL, V35, P355; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; KOPPITZ B, 1986, EUR J BIOCHEM, V161, P421, DOI 10.1111/j.1432-1033.1986.tb10462.x; KRAMPETZ IK, 1991, AM J PHYSIOL, V260, pL516, DOI 10.1152/ajplung.1991.260.6.L516; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVNAT T, 1993, INT J BIOCHEM, V25, P993, DOI 10.1016/0020-711X(93)90112-R; MATHUR RL, 1992, EXP EYE RES, V54, P253, DOI 10.1016/S0014-4835(05)80215-5; MATSUMOTO H, 1995, AM J PHYSIOL-CELL PH, V268, pC458, DOI 10.1152/ajpcell.1995.268.2.C458; MAYR GW, 1991, BIOCHEM J, V280, P631, DOI 10.1042/bj2800631; OREILLY G, 1993, FEBS LETT, V321, P69, DOI 10.1016/0014-5793(93)80623-3; PATTON C, 1993, MAX CHELATOR V 6 50; PENHOET E, 1966, P NATL ACAD SCI USA, V56, P1275, DOI 10.1073/pnas.56.4.1275; POPESCU LM, 1983, CELL CALCIUM, V34, P219; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PYNE S, 1993, BRIT J PHARMACOL, V110, P477, DOI 10.1111/j.1476-5381.1993.tb13835.x; RUTTER WJ, 1968, ANN NY ACAD SCI, V151, P102, DOI 10.1111/j.1749-6632.1968.tb11881.x; SOMLYO AP, 1990, ANNU REV PHYSIOL, V52, P857; SOMLYO AV, 1985, P NATL ACAD SCI USA, V82, P5231, DOI 10.1073/pnas.82.15.5231; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAGGART MJ, 1993, J PHYSIOL-LONDON, V472, P23, DOI 10.1113/jphysiol.1993.sp019933; TORNHEIM K, 1988, J BIOL CHEM, V263, P2619; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANSCHIJNDEL JWPM, 1993, FEBS LETT, V336, P239, DOI 10.1016/0014-5793(93)80811-8; VELICK SF, 1949, J PHYS COLLOID CHEM, V53, P135, DOI 10.1021/j150466a011; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZHAO H, 1990, J BIOL CHEM, V265, P14822; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	50	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20459	20465		10.1074/jbc.270.35.20459	http://dx.doi.org/10.1074/jbc.270.35.20459			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657622	hybrid			2022-12-25	WOS:A1995RR58400036
J	DECARVALHO, MGS; GARRITANO, J; LESLIE, CC				DECARVALHO, MGS; GARRITANO, J; LESLIE, CC			REGULATION OF LYSOPHOSPHOLIPASE ACTIVITY OF THE 85-KDA PHOSPHOLIPASE A(2) AND ACTIVATION IN MOUSE PERITONEAL-MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; CYTOSOLIC PHOSPHOLIPASE-A(2); CELL-LINE; ACID; LYSOPHOSPHATIDYLCHOLINE; PURIFICATION; BINDING; PHOSPHORYLATION; METABOLITES; PROTEINS	The regulation of the lysophospholipase activity of the 85-kDa cytosolic phospholipase A(2) (PLA(2)) was studied in vitro and in stimulated macrophages. Bovine serum albumin was found to inhibit lysophospholipase activity of the recombinant 85-kDa PLA(2) when assayed at a relatively low substrate concentration. Inhibition could be reversed if the substrate concentration was increased or if Ca2+ was present in the assay. Incubation of recombinant enzyme with macrophage membranes and lipid extracts from macrophage membranes resulted in the release of arachidonic acid, as well as, stearic acid, which is enriched at the sn-1 position of macrophage phospholipids. This suggests that with a bilayer substrate the PLA(2) can sequentially deacylate the sn-2 then sn-1 acyl groups. This was verified by demonstrating that the phospholipids, phosphatidylcholine and phosphatidylinositol, were hydrolyzed to glycerophosphocholine and glycerophosphoinositol by incubation with recombinant 85-kDa PLA(2). The 85-kDa enzyme was identified as the main lysophospholipase activity in mouse peritoneal macrophage cytosols. Addition of Ca2+ to the assay enhanced activity, but this effect decreased as the substrate concentration was increased. Incubation of macrophages with zymosan increased the lysophospholipase activity of the 85-kDa PLA(2) in cytosols. Phosphorylation of recombinant PLA(2) with mitogen-activated protein kinase resulted in an increase in lysophospholipase, as well as, PLA(2) activity. In macrophages stimulated with zymosan release of stearic acid (18:0) and palmitic acid (16:0) was observed in addition to arachidonic acid (20:4). These results are consistent with a role of the 85-kDa PLA(2) in regulating lysophospholipid levels in macrophages during zymosan stimulation.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PATHOL,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL034303, HL34303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BECKER GW, 1994, BIO-TECHNOL, V12, P69, DOI 10.1038/nbt0194-69; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHAM BE, 1976, J LIPID RES, V17, P176; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAWSON RMC, 1960, BIOCHEM J, V75, P45, DOI 10.1042/bj0750045; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; DIEZ E, 1992, J BIOL CHEM, V267, P18342; DIEZ E, 1990, J BIOL CHEM, V265, P14654; DOLE VP, 1960, J BIOL CHEM, V235, P2595; FUJIMORI Y, 1993, EUR J BIOCHEM, V218, P629, DOI 10.1111/j.1432-1033.1993.tb18416.x; GARSETTI D, 1992, BIOCHEM J, V288, P831, DOI 10.1042/bj2880831; GARSETTI DE, 1993, J LIPID MEDIATOR, V6, P223; GARSETTI DE, 1992, BIOCHIM BIOPHYS ACTA, V1165, P229, DOI 10.1016/0005-2760(92)90191-W; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; HALL PA, 1991, P SOC EXP BIOL MED, V197, P435; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P1135, DOI 10.1093/oxfordjournals.jbchem.a131169; KLIBANSKY C, 1963, BIOCHIM BIOPHYS ACTA, V70, P176, DOI 10.1016/0006-3002(63)90738-8; KLOPFENSTEIN WE, 1969, BIOCHIM BIOPHYS ACTA, V181, P323, DOI 10.1016/0005-2795(69)90256-6; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KUWAE T, 1990, J BIOL CHEM, V265, P5002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLIE C C, 1990, P216; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LESLIE CC, 1995, IN PRESS ADV MOL CEL; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; METZ SA, 1988, BIOCHIM BIOPHYS ACTA, V968, P239, DOI 10.1016/0167-4889(88)90013-4; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; OAKES J, 1973, EUR J BIOCHEM, V36, P553, DOI 10.1111/j.1432-1033.1973.tb02943.x; PORTMAN OW, 1973, BIOCHIM BIOPHYS ACTA, V326, P34, DOI 10.1016/0005-2760(73)90025-8; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; QUINN MT, 1991, BIOCHIM BIOPHYS ACTA, V1082, P293, DOI 10.1016/0005-2760(91)90205-V; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SHE HS, 1994, BIOCHEM J, V298, P23, DOI 10.1042/bj2980023; STAFFORD RE, 1988, COLLOID SURFACE, V30, P47; STOLL LL, 1993, AM J PHYSIOL, V264, pC885, DOI 10.1152/ajpcell.1993.264.4.C885; STRIFE RJ, 1984, J CHROMATOGR, V305, P3, DOI 10.1016/S0378-4347(00)83309-5; SUGIURA T, 1983, LIPIDS, V18, P125, DOI 10.1007/BF02536106; SWITZER S, 1965, J LIPID RES, V6, P506; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; ZHANG Y, 1988, J BIOL CHEM, V263, P9965	46	53	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	1995	270	35					20439	20446		10.1074/jbc.270.35.20439	http://dx.doi.org/10.1074/jbc.270.35.20439			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RR584	7657619	hybrid			2022-12-25	WOS:A1995RR58400033
J	HASAN, AAK; CINES, DB; HERWALD, H; SCHMAIER, AH; MULLERESTERL, W				HASAN, AAK; CINES, DB; HERWALD, H; SCHMAIER, AH; MULLERESTERL, W			MAPPING THE CELL-BINDING SITE ON HIGH-MOLECULAR-WEIGHT KININOGEN DOMAIN-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; LIGHT CHAIN; ANTIIDIOTYPIC ANTIBODIES; MONOCLONAL-ANTIBODIES; PLASMA PREKALLIKREIN; ANIONIC SURFACE; PLATELETS; EXPRESSION; BRADYKININ; IDENTIFICATION	Investigations mapped the region(s) on the light chain of high molecular weight kininogen (HK) that participates in cell binding. Sequential and overlapping peptides of domain 5 (D5(H)) were synthesized to determine its cell binding site(s). Three peptides from non-overlapping regions on D5(H) were found to inhibit biotin-HK binding to endothelial cells. Peptides GKE19 and HNL21 weakly inhibited biotin-HK binding with IC50 of 792 and 215 mu M, respectively. Peptide HKH20 inhibited biotin-HK binding with an IC50 of 0.2 mu M. Two peptides, GGH18 and HVL24, which overlapped HKH20, also inhibited biotin HK binding to endothelial cells with IC50 values of 108 and 0.8 mu M, respectively. Biotinylated HKH20 directly bound to endothelial cells. HK and HKH20 bound at or near the same site on endothelial cells because HK inhibited biotin-HKH20 binding (IC50 0.2 mu M). A polyclonal anti-HKH20 antibody also blocked biotin-HK binding. Peptides HKH20 and HVL24 and anti-HKH20 antibody also inhibited the procoagulant activity of plasma HK. These data indicated that the cell and artificial surface binding sites on D5(H) overlap. The orientation of HK on endothelial cells may be critical for the assembly and activation of contact system enzymes and the expression of kininogen's anti-thrombin activity.	UNIV MICHIGAN, DEPT INTERNAL MED, DIV HEMATOL & ONCOL, ANN ARBOR, MI 48109 USA; UNIV PENN, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, W-6500 MAINZ, GERMANY	University of Michigan System; University of Michigan; University of Pennsylvania; Johannes Gutenberg University of Mainz			Schmaier, Alvin/AAM-1063-2020; Herwald, Heiko/AAN-3708-2021	Schmaier, Alvin/0000-0002-3884-6234; Herwald, Heiko/0000-0002-8111-2842	NHLBI NIH HHS [HL35553, HL40387, HL50790] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035553, R01HL050790, P01HL040387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNASR A, 1995, BIOCHEM J, V305, P173, DOI 10.1042/bj3050173; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CINES DB, 1984, J CLIN INVEST, V73, P611, DOI 10.1172/JCI111251; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; GOODFRIEND TL, 1964, SCIENCE, V144, P1344, DOI 10.1126/science.144.3624.1344; GREEN NM, 1965, BIOCHEM J, V94, pC23, DOI 10.1042/bj0940023C; GUREWICH V, 1993, FEBS LETT, V318, P317, DOI 10.1016/0014-5793(93)80537-5; HAASEMANN M, 1991, J IMMUNOL, V147, P3882; HASAN AAK, 1994, J BIOL CHEM, V269, P31822; HASAN AAK, 1995, BLOOD, V85, P3134, DOI 10.1182/blood.V85.11.3134.bloodjournal85113134; HERWALD H, 1995, J BIOL CHEM, V270, P14634; HOLLAND JA, 1990, J CELL PHYSIOL, V143, P21, DOI 10.1002/jcp.1041430104; HONG SL, 1980, THROMB RES, V18, P787, DOI 10.1016/0049-3848(80)90201-7; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JIANG YP, 1992, J BIOL CHEM, V267, P3712; JIANG YP, 1992, THROMB HAEMOSTASIS, V68, P143; JOHNSON DA, 1987, THROMB RES, V48, P187, DOI 10.1016/0049-3848(87)90415-4; KAUFMANN J, 1993, J BIOL CHEM, V268, P9079; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; LOZA JP, 1994, THROMB HAEMOSTASIS, V71, P347; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MELONI FJ, 1992, BLOOD, V79, P1233; MELONI FJ, 1991, J BIOL CHEM, V266, P6786; MULLERESTERL W, 1988, METHOD ENZYMOL, V163, P240; NAKASHIMA M, 1993, J CLIN INVEST, V92, P2867, DOI 10.1172/JCI116907; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PURI RN, 1991, BLOOD, V77, P500; REDDIGARI SR, 1993, BLOOD, V81, P1306; SCHMAIER AH, 1989, METHOD ENZYMOL, V169, P276; SCHMAIER AH, 1984, THROMB RES, V33, P51, DOI 10.1016/0049-3848(84)90154-3; SCHMAIER AH, 1987, J BIOL CHEM, V262, P1405; SCHMAIER AH, 1990, BLOOD, V75, P1273; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; SMITH D, 1985, BLOOD, V66, P835; TAIT JF, 1986, J BIOL CHEM, V261, P5396; TAIT JF, 1987, J BIOL CHEM, V262, P11651; VOGEL R, 1990, J BIOL CHEM, V265, P12494; ZINI JM, 1993, BLOOD, V81, P2936	40	108	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19256	19261		10.1074/jbc.270.33.19256	http://dx.doi.org/10.1074/jbc.270.33.19256			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642598	hybrid			2022-12-25	WOS:A1995RP70300012
J	JIN, RZ; SHARIF, KA; KRAKOW, JS				JIN, RZ; SHARIF, KA; KRAKOW, JS			EVIDENCE FOR CONTACT BETWEEN THE CYCLIC-AMP RECEPTOR PROTEIN AND THE SIGMA(70) SUBUNIT OF ESCHERICHIA-COLI RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL REGION; TRANSCRIPTION ACTIVATION; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODIES; FUNCTIONAL MAP; DNA-BINDING; CAMP-CRP; PROMOTER; COMPLEX; CAP	The loop at the 52-position of the cAMP receptor pro tein (CRP) has been suggested as a potential site for contacting RNA polymerase on Class II promoters where the CRP binding site is located at position -41.5 (Bell, A., Gaston, K., Williams, R., Chapman, K., Kolb, A., Buc, H., Minchin, S., Williams, J., and Busby, S. (1990) Nucleic Acids Res. 18, 7243-7250), Using protein-protein photo-crosslinking, evidence is presented showing that the 52-loop of CRP is in physical proximity to the cr subunit of RNA polymerase holoenzyme. This interaction required the presence of a functional preinitiation complex. The CRP suppressor mutation, K52N, increased the efficiency of cross-linking, indicating an improved physical interaction between the CRP 52-loop and the cr subunit, Evidence for direct interaction between the CRP 156-162 loop and cu subunit of RNA polymerase on both gal and CRP promoters are also provided. The data indicate that CRP bound to the gal promoter contacts both the alpha and sigma(70) subunits of RNA polymerase.	CUNY HUNTER COLL,DEPT BIOL SCI,NEW YORK,NY 10021	City University of New York (CUNY) System; Hunter College (CUNY)					NIGMS NIH HHS [GM22619] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022619] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTEY A, 1994, NUCLEIC ACIDS RES, V22, P4375, DOI 10.1093/nar/22.21.4375; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; EILEN E, 1977, J MOL BIOL, V114, P47, DOI 10.1016/0022-2836(77)90282-0; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GIBSON W, 1981, ANAL BIOCHEM, V118, P1, DOI 10.1016/0003-2697(81)90147-0; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; ISHIHAMA A, 1988, TRENDS GENET, V4, P282, DOI 10.1016/0168-9525(88)90170-9; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI XM, 1985, J BIOL CHEM, V260, P4378; Miller J.H., 1972, EXPT MOL GENETICS; PENDERGRAST PS, 1992, P NATL ACAD SCI USA, V89, P10287, DOI 10.1073/pnas.89.21.10287; REN YL, 1988, P NATL ACAD SCI USA, V85, P4138, DOI 10.1073/pnas.85.12.4138; RIFTINA F, 1989, BIOCHEMISTRY-US, V28, P3299, DOI 10.1021/bi00434a027; ROCKWELL P, 1988, BIOCHEMISTRY-US, V27, P3512, DOI 10.1021/bi00409a058; SHARIF KA, 1994, J BIOL CHEM, V269, P23655; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054; TAO T, 1985, ARCH BIOCHEM BIOPHYS, V240, P627, DOI 10.1016/0003-9861(85)90070-0; WEST D, 1993, MOL MICROBIOL, V10, P789, DOI 10.1111/j.1365-2958.1993.tb00949.x; WILLIAMS R, 1991, NUCLEIC ACIDS RES, V19, P6705, DOI 10.1093/nar/19.24.6705; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x	32	19	19	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19213	19216		10.1074/jbc.270.33.19213	http://dx.doi.org/10.1074/jbc.270.33.19213			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642591				2022-12-25	WOS:A1995RP70300005
J	PICCOLO, S; BONALDO, P; VITALE, P; VOLPIN, D; BRESSAN, GM				PICCOLO, S; BONALDO, P; VITALE, P; VOLPIN, D; BRESSAN, GM			TRANSCRIPTIONAL ACTIVATION OF THE ALPHA-1(VI) COLLAGEN GENE DURING MYOBLAST DIFFERENTIATION IS MEDIATED BY MULTIPLE GA BOXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; VI COLLAGEN; EXPRESSION; PROMOTER; CELLS; CHAIN; FIBROBLASTS; PROTEINS; CLONING; ASSAY	During differentiation of C2C12 myoblasts in vitro, expression of alpha 1(VI) collagen mRNA was transiently stimulated severalfold. Promoter assays on cells transfected with chloramphenicol acetyltransferase (CAT) chimeric constructs have identified a region of the alpha 1(VI) collagen promoter that increases CAT activity about 8-fold during differentiation. The region, which overlaps with transcription initiation sites, was shown to contain three protected segments (A,B, and C) in DNase I footprinting assays. The contact points between nuclear factors and the protected segments were determined by methylation interference assay and included the sequence GGGAGGG (GA box) in all segments. Experiments in which CAT constructs were cotransfected with double-stranded oligonucleotides containing the GA box suggested that this motif was necessary for induction. Transfections with deletion constructs of the natural promoter and with minipromoters made of three copies of A, B, or C showed that the elements have inducing activity and that elements C and, to a lower extent, B are stimulatory for basal transcription, whereas the contribution of A in this process is limited. Electrophoretic mobility shift assays with nuclear extracts from C2C12 cells indicated that the three GA box-containing elements bound several transcription factors, including Spl. Comparison of the properties of the bands shifted under different experimental conditions (presence of 10 mM EDTA, heating of the nuclear extracts, addition of different concentrations of competitor oligonucleotides) established that A, B, and C probes form nine, eight and five main retarded complexes, respectively, and indicated that nuclear factors binding to C and B are subsets of proteins binding to A. UV crosslinking assays identified several peptides (seven with probe A, six with B, and five with C) in the range of 150-32 kDa. Comparison of the gel retardation pattern obtained with nuclear extracts from proliferating and differentiating cells revealed a particular increased intensity of two retarded bands. The data establish that multiple GA boxes mediate induction of the alpha 1(VI) collagen promoter during myoblast differentiation and suggest the attractive hypothesis that the effect may be related to variations of expression of transcription factors binding to these motifs.	UNIV PADUA, INST HISTOL & EMBRYOL, I-35100 PADUA, ITALY	University of Padua				Bonaldo, Paolo/0000-0002-9571-8140; PICCOLO, STEFANO/0000-0002-2037-0004	Telethon [119] Funding Source: Medline	Telethon(Fondazione Telethon)		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BONALDO P, 1993, MATRIX, V13, P223, DOI 10.1016/S0934-8832(11)80006-5; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; DANI C, 1989, J BIOL CHEM, V264, P10119; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; HATAMOCHI A, 1989, J BIOL CHEM, V264, P3494; HECKMANN M, 1992, FEBS LETT, V310, P79, DOI 10.1016/0014-5793(92)81151-B; HECKMANN M, 1989, EUR J BIOCHEM, V182, P719, DOI 10.1111/j.1432-1033.1989.tb14884.x; IBRAHIMI A, 1993, BIOCHEM J, V289, P141, DOI 10.1042/bj2890141; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Jackson S. P., 1993, Gene transcription: a practical approach., P189; KOLLER E, 1992, EUR J BIOCHEM, V208, P769, DOI 10.1111/j.1432-1033.1992.tb17246.x; KOLLER E, 1991, NUCLEIC ACIDS RES, V19, P485, DOI 10.1093/nar/19.3.485; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; MARIGO V, 1993, BIOCHIM BIOPHYS ACTA, V1172, P31, DOI 10.1016/0167-4781(93)90265-F; MUONA P, 1993, AM J PATHOL, V142, P1586; QUARTO R, 1993, DEVELOPMENT, V117, P245; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SAITTA B, 1994, EUR J BIOCHEM, V223, P675, DOI 10.1111/j.1432-1033.1994.tb19040.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIER T, 1988, BIOCHEM J, V253, P381, DOI 10.1042/bj2530381; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TOYOTA N, 1981, J CELL BIOL, V91, P497, DOI 10.1083/jcb.91.2.497; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILLIMANN TE, 1994, J BIOL CHEM, V269, P332; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	33	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19583	19590		10.1074/jbc.270.33.19583	http://dx.doi.org/10.1074/jbc.270.33.19583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642645	hybrid			2022-12-25	WOS:A1995RP70300061
J	TOKUMITSU, H; ENSLEN, H; SODERLING, TR				TOKUMITSU, H; ENSLEN, H; SODERLING, TR			CHARACTERIZATION OF A CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE CASCADE - MOLECULAR-CLONING AND EXPRESSION OF CALCIUM/CALMODULIN-DEPENDENT PROTEIN-KINASE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN; BRAIN; GR; AUTOPHOSPHORYLATION; IDENTIFICATION; PURIFICATION; ACTIVATION; SUBUNIT; CELLS	Recent studies have demonstrated that Ca2+/calmodulin dependent protein kinase IV (CaM-kinase IV) can mediate Ca2+-dependent regulation of gene expression through the phosphorylation of transcriptional activating proteins, We have previously identified and purified a 68-kDa rat brain CaM-kinase kinase that phosphorylates and increases total and Ca2+-independent activities of CaM-kinase IV (Tokumitsu, H., Brickey, D. A., Gold, J., Hidaka, H., Sikela, J., and Soderling, T. R. (1994) J. Biol. Chem, 269, 28640-28647), Using a partial amino acid sequence of the purified brain kinase, a CaM-kinase kinase cDNA was cloned from a rat brain cDNA library, Northern blot analysis showed that CaM-kinase kinase mRNA (3.4 kilobases) was expressed in rat brain, thymus, and spleen. Sequence analyses revealed that the cDNA encoded a 505-amino acid protein, which contained consensus protein kinase motifs and was 30-40% homologous with members of the CaM-kinase family, Expression of the cDNA in COS-7 cells yielded an apparent 68-kDa CaM-binding protein, which catalyzed in vitro activation in the presence of Mg2+/ATP and Ca2+/CaM of CaM-kinases I and IV but not of CaM-kinase II. Co-expression of CaM-kinase kinase with CaM-kinase IV gave a 14-fold enhancement of cAMP-response element-binding protein-dependent gene expression compared with CaM-kinase IV alone. These results are consistent with the hypothesis that CaM-kinases I and IV are regulated through a unique signal transduction cascade involving CaM-kinase kinase.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University			Enslen, Hervé/AAH-4492-2021; Enslen, Hervé/M-3400-2017; Tokumitsu, Hiroshi/M-3978-2015	Enslen, Hervé/0000-0001-9741-5293; Enslen, Hervé/0000-0001-9741-5293; Tokumitsu, Hiroshi/0000-0002-2193-6794	NIGMS NIH HHS [GM 41292] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; ENSLEN H, 1995, BIOCHEM BIOPH RES CO, V207, P1038, DOI 10.1006/bbrc.1995.1289; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; IRVING SG, 1989, MOL CELL BIOL, V9, P1034, DOI 10.1128/MCB.9.3.1034; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEE JSC, 1994, J BIOL CHEM, V269, P2158; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MIYANO O, 1992, J BIOL CHEM, V267, P1198; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SUN PQ, 1995, J BIOL CHEM, V270, P7041, DOI 10.1074/jbc.270.13.7041; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; WALSH DA, 1971, J BIOL CHEM, V246, P1968; WIEMANN S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P254, DOI 10.1016/0167-4781(91)90018-H	32	204	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19320	19324		10.1074/jbc.270.33.19320	http://dx.doi.org/10.1074/jbc.270.33.19320			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642608	hybrid			2022-12-25	WOS:A1995RP70300022
J	WAWRZYNOW, A; ZYLICZ, M				WAWRZYNOW, A; ZYLICZ, M			DIVERGENT EFFECTS OF ATP ON THE BINDING OF THE DNAK AND DNAJ CHAPERONES TO EACH OTHER, OR TO THEIR VARIOUS NATIVE AND DENATURED PROTEIN SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; REPLICATION PROTEIN; STRESS PROTEINS; RNA-POLYMERASE; GRPE; HSP70; BIP; DISSOCIATION; PURIFICATION	Using the native proteins lambda P, lambda O, sigma(32), and RepA, as well as permanently unfolded alpha-carboxymethylated lactalbumin, we show that DnaK and DnaJ molecular chaperones possess differential affinity toward these protein substrates. In this paper we present evidence that the DnaK protein binds not only to short hydrophobic peptides, which are in an extended conformation, but also efficiently recognizes large native proteins (RepA, lambda P). The best substrate for either the DnaK or DnaJ chaperone is the native P1 coded replication RepA protein. The native sigma(32) transcription factor binds more efficiently to DnaJ than to DnaK, whereas unfolded alpha-carboxymethylated lactalbumin or native lambda P binds more efficiently to DnaK than to the DnaJ molecular chaperone. The presence of nucleotides does not change the DnaJ affinity to any of the tested protein substrates. In the case of DnaK, the presence of ATP inhibits, while a nonhydrolyzable ATP analogues markedly stimulates the binding of DnaK to all of these various protein substrates. ADP has no effect on these reactions. In contrast to substrate protein binding, DnaK binds to the DnaJ chaperone protein in a radically different manner, namely ATP stimulates whereas a nonhydrolyzable ATP analogue inhibits the DnaK DnaJ complex formation. Moreover, the DnaKc94 mutant protein lacking 94 amino acids from its C terminal domain, which still possesses the ATPase activity and forms a transient complex with protein substrates, does not interact with DnaJ protein. We conclude that the DnaK-ADP form, derived from ATP hydrolysis, possesses low affinity to the protein substrates but can efficiently interact with DnaJ molecular chaperone.			WAWRZYNOW, A (corresponding author), UNIV GDANSK,DEPT MOLEC BIOL,DIV BIOPHYS,24 KLADKI,PL-80822 GDANSK,POLAND.			Zylicz, Alicja/0000-0003-4174-3073				BANECKI B, 1992, J BIOL CHEM, V267, P25051; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1993, P NATL ACAD SCI USA, V90, P11019, DOI 10.1073/pnas.90.23.11019; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; MCKAY DB, 1994, BIOL HEAT SHOCK PROT, P153; MONTGOMERY D, 1993, J MOL BIOL, V232, P680, DOI 10.1006/jmbi.1993.1418; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; PARK K, 1993, PROTEIN SCI, V2, P325; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PRASAD K, 1994, J BIOL CHEM, V269, P6931; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHMID SL, 1985, J BIOL CHEM, V260, P10050; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHMID SL, 1985, J BIOL CHEM, V260, P44; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHERMAN MY, 1992, EMBO J, V11, P71; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; TSAI MY, 1994, J BIOL CHEM, V269, P5958; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WICKNER S, 1992, NATURE, V350, P165; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1993, PHILOS T ROY SOC B, V339, P271, DOI 10.1098/rstb.1993.0025; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431; [No title captured]	60	99	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19300	19306		10.1074/jbc.270.33.19300	http://dx.doi.org/10.1074/jbc.270.33.19300			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642605	hybrid			2022-12-25	WOS:A1995RP70300019
J	HALLENBECK, PL; PHYILLAIER, M; NIKODEM, VM				HALLENBECK, PL; PHYILLAIER, M; NIKODEM, VM			DIVERGENT EFFECTS OF 9-CIS-RETINOIC ACID RECEPTOR ON POSITIVE AND NEGATIVE THYROID-HORMONE RECEPTOR-DEPENDENT GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							OSTEOCALCIN GENE; RESPONSIVE ELEMENT; RETINOIC ACID; BINDING; PROMOTER	The thyroid hormone (TH)-inducible expression of some genes has recently been shown to be enhanced by 9-cis-retinoic acid (9-cis-RA) receptor (RXR). This effect appears to be at least partially elicited by the ability of RXR to heterodimerize with TH receptor (THR) and enhance its binding to the cis-acting thyroid hormone responsive elements (TREs) found within those genes. However, whether RXRbeta enhances TH/THR-mediated transactivation of all TRE-containing genes, and if RXR has any effect on TH-dependent negative regulation are not known. In the present study, we show that the TH/THR-inducible expression of the myelin basic protein (MBP) gene is not enhanced by RXRbeta, despite high affinity binding of the RXRbeta.THRalpha heterodimer to the MBP-TRE. We also demonstrate that RXRbeta reverses the TH/THR-dependent down-regulation mediated by the negative TRE found within the promoter of the mouse thyroid stimulating hormone gene (TSH). The ligand for RXRbeta (9-cis-RA), either alone or in combination with TH, did not enhance the transcription mediated by either the MBP-TRE, TSH-TRE, or the malic enzyme (ME)-TRE. However, the ME-TRE is known to confer RXRbeta-dependent enhancement of TH-induced gene expression. Thus, the capacity of RXRbeta to modulate TH-dependent transcriptional regulation depends upon the nature of the TRE.	NIDDKD,GENET & BIOCHEM BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; DATTA S, 1992, MOL ENDOCRINOL, V6, P815, DOI 10.1210/me.6.5.815; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DEUSTER G, 1991, MOL CELL BIOL, V11, P1638; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FLINK IL, 1990, J BIOL CHEM, V265, P11233; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MAARKS MS, 1992, EMBO J, V11, P1419; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; MUNOZCANOVES P, 1990, J BIOL CHEM, V265, P20065; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; OZONO K, 1990, J BIOL CHEM, V265, P21881; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	28	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3825	3828						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680034				2022-12-25	WOS:A1993KN53300008
J	FLOTTE, TR; AFIONE, SA; SOLOW, R; DRUMM, ML; MARKAKIS, D; GUGGINO, WB; ZEITLIN, PL; CARTER, BJ				FLOTTE, TR; AFIONE, SA; SOLOW, R; DRUMM, ML; MARKAKIS, D; GUGGINO, WB; ZEITLIN, PL; CARTER, BJ			EXPRESSION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FROM A NOVEL ADENOASSOCIATED VIRUS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTOR; CHLORIDE CHANNELS; ADENOASSOCIATED VIRUS; EPITHELIAL-CELLS; GENE; DNA; REPLICATION; INTEGRATION; CLONING	Adeno-associated virus type 2 (AAV) vectors have been used for gene expression in respiratory epithelial cells and may be useful in gene therapy for diseases like cystic fibrosis (CF) which affect the airways. The AAV p5 promoter together with the AAV inverted terminal repeat (ITR) forms a 263-base pair cassette which mediated efficient expression in a CF bronchial epithelial cell line. We report here that the ITR itself can mediate gene expression. In stable transfection assays, AAV-CF vectors expressing the full-length cystic fibrosis transmembrane conductance regulator (CFTR) cDNA from either the p5 promoter or the ITR restored cAMP regulation of the chloride efflux characteristic of CFTR function. An AAV-ITR-CF vector deleted for the amino terminus of CFTR was also functional. This vector was packaged into AAV particles and used to transduce cells without selection. Transduced cells also exhibited cAMP-regulated Cl- efflux. The complemented cell lines showed increased levels of CFTR protein immunofluorescence, and the presence of intact AAV-CF vector sequence was confirmed by Southern blot analysis of rescued vector sequences. These studies provide.novel insights into AAV gene expression, and this newly described promoter allows for the production of AAV vectors expressing CFTR in those differentiated cells affected in CF.	TARGETED GENET CORP, SEATTLE, WA 98101 USA; JOHNS HOPKINS MED INST, DEPT PHYSIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS MED INST, EUDOWOOD DIV PEDIAT RESP SCI, BALTIMORE, MD 21205 USA; UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	FLOTTE, TR (corresponding author), NIDDKD, MOLEC & CELLULAR BIOL LAB, BETHESDA, MD 20892 USA.			Zeitlin, Pamela/0000-0002-2719-1834				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ARISPE N, 1992, P NATL ACAD SCI USA, V89, P1539, DOI 10.1073/pnas.89.5.1539; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARTER BJ, 1979, VIROLOGY, V92, P449, DOI 10.1016/0042-6822(79)90149-1; CARTER BJ, 1983, VIROLOGY, V126, P505, DOI 10.1016/S0042-6822(83)80008-7; CARTER BJ, 1990, HDB PARVOVIRUSES, V2, P247; CARTER BJ, 1992, IN PRESS CURR OPIN B, V3; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FLOTTE TR, 1992, AM J RESP CELL MOL, V7, P349, DOI 10.1165/ajrcmb/7.3.349; HERMONAT PL, 1984, P NATL ACAD SCI-BIOL, V81, P6466, DOI 10.1073/pnas.81.20.6466; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KOTIN RM, 1989, VIROLOGY, V170, P460, DOI 10.1016/0042-6822(89)90437-6; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; LAUGHLIN CA, 1988, GENE, V23, P65; LEVITT N, 1989, GENE DEV, V3, P1019, DOI 10.1101/gad.3.7.1019; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LUO L, 1989, PFLUGERS ARCH, V415, P198; MCLAUGHLIN SK, 1988, J VIROL, V62, P1963, DOI 10.1128/JVI.62.6.1963-1973.1988; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; PITLUK ZW, 1991, J VIROL, V65, P6661, DOI 10.1128/JVI.65.12.6661-6670.1991; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; Sambrook J, 1989, MOL CLONING LABORATO; SAMULSKI RJ, 1991, EMBO J, V10, P3941, DOI 10.1002/j.1460-2075.1991.tb04964.x; SAMULSKI RJ, 1989, J VIROL, V63, P3822, DOI 10.1128/JVI.63.9.3822-3828.1989; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; TRATSCHIN JD, 1984, MOL CELL BIOL, V4, P2072, DOI 10.1128/MCB.4.10.2072; TRATSCHIN JD, 1984, J VIROL, V51, P611, DOI 10.1128/JVI.51.3.611-619.1984; WALSH CE, 1992, P NATL ACAD SCI USA, V89, P7257, DOI 10.1073/pnas.89.15.7257; WALZ C, 1992, J VIROL, V66, P2990, DOI 10.1128/JVI.66.5.2990-3002.1992; WONDISFORD FE, 1988, MOL ENDOCRINOL, V2, P32, DOI 10.1210/mend-2-1-32; ZEITLIN PL, 1992, P NATL ACAD SCI USA, V89, P344, DOI 10.1073/pnas.89.1.344; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	48	295	352	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3781	3790						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679117				2022-12-25	WOS:A1993KM16100114
J	AUKHIL, I; JOSHI, P; YAN, YZ; ERICKSON, HP				AUKHIL, I; JOSHI, P; YAN, YZ; ERICKSON, HP			CELL-BINDING AND HEPARIN-BINDING DOMAINS OF THE HEXABRACHION ARM IDENTIFIED BY TENASCIN EXPRESSION PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; EXTRACELLULAR-MATRIX; ADHESIVE FUNCTION; DECREASING SULFATION; ELECTRON-MICROSCOPY; SUBSTRATE ADHESION; FIBROBLAST GROWTH; HUMAN FIBRONECTIN; CULTURED-CELLS; RECEPTOR	We have produced a set of bacterial expression proteins corresponding to 10 segments of tenascin and two of fibronectin and tested them for heparin binding and cell adhesion. We used polymerase chain reaction cloning to terminate the segments precisely at domain boundaries. Heparin binding activity was mapped to two different tenascin segments: one comprising the fourth and fifth fibronectin type III domains, and to TNfbg, the fibrinogen-like terminal knob. TNfbg, but none of the other tenascin segments, also supported adhesion of primary rat embryo skin fibroblasts. The fibroblasts did not spread on TNfbg but remained rounded. Cell binding to TNfbg occurred in the presence or absence of divalent cations and was not inhibited by RGD peptides, suggesting that integrins are not involved. Fibroblast binding to TNfbg was strongly inhibited by soluble heparin, by treating the cells with heparitinase, or by culture conditions that cause undersulfation of proteoglycans. These observations suggest that cell attachment to TNfbg is mediated by cell surface proteoglycans. We have also made full-length cDNA constructs for the largest and smallest splice variants of human tenascin, as well as one truncated after the 14th epidermal growth factor-like domain, in the pNUT mammalian cell expression vector. Stably transfected baby hamster kidney cell lines secreted large quantities of tenascin, and this was assembled into normal hexabrachions, the arm length corresponding to the construct.	DUKE UNIV, SCH MED, DEPT CELL BIOL, DURHAM, NC 27710 USA; UNIV N CAROLINA, SCH DENT, DEPT PERIODONT, CHAPEL HILL, NC 27514 USA	Duke University; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA-47056] Funding Source: Medline; NIDCR NIH HHS [DE-07801] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA047056, R01CA047056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007801] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AOTA S, 1991, J BIOL CHEM, V266, P15938; ARNHEIM N, 1992, ANNU REV BIOCHEM, V61, P131, DOI 10.1146/annurev.bi.61.070192.001023; AUKHIL I, 1990, MATRIX, V10, P98, DOI 10.1016/S0934-8832(11)80176-9; BORSI L, 1986, ANAL BIOCHEM, V155, P335, DOI 10.1016/0003-2697(86)90443-4; BOURDON MA, 1989, J CELL BIOL, V108, P1149, DOI 10.1083/jcb.108.3.1149; BRETSCHER MS, 1985, EMBO J, V4, P1941, DOI 10.1002/j.1460-2075.1985.tb03874.x; CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; CHIQUET M, 1991, EUR J BIOCHEM, V199, P379, DOI 10.1111/j.1432-1033.1991.tb16134.x; CHIQUETEHRISMANN R, 1991, CELL REGUL, V2, P927, DOI 10.1091/mbc.2.11.927; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; DELATORRE JG, 1981, Q REV BIOPHYS, V14, P81, DOI 10.1017/S0033583500002080; DRAKE SL, 1992, J CELL BIOL, V117, P1331, DOI 10.1083/jcb.117.6.1331; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; ERICKSON HP, 1987, J CELL BIOL, V105, P1387, DOI 10.1083/jcb.105.3.1387; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; FAISSNER A, 1990, J NEUROCHEM, V54, P1004, DOI 10.1111/j.1471-4159.1990.tb02350.x; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FRIEDLANDER DR, 1988, J CELL BIOL, V107, P2329, DOI 10.1083/jcb.107.6.2329; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GULCHER JR, 1990, GENOMICS, V6, P616, DOI 10.1016/0888-7543(90)90495-G; GULCHER JR, 1991, P NATL ACAD SCI USA, V88, P9438, DOI 10.1073/pnas.88.21.9438; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; HOFFMAN S, 1987, P NATL ACAD SCI USA, V84, P2523, DOI 10.1073/pnas.84.8.2523; HUMPHRIES DE, 1989, METHOD ENZYMOL, V179, P428; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHANSSON S, 1984, J CELL BIOL, V98, P810, DOI 10.1083/jcb.98.3.810; KIMIZUKA F, 1991, J BIOCHEM-TOKYO, V110, P284, DOI 10.1093/oxfordjournals.jbchem.a123572; KIMIZUKA F, 1991, J BIOL CHEM, V266, P3045; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LIGHTNER VA, 1989, J CELL BIOL, V108, P2483, DOI 10.1083/jcb.108.6.2483; LIGHTNER VA, 1990, J CELL SCI, V95, P263; Linker A., 1972, METHODS ENZYMOL, P902; LORIES V, 1992, J BIOL CHEM, V267, P1116; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MACKIE EJ, 1987, J CELL BIOL, V105, P2569, DOI 10.1083/jcb.105.6.2569; MARTON LS, 1989, J BIOL CHEM, V264, P13145; MOSESSON MW, 1970, J BIOL CHEM, V245, P5728; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; MURRAY BA, 1992, J CELL BIOL, V117, P1311, DOI 10.1083/jcb.117.6.1311; NIES DE, 1991, J BIOL CHEM, V266, P2818; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROHRBACH MS, 1973, ANAL BIOCHEM, V52, P127, DOI 10.1016/0003-2697(73)90338-2; SAGINATI M, 1992, EUR J BIOCHEM, V205, P545, DOI 10.1111/j.1432-1033.1992.tb16811.x; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAN SS, 1987, P NATL ACAD SCI USA, V84, P7977, DOI 10.1073/pnas.84.22.7977; TAYLOR HC, 1989, J CELL BIOCHEM, V41, P71, DOI 10.1002/jcb.240410204; VAUGHAN L, 1987, EMBO J, V6, P349, DOI 10.1002/j.1460-2075.1987.tb04761.x; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	60	216	223	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2542	2553						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679097				2022-12-25	WOS:A1993KK81500045
J	DESCAMPS, O; BILHEIMER, D; HERZ, J				DESCAMPS, O; BILHEIMER, D; HERZ, J			INSULIN STIMULATES RECEPTOR-MEDIATED UPTAKE OF APOE-ENRICHED LIPOPROTEINS AND ACTIVATED ALPHA-2-MACROGLOBULIN IN ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; TRANSFERRIN RECEPTORS; CELL-SURFACE; 3T3-L1 ADIPOCYTES; APOLIPOPROTEIN-E; PLASMA-MEMBRANE; HEPATIC-UPTAKE; PROTEIN; RAT; BINDING	The low density lipoprotein receptor-related protein (LRP) is a cell surface receptor that binds and internalizes several macromolecules including apolipoprotein E-enriched remnant lipoproteins and protease/antiprotease complexes such as activated alpha2-macroglobulin. Its function has been studied primarily in cultured fibroblasts and in liver. In the current studies, we provide evidence that LRP is present on the surface of primary adipocytes isolated from rat epididymal fat pads. The activity of the receptor increases 2-3-fold within minutes after the adipocytes are exposed to physiological concentrations of insulin as indicated by an increase in the uptake of I-125-labeled activated alpha2-macroglobulin. There is a corresponding increase in the uptake of [H-3]cholesteryl esters from radiolabeled apoE-enriched beta-very low density lipoprotein. The latter uptake was inhibited by an antibody against LRP and by a fusion protein containing the 39-kDa protein, also called receptor-associated protein, a known inhibitor of LRP function. In vivo, rats that had been fed ad libitum accumulated approximately 24-fold more chylomicron cholesteryl esters in their epididymal fat pads than did fasted control animals. We suggest that insulin stimulation of LRP, in a synergistic action with lipoprotein lipase, increases the endocytic uptake of cholesteryl esters and triglycerides from remnant lipoproteins in postprandial adipocytes.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	DESCAMPS, O (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV LIPID METAB,DALLAS,TX 75235, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angel A., 1983, ADIPOCYTE OBESITY CE, P179; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BERGMAN EN, 1971, J CLIN INVEST, V50, P1831, DOI 10.1172/JCI106674; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; CORVERA S, 1989, J BIOL CHEM, V264, P10133; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DAVIS RJ, 1987, J BIOL CHEM, V262, P13126; ECKEL RH, 1987, LIPOPROTEIN LIPASE, P79; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GLIEMANN J, 1983, BIOCHIM BIOPHYS ACTA, V756, P230, DOI 10.1016/0304-4165(83)90096-X; GOODMAN DS, 1962, J CLIN INVEST, V41, P1886, DOI 10.1172/JCI104645; GOODMAN DS, 1965, J LIPID RES, V6, P390; HAVEL RJ, 1961, J LIPID RES, V2, P389; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUSSAIN MM, 1989, J BIOL CHEM, V264, P17931; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KUWAJIMA M, 1988, METABOLISM, V37, P597, DOI 10.1016/0026-0495(88)90178-3; LOSSOW WJ, 1962, J LIPID RES, V3, P207; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MJOS OD, 1975, J CLIN INVEST, V56, P603, DOI 10.1172/JCI108130; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; NESTEL PJ, 1962, J CLIN INVEST, V41, P1915, DOI 10.1172/JCI104648; NESTEL PJ, 1963, J CLIN INVEST, V42, P1313, DOI 10.1172/JCI104815; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OKA Y, 1984, P NATL ACAD SCI-BIOL, V81, P4028, DOI 10.1073/pnas.81.13.4028; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; QUARFORDT SH, 1967, J LIPID RES, V8, P264; SHELBURNE F, 1980, J CLIN INVEST, V65, P652, DOI 10.1172/JCI109710; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TANNER LI, 1987, J BIOL CHEM, V262, P8975; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WINDLER E, 1980, J BIOL CHEM, V255, P5475; WINDLER E, 1985, J LIPID RES, V26, P556	42	94	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					974	981						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678262				2022-12-25	WOS:A1993KG07700035
J	UNEYAMA, H; UNEYAMA, C; AKAIKE, N				UNEYAMA, H; UNEYAMA, C; AKAIKE, N			INTRACELLULAR MECHANISMS OF CYTOPLASMIC CA2+ OSCILLATION IN RAT MEGAKARYOCYTE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; FREE CALCIUM-CONCENTRATION; INOSITOL TRISPHOSPHATE; CA-2+ OSCILLATIONS; FURA-2-LOADED HEPATOCYTES; PLATELET-AGGREGATION; POSITIVE FEEDBACK; SMOOTH-MUSCLE; ACINAR-CELLS; CYCLIC-AMP	Extracellular application of ATP and ADP evoked the oscillatory K+ currents (I(KCa)) resulting from the periodic rise in cytoplasmic Ca2+ concentration ([Ca2+]i) of megakaryocyte isolated from rat bone marrow (Uneyama, H., Uneyama, C., and Akaike, N. (1992) Jpn. J. Pharmacol. 58, 231). The intracellular mechanism of ATP-induced cytoplasmic Ca2+ oscillation was investigated by the use of nystatin-perforated patch-clamp technique. Caffeine and ryanodine, which release Ca2+ from the Ca2+-induced Ca2+ release pool (CICR), and procaine, a blocker of Ca2+ release from CICR, had no effect on the I(KCa) oscillation in megakaryocyte. Thapsigargin and A23187 activated I(KCa) irreversibly by mobilizing Ca2+, but under Ca2+-free conditions they activated I(KCa) transiently. Intracellular application of inositol 1,4,5-triphosphate (IP3) also induced I(KCa) oscillation. Phorbol myristate acetate (PMA), a strong activator of protein kinase C (PKC), inhibited the oscillation completely. The inhibitory action of PMA was reversed by an inhibitor of PKC, staurosporin. The oscillation of ATP-induced I(KCa) was disrupted by staurosporin or calmodulin (CaM) antagonists such as W-7 and trifluoperazine, resulting in a transient and successive plateau-like I(KCa). These results suggest that Ca2+ oscillation in megakaryocyte is caused by the interaction of both the Ca2+ release from IP3-sensitive Ca2+ pool and the Ca2+ uptake stimulated by PKC and Ca2+/CaM complex. Furthermore, forskolin, an activator of adenylate cyclase, and isobutylmethylxanthin, an inhibitor of phosphodiesterase, inhibited the frequency, latency, and current amplitude of the oscillation in a concentration-dependent manner. These reagents inhibited IP3-induced oscillation as well as an ATP-induced oscillation. Thus, the ATP-induced [Ca2+]i oscillation of rat megakaryocyte is also modulated by cAMP.	TOHOKU UNIV,SCH MED,DEPT NEUROPHYSIOL,SENDAI,MIYAGI 980,JAPAN	Tohoku University								BALL RL, 1990, J BIOL CHEM, V265, P12836; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOUCHARD RA, 1989, BRIT J PHARMACOL, V97, P1279, DOI 10.1111/j.1476-5381.1989.tb12590.x; CARAFOLI E, 1988, J CARDIOVASC PHARM, V12, pS77; DUBOURDIEU DJ, 1990, BIOCHIM BIOPHYS ACTA, V1054, P326, DOI 10.1016/0167-4889(90)90104-L; EBIHARA S, 1992, BRIT J PHARMACOL, V106, P823, DOI 10.1111/j.1476-5381.1992.tb14419.x; EDES I, 1987, Membrane Biochemistry, V7, P175, DOI 10.3109/09687688709039993; ENYEDI A, 1986, J BIOL CHEM, V261, P9558; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HAMATANI Y, 1991, AM J PHYSIOL, V261, pE325, DOI 10.1152/ajpendo.1991.261.3.E325; HAROOTUNIAN AT, 1988, COLD SPRING HARB SYM, V53, P935, DOI 10.1101/SQB.1988.053.01.108; HAROOTUNIAN AT, 1991, CELL CALCIUM, V12, P153, DOI 10.1016/0143-4160(91)90017-9; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; IKEDA M, 1992, J PHYSIOL-LONDON, V447, P711, DOI 10.1113/jphysiol.1992.sp019025; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; KAWA K, 1990, J PHYSIOL-LONDON, V431, P207, DOI 10.1113/jphysiol.1990.sp018327; KAWANISHI T, 1989, J BIOL CHEM, V264, P12859; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; KRISHNAMURTHI S, 1988, BIOCHEM J, V250, P209, DOI 10.1042/bj2500209; KROLL MH, 1988, BIOCHIM BIOPHYS ACTA, V970, P61, DOI 10.1016/0167-4889(88)90222-4; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LEVEN RM, 1982, J CELL BIOL, V92, P313, DOI 10.1083/jcb.92.2.313; LEVINE RF, 1976, J CELL BIOL, V69, P159, DOI 10.1083/jcb.69.1.159; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MURASE K, 1989, NEUROSCI LETT, V103, P56, DOI 10.1016/0304-3940(89)90485-0; NAKAGAWA T, 1990, NEUROSCI RES, V8, P114, DOI 10.1016/0168-0102(90)90063-K; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PALADE P, 1989, MOL PHARMACOL, V36, P673; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; PIKE GK, 1989, J MUSCLE RES CELL M, V10, P337, DOI 10.1007/BF01758430; POLLOCK WK, 1987, FEBS LETT, V210, P132, DOI 10.1016/0014-5793(87)81322-4; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SAGE SO, 1989, J BIOL CHEM, V264, P6; SANCHEZBUENO A, 1990, BIOCHEM J, V268, P627, DOI 10.1042/bj2680627; SCHICK BP, 1981, BIOCHIM BIOPHYS ACTA, V663, P239, DOI 10.1016/0005-2760(81)90210-1; SOCORRO L, 1990, BIOCHEM J, V265, P799, DOI 10.1042/bj2650799; SOSLAU G, 1989, BLOOD, V74, P984; TANAKA M, 1990, BIOCHEM PHARMACOL, V40, P991; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; UNEYAMA H, 1992, NEUROREPORT, V3, P633, DOI 10.1097/00001756-199207000-00023; UNEYAMA H, 1992, JPN J PHARMACOL, V58, P231; USHIYAMA S, 1988, PROSTAGLANDINS, V36, P477, DOI 10.1016/0090-6980(88)90044-5; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WALTER U, 1988, European Heart Journal, V9, P1; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8	55	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					168	174						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7677993				2022-12-25	WOS:A1993KE60300026
